American Thoracic Society International Conference

Where today's science meets tomorrow's care™

Final Program

ATS 2016
Where today's science meets tomorrow's care™

May 13 - May 18, 2016
San Francisco, California
conference.thoracic.org

ATS 2016 INTERNATIONAL CONFERENCE DISCLOSURES OF CONFERENCE PLANNERS

The following members of the Education Committee have disclosed no financial relationships with commercial interests:

Carey C. Thomson, MPH, MD, Chair
Jason T. Poston, MD, Vice Chair
Gaetane C. Michaud, MD, Vice Chair
Jay S. Balachandran, MD
Debra M. Boyer, MD
Courtney Broaddus
Samuel Brown, MD, MS
William G. Carlos, MD
Colleen L. Channick, MD
Charles Dela Cruz, MD, PhD
Rebecca Disler, MSc, BSc, BN, RN
Thomas W. Ferkol, MD
Henry E. Fessler, MD
David Gozal, MD
Mary Harbaugh, PhD
Shazia M. Jamil, MD
Carl A. Kaplan, MD
Patrick Lyons, MD
Atul Malhotra, MD
Jakob I. McSparron, MD
Paul E. Moore, MD
Jeremy E. Orr, MD
Susan Pasnick, MD
Grace W. Pien, MD, MS
Jessica E. Pittman, MD, MPH
Renee D. Stapleton, PhD, MD
Tisha S. Wang, MD
Carolyn H. Welsh, MD

The following members of the Education Committee have disclosed the following financial relationships with commercial interests:

Ira M. Cheifetz, MD: *Hill-Rom (research support) and Philips Respironics (advisory committee)*

Alison S. Clay, MD: *Oakstone Publishing (reviewer)*

Margaret M. Hayes, MD: *Oakstone Publishing (reviewer)*

Kevin L. Kovitz, MD, MBA: *Olympus (research support) and PneumRx (research support)*

Suzanne C. Lareau, RN, MS, FAAN: *Boehringer Ingelheim (advisory committee)*

Andrew Luks, MD: *Springer (author royalties)*

Samir S. Makani, FCCP, MD: *Covidien and Olympus (consultant)*

Daiana Stolz: *Brahms (speaker)*

Mary E. Strek, MD: *BMS and Gilead (research support)*

The following members of the International Conference Committee have disclosed no financial relationships with commercial interests:

Zea Borok, MD, Chair
Jess Mandel, MD, Chair Appointee
Juan C. Celedon, MD, DrPH
JiYeon Choi, PhD, RN
Colin R. Cooke, MD
Angela Haczku, MD, PhD
Steven M. Kawut, MD, MS
Anastassios C. Koumbourlis, MD, MPH
Marilyn Moy, MD, MSc
Robert L. Owens, MD
Karen M. Ridge, PhD
Margaret Rosenfeld, MD, MPH
Jussi J. Saukkonen, MD
Sally J. Singh, PhD
Gwen S. Skloot, MD
Anne I. Sperling, PhD
Renee D. Stapleton, PhD, MD
Lynn T. Tanoue, MD
Mihaela Teodorescu, MD, MS
Renda S. Wiener, MD, MPH
Janelle Yorke, RN, PhD

The following members of the International Conference Committee have disclosed the following financial relationships with commercial interests:

Sonye K. Danoff, MD, PhD: *Boehringer Ingelheim (speaker, Advisory Committee)*

Ivor S. Douglas, MD: *Accelerate Diagnostics (Advisory Committee)*

Charles Feldman, MD, PhD: *Aspen GlaxoSmithKline (speaker, Advisory Committee); Pfizer (speaker, Advisory Committee)*

Anna Hemnes, MD: *Actelion (Advisory Committee); Bayer (USA) (consultant: Advisory Committee)*

Ravi Kalhan, MD, MS: *GlaxoSmithKline (research support); PneumRx (research support)*

Augusto A. Litonjua, MD: *Springer Humana Press (author); UpToDate, Inc. (author)*

Geoffrey N. Maksym, PhD: *Thorasys Thoracic Medical Systems Inc. (Advisory Committee, stock/options owned)*

Patricia J. Sime, MD: *Boehringer Ingelheim (consultant); Galecto Pharmaceuticals (Advisory Committee); Intermune Pharmaceuticals (Data and Safety Monitoring Board); Maresins Pharma (Advisory Committee); Pulmonary Fibrosis Foundation (Advisory Committee)*

TABLE OF CONTENTS

ATS 2016 INTERNATIONAL CONFERENCE
MAY 13-18
SAN FRANCISCO, CALIFORNIA

This year the session portion of the Final Program for the ATS International Conference is available in printed and digital format. This publication contains the programs and speakers for the postgraduate courses, scientific and educational sessions presented at the conference.

You can download this PDF, the Conference APP or access the program via the online program itinerary.

1 Friday Postgraduate Courses
13 Saturday Postgraduate Courses
26 Sunday Conference Sessions
133 Monday Conference Sessions
234 Tuesday Conference Sessions
334 Wednesday Conference Sessions

The information contained in this program is up to date as of March 9, 2016. For the most current session information, please visit the online program itinerary.

CLINICAL

POSTGRADUATE COURSE

CME Credits Available: 6.75

PG1 STATE OF THE ART COURSE ON PLEURAL DISEASES: A CASE-BASED APPROACH

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $475 In-Training Member: $300
Non-Member: $550 In-Training Non-Member: $400

Registrants must bring a laptop to the course to view the course material.

Assemblies on Clinical Problems; Allergy, Immunology and Inflammation; Critical Care; Thoracic Oncology

8:00 a.m. - 4:00 p.m. **MOSCONE CENTER**

Room 2011 (West Building, Level 2)

Target Audience
Pulmonologist, thoracic surgeons, critical care specialists, nurses and healthcare professionals involved with the management of patients with pleural diseases.

Objectives
At the conclusion of this session, the participant will be able to:

- manage pleural space infections using the best evidence;
- learn and apply evidence-based approaches to management of patients with malignant pleural effusions;
- learn minimally invasive techniques for the diagnosis and treatment of pleural diseases and refer patients appropriately when needed.

Pleural diseases represent a considerable burden for patients, providers, and the healthcare system as a whole. Traditionally, management of pleural diseases has been based on empiric approaches largely relying on expert opinion and anecdotal evidence. The last decade has witnessed unprecedented research efforts from the pleural community, which have resulted in the development of evidence-based recommendations. In this session, we will review this evidence in a practical case-based format and provide hands-on experience highlighting the techniques now considered standard of care.

Chairing: F. Maldonado, MD, Nashville, TN
N.M. Rahman, MSc, PhD, Oxford, United Kingdom

8:00 **Ultrasound in the Management of Pleural Disease**
J.M. Wrightson, DPhil, MBBChir, MA, Oxford, United Kingdom

8:30 **Evidence-Based Approach to Malignant Pleural Effusions**
N.A. Maskell, MD, Bristol, United Kingdom

9:00 **Modern Approach to Pneumothorax**
R. Hallifax, MD, Oxford, United Kingdom

9:30 **Manometry Should Be Routinely Used During Thoracentesis: A Pro/Con Debate**
D.J. Feller-Kopman, MD, Baltimore, MD
F. Maldonado, MD, Nashville, TN

10:00 *Break*

10:15 **The Landscape of Pleural Space Infections: A Practical Review**
N.M. Rahman, MSc, PhD, Oxford, United Kingdom

10:45 **Pleuroscopy Should Be Performed When the Thoracentesis Is Non-Diagnostic: A Pro/Con Debate**
P. Lee, MBBS, MD, Singapore,
Y.C.G. Lee, MBChB, PhD, Perth, Australia

11:15 **Defining the Specialty: Building a Pleural Service Line**
Y.C.G. Lee, MBChB, PhD, Perth, Australia

11:35 **Panel Discussion**
F. Maldonado, MD, Nashville, TN

12:00 **Lunch**

1:00 **Practical Skills Sessions**

Pleural Manometry
D.R. Nelson, MD, Rochester, MN
F. Maldonado, MD, Nashville, TN

Pleural Ultrasound
J. Cardenas-Garcia, MD, Boston, MA
J.M. Wrightson, DPhil, MBBChir, MA, Oxford, United Kingdom
S. Shojaee, MD, Richmond, VA

Pleuroscopy
N.M. Rahman, MSc, PhD, Oxford, United Kingdom
R.M. Kern, MD, Rochester, MN

Indwelling Pleural Catheters
N.A. Ninan, MD, New Orleans, LA
G.C. Michaud, MD, New York, NY

Small-Bore Chest Tubes
Z.S. DePew, MD, Rochester, MN
R.J. Lentz, MD, Nashville, TN

Intrabronchial Valves for Persistent Air-Leak
C. Gilbert, DO, MS, Seattle, WA
A.C. Argento, MD, Chicago, IL

This session and the International Conference are supported by in-kind grants from ***BD, FUJIFILM SonoSite, Inc.***

All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

CLINICAL

POSTGRADUATE COURSE

CME Credits Available: 7.5

PG2A CRITICAL CARE ULTRASOUND AND ECHOCARDIOGRAPHY: PART I

This is part 1 of a two-part course which includes PG2B on Saturday, May 14. Those registering for PG2A will be registered for PG2A and PG2B.

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $900 In-Training Member: $675
Non-Member: $1,200 In-Training Non-Member: $775

Registrants must bring a laptop to the course to view the course material.

Assembly on Critical Care

8:00 a.m. - 4:00 p.m. **MOSCONE CENTER**

Room 2008 (West Building, Level 2)

Target Audience
Providers of adult and pediatric critical care or emergency medicine.

Objectives
At the conclusion of this session, the participant will be able to:

- apply hands-on ultrasound techniques at bedside to assess critically ill patients and recognize alternative etiologies of shock;
- understand and administer hands-on ultrasound techniques to guide fluid administration in the critically ill patient;
- apply hands-on ultrasound techniques to guide common ICU procedures.

This is a 2-day postgraduate course that consists of didactic lectures and hands-on stations. The focus is primarily bedside transthoracic echocardiography, with some diagnostic ultrasound. The topics include basic and intermediate critical care echocardiography (including hemodynamic measures), assessment of fluid status, procedural guidance for vascular access and thoracentesis, venography. The hands-on stations will include both healthy models and simulators that can demonstrate abnormal pathology. A track will be offered for pediatric intensivists as well, with pediatric intensivists teaching hands-on skills.

Chairing: M.J. Lanspa, MD, MS, Salt Lake City, UT
X. Monnet, MD, PhD, Paris, France

8:00 **Welcome and Introduction to Critical Care Ultrasound: Training and Competency**
M.J. Lanspa, MD, MS, Salt Lake City, UT

8:20 **Basic Physics, Artifacts, Knobology**
Z. Shaman, MD, Cleveland, OH

8:45 **Transthoracic Windows and Views, FATE Exam**
S. Nikravan-Weber, MD, Stanford, CA

9:15 **Basic Evaluation of LV, Systolic Function, Cardiac Output**
S. Price, MBBS, PhD, EDICM, London, United Kingdom

9:45 **Basic Evaluation of RV Size and Function**
A. Leibowitz, MD, Boston, MA

10:15 *Break*

10:30 **Practical Skills Sessions: Hands-On Stations I**

Apical Window
X. Monnet, MD, PhD, Paris, France
T. Brakke, MD, Omaha, NE
Z. Shaman, MD, Cleveland, OH
A. Leibowitz, MD, Boston, MA
L. Grecu, MD, Stony Brook, NY

Parasternal Window
P. Mohabir, MD, Stanford, CA
M. Hamlin, MD, Burlington, VT
J. Kasal, MD, St. Louis, MO
S. Price, MBBS, PhD, EDICM, London, United Kingdom
S. Nikravan-Weber, MD, Stanford, CA

Subcostal Window
C.K. Grissom, MD, Murray, UT
L. Rapoport, MD, Santa Clara, CA
V.A. Dinh, MD, Loma Linda, CA
E. Teo, MD, Atlanta, GA
J.E. Pittman, MD, Salt Lake City, UT

12:00 **Lunch and Clinical Cases**
L. Grecu, MD, Stony Brook, NY

12:45 **Chest Ultrasound: Pneumothorax, Edema, Effusion, and Thoracentesis**
P. Mohabir, MD, Stanford, CA

1:15 **Basic Valvulopathy**
T. Brakke, MD, Omaha, NE

1:45 **Basic Assessment of Diastolic Function**
S.M. Brown, MD, MS, Murray, UT

2:15 *Break*

2:30 **Practical Skills Sessions: Hands-On Station II**

Lung Ultrasound
P. Mohabir, MD, Stanford, CA
L. Rapoport, MD, Santa Clara, CA
V.A. Dinh, MD, Loma Linda, CA
Z. Shaman, MD, Cleveland, OH
E. Hirshberg, MD, MS, Salt Lake City, UT

Diastolic Measurements
J.E. Pittman, MD, Salt Lake City, UT
M. Hamlin, MD, Burlington, VT
S. Price, MBBS, PhD, EDICM, London, United Kingdom
X. Monnet, MD, PhD, Paris, France
A. Leibowitz, MD, Boston, MA

Cardiac Output
L. Grecu, MD, Stony Brook, NY
S. Nikravan-Weber, MD, Stanford, CA
J. Kasal, MD, St. Louis, MO
E. Teo, MD, Atlanta, GA
T. Brakke, MD, Omaha, NE

This session and the International Conference are supported by an in-kind grant from ***FUJIFILM SonoSite, Inc.***

All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

CLINICAL • TRANSLATIONAL

POSTGRADUATE COURSE

CME Credits Available: 6.5

PG3 GENETIC PULMONARY MEDICINE

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $350 In-Training Member: $200
Non-Member: $425 In-Training Non-Member: $300

Registrants must bring a laptop to the course to view the course material.

Assemblies on Allergy, Immunology and Inflammation; Clinical Problems; Respiratory Cell and Molecular Biology

8:00 a.m. - 4:00 p.m. **MOSCONE CENTER**

Room 2003 (West Building, Level 2)

Target Audience
All pulmonary physicians, pulmonary physician assistants, pulmonary fellows who care for patients with respiratory disease.

Objectives
At the conclusion of this session, the participant will be able to:

- recognize and diagnose genetic lung diseases including short telomere syndrome, primary ciliary dyskinesia, surfactant deficiency, LAM and BHD;
- better integrate new treatment options in discussing HHT, CF, or LAM with patients;
- apply basic principles of genetics and genotype-phenotype correlation, together with current classification of genetic variants to better interpret genetic test results.

This course will provide attendees with a comprehensive overview of the ever increasing role of genetics in the practice of pulmonary medicine. Regardless of background, attendees will come away from this course with a solid understanding of the basic principles of clinical genetics. Attendees will understand when to suspect genetic disease in patients with lung disease and will be able to determine if testing in these patients is warranted. Attendees will learn how to interpret genetic test results, and determine when further investigations are required. The course will conclude with an interactive case-based session of four clinical scenarios.

Chairing: B.A. Raby, MD, MPH, Boston, MA
M. Leigh, MD, Chapel Hill, NC

8:00 **Introductions and Outline**
B.A. Raby, MD, MPH, Boston, MA

8:15 **Molecular Genetics 101: Mutations vs SNPs and How They Cause Disease**
L. Yonker, MD, Boston, MA

8:40 **Interpreting Genetic Reports: Is My Mutation Pathogenic?**
S. Amr, PhD, Cambridge, MA

9:20 **Genetic Counseling: Why It Matters**
N. Carmichael, CGC, Boston, MA

9:45 *Break*

10:00 **Neonatal Respiratory Distress: How Rapid Genetic Screening is Changing Clinical Practice**
A. Hamvas, MD, Chicago, IL

10:25 **Interstitial Lung Disease: Telomeres, Surfactant, and All that MUC**
C.K. Garcia, MD, PhD, Dallas, TX

10:50 **Bronchiectasis 1: The Dawn of a New Age in the Treatment of CF**
J.M. Collaco, MD, Baltimore, MD

11:20 **Bronchiectasis 2: Primary Ciliary Dyskinesia - Time for a New Diagnostic Algorithm**
M. Knowles, MD, Chapel Hill, NC

11:45 *LUNCH*

12:45 **Emphysema: Alpha-1-Antitrypsin Deficiency and Beyond**
M. Brantly, MD, Gainesville, FL

1:10 **Cystic Lung Disease: From LAM to Birt-Hogg-Dube**
E. Henske, MD, Boston, MA

1:35 **Pulmonary Vasculopathies: From PPH to HHT**
C.G. Elliott, MD, Murray, UT

2:00 *Break*

2:15 **The Increasingly Blurring of the Lines Between Clinical Practice and Genetic Research**
L.M. Nogee, MD, Baltimore, MD

2:40 **Case-Based Workshop**
B.A. Raby, MD, MPH, Boston, MA
L. Yonker, MD, Boston, MA
N. Carmichael, CGC, Boston, MA
M. Leigh, MD, Chapel Hill, NC

3:50 **Concluding Remarks**
M. Leigh, MD, Chapel Hill, NC

*This session and the International Conference are supported by an educational grant from **Boehringer Ingelheim Pharmaceuticals, Inc.***

All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

BEHAVIORAL • CLINICAL

POSTGRADUATE COURSE

CME Credits Available: 7

Nursing Contact Hours Available: 8.5

PG4 PALLIATIVE CARE IN THE ICU: CLINICAL, ETHICAL, AND RESEARCH CHALLENGES

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $400 In-Training Member: $250
Non-Member: $475 In-Training Non-Member: $350

Registrants must bring a laptop to the course to view the course material.

Assemblies on Behavioral Science and Health Services Research; Critical Care; Nursing

8:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Room 3022 (West Building, Level 3)

Target Audience
Providers in the ICU (physicians, nurses, social workers and therapists) who wish to learn more about the importance of providing effective palliative care(PC) and end of life (EOL) care in the ICU. Additionally, anyone conducting research on dying patients in the ICU will benefit from this course.

Objectives
At the conclusion of this session, the participant will be able to:

- have new strategies to manage the care of the dying patient in the ICU;
- understand the ethical issues related to palliative and end of life care in the ICU and apply the recent ATS guidelines;
- improve communication with dying patients and their families in the ICU.

This novel postgraduate course will focus on providing the learner with the current evidence and best practices for palliative care in the ICU. This course is unique in that it will cover this topic from clinical, ethical and research perspectives, and will be appealing to multiple learners.

Chairing: M.M. Hayes, MD, Boston, MA
J.R. Curtis, MD, MPH, Seattle, WA

8:00 **Welcome and Conference Goals**
J.R. Curtis, MD, MPH, Seattle, WA
M.M. Hayes, MD, Boston, MA

Clinical Challenges

8:10 **Palliative Care (PC) in the ICU**
J.R. Curtis, MD, MPH, Seattle, WA

Case Studies in Specific Difficult EOL Issues

8:55 **Treating Dyspnea in the Dying**
M.L. Campbell, PhD, RN, Detroit, MI

9:25 **EOL in the Oncology ICU: Managing Chemotherapy and Chemotherapists**
R.S. Stephens, MD, Baltimore, MD

9:55 **Practical Considerations for the Withdrawal of ECMO**
D. Brodie, MD, New York, NY

10:25 **What Do We Do with the LVAD?- EOL in the Cardiac ICU**
S.P. Keller, MD, PhD, Pittsburgh, PA

10:55 **Questions and Answers: Panel Discussion**
M.L. Campbell, PhD, RN, Detroit, MI
R.S. Stephens, MD, Baltimore, MD
D. Brodie, MD, New York, NY
S.P. Keller, MD, PhD, Pittsburgh, PA

11:15 *Break*

11:30 **Effective Communications in the ICU**
M.M. Hayes, MD, Boston, MA

11:45 **Simulated Family Meetings**
M.M. Hayes, MD, Boston, MA
D. Lamas, MD, Boston, MA
E.K. Kross, MD, Seattle, WA
J.R. Curtis, MD, MPH, Seattle, WA
G.L. Anesi, MD, MBE, Philadelphia, PA
R.S. Stephens, MD, Baltimore, MD
A.C. Long, MD, MS, Seattle, WA
S.P. Keller, MD, PhD, Pittsburgh, PA
A.E. Turnbull, DVM, MPH, PhD, Baltimore, MD

12:45 *LUNCH*

Ethical Challenges

1:30 **The Ethics of End of Life**
Speaker To Be Announced

2:15 **Ask the Experts :A Multidisciplinary Discussion of the Policy Statement**
J.R. Curtis, MD, MPH, Seattle, WA
G.L. Anesi, MD, MBE, Philadelphia, PA
A.E. Turnbull, DVM, MPH, PhD, Baltimore, MD

2:50 *Break*

Research Challenges

3:00 **Conducting Research on the Dying**
A.E. Turnbull, DVM, MPH, PhD, Baltimore, MD

3:30 **Top 10 PC/EOL in the ICU Studies**
E.K. Kross, MD, Seattle, WA

4:00 **Wrap up, Questions and Answers**
M.M. Hayes, MD, Boston, MA
J.R. Curtis, MD, MPH, Seattle, WA

CLINICAL

POSTGRADUATE COURSE

CME Credits Available: 6.5

PG5 THORACIC IMAGING FOR THE PULMONOLOGIST AND CRITICAL CARE PHYSICIAN

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $350 | In-Training Member: $200
Non-Member: $425 | In-Training Non-Member: $300

Registrants must bring a laptop to the course to view the course material.

Assemblies on Clinical Problems; Microbiology, Tuberculosis and Pulmonary Infections; Pulmonary Circulation; Thoracic Oncology

8:00 a.m. - 4:00 p.m. **MOSCONE CENTER**
Room 3007 (West Building, Level 3)

Target Audience
Pulmonologists, critical care physicians, thoracic surgeons, mid level providers, residents, fellows, and students.

Objectives
At the conclusion of this session, the participant will be able to:

- formulate a differential diagnosis of respiratory diseases based on diagnostic imaging findings;
- improve strategies for the evaluation of solitary pulmonary nodules and for staging lung cancer;
- state the value of a multidisciplinary approach to diagnosis and management of patients with diffuse lung disease.

This course will review major aspects of thoracic imaging with presentations targeted toward the pulmonologist and critical care physician. Subspecialized thoracic radiologists will give lectures focusing on the practical aspects of chest

imaging. Lectures will be image rich and focus on key imaging findings, differential diagnoses, and potential pitfalls. Topics will cover a broad range of chest disease and will be relevant to trainees, generalists, and specialists, alike. At the conclusion of the course, learners will have increased knowledge about thoracic imaging and be able to apply this knowledge to their respective practices.

Chairing: J.P. Kanne, MD, Madison, WI
C.C. Wu, MD, Houston, TX

8:00 **Imaging of Small Airways Diseases**
T.S. Henry, MD, San Francisco, CA

8:30 **Imaging of Large Airways Diseases**
S. Rossi, MD, Buenos Aires, Argentina

9:00 **Imaging of Pulmonary Vascular Diseases**
J.P. Kanne, MD, Madison, WI

9:30 **Pulmonary Thromboembolism**
C. Schaefer-Prokop, MD, Nijmegen, Netherlands

10:00 *Break*

10:15 **Imaging of Pleural Diseases**
C.C. Wu, MD, Houston, TX

10:45 **Solitary Pulmonary Nodule**
J.H. Chung, MD, Chicago, IL

11:15 **Lung Cancer Imaging**
A. Leung, MD, Stanford, CA

11:45 *LUNCH*

12:45 **Pulmonary Infection**
L. Ketai, MD, Albuquerque, NM

1:15 **HRCT of Diffuse Lung Disease**
D.A. Lynch, MD, Denver, CO

1:45 *Break*

2:00 **Multidisciplinary Approach to Diffuse Lung Diseases**
K.K. Brown, MD, Denver, CO
D.A. Lynch, MD, Denver, CO
S. Groshong, MD, Denver, CO

This session and the International Conference are supported by an educational grant from ***AstraZeneca LP.***
All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

BASIC • BEHAVIORAL • CLINICAL • TRANSLATIONAL

POSTGRADUATE COURSE

CME Credits Available: 7.0

Nursing Contact Hours Available: 8.5

PG6 INTERSTITIAL LUNG DISEASE: THE LATEST ON DIAGNOSIS AND MANAGEMENT

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $350 In-Training Member: $200
Non-Member: $425 In-Training Non-Member: $300

Registrants must bring a laptop to the course to view the course material.

Assemblies on Clinical Problems; Allergy, Immunology and Inflammation; Behavioral Science and Health Services Research; Critical Care; Environmental, Occupational and Population Health; Nursing; Pulmonary Rehabilitation

8:00 a.m. - 3:55 p.m. **MOSCONE CENTER**
Room 3016/3018 (West Building, Level 3)

Target Audience
Clinicians, nurses, other allied health staff, researchers, investigators in basic and clinical science pertinent to interstitial lung disease, sponsors for research.

Objectives
At the conclusion of this session, the participant will be able to:

- accurately diagnosis patients with specific forms of ILD;
- understand the current concepts in the pathogenesis and genetic aspects of pulmonary fibrosis and new therapeutic strategies to treat patients with ILD/pulmonary fibrosis;
- provide better care to the patients with ILD through comprehensive management strategies.

This course provides an introduction and update on the diagnosis and management of interstitial lung disease (ILD), with particular attention to the chronic fibrotic ILDs and sarcoidosis. Discussion of the clinical, radiological, and pathological approaches to the diagnosis of ILD will be supplemented by case presentations that illustrate the multidisciplinary nature of diagnosis in action. Additional talks will focus on the comprehensive management of ILD including novel therapies, symptoms management, and lung transplantation.

Chairing: G. Raghu, MD, Seattle, WA
L. Richeldi, MD, PhD, Southampton, United Kingdom

8:00 **Introduction and Conference Goals**
G. Raghu, MD, Seattle, WA

8:05 **Interstitial Lung Disease : An Overview and Approach to Diagnosis**
G. Raghu, MD, Seattle, WA

8:30 **Imaging in ILD: Clues to Diagnosis**
D.A. Lynch, MD, Denver, CO

9:00 **Histopathology Features of ILD**
J.L. Myers, MD, Ann Arbor, MI

9:25 **Connective Tissue Disease for the Pulmonologist in Evaluating Interstitial Lung Disease: A Rheumatologists View**
V. Steen, MD, Washington, DC

9:50 **Genetic Predisposition Factors of Pulmonary Fibrosis: Time for Genetic Screening and Intervention?**
I. Noth, MD, Chicago, IL

10:15 *Break*

10:25 **Hypersensitivity Pneumonitis**
M. Vasakova, MD, PhD, Prague, Czech Republic

10:50 **Pulmonary Fibrosis: Concepts in Pathogenesis and Targets for Treatment**
A.M. Tager, MD, Charlestown, MA

11:15 **Case Discussion with Panel of Experts (Multidisciplinary Discussion)**
B. Collins, MD, Seattle, WA
L. Ho, MD, Seattle, WA

12:15 *LUNCH*

12:45 **Interstitial Lung Disease, Other than IPF Associated with Cigarette Smoking**
K.R. Flaherty, MD, MS, Ann Arbor, MI

1:10 **Lymphangioleiomyomatosis (LAM)**
M. Glassberg, MD, Miami, FL

1:35 **Sarcoidosis: New Treatment Beyond Prednisone and Methotrexate**
D.A. Culver, DO, Cleveland, OH

1:55 **Co-Morbidities in Patients with IPF**
J. Behr, MD, Munich, Germany

2:20 *Break*

2:30 **Idiopathic Pulmonary Fibrosis: Current Treatment, Assessment of Treatment Response and Monitoring Clinical Course**
F.J. Martinez, MD, New York, NY

2:55 **Reducing Symptoms and Cough and Improving Quality of Life for Patients with IPF: Therapeutic Needs Versus Palliative Care**
M. Wijsenbeek, MD, PhD, Rotterdam, Netherlands

3:15 **Lung Transplantation for Patients with ILD**
E.D. Lease, MD, Seattle, WA

3:35 **New Treatment Directions for IPF : Current Status of Ongoing and Upcoming Clinical Trials**
L. Richeldi, MD, PhD, Southampton, United Kingdom

This session and the International Conference are supported by an educational grant from ***Boehringer Ingelheim Pharmaceuticals, Inc.***
All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

BASIC • CLINICAL • TRANSLATIONAL

POSTGRADUATE COURSE

CME Credits Available: 6.25

PG7 PEDIATRIC ACUTE RESPIRATORY DISTRESS SYNDROME: AN EVIDENCE-BASED APPROACH TO MANAGEMENT

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $350 In-Training Member: $200
Non-Member: $425 In-Training Non-Member: $300

Registrants must bring a laptop to the course to view the course material.

Assemblies on Critical Care; Pediatrics

8:00 a.m. - 4:00 p.m. **MOSCONE CENTER**
Room 2005 (West Building, Level 2)

Target Audience
Pediatric intensivists; pediatric pulmonologists; adult intensivists who manage children; respiratory therapists; perfusionists; critical care nurse practioners.

Objectives
At the conclusion of this session, the participant will be able to:

- discuss the optimal conventional ventilatory approach to the child with ARDS;
- explore the recent advances based on published data in the management of the pediatric ARDS patient;
- consider the possibilities for future strategies to further improve clinical outcomes for pediatric ARDS.

The management approach for pediatric acute respiratory distress syndrome has traditionally been based on extrapolated data from adult patients and anecdotal experience in pediatrics. The recent Pediatric Acute Lung Injury Consensus Conference has provided the first pediatric based approach to the management of the child with ARDS. This course will review the available data, explore possible therapeutic options, and discuss recommended approaches to the pulmonary management of the pediatric ARDS patient. Time will be allocated to audience participation via two panel discussions and an interactive case discussion.

Chairing: I.M. Cheifetz, MD, Durham, NC
J. Arnold, MD, Boston, MA

8:00 **Welcome and Introduction**
I.M. Cheifetz, MD, Durham, NC
J. Arnold, MD, Boston, MA

8:10 **Optimizing Conventional Mechanical Ventilation**
I.M. Cheifetz, MD, Durham, NC

8:45 **PEEP Titration/Lung Recruitment**
G. Wolf, MD, Boston, MA

9:20 **High Frequency Oscillatory Ventilation**
J. Arnold, MD, Boston, MA

9:55 *Break*

10:15 **Modes to Augment Patient-Ventilator Synchrony**
G. Emeriaud, MD, PhD, Montreal, Canada

10:50 **Prone Positioning**
M.A.Q. Curley, PhD, RN, Philadelphia, PA

11:25 **Neuromuscular Blockade**
M.C.J. Kneyber, MD, PhD, Groningen, Netherlands

12:00 **Panel Discussion**

12:30 *LUNCH*

1:30 **Inhaled Nitric Oxide**
A. Rotta, MD, Cleveland, OH

2:00 **Venovenous ECMO**
H.J. Dalton, MD, Anchorage, AK

2:30 *Break*

2:50 **Case Discussion**
I.M. Cheifetz, MD, Durham, NC
M.A.Q. Curley, PhD, RN, Philadelphia, PA

3:25 **Panel Discussion**

3:50 **Course Summary**
I.M. Cheifetz, MD, Durham, NC
J. Arnold, MD, Boston, MA

CLINICAL

POSTGRADUATE COURSE

CME Credits Available: 6.75

Nursing Contact Hours Available: 8.1

PG8 CRITICAL CARE MEDICINE FOR ADVANCED PRACTICE PROVIDERS (NP/PA)

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $200 In-Training Member: $125
Non-Member: $238 In-Training Non-Member: $175

Registrants must bring a laptop to the course to view the course material.

Assemblies on Nursing; Critical Care

8:00 a.m. - 4:00 p.m. **MOSCONE CENTER**

Room 2024 (West Building, Level 2)

Target Audience
Advanced practice providers including nurse practitioners (NP) and physician assistants (PA) who work in critical care, NP and PA students, and critical care nurses.

Objectives
At the conclusion of this session, the participant will be able to:

- evaluate and manage patients with critical illness, including acute respiratory failure, acute respiratory distress syndrome, shock, sepsis, and nosocomial infections;
- develop a systematic approach to chest radiograph interpretation, arterial blood gas interpretation, and mechanical ventilation troubleshooting;
- describe a basic approach to the use of sedation and analgesia in the intensive care unit, including methods of assessment for sedation and delirium.

This postgraduate course is designed for advanced practice providers and is comprised of nine 45-minute sessions on core critical care topics. The talks will have a focus on evidence-based management of commonly encountered conditions such as acute respiratory failure, shock, sepsis, and nosocomial infections. Skill based sessions on chest radiograph interpretation, arterial blood gas interpretation, and mechanical ventilation troubleshooting will be included. Sessions will be designed to be interactive and case-based, with opportunities for breakout sessions and team-based problem solving.

Chairing: B. Coruh, MD, Seattle, WA
L.D. Rosenthal, ACNP, DNP, Aurora, CO

8:00 **Acute Respiratory Failure**
G.A. Schmidt, MD, Iowa City, IA

8:45 **Mechanical Ventilation**
B. Coruh, MD, Seattle, WA

9:30 *Break*

9:45 **Acute Respiratory Distress Syndrome**
P. Senecal, ACNP, CCNS, Aurora, CO

10:30 **Sedation, Analgesia, and Delirium**
L.D. Rosenthal, ACNP, DNP, Aurora, CO

11:15 **Shock and Vasopressors**
D. Holloway, ACNP, MSN, Cleveland, OH

12:00 *LUNCH*

12:45 **Sepsis**
C. Parkinson, ACNPC-AG, CCRN, MSN, Denver, CO

1:30 **Nosocomial Infections in the ICU**
A.S. Clay, MD, Durham, NC

2:15 *Break*

2:30 **Acid-Base**
J.T. Poston, MD, Chicago, IL

3:15 **Chest Radiograph Interpretation**
A.M. Luks, MD, Seattle, WA

BASIC • CLINICAL • TRANSLATIONAL

POSTGRADUATE COURSE

CME Credits Available: 7.0

PG9 THE PHYSIOLOGY OF PEDIATRIC RESPIRATORY FAILURE

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $350 In-Training Member: $200
Non-Member: $425 In-Training Non-Member: $300

Registrants must bring a laptop to the course to view the course material.

Assemblies on Pediatrics; Clinical Problems; Critical Care; Pulmonary Circulation; Respiratory Cell and Molecular Biology; Respiratory Structure and Function

8:00 a.m. - 4:00 p.m. **MOSCONE CENTER**

Room 3014 (West Building, Level 3)

Target Audience
Fellows in training as well as established physicians in the practice of pediatric pulmonology, critical care or neonatal medicine who are interested in reviewing basic physiology principles as they apply to clinical care.

Objectives
At the conclusion of this session, the participant will be able to:

- apply several basic respiratory principles to the diagnosis and management of children with respiratory failure;
- learn how physiologic measurements can be used to change interventions and enhance outcomes;
- identify the rationale for several measurement techniques and determine when these should be used.

The course will consist of a series of grouped lectures covering several topics in pediatric respiratory physiology, using respiratory failure as the unifying theme. The talks will review both normal physiological principles of a clinically important topic and the pathophysiology that leads to the particular problem being discussed. In addition, the physiology of several different forms of mechanical ventilation will be reviewed, and important distinctions in the underlying normal and abnormal physiological processes leading to respiratory failure between neonates, children and adults will be highlighted. An interactive format, using questions from the speakers and audience touch pads to give answers will be used to enhance audience participation, and to allow the participant to understand key concepts or to identify areas requiring additional study.

Chairing: H.B. Panitch, MD, Philadelphia, PA
J.L. Allen, MD, Philadelphia, PA

8:00 **Lung Development and Neonatal Predisposition to Respiratory Failure**
M.J. Wallace, PhD, Melbourne, Australia

8:35 **Acute and Chronic Neonatal Respiratory Failure**
L.D. Nelin, MD, Columbus, OH

9:10 **The Physiology of Pediatric Ventilator-Induced Lung Injury**
M.C.J. Kneyber, MD, PhD, Groningen, Netherlands

9:45 *Break*

9:55 **High Frequency Oscillatory Ventilation**
J.L. Allen, MD, Philadelphia, PA

10:30 **Lung Mechanics and Respiratory Failure**
J.P. Needleman, MD, Brooklyn, NY

11:05 **Ventilator Graphics**
H.B. Panitch, MD, Philadelphia, PA

11:40 *LUNCH*

12:20 **Cardiopulmonary Interactions**
S. Lakshminrusimha, MD, Buffalo, NY

12:55 **Positive and Negative Pressure Ventilation**
G. Kurland, MD, Pittsburgh, PA

1:30 **Respiratory Muscles, Failure and Ventilator-Induced Diaphragm Injury**
G.J. Redding, MD, Seattle, WA

2:05 *Break*

2:15 **Weaning in Pediatric Acute Respiratory Failure**
S. Venkataraman, MD, Pittsburgh, PA

2:50 **Weaning and Chronic Respiratory Failure**
T.G. Keens, MD, Los Angeles, CA

3:25 **Respiratory Muscle Weakness, Posture and Pulmonary Rehabilitation**
M. Massery, PT, DPT, DSc, Glenview, IL

BASIC • CLINICAL • TRANSLATIONAL

POSTGRADUATE COURSE

CME Credits Available: 7.25

PG10 AIRWAY REMODELING IN HUMAN LUNG DISEASE: A BIG LAB MEETING 2016

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $350 In-Training Member: $200
Non-Member: $425 In-Training Non-Member: $300

Registrants must bring a laptop to the course to view the course material.

Assemblies on Respiratory Cell and Molecular Biology; Allergy, Immunology and Inflammation; Clinical Problems; Critical Care; Environmental, Occupational and Population Health; Microbiology, Tuberculosis and Pulmonary Infections; Pediatrics; Pulmonary Circulation; Pulmonary Rehabilitation; Respiratory Structure and Function; Sleep and Respiratory Neurobiology; Thoracic Oncology

8:00 a.m. - 4:00 p.m. **MOSCONE CENTER**

Room 2022 (West Building, Level 2)

Target Audience
Lung health care providers, clinical and research fellow, investigators interested or involved in basic, translational and clinical research related to airway biology and pathogenesis of chronic lung diseases, research and care providers engaged in pulmonary and critical care medicine.

Objectives
At the conclusion of this session, the participant will be able to:

- understand fundamental principles, heterogeneous phenotypes and specific mechanisms of airway remodeling in chronic human lung diseases; and how different cell types in the human airways interact with each other during the development of disease-associated remodeling phenotypes.
- learn about advanced state of art methods and technologies to model and study human airway remodeling using patient derived samples.
- implement current knowledge about airway remodeling in everyday research and understand how to translate the novel knowledge about complex mechanisms and phenotypes of airway remodeling into clinically relevant precision medicine approaches to better prevent, diagnose and treat human lung disease in a personalized manner.

This course will have an innovative, “lab meeting” format, first successfully introduced at the ATS International Conference in 2015 by Dr. Shaykhiev and colleagues. As compared to the prior “big lab meeting” postgraduate course (PG25), which was focused on airway epithelium, the specific theme of the current session - airway remodeling - is broader and more multidisciplinary and translational in nature. The course will provide discussion of recent advancements in understanding of the contributions of and interactions among various tissue components (epithelium, fibroblasts, extracellular matrix, smooth muscle cells, vasculature, and innate immune cells) to airway remodeling in human chronic lung diseases. Special emphasis will be made on personalized approaches to study human airway remodeling and novel precision medicine approaches to prevent and treat lung diseases characterized by airway remodeling.

Chairing: R. Shaykhiev, MD, PhD, New York, NY
M. Konigshoff, MD, PhD, Munich, Germany
R. Freishtat, MD, MPH, Washington, DC

8:00 **Airway Remodeling: Introduction to a Big Lab Meeting 2016**
M. Konigshoff, MD, PhD, Munich, Germany

8:10 **Keynote Lecture: The Many Faces of Airway Remodeling in Lung Disease**
J.C. Hogg, MD, PhD, Vancouver, Canada

8:40 **Basal Stem Cells and Airway Remodeling in COPD**
R. Shaykhiev, MD, PhD, New York, NY

9:00 **Cellular Origins of Airway Remodeling in Asthma**
T. Hackett, PhD, Vancouver, Canada

9:20 **Airway Regeneration and Remodeling in Cystic Fibrosis**
C. Coraux, PhD, Reims, France

9:40 **Patient-Derived Models of Airway Remodeling**
S.H. Randell, PhD, Chapel Hill, NC

10:00 *Break*

10:10 **Extracellular Matrix, Mechanotransduction and Airway Remodeling**
D. Tschumperlin, PhD, Rochester, MN

10:30 **Epithelial-Matrix Interactions in Preclinical Models of Asthma**
R. Freishtat, MD, MPH, Washington, DC

10:50 **Airway Fibroblasts and Subepithelial Fibrosis in Asthma**
M. Kraft, MD, Tucson, AZ

11:10 **Angiogenesis and Vascular Remodeling in Chronic Lung Diseases**
E.H. Walters, DM, DSc, Hobart Tasmania, Australia

11:30 *Break*

11:45 **Luncheon Sessions: Airway Inflammation, Remodeling, and Disease**

Keynote Lecture: Inflammatory Mechanisms and Structural Changes in Airway Disease
P.J. Barnes, MD, DSc, London, United Kingdom

How Innate Immunity Contributes to Airway Remodeling in Lung Disease
M.J. Holtzman, MD, St. Louis, MO

Mechanisms Linking Inflammation and Airway Fibrosis in COPD
S. Nishimura, MD, San Francisco, CA

Mast Cells and Airway Smooth Muscle Remodeling in Asthma and COPD
C.E. Brightling, BSc, MBBS, PhD, Leicester, United Kingdom

Molecular Signatures of Airway Remodeling: Towards Precision Medicine
M. van den Berge, MD, Groningen, Netherlands

1:45 *Break*

2:00 **"A Big Lab Meeting"**
R. Shaykhiev, MD, PhD, New York, NY
M. Konigshoff, MD, PhD, Munich, Germany
R. Freishtat, MD, MPH, Washington, DC
J.C. Hogg, MD, PhD, Vancouver, Canada
T. Hackett, PhD, Vancouver, Canada
C. Coraux, PhD, Reims, France
S.H. Randell, PhD, Chapel Hill, NC
D. Tschumperlin, PhD, Rochester, MN
M. Kraft, MD, Tucson, AZ
E.H. Walters, DM, DSc, Hobart Tasmania, Australia
P.J. Barnes, MD, DSc, London, United Kingdom
M.J. Holtzman, MD, St. Louis, MO
S. Nishimura, MD, San Francisco, CA
C.E. Brightling, BSc, MBBS, PhD, Leicester, United Kingdom
M. van den Berge, MD, Groningen, Netherlands

CLINICAL

POSTGRADUATE COURSE

CME Credits Available: 6.75

PG11 TESTING IN THE PULMONARY FUNCTION LAB: FROM PHYSIOLOGY TO CLINICAL PRACTICE

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $350 In-Training Member: $200
Non-Member: $425 In-Training Non-Member: $300

Registrants must bring a laptop to the course to view the course material.

Assemblies on Respiratory Structure and Function; Clinical Problems

8:00 a.m. - 4:00 p.m. **MOSCONE CENTER**

Room 2014 (West Building, Level 2)

Target Audience
Current and future directors of PFT labs, attending physicians, respiratory therapists, trainees, fellows, and other interested health care providers.

Objectives
At the conclusion of this session, the participant will be able to:

- interpret with confidence basic and advanced PFT results;
- expand their interpretation repertoire to more involved and complicated spirometry, lung volumes, DLCO and pediatric test results;
- gain insight into the use and helpfulness of more advanced PFT testing modalities.

This course will review the physiologic underpinnings and basic concepts behind routine pulmonary function testing. Speakers will then address more advanced material and emerging testing modalities. Using an audience response system with a case-based approach, we will address which test to order, interpretation of basic and complex testing results, and troubleshooting equipment or technical issues. An expert in each topic will explain the evidence or rationale for right and wrong answers. The audience will have the opportunity to bring cases and questions for an interactive discussion.

Chairing: M.C. McCormack, MD, MHS, Baltimore, MD
D.A. Kaminsky, MD, Burlington, VT
C.E. Berry, MD, Tucson, AZ

8:00 **Introduction to Pulmonary Function Testing from Simple to Complex**
M.C. McCormack, MD, MHS, Baltimore, MD

8:10 **Lung Function Across the Ages**
M. Rosenfeld, MD, MPH, Seattle, WA

8:40 **As You Predicted...Interpretation of Spirometry and Updates In Reference Equations**
B.H. Culver, MD, Olga, WA

9:10 **When Size Matters- Measurement of Lung Volumes**
B. Borg, BAppSc, CRFS, Prahran, Australia

9:40 *Break*

9:55 **Clearing Up the Confusion Between DLCO and KCO (DLCO/VA)**
C.E. Berry, MD, Tucson, AZ

10:25 **Advanced Troubleshooting for Pulmonary Function Equipment**
G.L. Ruppel, MEd, RRT, RPFT, St. Louis, MO

10:55 **Make Your Case**
G. Hall, PhD, Subiaco, Australia

11:25 *LUNCH*

12:15 **The Forced Oscillation Technique: What's Forced? What's Oscillating? And How Can We Use It?**
D.A. Kaminsky, MD, Burlington, VT

12:45 **Measuring Airways Inflammation in the PFT Lab (Use of Fractional Exhaled Nitric Oxide)**
M.C. McCormack, MD, MHS, Baltimore, MD

1:15 **Going the Distance with High Altitude Simulation Testing**
C.D. Mottram, RRT, RPFT, Rochester, MN

1:45 *Break*

2:00 **Do We Have Clearance? The Use of Multiple Breath Nitrogen Washout**
P. Latzin, MD, PhD, Basel, Switzerland

2:30 **Bronchoprovocation Testing**
T.S. Hallstrand, MD, MPH, Seattle, WA

3:00 **Approaching the Patient with Suspected Neuromuscular Weakness**
N. Lechtzin, MD, Baltimore, MD

3:30 **Complex Cases**
D. Weiner, MD, Pittsburgh, PA

BEHAVIORAL • CLINICAL • TRANSLATIONAL

POSTGRADUATE COURSE

CME Credits Available: 6.75

PG12 SLEEP AND CRITICAL ILLNESS: BRIDGING THE TWO PILLARS!

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $350 In-Training Member: $200
Non-Member: $425 In-Training Non-Member: $300

Registrants must bring a laptop to the course to view the course material.

Assemblies on Sleep and Respiratory Neurobiology; Clinical Problems; Critical Care; Nursing; Pediatrics

8:00 a.m. - 4:00 p.m. **MOSCONE CENTER**

Room 3020 (West Building, Level 3)

Target Audience
Critical care and sleep physicians, nurses, researchers, trainees, and pharmacists.

Objectives
At the conclusion of this session, the participant will be able to:

- learn new findings about the mechanistic underpinnings of the interactions between sleep, circadian rhythms and critical illness;
- gain new strategies to manage the care of critically ill patients with sleep disturbances;
- improve the quality of life/health status of their critically ill patients by improving their sleep and circadian rhythms.

Sleep and critical illness are individually complex processes with significant implications to health and well being. The interaction between these two complex spheres can cause morbidity and mortality during critical illness and furthermore leave sequelae upon recovery. Sleep and circadian derangements and disorders are common in patients suffering from critical illness. Identifying the pathophysiology of sleep and circadian derangements in critically ill patients and instituting appropriate management improves sleep disturbances and may provide long term benefit. This postgraduate course will discuss the mechanistic underpinnings of the interactions between sleep, circadian rhythms and critical illness; the clinical implications of such complex interactions; and raise awareness and insights of clinicians and scientists.

Chairing: B.K. Gehlbach, MD, Iowa City, IA
R.L. Owens, MD, La Jolla, CA
M. Knauert, MD, PhD, New Haven, CT

8:00 **Introduction: Sleep and Critical Illness: The Two Pillars Shall Meet!**
S. Parthasarathy, MD, Tucson, AZ

8:10 **Neurobiology of Sleep and Sedation: Sleep = Sedation?**
M. Maze, MBChB, San Francisco, CA

8:40 **Circadian "Dys-Rhythms" of Critical Illness**
B.K. Gehlbach, MD, Iowa City, IA

9:10 **Measuring Sleep During Critical Illness: A Challenge?**
R.L. Owens, MD, La Jolla, CA

9:40 **Sleep and Mechanical Ventilation: Modes and Mechanics**
K. Bosma, MD, Ontario, Canada

10:10 *Break*

10:25 **Surviving Critical Illness but Suffering Sleep Problems and Sleep Deprivation**
S. McKinley, RN, PhD, Sydney, Australia

10:55 **Perceived Sleep Quality and Cognition**
B. Kamdar, MD, MBA, MHS, Los Angeles, CA

11:25 **Sedation Interventions During Critical Illness: More or Less?**
M. Pisani, MD, New Haven, CT

11:55 **Sleep, Critical Illness and the Developing Brain: The Pediatric ICU**
S.R. Kudchadkar, MD, Baltimore, MD

12:25 *LUNCH*

1:20 **Sleep and Death: Poor Sleep Leads to Eternal Sleep?**
P. Watson, MD, Nashville, TN

1:50 **Environmental Interventions to Promote Sleep: More than Just Noise?**
M. Knauert, MD, PhD, New Haven, CT

2:20 *Break*

2:30 **Sleep-Disordered Breathing During Critical Illness: Don't Stop Breathing!**
V. Malik, MD, Denver, CO

3:00 **Non-Invasive Ventilation During Critical Illness: Sleep Mask?**
X. Drouot, MD, PhD, Poitiers, France

3:30 **Sleep Promotion as a Patient-Centered Outcome: Sleep, Nourish, and Heal**
S. Parthasarathy, MD, Tucson, AZ

BEHAVIORAL • CLINICAL

POSTGRADUATE COURSE

CME Credits Available: 7.0

PG13 IMPLEMENTATION OF CORE COMPONENTS OF A LUNG CANCER SCREENING PROGRAM

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $350 In-Training Member: $200
Non-Member: $425 In-Training Non-Member: $300

Registrants must bring a laptop to the course to view the course material.

Assemblies on Thoracic Oncology; Behavioral Science and Health Services Research; Nursing

8:00 a.m. - 4:00 p.m. **MOSCONE CENTER**
Room 3011 (West Building, Level 3)

Target Audience
Physicians, nurses, and advanced practice nurses who are actively engaged in lung cancer screening or considering starting lung cancer screening programs.

Objectives
At the conclusion of this session, the participant will be able to:

- demonstrate an in depth understanding of the critical components of a lung cancer screening program;
- summarize the national screening recommendations and requirements in the provision of lung cancer screening;
- describe how to implement a safe and responsible lung cancer screening program.

This postgraduate course is organized to give participants the critical components of a responsible lung cancer screening program. Each critical component will be discussed in a panel format with 2 discussants followed by question and answer period. Evidence-based presentations will provide both knowledge and tangible tools for direct application to their respective programs. As an example the importance of shared decision making will be discussed and supported by the ATS tool for achieving effective shared decision making, this approach will be replicated for each component giving participants both the knowledge and the tools for effective lung cancer screening.

Chairing: J.A. Gorden, MD, Seattle, WA
C.G. Slatore, MD, Portland, OR
J.T. Fathi, DNP, ARNP, Seattle, WA

8:00 **Introduction**
J.A. Gorden, MD, Seattle, WA

8:10 **Patient and Provider Education. Shared Decision Making. What Do Patients Hear?**
C.G. Slatore, MD, Portland, OR

8:50 **CT Scan Performance, Nodule Identification and Structured Reporting (Standardization of Imaging and Reporting, LungRads and ACR/CMS Registry Data Base)**
E. Kazerooni, MD, Ann Arbor, MI

9:30 *Break*

9:40 **Screening Eligibility and the Referral. Who Is Offered Screening and for How Long (Avoiding Emotional Screening)**
N.T. Tanner, MD, MSCR, Charleston, SC

10:20 **Smoking Cessation (Effective Approaches to Counseling and Treatment in the Setting of Lung Cancer Screening)**
J.T. Fathi, ARNP, DNP, Seattle, WA

11:00 **Practical Implementation of a Lung Cancer Screening Program: Example 1 - Yale University**
P. Sather, APRN, New Haven, CT

11:30 **Panel Discussion**

12:00 *LUNCH*

12:45 **Nodule Management 1-7 mm. The Case for Watchful Waiting (Surveillance Intervals Understanding Nodule Change)**
M.K. Gould, MD, MS, Pasadena, CA

1:15 **Lung Nodule Management>8mm (Utilization of National Guidelines Counseling in the Face of the Anxious Patient)**
G.A. Silvestri, MD, Charleston, SC

1:45 *Break*

1:55 **Thoracic Surgery and the Multidisciplinary Lung Cancer Screening Program**
F.C. Detterbeck, MD, New Haven, CT

2:35 **Multidisciplinary Approaches to Nodule Sampling**
J.A. Gorden, MD, Seattle, WA

2:55 **Practical Implementation and Financial Model of an Innovative Lung Cancer Screening Program: Example 2 - Swedish Cancer Institute**
J.T. Fathi, ARNP, DNP, Seattle, WA

3:20 **Panel Discussion**

*This session and the International Conference are supported by an educational grant from **AstraZeneca LP.***
All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

CLINICAL

POSTGRADUATE COURSE

CME Credits Available: 6.75

PG14 PULMONARY AND CRITICAL CARE REVIEWS: BUILT AROUND THE 2015 ABIM-SEP MODULES

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $350 In-Training Member: $200
Non-Member: $425 In-Training Non-Member: $300

Education Committee

8:00 a.m. - 4:00 p.m. **MOSCONE CENTER**
Room 2016 (West Building, Level 2)

Target Audience
Clinicians practicing pulmonary and/or critical care medicine; clinicians seeking ABIM MOC credit.

Objectives

At the conclusion of this session, the participant will be able to:

- critically review and interpret recent literature in pulmonary and critical care medicine;
- apply recent literature in pulmonary and critical care medicine to clinical practice;
- complete the 2015 ABIM Pulmonary and Critical Care SEP module.

Led by expert faculty, this active learning course is a clinical practice and literature review designed around the most recent ABIM Self Evaluation Process modules in pulmonary and critical care medicine. In addition to a valuable review of high impact medical knowledge and critical thinking, this session will provide a convenient opportunity to fulfill ABIM maintenance of certification requirements while at the ATS international conference.

Chairing: J.T. Poston, MD, Chicago, IL

8:00 **Introduction**
J.T. Poston, MD, Chicago, IL

8:10 **Critical Care Review**
J.B. Hall, MD, Chicago, IL

9:50 *Break*

10:00 **Critical Care Review**
J.T. Poston, MD, Chicago, IL

11:40 *LUNCH*

12:30 **Pulmonary Review**
J. Mandel, MD, La Jolla, CA

2:10 *Break*

2:20 **Pulmonary Review**
K.A. Smith, MD, Philadelphia, PA

CLINICAL

POSTGRADUATE COURSE

CME Credits Available: 7.5

PG2B CRITICAL CARE ULTRASOUND AND ECHOCARDIOGRAPHY: PART II

This is part 2 of a two-part course which includes PG2A on Friday, May 13.

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

See PG2A for course fees.

Registrants must bring a laptop to the course to view the course material.

Assembly on Critical Care

8:00 a.m. - 4:00 p.m. **MOSCONE CENTER**

Room 2008 (West Building, Level 2)

Target Audience
Providers of adult and pediatric critical care or emergency medicine.

Objectives
At the conclusion of this session, the participant will be able to:

- apply hands-on ultrasound techniques at bedside to assess critically ill patients and recognize alternative etiologies of shock;
- understand and administer hands-on ultrasound techniques to guide fluid administration in the critically ill patient;
- apply hands-on ultrasound techniques to guide common ICU procedures.

This is a 2-day post-graduate course that consists of didactic lectures and hands-on stations. The focus is primarily bedside transthoracic echocardiography, with some diagnostic ultrasound. The topics include basic and intermediate critical care echocardiography (including hemodynamic measures), assessment of fluid status, procedural guidance for vascular access and thoracentesis, venography. The hands-on stations will include both healthy models and simulators that can demonstrate abnormal pathology. A track will be offered for pediatric intensivists as well, with pediatric intensivists teaching hands-on skills.

Chairing: M.J. Lanspa, MD, MS, Salt Lake City, UT
X. Monnet, MD, PhD, Paris, France

8:00 **Vascular Ultrasound: DVT Evaluation**
L. Rapoport, MD, Santa Clara, CA

8:20 **Vascular Access**
M.J. Lanspa, MD, MS, Salt Lake City, UT

8:45 **Tamponade: Diagnosis and Physioloy**
C.K. Grissom, MD, Murray, UT

9:15 **Using Ultrasound to Assess Intravascular Volume and Fluid Responsiveness**
X. Monnet, MD, PhD, Paris, France

9:45 **Ultrasound for Diuresis and Dialysis**
E. Hirshberg, MD, MS, Salt Lake City, UT

10:15 *Break*

10:30 **Practical Skills Sessions: Hands-On Station III**

Volume Status
X. Monnet, MD, PhD, Paris, France
P. Mohabir, MD, Stanford, CA
J. Kasal, MD, St. Louis, MO
E. Teo, MD, Atlanta, GA
A. Leibowitz, MD, Boston, MA

Tamponade Evaluation
M. Hamlin, MD, Burlington, VT
C.K. Grissom, MD, Murray, UT
S. Price, MBBS, PhD, EDICM, London, United Kingdom
S. Nikravan-Weber, MD, Stanford, CA
T. Brakke, MD, Omaha, NE

Vascular Ultrasound
L. Rapoport, MD, Santa Clara, CA
V.A. Dinh, MD, Loma Linda, CA
Z. Shaman, MD, Cleveland, OH
L. Grecu, MD, Stony Brook, NY
J.E. Pittman, MD, Salt Lake City, UT

12:00 **Lunch and Clinical Cases**
E. Teo, MD, Atlanta, GA

12:45 **Abdominal Ultrasonography: Hydronephrosis, Ascites, Paracentesis, FAST Exam**
V.A. Dinh, MD, Loma Linda, CA

1:15 **Goal Directed Management of Shock Using Echocardiography**
J. Kasal, MD, St. Louis, MO

1:45 **Incorporating Echocardiography into Shock and CPR**
M. Hamlin, MD, Burlington, VT

2:15 *Break*

2:30 **Practical Skills Sessions: Hands-On Session IV**

Echo in Shock and CPR
P. Mohabir, MD, Stanford, CA
S. Nikravan-Weber, MD, Stanford, CA
T. Brakke, MD, Omaha, NE
S. Price, MBBS, PhD, EDICM, London, United Kingdom
L. Grecu, MD, Stony Brook, NY

Abdominal Ultrasound
L. Rapoport, MD, Santa Clara, CA
V.A. Dinh, MD, Loma Linda, CA
Z. Shaman, MD, Cleveland, OH
A. Leibowitz, MD, Boston, MA
J.E. Pittman, MD, Salt Lake City, UT

Ask the Expert
E. Hirshberg, MD, MS, Salt Lake City, UT
J. Kasal, MD, St. Louis, MO
X. Monnet, MD, PhD, Paris, France
M. Hamlin, MD, Burlington, VT
E. Teo, MD, Atlanta, GA

This session and the International Conference are supported by an in-kind grant from ***FUJIFILM SonoSite, Inc.***
All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

CLINICAL

POSTGRADUATE COURSE

CME Credits Available: 7.0

PG15 BRONCHOSCOPY COURSE AND WORKSHOP

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $475 In-Training Member: $300
Non-Member: $550 In-Training Non-Member: $400

Registrants must bring a laptop to the course to view the course material.

Assemblies on Clinical Problems; Behavioral Science and Health Services Research; Thoracic Oncology

8:00 a.m. - 4:00 p.m. **MOSCONE CENTER**
Room 2005 (West Building, Level 2)

Target Audience
Pulmonary and thoracic surgery fellows in training, allied health professionals, anesthesiologists and those interested in quality improvement and implementation of clinical programs.Clinicians interested in skills in basic bronchoscopy.

Objectives
At the conclusion of this session, the participant will be able to:

- understand how to apply the techniques and principles of bronchoscopy, using both didactic teaching methods as well as hands-on training;
- support the standardization and the practice of bronchoscopy.

The bronchoscopy course and workshop addresses evidence-based bronchoscopy topics pertinent to core skills in an accredited pulmonary fellowship program. Techniques covered include various diagnostic skills with airway examination, biopsy of lung parenchyma and lymph nodes,as well as incorporating new technologies to apply to management of patients with chest and/or airway diseases.

Chairing: J.A. Gorden, MD, Seattle, WA
A.W. Sung, MD, Stanford, CA
K.L. Kovitz, MD, MBA, Elk Grove Village, IL

8:00 **Airway Anatomy**
C.R. Lamb, MD, Burlington, MA

8:20 **Indications and Contraindications of Bronchoscopy**
J.A. Gorden, MD, Seattle, WA

8:40 **Management Pneumothorax and Hemoptysis: Risk Factors and Management**
M.G. Slade, MBBS, Cheltenham, United Kingdom

9:00 **Coding and Documentation**
K.L. Kovitz, MD, MBA, Elk Grove Village, IL

9:15 **Lung Cancer Staging**
K. Czarnecka, MD, MPH Toronto, Canada

9:35 **Lung Cancer: EBUS/Radial EBUS**
F.J.F. Herth, MD, Heidelberg, Germany

9:55 Break

10:05 **Bronchoscopy in OB Patients and Patients with Trauma**
J.A. Akulian, MD, MPH, Chapel Hill, NC

10:20 **Quality Improvement Tools**
A.W. Sung, MD, Stanford, CA
S. Shojaee, MD, Richmond, VA

10:35 **Bronchoscopy of the Child**
A.G. Vicencio, MD, New York, NY

10:50 **Surgical Management of Airways Disease**
S.K. Ashiku, MD, Oakland, CA

11:05 **Conscious Sedation**
C. Gilbert, DO, MS, Seattle, WA

11:20 *LUNCH*

12:05 **Practical Skills Sessions**
J.A. Gorden, MD, Seattle, WA
A.W. Sung, MD, Stanford, CA
K.L. Kovitz, MD, MBA, Elk Grove Village, IL
C.R. Lamb, MD, Burlington, MA
M.G. Slade, MBBS, Cheltenham, United Kingdom
J.A. Akulian, MD, MPH, Chapel Hill, NC
K. Czarnecka, MD,MPH Toronto, Canada

This session and the International Conference are supported by educational grants from ***AstraZeneca LP, Boston Scientific Corporation, Inc.***
This session and the International Conference are supported by in-kind grants from ***Boston Scientific Corporation, Inc., ERBE USA, Inc., Smiths Medical, Veran Medical Technologies.***
All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

BASIC • CLINICAL • TRANSLATIONAL

POSTGRADUATE COURSE

CME Credits Available: 7.5

PG16 HETEROGENEITY AND PLASTICITY OF LUNG MACROPHAGES: TOWARDS PRECISION MEDICINE

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $350 In-Training Member: $200
Non-Member: $425 In-Training Non-Member: $300

Registrants must bring a laptop to the course to view the course material.

Assemblies on Allergy, Immunology and Inflammation; Clinical Problems; Critical Care; Environmental, Occupational and Population Health; Microbiology, Tuberculosis and Pulmonary Infections; Pediatrics; Pulmonary Circulation; Respiratory Cell and Molecular Biology; Respiratory Structure and Function; Thoracic Oncology

8:00 a.m. - 4:00 p.m. **MOSCONE CENTER**

Room 2022 (West Building, Level 2)

Target Audience
Lung health care providers, scientists and investigators interested or involved in basic and/or translational research related to lung biology, immunology, pathology, physiology, mechanisms and biologic phenotypes of human lung disease; research and care providers engaged in pulmonary and critical care medicine.

Objectives
At the conclusion of this session, the participant will be able to:

- understand fundamental principles of macrophage origins, nomenclature, markers/phenotypes, functions in lung immunity and tissue homeostasis;
- learn about novel state of art technologies that can be utilized to study human lung macrophages at the molecular (genome, transcriptome, epigenetics, bioinformatics, single cell analysis), and cellular (advanced imaging and molecular phenotyping methods, single cell analysis) levels and how information obtained using these methods can be used to better understand the role of macrophages in the pathogenesis of human lung diseases;
- understand how to translate the novel knowledge about lung macrophage heterogeneity, plasticity, and polarization into clinically relevant precision medicine approaches to better prevent, diagnose and treat human lung diseases in a personalized manner.

This postgraduate course is focused on:(1)recent advances in understanding of the origin, phenotypic and functional diversity, plasticity, polarization programs and local homeostasis of lung macrophages;(2)pathologic programming of macrophages in human lung disease;(3)the role of macrophages in lung host defense, inflammation and regeneration;(4)state of art personalized analysis of human lung macrophage biology; and(5)macrophage-based precision medicines for human lung disease.

Chairing: R. Shaykhiev, MD, PhD, New York, NY
A. Haczku, MD, PhD, Davis, CA
D. Singh, MD, Manchester, United Kingdom

8:00 **Introduction**
A. Haczku, MD, PhD, Davis, CA

8:10 **Keynote Lecture: Identity and Self-Renewal of Tissue Macrophages**
M.H. Sieweke, PhD,Marseille, France

8:40 **Unique Origins and Differentiation Pathways of Lung Macrophages**
M. Kopf, PhD, Zurich, Switzerland

9:10 **Macrophage Heterogeneity in the Human Lung**
C. Jakubzick, PhD, Denver, CO

9:35 **Live Imaging of Macrophage - Epithelium Interactions in the Lung**
J. Bhattacharya, MD, DPhil, New York, NY

10:00 *Break*

10:15 **Transcriptional Programming of Human Macrophages**
J. Schultze, MD, Bonn, Germany

10:40 **Human Alveolar Macrophage Polarization: M1, M2 and Beyond**
R. Shaykhiev, MD, PhD, New York, NY

11:00 **Personalized Macrophage Responses to Disease-Modifying Therapies in Asthma and COPD**
D. Singh, MD, Manchester, United Kingdom

11:20 **Defective Macrophage Phagocytosis of Bacteria in Chronic Lung Disease**
L. Donnelly, PhD, London, United Kingdom

11:45 **Luncheon Sessions: Alveolar Macrophages in Host-Microbe Interactions and Lung Homeostasis**

Alveolar Macrophage as a Niche for Mycobacteria and HIV
D. Russell, PhD, Ithaca, NY

How Respiratory Viruses Drive Alternative Macrophage Polarization in Lung Disease
M.J. Holtzman, MD, St. Louis, MO

Lung Macrophages, Th2 Inflammation and Pulmonary Fibrosis
T. Wynn, PhD, Bethesda, MD

The Role of Polarized Macrophages in Lung Regeneration
J.R. Rock, PhD, San Francisco, CA

Alveolar Macrophage-Based Precision Therapy for Human Lung Disease
B.C. Trapnell, MD, Cincinnati, OH

2:00 *Break*

2:15 **"Lab Meeting"**
R. Shaykhiev, MD, PhD, New York, NY
A. Haczku, MD, PhD, Davis, CA
D. Singh, MD, Manchester, United Kingdom
M. Kopf, PhD, Zurich, Switzerland
C. Jakubzick, PhD, Denver, CO
J. Bhattacharya, MD, DPhil, New York, NY
J. Schultze, MD, Bonn Germany
L. Donnelly, PhD, London, United Kingdom
D. Russell, PhD, Ithaca, NY
M.J. Holtzman, St. Louis, MO
T. Wynn, PhD, Bethesda, MD
J.R. Rock, PhD, San Francisco, CA
B.C. Trapnell, MD, Cincinnati, OH

*This session and the International Conference are supported by an educational grant from **AstraZeneca LP.***
All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

BASIC • BEHAVIORAL • CLINICAL • TRANSLATIONAL

POSTGRADUATE COURSE

CME Credits Available: 6.5

PG17 SCIENTIFIC WRITING: PUBLISHING FOR ACADEMIC SUCCESS

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $400 In-Training Member: $250
Non-Member: $475 In-Training Non-Member: $350

Registrants must bring a laptop to the course to view the course material.

Assemblies on Behavioral Science and Health Services Research; Allergy, Immunology and Inflammation; Clinical Problems; Critical Care; Environmental, Occupational and Population Health; Microbiology, Tuberculosis and Pulmonary Infections; Nursing; Pediatrics; Sleep and Respiratory Neurobiology

8:00 a.m. - 3:55 p.m. **MOSCONE CENTER**

Room 2014 (West Building, Level 2)

Target Audience
Postdoctoral fellows, junior faculty, pulmonary and critical care physicians, allergists, nurses,clinical,translational, and basic science researchers, behavioral scientists, and research scientists.

Objectives
At the conclusion of this session, the participant will be able to:

- identify strategies for becoming a successful scientific writer and describe the essential elements of a scientific manuscript;
- define authorship and identify the ethical responsibilities of authors;
- describe the peer review process, avoid common mistakes authors make during preparation and submission of manuscripts; and select appropriate journals based on the content of the article and the target audience.

Fellows, junior faculty, researchers, and clinicians need practical information about scientific writing and publishing. This course is designed to provide investigators from various disciplines the tools necessary to prepare scientific manuscripts that are likely to be published. Course faculty will give an overview of strategies for becoming a successful writer as well as teach participants about the elements of a manuscript, the responsibilities of authorship, the importance of journal selection, and the peer review process. The afternoon will include interactive discussions with the faculty in small group breakout sessions.

Chairing: B.J. Sheares, MD, MS, New York, NY
J. Bruzzese, PhD, New York, NY
G. Diette, MD, MHS, Baltimore, MD

8:00 **Introduction and Announcements**
B.J. Sheares, MD, MS, New York, NY

8:05 **Strategies for Becoming a Successful Writer**
H.J. Zar, MD, PhD, Cape Town, South Africa

8:35 **Start with the Easy Part: Describing Methods and Reporting Results**
C.R. Cooke, MD, MSc, Ann Arbor, MI

9:05 **Promises, Promises: Writing Informative and Succinct Introductions**
J.D. Thornton, MD, MPH, Cleveland, OH

9:35 **So What? Placing Your Results in Context: The Discussion**
G. Diette, MD, MHS, Baltimore, MD

10:05 *Break*

10:15 **The Responsibilities of Authorship**
J. Bruzzese, PhD, New York, NY

10:45 **Publishing for Promotion: The Tenure Review Committee's Perspective**
N.W. Schluger, MD, New York, NY

11:15 **Panel Discussion**
A.J. Apter, MD, MSc, MA, Philadelphia, PA
R.S. Irwin, MD, Worcester, MA
J.M. Drazen, MD, Boston, MA
K. Adler, PhD, Raleigh, NC

12:05 **General Discussion**

12:30 *LUNCH*

1:30 **Breakout Session I: Revise and Resubmit: Responding to Reviewers' Comments**
B.J. Sheares, MD, MS, New York, NY

2:15 *Break*

2:20 **Breakout Session II: Writing an Abstract and Choosing a Title**
R. Grad, MD, Tucson, AZ

3:05 *Break*

3:10 **Breakout Session III: Reporting Results: Univariate, Bivariate, and Multivariate Analysis**
W.M. Vollmer, PhD, Portland, OR

There will be a 5-minute discussion after each talk.

CLINICAL

POSTGRADUATE COURSE

CME Credits Available: 6.5

PG18 NTM LUNG DISEASE: IMPROVE YOUR PRACTICE/DEBUNK THE MYTHS

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $350 In-Training Member: $200
Non-Member: $425 In-Training Non-Member: $300

Registrants must bring a laptop to the course to view the course material.

Assemblies on Clinical Problems; Microbiology, Tuberculosis and Pulmonary Infections

8:00 a.m. - 4:00 p.m. **MOSCONE CENTER**

Room 3007 (West Building, Level 3)

Target Audience
Providers of lung health including pulmonologists, infectious disease clinicians and trainees.

Objectives
At the conclusion of this session, the participant will be able to:

- to diagnose active NTM infection;
- understand the pathophysiology and impact of exposure to the water supply with regards to NTM infection;
- appropriately refer more complex NTM patients to centers worldwide with special competence in NTM infections.

This postgraduate course includes a state of the art update on non tuberculous mycobacterial lung disease with an emphasis on case based learning to understand the prevalence, pathophysiology, treatment strategies and controversies about the disease.

Chairing: A. O'Donnell, MD, Washington, DC
R. Thomson, MBBS, PhD, Brisbane, Australia

8:00 **Why Are We Seeing an Increase in NTM Lung Disease?**
K.N. Olivier, MD, MPH, Bethesda, MD

8:50 **Does Exposure to Potable Water Cause NTM Infection?**
R. Thomson, MBBS, PhD, Brisbane, Australia

9:30 **NTM Identification: What Your Clinical Lab Needs to Tell You**
A. O'Donnell, MD, Washington, DC

10:00 *Break*

10:15 **NTM Has Been Isolated: Does the Patient Need Antibiotics?**
T.R. Aksamit, MD, Rochester, MN

10:55 **Antibiotic Treatment for MAC Lung Infection**
K. Winthrop, MD, MPH, Portland, OR

11:45 *LUNCH*

12:45 **M. Abscessus Lung Infection Antibiotic Treatment**
T.K. Marras, MD, Toronto, Canada

1:35 **Old Drugs for Old Bugs**
J. Philley, MD, Tyler, TX

2:15 *Break*

2:30 **Case Reviews**
A. O'Donnell, MD, Washington, DC
A. Basavaraj, MD, New York, NY

3:30 **ATS/ERS Updated NTM Guidelines/Panel Wrap Up**
D.E. Griffith, MD, Tyler, TX

This session and the International Conference are supported by an educational grant from ***Insmed Incorporated.***
All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

CLINICAL • TRANSLATIONAL

POSTGRADUATE COURSE

CME Credits Available: 7.0

PG19 COPD: A DYNAMIC AND EVOLVING DISEASE

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $350 In-Training Member: $200
Non-Member: $425 In-Training Non-Member: $300

Registrants must bring a laptop to the course to view the course material.

Assemblies on Clinical Problems; Behavioral Science and Health Services Research; Critical Care; Pulmonary Rehabilitation; Sleep and Respiratory Neurobiology

8:00 a.m. - 4:00 p.m. **MOSCONE CENTER**
Room 2001 (West Building, Level 2)

Target Audience
Clinicians, nurses and respiratory therapiststs; clinical and basic science researchers; physicians in training and anybody who designs or implements clinical trials in COPD.

Objectives
At the conclusion of this session, the participant will be able to:

- understand the many systemic comorbidities associated with COPD and how to treat them;
- describe interventions to use for the management of COPD and COPD exacerbations;
- describe how to use different medications in the treatment of COPD patients.

This course will provide an update on key advances in the pathophysiology, genetics and management of COPD patients. There have been extensive publications on topics related to phenotype classification, use of imaging, biomarker and early interventions in COPD. Furthermore, over the last year, there have been numerous publications of novel bronchodilators that were approved by different regulatory organizations including the FDA. COPD exacerbations continue to impact the morbidity and mortality of this disease. There is a need to address how this condition can be prevented and to discuss its treatment.

Chairing: G.J. Criner, MD, Philadelphia, PA
R. Casaburi, MD, PhD, Torrance, CA

8:00 **What is the Status of COPD Today?**
K.F. Rabe, MD, PhD, Grosshansdorf, Germany

8:15 **How Can We Predict Disease Progression?**
J. Soriano, MD, PhD, Madrid, Spain

8:45 **What Are the COPD Phenotypes Relevant for Clinical Practice?**
M. Miravitlles, MD, PhD, Barcelona, Spain

9:15 **Accelerated Aging in COPD and Its Comorbidities: Pathways to New Therapies**
P.J. Barnes, MD, DSc, London, United Kingdom

9:45 *Break*

9:55 **Integrating Disease Severity and Co-Morbid Conditions**
C. Vogelmeier, MD, Marburg, Germany

10:25 **How Can Radiological Imaging Change Our Concepts and COPD Phenotypes?**
G.R. Washko, MD, Boston, MA

10:55 **The Association Between COPD and Cardiovascular Disease: Mechanistic Links and Clinical Implications**
D. Chandra, MD, MSc, Pittsburgh, PA

11:25 **How is the COPD Biomarker Qualification Consortium Helping Develop Treatments Targeted for COPD Subsets?**
R. Tal-Singer, PhD, King of Prussia, PA

11:55 *LUNCH*

12:35 **In What Patients Should I Use Fixed LABA-LAMA Combination?**
A. Anzueto, MD, San Antonio, TX

1:05 **In What Patients Should I Use Inhaled Corticosteroids?**
P. Calverley, MD, Liverpool, United Kingdom

1:35 **Emerging Anti-Inflammatory Therapies**
W. MacNee, MD, MBChB, Edinburgh, United Kingdom

2:05 *Break*

2:15 **Update on Endobronchial Interventions**
C.B. Strange, MD, Charleston, SC

2:45 **How Should I Treat a Patient Who Has an Acute Worsening in Symptoms ?**
S. Sethi, MD, Buffalo, NY

3:15 **Putting It All Together**
B.R. Celli, MD, Boston, MA

3:35 **Questions and Answers**
G.J. Criner, MD, Philadelphia, PA
R. Casaburi, MD, PhD, Torrance, CA

This session and the International Conference are supported by an educational grant from ***AstraZeneca LP.***

All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

CLINICAL

POSTGRADUATE COURSE

CME Credits Available: 6.25

PG20 PHYSIOLOGY OF MECHANICAL VENTILATION IN ARDS

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $400 In-Training Member: $250
Non-Member: $475 In-Training Non-Member: $350

Registrants must bring a laptop to the course to view the course material.

Assemblies on Critical Care; Pulmonary Circulation; Respiratory Structure and Function

8:00 a.m. - 4:00 p.m. **MOSCONE CENTER**
Room 3011 (West Building, Level 3)

Target Audience
Intensivists, fellows and respiratory therapists who wish to improve thier ability to manage complex cases of respiratory failure.

Objectives
At the conclusion of this session, the participant will be able to:

- titrate PEEP in severe ARDS;
- assess patients for possible prone ventilation;
- interpret PV curves in severe ARDS.

This course is focused on the bedside management of mechanical ventilation in severe respiratory failure. Participants will learn a physiologic approach to managing the ventilator and interpreting the effects of interventions. We will cover the uses and physiologic effects of PEEP, heart and lung interaction as it relates to mechanical ventilation, and the physiology behind improved oxygenation in prone ventilation and improved V/Q matching with the use of pulmonary vasodilators. We will explore controversies in the physiologic literature concerning these techniques and critically examine common clinical rationales for their use. The course will include hands-on, case based simulations in which participants will apply the principles covered in the didactic sessions.

Chairing: C. Hardin, MD, PhD, Boston, MA
K.A. Hibbert, MD, Boston, MA
S. Loring, MD, Boston, MA

8:00 **Introduction - Overview of Physiologic Principles**
K.A. Hibbert, MD, Boston, MA

8:40 **The Pressure-Volume Curve in ARDS**
C. Hardin, MD, PhD, Boston, MA
J. Butler, PhD, Boston, MA

9:20 **Chest Wall and Mechanical Ventilation**
S. Loring, MD, Boston, MA

10:00 *Break*

10:20 **Heart-Lung Interaction**
S. Magder, MD, Montreal, Canada

11:00 **The Distribution of Perfusion and Ventilation-Perfusion Matching in Health and in Lung Injury**
S.R. Hopkins, MD,PhD, La Jolla, CA

11:40 *LUNCH*

12:40 **Physiologic Effects of PEEP**
A. Malhotra, MD, La Jolla, CA

1:20 **Driving Pressure**
L. Brochard, MD, Toronto, Canada

2:00 **Prone Ventilation**
I.S. Douglas, MD, Denver, CO

2:40 *Break*

2:55 **Vent Management and PEEP Titration**
K.A. Hibbert, MD, Boston, MA
C. Hardin, MD, PhD, Boston, MA

BASIC • CLINICAL • TRANSLATIONAL

POSTGRADUATE COURSE

CME Credits Available: 6.75

PG21 EPIGENETICS OF LUNG DISEASE

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $350 In-Training Member: $200
Non-Member: $425 In-Training Non-Member: $300

Registrants must bring a laptop to the course to view the course material.

Assemblies on Environmental, Occupational and Population Health; Allergy, Immunology and Inflammation; Behavioral Science and Health Services Research; Clinical Problems; Critical Care; Pediatrics; Respiratory Cell and Molecular Biology; Thoracic Oncology

8:00 a.m. - 4:00 p.m. **MOSCONE CENTER**
Room 2003 (West Building, Level 2)

Target Audience
Researchers and public health practitioners in respiratory and environmental health.

Objectives
At the conclusion of this session, the participant will be able to:

- understand and apply key concepts in the design and analysis of studies of DNA methylation and lung disease;
- comprehend the impact of epigenetic studies on prevention (e.g., biomarker development), diagnosis, and treatment of lung disease;
- learn new and alternative approaches to epigenetic studies.

Lung diseases are multi-factorial,resulting from interactions between genetic and environmental factors. Heritable and/or de novo changes in gene expression that occur without alterations in DNA sequence (epigenetic) mediate some environmental effects on lung disease. We will review state of the art approaches to designing and implementing studies of epigenetics in general and in pulmonary/critical care/sleep medicine in particular.

Chairing: J.C. Celedon, MD, DrPH, Pittsburgh, PA
C. Breton, ScD, Los Angeles, CA

8:00 **Designing Studies of DNA Methylation**
J.C. Celedon, MD, DrPH, Pittsburgh, PA

8:40 **Laboratory Assays for Epigenetic Studies**
S. Belinsky, PhD, Albuquerque, NM

9:25 **Data Analysis for Studies of DNA Methylation**
C. Breton, ScD, Los Angeles, CA

10:10 *Break*

10:20 **Murine Studies of Epigenetics**
L. Kobzik, MD, Boston, MA

11:05 **Birth Cohort Studies of Epigenetics**
J. Herbstman, PhD, New York, NY

11:50 **MicroRNA Studies**
P.G. Woodruff, MD, MPH, San Francisco, CA

12:35 *LUNCH*

1:35 **Twin Studies of Epigenetics**
J.C. Celedon, MD, DrPH, Pittsburgh, PA

2:20 *Break*

2:30 **Histone Modification**
K.H. Albertine, PhD, Salt Lake City, UT

3:15 **Where Do We Go from Here?**
B.A. Raby, MD, MPH, Boston, MA

CLINICAL

POSTGRADUATE COURSE

CME Credits Available: 6.5

PG22 DIFFICULT CLINICAL PROBLEMS IN PULMONARY AND CRITICAL CARE INFECTIONS

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $350 In-Training Member: $200
Non-Member: $425 In-Training Non-Member: $300

Registrants must bring a laptop to the course to view the course material.

Assemblies on Microbiology, Tuberculosis and Pulmonary Infections; Clinical Problems; Critical Care

8:00 a.m. - 4:00 p.m. **MOSCONE CENTER**
Room 3014 (West Building, Level 3)

Target Audience
Clinicians managing patients with pulmonary and critical care acquired infections.

Objectives
At the conclusion of this session, the participant will be able to:

- have a much greater understanding of the range of pulmonary infections that can occur in immunocompetent and immunocompromised hosts;
- gain a much better appreciation of the evidence supporting different treatment strategies in pulmonary infections;
- have a much better knowledge of new diagnostic tests, treatments and outcome measures that can be applied in their local setting.

This course will provide clinicians with a broad overview and an update of the current challenging issues in the management of pulmonary and critical care infections including typical bacterial pneumonia, mycobacterial, fungal, and viral infections as well as general approaches to infections in the immunocompromised host.

Chairing: C.A. Hage, MD, Indianapolis, IN
K.A. Crothers, MD, Seattle, WA
K.S. Knox, MD, Tucson, AZ

8:00 **ICU Acquired CLABSI: Prevention and Management in the Accountable Care Era**
I.I. Raad, MD, Houston, TX

8:30 **Emerging Viral Respiratory Tract Infections**
T.E. West, MD, MPH, Seattle, WA

9:00 **What Are the Big Changes in the New and Upcoming VAP/HAP Treatment Guidelines?**
M.L. Metersky, MD, Farmington, CT

9:30 **Panel Discussion**
M.L. Metersky, MD, Farmington, CT
I.I. Raad, MD, Houston, TX
T.E. West, MD, MPH, Seattle, WA

9:45 *Break*

10:00 **Empyema and Other Pleural Infections**
Y.C.G. Lee, MBChB, PhD, Perth, Australia

10:30 **Practical Guide for the Management of Bronchiectasis**
J.D. Chalmers, MBChB, PhD, Dundee, United Kingdom

11:00 **What Is New in CAP: Outcomes and Emerging Pathogens**
G.W. Waterer, MBBS, PhD, MBA, Perth, Australia

11:30 **Panel Discussion**
J.D. Chalmers, MBChB, PhD, Dundee, United Kingdom
G.W. Waterer, MBBS, PhD, MBA, Perth, Australia
Y.C.G. Lee, MBChB, PhD, Perth, Australia

11:45 *LUNCH*

12:45 **Pulmonary Infections and Respiratory Microbiome Alterations in HIV/AIDS**
K.A. Crothers, MD, Seattle, WA

1:15 **IGRA Versus TST for the Management of LTBI Including While on Anti-TNF Therapy**
C. Daley, MD, Denver, CO

1:45 **Panel Discussion**
K.A. Crothers, MD, Seattle, WA
C. Daley, MD, Denver, CO

2:00 *Break*

2:15 **Pneumonia in Patients with Hematologic Malignancies and HSCT Recipients**
S.E. Evans, MD, Houston, TX

2:45 **Pneumonia in the Solid Organ Transplant Recipient: Aspergillosis and Beyond**
C.A. Hage, MD, Indianapolis, IN

3:15 **Pneumonia in Patients Treated with Anti-TNF Therapy and Other Novel Biologics**
K. Winthrop, MD, MPH, Portland, OR

3:45 **Panel Discussion**
K. Winthrop, MD, MPH, Portland, OR
S.E. Evans, MD, Houston, TX
C.A. Hage, MD, Indianapolis, IN

CLINICAL

POSTGRADUATE COURSE

CME Credits Available: 6.75

PG23 DIAGNOSTIC TESTS IN PEDIATRIC PULMONOLOGY: INDICATIONS AND INTERPRETATIONS

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $350 In-Training Member: $200
Non-Member: $425 In-Training Non-Member: $300

Registrants must bring a laptop to the course to view the course material.

Assemblies on Pediatrics; Allergy, Immunology and Inflammation; Clinical Problems; Critical Care; Nursing; Pulmonary Rehabilitation; Sleep and Respiratory Neurobiology

8:00 a.m. - 3:50 p.m. **MOSCONE CENTER**
Room 3016 (West Building, Level 3)

Target Audience
Pediatric pulmonologists and allergists, adult pulmonologists and allergists who take care of children; pediatric intensivists, nurses and respiratory therapists.

Objectives
At the conclusion of this session, the participant will be able to:

- choose the appropriate tests for a variety of conditions encountered in clinical practice;
- recognize and avoid pitfalls in the interpretation of various diagnostic tests;
- learn how new diagnostic modalities may help in reaching a more accurate diagnosis in various clinical problems.

This course will provide a comprehensive overview of diagnostic tests that are available in clinical practice for the evaluation of pediatric patients with airway and lung parenchymal disorders. The presenters will discuss the advantages and limitations of each test in making a diagnosis, as well as the pitfalls in the performance of the tests that may result into erroneous results. Finally, when applicable, there will be a discussion on safety issues (e.g. when sedation may be necessary for the performance of the test) as well as on the cost of the various tests.

Chairing: A.C. Koumbourlis, MD, MPH, Washington, DC
S. Davis, MD, Indianapolis, IN
E. Eber, MD, Graz, Austria

8:00 **Genetic Testing for Pulmonary Disorders**
L.M. Nogee, MD, Baltimore, MD

8:40 **Evaluation of the Patient with Lung Disease Suspected to Be Secondary to Immune Dysfunction or Auto-Immunity**
A.M.H. Casey, MD, Boston, MA

9:20 **Testing for Disorders of Mucociliary Clearance**
A.J. Shapiro, MD, Montreal, Canada

9:55 *Break*

10:10 **When to Order and What to Do with the Results of a Sleep Study**
G. Nino, MD, Washington, DC

10:45 **Choosing and Interpreting an Exercise Test**
P. Pianosi, MD, Rochester, MN

11:20 **Chest Imaging**
B. Newman, MD, Palo Alto, CA

12:00 *LUNCH*

12:40 **Interpreting the Results of a Bronchoscopy**
E. Eber, MD, Graz, Austria

1:15 **Pulmonary Function Testing in Children**
S. Ranganathan, MBChB, MRCP, PhD, Parkville, Australia

1:50 **How to Define "Normal" in PFTs**
S. Stanojevic, PhD, Toronto, Canada

2:25 *Break*

2:40 **The Newer Tests: IOS**
N. Eid, MD, Louisville, KY

3:15 **Infant and Preschool Pulmonary Function Testing**
S. Davis, MD, Indianapolis, IN

CLINICAL • TRANSLATIONAL

POSTGRADUATE COURSE

CME Credits Available: 6.5

PG24 CRITICAL CARE OF THE PATIENT WITH PULMONARY VASCULAR DISEASE

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $350 In-Training Member: $200
Non-Member: $425 In-Training Non-Member: $300

Registrants must bring a laptop to the course to view the course material.

Assemblies on Pulmonary Circulation; Clinical Problems; Critical Care

8:00 a.m. - 4:00 p.m. **MOSCONE CENTER**

Room 3018 (West Building, Level 3)

Target Audience
Pulmonary and cardiology faculty, intensivists of all backgrounds, trainees, and allied health professionals.

Objectives
At the conclusion of this session, the participant will be able to:

- understand etiology and pathophysiology of RV failure in critically ill patients;
- integrate strategies for the diagnosis and treatment of pulmonary vascular disease in critically ill patients;
- interpret common pulmonary artery catheter waveform patterns and learn about the basics of RV echocardiography in critically ill patients with pulmonary vascular disease.

This comprehensive course will provide the learner with a strategy to care for critically ill patients with pulmonary hypertension of various etiologies. Presenters will provide a framework for understanding pathophysiology, etiology, hemodynamics, and specific high-risk scenarios using state of the art evidence and clinical expertise. Common pitfalls and knowledge gaps in caring for patients with pulmonary vascular and right heart failure will be addressed. By the conclusion, learners should have a refined approach for the management of these challenging patients.

Chairing: C.E. Ventetuolo, MD, MS, Providence, RI
T.M. Bull, MD, Aurora, CO
T. Lahm, MD, Indianapolis, IN

8:00 **Mechanisms of RV Failure in Critical Illness**
R. Naeije, MD, PhD, Brussels, Belgium

8:30 **Epidemiology of Pulmonary Vascular Disease and RV Failure in the ICU**
R.T. Zamanian, MD, Stanford, CA

9:00 **The PA Catheter in Critically Ill Patients with Pulmonary Vascular Disease: The Nuts and Bolts of PAC Waveform Analysis**
J.B. Hall, MD, Chicago, IL

10:00 *Break*

10:15 **Management of PAH in ICU: Supportive Care: Volume, Arrhythmias, Mechanical Ventilation**
T. Lahm, MD, Indianapolis, IN

10:45 **Management of PAH in ICU: Pulmonary Vasodilators and Management of Hemodynamics (Pressors and Inotropes)**
J.R. Klinger, MD, Providence, RI

11:15 **Pregnancy in PAH**
A.R. Hemnes, MD, Nashville, TN

11:45 **Perioperative Management of PAH**
J.L. Diaz-Gomez, MD, Jacksonville, FL

12:15 *LUNCH*

Controversies in the Management of High and Intermediate Risk (Massive and Sub-Massive) PE

1:15 **Pro/Con on the Treatment of High and Intermediate-Risk PE: To Lyse or Not to Lyse and How**
J.A. Kline, MD, Indianapolis, IN

1:30 **Rebuttal**
T.M. Bull, MD, Aurora, CO

1:45 **Pro/Con on IVC Filters**
T.M. Bull, MD, Aurora, CO

2:00 **Rebuttal**
J.A. Kline, MD, Indianapolis, IN

2:15 **RV Ischemia in PAH and RV Infarct**
S. Archer, MD, Kingston, Canada

2:45 *Break*

3:00 **Echo in the ICU: What Can It Help Us with in the Critically Ill Pulmonary Vascular Disease Patient?**
A. Vieillard-Baron, MD, Boulogne-Billancourt, France

3:30 **ECMO as a Bridge or Salvage Therapy in PH**
C.E. Ventetuolo, MD, MS, Providence, RI

BASIC • CLINICAL

POSTGRADUATE COURSE

CME Credits Available: 6.75

PG25 MASTER PHYSIOLOGY CLASS: CORE PRINCIPLES OF RESPIRATORY PHYSIOLOGY

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $400 In-Training Member: $250
Non-Member: $475 In-Training Non-Member: $350

Registrants must bring a laptop to the course to view the course material.

Assemblies on Respiratory Structure and Function; Clinical Problems; Critical Care

8:00 a.m. - 4:00 p.m. **MOSCONE CENTER**

Room 3022 (West Building, Level 3)

Target Audience
Practicing clinicians including physicians and advanced practice practitioners; resident and fellow level trainees whose clinical focus is pulmonary and/or critical care medicine.

Objectives
At the conclusion of this session, the participant will be able to:

- describe the basic principles of respiratory physiology that affect the transport of oxygen and carbon dioxide to and from the environment and tissues;
- explain how the core principles of respiratory physiology are altered in special patient populations including pregnant women, the obese and children;
- understand and explain how the respiratory system responds to stresses such as sustained high level exercise, hypobaric hypoxia and hyperbaria.

This postgraduate course will use a combination of didactic lectures and small group breakout sessions to review the core principles of respiratory physiology including advanced instruction in respiratory system mechanics, gas exchange, blood gas transport, control of breathing and the pulmonary circulation and how these principles apply in both special patient populations (pregnancy, obesity, pediatrics) and special circumstances (diving, exercise, high altitude).Emphasis will be placed throughout the course on the bedside application of the principles covered in each course component.

Chairing: A.M. Luks, MD, Seattle, WA
R.W. Glenny, MD, Seattle, WA

8:00 **Introduction**
A.M. Luks, MD, Seattle, WA

8:10 **Core Principles: Mechanics**
R. Schwartzstein, MD, Boston, MA

8:50 **Core Principles: The Pulmonary Circulation**
R.W. Glenny, MD, Seattle, WA

9:30 **Core Principles: Gas Exchange**
J. Petersson, MD, Stockholm, Sweden

10:10 *Break*

10:25 **Small Group Case Review**
A.M. Luks, MD, Seattle, WA
B. Coruh, MD, Seattle, WA
H.L. Manning, MD, Lebanon, NH
R. Schwartzstein, MD, Boston, MA
P.G. Carvalho, MD, Boise, ID
A.S. Clay, MD, Durham, NC
R.W. Glenny, MD, Seattle, WA
J.T. Poston, MD, Chicago, IL
M.M. Hayes, Boston, MA
B.A. Cockrill, MD, Boston, MA
F. Laghi, MD, Hines, IL

11:40 *LUNCH*

12:30 **Core Principles: Blood Gas Transport**
H.L. Manning, MD, Lebanon, NH

1:10 **Core Principles: Respiratory Muscle and Chest Wall Physiology**
F. Laghi, MD, Hines, IL

1:50 *Break*

2:05 **Core Principles: Control of Breathing**
J. Leiter, MD, Lebanon, NH

2:45 **Small Group Case Review**
A.M. Luks, MD, Seattle, WA
B. Coruh, MD, Seattle, WA
R. Schwartzstein, MD, Boston, MA
H.L. Manning, MD, Lebanon, NH
R.W. Glenny, MD, Seattle, WA
B.A. Cockrill, MD, Boston, MA
J.T. Poston, MD, Chicago, IL
M.M. Hayes, MD, Boston, MA
P.G. Carvalho, MD, Boise, ID
A.S. Clay, MD, Durham, NC
F. Laghi, MD, Hines, IL

BASIC • CLINICAL • TRANSLATIONAL

POSTGRADUATE COURSE

CME Credits Available: 6.75

PG26 CENTRAL APNEAS, CHEYNE-STOKES AND PERIODIC BREATHING: NEW INSIGHTS AND THEIR IMPACT ON DAILY PRACTICE

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $350 | In-Training Member: $200
Non-Member: $425 | In-Training Non-Member: $300

Registrants must bring a laptop to the course to view the course material.

Assemblies on Sleep and Respiratory Neurobiology; Clinical Problems; Critical Care; Pediatrics

8:00 a.m. - 4:00 p.m. **MOSCONE CENTER**
Room 3020 (West Building, Level 3)

Target Audience
Pulmonologists, sleep physicians, fellows, nurses, fellows in training, clinical researchers, everybody involved in critical care and ventilation, pediatricians, geriatric physicians and nurses, cardiologists.

Objectives
At the conclusion of this session, the participant will be able to:

- put the new results from basic and clinical research regarding the causality of central apneas and periodic breathing into clinical perspective and to understand treatment alternatives to improve patient outcome;
- understand the differences in the results between the two recent, Serve HF and ADVENT-HF trials, and their impact on treatment for patients with central apneas in heart failure;
- develop skills for the daily work with geriatric patients, who show signs of complex and difficult to treat forms of sleep apnea.

This postgraduate course is designed to give the learner the most updated information on knowledge about all forms of central apneas, and to build confidence in individualizing decisions concerning the importance of central apneas and periodic breathing for each patient. The course is also an opportunity to put the disturbing results of the Serve HF studies from previous year into the right perspective for each clinical practice. The opportunity to discuss controversial results of clinical studies with experts in the field after each talk and at the round table will reduce uncertainties in younger clinicians and nurses, when it comes to central apneas in younger and older patients.

Chairing: N.C. Netzer, MD, PhD, Bad Aibling, Germany
C. Marcus, MBBCh, Philadelphia, PA

8:00 **Introduction**
N.C. Netzer, MD, PhD, Bad Aibling, Germany

Part One: Central Apnea Physiology

8:05 **Rhytmogenesis and Loop Gain as Unifying Mechanisms of Periodic Central Apneas**
S.A. Sands, PhD, Boston, MA

8:35 **Upper Airway Physiology and Central Apneas: The Neuromechanical Interface**
D.J. Eckert, PhD, Sydney, Australia

9:05 **Brain and Carotid Body Sensors Involved in Generating Central Apneas**
J. Neubauer, PhD, New Brunswick, NJ

9:35 **Hypoxia Provoked Periodic Breathing During Sleep: A Model for CSR?**
N.C. Netzer, MD, PhD, Bad Aibling, Germany

10:05 **Panel Discussion**
K.P. Strohl, MD, Cleveland, OH
D.J. Eckert, PhD, Sydney, Australia

10:30 *Break*

Part Two: Clinical Aspects and Treatment of Central Breathing Disorders

10:45 **The ERS Task Force Consensus on Central Apneas**
W. Randerath, MD, Solingen, Germany

11:20 **Central Apneas in Infants and Children. When to Worry and How to Treat**
C. Marcus, MBBCh, Philadelphia, PA

11:55 **Central Apneas in the Geriatric Patient: A Buddy of Aging**
M. Morrell, MD, PhD, London, United Kingdom

12:30 *LUNCH*

1:15 **Role of Phrenic Nerve Stimulation and Cardiac Pacing in the Treatment of CA in Heart Failure**
M. Arzt, MD, Regensburg, Germany

1:45 **In Patients with Heart Failure, Should We Concentrate on Treating the Obstructive Events? What the SERVE HF Study Taught Us**
H. Woehrle, MD, Blaubeuren, Germany

2:15 **SERVE HF Is Not the Only Truth. What We Learned from the ADVENT-HF Study**
D. Bradley, MD, Toronto, Canada

2:45 *Break*

3:00 **Devil or Saint? Supplemental Oxygen Treatment in Central Breathing Disorders Including CSA in Stroke**
C. Roffe, PhD, Stoke on Trent, United Kingdom

3:30 **Panel Discussion**
C. Marcus, MBBCh, Philadelphia, PA
D. Bradley, MD, Toronto, Canada

BASIC • BEHAVIORAL • CLINICAL • TRANSLATIONAL

POSTGRADUATE COURSE

CME Credits Available: 6.5

PG27 LUNG CANCER: STATE OF THE ART IN 2016

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $350 In-Training Member: $200
Non-Member: $425 In-Training Non-Member: $300

Registrants must bring a laptop to the course to view the course material.

Assemblies on Thoracic Oncology; Behavioral Science and Health Services Research; Clinical Problems; Respiratory Cell and Molecular Biology

8:00 a.m. - 3:35 p.m. **MOSCONE CENTER**
Room 2011 (West Building, Level 2)

Target Audience
All providers caring for patients with lung nodules, lung cancer. This includes pulmonologists, thoracic surgeons, radiation oncologists, nurse practitioners and physician assistants.

Objectives
At the conclusion of this session, the participant will be able to:

- describe the benefits and risks of lung cancer screening;
- explain the roles that surgery and stereotactic body radiation therapy have for patients with early NSCLC;
- describe the recent advances in molecular medicine as it relates to lung cancer.

This course will provide a comprehensive review of topics in the evaluation and management of patients with lung cancer including risk assessment and screening, the approach to pulmonary nodules, and the importance of molecular characterization of lung cancer. In addition, we will discuss treatment options for early stage and locally advanced NSCLC, the role in interventional pulmonology and palliative care in the management of patients with lung cancer and disparities in lung cancer burden, evaluation and treatment. Novel diagnostic tools and treatment modalities including biomarkers /genomic classifiers and immunomodulating therapies. The importance of tobacco cessation programs and tobacco control will also be discussed. Interactive tumor boards will be held to highlight main teaching points.

Chairing: D.J. Feller-Kopman, MD, Baltimore, MD
M.P. Rivera, MD, Chapel Hill, NC

8:00 **Introduction**
D.J. Feller-Kopman, MD, Baltimore, MD

8:05 **Tobacco and E-Cigarettes: Control or Out of Control?**
A. Vachani, MD, MS, Philadelphia, PA

8:30 **Lung Cancer Screening: Who, Why and How**
N.T. Tanner, MD, MSCR, Charleston, SC

8:55 **The Role of Advanced Diagnostic Bronchoscopy in the Diagnosis and Staging of Lung Cancer**
J.A. Akulian, MD, MPH, Chapel Hill, NC

9:20 **Tumor Board**
D.J. Feller-Kopman, MD, Baltimore, MD

9:55 *Break*

10:10 **Is My Patient Fit for Surgery?**
K.I. Berger, MD, New York, NY

10:35 **Surgery Is Better for Stage 1 NSCLC**
J. Shrager, MD, Stanford, CA

11:00 **SBRT Is Better for Stage 1 NSCLC**
B. Loo, MD, PhD, Palo Alto, CA

11:25 **Rebuttal**

11:35 **Tumor Board**
M.P. Rivera, MD, Chapel Hill, NC

12:10 *LUNCH*

12:50 **Disparities in Lung Cancer**
M.P. Rivera, MD, Chapel Hill, NC

1:15 **"Systems Genetics" in Lung Cancer**
D. Jablons, MD, San Francisco, CA

1:40 **Treating YOU: Targeted Therapy and Immunotherapy in the Treatment of Lung Cancer**
C. Pecot, MD, Chapel Hill, NC

2:05 **Tumor Board**
D.J. Feller-Kopman, MD, Baltimore, MD

2:30 *Break*

2:45 **How Not to Die Short of Breath: Treatment of Malignant Pleural Effusions**
D.J. Feller-Kopman, MD, Baltimore, MD

3:10 **Journal Club: Last Year's Top 5 Papers in Lung Cancer**
G.A. Silvestri, MD, MS, Charleston, SC

This session and the International Conference are supported by educational grants from ***AstraZeneca LP, Boston Scientific Corporation, Inc.***
All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

CLINICAL

POSTGRADUATE COURSE

CME Credits Available: 6.5

PG28 CONFLICT RESOLUTION IN CRITICAL CARE: A SKILLS COURSE

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $350 In-Training Member: $200
Non-Member: $425 In-Training Non-Member: $300

Registrants must bring a laptop to the course to view the course material.

Assemblies on Ethics and Conflict of Interest Committee; Behavioral Science and Health Services Research; Critical Care; Nursing

8:00 a.m. - 4:00 p.m. **MOSCONE CENTER**
Room 2024 (West Building, Level 2)

Target Audience
Any clinician directly involved in providing healthcare, whether or not specifically in critical care, can benefit from enhancing his/her skills in resolving conflict.

Objectives
At the conclusion of this session, the participant will be able to:

- describe and explain at least ten specific skills and strategies for communicating in a setting of significant conflict;
- explain how and when each such skill or strategy is best used;
- gain practice in conflict resolution skills, so that they come readily into use when needed.

ATS's ground-breaking 2015 Policy Statement on potentially inappropriate treatments in critical care observes that "conflicts typically develop and worsen over time as communication breaks down and parties become entrenched in their positions," hence emphasizes the need for "increased efforts to teach clinicians end of life communication skills, including conflict resolution skills." This course, a compact version of a successful intensive 3-day training, provides ATS's first direct opportunity to meet that goal. Faculty will introduce a number of skills, beyond ordinary clinical communication skills, specifically attuned to address conflict. Participants will practice those skills in realistic scenarios followed by extensive debriefing.

Chairing: H. Morreim, JD, PhD, Memphis, TN
D.B. White, MD, MAS, Pittsburgh, PA

8:00 **ATS's Official Policy Statement Regarding Requests for Potentially Inappropriate Treatments in ICUs**
J.R. Curtis, MD, MPH, Seattle, WA

8:30 **ATS's Official Policy Statement Regarding Requests for Potentially Inappropriate Treatments in ICUs: Addressing Intractable Conflict**
D.B. White, MD, MAS, Pittsburgh, PA

9:00 **A Broad Look at Conflict in Health Care**
H. Morreim, JD, PhD, Memphis, TN

9:15 **First Set of Skills**
H. Morreim, JD, PhD, Memphis, TN
J.R. Curtis, MD, MPH, Seattle, WA
D.B. White, MD, MAS, Pittsburgh, PA
R.D. Stapleton, MD, PhD, Burlington, VT
L.F. Reinke, ARNP, PhD, Edmonds, WA
M. Bugnitz, MD, Memphis, TN

9:45 *Break*

10:00 **Practice Scenario #1 and Debrief**
H. Morreim, JD, PhD, Memphis, TN
D.B. White, MD, MAS, Pittsburgh, PA
J.R. Curtis, MD, MPH, Seattle, WA
R.D. Stapleton, MD, PhD, Burlington, VT
L.F. Reinke, ARNP, PhD, Edmonds, WA
M. Bugnitz, MD, Memphis, TN

10:30 **Second Set of Skills and Brief Exercise**
H. Morreim, JD, PhD, Memphis, TN
D.B. White, MD, MAS, Pittsburgh, PA
J.R. Curtis, MD, MPH, Seattle, WA
R.D. Stapleton, MD, PhD, Burlington, VT
L.F. Reinke, ARNP, PhD, Edmonds, WA
M. Bugnitz, MD, Memphis, TN

11:00 **Practice Scenario #2 and Debrief**
H. Morreim, JD, PhD, Memphis, TN
D.B. White, MD, MAS, Pittsburgh, PA
J.R. Curtis, MD, MPH, Seattle, WA
R.D. Stapleton, MD, PhD, Burlington, VT
L.F. Reinke, ARNP, PhD, Edmonds, WA
M. Bugnitz, MD, Memphis, TN

11:30 *LUNCH*

12:30 **Conflict Resolution Strategies**
H. Morreim, JD, PhD, Memphis, TN
D.B. White, MD, MAS, Pittsburgh, PA
J.R. Curtis, MD, MPH, Seattle, WA
R.D. Stapleton, MD, PhD, Burlington, VT
L.F. Reinke, ARNP, PhD, Edmonds, WA
M. Bugnitz, MD, Memphis, TN

1:15 **Practice Scenario #3 and Debrief**
H. Morreim, JD, PhD, Memphis, TN
D.B. White, MD, MAS, Pittsburgh, PA
J.R. Curtis, MD, MPH, Seattle, WA
R.D. Stapleton, MD, PhD, Burlington, VT
L.F. Reinke, ARNP, PhD, Edmonds,WA
M. Bugnitz, MD, Memphis, TN

2:00 *Break*

2:15 **Practice Scenario #4 and Debrief**
H. Morreim, JD, PhD, Memphis, TN
D.B. White, MD, MAS, Pittsburgh, PA
J.R. Curtis, MD, MPH, Seattle, WA
R.D. Stapleton, MD, PhD, Burlington, VT
L.F. Reinke, ARNP, PhD, Edmonds, WA
M. Bugnitz, MD, Memphis, TN

3:15 **Final Exercise**
H. Morreim, JD, PhD, Memphis, TN
D.B. White, MD, MAS, Pittsburgh, PA
J.R. Curtis, MD, MPH, Seattle, WA
R.D. Stapleton, MD, PhD, Burlington, VT
L.F. Reinke, ARNP, PhD, Edmonds, WA
M. Bugnitz, MD, Memphis, TN

4:30 p.m. - 5:30 p.m.

OPENING CEREMONY
MOSCONE CENTER
Gateway Ballroom 102-104 (South Building, Lower Level)

The American Thoracic Society invites you to attend the Opening Ceremony for the 2016 International Conference. The keynote speaker is pioneering scientific researcher, **J. Craig Venter, PhD.** Contributions in sequencing a draft human genome, the first complete diploid human genome and construction of the first synthetic bacterial cell are among his many accomplishments. He is the founder, chairman and CEO of the J. Craig Venter Institute (JCVI), founder and CEO of the company, Synthetic Genomics Inc. (SGI) and a co-founder and CEO of Human Longevity Inc. (HLI).

Sonia Buist, MD, ATS past president and founder of the ATS Methods in Epidemiologic, Clinical, and Operations Research (MECOR) program, will be the first recipient of the ATS Foundation Vision Award. This award honors innovative individuals who have had a transformative impact on the delivery of health care.

The Ceremony will be followed by a networking gathering with light refreshments, where attendees can meet up with friends and colleagues.

5:30 p.m. - 6:30 p.m.

S1 THE NETWORKING EXCHANGE FOR EARLY CAREER PROFESSIONALS
MOSCONE CENTER
Lobby (West Building, Level 2)

The Networking Exchange for Early Career Professionals is an annual networking event for medical students, residents, fellows, post docs, junior faculty and new conference attendees. This one hour event is intended to provide a relaxed atmosphere where attendees can network with peers, ATS leaders, program directors, associate program directors and division directors, as well as other prominent leaders. The Training Committee, Membership Committee, Education Committee, and Members in Transition and Training Committee (MITT) jointly host the Networking Exchange for Early Career Professionals. Cocktails and appetizers will be provided.

Conference badges are required for admission.
Space is limited. There is no additional fee.

CLINICAL

PEDIATRIC CLINICAL CORE CURRICULUM

CME Credits Available: 1.5

PCC1 PEDIATRIC CLINICAL CORE CURRICULUM

Pediatric Core Curriculum Working Group

6:45 a.m. - 7:45 a.m. **MOSCONE CENTER**

Room 3007/3009 (West Building, Level 3)

Target Audience
Pediatric pulmonary and critical care physicians who work in a clinical setting and are currently engaged in maintenance of certification.

Objectives
At the conclusion of this session, the participant will be able to:

- remain current with medical knowledge relevant to their practice in pediatric pulmonology;
- evaluate their understanding of key skills and content areas in pediatric pulmonology as well as receive feedback on their comprehension of a result of a pre-test/post-test comparison;
- support clinicians who are engaged in maintenance of certification activities by providing updates on subjects included in recertification requirements.

The Pediatric Core Curriculum symposia promotes lifelong learning and the enhancement of the clinical judgment and skills essential for practicing pediatricians. The symposia will address topics that have been identified by an ATS pediatric working group, which is comprised of members of the ATS Education Committee and the International Conference Committee, who have identified important areas within pediatric medicine (including vasculitic pulmonary diseases, lung defense mechanism, congenital abnormalities of the airways, and respiratory failure). Attendees will increase their medical knowledge as a result of attending this symposium, and this will be measured by a comparison of pre-test vs. post-test results on the corresponding maintenance of certification module. The ATS Pediatric Core Curriculum will focus on a 3-year content cycle of key medical content in the area of pediatric medicine.

Chairing: D.M. Boyer, MD, Boston, MA
P.E. Moore, MD, Nashville, TN

6:45 **Vasculitic Pulmonary Diseases**
S.D.M. Dell, MD, Toronto, Canada

7:15 **Sickle Cell Lung Disease**
R.T. Cohen, MD, MPH, Boston, MA

BASIC • CLINICAL • TRANSLATIONAL

ATS KEYNOTE SERIES

CME Credits Available: .75

The ATS Keynote Series provides state of the art lectures on selected topics in an unopposed format to showcase major discoveries in pulmonary, critical care and sleep medicine. The speakers have been chosen by input from the members and various ATS committees with consensus built via the ATS executive committee.

Two sessions are presented each morning during the conference. Below are the topics for the Sunday,May 15th series.

K1 PERSONALIZED MANAGEMENT OF OBSTRUCTIVE SLEEP APNEA

8:00 a.m. - 8:45 a.m. **MOSCONE CENTER**

Room 134 (North Building, Lower Level)

Speaker: John R. Stradling, MD, MPH, Oxford, United Kingdom

K2 IDIOPATHIC PULMONARY FIBROSIS: PAST, PRESENT, FUTURE

8:00 a.m. - 8:45 a.m. **MOSCONE CENTER**

Room 135 (North Building, Lower Level)

Speaker: Talmadge E. King, MD, San Francisco, CA

This session and the International Conference are supported by an educational grant from ***Boehringer Ingelheim Pharmaceuticals, Inc.***
All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

The information contained in this program is up to date as of March 9, 2016.
For the most current session information, please visit the online program itinerary.

CLINICAL

YEAR IN REVIEW

CME Credits Available: 2.0

A1 CLINICAL YEAR IN REVIEW 1

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Gateway Ballroom 102-104 (South Building, Lower Level)

Target Audience
Providers including physicians, nurses, respiratory therapists, nurse practitioners, and physician assistants. Trainees including residents fellows, and clinical researchers will also benefit.

Objectives
At the conclusion of this session, the participant will be able to:

- apply new clinical research knowledge to clinical practice;
- learn new findings about key conditions in pulmonary, critical care and sleep;
- gain new strategies to manage the care of common conditions in pulmonary, critical care, and sleep.

The annual Clinical Year in Review symposia topic reviews of the key clinical research publications over the last year. Each speaker is asked to review the 5-7 most important and influential publications on their topic from the prior year.

Chairing: J.L. Taylor-Cousar, MD, Denver, CO
D.J. Lederer, MD, MS, New York, NY
D.W. Ford, MD, MSCR, Charleston, SC

9:00 **COPD**
C.P. Hersh, MD, MPH, Boston, MA

9:30 **Pulmonary Rehabilitation**
S.J. Singh, PhD, Leicester, United Kingdom

10:00 **Lung Transplantation**
J.A. Belperio, MD, Los Angeles, CA

10:30 **Cystic Fibrosis**
J.L. Taylor-Cousar, MD, Denver, CO

*This session and the International Conference are supported by an educational grant from **AstraZeneca LP.***
All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

BASIC • CLINICAL

CLINICAL TOPICS IN PULMONARY MEDICINE

CME Credits Available: 2.0

A2 JAMA AND THE NEW ENGLAND JOURNAL OF MEDICINE. DISCUSSION ON THE EDGE: REPORTS OF RECENT PULMONARY RESEARCH

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 2002/2004 (West Building, Level 2)

This session will provide a forum for attendees to interact with the authors and editors about papers published in JAMA and the New England Journal of Medicine. Papers presented will be recent publications, selected by the editors, to be of significant importance to the field of pulmonary medicine. Attendees will have the opportunity to hear presentations directly from the author and address questions to both the authors and editors. The discussion is intended to provide a unique insight into these papers, the selection process, and how the research applies directly to the field of pulmonary medicine.

Chairing: J.M. Drazen, MD, Editor-in-Chief, New England Journal of Medicine
G.T. O'Connor, MD, MS, Associate Editor, JAMA

Speakers And Talks To Be Announced

CLINICAL

CLINICAL TOPICS IN PULMONARY MEDICINE

CME Credits Available: 2.0

A3 FELLOWS CASE CONFERENCE

Training Committee; Assemblies on Allergy, Immunology and Inflammation; Behavioral Science and Health Services Research; Clinical Problems

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 134 (North Building, Lower Level)

Target Audience
Clinicians, nurses, fellows, residents, and researchers looking to broaden their clinical acumen to facilitate clinical and translational research.

Objectives
At the conclusion of this session, the participant will be able to:

- recognize clinical, radiographic, and pathologic findings of rare diseases;
- gain insight into clinical decision making skills demonstrated by master clinicians, radiologists and pathologists which will improve the quality of learners' practice and potentially improve quality of care for the learner's patients;
- develop strategies to evaluate patients with common symptoms that include uncommon/rare diseases in the differential diagnosis when appropriate.

This session will consist of unique cases presented and discussed by fellows with a panel of clinical experts to moderate the discussion and provide commentary. The cases will provide new insights into disease pathogenesis, diagnosis, and/or treatment. Selected cases will include clear clinical teaching points with review of associated pathology and radiology as appropriate. Finally, the discussion will highlight medical decision making important for both physicians-in-training and seasoned clinicians.

Chairing: J.W. McCallister, MD, Columbus, OH

9:00 **Introduction**
J.W. McCallister, MD, Columbus, OH

9:10 **Case Presentations**

Progressive Dyspnea and Abnormal CT of the Chest
A. Singla, MD, Cincinnati, OH

Spontaneous Pneumothorax: an Unusual Presentation of Systemic Disease
K. Ma, MD, New York, NY

Chronic Cough: An Under Recognized Etiology
W. Warren, DO, Bethesda, MD

Progressive Dyspnea in a 40 Year Old Woman
H. Gaztambide, MD, Gainesville, FL

Lymphoproliferative Disorder: Diagnostic Considerations
V. Murthy, MD, New York, NY

A Diagnostic Dilemma: Waxing and Waning Pulmonary Nodules
K. Treger, DO, Jacksonville, FL

10:10 **Expert Discussants**

Expert Clinicians
M.I. Schwarz, MD, Aurora, CO
A.H. Limper, MD, Rochester, MN
P.E. Parsons, MD, Burlington, VT

Expert Pathologist
H.D. Tazelaar, MD, Scottsdale, AZ

Expert Radiologist
B.M. Elicker, MD, San Francisco, CA

CLINICAL

CRITICAL CARE TRACK

CME Credits Available: 2.0

A4 NEW ERA OF EVIDENCE GENERATION: MEASURING EFFECTIVENESS IN CRITICAL CARE

Assemblies on Critical Care; Clinical Problems; Nursing

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**
Room 3000/3002/3004 (West Building, Level 3)

Target Audience
Critical care providers; intensivists; nurse practitioners; quality improvement researchers; hospital administrators; ICU administrators.

Objectives
At the conclusion of this session, the participant will be able to:

- understand novel trial design aspects of comparative effectiveness research in critically ill patients and how the ICU can be a learning health care system;
- interpret and apply the results of large effectiveness trials done in critically ill patients;
- understand the ethics of comparative effectiveness research and issues of consent.

Clinical trials using pragmatic design principles aimed at truly testing effectiveness of process of care aspects or currently used treatments are becoming increasingly popular. Federal funding, including both the NIH and PCORI, have emphasized the need for these types of trials. Comparative effectiveness and pragmatic trials conducted in the ICU are an emerging field in both clinical and quality improvement research. This session will discuss the increasing use of novel trial designs to generate estimates of treatment effectiveness in the critically ill and how to interpret and apply the results of these types of ICU studies.

Chairing: T.W. Rice, MD, MSc, Nashville, TN
D. Janz, MD, MSc, New Orleans, LA

9:00 **What's Pragmatic about Pragmatic Trials?**
T.W. Rice, MD, MSc, Nashville, TN

9:10 **Patient Centered Outcomes and Other Endpoints in Practical ICU Studies**
D. Janz, MD, MSc, New Orleans, LA

9:25 **Unique Trial Designs: Recent Novel Pragmatic Trials in Critical Illness**
M.W. Semler, MD, Nashville, TN

9:40 **Interpreting ICU Effectiveness Trials: Are the Results Applicable to My ICU or Patients?**
B.T. Thompson, MD, Boston, MA

10:00 **To Ask or Not To Ask? Ethics, Informed Consent, and Stopping Rules in Comparative Effectiveness Trials in Critical Illness**
B. Cuthbertson, MD, Toronto, Canada

10:20 **Fusing RCTs with Big Data in Critical Illness**
D.C. Angus, MD, MPH, Pittsburgh, PA

10:40 **The ICU as a Learning Healthcare Environment**
J.V. Selby, MD, MPH, Washington, DC

BASIC • CLINICAL • TRANSLATIONAL

BASIC SCIENCE CORE

CME Credits Available: 2.0

A5 UNDERSTANDING LUNG DISEASE PHENOTYPES: NETWORKS AND SYSTEMS BIOLOGY

Assemblies on Allergy, Immunology and Inflammation; Respiratory Cell and Molecular Biology; Respiratory Structure and Function

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**
Room 2009/2011 (West Building, Level 2)

Target Audience
Basic and clinical scientists, research and clinical trainees, drug discovery and development sector workers, providers of lung health care.

Objectives
At the conclusion of this session, the participant will be able to:

- understand fundamental approaches for systems biology and their application in research of pathophysiology;
- become aware of approaches to study epigenetic, transcriptional, post translational mechanism that contribute to lung diseases;
- learn new findings about post-transcriptional gene regulation.

The session highlights the state of the art in high throughput technologies and bioinformatics relevant to a broad range of lung disorders. How advanced bioinformatics can be used to understand integration of complex responses will be discussed, focusing on how to understand complexities of cell signaling disease pathogenesis.

Chairing: A.J. Ammit, PhD, Sydney, Australia
A. Fedulov, MD, PhD, Boston, MA

9:00 **Asthma Is a Systemic Epigenetic Disease**
R.L. Miller, MD, New York, NY

9:24 **Integrated Approaches to Understanding Pulmonary Fibrosis**
D.A. Schwartz, MD, Aurora, CO

9:48 **What Gene Expression Networks Tell Us About the Mechanisms of Anti-Inflammatory Glucocorticoid Action**
R. Newton, PhD, Calgary, Canada

10:12 **DUSP1 and TTP Co-Operate to Regulate Cytokine Expression: Knowledge Gained from Experimental Models of Arthritis**
A.R. Clark, PhD, Birmingham, United Kingdom

10:36 **RNA-Protein Interactions on a Global Scale: Investigating mRNA-Binding Proteomes in Model Organisms**
A.P. Gerber, PhD, Guildford, United Kingdom

This session and the International Conference are supported by an educational grant from ***Boehringer Ingelheim Pharmaceuticals, Inc.***
All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

BASIC • CLINICAL • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 2.0

A6 JOINT ATS/ERS/JRS SYMPOSIUM ON SEVERE ASTHMA: A GLOBAL PERSPECTIVE

Assemblies on Allergy, Immunology and Inflammation; Clinical Problems; Environmental, Occupational and Population Health; Nursing; Pediatrics; Respiratory Cell and Molecular Biology; Respiratory Structure and Function

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**
Room 2001/2003 (West Building, Level 2)

Target Audience
Providers of lung health and those taking care of patients with asthma.

Objectives
At the conclusion of this session, the participant will be able to:

- review recent advances in the epidemiology and molecular basis of severe asthma;
- understand the clinical and molecular heterogeneity of severe asthma;
- highlight areas of needed research to reduce the impact of this disease on human health.

This symposium proposal represents an international collaborative effort between members of the Japanese Respiratory Society, The European Respiratory Society, and the American Thoracic Society to foster interactions towards a precision medicine approach to severe asthma. Globally, severe asthma represents a subset of asthma accounting for approximately 5-10% of patients with asthma. However health care utilization for this subset has been estimated to be up to 40% of the economic burned of asthma. Recently there has been significant efforts to determine the underlying basis for this disease in terms of epidemiology, physiology, immunology, and genetics that influence this phenotype. Data are emerging that serve asthma consists of several endotypes. This phenotypic and now molecular classification may greatly aid in patient management with improved disease control, improved clinical outcomes and reduced medical costs. This symposium will highlight recent advances as well as highlight needed areas of research to advance treatment and prevention of this disease.

Chairing: G.P. Downey, MD, Denver, CO
K. Asano, MD, Kanagawa, Japan
S. Hashimoto, MD, Tokyo, Japan
B.D. Levy, MD, Boston, MA
N.N. Jarjour, MD, Madison, WI

9:00 **Introduction and Overview of Severe Asthma**
B.D. Levy, MD, Boston, MA

9:05 **Severe Asthma: Lessons Learned from Global Studies**
K. Asano, MD, Kanagawa, Japan

9:22 **Severe Asthma in the Pediatric Population**
S.J. Szefler, MD, Aurora, CO

9:39 **Pathogenesis of Severe Asthma: A Clue from the Common Genes Underlying Asthma and COPD**
N. Hizawa, MD, Tsukuba, Japan

9:56 **Serum Periostin: A Key Marker to Dissect the Pathophysiology of Type 2-Predominant Asthma**
H. Matsumoto, MD, PhD, Kyoto, Japan

10:14 **Current Therapies for Severe Asthma in 2016**
M. Kraft, MD, Tucson, AZ
Parker B. Francis Speaker

10:32 **Severe Asthma Phenotype/Endotype Guided Therapy**
P.J. Sterk, MD, PhD, Amsterdam, Netherlands

10:50 **Summary of Symposium and Panel Discussion**
N.N. Jarjour, MD, Madison, WI

This session and the International Conference are supported by an educational grant from ***AstraZeneca LP.***
All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

BASIC • CLINICAL • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 2.0

A7 ATS MYTHBUSTER: REVERSING FIBROSIS IN THE LUNGS IS BIOLOGICAL MISSION (IM)POSSIBLE

Assemblies on Respiratory Cell and Molecular Biology; Allergy, Immunology and Inflammation; Clinical Problems; Respiratory Structure and Function

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**
Room 2016/2018 (West Building, Level 2)

Target Audience
Basic, translational, clinical researchers, and clinicians interested in fibrotic lung diseases, including IPF, connective tissue disease-ILD, chronic hypersensitivity pneumonitis and sarcoidosis.

Objectives
At the conclusion of this session, the participant will be able to:

- understand both the overall potential, and the current barriers, to reverse established fibrosis in patients with fibrotic lung diseases;
- understand how effector fibroblasts and extracellular matrix could be targeted to induce the regression of established fibrosis;

- understand the lung's capacity for compensatory re-growth of functional alveolar units after they are injured or lost.

In this provocative session we will explore the hypothesis that pulmonary fibrosis biology dictates that fibrosis cannot be reversed once it is established. We will use the very successful "mythbusters" format: leading researchers will give talks relevant to this hypothesis, after which expert "mythbusters" will discuss its validity. The session will end with an audience vote on the validity of the hypothesis. We hope to pair this session with another mythbusters session exploring the clinical implications of this hypothesis: that the best that we can hope to achieve with new therapies for fibrotic lungs diseases is the prevention of progression.

Chairing: M.R.J. Kolb, MD, PhD, Hamilton, Canada
M. Konigshoff, MD, PhD, Munich, Germany
A.M. Tager, MD, Charlestown, MA

9:00 **A Patient's Perspective**
S. Rock, Rancho Murieta, CA

9:05 **Once a Myofibroblast, Always a Myofibroblast? Can Lung Myofibroblasts Revert Like They Do in the Liver?**
T. Kisseleva, MD, PhD, La Jolla, CA

9:25 **Targeting Matrix Cross-Linking: The Achilles Heel of Fibrosis?**
P.J. Sime, MD, Rochester, NY

9:45 **Turning Fibrosis Down a Notch while Turning Up Regeneration: Progenitor Cell Notch Signaling Determines Outcome of Lung Injury**
H. Chapman, MD, San Francisco, CA

10:05 **Busting the Myth that the Lung Cannot Regenerate**
B. Ding, PhD, New York, NY

10:25 **Panel Discussion**
G. Laurent, PhD, Nedlands, Australia
J. Gauldie, PhD, Hamilton, Canada
Z. Borok, MD, Los Angeles, CA

There will be a 5-minute discussion after each talk.

This session and the International Conference are supported by an educational grant from ***Boehringer Ingelheim Pharmaceuticals, Inc.***
All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

BASIC • CLINICAL • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 2.0

A8 EVERYTHING YOU EVER WANTED TO KNOW ABOUT SEX STEROIDS AND LUNG DISEASE

Assemblies on Respiratory Structure and Function; Allergy, Immunology and Inflammation; Pulmonary Circulation; Respiratory Cell and Molecular Biology; Thoracic Oncology

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**
Room 2006/2008 (West Building, Level 2)

Target Audience
Lung health providers, trainees, and those involved in research or clinical care related to lung disease and reproductive hormones. This topic is expected to appeal to both scientists and clinicians.

Objectives
At the conclusion of this session, the participant will be able to:

- learn new findings about the effects of sex steroid signaling on lung structure and function;
- apply knowledge about sex steroids to management of patients with non-neoplastic lung diseases;
- apply knowledge about sex steroids to management of patients with lung cancer.

Sex steroids (i.e., reproductive hormones) have biologic and pathophysiologic actions in the lung mediated by both genomic and non-genomic mechanisms. This session will review the biology of sex steroids and their receptors in the lung, discuss the impact of sex steroids on lung structure and function, and explore the role of sex steroid signaling in lung diseases with known gender differences in incidence and in morbidity and mortality. The learner will better understand the impact of sex steroids on disease manifestation and severity and will appreciate the potential for these hormones as biomarkers and therapeutic targets in lung disease.

Chairing: G.S. Skloot, MD, New York, NY
Y.S. Prakash, MD, PhD, Rochester, MN
M. MacLean, PhD, Glasgow, United Kingdom

9:00 **Introduction to Sex Steroid Signaling and Effects on Lung Structure and Function**
Y.S. Prakash, MD, PhD, Rochester, MN

9:25 **The Role of Sex Steroid Signaling In Pulmonary Hypertension**
M. MacLean, PhD, Glasgow, United Kingdom

9:50 **The Role of Sex Steroid Signaling in Airway Disease**
B.N. Melgert, PhD, Groningen, Netherlands

10:15 **The Role of Sex Steroid Signaling In Lung Cancer**
C.A. Powell, MD, New York, NY

10:40 **Future Directions: Sex Steroids as Potential Biomarkers and Therapeutic Targets**
S.E. Wenzel, MD, Pittsburgh, PA

There will be a 5-minute discussion after each talk.

This session and the International Conference are supported by an educational grant from ***AstraZeneca LP.***
All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

CLINICAL • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 2.0

A9 CONTROVERSIES IN SLEEP MEDICINE: DAVIDS, GOLIATHS, AND SOME BLOOD ON THE FLOOR!

Assemblies on Sleep and Respiratory Neurobiology; Clinical Problems

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**
Room 3003/3005 (West Building, Level 3)

Target Audience
Sleep physicians, researchers, nurses, and trainees.

Objectives
At the conclusion of this session, the participant will be able to:

- learn about the mechanistic underpinnings of the interactions between sleep-disordered breathing and heart failure and consequent effects of patient outcomes;
- apply appropriate patient selection practices to identify candidates for novel emerging therapies for obstructive sleep apnea other than CPAP therapy;
- understand the relationship between sleep-disordered breathing and cancer and whether this can be translated into practice.

Sleep medicine is at the cusp of major advancements and impact on population health and well-being. However, there are thorny issues that have emerged as areas of controversies that need to be debated. While cardiovascular disease and cancer remain top killers, the role of treatment of sleep disordered breathing in patients with heart failure, and the relationship between sleep-disordered breathing and cancer are hotly debated. Moreover, emerging treatments for sleep-disordered breathing are rapidly changing the landscape as they disrupt and find their rightful place in the treatment hierarchy. This symposium features "world" heavy-weights in the respective areas of sleep medicine who will "reconcile" their differences while keeping bloodshed to a minimum. Attendees will learn about the mechanistic underpinnings of the interactions between sleep, heart failure and cancer; the clinical implications of such complex interactions; and emerging treatment approaches to sleep disordered breathing. This symposium is not for the weak hearted.

Chairing: N.A. Antic, MBBS, PhD, Adelaide, Australia
S. Parthasarathy, MD, Tucson, AZ
J.P. Bakker, PhD, Boston

9:00 **PRO: Should We Treat Sleep Disordered Breathing in Heart Failure?**
D. Bradley, MD, Toronto, Canada

9:20 **CON: Should We Treat Sleep Disordered Breathing in Heart Failure?**
M. Naughton, MBBS, MD, East Melbourne, Australia

9:40 **PRO: Sleep Disordered Breathing Causes Cancer?**
R. Farre, PhD, Barcelona, Spain

10:00 **CON: Sleep Disordered Breathing Causes Cancer?**
C.P. O'Donnell, PhD, Pittsburgh, PA

10:20 **PRO: There Will Never Be a Superior Treatment for OSA than CPAP**
C. Sullivan, MBBS, PhD, Sydney, Australia

10:40 **CON: There Will Never Be a Superior Treatment for OSA than CPAP**
D.P. White, MD, Denver, CO

There will be a 5-minute discussion after each talk.

BASIC • CLINICAL • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 2.0

A10 NEW INSIGHTS INTO THE PATHOGENESIS AND TREATMENT OF BRONCHOPULMONARY DYSPLASIA

Assemblies on Pediatrics; Respiratory Cell and Molecular Biology

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**
Room 3007/3009 (West Building, Level 3)

Target Audience
Neonatologists, pediatric pulmonologists, basic scientists interested in lung development, inflammation, genetic basis of disease and stem cell biology.

Objectives
At the conclusion of this session, the participant will be able to:

- learn new findings about molecular targets important in the pathogenesis of BPD identified through animal and human studies;
- apply stem cell based approaches to their patients in order to improve outcomes in BPD;
- describe new advances in the molecular understanding of the timing of normal birth and the importance of fetal lung maturity and inflammation in the process of initiation of labor.

Bronchopulmonary dysplasia (BPD) continues to be a major cause of morbidity and mortality for prematurely born infants. This session will highlight recent advances in our understanding of the causes of BPD from newer mouse models and large-scale human genetic studies, contributions of the lung microbiome to neonatal disease, and newer approaches to therapy using cell based therapies, as well as new links to understanding the causes of timing of parturition, as prevention of preterm birth is the ultimate therapy for the prevention of BPD.

Chairing: L.M. Nogee, MD, Baltimore, MD
B. Thebaud, MD, PhD, Ottawa, Canada

9:00 **Chronic Lung Injury Induced by Ventilation: Insights from Neonatal Mouse Models**
R. Bland, MD, Stanford, CA

9:20 **The Lung Microbiome and Chronic Lung Disease in the Premature Infant**
A. Hamvas, MD, Chicago, IL

9:40 **Genomic Approach to Understanding BPD**
N. Ambalavanan, MD, Birmingham, AL

9:55 **Honing in on Rare Variants Contributing to BPD**
H.M. O'Brodovich, MD, Stanford, CA

10:10 **Cell Based Therapies for BPD**
B. Thebaud, MD, PhD, Ottawa, Canada

10:30 **Lung Maturation, Inflammation and the Timing of Parturition**
C. Mendelson, PhD, Dallas, TX

10:50 **Discussion**
B. Thebaud, MD, PhD, Ottawa, Canada
L.M. Nogee, MD, Baltimore, MD

There will be a 5-minute discussion after each talk.

BASIC • BEHAVIORAL • CLINICAL • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 2.0

A11 GLOBAL LUNG CANCER HEALTH ISSUES

Assemblies on Behavioral Science and Health Services Research; Clinical Problems; Environmental, Occupational and Population Health; Thoracic Oncology

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**
Room 303/305 (South Building, Esplanade Level)

Target Audience
Clinicians, researchers and educators with an interest in lung cancer and in global lung health.

Objectives
At the conclusion of this session, the participant will be able to:

- learn new findings about best practices for early detection of lung cancer;
- apply recent guidelines and policy statements to be able to better diagnose and stage lung cancer;
- integrate new treatment and prevention options in discussing lung cancer with patients.

Lung cancer is the leading cause of cancer death in the world. The challenge to decrease lung cancer mortality through prevention, early detection, rapid diagnosis, staging, and precision therapy is global; yet approaches to these efforts vary. Speakers for this session are drawn from the International Relations Working Group of the ATS Thoracic Oncology Assembly with leaders from ATS, JRS, ERS, the Chinese Respiratory Association, and the Latin American Thoracic Association. Topics will include prevention, lung cancer screening, precision therapy, updates in lung cancer classification and staging, and quality benchmarks for diagnosis and treatment.

Chairing: C.A. Powell, MD, New York, NY
M. Gaga, MD, PhD, Athens, Greece
S. Quadrelli, MD, PhD, Buenos Aires, Argentina
C. Bai, MD, PhD, Shanghai, China

9:00 **The Role of Smoking Cessation in the Prevention of Lung Cancer**
J.M. Samet, MD, MS, Los Angeles, CA

9:20 **WHO-IARC, IASLC-ATS Updates of Lung Cancer Classification,**
C.A. Powell, MD, New York, NY

9:40 **Integration of Imaging and Molecular Biomarkers for Lung Cancer Detection**
C. Bai, MD, PhD, Shanghai, China

10:00 **Screening for Lung Cancer: Maximizing Benefits and Minimizing Harms**
M.K. Gould, MD, MS, Pasadena, CA

10:20 **Precision Therapy of Lung Cancer: Targets, Resistance, and Opportunities**
K. Kiura, MD, PhD, Okayama, Japan

10:40 **European Initiative for Quality Management in Lung Cancer Care**
M. Gaga, MD, PhD, Athens, Greece

This session and the International Conference are supported by an educational grant from ***AstraZeneca LP.***
All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests

BASIC • CLINICAL • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 2.0

A12 ENTREPRENEURSHIP: EMBRACING THE INNOVATIVE ENVIRONMENT - FROM BENCH TO BOARDROOM TO BEDSIDE

Drug and Device Discovery Development Committee

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**
Room 3010/3012 (West Building, Level 3)

Target Audience
Basic,translational and clinical investigators and those responsible for translating knowledge into innovations in academia, government, nonprofits and industry.

Objectives
At the conclusion of this session, the participant will be able to:

- understand how to turn discoveries into innovations;
- find funding sources for innovations;
- grow one's career.

The symposium will show the importance of entrepreneurship in creating an innovative environment. The session will focus on successful examples of entrepreneurship and innovation in big pharma, academia, biotech and government. Speakers will discuss different entrepreneurial mechanisms currently used to identify and fund innovation, including venture capital, philanthropy, patient support organizations and government (e.g., NIH, NSF) Small Business Innovation Research/Small Business Technology Transfer (SBIR/STTR), and their applicability to a diverse ATS membership. Regulatory insights will be provided into alternative pathways to develop and secure approval for innovative drugs and devices.

Chairing: T.F. Reiss, MD, New Hope, PA
J. Moss, MD, PhD, Bethesda, MD

9:00 **The Innovative Mindset**
M. Turner, PhD, Westfield, NJ

9:24 **Entrepreneurship: Academic Insights into Technology Transfer**
C. Wyskiel, MBA, Baltimore, MD

9:48 **Early Lessons in Entrepreneurship: A Venture Capital Perspective**
C. Berkland, PhD, Lawrence, KS

10:12 **SBIR/STTR Grants: Funding the Path from Academia to Industry**
C.G. Irvin, PhD, Burlington, VT

10:36 **The Cystic Fibrosis Foundation: A Profitable Non-Profit's Guide to Therapeutic Success**
R.J. Beall, PhD, Bethesda, MD

MINI SYMPOSIUM

A13 NOVEL INNATE IMMUNE PATHWAYS IN SEVERE ASTHMA

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 2005/2007 (West Building, Level 2)

Chairing: K.F. Chung, MD, PhD, London, United Kingdom
M. Idzko, MD, Freiburg, Germany
R.W. Harper, MD, Sacramento, CA

Oral Presentations

9:00 **Macrophage Inflammasome Activation in Sputum from Severe Asthmatics/**S. Pavlidis, C. Rossios, M. Loza, F. Baribaud, A. Rowe, C.H.S. Kuo, R. Lutter, U. Hoda, I. Pandis, Y.-K. Guo, A.R. Sousa, J. Corfield, P.J. Sterk, R. Djukanovic, I. Adcock, K.F. Chung, High Wycombe, United Kingdom, p.A1001

9:15 **NLRP3 Inflammasome-Mediated, IL-1β-Dependent Inflammatory Responses Drive Severe, Steroid-Insensitive Asthma/**R.Y. Kim, J.W. Pinkerton, A.-T. Essilfie, A.A. Robertson, K.J. Baines, J.R. Mayall, M.R. Starkey, P.A. Wark, P.G. Gibson, L.A. O'Neill, J.C. Horvat, M.A. Cooper, P.M. Hansbro, New Lambton Heights, Australia, p.A1002

9:30 **Overexpression of Gasdermin B, a Gene Target of the 17q12 Asthma-Susceptibility Regulatory Haplotype, Accentuates Allergic Airway Inflammation/**N. Krishnamoorthy, X. Zhou, M.A. Perrella, B.D. Levy, B.A. Raby, Boston, MA, p.A1003

9:45 **Airway Epithelial DUOX1 Mediates EGFR Activation, Mucus Metaplasia, and Remodeling During Allergic Asthma/**A. Van Der Vliet, M. Hristova, A. Habibovic, D. Heppner, Y. Janssen-Heininger, C.G. Irvin, M.E. Poynter, L.K.A. Lundblad, A.E. Dixon, M. Geiszt, Burlington, VT, p.A1004

10:00 **Role of Interferon Regulatory Factor-1 (IRF-1) in Modulating Steroid Insensitive Pathways in Severe Asthma/**A. Gavrila, L. Chachi, O. Tliba, C.E. Brightling, Y. Amrani, Leicester, United Kingdom, p.A1005

10:15 **P2Y6R Signaling: A Double-Edged Sword in Allergen-Induced Airway Inflammation/**A. Zech, A. Meyer, M. Idzko, Freiburg, Germany, p.A1006

10:30 **1,25D3 Prevents CD8+Tc2 Skewing and Asthma Development Through VDR Binding Changes to the Cyp11a1 Promoter/**M. Schedel, Y. Jia, S. Michel, K. Takeda, J. Domenico, A. Joetham, M. Strand, J. Han, M. Wang, J.L. Lucas, C. Vogelberg, E.W. Gelfand, M. Kabesch, B.P. O'Connor, Denver, CO, p.A1007

10:45 **TSLP in Patients with Asthma, COPD and ACOS/**P. Korosec, S. Korn, S. Skrgat, R. Marcun, R. Buhl, M. Flezar, Golnik, Slovenia, p.A1008

MINI SYMPOSIUM

A14 ADVANCE CARE PLANNING AND PALLIATIVE CARE: PATIENTS TO POLICY

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 307 (South Building, Esplanade Level)

Chairing: R.D. Stapleton, MD, PhD, Burlington, VT
E.K. Kross, MD, Seattle, WA

Oral Presentations

9:00 **Validation of a Prognostic Model to Predict 6-Month Mortality in Medical Intensive Care Unit (MICU) Patients/**R.G. Sangani, K. Chapman, S. Hadique, S. Culp, S. Khan, J.E. Parker, A. Moss, Morgantown, WV, p.A1009

9:15 **Principles of End-of-Life Care for the Critically Ill: Sources of Variability in Opinions About Autonomy, Advance Directives, and Intensive Care Unit Interventions/**A.C. Long, L. Downey, E.K. Kross, R.A. Engelberg, M. Baras, J.R. Curtis, C.L. Sprung, Seattle, WA, p.A1010

9:30 **What Is Palliative Care's Secret Ingredient? How Intensivists and Palliative Care Physicians Navigate Communication with Surrogates About a Patient's Values and Preferences in High-Fidelity Simulation/**L.P. Scheunemann, P.S. Rajagopal, R.M. Arnold, D.B. White, Pittsburgh, PA, p.A1011

9:45 **Using the Early Warning System (EWS) to Identify and Establish Goals of Care/Advanced Directives in a High Risk Patient Population: A Randomized, Prospective Trial/**D. Picker, M. Dans, T. Bailey, K. Heard, M.H. Kollef, St. Louis, MO, p.A1012

10:00 **Attitudes of Critical Care Clinicians Toward the Use of Triggers for Intensive Care Unit-Based Palliative Care Consultation/** N.G. Wysham, D.M. Jones, W. Reagan, H. Goucher, S. Gundel, C.T.L. Hough, J. Mcfarlin, M. Hua, C.E. Cox, Durham, NC, p.A1013

10:15 **Advance Directives and Their Impact on Real-World Stability of End-of-Life Preferences in Hospitalized Patients/**Y.S. Kim, V. Liu, P. Scheirer, J.D. Greene, G.J. Escobar, Oakland, CA, p.A1014

10:30 **The Association Between Hospice Utilization and Performance on Publicly Reported Outcome Measures/**S. Lah, E. Wilson, S.M. Brown, Murray, UT, p.A1015

10:45 **Do Not Resuscitate Orders with Unplanned Hospital Readmission Quality Measures in Pneumonia/**A.B. Mehta, C.R. Cooke, I.S. Douglas, P.K. Lindenauer, R.S. Wiener, A.J. Walkey, Boston, MA, p.A1016

MINI SYMPOSIUM

A15 EMERGING DATA ON COPD EXACERBATIONS

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 130-132 (North Building, Lower Level)

Chairing: J.A. Wedzicha, MD, PhD, London, United Kingdom
E.C. Oelsner, MD, MPH, New York, NY
S. Sethi, MD, Buffalo, NY

Oral Presentations

9:00 **Helicobacter Pylori Modifies the Effects of Azithromycin in COPD/**S.W. Ra, M. Sze, S. Tam, Y. Oh, G. Lee, N. Fishbane, G. Criner, P.G. Woodruff, R. Albert, J.E. Connett, S.C. Lazarus, M.K. Han, S.D. Aaron, P. Man, D.D. Sin, Ulsan, Korea, Republic of, p.A1017

9:15 **Serum Immunoglobulins and Risk of Exacerbations in COPD/**F.S.S. Leitao, S.W. Ra, A. Mattman, G. Criner, P.G. Woodruff, R. Albert, J.E. Connett, S.C. Lazarus, M.K. Han, S.D. Aaron, D.D. Sin, R.M. Reed, Vancouver, Canada, p.A1018

9:30 **The Influence of Stable State Eosinophil Count and Acute Exacerbations on the Airway Microbiome in COPD/**R. Singh, Z. Wang, J.R. Brown, B.E. Miller, R. Tal-Singer, S. Van Horn, L. Tomsho, B. Barker, U. Kolsum, D. Singh, C.E. Brightling, P.J. Barnes, G.C. Donaldson, J.A. Wedzicha, London, United Kingdom, p.A1019

9:45 **Dissociation Between Airway and Systemic Inflammatory Changes at Exacerbation in COPD/**G.C. Donaldson, K.B.R. Belchamber, R. Singh, U. Kolsum, B. Barker, C.E. Brightling, D. Singh, P.J. Barnes, L. Donnelly, J.A. Wedzicha, London, United Kingdom, p.A1020

10:00 **Long-Term Effects of Antibiotics in COPD Exacerbations: A Randomized Clinical Trial/**P. Van Velzen, G. Ter Riet, P. Bresser, B.T.J. Van Den Berg, J.W.K. Van Den Berg, J.M.A. Daniels, D.R.G.L. Groeneveld, R.E. Jonkers, F.H. Krouwels, K. Pool, A. Rudolphus, P.J. Sterk, J.M. Prins, Amsterdam, Netherlands, p.A1021

10:15 **Is There a Causal Association Between Past and Future Acute Exacerbations of COPD? Evidence from a Population-Based Study/**M. Sadatsafavi, H. Xie, J.M. FitzGerald, Vancouver, Canada, p.A1022

10:30 **Increased Systemic Inflammation, as Measured by Absolute Levels and Change in IL-6, at Exacerbation Onset Predicts Clinical Non-Recovery at 35 Days/**A.J. Mackay, A.R.C. Patel, R. Singh, R. Sapsford, C. Compton, N. Prasad, E. Cullen, G.C. Donaldson, J.A. Wedzicha, London, United Kingdom, p.A1023

10:45 **CRP and NT-proBNP in Combination are Promising Blood Tests to Diagnose COPD Exacerbations/**Y.-W.R. Chen, S. Tam, V. Chen, Z. Hollander, R.T. Ng, B.M. McManus, J.M. FitzGerald, S.C. Lazarus, P.G. Woodruff, J.E. Connett, G.J. Criner, R. Albert, M.K. Han, P. Man, D.D. Sin, Vancouver, Canada, p.A1024

MINI SYMPOSIUM

A16 EPIDEMIOLOGY AND HEALTH CARE COSTS OF PEDIATRIC AND ADULT ASTHMA

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 3020/3022 (West Building, Level 3)

Chairing: C.C. Johnson, MPH, PhD, Detroit, MI
C.D. Ramsey, MD, Winnipeg, Canada
S.B. Khatri, MD, MSc, Cleveland, OH

Oral Presentations

9:00 **Prevalence and Risk Factors for Persistent Very Poorly Controlled (VPC) Asthma After More Than a Decade in the TENOR II Cohort/**T. Haselkorn, R.S. Zeiger, L. Borish, B. Paknis, E.R. Bleecker, A. Foreman, F. Kianifard, S.T. Weiss, B.E. Chipps, S.J. Szefler, Los Altos, CA, p.A1025

9:15 **Early-Life Rhinitis Predicts Exercise-Induced Wheeze and Asthma Hospitalizations in School Age Children, Independent of Allergic Sensitization/**K.W. Savary, R.L. Miller, L. Hoepner, F.P. Perera, I.F. Goldstein, M.S. Perzanowski, New York, NY, p.A1026

9:30 **Surgical but not Natural Menopause Is Associated with an Increased Asthma Incidence: Results from the E3N Prospective Cohort/**B. Matulonga, D. Courbon, A. Fournier, A. Bedard, S. Mesrine, M. Sanchez, G. Thabut, F. Clavel, R. Varraso, B. Leynaert, Paris, France, p.A1027

9:45 **Environmental Exposures Associated with Childhood Asthma Sub-Phenotypes/**P. Ryan, K. Schmidlin, C. Brokamp, D. Bernstein, J. Lockey, G.K. Hershey, G. LeMasters, Cincinnati, OH, p.A1028

10:00 **Thiazolidinedione Drugs Decrease Risk for Incident Asthma in a 15-Year Longitudinal Study of Excess Weight Veterans/**A. Sood, C. Qualls, A. Murata, J.T. Mao, D. Schade, G. Murata, Albuquerque, NM, p.A1029

10:15 **Daily 1-Hour Peak Levels of Sulfur Dioxide Are Associated with Increased Respiratory Symptoms in Detroit Children with Asthma/**T.C. Lewis, T.G. Robins, S.A. Batterman, B. Mukherjee, G.B. Mentz, E.A. Parker, B.A. Israel, Ann Arbor, MI, p.A1030

10:30 **Prospective Study of Alternate Health Eating Index 2010 and Asthma Symptom Score: Mediation Through Body Mass Index and Effect Modification by Smoking/**Z. Li, E. Kesse-Guyot, O. Dumas, J. Garcia-Aymerich, B. Leynaert, C. Pison, N. Le Moual, I. Romieu, V. Siroux, C.A. Camargo, R. Nadif, R. Varraso, Villejuif, France, p.A1031

10:45 **Clinical and Economic Burden of Uncontrolled Asthma and Elevated Eosinophil Levels/**J. Casciano, Z. Dotiwala, C. Li, S. Sun, White Plains, NY, p.A1032

MINI SYMPOSIUM

A17 GENETICS AND GENOMICS OF CHILDHOOD LUNG DISEASE

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 3006/3008 (West Building, Level 3)

Chairing: A. Hamvas, MD, Chicago, IL
D. Pillai, MD, Washington, DC
E. Forno, MD, MPH, Pittsburgh, PA

Oral Presentations

9:00 **Exome Sequencing Identifies Common Coding Variants Associated with Severe Respiratory Outcomes Following Preterm Birth/**T.J. Mariani, R. Feng, F. Wang, M. Bhattacharjee, S. Bhattacharya, J. Mereness, Y. Bi, A. Ahmad, P.L. Ballard, A. Hamvas, Rochester, NY, p.A1033

9:15 **Polymorphisms of Genes Involved in Extracellular Matrix Remodeling and Bronchopulmonary Dysplasia in Extremely Low Birth Weight Infants/**U. Paudel, A. Amin, L.A. Parton, Valhalla, NY, p.A1034

9:30 **Early 'OMIC' Biomarkers Predict Bronchopulmonary Dysplasia (BPD)/**C.V. Lal, V. Bhandari, N. Ambalavanan, Birmingham, AL, p.A1035

9:45 **Genetic Ancestry and Genome-Wide Associations Related to Bronchopulmonary Dysplasia in Preterm Infants Treated with Inhaled Nitric Oxide (iNO)/**D.G. Torgerson, S. Oh, R.L. Keller, S. Huntsman, D. Hu, C. Eng, D. Black, E.G. Burchard, P.L. Ballard, R.A. Ballard, San Francisco, CA, p.A1036

10:00 **A Multi-Omics Approach to Identify Genes Associated with Childhood Asthma Risk and Morbidity/**E. Forno, Q. Yan, T. Wang, E. Acosta-Perez, A. Colon-Semidey, M. Alvarez, N. Boutaoui, J.F. Alcorn, G. Canino, W. Chen, J.C. Celedon, Pittsburgh, PA, p.A1037

10:15 **Gene Expression Reflective of Type 2 Inflammation in the Upper and Lower Airways of Children with Asthma in the Severe Asthma Research Program (SARP)/**A. Coverstone, L.B. Bacharier, M. Peters, A.M. Fitzpatrick, W.G. Teague, B. Gaston, W. Phipatanakul, N. Ly, S. Ramratnam, J.V. Fahy, A.T. Hastie, P.G. Woodruff, S.C. Kerr, D. Mauger, B. Phillips, S.E. Wenzel, M. Castro, St. Louis, MO, p.A1038

10:30 **Mitotic Asynchrony Induces a Pro-Inflammatory State in Airway Epithelium/**S. Alcala, A. Benton, A. Watson, E. Reeves, J. Damsker, Z. Wang, K. Nagaraju, M.C. Rose, E.P. Hoffman, R.J. Freishtat, Washington, DC, p.A1039

10:45 **Gene Therapy for Spinal Muscular Atrophy Type 1 Improves Survival and Stabilizes Pulmonary Outcomes in a Phase I/IIa Safety Study/**R.D. Shell, K. Kotha, S. Al-Zaidy, W.D. Arnold, L. Rodino-Klapac, J. Kissel, S. McElroy, C. Miranda, L. Lowes, L. Alfano, K. Berry, S. Corcoran, K. Meyer, S. Likhite, B. Kaspar, J. Mendell, Columbus, OH, p.A1040

MINI SYMPOSIUM

A18 BLINDED BY THE LIGHT: INSIGHT FROM GENETICS IN PAH

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 3016/3018 (West Building, Level 3)

Chairing: M. Aldred, PhD, Cleveland, OH
N.W. Morrell, MD, Cambridge, United Kingdom

Oral Presentations

9:00 **Pre-Capillary Specific Pulmonary Vascular Smooth Muscle Cell Growth Via Altered BMP Signaling in Idiopathic Pulmonary Arterial Hypertension (IPAH)/**K. Ihida-Stansbury, H. Li, M. Chokshi, T. Nguyen, R. Riley, S.M. Kawut, H. DeLisser, Philadelphia, PA, p.A1041

9:15 **Potassium Channel Subfamily K Member 3 (KCNK3) Contributes to the Development of Pulmonary Arterial Hypertension/**F. Antigny, A. Hautefort, J. Meloche, M. Belacel-Ouary, B. Manoury, F. Potus, C. Rucker-Martin, V. Nadeau, G. Ruffenach, E. Tremblay, A. Bourgeois, B. Ranchoux, S. Breuil-Bonnet, P. Dorfmuller, E. Fadel, P. Jourdon, B. Girerd, D. Montani, S. Provencher, S. Bonnet, M. Humbert, F. Perros, Le Plessis Robinson, France, p.A1042

9:30 **PPARγ Controls the DNA Damage Response by Modulating UBR5 Interaction with the MRE11-RAD50-NBS1 Complex, an Impaired Signalling Pathway in Pulmonary Arterial Hypertension/**C.G. Li, C.S. Mahon, E. Verschueren, V. Kantamani, N. Sweeney, I. Diebold, S. Sa, L. Wang, A. Cao, J.K. Hennigs, K. Cimprich, M. Rabinovitch, Stanford, CA, p.A1043

9:45 **Loss of Cavin-2 Contributes to Lung Caveolae Dysfunction Enhancing Pulmonary Arterial Hypertension/**B.J. Dunmore, A. Crosby, S. Moore, J. Cheng, G. Howard, M. Southwood, B.J. Nichols, N.W. Morrell, Cambridge, United Kingdom, p.A1044

10:00 **LPS-Induced Acute Lung Inflammation, Cav-1 Degradation, and eNOS Uncoupling Is Associated with Endothelial Dysfunction and Pulmonary Vascular Remodeling/**S.D.S. Oliveira, M. Castellon, J.W. Chen, R.F. Machado, M.G. Bonini, M.H. Elliot, R.D. Minshall, Chicago, IL, p.A1045

10:15 **Intracellular MIF Contributes to the Abnormal Hyper-Proliferative and Apoptosis-Resistant Phenotype in iPAH Endothelial Cells Via a p53/PTEN Dependent Mechanism/**M. Le Hiress, L. Tu, C. Phan, R. Thuillet, A. Seferian, E.-M. Jutant, E. Fadel, G. Simonneau, Y. Tamura, A. Huertas, M. Humbert, C. Guignabert, Le Plessis-Robinson, France, p.A1046

10:30 **BMPR2 Augmented EPC Delivery in a Rat Monocrotaline Induced PAH Model Alters Smad Signalling Profiles/**R.L. Harper, R. Ward, C. Bonder, P.N. Reynolds, Adelaide, Australia, p.A1047

Featured Speaker

10:45 **Genetics in PAH: 2016 and Beyond/**N.W. Morrell, MD, Cambridge, United Kingdom,

MINI SYMPOSIUM

A19 GETTING POLARIZED: MR IMAGING IN OBSTRUCTIVE LUNG DISEASE

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 2020/2022 (West Building, Level 2)

Chairing: J.C. Woods, PhD, Cincinnati, OH
S.B. Fain, PhD, Madison, WI

Oral Presentations

9:00 **Characterizing the Ventilation Distribution in Healthy Normal Subjects to Establish Robust Quantitative Analysis of 129Xe MRI/**M. He, S.H. Robertson, J.M. Wang, L.G. Que, K. Mahmood, B. Driehuys, Y.-C. Huang, Durham, NC, p.A1048

9:15 **Hyperpolarized Xenon-129 MRI: A New Tool to Evaluate COPD/**K. Qing, Y.M. Shim, N.J. Tustison, T.A. Altes, K. Ruppert, J.F. Mata, B. Mehrad, G.W. Miller, S. Guan, I.C. Ruset, F.W. Hersman, J.P. Mugler, Charlottesville, VA, p.A1049

9:30 **Testing the Fletcher-Peto Assumptions Using Pulmonary Imaging Biomarker Longitudinal Measurements/**R.L. Eddy, D. Pike, K. Sheikh, G. Paulin, M. Kirby, D.G. McCormack, G. Parraga, London, Canada, p.A1050

9:45 **Prediction of Future Lung Function Decline from Baseline Hybrid Hyperpolarized 3He MRI in Current Smokers and COPD Patients/**H. Hamedani, S. Kadlecek, Y. Xin, M. Cereda, H. Gatens, J. Naji, S. Siddiqui, M. Pourfathi, M. Rossman, R.R. Rizi, Philadelphia, PA, p.A1051

10:00 **Regional Ventilation Defects Measured on Hyperpolarized 3He MRI Are Associated with Mucus Plugging Measured on CT in Asthma/**E. Dunican, J.V. Fahy, D.G. Mummy, S. Fain, E.A. Hoffman, B.M. Elicker, D.S. Gierada, J.D. Newell, Jr, N.N. Jarjour, M. Castro, S. Nagle, San Francisco, CA, p.A1052

10:15 **Segmental Ventilation Defect Percentage in Hyperpolarized 3He MRI in Asthma Is Associated with Airway Wall Thickness Measured on CT/**D.G. Mummy, W. Zha, R. Sorkness, L.C. Denlinger, J.D. Quirk, D. Gierada, J.C. Woods, M. Castro, N.N. Jarjour, S. Fain, Madison, WI, p.A1053

10:30 **What Does Magnetic Resonance Imaging Signal-Intensity Mean in Asthma?/**K. Sheikh, F. Guo, S. Svenningsen, A. Ouriadov, D.P. Capaldi, R.L. Eddy, D.G. McCormack, G. Parraga, London, Canada, p.A1054

10:45 **Measurement of Asthma Treatment Response Using Free-Breathing 1H Ventilation MRI/**D.P. Capaldi, K. Sheikh, S. Svenningsen, M. Kirby, H. Coxson, D.G. McCormack, G. Parraga, London, Canada, p.A1055

POSTER DISCUSSION SESSION

A21 CHRONIC AIRWAY INFLAMMATION: MICROBIAL INFLUENCE

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 2024 (West Building, Level 2)

Poster Viewing **9:00-9:45**

Discussion **9:45-11:00**

Chairing: J.S. Deshane, PhD, Birmingham, AL
M.R. Stampfli, PhD, Hamilton, Canada
P.S. Foster, PhD, Callaghan, Australia
S. Bozinovski, PhD, Bundoora, Australia

601 **The Effects of Smoking on The Lower Airway DNA Virome/**B.C. Keller, G. Zhao, B.G. Wu, J.C. Clemente, L.N. Segal, St. Louis, MO, p.A1056

602 **Longitudinal Changes in Airway Microbiome Signatures and Immunoregulatory Cell Dynamics Following Bronchial Thermoplasty/**J.S. Deshane, J. Trevor, Y. Wang, D. Zhi, M. Curtiss, F. Wang, P.G. Eipers, V.D.P. William, C. Morrow, M.T. Dransfield, Birmingham, AL, p.A1057

603 **A Study to Define the Microbiome of the Asthmatic Airway/**E. Hunt, S. Lapthorne, C. Ward, J. Eustace, B. Plant, D. Murphy, J. MacSharry, Cork, Ireland, p.A1058

604 **Nasal Microbiome Composition Varies over Time in Pediatric Asthma/**M. Perez-Losada, L. Alamri, A. Goldstein, K.A. Crandall, R.J. Freishtat, Ashburn, VA, p.A1059

605 **The Infant Gut Microbiome, Respiratory Infection, and Repeated Wheeze in the First Year of Life: Findings from the Vitamin D Antenatal Asthma Reduction Trial (VDAART)/**J.E. Sordillo, Y. Zhou, M. McGeachie, N. Lange, N. Laranjo, J. Savage, V.J. Carey, E. Sodergren, S.T. Weiss, D.R. Gold, G. Weinstock, A.A. Litonjua, Boston, MA, p.A1060

606 **Factors Influencing the Infant Gut Microbiome at Age 3-6 Months: Findings from the Ethnically Diverse Vitamin D Antenatal Asthma Reduction Trial (VDAART)/**J.E. Sordillo, Y. Zhou, M. McGeachie, N. Lange, N. Laranjo, J. Savage, V.J. Carey, G. Weinstock, E. Sodergren, D.R. Gold, S.T. Weiss, A.A. Litonjua, Boston, MA, p.A1061

607 **Utilizing the Collaborative Cross Cohort to Identify the Genetics of Host Responses to Respiratory Syncytial Virus/**A.S. Buntzman, D. Francisco, K. Addison, A. Manne, J. Frelinger, J.G. Ledford, F.D. Martinez, M. Kraft, Tucson, AZ, p.A1062

608 **Rhinovirus-Induced Production of PGE2 by Asthmatic Bronchial Epithelial Cells: Inverse Association with Strain Pathogenicity/**L. Shi, E. Roti Roti, A. Guadarrama, P. Fichtinger, L.C. Denlinger, Madison, WI, p.A1063

609 **Group A Streptococcus (GAS) Indudes Bronchial Asthma (BA)/**T. Matsuda, Misato-shi, Saitama, Japan, p.A1064

610 **Bronchial Microbiome in Severe Persistent Oral Corticosteroid-Dependent Asthma/**L. Millares, G. Bermudo, M. Garcia-Nunez, C. Grimau, N. Martinez-Lopez, V. Perez-Brocal, C. Domingo, E. Monso, Sabadell, Spain, p.A1065

611 **Effects of Recombinant Myristoylated Rhinovirus VP4 Protein on Primary Alveolar Macrophages/**J.K. Bentley, S. Jaipalli, M. Han, J. Lei, M.B. Hershenson, Ann Arbor, MI, p.A1066

612 **Mycobiome Analysis of Lower Airway Secretions from Children with Fungal-Sensitized Severe-Persistent Asthma/**E.M. St. John Sutton, A. Tsuang, S. Viswanathan, R. Burke, D.L. Goldman, A.G. Vicencio, New York, NY, p.A1067

613 **Gene Expression and Protein Secretion in Normal Versus Diseased Human Lung Tissue/**L. Sherman, D. Mohn, K. Miner, C. Vezina, J.A. Johnston, Thousand Oaks, CA, p.A1068

614 **Infants with Early Wheeze Have Decreased Lung Function and Microbial Changes of Their Upper Airway at 3 Months of Age/**K. Kloepfer, S. Srivatsa, J.E. Hatch, D. Nelson, S. Janga, S.D. Davis, Indianapolis, IN, p.A1069

615 **Respiratory Syncytial Virus Exacerbates OVA-Mediated Asthma Through C3a/C3aR and C5a/C5aR Signaling Regulating CD4+T Cells Immune Responses/**X. Hu, X. Li, C. Hu, J. Feng, Changsha, China, p.A1070

616 **Relationship Between Environmental Fungal Spore Concentration and Acute Exacerbations of Obstructive Airway Disease in an Adult Population/**J. Aleman-Ortiz, O. Cantres-Fonseca, W. Rodriguez-Cintron, San Juan, Puerto Rico, p.A1071

617 **Changes in the Lung Microbiome Induced by Exposure to Tobacco Smoke in Healthy Mice and Mice with Chronically Inflamed Airways/**M. Engle, B. Zorn, C. Jania, J.R. Martin, M.C. Wolfgang, C.M. Doerschuk, Chapel Hill, NC, p.A1072

618 **Compromised Nasal Host Response Contributes to Invasive Pneumococcal Disease in Cigarette Smoke-Exposed Mice/**M.R. Stampfli, M.C. Morissette, D.M. Bowdish, R. Labiris, C.M. Bauer, C.S. Stevenson, P. Shen, Hamilton, Canada, p.A1073

619 **The Lung Microbiota Drives a COPD-Like Phenotype in Secretory IgA-Deficient Mice/**B.W. Richmond, R.M. Brucker, R.-H. Du, L. Gleaves, S. Bordenstein, T.S. Blackwell, V.V. Polosukhin, Nashville, TN, p.A1074

620 **Mannose Binding Lectin Deficient Haplotypes Are Associated with Fewer Exacerbations and a More Diverse Microbiome in Chronic Obstructive Pulmonary Disease/**A.J. Dicker, M. Crichton, A. Cassidy, G. Brady, A. Hapca, G.G. Einarsson, J.S. Elborn, S. Schembri, S. Marshall, C.N.A. Palmer, J.D. Chalmers, Dundee, United Kingdom, p.A1075

621 **Microbial Community Resemblance in the Airways Relates to a Comparable Immune Response in Asthma and Chronic Obstructive Pulmonary Disease/**C. Ascoli, K. Hogarth, R. Knowlton, A. Rani, R. Ranjan, D. Perkins, P.W. Finn, Chicago, IL, p.A1076

622 **Role of the Gut Microbiome in Obesity-Related Increases in Pulmonary Responses to Ozone: Sex Differences/**Y. Cho, D.I. Kasahara, G. Abu-Ali, C. Huttenhower, S.A. Shore, Boston, MA, p.A1077

623 **Lung Function is Inversely Associated with Interferon Inducible Gene Expression by Pediatric Asthmatic Bronchial Epithelial Cells in Response to in vitro RSV Infection/**M.C. Altman, E. Whalen, K. Misura, T.K. Kolstad, J.A. Rosenthal, S.R. Reeves, S.F. Ziegler, J.S. Debley, Seattle, WA, p.A1078

624 **Topographical Analysis of the Aerodigestive Microbiome in Children with Cough and Respiratory Symptoms/**L. Segal, B.D. Scaglione, B.G. Wu, Y. Li, A. Wang, J. Gilani, J. Erkman, K. Fitzgerald, J. Levine, L. Moy, M. Kazachkov, New York, NY, p.A1079

625 **In Inner-City Children with Asthma Infected with Rhinovirus, Viral Load Correlates with Nasal Aspirate Cytokine Expression but not Respiratory Symptoms/**T.C. Lewis, E.E. Metitiri, I.H. Winer, A.T. Comstock, A.M. Goldsmith, X. Ren, T.G. Robins, G.B. Mentz, S.A. Batterman, B. Mukherjee, M.B. Hershenson, Ann Arbor, MI, p.A1080

POSTER DISCUSSION SESSION

A22 TECHNOLOGY FOR DISEASE IDENTIFICATION AND MANAGEMENT IN PULMONARY AND CRITICAL CARE

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 309 (South Building, Esplanade Level)

Poster Viewing **9:00-9:45**

Discussion **9:45-11:00**

Chairing: C.E. Cox, MD, MPH, Durham, NC
M.R. Patel, PhD, MPH, Ann Arbor, MI
O. Gajic, MD, Rochester, MN

301 **Evaluating Patient Readiness for Health Portal Access/** N. Emeagwali, E. Maidan, S. McLaughlin, Providence, RI, p.A1081

302 **Harnessing Technology for Patient-Centered Self-Management: Assessing an Interactive Video Module Education for Inhaler Technique/**V.G. Press, C.A. Kelly, J.J. Kim, D.O. Meltzer, S.R. White, V.M. Arora, Chicago, IL, p.A1082

303 **Are Low-Income Asthmatic Adults Using the Patient Portal for Communicating with Their Health Care Providers?/**A.J. Apter, A.R. Localio, T. Bryant-Stephens, L. Perez, K. Morales, N. Mak, X. Han, S. Hardy, S. Reed-Wells, A. Nardi, J.T. Howell, Philadelphia, PA, p.A1083

304 **The Evaluation of Breathe - A Patient Mobile Health (mHealth) App for Adult Asthma/**C. Licskai, M. Ferrone, A. Taite, C. Madeley, A. Stevens Lavigne, T. To, M. Yeung, J. Cafazzo, A.G. Day, D. Lougheed, London, Canada, p.A1084

305 **Patients Find Inhaler Reminders Acceptable and Useful for Changing Adherence Behaviour/**J.M. Foster, T. Usherwood, L. Smith, S.M. Sawyer, H.K. Reddel, Sydney, Australia, p.A1085

306 **Smart COPD App: An iPhone COPD Triage App Using Machine Learning Modelling/**R.M. Jasmer, L.A. Louizos, A.N. Gerber, J.A. Schouten, C. Brendan, E.H. Anaya, C. Escoda, San Francisco, CA, p.A1086

307 **Validating an Automated Algorithm to Identify Outpatient Treated COPD Exacerbations Using Electronic Medical Records Data/**S. Ko, S. Greif, J.S. Lee, A. Liu, S.A. Desai, A. Harrington, S.M. Lee, M.L. Moy, V.S. Fan, M.K. Gould, H.Q. Nguyen, Fontana, CA, p.A1087

308 **Derivation and User-Testing of MyQ-COPD: A Question Prompt List App for Patients with Chronic Obstructive Pulmonary Disease/**N.G. Wysham, A. Mathews, J. Nicolla, C.E. Cox, A. Kamal, Durham, NC, p.A1088

309 **A Novel Text and Email Messaging Pilot Project to Help Improve Quality of Life and Management in Elderly ILD Patients/**T.D. Walker, D. Schwartz, M.I. Schwarz, J. Swigris, Aurora, CO, p.A1089

310 **A Smartphone Application for Reporting Symptoms in Adults with Cystic Fibrosis Has Excellent Usability and Its Data Is Interpreted Consistently by Clinicians/**J. Wood, S. Jenkins, D. Putrino, S. Mulrennan, S. Morey, N. Cecins, K. Hill, Perth, Australia, p.A1090

311 **Natural Language Processing to Systematically Identify All Patients with Abnormal Pulmonary Imaging Findings in Radiology Text Reports/**S.B. Zeliadt, K.W. Hammond, R. Laundry, J.E. Takasugi, L.C. Feemster, E.H. Pham, P.A. Greene, L.F. Reinke, S. Dawadi, D.H. Au, Seattle, WA, p.A1091

312 **Electronic Medical Record Smoking History Does Not Accurately Identify Candidates for Lung Cancer Screening - Disproportionately Affecting Vulnerable and High-Risk Populations/**Y.-C. Wu, M.T. Perkovich, K.M. Woldemichael, I.A. Gilbert, Milwaukee, WI, p.A1092

313 **Automated Detection of Undertreated Outpatient Pneumonia/** J. Gifford, S. DeLisle, Baltimore, MD, p.A1093

314 **Predicting 30-Day Pneumonia Readmissions Using Electronic Health Record Data from the First Day of Hospitalization: Model Development and Comparison/**A.N. Makam, O.K. Nguyen, S. Zhang, B. Xie, M.A. Weinreich, R. Amarasingham, E.M. Mortensen, E.A. Halm, Dallas, TX, p.A1094

315 **Predicting 30-Day Pneumonia Readmissions Using Electronic Health Record Data from the Full Hospital Stay: Model Development and Comparison/**A.N. Makam, O.K. Nguyen, S. Zhang, B. Xie, M.A. Weinreich, R. Amarasingham, E.M. Mortensen, E.A. Halm, Dallas, TX, p.A1095

316 **Iterative Development, Usability, and Acceptability Testing of a Communication App for Mechanically Ventilated Patients/**M.B. Happ, T. Von Visger, M.L. Weber, B. Vermillion, E. Chipps, B. Traughber, L. Patak, Columbus, OH, p.A1096

317 **Using the Electronic Medical Record to Define Pre-Hospital Frailty in Adults with Acute Respiratory Failure requiring Mechanical Ventilation/**A.A. Hope, O. Adeoye, S.J. Hsieh, H.B. Gershengorn, E.J. Chuang, M.N. Gong, Bronx, NY, p.A1097

318 **Development of EHR-Based Detection of Major Adverse Kidney Events Among Critically Ill Adults/**L.P. Halverson, M.W. Semler, C. Welch, J.M. Erhenfeld, J.P. Wanderer, M. Plante, A. Wheeler, T.W. Rice, Nashville, TN, p.A1098

319 **Electronic Health Record Recognition of Safety Issues by the Interprofessional Team During Simulated Rounds in the Intensive Care Unit/**K.K. Sakata, A. Mulanax, J. Bierman, K. McGrath, G. Scholl, A. McDougal, N. McCully, D. Bearden, V. Mohan, J.A. Gold, Portland, OR, p.A1099

320 **Usability Testing of an Online Advance Care Planning Tool for Advanced Lung Disease/**J. Chiarchiaro, J.M. Yeung, B.A. Myers, R.M. Arnold, D.B. White, Pittsburgh, PA, p.A1100

321 **Initial Clinician Impressions of a Novel Interactive Medical Record Timeline (MeRLin) to Facilitate Historical Chart Review During New Patient Encounters in the ICU/**M.E. Nolan, B.W. Pickering, V. Herasevich, Rochester, MN, p.A1101

322 **Charting Performance of the Checklist for Early Recognition and Treatment of Acute Illness (CERTAIN)/** A. Kogan, K. Pennington, S. Vallabhajosyula, J. Jensen, O. Gajic, J. O'Horo, Rochester, MN, p.A1102

323 **How Accurately Do ICU Providers Using an Electronic Health Record Communicate Patient Data During Daily Inter-Professional Patient Care Rounds?/**K.A. Artis, J. Bordley, K. McGrath, V. Mohan, J.A. Gold, Portland, OR, p.A1103

324 **Estimating Time Physicians and Other Healthcare Workers Spend with Patients in an Intensive Care Unit Using a Sensor Network/**R.R. Butler, M.N. Monsalve, A.M. Segre, T. Herman, P.M. Polgreen, H.L. Erickson, A.P. Comellas, Iowa City, IA, p.A1104

325 **Using Computer Vision and Depth Sensing to Measure Healthcare Worker-Patient Contacts/**H.L. Erickson, R.R. Butler, J. Ji, Z. Liu, J. Cremer, P.M. Polgreen, Iowa City, IA, p.A1105

POSTER DISCUSSION SESSION

A23 UNDERSTANDING AND REDUCING COPD REHOSPITALIZATIONS

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 3024 (West Building, Level 3)

Poster Viewing **9:00-9:45**

Discussion **9:45-11:00**

Chairing: S.S. Braman, MD, New York, NY
A. Lambert, MD, MHS, Baltimore, MD
G.J. Criner, MD, Philadelphia, PA

1001 **Early Refills of Inhaled Medication Are Associated with Increased 30-Day Risk of Hospitalization for COPD Exacerbation/**N.J. Parker, W. Bilker, S. Hennessy, J.D. Christie, Philadelphia, PA, p.A1106

1002 **Effectiveness of Discharge Care Bundles for Patients with Chronic Obstructive Pulmonary Disease: A Systematic Review/**M.B. Ospina, K. Mrklas, L. Deuchar, B.H. Rowe, R. Leigh, M. Bhutani, M. Stickland, Edmonton, Canada, p.A1107

1003 **A Delphi Consensus Study Among Clinicians to Inform a Discharge Care Bundle for Chronic Obstructive Pulmonary Disease/**M.B. Ospina, L. Deuchar, B.H. Rowe, R. Leigh, M. Bhutani, S. Couperthwaite, M. Oleszczuk, M. Stickland, Edmonton, Canada, p.A1110

1004 **Barriers and Facilitators for Implementing an Evidence-Based Discharge Care Bundle for Patients with Chronic Obstructive Pulmonary Disease/**M.B. Ospina, M. Oleszczuk, L. Deuchar, B.H. Rowe, R. Leigh, M. Bhutani, S. Couperthwaite, M. Davidson, J. Hall, E. Lang, K. Latoszek, C. McDavid, C. Peterson, R. Thomson, M. Stickland, Edmonton, Canada, p.A1111

1005 **Bridging the Gap - Hospital to Home Care in COPD Exacerbation: The Major Barriers in Preventing Re-Admission and Importance of Gender/**A. Le, B. Hutchins, J. Burns, S.F. Van Eeden, D.D. Sin, Vancouver, Canada, p.A1108

1006 **Analysis of COPD Readmissions Pre and Post Initiation of a COPD Care Coordination Pathway/**A. Chowdhury, M. Lee, M. Tan, A. Gupta, M. Kavuru, U. Vaid, Philadelphia, PA, p.A1109

1007 **Factors Associated with 30-Day Readmissions for COPD: A Health System Analysis/**R.G. Buhr, A.D. Zider, I. Barjaktarevic, M.K. Ong, C.B. Cooper, Los Angeles, CA, p.A1112

1008 **Chronic Obstructive Pulmonary Disease Hospitalizations in 2013-14: Demographic Trends in Readmission/**R. Regalbuto, C.P. Aaron, N. Yip, M. Brinson, M. Daley, B. Regan, B.M. Thomashaw, New York, NY, p.A1113

1009 **Understanding Failures in Delivery of Care for COPD Patients with 30-Day Readmission; Exploring Process Improvement Opportunities/**M.A. Zafar, E. Alessandrini, M.H. Eckman, E.J. Warm, R.J. Panos, Cincinnati, Ohio, p.A1114

1010 **The Impact of a COPD Care Coordination Program and Its Components on COPD 30-Day Readmission/**A.N. Russo, G. Sathiyamoorthy, C. Lau, D. Uzunaslan, X. Wang, U. Hatipoglu, Cleveland, OH, p.A1115

1011 **Health Coaching and COPD Re-Hospitalization: A Randomized Study/**R. Benzo, K. Vickers Douglas, P.J. Novotny, S. Tucker, J. Hoult, P. Neuenfeldt, J.E. Connett, K. Lorig, C. McEvoy, Rochester, MN, p.A1116

1012 **Predictors of Re-Admission After Hospitalization for Acute Exacerbation of COPD: Role of Glucocorticoid Dose and Duration/**N. Csikesz, L. Nici, Providence, RI, p.A1117

1013 **An Integrated Practice Unit Model to Reduce 30-Day Readmission for COPD: Results from a Medicare Bundled Payments for Care Improvement Initiative/**S.P. Bhatt, J.M. Wells, A.S. Iyer, D.P. Kirkpatrick, T.M. Parekh, E.M. Anderson, J.G. Sanders, J.K. Nichols, C.C. Blackburn, M.T. Dransfield, Birmingham, AL, p.A1118

1014 **Role of Long-Acting Bronchodilators and Inhaled Corticosteroids in 30 Days Readmission After Index Hospitalization for COPD/**R. Bishwakarma, W. Zhang, Y.F. Kuo, G. Sharma, Galveston, TX, p.A1119

1015 **Distribution of Cardiac Comorbidities Across GOLD Grades and Their Association with Readmission Outcomes/**R. Marron, S. Duffy, A. Kaur, N. Gaeckle, G. Criner, Philadelphia, PA, p.A1120

1016 **Comparative Effectiveness of Tiotropium Compared to No Long-Acting Bronchodilator After a Hospitalization for COPD/** M.H. Roberts, D.W. Mapel, H. Petersen, Albuquerque, NM, p.A1121

1017 **Chronic Obstructive Pulmonary Disease (COPD)-Related Hospitalizations by Health Status Response Among Patients Receiving Arformoterol Tartrate or Placebo: Post Hoc Analyses from a 52-Week Randomized, Controlled Study/** J. Donohue, V. Ganapathy, X. Zhou, L. Nelson, Chapel Hill, NC, p.A1122

1018 **Impact of Standardized Admission Order Template on COPD Exacerbation Admission Length of Stay and Readmission Rates/**K. Leung, A. Zakaria, I. Turk, B. Greib, E. Tommolino, S. Patel, G. Chand, C. Jackson, A. Carter, W. Farra, Southfield, MI, p.A1123

1019 **Stratifying Risk and Personalizing Care: The Path Forward for Reducing COPD Readmissions in an Inner-City Safety Net Hospital/**M. Islam, N. Ramesh, M. Harris, A. Chakravarti, J. Mecca, D. Steiger, P. Walker, New York, NY, p.A1124

1020 **Low Inspiratory Flow Rates Predict COPD and All Cause Readmissions/**C.H. Loh, T.M. Lovings, J.A. Ohar, Winston Salem, NC, p.A1125

1021 **Trends of COPD Exacerbation Length of Stay, Disposition, Mortality and Total Charges 2009 - 2013- A Review of a National Database/**M. Yaqoob, A. Alkhatib, J. Unterborn, Brighton, MA, p.A1126

1022 **COPD Is Associated with Significantly Higher Long-Term Readmission and Mortality but Has No Association with 30-Day All-Cause or Heart Failure Readmission or All-Cause Mortality in Older Medicare Beneficiaries Hospitalized for Heart Failure/**A.W. McLean, R. Khosla, P. Deedwania, A. Iyer, C. Inampudi, C. Morgan, S. Zhang, H. Sheriff, C. Faselis, R.D. Fletcher, G.C. Fonarow, W.S. Aronow, W.-C. Wu, C.J. Brown, S.D. Anker, R.M. Allman, A. Ahmed, Washington, DC, p.A1127

1023 **Characteristics and Comorbidities of Patients Readmitted to Yale-New Haven Hospital Following Index Admission for COPD Exacerbation/**S. Farasat, C.L. Rochester, J.D. Possick, Derby, CT, p.A1128

1024 **A Pilot Study Evaluating Predictors of Thirty-Day Hospital Readmissions for COPD/**V. Yap, A. Glucksman, D. Wilcox, R. ZuWallack, D. Datta, Farmington, CT, p.A1129

1025 **Chronic Obstructive Pulmonary Disease Risk Factors for Readmission in a Southern California Teaching Hospital/**K.C. Fan, D. Dworsky, P. Averell, J. Waalen, D. Elias, La Jolla, CA, p.A1130

POSTER DISCUSSION SESSION

A24 AUTOIMMUNE INTERSTITIAL LUNG DISEASE

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 133 (North Building, Lower Level)

Poster Viewing **9:00-9:45**

Discussion **9:45-11:00**

Chairing: J. Dematte, MD, MBA, Chicago, IL
R. Hallowell, MD, Boston, MA
T. Moua, MD, Rochester, MN

101 **Increased Concentration of BAFF and APRIL in Patients with Autoimmune Pulmonary Alveolar Proteinosis/**M. Hirose, A. Matsumuro, T. Arai, C. Sugimoto, M. Akira, Y. Inoue, Osaka, Japan, p.A1131

102 **Characterization of Patients Meeting Criteria for Interstitial Pneumonia with Autoimmune Features/**J.M. Oldham, A. Adegunsoye, E. Valenzi, C.T. Lee, L.J. Witt, S. Hsu, L.W. Chen, J.H. Chung, S. Montner, A. Husain, V. Cottin, A. Fischer, I. Noth, R. Vij, M.E. Strek, Chicago, IL, p.A1132

103 **Immunosuppressant Response Among Individuals Meeting Criteria for Interstitial Pneumonia with Autoimmune Features/**J.M. Oldham, A. Adegunsoye, L.J. Witt, E. Valenzi, C.T. Lee, L.W. Chen, S. Hsu, J. Chung, S. Montner, I. Noth, R. Vij, M.E. Strek, Chicago, IL, p.A1136

104 **Quantitative CT as an Outcome Measure in the Scleroderma Lung Study II/**J.G. Goldin, E. Kleerup, P. Lu, P. Clements, M. Brown, M.D. Roth, D.P. Tashkin, Los Angeles, CA, p.A1133

105 **Factors Associated with Relapse of Cryptogenic and Secondary Organizing Pneumonia/**Y. Onishi, T. Kawamura, R. Kagami, 8520, Japan, p.A1134

106 **Radiological Versus Histological Diagnosis in Antisynthetase -Associated Interstitial Lung Disease/**J.A. Huapaya, L.L. Silhan, S.K. Danoff, Baltimore, MD, p.A1135

107 **Additional Clinical Signs and Symptoms Develop in Patients with Antisynthetase Syndrome-Associated Interstitial Lung Disease Followed Over 24 Months/**J.A. Huapaya, L.L. Silhan, S.K. Danoff, Baltimore, MD, p.A1150

108 **Clinico-Radiological-Pathological Characteristics of Idiopathic Pleuroparenchymal Fibroelastosis/**K. Gocho, K. Sugino, K. Furuya, Y. Nakamura, T. Isshiki, T. Uekusa, K. Shibuya, S. Homma, Tokyo, Japan, p.A1137

109 **Transitional Voxel-Wise Changes in the Interstitial Lung Disease on High Resolution Computed Tomography using Scleroderma Lung Study-II/**G.H. Kim, D. Tashkin, P. Lo, P. Lu, M. Brown, E. Kleerup, M.D. Roth, J. Goldin, Los Angeles, CA, p.A1138

110 **Clinical Information of Secondary Pulmonary Alveolar Proteinosis in Japan: A Follow-Up Report (KAKEN26305028/AMED:H27-063)/**H. Ishii, R. Tazawa, T. Saraya, Y. Inoue, K. Nakata, Mitaka, Japan, p.A1139

111 **Short-Term Efficacy of Treatment in Myositis-Associated ILD/**M. Hachem, H. Nunes, J. Obert, Y. Uzunhan, D. Valeyre, J. Cadranel, J.-M. Naccache, Paris, France, p.A1140

112 **Observational Study of Therapeutic Response to Immunosuppression of CTD-ILD Versus AIF-ILD/**R. Parikh, P. Chung, K. Kuchta, R. Vij, S. Bellam, Evanston, IL, p.A1141

113 **Pleuroparenchymal Fibroelastosis (PPFE) Predicts Survival in Idiopathic Pulmonary Fibrosis (IPF)/**A. De Lauretis, H. Basra, W. Hakim, J. Jacob, D. Visca, M. Kokosi, M. Bonifazi, E. Renzoni, D.M. Hansell, A.U. Wells, London, United Kingdom, p.A1142

114 **Lung Cancer in Connective Tissue Disease-Associated Interstitial Lung Disease: Clinical Features and Impact on Outcome/**S. Watanabe, Y. Waseda, H. Takato, R. Matsunuma, K. Saeki, J. Hara, T. Sone, M. Abo, H. Kimura, K. Kasahara, Kanazawa, Japan, p.A1143

115 **Rheumatoid Arthritis Associated Usual Interstitial Pneumonia: Correlation of Histologic Features with Prognosis/**Y. Tsuchiya, D.A. Lynch, T. Johkoh, J. Fukuoka, T. Colby, S. Groshong, H. Taniguchi, K. Ichikado, A. Shiraki, N. Tanaka, H. Arakawa, Y. Waseda, K.K. Brown, J.J. Swigris, J.J. Solomon, Tokyo, Japan, p.A1144

116 **Whole Lung Lavage Therapy of Pulmonary Alveolar Proteinosis: A Global Survey of Current Practices and Procedures/**I. Campo, M. Luisetti, M. Griese, B.C. Trapnell, F. Bonella, J.C. Grutters, K. Nakata, C.H.M. Van Moorsel, U. Costabel, V. Cottin, T. Ichiwata, Y. Inoue, A. Braschi, G. Bonizzoni, G.A. Iotti, C. Tinelli, G. Rodi, Pavia, Italy, p.A1145

117 **Serum Anti-ARS and Anti-MDA-5 Antibodies Are Useful Biomarkers for Predicting the Prognosis in Patients with Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease/**H. Hozumi, T. Fujisawa, M. Kono, N. Enomoto, N. Inui, Y. Nakamura, T. Suda, Hamamatsu, Japan, p.A1146

118 **Rituximab in Progressive, Refractory to Conventional Treatment, Interstitial Lung Disease/**M.A. Kokosi, G. Keir, T. Corte, L. Troy, P. Saunders, F. Chua, T.M. Maher, E. Renzoni, A.U. Wells, London, United Kingdom, p.A1147

119 **Comparison of CTD-ILD, Autoimmune Featured ILD, and ILD with a Positive Autoimmune Serologic Marker/**P. Chung, R. Parikh, K. Kuchta, R. Vij, S. Bellam, Evanston, IL, p.A1148

120 **Acute Fibrinous and Organizing Pneumonia: A Newly Recognized, but Poorly Understood Disease/**A. Moraco, E. Bozkurtlar, U. Hironori, A. Akalin, E. Mark, S. Kopec, Worcester, MA, p.A1149

121 **Prevalence of Unclassifiable Interstitial Lung Disease (ILD) in a University Hospital in Buenos Aires, Argentina/**M.A. Grosso, P. Rossi, G. Legarreta, S. Acuna, J.I. Enghelmayer, Buenos Aires, Argentina, p.A1151

122 **Radiographic and Physiologic Abnormalities in Subjects with Myositis-Associated Interstitial Lung Disease/**D. Assayag, A. Hirsch, M. Baron, M. Hudson, Montreal, Canada, p.A1152

123 **Lung Cancer in Patients with Interstitial Lung Disease: Idiopathic Versus Connective Tissue Disease-Related Subtypes/**K. Saeki, S. Watanabe, Y. Waseda, H. Takato, R. Matsunuma, J. Hara, T. Sone, M. Abo, H. Kimura, K. Kasahara, Kanazawa, Japan, p.A1153

124 **Idiopathic Pleuroparenchymal Fibroelastosis and Its Mimickers/**S. Tomassetti, D.M. Nicotra, J.H. Ryu, S. Piciucchi, A. Dubini, P. Tantalocco, C. Ravaglia, C. Gurioli, A. Rossi, M. Chilosi, G.U. Di Maria, V. Poletti, Forli, Italy, p.A1154

125 **Effect of Mycophenolate Mofetil on Scleroderma-associated Interstitial Lung Disease/**M. Baqir, A. Makol, T.G. Osborn, B. Bartholmai, J. Ryu, Rochester, MN, p.A1155

POSTER DISCUSSION SESSION

A25 CRITICAL CARE: FUNCTIONAL OUTCOMES IN ICU SURVIVORS

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 3001 (West Building, Level 3)

Poster Viewing	**9:00-9:45**
Discussion	**9:45-11:00**

Chairing: D.M. Needham, MD, Baltimore, MD
R.N. Bakhru, MD, MS, Winston-Salem, NC
S.E. Jolley, MD, MSc, New Orleans, LA

701 **A Novel Noninvasive Method for Measuring Peripheral Muscle Strength in Fully Sedated Critically Ill Patients/**V.M. Da Silva, G. Cipriano Jr, J. Durigan, M. Machado, P.E. Silva, P.F. De Melo, L.T. Urache, Manaus, Brazil, p.A1156

702 **Accuracy of the Bedside Swallowing Evaluation and 3-Ounce Water Swallow Test for Diagnosing Aspiration In Survivors of Acute Respiratory Failure/**Y. Lynch, B. Clark, H. Taylor, L. Treviso, M. Macht, S.D. White, T. Wimbish, M. Moss, Denver, CO, p.A1157

703 **What Are Normal Nerve Conduction Study Amplitudes for Intensive Care Unit Patients?/**D.A. Kelmenson, D. Quan, M. Moss, Aurora, CO, p.A1158

704 **Physical Function Differs Among Intensive Care Unit Patients with Critical Illness Polyneuromyopathy, Deconditioning and Normal Strength/**D.A. Kelmenson, D. Quan, M. Moss, Aurora, CO, p.A1159

705 **Application of a Practice Assessment Tool for Rehabilitation of Critically Ill Patients/**J.T. Ellison, W.D. Schweickert, K. Kellner, B. Mirafuente, P. Morris, D.C. Files, R.N. Bakhru, Winston Salem, NC, p.A1160

706 **Effect of Daily Use of Electronic Checklist on Physical Rehabilitation Consultations in Critically Ill Patients/**R. Ali, V. Herasevich, O. Gajic, R. Kashyap, Rochester, MN, p.A1161

707 **Impact of Age and ICU Mobility Scores on Healthcare Outcomes/**A.M. Pastva, S. Silva, V. Sabol, Durham, NC, p.A1162

708 **Development of a Medical Record-Derived Frailty Index for ICU Patients/**E.J. Luxenberg, A.A. Hope, M.N. Gong, S.J. Hsieh, Bronx, NY, p.A1163

709 **"PERME Intensive Care Unit Mobility Score" e "Intensive Care Unit Mobility Scale (IMS)": Cross Cultural Validation and Reliability of the Portuguese Version/**Y.M.F. Kawaguchi, T.F. Borghetti, R.K. Nawa, L.C. Martins, R.C. Pires-Neto, Sao Paulo, Brazil, p.A1164

710 **A Prognostic Model to Predict Disability Free Survival One Year and Five Years After Mechanical Ventilation: A Population Based Cohort Study/**M. Wilson, K. Heise, T. Loftsgard, M.A. Dziadzko, K. sarvottam, P. Novotny, O. Gajic, M. Biehl, Rochester, MN, p.A1165

711 **Burden of Comorbid Illness Is Associated with 1-Year Survival but Not Early Disability After Critical Illness: Results from the RECOVER Program/**E. Merman, L. Chu, P. Robles, G. Tomlinson, C. Thomas, S.B. Burns, A. Andrea Matte, A. Matte, J. Friedrich, F. Lamontagne, G.M. Mehta, N. Adhikari, N. Ferguson, J. Rudkowski, H. Meggison, Y. Skrobik, J. Flannery, M. Bayley, J. Batt, C. Dos Santos, D. Cook, J. Cameron, M.S. Herridge, Toronto, Canada, p.A1166

712 **Protocolized Simple Bed-Side Rehabilitation for Patients in Intensive Care Unit/**S. Park, S. Kim, M. Lee, R. Ko, Y. Choe, S.R. Kim, Y. Lee, H. Lee, Jeonju, Korea, Republic of, p.A1167

713 **Early Progressive Mobility Protocol Implementation in the Surgical Intensive Care Unit: Analysis of Medical and Fiscal Benefits/**S. Yalamuri, C. Brudney, Durham, NC, p.A1168

714 **Characterization of Early Mobilization Practice in a Burn Critical Care Unit/**T.B. Figueiredo, K.F. Utsunomiya, R.C. Pires-Neto, Sao Paulo, Brazil, p.A1169

715 **Prospective Analysis of Levels of Activity and Functional Decline in Intensive Care Unit/**T.T. Gomes, D.S. Schujmann, A.C. Lunardi, C. Fu, Sao Paulo, Brazil, p.A1170

716 **The Early Neurocognitive Rehabilitation: Feasibility and Safety in Critically Ill Patients/**S. Fernandez-Gonzalo, M. Turon, G. Goma, M. Martinez-Perez, C. De Haro, J. Montanya, M. Jodar, J. Lopez-Aguilar, L. Blanch, Sabadell, Spain, p.A1171

717 **Identifying Clinically Important Outcomes in Clinical Trials of Neuromuscular Electrical Stimulation (NMES) in the ICU: A Survey of Key Stakeholders/**M.E. Kho, M. Duffett, M.S. Herridge, D.M. Needham, K.K. Koo, F. Lamontagne, P.M. Dodek, F.A. Costigan, D. Cook, Hamilton, Canada, p.A1172

718 **A Systematic Review of Clinically Important Outcomes in Clinical Trials of Neuromuscular Electrical Stimulation (NMES) in the ICU: Preliminary Results/**M.E. Kho, M. Duffett, D.M. Needham, M.S. Herridge, K.K. Koo, F. Lamontagne, P.M. Dodek, F.A. Costigan, D. Cook, Hamilton, Canada, p.A1173

719 **How Important Is the Functional Rehabilitation of Critically Ill Patients with Pulmonary Sepsis in the Hospital Context?/**Y.R. De Souza, D.L. Coelho, I.A. Fernandes, B.G. Almeida, V.S. Carvalho, V.H.B.P. Victorio, T.G.B. Melquiades, D.R. Teixeira, B.P. Rosa, C. Rachid, D.R. Oliveira, G. Pinheiro, S. Gomes, J.C. Rodrigues, S.F. Carvalho, Rio de Janeiro, Brazil, p.A1174

720 **Maximum Mobility Achieved Among Older Vs. Younger Patients in an Early Mobilization Program in the MICU/**L.E. Ferrante, T. Gill, T. Murphy, M. Douglas, M. Pisani, New Haven, CT, p.A1175

721 **Long-Term Cognitive Outcomes of Mechanically Ventilated Patients in a Randomized Controlled Trial of Early Mobilization/**E. MacKenzie, B.K. Patel, K.S. Wolfe, A.S. Pohlman, J.B. Hall, J.P. Kress, Chicago, IL, p.A1176

722 **Degree of Physical Impairment and Patient Age Influence Trajectory of Physical Functional Recovery in Survivors of Acute Respiratory Failure/**A. Neumeier, A. Nordon-Craft, D. Malone, M. Schenkman, B. Clark, M. Moss, Aurora, CO, p.A1177

723 **Mobility and Clinical Characteristics as Predictor and Protective Factors of Functional Decline in the Intensive Care Unit/**D.S. Schujmann, T.T. Gomes, A.C. Lunardi, C. Fu, Sao Paulo, Brazil, p.A1178

724 **Defining ICU Early Mobility as Walking: An Achievable Activity for Critically Ill Patients/**H. Engel, San Francisco, CA, p.A1179

725 **Recovery After ICU in Australia: Interim Results of Disability and Cognitive Dysfunction in Survivors at 6 Months/**C. Hodgson, T.J. Iwashyna, D.J. Cooper, T. ICU Recovery Study Investigators, Melbourne, Australia, p.A1180

POSTER DISCUSSION SESSION

A26 SMOKE, POLLUTANTS, AND TOXINS: INSIGHTS FROM BENCH STUDIES

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 2010/2012 (West Building, Level 2)

Poster Viewing **9:00-9:45**

Discussion **9:45-11:00**

Chairing: C. Carlsten, MD, MPH, Vancouver, Canada
N.E. Alexis, PhD, Chapel Hill, NC
M.J. Campen, PhD, Albuquerque, NM

401 **Interleukin-11 Receptor, Alpha Chain 1 Contributes to the Development of Ozone-Induced Airway Hyperresponsiveness in Mice/**R.A. Johnston, J.B. Richards, N.C. Mitchell, C.L. Atkins, I.U. Haque, Houston, TX, p.A1181

402 **Gut Microbiome, Bile Acids, and Pulmonary Responses to Ozone/**Y. Cho, D.I. Kasahara, T. Noonan, E. Karoly, S.A. Shore, Boston, MA, p.A1182

403 **Modeling Vascular Inflammation and Atherogenicity after Inhalation of Ambient Levels of Ozone: Exploratory Lessons from Transcriptomics/**A. Tham, San Francisco, CA, p.A1183

404 **Inhalation of Fine Particles from Mexico City Produce Fatal Asthma in a Guinea Pig Model of Allergic Airways Inflammation/**C.I. Falcon-Rodriguez, A. Osornio-Vargas, A. De Vizcaya-Ruiz, I. Rosas-Perez, P. Segura-Medina, Mexico City, Mexico, p.A1184

405 **Particulate Matter Stimulates Transforming Growth Factor Beta Synthesis and Secretion in Human Lung Epithelial Cells Via ROS Pathway/**X. Xu, X. Wu, J.G.N. Garcia, T. Wang, Beijing, China, p.A1185

406 **Tadalafil Ameliorates Halogen-Inhalation Injury During Pregnancy/**M.A. Carlisle, J. Lambert, A. Lam, S. Aggarwal, A.F. Zaky, L.J. Dell'Italia, W. Bradley, T. Jilling, S. Matalon, Birmingham, AL, p.A1186

407 **Effects of Ambient Air Pollution on Local Antibody Responses to Pneumocystis in HIV+ Patients/**R.J. Blount, K.R. Daly, E. Chang, S. Fong, R.F. Miller, P.D. Walzer, L. Huang, San Francisco, CA, p.A1187

408 **Diesel Activates Airway Sensory Nerves to Initiate Respiratory Symptoms/**R.K. Robinson, M.A. Birrell, M.A. Wortley, E.D. Dubuis, S. Chen, C.M. McGilvery, S. Hu, S.J. Bonvini, S.A. Maher, J.J. Adcock, I. Mudway, A.E. Porter, T.D. Tetley, M.G. Belvisi, London, United Kingdom, p.A1188

409 **Rapid Onset of Ozone-Induced Pulmonary Fibrosis in Diabetic KKAy Mice/**J.R. Harkema, D.N. Jackson-Humbles, R.P. Lewandowski, J.G. Wagner, R.M. Tighe, East Lansing, MI, p.A1189

410 **Effect of Environmental Irritants on the Respiratory Barrier in a 3D-Cell Culture Model/**S. Van Den Broucke, D. Oner, H. Vriens, P.H.M. Hoet, Leuven, Belgium, p.A1190

411 **Age-Related Modulation of Pulmonary and Systemic Innate Immunity Against Influenza A/PR/8/34 by Environmental Tobacco Smoke in Mice/**J.K. Dhillon, L. Wang, M. Kaur, K.E. Pinkerton, Davis, CA, p.A1191

412 **Molecular Impact of Electronic Cigarette Exposure on Bronchial Airway Epithelium/**M. Nitzberg, S. Corbett, E. Moses, T. Wang, G.R. Jackson, E. Drizik, C. Perdomo, E. Kleerup, D. Brooks, G.T. O'Connor, S.M. Dubinett, P. Hayden, M.E. Lenberg, A. Spira, Boston, MA, p.A1192

413 **E-cigarette Flavoring Aerosols Trigger Mitochondrial Stress Associated with Mitophagy in Lung Cells/**C.A. Lerner, P. Rutagarama, I.K. Sundar, I. Rahman, Rochester, NY, p.A1193

414 **The New Kid on the Block: E-cigarettes Can Cause Damage to Airway Cells and Cause Airway Macrophage Dysfunction/**M. Ween, G. Hodge, P. Reynolds, S. Hodge, Adelaide, Australia, p.A1194

415 **The Impact of New and Emerging Tobacco Products on the Airway Mucosal Barrier/**B. Reidel, G. Radicioni, A.A. Ford, P. Haridass, N.E. Alexis, I. Jaspers, M. Kesimer, Chapel Hill, NC, p.A1195

416 **Increase of Circulating Endothelial Progenitor Cells Following E-cigarette Inhalation in Human Subjects/**J. Bosson, L. Antoniewicz, J. Kuhl, S.A. Halim, F. Mobarrez, M. Lundback, Umea, Sweden, p.A1196

417 **Toxicological Effects of Electronic Cigarette Extracts on Lung Epithelial Cell Lines/**G.D. Rankin, H. Wingfors, B. Ekstrand-Hammarstrom, V. Alvarsson, M. Lundback, J. Bosson, Umea, Sweden, p.A1197

418 **Acute and Chronic Effects of Second-Hand Exposure to Nicotine and Propylene Glycol from an E-cigarette on Mucociliary Clearance in a Murine Model/**B. Laube, C. Bang, G. Chen, M. Collaco, P. Lazarus, S. McGrath-Morrow, Baltimore, MD, p.A1198

419 **Cigarette Smoke Exposure Is Associated with Increased Platelet Aggregation in Blunt Trauma Patients/**F. Moazed, C. Hendrickson, M. Nelson, A. Conroy, M.J. Cohen, C.S. Calfee, San Francisco, CA, p.A1199

420 **Development of an In Vitro Test to Assess the Inhalation Toxicity of Nanomaterials/**P.J. Hayden, M. Sharma, H. Barosova, S. Chortarea, F. Zerimariam, M. Clift, V. Stone, A. Maione, A. Clippinger, B. Rothen-Rutishauser, Ashland, MA, p.A1200

421 **A Toxicity Screening Platform Using Cryopreserved Precision Cut Lung Slices/**C.Y. Watson, F. Damiani, S. Ram-Mohan, T. Donaghey, J. Lichenstein, S. Rodrigues, P. Queiroz, J.D. Brain, R. Krishnan, R. Molina, Boston, MA, p.A1201

422 **Particle Exposure Impacts Iron Homeostasis in Alveolar Macrophages/**A. Ghio, J. Soukup, L. Dailey, Z. Shen, S. Kantrow, Chapel Hill, NC, p.A1202

423 **Increased Airway Dendritic Cell Activation and Altered Subset Distribution in London Children Exposed to Higher Levels of Pollution/**A. Whitehouse, N. Mushtaq, N. McCarthy, A. Stagg, J. Grigg, London, United Kingdom, p.A1203

424 **Smoking Upregulates the Serum Levels of Klotho-Related Molecules/**K. Nakanishi, M. Nishida, M. Murakami, T. Moriyama, K.Y. Takihara, Toyonaka, Japan, p.A1204

425 **Propylene Glycol and Glycerin in E-Cigarette Liquids Modulate Murine Respiratory Irritation Responses and Human Sensory Irritant Receptor Function/**S.E. Jordt, S. Jabba, K. Ghoreshi, G.J. Smith, J.B. Morris, Durham, NC, p.A7767

POSTER DISCUSSION SESSION

A27 ADVANCES IN PEDIATRIC SLEEP

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 3011 (West Building, Level 3)

Poster Viewing **9:00-9:45**

Discussion **9:45-11:00**

Chairing: M.L. Chen, MD, Seattle, WA
I. Narang, MD, Toronto, Canada
R. Bhattacharjee, MD, San Diego, CA

801 **A 10-Year Follow-Up Study on Childhood Obstructive Sleep Apnea in a Population-Based cohort: A Cardiovascular Perspective/**A.M. Li, C.T. Au, K. Chan, Y.K. Wing, Shatin, Hong Kong Prc, p.A1205

802 **Improving Adherence and Outcomes in Children with Obstructive Sleep Apnea Treated with Positive Airway Pressure/**G. Rulong, J. Crisalli, J. Brockbank, M. Dixon, L. Corlette, L. Mullen, G. Dinkins, N. Simakajornboon, Cincinnati, OH, p.A1206

803 **Behavioral Problems Among Young Community School-Aged Children: Impact of Sleep-Disordered Breathing/**L. Kheirandish-Gozal, D.L. Smith, S.J. Hunter, M.F. Philby, J. Kaylegian, D. Gozal, Chicago, IL, p.A1207

804 **Children with Obstructive Sleep Apnoea Have Lower T-Regulatory Cells in the Upper Airway and Peripherally Compared to Controls/**C.J. Grime, S. Saglani, C.M. Lloyd, M. Rosenthal, H.-L. Tan, London, United Kingdom, p.A1208

805 **Intelligent Volume-Assured Pressured Support (iVAPS) for the Treatment of Pediatric Congenital Central Hypoventilation Syndrome/**A. Khayat, D. Medin, S. Al-Saleh, T. Moraes, I. Narang, C. Daniels, F. Syed, R. Amin, Toronto, Canada, p.A1209

806 **Apnea in Term Infants: A National Estimate of Incidence and Costs/**J.C. Levin, J. Jang, L.M. Rhein, Boston, MA, p.A1210

807 **Functional Respiratory Imaging in Children and Adolescents with Obstructive Sleep Apnea and Down Syndrome/**M. Slaats, W. Vos, C. Van Holsbeke, M. Wojciechowski, J. De Backer, D. Loterman, W. De Backer, A. Boudewyns, S. Verhulst, Edegem, Belgium, p.A1211

808 **Functional Respiratory Imaging in Normal-Weight Children and Adolescents with Obstructive Sleep Apnea/**M. Slaats, W. Vos, C. Van Holsbeke, D. Loterman, J. De Backer, W. De Backer, A. Boudewyns, S. Verhulst, Edegem, Belgium, p.A1212

809 **Is PM10 Air Pollution a Risk Factor for Sleep-Disordered Breathing in Children? A Study in the Province of Varese/**L.M. Nosetti, C. Montomoli, S. Tentoni, F. Manzoni, A.C. Niespolo, L. Nespoli, Varese, Italy, p.A1213

810 **The Effect of Continuous Positive Airway Pressure (CPAP) Therapy on Obese Children with Stable Asthma/**H.E. Jalou, D. Givan, J. Wiebke, S.K. Gupta, J.E. Slaven, L.L. Bendy, R.S. Tepper, Indianapolis, IN, p.A1214

811 **Effect of Obstructive Sleep Apnea on Early Echocardiographic Changes in Children with Sickle Cell Anemia/**S. Pinto, G. Kato, M.M. Hossain, G. Huang, N. Simakajornboon, Cincinnati, OH, p.A1215

812 **GPCR Expression in Pulmonary Arterial Smooth Muscle Cells: Novel Targets for Pulmonary Hypertension/**K. Sriram, N. Aroonsakool, A.V. Michkov, P.A. Insel, La Jolla, CA, p.A1216

813 **Correlation Between Upper Airway Evaluation by Endoscopy and Polysomnogram Findings in Infants with OSA Treated with Supplemental Oxygen/**Z. Ehsan, J.C. Brockbank, C. Heubi, D. Benscoter, C.K. Hart, G. Rulong, M.M. Hossain, G. Huang, S.L. Ishman, N. Simakajornboon, Cincinnati, OH, p.A1217

814 **The Search for Racial Selection Bias in Pediatric Polysomnography Referrals/**J.Z. Bronstein, S. Hwang, Wilmington, DE, p.A1218

815 **The Usefulness of OSA-18 Quality of Life Questionnaire in Identifying Moderate-to-Severe Obstructive Sleep Apnea in Children Who Have Normal/Inconclusive McGill Oximetry Score/**S. Sritippayawan, K. Sunkonkit, S. Hantrakul, J. Deerojanawong, N. Prapphal, Bangkok, Thailand, p.A1219

816 **Predicting Presence of Sleep Disordered Breathing in Children with Down Syndrome/**S.L. Katz, J. Nehme, R. LaBerge, N. Barrowman, L. Hoey, A. Monsour, M. Kukko, M. Pothos, Ottawa, Canada, p.A1220

817 **Quality of Life Improvement with Positive Airway Pressure Therapy for Sleep Disordered Breathing in Obese Youth/**S.L. Katz, J. MacLean, L. Hoey, V. Kirk, G. Bendiak, N. Barrowman, L. Horwood, S. Hadjiyannakis, L. Legault, B. Foster, E. Constantin, Ottawa, Canada, p.A1222

818 **Obstructive Sleep Apnea and Vascular Stiffness in Obese Adolescents/**I. Narang, B. McCrindle, S. Al-Saleh, C. Manlhiot, C. Slorach, L. Mertens, C. Birken, J. Hamilton, Toronto, Canada, p.A1221

819 **Assessment of a Support Vector Machine Classifier in the Context of Overnight Oximetry-Based Pediatric Sleep Apnea Diagnosis/**A. Crespo, D. A?lvarez, L. Kheirandish-Gozal, G.C. Gutierrez-Tobal, M.F. Philby, M. Mohammadi, R. Hornero, D. Gozal, F. Del Campo, Valladolid, Spain, p.A1223

820 **Body Fat Distribution and Obstructive Sleep Apnea Severity in Children with Obesity/**A. Glicksman, S. Hadjiyannakis, N. Barrowman, S. Walker, L. Hoey, S.L. Katz, Toronto, Canada, p.A1224

821 **PFT in Muscular Dystrophy with Sleep Disordered Breathing in Children and Adolescents/**E.R. Concepcion, S.Q. Ahmad, S. Alkhairy, H. Lee, Brooklyn, NY, p.A1225

822 **Incidence of Altered Craniofacial Morphology and Malocclusion in Children and Youth with Obstructive Sleep Apnea/**F.R. Almeida, R. Amin, B. Pliska, K. Lee, J. Abikhzer, M. Laramee, D. Simone, M. Hamoda, E. Ayers, I. Narang, N. Huynh, Vancouver, Canada, p.A1226

823 **Anthropometric Measures in Obese Children to Predict the Risk of Obstructive Sleep Apnea/**S. Bin-Hasan, S. Al-Saleh, R. Amin, R. Narang, I. Narang, Toronto, Canada, p.A1227

POSTER DISCUSSION SESSION

A28 FROM PE TO CTEPH: FADE AWAY OR NOT?

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 3014 (West Building, Level 3)

Poster Viewing **9:00-9:45**

Discussion **9:45-11:00**

Chairing: G.A. Heresi, MD, Cleveland, OH
T.M. Bull, MD, Aurora, CO
J. Pepke-Zaba, MD, PhD, Cambridge, United Kingdom

901 **Endothelial Cells from Endarterectomized Tissue Possess High Angiogenic Potential in Patients with Chronic Thromboembolic Pulmonary Hypertension/**A. Naito, S. Seiichiro, T. Jujo, K. Ishida, F. Kato, T. Takeuchi, T. Sugiura, N. Tanabe, K. Tatsumi, Chiba, Japan, p.A1228

902 **Efficacy and Safety of Balloon Pulmonary Angioplasty in Patients with Inoperable Chronic Thromboembolic Pulmonary Hypertension/**T. Aoki, K. Sugimura, M. Miura, S. Tatebe, S. Yamamoto, N. Yaoita, H. Suzuki, H. Sato, K. Kozu, K. Satoh, H. Shimokawa, Sendai, Japan, p.A1229

903 **Serial Imaging Over 1 Year by Perfusion (Q) Scanning and CT Pulmonary Angiography (CTPA) After a First Episode of Pulmonary Embolism (PE): Results of the ELOPE Study/**A. Hirsch, S. Kahn, A. Akaberi, D. Anderson, P.S. Wells, M. Rodger, S. Solymoss, M.J. Kovacs, L. Rudski, A. Shimony, C. Dennie, C. Rush, P. Hernandez, S.D. Aaron, J.T. Granton, Montreal, Canada, p.A1230

904 **Do Baseline or Follow-Up Imaging Variables Correlate with Exercise Capacity on Cardio-Pulmonary Exercise Testing (CPET) 1 Year Post Pulmonary Embolism (PE)? Results from the ELOPE STUDY/**A. Hirsch, S. Kahn, A. Akaberi, D. Anderson, P.S. Wells, M. Rodger, S. Solymoss, M.J. Kovacs, L. Rudski, A. Shimony, C. Dennie, C. Rush, P. Hernandez, S. Aaron, J.T. Granton, Montreal, Canada, p.A1231

905 **Elucidating the Cause of Exercise Limitation 1 Year Post Acute Pulmonary Embilism (PE) Using Wasserman's Algorithm: Results of the ELOPE Study/**A. Hirsch, S. Kahn, A. Akaberi, D. Anderson, P.S. Wells, M. Rodger, S. Solymoss, M.J. Kovacs, L. Rudski, A. Shimony, C. Dennie, C. Rush, P. Hernandez, S. Aaron, J.T. Granton, Montreal, Canada, p.A1232

906 **Preemptive Anticoagulation for High Risk Patients with Suspected Pulmonary Embolism: Are Guidelines Followed?/**L.L. Willoughby, D.M. Adams, R.S. Evans, J.F. Lloyd, S.M. Stevens, S.C. Woller, J.R. Bledsoe, V. Aston, E. Wilson, C.G. Elliott, Salt Lake City, UT, p.A1233

907 **Impaired Pulmonary Artery Compliance in Patients with Chronic Thromboembolic Disease May Account for Exercise Limitation in Those without Pulmonary Hypertension at Rest/**E.W. Mims, T.M. Fernandes, D.S. Poch, D.G. Papamatheakis, P.F. Fedullo, K.M. Kerr, N.H. Kim, K.U. Knowlton, A. McDivit-Mizzell, L.B. Daniels, W.A. Auger, San Diego, CA, p.A1234

908 **Preoperative Serum CD40 Ligand Level as a Promising Predictor of Surgical Outcome in Patients with Chronic Thromboembolic Pulmonary Hypertension/**A. Shigeta, N. Tanabe, A. Naito, T. Jujo, A. Sekine, R. Nishimura, T. Sugiura, S. Sakao, K. Ishida, M. Masuda, K. Tatsumi, Los Angeles, CA, p.A1235

909 **Initial Combination Therapy with Endothelin Receptor Antagonist and PDE-5 Inhibitor in Inoperable Chronic Thromboembolic Pulmonary Hypertension/**O. Sitbon, D. Bourlier, X. Jais, V. Cottin, L. Savale, E. Bergot, C. Dauphin, H. Bouvaist, D. Horeau Langlard, L. Tetu, F. Bauer, C. Dromer, D. Montani, M. Humbert, G. Simonneau, Le Kremlin Bicetre, France, p.A1236

910 **Heritability in Chronic Thromboembolic Pulmonary Hypertension: Pedigree Analysis Suggests a High Prevalence of Venous Thromboembolism in Family Members of CTEPH Patients, But a Low Prevalence of CTEPH/**M.W. Dodson, J. Desmarais, D.H. Best, S. Knight, L.A. Cannon-Albright, L.M. Brown, C.G. Elliott, Salt Lake City, UT, p.A1237

911 **Clinical Presentation, Hemodynamics, Management Strategies and Outcomes of Saddle Vs. Non Saddle Pulmonary Embolism/**B. Alkinj, B.S. Pannu, M. Passe, R. Kashyap, V.N. Iyer, Rochester, MN, p.A1238

912 **Right Ventricular Sugar and Fat in Chronic Thromboembolic Pulmonary Hypertension/**S. Sakao, M. Daimon, N. Voelkel, H. Miyauchi, T. Jujo, T. Sugiura, N. Tanabe, Y. Kobayashi, K. Tatsumi, Chiba, Japan, p.A1239

913 **Patient Outcomes Following Suboptimal and Non-Diagnostic CT Pulmonary Angiography Performed for the Suspected Diagnosis of a Pulmonary Embolism/**B. Lou, M. Islam, J. Filopei, N. Ramesh, M. Lau, G. Bajpayee, E.E. Bondarsky, D. Steiger, New York, NY, p.A1240

914 **Hospital Length of Stay and Hospitalization Costs for Pulmonary Embolism Comparing Patients Receiving Rivaroxaban or Warfarin/**J.A. Kline, S. Deitelzweig, J.M. Margolis, M. Raut, O. Tran, D.M. Smith, C. Crivera, B. Bookhart, J. Schein, W. Olson, Indianapolis, IN, p.A1241

915 **Patient-Centered Outcomes from a Protocol to Treat Low Risk Patients with Venous Thromboembolism at Home with Monotherapy Oral Anticoagulation/**J.A. Kline, Z.P. Kahler, D.M. Beam, Indianapolis, IN, p.A1242

916 **Effect of Implementation of an Acute Pulmonary Embolism Risk Stratification Algorithm and Educational Initiative on Physician Behaviors and Resource Utilization**/K. Klipper, J. Thiboutot, N. Siegel, T.-T. Truong, A. Dunn, H. Poor, New York, NY, p.A1243

917 **CTEPH Associated Fibrinogen Abnormalities Among Patients with Acute PE**/B. Planquette, P. Chiles, J. Marsh, O. Sanchez, T. Morris, Paris, France, p.A1244

918 **Blood Transcriptome in Patients with Chronic Thromboembolic Pulmonary Hypertension Differs from Patients with Pulmonary Arterial Hypertension and Healthy Controls**/D.T. Matthews, J. West, E.D. Austin, A.R. Hemnes, Nashville, TN, p.A1245

919 **Incidence, Risk Factors and Outcomes of Upper Extremity Deep Venous Thrombosis Among Hospitalized Patients in the United States**/G.W. Williams, S. Giri, K. Siwakoti, A. Sodhi, D. Kadaria, Memphis, TN, p.A7768

POSTER DISCUSSION SESSION

A29 INFLAMMATION AND MECHANISMS OF AIRWAY SMOOTH MUSCLE CONTRACTION

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 2014 (West Building, Level 2)

Poster Viewing **9:00-9:45**

Discussion **9:45-11:00**

Chairing: S.J. Gunst, PhD, Indianapolis, IN
Y.S. Prakash, MD, PhD, Rochester, MN
J.E. Bourke, PhD, Clayton, Australia

501 **Pharmacologic Properties of Selective GABAA Receptor Ligands that Relax Airway Smooth Muscle**/G.T. Yocum, Y. Zhang, G. Forkuo, M. Guthrie, A. Youmans, R. Jahan, M.R. Stephen, D. Stafford, J. Cook, L. Arnold, C. Emala, New York, NY, p.A1246

502 **Overexpression of ORMDL3 to Upregulate SERCA2b Correlates with Increased Airway Contractility and Ca2+ Oscillations in Airway Smooth Muscle in Precision-Cut Lung Slices**/J. Chen, M. Miller, P. Rosenthal, D. Broide, M.J. Sanderson, Worcester, MA, p.A1247

503 **Polo-Like Kinase 1 Regulates Vimentin Phosphorylation and Airway Smooth Muscle Contraction** /J. Li, R. Wang, S. Jiang, R.A. Cleary, D.D. Tang, Albany, NY, p.A1248

504 **The Actin Severing and Capping Protein Gelsolin Mediates Airway Smooth Muscle Relaxation and Modulates Intracellular Calcium Responses**/M. Mikami, J. Danielsson, Y. Zhang, E.A. Townsend, S. Khurana, C. Emala, New York, NY, p.A1249

505 **TNFα Increases Airway Smooth Muscle Force Generation Through Changes in Actin and Myosin Remodeling**/M. Dogan, P. Delmotte, Y.-S. Han, G.C. Sieck, Rochester, MN, p.A1250

506 **Comparison of the Pharmacological Profile of Long-Acting Muscarinic Antagonists on Isolated Human Bronchi**/E. Naline, S. Grassin Delyle, H. Salvator, P. Devillier, Suresnes, France, p.A1251

507 **Inflammation Increases Mitochondria Fragmentation, Mitochondria Volume Density and Oxygen Consumption Rate in Human Airway Smooth Muscle**/P. Delmotte, M. Dogan, Y.S. Prakash, G.C. Sieck, Rochester, MN, p.A1252

508 **Intrapulmonary Airway Smooth Muscle Contractile Properties Are Not Intrinsically Altered in Cystic Fibrosis and Asthma**/G. Ijpma, O. Matusovsky, L. Kachmar, A. Panariti, J.G. Martin, A.-M. Lauzon, Montreal, Canada, p.A1253

509 **Naringin as Natural Fruit Product and Bitter Taste Agonist Induces Relaxation of Airway Smooth Muscle Cells Via Intracellular Calcium Signaling**/L. Deng, Y. Lu, Y. Wang, M. Luo, X. Shi, Y. Pan, Changzhou, China, p.A1254

510 **Serelaxin Is a Novel Potent Bronchodilator in Rat Precision Cut Lung Slices (PCLS) and Trachea**/J.E. Bourke, S.G. Royce, C. Donovan, M. Jelinic, L. Parry, C. Samuel, M. Lam, Clayton, Australia, p.A1255

511 **The Impact of Bronchial Thermoplasty on Airway Epithelial and Smooth Muscle Cells: An In Vitro and In Silico Study**/B.S. Brook, I.L. Chernyavsky, G.E. Morris, R.M. Saunders, F.R.A.J. Rose, O.E. Jensen, C.E. Brightling, Nottingham, United Kingdom, p.A1256

512 **Modulation of Mitochondrial Dynamics and Functions in Human Airway Smooth Muscle Cells by Bitter Taste Receptor Agonists**/S. Pan, B. Tiegs, D.A. Deshpande, Philadelphia, PA, p.A1257

513 **Analysis of the Splicing Regulation of the Smooth Muscle Myosin Heavy Chain Fast Contracting Isoform**/M. Issouf, A. Vargas, St-Hyacinthe, Canada, p.A1258

514 **Serine Phosphorylation of Non-Muscle Myosin II Heavy Chain Regulates the Contraction of Airway Smooth Muscle (ASM) by Regulating the Assembly of Adhesion Junction Signaling Complexes**/W. Zhang, S.J. Gunst, Indianapolis, IN, p.A1259

515 **A Narrow Spectrum Kinase Inhibitor, RV1729, Induces Bronchodilation of Human Small Airways and Rescues Agonist-Induced Desensitization of the β2 Adrenoreceptor (β2AR)**/C.J. Koziol-White, J. Zhang, E. Yoo, C. Charron, C. Stevenson, R.A. Panettieri, Philadelphia, PA, p.A1260

516 **Cigarette Smoke Influences Cellular Metabolic Signaling by Deregulating Mitochondrial Morphology and Function in Human Airway Smooth Muscle**/B. Aravamudan, M.A. Thompson, C. Pabelick, G.C. Sieck, R. Vassallo, Y.S. Prakash, Rochester, MN, p.A1261

517 **Obesity -Related Airway Hyperresponsiveness Is Regulated by Endothelin-1 in Mice**/D.I. Kasahara, N.G. Verbout, T.A. Brown, Y. Cho, S.A. Shore, Boston, MA, p.A1262

518 **Inhaled Simvastatin Concomitantly Prevents Generation of Oxidized Phosphatidylcholine, Airway Inflammation, and Hyperresponsiveness in Allergen-Challenged Mice**/A. Jha, M.H. Ryu, R. Chaudhry, A. Ravandi, A.J. Halayko, J. Schwartz, S. Basu, Winnipeg, Canada, p.A1263

519 **Maternal Hypoxia-Induced Intrauterine Growth Restriction Predisposed Offspring to Airway Hyperresponsiveness in Adulthood/**K.C. Wang, A. Larcombe, J. Morton, S. Davidge, A. James, P.B. Noble, Subiaco, Australia, p.A1264

520 **TNFα and IFNγ Alter Effects of Corticosteroids on NFκB in Developing Human Airway Smooth Muscle/**R. Britt, I. Kuipers, S. Sasse, M.A. Thompson, C. Pabelick, A. Gerber, Y.S. Prakash, Rochester, MN, p.A1265

521 **Calcium Sensing Receptor and Airway Reactivity in Mixed Allergen Treated Mouse Model of Asthma/**M. Thompson, M.R. Freeman, L.J. Manlove, Y.-H. Fang, R. Britt, I. Kuipers, D. Riccardi, C. Pabelick, Y.S. Prakash, Rochester, MN, p.A1266

522 **Differential Estrogen Receptor and Its Variants Expression Profile in Asthmatic Human Airway Smooth Muscle/** K.J. Goorhouse, B. Aravamudan, G. Unnikrishnan, M.R. Freeman, M.A. Thompson, J.R. Hawse, C.M. Pabelick, Y.S. Prakash, V. Sathish, Rochester, MN, p.A1267

523 **TGF-β1 Evokes Human Airway Smooth Muscle Shortening and Hyperresponsiveness: A New Job Description?/**C.A. Ojiaku, G. Cao, W. Zhu, S.S. An, R.A. Panettieri, Jr., Philadelphia, PA, p.A1268

524 **Desmethylbenzodiazepines Induce OGR1 Signaling in Airway Smooth Muscle Cells/**T. Pera, D.A. Deshpande, B. Tiegs, M. Ippolito, H. Schorsch, T. Murphy, R. Penn, Philadelphia, PA, p.A1269

525 **Inflammation Leads to Loss of β-Adrenergic Receptor Function in Asthma from Human Airway Smooth Muscle Cells/**M.K. Gupta, G. Cao, R.A. Panettieri, S.V. Naga Prasad, Cleveland, OH, p.A1270

POSTER DISCUSSION SESSION

A30 ADVANCES IN LUNG CANCER SCREENING AND PULMONARY NODULE ASSESSMENT

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 304 (South Building, Esplanade Level)

Poster Viewing **9:00-9:45**

Discussion **9:45-11:00**

Chairing: D.A. Arenberg, MD, Ann Arbor, MI
P. Mazzone, MD, MPH, Cleveland, OH
J.A. Gorden, MD, Seattle, WA

201 **Maximum Intensity Projection (MIP) Versus Computer-Aided-Detection (CAD) in CT Lung Cancer Screening/**A. Christe, L. Ebner, Bern, Switzerland, p.A1271

202 **Facilitators and Barriers to Lung Cancer Screening Among Veterans/**N.M. Kanodra, C. Pope, L.J. Rice, C. Hughes Halbert, N.T. Tanner, Charleston, SC, p.A1272

203 **Primary Care Providers' Views on Lung Cancer Screening/**N.M. Kanodra, C. Pope, L.J. Rice, C. Hughes Halbert, N.T. Tanner, Charleston, SC, p.A1273

204 **Attitudes Regarding Lung Cancer Screening and Decision Aids: A Survey and Focus Group Study/**K.A. Crothers, E.K. Kross, S.F. Shahrir, L.M. Reisch, C.G. Slatore, S.B. Zeliadt, M. Triplette, R. Meza, J.G. Elmore, Seattle, WA, p.A1274

205 **Cost-Effectiveness of Implementing Computed Tomography Screening for Early Diagnosis of Lung Cancer in Taiwan/**S.-C. Yang, L.-J. Ku, J.-D. Wang, Tainan, Taiwan, p.A1275

206 **Assessing Patient Attitudes and Barriers to Implementation of Low Dose CT Screening for Lung Cancer at an Academic Medical Center/**D.K. Duong, H. Naemi, L.M. Moy, R. Haile, I. Cheng, S. Shariff-Marco, A. Hsing, A. Leung, V.S. Nair, San Jose, CA, p.A1276

207 **Utilization of the Electronic Medical Record to Determine Smoking History: A Challenge for Population-Based Lung Cancer Screening/**H.E. Modin, J.T. Fathi, C.R. Gilbert, C.L. Wilshire, R.W. Aye, A.S. Farivar, B.E. Louie, E. Vallieres, J.A. Gorden, Seattle, WA, p.A1277

208 **The Impact of Structured Reading for Incidental Findings Identified on Lung Cancer Screening Low-Dose Computed Tomography (LDCT) Scans/**P. Sather, D. Dicks, J. Killam, A. Curtis, F.C. Detterbeck, M. Pisani, L.T. Tanoue, New Haven, CT, p.A1278

209 **Lessons Learned from Early-Adopting Lung Cancer Screening Programs: Staff Perspectives on Implementation/**Y.B. Gesthalter, E. Koppelman, C.G. Slatore, L. Kinsinger, S. Yoon, H. Cain, N.T. Tanner, D.H. Au, J. Clark, R.S. Wiener, Boston, MA, p.A1279

210 **Readiness for Implementation of CT Lung Cancer Screening Within a National Healthcare System/**M.H. Tukey, J. Clark, R. Bolton, C.G. Slatore, D.H. Au, R.S. Wiener, Providence, RI, p.A1280

211 **Utilization of Chest Computerized Tomography (CT) Scan as Screening Tool for Lung Cancer: Retrospective Analysis of Our Veteran Population/**J. Albors-Sanchez, J. Martinez-Gonzalez, A. Cordero-Gomez, E. Adorno-Fontanez, W. Rodriguez-Cintron, San Juan, Puerto Rico, p.A1281

212 **Lung Cancer Screening: Early Results Exceed NLST-Based Expectations/**S.E.E. Stephens, C. Chiles, C. Bellinger, Winston-Salem, NC, p.A1282

213 **Development of a Lung Cancer Screening Registry/**L. Henderson, P. Molina, K. Birchard, J.M. Bowling, S. Maygarden, D. Reuland, M. Marsh, M.A. Greenwood-Hickman, L. Jones, M.P. Rivera, Chapel Hill, NC, p.A1283

214 **Central Valley Lung Nodule Calculator: A Clinical Tool to Differentiate Lung Cancer from Coccidiodomycosis/**R. Ronaghi, A. Rashidian, P.K. Mills, M.W. Peterson, Fresno, CA, p.A1284

215 **Validation of a Radiomic Analysis for Improved Lung Cancer Prediction of Indeterminate Pulmonary Nodules: Preliminary Results/**V.S. Nair, A. Garcia, T. Atwater, H. Chen, Y. Balagurunathan, Y. Liu, S. Antic, O. Gevaert, M. Schabath, S. Napel, R. Walker, R. Gillies, P.P. Massion, Stanford, CA, p.A1285

216 **Physician Assessment of Pre-Test Probability of Malignancy Out Performs a Validated Nodule Prediction Model but Does Not Lead to Better Guideline Adherence/**N.T. Tanner, A. Vachani, A. Porter, G.A. Silvestri, Charleston, SC, p.A1286

217 **Modeling the Utility of a Bronchial Genomic Classifier on Procedure Utilization in Patients with Suspected Lung Cancer/**A. Vachani, E. Parsons, D. Whitney, J.S. Ferguson, M. Lenburg, G.A. Silvestri, A. Spira, Philadelphia, PA, p.A1287

218 **Emphysema and Coronary Artery Calcifications on Lung Cancer Screening Computed Tomography (CT) Scans: A Potential Missed Opportunity?/**A.J. Ghosh, M. Pirzadeh, A. Rebello, K. Steiling, H. Kathuria, C.C. Reardon, R.S. Wiener, A.J. Walkey, K.A. Sloan, Boston, MA, p.A1288

219 **Differentiating Coccidioidomycosis from Lung Cancer in High Risk Individuals/**V. Ifeacho, O. James, A. Ryazantsev, M. Risco, G. Rubiaco, K. Almodovar, D. Upadhyay, Fresno, CA, p.A1289

220 **Incidental Pulmonary Nodule Committee in a Community Hospital/**O. Kouskov, E. Shochat, M. Schoolfield, A. Falcone, R. Sandow, C. Duncan, P. Montgomery, Boise, ID, p.A1290

221 **Verification of Mayo Clinic Formula to Determine Lung Cancer Probability Among Patients Living in Tuberculosis Endemic Areas/**S. Saenghirunvattana, C. Saenghirunvattana, M.C. Gonzales, K. Sutthisri, C. Siangpro, Bangkok, Thailand, p.A1291

222 **A Preliminary Comparison Study of Bioconductance Measurement with 18FDG-PET in Evaluation CT Detected Lung Lesion Suspicious for Lung Cancer/**D. Yang, J. Li, X. Gong, R. Yung, C. Bai, Shanghai, China, p.A1292

223 **Incomplete and Inappropriate Recommendations by Radiologists for Small and Stable Lung Nodules/**S.B. Zeliadt, K.W. Hammond, J.E. Takasugi, L.C. Feemster, R. Laundry, E.H. Pham, P.A. Greene, S. Dawadi, L.F. Reinke, C.D. Helfrich, D.H. Au, Seattle, WA, p.A1293

224 **Availability of Resources and Processes of Care for Pulmonary Nodule Evaluation: A National Survey of American Thoracic Society Clinicians/**J. Iaccarino, J. Simmons, C.G. Slatore, M.K. Gould, R.S. Wiener, Boston, MA, p.A1294

225 **Analytical Performance of a Bronchial Genomic Classifier/**D. Whitney, Z. Hu, J. Anderson, M. Cao, C. Ho, Y. Choi, J. Huang, R. Frink, K. Porta-Smith, R. Monroe, G. Kennedy, P.S. Walsh, South San Francisco, CA, p.A1295

THEMATIC POSTER SESSION

A31 ASTHMA THERAPY: GLUCOCORTICOIDS AND BEYOND

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area A, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: K. Asano, MD, Kanagawa, Japan

P1 **Treatment with Novel Retinoid X Receptor Partial Agonist Attenuates Eosinophilic Airway Inflammation and Airway Hyperresponsiveness/**U. Fujii, A. Kanehiro, N. Miyahara, N. Oda, D. Morichika, A. Taniguchi, G. Ikeda, H. Nakayama, K. Waseda, E. Murakami, H. Kakuta, M. Kataoka, K. Kiura, M. Tanimoto, Okayama, Japan, p.A1296

P2 **A Soluble Fibre Challenge Reduces Airway Inflammation in Asthma/**L.G. Wood, I. Halnes, K. Baines, L. McDonald-Wicks, P.G. Gibson, New Lambton Heights, Australia, p.A1297

P3 **Histologic Patterns in Distal Lung Tissue from Treatment-Resistant Severe Asthma Patients/**D. Doberer, H.E. Trejo Bittar, C. Vitari, S.M. Nouraie, F. Holguin, S.A. Yousem, S.E. Wenzel, Pittsburgh, PA, p.A1298

P4 **FEV1 Improvement with Dupilumab by Different Baseline Patient Characteristics in Patients with Uncontrolled Persistent Asthma/**J. Corren, S. Spector, B. Zhang, G. Pirozzi, H. Staudinger, R.R. Evans, N.M.H. Graham, M. Louis-Tisserand, A. Teper, Los Angeles, CA, p.A1299

P5 **Beta-2 Agonists Induce Pro-Inflammatory Mediators in Airway Epithelial Cells/**A.I. Ritchie, A. Singanayagam, S.L. Johnston, London, United Kingdom, p.A1300

P6 **A Sub-Phenotype of Severe Asthma Patients Meet Criteria for Asthma-COPD Overlap Syndrome (ACOS): A Comparative Analysis of Clinical Criteria and Biomarkers/**A.A. Zeki, S. Louie, Davis, CA, p.A1301

P7 **Metabolomic and Lipidomic Analyses Reveal that Inhalation of Statins Affects Pulmonary and Systemic Metabolism in the Rhesus Macaque Non-Human Primate Model/**A.A. Zeki, M. Elbadawi, S. Ott, O. Fiehn, L.A. Miller, A. Haczku, Davis, CA, p.A1302

P8 **Exhaled Nitric Oxide as an Indirect Measure of Compliance in Asthma/**K.R. Chapman, T. Sen Dutt, G. Boparai, Toronto, Canada, p.A1303

P9 **Omalizumab Responder Analysis in Chinese Patients with Moderate-to-Severe Asthma/**J. Li, J. Kang, C. Wang, J. Yang, L. Wang, M. Humphries, S. Greenberg, N. Zhong, Guangzhou, China, p.A1304

Facilitator: M. Ge, PhD, Davis, CA

P10 **Quantitative Acetyl-Proteomic Study on Asthmatic Mice Highlights the Lysine Acetylation's Significance in Anti-Asthma Processes/**X. Su, Shen Yang, China, p.A1305

P11 **Airway Modification of Acetaminophen and Effect on Antigenicity to Der p1/**R.G. Thomas, D. Fletcher, M.T. Sutton, J.F. Hunt, B. Gaston, T.L. Bonfield, Cleveland, OH, p.A1306

P12 **A GSNOR Inhibitor Blocks HRV Infection of Primary Human Airway Epithelial Cells /**Z. Yang, Y. Bochkov, D.R. Voelker, M.W. Foster, L.G. Que, Durham, NC, p.A1307

P13 **Type 2 Immune Therapies for Severe Asthma: Overlapping Suitability Leads to Further Questions/**J.A. Chen, D.J. Jackson, London, United Kingdom, p.A1308

P14 **Anti-IgE Monoclonal Antibody Therapy as an Alternative for the Treatment of Occupational Asthma Caused by Exposure to Low Molecular Weight Agents/**M.-J. Cruz, M. Olle-Monge, J. Yllera-Retegui, M.-D. Untoria-Corral, D. Alvarez-Simon, X. Munoz, Barcelona, Spain, p.A1309

P15 **Predictors of Inhaled Corticosteroid Reduction Failure in Adult Asthmatics/**J.C. Cardet, T.S. King, L.B. Bacharier, T.F. Carr, V.M. Chinchilli, C.D. Codispoti, R.M. Dunn, F. Holguin, K.F. Nelson, V.E. Ortega, M. Peters, S. Ramratnam, M.E. Wechsler, E. Israel, Boston, MA, p.A1310

P16 **Knowledge of Risks of Asthma and Its Treatments Amongst Healthcare Professionals: A Questionnaire-Based Survey/**A. Rameh, J. Blakey, Liverpool, United Kingdom, p.A1311

P17 **Serum Periostin Level May Predict Asthma Exacerbation After Stepping Down Formoterol/Budesonide Combination Therapy in Adult Asthma/**H. Nagase, T. Shirai, T. Kawayama, H. Inoue, S. Sato, K. Asano, K. Izuhara, H. Kume, Tokyo, Japan, p.A1312

P18 **Characteristic Features of Late-Onset Hypereosinophilic Asthma/** M. Toyoshima, Y. Kamiya, T. Suda, Hamamatsu, Japan, p.A1313

Facilitator: N. Miyahara, MD, PhD, Okayama, Japan

P19 **IL-13 Decreases M3R Expression in the Human Airway, Reducing the Effect of Tiotropium on Mucin Production/**K. Komiya, S. Kawano, I. Suzaki, T. Akaba, J.L. Bradley, B.K. Rubin, Richmond, VA, p.A1314

P20 **Mechanism of Reduced Glucocorticoid Sensitivity in Human Pulmonary Epithelial Cells: Implications for Regulation by Interferon Regulatory Factor (IRF1)/**S.V. Shah, R. Newton, Calgary, Canada, p.A1315

P21 **STRETTO: Design and Baseline Characteristics of a Phase III, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Adult Patients with Mild-to-Moderate Asthma/**K. Yen, C.T.J. Holweg, J. Anzures-Cabrera, C. Martin, J. Olsson, J.G. Matthews, South San Francisco, CA, p.A1316

P22 **Clinical Symptom Burden in Severe Asthma One Year After Completion of Bronchial Thermoplasty/**M. Curtiss, Y. Wang, D. Zhi, F. Wang, J.T. Anderson, M.T. Dransfield, J.S. Deshane, J. Trevor, Birmingham, AL, p.A1317

P23 **LAVOLTA I and II: Design and Baseline Characteristics of Two Phase III, Randomized, Double-Blind, Placebo-Controlled Studies to Assess the Efficacy and Safety of Lebrikizumab in Adult Patients with Uncontrolled Asthma/**N.A. Hanania, P. Korenblat, K.R. Chapman, E.D. Bateman, P. Kopecky, P. Paggiaro, A. Yokoyama, J. Olsson, S. Gray, C.T.J. Holweg, M. Eisner, J.G. Matthews, Houston, TX, p.A1318

P24 **Topical NSAID and NERD Phenotype Asthma Control/**A.A. Hsu, Singapore, Singapore, p.A1319

P25 **Clinical Endpoint Bioequivalence Study of Salmeterol Xinafoate (SX)/Fluticasone Propionate (FP) Combination Brand and Generic Candidate Products in Patients with Asthma/**M. Longphre, K. Beasley, E. Burmeister Getz, R. Fuller, Berkeley, CA, p.A1320

P26 **Plasma Inhaled Fluticasone Levels and Their Clinical Implications in Asthma/**A. Matsubara, A. Takahashi, E. Yamaguchi, N. Yokoe, I. Okajima, K. Kosaka, M. Nishimura, H. Tanaka, N. Asai, A. Kubo, Nagakute, Japan, p.A1321

Facilitator: J.G. Zangrilli, MD, Philadelphia, PA

P27 **Step Down Strategy; Can LTRA Be Withdrawn Safely From Combination Therapy with Medium to High Dose of ICS/LABA, Tiotropium Bromide and LTRA in Severe Asthmatics?/**M. Hojo, M. Iikura, M. Suzuki, H. Sugiyama, Tokyo, Japan, p.A1322

P28 **Safety and Efficacy of Vilanterol and Fluticasone furoate/Vilanterol in the Treatment of Asthma: A Systematic Review and Meta-Analysis/**H. Zhou, C. Liu, Chengdu, China, p.A1323

P29 **Extraction of Membrane Cholesterol as a Potential New Therapeutic Mechanism in Asthma/**G. Dufour, N. Rocks, A. Duyckaerts, C. Gerard, M.-P. Mingeot-Leclercq, B. Evrard, D. Cataldo, Liege, Belgium, p.A1324

P30 **Chinese Herbs for Acute Asthma: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial/**G. Wang, Chengdu, China, p.A1325

P31 **Safety and Tolerability of AZD1419, an Inhaled Oligonucleotide-Based Toll-Like Receptor 9 Agonist in Healthy Volunteers: A Potential New Therapy for Asthma/**S. Jackson, S. Floettmann, A. Candia, C. Wong, S. Delaney, D. Keeling, R. Fuhr, R.L. Coffman, Berkeley, CA, p.A1326

P32 **Efficacy of the Anti-IgE Monoclonal Antibody Omalizumab in Patients with Severe Asthma Complicated with Eosinophilic Otitis Media/**E. Tagaya, R. Mizobuchi, A. Kubo, K. Hara, K. Takeyama, M. Kondo, J. Tamaoki, Tokyo, Japan, p.A1327

P33 **Interleukin 17 (IL-17) Targeting Therapy in Asthma/**M. Mahdavian, A. Ferrell, S. Asghari, Y. Yi, S.D. Aaron, Ottawa, Canada, p.A1328

P34 **A Novel Inhaled Non-Steroidal Modulator of Inflammation for the Control of Asthma; AZD7594/**C.K. Mardh, W. Russell, M. Gustavsson, N. Kurian, A.-H. Jansson, A. Smailagic, K. Edman, Molndal, Sweden, p.A1329

P35 **Assessment of Asthma Control in Adults Using Extrafine Inhaled Beclomethasone/Formoterol Combination as Maintenance Therapy or Maintenance and Reliever Therapy: A Multicentre Prospective Observational Study/**R. Pawliczak, B. Rogala, T. Debowski, Lodz, Poland, p.A7769

P36 **RPL554, a First-In-Class Dual Phosphodiesterase (PDE)3/4 Inhibitor, Is Equi-Effective as a Bronchodilator to Maximal Doses of Salbutamol in Asthmatics but with Fewer Adverse Events/**L. Bjermer, J. Stewart, K.H. Abbott-Banner, K. Newman, Lund, Sweden, p.A7770

P37 **A Potential Mechanism for Steroid Resistance in Severe Asthma/**M. Gauthier, T. Oriss, M. Raundhal, C. Morse, S.E. Wenzel, P. Ray, A. Ray, Pittsburgh, PA, p.A7771

THEMATIC POSTER SESSION

A32 ADAPTIVE IMMUNITY IN LUNG DISEASE

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area A, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: K.M. Gowdy, PhD, Research Triangle Park, NC

P38 **Flow Cytometric and Multiplexed Immunoassay Characterization of CD4+ T Cell Phenotype in Preterm Infants Who Develop Respiratory Morbidities/**R.S. Misra, S. Bhattacharya, H. Wang, H.L. Huyck, S.K. Misra, S. Shah, A.-M. Reynolds, R.M. Ryan, T.J. Mariani, G.S. Pryhuber, Rochester, NY, p.A1330

P39 **Human Lung Fibroblasts Are Antigen-Presenting Cells that Activate Bacteria-Specific Autologous Memory CD4+ T Cells/**A.J. Hutton, K.J. Staples, T.M.A. Wilkinson, J. Warner, Southampton, United Kingdom, p.A1331

P40 **Lungs from Mice with Intestinal Inflammation Exhibit a Proinflammatory Profile/**A. Metwali, P.S. Thorne, N. Inc., D.E. Elliott, Iowa City, IA, p.A1332

P41 **Comparison of IL-17A and IL-17F Cytokine-Expression in CD4+ Lymphocytes Between Asthma, COPD and Healthy Subjects/**T. Morimoto, S.G. Smith, J.P. Oliveria, S. Beaudin, A. Schlatman, K. Howie, C. Obminski, G. Nusca, R. Sehmi, G.M. Gauvreau, P.M. O'Byrne, Hamilton, Canada, p.A1333

P42 **Pulmonary Manifestations in Adult Patients with Primary Predominantly Humoral Immune Deficiencies: A Paris Area Reference Network Study/**M. Didier, N. Mahlaoui, E. Oksenhendler, A. Fischer, F. Suarez, O. Hermine, H. Salvator, E. Rivaud, E. Catherinot, L.-J. Couderc, Suresnes, France, p.A1334

P43 **Longitudinal Changes in Proportions of Regulatory T Cell and Myeloid Cell Populations Following Bronchial Thermoplasty/**J. Trevor, D. Zhi, F. Wang, M.T. Dransfield, M. Curtiss, J. Deshane, Birmingham, AL, p.A1335

Facilitator: C.L. Hrusch, PhD, Chicago, IL

P44 **Role of Tumor Necrosis Factor-Related Apoptosis Inducing Ligand and Th1, Th2 and Th17 Inflammation in Asthma/**M. Marks, A.T. Hastie, C. Steele, W.C. Moore, E.J. Ampleford, D.A. Meyers, E.R. Bleecker, Winston-Salem, NC, p.A1336

P45 **Enhancing MAPK Activation Limits PD-1-Mediated T Cell Activation/**J. McAlees, I. Lewkowich, Cincinnati, OH, p.A1337

P46 **TLR2 Engagement on CD4+ T Cells Promotes Malignant Pleural Effusion by Regulation of Th17/Th9/Th2 Responses/** X. Wu, Q. Zhou, H. Lin, K. Zhai, X.-J. Wang, W.-L. Ma, L.-L. Xu, H.-Z. Shi, Beijing, China, p.A1338

P47 **Repeated Treatment with Anti-IL17 Attenuates Airway Responsiveness in Mice with Chronic Pulmonary Inflammation/**I.F.L.C. Tiberio, T.M. Santos, R.F. Righetti, L.R.D.C.R.B. Aristoteles, F.C.R. Souza, C.M. Prado, P.S. Pigati, M.A. Martins, M.V.R. Agrela, E.A. Leick, B.S. Romanholo, Sao Paulo, Brazil, p.A1339

P48 **Secreted Phospholipase A2 Group X Acts as an Adjuvant for Type-2 Inflammation and Induces an Allergen-Specific IgE Response/**J.D. Nolin, H.L. Ogden, Y. Lai, D. An, M. Pepper, C.W. Frevert, M.W. Gelb, W.A. Altemeier, T.S. Hallstrand, Seattle, WA, p.A1340

P49 **A Novel Pneumocystis Antigen Driven Model of Murine Asthma Requiring CD4+ T Cells/**T.J. Eddens, B. Campfield, M.L. Manni, J.F. Alcorn, S.E. Wenzel, J.K. Kolls, Pittsburgh, PA, p.A1341

P50 **Ablation of Adaptive Immune Responses Ameliorates Pathological Features in a Mouse Model of Chronic Bronchitis (CB)/**B.W. Lewis, Baton Rouge, LA, p.A7772

THEMATIC POSTER SESSION

A33 AIRWAY SMOOTH MUSCLE

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area N, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: O. Tliba, DVM, PhD, Philadelphia, PA

P1539 **Transient Receptor Potential (TRP) Ion Channels Activation in Vital Human Precision-Cut Lung Slices Lead to Bronchoconstriction and Is Neuropeptide Substance P-Dependent/**S.M. Jimenez Delgado, H. Obernolte, S. Hobbie, S. Schindler, D. Jonigk, G. Warnecke, P. Braubach, C. Bersch, O. Pfennig, H.-G. Fieguth, K. Sewald, A. Braun, Hannover, Germany, p.A1342

P1540 **Bitter Taste Receptors (TAS2R) Function in Human Airway Smooth Muscle Cells Is Partially Gustducin-Independent/** A. Cirelli, B. Shariff, B. Camoretti-Mercado, Tampa, FL, p.A1343

P1541 **Regulation of RhoA Activation in Airway Smooth Muscle/**A. Hsu, P. Ganesan, D. Sheppard, M. Bhattacharya, San Francisco, CA, p.A1344

P1542 **The Role of Epac as a Novel Regulator of Airway Smooth Muscle Proliferation in Asthma/**R. Alsaffar, A. Gardner, Worcester, MA, p.A1345

P1543 **CYP1 P450 Via an EETs Mechanism Controls NF-kB Signaling in Asthmatic Airway Smooth Muscle/**B. Al Suliman, A. Gardner, Worcester, MA, p.A1346

P1544 **ET-1 Enhances EGFR Phosphorylation Via Src Activation in Asthmatic Airway Smooth Muscle/**A. Bahauddin, A. Gardner, Worcester, MA, p.A1347

P1545 **In-Situ Proliferation of Airway Smooth Muscle Cells Is Not Related to Cell Size or Number in Asthma/**J. Elliot, S.-A. Drew, T. Mauad, M. Abramson, K. McKay, T. Bai, F.H.Y. Green, A. James, Nedlands, Australia, p.A1348

P1546 **MMI-0100, an Inhibitor of Mitogen Activated Kinase-Activated Protein Kinase 2 (MK2) Potentiates Isoproterenol-Induced Relaxation of Human Airway Smooth Muscle/**P. Komalavilas, J. Cheung-Flynn, A. Luber, B. Bradford, C. Peterson, C. Lander, C.M. Brophy, Nashville, TN, p.A1349

Facilitator: R. Sehmi, PhD, Hamilton, Canada

P1547 **IL-13 Promotes Airway Hyperresponsiveness in Asthma Through a PTEN Dependent Mechanism/**A. Khalifeh-Soltani, D. Gupta, D. McCarthy, A. Ha, K. Atabai, San Francisco, CA, p.A1350

P1548 **Towards Standardized Airway Hyperresponsiveness Measurements in Mice/**O. Schmid, W. Moller, A. Stelzl, O.V. Amarie, O. Eickelberg, A.O. Yildirim, Neuherberg/Munich, Germany, p.A1351

P1549 **The Pharmacological Gq Inhibitor FR900359 Induces Airway Relaxation Without Systemic Side Effects/**D. Wenzel, M. Matthey, R. Schroder, R. Roberts, M. Kuschak, S. Annala, I.P. Hall, H. Meurs, C. Muller, G. Konig, E. Kostenis, B.K. Fleischmann, Bonn, Germany, p.A1352

P1550 **Delineating the Importance of CD34 Expression in Contractile and Non-Contractile Elements of Airway Reactivity/**K. Lortie, A. Langlois, Y. Bosse, M.-R. Blanchet, Sainte-Foy, Canada, p.A1353

P1551 **The Molecular Basis for the Gain in Contractile Capacity Elicited by Tone in Airway Smooth Muscle/**M. Gazzola, A. Lee-Gosselin, L. Auger, K. Lortie, M.-R. Blanchet, Y. Bosse, Ste Foy, Canada, p.A1354

P1552 **Theophylline Represses IL-8 Secretion from ASM Cells Independently of PDE Inhibition: Novel Role as a PP2A Activator/**B.S. Patel, M.M. Rahman, N.N. Rumzhum, B.G. Oliver, N.M. Verrills, A.J. Ammit, Sydney, Australia, p.A1355

P1553 **Interleukin-17A Induces Glucocorticoid Insensitivity in Human Airway Smooth Muscle Cells/**W.-J. Wang, X.-Y. Qu, X.-M. Dang, D. Shang, J.G. Matin, Q. Hamid, D. Xu, Y.-P. Shao, W.-Y. Lu, Y. Chang, Xi'an, China, p.A1356

P1554 **Long-Term Nicotine Exposure Dampens LPS-Induced Nerve-Mediated Airway Hyperreactivity in Murine Airways/**Y. Xu, L.-O. Cardell, Solna, Sweden, p.A1357

THEMATIC POSTER SESSION

A34 ARDS AND LUNG INJURY

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area E, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: C. Mikacenic, MD, Seattle, WA

P513 **Hypothermia and TRPV4 Channel Inhibition Mitigates Thrombin-Induced Endothelial Permeability/**D. Corwin, N.G. Shah, A. Ramarathnam, D. Slack, M.A. Olman, R.G. Scheraga, J.D. Hasday, Baltimore, MD, p.A1358

P514 **JNK Regulates Nox-Independent NETosis/**M.A. Khan, A. Farahvash, N. Sweezey, N. Palaniyar, Toronto, Canada, p.A1359

P515 **Human Mesenchymal Stromal Cell Derived Exosomes and Conditioned Medium Are Nebulisable by Aerogen Vibronic Micropump and Retain Anti-Inflammatory Properties/** J. Devaney, J. Chao, S. Elliman, D. O'Toole, J.G. Laffey, R. MacLoughlin, Galway, Ireland, p.A1360

P516 **Attenuation of Functional ACE2 Impairs Inactivation of Des-Arg9 Bradykinin and Promotes Endotoxin-Induced Pulmonary Neutrophil Infiltration/**H. Jia, C. Wohlford-lenane, P.B. McCray, Baltimore, MD, p.A1361

P517 **N-Acetyl-de-O-Sulfated Heparin Inhibits Leukocyte Migration In Vitro by a Platelet Dependent Mechanism/**Y. Riffo-Vasquez, R.T. Amison, S.C. Pitchford, C.P. Page, London, United Kingdom, p.A1362

P518 **Effect of Iron Deficiency on Lipopolysaccharide-Induced Acute Lung Injury/**K. Sato, Y. Abe, M. Kobayashi, M. Sato, T. Nemoto, M. Nishiwaki, T. Kimura, K. Yamauchi, A. Igarashi, Y. Tokairin, S. Inoue, I. Kubota, Y. Shibata, Yamagata, Japan, p.A1363

P519 **Inhibition of NALP7 Inflammasome Activity with a Novel Small Molecule Antagonist of the Deubiquitinase STAMBP/**J.S. Bednash, N. Weathington, R. Fort, A. Mckelvey, B.B. Chen, R.K. Mallampalli, Pittsburgh, PA, p.A1364

P520 **Substrate Stiffness Modulates Human Pulmonary Microvascular Endothelial Cell Function/**C. Hahn, G. Cheng, D.W. Scott, K. Burridge, C.M. Doerschuk, Chapel Hill, NC, p.A1365

P521 **Phospholipase D Regulates Inflammatory Responses During Acute Lung Injury/**R.E. Abdulnour, J.A. Howrylak, T. Carlo, H.P. Sham, K.M. Henkels, T.E. Miller, T. Dolinay, R.M. Baron, A.M.K. Choi, J.G. Cambronero, B.D. Levy, Boston, MA, p.A7773

P522 **Manipulating the Air-filled Zebrafish Swim Bladder as an Easily Accessible Model for Functional Characterization of Neutrophil Recruitment into Alveoli during Acute Lung Injury/**Y. Zhang, H. Liu, S. Qin, Z. Sun, H. Cheng, C. Li, X. Zhang, Y. Ke, Hangzhou, China, p.A7774

P523 **The Role of Thymic Stromal Lymphopoietin in Acute Lung Injury/**N.J. Shubin, M. Clauson, K. Niino, S.F. Ziegler, A.M. Piliponsky, Seattle, WA, p.A7775

THEMATIC POSTER SESSION

A35 CASE REPORTS IN AUTOIMMUNE LUNG DISEASE

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area G, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: T. Dolinay, MD, PhD, Philadelphia, PA

P691 **C-ANCA Vasculitis: A 12 Hour Journey to Respiratory Failure/** E. Espinoza Moscoso, D. Ouellette, N. Huda, detroit, MI, p.A1366

P692 **37 Year Old Female with 7 Year History of Intermittent Dyspnea of Few Minutes Duration/**D. Cota, P. Slocum, S. Al-Farrah, Fort Worth, TX, p.A1367

P693 **Pulmonary Hemorrhage in Cryoglobulinemia/**G. Kirkpatrick, T. Winstone, P. Wilcox, S. Van Eeden, Vancouver, Canada, p.A1368

P694 **Hypersensitivity Pneumonitis in a Patient with Known Sarcoidosis: A Tale of Two Granulomas/**C.A. Kloefkorn, S. Medrek, A.D. Parulekar, Houston, TX, p.A1369

P695 **Sjogren's Syndrome Presenting as an Isolated Pleural Effusion/**C.R. Grossman, K. Gafoor, D.M. Wisa, B. Mina, New York, NY, p.A1370

P696 **A Case Report of IgG4-Related Disease Masquerading as a 4.1 Centimeter Necrotic Pulmonary Mass with Bilateral Pulmonary Nodules/**C.C. Radchenko, A. Gohar, Kansas City, MO, p.A1371

P697 **A Rare Cause of Extrapulmonary Respiratory Failure/**M. Mahmoudi, B.G. Wu, N. Ahmed, D. Katzman, N. Chitkara, E. Leibert, R. Zamuco, D. Addrizzo-Harris, New York, NY, p.A1372

Facilitator: M.E. Strek, MD, Chicago, IL

P698 **Rare Association of Anti-Threonyl tRNA (PL-7) Antisynthetase Syndrome and Pulmonary Alveolar Proteinosis/**R. Bishwakarma, S.K. Shah, M.D. Bailey, R. Papani, R.S. Nawgiri, V. Valentine, S.P. Nishi, Galveston, TX, p.A1373

P699 **IgG4 Related Disease in the Pleura Manifested as Weight Loss in an Immunocompromised Patient/**R. Krishna, J. Civan, D. Sass, J. Farber, B.T. Hehn, Philadelphia, PA, p.A1374

P700 **A Case of Idiopathic Pauci Immune Pulmonary Capillaritis (IPIPC)/**R. Malik, J. Jaddaoui, S. Beegle, Albany, NY, p.A1375

P701 **Zebras Have Hooves Too: A Case of Granulomatosis with Polyangiitis/**S.K. Avasarala, B. Small, H. Ahmad, G. Tatem, Detroit, MI, p.A1376

P702 **Pulmonary AA Amyloidosis Presenting as Interstitial Infiltrates in Rheumatoid Arthritis/**M. Aljasmi, C. Stone, J. Jennings, K. Thavarajah, Detroit, MI, p.A1377

P703 **Necrotizing Sarcoid Granulomatosis: A Masquerader/**B. Li, N. Nagella, S. Jagpal, New Brunswick, NJ, p.A1378

P704 **Mycobacterium Avium Complex Secondary to Pulmonary Alveolar Proteinosis: A Case Report/**M.A. Azevedo, M.D. Kaushal, A. Rossetti, Columbus, OH, p.A1379

Facilitator: P.G. Belvitch, MD, Chicago, IL

P705 **IgG4 Related Disease (IgG4-RD): A Differential Diagnosis for Fever of Unknown Origin/**S. Zanoria, R. Foley, Farmington, CT, p.A1380

P706 **When Zebras Gallop: Isolated Pulmonary Granulomatosis with Polyangiitis Presenting Solely as Acute Respiratory Distress Syndrome/**T.L. Griffiths, G. Cumbo-Nacheli, S.L. Schmidt, Grand Rapids, MI, p.A1381

P707 **Diffuse Alveolar Hemorrhage and Cardiac Involvement in Eosinophilic Granulomatosis with Polyangiitis: A Rare Presentation of a Rare Disease/**L. Cagino, A. Somoracki, A. Ataya, Gainesville, FL, p.A1382

P708 **Do Not IGnore G4/**M. Thi, S.A. Habib, M.I. Restrepo, San Antonio, TX, p.A1383

P709 **The Important of Complete Evaluation of a Patient with Recurrent Diffuse Alveolar Hemorrhage: A Case Study/**L. McCullough, A. Shahmohammadi, H. Alnuaimat, Gainesville, FL, p.A1384

P710 **Hydralazine Induced ANCA Vasculitis/**B.S. Pannu, V.N. Iyer, M. Baqir, Rochester, MN, p.A1385

P711 **Rituximab - Respiratory Rescue; Salvage Therapy in Acute Antisynthetase Syndrome/**N.P. Cosgrave, C. McCarthy, K. Balgobin, T. McEnery, M. Butler, M. Keane, B. Keogh, Dublin, Ireland, p.A1386

THEMATIC POSTER SESSION

A36 CLINICAL PROBLEMS IN ASTHMA AND ALLERGY

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area A, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: A.L. Fuhlbrigge, MD, Boston, MA

P53 **Caregiver Perspectives on Symptom-Based Inhaled Corticosteroid Therapy in Asthma/**T. Dy, E. Lewis, V. Murugan, S. Gehlert, J. Taylor, J. Garbutt, L.B. Bacharier, M. Castro, K. Sumino, St. Louis, MO, p.A1387

P54 **Metabolic Syndrome Limits the Bariatrically-Induced Weight Loss Benefit on Asthma Control/**P. Zhang, M. Nouraie, F. Holguin, Pittsburgh, PA, p.A1388

P55 **The Steady-State Pharmacokinetic (PK) Profile Across a Range of Patient Body Weight Categories Supports Weight-Based Dosing for Intravenous (IV) Reslizumab/**D. Jaworowicz, J. Fiedler-Kelly, L. Rabinovich-Guilatt, M. Bond, Buffalo, NY, p.A1389

P56 **Impact of Sensitization to Penicillium Chrysogenum in Patients with Adult Asthma/**A. Tanaka, M. Jinno, M. Yamaguchi, S. Ohta, T. Homma, M. Yamamoto, Y. Watanabe, S. Suzuki, T. Yokoe, H. Sagara, Tokyo, Japan, p.A1390

P57 **Evaluation of the Inhaler Technique, Patients Knowledge and Disease Control Among Asthmatic Patients/**F.P.G. Rizzatti, T.L. Silva, Sao Carlos, Brazil, p.A1391

P58 **A Phase III Multi-Center, Randomized, Placebo-Controlled, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Desloratadine in Japanese Patients with Chronic Urticaria/**S. Hisada, Y. Imai, N. Oshima, Y. Tanaka, C.I. Weinstein, M. Hide, Tokyo, Japan, p.A1392

P59 **A Phase III Multi-Center, Randomized, Placebo-Controlled, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety**

of Desloratadine in Japanese Patients with Seasonal Allergic Rhinitis/S. Hisada, Y. Maeda, N. Oshima, Y. Tanaka, C.I. Weinstein, K. Okubo, Tokyo, Japan, p.A1393

P60 **Clinical Implication of Adenosine Triphosphate in Sputum in Asthma/**T. Soma, T. Kobayashi, K. Nakagome, M. Nagata, Saitama, Japan, p.A1394

P61 **Functional Antibody Deficiency in Chronic Lung Disease/**R.M. Trafford, V. Moffat, T. Brockley, C. Pantin, M. Babores, S. Iyer, Macclesfield, United Kingdom, p.A1395

Facilitator: A. Yokoyama, MD, PhD, Kochi, Japan

P62 **Responder Rate Analysis of Asthma Control Questionnaire Scores in Patients Treated with Once-Daily Fluticasone Furoate/ Vilanterol or Fluticasone Furoate/**C. Poor, S. Faison, L. Sutton, D. Stempel, Research Triangle Park, NC, p.A1396

P63 **Impact of Irreversible Airflow Obstruction in Clinical Course of Patients with Severe Atopic Asthma/**K. Orimo, K. Takeyama, E. Tagaya, M. Kondo, J. Tamaoki, Tokyo, Japan, p.A1397

P64 **Exploring Asthma Patients for Whom Switching to Formoterol/Fluticasone Is Recommendable Among Patients Inadequately Controlled with Salmeterol/Fluticasone/**T. Kamei, K. Kato, H. Mizutani, M. Hayashi, N. Kihara, Takamatsu, Japan, p.A1398

P65 **Development of a Questionnaire to Evaluate Asthma Control in Japanese Asthma Patients: A Pilot Study/**S. Hozawa, H. Tanaka, F. Mori, Y. Tohda, Hiroshima, Japan, p.A1399

P66 **Short-Term Effectiveness of Bronchial Thermoplasty on Quality of Life and Control in Patients with Severe Asthma/**K. Kobayashi, M. Iikura, A. Shiozawa, I. Takazawa, S. Yamamoto, H. Kawamoto, S. Ro, S. Ishii, S. Izumi, M. Hojo, H. Sugiyama, Tokyo, Japan, p.A1400

P67 **Does Asthma Phenotype Have Impact on Disease Control - Can Detection of Inflammation and Hyperresponsiveness Ensure Stable Disease Faster (APERITIF)?/**K.F. Bernholm, A.-S., Homøe, H. Meteran, C. Porsbjerg, V. Backer, Copenhagen, Denmark, p.A1401

P68 **Optimal Sampling Designs for Studies of Multiple Flow Exhaled Nitric Oxide/**S.P. Eckel, N. Molshatski, Los Angeles, CA, p.A1402

P69 **Allergic Bronchopulmonary Aspergillosis in South Asia with Special Reference to Indian Children: The Demographic and Clinical Presentation/**M. Singh, N. Paul, A. Chauhan, K.S. Sodhi, A. Chakrabarti, Chandigarh, India, p.A1403

P70 **Prevalence of Allergic Diseases in Children Living in Rural and Urban Areas in Turkey/**Y. Gokdemir, E. Civelek, B. Cakir, A. Demir, C.N. Kocabas, R. Ersu, Istanbul, Turkey, p.A1404

Facilitator: J.G. Zein, MD, Cleveland, OH

P71 **Reduction in FeNO Is Correlated with FEV1 Improvement in Lebrikizumab Treated Asthma Patients/**F. Cai, Y. Zheng, C. Holweg, D. Choy, J. Olsson, J. Matthews, H. Schereens, South San Francisco, CA, p.A1405

P72 **Efficacy and Safety of Tratinterol Hydrochloride Tablets in Bronchial Asthma: A Randomized, Double-Blind and Multicenter Clinical Trial/**L. Kong, J. Kang, Y. Zhao, Shenyang, China, p.A1406

P73 **Clinical Effectiveness of Omalizumab in Severe Allergic Asthma Above the Recommended Dosing Range: The Australian Xolair Registry/**M. Hew, A. Gillman, M. Sutherland, P. Wark, J. Bowden, V. McDonald, M. Guo, H. Reddel, C. Jenkins, G. Marks, J. Upham, F. Thien, J. Rimmer, G.P. Katsoulotos, M. Cook, I. Yang, C. Katelaris, S. Bowler, D. Langton, P.G. Gibson, P.D. Robinson, C. Wright, M. Bint, V. Yozghatlian, S. Burgess, P. Sivakumaran, A. Jaffe, K. Yan, M. Peters, V. Kritikos, M. Baraket, A. Aminazad, Melbourne, Australia, p.A1408

P74 **A Phase IIb Dose-Finding Study to Assess the Efficacy and Safety of QAW039 (Fevipiprant) in Patients with Allergic Asthma Uncontrolled on Low-Dose ICS Therapy/**E.D. Bateman, A.M. Mesquita, A.G. Guerreros, F. Brockhaus, B. Holzhauer, A. Pethe, R.A. Kay, R.G. Townley, Cape Town, South Africa, p.A1408

P75 **Airway Eosinophilic Inflammation Assessed by Induced Sputum and Blood IgE In Asthmatic Children/**M. Ghezzi, A. Kantar, Ponte San Pietro, Italy, p.A1409

P76 **The Effects of Low- and High- Expression of Brain-Derived Neurotrophic Factor on the Intensity of Psychopathological Variables in Asthma Patients: A Preliminary Report/**M.G. Panek, J. Ziolo, M. Jonakowski, T. Pietras, A. Antczak, J. Szemraj, P. Kuna, Lodz, Poland, p.A1410

P77 **Reduction of Systemic Corticosteroid Requirement for Severe Asthma Following Minimally-Invasive Nissen Fundoplication for Severe GERD/**S. Patel, A.K. Mathur, C. Galvani, T.F. Carr, Tucson, AZ, p.A1411

P78 **House Dust Mite Sensitization as a Risk Factor for Exacerbation of Asthma in the Fall/**H.H. Kim, J.-S. Yoon, Y.H. Chun, H.S. Kim, Uijeongbu-si, Gyeonggi-do, Korea, Republic of, p.A1412

P79 **Gender-Specific Effect of Overweight and Obesity on Total Serum IgE in Adults with Allergic Asthma/**M. Imaoka, Fukuoka, Japan, p.A7776

P80 **The Potential Association between Adipocytokine and Steroid Insensitivity in Obese Asthmatic Patients/**M. To, N. Ogura, S. Mikami, S. Soeda, H. Hara, N. Honda, A. Hitani, I. Kano, K. Haruki, Y. To, Saitama, Japan, p.A7777

P81 **Clinical Characteristics of Obese Asthmatic Patients: Obese Asthmatic Patients Need More Frequent Unscheduled Visits and Rescue Uses of Corticosteroids/**M. To, N. Ogura, S. Mikami, S. Soeda, H. Hara, N. Honda, A. Hitani, I. Kano, K. Haruki, Y. To, Saitama, Japan, p.A7778

THEMATIC POSTER SESSION

A37 CYSTIC FIBROSIS: IMMUNE REGULATORY PATHWAYS

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area G, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: B.M. Morrissey, MD, Sacramento, CA

P715 **PB01: A Recombinant Human Follistatin Protein for the Treatment of Neutrophilic Lung Diseases/**B.M. Kita, C.L. Hardy, R.E. O'Hehir, M. Hedger, D.M. De Kretser, Caulfield North, Australia, p.A1413

P716 **CF Airway Epithelia Contribute to the Compromised Innate Immunity Against Bacterial Infection/**X. Yang, V. Patel, M. Wang, D.D. Thomas, L.L. Mantell, Jamaica, NY, p.A1414

P717 **Altered Phagosomal Degranulation in Neutrophils of Individuals with Cystic Fibrosis; an Impairment Corrected by CFTR Potential Therapy/**N. Browne, F. Gargoum, P. Hawkins, E. Reeves, N.G. McElvaney, Dublin, Ireland, p.A1415

P718 **Use of the Basophil Surface Marker CD203c in the Identification of Aspergillus Fumigatus Sensitisation in Cystic Fibrosis/**G.M. Lavelle, B. Mirkovic, A.A. Azim, K. Helma, F. Gargoum, K. Molloy, Y. Gernez, K. Dunne, J. Renwick, P. Murphy, C.M. Greene, R.B. Moss, C. Gunaratnam, S.H. Chotirmall, N.G. McElvaney, Dublin, Ireland, p.A1416

P719 **The Metalloprotease LasB from Pseudomonas Aeruginosa Subverts Innate Immunity In Vitro and In Vivo/**J.-M. Sallenave, V. Saint-Criq, F. Bastaert, B. Villeret, A. Hatton, A. Edelman, Paris, France, p.A1417

P720 **Electrolyte Transport Properties in Distal Small Airways from Cystic Fibrosis Pigs with Implications for Host Defense/**X. Li, X.X. Tang, L.G. Vargas Buonfiglio, P. Karp, P. Taft, K. Sheets, M. Welsh, D. Stoltz, J. Zabner, Coralville, IA, p.A1418

THEMATIC POSTER SESSION

A38 DIAGNOSTIC MARKERS OF ASTHMA AND COPD

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area B, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: M.R. Stampfli, PhD, Hamilton, Canada

P135 **Cluster Analysis of Asthma Patients with Allergic Rhinitis Including Rhinitis Symptoms and Serum Periostin Levels as Variable/**N. Sugimoto, H. Nagase, M. Kinoshita, H. Sakasegawa, T. Esaki, M. Ohsumi, Y. Koizumi, Y. Tanaka, S. Ro, H. Yoshihara, M. Kuramochi, H. Arai, M. Yamaguchi, K. Izuhara, K. Ohta, Tokyo, Japan, p.A1419

P136 **Reference Ranges for Serum Periostin in a Population Without Asthma or COPD/**I. Braithwaite, R. Caswell-Smith, A. Hosking, T. Cripps, C. Holweg, J. Matthews, M. Holliday, C. Maillot, J. Fingleton, M. Weatherall, R. Beasley, Wellington, New Zealand, p.A1420

P137 **Sinus Computed Tomographic Findings in Smoking and Non-Smoking Asthmatics: Associations with Asthma-Related Indices and Biomarkers Analysis/**H. Kimura, S. Konno, Y. Nakamaru, H. Makita, N. Taniguchi, K. Shimizu, M. Suzuki, J. Ono, K. Izuhara, M. Nishimura, Sapporo, Japan, p.A1421

P138 **Multi-Level Differential Network Analysis of COPD Exacerbations/**R. Faner, G. Noell, B.G. Cosio, T. Casserras, I. Coca, E. Monso, G. Peces-Barba, A. De Diego, C. Esteban, J. Gea, S. Kalko, A. Agusti, Barcelona, Spain, p.A1422

P139 **The Relative Importance of αv-Integrins in Chronic Obstructive Pulmonary Disease/**C. Moermans, H. Lou, O.J. Brand, A. Cormier, A. Bondesson, P.J. Wolters, D. Jablons, L. Murray, S. Nishimura, San Francisco, CA, p.A1423

P140 **Discovery of Non-Invasive Biomarkers of IL-17 Activity from Experimental Models of Asthma/**M. Bremer, D. Choy, G. Jia, D. Nagarkar, S. Kotwal, W. Lee, A. Abbas, F. Cai, J. Arron, H. Scheerens, T. Staton, South San Francisco, CA, p.A1424

P141 **Different Pathways of Inflammasome Activation in Human Precision-Cut Lung Slices (PCLS)/**S. Konzok, P. Braubach, D. Peter, D. Jonigk, H.-G. Fieguth, A. Braun, K. Sewald, Hannover, Germany, p.A1425

P142 **Biomarker Characterization of a Debilitated Phenotype in SPIROMICS/**I. Barjaktarevic, C.H. Martinez, J.L. Curtis, R.P. Bowler, W.K. O'Neal, E.A. Hoffman, E.E. Carretta, M. Quibrera, R.G. Barr, E. Bleecker, D.J. Couper, G.J. Criner, M.T. Dransfield, M.K. Han, N.N. Hansel, R. Kanner, S.C. Lazarus, F.J. Martinez, R. Paine, III, D.P. Tashkin, P.G. Woodruff, C.B. Cooper, Los Angeles, CA, p.A1426

Facilitator: S.M. Lyon, MD, Philadelphia, PA

P143 **Cigarette Smoke and Cigarette Smoke Condensate Induce Early Biomarkers of Inflammation and Cytotoxicity in Precision-Cut Lung Slices/**H. Obernolte, D. Ritter, J.W. Knebel, P. Braubach, D. Jonigk, H.-G. Fieguth, A. Braun, K. Sewald, Hannover, Germany, p.A1427

P144 **Evaluation of Th2 and Th17 Cytokine Levels in Serum from Asthmatics Using the High Sensitivity Quanterix Simoa HD-1 Platform/**M.L. Gavala, D. Smith, South San Francisco, CA, p.A1428

P145 **Airway Inflammation and Clinical Manifestations in Patients with Mild Asthma: Time Course of Human Rhinovirus (HRV) Induced Changes/**J. Efthimiou, A. Mann, G. Balaratnam, J. Gunter, P. Rucki, C. Poll, M. Johnson, T. Lockett, London, United Kingdom, p.A1429

P146 **What Are the Priorities for Future Research into Diagnostic Tools for Asthma? A Pan-EU Consensus Exercise/**L. Garcia-Marcos, J.L. Edwards, E.J. Kennington, S. Walker, Murcia, Spain, p.A1430

P147 **Multidimensional Analysis of Human Lung Myeloid Cells Reveal Unique Subpopulations in COPD and IPF/**J.J. Atkinson, B.C. Keller, D.G. Kelley, X. Jin, R.M. Senior, R.M. Presti, D.E. Byers, St. Louis, MO, p.A1431

P148 **Current Smoking Increases Macrophage Numbers and Immunoregulatory Receptor Expression in Bronchoalveolar Lavage but not Sputum in Chronic Obstructive Pulmonary Disease: SPIROMICS Immunophenotyping Sub-Study/** J.P. Brown, C.M. Freeman, S.W. Crudgington, V.R. Stolberg, J. Sonstein, N.E. Alexis, P.V. Basta, E.E. Carretta, S. Christenson, D.J. Couper, C.M. Doerschuk, N.N. Hansel, M.K. Han, A.T. Hastie, R.J. Kaner, F.J. Martinez, W.K. O'Neal, R. Paine, III, S.I. Rennard, D. Shimbo, P.G. Woodruff, M. Zeidler, J.L. Curtis, Ann Arbor, MI, p.A1432

P149 **Allergen Sensitization and Obstruction Indices of Allergic Asthmatics with High IgE (30-700 IU/ml) in an Urban Population: Super-obese (BMI 40 Kg/m²) vs Normal BMI (BMI =18-25 Kg/m²)/**M. Ahmad, N. Tambe, T. Thakur, J. Zacharias, A. Sharma, E. Schulman, Philadelphia, PA, p.A1433

P150 **Comparison of COPD Related Breath VOCs Assessed by a Compact High-Resolution Closed-Loop GC-IMS and by Standard GC-MS/**O. Holz, M. Allers, A. Gaida, S. Schuchardt, J.M. Hohlfeld, S. Zimmermann, Hannover, Germany, p.A1434

Facilitator: L.E. Crotty Alexander, MD, San Diego, CA

P151 **Study on the Grass Pollen Allergen Sensitization Mode and Their Relationships with Bronchial Hyperresponsiveness Patients with Asthma and/or Allergic Rhinitis in Southern China/**W. Luo, B. Sun, Guangzhou, China, p.A1435

P152 **Sex Hormones Impact Asthma Severity and Lung Function in Adult Men and Women/**J.G. Zein, M.D. DeBoer, W.G. Teague, S. Comhair, M. Castro, W.W. Busse, N.N. Jarjour, E.R. Bleecker, W.C. Moore, S.E. Wenzel, W.J. Calhoun, B. Gaston, S.C. Erzurum, Cleveland, OH, p.A1436

P153 **Investigation of Possibility as the Biomarker and the Function of Intelectin-1 (ITLN-1) in Bronchial Asthma Airway/**T. Watanabe, K. Chibana, T. Shiobara, Y. Horigane, A. Takemasa, Y. Ishii, Mibu town Tochigi prefecture, Japan, p.A1437

P154 **Lung Function Is Predicted by Resistin and Resistin: Adiponectin Ratio in Asthma/**L.G. Wood, D. Ballantyne, H. Scott, L. McDonald-Wicks, P.G. Gibson, New Lambton Heights, Australia, p.A1438

P155 **Nasal Polyps and Airway Hyperresponsiveness Determine Outcome of Adult-Onset Asthma; a 5 Year Prospective Follow-Up Study/**G. Westerhof, H. Coumou, S. De Nijs, E. Weersink, E.H. Bel, Amsterdam, Netherlands, p.A1439

P156 **Bronko Test® Sputum Colour as a Marker of Neutrophilic Bronchitis in Adults with Asthma/**J.L. Simpson, A. Lochrin, L.G. Wood, P.G. Gibson, New Lambton, Australia, p.A1440

P157 **Peripheral Blood Basophils as a Biomarker in Patients with Adult Bronchial Asthma/**S. Ohta, A. Tanaka, A. Fujiwara, Y. Uchida, R. Manabe, H. Furukawa, N. Kuwahara, Y. Fukuda, T. Kimura, T. Homma, K. Hirai, Y. Miyata, M. Jinno, M. Yamamoto, Y. Watanabe, T. Yokoe, H. Sagara, Tokyo, Japan, p.A1441

P158 **Changes in Skin Prick Test Reactivity: A 20-Year Longitudinal Study/**J.S. Nielsen, H. Meteran, C.S. Ulrik, C. Porsbjerg, V. Backer, Copenhagen, Denmark, p.A1442

Facilitator: T. Suzuki, MD, Aizuwakamatsu, Japan

P159 **Lack of Allergy Diagnostics in Severe Asthmatic Patients in Germany/**J. Schreiber, K. Garg, Magdeburg, Germany, p.A1443

P160 **Raised Serum IgG4 as a Marker for Th2 Mediated Inflammation in Persistent Asthma/**A. Rashidian, S. Sazgar, J. Mejia, T. Tyner, B. Abejie, V.V. Jain, J.J. Vempilly, Fresno, CA, p.A1444

P161 **Ability of Exhaled Nitric Oxide to Discriminate for Airflow Obstruction Among Frequent Exacerbators of Clinically Diagnosed Asthma/**L. Jalota, R. Allison, J. Vempilly, V.V. Jain, Fresno, CA, p.A1445

P162 **Dynamic Models of Exhaled Nitric Oxide/**P. Muchmore, S.P. Eckel, Los Angeles, CA, p.A1446

P163 **Bone Density Is Inversely Correlated with Plasma Levels of Platelet Factor 4 (PF4, CXCL4) in Severe Asthma/**M.W. Johansson, C.C. Chow, M.D. Evans, L.C. Denlinger, N.N. Jarjour, D.F. Mosher, S. Fain, M.L. Schiebler, Madison, WI, p.A1447

P164 **Fractal Dimension as a Global Index of Air Trapping/**G. Marin, S. Bommart, N. Molinari, L. Knabe, Y. Cabon, I. Vachier, C. Devautour, A. Bourdin, Montpellier, France, p.A1448

P165 **The Twitch and the Refractory Period: Testing the Allergic Inflammatory Response in the Lung/**J.J. Pothen, M.E. Poynter, L.K.A. Lundblad, J.H.T. Bates, Burlington, VT, p.A1449

P166 **Mucin Secretion in Asthmatics with Osmotic Airway Hyperresponsiveness/**J.M. Perelman, E. Nekrasov, D. Naumov, A. Prikhodko, G. Makarova, E. Ushakova, V. Kolosov, Blagoveshchensk, Russian Federation, p.A1450

P167 **Clinical Significance of Symptoms in Smokers with Preserved Spirometry/**P.G. Woodruff, R.G. Barr, E.R. Bleecker, S.A. Christenson, D.J. Couper, J.L. Curtis, N. Gouskova, N.N. Hansel, E.A. Hoffman, R. Kanner, E. Kleerup, S.C. Lazarus, F.J. Martinez, R. Paine, III, S.I. Rennard, D.P. Tashkin, M.K. Han, San Francisco, CA, p.A7779

P168 **Fetuin-B (FETUB): A Plasma Biomarker Candidate Related to the Severity of Lung Function in COPD/**W.-Q. Diao, B. He, N. Shen, Beijing, China, p.A7780

P169 **Indices of Pulmonary Function in a Nonhuman Primate Model of Nonatopic Asthma: Contribution of Lung Growth to Airway Hyperresponsiveness/**C.M. Royer, K. Chun, E.S. Schelegle, L.A. Miller, J.P. Capitanio, Davis, CA, p.A7781

THEMATIC POSTER SESSION

A39 EOSINOPHILIC AIRWAYS DISEASE

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area G, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: I. Ito, MD, PhD, Kyoto, Japan

P724 **Serum High Density Lipoprotein (HDL) Cholesterol and Large HDL Particles Are Negatively Correlated with Blood Eosinophils in Atopic Asthma/**A.V. Barochia, M. Kaler, R. Cuento, E.M. Gordon, P. Theard, D. Figueroa, N. Weir, M. Sampson, A.T. Remaley, S.J. Levine, Bethesda, MD, p.A1451

P725 **Eosinophils in Broncho-Alveolar Lavage in Young Children with Wheezing/**G. Gut, K. Armoni-Domany, E. Sadot, E.M. Fireman, Y. Sivan, Tel Aviv, Israel, p.A1452

P726 **Type 2 Cytokines IL-5 and IL-13 Act Synergistically on Eosinophils but Only IL-13 Induces Airway Hyperreactivity and Goblet Cell Metaplasia in Murine Asthma/**H. Beckert, S. Reuter, H. Meyer-Martin, S. Korn, R. Buhl, Mainz, Germany, p.A1453

P727 **Both Eosinophilic and Neutrophilic Inflammation Were Associated with Pulmonary Function in Ex-Smokers with Asthma/**T. Nagasaki, H. Matsumoto, T. Oguma, H. Inoue, T. Iwata, T. Tajiri, Y. Kanemitsu, Y. Izuhara, H. Sunadome, I. Ito, A. Niimi, M. Mishima, Kyoto, Japan, p.A1454

P728 **Correlation Between Sputum Eosinophilia and Exhaled Nitric Oxide/**J. Lee, J.-W. Paeng, D.-C. Choi, B.-J. Lee, Seoul, Korea, Republic of, p.A1455

P729 **Patients with Difficult to Control Eosinophilic Granulomatosis with Polyangiitis of a Vasculitis Clinical Center in Sao Paulo, Brazil/**E.P. Oliveira, J. Pinaffi, M.S. Tavares, L.K. Dourado, C.S.V. Barbas, Sao Paulo, Brazil, p.A1456

P730 **Long-Term Outcome and Prognostic Factors of Chronic Eosinophilic Pneumonia: Fujiyama Cohort Study/**Y. Suzuki, S. Imokawa, M. Toyoshima, K. Yokomura, H. Nakamura, S. Kuroishi, N. Koshimizu, Y. Ohyama, K. Furuhashi, T. Fujisawa, N. Enomoto, N. Inui, Y. Nakamura, T. Yamada, T. Shirai, M. Masuda, H. Hayakawa, T. Suda, Hamamatsu, Japan, p.A1457

P731 **Fluid Shear Stress Modulates Changes in Cell Morphology in Human Eosinophils/**K. Son, M. Small, L. Janssen, Hamilton, Canada, p.A1458

P732 **Association Between Early Improvements in Lung Function and Asthma Control with Reslizumab and the Annual Rate of Asthma Exacerbations/**E.D. Bateman, J. Zangrilli, M. Germinaro, S. Weiss, M. Castro, Cape Town, South Africa, p.A7782

P733 **Effect of Reslizumab Treatment on Rescue Systemic Corticosteroid Use in Patients with Asthma and Elevated Blood Eosinophils: Results from a Pooled Analysis of Two Phase 3, Placebo-Controlled Trials/**P. Bardin, K. Murphy, M. Garin, Melbourne, Australia, p.A7783

P734 **The Circadian Clock Regulates Allergic Lung Inflammation: Implications for Asthma/**H. Durrington, A. Loudon, D. Ray, Manchester, United Kingdom, p.A7784

THEMATIC POSTER SESSION

A40 EPITHELIAL REGULATION OF INFLAMMATION

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area G, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: R. Wu, PhD, Davis, CA

P735 **The Effect of IL-13 and IL-33 on the Efficacy of Albuterol on Airway Hyperresponsiveness in a Mouse Model of Asthma/**R.G. Townley, S. Agrawal, M.R. Hanna, B. Chang, N. Nettagul, Omaha, NE, p.A1459

P736 **PERK Inhibition Improves Permeability in Mechanical Stretch-Induced Epithelial Injury/**T. Dolinay, N. Yehya, G. Gray Lawrence, S.S. Margulies, Philadelphia, PA, p.A1460

P737 **Heat-Shock Accelerates Human Lung Epithelial Wound Healing by Activating Expression of Fibroblast Growth Factor (FGF)-1: Implications for Idiopathic Pulmonary Fibrosis (IPF)/**J.D. Hasday, R.G. Scheraga, C. Thompson, M. Tulapurkar, M.J. Cowan, J. Sun, R. Cai, C. Logun, N.W. Todd, J. Shelhamer, S.P. Atamas, I.G. Luzina, Baltimore, MD, p.A1461

P738 **L-citrulline Prevents Asymmetric Di-methyl Arginine Uncoupling of Nitric Oxide Synthase in Primary Human Airway Epithelial Cells/**D.E. Winnica, H. Grasemann, L.G. Que, B. Freeman, K. Wasil, S.E. Wenzel, F. Holguin, Pittsburgh, PA, p.A1462

P739 **Intranasal Elastase Induces Mucus Accumulation and Alterations in Lung Mucus Proteome in Mice/**J.A. Fernandez-Blanco, A. Ermund, A.M. Rodriguez-Pineiro, J. Root, C. McCrae, A. Astrand, G.C. Hansson, Molndal, Sweden, p.A1463

P740 **Relationship of ER Stress to Type 2 Inflammation in Asthma/**K.L. Jung, S.A. Christenson, S. Nerella, O.D. Solberg, C.P. Nguyen, P.G. Woodruff, N.R. Bhakta, San Francisco, CA, p.A1464

P741 **TWEAK Induced Chemokine, MCP-1, RANTES and IL-8 Production in Human Bronchial Epithelial Cells/**K. Matsuno, N. Harada, A. Ishimori, S. Harada, T. Takeshige, J. Ito, R. Atsuta, K. Takahashi, Tokyo, Japan, p.A1465

P742 **Histamine Stimulates Mucus Secretion Through IL-4 Induced TMEM16A in Human Nasal Epithelium/**H.-J. Cho, Y.H. Lee, C.-H. Kim, J.-H. Yoon, Seoul, Korea, Republic of, p.A1466

P743 **Regulation of Dipeptydyl Peptidase-4 (DPP4) Expression in Bronchial Epithelial Cells (BECs)/**K. Chibana, T. Shiobara, T. Watanabe, Y. Horigane, A. Takemasa, Y. Ishii, Mibu Machi, Tochigi prefecture, Japan, p.A1467

P744 **Chloride Ion Transport and Localization of TMEM16A in IL-13-Induced Goblet Cell Metaplasia/**M. Kondo, K. Hara, M. Tsuji, K. Takeyama, E. Tagaya, J. Tamaoki, Tokyo, Japan, p.A1468

P745 **Bronchial Epithelial Cells Expression of IL-17A and IL-17F in Asthma and COPD/**T. Morimoto, S.G. Smith, J.P. Oliveria, S. Beaudin, A. Schlatman, K. Howie, C. Obminski, G. Nusca, R. Sehmi, G.M. Gauvreau, P.M. O'Byrne, Hamilton, Canada, p.A1469

Facilitator: A.L. Linderholm, PhD, Davis, CA

P746 **Airway Progenitor Clone Formation Is Enhanced by Y-27632-Dependent Changes in the Transcriptome/**S.D. Reynolds, C. Rios, A. Wesolowska-Andersen, M. Pinter, C. Happoldt, G.M. Solomon, D.P. Nichols, M.A. Seibold, Columbus, OH, p.A1470

P747 **Alternaria Alternata Induces Pulmonary Inflammation in In Vivo and In Vitro Models of Asthma: Relative Contribution of Th2 Cytokines/**K. Hilliard, M. Caniga, I. Kariv, R. De Waal Malefyt, H. Chen, M. Salmon, M. Cicmil, Boston, MA, p.A1471

P748 **The Physiological Glucocorticoid (GC), Hydrocortisone, Limits Selected Actions of Synthetic GC in Human Airway Epithelium/**D. Radojicic, C.R. Keenan, A.G. Stewart, Parkville, Australia, p.A1472

P749 **Induction of Human Airway Epithelial to Mesenchymal Transition (EMT) upon Human Rhinovirus Infection/**D. Minor, S. Traves, D. Proud, Calgary, Canada, p.A1473

P750 **An Exploratory Pathway Analysis of Wound-Induced Gene Responses in Healthy and Asthmatic Human Airway Epithelial Cells (HAEC)/**H. Inoue, W. Horne, J.K. Kolls, X. Zhou, J.B. Trudeau, S.E. Wenzel, Pittsburgh, PA, p.A1474

P751 **Clarithromycin Attenuates IL-13-Induced Goblet Cell Hyperplasia Through SPDEF/CLCA1 Suppression in Normal Human Bronchial Epithelial Cells/**A. Nagashima, M. Shinkai, T. Shimokawaji, M. Shinoda, K. Mishina, H. Ishii, Y. Kimura, S. Sudo, Y. Tei, Y. Hara, T. Kodama, K. Tanaka, M. Toda, J. Tsukiji, M. Kudo, Y. Inayama, T. Sato, M. Yamamoto, B.K. Rubin, T. Kaneko, Yokohama, Japan, p.A1475

P752 **Mucosal Cytokines in Asthmatic Bronchoalveolar Lavage (BAL) Fluid Reflect Systemic Inflammation and Disease Severity/**E. Hunt, S. Lapthorne, A. Sullivan, C. Ward, J. Eustace, B. Plant, J. MacSharry, D. Murphy, Cork, Ireland, p.A1476

P753 **Transcriptomic Profiles of Bronchial Epithelial Cells in Asthmatics Differ From Controls/**N. Assad, Y. Tesfaigzi, S.A. Ness, A. Sood, Albuquerque, NM, p.A1477

P754 **Relationship Between AirwayHyperresponsiveness to Dosed Exercise Load and Hyperosmolar Stimuli in Patients with Asthma/**J.M. Perelman, L.G. Nakhamchen, E. Afanas'eva, A. Prikhodko, V. Kolosov, Blagoveshchensk, Russian Federation, p.A1478

P755 **Glucocorticoid-Driven Expression of Transcriptional Regulators in the Human Airways/**M.M. Mostafa, C.F. Rider, R. Leigh, R. Newton, Calgary, Canada, p.A1479

Facilitator: R.W. Harper, MD, Sacramento, CA

P756 **The Role of Secreted HSP90a on Asthmatic Airway Epithelial Barrier Dysfunction Induced by HDM/**H. Dong, C. Huang, Y. Le, L. Luo, Z. Xie, S. Cai, Guangzhou, China, p.A1480

P757 **Inflammatory Pattern of Bronchial Mucosa in Asthmatics with Hyperresponsiveness to Hyposmolar Stimulus/**V. Kolosov, A.B. Pirogov, A. Prikhodko, J.M. Perelman, E. Borodin, S.V. Zinovyev, M. Shtarberg, D. Naumov, E. Ushakova, Blagoveshchensk, Russian Federation, p.A1481

P758 **Pseudomonas Aeruginosa Flagellin Stimulates Broad Gene Expression in Human Airway Epithelial Cells that Is Mitigated by Concurrent Treatment with Azithromycin/**S.R. White, B. Laxman, S. Hashemifar, B. Xie, R. Stern, N. Maltsev, Chicago, IL, p.A1482

P759 **Inhaled Corticosteroids Upregulate IL10 and GILZ in Human Sputum-Derived Bronchial Epithelial Cells in Asthma/**B. Bleck, J.P.I. Egan, M. Cotrina-Vidal, A. Kazeros, G. Grunig, J. Reibman, New York, NY, p.A1483

P760 **Epithelial Cells and Fibroblasts from Asthmatic and COPD Patients Cocultures, an In Vitro Model of Asthma-COPD Overlap Syndrome (ACOS)?/**O. Le Rouzic, N. Ijiri, S. Audusseau, C. Baglole, M.S. Ludwig, D.H. Eidelman, Q. Hamid, Montreal, Canada, p.A1484

P761 **Human ß-Defensin 1, 2 and 3 Enhance TGF-ß1-Mediated Epithelial-Mesenchymal Transition (EMT) in Bronchial Epithelial Cells/**X.-Y. Qu, X.-M. Dang, D. Shang, W.-J. Wang, D. Xu, Y.-P. Shao, W.-Y. Lu, Y. Chang, Xi'an, China, p.A1485

P762 **Spleen Tyrosine Kinase and Calcium Play Critical Roles in the Release of IL-33 from Airway Epithelial Cells Exposed to Fungus Alternaria Alternata/**N. Sasaki, H. Kita, Y. Nakamura, K. Yamauchi, Rochester, MN, p.A1486

P763 **Studying the Relationship Between Lung Inflammation and Epithelial Cell Outside-in Barrier Permeability In Vivo/**T.J. Chapman, S. Hillman, S. Knowlden, J. Veazey, S. Georas, Rochester, NY, p.A1487

P764 **Antisense microRNA Therapy Reduces Goblet Cell Mucousal Metaplasia and MUC5AC Production in House Dust Mite (HDM)-Sensitized Mice/**S.C. Ramelli, J.M. McLendon, A. Ferretti, I. Aragon, J. Fewell, R. Barringtion, W. Gerthoffer, Mobile, AL, p.A1488

P765 **The Role of miR-141 in IL-13-Mediated Mucus Production/**S. Siddiqui, L. Zlock, D. Jun, L.R. Bonser, W. Finkbeiner, D. Erle, P.G. Woodruff, San Francisco, CA, p.A1489

Facilitator: D.A. Knight, PhD, Callaghan, Australia

P766 **Potentiation of MARCKS Phosphorylation in Airway Epithelia in Response to IL-13: Important Implications in Asthma/**C.-H. Chen, R. Li, C.-C. Lee, A.L. Linderholm, R. Harper, N.J. Kenyon, R. Wu, Davis, CA, p.A1490

P767 **A New Role for the Bcl-2 Family of Proteins in Blocking NF-kappaB Activation and Regulating House Dust Mite-induced Inflammation/**J.T. Jones, H.S. Chand, E.G. Awji, Y. Mebratu, Y. Tesfaigzi, Albuquerque, NM, p.A1491

P768 **Malondialdehyde-Acetaldehyde (MAA) Adducted Surfactant Protein Alters SRA/CD204 Gene and Protein Expression in Mouse Lung/**M. Sapkota, J.M. DeVasure, T.A. Wyatt, Omaha, NE, p.A1492

P769 **Surfactant Protein-A Promotes Resolution of Allergic Airways/**J.G. Ledford, K. Addison, D. Francisco, A.M. Pastva, J.J. Lee, M. Kraft, Tucson, AZ, p.A1493

P770 **A Peptide Modeled After the Bik BH3 Helix Dissociates the Bak-Bcl-2 Complex to Stabilize Bak and Reduce Allergen- and Cigarette Smoke-Induced Mucous Cell Metaplasia in Culture and In Vivo/**Y. Mebratu, I. Leyva-Baca, E.G. Awji, M. Delgado-Vargas, J.T. Jones, H.S. Chand, Y. Tesfaigzi, Albuquerque, NM, p.A1494

P771 **In the Maturing Layer of Primary Human Bronchial Epithelial Cells, Transforming Growth Factor-Beta Priming of Normal Cells Recapitulates Delayed Jamming as Seen in Asthmatic Cells/**J.A. Mitchel, J. Notbohm, J. Butler, J.J. Fredberg, J.-A. Park, Boston, MA, p.A1495

P772 **IL-13 Induces Periostin Production by MAP Kinase and STAT6 Phosphorylation. Inhibiting Periostin Production Modestly Decreases MUC5AC Mucin Secretion/**I. Suzaki, K. Komiya, T. Akaba, S. Kawano, T. Tanabe, B.K. Rubin, Richmond, VA, p.A1496

P773 **β2-Adrenoceptor-Mediated Gene Expression In Human Airway Epithelial Cells: Can a Given Long-Acting β2-Adrenoceptor Agonist Induce Gene Expression with Different Operational Efficacies?**/D. Yan, O. Hamed, N. Antony, R. Newton, M.A. Giembycz, Calgary, Canada, p.A1497

P774 **Antagonistic Interactions Between TGFβ1 and Nrf2 in the Alveolar Epithelium of HIV-1 Transgenic Rats**/X. Fan, B. Staitieh, R. Raynor, D.M. Guidot, Atlanta, GA, p.A1498

P775 **Human Rhinovirus-Induced Responses Differ Between Two Models of Well-Differentiated Human Bronchial Epithelial Cells**/S. Warner, D. Proud, Calgary, Canada, p.A1499

P776 **Increased Expression of a Proliferation-Inducing Ligand (APRIL) in Lung Leukocytes and Alveolar Epithelial Cells in COPD Patients with Non Small Cell Lung Cancer: A Possible Link Between COPD and Lung Cancer?**/F. Polverino, M. Laucho-Contreras, J. Rojas Quintero, M.J. Divo, V. Pinto-Plata, L.M. Sholl, J.P. De-Torres, B.R. Celli, C.A. Owen, Boston, MA, p.A7785

P777 **Mitochondrial DNA Released by Endotracheal Intubation Is Linked to Neutrophil Activation and Sore Throat Pain**/C. Puyo, D. Peruzzi, A. Earhart, M. Ibrahim, A.E. Gelman, St. Louis, MO, p.A7786

THEMATIC POSTER SESSION

A41 THE SPECTRUM COPD CARE: FROM IDENTIFICATION TO POLICY

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area B, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: M.J. Joo, MD, PhD, Chicago, IL

P170 **Peer Researchers' Knowledge, Confidence and Self-Reported Readiness to Administer Spirometry After Training**/C.B. Charron, T. Kaur, T. Rose, K. Florence, S. Pakhale, Ottawa, Canada, p.A1500

P171 **Role of Spoken Languange in Education of Inhaler Technique: Differences Among English and Non-English Speaking Patients**/H. Landau, S.M. Hon, N. Al-Naamani, R. Tsacoyianis, C. Balbuena, S. Kher, Boston, MA, p.A1501

P172 **Chronic Obstructive Pulmonary Disease Access to Community Health**/C. Landon, R. Higgins, H. Hansen, S. White-Wood, Ventura, CA, p.A1502

P173 **Diagnosis and Management of Chronic Obstructive Pulmonary Disease Care in Urban Versus Rural Veterans Affairs Clinics**/E.J. Swanson, A.D. Westanmo, T.S. Rector, K.L. Rice, P.G. Duane, Minneapolis, MN, p.A1503

P174 **Do We Confirm the "O" in COPD?**/D.A. DeLapp, A. Hotz, D. Bricker, Dayton, OH, p.A1504

P175 **Chronic Obstructive Pulmonary Disease: How Accurate Is the Diagnosis in Hospitalized Patients?**/H. Wu, S. Beygi, A. Medinger, Washington, DC, p.A1505

Facilitator: R.G. Barr, MD, DrPH, New York, NY

P176 **Prevalence of Low Peak Inspiratory Flow Rate (PIFR) in Chronic Obstructive Pulmonary Disease (COPD) Patients at Discharge After an Exacerbation- Interim Findings from a Prospective Study**/G.G. Sharma, D.A. Mahler, V. Mayorga, K. Deering, V. Ganapathy, Galveston, TX, p.A1506

P177 **The Distribution of COPD Categories in General Practice According to GOLD 2011 Classification in Russian Federation**/K. Piontkovskaya, V.V. Arkhipov, M. Miravitlles, D.E. Arkhipova, E. Stukalina, I. Osipova, A. Ipatov, Moscow, Russian Federation, p.A1507

P178 **Prevalence of Chronic Obstructive Pulmonary Disease (COPD) Among Patients Previously Treated for Pulmonary Tuberculosis (PTB) in Manila: A Multi-Center Study (PreCOPT Study)**/C.B. Gulay, H.S. Delfin, J. Benedicto, L. Fernandez, R. Pagcatipunan Jr, Manila, Philippines, p.A1508

P179 **Use of Artificial Intelligence Versus Traditional Methods in the Diagnosis of COPD**/A.R. Bastidas Goyes, D. Botero Rosas, L.P. Fajardo Latorre, C. Labrador Lopez, 140013, Colombia, p.A1509

P180 **Empirically Identifying Clinical COPD Subphenotypes and Their Stability**/D. Blagev, S. Rea, D.S. Collingridge, Murray, UT, p.A1510

P181 **Diagnosis Differences for Pulmonary Restrictive Defects Between NHANESIII and GLI12 Predictions on Caucasian Populations**/O.J. Linares, M. Hegewald, R.L. Jensen, J. Hankinson, A. Morris, Salt Lake City, UT, p.A1511

Facilitator: A.S. Gershon, MD, MSc, Toronto, Canada

P182 **Prevalence of Age-Adjusted Comorbid Diseases and Implications for Survival in a COPD Population in a Primary Care Accountable Care Organization**/A. Kleppinger, J. Lynch, K.M. Fox, J.R. Davis, M. DePietro, Farmington, CT, p.A1512

P183 **Mortality Outcomes of Long-Term Domiciliary Non-Invasive Ventilation in Stable Chronic Obstructive Pulmonary Disease with Chronic Type 2 Respiratory Failure**/P. Lee, E. Innes, J. Qian, C. Chen, A.T. Ng, Sydney NSW, Australia, p.A1513

P184 **A Systematic Review and Correlation and Regression Analysis of Rescue Medication Use with Standard COPD Endpoints**/Y.S. Punekar, S. Sharma, A. Pahwa, J. Takyar, I. Naya, P.W. Jones, Brentford, United Kingdom, p.A1514

P185 **How Does Chronic Obstructive Pulmonary Disease Management Affect Patient-Centered Health Outcomes and Cardiovascular Risk - The Command Study**/M. Bhutani, D. Fuhr, I.J. Andersson, R. Damant, B.H. Rowe, R. Leigh, M. Stickland, Edmonton, Canada, p.A1515

P186 **Disease Severity as a Determinant of Health Status in Patients with Chronic Obstructive Pulmonary Disease**/N. Malik, K. Chima, Lahore, Pakistan, p.A1516

P187 **Steroid Use in Inpatient Management of COPD Exacerbation**/G.W. Heckert, M. Stephen, Philadelphia, PA, p.A1517

Facilitator: V.G. Press, MD, MPH, Chicago, IL

P188 **Portable Spirometry in Hospitalized Patients with AECOPD Predicts Followup Airflow Obstruction/**C.H. Loh, K.K. Kannan, J.A. Ohar, Winston Salem, NC, p.A1518

P189 **Standardizing Inhaler Training Across a COPD Care Management Project/**B.W. Carlin, K. Kanel, G. Thomas, S. Campus, Pittsburgh, PA, p.A1519

P190 **The Use of an Spirometry Instructional Program for Healthcare Providers as a Component of a COPD Care Management Project/**B.W. Carlin, G. Thomas, K. Kanel, Sewickley, PA, p.A1520

P191 **Determinants and Patterns of Adherence to Inhaled Therapy by Patients with Severe Chronic Obstructive Pulmonary Disease (COPD)/**I. Sulaiman, J. Seheult, E. MacHale, D. Seow, F. Rawat, B. Deering, B. Cushen, M. Mokoka, C. Moran, F. Bolland, R. Costello, Dublin, Ireland, p.A1521

P192 **Examination of Quality Measure Application in Chronic Obstructive Pulmonary Disease Care in an Internal Medicine Residents' Teaching Clinic/**R.M. Burkes, U. Chaddha, T. Mkorombindo, N. Kubiak, K. El-Kersh, R. Cavallazzi, Louisville, KY, p.A1522

P193 **A Chronic Obstructive Pulmonary Disease (COPD) Service Integrating Community and Hospital Services Can Improve Patient Care and Reduce Hospital Stays/**M. Apps, D. Mukherjee, S. Abbas, J. Minter, J. Whitfield, S. Field, S. Pearce, M. Haigh, P. Rosier, B. Hawkes, L. Ateli, S. Webb, D. Carter, S. Barfield, H. Olympio-anang, P. Bannister, C. Goodrich, J. Finney, K.-A. Keeling, C. Wigmore, A. Kopacz, J. Downham, I. Young, J. Morgan, Basildon, United Kingdom, p.A1523

Facilitator: C.H. Martinez, MD, MS, MPH, Ann Arbor, MI

P194 **Effect of an Online, Case-Based Educational Intervention in COPD Among Pulmonologists and Primary Care Physicians/**E.L. Jackson, P. Chatterjee, New York, NY, p.A1524

P195 **A Telemedicine-Based Disease Management Program for Daily COPD Symptom Reporting Reduces Hospitalizations, Hospital Length of Stay, and Emergency Room Visits/**R.N. Criner, M.R. Jacobs, A.J. Criner, A. Rastogi, S.S. Strasburger, S.S. Cheng, M.J. Markus, G. Criner, Philadelphia, PA, p.A1525

P196 **Clinical Features and Discharge Characteristics of Patients Readmitted Within 30 Days Following Index Admission for COPD Exacerbation at Yale-New Haven Hospital/**S. Farasat, J.D. Possick, C.L. Rochester, Derby, CT, p.A1526

P197 **Factors Affecting the 30 Day Readmission Rate for Chronic Obstructive Pulmonary Disease(COPD) in a Tertiary Care Community Hospital/**B. Diede, D. Sese, M. Nasser, R. Rosario, T. McNatt, A. Diwakar, Akron, OH, p.A1527

P198 **Impact of Continuous Positive Airway Pressure Use on Hospitalization Rates in Medicare Beneficiaries with Coexisting COPD and Obstructive Sleep Apnea: The Overlap Syndrome/**G.P. Singh, W. Zhang, Y.F. Kuo, R. Sultana, G. Sharma, Galveston, TX, p.A1528

P199 **BiPAP Use in Type Two Respiratory Failure: A Predictor of Mortality?/**M. Quinn, R.J. Fahy, Dublin, Ireland, p.A1529

Facilitator: J.K. Quint, MBBS, PhD, London, United Kingdom

P200 **Effects of Outside Environment on the Performance of the 6 Minute Walk Test in COPD/**P. Patel, S. Paredes, M. Campos, Miami, FL, p.A1530

P201 **Mindfulness Based Stress Reduction for Patients with Chronic Lung Disease/**N.-C. Liang, E.C. Bernadas, R. Jen, Y. Li, A. Minassian, A. Malhotra, A. Ries, S. Hickman, San Diego, CA, p.A1531

P202 **Depression, Anxiety, and Cognitive Impairment: Risk of Exacerbations in Chronic Obstructive Pulmonary Disease/**N. Tobey, H.Q. Nguyen, K.C. Pike, S. Borson, Z. Chen, J. Lee, V.S. Fan, Seattle, WA, p.A1532

P203 **Depressive Symptoms and Lung Function and Percent Emphysema in the Multi-Ethnic Study of Atherosclerosis (MESA) Lung Study/**C. Almonte, C. Lo Cascio, H.F. Armstrong, M. Parikh, J.E. Schwartz, J.H.M. Austin, K. Watson, V.S. Fan, K.E. Killeen, R.G. Barr, New York, NY, p.A1533

P204 **The Impact of Incorrect Coding on a Medicare Bundled Payment for Care Improvement Initiative (BPCI) for COPD Exacerbations/**S. Khanijo, A. Palkar, A. Cohen, R. Ramdeo, A. Eichorn, Z. Brown, G.N. Lisker, New Hyde Park, NY, p.A1534

P205 **Clinical Characteristics and Outcomes of COPD Patients Included and Excluded from a Medicare Bundled Payment Care Initiative/**T.M. Parekh, S.P. Bhatt, J.M. Wells, D.P. Kirkpatrick, J.K. Nichols, C.C. Blackburn, A. Westfall, M. Mugavero, J. Willig, M.T. Dransfield, Birmingham, AL, p.A1535

P206 **How Do Symptoms and Comorbidities Affect Healthcare Costs in Patients with COPD? Results from the New German COSYCONET Cohort/**M.E. Wacker, R.A. Jorres, H. Schulz, J. Heinrich, S. Karrasch, A. Karch, A. Koch, R. Leidl, C. Vogelmeier, R. Holle, Neuherberg, Germany, p.A7787

P207 **Longitudinal Association of Percent Emphysema and Progression of Coronary Artery Calcium (CAC): The Multi-Ethnic Study of Atherosclerosis (MESA) Lung Study./**M.E. Gomez Almonte, M.J. Budoff, T. Di Vitantonio, E.A. Hoffman, J. Kaufman, M. Parikh, A. Gassett, E.D. Michos, R.G. Barr, New York, NY, p.A7788

THEMATIC POSTER SESSION

A42 AUTOIMMUNE MYOSITIS, ANTISYNTHETASE, SCLERODERMA, AND IPAF

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area L, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: A. Fischer, MD, Denver, CO

P1219 **Clinical and Radiological Predictor of Polymyositis and Dermatomyositis Associated Interstitial Lung Disease/**T. Kishaba, H. Nagano, Y. Nei, S. Yamashiro, Uruma, Japan, p.A1536

P1220 **Clinical Features and Predictive Factors for Long-Term Follow-Up in Polymyositis/Dermatomyositis-Associated Interstitial Lung Diseases/**T. Fujisawa, H. Hozumi, M. Kono, N. Enomoto, Y. Nakamura, N. Inui, R. Nakashima, Y. Imura, T. Mimori, T. Suda, Hamamatsu, Japan, p.A1537

P1221 **Anti-Aminoacyl-tRNA Synthetase Antibodies in Patients with Nonspecific Interstitial Pneumonia Diagnosed by Surgical Lung Biopsy/**M. Yamasue, M. Ando, H. Matsumoto, H. Yoshikawa, S. Toba, K. Umeki, J. Kadota, Yufu, Japan, p.A1538

P1222 **Mycophenolate Mofetil (MMF) as Initial Treatment in Antisynthetase Syndrome - A Case Report/**J.M. Intaphan, A. Selvaggio, Los Angeles, CA, p.A1539

P1223 **Retrospective Analysis of Twelve Patients with Anti-Synthetase Syndrome - Mayo Clinic Experience/**K. Linga, S.W. Robison, A. Lee, I. Mira-Avendano, Jacksonville, FL, p.A1540

P1224 **Interstitial Lung Disease and Myositis-Specific and Associated Autoantibodies: Patients Have Similar Clinical Manifestations Although a Heterogeneous Serologic Profile and Prognosis/**J. Rojas Serrano, D.I. Perez-Roman, D. Herrera-Bringas, P. Castorena-Garcia, M. Mejia, H. Mateos-Toledo, J. Castillo-Pedroza, A. Estrada, R. Guevara, Mexico City, Mexico, p.A1541

P1225 **Clinical Characteristics of 27 Patients with Interstitial Pneumonia Associated with Anti-Aminoacyl-tRNA-Synthetase Antibodies/**S. Izumi, A. Shiozawa, H. Kawamoto, S. Ishii, M. Suzuki, E. Morino, J. Takasaki, G. Naka, T. Sato, M. Iikura, Y. Takeda, M. Hojo, H. Sugiyama, Tokyo, Japan, p.A1542

P1226 **Serum Cytokine Profiles of Anti-CADM-140/MDA5 Positive Patients with Amyopathic Dermatomyositis and Rapidly Progressive Interstitial Lung Disease/**T. Takada, A. Aoki, K. Asakawa, T. Sakagami, H. Moriyama, T. Kikuchi, S. Sato, Minami-uonuma, Japan, p.A1543

P1227 **Prognostic Factors in Dermatomyositis-Associated Rapidly Progressive Interstitial Pneumonias Treated by Direct Hemoperfusion Using Polymyxin B-Immobilized Fiber Column/**H. Okabayashi, H. Ichiyasu, S. Hirooka, K. Kojima, T. Jodai, Y. Sakamoto, H. Ideguchi, S. Hamada, C. Yoshida, S. Hirosako, S. Okamoto, H. Kohrogi, Kumamoto city, Japan, p.A1544

P1228 **Interstitial Pneumonia with Autoimmune Features (IPAF) Presenting with Acute Respiratory Failure and Critical Illness: A Case Series/**G. Grasselli, B. Vergnano, M.R. Pozzi, V.L. Sala, A. Pesci, A. Pesenti, Milano, Italy, p.A1545

Facilitator: K.E. Black, MD, Boston, MA

P1229 **Differences in Lung Abnormalities Between Primary and Secondary Sjogren's Syndrome/**N. Kobayashi, H. Koizumi, K. Takahashi, A. Ihata, S. Nagaoka, T. Kaneko, Yokohama, Japan, p.A1546

P1230 **Diffuse Alveolar Hemorrhage Secondary to ANCA-Associated Vasculitis: Role of Plasma Exchange and Induction of Remission Therapy/**R. Cartin-Ceba, L.A. Diaz-Caballero, M.O. Al-Qadi, S. Tryfon, F.C. Fervenza, S.R. Ytterberg, U. Specks, Scottsdale, AZ, p.A1547

P1231 **Pulmonary Risk Factors for Lung Cancer in Systemic Sclerosis: A Single Center Case-Control Study/**K. Secunda, J. Katzen, R. Agrawal, J. Patel, M. Hinchcliff, A. Rademaker, J.E. Dematte, Chicago, IL, p.A1548

P1232 **Effect of Diastolic Dysfunction on Six Minute Walk Test Performance in Patients With Scleroderma/**A. Gadre, C. Ghattas, O.A. Minai, K.B. Highland, Cleveland, OH, p.A1549

P1233 **Differential Expression of Proteins in Scleroderma Patients with and Without Interstitial Lung Disease/**J.S. Lee, R. Keith, C. Meadows, A. Fischer, T.M. Bull, Aurora, CO, p.A1550

P1234 **HLA- Genotyping and Clinical Manifestation in Patients with Granulomatosis with Polyangiitis/**M.S. Tavares, L.K. Dourado, J. Pinaffi, E.P. Oliveira, H. Rodrigues, C.S.V. Barbas, Sao Paulo, Brazil, p.A1551

P1235 **The Importance of the Systemic Sclerosis Phenotype and the New Criteria for Interstitial Pneumonia with Autoimmune Features in the Prognosis of Patients Affected by Interstitial Lung Disease/**H. Mateos-Toledo, L. Quintana-Arroyo, J. Rojas-Serrano, D. Perez-Roman, A. Garrido, J. Castillo-Pedroza, M. Mejia, Mexico City, Mexico, p.A1552

P1236 **Physiologic Variance of Serial DLCO in Scleroderma Lung Disease/**A. Flora, Toledo, OH, p.A1553

P1237 **An Analysis of Prognostic Factors in Patients with Interstitial Pneumonia with Autoimmune Features/**Y. Ito, T. Ishida, M. Arita, H. Yoshioka, M. Noyama, F. Tokioka, A. Ito, H. Yokoyama, T. Kaneda, R. Takei, S. Kumagai, Kurashiki okayama, Japan, p.A1554

P1238 **Hepatic Steatosis Accompanies Pulmonary Alveolar Proteinosis/**A.N. Hunt, A. Malur, T. Montfort, S. Mahajan, A.D. Postle, M.J. Thomassen, Southampton, United Kingdom, p.A1555

THEMATIC POSTER SESSION

A43 ALPHA-1-ANTITRYPSIN DEFICIENCY

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area L, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: R.A. Sandhaus, MD, PhD, Littleton, CO

P1240 **Cardiovascular Risk and Lung Disease Severity in Alpha 1 Antitrypsin Deficiency/**D. Griffiths, C.E. Bolton, P. Nightingale, R.A. Stockley, E. Sapey, Birmingham, United Kingdom, p.A1556

P1241 **Prevalence and Nature of Liver Involvement in Patients with PiZZ-Emphysema, Candidates for Lung Transplantation/**H. Mal, L. Morer, L. Choudat, G. Dauriat, F. Durand, D. Cazals-Hatem, G. Thabut, O. Brugiere, Paris, France, p.A1557

P1242 **The Effect of Alpha-1 Proteinase Inhibitor (A1-PI) Therapy on Changes in Regional Lung Density: A Post-Hoc Analysis of the RAPID Trial/**D. Parr, N.G. McElvaney, K.R. Chapman, J. Burdon, N. Seersholm, J.M. Stocks, R.A. Sandhaus, O. Vit, M. Fries, J.M. Edelman, Coventry, United Kingdom, p.A1558

P1243 **The Relationship Between Changes in CT-Measured Lung Density and Lung Volume in Severe Alpha-1 Antitrypsin Deficiency: Post-Hoc Analysis of the RAPID Trial/**D. Parr, N.G. McElvaney, K.R. Chapman, J. Burdon, N. Seersholm, J.M. Stocks, R.A. Sandhaus, O. Vit, M. Fries, J.M. Edelman, Coventry, United Kingdom, p.A1559

P1244 **Rate of FEV1 Decline in Never-Smoking Alpha-1 Antitrypsin Deficiency Patients with and Without Small Airways Disease/**J. Stockley, S. Hughes, A. Ismail, B.G. Cooper, R.A. Stockley, E. Sapey, Birmingham, United Kingdom, p.A1560

P1245 **Health Status in Never-Smoking Alpha-1 Antitrypsin Deficiency Patients with and Without Airflow Obstruction/**J. Stockley, A. Ismail, S. Hughes, B.G. Cooper, R.A. Stockley, E. Sapey, Birmingham, United Kingdom, p.A1561

P1246 **The Prevalence of Alpha-1-Antitrypsin Allele Abnormalities Among Patients with COPD on Chest CT/**Z.A. Mirza, H. Phan, B. Khan, J. Miskoff, M.P. Carson, Neptune City, NJ, p.A1562

P1247 **Serum Proteins Associated with Radiographic Emphysema and Its Progression in Severe Alpha-1 Antitrypsin Deficiency/** T. Beiko, M. Janech, C.B. Strange, Charleston, SC, p.A1563

P1248 **Serum Desmosine, Isodesmosine and Emphysema in Spirometrically Mild PiZZ Alpha-1 Antitrypsin Deficiency/**T. Beiko, S. Ma, C.B. Strange, G. Turino, Charleston, SC, p.A1564

P1249 **Impact of Augmentation Treatment in Alpha-1 Deficiency Patients on Lung Transplantation Result/**T. Fuehner, S. Janciauskiene, T. Kohnlein, J. Gottlieb, T. Welte, Hannover, Germany, p.A1565

Facilitator: C.P. Hersh, MD, MPH, Boston, MA

P1250 **Liver Fibrosis in Alpha 1 Antitrypsin Deficiency-Related Lung Disease/**G.W. Marek, V.C. Clark, C. Liu, T. Kurtz, F. Rouhani, M.L. Brantly, Gainesville, FL, p.A1566

P1251 **Osteoporosis and Osteopenia in COPD Alpha-1 Antitrypsin Deficiency/**M. Berlacher, K. Diab, Indianapolis, IN, p.A1567

P1252 **Demographics and Clinical Profile of Patients with Alpha-1 Antitrypsin Deficiency PiMS Genotype Started on Augmentation Therapy/**N.S. Zaidi, D.L. Greek, S. Kearns, L. Kristofek, Joplin, MO, p.A1568

P1253 **Improving Survival Among ZZ Patients in the AlphaNet Program/**R. Choate, D. Mannino, R.A. Sandhaus, D. Barber, K. Holm, Lexington, KY, p.A1569

P1254 **Differences Between ZZ and SZ Patients in the AlphaNet Program/**R. Choate, D. Mannino, D. Barber, R.A. Sandhaus, K. Holm, Lexington, KY, p.A1570

P1255 **Gender Differences in Alpha-1-Antitrypsin Deficiency/**M.A. Pardinas Gutierrez, M. Mirsaeidi, R.A. Sandhaus, M. Campos, Miami, FL, p.A1571

P1256 **Rare Alpha-1 Antitrypsin Mutations Detected in Ireland/**T. Carroll, L. Fee, C. O'Connor, I. Ferrarotti, S. Ottaviani, P. O'Brien, E. Pentony, M. Luisetti, N.G. McElvaney, Dublin, Ireland, p.A1572

P1257 **The Irish Alpha-1 Antitrypsin Deficiency National Targeted Detection Programme/**L. Fee, T. Carroll, C. O'Connor, P. O'Brien, E. Pentony, I. Ferrarotti, S. Ottaviani, M. Luisetti, N.G. McElvaney, Dublin, Ireland, p.A1573

P1258 **Alpha-1 Antitrypsin Deficiency in Romania - First Steps (Results of First Three Years of Screening)/**R. Ulmeanu, A.-M. Zaharie, J. Chorostowska Wynimko, O.C. Deleanu, F.D. Mihaltan, Bucharest, Romania, p.A1574

P1259 **Alpha-1 Antitrypsin Level Increase During an Inflammatory State: A Potential Cause of Missed Diagnosis in Alpha-1 Antitrypsin Deficiency/**D.A. DeLapp, P. Nystrom, Dayton, OH, p.A1575

Facilitator: D.F. Dilling, MD, Maywood, IL

P1260 **Alpha-1 Antitrypsin Deficiency - Do We Really Understand It? Case Presentations/**A.-M. Zaharie, F.D. Mihaltan, C. Popa, O.C. Deleanu, R. Ulmeanu, Bucharest, Romania, p.A1576

P1261 **Bronchiectais as the Sole Presentation of Alpha-1 Antitrypsin Deficiency in a Never-Smoker/**E. Kawar, N. Batarseh, Sioux Falls, SD, p.A1577

P1262 **A Unique Case of Alpha-1-Antitrypsin Deficiency Recurrence After Bilateral Lung Transplant/**A. Somoracki, L. Cagino, A. Ataya, J. Salgado, H. Alnuaimat, M.L. Brantly, Gainesville, FL, p.A1578

P1263 **Impact of AATD Patient Management Program on Health-Related Outcomes and Costs/**M.C. Runken, A. Davis, M.P. Johnson, A.R. Buikema, Research Triangle Park, NC, p.A1579

P1264 **Evaluation of Strategies for Comprehensive Diagnostic Testing for α1-Antitrypsin Deficiency that Include Quantitative Isoelectric Focusing and DNA Sequencing/**L. Scott, M. Campbell, E.J. Campbell, Salt Lake City, UT, p.A1580

P1265 **The Elephant in the Room/**K.K. Wickstrom, S.W. Low, H.H. Desai, N. Mahmoud, J. Knepler, Tucson, AZ, p.A1581

P1266 **Generating a Novel Model of Alpha-1 Antitrypsin Deficiency Pathogenesis by Deriving Type II Alveolar Cells from Pluripotent Stem Cells/**K. Hurley, A. Jacob, D.C. Thomas, F. Hawkins, A. Wilson, D.N. Kotton, Boston, MA, p.A1582

P1267 **Metabolomic Profiling and Lung Function Impairment in Alpha-1 Antitrypsin Deficiency/**E.S. Wan, W. Qiu, R.A. Sandhaus, A.F. Barker, M.L. Brantly, E. Eden, G. Turino, N.G. McElvaney, S.I. Rennard, J.M. Stocks, J.K. Stoller, C.B. Strange, E.J. Campbell, C. Clish, D.L. DeMeo, E.K. Silverman, Boston, MA, p.A1583

P1268 **Effects of Recombinant Alpha1-Antitrypsin IgG1 Fc-Fusion Protein (AAT-Fc) in Experimental Emphysema/**K. Takeda, S. Kim, E.W. Gelfand, Denver, CO, p.A1584

THEMATIC POSTER SESSION

A44 DRUG INDUCED AND RARE LUNG DISEASE

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area L, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: M.P. Keane, MD, Dublin, Ireland

P1270 **Nanosilica and Polyacrylate/Nanosilica: A Comparative Study of Acute Toxicity/**Y. Niu, X.-L. Zhu, B. Chang, Z.-H. Tong, W. Cao, P.-H. Qiao, L.-Y. Zhang, J. Zhao, Y.-G. Song, Beijing, China, p.A1585

P1271 **Eosinophilic Pneumonia Caused by Daptomycin: Five Case Reports and Review of the Literature/**J. Hirai, T. Kinjo, M. Hagihara, H. Hashioka, M. Nakamatsu, S. Haranaga, Y. Yamagishi, H. Mikamo, J. Fujita, Okinawa, Japan, p.A1586

P1272 **Clinical Analysis of Drug-Induced Lung Disease/**M. Nemoto, S. Noma, S. Yamawaki, F. Suzuki, R. Tsuzuki, A. Otsuki, K. Nakashima, M. Misawa, M. Aoshima, Kamogawa City, Japan, p.A1587

P1273 **Monitoring for Amiodarone Pulmonary Toxicity Is of Limited Utility in Real World Practice/**A. Toscano, T. Siddiqui, K. Tahir, S. DeLisle, Baltimore, MD, p.A1588

P1274 **Radiation Bronchial Necrosis: Clinical and Bronchoscopy Features/**O. Shtraichman, O. Fruchter, D. Rosengarten, A.R. Nader, M.R. Kramer, Petach Tikva, Israel, p.A1589

P1275 **Breast Cancer Therapy Is Associated with Respiratory Muscle Weakness/**K. Dittus, N. Kokinda, D. Rubin, D.A. Kaminsky, B.T. Suratt, Burlington, VT, p.A1590

Facilitator: E.M. Fireman, PhD, Tel Aviv, Israel

P1276 **Baseline Characteristics and Demographics of Patients Receiving Daptomycin and Incidence of Toxicity Associated with Daptomycin Use/**M.K. Ellis, A. Szabo, K. Joshi, Milwaukee, WI, p.A1591

P1277 **Infectious Complications in Patients Receiving Biologic Therapy/**C. Ochoa, P. Rajaram, S. Tanukonda, R.T. Sadikot, Atlanta, GA, p.A1592

P1278 **Case-Control Study of HLA Region in Brazilian Carriers of Granulomatosis with Polyangiitis (Wegener's)/**M.S. Tavares, C.S.V. Barbas, L.K. Dourado, T. Antunes, J. Pinaffi, Sao Paulo, Brazil, p.A1593

P1279 **An Analysis of Pulmonary Manifestations of IgG4-Related Disease/**H. Sadamatsu, K. Takahashi, H. Tashiro, N. Sueoka-Aragane, Saga, Japan, p.A1594

P1280 **Clinical Features of IgG4-Related Respiratory Disease/**S. Matsui, H. Yamamoto, S. Minamoto, T. Handa, Y. Waseda, M. Mishima, K. Kubo, Toyama, Japan, p.A1595

THEMATIC POSTER SESSION

A45 LUNG DISEASE ASSOCIATED WITH BIOLOGICAL THERAPY AND IMMUNOTHERAPY: CASE REPORTS

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area L, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: J.A. De Andrade, MD, Birmingham, AL

P1282 **Acute Fibrinous Organizing Pneumonia: Rituximab Induced Fibrin Balls Within Alveoli, an Unknown Entity/**N. Victor, Dover, DE, p.A1596

P1283 **Cryptogenic Organizing Pneumonia in a Patient with Crohn's Disease on Infliximab- An Extra Intestinal Pulmonary Manifestation or Drug Induced Complication?/**M. Mauro, N. Yellappa, I. Harbuz-Miller, D. Markley, Morristown, NJ, p.A1597

P1284 **Clinical Conundrum: A Case of Afatinib-Induced Interstitial Lung Disease/**S.E. Wu, M.H. Lee, A. Mednick, New York, NY, p.A1598

P1285 **Drug Induced Organizing Pneumonia by Immune-Checkpoint Inhibitor, Nivolumab/**M. Nagamata, M. Yomota, T. Okamura, K. Yoshino, T. Hishima, Tokyo, Japan, p.A1599

P1286 **Tarceva Induced Fatal Interstitial Lung Disease: An Underreported Toxicity/**R. Sedhom, E. Gorshein, S. Wong, New Brunswick, NJ, p.A1600

P1287 **Severe Symptomatic Hypercalcemia and Diffuse Pulmonary Nodules as the Presenting Symptoms of Adalimumab Induced Sarcoid-Like Granulomatosis/**C. Bielick, W. Wong, A. Sosa, Worcester, MA, p.A1601

P1288 **Golimumab Induced Sarcoid-Like Interstitial Lung Disease and Pulmonary Hypertension/**W. He, B. Mann, M.B. Beasley, H. Poor, New York City, NY, p.A1602

P1289 **Pneumonitis Secondary to Combination CTLA-4 and PD-L1 Inhibitor Therapy: A Case Report/**A.D. Zider, O. Fried, K. Ruchalski, A. Gutierrez, D. Wong, J.W. Goldman, Los Angeles, CA, p.A1603

P1290 **Rituximab-Induced Hypersensitivity Pneumonitis Masked by Concomitant Corticosteroid Therapy/**M.Q. Khan, S. Bellam, Evanston, IL, p.A1604

P1291 **Immunotherapy in Metastatic Melanoma: A Case of Pulmonary Non-Caseating Granulomas/**S. Srinivas, C. Reichner, Washington, DC, p.A1605

P1292 **Did Rituximab Do the Trick?/**A. Gupta, R. Gripaldo, Columbia, SC, p.A1606

THEMATIC POSTER SESSION

A46 LUNG DISEASE DUE TO OTC AND ILLICITS: CASE REPORTS

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area L, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: N. Patel, MD, Philadelphia, PA

P1294 **Jagged Little Pills: A Case of Pulmonary Deposition of Intravenously Injected Crushed Oral Tablets/**M. Werlang, B. Hiroto, I. Mira-Avendano, Jacksonville, FL, p.A1607

P1295 **Dirty Urine, Dirty Drug/**E. Crowley, N. Sigua, Indianapolis, IN, p.A1608

P1296 **Silicone Pulmonary Embolism Syndrome Presenting with Pneumomediastinum, Diffuse Alveolar Hemorrhage, and Hypoxemic Respiratory Failure/**S. Medrek, E. Guy, C.C. Kao, P. Sarkar, Houston, TX, p.A1609

P1297 **Sun Damage or Lung Damage: HeliocareT (Polypodium Leucotomas)-Induced Eosinophilic Pneumonitis/**A. Foderaro, M. Jankowich, Providence, RI, p.A1610

P1298 **An Unusual Case of Crack-Lung/**R.R. Miranda, D. Vilela, J.R. Bandeira Filho, F.E. Arimura, E.C.T. Nascimento, F.D.C. Bernardi, M. Dolhnikoff, R. Kairalla, C.R.R. Carvalho, B.G. Baldi, Sao Paulo, Brazil, p.A1611

P1299 **Severe Inhalational Toxicity from Chlorine Dioxide/**A. Bosak, M. Mathew, Phoenix, AZ, p.A1612

P1300 **All That Glitters Is Not Gold: A Case of Mercury Pneumonitis/**A. Surender, C. Barrett, W. Nichols, Kalamazoo, MI, p.A1613

P1301 **Not Your Everyday Pneumonia Lipoid Pneumonia Caused by Silent Aspiration of Vicks Vapo-Rub/**N. Alqsous, Y. Naidu, J. Murray, Rochester, NY, p.A1614

P1302 **Cocaine-Induced Bronchial Laceration/**I. Choudhry, S. Tavares, C. Bulathsinghala, Corpus Christi, TX, p.A1615

P1303 **As Molly Takes the Party Toll: MDMA Toxicity Presenting with Pulmonary Hemorrhage/**S. Rehman, F. Khalid, S. Kowsika, I. Ghobrial, McKeesport, PA, p.A1616

P1304 **Iron Pill Pneumonitis with Reactive Lymph Nodes/**R. Mankikar, R. Arya, Columbia, SC, p.A1617

P1305 **Massive Pneumomediastinum, Epidural Pneumatosis, and Pneumopericardium Following Inhalation of Methamphetamine/**E. Horn, T. Heynekamp, K. Gelfenbeyn, Albuquerque, NM, p.A1618

P1306 **Is Carbon Monoxide Level Predictive of Cortical Blindness?/**S.U. Rehman, A. Ali, F. Safi, R. Assaly, Toledo, OH, p.A1619

P1307 **Cannabinoid Hyperemesis Syndrome with Pneumomediastinum: An Unusual Complication of an Under-Recognized Entity/**S. Chaudhary, A. Chaudhary, A. Ghatol, Flint, MI, p.A1620

P1308 **Pulmonary Cavities and IVDU, Not Always Septic Emboli: A Case Report/**D. Belz, A. Ajakumar Menon, Boston, MA, p.A1621

P1309 **Don't Blame the Birds/**M.G. MacMurdo, H. Poonyagariyagorn, R. Sasich, Portland, OR, p.A1622

P1310 **Just Say No! A Case of MDMA-Associated Cerebral and Pulmonary Edema Requiring Extra-Corporeal Membrane Oxygenation (ECMO)/**A. Thakkar, K. Parekh, K. El Hachem, E.M. Mohanraj, New York, NY, p.A1623

P1311 **Exogenous Lipoid Pneumonia Caused by Paraffin Oral Enema: An Atypical Case/**Y.-L. Liu, B. Sun, Z.-H. Tong, Beijing, China, p.A1624

THEMATIC POSTER SESSION

A47 RARE INTERSTITIAL LUNG DISEASE: CASE REPORTS

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area L, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: M. Scholand, MD, Salt Lake City, UT

P1313 **Unusual Presentation of Organizing Pneumonia in Primary Sjogren's Syndrome/**J.P. Sugunaraj, Y.B. Mehta, C.S. Greco, Danville, PA, p.A1625

P1314 **A Challenging Case of Severe Pulmonary Arterial Hypertension with P-ANCA and Anti-Myeloperoxidase Antibody: Supported with Extracorporeal Membrane Oxygenation (ECMO). Should Biopsy Be Performed?/**J.H. Rhee, J. Sullivan, Omaha, NE, p.A1626

P1315 **A Case Report of Rheumatoid Pneumoconiosis (Caplan's Syndrome)/**G.W. Li, Z.N. Fu, GuangZhou, China, p.A1627

P1316 **Recognizing the Pattern: Relapsing Polychondritis Presenting with Recurrent Otitis Externa and Scleritis/**A. Abu Homoud, D. Alpert, Neptune City, NJ, p.A1628

P1317 **Necrobiotic Pulmonary Nodules Secondary to Crohn's Disease/**M. Rezik, G. Choe, H. Kinni, G. Samuel, D. Ouellette, Detroit, MI, p.A1629

P1318 **Fatal Hemoptysis Secondary to Fibro-Inflammatory IgG4-Related Lung Disease: A Case Report/**L. Fernandez, L.F. Sua, J.P. Amariles, C.A. Munoz, Cali, Colombia, p.A1630

P1319 **Non-specified Interstitial Pneumonia (NSIP) and Thromboembolic Disease as First Manifestation of Disease in Primary Sjogren Syndrome: Case Report/**L. Fernandez, M.F. Rojas, C.A. Munoz, L.I. Gomez, L.F. Sua, Cali, Colombia, p.A1631

P1320 **Case Report: Pulmonary Lymphangioleiomyomatosis in a Post-Menopausal Female Patient/**D. Modh, Surat, India, p.A1632

P1321 **Thick Walled Lung Cavity as the Sole Presentation of Granulomatosis with Polyangiitis (Wegener's Granulomatosis)/**K. Gunasekaran, S. Kotakonda, A. Chaudhary, M.J. Bauer, E. Bischof, Cooperstown, NY, p.A1633

P1322 **Flash Blood- An Unusual Case of Intermittent Massive Hemoptysis/**N. Barberis, J. Hippensteel, K. Lyn-Kew, Denver, CO, p.A1634

P1323 **Sclerosing Mediastinitis: The Story Within/**A. Alharbi, J.H.G. Cal, M. Alhajjaj, Riyadh, Saudi Arabia, p.A1635

P1324 **A Case of IgG4 Related Disease Presented with Diplopia, Generalised and Mediastinal Lymph Adenopathy, Lung Nodules, Pancreas and Renal Involvement/**M. Paramasivam, A.R. Nadama, Riyadh, Saudi Arabia, p.A1636

P1325 **Microscopic Polyangiitis with an Unusual Pulmonary Manifestation and no Renal Involvement/**H. Simo, A. Kubbara, C. Kakish, Y. Yoon, Toledo, OH, p.A1637

P1326 **A Curious Case of Acute Respiratory Failure - Anti-Synthetase Syndrome/**G. Malhotra, N. Ramreddy, M. Iliescu, Chicago, IL, p.A1638

P1327 **PM-DM Associated Interstitial Lung Disease/**Z.S. Shakir, Kansas City, KS, p.A1639

P1328 **Flare of Anti-Synthetase Interstitial Lung Disease with Cessation of Immunosuppression/**L.J. Witt, J.M. Oldham, J.J. Curran, M.E. Strek, Chicago, IL, p.A1640

P1329 **Infliximab for Treatment of Anti PL-12 Antisynthetase Syndrome: Misdiagnosis Led to New Potential Treatment for Rare Disease/**T. Thaniyavarn, Atlanta, GA, p.A1641

P1330 **Improved Pulmonary Function and Lung Shadow with Pirfenidone Administration for a Chinese Case with Systemic Sclerosis Associated Interstitial Lung Disease/**H. Huang, S. Li, K. Xu, Y. Bi, R. Feng, Z. Xu, Beijing, China, p.A1642

P1331 **Necrotizing Palisaded Granulomas of the Lung Parenchyma in a Patient with Systemic Lupus Erythematosus/**M.M. Herrera, K.G. Mayhall, L. Santo Tomas, Milwaukee, WI, p.A1643

P1332 **Acute Cardiopulmonary Complications of Systemic Lupus Erythematosus/**A.L. Smith, A. Mora, Dallas, TX, p.A1644

P1333 **Shrinking Lung Syndrome - An Unusual Cause of Dyspnea in Patients with Systemic Lupus Erythematosus/**A. Vyas, La Jolla, CA, p.A1645

P1334 **Dyspnea in Systemic Lupus Erythematosus: A Case of Shrinking Lung Syndrome/**J. Norsworthy, Brooklyn, NY, p.A1646

THEMATIC POSTER SESSION

A48 CONVENTIONAL DRUG ASSOCIATED LUNG DISEASE

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area L, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: M.J. Hamblin, MD, Kansas, City, KS

P1336 **Amiodarone Induced Pulmonary Toxicity - A Frequently Missed Complication/**A.J. Sweidan, N.K. Singh, N. Dang, J. Datta, Long Beach, CA, p.A1647

P1337 **Alveolar Hemorrhage Induced by Chemotherapy/**R. Bansal, A. Surana, K. Thakur, Upland, PA, p.A1648

P1338 **Imipenem/Cilastatin-Induced Acute Eosinophilic Pneumonia: A Case Report/**K.S. Foong, A. Lee, M. Pekez, J. Deaner, W. Bin, Upland, PA, p.A1649

P1339 **Successful Treatment of Amiodarone Induced Lung Toxicity with Steroids and Veno-Venous Extra-Corporeal Membrane Oxygenation/**A. Avula, A. Saqib, A. Khalil, New York, NY, p.A1650

P1340 **Progressive Dyspnea in a Heart Transplant Recipient: Sirolimus-Induced Pulmonary Alveolar Proteinosis/**H.C. Sasieta, M. Brutinel, Rochester, MN, p.A1651

P1341 **Pulmonary Eosinophilia from Inhaled Colistin/**P.-A. Lepine, A. Dumas, L.-P. Boulet, Quebec, Canada, p.A1652

P1342 **Capecitabine-Induced Lung Injury/**C.J. Benthin, G. Allada, Portland, OR, p.A1653

P1343 **Concomitant Daptomycin and Ceftaroline-Induced Eosinophilic Pneumonia: A Case Report/**D.J. Pepper, E. Delbecq, A.P. Burke, C. White, E.J. Britt, Bethesda, MD, p.A1654

P1344 **Daptomycin Induced Myopathy, Eosinophilic Interstitial Nephritis, and Acute Eosinophilic Pneumonia/**A. Bosak, C. Jivcu, Phoenix, AZ, p.A1655

P1345 **Hydralazine Induced Hemoptysis/**Y.A. Al Ahwel, A. Ali, A. Kubbara, S.U. Rehman, V. Anandan, R. Booth, R. Assaly, Toledo, OH, p.A1656

P1346 **Dual Antiplatelet Therapy Induced Hemoptysis/**Y.A. Al Ahwel, A. Ali, M. Taleb, A. Kubbara, S.U. Rehman, J. Hammersley, Toledo, OH, p.A1657

P1347 **Daptomycin-Induced Acute Eosinophilic Pneumonia: Case Report and Review of Literature/**P. Goyal, M.J. Breen, P. Hountras, R. Raj, M.K. Bolon, Chicago, IL, p.A1658

P1348 **Recurrent Gemcitabine-Induced Pneumonitis After Cessation of Oral Corticosteroid Therapy, a Rebound Effect?/**M.A. Pardinas Gutierrez, J. Duque, D.J. De La Zerda, Miami, FL, p.A1659

P1349 **Barium Bronchogram/**A. Shawkat, G. Trikha, Syracuse, NY, p.A1660

P1350 **Acute Eosinophilic Pneumonia Secondary to Sertraline Use/**A.B. Nassri, P. Harford, Austin, TX, p.A1661

P1351 **Carbimazole Induced Hypersensitivity Pneumonitis/**F. Claude, A. Gondoin, P. Manzoni, C. Singeorzan, M. Veil Picard, N. Belin, G. Capellier, B. Degano, J.-C. Dalphin, Besancon, France, p.A1662

P1352 **Sarcoidosis as Paradoxical Effect of Tumor Necrosis Factor-α Blockers/**B.K. Patibandla, B.C. Moulton, Portland, OR, p.A1663

P1353 **Drug-Induced Lupus Secondary to Trimethoprim/Sulfamethoxazole Presenting with Pleural Effusions and Pericardial Tamponade/**A. Jose, A. Cramer, K. Davar, A. Bawa, G. Gutierrez, Washington, DC, p.A1664

P1354 **Pulmonary Infiltrates Following Peripheral Stem Cell Transplantation, Not Always Infectious Pneumonia. A Case of Busulfan-Induced Pulmonary Injury/**M.R. Mourad, M.S. Crosser, Kansas City, KS, p.A1665

P1355 **A Common Drug with an Uncommon Complication/**K. Johnson, W. Nasser, Gainesville, FL, p.A1666

P1356 **Giant Cell Interstitial Pneumonitis (GIP) as a Rare Manifestation of Chronic Nitrofurantoin Lung Toxicity/**E. Alkhankan, M. Alzoby, M. Al-Ourani, Huntington, WV, p.A1667

P1357 **Drug-Induced Pneumonitis Detected Earlier by 18 F-FDG-PET than by High-Resolution CT/**J. Falco, A.R. Garcia, H. Karlen, E. Medinacelli, M. Hernandez, M.A. Solis, S. Quadrelli, Buenos Aires, Argentina, p.A1668

P1358 **Paclitaxel Induced Pneumonitis as an Uncommon Cause of Severe Acute Respiratory Distress Syndrome/**J. MacLeod, E. Chen, G.R. Bourjeily, R. El-Bizri, Providence, RI, p.A1669

P1359 **Metastatic Pulmonary Calcification Following Orthotopic Liver Transplant: A Bronchoscopic Diagnosis/**V. Kundel, T.J. Harkin, New York, NY, p.A1670

P1360 **Ulcerative Colitis: Inflammation Beyond the Bowel/**S.N. Jogani, P.B. Brasher, M.K. Subik, M.A. Judson, S. Beegle, Albany, NY, p.A1671

P1361 **Eosinophilic Pneumonia Induced by IM Progesterone After In Vitro Fertilization/**A. Baig, S.L. Schmidt, Grand Rapids, MI, p.A1672

P1362 **Delayed Paclitaxel-Induced Interstitial Pneumonitis in Breast Cancer/**N. Durairajan, A. Ali, Detroit, MI, p.A1673

P1363 **A Case of ILD as a Consequence of Volatile Anesthetic Exposure/**N. Najjar, W. Palfrey, P. Patel, M. Faisal, V. Seeram, J. Cury, Jacksonville, FL, p.A1674

P1364 **Ground Glass Attenuation: Atypical Presentation of Atypical Antipsychotics/**K. Gunasekaran, S. Murthi, N. Panneerselvam, O. Ahmad, N. Lone, Cooperstown, NY, p.A1675

P1365 **"Into the Blue": A Case of Symptomatic Rasburicase-Induced Methemoglobinemia/**D. Rudym, N. Jindal, R. Greene, New York, NY, p.A1676

P1366 **Daptomycin Induced Eosinophilic Pneumonia/**R. Sharara, A.C. Singh, Y. Hattab, B. Barker, Pittsburgh, PA, p.A1677

P1367 **Blitz Attack: An Unusual Presentation of Amiodarone Toxicity/**P. Sen, A. Abu Arqoub, A. Patel, R. Miller, V. Patel, Newark, NJ, p.A1678

P1368 **Amiodarone: A Cryptic Culprit for Cirrhosis Associated Respiratory Failure/**O. Awan, M. Mahmoudi, A. Basavaraj, R. Rajmane, New York City, NY, p.A1679

P1369 **Biloptysis as a Late Complication of Hepatic TheraSpherer Radiation for Metastatic Breast Cancer/**S. Hayat, Grand Rapids, MI, p.A1680

P1370 **Spontaneous Mediastinal Hematoma: Complication of Anticoagulation in a Patient Presenting with Dyspnea/**W. Mansour, E. Moussaly, J. Zaidan, A. Abou Yassine, M. Chalhoub, Staten Island, NY, p.A1681

P1371 **Pulmonary Embolism Secondary to Intravenous Immunoglobulin Therapy/**S. Patel, H. Hawamdeh, A. Ataya, D. Urbine, Gainesville, FL, p.A1682

THEMATIC POSTER SESSION

A49 COPD: CARE DELIVERY

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area B, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: F.C. Sciurba, MD, Pittsburgh, PA

P209 **Current Treatment and Symptomatic Burden of Patients with COPD Consulting for Routine Care According to 2014 GOLD Classifications/**B. Ding, M. Small, G. Bergstrom, U. Holmgren, Gothenburg, Sweden, p.A1683

P210 **Hospital Utilization for COPD Patients Enrolled in a Home Based Pulmonary Population Health Program Utilizing Respiratory Therapists in Partnership with a National Medicare Advantage Plan/**A.H. Greene, Nashville, TN, p.A1684

P211 **Inhaler Preference, Attribute Importance and Satisfaction for Asthma and Patients with COPD Consulting for Routine Care/**B. Ding, M. Small, G. Bergstrom, U. Holmgren, Gothenburg, Sweden, p.A1685

P212 **Results of a Canadian Parallel Survey for Family Physicians and COPD Patients: The Exacerbation Prevention in Canada Program/**A.G. Kaplan, M. Balter, C. Poirier, R. Leigh, Richmond Hill, Canada, p.A1686

P213 **Developing a Spirometry Program in the Primary Care Setting to Enhance COPD Diagnosis/**C. Rodriguez Flores, M.V. Lopez Varela, E. Pacheco, M. Mamchur, J. Nunez, K. Rabunal, F. Gimenez, A. Tempone, K. Fagundez, C. Silva, Montevideo, Uruguay, p.A1687

P214 **Participation in a Telemedicine Program for Chronic Obstructive Pulmonary Disease Improves Daily Symptoms/**N. Gaeckle, D. Ciccolella, A. Criner, G. Criner, Philadelphia, PA, p.A1688

P215 **Inappropriate Use of Inhaled Corticosteroids in COPD/**E. Dabscheck, A. Harrison, B. Borg, B.R. Thompson, M. Hew, Prahran, Australia, p.A1689

P216 **The Alliance Between General Practitioners and Pulmonologists Improves Characterization and Appropriate Treatment of Chronic Respiratory Diseases/**A. Benfante, R. Messina, V. Milazzo, U. Nesti, N. Scichilone, Palermo, Italy, p.A1690

Facilitator: N.E. Bracken, ACNPC, MSN, Chicago, IL

P217 **Assessment of Current States and Future Risks of COPD by Questionnaire-Based Survey in Japan/**H. Takeuchi, T. Koya, T. Hasegawa, M. Hayashi, T. Sakagami, Y. Kimura, A. Aoki, S. Watanabe, E. Suzuki, T. Kikuchi, Niigata, Japan, p.A1691

P218 **Impact of Education in Chronic Obstructive Pulmonary Disease (COPD) Patients: A Single Center Experience/**C. Boily-Daoust, S. Preville-Ratelle, Y. Dubois, C. Poirier, C. Bergeron, Montreal, Canada, p.A1692

P219 **Economic Analysis for Inpatient Therapy for Patients with Acute Exacerbation of COPD in Japan: Comparison with Bronchial Asthma/**H. Katsura, A. Sato, M. Hasegawa, A. Okabayashi, N. Yokohori, Chiba, Japan, p.A1693

P220 **Clinical Assessment and Management of Inhaler Therapy in Patients Diagnosed With Chronic Obstructive Pulmonary Disease/**E.J. Soto Hurtado, A. Albarracin Arregosa, M.D. Almenara Escribano, A. Ruz Zafra, F.J. Cabello Rueda, A. Ruiz Cantero, Ronda, Spain, p.A1694

P221 **Feasibility of Using Smartwatches and Smartphones to Monitor Patients with COPD/**R. Wu, E. De Lara, D. Liaqat, I. Thukral, A.S. Gershon, Toronto, Canada, p.A1695

P222 **Developing a Simple Screening Tool for Detecting COPD in Primary Care Setting: The PUMA Study/**M. Montes De Oca, M.V. Lopez Varela, A. Rey, A. Casas Herrera, R. Stirvulov, V. Di Boscio, Caracas, Venezuela, p.A1696

P223 **Factors Associated with COPD Underdiagnosis in a High-Risk Primary Care Population: The PUMA Study/**A. Casas Herrera, J. Jardim, M. Montes De Oca, M.V. Lopez Varela, E. Schiavi, C. Aguirre, Bogota, Colombia, p.A1697

P224 **Therapeutic Choices for COPD Following the Revised GOLD Guidelines/**B.B. Aarli, B.K. Nore, K.Y. Garatun-Tjeldstoe, Bergen, Norway, p.A1698

P225 **Respiratory Medication Use in Primary Care of Four Latin American Countries: The PUMA study/**J. Jardim, R. Stirvulov, D. Moreno, G. Zabert, M.V. Lopez Varela, M. Montes De Oca, Sao Pablo, Brazil, p.A1699

Facilitator: W.A. Quezada, MD, New York, NY

P226 **The Clinical Impact of an Integrated Care Model for COPD: Results from the Velletri-Lariano (VELA) Cohort/**G. De Filippi, M. Lallini, G. De Riggi, G. Marchetti, C. Dimartino, A.M. Russetti, E. Ferrari, R. Pistellli, M.S. Magnoni, M. Riparbelli, A. Rizzi, P. Angeletti, Velletri, Italy, p.A1700

P227 **Risk Factors and a Model Predictive of AECOPD in Patients Rehospitalized Within 3 Months/**Y. Zhou, W. Li, D.Y. Feng, H.L. Yang, C.T. Liu, T.T. Zhang, Guang Zhou, China, p.A1701

P228 **New Diagnosis of COPD with Spirometry Associated with Reduction in First All-Cause Hospitalization/**T.T. Yamanaka, S. Adimadhyam, T. Lee, M. Joo, Chicago, IL, p.A1702

P229 **Absence of Wheezing Is Associated with Underdiagnosis of Chronic Obstructive Pulmonary Disease: Analysis of the NHANES, 2007-2012/**T. Goto, C.A. Camargo, K. Hasegawa, Boston, MA, p.A1703

P230 **How Accurate Is the Clinical Diagnosis of COPD in Hospitalized Patients?/**M. Hanna, F.D. Ponce, Z. Ghazarian, R. Sekhon, M. Lange, M. Ismail, M.A. Khan, Paterson, NJ, p.A1704

P231 **Accuracy of Self-Reporting in Diagnosis of COPD/**N.P. Kozodoy, E.C. Crawford, J. Hammersley, J.C. Willey, Toledo, OH, p.A1705

P232 **Assessment of COPD Severity in a Real-Life Cohort of German Patients- 1-Year Follow-Up Data from the DACCORD Study/**H. Worth, R. Buhl, C.-P. Criee, P. Kardos, N. Lossi, C. Mailaender, C. Vogelmeier, Fuerth, Germany, p.A1706

P233 **A Brief Mindfulness Program to Increase Quality of Life in Chronic Lung Disease/**R. Benzo, J.L. Kirsch, J. Hoult, D. Rasmussen, Rochester, MN, p.A1707

THEMATIC POSTER SESSION

A50 ASTHMA: OBSERVATIONAL STUDIES

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area A, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: A. Sood, MD, MPH, Albuquerque, NM

P82 **Physician Perspectives on the Burden and Management of Asthma in Six Countries: The Global Asthma Physician Survey (GAPS)/**D. Hinds, K.R. Chapman, P. Piazza, M. Gibbs, C. Raherison, K. Gaalswyk, T. Greulich, J. Lin, K. Davis, Collegeville, PA, p.A1708

P83 **Obesity Predisposes to Airway Closure During Bronchial Challenge in Asthma/**M. Subramanian, D.G. Chapman, D.A. Kaminsky, C.G. Irvin, L.J. Smith, J.H.T. Bates, A.E. Dixon, Burlington, VT, p.A1709

P84 **Establishing a Correct Diagnosis in Adults Who Have Been Mis-Diagnosed with Asthma/**H. Pham, K. Vandemheen, L.-P. Boulet, J.M. FitzGerald, M. Ainslie, S. Gupta, C. Lemiere, S. Field, A. McIvor, P. Hernandez, I. Mayers, S.D. Aaron, Ottawa, Canada, p.A1710

P85 **Trends in Healthcare Utilization for Asthma Exacerbations Among Diverse US Populations and Geographic Regions: 2004-2010/**E.K. Larkin, T. Gebretsadik, T. Hartert, R.L. Lee, A.M. Evans, N.M. Sicignano, A.C. Wu, C. Iribarren, M. Butler, E. Mitchell, J. Morrow, C. Stone, K. Turi, P. Wu, Nashville, TN, p.A1711

P86 **Risk Factors Of Severe Asthma Exacerbations: A Real World Study/**K. Verhamme, M. Engelkes, M. De Ridder, E. Svensson, K. Berencsi, D. Prieto-Alhambra, C. Giaquinto, F. Lapi, G. Picelli, N. Boudiaf, F.C. Albers, S. Cockle, E. Bradford, R. Suruki, P. Rijnbeek, M. Sturkenboom, Rotterdam, Netherlands, p.A1712

P87 **Predictors of Added Value of Exhaled Nitric Oxide (FeNO) in the Management of Asthma: Insight from Medical Practice/**I. Coman, Y. Dubois, C. Bergeron, Montreal, Canada, p.A1713

P88 **Feedback on Adherence and Inhaler Technique Using the INCA Device: A Randomised Control Trial in Severe Asthma/**I. Sulaiman, E. MacHale, J. Seheult, S. D'Arcy, V. Rapcan, M. Mokoka, B. Cushen, I. Killane, A. Franciosi, A. Sahadevan, M. Keane, J.M. Keane, S. Lane, D. Murphy, R. Reilly, R. Costello, Dublin, Ireland, p.A1714

P89 **Inhaler Technique Errors Have an Impact on Drug Delivery./**I. Sulaiman, J. Seheult, N. Sadasivuni, B. Cushen, M. Mokoka, R. Costello, Dublin, Ireland, p.A1715

P90 **Does Personality Traits and Medication Adherence Affect Control of Asthma?/**A.F. Kalpaklioglu, A. Baccioglu, A. Yorgancioglu, Y. Havlucu, B. Gemicioglu, S. Sheikh, M. Erdinc, O. Goksel, Kirikkale, Turkey, p.A1716

P91 **Differences of Clinical Features and Airway Structural Changes Between Asthma and Asthma-COPD Overlap Syndrome/**M. Niwa, T. Fujisawa, M. Karayama, K. Mori, Y. Suzuki, K. Furuhashi, D. Hashimoto, N. Enomoto, Y. Nakamura, N. Inui, T. Suda, Hamamatsu, Japan, p.A1717

Facilitator: J. Trevor, MD, Birmingham, AL

P92 **Symptom Perception and Health Care Utilization for Asthma: Clinical Relevance of Abnormal Perception of Bronchoconstriction and Dynamic Hyperinflation/**S. O'Loghlen, L. Levesque, T. Fisher, G. Liu, T. To, M.D. Lougheed, Kingston, Canada, p.A1718

P93 **An Exacerbation-Prone Phenotype Exists in Blacks Independent of Patient Perceived Severity as Assessed by Asthma Control/**N.L. Grossman, G.D. Doros, F. Laden, A.L. Fuhlbrigge, M. Wechsler, W.D. Pace, B.P. Yawn, E. Israel, Boston, MA, p.A1719

P94 **Simultaneously Elevated Fraction of Exhaled Nitric Oxide and Blood Eosinophil Counts Relates to Recent Asthma Events/**I. Mogensen, K. Alving, J.A. Fonseca, T. Jacinto, C. Janson, A. Malinovschi, Uppsala, Sweden, p.A1720

P95 **Bronchiectasis and Asthma, a Fairly Ordinary Couple: Preliminary Study of 98 Patients/**A. Padilla, L. Fernandez De Rota Garcia, J. Perez Stachowski, C. Olveira, I. Marco Galve, M.A. Martinez-Garcia, Marbella, Malaga, Spain, p.A1721

P96 **Impact of Asthma on Pregnancy Outcome: A Case-Control Study/**Z. Ali, L. Nilas, C.S. Ulrik, Hvidovre, Denmark, p.A1722

P97 **Asthma Treatment Transition and Its Asthma-Related Clinical Events in Patients with Severe Asthma/**P. Dilokthornsakul, A.M. Thompson, J.D. Campbell, Muang, Phitsanulok, Thailand, p.A1723

P98 **Association of Asthma Treatment Transitions and Clinical Events in Patients with Mild Asthma/**P. Dilokthornsakul, A.M. Thompson, J.D. Campbell, Muang, Phitsanulok, Thailand, p.A1724

P99 **Factors Associated with In-Hospital Mortality in Patients with Asthma Exacerbations in Japan/**W. Hasegawa, Y. Yamauchi, H. Yasunaga, H. Takeshima, T. Jo, H. Matsui, K. Fushimi, T. Nagase, Tokyo, Japan, p.A1725

P100 **The Utility of Spirometry in Assessment of Presumptive Diagnosis of Bronchial Asthma in a Developing Country/**N.I. Nwosu, C. Chukwuka, C. Onyedum, H. Odilinye, P. Nlewedim, Enugu, Nigeria, p.A1726

P101 **Peripheral Airway Dysfunction in the Dunedin Cohort at Age 38 Years/**P.D. Robinson, G.G. King, M.R. Sears, C. Yen Hong, R. Hancox, Sydney, Australia, p.A1727

Facilitator: F. Holguin, MD, MPH, Pittsburgh, PA

P102 **The Association of Non-Invasive Ventilation and Endotracheal Intubation in Severe Acute Asthma: A Propensity Score Stratified Analysis/**K. Mahan, C. Elm, E. Soto, A. O'Brien, J. Leatherman, M. Prekker, Minneapolis, MN, p.A1728

P103 **The Serological Response of Asthmatics to the 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23)/**C.R. Laratta, K. Williams, D. Vethanayagam, M. Ulanova, H. Vliagoftis, Edmonton, Canada, p.A1729

P104 **Evaluation of US Subjects in the Identification and Description of Severe Asthma Patients in a Cross-Sectional Study-The IDEAL Study/**R. Suruki, N. Gunsoy, J.-Y. Shin, L.M. Nelsen, E. Bradford, F. Albers, Research Triangle Park, NC, p.A1730

P105 **Prevalence of Severe Eosinophilic Asthma in Pediatric Asthma Patients Identified in a US Healthcare Claims Database/**R. Suruki, C. Carroll, H. Mullerova, K.J. Davis, Research Triangle Park, NC, p.A1731

P106 **Seasonal Pattern of Asthma Medication Fills among Diverse US Populations/**K. Turi, T. Gebretsadik, T. Hartert, R.L. Lee, A.M. Evans, N.M. Sicignano, A.C. Wu, C. Iribarren, M. Butler, E. Mitchel, J. Morrow, E.K. Larkin, P. Wu, Nashville, TN, p.A1732

P107 **The Effect of Prolonged Duration of Clinic Visits on Asthma Control and Patient-Doctor Relationships/**S. Cai, Z.Y. Qin, C. Ping, J. Fen, Hunan Province, China, p.A1733

P108 **Validity of Asthma Control Questionnaires Among Smoking Asthmatics/**X. Soler, J. Holbrook, K. Kinninger, J. Saams, A.E. Burke, R.A. Wise, J.W. Ramsdell, San Diego, CA, p.A1734

P109 **A One-Day-Visit Program in a Specialized Severe Asthma Center Improves Asthma Control, Quality of Life and Healthcare Utilization After One Year/**A.N. Van Der Meer, H. Pasma, W. Kempenaar, J. Pelinck, M. Schutten, H. Storm, A. Ten Brinke, Leeuwarden, Netherlands, p.A1735

P110 **Characteristics of Severe Asthma Exacerbations Among Inner-City Women in Pregnancy/**N. Kamath, N. Patel, L.T. Kose, D. Desai, E. Schulman, E.J. Yoo, Philadelphia, PA, p.A1736

P111 **Association Between Socioeconomic Status and Asthma in Adults in Japan/**R. Tsugitomi, E. Hoshino, T. Tanigawa, H. Nakaoka, K. Okafuji, A. Kitamura, Y. Tomishima, N. Uchiyama, T. Jinta, N. Nishimura, O. Takahashi, T. Tamura, N. Chohnabayashi, Chuo-ku, Tokyo, Japan, p.A1737

Facilitator: W. Stevens, MD, Chicago, IL

P112 **Inhaler Errors After Reading the Patient Information Leaflet in Patients with Asthma: Elliptar Compared with Three Inhaler Devices/**M. Thomas, J. Van Der Palen, H. Chrystyn, R. Sharma, V. Imber, H. Svedsater, N. Barnes, Southampton, United Kingdom, p.A1738

P113 **Time to Achieve Correct Inhaler Use and Inhaler Preference: A Comparison of Elliptar with Three Inhaler Devices in Patients with Asthma/**M. Thomas, J. Van Der Palen, H. Chrystyn, C.-Q. Zhu, S. Ghatta, H. Svedsater, Southampton, United Kingdom, p.A1739

P114 **Prevalence of Peripheral Airway Dysfunction in Adult Asthmatics/**S. Kjellberg, B. Houltz, O. Zetterström, P. Robinson, P. Gustafsson, Skövde, Sweden, p.A1740

P115 **Protocolised Difficult Asthma Assessment Improves Asthma Outcomes/**T.R. Tay, N. Radhakrishna, F. Hore-Lacey, R. Hoy, E. Dabscheck, M. Hew, Melbourne, Australia, p.A1741

P116 **Deposition of Radioaerosol in Obese Women With and Without Asthma: A Pilot Study/**J.M. Barcelar, L. Alcoforado, T. Rocha, S.C.S. Brandao, J.B. Fink, A. Dornelas De Andrade, Recife, Brazil, p.A1742

P117 **Cluster Analysis of Uncontrolled Asthma in Japanese Population/**S. Watanabe, T. Koya, T. Hasegawa, M. Hayashi, T. Sakagami, Y. Kimura, A. Aoki, H. Takeuchi, E. Suzuki, T. Kikuchi, Niigata, Japan, p.A1743

P118 **The Impact of Psychological Factors on Asthma Patients/**S. Beyhan Sagmen, S. Olgun, H. Baykan, M. Ozdemir, B. Ceyhan, Malatya, Turkey, p.A1744

P119 **Causes of Uncontrolled Clinical Course of Bronchial Asthma in Belarus/**D. Ruzanau, E. Davidouskaya, T. Baranovskaya, I. Manichev, Gomel, Belarus, p.A1745

P120 **Evaluation of Swedish Integrated Electronic Health Records and Register Health Care Data to Support Interpretation of a Reference Population in Asthma Clinical Trials (PACEHR)/**S. Franzen, G. Magnusson, G. Telg, U. Olsson, C. Janson, K. Larsson, M. Petzold, M. Sundgren, Gothenburg, Sweden, p.A1746

P121 **Qualitative Interviews and Focus Groups with COPD and Asthma Patients: Understanding Patient Burden, Life Impact and Treatment Preferences/**H. Svedsater, E. Hilton, C. Patel, J. Macey, J. Roberts, L. Bradshaw, Uxbridge, United Kingdom, p.A1747

Facilitator: K. Sumino, MD, MPH, St. Louis, MO

P122 **Effect of Khat (catha edulis) on Bronchial Asthma in Jimma University Specialized Hospital, Adult Chest Clinic, Jimma, Ethiopia/**E.Y. Teferedegn, A. Ayana, Izmir, Turkey, p.A1748

P123 **Perioperative Asthma Management Is Possible by Evaluation and Treatment with Consulting Respiratory Physicians/**K. Nakamura, S. Hirosako, Y. Horio, K. Fujii, H. Kohrogi, Kumamoto, Japan, p.A1749

P124 **Improving the Burden of Respiratory Disease Through Data-Driven Innovation: The AIR Louisville Program in Jefferson County, Kentucky/**T. Smith, D. Van Sickle, M. Barrett, K. Henderson, O. Humblet, C. Hogg, V. Combs, Louisville, KY, p.A1750

P125 **Comparison of Change in Oxygen Consumption and Heart Rate Following Albuterol and Levalbuterol in Healthy Adults/**M.K. Virk, J. Hotz, R.G. Khemani, C.J. Newth, P.A. Ross, Los Angeles, CA, p.A1751

P126 **Nasal Disease, a Common Comorbidity in Patients with Chronic Severe Asthma (CSA) and Eosinophilic Granulomatosis with Poliangiitis (EGPA)/**M. Latorre, V. Seccia, C. Baldini, F.L. Dente, E. Bacci, S. Cianchetti, P. Paggiaro, Pisa, Italy, p.A1752

P127 **Impact of Fixed Airway Obstruction on Acute Exacerbations of Asthma in the Cohort for Reality and Evolution of Adult Asthma in Korea/**J.-Y. Moo, S.-H. Kim, D.W. Park, T.-B. Kim, H.-B. Moon, H.J. Yoon, Seoul, Korea, Republic of, p.A1753

P128 **Association of Maternal Asthma and Vitamin D Status in Early Pregnancy with Risk of Preeclampsia: An observation from the Vitamin D Antenatal Asthma Reduction Trial (VDAART)/**H. Mirzakhani, V.J. Carey, R.S. Zeiger, R.C. Strunk, T.F. McElrath, G.T. O'Connor, R.E. Iverson, A. Lee-Parritz, G.A. Macones, A.A. Litonjua, S.T. Weiss, Boston, MA, p.A1754

P129 **Performance of Different Types of Nebulizer with Spontaneous Adult Breathing Pattern/**H.-L. Lin, H.-S. Cho, G.-H. Wan, M.-J. Hsieh, Tao-Yuan, Taiwan, p.A1755

P130 **2-Minute Tidal Breathing Methacholine Challenge: Comparison of Two Jet Nebulizers/**Z. Zhu, H. Wang, Y. Xie, J. An, P. O'Byrne, J. Zheng, Guangzhou, China, p.A1756

P131 **The Use of Fractional Exhaled Nitric Oxide-Based Management for Non-Eosinophilic Asthma During Pregnancy/**V.E. Murphy, P.G. Gibson, Callaghan, Australia, p.A1757

THEMATIC POSTER SESSION

A51 BRONCHIECTASIS: CLINICAL AND EPIDEMIOLOGIC STUDIES

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area F, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: G. Tino, MD, Philadelphia, PA

P609 **Characterization of Idiopathic Bronchiectasis in Patients with and Without Pulmonary Nontuberculous Mycobacterial Disease/**J.A. Nguyen, D.R. Prevots, J. Adjemian, S.E. Strollo, M.L.A. Daniels, C. Daley, M. Knowles, K.N. Olivier, Bethesda, MD, p.A1758

P610 **The Bronchiectasis Severity Index as a Surrogate Marker of Morbidity, Quality of Life and Future Risk/**S.M. Finch, M. Crichton, T. Fardon, J.D. Chalmers, Dundee, United Kingdom, p.A1759

P611 **Hypogammaglobinemia: A Predictor of Frequent Exacerbations in Patients with Non-Cystic Fibrosis Bronchiectasis/**J. Lee, S. Touray, P. Oliveira, Worcester, MA, p.A1760

P612 **The Effect of Inhaled Hypertonic Saline on Quality of Life in Primary Ciliary Dyskinesia Patients: A Double-Blind Randomized Controlled Cross-Over Trial/**T. Paff, J. Daniels, A. Vonk-Noordegraaf, E. Weersink, R. Lutter, E. Haarman, Amsterdam, Netherlands, p.A1761

P613 **The Clinical and Economic Impact of a Multidisciplinary Clinical Pathway on Management of Acute Exacerbation of Bronchiectasis/**K.S. Tee, K.H. Lim, A. Verma, Y.P. Wong, S.K. Goh, J. Abisheganaden, A.Y.H. Lim, Singapore, Singapore, p.A1762

P614 **International Validation of FACED Score in 672 Patients with Non-Cystic Fibrosis Bronchiectasis/**M.A. Martinez-Garcia, R.A. Athanazio, G. Gramblicka, M. Corso, F.L. Cavalcanti-Lundgren, M.R. Fernandes De Figueiredo, F. Arancibia, Valencia, Spain, p.A1763

P615 **Clinical Predictors for Outcomes of Patients with Non-Cystic Fibrosis Bronchiectasis over a 4-Year Period/**W. Sim, S.H. Puah, A. Verma, Y.S. Lee, J. Abisheganaden, S.H. Chotirmall, A.Y.H. Lim, Singapore, Singapore, p.A1764

P616 **Clinical Features and Associated Likelihood of Primary Ciliary Dyskinesia in Adults** /K.M. Sullivan, M.L.A. Daniels, J.J. Atkinson, T.W. Ferkol, D. Hall, H.-S. Lee, H. Metjian, K.N. Olivier, M. Rosenfeld, C.E. Milla, M. Zariwala, S.D. Sagel, J. Carson, J. Krischer, M. Hazucha, M. Knowles, M. Leigh, Genetics Disorders Of Mucociliary Clearan, p.A1765

P617 **Determinants of Respiratory Function in Adults Patients with Primary Ciliary Dyskinesia/**J. Frija-Masson, L. Bassinet, I. Honore, N. Dufeu, B. Housset, A. Coste, J.-F. Papon, E. Escudier, P.-R. Burgel, B. Maitre, Creteil, France, p.A1766

P618 **Maximal Mid-Expiratory Flow Is a Surrogate Marker of Lung Clearance Index for Assessment of Adults with Bronchiectasis/**W.-J. Guan, J.-J. Yuan, Y.-H. Gao, H.-M. Li, J.-P. Zheng, R. Chen, N. Zhong, Guangzhou, China, p.A1767

P619 **Baseline Demographic Profile of Subjects of the Phase 3 RESPIRE 2 Trial of Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-Cystic Fibrosis Bronchiectasis (NCFB)/**T.R. Aksamit, A. De Soyza, E. Operschall, T.-J. Bandel, U. Krahn, E. Montegriffo, M. Criollo, R.C. Wilson, Rochester, MN, p.A1768

P620 **Prevalence of Airflow Limitation in Patients with Bronchiectasis, and Its Effect on Acute Exacerbation and the Decline of Lung Function/**J.-M. Kim, S.M. Choi, J. Lee, Y.S. Park, C.-H. Lee, S.-M. Lee, J.-J. Yim, Y.W. Kim, S.K. Han, C.-G. Yoo, Seoul, Korea, Republic of, p.A1769

P621 **Relationship Between Airway Inflammatory Biomarkers and Functional Status in Non-Cystic Fibrosis Bronchiectasis/**M.A. Roggi, F.L. Dente, M. Latorre, M. Bilotta, D. Nieri, M.L. Bartoli, S. Cianchetti, B. Vagaggini, P. Paggiaro, Pisa, Italy, p.A1770

Facilitator: N.M. Quesada, MD, Chicago, IL

P622 **Acute Exacerbations of Non-Cystic Fibrosis Bronchiectasis: What Can Promise Non-Invasive Ventilation for Patients with Type 2 Respiratory Failure?/**A. Sadigov, S. Akhundov, F. Abdullayev, Baku, Azerbaijan, p.A1771

P623 **Pseudomonas Colonization, Lung Function, Computed Tomography, and Macrolides in Non-Cystic Fibrosis Bronchiectasis: What Can We Wait from These Dates?/**A. Sadigov, G. Sadigova, S. Huseynova, I. Ashirova, Baku, Azerbaijan, p.A1772

P624 **The Relationship Between Vitamin D Levels and Lung Function, Clinical Indices, Depression and Anxiety Symptoms in Adult Patients with Non-Cystic Fibrosis Bronchiectasis/**M. Bekir, D. Kocakaya, S. Olgun Yildizeli, H. Arikan, E. Eryuksel, B. Bagci Ceyhan, Istanbul, Turkey, p.A1773

P625 **Non-Cystic Fibrosis Bronchiectasis in Patients with Hematologic Malignancy/**L.W. Chen, W.B. Karkowsky, S. Montner, P.J. McShane, S.R. White, M.E. Strek, Chicago, IL, p.A1774

P626 **ORBIT-3 and ORBIT-4: Design of a Phase 3 Program to Investigate Safety and Efficacy of Pulmaquinr in Non-Cystic Fibrosis Bronchiectasis (NCFBE) Patients Chronically Colonized with Pseudomonas Aeruginosa (PA)/**A. O'Donnell, D. Bilton, D. Serisier, A. Wanner, J. Froehlich, P. Bruinenberg, I. Gonda, Washington, DC, p.A1775

P627 **Profile of Exacerbations Among Patients with Non-Cystic Fibrosis Bronchiectasis at the State University of Rio de Janeiro/**R.K.R. Leal, R.E.B. Salles, W. Costa, A.B.A. Silva, T.F. Cruz, B.R.A. Silva, Rio de Janeiro, Brazil, p.A1776

P628 **Respiratory Failure After Bronchial Arterial Embolization in Patients with Cystic Fibrosis: An Institutional Review/**J.A. Town, M.L. Aitken, Seattle, WA, p.A1777

P629 **Procalcitonin Levels in Cystic Fibrosis Exacerbations/**G. Loh, A. Skabelund, A. French, J. Morgan, San Antonio, TX, p.A1778

P630 **Perfluorinated Gas MRI to Detect Regional Ventilation Heterogeneity in Cystic Fibrosis/**J.L. Goralski, E.O. Akinnagbe, C. Salazar, R.C. Boucher, Y.Z. Lee, S. Donaldson, Chapel Hill, NC, p.A1779

P631 **Use of Ultra-Low Dose Chest Computed Tomography Scanning to Detect Emphysema in Patients with Cystic Fibrosis/**G. Dalgleish, H. Sahi, K. Lau, C. Daley, D. Garner, P. King, Clayton, Australia, p.A1780

P632 **Atlas-Based Analysis of MRI Measures of Lung Water Density to Identify Regional Lung Abnormalities in CF Adults/** R.J. Theilmann, A.R. Elliott, C. Darquenne, D.J. Conrad, La Jolla, CA, p.A1781

P633 **The Impact of Aspergillus Fumigatus and Its Treatment on Outcomes in Cystic Fibrosis/**T. Basnayake, F. Finlayson, A. Peleg, J. Wilson, T. Kotsimbos, Prahran, Australia, p.A1782

Facilitator: E.T. Naureckas, MD, Chicago, IL

P634 **The Genetic Profile of Chinese Patients with Cystic Fibrosis/**X. Tian, Y. Liu, X. Li, X. Zhang, K.-F. Xu, Beijing, China, p.A1783

P635 **Fenretinide Normalizes Aberrant Lipid Metabolism and Prevents Excessive Inflammation During Pulmonary Exacerbation in Adult Cystic Fibrosis Patients/**D. Radzioch, G. Wojewodka, S. Cupri, P. Colin, R. Pislariu, D. Garic, I. Kianicka, E. Matouk, Montreal, Canada, p.A1784

P636 **How does CPET Compared to Yearly Lung Function Follow-Up in Adult Cystic Fibrosis Patients/**T.S. Hynes, P. Harnett, B. Casserly, Limerick, Ireland, p.A1785

P637 **Severity Index in Pulmonary Exacerbations in Cystic Fibrosis/**L. Diab, R.M. Giron, E. Garcia, C. Marcos, M. Hernandez, J.L. Justicia, C. Acosta, J. Ancochea, Madrid, Spain, p.A1786

P638 **Nebulizer Aerosol Performance and Patient Acceptance in Cystic Fibrosis/**C. Landon, G. Garza, Ventura, CA, p.A1787

P639 **Study Design: Effects of Long Term TobrAmycin Inhalation Solution (TIS) Once Daily on Exacerbation Rate in Patients with Non-Cystic Fibrosis Bronchiectasis. A Double Blind, Randomized, Placebo and TIS Twice Daily (open label) Controlled Trial. The BATTLE/**L. Terpstra, J. Altenburg, R. Duijkers, W.G. Boersma, Alkmaar, Netherlands, p.A1788

P640 **Epidemiology And Natural History of Pseudomonas aeruginosa Infection in Patients with Non-Cystic Fibrosis Related Bronchiectasis/**R. Lim, T. Woo, J. Duong, B. Waddell, C. Mody, H. Rabin, D.G. Storey, M.D. Parkins, Calgary, Canada, p.A1789

P641 **Prevalence of Mycobacterial Infection in Adult Brazilian Patients with Cystic Fibrosis/**E.P. Oliveira, A.N. Costa, Sao Paulo, Brazil, p.A1790

P642 **Clinical Analysis of The Aspiration Pneumonia in Which Percutaneous Endoscopic Gastrostomy Was Constructed: Our 10-year Experience/**H. Tomioka, S. Yamahita, T. Kamada, H. Takata, N. Mamesaya, K. Furuta, Y. Kida, M. Kaneko, Kobe, Japan, p.A1791

P643 **DNA Extraction from Cystic Fibrosis Sputum Samples is Not Method Dependent/**M.C. Tracy, A. Yacob, C. Chen, C.E. Milla, D.N. Cornfield, Palo Alto, CA, p.A1792

P644 **Airway Microbiome Prior To M. Abscessus Complex Or M. Avium Complex Infections In Cystic Fibrosis/**L. Caverly, A. Forde, J. LiPuma, Ann Arbor, MI, p.A1793

P645 **The Impact of Persistent Growth of Non-tuberculous Mycobacteria on Rate of Lung Function Decline in Adults with Cystic Fibrosis/**G. Kirkpatrick, B. Quon, Vancouver, Canada, p.A1794

P646 **QBW251 Is a Safe and Efficacious CFTR Potentiator for Patients with Cystic Fibrosis/**S. Kazani, J. Alcantara, L. Debonnett, J. Doucet, I. Jones, K. Kulmatycki, S. Machineni, L. Mostovy, I. Nicholls, R. Vegesna, J. Verheijen, D.J. Rowlands, Cambridge, MA, p.A7789

P647 **Lumacaftor/Ivacaftor: An Observational Study of Outcomes and Tolerances in Patients with Cystic Fibrosis/**M.T. Jennings, R. Dezube, G. Hong, N.E. West, A. Braun, C. Merlo, N. Lechtzin, Baltimore, MD, p.A7790

THEMATIC POSTER SESSION

A52 CRITICAL CARE: ICU PROCEDURES, PROCESSES OF CARE, AND NOVEL TECHNIQUES

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area H, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitators: D. Park, MD, Seattle, WA
E.J. Schenck, MD, New York, NY

P897 **The Diagnostic Yield, Safety, and Impact of Flexible Bronchoscopy in Non-HIV Immunocompromised Critically Ill Patients in the Intensive Care Unit/**M.O. Al-Qadi, R. Cartin-Ceba, R. Kashyap, S. Kaur, S. Peters, Providence, RI, p.A1795

P898 **Safety, Feasibility, and Cellular Recovery of Serial Bronchoscopic Alveolar Lavage in Patients with ARDS in the Modern Era/**A. Koch, M. Sanchez, L. Flores, C. Thompson, L. Purcell, K. Gibbs, R.N. Bakhru, P. Morris, D.C. Files, Winston-Salem, NC, p.A1796

P899 **A New Method for Measuring Oxygen Consumption (VO2): Avoiding the Need for Flow and Oxygen Signals Synchronization/** R.S. Nobrega, P.J.C. Biselli, Sao Paulo, Brazil, p.A1797

P900 **Oral Care Kits Used During Mechanical Ventilation in the Intensive Care Unit (ICU): A Retrospective Comparison of Outcomes/**M.N. Dubosky, F.A. Turkestani, J. Dietz, Y. Kim, D.L. Vines, Chicago, IL, p.A1798

P901 **Accuracy of Oscillometric Blood Pressure Monitoring in Obese Critically Ill Patients Receiving Vasopressors/**O. Okoye, C. Long, M. Delk, K. Eissa, F. Simeone, F. Kheir, New Orleans, LA, p.A1799

P902 **Impaired Brachial Artery Reactive Hyperemia in Critical Illness/**T. Bice, G. Tsang, O. Wexler, J. Meyer, D. Oldfield, K. Falkner, A.P. Pietropaoli, Rochester, NY, p.A1800

P903 **Difference in Humidification when Comparing Two Heaters/**R.L. Glancy, D.L. Vines, J. Li, Chicago, IL, p.A1801

P904 **Evaluation on the Safety and Effectiveness of Manual Rapid Flow Expulsion Maneuver to Clear Subglottic Secretion: A Vitro and Vivo Study/**J. Li, Y. Zong, Q. Zhou, N. Wan, B. Sun, H. Dai, C. Wang, Chicago, IL, p.A1802

P905 **Bronchodilator Response Test in Mechanically Ventilated COPD Patients: A Two Phase Study/**J. Li, B. Sun, J. Duan, Q. Zhan, H. Dai, J.B. Fink, C. Wang, Chicago, IL, p.A1803

P906 **Endotracheal Tube Position Confirmation by the Bedside Ultrasound in Respiratory Intensive Care Unit Patients/**W. Lei, F. Dong, J. Wang, Y. Zhu, J. Huang, Suzhou, China, p.A1804

Facilitators: M.T. Kearns, MD, Aurora, CO
A.M. Luks, MD, Seattle, WA

P907 **Level of Fellowship Training Is Associated with Independent Procedure Performance in Endotracheal Intubation of Critically Ill Adults/**M.B. Fashho, M.W. Semler, T.W. Rice, B. DeBoisblanc, D. Janz, New Orleans, LA, p.A1805

P908 **The "Waterfall Sign": A Novel M-Mode Thoracic Ultrasound Sign to Objectively Quantify B Lines/**V. Sharma, E. Christian, R. Gueret, J. Bailitz, Chicago, IL, p.A1806

P909 **Can Exhaled Breath Condensate Be Used to Seek A Mitochondrial DNA Signature for Acute Respiratory Distress Syndrome?/**A. Harriott, R. Bascom, A.E.F. Dimmock, T. Kuhlengel, J.A. Howrylak, Hershey, PA, p.A1807

P910 **Accuracy of Arterial Blood Gas (ABG) Hemoglobin in the Intensive Care Unit (ICU)/**N. Jiramethee, A. Lee, Jacksonville, FL, p.A1808

P911 **Comparison of Arterial and Venous Blood Gases: Correlation in a General Patient Population/**A. Scavone, A. Ahmed, K. Kuchta, S. Bellam, Evanston, IL, p.A1809

P912 **Questioning the Utility of Central Venous and Arterial Catheters in the Management of Sepsis/**S.G. Pape, J. Lascano, J. Chertoff, Gainesville, FL, p.A1810

P913 **Standard and Deferred Consent in the Age of Transfused Blood (ABLE) Trial in Critically Ill Adults/**K.E.A. Burns, P. Hebert, D. Fergusson, J. Lacroix, Toronto, Canada, p.A1811

P914 **Development and Validation of a Computerized Algorithm for Retrieval of Blood Product Transfusion Data in the ICU Setting/**D. Sanghavi, R. Ali, B.S. Pannu, M. Passe, R. Kashyap, V.N. Iyer, Rochester, MN, p.A1812

P915 **Transfusion Strategy in Post-Cardiac Arrest Syndrome/**S. Tyagi, T.B. Ghafouri, L. Hsu, R.J. Anderson, J. Joshua, J.R. Beitler, San Diego, CA, p.A1813

P916 **Proton Pump Inhibitors Versus Histamine 2 Receptor Antagonists for Stress Ulcer Prophylaxis: A Systematic Review and Meta-Analysis of Randomized Trials/**F. Alshamsi, E. Belley-Cote, D. Perri, A. Al-Omari, L. Thebane, S. Almenawer, Z. Alqahtani, G. Guyatt, D. Cook, W. Alhazzani, Al Ain, United Arab Emirates, p.A1814

Facilitators: G.F. Curley, MD, PhD, Toronto, Canada
M. Fernandez Sanchez, MD, Bogota, Colombia

P917 **Use of Antiplatelet Drugs in Critically Ill Patients: Systematic Review and Meta-Analysis/**J. Sethi, D. Mohananey, R. Kumar, Z. Hussain, M. Ali, Chicago, IL, p.A1815

P918 **Evaluation of the Use of Topical Nitroglycerin for Radial Arterial Line Insertion in the Critically Ill Patient/**H. Yanashyan, A. Motabar, R. Fargo, S. Afaneh, B. Tabibian, L. Ilano, W. Klein, Moreno Valley, CA, p.A1816

P919 **Remifentanil Target-Controlled Infusion for ICU Thoracic Procedures Generating Pain or Discomfort: Feasability, Safety and Tolerance Evaluation/**T. Pham, M. Caron, M. Decavele, C. Blayau, J.P. Fulgencio, V. Labbe, M. Djibre, E.M. Hafiani, C. Quesnel, A. Parrot, M. Fartoukh, Paris, France, p.A1817

P920 **Does Increase Positive End Expiratory Pressure Affect Shock in Sepsis Related Deaths/**A. Mora, R. Gardner, T. Endicott-Yazdani, A.L. Smith, T.K. Ynosencio, G. Tsai-Nguyen, Dallas, TX, p.A1818

P921 **Invasive Mechanical Ventilation in Idiopathic Pulmonary Fibrosis: Predictors of Use and Impact on Resource Utilization and Mortality/**J. Mooney, K. Raimundo, E. Chang, M.S. Broder, Stanford, CA, p.A1819

P922 **Impact of RASS Scores and Elapsed Time from SBT on Extubation Success in the ICU: A Retrospective Study/**S. Yau, M.N. Dubosky, C. Kaplan, D.L. Vines, Chicago, IL, p.A1820

P923 **Predictors of Intensive Care Unit Transfer from the Medical Ward of Patients with Acute Exacerbations of Chronic Obstructive Pulmonary Disease: Subgroup Analysis of Pneumonic and Non-Pneumonic Acute Exacerbations/**H.-J. Shin, T.-O. Kim, C.-K. Park, H.-J. Ban, I.-J. Oh, Y.-I. Kim, S.-C. Lim, Y.-C. Kim, Y.-S. Kwon, Y.H. Kim, Gwangju, Korea, Republic of, p.A1821

P924 **COPD and ITU: Not All Is Doom and Gloom/**A. Hufton, C.T. Pantin, A. Williams, M. Babores, S. Iyer, Cheshire, United Kingdom, p.A1822

P925 **Classical Music Therapy: Helping Mechanically Ventilated Intensive Care Patients/**T. Javed, Islamabad, Pakistan, p.A1823

P926 **Morbidity and Mortality Project: Learning from Unintended Medical Errors and Adverse Events/**C. Meenakshisundaram, S.E. Ali, H. Friedman, Evanston, IL, p.A1824

P927 **Medication Reconciliation in an ICU Recovery Clinic/**R. Bookstaver, K. Griffin, J.F. Davidson, P. Morris, D.C. Files, C. Guest, R.N. Bakhru, Winston-Salem, NC, p.A1825

THEMATIC POSTER SESSION

A53 RESPIRATORY FAILURE: RISK FACTORS AND OUTCOMES IN ARDS

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area E, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitators: A.M. Esper, MD, MSc, Atlanta, GA
R. Kashyap, MBBS, Rochester, MN

P524 **Risk Factors for the Development of Acute Respiratory Distress Syndrome (ARDS) in Patients with Pneumonia, a Nationwide Retrospective Study Using the Nationwide Inpatient Sample (NIS) Database from Year 2002-2012/**S. Baig, S. Ahmad, N. Devogel, A. Szabo, K. Thandra, J. Hussain, E. Khan, East Brunswick, NJ, p.A1826

P525 **Modified Early Warning Score Is Associated with the Later Development and Timing of Acute Respiratory Failure in Acutely Ill Patients Admitted from an Emergency Department/**C. Risaliti, M. Exline, J. Kynyk, E. Adkins, N. Ali, Columbus, OH, p.A1827

P526 **Decreased Risk of Acute Respiratory Distress Syndrome in ICU Patients with Septic Shock and Elevated Hemoglobin A1C in a Single Institution/**M. Aldana-Campos, B. Garnet, E. Donath, V. Shah, S. Fahmy, F. Williams, Atlantis, FL, p.A1828

P527 **Acute Respiratory Distress Syndrome in Burn-Injured Adults: Clinical Risk Factors and Biomarkers/**M. Afshar, J.M. Albright, L. Ramirez, P. Conrad, M.J. Mosier, E.L. Burnham, E.J. Kovacs, Maywood, IL, p.A1829

P528 **Association of Tobacco Exposure with Development of Acute Respiratory Distress Syndrome in Burn-Injured Adults/**M. Afshar, W. Adams, G. Netzer, M.J. Mosier, E.J. Kovacs, R.S. Cooper, R. Durazo-Avizu, S. Kliethermes, Maywood, IL, p.A1830

P529 **Clinician Recognition of ARDS in the Medical Intensive Care Unit/**R.M. Brown, M.W. Semler, Z. Zhao, T. Koyama, D. Janz, J.A. Bastarache, L. Ware, Nashville, TN, p.A1831

P530 **Comorbidities Affecting Immune Function Are Independently Associated with ARDS/**D. Tirumala Rao, J.A. Kempker, E.M. Annette, A. Srinadh, G.S. Martin, Atlanta, GA, p.A1832

P531 **Factors Affecting the Occurrence of Postoperative Pulmonary Complications Requiring Corticosteroid Pulse Therapy After Thoracic and Abdominal Surgery/**H. Takeshima, Y. Yamauchi, H. Yasunaga, W. Hasegawa, T. Jo, H. Matsui, K. Fushimi, T. Nagase, Tokyo, Japan, p.A1833

P532 **Evaluating the Performance of the Pediatric Acute Lung Injury Consensus Conference Definition of Acute Respiratory Distress Syndrome/**K. Parvathaneni, S. Belani, D. Leung, C.J. Newth, R.G. Khemani, Los Angeles, CA, p.A1834

P533 **High Altitude Pulmonary Edema in Mountain Children with No Recent Travel/**C.A. Ebert-Santos, Frisco, CO, p.A1835

P534 **Predictors of Survival in Critically Ill Patients with Acute Respiratory Distress Syndrome (ARDS)/**F. Balzer, M. Menk, J. Ziegler, C. Pille, K.-D. Wernecke, C. Spies, M. Schmidt, M. Deja, S. Weber-Carstens, Berlin, Germany, p.A1836

P535 **The Validity of Outcome Prediction Scoring Systems in Korean Patients with Severe Adult Respiratory Distress Syndrome Receiving Extracorporeal Membrane Oxygenation Therapy/**S. Lee, H.J. Yeo, W.H. Cho, Y.S. Kim, D. Jeon, K.S. Byun, H.S. Kim, S.E. Lee, S.H. Yoon, Yangsan, Gyeongsangnamdo, Korea, Republic of, p.A1837

Facilitators: M.N. Gong, MD, MS, Bronx, NY
J.P. Reilly, MD, MS, Philadelphia, PA

P536 **The Berlin Definition Criteria of ARDS Severity Is Associated with Prognosis and Fibroproliferative Changes on High-Resolution CT/**T. Kamo, S. Tasaka, T. Suzuki, T. Asakura, S. Suzuki, K. Yagi, H. Namkoong, M. Ishii, H. Morisaki, T. Betsuyaku, Tokyo, Japan, p.A1838

P537 **Respiratory Mechanics in Acute Respiratory Distress Syndrome: Variables and Indexes Associated with Clinical Outcome/**L. Chen, M. Xu, G.-Q. Chen, I. Soliman, N. Rittayamai, M. Sklar, O. Shklar, C. Martins, P. Greco, H. Every, J.O. Friedrich, A. Pronovost, A. Baker, J.-X. Zhou, L.J. Brochard, Toronto, Canada, p.A1839

P538 **Pulmonary Physiologic Variables Predicting Mortality in Moderate to Severe Acute Respiratory Distress Syndrome/**J.C. Diaz Soto, M.N. Vogt, J.K. Bohman, Rochester, MN, p.A1840

P539 **Association Between Spontaneous Breathing Early in ARDS, Inflammation, and Clinical Outcomes/**A.C. McKown, M.W. Semler, C.S. Calfee, T.W. Rice, Nashville, TN, p.A1841

P540 **Trajectory of Red Cell Distribution Width (RDW) and In-Hospital Mortality in Acute Respiratory Distress Syndrome (ARDS) Patients/**A. Alkhatib, R. Esteitie, L.L. Price, H. Chang, P. LaCamera, Brighton, MA, p.A1842

P541 **Clinical Characteristics and Predictors of Hospital Mortality Differ Between Direct and Indirect Acute Respiratory Distress Syndrome (ARDS)/**L. Luo, C.M. Shaver, Z. Zhao, T. Koyama, C.S. Calfee, J.A. Bastarache, L.B. Ware, Wuxi, China, p.A1843

P542 **Inspiratory Pressure as a Surrogate of Driving Pressure in Predicting Survival of Acute Respiratory Distress Syndrome/**D. An-shiou, S.-Y. Ruan, H. Shih-Wen, P.-H. Kuo, H.-D. Wu, C.-J. Yu, Taipei, Taiwan, p.A1844

P543 **Patient Characteristics, Etiologies and Outcomes of Acute Respiratory Failure by Assessment of APACHE-II Score/**A. Gaud, K. Trivedi, N. Sinha, P. Ajankar, M.S. Pandharipande, P.P. Joshi, Nagpur, India, p.A1845

P544 **Low Vitamin D Status Occurs in 90% of Patients with ARDS and Is Associated with Longer Duration of Mechanical Ventilation/**E.K. Bajwa, I. Bhan, S. Quraishi, M. Matthay, B.T. Thompson, Boston, MA, p.A1846

P545 **Risk Stratification of the Toronto ARDS Cohort Using RECOVER Program Disability Groups/**M. Parotto, G. Tomlinson, C.M. Tansey, A. Matte, P. Robles, S. Mehta, C. Guest, D. Mazer, J. Friedrich, A. Slutsky, D. Cook, A.M. Cheung, M.S. Herridge, Toronto, Canada, p.A1847

P546 **Validation of Mortality Risk Factors for Patients with Acute Respiratory Distress Syndrome in a Mayo Clinic Cohort /**M.N.P. Vogt, J.C. Diaz Soto, J.K. Bohman, Rochester, MN, p.A1848

P547 **Incidence, Characteristics and Mortality of Adult Mechanically Ventilated Patients with and Without ARDS in Peru/**E. Gupta, P. Herrera, R. Roldan, E. Paz, A.A. Jaymez, E.E. Chirinos, J. Portugal, R. Quispe, R.G. Brower, W. Checkley, Jacksonville, FL, p.A1849

Facilitators: A.B. Mehta, MD, Boston, MA
F. Moazed, MD, San Francisco, CA

P548 **Clinical Practice Regarding Acute Respiratory Distress Syndrome in Japan: A Nationwide Web-Based Survey by the Japanese Respiratory Society/**S. Tasaka, K. Tatsumi, Tokyo, Japan, p.A1850

P549 **Fever Is Common in Patients with Severe ARDS Receiving Neuromuscular Blocking Agents and Associated with Lack of Improvement in Oxygenation/**D. Slack, D. Corwin, J. Buchner, H. Reddy, N.G. Shah, A. Verceles, G. Netzer, C. Shanholtz, J.D. Hasday, Baltimore, MD, p.A1851

P550 **Comparison of Three Chest Radiographic Scores as Indices of Pulmonary Edema/**M.A. Warren, M. Matthay, C.S. Calfee, L.B. Ware, Nashville, TN, p.A1852

P551 **Intravenous Medications Contribute Substantially to Fluid Balance in Patients with Acute Respiratory Failure/**C.B. Shanholtz, T. Harrington, J. McGrain, J.P. Gonzales, L.E. Seiberlich, D.L. Child, Baltimore, MD, p.A1853

P552 **Factors Associated with the Use of Rescue Therapies in Acute Respiratory Distress Syndrome/**J. Mahar, S.S. Kalra, S. Duara-Cerejo, D. Golovyan, A. Duggal, Cleveland, OH, p.A1854

P553 **Interstitial Lung Abnormalities and Acute Respiratory Distress Syndrome/**R.K. Putman, G.M. Hunninghake, D. Barragan-Bradford, P.B. Dieffenbach, U. Adams, A. McKeon, H. Hatabu, M. Nishino, R.F. Padera, L. Fredenburgh, R.M. Baron, J.A. Englert, Boston, MA, p.A1855

P554 **A Randomized, Double-Blind, Placebo-Controlled, Single-Centre, Single Ascending Dose and Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Molgramostim (rhGM-CSF) Administered by Inhalation to Healthy Adu/**I. Tarnow, K. Nymark, M. Vinge, K.A. Nielsen, C. Ganslandt, Horsholm, Denmark, p.A1856

P555 **Potential Impact of Acute Respiratory Distress Syndrome Measurement Error on Clinical Study Results/**M.W. Sjoding, T.J. Iwashyna, C.R. Cooke, T.P. Hofer, Ann Arbor, MI, p.A1857

P556 **Inhaled Nitric Oxide and Risk of Renal Dysfunction in Acute Respiratory Distress Syndrome: A Preliminary Report/** S.-Y. Ruan, C.-T. Huang, P.-H. Kuo, S.-C. Ku, H.-D. Wu, C.-J. Yu, M.-S. Lai, Taipei, Taiwan, p.A1858

P557 **Comparison of rhCC10 Effects in Ovine Model of Traumatic Smoke Inhalation with and Without Dermal Burn/**A.L. Pilon, E. Lopez, M.E. Winn, R.S. Clayton, P. Enkhbaatar, Rockville, MD, p.A1859

P558 **Effect of Preadmission Metformin Use on Clinical Outcome of ARDS Among Critically Ill Patients with Diabetes/**Y.S. Jo, S.M. Choi, J.W. Lee, Y.S. Park, C.-H. Lee, J.J. Yim, C.-G. Yoo, Y.W. Kim, S.K. Han, S.-M. Lee, Seoul, Korea, Republic of, p.A1860

P559 **Long Term Pulmonary Outcomes from Thoracic Trauma During OIF/OEF Deployment/**C. Borders, M.J. Morris, Fort Sam Houston, TX, p.A1861

P560 **Latent Class Analysis Demonstrates the Stability of Acute Respiratory Distress Syndrome (ARDS) Endotypes over Time/**K.R. Famous, K. Delucchi, L.B. Ware, P.E. Parsons, B.T. Thompson, M.A. Matthay, C.S. Calfee, San Francisco, CA, p.A7791

P561 **Targeted Sequencing of Top Loci Identified by Genome-Wide Association Study (GWAS) Associated with Acute Respiratory Distress Syndrome (ARDS)/**Z. Wang, Y. Wei, R. Zhang, L. Su, R. Khetani, S. Ho Sui, X. Lin, E.K. Bajwa, B.T. Thompson, M.M. Wurfel, D.C. Christiani, Boston, MA, p.A7792

P562 **Identification of Patients with Acute Respiratory Distress Syndrome Using an Algorithm that Mines the Data from the Electronic Medical Record/**C.-P. Wu, L. Lee, M.N. Gong, New York, NY, p.A7793

P563 **A Two-Stage Association Study Identifies a High Risk Window of Acute Respiratory Distress Syndrome Onset Time Correlated with Poor 28 Day Overall Survival/**R. Zhang, Z. Wang, Y. Wei, P.T. Alvarez, Z. Zhu, L. Su, E.K. Bajwa, B.T. Thompson, D.C. Christiani, Boston, MA, p.A7794

P564 **Whole Blood RNA Sequencing in Stem Cell Transplant Patients with the Acute Respiratory Distress Syndrome Reveals a Unique Transcriptomic Profile/**J.A. Englert, M.H. Cho, A. Lamb, M. Shumyatcher, D. Barragan-Bradford, P. Dieffenbach, L. Fredenburgh, B.E. Himes, R.M. Baron, Columbus, OH, p.A7795

THEMATIC POSTER SESSION

A54 CRITICAL CARE CASE REPORTS: ACUTE HYPOXEMIC RESPIRATORY FAILURE/ARDS

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area E, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitators: D.L. Hotchkin, MD, MSc, Portland, OR
A. Basit, MBBS, PhD, New Haven, CT

P565 **Diffuse Alveolar Hemorrhage Due to Electronic Cigarette Use/**J.L. Long, S. Devabhaktuni, S. Hadique, P. Jain, Morgantown, WV, p.A1862

P566 **Primary Cardiac Angiosarcoma: A Rare Cause of Diffuse Alveolar Hemorrhage/**Y.Y. Greenstein, A. Palkar, E. Gottesman, N. Hajizadeh, New Hyde Park, NY, p.A1863

P567 **Diffuse Alveolar Hemorrhage Caused by Inhalation of a Waterproofing Spray/**A. Fujiwara, M. Yamamoto, M. Jinno, Y. Murata, O. Shin, T. Homma, A. Tanaka, T. Yokoe, H. Sagara, T. Onishi, Tokyo, Japan, p.A1864

P568 **An Unusual Presentation of Diffuse Alveolar Hemorrhage in a Transplant Recipient/**O. Anozie, D. Manta, Syracuse, NY, p.A1865

P569 **Brachial Plexopathy Associated with Extracorporeal Membrane Oxygenation/**A. Agarwal, P. Gorukanti, P.K. Irukulla, C. Seneviratne, W. Pascal, Y. Kupfer, New York, NY, p.A1866

P570 **Metastatic Gastric Adenocarcinoma Masquerading as Pulmonary Edema/**A. Agarwal, P. Gorukanti, M.A. Shenoy, P.K. Irukulla, W. Pascal, Y. Kupfer, New York, NY, p.A1867

P571 **Use of Venovenous ECMO for Post-Pneumonectomy ARDS in a Community Hospital/**J. Berrocal, P. Saunders, G. Crooke, J. Shaw, Brooklyn, NY, p.A1868

P572 **Use of VV ECMO as a Novel Therapy for Severe Acute Chest Syndrome with Diffuse Alveolar Hemorrhage/**S. Sultan, G. Chu, R.A. Raschke, S. Uppalapu, Phoenix, AZ, p.A1869

P573 **Long Term Extracorporeal Membrane Oxygenation Therapy and an Importance of Prone Position for H1N1 Influenza Related Acute Respiratory Distress Syndrome and Several Complications During the Treatment/**B.D. Kosovali, F.I. Yesiler, T.T. Peker, M. Ozcelik, M.K. Bayar, Ankara, Turkey, p.A1870

P574 **Successful Use of Extracorporeal Membrane Oxygenation (ECMO) Therapy Without Intravenous Heparin in a Patient with Acute Intracranial Hemorrhage and Severe ARDS/**T. Plush, E. Casanova-Ghosh, E. Gnall, L. Samuels, S. Gregory, Wynnewood, PA, p.A1871

Facilitators: J.A. Gold, MD, Portland, OR
M. Jabaudon, MD, MSc, Clermont-Ferrand, France

P575 **A Rapid, Almost Fatal, Presentation of Eosinophilic Pneumonia in a Previously Healthy Child/**G. Phull, P.J. Shukla, A. Jain, N. Kotwal, F. Ogunlesi, Washington, DC, p.A1872

P576 **A 29-Year-Old Woman with Acute Respiratory Failure and Eosinophilic Lung Disease/**N. Chalhoub, D.-A. Hernandez, Toledo, OH, p.A1873

P577 **An Unusual Case of Barium Aspiration Unmasking a New Diagnosis of ALS/**P. Aleksiejuk, S. George, K. Gupta, A. Kalakonda, S. Walia, P. Kohlitz, Syracuse, NY, p.A1874

P578 **Candida Tracheobronchitis: A Case Report of a Rare Disease/**A.H. Khan, R. Tandon, Chicago, IL, p.A1875

P579 **Spontaneous Tracheal Rupture After Severe Coughing as First Presentation of Adolescent Asthma/**C.J. Grime, C. Barker, P. James, A. Nyman, A. Durward, London, United Kingdom, p.A1876

P580 **Rescue Therapy with Flow Ventilationr in Non-Cardiac Surgical Patients Failing Conventional Ventilation/**I. Wong, B. Worku, A. Afzal, B. Fahoum, J. Weingarten, F. Khusid, I. Gulkarov, Brooklyn, NY, p.A1877

P581 **Heliox as Adjunctive Therapy in a Mechanically Ventilated Patient with Rhinovirus/Enterovirus-Related Respiratory Failure/**S.E. Morgan, L.J. Witt, S. Mosakowski, S. Barnes, J.P. Kress, G.M. Mutlu, M.D. Howell, Chicago, IL, p.A1878

P582 **One Hamburger, Two Causes of Edema/**M. Bergman, S. Thomas, Y.I. Lee, New York, NY, p.A1879

P583 **Recurrent "Delayed TRALI"/**A. Yankovich, T. Mckenna, S.E. Tieku, Trenton, NJ, p.A1880

P584 **Paclitaxel Induced Acute Lung Injury: A Case Report/**S. Samavedam, M. Baqir, Rochester, MN, p.A1881

Facilitators: M. Hua, MD, MSc, New York, NY
D. Baheti, MBBS, Baltimore, MD

P585 **Catastrophic Influenza Infection in Systemic Lupus Erythematosus-A Management Challenge/**F.I. Malik, I. Ahsan, S.I. Jafri, Abington, PA, p.A1882

P586 **Reactivation of Indolent Pulmonary Coccidiodomycosis Presenting as Acute Respiratory Distress Syndrome/**A. Arunachalam, H. Grewal, G. Khirafan, S. Krishnan, Cleveland, OH, p.A1883

P587 **Severe ARDS and Necrotizing Myopathy- Not Your Usual Case of Influenza B/**L. Littlefield, I. Subramanian, C. Feeney, Oakland, CA, p.A1884

P588 **Surviving Herpes Simplex Virus Type 1 Interstitial Pneumonitis with Viremia Presenting as Acute Respiratory Distress Syndrome in an Immunocompromised Host/**N. Bajaj, S.K. Tan, A.H. Tan, Singapore, Singapore, p.A1885

P589 **Prone Positioning for Severe Acute Respiratory Distress Syndrome in Pregnancy/**M.M. Ali, N.S. Sajjad, Riyadh, Saudi Arabia, p.A1886

P590 **Acute Respiratory Distress Syndrome: An Indolent Presentation of Histoplasmosis/**C. Patel, C. Henry, S. Ghamande, Temple, TX, p.A1887

P591 **Acute Respiratory Distress Syndrome as a Result of Longstanding Cutaneous Blastomycosis/**A.A. Al-Fares, Montreal, Canada, p.A1888

P592 **Defective Alveolar Epithelial Cell Regeneration in a 27 Year-Old Man with Acute Respiratory Distress Syndrome (ARDS)/**M.S. Taylor, R.R. Chivukula, M.K. Selig, J. Rajagopal, W.J. O'Donnell, R.L. Kradin, Boston, MA, p.A1889

P593 **Drug Induced Fatal ARDS/**A.K. Rai, N. Aggarwal, P.K. Gorukanti, I. Malhotra, H. Kausar, Y. Kupfer, Brooklyn, NY, p.A1890

P594 **Vitamin Derivative Induced Acute Lung Injury/**J. Contreras, P. Nangrani, A. Khokar, H. Upadhyay, Z. Hashemi, K.A. Nangrani, F. Arjomand, V. Vasudevan,, L. Gerolemou, Brooklyn, NY, p.A1891

Facilitator: E.C. Goligher, MD, Toronto, Canada

P595 **Intravenous Vitamin C Employed as Adjunctive Therapy in Recurrent Acute Respiratory Distress Syndrome (ARDS): A Case Report/**A. Bharara, C. Grossman, D. Grinnan, A. Syed, B. Fisher, C. DeWilde, A. Priday, R. Natarajan, A.A. Fowler, Richmond, VA, p.A1892

P596 **Subpleural Cystic Lung Disease in Severe H1N1 Influenza-Induced Acute Respiratory Distress Syndrome (ARDS)/**Y. Matusov, A. Aggarwal, J.S. Sager, Santa Barbara, CA, p.A1893

P597 **Acute Respiratory Distress Syndrome Associated with Acute Chest Syndrome - A Case of Successful Treatment with Exchange Transfusion and Aerosolized Epoprostenol/**L. Shehu, M. Al-Jumayli, M. Hassanein, A. Majko, M. Xhikola, M. Raza, Trenton, NJ, p.A1894

P598 **Successful Treatment of Legionella-Induced Severe ARDS with Antibiotics and IVIG/**A. Attaway, J. Fernandez, C. Teba, Cleveland, OH, p.A1895

P599 **Antithymocyte Globulin-Induced Acute Respiratory Distress Syndrome After Liver Transplantation/**M.J. Kioka, G. Tatem, K. Takahashi, Detroit, MI, p.A1896

P600 **Autonomic Instability of Hemodynamic Vital Signs in a Patient with Legionella Pneumonia on ARDS Protocol/**A. Flora, Toledo, OH, p.A1897

P601 **Severe ARDS Secondary to Legionella Pneumonia Requiring Sedation, Paralysis, and Pronation/**I.O. Emeruwa, D. Chong, New York, NY, p.A1898

P602 **Acute Lung Injury After Antithymocyte Globulin Transfusion/**S. Patel, H. Hawamdeh, A. Ataya, H. Alnuaimat, Gainesville, FL, p.A1899

P603 **The Corticosteroid Conundrum: A Case of Systemic Glucocorticoids Resulting in Dramatic Improvement Influenza A (H1N1) Associated ARDS/**A. Egan, P.R. Bauer, V.N. Iyer, Rochester, MN, p.A1900

P604 **Early Tracheostomy in a Patient on ECMO with Severe ARDS Due to Legionella Pneumonia/**M. Shahidi, S. Leung, Bronx, NY, p.A1901

P605 **Severe Rhabdomyolysis in a Patient with Legionella Pneumonia Complicated by ARDS/**S. Korzan, S. Zanoria, S. Prunk, Farmington, CT, p.A1902

THEMATIC POSTER SESSION

A55 CRITICAL CARE CASE REPORTS: NEURO CRITICAL CARE AND TOXICOLOGY

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area H, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitators: A. Goffi, MD, Toronto, Canada
D.A. Kelmenson, MD, Aurora, CO

P931 **Novel Approach for Independent Control of Brain Hypothermia and Systemic Normothermia - Cerebral Selective Deep Hypothermic Therapy/**Y.-S. Chen, C.-H. Wang, Taipei, Taiwan, p.A1903

P932 **Sinusitis and Seizures, Nothing to Snoooze or Sneeze At/**A. Tirmizi, Jackson, MS, p.A1904

P933 **Creutzfeldt-Jakob Disease, Incurable and Fatal/**A. Tirmizi, S. Butt, Jackson, MS, p.A1905

P934 **Propofol Infusion Syndrome - A Rare Complication of Propofol Use!/**G. Malhotra, N. Verma, M. Iliescu, Chicago, IL, p.A1906

P935 **Methadone - A Replacement for Deadly Heroin, Can Kill You Too!/**G. Malhotra, S. Sivaraman, Chicago, IL, p.A1907

P936 **Surviving Sedation/**N.M. Vasquez, M. Fadila, D. Chairman, Columbia, MO, p.A1908

P937 **Successful Use of Intravenous Lipid Emulsion to Treat Psychotropic Drug Overdose/**A. Ali, Y.A. Al Ahwel, A. Milad, M. Taleb, R. Assaly, Toledo, OH, p.A1909

P938 **Two Cases of Moya Moya in Middle-Aged Females in a Suburban Hospital in Missouri/**E. Leung, O. Al-Abboud, M. Salih, M. Benzaquen, St. Louis, MO, p.A1910

P939 **Anti-NMDA Receptor Encephalitis: A Potentially Reversible Form of Psychosis/**N. Dodia, C. Kapp, Chicago, IL, p.A1911

P940 **Intravenous Lipid Emulsion Therapy as an Antidote in Lipophilic Medication Intoxication/**H. Gaztambide, J. Cope, Gainesville, FL, p.A1912

P941 **A Rare Presentation of Delayed Onset Central Pontine Myelinolysis/**R. Supakul, A. Sodhi, D. Kadaria, Memphis, TN, p.A1913

Facilitators: S.R. Kudchadkar, MD, Baltimore, MD
R.D. Mantilla, MD., Roanoke, VA

P942 **Unusual Case of Intracranial Vasculitis/**A. Vasudevan, S. Vanaik, K.S. Sandhu, S. Dhesi, J. Mora, Philadelphia, PA, p.A1914

P943 **A Non-Epidemic Influenza Vaccine Associated Refractory Guillain-Barre Syndrome/**I. Ahsan, F.I. Malik, S.I. Jafri, Abington, PA, p.A1915

P944 **Not Your Typical Encephalitis/**G.K. Lin, C.M. Kirsch, San Jose, CA, p.A1916

P945 **Cerebral Air Emboli After Transthoracic CT Guided Needle Biopsy/**G.S. Sahota, J.J. Vempilly, Fresno, CA, p.A1917

P946 **Spontaneous Intracranial Hypotension as a Rare Cause of Chronic Bilateral Subdural Hematomas/**B. Li, W. Khan, New Brunswick, NJ, p.A1918

P947 **Severe Acute Pancreatitis in a Patient Recently Started on Tamoxifen/**B. Li, W. Khan, New Brunswick, NJ, p.A1919

P948 **Kikuchi-Fujimoto Disease: An Unusual Presentation of Altered Mental Status in an Elderly Patient/**A. Charya, S. Srinivas, R. Gross, Washington, DC, p.A1920

P949 **Spongebrain: The Evolution of Brain Imaging in a Patient with DIC/**D. Pearson, L. Lee, A. Skabelund, M.J. Morris, Fort Sam Houston, TX, p.A1921

P950 **Treatment of Non Resolving Posterior Reversible Encephalopathy Syndrome (PRES) with Magnesium Sulphate/**A. Pandita, O. Chaudhary, J. Sexton, Syracuse, NY, p.A1922

P951 **Dialysis Disequilibrium Syndrome. A Unique Case of Dialysis Related Encephalopathy/**M.Z. Rizwan, A. El Bakush, S.N. Chalise, Z. Rehman, R. Dietrich, Greenville, NC, p.A1923

P952 **Super Refractory Status Epilepticus(SRSE) in ICU, a Therapeutic Challenge/**B. Sharma, E. Hennessey, Palo Alto, CA, p.A1924

Facilitators: H. Bhardwaj, MD, Oklahoma City, OK
J. Heavner, MD, New Haven, CT

P953 **A Case of Central Diabetes Insipidus in a Non HIV Patient with Cryptococcal Meningitis/**M.K. Loya, Sayre, PA, p.A1925

P954 **Wernicke's Encephalopathy: An Unusual Cause of Shock/**A. Krishna, A. Ali, S. Santosh, St. Louis, MO, p.A1926

P955 **Cerebral Edema Induced Altered Mental Status as a Presenting Symptom of Acute Hypercapnic Respiratory Failure/**A. Abu Homoud, A. Khan, E. Costanzo, Neptune City, NJ, p.A1927

P956 **Superior Sagittal Sinus Thrombosis: A Rare Life Threatening Disease/**S. Sahni, M.A.I. Cheema, M. Patel, A. Iftikhar, New Hyde Park, NY, p.A1928

P957 **Heroin Induced Sudden Sensorinueral Hearing Loss Treated with Steroids/**J. Leap, S. Yadam, R. Adurty, Pittsburgh, PA, p.A1929

P958 **A Not So SILENT Manifestation of Lithium Toxicity/**A. Gour, M.A. Shenoy, A.P. Kamath, S. Khanijao, A. Saxena, K. Kitchloo, Brooklyn, NY, p.A1930

P959 **DEET..What's the Big Deal!!' An Interesting Case of Insect Repellant Poisoning/**M. Raza, H. Hashmi, J. Scott, Grand Rapids, MI, p.A1931

P960 **An Unlikely Recovery from Severe Lithium Neurotoxicity/**E.L. Altschul, C.R. Grossman, D.M. Wisa, New York, NY, p.A1932

P961 **Triple Synergy Effect that Resulted in a Protracted ICU Course in a Case of Baclofen Overdose/**S. Sangli, D. Young, S. Kurtz, New York, NY, p.A1933

P962 **Superwarfarin Toxicity from Internet-Purchased Zolpidem Causing Intracerebral Hemorrhage Treated with Repeated-Dose 4PCC/**C.B. McKinney, S.C. Woller, S.M. Stevens, Murray, UT, p.A1934

P963 **Near-Fatal Arrhythmia from High Dose Loperamide- "The Poor Man's Methadone"/**S.W. Robison, R. Ung, J. Yataco, Jacksonville, FL, p.A1935

P964 **High Dose Insulin Infusion for Life Threatening Calcium Channel Blocker Overdose/**P. Jagtap, S.S. Hoskote, F. Hashmi, R.A. Oeckler, Rochester, MN, p.A1936

Facilitators: N.E. Brummel, MD, Nashville, TN
M.C. Antkowiak, MD, Burlington, VT

P965 **Severe Autoimmune Hemolytic Anemia and Pancytopenia Induced by Peginterferon Alfa-2a and Ribavirin Refractory to Glucocorticosteroids and Erythropoeitin/**J. Pinto, F. Hafeez, M. Olibrice, New York, NY, p.A1937

P966 **Propylene Glycol Toxicity Resulting in Severe Lactic Acidosis After Standard Dose Trimethoprim/Sulfamethoxazole Infusion/** M. Bulathsinghala, K. Keefer, A. Van De Louw, Hershey, PA, p.A1938

P967 **Ketamine Associated Urinary Tract Dysfunction/**M.A. Shenoy, A. Gour, I. Malhotra, P.K. Irukulla, Y. Kupfer, C. Seneviratne, Brooklyn, NY, p.A1939

P968 **Ibogaine Toxicity in a Case of Good Intentions/**P.H. Hanneman, A.J. Oberle, W.G. Carlos, Indianapolis, IN, p.A1940

P969 **A Case of Profound Bleeding in the Setting of Brodifacoum Rodenticide/**K.M. Wiese, J.M. Coleman, Chicago, IL, p.A1941

P970 **An Unusual Case of Imidaclopride Poisoning with Methemoglobinemia/**J. Nikhilesh, G. Ankur, Indore, India, p.A1942

P971 **Profound Lactic Acidosis Associated with Metformin Use in a Patient Without Chronic Kidney Disease/**A. Vengerovsky, V. Trivedi, D. Sanghavi, O. Gajic, K.B. Kashani, Rochester, MN, p.A1943

P972 **A Case of Viekira Pak-Induced Lactic Acidosis and Shock/**M. Acho, H. Poor, New York, NY, p.A1944

P973 **Tamoxifen Induced Hypertriglyceridemia: An Underrecognized and Rare Cause of Pancreatitis/**R. Sedhom, D. Schaer, W. Khan, New Brunswick, NJ, p.A1945

P974 **Linezolid: An Uncommon Cause of Lactic Acidosis/**E. Ho, N. Kamangar, Sylmar, CA, p.A1946

P975 **Lower Extremity Numbness and Aortic Dissection/**A. Audi, T. Ashour, Rochester, NY, p.A1947

THEMATIC POSTER SESSION

A56 CRITICAL CARE CASE REPORTS: HEMATOLOGY/ONCOLOGY

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**
Area H, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitators: M.P. Kerlin, MD, Philadelphia, PA
R. Kohn, MD, Philadelphia, PA

P979 **Ticking Time Bomb in the Chest: Mycotic Thoracic Aneurysm Presenting with Massive Hemoptysis/**J.C.D. Hasmatali, S.S. Nosib, K.F. Laframboise, Saskatoon, Canada, p.A1948

P980 **Thrombotic Thrombocytopenic Purpura Coma: Hope Is Not Lost/**C. Bernabe, N. Ramesh, B. Lou, C. Olazagasti, J. Filopei, P. Patrawalla, Y.I. Lee, New York, NY, p.A1949

P981 **Acute Thrombocytopenia in An Elderly Female Status Post Hip Hemiarthroplasty/**R.M. Hoffman, Y.A. Khan, I. El-Abbassi, New Orleans, LA, p.A1950

P982 **Acquired Inhibitor-Mediated Hemophilia: A One-in-a-Million Diagnosis/**S.F. Noronha, J. Panchal, J. Salonia, J. Shapiro, New York, NY, p.A1951

P983 **An Unusual Case of Thrombocytopenia/**S.R. Dudekonda, E.M. Mohanraj, New York, NY, p.A1952

P984 **Deadly Fall: Unusual Case of Superior Gluteal Artery Injury from Low Energy Buttock Contusion/**E. Patel, A. Patel, D. Connor, S. Shahzad, Brooklyn, NY, p.A1953

P985 **Mixed-Type Hyaline Vascular and Plasma Cell Variant Castleman's Disease with Paraneoplastic Pemphigus/**H. Sharifi, W. Sauer, A. Gohil, Stanford, CA, p.A1954

P986 **Thrombotic Microangiopathy: It's Not All Thrombotic Thrombocytopenic Purpura (TTP)/**N. Thomas, C. Wentowski, New Orleans, LA, p.A1955

Facilitators: A.B. Lipke, MD, Seattle, WA
T.R. Leclair, MD, Burlington, VT

P987 **FEIBA Associated Compartment Syndrome/**A. Agarwal, E. Guzman Suarez, Camden, NJ, p.A1956

P988 **Utilization of HBOC-201 in Treatment of a Jehovah's Witness with Critical Anemia During Sickle Crisis: A Case Report/**J.M. Davis, N. El-Haj, N. Shah, M.A. Tidswell, E. DiNino, Springfield, MA, p.A1957

P989 **Lactic Acidosis in a Critically Ill Cancer Patient: Beware the Warburg Effect/**J.H. Short, A. Sen, Scottsdale, AZ, p.A1958

P990 **Primary Aorto-Esophageal Fistula Secondary to Benign Barrett's Ulcer Causing Massive Upper Gastrointestinal Bleeding Treated with Endovascular Graft: A Success Story/**S. Nepal, A. Niroula, W. Ward, M. Naglak, Abington, PA, p.A1959

P991 **Wirsungorrhagia Emanating from Multiple Pseudoaneurysms in a Patient with Chronic Pancreatitis/**S. Morais, M. Siyamwala, V. Bhagat, P. Sandhu, J. Meharg, Providence, RI, p.A1960

P992 **Non-Islet Cell Tumor Induced Hypoglycemia/**S. Shankar, M.A. Shenoy, S. Gupta, C. Seneviratne, Y. Kupfer, Brooklyn, NY, p.A1961

P993 **Acute Cholangitis: More than Just an Obstruction/**A.K. Sabharwal, A.K. Arumugam Raajasekar, A. Chandra, Brooklyn, NY, p.A1962

P994 **Persistent Type B Lactic Acidosis and Hypoglycemia as a Complication of Burkitt's Lymphoma Without Hepatic Involvement: A Rare Presentation/**T. Jain, J.R. Sanchez, R. Sengupta, N. Huda, D. Ouellette, Detroit, MI, p.A1963

Facilitators: J. Palakshappa, MD, Philadelphia, PA
J. Chen, MD, Bronx, NY

P995 **Lactic Acidosis Presenting in Newly Diagnosed Hematologic Malignancy/**N.M. Patel, A. Michaels, B. DiGiovine, G. Tatem, S. Gezahegne, Detroit, MI, p.A1964

P996 **A Pediatric Tumor Causing a Neurosurgical Emergency in an Adult/**Z.S. Dreyfuss, T. Simpson, San Antonio, TX, p.A1965

P997 **A Misdiagnosis of TTP Caused by Occult Metastatic Breast Cancer/**M. Gilmore, D.G. Washburn, C. Patel, Loma Linda, CA, p.A1966

P998 **Spontaneous Tumor Lysis Syndrome in a Patient with Metastatic Melanoma Presenting in Septic Shock/**C. Teba, G. Thornton, N. Fouladpour, Cleveland, OH, p.A1967

P999 **Acute Papular Rash Associated with Spontaneous Splenic Rupture: A Rare Presentation of Anaplastic T-Cell Lymphoma/**O. Rahman, R. Kapoor, E. Valinetz, S. Khan, M.T. Ayub, N. Jasani, Indianapolis, IN, p.A1968

P1000 **Pulmonary, Thrombotic and Hemorrhagic Complications in the Acute Stage of Promyelocytic Leukemia/**H.-C. Chang, L.-N. Lee, S.-C. Lo, I.-S. Jan, C.-C. Lin, M.-K. Chuang, W.-C. Chou, W.-C. Cheng, Y.-F. Lee, J.-Y. Wang, C.-L. Hsu, Taipei, Taiwan, p.A1969

THEMATIC POSTER SESSION

A57 CRITICAL CARE CASE REPORTS: NON-PULMONARY CRITICAL CARE

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area H, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitators: R.C. Hyzy, MD, Ann Arbor, MI
C.R. Nitkin, MD, Cleveland, OH

P1004 **Reverse Pseudohyperkalemia in a Patient with Chronic Lymphocytic Leukemia/**E. Tan, K. Ramar, H. Yadav, Rochester, MN, p.A1970

P1005 **Near Fatal Result from Use of a Salt Substitute/**S. Amin, K. Johnson, I. Faruqi, Gainesville, FL, p.A1971

P1006 **Non-Conventional Use of Acetazolamide with Simultaneous Chloride Repletion in Severe Metabolic Alkalosis/**D.P. Katzman, M.C. Mirant-Borde, M. Kline, B.W. Oppenheimer, New York, NY, p.A1972

P1007 **Case Report of a Patient with Hyperkalemia Greater than What Is Expected for Survival/**F.T. Ogundipe, S. Afreen, M. Musbah, C. Mere, Washington, DC, p.A1973

P1008 **Severe Hypernatremia: A Rare Cause of Rhabdomyolysis/**A.P. Kamath, A. Gour, P. Chandar, A.K. Sabharwal, Brooklyn, NY, p.A1974

P1009 **It Is Not a Salt Problem; It Is a Water Problem: An Interesting Case of Hyponatremia/**V. Thoguluva Chandrasekar, K. Gupta, K.M. Dziamski, M. Ignaszewski, A. Ghimire, Syracuse, NY, p.A1975

P1010 **Unusual Complication of a Bone Marrow Biopsy/**G. Trikha, I. Amzuta, Syracuse, NY, p.A1976

P1011 **A Complication of a Port-a-cath Venous Access Requiring Urgent Intervention and ICU Management: A Case Report/**L. Premachandra, A. Misra, E. Hamaty, Atlantic City, NJ, p.A1977

P1012 **A Woman in Her 70s Presenting with Neck Abnormalities After a Difficult Endotracheal Intubation/**M. Ijaz, A.L. Shiloh, L.A. Eisen, Bronx, NY, p.A1978

Facilitators: M.A. Tamae Kakazu, MD, Grand Rapids, MI
M. Wilson, MD, Rochester, MN

P1013 **Porto-Mesenteric Venous Thrombosis Complicated by Hemorrhagic Shock: A Rare Complication of Laparoscopic Sleeve Gastrectomy/**S. Morais, E. Jabbour, G. Cholankeril, E. Copelin, J. Meharg, Providence, RI, p.A1979

P1014 **SVC Syndrome Induced by Dialysis Catheters/**T. Lat, P. Yau, Temple, TX, p.A1980

P1015 **Sustained Bradycardia Following Internal Jugular Catheter Insertion/**S. Vallabhajosyula, B. Selim, Rochester, MN, p.A1981

P1016 **An Enlightening Method of Performing Percutaneous Dilational Tracheostomy (PDT)/**D.G. Washburn, L. Tan, Loma Linda, CA, p.A1982

P1017 **"Super-Obesity" in the ICU - Unique Set of Challenges/**M. Gobrial, P.K. Gorukanti, A. Agarwal, P.K. Irukulla, C. Kwan, M.A. Shenoy, K. Chawla, T. Yoon, W. Pascal, Brooklyn, NY, p.A1983

P1018 **Penile Calciphlaxis Masquerading as Fournier's Gangrene/**A.K. Sabharwal, A.K. Arumugam Raajasekar, A.P. Kamath, M. Hecht, Brooklyn, NY, p.A1984

P1019 **Shoshin Beriberi, an Under-Recognized Etiology of Distributive Shock/**T. Thaniyavarn, Atlanta, GA, p.A1985

P1020 **IgG4-Related Disease Causing Acute Cholangitis-A Rare Disease with Rare Presentation/**A. Minami, N. Yang, A. Olszewski, I. Grillo, M.O. Al-Qadi, T. Minami, Pawtucket, RI, p.A1986

P1021 **Euglycemic Diabetic Ketoacidosis in Pregnancy/**B. Mirza, A. Cantillep, Long Beach, CA, p.A1987

Facilitator: B. Ergan, MD, Izmir, Turkey

P1022 **Hyperammonemia in the Intensive Care Unit: The Catastrophic Effects of a Late Initial Presentation of a Urea Cycle Disorder/**M. Kappelman, S. Skolasinski, S. Erickson, Minneapolis, MN, p.A1988

P1023 **Graves' and Gravis: An Atypical Cause of Muscular Weakness/** O. Ishikawa, K.G. Lazo, D.M. Wisa, B. Mina, New York, NY, p.A1989

P1024 **Refractory Hyperammonemia: A Case Report of a Patient with Adult Onset Ornithine Carbamoyltransferase Deficiency/**H.A.A. Nayef, H.V. Parmar, E. Costanzo, Neptune, NJ, p.A1990

P1025 **Myxedema Coma with Cardiogenic Shock Treated with Enteral T3/**J.S. Kurman, S. Swartz, J.J. Patel, Milwaukee, WI, p.A1991

P1026 **5BX: A Novel Precipitant of Severe Ketoacidosis/**R. Haberman, B. Zakhary, New York, NY, p.A1992

P1027 **A Unique Thoracic Mass: Esophageal Bezoar/**K.T. Abu-Ihweij, S. Shah, L. Chong, A. Lardizabel, Newark, NJ, p.A1993

P1028 **A Post-Partum Woman with Severe Abdominal Pain. Ovarian Vein Thrombosis- A Diagnostic Challenge/**H.S. Arshad, M. Biyyam, G. Diaz-Fuentes, M. Lombino, S. Venkatram, Bronx, NY, p.A1994

P1029 **Thyrotoxic Periodic Paralysis in a Hispanic Male/**P. Chandar, I. Malhotra, S. Kulandaisamy, A. Gajankush, T. Yoon, Y. Kupfer, C. Seneviratne, Brooklyn, NY, p.A1995

P1030 **Sometimes the Best Thing to Do Is Nothing at All/**E. Feuerborn, H. Avella, Boise, ID, p.A1996

P1031 **An Unusual Cause of a Chylous Pleural Effusion/**A.R. Tomlinson, M. Luna, J.E. Fitzgerald, Dallas, TX, p.A1997

THEMATIC POSTER SESSION

A58 EPIDEMIOLOGY OF COPD AND LUNG CANCER

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area C, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: D.M. Mannino, MD, Lexington, KY

P237 **Relationship Between Lung Function and Chest X-Ray Findings in Koreans: A Population-Based Study/**S. Myung Jin, L. Sang Hoon, K. Song Yee, K. Young Sam, Seodaemun-gu, Seoul, Korea, Republic of, p.A1998

P238 **Understanding the Relationship Between Lung Function Measures and Mortality in the Very Old/**M.E. Yadegarfar, A.J. Fisher, P.A. Corris, C. Jagger, Newcastle Upon Tyne, United Kingdom, p.A1999

P239 **How Consistent and Reproducible Are Prevalence Estimates of COPD in the General Population?/**W.C. Tan, L. Zheng, J. Bourbeau, D.D. Sin, D.E. O'Donnell, F. Maltais, P. Hernandez, K.R. Chapman, D. Marciniuk, J. Road, J. Leipsic, C. Hague, H. Coxson, M. Kirby, J.M. FitzGerald, J.C. Hogg, S.D. Aaron, Vancouver, Canada, p.A2000

P240 **Country-Level Effects on COPD Prevalence/**S.D. Aaron, A.S. Gershon, C. Gao, J. Yang, G.A. Whitmore, Ottawa, Canada, p.A2001

P241 **Epidemiology of Chronic Bronchitis in Chronic Obstructive Pulmonary Disease (COPD)/**L.J. Seys, L. Lahousse, G.F. Joos, A. Hofman, B. Stricker, G.G. Brusselle, Ghent, Belgium, p.A2002

P242 **Prevalence and Correlates of Obstructive Lung Disease in Rural Uganda: A Population-Based, Cross-Sectional Study/**C.M. North, B. Kakuhikire, D. Vorechovska, S.H. Kigozi, A.Q. McDonough, D.C. Christiani, D.R. Bangsberg, A.C. Tsai, M.J. Siedner, Boston, MA, p.A2003

Facilitator: D.L. DeMeo, MD, MPH, Boston, MA

P243 **Prevalence and Clinical Characteristics of Non-Smoker's COPD/**H. Takiguchi, K. Harada, M. Sato, Y. Horio, J. Tanaka, H. Tomomatsu, K. Tomomatsu, T. Takihara, K. Niimi, N. Hayama, T. Oguma, T. Aoki, T. Urano, S. Asai, H. Miyachi, K. Asano, Kanagawa, Japan, p.A2004

P244 **Prevalence of Undiagnosed Airflow Limitation: Preliminary Report from a Cross Sectional Survey of Cardiac Patients in a Resource-Limited Setting/**A.A. Akinremi, K.K. Sobande, K. Hamzat, Pasifika, Fiji, p.A2005

P245 **Descriptive Analysis of Spirometric Patterns Defined by GOLD Criteria and LLN in the Population Evaluated in the Pulmonary Physiology Service of the Hospital General de Mexico in the Period of 2012-2014/**Y. Mares, I. Rodriguez de Molina, R. Hernandez, A. Rodriguez, Mexico, Mexico, p.A2006

P246 **The Role and Diagnostic Value of Gene Variants in Chronic Obstructive Pulmonary Disease Risk/**Z. Yan, X. Tong, H. Fan, Chengdu, China, p.A2007

P247 **A Web-Based Approach for Awareness and Management of Alpha1-Antitryspin Deficiency/**I. Ferrarotti, M. Zorzetto, S. Ottaviani, V. Barzon, L. Dolfi Agostini, S. Bendinelli, A.G. Corsico, Pavia, Italy, p.A2008

P248 **Social Media (Twitter) for Assessing Concerns About Obstructive Airway Disease/**P.I. Harber, G. Leroy, Tucson, AZ, p.A2009

Facilitator: W.G. Kuschner, MD, Palo Alto, CA

P249 **Urban Heat Stress Related Disease Deterioration- Patients with Chronic Lung Disease Will Be Mobilized Earlier Through Innovative Radiant Indoor Climatization During Hospital Stay/**C. Witt, U. Liebers, M. Drosdzek, A. Bendjus, M. Jehn, A.J. Schubert, Berlin, Germany, p.A2010

P250 **Evaluation of the Risk of Pneumonia in COPD Patients Treated with ICS: Limitations of Retrospective Database Studies/**G. Nadeau, J. Bourbeau, Y. Lacasse, S.D. Aaron, K. Davis, N. Barnes, Mississauga, Canada, p.A2011

P251 **COPD Uncovered: Quality of Life, Work and Activity Impairment in Patients with Chronic Obstructive Pulmonary Disease in Japan/**A. Igarashi, Y. Fukuchi, K. Hirata, M. Ichinose, A. Nagai, M. Nishimura, M. Pedros, S. Murata, J.-B. Gruenberger, Tokyo, Japan, p.A2012

P252 **Validation of a "Dedicated COPD Coordination Team" on Readmissions: Challenge Met!/**A.C. Singh, T. Cheema, J.K. Gordon, X. Tang, C. Pappal, Pittsburgh, PA, p.A2013

P253 **Chronic Obstructive Pulmonary Disease (COPD) Risk Stratification Among Hospitalised COPD Exacerbators: A Bradford Experience/**R. Czajka, D. Saralaya, K. Regan, L. Walker, Bradford, United Kingdom, p.A2014

P254 **COPD-Specific Patient Reported Outcomes in a Working Population: Breathlessness, Symptoms and Health Status/**K. Nishimura, S. Mitsuma, Obu, Japan, p.A2015

Facilitator: A.M. Ahasic, MD, MPH, New Haven, CT

P255 **Health-Related Quality of Life in New Mexican Hispanic Smokers with Asthma and Chronic Bronchitis/**A.A. Diaz, H. Petersen, P.M. Meek, A. Sood, B. Celli, Y. Tesfaigzi, Boston, MA, p.A2016

P256 **Gender Differences by Age in St. George's Respiratory Questionnaire Total Scores and Self-Reported Overall Health Among Subjects with and Without COPD in the COPDGene Cohort/**D.L. DeMeo, M.K. Han, E.A. Regan, A. Yadao, A. Kavati, A. Vegerna, D. Keininger, T.K. Wilcox, S. Ramagopalan, M. Pereira, B.J. Make, Boston, MA, p.A2017

P257 **Hormone Therapy and Pulmonary Emphysema: The Multi-Ethnic Study of Atherosclerosis (MESA) Lung Study/**K.E. Killeen, E.D. Michos, E.A. Hoffman, C.P. Aaron, C.E. Ventetuolo, S.M. Kawut, P. Balte, C.M. Lo Cascio, R.G. Barr, New York, NY, p.A2018

P258 **Pilot Program to Reduce the Burden of Lung Cancer Mortality by 5% Within 5 Years/**P. Whitten, J. McGee, K. Hall, K. Copelen, J. Stoner, M. Rappleyea, A. Wright, L. Wolfe, Peoria, IL, p.A2019

P259 **Lung Cancer, Has It Changed in the Last Ten Years?/**D. Bravo Blanco, O. Llaguno Ochandiano, I. Murga Arizabaleta, E. Marijuan Gomez, L. Tomas Lopez, J.L. Lobo Beristain, P. Sobradillo Ecenarro, Vitoria-Gasteiz, Spain, p.A2020

P260 **High BMI and Risk of Exacerbations and Pneumonias in Individuals with COPD: Observational and Genetic Risk Estimates from the Copenhagen General Population Study/** Y. Colak, S. Afzal, P. Lange, B.G. Nordestgaard, Herlev, Denmark, p.A7796

THEMATIC POSTER SESSION

A59 TOBACCO, NICOTINE, AND MARIJUANA USE

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area F, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: D.J. Upson, MA, MD, Albuquerque, NM

P649 **Does the School Neighborhood Play a Role in Health Behaviour? A Study on the Prevalence of Smoking in Youths and Teenagers/**K. Larsen, T. To, R. Mann, A. Boak, H. Hamilton, H. Irving, G. Faulkner, Toronto, Canada, p.A2021

P650 **Smoking and Asthma: Examining Factors Associated with Smoking in Ontario Teenagers with Asthma/**K. Larsen, T. To, R. Mann, A. Boak, H. Hamilton, G. Faulkner, Toronto, Canada, p.A2022

P651 **Short Term Effects of a School-Based Computer Assisted Intervention for Smoking Prevention Among Adolescents in Tirgu Mures, Transylvania, Romania/**V. Nadasan, S. Mihaicuta, J. Balint, M. Csibi, Z. Abram, Tirgu Mures, Romania, p.A2023

P652 **Synthetic Cannabinoid Poisoning in New York City - a Growing Burden on Critical Care Resources/**O.T. Otusanya, A. Hafiz, V. Reddy, M. Langston, H. Ali, Bronx, NY, p.A2024

P653 **How Much Increases the Risk of Cardiovascular Disease at Smoker Workers?/**N. Bozkurt, E. Dikbas, A.I. Bozkurt, Denizli, Turkey, p.A2025

P654 **Smoking Prevalence Among Employees of a University Hospital/**M.M. Knorst, M.B. Sarmento, G. Buffon, T. Muller, L. Grimaldi, L. Vedana, S.T. Felipe, F.J.A.Q. Oliveira, Porto Alegre, Brazil, p.A2026

P655 **Smoking Related Interstitial (SRIF) Is Less Prevalent with Smoking Cessation and In Those Aged &)+ Years:Regression or Marker of Increased Mortality?/**K. Sharma, T. McEnery, A. Fabre, M.P. Keane, D. Healy, J.D. Dodd, M. Butler, Dublin, Ireland, p.A2027

Facilitator: S.E. Jordt, PhD, Durham, NC

P656 **Outpatient Prescription Narcotic Use in Patients Admitted to a Community Hospital General Medicine Service with a Primary Respiratory Diagnosis/**C.J. VanHook, B. Warner, A. Taylor, M. Beer, J. Gould, A. Laursen, R. Loredo, U. Mba, C. O'Neil, E. Wei, B. Delgado, D. Tangel, Longmont, CO, p.A2028

P657 **Effect of Altitude and Cigarette Smoke Exposure on Bronchoalveolar Lavage Fluid Cellularity/**M.K. Ishaq, C. Cross, H. Youness, L. Booth, E. Duggan, L. Howard, B. Petrone-Holtslander, A. Ahmed, D. Burian, J.P. Metcalf, Oklahoma City, OK, p.A2029

P658 **Mass Media Interventions for Preventing Smoking in Young People: A Cochrane Systematic Analysis/**H. Jayasinghe, K.V. Carson, J. Van Agteren, F. Ameer, K. Hnin, B. Smith, Adelaide, Australia, p.A2030

P659 **The Impact of Acute Smoking on Airway Gene-Expression/**E. Billatos, Y.B. Gesthalter, N.H.T. Ten Hacken, D.S. Postma, I.H. Heijink, W. Timens, C.A. Brandsma, A. Faiz, M. van den Berge, M. Lenburg, A. Spira, Boston, MA, p.A2031

P660 **Effects of Nicotine-Containing E-Cigarette Vapor on Mucociliary Clearance in NHBE Cells/**A. Grosche, N. Baumlin-Schmid, S. Krick, J.S. Dennis, M. Salathe, Miami, FL, p.A2032

P661 **The Effect of Electronic Cigarette Exposure on Bronchial Epithelial Cells/**A. Higham, G. Booth, D. Singh, Manchester, United Kingdom, p.A2033

Facilitator: E.R. Neptune, MD, Baltimore, MD

P662 **In Vitro Cytotoxicity and Molecular Effects of Electronic Cigarette Vapor Extract on Primary Isolated Mouse Lung Cells/**E.T. Roxlau, A. Pichl, R.T. Schermuly, H.A. Ghofrani, W. Seeger, F. Grimminger, N. Weissmann, Giessen, Germany, p.A2034

P663 **Inspiratory Performance of Smokers and Nonsmokers Using the Test of Incremental Respiratory Endurance (TIRE)/** M.F. Formiga, N.D. DeLuca, C. Garcia, T.S. Denis, B. Eisenhardt, S. Colas-Salgado, M. Cohen, L.P. Cahalin, Coral Gables, FL, p.A2035

P664 **Environmental Influence on Tobacco Use in Pulmonary Patients/**M. Weir, H. Cuesta, D. Kolman, F. Patterson, A. Satti, Philadelphia, PA, p.A2036

P665 **Could Nicotine Patches Be Making People More Addicted to Nicotine? An Evaluation of Auto-Induction as a Surrogate to Up-Regulation of Nicotine Receptors/**K.V. Carson, R. To-A-Nan, M.P. Brinn, M. Roberts, L. MacKenzie, S. Gunn, B.J. Smith, Adelaide, Australia, p.A2037

P666 **Prevalence of Alternative Tobacco Product Use in a Cohort of Critically Ill Patients/**T. Liu, T. Deiss, M. Lippi, K.N. Kangelaris, A. Gomez, K. Liu, C.S. Calfee, San Francisco, CA, p.A2038

THEMATIC POSTER SESSION

A60 ILD, IPF, SARCOIDOSIS, AND DIFFUSE LUNG DISEASE

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area F, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: D.N. Weissman, MD, Morgantown, WV

P668 **Decreasing Trend of In-Hospital Mortality in Patients Diagnosed with Acute Respiratory Distress Syndrome: An Analysis of Teaching Vs Non-Teaching Hospitals of a US Nationwide Inpatient Sample 2007-2011/**C.-P. Wu, C. Yu-Wei, M.-J. Wang, V. Reddy, M. Langston, New York, NY, p.A2040

P669 **Proteomics Analysis of BALF in Sarcoidosis Associated Pulmonary Fibrosis/**Y. Nukui, Y. Miyazaki, N. Inase, Tokyo, Japan, p.A2041

P670 **Sarcoidosis Undergoing Clinical Resolution Demonstrates Reduced Numbers of Apoptotic Bronchoalveolar Lavage (BAL)-Derived CD4+ T Cells/**S. Ladhani, C. Hawkins, D.A. Shelton, W. Drake, Nashville, TN, p.A2042

P671 **Sarcoidosis CD4+ T Cells Derived from Peripheral Blood Mononuclear Cells (PBMC) Exhibit an Activation Defect that Is Associated with Increased Apoptosis/**C. Hawkins, G. Shaginurova, K.A. Richter, W. Drake, Nashville, TN, p.A2043

P672 **Sarcoidosis in Active Duty Military Personnel Deployed to Southwest Asia/**D. Mabe, M. Sobieszczyk, A. Holley, K. Sheikh, Bethesda, MD, p.A2044

P673 **Successful Enrollment of Diverse Patient Populations Reflected in The GRADS Sarcoidosis Study/**D.A. Shelton, W. Drake, N. Hamzeh, K.C. Patterson, D.R. Moller, E. Herzog, K. Gibson, S.R. Wisniewski, Nashville, TN, p.A2045

Facilitator: G.M. Hunninghake, MD, MPH, Boston, MA

P674 **Idiopathic Pulmonary Fibrosis: Acute Events, Mortality and Associated Hospital Costs/**V. Cottin, A. Schmidt, L. Catella, F. Porte, K. Le Lay, C. Fernandez-Montoya, S. Benard, Lyon, France, p.A2046

P675 **The Challenge of Estimating the Burden of Idiopathic Pulmonary Fibrosis (IPF) Using Medical and Public Records Databases/**J.E. Gibson, V. Navaratnam, D. Strachan, R. Hubbard, Nottingham, United Kingdom, p.A2047

P676 **Role of Pollution on the Natural History of Idiopathic Pulmonary Fibrosis (IPF)/**L. Sese, H. Nunes, V. Cottin, Z. Carton, D. Isral-Biet, B. Crestani, J. Cadranel, B. Wallaert, A. Tazi, B. Maitre, G. Prevot, S. Marchand-Adam, S. Guillot-Dudoret, A. Nardi, S. Dury, V. Giraud, R. Borie, D. Valeyre, I. Annesi Maesano, Bobigny, France, p.A2048

P677 **Association of Mucin (MUC2 and MUC5B) Gene Variants and Idiopathic Pulmonary Fibrosis: A Genotyping Study by Sequenom MassARRAY in French and Greek Populations/**A. Kishore, V. Zizkova, L. Kocourkova, J. Petrkova, E. Bouros, H. Nunes, D. Bouros, D. Valeyre, M. Petrek, Olomouc, Czech Republic, p.A2049

P678 **Are Interstitial Lung Diseases an Antecedent of Lung Cancer?/**W.-I. Choi, B. Park, C.W. Lee, Daegu, Korea, Republic of, p.A2050

Facilitator: K.A. Johannson, MD, Calgary, Canada

P679 **Incidence and Prevalence of Hypersensitivity Pneumonitis/**E. Fernandez Perez, A. Farr, K. Raimundo, R. Kulkarni, A. Cole, Denver, CO, p.A2051

P680 **Inhaled Inorganic Elemental Analysis of Idiopathic Pulmonary Fibrosis by In-Air Microparticle Induced X-Ray Emission Analysis/**Y. Koga, T. Satoh, K. Kaira, M. Koka, Y. Hachisu, T. Hisada, A. Ono, Y. Shimizu, T. Maeno, K. Shimizu, A. Mogi, T. Ishizuka, M. Yamada, K. Dobashi, Maebashi, Gunma, Japan, p.A2052

P681 **Blunt Thoracic Trauma with Pulmonary Blast Injury Phenotype: Perfluorochemical Intervention within the "Golden Hour"/**M.R. Wolfson, J. Wu, E.M. Sivieri, E. Brady, M.M. Marcinkiewicz, S.T. Baker, T.H. Shaffer, Philadelphia, PA, p.A2053

P682 **Persistent Small Airway Disease in Rabbits Following Recovery from Acute Chlorine Inhalation Injury/**G.W. Hoyle, C.F. Schlueter, D.M. Humphrey, R. Casey, S. Musah, Louisville, KY, p.A2054

P683 **Expression Levels of Developmenal Genes Distinguish Non Specific Interstitial Pneumonia from Idiopathic Pulmonary Fibrosis and Highlight Potential Diagnostic Markers/**K. Konishi, Y. Kondoh, H. Taniguchi, A. Okamoto, K.O. Lindell, K. Asai, Y. Zhang, K. Gibson, N. Kaminski, D.S. Kim, Osaka, Japan, p.A2055

P684 **Prevalence of, and Risk Factors for, Restrictive Spirometry Patterns in Four Resource-Poor Settings in Peru/**T. Siddharthan, M. Grigsby, C.H. Miele, J.J. Miranda, R.H. Gilman, R.A. Wise, J.R. Hurst, W. Checkley, Baltimore, MD, p.A7797

P685 **Effect of Focal Tracheal Deviation (Tracheal Kink) on Ozone Tracheal Flux in Fibrotic Lung Disease Patients: A Simulation Study/**S. Borhan, S.P. Motevalian, J. Ultman, T. Kuhlengel, A.E.F. Dimmock, R. Bascom, A. Borhan, University Park, PA, p.A7798

THEMATIC POSTER SESSION

A61 CLINICAL ASPECTS OF NON-BACTERIAL LUNG INFECTIONS

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area G, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: D.J. Marchant, PhD, Edmonton, Canada

P779 **Role of Respiratory Viruses in Acute Respiratory Infections/**S. Tanguturi, N. Ettinger, T.C. Strand, Chesterfield, MO, p.A2056

P780 **Physician's Attitude to a Positive Respiratory Viral Panel (RVP) on Bronchoalveolar Lavage (BAL) in Adult In-Patients with Acute Lower Respiratory Tract Infection/**P. Agarwal, A.S. Nyquist, J. Timpone, D. Lazarous, Washington, DC, p.A2057

P781 **Detection of Respiratory Viruses from Lower Respiratory Tract Specimens in Patients with Lung Lesions: Summary of 3-Year Data Using Multiplex PCR Method/**N. Ikemiyagi, D. Nabeya, T. Kinjo, G. Parrott, A. Uehara, S. Haranaga, M. Tateyama, J. Fujita, Okinawa, Japan, p.A2058

P782 **Acute Respiratory Infections in Hospitalized Patients in a Community Medical Center: Retrospective Review of Patients with Viral Respiratory Infections After Implementation of Rapid Polymerase Chain Reaction Viral Detection Test/**M. Calder, E. Rains, M. Ingerman, O. Giger, L. Lande, Wynnewood, PA, p.A2059

P783 **Additive Benefit of Repeat Respiratory Viral PCR Testing/**J.J. Barretto, J. Nolte, Y. Samra, V. Vanam, M. Barnes, I. Faruqi, Gainesville, FL, p.A2060

P784 **Association of rt-PCR Respiratory Viral Assay Results with Antibiotic Usage and Length of Stay in Hospitalized Patients/**S. Ashraf, N. Hakimi, D. Wakefield, J. Fine, Norwalk, CT, p.A2061

P785 **Pathogen Profiles and Molecular Epidemiology of Respiratory Viruses in Japanese Inpatients with Community-Acquired Pneumonia/**D. Kurai, T. Saraya, H. Ishii, Y. Sasaki, H. Tsukagoshi, H. Kimura, H. Takizawa, Mikata, Japan, p.A2062

P786 **Diagnostic Accuracy of Serum Procalcitonin to Identify Viral Pneumonia in Patients Admitted to the Intensive Care Unit/**J. Krings, J.E. Reynolds, N.W. Lin, B. Trinh, R.D. Shah, R.G. Wunderink, Chicago, IL, p.A2063

Facilitator: Y. Imai, MD, Akita, Japan

P787 **Bronchoalveolar Cell Counts in Severe Viral Pneumonia/**N.W. Lin, J.E. Reynolds, J. Krings, B. Trinh, R.D. Shah, R.G. Wunderink, Chicago, IL, p.A2064

P788 **Factors Associated with Death Among Patients Admitted to the Intensive Care Unit with Viral Pneumonia/**R.D. Shah, J.E. Reynolds, N.W. Lin, J. Krings, B. Trinh, R.G. Wunderink, Chicago, IL, p.A2065

P789 **Concordance Between Rhinovirus Found in Exhaled Breath and Bronchoalveolar Lavage Fluid/**A. Mitchell, H. Lam, M. Peters, L. Morgan, B.G. Oliver, Glebe, Australia, p.A2066

P790 **Detecting the Virulence of Rhinovirus: An Epidemiological Study in a Single Tertiary Institution/**P. Vishwasrao, R. Sagalla, L. Palmer, Stony Brook, NY, p.A2067

P791 **Clinical Epidemiology and Seasonality of Influenza-Associated Severe Acute Respiratory Illness in Uganda, 2010-2015/**M.J. Cummings, B. Bakamutumaho, J. Lutwama, J. Kayiwa, T. Byaruhanga, B. Namagambo, A. Wolf, J.F. Wamala, M. O'Donnell, New York, NY, p.A2068

P792 **Cluster Analysis and Spatial Dynamics of Influenza-Associated Acute Respiratory Infections in Uganda/**M.J. Cummings, B. Bakamutumaho, J. Lutwama, J. Kayiwa, T. Byaruhanga, B. Namagambo, A. Wolf, J.F. Wamala, M. O'Donnell, New York, NY, p.A2069

P793 **Incidence and Risk Factor of Pneumonia in Hospitalized Patients with Influenza A or B/**S.-T. Uh, S.J. Park, T.H. Kim, S.M. Koo, Y.K. Kim, K.U. Kim, Seoul, Korea, Republic of, p.A2070

P794 **Comparison of Disease Severity Between H1N1 and H3N2 Influenza A Viral Infection/**A.L. Figueredo Cacacho, E. Minchole Lapuente, D. Polanco Alonso, J.J. Vengoechea, L. Royo, S. Bello Dronda, C. Panadero Paz, Zaragoza, Spain, p.A2071

Facilitator: S.T. Qureshi, MD, Montreal, Canada

P795 **Safety and Efficacy of the Monoclonal Antibody VIS410 in a Human Volunteer Challenge Model of Infection with an H1N1 Influenza A Virus/**J.M. Trevejo, S. Sloan, K. Szetter, S. Bedard, C. Hay, Cambridge, MA, p.A2072

P796 **The Impact of Vaccination on Influenza Morbidity and Mortality in Hospitalized Elderly Patients Over the 2014-2015 Season/**K. Chatterjee, P. Mittadodla, M. Joshi, Little Rock, AR, p.A2073

P797 **Validation of International Classification of Diseases, Ninth Edition (ICD-9) Codes for Identification of Adult Patients with RSV Infection/**R.I. Asad, N.I. Martinez Schlurmann, A. Keene, H.B. Gershengorn, Bronx, NY, p.A2074

P798 **Monitoring Respiratory Syncytial Virus (RSV) Infections in Alberta, Canada During the 2014 - 2016 Seasons Using Whole Genome Sequencing, Descriptive Epidemiology and Virological Analysis Revealed the Transmission Dynamics and the Age Group Tropism of RSV /**D.J. Marchant, D. Zhu, L. Forss, B. Hazes, L. Bilawchuk, C. Griffiths, L. Jensen, S.J. Drews, Edmonton, Canada, p.A2075

P799 **Canadian Experience with Ribavirin Therapy in RSV Infected Patients and the Time to Negative PCR/**G. Wong, P. Patel, B. Kisic, P. Brown, Toronto, Canada, p.A2076

P800 **Invasive Pulmonary Aspergillosis in Non-Immunocompromised Patients: Clinical Features and Treatment/**Y.-L. Liu, Z. Wang, Beijing, China, p.A2077

P801 **The Distribution of Aspergillus Species Recovered in Thoracic Cultures of an International Community Population in New York City/**G. Patel, M. Farokhi, O. Epelbaum, Queens, NY, p.A2078

Facilitator: V.E. Brito, MD, Temple, TX

P802 **The Clinical Epidemiology of Pulmonary and Extrapulmonary Cryptococcal Infection in the International Hispanic Population of New York City/**G. Patel, M. Farokhi, O. Epelbaum, Queens, NY, p.A2079

P803 **Evaluation of Voriconazole Concentration in Patients with Chronic Pulmonary Aspergillosis/**J. Suzuki, H. Matsui, H. Nagai, M. Kawashima, N. Ohshima, K. Masuda, K. Ohta, Tokyo, Japan, p.A2080

P804 **The Effects of Corticosteroid on Acute Exacerbations of Chronic Pulmonary Aspergillosis/**J. Kanazawa, T. Saito, M. Taguchi, S. Nishima, N. Hida, K. Yazaki, K. Yoshida, K. Hyodo, K. Nemoto, Y. Miura, T. Takaku, S. Oh-ishi, K. Hayashihara, Naka-gun, Tokai-mura, Ibaraki-ken, Japan, p.A2081

P805 **Voriconazole Pharmacokinetics and Security in Critically Ill Elderly Patients with Fungal Infection/**H.-L. Zhu, H. Li, Shanghai, China, p.A2082

P806 **Frequency of Isolation of Candida from the Respiratory Tract in Immunocompromised Patients at the University of Michigan/**K. Pendleton, R.P. Dickson, D. Newton, G.B. Huffnagle, Ann Arbor, MI, p.A2083

P807 **Procalcitonin Levels in Different Presentations of Coccidioidomycosis/**C. Strawter, R. Chahal, K. Song, E. Oren, K. Knox, Tucson, AZ, p.A2084

P808 **False Positivity of Coccidioides Enzyme Immunoassay (EIA) for the Serologic Diagnosis of Coccidioidomycosis in Children/**S. Maw, F. Naeem, M.A. Tablizo, Fresno, CA, p.A2085

P809 **Clinical Outcomes of Blastomycosis at a Tertiary Care Center - a Retrospective Study/**S. Prueksaritanond, P. Jagtap, B.S. Pannu, R. Tedja, C. Thongprayoon, V.N. Iyer, Rochester, MN, p.A2086

THEMATIC POSTER SESSION

A62 CLINICAL ASPECTS OF CAP, HCAP, HAP, AND VAP

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area G, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: N.C. Dean, MD, Murray, UT

P811 **Burden of Ambulatory and Hospitalized Community-Acquired Pneumonia: A Population Based Study in Germany/**M. Kolditz, L. Mocke, G. Hoffken, J. Schmitt, Dresden, Germany, p.A2087

P812 **Predictors of Very Early Mortality Within 72 Hours After Hospitalization in Patients with Community-Acquired Pneumonia/**M. Kolditz, T.T. Bauer, T. Konig, G. Rohde, S. Ewig, Dresden, Germany, p.A2088

P813 **Global Burden of MRSA Pneumonia: An International Point-Prevalence Study/**L.F. Reyes, S. Aliberti, P. Faverio, M.I. Restrepo, San Antonio, TX, p.A2089

P814 **Clinical Impact of Methicillin-Resistant Staphylococcus Aureus on Bacterial Pneumonia: Comparison of the Results of Cultivation and the Molecular Method of 16S Ribosomal RNA Gene Analysis Using Bronchoalveolar Lavage Fluid/**T. Kawanami, K. Yatera, K. Yamasaki, S. Noguchi, K. Fukuda, K. Akata, K. Naito, T. Kido, H. Ishimoto, H. Taniguchi, H. Mukae, Kitakyusu, Japan, p.A2090

P815 **Dynamics of Carriage of Streptococcus Pneumoniae in Adults Living in Portugal: A Longitudinal Study/**F. Froes, S. Almeida, C. Valente, A.C. Paulo, H. De Lencastre, R. Sa-Leao, Lisboa, Portugal, p.A2091

P816 **Characterizing Secondary Pneumococcal Superinfection Following Seasonal Influenza Virus -Clinical and Radiologic Features Distinguished from the Primary Pneumococcal Pneumonia-/**K. Ota, K. Yamamoto, N. Iwanaga, Y. Nagayoshi, K. Yamasaki, T. Miyazaki, H. Mukae, K. Yanagihara, K. Ashizawa, S. Kohno, Nagasaki City, Japan, p.A2092

P817 **Streptococcus Pneumoniae Infection Is an Independent Cause of Cardiac Rhythm Alteration in Community-Acquired Pneumonia/**F. Sanz Herrero, M.I. Restrepo, E. Fernandez-Fabrellas, E. Chiner, M.L. Briones, M.C. Aguar, R. Lera, A. Cervera, J. Blanquer, Valencia, Spain, p.A2093

Facilitator: J.D. Chalmers, MBChB, PhD, Dundee, United Kingdom

P818 **Cardiac Complications in Adult Patients with Community-Acquired Pneumonia and Diabetes Mellitus/**M.S. Bader, Y. Yi, K. Abouchehade, L. Bishop, B. Haroon, J. Hawboldt, Hamilton, Canada, p.A2094

P819 **Biomarkers as Predictors of Early and Long-Term Cardiovascular Events in Community-Acquired Pneumonia. Preliminary Results/**R. Mendez, I. Aldas, I. Amara, A. Gimeno, T. Posadas, S. Reyes, M. Suescun, R. Alonso, R. Menendez, Valencia, Spain, p.A2095

P820 **Atypical Bacterial Implicated in Community-Acquired Pneumonia and Patient Management/**E.J. Soto Hurtado, M.J. Gutierrez Fernandez, J. Castro Rodriguez, J.M. Gonzalez-Miret, L. Garcia Aranguena, A. Ruiz Cantero, Ronda, Spain, p.A2096

P821 **Relationship Clinical and Radiological Findings Between Child and Adult Patients with Mycoplasma Pneumoniae Pneumonia Using Scoring System on Chest X-Ray/**T. Watanabe, T. Saraya, Y. Tsukahara, K. Ohkuma, D. Kurai, H. Ishii, H. Takizawa, Mitaka, Japan, p.A2097

P822 **The Characteristic Findings of Mycoplasma Pneumoniae Pneumonia on High-Resolution CT: The Significance of the Areas Served by Lateral Bronchus and Less Air-Bronchogram in Infiltrates/**M. Nakanishi, H. Fujiwara, T. Kabayashi, S. Tani, T. Yagi, K. Yamaki, Ichinomiya City, Japan, p.A2098

P823 **Utility of Multiplex PCR to Diagnose Atypical Pneumonia Due to Legionella Pneumophila and Mycoplasma Pneumoniae in the Clinical Setting/**T. Kinjo, A. Uehara, G. Parrott, D. Nabeya, N. Ikemiyagi, S. Haranaga, M. Tateyama, J. Fujita, Okinawa, Japan, p.A2099

P824 **Legionella Pneumonia: Five Years' Experience in an Inner-City Hospital in New York City. Comparison Between Sporadic and Outbreak Cases/**H.R.T. Hashmi, G. Diaz-Fuentes, S. Lakshmi, F. Peteresen-Fitzpatrick, M. Khaja, Bronx, NY, p.A2100

Facilitator: M. Prickett, MD, MPH, Chicago, IL

P825 **A Case Series of Legionnaires' Disease Outbreak in the Bronx, NY in 2015/**J.-T. Chen, R.I. Asad, H.B. Gershengorn, Bronx, NY, p.A2101

P826 **Clinical Disease Severity Scores and a Legionella Outbreak in the Bronx, NY: An Institutional Experience/**G. Harris, M. Langston, V. Reddy, C. Coyle, New York, NY, p.A2102

P827 **Legionnaire's Disease in Eight Potentially Epidemiologically-Linked Patients During Two Recent New York City Outbreaks: Case Reports and Literature Review/**S. Fahme, M. O'Donnell, New York City, NY, p.A2103

P828 **Variation in Detection and Coverage of Resistant Pathogens in Hospitalized Veterans with Pneumonia at 128 Medical Centers/**B.E. Jones, K.A. Brown, M.M. Jones, B. Huttner, T. Greene, B. Sauer, K. Madaras-Kelly, M. Rubin, M.B. Goetz, M. Samore, Salt Lake City, UT, p.A2104

P829 **Anaerobic Bacteria Dominate the Airway Microbiome of Patients with Acute Lung Injury Following Burn and Inhalation Injury/**D.M. Walsh, S.D. McCullough, S. Yourstone, J.J. Kahle, S.W. Jones, C.D. Jones, I. Jaspers, D. Diaz-Sanchez, Chapel Hill, NC, p.A2105

P830 **Neutrophil Extracellular Traps Are Associated with Disease Severity in Chronic Obstructive Pulmonary Disease/**C. Fong, A.J. Dicker, M. Crichton, G. Suarez-Cuartin, O. Sibila, S. Schembri, S. Marshall, C.N.A. Palmer, J.D. Chalmers, Dundee, United Kingdom, p.A2106

P831 **Relation Between Biomarkers on Admission, Radiologic Abnormalities and Risk Score in Patients with Community Acquired Pneumonia (CAP)/**R. Duijkers, W.G. Boersma, Alkmaar, Netherlands, p.A2107

Facilitator: M.I. Restrepo, MD, MSc, San Antonio, TX

P832 **Diagnostic and Prognostic Utility of Procalcitonin in Patients Presenting to the Emergency Department with Dyspnea/** G.A. Alba, Q.A. Truong, H.K. Gaggin, P.U. Gandhi, B. De Berardinis, L. Magrini, E.K. Bajwa, S. Di Somma, J.L. Januzzi, Boston, MA, p.A2108

P833 **A Retrospective Study Comparing Procalcitonin with Physiological Severity Score in Community Acquired Pneumonia in a Middle Eastern Tertiary Centre/**J.A. Palaki, A.M. Maliyakkal, L. Ahmed, M. Ganeshdas, N.M. Shaath, Al Wakra, Qatar, p.A2109

P834 **Impact and Safety of a Procalcitonin-Based Algorithm on Antibiotic Use in Hospitalized Patients with Lower Respiratory Tract Infections/**G. Soucy, E. Roy Richard,, G. Soucy, J.-P. Lafrance, K. Chagnon, R. Robitaille, K. Weiss, Quebec, Canada, p.A2110

P835 **Is Neutrophil to Lymphocyte Ratio Useful Prognostic Marker for Patients with Community Acquired Pneumonia/**C. Son, Busan, Korea, Republic of, p.A2111

P836 **Streamlining Antibacterial Drug Development Programs to Address Unmet Medical Need: Patient and Provider Attitudes on a Modified Benefit-Risk Calculus/**T. Holland, S. Mikita, A. Corneli, J. Roberts, J. McCall, D. Collyar, J. Santiago, R. Tiernan, Durham, NC, p.A2112

P837 **Influence of Flexible Bronchoscopy on Antibiotic Selection in the Inpatient Setting/**E.E. O'Shea, M. Davis, S. Davis, Worcester, MA, p.A2113

P838 **Beta-Lactam Plus Macrolides or Beta-Lactam Alone for Community-Acquired Pneumonia: Systematic Review and Meta-Analysis/**N. Horita, A. Narita, M. Ikeda, K. Nakashima, R. Ushio, H. Watanabe, K. Nagai, Y. Shibata, K. Tashiro, H. Nagakura, T. Tsukahara, M. Yamamoto, T. Sato, T. Kaneko, Yokohama, Japan, p.A2114

Facilitator: J.A. Ramirez, MD, Louisville, KY

P839 **Respiratory Fluoroquinolones Versus β-Lactams for Non-Intensive Care Unit Hospitalized Community-Acquired Pneumonia Patients: A Pooled Analysis/**S. Liu, X. Tong, H. Fan, Chengdu, China, p.A2115

P840 **SOLITAIRE-IV: Results of a Phase 3 IV to Oral Trial in Adults with Community-Acquired Bacterial Pneumonia Comparing Solithromycin to Moxifloxacin/**T.M. File, Jr., B. Rewerska, C.M. Tanaseanu, V. Mihailovic-Vucinic, J.R. Gonong, B.D. Jamieson, D. Taylor, A. Sheets, K. Keedy, D.W. Oldach, P. Fernandes, Akron, OH, p.A2116

P841 **Ceftaroline Activity Against MDR Streptococcus Pneumoniae Subsets from United States Medical Centers (2014)/**D.J. Farrell, R.E. Mendes, R.K. Flamm, H.S. Sader, R.N. Jones, North Liberty, IA, p.A2117

P842 **Clinical Efficacy and Safety of High-Dose Doripenem in Japanese Patients with Pneumonia/**K. Naito, K. Yatera, S. Noguchi, K. Akata, K. Yamasaki, T. Kawanami, T. Kido, H. Ishimoto, H. Mukae, Kitakyusu, Japan, p.A2118

P843 **An Exploration of De-Escalation Strategies in Hospitalized Patients with Community Acquired Pneumonia/**F. Papik, G. Nair, P.R. Yeturu, M.J. Fazzari, D. Kurbanov, M.S. Niederman, Mineola, NY, p.A2119

P844 **Current Management and Associated Risks of Pediatric Patients Diagnosed with Community-Acquired Pneumonia (CAP) in Mongolia/**G. Dorj, Ulaanbaatar, Mongolia, p.A2120

P845 **Social Factors on Hospitalization Period of Elderly Patients with Pneumonia in Japan/**Y. Fuseya, Y. Yamamoto, T. Takahashi, D. Naito, K. Shima, K. Takahashi, N. Sakai, Otsu, Shiga, Japan, p.A2121

Facilitator: R.G. Wunderink, MD, Chicago, IL

P846 **Risk Factors to Early Mortality Among Dead Patients by Pneumonia Coming from Community/**A. Ceccato, M. Toranzo, M. Galperin, L. Cristaldo, G. Yusti, A. Gonzalez, A. Monteverde, Palomar, Argentina, p.A2122

P847 **Modelling Symptomatic Recovery from Community Acquired Pneumonia Reveals the Association of Age and Smoking with Extent of Recovery/**D. Wootton, L. Keogan, S. Gordon, O. Eneje, J. Court, L. Macfarlane, S. Wilks, M. Woodhead, P. Diggle, Liverpool, United Kingdom, p.A2123

P848 **Factors for the Long-Term Survival of Patients with Pneumonia After Completing Acute Phase Treatment in a Super-Aged Society; Retrospective Cohort Study in an Acute-Care Hospital in Japan/**K. Sato, S. Okada, A. Sugawara, Z. Watanuki, N. Tode, K. Suzuki, M. Ichinose, Sendai, Japan, p.A2124

P849 **Early Readmission and Related Costs for Pneumonia: The Trade-Off Between the Rehospitalization and the Quality of Assistance Marginal Costs. Evidence from an Italian Regional Hospital Discharge Registry/**A. Rossi Zadra, C. Di Novi, Torino, Italy, p.A2125

P850 **Pneumonia Readmission Risk Prediction Models: A Systematic Review of Model Performance/**M.A. Weinreich, O.K. Nguyen, D. Wang, H.G. Mayo, E.M. Mortensen, E.A. Halm, A.N. Makam, Dallas, TX, p.A2126

P851 **Auditing the Effectiveness of a Novel Virtual Pneumonia Follow-Up Clinic/**J.V. Krishnan, C. Duffus, B.G. Marshall, Southampton, United Kingdom, p.A2127

P852 **Bronchoscopy in Immunosuppressed Patients: Determinants of Yield and Impact on Medical Management/**D. Lachant, H. Mcgrane-Minton, N. Kumar, P. Prasad, R.M. Kottmann, Rochester, NY, p.A2128

Facilitator: E. Polverino, MD, PhD, Barcelona, Spain

P853 **Bronchoalveolar Lavage Among Hematopoietic Stem Cell Transplant Recipients: Diagnostic Yield and Change in Management/**I. Habtes, P. Shah, B. Harris, D. Stover, M. Feinstein, New York, NY, p.A2129

P854 **An Analysis of 58 Cases of Community-Acquired Lung Abscess Whose Pathogen was Microbiologically Confirmed by Transthoracic Needle Aspiration/**R. Kagami, T. Kawamura, Y. Onishi, Y. Mochizuki, Y. Nakahara, S. Sasaki, Himeji, Japan, p.A2130

P855 **Factors Associated with Positive Ratio of Pleural Effusion Culture in Empyema and Complicated Parapneumonic Effusion at Our Hospital/**H. Makino, T. Kato, M. Kohno, K. Kajiwara, K. Itou, N. Hamaguchi, T. Kanematsu, H. Yokoyama, Matsuyama, Japan, p.A2131

P856 **Clinical Characteristics of Community-Acquired Pneumonia in the Patients with Pulmonary Fibrosis/**T. Tateishi, T. Fujie, Y. Miyazaki, N. Inase, Tokyo, Japan, p.A2132

P857 **An Analysis of Hospital Acquired Infection Focused on Hospital Acquired Pneumonia Based on a One Year Surveillance for All Hospitalized Patients in a Japanese Community Hospital/**H. Nakamura, T. Inoue, K. Tanimoto, K. Yokota, Kagawa, Japan, p.A2133

P858 **Empiric Antibiotic Treatment for Ventilator-Associated Pneumonia/**L. Arthur, L. Seoane, R. Kizor, M. Van Driel, New Orleans, LA, p.A2134

P859 **Clinical Efficacy and Safety of Telavancin in Hospital-Acquired and Ventilator-Associated Pneumonia (HAP/VAP) Patients with Monomicrobial S. aureus Infection/**M.S. Niederman, P.S. Lee, S.L. Barriere, C. Sherman, J.B. Bruss, New York, NY, p.A2135

Facilitator: M. Kolditz, MD, Dresden, Germany

P860 **A Prospective, Randomized, Controlled Trial to Evaluate the Safety and Efficacy of Nebulized Amikacin as Adjunctive Therapy in Hospital Acquired and Ventilator Associated Pneumonia in Surgical ICUs/**N.A.E.K. Hassan, F.F. Awadallah, N.A. Sabry, Giza, Egypt, p.A2136

P861 **Clinical Features and Outcomes of Patients with Hospital Acquired Pneumonia in a 12-Month Service Evaluation Project of a UK Cohort/**C. Morris, E. McCance, S. Sushanth Vayalapra, T. Cuthbert, A.M. Turner, D. Dosanjh, Birmingham, United Kingdom, p.A2137

P862 **Factors Associated with Increased Mortality in Patients Identified by Healthcare-Associated Pneumonia Criteria/**B.J. Webb, J. Sorensen, N.C. Dean, Murray, UT, p.A2138

P863 **Azithromycin is Associated with Improved Survival in Patients with Healthcare-Associated Pneumonia/**E.M. Mortensen, M.L. Metersky, C.R. Frei, R.T. Attridge, A. Anzueto, Dallas, TX, p.A2139

THEMATIC POSTER SESSION

A63 PEDIATRIC ASTHMA: PREDICTORS AND OUTCOMES

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area J, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: M. Kattan, MD, New York, NY

P1049 **Maternal-Infant Bonding Disruption and the Development of Childhood Respiratory Symptoms/**R.D. Anbar, P.T. Skummer, A.D. Madrid, La Jolla, CA, p.A2140

P1050 **Maternal Depressive Symptoms, Maternal Asthma, and Childhood Asthma in Puerto Ricans/**B. Medsker, E. Forno, Y.Y. Han, E. Acosta-Perez, G. Canino, J.C. Celedon, Pittsburgh, PA, p.A2154

P1051 **Does Maternal Stress Influence the Development of Asthma in Childhood?/**D.K. Radhakrishnan, S. Shariff, L. Richard, T. To, Ottawa, Canada, p.A2158

P1052 **Protective Effect of Exclusive Breastfeeding on Frequent Cough in Adulthood/**A.L. Wright, D.A. Stern, S. Guerra, K.D. Gerhart, W.J. Morgan, F.D. Martinez, Tucson, AZ, p.A2165

P1053 **Maternal Serum Ditamin D Levels =75nmol/L During Pregnancy Are Associated with Fewer Adverse Respiratory Outcomes in Infants at 12 Months of Age/**M.E. Jensen, C.A. Camargo, P.G. Gibson, J. Mattes, V.E. Murphy, New Lambton Heights, Australia, p.A2172

Facilitator: E. Forno, MD, MPH, Pittsburgh, PA

P1054 **Prevalence of Allergies, Asthma Severity, and Asthma Control in Inner-City Asthmatic Children and Adolescents/**S.Q. Ahmad, P. Lee, A. Mandrov, E. Manilich, H. Lee, Brooklyn, NY, p.A2142

P1055 **Relationship Between Health Literacy and Numeracy of Parents and Asthma Control in Their Children/**S. Krishnan, A. Rohman, A.J. Dozor, Valhalla, NY, p.A2149

P1056 **The Effects of Early Life Exposure to Air Pollution on Asthma Risk Differs by Level of Perceived Discrimination in African American Youth/**J. An, N. Thakur, C. Eng, E. Emerita Brigino-Buenaventura, A. Davis, K. Meade, M. LeNoir, H.J. Farber, S. Thyne, S. Sen, J.R. Balmes, L. Borrell, E.G. Burchard, Berkeley, CA, p.A2166

P1057 **Identifying Barriers to Care and Health/Treatment Beliefs Facilitates a Better Understanding of Uncontrolled, Severe Asthma in the Pediatric Patient/**L. Kertz, K. Rivera-Spoljaric, St. Louis, MO, p.A2167

Facilitator: S. Lovinsky-Desir, MD, New York, NY

P1058 **Factors Predicting Asthma Evolution in Wheezing Children/**S. Baraldo, G. Turato, M. Bonato, D. Snjiders, E. Bazzan, C. Rigobello, M.E. Tine, K. Lokar-Oliani, M.G. Cosio, A. Barbato, M. Saetta, Padova, Italy, p.A2141

P1059 **Bronchiolitis: 5 Years Follow-Up with Skin Prick Test and Spirometry/**A. Frassanito, R. Nenna, L. Petrarca, G. Cangiano, L. Lo Russo, F. Scalercio, F. Mileto, C. Scagnolari, A. Pierangeli, C. Moretti, F. Midulla, Rome, Italy, p.A2144

P1060 **Meta-Analysis of Obesity and Lung Function/**E. Forno, Y.Y. Han, J. Mullen, J.C. Celedon, Pittsburgh, PA, p.A2153

P1061 **Race, BMI, and Asthma Control in an Equal Access to Care Population/**M.L. Frye, C.R. Esther, C. Loughlin, L. Vanscoy, Chapel Hill, NC, p.A2155

P1062 **Early Child Care Exposure and Wheezing: A Meta-Analysis/**A. Swartz, M.D. Cabana, San Francisco, CA, p.A2161

Facilitator: M.N. Eakin, PhD, Baltimore, MD

P1063 **Time-Motion Study of Health Assistant Activities in Tucson Unified School District Elementary Schools/**N. Patel, J. Van Buren, A.A. Lowe, A.G. Pongratz, M. Moore, N. Stefan, D. Johnson, L.B. Gerald, J.K. Gerald, Tucson, AZ, p.A2147

P1064 **Missing the Mark: Schools Underestimate Asthma Prevalence/**A. Volerman, S. Ignoffo, M. Vela, V.G. Press, Chicago, IL, p.A2160

P1065 **Suboptimal Asthma Control and Asthma Medication Adherence in UK Secondary School Children/**K. Harris, G. Mosler, S. Williams, J. Grigg, London, United Kingdom, p.A2162

P1066 **Evaluating Asthma Exacerbations After Participation in a School-Centered Asthma Program: The Step-Up Asthma Program/**D.R. Liptzin, M.C. Gleason, B. Wagner, S.J. Szefler, Aurora, CO, p.A2164

P1067 **Assessment of Pediatric Asthma Knowledge After the First Year of Residency Training/**S.Q. Ahmad, S. Agrawal, M. George, D. Weaver, Brooklyn, NY, p.A2143

P1068 **Guideline Defined Asthma Management: How Compliant Are General Practitioners/**W.O. Osarogiagbon, W.E. Sadoh, D. Osaghae, Benin City, Nigeria, p.A2170

Facilitator: S.K. Ramratnam, MD, MPH, Madison, WI

P1069 **Improving Asthma Care in a Pediatric Teaching Clinic/**J.S. Lee, A. Gogo, D. Tancredi, U. Shaikh, Sacramento, CA, p.A2145

P1070 **Asthma and Allergy Screening in a Sports Medicine Clinic/** R.C. Cohn, C. Driscoll, E. Koenig, L. Scott, Dayton, OH, p.A2146

P1071 **Effects of Lung Function Tests on Doctor's Decision in Modifying the Diagnosis and Outcome of Asthma/**J.H. Baek, M.Y. Han, Hwaseong, Korea, Republic of, p.A2148

P1072 **A Multidisciplinary Clinic for Difficult to Treat (DTT) Asthma Improves Asthma Control/**K.M. McDowell, T.W. Guilbert, L. Gu, C.M. Kercsmar, Cincinnati, OH, p.A2150

P1073 **Improving the Utilization of Spirometry in Pediatric Status Asthmaticus/**A. Winslow, A. O'Hagan, K. Caperell, Louisville, KY, p.A2163

P1074 **Continuous Quality Network (CQN) Pediatric Asthma/**C. Landon, T. Torices, Ventura, CA, p.A2171

Facilitator: S.O. Okelo, MD, PhD, Los Angeles, CA

P1075 **Prescribing Controller Therapy for Asthma Upon Discharge from a Pediatric Emergency Department: A Quality Improvement Initiative/**T. Liang, M. Kumar, C. Miller, D. Patel, A.J. Dozor, S. Krishnan, Valhalla, NY, p.A2151

P1076 **Asthma Management of Non-ICU Pediatric Patients Using a Multidisciplinary Stakeholder-Developed Protocol/**M.S. Jassal, S.C. Sadreameli, I. Pereira, S. Mann, C. Garger, L. Mercier, C.K. Lee, M. Vidunas, N. Stanley, J. Rohde, Baltimore, MD, p.A2152

P1077 **A Comparative Analysis of the Management of Paediatric Asthma in Community Pharmacy in the USA and Australia/** A. Elaro, M.R. Patel, S. Shah, C. Armour, K. Kraus, K.B. Farris, S. Bosnic-Anticevich, Glebe, Australia, p.A2156

P1078 **Pharmacists' Attitudes and Practices Around Pediatric Asthma Management in the USA/**A. Elaro, S. Bosnic-Anticevich, K. Kraus, K.B. Farris, S. Shah, C. Armour, M.R. Patel, Sydney, Australia, p.A2157

P1079 **Controller Therapy in Children with Asthma Presenting to the Pediatric Emergency Department/**M. Kumar, T. Liang, D. Patel, A.J. Dozor, S. Krishnan, Valhalla, NY, p.A2159

P1080 **Characteristics of Children Attending Emergency Care for Acute Asthma in the City of Esmeraldas, Ecuador/** C. Ardura-Garcia, P. Hurtado, E. Arias, C. Sandoval, J. Blakey, P.J. Cooper, Liverpool, United Kingdom, p.A2168

P1081 **Pediatric Asthma, Passive Smoking and Periodontal Diseases in Developing Countries: Exploring New Connections for Providing Multidisciplinary Asthma Care/**N.K. Bhatta, P.K. Singh, B. Koirala, R.R. Singh, Dharan, Nepal, p.A2169

THEMATIC POSTER SESSION

A64 TRANSLATIONAL RESEARCH IN PEDIATRIC ASTHMA

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area J, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: J.S. Debley, MD, MPH, Seattle, WA

P1083 **Urinary Prostanoids in Preschool Wheeze/**A. Whitehouse, C. Nwokoro, R. Brugha, M. Sanak, J. Grigg, London, United Kingdom, p.A2175

P1084 **The Increased Cholinergic Innervation Following Early Life Allergen Exposure Induces Persistent Airway Hyper-Reactivity and Remodeling/**K. Patel, Y. Bai, K. Trieu, X. Ai, Boston, MA, p.A2177

P1085 **The Role of Hyaluronan on Chronic Asthma: Expanded Target for Mesenchymal Stem Cells?/**B.D. Goldstein, M.E. Lauer, T.L. Bonfield, Cleveland, OH, p.A2182

P1086 **Airway Epithelial Cell Gene Expression Signatures Inform Level of Disease Control Among Children with Asthma/**D.-A. Shirley, K. Pollack, S. Williams, K. Wavell, L. Borish, J.W. Steinke, W.G. Teague, Charlottesville, VA, p.A2188

P1087 **Effect of a Purinergic P2Y6 Receptor Agonist on Airway Remodeling and Responsiveness in a Mouse Model of Asthma/**A. Chetty, A. Sharda, R. Warburton, T. Chen, C. Xue, J. Castellot, P.G. Haydon, H.C. Nielsen, Boston, MA, p.A2173

Facilitator: G.R. Nino, MD, Washington, DC

P1088 **Subepithelial Accumulation of Versican in a Cockroach Antigen Induced Murine Model of Allergic Asthma/**S.R. Reeves, A. Sheih, G. Kaber, J.S. Debley, M.J. Merrilees, C.W. Frevert, S.F. Ziegler, T.N. Wight, Seattle, WA, p.A2178

P1089 **A Clinically Relevant Laboratory Investigation Into Facemask-to-Face Seal, Simulating the Administering of Inhaled Medication Via a Valved Holding Chamber (VHC) with Facemask (FM) to an Infant Face Model/**J. Suggett, M. Nagel, C. Doyle, V. Wang, D. Coppolo, J.P. Mitchell, London, Canada, p.A2181

P1090 **Are Inflammation, Oxidative Stress and Epithelial Permeability Markers During Acute Bronchiolitis Associated with Recurrent Wheezing in Children?/**O. Yilmaz, Y. Yigit, Y. Simsek, E. Toprak, E. Onur, A. Oran, H. Yuksel, Manisa, Turkey, p.A2180

P1091 **Plasma Cathelicidin and Vitamin D Changes in Relation to Respiratory Viruses in Children Presenting with Acute Wheeze/**S. Oo, K. Franks, S.-K. Khoo, D. Cox, G. Chidlow, L. Weeke, F. Prastanti, J.E. Everard, Y. Bochkov, M. Borland, S. Gorman, M. Clarke, J.E. Gern, J. Goldblatt, I.A. Laing, D. Smith, J. Bizzintino, P. Le Souef, Subiaco, Australia, p.A2183

P1092 **IFITM3 Variants Were Associated with Rhinovirus (RV) Species A Infection and Recurrent Hospital Visits in Children with Acute Lower Respiratory Illness/**L.M. Harris, S.-K. Khoo, K.M. Franks, F. Prastanti, S. Oo, J.E. Everard, J. Bizzintino, J. Goldblatt, P.N. Le Souef, I.A. Laing, Subiaco, Australia, p.A2184

P1093 **Vertical Transmission of Respiratory Syncytial Virus to Fetuses in Utero Conveys Elevated Nerve Growth Factor Expression and Airway Hyperreactivity Upon Repetitive Post-Natal RSV Re-Challenge Infections/**P.M. Brown, T.J. Harford, A. Belkadi, V. Agrawal, F. Rezaee, G. Piedimonte, Cleveland, OH, p.A2186

Facilitator: D.J. Lee, MD, Hacksensack, NJ

P1094 **Leukocytes in Expressed Breastmilk of Asthmatic Mothers Differ in Both Proportion and Activation State/**D.-L. Dixon, K. Forsyth, Bedford Park, Australia, p.A2174

P1095 **Pubertal Changes Associated with Estrogen and Not Androgens Are More Strongly Associated with Lower Lung Function and Fixed Airflow Obstruction: A Cross-Sectional Analysis of Children and Adolescents in SARP III/**B. Gaston, R.E. Myers, B. Phillips, D. Mauger, L.B. Bacharier, K. Ross, J.F. Chmiel, N. Marozkina, A.M. Fitzpatrick, E. Bleecker, M. Castro, J.V. Fahy, N. Ly, N.N. Jarjour, S. Ramratnam, J.G. Zein, A.-M. Irani, B.D. Levy, W. Phipatanakul, F. Holguin, S. Aujla, S.E. Wenzel, S.C. Erzurum, W.G. Teague, M.D. DeBoer, Cleveland, OH, p.A2176

P1096 **Sphingolipid Synthesis and Composition are Altered in Children with Asthma/**J.G. Ono, T. Worgall, S. Worgall, New York, NY, p.A2179

P1097 **IL-6 Deficiency Protects Offspring of Obese Dams Against Bronchial Smooth Muscle Hypertrophy and Asthma-Like Lung Disease/**K. Dinger, P. Kasper, C. Vohlen, E. Rother-Hucklenbruch, R. Janoschek, I. Bae-Gartz, J. Doetsch, M.A. Alejandre Alcazar, Cologne, Germany, p.A2185

P1098 **An 8 Week Exercise Training Reduces Glucocorticoid Receptor Expression on Circulating Leukocyte in Healthy and Asthmatic Adolescents/**K.D. Lu, D. Cooper, F. Haddad, F. Zaldivar, S. Radom-Aizik, Irvine, CA, p.A2187

THEMATIC POSTER SESSION

A65 NICU, PICU AND CHRONIC VENTILATION

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area J, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: C.L. Carroll, MD, Hartford, CT

P1100 **Phasic Alteration in High Frequency Flow Acceleration by Removal of the Active Exhalation Phase/**M.R. Goldstein, M. Patel, B. Harding, T.A. Merritt, C. Tong, E. Fayard, R. Peverini, Loma Linda, CA, p.A2192

P1101 **Effect of Anti-Factor Xa and aPTT Levels on Mortality in Pediatric Extracorporeal Membrane Oxygenation/**A. Bourguet-Vincent, S. Hupp, S. Martin, C. Hornik, C. Ozment, Durham, NC, p.A2194

P1102 **Early Exogenous Surfactant Therapy in Pediatric Near Drowning May Decrease Acute Lung Injury/**J. Attebery, K. Remy, St. Louis, MO, p.A2198

P1103 **Provider Attitudes and Opinions on Enteral Nutrition for Critically Ill Infants and Children on Non-Invasive Positive Pressure Ventilation/**M.K. Leroue, R. Good, H.E. Skillman, A.S. Czaja, Aurora, CO, p.A2200

P1104 **Aerosol Delivery in a Pediatric Model of Non-Invasive Ventilation/**J.M. Velasco, A. Berlinski, Little Rock, AR, p.A2201

P1105 **Performance of Pressure Control with Adaptive Targeting in Simulated Neonatal Ventilation/**V. Sanghi, K. Fedor, R.L. Chatburn, Cleveland, OH, p.A2204

Facilitator: G.F. Perez, MD, Washington, DC

P1106 **Flexible Bronchoscopy for Meconium Aspiration Syndrome on Extracorporeal Membrane Oxygenation (ECMO)/**J. Hong, T. Sweberg, A. Kessel, M. Zinger, K. Tsirilakis, New Hyde Park, NY, p.A2189

P1107 **Particle Size Characterization of Nebulized Albuterol Delivered by a Vibrating Mesh Nebulizer Through Pediatric Endotracheal Tubes/**A. Berlinski, S. Kumaran, Little Rock, AR, p.A2191

P1108 **Factors Associated with Hypoxaemia in High Risk Neonates at the Special Care Baby Unit of a Resource-Constraint Centre/**B.P. Kuti, D.K. Kuti, T. Ogundele, Ile-Ife, Nigeria, p.A2193

P1109 **Aerosol Therapy During Nasal High Flow Therapy in Infants and Toddlers: An In Vivo Study/**F. Reminiac, L. Vecellio, R. Mac Loughlin, D. Le Pennec, M. Cabrera, N. Heuze Vourc'h, J.B. Fink, S. Ehrmann, Tours, France, p.A2197

P1110 **Outcomes of Children Post Congenital Heart Surgery Who Were Discharged on Home Mechanical Ventilation Via Tracheostomy/**A.I. Cristea, B. Benneyworth, S. Davis, V. Ackerman, Indianapolis, IN, p.A2202

P1111 **Patterns of Home Ventilator Assistance In The Province Of Alberta, Canada: A Retrospective Population-Based Cohort Study/**E.J. MacIntyre, K. Rimmer, C. Cyr, D.A. McKim, J. MacLean, D. Littmann, M. Heule, A. Massia, L. Rose, S.M. Bagshaw, Edmonton, Canada, p.A2206

Facilitator: T.T. Karsies, MD, Columbus, OH

P1112 **Predicting the Effects of NIV Following Extubation in Infants/**A. Kamerkar, J. Hotz, R. Morzov, C.J. Newth, R.G. Khemani, Los Angeles, CA, p.A2190

P1113 **Association Between Serum Brain-Derived Neurotrophic Factor (BDNF) Levels at Birth and Neurodevelopmental Outcome at One Year of Age in the NICU Population/**S.L. Simpson, M. Alejandro-Rodriguez, C. LoPiccolo, S. Worley, A.S. Tang, G. Piedimonte, J.H. Peterson, Cleveland, OH, p.A2195

P1114 **Clinical Risk Factors and Outcomes After a Modified EGDT in Pediatric Septic Shock/**R. Samransamruajkit, T. Saetae, K. Pongsanon, L. Kongkietikul, S. Sritipayawan, J. Deerojanawong, Bangkok, Thailand, p.A2196

P1115 **A Novel Delivery System for Aerosolized Ribavirin During Invasive Mechanical Ventilation/**S.M. Hartmann, D. Foubare, D. Crotwell, O. Yanay, Seattle, WA, p.A2199

P1116 **Pediatric Tracheocutaneous Fistula Closure Following Tracheostomy Decannulation/**B.L. Wisniewski, E.L. Jensen, J.D. Prager, T.M. Wine, C.D. Baker, Atlanta, GA, p.A2203

P1117 **Nebulized Corticosteroid for Preventing Post-Extubation Stridor in Children: A Randomized, Double Blind Controlled Trial (Preliminary Study)/**P. Prasertsan, N. Anantasit, Bangkok, Thailand, p.A2205

THEMATIC POSTER SESSION

A66 PH: MOLECULES, CELLS AND ANIMAL MODELS

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area M, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: S.S. Pullamsetti, PhD, Bad Nauheim, Germany

P1393 **High Intensity Interval Training Is Superior to Continuous Training at Two Different Intensities and Reverses RV Remodeling and Dysfunction in a Rat Model of Pulmonary Hypertension/**M.B. Brown, E. Neves-Netes, G. Long, R. Novack, A.J. Fisher, R. Presson, I. Petrache, Indianapolis, IN, p.A2207

P1394 **In Patients with Pulmonary Arterial Hypertension, Pulmonary Artery Smooth Muscle Cell Hypoxia Inducible Factor-1α Expression and Activity Is Decreased/**E.A. Barnes, C. Chen, O. Sedan, D.N. Cornfield, Stanford, CA, p.A2208

P1395 **The Terminal Remodling Index (TRI): A Novel Biological Measurement Obtained Via Right Heart Catheterization that Differentiates PAH from Other Etiologies of PH/**M.J. Passineau, G. Lentz, C. Wu, S. Murali, R.L. Benza, Pittsburgh, PA, p.A2209

P1396 **Endothelial Cell Derived Factors Enhance Differentiation of Human Airway Basal Stem/Progenitor Cells into a Mucociliated Epithelium/**K. Gomi, R.G. Crystal, M.S. Walters, New York, NY, p.A2210

P1397 **Pharmacological Inhibition of mTOR Kinase Activity Reverses Sugen/Hypoxia-Induced Pulmonary Hypertension, Right Ventricular Hypertrophy, and Improves Heart Functional Parameters in Rats/**A. Kobir, A. Goda, A. Delgado-Montero, B. Tayal, R.R. Vanderpool, J. Baust, A. Pena, D.A. Goncharov, J. Gorcsan, E.A. Goncharova, Pittsburgh, PA, p.A2211

P1398 **Susceptibility to Develop Pulmonary Hypertension in SAD Mice: Effects of NO Donors/**S. Abid, K. Kebe, A. Houssaini, E. Marcos, E. Bizard, M. Breau, A. Parpaleix, F. Wan, C. Tissot, G. Gary-Bobo, B. Maitre, E. Bastia, A. Mekontso-Dessap, S. Adnot, Creteil, France, p.A2212

P1399 **Autocrine and Paracrine Nicotinamide Phosphoribosyltransferase (NAMPT) Activity Promote Proliferation of Human Pulmonary Artery Smooth Muscle Cells/**J. Chen, S. Singla, J.R. Sysol, S. Comhair, S. Ye, S.C. Erzurum, R.F. Machado, Chicago, IL, p.A2213

P1400 **Contribution of Vascular Smooth Muscle ROCK1 to SUGEN5416/Hypoxia-Induced Pulmonary Hypertension in Mice/**D. Toksoz, R. Warburton, S. Abualkhair, K.C. Penumatsa, I.R. Preston, U. Kayyali, N.S. Hill, B.L. Fanburg, Boston, MA, p.A2214

P1401 **Interplay Between IL-13 and Energy Metabolism in Pulmonary Hypertension/**W.-K. Cho, M.O. Kim, C.-M. Lee, J.A. Elias, C.G. Lee, S.I.S. Rounds, Providence, RI, p.A2215

P1402 **Osteopontin, a Key Mediator Expressed by Senescent Pulmonary Vascular Cells and Involved in Pulmonary Hypertension/**E. Marcos, M. Saker, L. Lipskaia, S. Abid, A. Parpaleix, A. Houssaini, P. Validire, H. Noureddine, L. Boyer, N. Vienney, C.J. Lesaux, B. Maitre, M. Delcroix, R. Quarck, S. Adnot, Creteil, France, p.A2216

Facilitator: R.L. Damico, MD, PhD, Baltimore, MD

P1403 **Abnormal Platelet Phenotype and Function in Pulmonary Arterial Hypertension/**D. Taboada, K. Downes, H. McKinney, J.A. Guerrero, M.W. Besser, W.N. Erber, K. Freson, N.W. Morrell, W.H. Ouwehand, J. Pepke-Zaba, Cambridge, United Kingdom, p.A2217

P1404 **Calpain-Mediated Increase in Sodium-Hydrogen Exchanger Activity Is Necessary for Pathologic Smooth Muscle Proliferation in Pulmonary Arterial Hypertension/**J. Huetsch, C. Larrain, L. Shimoda, Baltimore, MD, p.A2218

P1405 **Genome-Wide Association Study with Interactome-Based Scoring Identifies Dok4 and Ppp2ca as Novel Candidate Genes in High-Fat Diet-Induced Pulmonary Hypertension/**N. Kelly, J. Radder, J. Baust, C. Burton, B. Agostini, J. Wood, A. Gregory, A. Leme, S.D. Shapiro, Pittsburgh, PA, p.A2219

P1406 **A Novel, Inhaled Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension/**D.J. Rowlands, K. Coote, O. Bonneau, K. Choy, N. Duggan, M. Thomas, C. LeBlanc, S. Charlton, M. Healy, S. Grant, R. Strieter, Cambridge, MA, p.A2220

P1407 **Pulmonary Plexiform Arteriopathy in a Murine Model of Pulmonary Arterial Hypertension: Incidence and Histology/**C. Bardita, M. Patel, M. Pritchard, N. Jeganathan, D. Predescu, S.A. Predescu, Chicago, IL, p.A2221

P1408 **Krüppel-Like Factor 4 in Pulmonary Arterial Endothelial Cells Modulates Smooth Muscle Cell Phenotype/**M.A. Shatat, J. Peachey, A. Hamik, Cleveland, OH, p.A2222

P1409 **IL-18 Induces p38 MAP Kinase Activation and Adhesion Capacities in BMPR-II Impaired Pulmonary Microvascular Endothelial Cells/**L. Vengethasamy, R. Gijsbers, A. Michiels, B. Tielemans, A. Wagenaar, R. Farre Marti, C. Belge, M. Delcroix, R. Quarck, Leuven, Belgium, p.A2223

P1410 **A High Throughput Screening Platform Targeting PDLIM5 for Pulmonary Hypertension/**G. Zhou, H. Cheng, T. Chen, M. Tor, D. Park, J. Huang, N. Khati, Q. Zhou, L. Rong, Chicago, IL, p.A2224

P1411 **Altered Sugar Nucleotide Levels Facilitate Changes in Glycosylation in IPAH/**L. Tian, J.W. Barnes, J. Loftis, J.M. Hiznay, S.A.A. Comhair, M.E. Lauer, R. Dweik, Cleveland, OH, p.A2225

Facilitator: M.R. Nicolls, MD, Palo Alto, CA

P1412 **Alpha Globin Expressed by Pulmonary Artery Endothelial Cells Inhibits NO/sGC/cGMP Signaling in Response to Hypoxia/**R.A. Alvarez, M.P. Miller, S. Hahn, D.A. Goncharov, E.A. Goncharova, M.T. Gladwin, A. Straub, Pittsburgh, PA, p.A2226

P1413 **Mechanical Stretch Combines with Adventitial Fibroblast-Derived Signals to Promote Macrophage Activation Through Metabolic Reprogramming in Vascular Remodeling/**K. EL Kasmi, C. Myers, A. Flockton, S. Riddle, B.A. McKeon, M. Frid, K. Brodsky, H. Eltzschig, K.R. Stenmark, Aurora, CO, p.A2227

P1414 **Administration of Exosomes from Cardiosphere-Derived Cells in an Animal Model of Pulmonary Arterial Hypertension/**R.C. Middleton, M. Fournier, E. Marban, M.I. Lewis, Los Angeles, CA, p.A2228

P1415 **Identification of Candidate GPCRs in Pulmonary Arterial Hypertension: Role of Purinoceptor 2 (P2Y2) in Pulmonary Vascular Remodeling/**G. Viswanathan, X. Tian, S. Tunaru, P. Singh, W. Seeger, S. Offermanns, R.T. Schermuly, Giessen, Germany, p.A2229

P1416 **Oral CAR Peptide Adjuvant Enhances Sildenafil Therapy for Pulmonary Arterial Hypertension/**D. Mann, X. Yue, J. Sawada, M. Komatsu, Goleta, CA, p.A2230

P1417 **CAR Peptide Adjuvant Enables Effective Pulmonary Hypertension Treatment with Imatinib at Reduced Doses/**D. Mann, X. Yue, J. Sawada, N. Ambalavanan, M. Komatsu, Goleta, CA, p.A2231

P1418 **Composition and Structure of the Vascular Basement Membrane in Pulmonary Hypertension/**J. Hoffmann, B. Ghanim, W. Klepetko, G. Kovacs, H. Olschewski, A. Olschewski, G. Kwapiszewska, Graz, Austria, p.A2232

P1419 **Inhibition of L-Type Amino Acid Transporter 1 (LAT-1) Export of S-Nitrosothiols (SNO) Promotes Red Blood Cell Adhesion to Endothelial Cells/**L.B.M. Dosier, H. Zhu, T.J. McMahon, Durham, NC, p.A2233

P1420 **Mas Receptor Activation Increases SOD2 Expression in Pulmonary Vessels and Decreases Endothelial Dysfunction/**E.J. Carrier, A. Rathinasabapathy, S. Menon, M.R. Kaplowitz, C.D. Fike, J.D. West, Nashville, TN, p.A2234

Facilitator: S. Bonnet, PhD, Quebec City, Canada

P1421 **Serotonin Augments Proliferation of Neonatal Calf Pulmonary Artery Fibroblasts/**C.A. Delaney, A. Flockton, E. Nozik-Grayck, K.R. Stenmark, Aurora, CO, p.A2235

P1422 **Comparative Analysis of Global Gene Expression Profile in Mouse Strains After Hypoxic Challenge Either Susceptible to or Resistant to Chronic Hypoxia-Induced Pulmonary Hypertension/**W. Nichols, N. Dasgupta, P. Hale, T. Le Cras, P. Pastura, M. Pauciulo, Cincinnati, OH, p.A2236

P1423 **Kynurenine Causes Pulmonary Arterial Relaxation in Pulmonary Hypertension/**B.M. Nagy, C. Nagaraj, H. Mangge, A. Meinitzer, K. Leithner, G. Kwapiszewska, G. Kovacs, V. Foris, A. Olschewski, H. Olschewski, Graz, Austria, p.A2237

P1424 **Selectivity of the Selexipag Active Metabolite ACT-333679 for the IP Receptor Avoids DP1/EP2-Mediated Inhibition of Natural Killer Cell Responses in Vitro/**J. Gatfield, K. Menyhart, M. Tunis, R. Studer, G. Ferrari, O. Nayler, Allschwil, Switzerland, p.A2238

P1425 **Influence of IP Receptor Density on Agonist Activity of ACT-333679, the Active Metabolite of Selexipag/**J. Gatfield, K. Menyhart, O. Nayler, Allschwil, Switzerland, p.A2239

P1426 **BMP Signaling in Pulmonary Microvascular Endothelial Cells of Pulmonary Arterial Hypertension Patients/**N. Rol, K. Kurakula, R. Szulcek, C. Dickhoff, A. Vonk-Noordegraaf, M.-J. Goumans, H.J. Bogaard, Amsterdam, Netherlands, p.A2240

P1427 **Bone Morphogenetic Protein 9 (BMP9), a Vascular Quiescence Factor, Is Regulated by Inflammation and Neutrophil Activation/**W. Li, L. Long, K. Hoenderdos, P.D. Upton, X. Yang, A.M. Condliffe, E.R. Chilvers, N. Morrell, Cambridge, United Kingdom, p.A2241

P1428 **Ubiquitin Proteasome System Is Altered in Severe Pulmonary Hypertension and Right Ventricular Dysfunction/**S. Umar, S. Dewey, N. Motayagheni, N. Barakati, A. Gomes, M. Eghbali, Los Angeles, CA, p.A2242

P1429 **Transportation of Translationally Controlled Tumor Protein (TCTP) Via Exosomes Contributes to The Pathology of Pulmonary Arterial Hypertension/**E. Ferrer-Andres, B.J. Dunmore, M.L. Ormiston, S. Moore, J.R. Lavoie, D.J. Stewart, N.W. Morrell, Cambridge, United Kingdom, p.A2243

Facilitator: D.E. Green, MD, Atlanta, GA

P1430 **Modifier Mutations Associated with Hyper-Responsiveness to VEGFR2 Ihibition Resulting in Severe Pulmonary Arterial Hypertension in a Sub-Strain of Sprague-Dawley Rats/**K.R. Chaudhary, Y. Deng, A. Yang, X. Wen, E. Cuppen, D.J. Stewart, Ottawa, Canada, p.A2244

P1431 **O-GlcNAc Transferase Regulates Glucose Metabolism in Idiopathic Pulmonary Arterial Hypertension/**J.W. Barnes, L. Tian, S.A.A. Comhair, R. Dweik, Cleveland, OH, p.A2245

P1432 **NKX2-5 Is Associated with Pulmonary Arterial Hypertension/**A. Dritsoula, C. Fonseca, J. Martin, C. Denton, M. Ponticos, London, United Kingdom, p.A2246

P1433 **Activation of Anoctamin-1 Causes Apoptosis of Pulmonary Endothelial Cells Mediated Via p38/**A. Allawzi, A. Vang, N. Kue, G. Choudhary, Providence, RI, p.A2247

P1434 **Multiple Metabolic Pathways Are Involved in Hypoxia-Induced Proliferation of Pulmonary Artery Endothelial Cell/**M. Husain, N. Mariappan, I. Zafar, S. Ahmad, A. Ahmad, Birmingham, AL, p.A2248

P1435 **Altered Expression of Bone Morphogenetic Protein (BMP) Antagonists in Pulmonary Hypertension/**L. Li, S.C. Rowan, C. Keane, P. McLoughlin, Dublin, Ireland, p.A2249

P1436 **BMPR2 Deficiency Potentiates the LTB4 Mediated PAEC Transformation in PAH/**W. Tian, X. Jiang, J. Qian, A. Tu, E. Shuffle, P. Mesange, M. Nicolls, Palo Alto, CA, p.A2250

P1437 **PPAR Gamma Modulates PINK1 in Hypoxia-Exposed Human Pulmonary Artery Smooth Muscle Cells/**A. Chaudhry, T. Murphy, M. Hart, D.E. Green, Atlanta, GA, p.A2251

P1438 **Smooth Muscle-Specific Insulin-Like Growth Factor-1 Mediates Chronic Hypoxia-Induced Pulmonary Hypertension in Neonatal Mice/**M. Sun, R. Ramchandran, J. Chen, Q. Yang, J.U. Raj, Chicago, IL, p.A2252

THEMATIC POSTER SESSION

A67 CASE REPORTS IN PULMONARY VASCULAR DISEASE

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area M, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: W.H. Fares, MD, MSc, New Haven, CT

P1440 **A Case of Inflammatory Pseudotumor Presenting as Chronic Thromboembolic Disease: A Rare and Controversial Entity/**C.M. Bojanowski, E.S. Yi, H.-Y. Wang, G.V. Pretorius, W.R. Auger, G.Y. Lin, La Jolla, CA, p.A2253

P1441 **Prominent Bronchial Artery Contributing to Pulmonary Hypertension in a Patient with Hereditary Hemorrhagic Telangiectasia/**N. Li, H. Poor, New York, NY, p.A2254

P1442 **A Case Report of Pulmonary Tumor Emboli Leading to the Diagnosis of Underlying Squamous Cell Cancer: The Role of Thromboendartectomy/**J.N. McNeill, R. Channick, Boston, MA, p.A2255

P1443 **A Rare Cause of Extensive Deep Vein Thrombosis: Agenesis of Infrarenal Inferior Vena Cava/**K.S. Foong, A. Lee, S. Kudakachira, J. Brandfass, C. Fay, S. Sajja, Upland, PA, p.A2256

P1444 **A Ballooning Problem/**A. Law, B. Murphy, B.L. LeVarge, Boston, MA, p.A2257

P1445 **Severe Pulmonary Hypertension with Unexpected Autopsy Finding in a 70 Years Old Man/**A. Ali, Y.A. Al Ahwel, A. Milad, S.U. Rehman, M. Taleb, R. Assaly, Toledo, OH, p.A2258

P1446 **Unusual Clinical Presentation for Swyer-James-Macleod Syndrome/**A. Ali, Y.A. Al Ahwel, A. Milad, S.U. Rehman, M. Taleb, R. Assaly, Toledo, OH, p.A2259

P1447 **Worsening Hepatopulmonary Syndrome (HPS) After Liver Transplant Successfully Treated with Inhaled Treprostinil/**S. Libricz, K. Swanson, A. Krstic, K. Yaqub, M.J. Krowka, R. Cartin-Ceba, Scottsdale, AZ, p.A2260

P1448 **Pulmonary Arterial Hypertension (PAH) Associated with Interferon ß1B: A Case Report/**R. Papani, A. Duarte, Galveston, TX, p.A2261

P1449 **Embolic Temblor: A Case of Rapidly Progressive RV Failure in a Patient with Severe Pulmonary Hypertension and Metastatic Cancer/**E. Mou, D. Lazzareschi, D. Blayney, A. Connolly, A. Rogers, Palo Alto, CA, p.A2262

P1450 **Diffuse Alveolar Hemorrhage Due to Intravascular Large B Cell Lymphoma: The Great Imitator/**A. Somoracki, L. Cagino, R. Helton, A. Ataya, H. Alnuaimat, Gainesville, FL, p.A2263

P1451 **Atypical Plastic Bronchitis Two Decades After Tetralogy of Fallot Repair/**J.M. Radbel, J. Sunderram, New Brunswick, NJ, p.A2264

P1452 **Successful Management of Massive Pulmonary Tumor Embolism/**S. Ayub, M.T. Shakoor, T. Bartter, Little Rock, AR, p.A2265

P1453 **Airway and Pulmonary Effects of A Giant Left Atrium/**K.C. Poh, A.A. Hsu, Singapore, Singapore, p.A2266

P1454 **A 45-Year-Old Woman with Neurofibromatosis Type-1-Associated Pulmonary Arterial Hypertension Responsive to Epoprostenol/**M.L. Gibbs, J.L. Garland, Jacksonville, FL, p.A2267

P1455 **Management of Pulmonary Hypertension in In-Vitro Fertilization Twin Pregnancy/**T.J.T. Aldan, B. Matsuda, G.P. Devendra, Honolulu, HI, p.A2268

Facilitator: M.J. Cuttica, MD, Chicago, IL

P1456 **Pulmonary Hypertension Diagnosed 20 Years After Onset of Castleman's Disease in a 58 Year Old Female/**B.A. Kelly, M. Mendez, R. Awdish, Detroit, MI, p.A2269

P1457 **An Unusual Case of Severe Pulmonary Hypertension Due to Pulmonary Amyloidosis Along with Cardiac Amyloidosis Presenting with Atypical Features in the Same Patient/**S. Afreen, F.T. Ogundipe, F. Khan, S. Sawhney, J. Arhinful, Y. Habtegebriel, A. Thomas, P. Mehrotra, V. Poddar, Washington, DC, p.A2270

P1458 **Intimal Sarcoma of the Pulmonary Artery Presented as Pulmonary Embolism/**C. Villaquiran-Torres, D.L. Rey, Bogota, Colombia, p.A2271

P1459 **Pulmonary Artery Obstruction Secondary to a Primary Mediastinal Ewing's Sarcoma/Primitive Neuroectodermal Tumor (ES/PNET)/**C. Villaquiran-Torres, J.E. Cita, A. Canas-Arboleda, Bogota, Colombia, p.A2272

P1460 **Two Rare Conditions Linked by an Activin Receptor-Like Kinase 1 (ALK-1) Mutation/**A. McCambridge, R. Cartin-Ceba, Rochester, MN, p.A2273

P1461 **Pulmonary Arterial Hypertension (PAH) Masked by Coexisting Respiratory Bronchiolitis Interstitial Lung Disease (RB-ILD), Diagnosed Histologically/**M. Mahmoud, S. Hegab, M. Mendez, C. Stone, R. Awdish, Detroit, MI, p.A2274

P1462 **An Unusual Cause of Pulmonary Hypertension and Cor Pulmonale/**C. Liu, T. Brown, R. Tangel, R. Sharma, New Brunswick, NJ, p.A2275

P1463 **Scimitar Syndrome Presenting with Pulmonary Emboli and Right Heart Failure Requiring ECMO/**P.J. Simpson, G. Are, R.A. Lopez, Jamaica, NY, p.A2276

P1464 **A Case of Behcet's Disease Presenting with Right Atrial Thrombus and Pulmonary Embolism/**Y. Yang, K. Xu, Beijing, China, p.A2277

P1465 **Pulmonary Hypertension Due to Pulmonary Tumor Embolism Syndrome Successfully Treated with Pulmonary Vasodilator Therapy as a Bridge to Chemotherapy/**M. Bender, S.S. Kim, O. Friedman, New York, NY, p.A2278

P1466 **A Case of a Runaway Wire/**L. Sargsyan, S. Sahay, B. Patel, Houston, TX, p.A2279

P1467 **Radiation Induced Pulmonary Artery Stenosis. Use of SPECT CT Perfusion Scan for Accurate Diagnosis/**M. Rudrappa, K. Trivedi, S.R.K. Marri, L. Kokatnur, Shreveport, LA, p.A2280

P1468 **Pulmonary Embolism; Idiopathic or from Very Rare Etiology?/**Y. Im, J. Kopita, Dallas, TX, p.A2281

P1469 **Resolution of Severe Pulmonary Hypertension and Right Ventricular Failure in a Patient with Antiphospholipid Antibody Syndrome and Suspected Chronic Thromboembolic Pulmonary Hypertension/**B.T. Bevill, R.G. Argula, C.B. Strange, G. Gilkeson, N.H. Kim, Charleston, SC, p.A2282

P1470 **An Unusual Cause of Pulmonary Arterial Hypertension in a Young Mother of Two/**M. Plataki, A. Jacobi, S. Dua, New York, NY, p.A2283

P1471 **Spontaneous Pneumothorax Resulting from an Aseptic Ruptured Pulmonary Infarct/**A. Vasudevan, S. Khanna, S. Dhesi, M. Lippmann, Philadelphia, PA, p.A2284

THEMATIC POSTER SESSION

A68 THE RISING: UNDERSTANDING THE RIGHT VENTRICLE

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area M, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: B. Fenster, MD, Denver, CO

P1473 **The Effects of the Bone Morphogenetic Protein Receptor Type 2 Mutation on Histological and Morphological Characteristics and RNA Expression in the Right Ventricle in Pulmonary Arterial Hypertension/**C.E. Van Der Bruggen, C.M. Happe, P. Dorfmuller, P. Trip, O.A. Spruijt, N. Rol, A. Houweling, B. Girerd, O. Mercier, M. Humbert, L. Handoko, J. Van Der Velden, A. Vonk-Noordegraaf, H.J. Bogaard, M.-J. Goumans, F.S. De Man, Amsterdam, Netherlands, p.A2285

P1474 **Statistical Shape Modeling of the Interventricular Septum Reveals Key Associations Between Hemodynamic Markers and Septum Morphology in Children with Pulmonary Hypertension: Initial Analysis of 31 Patients/**F. Agyei-Ntim, V. Kheyfets, K.S. Hunter, U. Truong, D. Ivy, R. Shandas, Aurora, CO, p.A2286

P1475 **Chitinase 3-like-1 Plays an Important Role in the Development of Right Ventricular Hypertrophy and Pulmonary Vascular Remodeling/**C.E. Ventetuolo, J. Aliotta, M. Pereira, D. Banerjee, Y. Zhou, B. Ma, J.A. Elias, C.G. Lee, J.R. Klinger, Providence, RI, p.A2287

P1476 **Mechanism of RV Dysfunction Associated with Cigarette Smoke Exposure/**A. Vang, H. Chichger, A. Allawzi, K. O'Connell, P. Sakhatskyy, Q. Lu, S.I.S. Rounds, G. Choudhary, Providence, RI, p.A2288

P1477 **Receptor Tyrosine Kinase Inhibitor Nintedanib Improves Cardiac Adaptation in Experimental Pulmonary Hypertension/**N. Rol, M.A. De Raaf, V. Kuiper, I. Schalij, R. Thuillet, L. Tu, C. Guignabert, P. Koolwijk, F.S. De Man, N. Westerhof, C. Dickhoff, H.J. Bogaard, A. Vonk-Noordegraaf, L. Wollin, Amsterdam, Netherlands, p.A2289

P1478 **The L-Carnitine Ameliorates Pulmonary Arterial Hypertension by Improving Energy Metabolism Dysfunction of Right Ventricular Failure/**X.-J. Wang, Y. Liu, Y.-Y. He, Y. Yan, Q.-Q. Liu, S.-H. Yang, S.-Q. Li, S.-S. Huang, Z.-C. Jing, Beijing, China, p.A2290

P1479 **Automatic Segmentation of the Heart with a Statistical Shape Model and Tissue Characteristics in CT Scans from the COPDGene Study/**G. Vegas Sanchez-Ferrero, G. Gonzalez, F.N. Rahaghi, J. Minhas, R.P. Bowler, J.M. Wells, C.E. Come, I. De La Bruere, B. Fenster, A.A. Diaz, P. Kohli, S.P. Bhatt, D.A. Lynch, M.T. Dransfield, G. Washko, R. San Jose Estepar, Boston, MA, p.A2291

P1480 **Exercise Cardiac Magnetic Resonance Imaging: A Novel Technique for Assessing Right Ventricular Contractile Reserve/**L. Troy, C. Arnott, T. Corte, P. Munoz, K. Laohachai, H. Lackey, E. Lau, P. Torzillo, P. Corte, D. Celermajer, R. Puranik, Camperdown, Sydney, Australia, p.A2292

Facilitator: H.J. Bogaard, MD, PhD, Amsterdam, Netherlands

P1481 **Right Heart Function and Gas Exchange During Simulated Altitude in Pulmonary Arterial Hypertension/**L. Seccombe, V. Chow, P.R. Concord Hospital, L. Buddle, W. Zhao, M. Peters, A. Ng, E. Veitch, L. Kritharides, Concord, Australia, p.A2293

P1482 **Use of Focused Right Heart Echocardiography in Pulmonary Hypertension Clinic/**T. He, A. Iftikhar, S. Verma, A. Talwar, M. Oks, P. Mayo, S. Koenig, M. Narasimhan, New Hyde Park, NY, p.A2294

P1483 **Resting, Non-Invasive Cardiac Output Monitoring (NICOMr) Predicts Change in Six Minute Walk Test (6MWT) in Pulmonary Artery Hypertension Patients/**E. Gupta, V. Seeram, A. Shujaat, J. Cury, E.T. Boshra, L. Jones, M. Louis, A. Bajwa, Jacksonville, FL, p.A2295

P1484 **Relationship Between the Right Ventricular Stroke Work with the Severity of Pulmonary Hypertension in Patients of Group I and Group IV/**J.L. Hernandez-Oropeza, M. Moncada-Navas, J.D.J. Rodriguez-Andoney, E. Villegas-Antelo, M.A. Cacho-Diaz, E. Rivero-Sigarroa, G. Dominguez-Cherit, Mexico, Mexico, p.A2296

P1485 **Left Ventricular Systolic Torsion Is Decreased Due to Right Ventricular Dilation in Pulmonary Hypertension Patients/**B. Lamia, L.-C. Molano, C. Viacroze, C. Gounane, A. Cuvelier, J.-F. Muir, Rouen, France, p.A2297

P1486 **Lack of ABCG2 Leads to Biventricular Dysfunction and Remodelling in Response to Hypoxia/**B.M. Nagy, C. Nagaraj, B. Egemnazarov, G. Kwapiszewska, R. Stauber, A. Avian, A. Olschewski, H. Olschewski, Graz, Austria, p.A2298

P1487 **Estrogen Maintains Mitochondrial Content and Function in the Right Ventricle of Rats with Severe Angioproliferative Pulmonary Hypertension/**A. Liu, K.C. Vinnakota, M.B. Oskouei, D.A. Beard, N. Chesler, Madison, WI, p.A2299

THEMATIC POSTER SESSION

A69 PULMONARY REHABILITATION IN PULMONARY HYPERTENSION, INTERSTITIAL LUNG DISEASE, AND OTHER CONDITIONS: WHAT'S NEW?

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area M, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: R.S. Novitch, MD, White Plains, NY

P1489 **Advantages of Perioperative Pulmonary Rehabilitation in Thoracic Surgery/**A. Vagvolgyi, Z. Rozgonyi, C. Feher, M. Molnar, M. Kerti, Z. Balogh, Z. Hodovan, P. Vadasz, J. Varga, Budapest, Hungary, p.A2300

P1490 **Early Mobilization of Patients on Mechanical Ventilators: A Pilot Study/**M. Sigler, J. Tseng, A. Turner, K. Valdez, H. Edriss, K. Selvan, R. Alalawi, K. Nugent, Lubbock, TX, p.A2301

P1491 **Exploring the Relationship Between the Rapid Shallow Breathing Index and Weaning From Prolonged Mechanical Ventilation in ICU Survivors Receiving Multimodal Rehabilitation/**C.A.C. Brillante, E. Otto, A. Verceles, Baltimore, MD, p.A2302

P1492 **Positive Airway Pressure Versus Incentive Inspiratory Load in Postoperative of Gastroplasty/**E.M. Pazzianotto-Forti, M. Rocha, C. Costa, S. Souza, D. Merino, I. Rasera-Junior, Piracicaba, Brazil, p.A2303

P1493 **High-Intensity Interval Training Improves Maximal Oxygen Consumption in Untrained Adult Asthmatics/**L.L. Toennesen, N. Meier, M. Hostrup, C. Porsbjerg, V. Backer, Copenhagen, Denmark, p.A2304

P1494 **Autonomic Modulation in Supine and Standing Positions in Patients with Difficult-to-Control Asthma/**I. Peres Costa, M.G. Fernandes Silva, V.L.D. Santos Alves, F. Aletti, R. Stirbulov, D. Costa, L.P. Cahalin, R. Arena, L.M.M. Sampaio, Sao Paulo, Brazil, p.A2305

P1495 **Determinants of Peak Aerobic Capacity and Six-Minute Walk Distance in Patients Treated for Lung Cancer/**C. Burtin, F. Franssen, L. Vanfleteren, M.T. Groenen, E. Wouters, M. Spruit, Diepenbeek, Belgium, p.A2306

P1496 **Registry Outcomes for HFCWO Vest Therapy in Adult Patients with Bronchiectasis/**G. Hansen, S. Daignault, J. Stiglich, St. Paul, MN, p.A2307

Facilitator: A.E. Holland, PhD, Melbourne, Australia

P1497 **High-Intensity Exercise to Treat a Patient with Tuberous Sclerosis Complex-Lymphangioleiomyomatosis (TSC-LAM)/**T.W. Lowder, T.J. Whitney, Houston, TX, p.A2308

P1498 **Exercise Training Improves Pulmonary Function and Bone Mineral Density in Women with Lymphangioleiomyomatosis (LAM)/**T.W. Lowder, T.J. Whitney, Houston, TX, p.A2309

P1499 **Comparison of a Cycle Exercise Test and a Six-Minute Walk Test in Idiopathic Pulmonary Fibrosis/**J.C. Glerant, P. Imandad, P. Surpas, V. Cottin, J.-F. Cordier, S. Turquier, Lyon, France, p.A2310

P1500 **Etiology and Level of Lung Derangement Do Not Affect the Beneficial Effect of Pulmonary Rehabilitation in Patients with Interstitial Lung Diseases** /R. Tonelli, B. Lanini, I. Romagnoli, I. Presi, F. Florini, E. Cocconcelli, I. Castaniere, S. Cerri, F. Luppi, F. Gigliotti, E.M. Clini, Modena, Italy, p.A2311

P1501 **Pulmonary Rehabilitation for Interstitial Lung Diseases: An Italian Experience/**G. Brunetti, E. Paracchini, C. Beretta, A. Malovini, G. Piaggi, V. Rossi, Pavia, Italy, p.A2312

P1502 **Pulmonary Rehabilitation in Patients with Interstitial Lung Disease: A Respiratory Specialized Hospital Experience/**M.E. Fernandez, M. Saadia Otero, J. Steimberg, M.L. Alberti, F.M. Caro, F. Paulin, Buenos Aires, Argentina, p.A2313

P1503 **Changes in Systolic Blood Pressure Influence Ventilatory Power during Exercise in Cystic Fibrosis/**E.H. Van Iterson, S.E. Baker, C.M. Wheatley, W.J. Morgan, T.P. Olson, E.M. Snyder, Rochester, MN, p.A2314

Facilitator: D. Langer, PhD, PT, Leuven, Belgium

P1504 **Functional Performance Tests Elicit a Maximal Cardiovascular Response in Patients with Pulmonary Hypertension/**A. Marsico, E.F. Teixeira De Carvalho, V. Arakelian, I. Peres Costa, L.P. Cahalin, S. Dal Corso, R. Stirbulov, R. Arena, L.M.M. Sampaio, Sao Paulo, Brazil, p.A2315

P1505 **A Simple Daily Walking Program Plus L-Arginine Supplementation Improves Aerobic Capacity and Quality of Life in Patients with Pulmonary Arterial Hypertension/**M.B. Brown, A. Kempf, C. Collins, S. Gupta, Y. Hellman, V. Wong, M. Farber, T. Lahm, Indianapolis, IN, p.A2316

P1506 **Pulmonary Rehabilitation for Patients with Pulmonary Hypertension: A Single Center Experience/**N. Csikesz, M.-M. Lee, I. Krishnan, A. Palmisciano, M. Whittenhall, J.R. Klinger, J. Pierce, L. Nici, C.E. Ventetuolo, Providence, RI, p.A2317

P1507 **Monitoring Physical Activities in Daily Life in Patients with Pulmonary Arterial Hypertension and COPD/**V.A.P. Di Lorenzo, E.M.G. Regueiro, A.A. Simsic, A.I. De Padua, J. Baddini-Martinez, Sao Carlos, Brazil, p.A2318

P1508 **Outpatient-Based Rehabilitation Program Improves Right Ventricular Function in Patients with Pulmonary Hypertension: Results from a Pilot Study/**N.R. Morris, W. Strugnell, H. Seale, A. Lin, J. Harris, C. Hamilton-Craig, F. Kermeen, Southport, Australia, p.A2319

P1509 **Veterans Entering Pulmonary Rehabilitation with Posttraumatic Stress Disorder and Anxiety May Be Greater than Expected and Be at a Substantial Disadvantage/**N.D. DeLuca, M.F. Formiga, M. Campos, M.A. Pardinas Gutierrez, L.P. Cahalin, Coral Gables, FL, p.A2320

P1510 **Pulmonary Rehabilitation on Aerobic Capacity and Health-Related Quality of Life in Patients with Sequelae of Pulmonary TB/**J.A. Rivera Motta, E.C. Wilches, R.P. Mosquera, Cali, Colombia, p.A2321

SUNDAY MORNING

THEMATIC POSTER SESSION

A70 THE GOOD, THE BAD, AND THE UGLY OF AGING

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area D, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: D.M. Guidot, MD, Atlanta, GA

P371 **Alcohol Induces Lung Fibroblast Senescence Via Induction of DNA Methyl Transferase/**W.A. Neveu, S.T. Mills, D.M. Guidot, V. Sueblinvong, Atlanta, GA, p.A2322

P372 **JunD Protects Mice from Age-Related Lung Alterations Consisting of Emphysema, Lymphoid Hyperplasia, and Adenocarcinoma/**M. Breau, E. Marcos, J. Tran Van Nhieu, A. Parpaleix, S. Abid, A. Houssaini, E. Bizard, L. Boyer, A.J.F. Tiendrebeogo, J. Boczkowski, F. Mechta-Grigoriou, S. Adnot, Creteil, France, p.A2323

P373 **Pulmonary Vascular Stiffening in Human PAH and with Aging/**D. Sicard, L. Fredenburgh, D.J. Tschumperlin, Rochester, MN, p.A2324

P374 **Genetic Inactivation of the Phospholipase A2 Receptor (PLA2R1) Protects Against Lung Cell Senescence in Chronic Obstructive Pulmonary Disease (COPD)/**J. Huang, A. Attwe, E. Marcos, V. Amsellem, M. Breau, K. Kebe, A. Houssaini, P. Validire, B. Maitre, D. Vindrieux, D. Bernard, S. Adnot, Creteil, France, p.A2325

P375 **Endothelial TLR4 Regulates DNA Damage, Genome Stability and Senescence During Oxidant Stress/**Y. Zhang, J.-N. Min, P. Shan, X. Zhang, P.J. Lee, New Haven, CT, p.A2326

Facilitator: D.J. Tschumperlin, PhD, Rochester, MN

P376 **Cigarette Smoke Causes Shelterin TPP1 Reduction and Telomeric DNA Damage Leading to Lung Cellular Senescence in COPD/**H. Yao, T. Ahmed, I.K. Sundar, A. Tormos, I. Rahman, Rochester, NY, p.A2327

P377 **Attenuation of EC-SOD Gene Expression in Aging Lung Fibroblasts: Role of Histone Acetylation/**I.N. Zelko, J.D. Ritzenthaler, S. Barve, S. Ghare, J. Roman, Louisville, KY, p.A2328

P378 **AMPK Activators Reduces Cigarette Smoke-Induced Inflammatory Responses and Elastase-Induced Mouse Emphysema/**Y.-Y. Li, C. Huang, J. Li, H.-W. Yao, Hefei, China, p.A2329

P379 **Targeting the mTOR Signaling Pathway to Inhibit Lung Cell Senescence in Chronic Obstructive Pulmonary Disease (COPD)/**A. Houssaini, K. Kebe, M. Breau, E. Marcos, J. Huang, A. Attwe, E. Bizard, S. Abid, P. Validire, B. Maitre, S. Meiners, V. Amsellem, S. Adnot, Creteil, France, p.A2330

P380 **Mitochondrial Uncoupling Protein UCP2 Regulates Aging-Related Experimental Lung Fibrosis/**S. Rangarajan, D. Kurundkar, A. Kurundkar, M.L. Locy, K. Bernard, J. Deshane, V.J. Thannickal, Birmingham, AL, p.A2331

Facilitator: R.J. Freishtat, MD, MPH, Washington, DC

P381 **Regenerative Asynchrony Is a Driver in Chronic Inflammation in Aging/**C.E. Hoptay, S. Alcala, E.P. Hoffman, R.J. Freishtat, Washington, DC, p.A2332

P382 **Telomerase-Dependent Modulation of Small Airway Remodeling in Chronic Obstructive Pulmonary Disease/**A.J.F. Tiendrebeogo, M. Dagouassat, F. Schlemmer, J. Tran Van Nhieu, P. Caramelle, A. Samb, J. Boczkowski, S. Lanone, Creteil, France, p.A2333

P383 **Cigarette Smoke Exposure- and Aging- Impair Autophagy that Mediates COPD-Emphysema Pathogenesis/**N. Vij, P. Chandramani, C.V. Westphal, R. Hole, T. Min, M. Bodas, Mt. Pleasant, MI, p.A2334

P384 **The Role of ER Stress in Aging In Vitro and In Vivo Models of Ventilator Induced Lung Injury/**J.A. Herbert, M.S. Valentine, J. Nkwocha, F.K. Gninzeko, R. Singh, P. Patel, A.A. Fowler, A. Reynolds, R. Pidaparti, R.L. Heise, Richmond, VA, p.A2335

P385 **Involvement of Lamin B1 in COPD Pathogenesis/**N. Saito, J. Araya, S. Ito, T. Kadota, M. Yoshida, N. Sato, K. Tsubouchi, Y. Kurita, K. Kobayashi, S. Minagawa, H. Hara, H. Utsumi, H. Yanagisawa, M. Hashimoto, H. Wakui, J. Kojima, T. Numata, Y. Kaneko, T. Morikawa, K. Nakayama, K. Kuwano, Tokyo, Japan, p.A2336

Facilitator: L.M. Schnapp, MD, Charleston, SC

P386 **Aging Is Not Enough!: Bleomycin-Induced Fibrosis in an Accelerated Aging Mouse Model/**J. Calyeca, R. Olmos, R. Jasso, M. Gaxiola, C. Lopez-Otin, M. Selman, A. Pardo, Mexico City, Mexico, p.A2337

P387 **Biological Aging of the Idiopathic Pulmonary Fibrosis Lung/**J.E. McDonough, D.S. Martens, S. Verleden, G.M. Verleden, N. Kaminski, J.C. Hogg, T.S. Nawrot, B.M. Vanaudenaerde, W. Wuyts, Leuven, Belgium, p.A2338

P388 **Analysis of the Telomerase Activity of Alveolar Cells in COPD/**M. Ueno, T. Maeno, H. Masubuchi, K. Yamaguchi, K. Hara, M. Sato, N. Harada, Y. Shimizu, M. Motegi, T. Suga, M. Kurabayashi, Takasaki, Gunma, Japan, p.A2339

P389 **Telomere Shortening and Progression in Patients with Chronic Obstructive Pulmonary Disease (COPD)/**E. Cordoba-Lanus, A. Espinoza-Jimenez, R. Baz-Davila, S. Cazorla, A. Montejo-de-Garcini, A. Aguirre-Jaime, B. Celli, C. Casanova, Santa Cruz de Tenerife, Spain, p.A2340

P390 **HIV Infection Promotes Lung Cellular Senescence/**S. Stephenson, Y.-H. Chow, C. Wilson, K.A. Crothers, I. Petrache, L.M. Schnapp, Charleston, SC, p.A2341

THEMATIC POSTER SESSION

A71 EPIGENETICS

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area D, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

P392 **Next-Generation Sequencing Identifies DNA Methylation of the Dhx58/LGP2 Locus as a Candidate Pathway Limiting Regulatory T Cell-Mediated Acute Lung Injury Resolution/**B.D. Singer, S. Yegnasubramanian, F.R. D'Alessio, Chicago, IL, p.A2342

P393 **In Utero Epigenetic Programming and Asthma Pathogenesis/**W.W.-Y. Tang, N. Limjunyawong, T. Dao, B.H.-Y. Yeung, W. Mitzner, Baltimore, MD, p.A2343

P394 **Dynamic Changes of DNA Methylation During Different Stages of Normal Mouse Lung Development/**C.R. Espinoza, D. Chhabra, T. Nicola, N. Ambalavanan, N. Kaminski, E. Sefer, Z. Bar-Joseph, J.S. Hagood, La Jolla, CA, p.A2344

P395 **Primary Human Bronchial Epithelial Cells (HBECs) Isolated from Smokers Have Epigenetically Impaired Antiviral Innate Immune Response/**W. Wu, W. Zhang, J.L. Booth, X. Wang, J.P. Metcalf, Oklahoma City, OK, p.A2345

P396 **Single Cell Sequencing Characterization of the Human Small Airway Epithelium Club ("Clara") Cell Transcriptome/**W.-L. Zuo, L. Sheng, P. Vijay, C. Mason, R.J. Kaner, S. O'Beirne, M. Staudt, R.G. Crystal, New York, NY, p.A2346

P397 **Gene-Based Segregation Analysis in Whole Exome Sequencing Studies/**D. Qiao, C. Lange, J.D. Crapo, T.H. Beaty, N.M. Laird, S. Won, E.K. Silverman, M.H. Cho, Boston, MA, p.A2347

P398 **Mining the Exome Chip for Genetic Variants Associated with Body Mass Index (BMI) and Pectoralis Muscle Index (PMI) in COPDGene COPD Cases and Controls/**M.-L. McDonald, A.A. Diaz, J.C. Ross, R.S.J. Estepar, B.D. Hobbs, M.M. Parker, E.S. Wan, E.A. Regan, E. Eckbo, N. Muralidhar, C.E. Come, C.P. Hersh, R. Casaburi, J. Hokanson, T.H. Beaty, M.H. Cho, E.K. Silverman, G. Washko, D.L. DeMeo, Boston, MA, p.A2348

P399 **The Relationship Between Exome Chip Variants and Resting Blood Oxygenation in COPD/**M.-L. McDonald, B.D. Hobbs, M.M. Parker, P.J. Castaldi, R. Casaburi, J.M. Wells, S.M. Lutz, E.A. Regan, B.J. Make, J. Hokanson, J.D. Crapo, T.H. Beaty, M.H. Cho, E.K. Silverman, C.P. Hersh, Boston, MA, p.A2349

P400 **Light-Use Waterpipe (Shisha) Smoking Induces Epigenetic Changes in the Small Airway Epithelium/**M.S. Walters, J. Salit, J.H. Ju, Y. Strulovici-Barel, R.J. Kaner, G. Wang, V. Shanmugam, A. Almulla, H. Sattar, M. Mahmoud, J.G. Mezey, M.R. Staudt, R.G. Crystal, New York, NY, p.A2350

P401 **Identification of Lung Specific Genes by Meta-Analysis of Multiple Tissue RNA-seq Data/**M. Xiong, D. Heruth, L.Q. Zhang, S.Q. Ye, Kansas City, MO, p.A2351

P402 **DNA Methylation Sites in Human Lung Tissue Are Associated with COPD Status/**J.D. Morrow, C.P. Hersh, V. Pinto-Plata, B.R. Celli, N. Marchetti, G.J. Criner, R. Bueno, G. Washko, K. Glass, J. Quackenbush, E.K. Silverman, D.L. DeMeo, Boston, MA, p.A2352

P403 **Achaete-Scute Homologue 1 (ASCL1) Expression in the Peripheral Airways of Smokers with Lung Adenocarcinoma/**M.H. Lee, J.J. Tsay, T.-A. Yie, W.N. Rom, New York, NY, p.A2353

THEMATIC POSTER SESSION

A72 MECHANISMS OF LUNG CANCER BIOLOGY

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area C, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: Y.M. Janssen-Heininger, PhD, Burlington, VT

P262 **Lipopolysaccharides Induce Radiotherapy Resistance in Non-Small Cell Lung Cancer Cell Lines - the Role of Protein Kinase-Activation/**M.Y. Gokyildirim, F. Subtil, U. Grandel, W. Seeger, R. Engenhart-Cabillic, U. Sibelius, F. Grimminger, K. Hattar, Giessen, Germany, p.A2354

P263 **Expression and Clinical Significance of S100 Calcium Binding Protein A2 in Lung Cancer/**H. Ren, T. Wang, M. Chen, Xi'an, China, p.A2355

P264 **Effects of E-Cigarettes Vapor on Lung Neoplastic Cells Proliferations and Cancer-Relevant Gene Expression Profiles in A549 Cells/**B. Xue, J. Smoake, J.T. Mao, Albuquerque, NM, p.A2356

P265 **Study of Erythromycin on Histone Deacetylase 2 in A549 Cells Exposed to Cigarette Smoke Extract/**H.S. Ming, L.L. Hua, Y.L. Kai, X.M. Peng, G.N. Liu, Nanning, China, p.A2357

P266 **Grape Seed Proanthocyanidin Extract Modulates RNA Exosome Expression in A549 Lung Cancer Cells/**J.T. Mao, J. Smoake, H. Park, B. Xue, Albuquerque, NM, p.A2358

P267 **Fibronectin and Hepatocyte Growth Factor Produced from Lung Fibroblasts Can Increase in Migration and Invasion of Malignant Pleural Mesothelioma Cells/**N. Kanaji, A. Tadokoro, N. Kita, T. Takagi, T. Ishii, N. Watanabe, S. Bandoh, Kagawa, Japan, p.A2359

Facilitator: V. Keshamouni, PhD, Ann Arbor, MI

P268 **Leptin Gene Polymorphism Increases Risk of Lung Cancer?/**S. Peng, X. Tong, H. Fan, Chengdu, China, p.A2360

P269 **Vimentin Regulates the Invasive Ability of Lung Cancer Cells and Is a Poor Prognostic Marker in Non-Small Cell Lung Cancer/**A. Tadokoro, N. Kanaji, T. Ishii, T. Takagi, N. Watanabe, N. Kita, S. Bandoh, Kagawa, Japan, p.A2361

P270 **Fibrocytes Mediate Acquired Resistance to Anti-Angiogenic Therapy with Bevacizumab in Thoracic Tumors/**H. Goto, A. Mitsuhashi, A. Saijo, T. Kuramoto, S. Tabata, Y. Aono, H. Uehara, M. Hanibuchi, Y. Nishioka, Tokushima, Japan, p.A2362

P271 **Bone Marrow-Derived Fibrocytes Maintain Stem Cell-Like Properties of Lung Cancer /**A. Saijo, H. Goto, A. Mitsuhashi, M. Nakano, H. Ogino, Y. Aono, S. Sakaguchi, M. Tobiume, K. Otsuka, M. Hanibuchi, Y. Nishioka, Tokushima, Japan, p.A2363

P272 **Induction of L1 Retroelement in Human Bronchial Epithelial Cells by Tobacco Carcinogens/**P. Bojang, K. Ramos, Tucson, AZ, p.A2364

P273 **Inflammatory Microenvironment in Chronic Obstructive Pulmonary Disease Induces Epithelial-Mesenchymal Transition in Lung Cancer Cells Via TGF-β1/Smad3 Signaling Pathway/**N. Wang, Q. Hong, C. Bai, Shanghai, China, p.A2365

Facilitator: K. Kishi, MD, Tokyo, Japan

P274 **Suppression of KRAS Expression in Normal Airway Basal Cells Shifts Differentiation to a Squamous/EMT Phenotype/**F. Ogawa, M.S. Walters, Y. Strulovici-Barel, F. Agosto-Perez, J. Salit, M.R. Staudt, R.G. Crystal, New York, NY, p.A2366

P275 **Neutral Sphingomyelinase 2 Promotes Cell Proliferation of Human Airway Epithelial Cells During Chronic Cigarette Smoke Exposure Via Sphingosine-1-Phosphate/**S. Chung, S.L. Vu, S. Filosto, T. Goldkorn, Davis, CA, p.A2367

P276 **Osteopontin as an Airway Epithelial Tumor Promoter/**I. Psallidas, N. Kanellakis, M. Vreka, A. Giannou, L. Maniatis, S. Magkouta, C. Moschos, I. Giopanou, T. Agalioti, I. Lillis, I. Kalomenidis, N.M. Rahman, G. Stathopoulos, Oxford, United Kingdom, p.A2368

P277 **Molecular Discrimination of Intrapulmonary Metastasis and Multiple Primary Lung Cancer/**C. Shen, X. Wang, L. Liu, G. Che, Chengdu, China, p.A2369

P278 **Leptin Enhances the Cytotoxicity Effect of Human Peripheral Blood γδT Cells on Lung Cancer Celli¼?An Experimental Study/**L.H. Quan, Xuzhou, China, p.A2370

P279 **Lung Fibroblast Soluble Microenvironment Affects Response to Nintedanib in Lung Epithelial Cancer Cells/**G. Epstein Shochet, M. Koslow, L. Israeli, A. Matveychuk, D. Shitrit, Kfar Saba, Israel, p.A2371

Facilitator: J.P. Koo, PhD, New Haven, CT

P280 **Prognostic Significance of Neutrophil to Lymphocyte Ratio in Pleural Fluid and Blood of Patients with Malignant Mesothelioma/**N. Popowicz, C. Gregory, H.M. Cheah, Y.C.G. Lee, J. Creaney, Perth, Australia, p.A2372

P281 **N-myc Downstream Regulated Gene 1(NDRG1) Promotes the Stem-Like Properties of Lung Cancer Cells Through Stabilized c-Myc/**K. Wang, Y. Wang, Hangzhou, China, p.A2373

P282 **Targeting the HDAC6/HSP90 Axis to Destabilize the Notch1 Receptor in Non-Small Cell Lung Cancer/**B. Deskin, B. Shan, J. Lasky, New Orleans, LA, p.A2374

P283 **Erlotinib-Cyclodextrin Complex Loaded Biodegradable Nanoparticles for Enhanced Anti-Proliferative Efficacy Against Non-Small Cell Lung Cancer/**V. Gupta, B. Vaidya, Claremont, CA, p.A2375

P284 **GSTP1-Catalyzed S-Glutathionylation in Non-Small Cell Lung Cancer/**J. Van Der Velden, C.M. Kinsey, D.H. McMillan, K.G. Lahue, R.W. Schneider, S. Abdalla, J.D. Nolin, Y. Janssen-Heininger, Burlington, VT, p.A2376

P285 **Role of Aging, Inflammation, and Tissue Remodeling in Lung Cancer Progression/**J.C. Greenwell, J.D. Ritzenthaler, E. Torres-Gonzalez, J. Roman, Louisville, KY, p.A2377

THEMATIC POSTER SESSION

A73 LUNG FIBROSIS: NEW DIRECTIONS TO INFORM THE FUTURE

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area D, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

P405 **Using Pulmonary Surfactant as Pirfenidone Vehicle to Target Lung Epithelium in Bleomycin-Induced Lung Fibrosis/**E. Lopez-Rodriguez, C. Laukamp, A. Hidalgo, A. Cruz, J. Perez-Gil, M. Ochs, L. Knudsen, Hannover, Germany, p.A2378

P406 **Adenovirus-Mediated Overexpression of Lactate Dehydrogenase Induces Pulmonary Fibrosis/**J.L. Judge, T.H. Thatcher, R.P. Phipps, P.J. Sime, R.M. Kottmann, Rochester, NY, p.A2379

P407 **Bridging the Gap Between HRCT and Final IPF Diagnosis: Classifying the Usual Interstitial Pneumonia Pattern in Transbronchial Biopsies Using Machine Learning on High Dimensional Genomic Data/**G. Kennedy, D. Pankratz, Y. Choi, T. Colby, J.L. Myers, K.K. Brown, K.R. Flaherty, D.A. Lynch, M.P. Steele, U. Imtiaz, G. Fedorowicz, C. Conley, J. Huang, South San Francisco, CA, p.A2380

P408 **A Change in Lipid Composition Depending on the Progression of Bleomycin-Induced Pulmonary Fibrosis was Revealed by Matrix-Assisted Laser Desorption/Ionization Imaging Mass Spectrometry/**Y. Oyama, S. Takei, N. Masaki, M. Kono, N. Enomoto, Y. Nakamura, T. Fujisawa, N. Inui, T. Suda, M. Setou, Hamamatsu, Japan, p.A2381

P409 **Developmental Reprogramming in Progressive Idiopathic Pulmonary Fibrosis/**D. Chanda, A. Kurundkar, S. Rangarajan, M.L. Locy, K. Bernard, N.S. Sharma, N.J. Logsdon, H. Liu, D.K. Crossman, J.C. Horowitz, V.J. Thannickal, Birmingham, AL, p.A2382

P410 **Increased C3 Expression in the Lung of Idiopathic Pulmonary Fibrosis Is Associated with the MUC5B Promoter Variant/**T. Okamoto, S.K. Mathai, J.M. Thurman, N.K. Banda, V.M. Holers, I.V. Yang, M.I. Schwarz, D.A. Schwartz, Aurora, CO, p.A2383

P411 **The Effect of Nintedanib on Platelet Derived Growth Factor-Stimulated Contraction of Human Primary Lung Fibroblasts/**L. Wollin, J. Schuett, A. Ostermann, F. Herrmann, Biberach, Germany, p.A2384

P412 **Common Subcellular Pathways Underlying Cell Toxicity Induced by Mistargeted ABCA3 Mutant Proteins/**S. Mulugeta, M. Zhao, M.F. Beers, Philadelphia, PA, p.A2385

P413 **Cigarette Smoke Enhances the Expression of Profibrotic Molecules in Alveolar Epithelial Cells/**M. Checa, A. Pardo, V. Ruiz, J. Hagood, S. Garcia-Trejo, C. Becerril, C. Garcia-de-Alba, J. Cisneros-Lira, M. Montano, M. Selman, Mexico City, Mexico, p.A2386

P414 **PAI-1 Plays an Important Role in Radiation-Induced Pulmonary Fibrosis/**S. Shioya, N. Hattori, T. Masuda, T. Senoo, Y. Horimasu, T. Nakashima, H. Iwamoto, K. Fujitaka, N. Kohno, Hiroshima, Japan, p.A2387

P415 **The Slow Rate of Fibrinolyisis Limits Inhibitor Selection When Targeting Plasminogen Activator Inhibitor 1 to Enhance Intrapleural Fibrinolytic Therapy/**A. Komissarov, A.O. Azghani, S. Karandashova, C. Schaefer, S.V. Yarovoi, P.J. Declerck, D.B. Cines, S. Idell, G. Florova, Tyler, TX, p.A2388

P416 **IPF Fibroblasts: From the Aberrantly Activated State to the Senescent Phenotype/**D. Alvarez, N. Cardenes, J. Sembrat, C. Corey, M. Bueno, M. Kapetanaki, S. Shiva, V.S. Hanumanthu, M. Armanios, A.L. Mora, M. Rojas, Pittsburgh, PA, p.A2389

P417 **SOCS-Regulation of Jak/STAT Signalling in Idiopathic Pulmonary Fibrosis (IPF)/**C. Prele, T. Iosifidis, R. McAnulty, B. Badrian, S. Jamieson, D. Pearce, M. Ernst, P. Thompson, G. Laurent, D.A. Knight, S. Mutsaers, Perth, Australia, p.A2390

P418 **FRNK Knock-In Expression in S100A4-Specific Manner Regulates Lung Fibrosis/**M. Hu, G. Cai, J.M. Taylor, R.-M. Liu, V.J. Thannickal, M.A. Olman, Q. Ding, Birmingham, AL, p.A2391

P419 **Telomere Dysfunction in Alveolar Epithelial Cells Causes Pulmonary Fibrosis/**R.P. Naikawadi, S. Disayabutr, B. Mallavia, M. Donne, G. Green, J.R. Rock, M.R. Looney, P.J. Wolters, San Francisco, CA, p.A2392

P420 **Epithelial Nox4 Contributes to Fibrotic Susceptibility in Hermansky-Pudlak Syndrome Mice/**P.M. Gulleman, C.S. White, W. Han, E.J. Plosa, B. Gochuico, W. Gahl, T.S. Blackwell, L.R. Young, Nashville, TN, p.A2393

P421 **Equilibrative Nucleoside Transporter Down-Regulation Exacerbates Bleomycin Induced Pulmonary Fibrosis/**F. Luo, T.W. Mills, K.M. Philip, H. Karmouty-Quintana, J. Molina, N.-Y. Chen, Y. Xia, J. Davies, H. Eltzschig, M.R. Blackburn, Houston, TX, p.A2394

P422 **The Anti-Fibrotic Effect of Endostatin-Derived Peptide Is Mediated by the Urokinase Pathway Via Binding to Enolase-1 and Urokinase Plasminogen Activator Receptor/**T. Nishimoto, T. Takihara, L. Mlakar, Y. Su, R. Chambers, C. Feghali-Bostwick, Charleston, SC, p.A2395

P423 **Chitinase 3-Like-1 and Its Receptors in Hermansky-Pudlak Syndrome-Associated Lung Disease/**Y. Zhou, C.H. He, E. Herzog, X. Peng, C.-M. Lee, T. Nguyen, M. Gulati, B. Gochuico, W. Gahl, M. Slade, C.G. Lee, J.A. Elias, Providence, RI, p.A2396

P424 **Epithelial Mesenchymal Transition: Is It Still Relevant to Pulmonary Fibrosis?/**E.S. Baker, D. Kass, Pittsburgh, PA, p.A2397

P425 **Involvement of the β-catenin-Inhibitor ICAT and Non-Canonical Signaling in Idiopathic Pulmonary Fibrosis/**K. Rydell-Tormanen, X.-H. Zhou, O. Hallgren, J. Einarsson, L. Eriksson, A. Andersson-Sjoland, G. Westergren-Thorsson, Lund, Sweden, p.A2398

P426 **WISP1 Mediates IL6-Dependent Proliferation in Healthy and IPF-Derived Primary Human Lung Fibroblasts/**S. Klee, M. Lehmann, D.E. Wagner, H.A. Baarsma, M. Konigshoff, Munich, Germany, p.A2399

P427 **Aberrant Activation of Wilms' Tumor 1 Protein Regulates Pulmonary Fibrosis/**V. Sontake, S.K. Shanmukhappa, B. DiPasquale, G. Bhanuprakash Reddy, E.S. White, S.K. Madala, Cincinnati, OH, p.A2400

P428 **PM2.5 May Play an Important Role in the Pathogenesis of Pulmonary Fibrosis by Initiating Oxidative Stress, Inflammation and TGF-β Signaling/**Y. Hu, D. Weng, Shanghai, China, p.A2401

P429 **Myofibroblast Populations in IPF: Novel Differences in Gene Expression and Functionality/**S.M. Walsh, J.C. Worrell, A. Fabre, R. Kane, M.P. Keane, Dublin, Ireland, p.A2402

P430 **Impairment of Chaperone-Mediated Autophagy Promotes the Development of Pulmonary Fibrosis/**Q. Yin, J.L. Schneider, R.E. Gongora, A.M. Cuervo, C.G. Sanchez, New Orleans, LA, p.A2403

P431 **Repetitive Intradermal Bleomycin Injections Evoke Th2 Cytokine-driven Lung Function Decline and Pulmonary Fibrosis/**S.K. Madala, B. Singh, V. Sontake, Cincinnati, OH, p.A2404

P432 **c-Jun-N-Terminal Kinase 1 in Airway Epithelial Cells Augments Fibrotic Airway Remodeling by Limiting Epithelial Restitution/**J. Van Der Velden, D.E. Wagner, K.G. Lahue, J.D. Nolin, S. Abdalla, S.M. Hoffman, J.F. Alcorn, C.G. Irvin, J.T. Jones, D.G. Chapman, V. Anathy, Y.W. Lam, R.J. Davis, D.J. Weiss, Y. Janssen-Heininger, Burlington, VT, p.A2405

P433 **The Role of HMGB1 and MIP3A in the Pathogenesis of Idiopathic Pulmonary Fibrosis/**Y.D. Zhao, K. Lin, E. Granton, A. Yu, H.Z.H. Yun, M.O. Wu, L. Wu, J. Granton, M. De Perrot, Toronto, Canada, p.A2406

P434 **The Role of Extracellular Heat Shock Protein 90 Alpha on Pulmonary Fibrosis/**H. Dong, L. Luo, C. Huang, Z. Xie, Y. Le, S. Cai, Guangzhou, China, p.A2407

P435 **Could Infection Be a Significant Factor in IPF?/**L. Rodriguez, S. Bui, S.D. Nathan, H. Mani, G. Grant, Fairfax, VA, p.A2408

P436 **FGF2 Overexpression Decreases Bleomycin-Induced Pulmonary Fibrosis/**R. Guzy, L. Li, S. Cilvik, S. House, D. Ornitz, Chicago, IL, p.A2409

P437 **Apoptotic Challenge Evokes Differential Response Mechanisms of Idiopathic Pulmonary Fibrosis Fibroblasts/** S. Bui, S.D. Nathan, M. Chhina, S. Khandhar, G. Grant, Manassas, VA, p.A2410

P438 **The GPCR Repertoire Changes in Lung Fibroblasts Treated with TGFIβ and in Fibroblasts of Patients with Idiopathic Pulmonary Fibrosis/**A.V. Michkov, K. Sriram, N. Aroonsakool, P.A. Insel, La Jolla, CA, p.A2411

P439 **Estimation of the True GM-CSF Autoantibody Concentration in the Sera of Healthy Subjects/**K. Shiiya, Y. Itoh, A. Hashimoto, R. Tazawa, K. Nakata, Niigata, Japan, p.A2412

P440 **Glucose Uptake in TGFβ-Induced Fibroblast Differentiation/**I. Azuelos, B. Selvarajah, E. Forty, M. Plate, D. Anastasiou, P. Mercer, R. Chambers, London, United Kingdom, p.A2413

P441 **The IL-33/ST2 Axis Is Upregulated in Fibrotic Lung Disease/**R.J. Toshner, S.J. Allden, A.J. Byrne, C.M. Lloyd, T.M. Maher, London, United Kingdom, p.A2414

P442 **Differential Role of Phospholipase D in Regulating EMT and Fibroblast Differentiation in Bleomycin-Induced Pulmonary Fibrosis/**V. Suryadevara, L.S. Huang, E.V. Berdyshev, A.M. Tager, T. Royston, V. Natarajan, Chicago, IL, p.A2415

P443 **Role of Epithelial to Mesenchymal Transition (EMT) in Idiopathic Pulmonary Fibrosis/**G. Cholankeril, S. Morais, S. Swami, J. Meharg, P. Dubielecka, Providence, RI, p.A2416

P444 **Limp2 Mediates Prdx6 Delivery to Lamellar Bodies in AP3-Deficient Cell and Mouse Models/**S. Kook, P. Wang, S. Guttentag, Nashville, TN, p.A2417

P445 **Macitentan Prevents Pulmonary Fibrosis Progression and Secondary Pulmonary Hypertension Induced by TGF-β1 Overexpression in Rats/**P.-S. Bellaye, C. Shimbori, K. Ask, J. Gauldie, M. Iglarz, M.R.J. Kolb, Hamilton, Canada, p.A2418

P446 **Atrial Natriuretic Peptide Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice/**A. Okamoto, K. Konishi, T. Nojiri, H. Hosoda, T. Tokudome, K. Asai, K. Hirata, K. Kangawa, Suita, Japan, p.A2419

P447 **New Promising Therapy for Idiopathic Pulmonary Fibrosis and Its Application Using Wound Healing Facilitator Stannioclaicn-1 (STC1)/**S. Ohkouchi, M. Ono, M. Ichinose, H. Kurosawa, Sendai, Japan, p.A2420

P448 **Targeting the Hedgehog Signaling Pathway as Therapy for Pulmonary Fibrosis/**B. Hu, Z. Wu, D. Bai, J. Liu, T. Liu, S.H. Phan, Ann Arbor, MI, p.A2421

P449 **The Co-Ordinated Expression of VEGF-Axxxa and VEGF-Axxxb Isoforms Are Important in the Development and Progression of Pulmonary Fibrosis/**S.L. Barratt, T. Blythe, C. Jarrett, K. Ourradi, G.I. Welsh, D.O. Bates, A.B. Millar, Bristol, United Kingdom, p.A2422

P450 **Cleavage Factor Im 25 (CFIM25) Regulates Pulmonary Fibrosis Through Alternative Polyadenylation/**T.W. Mills, N.-Y. Chen, J. Molina, H. Karmouty-Quintana, K.M. Philip, F. Luo, J. Davies, E.J. Wagner, M.R. Blackburn, Houston, TX, p.A2423

P451 **Activated Primary Human Lung Fibroblasts Produce Anti-Inflammatory and Anti-Fibrotic Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) Ligands/** S.H. Lacy, C.F. Woeller, T.H. Thatcher, P.J. Sime, R.P. Phipps, Rochester, NY, p.A2424

THEMATIC POSTER SESSION

A74 MATRIX: DRIVERS AND TARGETS

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area D, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

P453 **Sirtuin 7 Is Associated with Pulmonary Fibrosis and Attenuates Collagen Expression in Lung Fibroblasts/**A.E. Wyman, Z. Noor, N.W. Todd, I.G. Luzina, S.P. Atamas, Baltimore, MD, p.A2425

P454 **Regulation of Non-Muscle Myosin Light Chain Kinase Alternative Splicing by Mechanical Stress and Genetic Influences/**J.B. Mascarenhas, G.T. Kelly, A.Y. Tchourbanov, T. Zhou, S.M. Danillov, T. Wang, J.G.N. Garcia, Tucson, AZ, p.A2426

P455 **Post-Transcriptional Regulation of NOX4 by the Mechanosensing ROCK/mTOR Pathway/**A. Venado, H. Chen, J. Qu, N.J. Logsdon, Y. Zhou, V.J. Thannickal, Birmingham, AL, p.A2427

P456 **Patterns of Elastic Fiber Breakdown in Bleomycin-Induced Fibrosis and Elastase-Induced Emphysema May Reflect Pulmonary Microarchitectural Changes/**X. Liu, S. Ma, G. Turino, J. Cantor, Queens, NY, p.A2428

P457 **XPLN Negatively Regulates SPARC Expression by Targeting mTORC2 in Human Lung Fibroblasts/**K. Kamio, A. Azuma, J. Usuki, K. Matsuda, M. Inomata, N. Nishijima, S. Itakura, N. Kokuho, H. Hayashi, T. Yamaguchi, K. Fujita, Y. Saito, S. Abe, K. Kubota, A. Gemma, Tokyo, Japan, p.A2429

P458 **Expression of Extracellular Matrix Constituents by Fibroblasts Conditioned by Bronchial Epithelial Cells (BECs) from Asthmatic and Healthy Children Is Correlated with Lung Function Measures of BEC Donors/**S.R. Reeves, T.K. Kolstad, A. Arrigoni, K. Barrow, J.S. Debley, Seattle, WA, p.A2430

P459 **Loss of Fatty Acid Synthase Increases the Severity of Lung Fibrosis by Preventing Collagen Resorption/**D. McCarthy, A.K. Soltani, A. Ha, K. Atabai, San Francisco, CA, p.A2431

P460 **Type I Collagen Signaling Regulates Fibroblast Activation, Proliferation, and Apoptosis/**S. Jia, J.C. Horowitz, T. Loo, M. Agarwal, K.K. Kim, Ann Arbor, MI, p.A2432

P461 **Expression of Heparan Sulfate and Heparan Sulfate Proteoglycans in Idiopathic Pulmonary Fibrosis/**X. Yue, M.A. Jessee, New Orleans, LA, p.A2433

P462 **Serum Matrix Metalloproteinase-7 Is a Potential Marker of Active Disease in Patients with Idiopathic Pulmonary Fibrosis/** J. Jaffar, K. Symons, N. Goh, R. O'Hehir, M. Schuliga, A.G. Stewart, G. Westall, I. Glaspole, Melbourne, Australia, p.A2434

P463 **Inhibition of Lysyl Oxidase Enzyme Activity In Vitro Inhibits TGF-β Induced Collagen Remodeling in 3D Collagen Models/** G. Tjin, E.S. White, E.P.W. Kable, J.K. Burgess, Sydney, Australia, p.A2435

P464 **Tissue Turnover of Collagen Type I, III and Elastin Are Elevated in the Rat Precision-Cut Lung Slice Model of IPF and Can Be Restored Back to Vehicle Levels Using a PDE Inhibitor/**N.U.B. Hansen, M.A. Karsdal, S. Brockbank, S. Cruwys, A. Young, P. Nath, D.J. Leeming, Herlev, Denmark, p.A2436

P465 **Assessment of Clinically Relevant Extracellular Matrix Markers in a Bleomycin-Induced Model of Lung Fibrosis in the Mouse/**A. Young, S. Brockbank, N.U.B. Hansen, M.A. Karsdal, D.J. Leeming, P. Nath, V. Russell, E. Sadler, S. Cruwys, Harlow, United Kingdom, p.A2437

P466 **Serum Syndecan-1 in Patients with Acute Exacerbation of Idiopathic Interstitial Pneumonia/**R. Togawa, Y. Tanino, T. Nikaido, K. Misa, Y. Sato, Y. Suzuki, M. Uematsu, A. Fukuhara, S. Sato, J. Saito, X. Wang, M. Munakata, Fukushima, Japan, p.A2438

P467 **Inhibition of Extracellular Matrix Cross-Linking Affects Proliferation, Adhesion and Proteolysis of Extracellular Matrix Derived from IPF Fibroblasts and Aids Resolution in the Murine Bleomycin Model/**C.J. Philp, I. Siebeke, D. Clements, A.E. John, A. Habgood, R.G. Jenkins, S.R. Johnson, Nottingham, United Kingdom, p.A2439

P468 **Extracellular Matrix Changes After Repetitive Instillations of Whole Gastric Contents in the Rat Lung/**P. Ayala, M. Meneses, J. Torres, J. Araos, G.R. Borzone, Santiago, Chile, p.A2440

P469 **Lysyl Oxidase Induces Fibrosis Via Upregulation of IL-6 and Serves as a Biomarker to Monitor Response to Therapy/**T. Nishimoto, T. Takihara, L. Mlakar, J. Heywood, A. Bradshaw, C. Feghali-Bostwick, Charleston, SC, p.A2441

P470 **Senescent Stroma-Induced Oncogenesis in Idiopathic Pulmonary Fibrosis/**D.M. Habiel, N. Krepostman, M. Lilly, T. Shibata, K. Cavassani, A.L. Coelho, A. Kurkciyan, V. Funari, C.A. Henke, B. Stripp, W. Parks, P. Chen, D. Jiang, P.W. Noble, K. Elenitoba-Johnson, C. Hogaboam, Los Angeles, CA, p.A2442

P471 **Clinically Validated Serum Extracellular Matrix Turnover Markers of IPF in Combination with a Bleomycin In-Vivo and an Ex-Vivo Model May Be Used as an Intelligent Drug Screening Tool/**D.J. Leeming, S. Brockbank, N.U.B. Hansen, M.A. Karsdal, P. Nath, D. Rider, V.P. Russel, E. Sadler, A. Young, S. Cruwys, Herlev, Denmark, p.A2443

P472 **Differential Responses to the Protein Components of the SSc-ILD lung Extra-Cellular Matrix by Control and SSc-ILD Fibrocytes/**H. Sun, H. Pan, H. Ding, Y. Cheng, M. Gulati, W.H. Fares, P. Adonteng-Boateng, D.A. Carrano, D.E. Antin-Ozerkis, C. Ryu, X. Peng, E. Herzog, New Haven, CT, p.A2444

P473 **Three-Dimensional Distribution of Fibroproliferation in Idiopathic Pulmonary Fibrosis/**M.G. Jones, A. Fabre, P. Schneider, F. Cinetto, G. Sgalla, M. Mavrogordato, S. Jogai, A. Alzetani, B.G. Marshall, K.M.A. O'Reilly, J. Warner, P.M.A. Lackie, D.E. Davies, D. Hansell, A. Nicholson, I. Sinclair, L. Richeldi, Southampton, United Kingdom, p.A2445

P474 **Dityrosine Cross-Linking of Fibronectin Is Increased in Plasma of Human Subjects with Interstitial Lung Disease/**M.L. Locy, S. Rangarajan, A. Kurundkar, K. Bernard, N.J. Logsdon, J.A.M. De Andrade, S. Pennathur, V.J. Thannickal, Birmingham, AL, p.A2446

THEMATIC POSTER SESSION

A75 STEM CELLS

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area D, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitators: F.F. Cruz, MD, PhD, Rio de Janeiro, Brazil
A.E. Tzouvelekis, MD, PhD, New Haven, CT

P476 **Lef1 Transcription Factor Controls Submucosal Gland Hypertrophy/**P.J. Anderson, T. Lynch, B. Mathews, T. Neff, M. Goodheart, A. Dupuy, J. Engelhardt, Iowa City, IA, p.A2447

P477 **Sonic Hedgehog (SHH) Signaling Regulates Myofibroblast Function During Alveolar Septum Formation in Postnatal Lung/**M.C. Kugler, C.A. Loomis, J. Ramos, A.L. Joyner, W.N. Rom, D.B. Rifkin, J. Munger, New York, NY, p.A2448

P478 **Distinct Mesodermal Cell Populations Are Targeted by Hedgehog Signaling During (Postnatal) Lung Development/**C. Li, S. Li, H. Di, X. Wen, Z. Borok, P. Minoo, Los Angeles, CA, p.A2449

P479 **Doxycycline Inhibits TGF-β1-Induced Epithelial-Mesenchymal Transition and Migration Via Smad2/3 and p38 Pathways in Respiratory Epithelial Cells/**H.-M. Lee, J.-H. Kang, J.-H. Park, H.-J. Kim, J.-M. Shin, Seoul, Korea, Republic of, p.A2450

P480 **Myeloid Cell Regulation of Adult Lung Alveologenesis Post-Pneumonectomy/**A.J. Lechner, J.R. Rock, San Francisco, CA, p.A7799

THEMATIC POSTER SESSION

A76 LAM: NEW BIOLOGY AND NEW INSIGHTS

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area D, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: S.Y. El-Chemaly, MD, MPH, Boston, MA

P481 **Expression and Activity of Cathepsin K in Lymphangioleiomyomatosis (LAM)/**A. Dongre, D. Clements, S.R. Johnson, Nottingham, United Kingdom, p.A2451

P482 **Transcriptomic Differences Associated with TSC2 Gene Expression Loss in Lymphangioleiomyomatosis/**B.E. Himes, M. Shumyatcher, E.N. Atochina-Vasserman, A.J. Gow, C.-J. Guo, V.P. Krymskaya, Philadelphia, PA, p.A2452

P483 **Pulmonary Lymphangioleiomyomatosis (LAM): Inflammatory Cell Infiltration in Human LAM Lung/**E.N. Atochina-Vasserman, L.F. Angel, E. Eruslanov, V.P. Krymskaya, Philadelphia, PA, p.A2453

Facilitator: A.S. Kristof, MD, Montreal, Canada

P484 **Myeloid Cell Recruitment in a TSC2-Null Mouse Model of Lymphangioleiomyomatosis (LAM)/**E. Atochina-Vasserman, T. Golden, C. Guo, R. Rue, E. Abramova, V.P. Krymskaya, A.J. Gow, Philadelphia, PA, p.A2454

P485 **Mesenchymal Tsc2 Deficiency Causes Retarded Lung Alveolarization and Polycystic Kidney Lesion/**S. Ren, Y. Luo, H. Chen, E.P. Henske, W. Shi, Los Angeles, CA, p.A2455

P486 **Integrin β5 Implication in the Tumorigenic Potential of TSC-Deficient LAM Cells/**A. Tyryshkin, N.T. Eissa, Houston, TX, p.A2456

THEMATIC POSTER SESSION

A77 AIRWAY SMOOTH MUSCLE: TUNING, TINKERING, AND TREATING

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area N, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: C.A. Singer, PhD, Reno, NV

P1558 **Novel Role of IGFBP1 in Mediating the Anti-Proliferative Effect of Glucocorticoids in Steroid-Insensitive Airway Smooth Muscle Cells/**H. Bui, D. O'Connell, O. Tliba, Philadelphia, PA, p.A2457

P1559 **Post-Treatment Effects of Anti-Malarial Drug, Artesunate, on Primary Human Cultured Airway Smooth Muscle Cell Proliferation/**T. Tran, D.H.J. Cheong, S.S. Tan, Y.K. Qiao, J.K.C. Tam, Singapore, Singapore, p.A2458

P1560 **Pulsed Electromagnetic Field (PEMF) Stimulation Impairs Human Airway Smooth Muscle Cell Proliferation Via Regulation of TRP Channels and Reactive Oxygen Species/**T. Tran, Y.K. Tai, S.S. Tan, J.K.C. Tam, A. Franco-Obregon, Singapore, Singapore, p.A2459

P1561 **Effects of POST Bronchial Thermoplasty Treatment on Airway Inflammation Parameters: A Pilot Study/**T. Tran, K.N. Win, T.K. Chan, W.-S.F. Wong, P. Lee, Singapore, Singapore, p.A2460

P1562 **Modulation of Airway Smooth Muscle Cell Functions Via Isocitrate Dehydrogenase 2 and TET-Mediated Hydroxymethylation/**B.H.-Y. Yeung, T. Dao, J. Huang, S. An, W.-Y. Tang, Baltimore, MD, p.A2461

P1563 **Elevated Histone H3K27 Methylation Mediates Intrinsic Hypercontractility in Human Airway Smooth Muscle Cells from Fatal Asthma Subjects/**E. Yoo, J. Vivieros, S. Sidoli, G. Cao, B.A. Garcia, R.A. Panettieri, Philadelphia, PA, p.A2462

P1564 **Inhibition of Oxidized Phosphatidylcholine Formation in the Lung of Allergen-Challenged Mice: Comparison of Effects for Inhaled Simvastatin and Corticosteroid Treatment/**A. Jha, M.H. Ryu, C.D. Pascoe, R. Chaudhary, A. Ravandi, A.J. Halayko, Winnipeg, Canada, p.A2463

Facilitator: T. Tran, PhD, Singapore, Singapore

P1565 **MicroRNA-155 Targets Tristetraprolin and Enhances Cytokine Expression in Airway Smooth Muscle/**B.S. Comer, A.J. Halayko, W. Gerthoffer, Indianapolis, IN, p.A2464

P1566 **microRNA-25 Targets TSC1 and KLF4 to Regulate ASM Phenotype/**M. Ba, M. Hernandez, J. Evasovic, C.A. Singer, Reno, NV, p.A2465

P1567 **Enhanced α7-Integrin Expression Inhibits miR-124a Expression and Supports a Contractile Phenotype in Airway Smooth Muscle/**L. Schultz, J. Evasovic, P. Cay, A. Aiyuk, S. Romanick, M. Ba, R. Wuebbles, D. Burkin, N. Leblanc, C.A. Singer, Reno, NV, p.A2466

P1568 **Effects of Roflumilast and Albuterol on Airway Hyperresponsiveness (AHR) Induced by IL-13/**R.G. Townley, S. Agrawal, M.R. Hanna, P.J. Oldenburg, Omaha, NE, p.A2467

P1569 **Scaffolding Protein A-Kinase Anchoring Protein 12 Enhances β2-Adrenoceptor Sensitivity in Tracheal Smooth Muscle/** M. Schmidt, W.J. Poppinga, C. Elzinga, H. Meurs, H. Maarsingh, Groningen, Netherlands, p.A2468

P1570 **Airway Responsiveness and Inflammation Is Regulated by p21 Activated Kinase (Pak)1 in Airway Smooth Muscle (ASM) in a Murine Model of Asthma/**W. Zhang, H. Gao, Q. Yu, R.S. Tepper, S.J. Gunst, Indianapolis, IN, p.A2469

P1571 **Multiwalled Carbon Nanotubes Inhibit Migration of Airway Smooth Muscle Cells/**L. Deng, M. Luo, Z. Sun, Y. Lu, Y. Wang, L. Liu, Changzhou, China, p.A2470

THEMATIC POSTER SESSION

A78 AIRWAY SMOOTH MUSCLE: WHAT'S UNDER THE HOOD?

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area N, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: C.Y. Seow, PhD, Vancouver, Canada

P1573 **Distinct Airway Nerve Subtypes Mediate a Toll-Like Receptor 7-Dependent Bronchodilation/**M.G. Drake, B. Proskocil, E. Blum, K. Lebold, A.D. Fryer, D.B. Jacoby, Portland, OR, p.A2471

P1574 **Structural Insights into the Serotonin- and Muscarinic-Induced Smooth Muscle Constriction of Murine Caveolin-3 in Airways/**M. Keshavarz, M. Skill, U. Pfeil, M. Walecki, W. Kummer, G. Krasteva-Christ, Giessen, Germany, p.A2472

P1575 **An Assessment of Ca2+ Sensitivity of Intact Airway Smooth Muscle Contraction Using Phase Loop Plots/**Y.-S. Han, M. Dogan, P. Delmotte, G.C. Sieck, Rochester, MN, p.A2473

P1576 **A Comparison of Airway Contractility and Ca2+ Oscillations in Airway Smooth Muscle in Precision-Cut Lung Slices from BALB/c and C57BL/6 Mice/**J. Chen, M.J. Sanderson, Worcester, MA, p.A2474

P1577 **High CO2 Induces Airway Smooth Muscle Contraction Via Inhibition of Micro RNA 133a/**M. Shigemura, E. Lecuona, M. Angulo, E. Ceco, L.C. Welch, J.I. Sznajder, Chicago, IL, p.A2475

P1578 **Necroptosis Signalling in Lung Epithelial Cells Modulates Mitochondrial Function and Reactive Oxygen Species Generation in Healthy and Asthmatic Airway Smooth Muscle (ASM) Cells/**O.O. Ojo, C. Wiegman, K.F. Chung, I.M. Adcock, London, United Kingdom, p.A2476

P1579 **Airway Hyperresponsiveness Is Associated with Peripheral Airway Smooth Muscle Hypercontractility in the Horse Model of Severe Asthma/**O. Matusovsky, L. Kachmar, G. Ijpma, N. Zitouni, G. Bates, J.-P. Lavoie, A.-M. Lauzon, Montreal, Canada, p.A2477

Facilitator: H. Parameswaran, PhD, Boston, MA

P1580 **Elution of Contractile and Cytoskeletal Proteins from Skinned Airway Smooth Muscle/**L. Wang, C.Y. Yu, P.D. Pare, C.Y. Seow, Vancouver, Canada, p.A2478

P1581 **Time Course of Incorporation of Myosin Molecules into the Contractile Units of Smooth Muscle/**L. Wang, C. Labonte Raymond, P.D. Pare, C.Y. Seow, Vancouver, Canada, p.A2479

P1582 **The Influence of Interleukin-13 on Airway Smooth Muscle Tissue Mechanics/**N.E. Swyngedouw, L. Wang, P.D. Pare, C.Y. Seow, Vancouver, Canada, p.A2480

P1583 **Nicotine-Induced Airway Hyperresponsiveness May Be Due to Inappropriate Lynx1 Levels in Airway Smooth Muscle Cells/**C. Wongtrakool, D. Jia, K. Grooms, M. Hart, Decatur, GA, p.A2481

P1584 **Airway Smooth Muscle Cell Mechanical Force Characterization from In-Utero to Elderly/**R.M. Buchmann, M. Freeman, L.J. Manlove, I. Kuipers, A.J. Haak, V. Sathish, M.A. Thompson, D.J. Tschumperlin, C. Pabelick, Y.S. Prakash, Milwaukee, WI, p.A2482

P1585 **Airway Smooth Muscle Cell Size Increases with Age in Healthy Individuals/**J. Elliot, R. Jones, N. Sandosham, S.-A. Drew, K. McKay, P. Noble, A. James, Nedlands, Australia, p.A2483

P1586 **Collapsibility of Ovine Bronchi Decreases Throughout Life Due to the Emergence of Basal Smooth Muscle Tone/**A.Y.-H. Chang, N. Sorensen, S. Ahmadi-Noorbakhsh, J.J. Pillow, P.B. Noble, Perth, Australia, p.A2484

THEMATIC POSTER SESSION

A79 LUNG IMAGING: CT AND BEYOND

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area N, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: G.K. Prisk, DSc, PhD, La Jolla, CA

P1588 **Ventilation Measurement Using CT End-Inspiration/End-Expiration Image Comparison and a Novel Registration Method/**S. Kadlecek, Y. Xin, H. Hamedani, S. Siddiqui, M. Pourfathi, H. Profka, R.R. Rizi, Philadelphia, PA, p.A2485

P1589 **Ventilation Distribution Based on High Resolution Computed Tomography (HRCT) Determined Lobar Characteristics Improves Aerosol Deposition Modeling/**M. Pichelin, I.M. Katz, S. Montesantos, C. Dubau, C. Majoral, G. Caillibotte, Jouy en Josas, France, p.A2486

P1590 **Estimation of Tissue Volume of Lung Tissue Using Computed Tomography Imaging and Local Reference Values/**R. Thomas, R. Gerber, M. Silva, S. Patz, J. Butler, A. Bankier, S. Loring, Boston, MA, p.A2487

P1591 **CT Image Matching Assessment of Multiscale Lung Responses to Serial Methacholine and Bronchodilator Inhalations in Asthmatic and Healthy Subjects/**J. Choi, S. Choi, C. Lee, E.A. Hoffman, J.D. Newell, C.-L. Lin, Iowa City, IA, p.A2488

P1592 **Statistical Comparison of Segmented High Resolution Computed Tomography (HRCT) Images Taken at Mean Lung Volume Versus Total Lung Capacity in Subjects with Asthma/**S. Montesantos, I.M. Katz, M. Pichelin, R.S. Harris, J.G. Venegas, G. Caillibotte, Jouy en Josas, France, p.A2489

P1593 **3rd Generation Dual Source/Dual Energy CT Allows for Reduction in Radiation Dose and Iodine Concentration Used to Assess Pulmonary Perfused Blood Volume Heterogeneity/**T.M. Dougherty, J.D. Newell, Jr, C.M. Sloan, E. Hammond, S. Hogue, E.A. Hoffman, Iowa City, IA, p.A2490

P1594 **Comparison of Low and Ultra-Low Dose Computed Tomography Protocols Through Quantitative Lung Airway Assessment/**C.M. Sloan, J.C. Sieren, J.D. Newell, Jr, J. Sieren, M. Shirk, C. Vidal, S. Hogue, F. DeStefano, E. Hammond, E.A. Hoffman, Iowa City, IA, p.A2491

P1595 **Tracheomalacia: Getting the Diagnosis Right/**M. Nygaard, E. Bendstrup, O. Hilberg, F. Rasmussen, Aarhus, Denmark, p.A2492

Facilitator: T. Winkler, PhD, Boston, MA

P1596 **Deposition of Coarse Particles in the Lung Periphery Is Mainly Determined by Ventilation/**R.C. Sa, K.L. Zeman, W.D. Bennett, G.K. Prisk, C. Darquenne, La Jolla, CA, p.A2493

P1597 **Airway Closure Measured by Ventilation (V) SPECT/CT Is Reduced After Treatment in Uncontrolled Asthmatics/** C.E. Farrow, J. Watts, F.S.M. Tang, M. Trifunovic, J. Dame Carroll, J. Magnussen, G.G. King, Glebe, Australia, p.A2494

P1598 **Improved Estimations of Flow Distribution Using A 1-D Resistance Network Model in Asthmatic Airways/**S. Choi, J. Choi, S. Miyawaki, E.A. Hoffman, C.-L. Lin, Iowa City, IA, p.A2495

P1599 **Characterizing Patterns of fSAD in Asthma Using an Automated Parametric Response Map Algorithm/**V. Zavaletta, D.G. Mummy, M.L. Schiebler, C. Akgun, E. Anderson, A. Rodriguez, N.N. Jarjour, L.C. Denlinger, S. Fain, Madison, WI, p.A2496

P1600 **Numerical Simulation on Human Trachea Stenosis and Stent Implantation/**Z. Zhang, M. Zhu, X. Shi, L. Deng, Changzhou, China, p.A2497

P1601 **Influence of Airflow Limitation on Regional Variation in the Maximal Respiratory Change in the Distance Between the Pleura and Chest Wall: A Step for the Establishment of Detection Algorithm of Localized Pleural Adhesion on Dynamic Four-Dimensional Ultra-/**Y. Nagatani, M. Hashimoto, N. Nitta, J. Hanaoka, Y. Oshio, K. Iwai, K. Tanaka, S. Tsukagoshi, T. Kimoto, A. Sonoda, H. Otani, K. Murata, Otsu, Japan, p.A2498

P1602 **Reassess the Value of 18F-FDG PET/CT for Relapsing Polychondritis Diagnose and Therapeutic Response Monitoring/**J. Wang, S. Li, Y. Zeng, Guangzhou, China, p.A2499

P1603 **In Vivo Quantitative Assessment of Lung Structural Abnormalities and Inflammation in Small Animal Emphysema and Fibrosis Models Using Micro-Computed and Optical Tomography/**A. KleinJan, Y. Ridwan, P. Van Heijningen, S. Belenkov, F. Stellari, J. Essers, Rotterdam, Netherlands, p.A2500

Facilitator: M.J. Suter, PhD, Boston, MA

P1604 **Preoperative Assessment of Pleural Adhesion Using Dynamic Four-Dimensional Ultra-Low-Dose Computed Tomography (4D-ULDCT) with AIDR 3D; a Preliminary Study/**M. Hashimoto, Y. Nagatani, Y. Oshio, N. Nitta, M. Masumi, N. Ushio, S. Tsukagoshi, T. Kimoto, K. Murata, J. Hanaoka, Otsu, Japan, p.A2501

P1605 **The Effects of Iterative Reconstruction Techniques and High Resolution Kernels on Quantitative Computed Tomography (qCT) Lung Densitometry/**A. Rodriguez, H.H. Chen-Mayer, M. Fuld, D.A. Lynch, P.F. Judy, S. Fain, Madison, WI, p.A2502

P1606 **Harmonization of Dose Reduction Protocols Across Vendor Platforms for Measures of CT Density of the Lungs/**A. Rodriguez, H.H. Chen-Mayer, M. Fuld, D.A. Lynch, P.F. Judy, S. Fain, Madison, WI, p.A2503

P1607 **Survey of Semi-Automatic Segmentation Tools for Computed Tomography Lung Nodule Assessment/**J. Uthoff, S.K.N. Dilger, J.C. Sieren, N. Koehn, F.A. De Stefano, Iowa City, IA, p.A2504

P1608 **Comparison of Chest CT with Spirometry-Assisted Breath Hold or Voluntary Breath Hold in Children/**M. Rosenfeld, J. Otjen, A. Oron, R. DiBlasi, T. Swortzel, E. Gommers, J. Van Weil, J. Swanson, Seattle, WA, p.A2505

P1609 **Metachrony Markedly Accelerates Mucociliary Transport in a Ca2+ and cAMP-Dependent Fashion/**K.B. Turner, V.Y. Lin, S. Birket, S.V. Raju, K. Chu, G. Tearney, G.M. Solomon, S. Rowe, Birmingham, AL, p.A2506

THEMATIC POSTER SESSION

A80-A ARE HSTS OBSOLETE? NOVEL DIAGNOSTICS IN SDB

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area K, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: I.A. Ayappa, PhD, New York, NY

P1127 **Obstructive Sleep Apnea - Corelations Between Clinical Exam, Epworth Sleepiness Scale and Sleep Study Tools (Poligraphy and Polysomnography)/**G. Jimborean, I. Dombi, P. Postolache, E.S. Ianosi, Targu Mures, Romania, p.A2507

P1128 **Risk Factors Associated to Clinical Diagnosis of Moderate/Severe Obstructive Sleep Apnea-Hypopnea Syndrome in a Cohort of Patients Referred to Polysomnography in Northeastern Colombia/**A.F. Villabona-Rueda, T. Mendoza-Herrera, O.L. Rueda-Ochoa, Y. Santamaria-Alza, F. Rojas-Rodriguez, F. Bolivar-Grimaldos, A.C. Rueda-Rivero, A.M. Roca-Amaya, Bucaramanga, Colombia, p.A2508

P1129 **The Role of Berlin Questionnaire in Predicting Obstructive Sleep Apnoea Syndrome Confirmed by Hospital-Based Polysomnography or Home Embletta Sleep Tests/**D.S.-C. Hui, S. Ng, K.-W. To, F. Ko, J. Ngai, K.K. Chan, W.-H. Yip, T.-O. Chan, W.W.-S. Tam, Shatin, Hong Kong Prc, p.A2509

P1130 **Comparison of the Berlin Questionnaire, ASA Checklist and STOP-BANG Questionnaire as Screening Tools for Obstructive Sleep Apnea in a Filipino Population/**J.L. Morales, R.C. Cabana, A.B. Dayo, A.R. Nicolasora, Iloilo, Philippines, p.A2510

P1131 **Investigating Factors Related with High AHI Level Using Portable Monitor in 1275 Occupational Drivers/**M. Ueyama, S. Matsuda, T. Osawa, H. Kokuto, Y. Sasaki, K. Yoshimori, S. Oikawa, F. Suzuki, H. Goto, S. Kudo, Tokyo, Japan, p.A2511

Facilitator: A. Yadollahi, PhD, Toronto, Canada

P1132 **DO I Snore 50: A Preoperative Sleep Questionnaire Derived from Hospital Complications/**A.M. Namen, D. Forest, A. Chatterjee, Z. Ahmad, S. Kumar, K. Huang, A.W. Pickens, E.F. Haponik, Winston-Salem, NC, p.A2512

P1133 **Do I Snore 50: A Sleep Questionnaire that Predicts Major Complications in the Hospitalized Elderly Population/**A.W. Pickens, A.M. Namen, D. Forest, K. Huang, J.A. Williams, R.J. Wyderski, W.R. Hazzard, E.F. Haponik, Winston-Salem, NC, p.A2513

P1134 **Identifying Risk for Obstructive Sleep Apnea in an Inpatient Population/**A.W. Pickens, A.M. Namen, R.J. Wyderski, J.A. Williams, K. Huang, W.R. Hazzard, E.F. Haponik, Winston-Salem, NC, p.A2514

P1135 **Predicting Obstructive Sleep Apnea Using STOP-Bang Questionnaire in the General Population/**A. Tan, Y.Y. Cheung, J. Yin, W.-Y. Lim, L. Tan, C.-H. Lee, Singapore, Singapore, p.A2515

P1136 **Multivariable Apnea Prediction Tool Predicts Obstructive Sleep Apnea (OSA) in Community-Dwelling Habitual Snorers/**M. Sowho, R.S. Arias, H. Pho, T. Otvos, E. Wolfe, I. Hawks, M. Guzman, F. Sgambati, P.L. Smith, H. Schneider, J.P. Kirkness, A.R. Schwartz, Baltimore, MD, p.A2516

Facilitator: T. Penzel, PhD, Berlin, Germany

P1137 **Comparison of Outcomes Using Two Different Scoring Criteria for Obstructive Sleep Apnea (OSA) - Unlocking Pandora's Box?/**A. Fazleen, P. Sankaran, R. Phillips, P.F. Grunstein, Norwich, United Kingdom, p.A2517

P1138 **Variation in Sleep Apnea Severity According to Hypopnea Definition/**A. Prince, O. Llanos, K. Ayoub, S. Ayub, C. Colaco, K. Khasawneh, Little Rock, AR, p.A2518

P1139 **Automated Apnea-Hypopnea Index Estimation by means of Neural Networks to Assist in the Diagnosis of Sleep Apnea in Adults/**A. Crespo, D. Alvarez, G.C. Gutierrez-Tobal, T. A?lvaro De Castro, C.A. Arroyo, R. Hornero, F. Del Campo, Valladolid, Spain, p.A2519

P1140 **Importance of Red Cell Distribution Width for Evaluation of Response to Positive Airway Pressure Therapy in Patients with Obstructive Sleep Apnea Syndrome/**H. Lakadamyali, T. Kivanc, B.D. Yagbasan, Antalya, Turkey, p.A2520

P1141 **Inflammatory Markers in Obstructive Sleep Apnea Syndrome. May Neutrophil/Lymphocyte Ratio Be a New Marker?/**D. Dogan, N. Ocal, C. Tasci, R. Ocal, E. Tozkoparan, S. Gumus, E. Ucar, O. Deniz, B. Yildiz, G. Taskin, Ankara, Turkey, p.A2521

Facilitator: D.P. White, MD, Denver, CO

P1142 **Roles and Relationships of Serum Ischemia-Modified Albumin in Obstructive Sleep Apnea in Comparison with Interleukin-6/**D. Dogan, N. Ocal, M. Aydogan, C. Tasci, S. Tapan, S. Yetkin, Ankara, Turkey, p.A2522

P1143 **A New Marker of Cardiovascular Disease in Patients with Sleep-Disordered Breathing: Results from the Wisconsin Sleep Cohort Study/**A. Sankari, L.A. Finn, S. Maresh, M.S. Hamdon, G. Al-kubaisi, M.S. Badr, P.E. Peppard, Detroit, MI, p.A2523

P1144 **Investigating New Pre-Sleep Biomarkers to Predict the Risk of Sleep Apnea Due to Fluid Overloading/**D. Vena, B. Gavrilovic, O. Lyons, D. Bradley, M.R. Popovic, A. Yadollahi, Toronto, Canada, p.A2524

P1145 **Sex Specific Variations in Tracheal Sound Features Due to Fluid Retention in the Neck/**M. Shokrollahi, F. Rudzicz, A. Yadollahi, Toronto, Canada, p.A2525

P1146 **Periodic Mandibular Movements Detect Cheyne-Stokes Breathing/**J.-B. Martinot, J.C. Borel, V. Cuthbert, H. Guenard, P. Silkoff, D. Gozal, J.L. Pepin, Namur, Belgium, p.A2526

Facilitator: S.A. Sands, PhD, Boston, MA

P1147 **Assessment of Acute Mountain Sickness: All Psychology or What? Do the Lake Louise Scale, a Visual Analogue Scale and Psychological Well-Being Scales Measure the Same?/**A. Fruhauf, N. Netzer, M. Burtscher, M. Faulhaber, S. Wimmer, M. Koop, Innsbruck, Austria, p.A2527

P1148 **Evaluation of the Autonomic Nervous System's Variations in Laboratory-Induced Dyspnea in Healthy Subjects/**L. Beaumont, C. Sevoz-Couche, T. Similowski, C. Morelot-Panzini, Suresnes, France, p.A2528

P1149 **Risks of False Negative Obstructive Sleep Apnea Diagnosis: The Single Tertiary Hospital Base Study/**L.W. Hang, Taichung, Taiwan, p.A2529

P1150 **Electrocardiographic Associations Seen with Obstructive Sleep Apnea/**S. Shankar, C. Obiagwu, A. Saxena, S. Demir, S. Gupta, G. Rojas-Marte, A. Rai, P. Homel, Y. Kupfer, Brooklyn, NY, p.A2530

THEMATIC POSTER SESSION

A80-B VIEWING OSA PATHOGENESIS IN COLOR INSTEAD OF BLACK AND WHITE

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area K, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: D.A. Wellman, MD, PhD, Boston, MA

P1152 **Loop Gain Measurements from Home Sleep Testing in Obstructive Sleep Apnea/**J.E. Orr, S.A. Sands, B.A. Edwards, Y. Li, R. Jen, N.L. Deacon, A. Malhotra, R.L. Owens, La Jolla, CA, p.A2531

P1153 **Mean Segment Duration of Hypoxemia (MSD) in Obstructive Sleep Apnea: A Review of 4041 Baseline Polysomnograms/** J.A. Turner, R.K. Bogan, Columbia, SC, p.A2532

P1154 **Mean Segment Duration of Oxygen Desaturations (Seconds) in Sleep Induced Hypoxemia: A Review of 85886 Cases/**R.K. Bogan, J.A. Turner, Columbia, SC, p.A2533

P1155 **Characteristics and Clinical Impact of the Arousal Threshold in Korean Obstructive Sleep Apnea Patients/**W.C. Shin, Y. Li, R. Jen, D. Pamela, R.L. Owens, A. Malhotra, Seoul, Korea, Republic of, p.A2534

P1156 **Gender Differences in Prevalence of Obstructive Sleep Apnea (OSA) and Arousal Threshold in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)/**R. Jen, R.L. Owens, A. Malhotra, A.L. Ries, X. Soler, La Jolla, CA, p.A2535

Facilitator: N.L. Deacon, PhD, La Jolla, CA

P1157 **Obstructive Sleep Apnea Is Common in the Absence of Obesity and Is Difficult to Treat: Evidence for a Distinct Pathophysiological Phenotype/**E.L. Gray, D.K. McKenzie, D.J. Eckert, Sydney, Australia, p.A2536

P1158 **Positional Sleep Apnea Is a Cause of Inter-Night Variability in the Apnea Hypopnea Index/**H. Alshaer, T.D. Bradley, Toronto, Canada, p.A2537

P1159 **The Effect of Body Mass Index on the Upper Airway of Severe Obstructive Sleep Apnea Patients/**L. Oliveira, N.T. Fonseca, J.J. Urbano, S. Romano, G. Insalaco, Sao Paulo, Brazil, p.A2538

P1160 **Impact of the Supine Position on Gas Exchange and Vital Capacity in Patients with Morbid Obesity/**S. Sivam, K. Wong, C. Zwillich, B. Yee, D. Wang, R. Grunstein, A.J. Piper, Camperdown, Australia, p.A2539

P1161 **Low Lung Volumes Predispose to Obstructive Apnea More than Airway Hyper-Reactivity/**S.C. Shah, E. Gartman, F.D. McCool, Providence, RI, p.A2540

Facilitator: K. Kairaitis, MD, Sydney, Australia

P1162 **Development of a Non-Invasive Treatment for Sleep Apnea/**F.H.Y. Green, A. Chiu, S. Dalberg, G. Shrestha, M. Fadayomi, C. Pieron, T. El Mays, D.E. Nelson, G. Lewis, G. Lalli, J. Dennis, Calgary, Canada, p.A2541

P1163 **Evaluation of the Nasal Microbiome in World Trade Center Dust Exposed Subjects/**L. Segal, J. Sunderram, H. Kipen, R.J. Laumbach, S.-E. Lu, I. Udasin, J.L. Carson, O. Le-Hoang, A. Perez, S. Alimokhtari, K. Black, B.G. Wu, M. Plietz, A. Twumasi, B.D. Scaglione, Y. Li, A. Wang, J. Gilani, D.M. Rapoport, D. Harrison, N. Chitkara, T. Gumb, C. Lewis, I.A. Ayappa, New York, NY, p.A2542

P1164 **Upper Airway Effective Compliance Determined by Image-Based Computational Fluid Dynamics Correlates with Critical Closing Pressure and Apnea-Hypopnea Index in Obese Adolescent Girls/**D.M. Wootton, H. Luo, A. Yazdani, S. Sin, M.E. Wagshul, C.R. Isasi, R. Arens, New York, NY, p.A2543

P1165 **Effect of PCI on the Stability of Respiratory Center Function in Coronary Heart Disease Patients Complicated with OSAHS/** X. Zhao, F. Zhao, L. Zhang, G. Li, Y. Li, Tianjin, China, p.A2544

P1166 **Effects of Overnight Rostral Fluid Shift on the PCO2 in Patients with Heart Failure and Sleep Apnea/**A. Yadollahi, T. Inami, T.D. Bradley, Toronto, Canada, p.A2545

Facilitator: B.A. Edwards, PhD, Melbourne, Australia

P1167 **Effects of Fluid Shift on Upper Airway Patency and Neck Circumference in Obstructive Sleep Apnea Patients/**Y. Huang, C. Wang, H. Zhang, H. Lin, Z. Li, H. Xu, Y. An, J. Xian, Beijing, China, p.A2546

P1168 **Evaluation of Upper Airway Inflammation; a Potential Role for Pharyngeal Lavage/**X. Soler, R. Jen, E. Vicente, A.L. Ries, A. Malhotra, J.M. Marin, La Jolla, CA, p.A2547

P1169 **The Developmental Change of Central Sleep Apnea in Infants with Congenital Laryngomalacia/**W. Ratanakorn, J. Zhou, N. Simakajornboon, Cincinnati, OH, p.A2548

P1170 **Age-Related Changes in Baroreflex Sensitivity in Children with Obstructive Sleep Apnea/**A. Shamsuzzaman, K. McConnell, M. DiFrancesco, S.L. Ishman, N. Zhang, G. Huang, R.S. Amin, Cincinnati, OH, p.A2549

P1171 **Anatomic Predictors of Response to Upper Airway Stimulation in OSA Patients/**R.J. Schwab, S.H.C. Wang, J. Verbraecken, W. De Backer, P. Van De Heyning, J.W. De Backer, B.T. Keenan, Q. Ni, O.M. Vanderveken, Philadelphia, PA, p.A2550

Facilitator: R. Mehra, MD, Cleveland, OH

P1172 **Acoustic Pharyngometry Assessments with Unilateral Hypoglossal Stimulation for OSA**/D.G. Venkat, M. Ayache, Y. Gopalan, C. Burant, K.P. Strohl, Cleveland, OH, p.A2551

P1173 **Evaluation of Upper Airway Characteristics and Upper Airway Stimulation Response**/C. Kastoer, Q. Ni, O.M. Vanderveken, P.H. Van De Heyning, Edegem, Belgium, p.A2552

P1174 **The Effect of Different Altitude on Sleep Apnea of Han Nationality and Uyghur Nationality**/H. Zhongming, H. Fang, L. Yunhui, D. Xiaosong, L. Jianping, L. Qingsheng, K.P. Strohl, Keramay, China, p.A2553

P1175 **Prevalence of Acromegaly Among Patients Referred for Sleep Apnea Syndrome: ACROSAS Study**/L.-M. Galerneau, J.L. Pepin, A.-L. Borel, O. Chabre, M. Sapene, B. Stach, J. Girey-Rannaud, R. Tamisier, P. Caron, Grenoble, France, p.A2554

Facilitator: D.M. Rapoport, MD, New York, NY

P1176 **Prevalence of Sleep Disordered Breathing in a Saudi Population**/S.O. Wali, B. Abalkhail, M. Alotaibi, A. Krayem, Jeddah, Saudi Arabia, p.A2555

P1177 **Obstructive Sleep Apnea Risk and Excessive Daytime Sleepiness Among Intercity Commercial Drivers in Benin City, Nigeria**/A.Q. Aigbokhaode, A.R. Isara, Umuahia, Abia State, Nigeria, p.A2556

P1178 **Prevalence of Sleep-Disordered Breathing in a Multiethnic Asian Population in Singapore: A Community-Based Study**/A. Tan, Y.Y. Cheung, J. Yin, W.-Y. Lim, L. Tan, C.-H. Lee, Singapore, Singapore, p.A2557

P1179 **Membrane Progestrone Receptors α and β Contribute to Regulation of Breathing in Adult Male and Female Mice**/ R. Boukari, O. Rossignol, F. Marcouiller, A. Bairam, V. Joseph, Quebec, Canada, p.A2558

THEMATIC POSTER SESSION

A80-C MOLECULAR AND IMMUNOBIOLOGY OF LUNG CANCER

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area C, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: R. Savai, PhD, Bad Nauheim, Germany

P289 **ADAM9 Enhances CDCP1 Protein Expression by Suppressing miR-218 for Lung Tumor Metastasis**/K.-L. Chiu, T.-T. Kuo, Q.-Y. Kuok, Y.-S. Lin, C.-H. HUA, C.-Y. LIN, P.-Y. Su, L.-C. Lai, Y.-P. Sher, Taichung, Taiwan, p.A2559

P290 **Dynamic Monitoring of EGFR Mutation in Plasma Cell-Free DNA by Digital PCR**/L. Zhang, X. Si, F. Qiu, H. Wang, X. Zhang, M. Wang, Beijing, China, p.A2560

P291 **Self-Assembled Triangular DNA Nanoparticles-Conjugated Atg101 siRNA Induces the Apoptosis of Lung Cancer A549 Cells by Activating p53-p21 Pathways**/G. Wang, B. He, Chognqing, China, p.A2561

P292 **Histology-Specific Effects of Parathyroid Hormone-Related Protein on Integrin Traffic in Human Lung Cancer**/P.R. Montgrain, O.H. Mohamedaly, A. Davani, R. Quintana, R.H. Hastings, San Diego, CA, p.A2562

P293 **PAI-1 Plays an Important Role in Lung Cancer Progression Through Differentiation of Cancer-Associated Fibroblasts to Myofibroblasts**/T. Masuda, N. Hattori, Y. Horimasu, S. Miyamoto, T. Nakashima, H. Iwamoto, K. Fujitaka, N. Kohno, Hiroshima, Japan, p.A2563

P294 **Laricitrin, a Polyphenolic Compound of Red Grape, Inhibits Lung Cancer-Mediated Dendritic Cell Suppression by Decreasing Signal Transducer and Activator of Transcription 3 Pathway**/Y.-L. Hsu, Kaohsiung, Taiwan, p.A2564

P295 **Modulation of FAK Activity by MARCKS Is Involved in Migration of Lung Cancer Cells**/J. Park, S. Fang, Q. Yin, A. Crews, K. Adler, Raleigh, NC, p.A2565

P296 **FASN Promote Non-Small-Cell Lung Cancer Growth and Chemoresistance by Upregulation PKM2 and Enhancing Warburg Effect**/X. Jin, W. Huang, S. Wang, Wuhan, China, p.A2566

P297 **The Role of Acyl-CoA Thioesterase Gene Family in Lung Adenocarcinoma**/M.-J. Tsai, M.-C. Yen, S.-R. Chiang, J.-Y. Hung, M.-S. Huang, Y.-L. Hsu, Kaohsiung, Taiwan, p.A2567

P298 **Microsomal Prostaglandin E Synthase-1 (mPGES-1) Facilitates Mobilization of MDSC from Bone Marrow and Induces Lung Metastasis Formation**/R. Takahashi, H. Amano, K. Eshima, T. Satoh, S. Akira, M. Majima, Kanagawa, Japan, p.A2568

P299 **Cosuppression of Stat3 and Src/p190RhoGAP Leads Synergistic Growth Inhibition in KRAS Mutant Lung Adenocarcinoma**/K. Onodera, A. Sakurada, H. Notsuda, T. Watanabe, Y. Matsuda, M. Noda, Y. Hoshikawa, Y. Okada, Sendai, Japan, p.A2569

P300 **Lung Cancer Associated Fibroblast-Mediated Cancer Progression and Immune Inhibition Through TDO2/Kynurenine Loop**/P.-L. Kuo, Kaohsiung, Taiwan, p.A2570

Facilitator: H. Kathuria, MD, Boston, MA

P301 **Angiotensin Antagonist Drugs Inhibit the Growth and Lymphatic Metastasis of Lung Adenocarcinoma in Nude Mice**/W.X. Qu, G. Lu, Y. Li, Y. Zhao, P. He, Shenyang, China, p.A2571

P302 **Genome-Wide DNA Methylation Study Identified Lung Cancer Specific Differentially Methylated Regions**/J. Park, H.-K. Koo, W.J. Kim, Seoul, Korea, Republic of, p.A2572

P303 **Elevated Plasma Ciz1b Variant Expressions in Non-Small Cell Lung Cancer Are Reduced After Surgical Resection of Stage I Lung Cancer**/V. Ifeacho, G. Rubiaco, A. Ryazantsev, M. Risco, K. Almodovar, O. James, D. Upadhyay, Fresno, CA, p.A2573

P304 **Role of Plasma ELMO3 in the Diagnosis of Non-Small Cell Lung Cancer/**V. Ifeacho, K. Almodovar, M. Sachadeva, A. Ryazantsev, O. James, G. Rubiaco, M. Risco, D. Upadhyay, Fresno, CA, p.A2574

P305 **Different Effects of STAT5b and AKT Activation by Celecoxib in High and Low Doses on TGF-β1-Induced Epithelial-Mesenchymal Transition/**H.-R. Kim, K.-E. Hwang, K.-H. Cho, E.-T. Jeong, Iksan, Jeonbuk, Korea, Republic of, p.A2575

P306 **Regulation of Tumor Cell Proliferation by PECAM-1/**V. Abraham, A. Parambath, G. Cao, R. Debs, H. DeLisser, Philadelphia, PA, p.A2576

P307 **Implication of YY1 in Non-Small Cell Lung Cancer/**O. Boucherat, S. Chabot, A. Bourgeois, S. Provencher, R. Paulin, F. Maltais, S. Bonnet, Quebec, Canada, p.A2577

P308 **High Levels of Beclin-1 in Induced Sputum of Lung Cancer Patients as a Marker of Increased Autophagy/**A. Bar-Shai, A. Ahimor, N. Ofir, Y. Schwarz, E.M. Fireman, Tel-Aviv, Israel, p.A2578

P309 **Transcriptome Analysis of Small Cell Lung Cancer/**M. Horie, A. Saito, T. Nagase, Tokyo Bunkyoku, Japan, p.A2579

P310 **IARS2 Silencing Induced Non-Small Cell Lung Cancer Cells Proliferation Inhibition, Cell Cycle Arrest and Promoted Cell Apoptosis/**K. Wang, J. Yin, R. Li, Changchun, China, p.A2580

P311 **Inhibiting Autophagy Promotes Cisplatin-Induced Apoptotic Cell Death in A549 Human Lung Cancer Cells/**L. Zhang, Changsha, China, p.A2581

P312 **Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients that Harbors A HER2 Gene Mutation in Comparison with Other Driver Mutations/**C.-H. Gow, H.-T. Chang, J.-Y. Shih, New Taipei City, Taiwan, p.A2582

Facilitator: S.J. Moghaddam, MD, Houston, TX

P313 **The Potential Mechanism of SPP1 Related Extra Cellular Matrix Remolding in Lung Adenocarcinoma Development/**Y. Zhang, L. Wang, H. Wang, X. Wang, Shanghai, China, p.A2583

P314 **Effect of Gene Silencing of Transketolase Mediated by RNAi in A549 Lung Cancer Cells/**H.-L. Zhu, H. Lu, Shanghai, China, p.A2584

P315 **Adenylate Cyclase-Associated Protein 1 Is Associated with Metastasis of Non-Small Cell Lung Cancer Especially in Brain Metastasis Patients and Promotes the Lung Cancer Cell Proliferation and Migration In Vitro as Well as Its Growth and Metastasis In Vivo /**C. Wang, S. Xie, shanghai, China, p.A2585

P316 **PTX-3 Overexpression in BLAF Is Associated with High Value for the Diagnosis of Lung Cancer/**Z. Sun, Q. Shadike, T. Wang, Xi'an, China, p.A2586

P317 **Expression and Function of Mononuclear Cell Tissue Factor in Patients with Non-Small Cell Lung Cancer/**S. Wu, Fuzhou, China, p.A2587

P318 **Expression of Protein Kinase EML4-ALK Gene in Non-Small Cell Lung Cancer in Fundacion Valle del Lili, a University Hospital of Reference in Latin America/**L. Fernandez, L.F. Sua, C.A. Munoz, J.G. Restrepo, Cali, Colombia, p.A2588

P319 **Epidermal Growth Factor Receptor Mutation in Patients with Non-Small Cell Lung Carcinoma in Fundacion Valle del Lili, a University Hospital of Reference in Latin America/**L. Fernandez, L.F. Sua, L.X. Rodriguez, C.A. Munoz, M. Velasquez, J.G. Restrepo, Cali, Colombia, p.A2589

P320 **RBM5 Overexpression Is Associated with Acquired Resistance of EGFR-TKI in Non-Small Cell Lung Cancer Cells/**Z. Jie, L.X. Jiao, H.Y. Qiu, S.Z. Zhong, W. Qi, M.G. Ping, Z. Lin, Changchun, Jilin Province, China, p.A2590

P321 **Epidermal Growth Factor Receptor Mutations Enhances Expression of Cadherin-5 in Lung Cancer/**M.-S. Hung, J.-H. Lung, Y.-H. Fang, Y.-C. Lin, Y.-H. Tsai, Puzih City, Taiwan, p.A2591

P322 **The Effect of Prostacyclin on miRNAs in a Murine Model of Lung Cancer Chemoprevention/**M. New, L. Dwyer-Nield, D. McArthur, M. Tennis, R.L. Keith, Aurora, CO, p.A2592

P323 **MiR-1 Expression in the Vicinity of Non-Small Cell Cancer Correlates with Patient Survival/**A. Ramaswamy, L. Jin, B. Hu, D. Boffa, M. Pisani, J.T. Puchalski, S. Takyar, New Haven, CT, p.A2593

11:45 a.m. - 1:15 p.m.

S2 ATS DIVERSITY FORUM

SAN FRANCISCO MARRIOTT MARQUIS
Yerba Buena Salon 7 (Lower B2 Level)

The annual ATS Diversity Forum focuses on diversity within the fields of pulmonary, critical care, and sleep medicine and research. The forum will feature **Sonia C. Flores**, **PhD**, Professor, Department of Medicine, Division of Pulmonary Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado, who will address career and diversity issues and answer questions from the audience.

The Minority Trainee Development Scholarships (MTDS), which recognize trainees who are members of underrepresented minority groups, will also be presented at this forum. MTDS recipients are selected for the quality of the science in their submitted abstract, among other criteria. Their abstracts will be presented in other sessions at this conference, and also displayed at this Diversity Forum.

Mentors, past MTDS (formerly MTTA) recipients, and other conference attendees are encouraged to attend this forum which provides an opportunity for discussion and networking among attendees and to congratulate the scholarship recipients! Attendees will find inspiration and valuable career insights.

The Diversity Forum is organized and presented by the ATS Membership Committee and will be hosted by its chair **Yolanda Mageto, MD, MPH**. The Minority Trainee Development Scholarships are supported by the American Thoracic Society.

Conference badges are required for admission.
Space is limited and admittance is on a first-come, first-served basis. There is no additional fee. A plated lunch will be served.

11:00 a.m.-12:15 p.m.

SECTION MEMBERSHIP MEETING

San Francisco Marriott Marquis
Yerba Buena Salon 13-15 (Lower B2 Level)

The Section meetings are open to all ATS members and other interested individuals. Items to be discussed include the Sections' current projects and future directions.

MEDICAL EDUCATION

Chairing: P.A. Kritek, MD, Seattle, WA

CLINICAL

WORKSHOP

CME Credits Available: 1.5

WS1 GUIDELINES FOR THE EVALUATION OF THE WHEEZING INFANT

Registration Fee: $75.00 (includes box lunch)
Attendance is limited. Pre-registration is required.

Assemblies on Pediatrics; Allergy, Immunology and Inflammation; Clinical Problems; Respiratory Structure and Function

11:45 a.m. - 1:15 p.m. **MOSCONE CENTER**
Room 301 (South Building, Esplanade Level)

Target Audience
Clinicians caring for infants and young children with respiratory disease .

Objectives
At the conclusion of this session, the participant will be able to:

- use bronchoscopy to identify causes of infantile wheezing;
- know the role of food allergy testing in the evaluation of infantile wheezing;
- diagnose GERD in wheezing infants.

Infantile wheezing is a common clinical problem encountered by pediatric respiratory specialists. In 2011, an ATS project to develop evidence based guidelines for diagnostic evaluation of infantile wheezing was initiated. The recommendations have been completed and will be submitted for peer review this summer. This workshop will review the key recommendations that the working group developed.

Chairing: C.L. Ren, MD, Indianapolis, IN

11:45 **Introduction**
C.L. Ren, MD, Indianapolis, IN

12:05 **Role of Bronchoscopy in the Evaluation of the Wheezing Infant**
C.R. Esther, MD, PhD, Chapel Hill, NC

12:25 **Evaluation of Food Allergy in Infantile Wheezing**
O. Yilmaz, MD, Manisa, Turkey

12:40 **Role of Infant PFTs in the Evaluation of Infantile Wheezing**
J.S. Debley, MD, MPH, Seattle, WA

12:55 **GERD and Infantile Wheezing**
M.M. Sockrider, MD, DrPH, Houston, TX

1:10 **Wrap Up**
C.L. Ren, MD, Indianapolis, IN

The information contained in this program is up to date as of March 9, 2016.
For the most current session information, please visit the online program itinerary.

CLINICAL • TRANSLATIONAL

WORKSHOP

CME Credits Available: 1.5

WS2 OBSTRUCTIVE SLEEP APNEA IN THE ELDERLY: A DISCUSSION OF KEY CLINICAL QUESTIONS

Registration Fee: $75.00 (includes box lunch)
Attendance is limited. Pre-registration is required.

Assembly on Sleep and Respiratory Neurobiology

11:45 a.m. - 1:15 p.m. **MOSCONE CENTER**

Room 302 (South Building, Esplanade Level)

Target Audience
Pulmonologists, sleep physicians, fellows, nurses, fellows in training, clinical researchers, everybody involved in sleep units, pediatricians, geriatric physicians and nurses.

Objectives
At the conclusion of this session, the participant will be able to:

- understand the preconditioning hypoxia phenomenon and its relationship with intermittent hypoxia;
- distinguish between physiology and pathology related to the number and severity of sleep disorder-breathing in elderly;
- know the effect of CPAP treatment on cardiovascular, quality of life and neurocognitive domains in elderly with OSA compared with the effect in younger people and decide what to do in very old patients (more than 80 years) with clinical suspicion of obstructive sleep apnea, regarding treatment with CPAP.

This workshop has been designed to discuss some important clinical questions that all clinicians who follow elderly patients with obstructive sleep apnoea have. The course is also an opportunity to discuss with some of the most important researchers in the area of sleep apnoea in the elderly, what is the impact of OSA and treatment of CPAP in older patients compared with younger ones, to understand the pathophysiological pathways which govern this impact and decide, from a a clinical point of view, the limits of OSA studies and treatment in very old patients.

Chairing: M. Martinez-Garcia, MD, Valencia, Spain
N.C. Netzer, MD, PhD, Bad Aibling, Germany

11:45 **Introduction**
M. Martinez-Garcia, MD, Valencia, Spain

11:50 **Sleep-Disordered Breathing in the Elderly: Where Is the Limit Between the Physiology and Pathology?**
N.C. Netzer, MD, PhD, Bad Aibling, Germany

12:10 **Preconditioning by Intermittent Hypoxia in the Elderly: Clinical Implications**
M. Morrell, MD, PhD, London, United Kingdom

12:30 **From Cardiovascular to Neurocognitive Effects of CPAP in the Elderly**
M. Martinez-Garcia, MD, Valencia, Spain

12:50 **Is CPAP Forever? How Should We Manage Patients Over 80 Years?**
S. Ancoli-Israel, PhD, La Jolla, CA

CLINICAL

ADULT CLINICAL CORE CURRICULUM

CME Credits Available: 1.5

CC1 PULMONARY CLINICAL CORE CURRICULUM I

Adult Core Curriculum Working Group

11:45 a.m. - 1:15 p.m. **MOSCONE CENTER**

Gateway Ballroom 102-104 (South Building, Lower Level)

Target Audience
Internists and subspecialists in pulmonary, critical care, and sleep medicine who work in a clinical setting and are currently engaged in maintenance of certification.

Objectives
At the conclusion of this session, the participant will be able to:

- remain current with medical knowledge relevant to their practice in pulmonary, critical care, and sleep medicine;
- evaluate their understanding of key skills and content areas in pulmonary, critical care and sleep medicine, as well as receive feedback on their comprehension of a result of a pre-test/post-test comparison;
- support clinicians who are engaged in maintenance of certification activities by providing updates on subjects included in recertification requirements.

The ATS Clinical Core Curriculum Symposia focus on a 3-year content cycle of key medical content in the areas of pulmonary, critical care, and sleep medicine. The topics are also aligned with corresponding MOC Medical Knowledge modules. This symposium is intended to assist clinicians with staying current with the growth of information relevant to their medical practice, as well as provide an opportunity to evaluate individual knowledge and skills while earning MOC Medical Knowledge points.

Chairing: G.C. Michaud, MD, New York, NY
C.L. Channick, MD, Boston, MA

11:45 **COPD: Pathophysiology/Diagnosis/PFT**
J.B. McCannon, MD, Boston, MA

12:05 **COPD Management: Pharmacological and Non-Pharmacological**
G. Garrison, MD, Burlington, VT

12:45 **Rare Lung Diseases: Rare Vascular Abnormalities and Rare Complications of Asthma**
P. Akuthota, MD, San Diego, CA

*This session and the International Conference are supported by an educational grant from **AstraZeneca LP.***

All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

U.S. FOOD AND DRUG ADMINISTRATION CENTER FOR DRUG EVALUATION AND RESEARCH

L1 GENERIC DRUG DEVELOPMENT FOR RESPIRATORY PRODUCTS: U.S. FOOD AND DRUG ADMINISTRATION UPDATE

12:15 p.m. - 1:15 p.m. **MOSCONE CENTER**

Room 3016/3018 (West Building, Level 3)

Target Audience
Clinicians in practice, researchers, pharmaceutical industry representatives, international drug regulators.

Objectives
At the conclusion of this session, the participant will be able to:

- recognize key aspects of the generic drug regulatory approval process, and their impact on inhaled generic drug products;
- describe how the Office of Generic Drugs (OGD) evaluates bioequivalence for complex inhaled generic drug products, using a weight-of-evidence approach, and how pharmacodynamic (PD) studies are used to establish equivalent local delivery;
- articulate how device and formulation similarity, in vitro performance studies, and pharmacokinetic (PK) studies are utilized within the weight-of-evidence approach to establish bioequivalence for generic inhaled drug products.

This session will describe respiratory product development of generic drugs within the U.S., focusing on paths forward to bring safe and effective generic respiratory products to the American public. History of the generic drug approval process will be explored, distinguishing generic approval from new drug approvals, and identifying key regulations by which approvals are governed. Generic drug program requirements including bioequivalence, pharmaceutical equivalence, and product performance will be discussed, including the role of clinical endpoint studies, recommendations for combination drug products, and drug-device issues specific for metered dose inhaler (MDI) and dry powder inhaler (DPI) products.

Chairing: K.A. Witzmann, MD, Silver Spring, MD

12:15 **Introduction**
K.A. Witzmann, MD, Silver Spring, MD

12:18 **Overview of FDA Generic Inhaled Drug Approval Process**
L. Lapteva, MD, MHS, Silver Spring, MD

12:35 **Discussion of the Generic Approval Process, Specific to Inhaled Drug Products**
K.A. Witzmann, MD, Silver Spring, MD

12:52 **Bioequivalence for Complex Inhaled Generic Drug Products: Formulation Similarity, In Citro Studies and Pharmacokinetics (PK)**
B. Saluja, PhD, Silver Spring, MD

1:09 **Questions and Answers**
K.A. Witzmann, MD, Silver Spring, MD

NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES, NIH

L2 INSIGHTS INTO ASTHMA SEVERITY FROM THE INNER-CITY ASTHMA CONSORTIUM

12:15 p.m. - 1:15 p.m. **MOSCONE CENTER**

Room 3006/3008 (West Building, Level 3)

Target Audience
Clinicians, researchers, health care administrators, public health specialists, asthma educators.

Objectives
At the conclusion of this session, the participant will be able to:

- understand how host and environmental factors work in concert to determine asthma severity;
- learn how IgE levels influence viral infection and illness;
- learn how lowering IgE levels restores anti-viral immunity focusing on the dendritic cell.

The Inner City Asthma Consortium (ICAC) has over 20 years experience studying asthma morbidity among inner city children and adolescents. This session will present data from two recently completed ICAC studies demonstrating the complex interaction of host and environmental factors on asthma severity and the impact of IgE level on viral respiratory infections and subsequent exacerbations.

Chairing: P.J. Gergen, MD, MPH, Rockville, MD

12:15 **Risk Pathways Determining Asthma Severity**
A. Liu, MD, Denver, CO

12:35 **How Does Omalizumab Affect Viral Respiratory Infections and Illnesses in Asthma?**
J.E. Gern, MD, Madison, WI

12:55 **Understanding the Role of Dendritic Cells in Anti-Viral Immunity**
M. Gill, MD, Dallas, TX

NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES 50TH ANNIVERSARY SESSION

L3 INDOOR EXPOSURE TO BIOMASS/WOODSMOKE EXPOSURE AND PULMONARY HEALTH

12:15 p.m. - 1:15 p.m. **MOSCONE CENTER**

Room 3010/3012 (West Building, Level 3)

Target Audience
Basic and clincal researchers, physicians, pulmonologists and community and public health specialists.

Objectives
At the conclusion of this session, the participant will be able to:

- understand the levels and potential effects of indoor air pollution on pulmonary health;

- gain knowledge on biochemical and molecular pathways involved in exposure to particulates from biomass combustion;
- understand current efforts on developing potential interventions strategies.

Globally half of the population relies on solid fuels for their everyday energy requirements. The rural households in developing and underdeveloped countries mainly use biomass fuels (wood, dung, crop wastes) that are typically burned in inefficient, poorly ventilated homes (often open fires). Women and infants in these homes have very high exposures to smoke, typically levels that are considered harmful to health by the U.S. Environmental Protection Agency (EPA) and the World Health Organization (WHO). The presentations at this session will highlight our current efforts in addressing these issues from monitoring exposure to developing preventive and intervention measures.

Chairing: S.S. Nadadur, PhD, Durham, NC
J.R. Balmes, MD, San Francisco, CA

12:15 **Introduction**
S.S. Nadadur, PhD, Durham, NC

12:20 **Use of the MicroPEM to Support Biomass Cookstove Exposure and Health Outcome Studies**
J. Thornburg, PhD, Durham, NC

12:37 **Household Air Pollution: A Major Preventable Cause of COPD**
J.R. Balmes, MD, San Francisco, CA

12:54 **Development of Interventions for PM Induced Airway and Systemic Diseases**
D. Peden, MD, Chapel Hill, NC

PATIENT CENTERED OUTCOME RESEARCH INSTITUTE

L4 UPDATES ON PATIENT-CENTERED OUTCOME RESEARCH INSTITUTE (PCORI): PCORNET AND EVIDENCE TO ACTION NETWORKS

12:15 p.m. - 1:15 p.m. **MOSCONE CENTER**
Room 3020/3022 (West Building, Level 3)

Target Audience
Clinicians (physicians, nurses, fellows, residents), researchers, administrators and policymakers; anyone involved in delivery of care and the science of patient-centered research.

Objectives
At the conclusion of this session, the participant will be able to:

- understand the role of Patient Centered Outcomes Research Institute in funding comparative effectiveness research;
- understand how a patient stakeholder is engaged in PCORI projects;
- learn from PCORI researchers what network activities are ongoing.

A PCORI official will introduce summaries of PCORI funded projects in pulmonary, critical care and sleep disorders and the presenters will expand on this by introducing the unique network activities in asthma, COPD and transition of care. A patient stakeholder/reviewer will also discuss their involvement in PCORI funded projects and their view as a patient grant reviewer. The purpose of the session will be to raise awareness of PCORI activities relevant to patient centered care for patients with pulmonary, critical care, and sleep disorders.

Chairing: J.V. Selby, MD, MPH, Washington, DC
K. Sumino, MD, MPH, St. Louis, MO

12:15 **Patient Centered Outcome Research Institute in Thoracic Disease**
J.V. Selby, MD, MPH, Washington, DC

12:25 **Lay PCORI Grant Reviewer Perspective**
J. Sullivan, MPH, Washington, DC

12:30 **Update on COPD Patient-Powered Research Network and PCORnet**
R.A. Mularski, MD, MSHS, Portland, OR

12:40 **Update in Evidence to Action Network in Asthma**
K. Sumino, MD, MPH, St. Louis, MO

12:50 **Update on PCORI Evidence to Action Network for Transitions in Care**
J.A. Krishnan, MD, PhD, Chicago, IL

1:00 **Panel Discussion**
J.V. Selby, MD, MPH, Washington, DC

NATIONAL HEART, LUNG, AND BLOOD INSTITUTE, DIVISION OF LUNG DISEASES, NIH

L5 PREMATURITY AND RESPIRATORY OUTCOMES PROGRAM (PROP): RESPIRATORY OUTCOMES AT ONE YEAR

12:15 p.m. - 1:15 p.m. **MOSCONE CENTER**
Room 2002/2004 (West Building, Level 2)

Target Audience
Pediatric providers of lung health, basic and clinical researchers interested in neonatal lung diseases, including pediatric, pulmonologists, neonatologists and basic pulmonary biology researchers.

Objectives
At the conclusion of this session, the participant will be able to:

- understand that respiratory outcomes of the premature can persist beyond the NICU period;
- learn and understand how to measure respiratory morbidity of extremely premature infants after the NICU;
- learn that objective measures of respiratory physiology can detect consequences of extremely premature birth.

PROP is a multicenter, observational cohort of extremely low birth weight infants at high risk of bronchopulmonary dysplasia (BPD) and long-term respiratory morbidity. Infants 29 weeks gestation were enrolled and reached a neonatal outcome at 12 months corrected age (n = 765). PROP prospectively collected standardized clinical data to test for associations between neonatal clinical parameters, respiratory physiology at 36 weeks postmenstrual age, and respiratory status at one-year corrected age. This session will focus on presentations of the 12 month corrected age outcomes of the PROP cohort including respiratory symptoms, respiratory medication use, and infant pulmonary function.

Chairing: L.M. Taussig, MD, Denver, CO
C.J. Blaisdell, MD, Bethesda, MD

12:15 **Post-Prematurity Respiratory Disease**
R. Keller, MD, San Francisco, CA

12:45 **Assessing Severity of Post-Prematurity Respiratory Disease**
P.E. Moore, MD, Nashville, TN

1:00 **Infant Lung Function Outcomes at 1 Year in ELGANs**
S. Davis, MD, Indianapolis, IN

NATIONAL HEART, LUNG, AND BLOOD INSTITUTE, DIVISION OF LUNG DISEASES, NIH

L6 MOLECULAR ATLAS OF LUNG DEVELOPMENT

12:15 p.m. - 1:15 p.m. **MOSCONE CENTER**

Room 2001/2003 (West Building, Level 2)

Target Audience
Providers of lung health, medical fellows in training, and basic researchers on lung biology, developmental biology, pediatrics, and informatics.

Objectives
At the conclusion of this session, the participant will be able to:

- learn the newest datasets of LungMAP;
- understand and learn the innovative technologies for molecular profiling and imaging of the developing lung;
- learn how to access the LungMAP resources.

Molecular Atlas of Lung Development (LungMAP) is an NHLBI-sponsored program. The overall goal of this program is to build an open-access reference resource by creating a comprehensive molecular atlas of the late-stage developing lung with data and reagents available to the research community. The atlas will integrate gene and protein expression profiles, transcriptome, epigenome, and other molecular characterizations with high-resolution anatomical information to provide molecular profiles of functionally or anatomically defined cell types in the developing lung. Participants in this session will learn about the newest data generated by the LungMAP, data analysis tools, and how to access the website, database and other publicly available resources of LungMAP.

Chairing: R.F. Clark, PhD, Research Triangle Park, NC
S. Lin, PhD, Bethesda, MD

12:15 **BREATH: A Web Accessible Database of Normal Human and Mouse Lung Development**
R.F. Clark, PhD, Research Triangle Park, NC

12:27 **Mass Spectrometry-Based Omics and High Throughput Imaging Characterization of Lung Development**
C. Ansong, PhD, Richland, WA

12:39 **Reconstructed Regulatory Networks Provide Novel Insights into Mechanisms of Postnatal Mouse Lung Development**
N. Ambalavanan, MD, Birmingham, AL

12:51 **LungMAP Postnatal Human Lung Tissue and Dissociated Cell Repository**
G.S. Pryhuber, MD, Rochester, NY

NATIONAL HEART, LUNG, AND BLOOD INSTITUTE, DIVISION OF LUNG DISEASES, NIH

L7 NEW INSIGHTS ABOUT SEVERE ASTHMA FROM THE NHLBI SEVERE ASTHMA RESEARCH PROGRAM

12:15 p.m. - 1:15 p.m. **MOSCONE CENTER**

Room 2006/2008 (West Building, Level 2)

Target Audience
Providers of lung health, especially providers who manage patients with asthma; investigators interested in mechanisms of disease in asthma.

Objectives
At the conclusion of this session, the participant will be able to:

- learn new findings about clinical and molecular phenotypes of severe asthma;
- review research being supported by NHLBI to improve understanding of severe asthma and accelerate progress toward new treatments;
- improve understanding of how the clinical features of severe asthma varies in children and adults.

In this session on work in progress in the NHLBI-sponsored severe asthma research program, there are four presentations planned to provide the learner with a cutting-edge, data-driven understanding of the clinical features of pediatric and adult severe asthma. Each presentation will cover the context, rationale and recent progress in addressing clinically relevant questions in severe asthma pathobiology, diagnosis and management, including baseline cross-sectional data on recruited healthy and asthmatic subjects, their response to systemic corticosteroids, risk factors for asthma exacerbations as well as advances in imaging for the detection of pathologic mucus and its association with clinical outcome.

Chairing: S.E. Wenzel, MD, Pittsburgh, PA
T. Croxton, MD, PhD, Bethesda, MD

12:15 **Age and Gender Impacts**
W.G. Teague, MD, Charlottesville, VA

12:30 **Phenotypic Characteristics**
L.C. Denlinger, MD, PhD, Madison, WI

12:45 **Identification of Intraluminal Mucus by CT Imaging**
E. Dunican, MD, San Francisco, CA

1:00 **Characterization of Steroid Responsiveness**
E. Israel, MD, Boston, MA

NATIONAL HEART, LUNG, AND BLOOD INSTITUTE, DIVISION OF LUNG DISEASES, NIH

L8 LESSONS LEARNED FROM THE NHLBI-SPONSORED TUBERCULOSIS SYSTEM BIOLOGY PROGRAM

12:15 p.m. - 1:15 p.m. **MOSCONE CENTER**

Room 2016/2018 (West Building, Level 2)

Target Audience
Providers of lung health, medical fellows in training, graduates, post-doctoral

fellows and established scientists in basic research on lung biology, tuberculosis pathogenesis, infectious disease, informaticians and systems biology researchers.

Objectives
At the conclusion of this session, the participant will be able to:

- understand the potential impact of the implementation of systems biology;
- learn new findings about the pathobiology of tuberculosis in the human lung;
- apply new learned knowledge to their own ongoing research.

Approximately one-third of the world's population is latently infected with Mtb with a 10% risk of developing pulmonary tuberculosis. It is the second highest cause of death from infectious diseases after HIV/AIDS, and is the biggest killer of people infected with HIV. The primary route of infection with Mtb is through the lung and interactions with the host lung defenses determine the course of the disease. This session will present the overall results from the NHLBI sponsored TB Systems Biology Program that was conceived with the objective of applying systems biology approaches to better understand the pathobiology of TB. Results from the integration of computational modeling strategies, "omics" technologies, and advances in bioengineering will be presented and how the implementation of such methodologies can help overcome obstacles in understanding complex host-mycobacterial interactions and host immune response networks, and helped to understand the latency and reactivation cycle of TB in the human lung.

Chairing: P.C. Karakousis, MD, Baltimore, MD
E. Caler, PhD, Bethesda, MD

12:15 **Novel Approaches to Understanding and Combating Latent TB Infection**
P.C. Karakousis, MD, Baltimore, MD

12:30 **Systems Biology of Immune Evasion by M. Tuberculosis**
W.H. Boom, MD, Cleveland, OH

12:45 **Tuberculosis: Learning from In Vivo and In Silico Models**
J. Flynn, PhD, Pittsburgh, PA

1:00 **Vitamin D Receptor Signaling in Tuberculosis: Multiple Systems**
H. Salamon, PhD, Berkeley, CA

NATIONAL HEART, LUNG, AND BLOOD INSTITUTE, DIVISION OF LUNG DISEASES, NIH

L9 BEHAVIOR TO BIOMARKERS: RESEARCH FROM THE TOBACCO REGULATORY SCIENCE PROGRAM

12:15 p.m. - 1:15 p.m. **MOSCONE CENTER**
Room 2020/2022 (West Building, Level 2)

Target Audience
Those with clinical or research responsibilities.

Objectives
At the conclusion of this session, the participant will be able to:

- understand and learn about the Tobacco Regulatory Science Program;
- learn about biomarkers of tobacco related pulmonary toxicity;
- learn about the effects of tobacco products on lung health.

With the passage of the 2009 Family Smoking Prevention and Tobacco Control Act, the FDA acquired the authority to regulate the manufacture, marketing, and distribution of tobacco products in order to protect human health. Within the framework of this Act, the NIH and FDA formed an interagency partnership to foster tobacco regulatory research administered through the Tobacco Regulatory Science Program (TRSP). Projects supported through TRSP include behavioral, clinical, animal, and in vitro research. This session will focus on TRSP-supported research that touches on tobacco products — including cigarettes, cigars, waterpipe, and e-cigarettes — and their effects on pulmonary health.

Chairing: P. Callahan-Lyon, MD, Silver Spring, MD
L. Postow, PhD, Bethesda, MD

12:15 **The Relationship Between Use of Electronic Cigarettes and Smoking Cigarettes in California Youth**
J.M. Samet, MD, MS, Los Angeles, CA

12:27 **Improved Models to Inform Tobacco Product Regulation**
S. Glantz, PhD, San Francisco, CA

12:39 **Disordered Lung Biology Associated with Alternative Tobacco Use**
R.G. Crystal, MD, New York, NY

12:51 **PGP: A Possible Biomarker for COPD Exacerbations and/or Progression**
J.M. Wells, MD, Birmingham, AL

1:03 **Impact of Tobacco Exposure on the Lung's Innate Defense System**
R. Tarran, PhD, Chapel Hill, NC

MEET THE PROFESSOR SEMINARS

CME Credits Available: 1.0

Registration Fee: $70.00 (includes box lunch.)
Attendance is limited. Pre-registration is required.

12:15 p.m. - 1:15 p.m. **INTERCONTINENTAL HOTEL**

MP401 **PROSTAGLANDIN REGULATION OF ASTHMA**
R.S. Peebles, MD, Nashville, TN
Union Square (Third Floor)

MP402 **THE ASTHMA-COPD OVERLAP SYNDROME (ACOS): INSIGHTS INTO A NEW DISEASE PHENOTYPE**
A.A. Zeki, MD, MAS, Sacramento, CA
SoMa (Third Floor)

MP403 **THE FUTURE OF IPF: WHAT WILL IT LOOK LIKE?**
H.R. Collard, MD, San Francisco, CA
L. Richeldi, MD, PhD, Southampton, United Kingdom
Mission (Third Floor)

MP404 **ALPHA-1 ANTITRYPSIN DEFICIENCY**
C.B. Strange, MD, Charleston, SC
Marina (Third Floor)

MP405 **LUNG AND PLEURAL INFECTIONS: CONTROVERSIES AND ADVANCES**
G.W. Waterer, MBBS, PhD, MBA, Perth, Australia
Y.C.G. Lee, MBChB, PhD, Perth, Australia
Grand Ballroom C (Third Floor)

MP406 RHEUMATOLOGIC DISORDERS FOR THE PULMONOLOGIST
M. Kreider, MD, Philadelphia, PA
Grand Ballroom B (Third Floor)

MP407 CF UPDATE FOR THE NON-CF PROVIDER
G. Allada, MD, Portland, OR
Grand Ballroom A (Third Floor)

MP408 SHOULD MY PATIENT WITH INTERSTITIAL LUNG DISEASE GET A SURGICAL LUNG BIOPSY?
R. Raj, MD, Chicago, IL
Twin Peaks (Fourth Floor)

MP409 NEUROLOGIC DISASTERS IN THE ICU
T.P. Bleck, MD, Chicago, IL
Telegraph Hill (Fourth Floor)

MP410 PUBLIC HEALTH CO-BENEFITS FROM CLIMATE CHANGE ACTION
G.D. Thurston, DSc, Tuxedo, NY
Potrero Hill (Fourth Floor)

MP411 TUBERCULOSIS AND THE TNF-ALPHA INHIBITORS
L.N. Friedman, MD, New Haven, CT
Nob Hill (Fourth Floor)

MP412 INTERPRETATION STRATEGIES FOR PEDIATRIC SPIROMETRY
W.D. Hardie, MD, Cincinnati, OH
Laurel Hill (Fourth Floor)

MP413 LUNG TRANSPLANTATION FOR PAH: WHEN SHOULD YOU REFER YOUR PATIENT?
R.E. Girgis, MD, Grand Rapids, MI
Cathedral Hill (Fourth Floor)

MP414 FIRESTARTER: UNDERSTANDING HOW HOUSEHOLD AIR POLLUTION CAUSES LUNG DISEASES
T.H. Thatcher, PhD, Rochester, NY
Sutter (Fifth Floor)

MP415 VENTILATOR WAVEFORMS: UNDERSTANDING WHAT THE VENTILATOR IS TELLING YOU
H.L. Manning, MD, Lebanon, NH
Stockton (Fifth Floor)

MP416 CHOMPING AT THE BIT: ORAL APPLIANCES FOR OSA
R.J. Schwab, MD, Philadelphia, PA
J. Parker, DDS, Edina, MN
F. Almeida, DDS, MSc, PhD, Vancouver, Canada
J. Metz, DDS, Columbus, OH
Howard (Fifth Floor)

MP417 INTO THE THIRD DIMENSION: HOW 3D CULTURES PROVIDE INSIGHTS IN CANCER BIOLOGY
V.C. Broaddus, MD, San Francisco, CA
Fremont (Fifth Floor)

MEDICAL EDUCATION SEMINAR

CME Credits Available: 1.0

ME1 HOW TO IMPROVE YOUR BEDSIDE TEACHING

Registration Fee: $70.00 (includes box lunch)
Attendance is limited. Pre-registration is required.

12:15 p.m. - 1:15 p.m. **INTERCONTINENTAL HOTEL**
InterContinental Ballroom A (Fifth Floor)

Target Audience
This session is aimed at faculty members and trainees who perform clinical teaching at the patient's bedside.

Objectives
At the conclusion of this session, the participant will be able to:

- describe the advantages and disadvantages of bedside teaching in various formats;
- identify and address barriers to successful bedside teaching;
- implement specific strategies and techniques to round effectively at the bedside.

Bedside rounding has decreased from 75% of medicine attending rounds in the 1960's to less than 15% currently. The data show patients, learners, and attendings prefer it to conference room attending but concerns for lost efficiency and patient discomfort create barriers to doing so. The MiPLAN approach to effective bedside teaching is based on adult learning theory and structured interviews with master clinicians. Participants will review the primary literature on bedside rounding from the patient, learner, and attending perspectives. Videos will help attendees deconstruct the MiPLAN approach and adopt it to their own attending practice going forward.

Speakers: J.M. Beck, MD, Denver, CO
M. Anderson, MD, Denver, CO

THEMATIC SEMINAR SERIES

CME Credits Available: 1.0

TSS1 CONTEMPORARY CONTROVERSIES IN THE DIAGNOSIS AND MANAGEMENT OF IDIOPATHIC PULMONARY FIBROSIS: A PRO/CON DEBATE

Registration Fee: $140.00 for full series (includes box lunch)
Attendance is limited. Pre-registration is required.

This is a 3-part series. Those registering for this seminar series will be registered for all 3 parts. The topics and schedule for each part are listed below.

Assembly on Clinical Problems

Sunday 12:15 p.m. - 1:15 p.m. **INTERCONTINENTAL HOTEL**
InterContinental Ballroom C (Fifth Floor)

PRO: Transbronchial Cryobiopsies Should Replace Surgical Lung Biopsy in the Diagnosis of IPF
V. Poletti, MD, Forli, Italy

CON: Transbronchial Cryobiopsies Should Replace Surgical Lung Biopsy in the Diagnosis of IPF
F.J. Martinez, MD, New York, NY

Monday 12:15 p.m. - 1:15 p.m.

PRO: Bronchoalveolar Lavage Should Routinely be Performed in the Diagnostic Work-Up of IPF
A.U. Wells, MD, London, United Kingdom

CON: Bronchoalveolar Lavage Should Routinely be Performed in the Diagnostic Work-Up of IPF
H.R. Collard, MD, San Francisco, CA

Tuesday 12:15 p.m. - 1:15 p.m.

PRO: Decline of 10% or Greater in FVC Should be Regarded as Treatment Failure in IPF
V. Cottin, MD, PhD, Lyon, France

CON: Decline of 10% or Greater in FVC Should be Regarded as Treatment Failure in IPF
P.W. Noble, MD, Los Angeles, CA

THEMATIC SEMINAR SERIES

CME Credits Available: 1.0

TSS2 REDUCING HOSPITAL READMISSIONS

Registration Fee: $140.00 for full series (includes box lunch)
Attendance is limited. Pre-registration is required.

This is a 3-part series. Those registering for this seminar series will be registered for all 3 parts. The topics and schedule for each part are listed below.

Assembly on Clinical Problems

Sunday 12:15 p.m. - 1:15 p.m. **INTERCONTINENTAL HOTEL**

InterContinental Ballroom B (Fifth Floor)

Patients at High Risk of Hospital Readmissions

Impact of Hospital Readmissions
B.J. Make, MD, Denver, CO

Targeting Populations at High Risk for Readmission
D.H. Au, MD, MS, Seattle, WA

Why Are Patients with Pneumonia Readmitted?
S. Sethi, MD, Buffalo, NY

Why Are Patients with COPD Readmitted?
D.M. Mannino, MD, Lexington, Kentucky

Monday 12:15 p.m. - 1:15 p.m.

Approaches to Reduce Hospital Readmissions

Effective Components of a Readmission Reduction Program
S.S. Braman, MD, New York, NY

Novel Interventions to Reduce Readmissions
V.G. Press, MD, MPH, Chicago, IL

Partnering with Patient Navigators and Peer Advocates
J.A. Krishnan, MD, PhD, Chicago, IL

Tuesday 12:15 p.m. - 1:15 p.m.

PRO: Medications Are the Key to Reducing Readmissions in COPD
G.T. Ferguson, MD, Livonia, MI

CON: Medications Are the Key to Reducing Readmissions in COPD
R.A. Wise, MD, Baltimore, MD

1:15 p.m. - 2:15 p.m

VISIT THE EXHIBIT HALL

Take this opportunity between sessions to visit the Exhibit Hall to gain practical knowledge to advance care and research. Exhibitors will be on hand to provide information on pharmaceutical products, medical equipment, publications and research services.

CLINICAL • TRANSLATIONAL

YEAR IN REVIEW

CME Credits Available: 2.0

Nursing Contact Hours Available: 2.4

A81 PEDIATRIC YEAR IN REVIEW

Assemblies on Pediatrics; Clinical Problems; Microbiology, Tuberculosis and Pulmonary Infections; Nursing; Sleep and Respiratory Neurobiology

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 3006/3008 (West Building, Level 3)

Target Audience
Pediatric pulmonologists, pediatric intensivists, neonatologists, registered nurses, advanced practice nurses, respiratory therapists, clinical and translational researchers and other providers of health care to children with lung diseases.

Objectives
At the conclusion of this session, the participant will be able to:

- discuss new findings from current literature related to pediatric cardiopulmonary conditions;
- apply recent advances and evidence-based care practices to pediatric cardiopulmonary care;
- describe strategies to manage the care of patients with pediatric cardiopulmonary conditions.

Important advances in the diagnosis and treatment of respiratory disorders in children occur every year. The range of new discoveries makes it difficult for the

clinician and researcher to stay current. However, health care providers who deal with children must be informed of the most recent advances and evidence-based care practices. Pediatric Year in Review will present a scholarly discussion of several of the most important and influential papers in key clinical topic areas published within the past two years. Experts in their respective fields will discuss the selected papers and allow time for discussion.

Chairing: M. Rosenfeld, MD, MPH, Seattle, WA
A.C. Koumbourlis, MD, MPH, Washington, DC

2:15 **Sleep Medicine**
E.S. Katz, MD, Boston, MA

2:45 **Bronchiectasis in Children**
A. Chang, MBBS, PhD, Brisbane, Australia

3:15 **Pediatric Pulmonary Genetics and Genomics**
L.M. Nogee, MD, Baltimore, MD

3:45 **Sickle Cell Disease**
A. Greenough, MBBS, MD, London, United Kingdom

There will be a 5-minute discussion after each talk.

CLINICAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 2.0

A82 TREATMENT OF EARLY STAGE AND SCREEN-DETECTED LUNG CANCER: A PRO/CON DEBATE

Assemblies on Thoracic Oncology; Behavioral Science and Health Services Research; Clinical Problems

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**
Room 303/305 (South Building, Esplanade Level)

Target Audience
Clinicians who care for patients with lung cancer; researchers and policy makers interested in thoracic oncology;patients and family members of patients with lung cancer.

Objectives
At the conclusion of this session, the participant will be able to:

- determine when to refer patients for limited resection versus lobectomy for stage I NSCLCa;
- learn new findings about the role of SBRT for treatment of early stage NSCLCa;
- improve discussions around appropriateness of therapy for non-solid lung cancers.

Early stage lung cancer accounts for ~15% of cases. However, a considerable increase in the number of cases is expected based on the new USPSTF guidelines for CT screening. The optimal treatment of patients with stage I non-small cell lung cancer, and screen-detected malignancies in particular, is unclear. Using a pro-con debate approach, this session will address key questions such as: what are the indications for limited resection for lung cancer ≤ 2 cm in size, cancer ≤ 2 cm in size,, what is the role of SBRT for clinically and screen detected cancers, and what is the best management of subsolid cancers identified via screening.

Chairing: J.P. Wisnivesky, MD, New York, NY
G. Veronesi, MD, Milan, Italy
R.S. Wiener, MD, MPH, Boston, MA

2:15 **PRO: Limited Resection Should Be the Standard of Care for Stage I Non-Small Cell Lung Cancer ≤ 2 cm in Size**
F.C. Detterbeck, MD, New Haven, CT

2:35 **CON: Limited Resection Should Be the Standard of Care for Stage I Non-Small Cell Lung Cancer ≤ 2 cm in Size**
A.A. Balekian, MD, MS, Los Angeles, CA

2:55 **PRO: SBRT Should Be the Standard of Care for Early Stage NSCLCa Patients at High Risk for Resection**
P. Mazzone, MD, MPH, Cleveland, OH

3:15 **CON: SBRT Should Be the Standard of Care for Early Stage NSCLCa Patients at High Risk for Resection**
C.G. Slatore, MD, Portland, OR

3:35 **PRO: Subsolid Screen-Detected Lung Cancers Should Not Be Treated**
G.A. Silvestri, MD, MS, Charleston, SC

3:55 **CON: Subsolid Screen-Detected Lung Cancers Should Not Be Treated**
G. Veronesi, MD, Milan, Italy

*This session and the International Conference are supported by an educational grant from **AstraZeneca LP.***
All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

CLINICAL

CLINICAL TOPICS IN PULMONARY MEDICINE

CME Credits Available: 2.0

A83 GREAT CASES: CLINICAL, RADIOLOGIC, AND PATHOLOGIC CORRELATIONS BY MASTER PHYSICIANS

Council of Chapter Representatives

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**
Room 134 (North Building, Lower Level)

Target Audience
Clinicians in the fields of pulmonary and critical care medicine, pediatric pulmonology, sleep medicine, thoracic surgery, and infectious disease.

Objectives
At the conclusion of this session, the participant will be able to:

- integrate the clinical presentation, radiologic and pathologic findings for 7 challenging cases;
- understand the clinical reasoning used to determine differential diagnosis by master clinicians using a multidisciplinary approach;
- describe the associated pathology and radiology of the cases.

Learners will have the opportunity to observe master clinicians approach challenging clinical problems by working through 7 unknown cases selected from the abstract pool. Collaboration with a master radiologist reviewing the films and a master pathologist reviewing pathology slides will demonstrate the multidisciplinary approach to difficult cases. The audience will participate though

interactive questions that are tallied electronically. Additional discussion by presenters and master panelists will enhance the educational experience.

Chairing: S. Kirtland, MD, Seattle, WA
R. Gross, MD, Washington, DC

2:15 **Case Presentations**

Mysterious Antibodies
B. Tashtoush, MD, Weston, FL

The Heart of the Matter
R. Beg, MD, Miami, FL

Simply Breathtaking
H. Wu, MD, Washington, DC

It's Not Easy Being Green
S. Pandey, MD, Pittsburgh, PA

Noisy Baby
C. Leon Astudillo, MD, Boston, MA

Pop Goes the Lung
J. Lee, MD, Newark, NJ

Full of Fluid
A. Ataya, MD, Gainesville, FL

3:15 **Experts**

Master Clinicians
S.I.S. Rounds, MD, Providence, RI
M.I. Schwarz, MD, Aurora, CO
P.C. Stillwell, MD, Aurora, CO

Master Radiologist
J.D. Newell, MD, Iowa City, IA

Master Pathologist
H. Tazelaar, MD, Scottsdale, AZ

BASIC • CLINICAL

CRITICAL CARE TRACK

CME Credits Available: 2.0

A84 THE NEW ENGLAND JOURNAL OF MEDICINE AND JAMA. DISCUSSION ON THE EDGE: REPORTS OF RECENT CRITICAL CARE RESEARCH

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**
Room 2002/2004 (West Building, Level 2)

This session will provide a forum for attendees to interact with the authors and editors about papers published in the New England Journal of Medicine and JAMA. Papers presented will be recent publications, selected by the editors, to be of significant importance to the field of critical care medicine. Attendees will have the opportunity to hear presentations directly from the author and address questions to both the authors and editors. The discussion is intended to provide a unique insight into these papers, the selection process, and how the research applies directly to the field of critical care medicine.

Chairing: D.C. Angus. MD, MPH, Associate Editor, JAMA
J.M. Drazen, MD, Editor-in-Chief, New England Journal of Medicine

Speakers And Talks To Be Announced

BASIC • TRANSLATIONAL

BASIC SCIENCE CORE

CME Credits Available: 2.0

A85 MOVING TOWARD PRECISION MEDICINE FOR LUNG DISEASE

Assemblies on Allergy, Immunology and Inflammation; Respiratory Cell and Molecular Biology; Respiratory Structure and Function

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**
Room 2009/2011 (West Building, Level 2)

Target Audience
Basic scientists, clinician scientists, research and clinical trainees, providers of lung health care, and individuals in areas of health policy and health delivery.

Objectives
At the conclusion of this session, the participant will be able to:

- understand and describe how work that has led to understanding biological processes is being used to underpin its application to medicine, as well as practical, ethical and policy issues;
- identify ongoing research in pulmonary medicine that is identifying opportunities and approaches for precision medicine;
- describe technologies and their use to generate data and understanding to enable precision medicine delivery for lung disease.

Progress in biomedical research has revealed that health and disease result from combinatorial interacting responses, determined by genetics and posttranslational control, to complex factors. This session will address how composite knowledge and capacity in biology and medicine is now seated for the delivery of "precision medicine", and provides some current examples in pulmonary medicine of emerging and ongoing effort in this area. Talks that cover broad lung disease areas are presented, emphasizing how networks, bioinformatics, high throughput and stem cell technologies are being harnessed. The session also features discussion about emerging policies for the delivery of precision medicine care.

Chairing: M. McDonald, PhD, Boston, MA
D.J. Weiss, MD, PhD, Burlington, VT

2:15 **Cystic Fibrosis Genetics: From Molecular Understanding to Clinical Application**
G.R. Cutting, MD, Baltimore, MD

2:39 **Induced Pluripotent Stem Cells: The Ultimate in Personalized Stem Cells for Lung Diseases**
A. Firth, PhD, Los Angeles, CA

3:03 **Translating the Airway Transcriptome into Biomarkers for Lung Cancer and COPD**
A. Spira, MD, Boston, MA

3:27 **Pharmacogenetic Discoveries and the Future of Personalized Medicine in Asthma**
E. Bleecker, MD, Winston-Salem, NC

3:51 **The Path to Personalized Medicine in COPD**
D.D. Sin, MD, Vancouver, Canada

There will be a 5-minute discussion after each talk.

*This session and the International Conference are supported by an educational grant from **AstraZeneca LP.***

All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

BASIC • CLINICAL • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 2.0

A86 BRINGING ORDER TO THE CHAOS OF ACOS (ASTHMA-COPD OVERLAP SYNDROME)

Assemblies on Allergy, Immunology and Inflammation; Clinical Problems; Nursing; Respiratory Cell and Molecular Biology; Respiratory Structure and Function

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 2005/2007 (West Building, Level 2)

Target Audience
Physicians, basic scientists, physiologists, physician-scientists, clinical fellows and residents, graduate and postdoctoral research trainees, and nurses interested in asthma, COPD, and ACOS. This topic also has broader appeal for epidemiologists, nurses, and respiratory therapists, given the significant clinical and public health impact of this new syndrome/disease phenotype.

Objectives
At the conclusion of this session, the participant will be able to:

- understand the molecular, pathophysiological, and clinical features of ACOS and use these criteria to distinguish ACOS from asthma or COPD;
- offer timely and appropriate diagnosis and treatment by recognizing ACOS patients, their higher disease severity, and risk profile, while closely monitoring patient outcomes;
- discuss and appreciate the significant heterogeneity and overlap between asthma and COPD where ACOS serves as an emerging and important clinical phenotype linking both diseases.

Some patients manifest an intermediate or overlapping phenotype of asthma and COPD, i.e. the "asthma-COPD overlap syndrome" (ACOS). Yet, ACOS has largely been ignored in clinical trials. ACOS comprises 15 to 55% of patients with obstructive lung diseases, and manifests more symptoms, greater lung function decline, increased risk of severe exacerbations, and possibly a reduced life span. Such observations have spawned a recent and broad international interest in ACOS. This session presents a comprehensive overview of ACOS in relation to the controversial British and Dutch Hypotheses, and offers novel insights regarding the genetic origins, pathogenesis, diagnosis, and treatment of ACOS.

Chairing: A.A. Zeki, MD, MAS, Sacramento, CA
K. Chung, MD, PhD, London, United Kingdom
M.J. Holtzman, MD, St. Louis, MO

2:15 **How to Clinically Distinguish ACOS from Asthma and COPD**
P.G. Gibson, MBBS, Newcastle, Australia

2:35 **Shared Immunity in Asthma and COPD**
M.J. Holtzman, MD, St. Louis, MO

2:55 **Genetic Origins of ACOS**
M.E. Hardin, MD, Boston, MA

3:15 **Genomic and Molecular Phenotyping to Distinguish ACOS from Asthma and COPD**
P.G. Woodruff, MD, MPH, San Francisco, CA

3:35 **Smoking in Asthma: An ACOS Phenotype?**
K. Chung, MD, PhD, London, United Kingdom

3:55 **Treatment of ACOS: Lessons From Clinical Studies in Asthma and COPD**
S.I. Rennard, MD, Melbourne, United Kingdom

*This session and the International Conference are supported by an educational grant from **AstraZeneca LP.***
All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

BASIC • BEHAVIORAL • CLINICAL • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 2.0

A87 E-CIGARETTE VAPING: PRECLINICAL AND CLINICAL PULMONARY HEALTH EFFECTS

Assemblies on Environmental, Occupational and Population Health; Allergy, Immunology and Inflammation; Behavioral Science and Health Services Research; Respiratory Cell and Molecular Biology; Respiratory Structure and Function

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 130-132 (North Building, Lower Level)

Target Audience
Basic and translational/clinician scientists working on lung diseases. Lung health researchers, nurses, pharmacists, users of e-cigarettes, smoking cessation professionals, manufacturers and retailers of e-cigarettes and e-fluids/e-juices, students, fellows, residents with clinical, research, tobacco control lobbyists, or people with health care and administrative responsibilities.

Objectives
At the conclusion of this session, the participant will be able to:

- learn about e-cigarettes vaping and flavorings pulmonary health consequences;
- learn and understand the current clinical trials based on harm reduction, perceptions, addictions, and environmental effects of vaping in suceptible populations and patients with respiratory diseases;
- learn scientific debates and regulatory aspects on public and environmental health and understanding the pulmonary and extrapulmonary effects of vaping will provide insights on behavior, addiction, cessation and/or aggravating pulmonary diseases and their exacerbations.

Electronic cigarettes (e-cigs) use flavored/non-flavored e-liquids/e-fluids, which contain propylene glycol/glycerol (humectants), nicotine, and flavors (e.g. candy flavors including sweeteners). These device generate aerosol containing reactive oxygen species, aldehydes, ultrafine/nanoparticles, and heavy metal particles. E-cig products are launched without the FDA approval, and an increasing number of products are being launched every day without knowing the harmful consequences. This symposium is aimed towards understanding the pulmonary studies on e-cig exposure including biomarkers, inhalation and basic preclinical/translational science, and host-innate response, as well as clinical epidemiological studies for prediction of pulmonary health effects of e-cigarette vaping and flavoring agents.

Chairing: I. Rahman, PhD, Rochester, NY
I. Jaspers, PhD, Chapel Hill, NC
S. Biswal, PhD, Baltimore, MD
B. Tomoko, MD, Tokyo, Japan

2:15 **What's in E-cigarettes and Are They Safe?: Pulmonary Biomarkers and Harmful Pulmonary Pathological Consequences**
N. Benowitz, MD, San Francisco, CA

2:35 **What's Inhaled by Vaping? Dosimetry, Deposition, Distribution, and Topography: Pulmonary Physiological and Clinical Effects**
R. Robinson, PhD, Rochester, NY

2:55 **Basic and Translational Science of E-Cigarette with Flavoring Agents: In Vitro and In Vivo Pulmonary Effects**
I. Rahman, PhD, Rochester, NY

3:15 **Mucosal Immune Responses to E-Cigarette Exposures: Preclinical and Clinical Models**
I. Jaspers, PhD, Chapel Hill, NC

3:35 **Electronic Cigarette Use and Harm Reversal in Clinic: Users' Perspectives**
R. Polosa, MD, PhD, Catania, Italy

3:55 **E-Cigarettes and Public Health: Pulmonary Clinical Data on Behavioral, Perception, Addiction Vs. Cessation Tools of E-Cigarettes and Flavorings**
J.M. Samet, MD, MS, Los Angeles, CA

BASIC • BEHAVIORAL • CLINICAL • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 2.0

A88 COMMUNITY ACQUIRED PNEUMONIA IN THE ELDERLY PATIENT

Assemblies on Microbiology, Tuberculosis and Pulmonary Infections; Allergy, Immunology and Inflammation; Behavioral Science and Health Services Research; Clinical Problems; Critical Care; Nursing; Respiratory Cell and Molecular Biology

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 3016/3018 (West Building, Level 3)

Target Audience
Health care providers, at all levels of training, who are caring for patients with pneumonia; clinical researchers, translational and bench investigators.

Objectives
At the conclusion of this session, the participant will be able to:

- learn new findings regarding alterations associated with aging that affect host response to lung infections and effectiveness of vaccines;
- identify risk factors for and implement strategies to prevent pneumonia in elderly patients;
- implement appropriate management of pneumonia.

Pneumonia is a leading cause of mortality globally. As the population is aging, the incidence of pneumonia is increasing, related to alterations in host defense as a consequence of aging and cellular senescence, and also the concomitant greater burden of comorbidities and polypharmacy in older patients. This translational session will discuss bench investigations elucidating mechanisms impacting host defense to lung infection and host immune responses to vaccines in older adults. Clinically oriented presentations will consider the syndrome of aspiration pneumonia and the impact of comorbidities and medications on risk for community acquired pneumonia. Talks will also address management and prevention of pneumonia in elderly patients.

Chairing: K.A. Crothers, MD, Seattle, WA
C.M. Luna, MD, PhD, Buenos Aires, Argentina
E.R. Neptune, MD, Baltimore, MD

2:15 **Aging and Host Defense in Pneumonia**
E.R. Neptune, MD, Baltimore, MD

2:35 **Importance of Comorbidities on Risk for Pneumonia in an Aging Population**
M.I. Restrepo, MD, MSc, San Antonio, TX

2:55 **Aspiration Pneumonia: A Distinct Pneumonia Phenotype?**
M.J. Lanspa, MD, MS, Salt Lake City, UT

3:15 **Tailoring Management of Pneumonia to the Elderly Patient**
J.D. Chalmers, MBChB, PhD, Dundee, United Kingdom

3:35 **Immunosenescence and Vaccination**
C. Weyand, MD, PhD, Stanford, CA

3:55 **Pneumonia Prevention**
M.S. Niederman, MD, New York, NY

There will be a 5-minute discussion after each talk.

BASIC • CLINICAL • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 2.0

A89 FROM BEAUTY TO BREAKING BAD: UNCOVERING THE WORLD OF DRUG INDUCED PULMONARY HYPERTENSION

Assembly on Pulmonary Circulation

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 3007/3009 (West Building, Level 3)

Target Audience
Pulmonary and critical care physicians, nurse practitioners, social workers, researchers in pulmonary vascular biology, addiction specialists and trainees who care for patients with pulmonary hypertension.

Objectives
At the conclusion of this session, the participant will be able to:

- diagnose drug related pulmonary vascular toxicity;
- learn new findings about the mechanism and pathobiology of drug induced pulmonary hypertension;
- relate recent clinical and basic findings to future scientific environment and patient exposures.

Timed to the 50th anniversary of the European Aminorex epidemic, the goal of this symposium is to highlight the impact of therapeutics and illicit drugs in causing pulmonary vascular disease and bring awareness to a disease sub-phenotype which is often less focused on. This session will start with a broad historical perspective on known and recently discovered drug induced PH entities, move quickly to pathobiology and mechanisms underlying the clinical disorder, and identify novel phenotypes associated with prescribed and illicit drugs. The session will then advance onto the discussion of aberrancies in drug metabolism and the unique role of the pulmonary vasculature in this process. The session will conclude with a perspective from regulatory agencies (US-FDA) on post-approval drug safety monitoring and the concept of pharmacovigilance.

Chairing: M.J.C. Humbert, MD, PhD, Le Kremlin Bicetre, France
I. Lang, MD, Vienna, Austria
N. Voelkel, MD, Richmond, VA

2:15 **A Patient's Perspective**
J. Mato, Chowchilla, CA

2:20 **Fifty Years of Anorexigen-Induced PAH: From Aminorex to Benfluorex**
M.J.C. Humbert, MD, PhD, Le Kremlin Bicetre, France

2:40 **Drug Induced Pulmonary Veno-Occlusive Disease**
D. Montani, MD, PhD, Le Kremlin Bicetre, France

3:00 **Pulmonary Hypertension as a Complication of Chronic Amphetamine Abuse**
R.T. Zamanian, MD, Stanford, CA

3:20 **Impact of Aberrant Drug Metabolism in Drug Induced PH: Lessons Learned from CES1**
V. De Jesus Perez, MD, Stanford, CA

3:35 **From Mechanism to Disease: A Perspective on Drug Induced PH**
N. Voelkel, MD, Richmond, VA

3:55 **Pharmacovigilence and Drug Safety in the Current Therapeutic Environment**
M.R. Southworth, PharmD, Silver Spring, MD

There will be a 5-minute discussion after each talk.

BASIC • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 2.0

A90 ABNORMAL METABOLISM: EMERGING CONCEPTS IN UNDERSTANDING LUNG DISEASE

Assemblies on Respiratory Cell and Molecular Biology; Allergy, Immunology and Inflammation; Clinical Problems; Pulmonary Circulation; Thoracic Oncology

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**
Room 2016/2018 (West Building, Level 2)

Target Audience
Basic and clinician scientists, clinicians, public health officials, student and postdoctoral trainees with an interest in the biology of metabolism and its role in respiratory disease.

Objectives
At the conclusion of this session, the participant will be able to:

- improve the health of patients by identifying new biomarkers for disease using metabolomics approaches;
- identify metabolic modifiers in lung disease;
- understand how metabolic processes can contribute to lung disease.

This session will provide information about the impact of metabolic processes in the development and progression of lung diseases. Topics will include many pulmonary diseases, including fibrosis, hypertension, cancer, and COPD, but will all include the underlying theme of the role of altered metabolism. The goal of this session is to fill a knowledge gap in our understanding of the role that metabolic pathways and metabolites play in lung disease.

Chairing: P.J. Sime, MD, Rochester, NY
S. Archer, MD, Kingston, Canada
J.L. Judge, MS, Rochester, NY
G. Liu, MD, PhD, Birmingham, AL

2:15 **Metabolic Reprogramming and Hypoxia in Pulmonary Arterial Hypertension**
K.R. Stenmark, MD, Aurora, CO

2:35 **The Role of Metabolic Dysregulation in the Development of Pulmonary Fibrosis**
R.M. Kottmann, MD, Rochester, NY

2:55 **Metabolic Proteins as Drug Targets for Lung Cancer**
I. Stratford, PhD, Manchester, United Kingdom

3:15 **Metabolic Reprogramming in Aging and Lung Fibrosis**
V.J. Thannickal, MD, Birmingham, AL

3:35 **Beyond ATP: Mitochondria as Signaling Organelles**
N. Chandel, PhD, Chicago, IL

3:55 **Using Metabolomics Approaches to Identify Biomarkers in Development of Lung Diseases**
C.H. Wendt, MD, Minneapolis, MN

BEHAVIORAL • CLINICAL • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 2.0

A91 HOT TOPICS IN DISPARITIES IN PULMONARY, CRITICAL CARE AND SLEEP MEDICINE

Assemblies on Allergy, Immunology and Inflammation; Behavioral Science and Health Services Research; Clinical Problems; Critical Care; Environmental, Occupational and Population Health; Microbiology, Tuberculosis and Pulmonary Infections; Nursing; Pediatrics; Pulmonary Circulation; Pulmonary Rehabilitation; Respiratory Cell and Molecular Biology; Respiratory Structure and Function; Sleep and Respiratory Neurobiology; Thoracic Oncology

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**
Room 2001/2003 (West Building, Level 2)

Target Audience
Clinicians, researchers and public health practitioners in the fields of pediatric and adult pulmonary, critical care and sleep medicine.

Objectives
At the conclusion of this session, the participant will be able to:

- learn new findings about the impact of major barriers to the care of minority patients with pulmonary, critical care and sleep disorders;
- apply new strategies to care for minority patients, and advocate for health equality;
- discuss feasible and necessary policies to achieve respiratory health equality.

Health disparities are commonly encountered in pediatric and adult pulmonary, critical care and sleep medicine. Attainment of respiratory health equality requires the ending of respiratory health disparities, which can be achieved only through multidisciplinary efforts. In this symposium, we will first review and discuss state-of-the-art approaches to overcoming major barriers to health equality, namely non-adherence, lack of access to personalized medicine, healthcare for migrant populations, and inadequate communication with minorities who are critically ill.

Finally, a clinical case study of obstructive sleep apnea will be used to review and highlight key points discussed in the other lectures.

Chairing: J.C. Celedon, MD, DrPH, Pittsburgh, PA
M.S. Badr, MD, Detroit, MI
E.R. Neptune, MD, Baltimore, MD

2:15 **Introduction and Overview**
J.C. Celedon, MD, DrPH, Pittsburgh, PA

2:20 **A Patient's Perspective**
T. Massey Davis, Decatur, GA

2:25 **Improving Illness Self-Management in Minority Patients**
K. Riekert, PhD, Baltimore, MD

2:46 **Personalized Medicine: What About Minorities and the Poor?**
E.G. Burchard, MD, MPH, San Francisco, CA

3:07 **Migrant Health**
M.B. Schenker, MD, MPH, Davis, CA

3:28 **Systems Approaches to Addressing Disparities in Critical Care**
C.R. Cooke, MD, MSc, Ann Arbor, MI

3:49 **Obstructive Sleep Apnea: A Clinical Case Study in Health Disparities**
S.S. Redline, MD, MPH, Boston, MA

MINI SYMPOSIUM

A93 EXPLORING THE HUMAN RESPIRATORY ADAPTIVE IMMUNE RESPONSE

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**
Room 3020/3022 (West Building, Level 3)

Chairing: A.P. Fontenot, MD, Aurora, CO
B.D. Medoff, MD, Boston, MA

Oral Presentations

2:15 **Lung-Specific Clonality and Plasticity of T Cell Receptor-Restricted CD4+ T Cells in Sarcoidosis - Implications for Pulmonary Antigen Recognition/**Y. Kaiser, R. Lepzien, M. Ronninger, S. Kullberg, M. Kaller, S. Lundin, F. Vezzi, R.-A. Olsen, T. Sandalova, J. Wahlstrom, A. Smed Sorensen, A. Eklund, A. Achour, J. Grunewald, Stockholm, Sweden, p.A2594

2:30 **Regulatory T Cells in Pulmonary Sarcoidosis/**K.C. Patterson, T. Akimova, W. Hancock, Philadelphia, PA, p.A2595

2:45 **Anti-Inflammatory Effects of Bromodomain and Extra-Terminal Domain Inhibition in Cystic Fibrosis Lung Inflammation/**K. Chen, B. Campfield, S.E. Wenzel, J. McAleer, J. Kreindler, G. Kurland, R. Gopal, T. Wang, W. Chen, T.J. Eddens, M.M. Myerburg, W. Horne, J. Lora, B. Albrecht, J.M. Pilewski, J.K. Kolls, Pittsburgh, PA, p.A2596

3:00 **CCR4-Expressing CD4+ T Cells Are Increased in Lungs of Patients with Idiopathic Pulmonary Fibrosis and Correlate with Lung Function/**A. Adegunsoye, C.L. Hrusch, C. Bonham, M. Jaffery, K. Blaine, I. Noth, M.E. Strek, A.I. Sperling, Chicago, IL, p.A2597

3:15 **Th17 Cells Are Associated with Protection Against Ventilator Associated Pneumonia/**M. Orlov, M.M. Wurfel, C. Mikacenic, Seattle, WA, p.A2598

3:30 **T Regulatory Cell Levels in Asthmatic Children Correlate With Yearly Ambient Air Pollution Levels Using Single-Cell Mass Spectrometry/**M. Prunicki, X. Zhou, T. Schurz, R.W. Lucas, K.C. Nadeau, Stanford, CA, p.A2599

3:45 **Innate Type 2 Receptor Expression on Airway Allergen-Specific CD4+ T Cells Distinguishes Allergic Asthmatics from Allergic Non-Asthmatics/**J.L. Cho, M.F. Ling, L. Faustino, S. Islam, R. Afshar, J.W. Griffith, R.S. Harris, A. Ng, A.A. Ford, R. Xavier, R.C. Boucher, W.W. Kwok, D.L. Hamilos, M. Kesimer, J.J. Moon, A.D. Luster, B.D. Medoff, Boston, MA, p.A2600

4:00 **Exosomes and T Helper Cell Polarization in Asthma/**K.P. Hough, D. Chanda, J. Trevor, Y. Wang, M. Curtiss, V.B. Antony, M.T. Dransfield, C. Steele, S.R. Duncan, V.J. Thannickal, J.S. Deshane, Birmingham, AL, p.A2601

MINI SYMPOSIUM

A94 NEW INSIGHTS IN IPF

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**
Room 306/308 (South Building, Esplanade Level)

Chairing: R.J. Kaner, MD, New York, NY
K.A. Johannson, MD, Calgary, Canada

Oral Presentations

2:15 **Case-Validated Epidemiology of Idiopathic Pulmonary Fibrosis in the Kaiser Permanente Northern California Member Population/**B.J. Ley, T. Urbania, G. Husson, M. Eisner, C. Iribarren, H.R. Collard, San Francisco, CA, p.A2602

2:30 **Quantitative Computed Tomography Analysis Predicts Outcomes in Idiopathic Pulmonary Fibrosis/**S.Y. Ash, D. Lassala Lopez Vallejo, J.A. Villalba, K. Ostridge, R. Gunville, J. Onieva Onieva, J.C. Ross, R. San Jose Estepar, H.J. Goldberg, I.O. Rosas, G. Washko, Boston, MA, p.A2603

2:45 **Pirfenidone and Nintedanib for Pulmonary Fibrosis in Real-World Clinical Practice: Tolerability and Adverse Drug Reactions/**J. Galli, A. Pandya, M. Vega-Olivio, G. Criner, Philadelphia, PA, p.A2604

3:00 **Contribution of Mutations in Genes Encoding Proteins of the Surfactant Metabolism to Idiopathic Interstitial Pneumonia and Idiopathic Pulmonary Fibrosis in a Cohort of 265 Families/** N. Nathan, R. Borie, C. Kannengiesser, F. Dastot Le Moal, H. Nunes, D. Valeyre, M. Reynaud-Gaubert, S. Marchand-Adam, J.-M. Naccache, G. Prevot, C. Delacourt, C. Marguet, D. Israel Biet, C. Thumerelle, A. Deschildre, P. Reix, V. Cottin, M.-L. Dalphin, A. Gondouin, C. Picard, V. Girault, M. Legendre, L. Gouya, B. Crestani, S. Amselem, A. Clement, Paris, France, p.A2605

3:15 **Anxiety and Depression in Idiopathic Pulmonary Fibrosis/**I. Glaspole, A. Watson, S. Macansh, S. Chapman, W. Cooper, H. Allan, S. Ellis, N. Goh, C. Grainge, P. Hopkins, G. Keir, A. Mahar, P.N. Reynolds, E.H. Walters, C. Zappala, S. McCormack, Y. Moodley, T.J. Corte, A.E. Holland, Melbourne, Australia, p.A2606

3:30 **High Prevalence of Obstructive Sleep Apnea in Patients with Incident Idiopathic Pulmonary Fibrosis/**T.F. Gille, M. Didier, M. Boubaya, L. Moya, Z. Carton, D. Sadoun Danino, D. Israel Biet, V. Cottin, F. Gagnadoux, B. Crestani, P.Y. Brillet, D. Valeyre, H. Nunes, C. Planes, Bobigny, France, p.A2607

3:45 **Bronchoscopic Optical Coherence Tomography as a Low Risk Method for Microscopic Diagnosis of Idiopathic Pulmonary Fibrosis/**L.P. Hariri, D.C. Adams, M. Lanuti, J.C. Wain, A.M. Tager, M.J. Suter, Boston, MA, p.A2608

4:00 **A 52-Gene Signature in Peripheral Blood Identifies an IPF Subphenotype with Rapid Disease Progression and Poor Disease Outcomes/**J. Herazo-Maya, J. Sun, S.R. Duncan, A. Prasse, I. Noth, J. Villabla-Nunez, Q. Li, N. Aurelin, X. Yang, H. Lynn, A.E. Tzouvelekis, K.O. Lindell, K. Gibson, H. Zhao, T.M. Maher, P.L. Molyneaux, I.O. Rosas, N. Kaminski, New Haven, CT, p.A2609

MINI SYMPOSIUM

A95 CRITICAL CARE: RECOVERY OF PHYSICAL FUNCTION AFTER CRITICAL ILLNESS

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 3000/3002/3004 (West Building, Level 3)

Chairing: C.T. Hough, MD, MSc, Seattle, WA
D.C. Files, MD, Winston-Salem, NC
B. Connolly, PhD, London, United Kingdom

Oral Presentations

2:15 **The Association Between Biomarkers of Inflammation and Long-Term Cognitive Impairment and Disability in Survivors of Critical Illness/**N.E. Brummel, P. Pandharipande, C.G. Hughes, J.C. Jackson, J.L. Thompson, R. Chandrasekhar, E.W. Ely, T.D. Girard, Nashville, TN, p.A2610

2:30 **Sarcopenia on Admission to the ICU Is Associated with Critical Illness Neuromyopathy/**C. Davis, J. Khattab, M. Mourtzakis, C.L. Hough, Seattle, WA, p.A2611

2:45 **Ultrasonographic Assessment of Skeletal Muscle in Severe Sepsis: Rectus Femoris Cross-Sectional Area May Be Superior to Quadriceps Thickness/**J.A. Palakshappa, J.P. Reilly, W.D. Schweickert, B.J. Anderson, V. Khoury, C.A.G. Ittner, D. Fitzgerald, K. Butler, C. Centeno, K. Campbell, M.G.S. Shashaty, J.D. Christie, N.J. Meyer, Philadelphia, PA, p.A2612

3:00 **Inspiratory Muscle Training to Enhance Recovery from Prolonged Mechanical Ventilation: A Randomized Trial/**B. Bissett, I.A. Leditschke, T. Neeman, R. Boots, J. Paratz, Canberra, Australia, p.A2613

3:15 **Frailty Is Associated with New Or Worsening Disability After Critical Illness/**L.E. Ferrante, M. Pisani, T. Murphy, E. Gahbauer, L. Leo-Summers, T. Gill, New Haven, CT, p.A2614

3:30 **Muscle Atrophy and Clinical Outcomes in Patients with ARDS/** A. Lin, L. Gonzalez-Cuyar, A. Bunnell, C.L. Hough, Seattle, WA, p.A2615

3:45 **Early Mobilization Attenuates the Risk of ICU-Acquired Weakness in Patients Receiving Vasoactive Medications/**K.S. Wolfe, B.K. Patel, A.S. Pohlman, J.B. Hall, J.P. Kress, Chicago, IL, p.A2616

4:00 **Pre-Hospital Alcohol Use is Associated with Long-Term Physical Functional Impairment in Acute Respiratory Distress Syndrome Survivors/**S.E. Jolley, D.M. Needham, R.O. Hopkins, D.A. Welsh, C.L. Hough, New Orleans, LA, p.A2617

MINI SYMPOSIUM

A96 CLINICAL TRIALS AND NOVEL INTERVENTIONS IN PULMONARY REHABILITATION

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 3010/3012 (West Building, Level 3)

Chairing: T. Troosters, PhD, Leuven, Belgium
V. Pepin, PhD, Montreal, Canada

Oral Presentations

2:15 **Cardiometabolic Benefit of Exercise Training in Obese Patients with Obstructive Sleep Apnea (OSA): Respective Impact of Non-Invasive Ventilation and Respiratory Muscle Training in a Randomized Controlled Trial/**I. Vivodtzev, R. Tamisier, M. Croteau, A. Grangier, J.C. Borel, A.-L. Borel, B. Wuyam, P. Levy, C. Minville, F. Series, F. Maltais, J.L. Pepin, Grenoble, France, p.A2618

2:30 **Angiotensin-Converting Enzyme Inhibition as an Adjunct to Pulmonary Rehabilitation: A Randomised Controlled Trial /**K.J. Curtis, V.M. Meyrick, B. Mehta, G. Haji, K. Li, H. Montgomery, W.D.-C. Man, M.I. Polkey, N.S. Hopkinson, London, United Kingdom, p.A2619

2:45 **Low Cost Home-Based Pulmonary Rehabilitation for Chronic Obstructive Pulmonary Disease: A Randomized Controlled Equivalence Trial/**A.E. Holland, A. Mahal, C.J. Hill, A.L. Lee, A.T. Burge, N.S. Cox, R. Moore, C. Nicolson, P. O'Halloran, A. Lahham, R. Ndongo, C.F. McDonald, Melbourne, Australia, p.A2620

3:00 **Electrical Muscle Stimulation In MSICU Patients Mechanically Ventilated for ≥ 7 Days: Results of a Nested Randomized Controlled Pilot Trial Within Towards RECOVER/**S. Mathur, T. Torres, P. Mendes, D. Dance, J. Cameron, N. Cote, E. Fan, J. Flannery, W. Gage, M.S. Herridge, V. Lo, Toronto, Canada, p.A2621

3:15 **Greater Loss of Peak Aerobic Power than Peak Power in Chronic Obstructive Pulmonary Disease: Implications for Rehabilitation/**H.B. Rossiter, A.C. Coelho, D.T. Cannon, R. Cao, R. Casaburi, J. Porszasz, Torrance, CA, p.A2622

3:30 **Acute Effects of Partitioning Exercise on Exercise Workload and Dyspnea During Upper and Lower Extremity Limb Muscle Endurance Exercises in Patients with COPD and Healthy Controls/**A. Nyberg, D. Saey, M. Martin, F. Maltais, Quebec, Canada, p.A2623

3:45 **Peak Aerobic Power in Chronic Obstructive Pulmonary Disease is Predominantly Constrained by Central Fatigue/**A. Cheng, D.T. Cannon, A.C. Coelho, R. Cao, J. Porszasz, R. Casaburi, H.B. Rossiter, Torrance, CA, p.A2624

4:00 **Twice the 'Work' for Similar Effort: One Legged Cycling in Idiopathic Pulmonary Fibrosis/**T. Reilly, S. Majd, B. Popat, N. Greening, S. Agrawal, F. Woodhead, T.E. Dolmage, R.A. Evans, Leicester, United Kingdom, p.A2625

MINI SYMPOSIUM

A97 ROLE OF AGING ON THE DEVELOPMENT OF LUNG DISEASE(S)

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 2020/2022 (West Building, Level 2)

Chairing: V.J. Thannickal, MD, Birmingham, AL
A.L. Mora, MD, Pittsburgh, PA
C.J. Le Saux, PhD, San Antonio, TX

Featured Speaker

2:15 **Macrophage Heterogeneity in the Aging Lung/**G.R.S. Budinger, MD, Chicago, IL,

Oral Presentations

2:30 **Transcriptional Profiling Reveals an Aging Signature that Persists During Influenza Infection/**P.A. Reyfman, S. Berdnikovs, A.C. Mc Quattie-Pimentel, F.J. Gonzalez-Gonzalez, M. Chi, N. Chandel, H.R. Perlman, K.M. Ridge, W.E. Balch, R.I. Morimoto, J.I. Sznajder, G.S. Budinger, A.V. Misharin, Chicago, IL, p.A2626

2:45 **Accelerated Lung Aging in COPD: A Lung Tissue Gene Expression Signature/**M. De Vries, A. Faiz, D.S. Postma, D.D. Sin, Y. Bosse, D.C. Nickle, W. Timens, M. Van Den Berge, C.A. Brandsma, Groningen, Netherlands, p.A2627

3:00 **Role of p16(Ink4a) in Cigarette Smoke-Induced Lung Senescence/**I.K. Sundar, C.A. Lerner, J. Gerloff, H. Yao, I. Rahman, Rochester, NY, p.A2628

3:15 **Altered Mitochondrial Dynamics and Function in Aged Airway Smooth Muscle/**S. Pan, P. Sharma, D.A. Deshpande, Philadelphia, PA, p.A2629

3:30 **Nox4 Mediates Age-Associated Endothelial Barrier Dysfunction and Acute Lung Injury Severity/**L. Hecker, T. Wang, T. Zhou, Y.-J. Shin, S. Palumbo, J.G.N. Garcia, Tucson, AZ, p.A2630

3:45 **Histone Modification H4K16 Acetylation Regulates Pro-Fibrotic Gene Expression in IPF Lung Fibroblasts and in an Aging Model of Persistent Lung Fibrosis/**Y. Sanders, H. Liu, V.J. Thannickal, Birmingham, AL, p.A2631

4:00 **Aging and ER Stress Regulates Mitochondrial Homeostasis in Lung Epithelial Cells: ATF3 Regulates PINK1 Transcription./**M. Bueno, J. Brands, R. Mallampalli, A.L. Mora, Pittsburgh, PA, p.A2632

MINI SYMPOSIUM

A98 DOES THIS MEAN I HAVE TO WEAR THAT MASK? NON PAP THERAPIES FOR SDB

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 2006/2008 (West Building, Level 2)

Chairing: R.J. Schwab, MD, Philadelphia, PA
D.J. Eckert, PhD, Sydney, Australia
F.R. Almeida, DDS, MSc, PhD, Vancouver, Canada

Oral Presentations

2:15 **Comparative Efficacy of Continuous Positive Airway Pressure, Mandibular Advancement Devices, Dietary Weight Loss and Exercise Training in the Treatment of Obstructive Sleep Apnea: A Network Meta-Analysis/**I.H. Iftikhar, L. Bittencourt, S.D. Youngstedt, N. Ayas, P.A. Cistulli, R.J. Schwab, M. Durkin, U.J. Magalang, Columbus, OH, p.A2633

2:30 **Effects of Oral Appliance Therapy on the Phenotypic Causes of Obstructive Sleep Apnea/**B.A. Edwards, C. Andara, S.A. Sands, S.A. Joosten, S. Landry, R.L. Owens, D.P. White, G. Hamilton, A. Wellman, Melbourne, Australia, p.A2634

2:45 **Multimodal Phenotyping for Prediction of Oral Appliance Treatment Outcome in Obstructive Sleep Apnea/**K. Sutherland, A. Chan, J. Ngiam, O. Dalci, A. Darendeliler, P.A. Cistulli, Sydney, Australia, p.A2635

3:00 **Predicting Pharyngeal Collapsibility (Pcrit) Using Polysomnographic and Anthropometric Indices/**P. Genta, F. Schorr, B.A. Edwards, A. Wellman, G. Lorenzi-Filho, Sao Paulo, Brazil, p.A2636

3:15 **Desipramine Reduces Upper Airway Collapsibility and Improves Obstructive Sleep Apnea in Selected Patients/**L. Taranto Montemurro, S.A. Sands, B.A. Edwards, M. Marques, A. Azarbarzin, D.P. White, A. Wellman, Boston, MA, p.A2637

3:30 **Effects of Electrode Placement on Tongue Movement in Upper Airway Stimulation Therapy/**S.H.C. Wang, J. Verbraecken, J.W. De Backer, W. De Backer, P. Van De Heyning, Q. Ni, B.T. Keenan, O.M. Vanderveken, R.J. Schwab, Philadelphia, PA, p.A2638

3:45 **Effect of Electrical Stimulation of the Calf Muscle to Reduce Seated Leg Fluid Accumulation and Rostral Fluid Shift While Supine/**D. Vena, J. Rubianto, Y. Qorashi, M.R. Popovic, A. Yadollahi, Toronto, Canada, p.A2639

Featured Speaker

4:00 **Disentangling the Traits: Role of Phenotyping in Developing New Treatment for Sleep Apnea/**D.A. Wellman, MD, PhD, Boston, MA

POSTER DISCUSSION SESSION

A101 HOST DEFENSE, LUNG INJURY, AND FIBROSIS: INNATE MECHANISMS

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 133 (North Building, Lower Level)

Poster Viewing **2:15-3:00**

Discussion **3:00-4:15**

Chairing: A. Rogers, MD, MPH, Palo Alto, CA
M.T. Borchers, PhD, Cincinnati, OH
C.S. Dela Cruz, MD, PhD, New Haven, CT

101 **Pirfenidone Exacerbates Granulomatous Inflammation and Disease Progression in Tuberculosis/**W. Bishai, B.A. Ahidjo, M. Maiga, A.A. Ordonez, L.S. Cheung, S. Beck, B. Andrade, M. Klunk, S. Jain, Baltimore, MD, p.A2640

102 **Toll-Like Receptor Signaling in Human Lung Pericytes/**J.P. Higuero, C.L. Wilson, L.M. Felton, S.E. Stephenson, C.F. Hung, W.A. Altemeier, J.E. Baatz, L.M. Schnapp, Charleston, SC, p.A2641

103 **The RIG-I-Like Receptor Pathway Is Protective During Sterile Acute Lung Injury/**M.P. Mohning, A.L. McCubbrey, K.J. Mould, P.M. Henson, W. Janssen, Aurora, CO, p.A2642

104 **Toll-Like Receptor 5 Modulates MyD88-Dependent Toll-Like Receptor 4 Signaling/**C.G. Johnson, J. Sciurba, A. Rice, J. Aloor, J. Cyphert, K. Bulek, X. Li, M.B. Fessler, S. Garantziotis, Research Triangle Park, NC, p.A2643

105 **ApoA-I Binding Protein Attenuates Murine ARDS/**B.T. Suratt, E. Burg, N. Ubags, S.-H. Choi, L. Fang, Y. Miller, Burlington, VT, p.A2644

106 **Overexpression of Decay Accelerating Factor Mitigates Fibrotic Responses to Lung Injury/**R. Vittal, A.J. Fisher, E.L. Thompson, E.A. Mickler, M.R. Vasko, D.S. Wilkes, H. Gu, Ann Arbor, MI, p.A2645

107 **Modulation of TLR3-Stimulated Release of IL-26 by IL-17A and IL-22 in Bronchial Epithelial Cells/**K.F. Che, L. Palmberg, A. Linden, Stockholm, Sweden, p.A2646

108 **Plasminogen Activator Inhibitor-1 (PAI-1) Plays a Critical Role in Alcohol-Enhanced Acute Lung Injury/**L. Poole, V. Massey, E. Torres-Gonzalez, D. Siow, N. Warner, J. Luyendyk, J.D. Ritzenthaler, J. Roman, G. Arteel, Louisville, KY, p.A2647

109 **Transient Receptor Potential Vanilloid Antagonism Alleviates the Propagation of Lung Injury/**M. Cereda, Y. Xin, S. Kadlecek, J. Zeng, A. Rodriguez, H. Staroba, N. Meeder, Q. Bey, H. Profka, S. Siddiqui, M. Pourfathi, H. Hamedani, R.R. Rizi, Philadelphia, PA, p.A2648

110 **Targeting Glutamine Metabolism as a Novel Means to Prevent LPS-Induced Acute Lung Injury/**C.L. Vigeland, Y. Chan-Li, S.L. Collins, A.H. Hughes, M.-H. Oh, J.D. Powell, M.R. Horton, Baltimore, MD, p.A2649

111 **Orchestrating Role of Apoptosis Inhibitor of Macrophage (AIM) in Resolution of Acute Lung Injury in Mice/**H. Kimura, M. Suzuki, S. Konno, T. Miyazaki, H. Shindou, M. Nishimura, Sapporo, Japan, p.A2650

112 **Uncoupled Inducible Nitric Oxide Synthase Influences Macrophage Polarization in Acute Lung Injury/**T. Golden, M. Crabtree, K. Channon, A.J. Gow, Piscataway, NJ, p.A2651

113 **1,5-Anhydro-D-Fructose, a Monosaccharide from Glycogen/Starch, Ameliorates Bleomycin-Induced Lung Injury by Inhibiting Inflammasome Activation/**S. Noma, T. Saitoh, K.-I. Kawahara, Y. Ito, H. Inoue, I. Maruyama, Kamogawa City, Japan, p.A2652

114 **Deficiency of α7 Nicotinic Acetylcholine Receptor Lessens Bleomycin-Induced Lung Injury and Fibrosis/**X. Su, P. Sun, M. Pan, C. Zhao, L. Li, Shanghai, China, p.A2653

115 **Heme Oxygenase-1 Regulates ROS-ERK1/2 Signaling in Silica-Induced Lung Injury/**K. Nakashima, T. Sato, Y. Shibata, R. Ushio, M. Ikeda, H. Watanabe, K. Nagai, K. Tashiro, H. Nagakura, N. Horita, M. Yamamoto, M. Shinkai, M. Kudo, T. Kaneko, Yokohama, Japan, p.A2654

116 **Immune Exhaustion and IL-6/STAT3 Activation in IPF Lymphocytes/**A. Young, G. Shaginurova, J.A. Kropski, T.S. Blackwell, W. Drake, Nashville, TN, p.A2655

117 **The EC-SOD R213G Polymorphism Enhances Recovery of Bleomycin-Induced Airway Inflammation Mitigating Subsequent Fibrosis and Pulmonary Hypertension/**G.C. Mouradian, R. Gaurav, J. Maltzahn, J. Varasteh, B.C. Hartman, R.P. Bowler, E. Grayck, Aurora, CO, p.A2656

118 **Circulating Fibrocytes as Biomarkers of Outcome in Acute Respiratory Distress Syndrome/**A. Alrbiaan, M. Burdick, A. Kadl, K.B. Enfield, B. Mehrad, Charlottesville, VA, p.A2657

119 **In Immature Mice, Hyperoxia-Activated CLEC9A+, CD103+ Dendritic Cells Are Sufficient to Confer Exaggerated T Cell Activation and Type 1 Inflammation/**T. Cui, B. Maheshwer, A.P. Popova, Ann Arbor, MI, p.A2658

120 **A Genome-Wide Association Study Identifies Genetic Variation in MBP that Is Associated with Ventilator-Free Days in Patients with ARDS in the iSPAAR Consortium/**I. Barnett, C.S. Calfee, M. Matthay, N.J. Meyer, C. Mikacenic, G. O'Keefe, H. Hakonarson, A.J. Sandford, M. Obeidat, D.S. Postma, D.C. Nickle, Y. Bosse, G.P. Jarvik, K. Walley, J. Russell, X. Lin, D.C. Christiani, M.M. Wurfel, Boston, MA, p.A2659

121 **Airway Inflammation at Birth and Lung Function at School Age in Preterm Neonates: A Pilot Study/**M. Slaats, M. Al-Nejar, N. Everaars, E. Wouters, L. Mahieu, E. Oostveen, J. De Dooy, W. De Backer, S. Verhulst, Edegem, Belgium, p.A2660

122 **Regulation of Pseudomonas Aeruginosa Exoprotease and Elastase Activity by Thrombospondin-1/**J. Zupetic, Y. Qu, T.F. Olonisakin, M. Hulver, Z. Xiong, J. Bomberger, P. Thibodeau, P. Ray, J.S. Lee, Pittsburgh, PA, p.A2661

123 **Circulating Thrombogenic Endothelial Cell-Derived Microparticles Are Present in Patients with Systemic Sclerosis/**M.J. Scott, S. Osher, M. Hinchcliff, J.E. Dematte, I. Weiss, M. Cuttica, L. Morales-Nebreda, J. Varga, D. Vaughan, H.C. Kwaan, G.S. Budinger, G.M. Mutlu, Chicago, IL, p.A2662

124 **G-CSF and IL-6 Are Required for Early Post Burn Neutrophilia and Increased Lung Myeloperoxidase Activity/**J.C. Gardner, J.G. Noel, L. Pitstick, N.M. Nikolaidis, F.X. McCormack, Cincinnati, OH, p.A2663

125 **Genome-Wide Expression Profiling of Acute Respiratory Distress Syndrome (ARDS)/**P. Tejera, R. Zhang, Y. Wei, Z. Zhu, Z. Wang, L. Su, D.C. Christiani, Boston, MA, p.A2664

POSTER DISCUSSION SESSION

A102 HIGHLIGHTS IN PATIENT-CENTERED RESEARCH: METHODS AND OUTCOMES

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 309 (South Building, Esplanade Level)

Poster Viewing	**2:15-3:00**
Discussion	**3:00-4:15**

Chairing: M.K. Gould, MD, MS, Pasadena, CA
S.J. Bartlett, PhD, Montreal, Canada
R.A. Mularski, MD, MSHS, Portland, OR

301 **The PROMPT Study: Participatory Research in Ottawa: Management and Point-of-Care of Tobacco - A Community-Based Participatory Action Research Project/**S. Pakhale, T. Kaur, T. Rose, K. Florence, S. LeBlanc, W. Muckle, R. Boyd, D. Pettey, J. Haddad, A. Pipe, R. Reid, M. Tyndall, Ottawa, Canada, p.A2665

302 **Patients as Research Partners in Chronic Respiratory Disease (CRD) Research: Priorities, Challenges and Suggestions Made by Patients and Caregivers/**I. Poureslami, S. Pakhale, K. Lavoie, T. To, L.-P. Boulet, S. Gupta, S. Aaron, M. Fitzgerald, Vancouver, Canada, p.A2666

303 **Using Exploratory Study to Inform the Development of a Peer Supported Pulmonary Rehabilitation Program: Directions for Further Research/**I. Poureslami, J. Shum, M.J. Fitzgerald, Vancouver, Canada, p.A2667

304 **Driving Investment in Asthma Research in Europe: Priorities to Prevent, Cure and Manage Asthma More Effectively/**S.C. Masefield, P. Powell, E.J. Kennington, J.L. Edwards, K. Cowan, L. Metcalf, S. Walker, Sheffield, United Kingdom, p.A2668

305 **What Asthma Self-Management Tools and Systems Should Have Higher Priority in Future Research: A Delphi Exercise from the EU/**L. Garcia-Marcos, J.L. Edwards, E.J. Kennington, S. Walker, Murcia, Spain, p.A2669

306 **Transforming Asthma Outcomes Through Co-Ordinated National and Regional Health Initiatives: Review and Policy Recommendations/**G. De Carlo, J. De Vocht, J.L. Edwards, E.J. Kennington, S. Walker, Brussels, Belgium, p.A2670

307 **Asking Patients, Caregivers, and Clinicians for Input When Designing the Roflumilast or Azithromycin to Prevent COPD Exacerbations (RELIANCE) Trial/**J.A. Krishnan, J.W. Walsh, H.A. Gussin, N.E. Bracken, E. Malanga, J. Sullivan, R. Albert, K. Erwin, J. Holbrook, S.I. Rennard, E. Sugar, R.A. Wise, Chicago, IL, p.A2671

308 **First Year Registration Data for Enrollees in the COPD Foundation Patient Powered Research Network/**R.A. Mularski, J.W. Walsh, D.M. Mannino, C. Pasquale, S.E. Gillespie, P. Crawford, E. Malanga, M.A. McBurnie, Portland, OR, p.A2672

309 **Alpha-1 Clinical Demographics and Outcomes: Data from the Alpha-1 Therapy, Evaluation and Research (AL1TER) Patient Registry Program/**S. Kearns, L. Kristofek, B. Bolgar, D. Schmechel, Denver, CO, p.A2673

310 **Characteristics of COPD Patients Who Agree to Participate in a Pragmatic Trial of Physical Activity Coaching Compared to Non-Participants/**L. Maddock, E. Rippberger, J. Wang, J.S. Lee, K.J. Coleman, S.A. Desai, V.S. Fan, M.K. Gould, M.L. Moy, W.J. Towner, A. Xiang, H.Q. Nguyen, Pasadena, CA, p.A2674

311 **Predictors of Drop-Out from a Longitudinal Biobehavioral Research Study/**E. Cuenco, V. Carrieri-Kohlman, R.T. Disler, D. Donesky, Benicia, CA, p.A2675

312 **Structured Reporting Forms (SRF) and a Pilot Study in Interstitial Lung Disease (ILD) and Idiopathic Pulmonary Fibrosis (IPF)/**D. Szapiro, L. Bidaut, A. Gangi, T. Hartley, D.J. Dhasmana, Kirkcaldy, United Kingdom, p.A2676

313 **Expanding ICU Stakeholder Participation in the Delphi Method: The Critical Care Aligned with Patient Goals Project/**A.E. Turnbull, S.K. Sahetya, M.D. Hashem, D.M. Needham, Baltimore, MD, p.A2677

314 **Care Practices and Health-Related Quality of Life for Ventilator-Assisted Individuals: A Cross-National Study/**L.M. Hannan, H. Sahi, J. Road, C.F. McDonald, D.J. Berlowitz, M.E. Howard, Melbourne, Australia, p.A2678

315 **Relative and Absolute Reliability and Other Properties of the Asthma Impact on Quality of Life Scale (A-IQOLS) and Flanagan QOLS: Results of the AQOLIS Test-Retest Study/**S.R. Wilson, S.B. Knowles, M. Mulligan, A. Chausow, E. Ayala, R.A. Wise, M. Castro, Q. Huang, Palo Alto, CA, p.A2679

316 **Efficacy of the Adherence Starts with Knowledge 12 (ASK-12) Questionnaire Japanese Version in Japanese Actual Clinical Setting/**Y. Kimura, A. Aoki, H. Takeuchi, M. Kurokawa, M. Hayashi, T. Sakagami, T. Koya, T. Hasegawa, Niigata, Japan, p.A2680

317 **Alexithymia Related to Control, Severity and Adherence in Asthmatic Patients: Pilot Study in Ecuador/**I. Cherrez, F. Reyes, J.C. Calderon, P. Beltran, E. Calero, A. Cherrez, Guayaquil, Ecuador, p.A2681

318 **The Relationship Between Disease Knowledge, Self-Efficacy and Adherence to Treatment in Adolescents with Cystic Fibrosis/**J.M. Foster, N. Faint, J. Staton, S. Stick, A. Schultz, Sydney, Australia, p.A2682

319 **Shared Decision Making Tool for Self-Management of Home Therapies for Patients with Cystic Fibrosis/**M.H. Eckman, P.M. Joseph, E.J. Kopras, K. Montag-Leifling, M. Meyers, Cincinnati, OH, p.A2683

320 **Association of Actual and Preferred Decision-Making Roles with Patient-Reported Satisfaction and Quality of Medical Care Among Patients with Pulmonary Nodules/**D.R. Sullivan, S.E. Golden, L. Ganzini, R.S. Wiener, C.G. Slatore, Portland, OR, p.A2684

321 **Even if I Don't Remember I Feel Better: A Qualitative Study of Early Stage Non-Small Cell Lung Cancer Patients Undergoing Treatment/**S.E. Golden, C. Thomas, C.G. Slatore, Portland, OR, p.A2685

322 **Lung Nodules: Less Is Not More/**C.T. Pantin, K. Hughes, M. Cheema, J. Corless, S. Iyer, Macclesfield, United Kingdom, p.A2686

323 **Alcohol Misuse, Social Support, and Delays in Seeking Medical Care/**M. Reisinger, M. Moss, B. Clark, Denver, CO, p.A2687

324 **Perceptions of a Modified Mindfulness Training (MT) Program in Sarcoidosis/**L.A. Saketkoo, J. Young, R. Adell, A.C. Karpinski, M. Walker, A.-M. Russell, New Orleans, LA, p.A2688

POSTER DISCUSSION SESSION

A103 IPF: MORE ABOUT THERAPY AND OUTCOMES

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 304 (South Building, Esplanade Level)

Poster Viewing **2:15-3:00**

Discussion **3:00-4:15**

Chairing: P.J. Sime, MD, Rochester, NY
C.J. Ryerson, MD, Vancouver, Canada

201 **Antiacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis (IPF) Under Pirfenidone Treatment/**M. Kreuter, P. Spagnolo, W. Wuyts, E. Renzoni, D. Koschel, T.M. Maher, M. Kolb, D. Weycker, K.-U. Kirchgaessler, U. Costabel, Heidelberg, Germany, p.A2689

202 **Efficacy of Nintedanib on Acute Exacerbations Reported as Serious Adverse Events in the INPULSISr Trials in Idiopathic Pulmonary Fibrosis (IPF)/**M. Kreuter, H. Koegler, M. Trampisch, S. Geier, L. Richeldi, Heidelberg, Germany, p.A2690

203 **Effect of Baseline GAP Index Stage on Decline in Lung Function with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis (IPF)/**C.J. Ryerson, M. Kolb, L. Richeldi, J. Lee, T. Kimura, S. Stowasser, V. Poletti, Vancouver, Canada, p.A2691

204 **Safety and Tolerability of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis (IPF): One-Year Data from Post-Marketing Surveillance in the United States/**I. Noth, A. Allinger, M. Kaul, C.S. Conoscenti, D. Oelberg, Chicago, IL, p.A2692

205 **Effect of Nintedanib on Disease Progression in the INPULSISr Trials in Patients with Idiopathic Pulmonary Fibrosis (IPF)/**G. Raghu, Y. Inoue, J. Behr, V. Cottin, S. Stowasser, W. Stansen, T.M. Maher, Seattle, WA, p.A2693

206 **Efficay of Pirfenidone for Acute Exacerbation of Idiopathic Pulmonary Fibrosis/**K. Furuya, S. Sakamoto, H. Shimizu, M. Sekiya, A. Kinoshita, T. Isshiki, K. Sugino, S. Homma, Tokyoto, Japan, p.A2694

207 **Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in a US Expanded Access Program/**L. Lancaster, L. Morrison, A. Auais, B. Ding, A. Iqbal, K. Flaherty, Nashville, TN, p.A2695

208 **Effect of Pirfenidone on Cough in Patients with Idiopathic Pulmonary Fibrosis/**M.J.G. Van Manen, S.S. Birring, C. Vancheri, V. Vindigni, M. Wapenaar, V. Cottin, M.S. Wijsenbeek, Rotterdam, Netherlands, p.A2696

209 **Treatment Destiny in Idiopathic Pulmonary Fibrosis Patients Following Approval of Two Drug Therapies/**M.L. Salisbury, M. Xia, S. Murray, E.A. Belloli, R.A. Beckford, J.S. Sheth, E.S. White, K.R. Flaherty, Ann Arbor, MI, p.A2697

210 **PROOF: A Prospective Observational Registry to Describe the Disease Course and Outcomes of Idiopathic Pulmonary Fibrosis Patients in a Real-World Clinical Setting. PROOF-Registry Belgium - Luxembourg: Comorbidities in 175 IPF Patients at Inclusion/**W. Wuyts, B. Bondue, C. Dahlqvist, H. Slabbynck, M. Schlesser, K. Richir, C. Compere, N. Gusbin, G. Joos, Leuven, Belgium, p.A2698

211 **Sarc-IPF: Combined Sarcoidosis and Idiopathic Pulmonary Fibrosis; "Sarc-IPF"-A Distinct Clinical Entity or Phenotype/**B.F. Collins, L. Ho, J. Hayes, C. Spada, G. Raghu, Seattle, WA, p.A2699

212 **Two Agents for Idiopathic Pulmonary Fibrosis: Which One to Choose?/**S. Daouk, A. Aljaafareh, I. Faruqi, Gainesville, FL, p.A2700

213 **Favorable Human Safety, Pharmacokinetics and Pharmacodynamics of the Autotaxin Inhibitor GLPG1690, a Potential New Treatment in Idiopathic Pulmonary Fibrosis/**E.M. Van Der Aar, L. Fagard, J. Desrivot, S. Dupont, B. Heckmann, R. Blanque, L. Gheyle, J. Ralic, F. Vanhoutte, Mechelen, Belgium, p.A2701

214 **Peripheral Blood Myeloid-Derived Suppressor Cells Reflect Disease Status in IPF/**I.E. Fernandez, F. Greiffo, M. Frankenberger, K. Heinzelmann, C. Neurohr, R. Hatz, J. Behr, O. Eickelberg, Munich, Germany, p.A2702

215 **Effect of Nintedanib on Decline in Forced Vital Capacity (FVC) over Time in the INPULSISr Trials in Patients with Idiopathic Pulmonary Fibrosis/**T.M. Maher, K.R. Flaherty, A. Azuma, V. Cottin, W. Stansen, M. Quaresma, A. Wells, London, United Kingdom, p.A2703

216 **Comparison of the GAP Index and Staging System with the Japanese Severity Classification System in Patients with Idiopathic Pulmonary Fibrosis/**M. Bando, Y. Sugiyama, A. Azuma, M. Ebina, H. Taniguchi, Y. Taguchi, H. Takahashi, S. Homma, Shimotsuke, Japan, p.A2704

217 **Cumulative Distribution of Patients by Change in FVC % Predicted in the INPULSISr Trials of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis/**K.R. Flaherty, K.K. Brown, U. Costabel, W. Stansen, R. Schlenker-Herceg, G. Raghu, Ann Arbor, MI, p.A2705

218 **Prediction of IPF with the Early Changes in Quantitative Imaging Patterns Using High Resolution Computed Tomography/**G.H. Kim, M. Brown, S. Weigt, J.A. Belperio, J. Goldin, Los Angeles, CA, p.A2706

219 **Serum Anti-Myxovirus Resistance Protein-1 Autoantibody; a Possible Novel Biomarker for Disease Severity and Prognosis of Idiopathic Pulmonary Fibrosis/**T. Arai, H. Kida, Y. Hamano, M. Hirose, A. Murakami, T. Kagawa, A. Matsumuro, T. Koba, C. Sugimoto, M. Akira, M. Kitaichi, S. Ihara, A. Kumanogoh, Y. Inoue, Sakai, Japan, p.A2707

220 **High Resolution CT Scan Pattern as a Predictor of Disease Progression and Survival in Idiopathic Pulmonary Fibrosis/**R. Sharif, T. Kulkarni, P. Acosta-Lara, J.R. Watts, S.K. Sonavane, V.J. Thannickal, T. Luckhardt, J.A. De Andrade, Birmingham, AL, p.A2708

221 **Acid and Non-Acid Reflux in Idiopathic Pulmonary Fibrosis/**T. Lee, L. Liu, S. Shapera, T.K. Marras, J.H. Fisher, Toronto, Canada, p.A2709

222 **Effects of Emphysema on Physiologic and Prognostic Characteristics in Idiopathic Pulmonary Fibrosis/**T. Kim, S.M. Lee, N. Kim, J.B. Seo, J.W. Song, Seoul, Korea, Republic of, p.A2710

223 **Prognostic Value of Plasma Leptin in Acute Exacerbation Idiopathic Pulmonary Fibrosis/**M. Cao, J. Swigris, H. Cai, Nanjing, China, p.A2711

224 **Idiopathic Pulmonary Fibrosis in Patients with Possible Usual Interstitial Pneumonia Pattern on High-Resolution CT/**Y. Kondoh, H. Taniguchi, T. Suda, T. Fujisawa, M. Arita, K. Ichikado, K. Kishi, T. Kishaba, O. Nishiyama, T. Ogura, S. Homma, Seto, Japan, p.A2712

225 **Reduction in Non-Elective Respiratory-Related Hospitalizations in Patients Treated with Pirfenidone: Pooled Analyses from Three Phase 3 Trials of Pirfenidone in Idiopathic Pulmonary Fibrosis/**J. Swigris, B.J. Ley, B.-M. Day, J. Stauffer, W. Chou, K. Raimundo, H.R. Collard, Denver, CO, p.A2713

POSTER DISCUSSION SESSION

A104 CRITICAL CARE: SEPSIS TRANSLATIONAL INSIGHTS

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 3001 (West Building, Level 3)

Poster Viewing **2:15-3:00**

Discussion **3:00-4:15**

Chairing: M.M. Wurfel, MD, PhD, Seattle, WA
W. Fang, MD, Kaohsiung, Taiwan
E.P. Schmidt, MD, Aurora, CO

701 **Identifying Time-Dependent Mortality Signatures in Cases of Suspected Infection Using Scalable Predictive Models/**M.B. Mayhew, A.P. Sales, J.D. Greene, J.M. Baker, A. Santucci, G.J. Escobar, V. Liu, T. Wasson, Livermore, CA, p.A2714

702 **Regulation of Creb-Binding Protein Ubiquitination-Deubiquitination Modulates Histone Acetylation and Systemic Inflammation/**Y. Zhao, S. Dong, J. Wei, R.K. Boswer, A. Khoo, L. Zhang, A.M. Jacko, J. Zhao, Pittsburgh, PA, p.A2715

703 **Circulating Levels of Interleukin-17A Are Associated with Mortality and Organ Dysfunction in Sepsis/**C. Mikacenic, S. Harju-Baker, V. Dmyterko, M.M. Wurfel, Seattle, WA, p.A2716

704 **Heterogeneous Treatment Effect of Recombinant Human Interleukin-1 Receptor Antagonist for Human Severe Sepsis/**N.J. Meyer, T.G. Dunn, J.P. Reilly, J.A. Palakshappa, R. Feng, J.D. Christie, J.E. Palardy, S.M. Opal, Philadelphia, PA, p.A2717

705 **Reduced PCSK9 Function Is Associated with Improved Outcomes in Gram-Positive Septic Shock Patients/**E. Topchiy, C. Fjell, J.A. Russell, J.H. Boyd, K.R. Walley, Vancouver, Canada, p.A2718

706 **Lipopolysaccharide Is Cleared from the Circulation by Hepatocytes Via the Low Density Lipoprotein Receptor/**E. Topchiy, J.H. Boyd, J.A. Russell, K. Walley, Vancouver, Canada, p.A2719

707 **Inheritance of Loss-of-Function Tryptase Alleles Is Linked to Reduced Survival from Severe Sepsis/**N. Trivedi, R. Ahuja, K. Walley, M. Babina, S. Guhl, G. Caughey, San Francisco, CA, p.A2720

708 **Modulation of Annexin A2 Expression in Human Sepsis/**M. Bender, F. West, J. Lanfranco, H. Chen, D. Almeida, D. Berlin, K.A. Hajjar, New York, NY, p.A2721

709 **High Levels of Methylarginines Are Associated with Increased Mortality in Patients with Severe Sepsis/**K.M. Mortensen, T.S. Itenov, N. Haase, R. Muller, S.R. Ostrowski, P.I. Johansson, N.V. Olsen, A. Perner, P. Soe-Jensen, M. Bestle, Hillerod, Denmark, p.A2722

710 **Plasma Asymmetric Dimethylarginine (ADMA) Association with Risk of Death in Septic Shock - Subgroup Analysis of Patients from the VANISH Trial/**S. Lambden, J. Leiper, A. Gordon, London, United Kingdom, p.A2723

711 **Increased Receptor Interacting Serine/Threonine-Protein Kinase 3 Plasma Levels Is Associated with Severity of Sepsis/**K.C. Ma, M. Pabon, E.J. Schenck, E. Finkelsztein, A. Hernandez, D. Berlin, K. Nakahira, A.M.K. Choi, New York, NY, p.A2724

712 **Impaired Immune Response and Lower Serum Monocyte/Neutrophil Ratio Can Predict Outcomes in Patients with Severe Sepsis/**W.-F. Fang, H.-C. Kao, Y.-T. Fang, K.-T. Huang, Y.-H. Wang, C.-H. Huang, Y.-T. Chang, H.-L. Huang, C.-C. Wang, M.-C. Lin, Kaohsiung, Taiwan, p.A2725

713 **Early High Density Lipoprotein (HDL) Level Predicts the Development of Organ Dysfunction and Mortality in Patients Presenting with Suspected Sepsis/**M. Cirstea, K. Walley, J. Russell, J. Boyd, Vancouver, Canada, p.A2726

714 **Randomised Controlled Trial of Granulocyte Macrophage Colony Stimulating Factor in Critically Ill Patients with Impaired Neutrophil Function/**E.M. Pinder, A.J. Rostron, T.P. Hellyer, M.-H. Ruchaud-Sparagano, J. Scott, J.G. Macfarlane, S. Wiscombe, J.D. Widdrington, T. Allen, A.I. Roy, V.C. Linnett, S.V. Baudouin, S.E. Wright, T. Chadwick, A. Fouweather, S. Bowett, J. Parker, P.A. Corris, D.F. D. McAuley, A. Conway Morris, A. Simpson, Newcastle upon Tyne, United Kingdom, p.A2727

715 **Hydrocortisone Treatment Decreases Nitric Oxide Levels and Increases Blood Pressure and Survival Following B. anthracis Cell Wall Peptidoglycan Challenge in Rats/**D.A. Suffredini, X. Cui, Y. Li, Y. Fitz, P. Eichacker, Bethesda, MD, p.A2728

716 **PCSK9 Loss-of-Function Genotype and Outcomes of Sepsis/**K. Roveran Genga, M. Cirstea, C. Lo, K. Walley, J.A. Russell, J.H. Boyd, Vancouver, Canada, p.A2729

717 **Adipokines Early in Critical Illness/**A.M. Ahasic, M. Pisani, New Haven, CT, p.A2730

718 **Acute Respiratory Distress Syndrome Does Not Independently Predict Mortality Among All Critically Ill Patients with Sepsis/**C.L. Auriemma, H. Zhuo, T. Deiss, T. Liu, M. Lippi, K.R. Famous, E. Seeley, K.N. Kangelaris, A. Gomez, M. Matthay, K. Liu, C.S. Calfee, San Francisco, CA, p.A2731

719 **Lactate Rebound as an Independent Predictor of Mortality in Intensive Care/**J. Salciccioli, P. Charlton, A. Hartley, M. Komorowski, D. Marshall, J. Shalhoub, M.C. Sykes, L.A. Celi, London, United Kingdom, p.A2732

720 **Highly Effective Treatment of Endothelial Disorders in Sepsis by CAR Peptide Adjuvant for Hydrocortisone Therapy/**H. Okada, K. Suzuki, K. Oda, G. Takemura, C. Takada, D. Mann, M. Komatsu, S. Ogura, Gifu, Japan, p.A2733

721 **Therapeutic Effect of Gut-Derived Incretin Hormones in an Endotoxemic Mouse Model of Impaired Glucose Metabolism/**F. Shah, S. Singamsetty, L. Guo, B. Chuan, S. McDonald, B. O'Donnell, Y. Zhang, C.P. O'Donnell, B.J. McVerry, Pittsburgh, PA, p.A2734

722 **Heat Shock Protein 90 (HSP90) Stabilizes a Molecular Complex of Caspase-8 and Toll-Like Receptor-4 (TLR-4) to Prolong Polymorphonuclear Neutrophil (PMN) Survival and Regulate Respiratory Burst Activity/**S. Gupta, H. Amatullah, R. D'Cruz, S. Jia, J. Tsang, C. Dos Santos, J.C. Marshall, Toronto, Canada, p.A2735

723 **Protection Effect of Shenfuhuang Prescription on Organs of Septic Rats and its Molecular Machanism/**L. Wang, X. Zhu, G. Li, Q. Liu, Beijing, China, p.A2736

724 **Type 2 Inflammatory Responses Protect Against Staphylococcus aureus-Induced Sepsis/**P.A. Verhoef, P.A. Krishack, J. Bubeck Wardenburg, A.I. Sperling, Chicago, IL, p.A2737

725 **The rs805305 SNP of Dimethylarginine Dimethylaminohydrolase 2(DDAH2) Is Associated with Reduced Duration of Shock, Improved Mortality and an Elevated Plasma ADMA:SDMA Ratio in Septic Shock - Subgroup Analysis of Patients from the VANISH Trial/**S. Lambden, J. Leiper, A. Gordon, London, United Kingdom, p.A7800

POSTER DISCUSSION SESSION

A105 CRITICAL CARE : VARIABILITY IN CARE, OPPORTUNITIES FOR ADOPTION OR DEADOPTION

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 3011 (West Building, Level 3)

Poster Viewing **2:15-3:00**

Discussion **3:00-4:15**

Chairing: C.R. Cooke, MD, MSc, Ann Arbor, MI
J.M. Kahn, MD, MSc, Pittsburgh, PA
K.S. Mathews, MD, MPH, New York, NY

801 **Deciding Factors for Admission: Intensive Care Versus Intermediate Care/**J.T. Talbot, A. Isakov, A. Yancey, I. Bloom, G.S. Martin, J.E. Sevransky, C. Polito, Atlanta, GA, p.A2738

802 **Diagnosing Sepsis Is Subjective and Highly Variable: Results from a Survey of Intensivists Using Case Vignettes/**C. Rhee, S.S. Kadri, R. Danner, A. Suffredini, A. Massaro, B.T. Kitch, G. Lee, K. Kleinman, R. Platt, M. Klompas, Boston, MA, p.A2739

803 **Antibiotic Delivery Delays and Mortality Among Patients with Sepsis: A Propensity-Matched Case-Control Study/**M. Sisk, M.G. Kashiouris, S. Pedram, S.M. Hartigan, R. Naylor, K. Miller, S. Miller, R. Sampson, J. Trull, C. Mays, C.N. Sessler, Richmond, VA, p.A2740

804 **The Timing of Early Antibiotics and Hospital Mortality in Sepsis/**V. Fielding-Singh, J.D. Greene, J.M. Baker, G.J. Escobar, V. Liu, San Francisco, CA, p.A2741

805 **Factors Associated in De-Escalation of Antibiotics in Critically Ill Patients with Nosocomial Pneumonia/**N. Ariyoshi, J. Davis, J. Dworkin, G.P. Devendra, Honolulu, HI, p.A2742

806 **Antibiotic Stewardship in Medical ICU: Importance of a Multidisciplinary Approach for Antibiotic De-Escalation/**G.E. Holguin, M.F. Petrini, D. Haynes, Jackson, MS, p.A2743

807 **How Procalcitonin Changed Antimicrobials Use in ICU Patients with Lower Respiratory Infections/**S. AlSamman, K. Shawwa, J. Hong, M.A. AlSamman, C. Hayner, S. Friedstrom, J. Steinbrunner, Detroit, MI, p.A2744

808 **Permissive Underfeeding or Standard Enteral Feeding in Critically Ill Adults at High and Low Malnutrition Risk/**Y.M. Arabi, A.S. Aldawood, S.H. Haddad, H.M. Al-Dorzi, H.M. Tamim, G. Jones, S. Mehta, L. McIntyre, O. Solaiman, M.H. Sakkijha, M. Sadat, L. Afesh, A. Kumar, S.M. Bagshaw, C. Lee, N. Salahuddin, Riyadh, Saudi Arabia, p.A2745

809 **Hospital Variation in Acute Hemodialysis for Sepsis in the U.S./**T.S. Valley, B.K. Nallamothu, M. Heung, T.J. Iwashyna, C.R. Cooke, Ann Arbor, MI, p.A2746

810 **Wide Practice Variability in Fluid Resuscitation of Critically Ill Patients with Acute Respiratory Distress Syndrome (ARDS)/**J.N. Mansoori, W.T. Linde-Zwirble, P.C. Hou, E. Havranek, I.S. Douglas, Denver, CO, p.A2747

811 **Early Hyperoxia, Neurologic Outcome, and Mortality in Post-Cardiac Arrest Syndrome/**L. Hsu, R.J. Anderson, T.B. Ghafouri, S. Tyagi, J. Joshua, J.R. Beitler, La Jolla, CA, p.A2748

812 **Sedative Infusions in Already-Comatose Patients After Out-of-Hospital Cardiac Arrest/**J. Joshua, R.J. Anderson, L. Hsu, T.B. Ghafouri, S. Tyagi, J.R. Beitler, La Jolla, CA, p.A2749

813 **Survey of Glucose Control Practices in All ICUs Within British Columbia, Canada/**S. Yue, V. Dhingra, J.J. Ronco, C. Pamplin, S. McKeown, P. Dodek, Vancouver, Canada, p.A2750

814 **Trends in Mechanical Ventilation and Vasopressor Use and Relevance to Mortality Outcomes in Critical Care Settings/**J.D. Raffa, R.A. Montgomery, R. Stretch, A.E.W. Johnson, L.A. Celi, T. Pollard, Cambridge, MA, p.A2751

815 **The Effect of Clinical Trial Results on the Use of Neuromuscular Blockade for Severe ARDS/**M.P. Siedsma, T.Q. Le, J.M. Kahn, C.W. Seymour, Pittsburgh, PA, p.A2752

816 **Suboptimal Adherence to Low Tidal Volume and Higher PEEP Strategies in Patients with Moderate to Severe Hypoxemia/** K.S. Mathews, I.H. Shalom, L.S. Richman, E.Y. Fass, L.D. Richardson, New York, NY, p.A2753

817 **Poor Adherence to Lung Protective Mechanical Ventilation in Pediatric Acute Respiratory Distress Syndrome/**S.L. Ward, C.M. Quinn, M.A. Matthay, H.R. Flori, San Francisco, CA, p.A2754

818 **Reduction of Unplanned Extubations in an Inner City Hospital Intensive Care Unit:A Quality Improvement Project/**H.R.T. Hashmi, D. Miller, O. Osayande, G. Diaz-Fuentes, Bronx, NY, p.A2755

819 **Patients with Multiple Rapid Response Activations Have Worse Outcomes and Increased Health Care Costs/**J. Yang, E. Hemmen, E. Botts, D. Paulson, R. Sell, San Diego, CA, p.A2756

820 **Decision Model Assessing Effects of a Restrictive Transfusion Strategy on Transfusion-Associated Pulmonary Adverse Events Among Patients with Cardiovascular Disease Following Hip Surgery/**M.V. Fusaro, N.D. Nielsen, A. Nielsen, M.J. Fontaine, J.R. Hess, G. Netzer, Baltimore, MD, p.A2757

821 **Encouraging Appropriate Blood Transfusions Through a Direct Educational Intervention/**B. Small, R. Sengupta, J. Jordan, I. Lopez-Plaza, B. DiGiovine, Detroit, MI, p.A2758

822 **Reducing Inappropriate Blood Transfusions with the Use of an Electronic Medical Record (EMR)/**R. Sengupta, B. Small, I. Lopez-Plaza, B. DiGiovine, Detroit, MI, p.A2759

823 **Annual Cumulative Radiation Dose Exposure in a Cohort of Young Medical Intensive Care Unit (MICU) Survivors-Characteristics and Predictors/**S. Krishnan, S. Narechania, A. Moghekar, A.K. Changarath Vijayan, F. Dong, F. Adhi, J. Yella, A. Mehta, A. Duggal, J. Guzman, Cleveland, OH, p.A2760

824 **Reversing Established Medical Practices in Critical Care Medicine: An Analysis of Three Medical Journals from 2011 - 2014/**J. Rho, T. Patel, M. Weinreich, B. Block, A. Cifu, V. Prasad, Dallas, TX, p.A2761

825 **Pharmacological Management of Delirium (PMD) Trial/**B. Khan, A. Perkins, S. Gao, M. Boustani, Indianapolis, IN, p.A7801

POSTER DISCUSSION SESSION

A106 EPIDEMIOLOGY AND RISK FACTORS OF ASTHMA: FROM THE CRIB TO ADULTHOOD

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 3024 (West Building, Level 3)

Poster Viewing **2:15-3:00**

Discussion **3:00-4:15**

Chairing: F. Holguin, MD, MPH, Pittsburgh, PA
S. Sharma, MD, MPH, Aurora, CO
C. Lemiere, MD, Montreal, Canada

1001 **Pairwise Interactions Between Clinical, Genetic, Environmental, and Social factors Are Significantly Associated with Brochodilator Response in Minority Youth with Asthma/**M.J. White, J. Magana, O. Risse-Adams, M. Spear, N. Thakur, J. An, S. Oh, C. Eng, S. Huntsman, D. Hu, L. Borrell, E.G. Burchard, San Francisco, CA, p.A2762

1002 **Plasma Vitamin D Level and Th17 Cytokines in Children with Asthma/**J.M. Brehm, Y.Y. Han, N. Boutaoui, A. Colon-Semidey, M. Alvarez, E. Acosta-Perez, J.F. Alcorn, G. Canino, J.C. Celedon, Pittsburgh, PA, p.A2763

1003 **Measured Free 25(OH)D but Not Total 25(OH)D Is Associated with Atopy and Measures of Pulmonary Function in Peruvian Children with Asthma/**S.L. Pollard, J.J. Lima, K. Romero, E.B. Mougey, C.E. Tarazona-Meza, K. Tomaino, G. Malpartida Guzman, N.N. Hansel, W. Checkley, Baltimore, MD, p.A2764

1004 **Effects of Long-Term Exposure to PM2.5 on Asthma Control in Children: Longitudinal Study in a Peri-Urban Community in Lima, Peru/**K.M. Romero Rivero, W. Checkley, C. Chen, L. Underhill, S.L. Pollard, C. Johson, P. Breysse, D. Williams, N.N. Hansel, Lima, Peru, p.A2765

1005 **Associations of Residence Near Primary Traffic Arterials with Asthma and Wheezing in a Sample of Mexican American Children/**K. Eldeirawi, V. Persky, C. Kunzweiler, B. Riley, Y. Gao, N. Rosenberg, Chicago, IL, p.A2766

1006 **A Longitudinal Assessment of Particulate Air Pollution and Rhinitis Quality of Life Scores in Peri-Urban Peruvian School-Aged Children/**S. Bose, D. Kaji, K. Romero, W. Checkley, C. Chen, P. Breysse, D. Williams, N.N. Hansel, Baltimore, MD, p.A2767

1007 **Prevalence of Asthma in Adolescents Across the Arizona-Sonora Border Using ISAAC Written and Video Questionnaires/**T.F. Carr, P. Beamer, J. Rothers, D.A. Stern, L.B. Gerald, C. Rosales, D. Vercelli, M. Gameros, M. Halonen, F.D. Martinez, A. Wright, Tucson, AZ, p.A2768

1008 **Environmental Exposure to Polycyclic Aromatic Hydrocarbons and the Relationship with Lung Function and Oxydative Damage/**M.L. Perez Humara, L. Hernandez Cadena, A. Barraza-Villarreal, I. Alvarado Cruz, B. Quintanilla Vega, M.C. Escamilla-Nunez, Cuernavaca, Morelos, Mexico, p.A2769

1009 **Quality of Life and Health Care Use Among School-Age Children with Asthma-2006-2010 Behavioral Risk Factor Surveillance System Asthma Call-Back Survey/**M.J. Lozier, H.S. Zahran, C.M. Bailey, Atlanta, GA, p.A2770

1010 **Environmental Exposure to NOx and NO2 and Respiratory Function in Schoolchildren from Mothers who Participated in a Randomized Clinical Trial During Pregnancy/**A. Barraza-Villarreal, M.C. Escamilla-Nunez, L. Hernandez-Cadena, P.D. Sly, U. Ramakrishnan, I. Romieu, Cuernavaca, Morelos, Mexico, p.A2771

1011 **Airway Inflammation and Oxidative Stress as a Response to Exposure to PM2.5 in Adolescents with and Without Asthma in Mexico City/**L. Hernandez Cadena, P. Ibinarriaga Montiel, B.E. Del Rio Navarro, I. Romieu, E. Navarro, M.C. Escamilla-Nunez, A. Barraza-Villarreal, Cuernavaca, Morelos, Mexico, p.A2772

1012 **Lung Size and Function Among Offspring Following Maternal Immunization with Influenza or Pneumococcal Vaccine During Pregnancy/**M. Caravedo, K. Zaman, W. Checkley, E. Roy, M. Steinhoff, Baltimore, MD, p.A2773

1013 **EPA Air Quality Index: Limitations as a Risk Communication Tool/**K.R. Cromar, L.D. Perlmutt, New York, NY, p.A2774

1014 **Determinants and Characteristics of Asthma in the Athletes According to the Training Environment/**A. Cote, J. Turmel, L.-P. Boulet, Quebec, Canada, p.A2775

1015 **Meta-Analysis of the Association of Serum Vitamin D with Pulmonary Function/**J. Xu, T.M. Bartz, G. Chittoor, G. Eiriksdottir, A.C. Frazier-Wood, L. Lahousse, J. Latourelle, A.W. Manichaikul, F. Sun, N. Terzikhan, R.G. Barr, G.G. Brusselle, J. Dupuis, S.A. Gharib, S. London, K.E. North, B. Psaty, A. Smith, D.B. Hancock, P.A. Cassano, Ithaca, NY, p.A2776

1016 **Predictors of Asthma Morbidity in World Trade Center (WTC) Rescue and Recovery Workers/**K. Xu, E.R. Goodman, R. Goswami, M. Crane, L.E. Crowley, P. Busse, C.L. Katz, S. Markowitz, J.P. Wisnivesky, New York, NY, p.A2777

1017 **Mental Health Services Use and Adult Onset Asthma in Ontario, Canada/**T. To, J. Zhu, K. Ryckman, L.Y. Feldman, K. Larsen, D.P. Williams, A.S. Gershon, Toronto, Canada, p.A2778

1018 **Asthma Hospitalizations and ED Visits Before, During and After Pregnancy Among Women with Asthma/**T. To, J. Zhu, L.Y. Feldman, K. Ryckman, K. Larsen, A.S. Gershon, Toronto, Canada, p.A2779

1019 **High Blood Eosinophils as Predictor of Asthma Exacerbations in 4,838 Individuals with Asthma: A Study of 81,639 Individuals from the Copenhagen General Population Study/**S. Vedel-Krogh, S.F. Nielsen, P. Lange, J. Vestbo, B.G. Nordestgaard, Herlev, Denmark, p.A2780

1020 **House Dust Endotoxin Levels Are Associated with Adult Asthma in the Agricultural Lung Health Study/**S. London, J.A. Hoppin, A. Wyss, J.S. House, P.K. Henneberger, D.M. Umbach, P.S. Thorne, M.U. Carnes, Research Triangle Park, NC, p.A2781

1021 **Urbanization but Not Biomass Fuel Smoke Exposure Is Associated with Asthma Prevalence in Four Resource-Limited Settings/**C.H. Miele, C. Gaviola, R.A. Wise, R.H. Gilman, D. Jaganath, J.J. Miranda, A. Bernade-Ortiz, N.N. Hansel, W. Checkley, Baltimore, MD, p.A2782

1022 **Cycling During Diesel Exhaust Exposure May Decrease the Bronchodilatory Response to Exercise in Asthmatics/**R. Tran, S. Koch, A. Lee, C. Carlsten, J. Guenette, M. Koehle, Vancouver, Canada, p.A2783

1023 **Longitudinal Asthma Patterns in a Large Cohort of US Women with 22-Year Follow-Up/**O. Dumas, R. Varraso, F.E. Speizer, C.A. Camargo, VilleJuif, France, p.A2784

1024 **Medication Use Among Individuals with Work-Related Asthma, Asthma Call-Back Survey, 2012-2013/**K.E. Dodd, J.M. Mazurek, Morgantown, WV, p.A2785

1025 **Fourteen-Year Trends in the Direct Costs of Asthma: A Population-Based Study/**H. Tavakoli, J.M. FitzGerald, W. Chen, T. Kendzerska, S. Aaron, A.S. Gershon, C. Marra, M. Sadatsafavi, Vancouver, Canada, p.A2786

POSTER DISCUSSION SESSION

A107 ETIOLOGY OF PAH: GO YOUR OWN WAY

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 3014 (West Building, Level 3)

Poster Viewing **2:15-3:00**

Discussion **3:00-4:15**

Chairing: J.P. Fessel, MD, PhD, Nashville, TN
R.F. Machado, MD, Chicago, IL
S.Y. Farha, MD, Cleveland, OH

901 **BMPR2 Mutation-Independent Mechanisms of Disrupted BMP Signaling in IPAH/**J.W. Barnes, L. Tian, E.T. Kucera, M. Aytekin, N. Dvorina, W. Baldwin, M. Aldred, C.F. Farver, S.A.A. Comhair, R. Dweik, Cleveland, OH, p.A2787

902 **Therapeutic Effects of Blockade of IL-6/gp130 Signaling in Pulmonary Arterial Hypertension/**Y. Tamura, C. Phan, L. Tu, R. Thuillet, M. Le Hiress, A. Huertas, E. Fadel, G. Simonneau, M. Humbert, C. Guignabert, Le Plessis Robinson, France, p.A2788

903 **Isolation and Characterization of Endothelial-to-Mesenchymal Transition-Cells in Pulmonary Arterial Hypertension/**T. Suzuki, R. Nishimura, Y. Tada, T. Urushibara, A. Sekine, T. Kawasaki, K. Tatsumi, J. West, Chiba, Japan, p.A2789

904 **Bone Marrow Transplantation Reduces Susceptibility to Pulmonary Hypertension in Bone Morphogenetic Receptor Type 2 (BMPR2) Deficient Mice/**A. Crosby, E. Soon, E. Groves, M. Southwood, B.J. Dunmore, M. Toshner, N.W. Morrell, Cambridge, United Kingdom, p.A2790

905 **Tuberous Sclerosis Complex 2 Deficiency Contributes to Proliferation/Apoptosis Imbalance of Pulmonary Vascular Smooth Muscle Cells in Pulmonary Hypertension/**B. Chang, D.A. Goncharov, A. Pena, A. Kobir, K. Ihida-Stansbury, H. DeLisser, S.M. Kawut, E.A. Goncharova, Pittsburgh, PA, p.A2791

906 **Reduced CFIm25 Expression as a Regulator of Pulmonary Hypertension Through HAS2/**S.D. Collum, T. Weng, A. Hernandez, N.-Y. Chen, J. Molina, J. Amione-Guerra, O. Al-Jabbari, R.R. Bunge, N. Singha, M.R. Blackburn, L. Han, H. Karmouty-Quintana, Houston, TX, p.A2792

907 **Whole Genome Sequencing in Idiopathic and Heritable Pulmonary Arterial Hypertension/**S. Graf, M. Bleda, C. Hadinnapola, M. Haimel, H.J. Bogaard, G. Coghlan, P.A. Corris, J.S. Gibbs, D.G. Kiely, A. Lawrie, R.D. Machado, A.J. Peacock, J. Pepke-Zaba, R.C. Trembath, A. Vonk-Noordegraaf, J. Wharton, M.R. Wilkins, S.J. Wort, N.W. Morrell, Cambridge, United Kingdom, p.A2793

908 **Loss of Endothelial Nitric Oxide (NO) Synthase Drives Mortality in Bone Morphogenic Protein Receptor Type II (BMPR2) Mutant Mice and Is Associated with Increased Inducible NO Synthase and Increased Glycolysis/**E.G. Kocurek, C. Moore, T. Luong, S. Shay, J. French, S. Gladson, J. West, J.P. Fessel, Nashville, TN, p.A2794

909 **Spatiotemporal Overexpression of Human Resistin in Mouse Lungs Results in Vascular Remodeling and Pulmonary Hypertension/**X. Fang, J. Gomez-Arroyo, J. Skinner, L. Meuchel, K. Yamaji-Kegan, J. Dong, C. Fan, Z. Zhu, R. John, Baltimore, MD, p.A2795

910 **Amelioration of SU5416/Hypoxia-Induced Pulmonary Hypertension Following Treatment with EMAPII-Neutralizing Antibodies/**M. Clauss, M. Bednorz, L. Green, R. Yi, M. Seimetz, I. Petrache, T. Lahm, Indianapolis, IN, p.A2796

911 **Dasatinib Causes Pulmonary Endothelial Damage and Increases Endothelial Permeability/**E.-M. Jutant, C. Phan, L. Tu, Y. Tamura, R. Thuillet, M. Le Hiress, E. Fadel, G. Simonneau, A. Seferian, D. Montani, A. Huertas, M. Humbert, J. Aman, C. Guignabert, Le Plessis-Robinson, France, p.A2797

912 **The Extracellular Matrix Collagen Fragment AcPGP Facilitates Pulmonary Vascular Remodeling Through Rho Kinase Signaling/**D.W. Russell, G.A. Payne, D. Xing, Y. Wu, L. Viera, T. Szul, J. Gautney, C.M. McNicholas-Bevensee, A. Gaggar, Q. Yang, X. Xu, P.L. Jackson, M.T. Dransfield, J.E. Blalock, J.M. Wells, Birmingham, AL, p.A2798

913 **Transgenic Endothelial Specific HIV-Nef Expression Induces Vascular Dysfunction and Mild Pulmonary Hypertension/**S. Chelvanambi, M. Clauss, N. Dahl, X. Chen, A. Obukhov, K.L. March, T. Lahm, P. Jolicoeur, Indianapolis, IN, p.A2799

914 **Role of the Macrophage Mineralocorticoid Receptor in Pulmonary Arterial Hypertension/**D.P. Menon, K.C. Penumatsa, R. Warburton, E.A. Yu, D. Toksoz, N.S. Hill, B.L. Fanburg, U. Kayyali, I.R. Preston, Boston, MA, p.A2800

915 **Influence of Sex on TGFβ and BMPR2 Signalling in the Hypertrophic Right Ventricle in a Mouse Model of Pulmonary Arterial Hypertension/**D. Morales-Cano, K.M. Mair, F. Perez Vizcaino, M. MacLean, Madrid, Spain, p.A2801

916 **Vascular Olfactory Receptors: New Suspects in Pulmonary Arterial Hypertension/**A. Courboulin, M. Quatredeniers, G. Sanz, S. Breuils-Bonnet, M. Vocelle, M. Lafond, F. Antigny, F. Perros, S. Bonnet, E. Pajot-Augy, M. Humbert, S. Cohen-Kaminsky, Le Plessis Robinson, France, p.A2802

917 **Stiffness-Dependent Alteration of BMP Signaling and Vascular Smooth Muscle Cell Growth in Pulmonary Arterial Hypertension/**K. Ihida-Stansbury, R. Malik, M. Chokshi, L. Philip, S. Nguyen, Philadelphia, PA, p.A7802

918 **Therapeutic Proof-of-Concept for Novel siRNA Technology in Experimental Pulmonary HYpertension/**R.S. Baliga, A.J. Moyes, I.C. Villar, U. Schaeper, L. Iannone, A.J. Hobbs, London, United Kingdom, p.A7803

POSTER DISCUSSION SESSION

A108 MICRO RNAS, RNA SEQ, LNCRNA: BIOLOGY AND FUNCTION

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 2024 (West Building, Level 2)

Poster Viewing **2:15-3:00**

Discussion **3:00-4:15**

601 **Differential miRNome Expression Profiles of Alveolar Cells in Humanized SP-A2 Transgenic and SP-A Knockout Male Mice, and Cell-Specific Biogenesis of miRNAs Predicted to Regulate SP-A2/**G.T. Noutsios, T.M. Umstead, X. Zhang, J. Floros, Hershey, PA, p.A2803

602 **Epithelial Barrier Associated MicroRNAs Are Reduced in Rhinovirus Infected Epithelial from Healthy and Asthmatic Donors/**N. Day, E. Wilkinson, M. Hardyman, G. Dingley, R. Felwick, R. Martinez-Nunez, T. Sanchez-Elsner, J. Collins, Southampton, United Kingdom, p.A2804

603 **MicroRNA-34a Blockade Partially Restores Normal Septal Thickness in an Experimental Animal Model of Bronchopulmonary Dysplasia/**J. Ruiz Camp, J. Quantius, P. Arndt, I. Mizikova, S. Herold, W. Seeger, R.E. Morty, Bad Nauheim, Germany, p.A2805

604 **A Role for microRNA-29c in Arrested Alveolarization Associated with Experimental Bronchopulmonary Dysplasia/**D.E. Surate Solaligue, D. Silva, W. Seeger, R.E. Morty, Bad Nauheim, Germany, p.A2806

605 **Identification of Novel microRNA Targets in Neonatal Lungs of CTGF-Transgenic Mice/**C. Miranda, R. Zambrano, S. Luo, C. Dong, S. Wu, Miami, FL, p.A2807

606 **MicroRNA-145 Regulates TGF-β1 Mediated Down-Regulation of CFTR Expression in CF and Non-CF Airway Epithelia/** F.M. Lutful Kabir, W.T. Harris, Birmingham, AL, p.A2808

607 **Peripheral Blood MicroRNA Signature Differentiates Sarcoidosis/**N.G. Casanova, T. Zhou, J. Navarrete, K.S. Knox, J.G.N. Garcia, Tucson, AZ, p.A2809

608 **Analysis of MicroRNAs in the Developing Mouse Lung Reveals Changes Relevant to Adult Human Disease/**F. Ahangari, J. Herazo-Maya, B. Juan-Guardela, A. Munivar, A.E. Tzouvelekis, T. Nicola, N. Ambalavanan, Z. Bar-Joseph, J. Hagood, N. Kaminski, New Haven, CT, p.A2810

609 **Identification of Serum Extracellular Vesicle microRNA as a Biomarker for Prognosis in Idiopathic Pulmonary Fibrosis/**T. Makiguchi, M. Yamada, Y. Yoshioka, H. Sugiura, A. Koarai, H. Kubo, T. Ochiya, M. Ichinose, Sendai, Japan, p.A2811

610 **Serum MicroRNA in IPF Patients Display Fibrotic Profiles -Potential Prognostic Indicators or Markers of Disease Burden?/**P. Minnis, R. Kane, G. Cooke, R. Lumsden, S.M. Walsh, S. Whitty, A. Fabre, M.P. Keane, Dublin, Ireland, p.A2812

611 **Plasma MicroRNAs Expression Associated with Acute Exacerbation in Idiopathic Pulmonary Fibrosis/**D. Jinghong, C. Hourong, G. Qian, Nanjing, China, p.A2813

612 **VEGF Induces Lung Angiogenesis Through "Tailing and Trimming" of MicroRNAs and Production of 3'-Modified IsomiRs/**A. Korde, L. Dela-Moss, M. Haslip, S. Takyar, New Haven, CT, p.A2814

613 **HIV-1 Nef Downregulates miRNA Expression in Lung Cells/**W. Chatila, M. Santerre, G. Criner, B. Sawaya, Philadelphia, PA, p.A2815

614 **Identification of MiR-124 as a Major Regulator of Enhanced Endothelial Cell Glycolysis in Pulmonary Arterial Hypertension/**P. Caruso, B.J. Dunmore, K. Schlosser, S. Schoors, C. Dos Santos, C. Perez-Iratxeta, J. Lavoie, L. Long, L. Hurst, M.L. Ormiston, A. Hata, P. Carmeliet, D.J. Stewart, N.W. Morrell, Cambridge, United Kingdom, p.A2816

615 **Influence of Sex on the miRNA Profile in the Right Ventricle from Mouse Models of Pulmonary Arterial Hypertension/**D. Morales-Cano, K.M. Mair, N.W. Morrell, F. Perez Vizcaino, M. MacLean, Madrid, Spain, p.A2817

616 **Bi-phasic Expression of MiR-17~92 in PASMC During Hypoxia Induced by HIF and p53/**T. Chen, S. Gonzales, J.B. Huang, Q. Zhou, H. Yan, S.-H. Sun, G. Zhou, J.U. Raj, Chicago, IL, p.A2818

617 **MicroRNA-26b Attenuates Monocrotaline-Induced Pulmonary Vascular Remodeling Via Targeting Connective Tissue Growth Factor (CTGF) and Cyclin D1 (CCND1)/**R. Wang, G. Sun, Anhui, China, p.A2819

618 **Non-Invasive Sampling of the Airspace Proteome Using HME Filter Condensate in Mechanically Ventilated Patients with ARDS/**J.B. McNeil, W.H. McDonald, C.M. Shaver, M.A. Warren, D.W. Russell, L. Ware, J.A. Bastarache, Nashville, TN, p.A2820

619 **MicroRNA-185 Mediates Lung Epithelial Cell Death After Oxidative Stress/**D. Zhang, H. Lee, Y. Cao, H.-G. Moon, J.-H. Hwang, Y. Jin, Boston, MA, p.A2821

620 **The Distribution and Efficacy of MiR-29 Mimicry as a Therapy for Pulmonary Fibrosis Induced by Bleomycin in Mice/**G. Yu, R. Wang, R. Rusty Montgomery, C. Gallant-Behm, A. Gigliotti, T. Woolard, A. Tzouvelekis, J. Herazo-Maya, K. Sakamoto, Q. Li, G. Deluliis, F. Ahangari, M. Vukmirovic, N. Aurelien, T. Adams, A. Munivar, L. Pestano, J. McDonald, N. Kaminski, New Haven, p.A2822

621 **The Long Non-Coding RNA FALCOR Directs Lung Epithelial Development and Repair After Injury by Regulating the Expression of Foxa2/**D.T. Swarr, M. Morley, K. Rathi, S. Zhou, M. Herriges, E.E. Morrisey, Philadelphia, PA, p.A2823

POSTER DISCUSSION SESSION

A109 REMODELING AND THE MATRIX

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 2014 (West Building, Level 2)

Poster Viewing **2:15-3:00**

Discussion **3:00-4:15**

Chairing: A.R. West, PhD, Winnipeg, Canada
S.S. An, PhD, Baltimore, MD
A.G. Stewart, PhD, Melbourne, Australia

501 **A Lumped Parameter Model of Fiber Recruitment in the Extracellular Matrix: Implications for the Aging Lung/**S. Bou Jawde, A. Takahashi, B. Suki, Boston, MA, p.A2824

502 **Dynamic Changes in Extracellular Matrix Elastin, Laminin, and Fibronectin During Mouse Lung Development/**N. Li, D. Warburton, W. Shi, Los Angeles, CA, p.A2825

503 **Early Impairment of Lung Mechanics in a Murine Model of Marfan Syndrome/**J.J. Uriarte, T. Meirelles, D. Gorbenko Del Blanco, P.N. Nonaka, N. Campillo, E. Sarri, D. Navajas, G. Egea, R. Farre, Barcelona, Spain, p.A2826

504 **The Integrin Receptor Beta7 Subunit Mediates Lung Fibroblast Activation: Implications for Airway Remodeling and Hyperresponsivenss in a Murine Model of Chronic Allergen-Induced "Asthma"/**N. Berkman, T. Obedeyah, M. Assayag, Jerusalem, Israel, p.A2827

505 **Bone Marrow, Adipose and Lung Tissue-Derived Mesenchymal Stromal Cells Yield Distinct Effects on Lung inflammation and Remodeling in Experimental Allergic Asthma/**S.C. Abreu, M.A. Antunes, V.C. Branco, F.F. Cruz, B.L. Diaz, M.M. Morales, D.G. Xisto, P.R.M. Rocco, Rio de Janeiro, Brazil, p.A2828

506 **Mechanical Stress-Induced Mast Cell Degranulation Activates TGFβ-1 Signalling Pathway in Pulmonary Fibrosis/**C. Shimbori, P.-S. Bellaye, J. Gauldie, M.R.J. Kolb, Hamilton, Canada, p.A2829

507 **Desmoplakin (DSP), a GWAS-Identified Genetic Risk Allele of IPF, Is a Matrix Stiffness-Regulated Mechanosensitive Gene/**J. Qu, H. Chen, A.V. Estrada, L. Zhu, V.J. Thannickal, Y. Zhou, Birmingham, AL, p.A2830

508 **High Substrate Stiffness Enhances Transforming Growth Factor Beta Induced Internalization of E-Cadherin in Airway Epithelial Cells/**N. Roy, E. Turner-Brannen, A.R. West, Winnipeg, Canada, p.A2831

509 **Characterization of Extracellular Matrix Remodeling in Stable COPD Using Serological Biomarkers/**J.M.B. Sand, D.J. Leeming, G. Martinez, A.-K. Midjord, M.A. Karsdal, P. Lange, Herlev, Denmark, p.A2832

510 **Defective Collagen I Remodeling and Contraction Is a Feature of Asthmatic Airway Fibroblasts/**E.T. Osei, L. Mostaco-Guidolin, S. Hajimohammadi, J. Ullah, F. Shaheen, T.-L. Hackett, Vancouver, Canada, p.A2833

511 **A Digestion-Repair Model of Collagen Fiber Homeostasis and Its Application to Aging of Lung Tissue/**C. Alves, A.D. Araujo, B. Suki, Boston, MA, p.A2834

512 **Human Chymase and the Identification of Integrin α5Iβ as Novel Target for Bronchoconstriction in Asthma/**A. Sundaram, A. Atakilit, C. Chen, A. Khalifeh-Soltani, K. Atabai, D. Sheppard, San Francisco, CA, p.A2835

513 **In vivo Effectiveness of Bitter Taste Receptor Agonists in Mouse Models of Allergic Asthma/**P. Sharma, R. Yi, N. Wang, D.A. Deshpande, Philadelphia, PA, p.A2836

514 **Validation of the 3DBioRingTM Airway; a 3D-Bioprinted Contractile Airway Tissue/**S.J. Wadsworth, S. Pan, T. Mohamed, S. Beyer, Vancouver, Canada, p.A2837

515 **Development of a Novel 3 Dimensional Organoid Culture of the Airway Lumen/**T.G. Guney, H. Danahay, F. Chung, S. Mumby, M. Dowling, I.M. Adcock, O. Ojo, A.L. Durham, London, United Kingdom, p.A2838

516 **Secretion of Brain Derived Neurotrophic Factor Is Regulated by Inflammation-Induced Signals in Asthmatic Airway Smooth Muscle Cells/**B. Aravamudan, M.A. Thompson, C. Pabelick, Y.S. Prakash, Rochester, MN, p.A2839

517 **BDNF Potentiates and Mediates Inflammation Induced Remodeling of Airway Smooth Muscle/**M. Freeman, V. Sathish, L.J. Manlove, S.-Y. Wang, M.A. Thompson, C. Pabelick, Y.S. Prakash, Rochester, MN, p.A2840

518 **Estrogen and Testosterone Influence Brain-Derived Neurotropic Factor Release from Human Airway Smooth Muscle Cells/**S.-Y. Wang, M.R. Freeman, V. Sathish, M.A. Thompson, C.M. Pabelick, Y.S. Prakash, Xi'an, China, p.A2841

519 **Molecular Mechanism and Functional Role of TRPC3 Channels in Asthmatic Airway Hyperresponsiveness and Remodeling/**Y.-M. Zheng, Albany, NY, p.A2842

520 **MicroRNA-221 Is Upregulated in the Equine Asthmatic Airway Smooth Muscle and Modulates Smooth Muscle Cell Proliferation/**M. Issouf, A. Vargas, R. Boivin, J.-P. Lavoie, Saint-Hyacinthe, Canada, p.A2843

521 **Extracellular Matrix Within the Airway Smooth Muscle Layer Correlates with Age but Not in Cases of Asthma/**J. Elliot, N. Sandosham, R. Jones, S.-A. Drew, K. McKay, P. Noble, A. James, Nedlands, Australia, p.A2844

522 **Increased Stiffness and Changes in TGFbeta-Induced Gene Expression in Lung Fibroblast Spheroids from IPF Fibroblasts/** A.G. Stewart, F.R. Jativa, M. Schuliga, Z. Wang, T. Harris, J. Jaffar, G. Westall, P.V. Lee, Melbourne, Australia, p.A7804

523 **Inhibition of Airway Smooth Muscle Cell Proliferation by MicroRNA-509 Through Its Directly Targeting Polo-Like Kinase-1/**G. Liao, R. Wang, D.D. Tang, Albany, NY, p.A7805

POSTER DISCUSSION SESSION

A110 THE SLEEPY AND AGING BRAIN: OSA AND COGNITION IN THE ELDERLY

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 2010/2012 (West Building, Level 2)

Author Summaries **2:15-2:45**

Poster Viewing/Discussion **2:45-4:15**

Chairing: M.J. Morrell, MD, PhD, London, United Kingdom
A. Vakulin, PhD, Daw Park, Australia
T.E. Weaver, PhD, RN, Chicago, IL

401 **Six Months of Continuous Positive Airway Pressure (CPAP) Treatment Improves Neurobiological Function and Quantitative Sleep Electroencephalographic (EEG) Parameters in Obstructive Sleep Apnea/**C.M. Hoyos, A. D'Rozario, K. Wong, J.W. Kim, D. Kim, C. Field, A. Vauklin, R. Grunstein, D. Bartlett, Glebe, Australia, p.A2845

402 **Associations Between Sleep Apnea and Cognitive Function; Effect Modification by Apolipoprotein E-4 in the Multi-Ethnic Study of Atherosclerosis (MESA)/**D.A. Johnson, R. Wang, I. Djonlagic, A.L. Fitzpatrick, S.R. Rapp, L.E. Charles, S. Redline, Boston, MA, p.A2846

403 **Evaluation of CPAP Treatment on Memory Processes in Obstructive Sleep Apnea Patients Through a Randomized Controlled Trial/**J.L. Pepin, M. Joyeux-Faure, B. Naegele, R. Tamisier, P. Levy, S. Launois, Grenoble, France, p.A2847

404 **Obstructive Sleep Apnea Is Not a Risk Factor for Incident Hospitalized Depression: A Historical Cohort Study/**T. Kendzerska, A.S. Gershon, G. Hawker, G. Tomlinson, R.S. Leung, Toronto, Canada, p.A2848

405 **Decision Time Is AHI Dependent Significantly Reduced After Sleep at Simulated 5500m in a Normobaric Chamber/**N. Netzer, S. Wimmer, M. Koop, H. Gatterer, M. Faulhaber, M. Burtscher, N.C. Netzer, Bad Aibling, Germany, p.A2849

406 **Nightly Hypoxemia in the Elderly Inpatient Population and Its Correlation to Dementia/**S. Wimmer, S. Pramsohler, M. Koop, H. Gatterer, M. Faulhaber, M. Burtscher, Bad Aibling, Germany, p.A2850

407 **Not Too Old For CPAP/**A. Neill, H. Hills, A. Davies, A. Campbell, Wellington, New Zealand, p.A2851

408 **A Pilot Study of Obstructive Sleep Apnea (OSA) Treatment in Parkinson's Disease: Effect on Cognitive and Motor Function/** M. Kaminska, G. Leonard, J. Crane, A.-L. Lafontaine, A. Robinson, V. Mery, A. Benedetti, P. Gros, R.J. Kimoff, Montreal, Canada, p.A2852

409 **7 Years Follow-Up: The Correlation Among Sleep Apnea Syndrome and Hypertension, Diabetes Disease/**H. Zhongming, H. Fang, L. Jiangping, D. Xiaosong, S. Juan, Keramay, China, p.A2853

410 **Gender, Nocturnal Hypoxia and Arousal Influence Brainstem Auditory Evoked Potentials in Patients with Obstructive Sleep Apnea/**W. Wang, J. Su, D. Kong, J. Pang, J. Kang, Shenyang City, China, p.A2854

411 **Effect of Continuous Positive Airway Pressure on Quality of Life in Women with Obstructive Sleep Apnea. A Randomized-Controlled Trial/**F. Campos-Rodriguez, J. Cordero-Guevara, M. Gonzalez, C. Carmona-Bernal, B. Jurado-Gamez, F. Troncoso-Acevedo, A. Abad-Fernandez, J. Teran-Santos, J. Caballero-Rodriguez, M. Martin-Romero, A. Encabo-Motino, M.A. Martinez-Garcia, L. Sacristan-Bou, J. Navarro-Esteva, M. Somoza-Gonzalez, J.F. Masa, M.A. Sanchez-Quiroga, B. Jara-Chinarro, B. Orosa-Bertol, F. Del Campo-Matias, Sevilla, Spain, p.A2855

412 **Daytime Sleepiness and Academic Performance Among Arab Medical Students/**J.M. Al Zahrani, K.K. Al Dossari, I. Abdulmajeed, S.H. Al Ghamdi, A. Al Shamrani, N. Al Qahtani, Al-Kharj, Saudi Arabia, p.A2856

413 **Neuroinflammation Following Sleep Fragmentation in a Pediatric Model/**S.R. Kudchadkar, S.J. Bertrand, Z. Zhang, N. Punjabi, S. Kannan, Baltimore, MD, p.A2857

414 **Initiation and Adherence to Positive Airway Pressure in Post-Stroke Patients/**K. Wilton, C.M. Ryan, Toronto, Canada, p.A2858

415 **Estradiol Prevents Brain Oxidative Stress Induced by Chronic Intermittent Hypoxia in Female Rats/**S. Laouafa, V. Pialoux, A. Ribon, D. Roussel, A. Bairam, V. Joseph, Quebec, Canada, p.A2859

416 **Intermittent Hypoxia Increases Alzheimer's Disease Related Amyloid Beta Release from Human Neuroblastoma Cells/** I. Almendros, M.J. Menal, G. Pinol-Ripoll, R. Farre, Barcelona, Spain, p.A2860

4:30 p.m. - 6:30 p.m.

2016 RESPIRATORY HEALTH AWARDS
GIVEN BY THE AMERICAN THORACIC SOCIETY
MOSCONE CENTER
Gateway Ballroom 102-104 (South Building, Lower Level)

Amberson Lecture

The Amberson Lecturer is an individual with a career of major lifetime contributions to clinical or basic pulmonary research and/or clinical practice. The Lecture is given in honor of James Burns Amberson, an international authority on chest disease and tuberculosis.
Lecturer: Marlene Rabinovitch, MD, Stanford, CA
Lecture Title: From EVE to ADAM to Finding a Cure for Pulmonary Hypertension
Introducer: Michael A. Matthay, MD, San Francisco CA

Trudeau Medal

The Trudeau Medalist is an individual with lifelong major contributions to prevention, diagnosis and treatment of lung disease through leadership in research, education, or clinical care. This award was established in 1926 and is given in honor of Edward Livingston Trudeau, a founder and the first president of the American Lung Association.
Awardee: Joe G.N. Garcia, MD, Tucson, AZ
Introducer: Juan C. Celedon, MD, DrPH, Pittsburgh, PA

Distinguished Achievement Award

The Distinguished Achievement Award is given to individuals who have made outstanding contributions to fighting respiratory disease through research, education, patient care, or advocacy.
Awardees: Claire M. Doerschuk, MD, Chapel Hill, NC
J. Usha Raj, MD, Chicago, IL

World Lung Health Award

The World Lung Health Award is given to an individual with recognized contributions to improving world lung health in the area of translational or implementation research, delivery of healthcare, continuing education or care of patients with lung disease, or related political advocacy with a special emphasis on efforts that have the potential to eliminate gender, racial, ethnic, or economic health disparities worldwide.
Awardee: Charles L. Daley, MD, Denver, CO

Outstanding Educator Award

The Outstanding Educator Award recognizes lifetime contributions in education and mentoring in the fields of pulmonary, critical care or sleep medicine. This award honors excellence in clinical or research education as it relates to pulmonary disease.
Awardee: Robert Kotloff, MD, Cleveland, OH
This award will be presented at the ATS Plenary Session, Tuesday, May 17, 11:45 a.m.

Jo Rae Wright Award for Outstanding Science

The Jo Rae Wright Award for Outstanding Science is based on demonstrated potential for significant scientific achievement and contributions. This award is aimed at the rising generation of individuals who will be tomorrow's leaders in science.
Awardee: Megan N. Ballinger, PhD, Columbus, OH

Public Service Award

The Public Service Award is presented to an individual with recognized contributions in public health related to improvement of indoor and outdoor air quality, eradication of tobacco usage, prevention of lung disease, improved management of communicable respiratory diseases, or improvement in the ethical delivery, and access to healthcare in areas related to lung diseases, sleep disorders, or critical care. There is a special emphasis on efforts that have the potential to eliminate gender, racial, ethnic or economic disparities.
Awardee: John R. Balmes, MD, San Francisco, CA

Outstanding Clinician Award

The Outstanding Clinician Award is presented to an individual who embodies excellence in the clinical practice of lung health medicine. The awardee has spent a substantial part of his/her career in the clinical care of patients with lung disease, and has made substantial contributionsin the clinical care of patients with lung disease on a local or national level.
Awardee: Jay M. Shames, MD, New Orleans, LA

The Recognition Awards for Scientific Accomplishments will be presented on Monday, May 16th at 2:15 p.m.

6:30 p.m. - 8:30 p.m.

ASSEMBLY MEMBERSHIP MEETINGS

The fourteen Assemblies are the primary groups of the American Thoracic Society. Each Assembly holds an annual Membership Meeting at the International Conference. All Assembly members and other interested individuals are invited to attend.

The Assembly Membership Meetings provide an update on the Assembly's activities via the Assembly's Leadership and provide Assembly members the chance to have input on future directions, information on how to get involved and networking opportunities. Voting results for the Assembly's future leaders will also be announced.

The Assembly Membership Meetings will be held on Monday, May 16, 5:00 p.m. - 7:00 p.m., with the exception of the Assemblies on Behavioral Science and Health Services Research and Pediatrics (see below.)

BEHAVIORAL SCIENCE AND HEALTH SERVICES RESEARCH

SAN FRANCISCO MARRIOTT MARQUIS
Yerba Buena Salon 10-12 (Lower B2 Level)

Chairing: K.A. Riekert, PhD, Baltimore, MD

PEDIATRICS

SAN FRANCISCO MARRIOTT MARQUIS
Yerba Buena Salon 8 (Lower B2 Level)

Chairing: J.F. Chmiel, MD, MPH, Cleveland, OH

6:30 p.m. - 8:30 p.m.

SECTION MEMBERSHIP MEETINGS

The Section meetings are open to all ATS members and other interested individuals. Items to be discussed include the Sections' current projects and future directions.

GENETICS AND GENOMICS

SAN FRANCISCO MARRIOTT MARQUIS
Yerba Buena Salon 4-6 (Lower B2 Level)

Chairing: M.M. Wurfel, MD, Seattle, WA
C.P. Hersh, MD, MPH, Boston, MA

TERRORISM AND INHALATION DISASTERS

SAN FRANCISCO MARRIOTT MARQUIS
Yerba Buena Salon 1-2 (Lower B2 Level

Chairing: E. Summerhill, MD, Pawtucket, RI
S. Matalon, PhD, Birmingham, AL

7:00 p.m. - 9:00 p.m.

STRATEGIES FOR TB CONTROL: POSTER SESSION

INTERCONTINENTAL HOTEL
InterContinental Ballroom B-C (Fifth Floor)

Sponsored by:
U.S. CENTERS FOR DISEASE CONTROL AND PREVENTION STOP TB USA

This public health poster forum will focus on innovative techniques, which are helping to meet the challenges of TB control, prevention, and elimination in the United States. Specific topics include: targeted TB testing and treatment of latent TB infection; conducting/expanding contact investigations; performing outbreak investigations; improving treatment adherence; addressing multi-drug-resistant TB; dealing with TB related to HIV/AIDS; providing TB education; and building TB-related coalitions.

Target Audience:
National, state and local TB program staff, public health professionals (nurses, physicians, epidemiologists), pulmonary specialists, infectious disease specialists, TB and HIV clinicians, epidemiologists, TB consultants, laboratory scientists, and microbiologists.

Chairing: S. Mase, MD, Atlanta, GA
K. Schmit, MD, Atlanta, GA
M. Sage, MPH, Washington, DC

CLINICAL

PEDIATRIC CLINICAL CORE CURRICULUM

CME Credits Available: 1.0

PCC2 PEDIATRIC CLINICAL CORE CURRICULUM

Pediatric Core Curriculum Working Group

6:45 a.m. - 7:45 a.m. **MOSCONE CENTER**

Room 3007/3009 (West Building, Level 3)

Target Audience
Pediatric pulmonary and critical care physicians who work in a clinical setting and are currently engaged in maintenance of certification.

Objectives
At the conclusion of this session, the participant will be able to:

- remain current with medical knowledge relevant to their practice in pediatric pulmonology;
- evaluate their understanding of key skills and content areas in pediatric pulmonology as well as receive feedback on their comprehension of a result of a pre-test/post-test comparison
- support clinicians who are engaged in maintenance of certification activities by providing updates on subjects included in recertification requirements

The Pediatric Core Curriculum symposia promotes lifelong learning and the enhancement of the clinical judgment and skills essential for practicing pediatricians. The symposia will address topics that have been identified by an ATS pediatric working group, which is comprised of members of the ATS Education Committee and the International Conference Committee, who have identified important areas within pediatric medicine (including vasculitic pulmonary diseases, lung defense mechanism, congenital abnormalities of the airways, and respiratory failure). Attendees will increase their medical knowledge as a result of attending this symposium, and this will be measured by a comparison of pre-test vs. post-test results on the corresponding maintenance of certification module. The ATS Pediatric Core Curriculum will focus on a 3-year content cycle of key medical content in the area of pediatric medicine.

Chairing: D.M. Boyer, MD, Boston, MA
P.E. Moore, MD, Nashville, TN

6:45 **Lung Defense Mechanisms**
R. Wang, MD, Boston, MA

7:15 **Lung Growth and Development**
J. Wambach, MD, St. Louis, MO

SUNRISE SEMINARS

CME Credits Available: 1.0

Registration Fee: $65.00 (includes continental breakfast.)
Attendance is limited. Pre-registration is required.

6:45 a.m. - 7:45 a.m. **INTERCONTINENTAL HOTEL**

SS101 **LUNG TRANSPLANTATION IMMUNOLOGY MADE EASY: SIMPLE RATIONALES FOR SOPHISTICATED DRUGS**
J.R. Greenland, MD, PhD, San Francisco, CA
Union Square (Third Floor)

SS102 **EFFECTIVE UTILIZATION AND INTEGRATION OF PALLIATIVE CARE IN PULMONARY AND CRITICAL CARE MEDICINE**
D.R. Sullivan, MD, MA, Portland, OR
SoMa (Third Floor)

SS103 **AN UPDATE IN SCLERODERMA LUNG DISEASE**
F. Castelino, MD, Boston, MA
Mission (Third Floor)

SS104 **ASTHMA/COPD OVERLAP SYNDROME**
M.E. Hardin, MD, Boston, MA
D.J. Maselli, MD, San Antonio, TX
Marina (Third Floor)

SS105 **IDENTIFICATION, DIAGNOSIS AND MANAGEMENT OF IMMUNODEFICIENCY IN LUNG DISEASE**
K.A. Provost, DO, PhD, Buffalo, NY
Grand Ballroom C (Third Floor)

SS106 **PRACTICAL APPLICATION OF LUNG CANCER SCREENING USING LOW INTENSITY CT SCANS**
A. Malave, MD, San Antonio, TX
Grand Ballroom B (Third Floor)

SS107 **MANAGEMENT OF MALIGNANT PLEURAL EFFUSION**
A.H. Sardi, MD, Columbus, OH
Grand Ballroom A (Third Floor)

SS108 **RHEUMATOID ARTHRITIS-ASSOCIATED ILD: CURRENT KNOWLEDGE AND FUTURE DIRECTIONS**
T.J. Doyle, MD, MPH, Boston, MA
Twin Peaks (Fourth Floor)

SS109 **BRONCHIOLITIS OBLITERANS SYNDROME AFTER HEMATOPOIETIC CELL TRANSPLANTATION: DIAGNOSIS AND MANAGEMENT**
G. Cheng, MD, Seattle, WA
Telegraph Hill (Fourth Floor)

SS110 **THORACOSCOPY: AN EVIDENCE BASED REVIEW OF RIGID AND FLEXIBLE TECHNIQUES**
N.M. Rahman, MSc, PhD, Oxford, United Kingdom

F. Maldonado, MD, Nashville, TN
Potrero Hill (Fourth Floor)

SS111 SHARED MEDICAL APPOINTMENTS: WHAT THEY CAN DO FOR YOUR PRACTICE AND FOR YOUR PATIENTS
F.F. Rahaghi, MD, Weston, FL
Nob Hill (Fourth Floor)

SS112 CREATING A BIOCONTAINMENT UNIT: LESSONS LEARNED FROM THE JOHNS HOPKINS HOSPITAL
B.T. Garibaldi, MD, Baltimore, MD
Laurel Hill (Fourth Floor)

SS113 E-CIGARETTES: EPIDEMIOLOGY AND TOXICITY
F. Moazed, MD, San Francisco, CA
Cathedral Hill (Fourth Floor)

SS114 IMMUNODIAGNOSTICS IN LATENT TB INFECTION
P. Escalante, MD, Rochester, MN
Sutter (Fifth Floor)

SS115 IMPLICATIONS OF COGNITIVE IMPAIRMENT IN CHRONIC LUNG AND SLEEP DISEASE
M. Bors, MA, RN, Minneapolis, MN
R. Tomic, MD, Minneapolis, MN
Stockton (Fifth Floor)

SS116 DOWN SYNDROME RESPIRATORY COMPLICATIONS
D.I. Craven, MD, Cleveland, OH
Howard (Fifth Floor)

SS117 TREATMENT DILEMMAS IN PULMONARY HYPERTENSION
K.A. Smith, MD, Philadelphia, PA
Fremont (Fifth Floor)

SS118 MATRIX BASICS: UNDERSTANDING COLLAGEN PROCESSING AND SECRETION
C.A. Staab-Weijnitz, PhD, Munich, Germany
InterContinental Ballroom C (Fifth Floor)

SS119 (S)HE SAYS I SNORE: USING BED PARTNERS TO OPTIMIZE CPAP ADHERENCE
L. Ye, PhD, BSN, Boston, MA
InterContinental Ballroom B (Fifth Floor)

FACULTY DEVELOPMENT SEMINAR

FD1 HOW TO SUCCESSFULLY COMPETE FOR AN ACADEMIC JOB: WHAT DIVISION DIRECTORS WANT AND DO NOT WANT IN CANDIDATES

R Pre-registration is required. There is no additional fee. Attendance is limited.

6:45 a.m. - 7:45 a.m. **INTERCONTINENTAL HOTEL**
InterContinental Ballroom A (Fifth Floor)

Target Audience
Early career clinical and/or research faculty, clinical and post doctoral fellows, graduate students, residents, nurses, and allied health professionals already involved in or seeking a career in academic pulmonary, allergy, critical care, and/or sleep medicine.

Objectives
At the conclusion of this session, the participant will be able to:

- identify components necessary for success in their career path;
- understand key steps needed to build a competitive portfolio;
- strategies to improve their chances in obtaining a faculty appointment.

This seminar will identify and review critical steps in finding a successful placement in an academic career with topics broadly applicable to fellows, post-docs and junior faculty regardless of specialty or career track. This seminar will provide guidance for fellows and post-docs who are looking for their first jobs as well as for junior faculty who are looking to relocate to new positions.

Chairing: D.W. Ford, MD, MSCR, Charleston, SC

Speakers: I. Petrache, MD, Denver, CO
L.M. Schnapp, MD, Charleston, SC
J. Roman, MD, Louisville, KY
G. Loughlin, MD, New York, NY

BASIIC • CLINICAL • TRANSLATIONAL

ATS KEYNOTE SERIES

CME Credits Available: .75

The ATS Keynote Series provides state of the art lectures on selected topics in an unopposed format to showcase major discoveries in pulmonary, critical care and sleep medicine. The speakers have been chosen by input from the members and various ATS committees with consensus built via the ATS executive committee.

Two sessions are presented each morning during the conference. Below are the topics for the Monday, May 16th series

K3 LUNG CANCER DETECTION AND PREVENTION IN THE PRECISION MEDICINE ERA

8:00 a.m. - 8:45 a.m. **MOSCONE CENTER**
Room 134 (North Building, Lower Level)

Speaker: Avrum Spira, MD, Boston, MA

*This session and the International Conference are supported by an educational grant from **AstraZeneca LP.***
All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

K4 PULMONARY HYPERTENSION: EVOLUTION OF PAH AND CTEPH

8:00 a.m. - 8:45 a.m. **MOSCONE CENTER**
Room 135 (North Building, Lower Level)

Speaker: Nick H. Kim, MD, La Jolla, CA

CLINICAL

YEAR IN REVIEW

CME Credits Available: 2.0

B1 CLINICAL YEAR IN REVIEW 2

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Gateway Ballroom 102-104 (South Building, Lower Level)

Target Audience
Providers including physicians, nurses, respiratory therapists, nurse practitioners, physician assistants. Trainees including residents and fellows; clinical researchers.

Objectives
At the conclusion of this session, the participant will be able to:

- apply new clinical research knowledge to clinical practice;
- learn new findings about key conditions in pulmonary, critical care and sleep;
- gain new strategies to manage the care of common conditions in pulmonary, critical care, and sleep.

The annual Clinical Year in Review symposia topic reviews of the key clinical research publications over the last year. Each speaker is asked to review the 5-7 most important and influential publications on their topic in the prior year.

Chairing: J.L. Taylor-Cousar, MD, Denver, CO
D.J. Lederer, MD, MS, New York, NY
D.W. Ford, MD, MSCR, Charleston, SC

9:00 **ARDS**
C.S. Calfee, MD, San Francisco, CA

9:30 **Non-Invasive and Mechanical Ventilation**
B. Fauroux, MD, PhD, Paris, France

10:00 **Update in Critical Care**
E.L. Burnham, MD, Aurora, CO

10:30 **Sepsis**
D. Scales, MD, PhD, Toronto, Canada

CLINICAL • TRANSLATIONAL

CLINICAL TOPICS IN PULMONARY MEDICINE

CME Credits Available: 2.0

Nursing Contact Hours Available: 2.4

B2 HOT TOPICS IN COPD: A PRO/CON DEBATE

Assemblies on Clinical Problems; Behavioral Science and Health Services Research; Environmental, Occupational and Population Health; Nursing

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 135 (North Building, Lower Level)

Target Audience
Providers of lung health including registered nurses, advanced practice nurses, and those with clinical and research responsibilities.

Objectives
At the conclusion of this session, the participant will be able to:

- appropriately use dual bronchodilator therapy in practice;
- implement case finding approaches to COPD;
- appropriately use new imaging methodologies in COPD.

COPD is a rapidly evolving field with new research and treatments that are leading us to rethink our approach to the COPD patient. This session highlights important current controversies in COPD diagnosis and management in a pro con debate format.

Chairing: R.A. Wise, MD, Baltimore, MD
C. Jenkins, MD, MBBS, Concord, Australia
R.A. Stockley, MD, DSc, Birmingham, United Kingdom

9:00 **PRO: GOLD 0 Should Be Brought Back**
P.G. Woodruff, MD, MPH, San Francisco, CA

9:12 **CON: GOLD 0 Should Not Be Brought Back**
R. Rodriguez-Roisin, MD, PhD, Barcelona, Spain

9:24 **PRO: Screening for COPD Improves Outcomes**
F.J. Martinez, MD, New York, NY

9:36 **CON: Screening for COPD Does Not Improve Outcomes**
D.M. Mannino, MD, Lexington, KY

9:48 **PRO: The GOLD Strategy Results in Improved COPD Patient Care**
C. Vogelmeier, MD, Marburg, Germany

10:00 **CON: The GOLD Strategy Does Not Result in Improved COPD Patient Care**
K.F. Rabe, MD, PhD, Grosshansdorf, Germany

10:12 **PRO: CT Should Be Part of Routine Clinical Care for COPD**
G. Washko, MD, Boston, MA

10:24 **CON: CT Should Not Be Part of Routine Clinical Care for COPD**
M.K. Han, MD, MS, Ann Arbor, MI

10:36 **PRO: LAMA/LABA Combination Therapy Should Be Used as Initial Maintenance Treatment for COPD**
J.A. Wedzicha, MD, PhD, London, United Kingdom

10:48 **CON: LAMA/LABA Combination Therapy Should Not Be Used as Initial Maintenance Treatment for COPD**
B.R. Celli, MD, Boston, MA

This session and the International Conference are supported by an educational grant from ***AstraZeneca LP.***
All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

CLINICAL • TRANSLATIONAL

CLINICAL TOPICS IN PULMONARY MEDICINE

CME Credits Available: 2.0

B3 NON-IPF ILD: HOW DO I MAKE THE DIAGNOSIS?

Assembly on Clinical Problems

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 134 (North Building, Lower Level)

Target Audience
Pulmonologists, post graduate fellows and trainees, advanced practice nurses.

Objectives
At the conclusion of this session, the participant will be able to:

- identify clinical features from a patient's history that can help distinguish among the non-IPF ILDs in a patients with newly recognized ILD;
- identify radiographic features from a patient's HCRT that can help distinguish among the non-IPF ILDs in a patients with newly recognized ILD;
- identify pathologic features from a patient's biopsy that can help distinguish among the non-IPF ILDs in patients with newly recognized ILD.

Distinguishing among the non-IPF interstitial lung diseases can be very challenging for the clinician. This symposium will seek to review the evidence for the best discriminating clinical, pathologic and radiologic features that can be used to differentiate among the non IPF ILDs. Following a review of these characteristics, 3 ILD clinicians will discuss real life cases that they will have been given ahead of time (without the diagnosis) to demonstrate how best to work thorough these challenging cases.

Chairing: M. Kreider, MD, Philadelphia, PA
G. Tino, MD, Philadelphia, PA
A. Olson, MD, MSPH, Denver, CO

9:00 **Introduction**
G. Tino, MD, Philadelphia, PA

9:10 **Top 5 Clinical Features to Differentiate Among Non-IPF ILD**
K.K. Brown, MD, Denver, CO

9:30 **Top 5 Radiographic Features to Differentiate Among Non-IPF ILD**
D. Hansell, MD, London, United Kingdom

9:45 **Top 5 Pathologic Features to Differentiate Among Non-IPF ILD**
W.D. Travis, MD, New York, NY

10:00 **Case I**
T.M. Maher, MD, MSc, PhD, London, United Kingdom
A. Olson, MD, MSPH, Denver, CO

10:15 **Case II**
C.D. Fell, MD, MSc, Calgary, Canada
M. Kreider, MD, Philadelphia, PA

10:30 **Case III**
G. Tino, MD, Philadelphia, PA
J.S. Lee, MD, Aurora, CO

10:45 **Questions and Answers**
M. Kreider, MD, Philadelphia, PA

This session and the International Conference are supported by an educational grant from ***Boehringer Ingelheim Pharmaceuticals, Inc.***
All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

BASIC • CLINICAL • TRANSLATIONAL

CRITICAL CARE TRACK

CME Credits Available: 2.0

B4 MECHANISMS OF ORGAN FAILURE IN SEPSIS

Assemblies on Critical Care; Respiratory Cell and Molecular Biology; Respiratory Structure and Function

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**
Room 3000/3002/3004 (West Building, Level 3)

Target Audience
Pulmonary and critical care researchers (undergraduates, graduates, post graduates and postdoctoral), clinicians (adults and peds), and trainees interested in understanding the athophysiology and pathogenesis of organ failure in sepsis.

Objectives
At the conclusion of this session, the participant will be able to:

- learn new paradigms about sepsis-induced organ failure;
- recognize risk and development of sepsis-induced organ failure;
- translate new advancements in basic research with current and future clinical practice.

This session will review seminal concepts in sepsis-induced organ failure as well as present novel and cutting edge research in the field. The aim is to translate cutting-edge advancements in molecular physiology and functional genomics of organ failure in the septic patient to a broad clinical and translational audience. The session will engage/stimulate and enhanced understanding of the leading concepts regarding the relative contributions of over-inflammation, immunosuppression, the microbiome, epithelium and endothelium as critical target(s) of organ failure that ultimately determine (lung, kidney, liver, heart, muscle, gut and brain) dysfunction and clinical outcomes in the critically ill. The session will have broad appeal to physicians and scientists at any level of training who work on diverse problems in the critically ill, and it will draw a diverse international audience because of the generalizability of the topics.

Chairing: C.C. Dos Santos, MD, Toronto, Canada
I.S. Douglas, MD, Denver, CO
J. Chiche, MD, PhD, Paris, France

9:00 **Mechanisms of Organ Failure in Sepsis**
R. Hotchkiss, MD, St. Louis, MO

9:15 **Innate Immune Training in Sepsis?**
M. Netea, MD, PhD, Nijmegen, Netherlands

9:30 **Liver Dysfunction in Sepsis**
M. Bauer, MD, Jena, Germany

9:45 **Is the Microbiome an "Organ" that Fails in Septic Patients?**
J. Alverdy, MD, Chicago, IL

10:00 **Is All Organ Failure Created Equal?**
C.C. Dos Santos, MD, Toronto, Canada

10:15 **Sepsis Induced Immunosuppression Shift in Therapeutic Paradigm**
J. Chiche, MD, PhD, Paris, France

BASIC • TRANSLATIONAL

BASIC SCIENCE CORE

CME Credits Available: 2.0

B5 HARNESSING BREAKTHROUGHS IN CRISPR GENE EDITING TECHNOLOGY FOR RESEARCH AND THERAPY

Assemblies on Respiratory Cell and Molecular Biology; Allergy, Immunology and Inflammation; Microbiology, Tuberculosis and Pulmonary Infections; Respiratory Structure and Function; Thoracic Oncology

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 2009/2011 (West Building, Level 2)

Target Audience
Basic and translational researchers seeking to understand the most important advance in biotechnology in the last decade and clinical investigators and clinicians interested in learning more about this technology that is poised to move into clinical application in the coming decade.

Objectives
At the conclusion of this session, the participant will be able to:

- learn new findings about the CRISPR system functions and how it can be adapted to edit human and other animal genomes;
- improve lung research by learning new strategies for selectively turning genes on and off, creating lung cancer models, performing genome-wide screens, and imaging the genome;
- contribute to conversations that will shape scientific and ethical approaches to the use of CRISPR technology to treat human disease.

The development of the CRISPR system for efficient and selective editing of the human genome represents the most important scientific breakthrough of the past decade. CRISPR-based systems are already being widely used for inactivating or repairing individual genes in human cells and animal models and for genome-wide studies of the functions of coding and non-coding RNAs. This session will introduce the basic CRISPR/Cas9 system, explain how this technology is being modified to allow selective inactivation, activation, and live imaging of the genome, and illustrate how the technology can be applied to study and treat lung diseases, including cancer.

Chairing: D. Erle, MD, San Francisco, CA
S. Albelda, MD, Philadephia, PA
N. Chandel, PhD, Chicago, IL

9:00 **CRISPR: From Biology to Transformative Technology**
J. Corn, PhD, Berkeley, CA

9:30 **Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation**
J. Weissman, PhD, San Francisco, CA

10:00 **Dissecting the Role of Oxidative Homeostasis in Lung Cancer Using CRISPR/Cas9 Genome Engineering**
T. Papagiannakopoulos, PhD, New York, NY

10:30 **CRISPR Tools for Complex Transcription Control and Functional Study**
S. Qi, PhD, Stanford, CA

*This session and the International Conference are supported by an educational grant from **AstraZeneca LP.***
All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

BEHAVIORAL • CLINICAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 2.0

B6 BUILDING E-BRIDGES: TOOLS AT OUR FINGERTIPS FOR ENHANCING COLLABORATIVE CARE

Assemblies on Behavioral Science and Health Services Research; Clinical Problems; Critical Care; Nursing; Thoracic Oncology

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 303/305 (South Building, Esplanade Level)

Target Audience
Clinicians and scientists seeking to understand developments in shared decision-making and to explore cutting edge tools aimed at advancing interdisciplinary, patient centered collaboration across pulmonary and critical care.

Objectives
At the conclusion of this session, the participant will be able to:

- present new findings about the complexity of shared decision-making to enhance patient-centered care;
- apply novel, innovative tools to enrich risk communication and improve the quality of life and health of patients;
- evaluate future directions in and barriers to collaborative, personalized care.

For most medical decisions, multiple options are available with each choice having its own list of benefits and harms. Decisions inconsistent with patient preferences may have unintended consequences to both patients and the health system. Shared decision-making provides a model for personalized medicine to enhance patient-centered care. This session will allow leading experts to discuss: (1) how traditional communication has failed and why shared decision-making has evolved; (2) the complexity of the decision-making process; (3) what tools are available, across pulmonary and critical care, to enhance communication; (4) what future directions and barriers may lie ahead in patient-centered risk communication.

Chairing: T.S. Valley, MD, Ann Arbor, MI
R.S. Wiener, MD, MPH, Boston, MA
C.E. Cox, MD, MPH, Durham, NC

9:00 **A Patient's Perspective**
K. Erickson, Coral Gables, FL

9:05 **Helping Me Help You: Making the Right Decision for Different Patients**
T.S. Valley, MD, Ann Arbor, MI

9:23 **So You're Telling Me There's a Chance? Theories to Improve Risk Communication**
J.L. Hart, MD, Philadelphia, PA

9:40 **Empowering Patients with Asthma: Customizing Care to Patient Beliefs**
M.R. George, AE-C, PhD, RN, New York, NY

10:00 **Why Wouldn't I Want to Know? Moving Lung Cancer Screening from Standardized to Personalized**
R.S. Wiener, MD, MPH, Boston, MA

10:20 **Great Expectations: Using Digital Tools to Assist ICU Patients, Families, and Clinicians with Shared Decision Making**
D.B. White, MD, MAS, Pittsburgh, PA

10:40 **Transforming the Future of Effective Patient Provider Communication Through Universal Decision Support**
C.E. Cox, MD, MPH, Durham, NC

There will be a 5-minute discussion after each talk.

CLINICAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 2.0

B7 ONE STEP AT A TIME: HAS PHYSICAL ACTIVITY DELIVERED AS AN OUTCOME IN CLINICAL TRIALS?

Assemblies on Pulmonary Rehabilitation; Clinical Problems; Nursing

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**
Room 2020/2022 (West Building, Level 2)

Target Audience
Health care professionals who are interested in the measurement and enhancement of clinical activity. Researchers who use physical activity as outcomes in clinical trials.

Objectives
At the conclusion of this session, the participant will be able to:

- understand the importance of physical activity in patients with COPD and the wider health implications of inactivity;
- learn about new developments with respect to measuring physical activity;
- understand new strategies to improve physical activity.

This session will provide an overview of the importance of physical activity to the population at large and of course for those with respiratory disease, specifically COPD. We will explore the development of the measurement, and the physical and psychological benefits of physical activity. The complexities of measurement for clinical trials will be addressed and finally how we might improve physical activity through rehabilitation or novel technologies.

Chairing: S.J. Singh, PhD, Leicester, United Kingdom
M.L. Moy, MD, MSc, Boston, MA

9:00 **The (Short) History of Physical Activity Measurement in COPD**
R. Casaburi, MD, PhD, Torrance, CA

9:10 **Physical Activity: Does it Keep Us Alive?**
J. Myers, PhD, Palo Alto, CA

9:35 **Physical Activity: Does it Keep Those with COPD Happy? The Patient Centered Perspective**
T. Troosters, PhD, Leuven, Belgium

10:00 **Physical Activity: Should it Be an Outcome for Large Clinical Trials?**
A. Hamilton, PhD, Burlington, Canada

10:20 **Enhancing Physical Activity with Rehabilitation**
R.S. Goldstein, MD, Toronto, Canada

10:40 **How Can We Use Technology to Improve Physical Activity for Individuals with COPD?**
H. Demeyer, PhD, Leuven, Belgium

*This session and the International Conference are supported by an educational grant from **AstraZeneca LP.***
All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

CLINICAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 2.0

B8 SLEEP, SLEEP DISORDERS AND PERFORMANCE IN ATHLETES

Assemblies on Sleep and Respiratory Neurobiology, Behavioral Science and Health Services Research

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**
Room 2001/2003 (West Building, Level 2)

Target Audience
Sleep physicians, those interested in public health, those interested in human performance, those interested in real-world applications of sleep medicine

Objectives
At the conclusion of this session, the participant will be able to:

- learn new findings about the role of sleep and health in athletic performance;
- better understand how sleep impacts health and performance from the perspective of an elite athlete;
- better assess, diagnose, and treat sleep disorders among athletes.

Insufficient and/or misaligned sleep, sleep apnea and other sleep disorders have been shown to impact health, neurocognitive and physical performance. In addition, training at altitudes, hypoxic training, and other respiratory effects have also been studied. These are all domains that are relevant to athletes. For this reason, there has been increased attention from both the scientific community and from athletic organizations regarding the importance of sleep and respiratory health. Some of this effort has focused on the high prevalence of sleep apnea in football players. Further, the National Collegiate Athletic Association recently adopted best practices for addressing mental health in student athletes, and screening for sleep disorders (including sleep apnea) is prominently featured in those guidelines. This session will be the first of its kind at the ATS meeting and will focus on the (1) state of the science of sleep and respiratory health in athletes and then delve into the specific areas of (2) the new NCAA guidelines for student athletes related to sleep and (3) sleep apnea in athletes, football players specifically. Finally, the session will feature the perspectives of a professional athlete and a coach who can discuss their experiences when it comes to sleep and related aspects in maintaining performance.

Chairing: M. Grandner, PhD, Tucson, AZ
P.J. Strollo, MD, Pittsburgh, PA
S. Halson, PhD, Belconnen, Australia

9:00 **Improving Sleep in Athletes: An Overlooked and Underutilized Training Method**
B. Marcello, PhD, Carlsbad, CA

9:15 **Sleep and Circadian Misalignment in Athletes**
S. Halson, PhD, Belconnen, Australia

9:35 **Athletes Sleeping/Training in Hypoxia: Good Idea or Bad?**
J. Dempsey, PhD, Madison, WI

9:55 **Sleep, Health, and Performance in Student Athletes**
M. Grandner, PhD, Tucson, AZ

10:15 **Sleep Apnea Risk, Diagnosis and Treatment in Professional Football**
I. Gurubhagavatula, MD, MPH, Philadelphia, PA

10:45 **Sleep Disorders in Athletes: A Player's Perspective**
A. Taylor, San Diego, CA

CLINICAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 2.0

B9 SICKLE CELL DISEASE AND THE LUNG ACROSS THE LIFESPAN

Assemblies on Pediatrics; Allergy, Immunology and Inflammation; Clinical Problems; Pulmonary Circulation; Sleep and Respiratory Neurobiology

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 3007/3009 (West Building, Level 3)

Target Audience
Pediatric and adult pulmonary fellows, clinicians and researchers interested in the pulmonary complications of sickle cell disease (SCD) across the lifespan.

Objectives
At the conclusion of this session, the participant will be able to:

- gain an understanding of the burden of SCD around the globe and the importance of newborn screening and early intervention in the context of early SCD mortality in resource-poor settings;
- review the state of evidence-based management of pulmonary complications of SCD with emphasis on current guidelines as well as areas where evidence is lacking;
- understand the impact of abnormalities throughout the respiratory system (airway, gas exchange, and vascular) as disease modulators in the long term pathogenesis of SCD throughout the lifespan.

Despite a high and growing global burden of SCD with an estimated 400,000 births per year by 2050, evidence-based interventions against its pulmonary complications are limited. Pulmonary complications are among the most common causes of the observed accelerated mortality in the SCD population. The goal of this session is to present the spectrum of acute and chronic pulmonary complications of SCD that impact patients across the lifespan to actively engage pediatric and adult clinicians and researchers with the goals of improved coordination of scientific efforts and implementation of state of the art clinical care for patients.

Chairing: E.S. Klings, MD, Boston, MA
S.C. Sadreameli, MD, MHS, Baltimore, MD
M.T. Gladwin, MD, Pittsburgh, PA

9:00 **A Patient's Perspective**
T. Pruitt, Oakland, CA

9:05 **Unanswered Questions in the Pathophysiology of Sickle Cell Lung Disease in Pediatric and Adult Care**
E.S. Klings, MD, Boston, MA

9:25 **Global Health Care Equality in Sickle Cell Disease**
A.P. Ruhl, MD, MHS, Bethesda, MD

9:40 **Night and Day: Intermittent Hypoxia in SCD**
J.L. Allen, MD, Philadelphia, PA

10:00 **How Should We Characterize Airway Disease in Sickle Cell Patients?**
R.T. Cohen, MD, MPH, Boston, MA

10:20 **State of the Art Management of the Acute Chest Syndrome**
J. Howard, MD, London, United Kingdom

10:40 **Thrombosis, Hypoxia, and Hemolysis as Modulators of Pulmonary Vascular Dysfunction in Sickle Cell Disease**
R.F. Machado, MD, Chicago, IL

There will be a 5-minute discussion after each talk.

BASIC • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 2.0

B10 NEW CONCEPTS IN ASTHMA BIOLOGY

Assemblies on Respiratory Structure and Function; Allergy, Immunology and Inflammation; Respiratory Cell and Molecular Biology

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 2005/2007 (West Building, Level 2)

Target Audience
Basic scientists and clinicians interested in emerging concepts in asthma pathobiology.

Objectives
At the conclusion of this session, the participant will be able to:

- appreciate newly discovered facets of the asthma phenotype;
- learn about asthma mechanisms that may be independent of type 2 inflammation;
- identify new experimental methods to assess function and dysfunction of structural cells of the airway.

Type 2 inflammation occurs in many asthma patients, but not all, and has shaped much of current thinking. Nevertheless, origins of the disease remain unclear. This symposium is designed to consider new thinking in asthma pathobiology, key structural cells of the airway, and unrecognized mechanisms of disease that may be independent of type 2 inflammation.

Chairing: J.J. Fredberg, PhD, Boston, MA
R. Krishnan, PhD, Boston, MA

9:00 **A Patient's Perspective**
K. Przywara , Mountain View, CA

9:05 **Inflammation in Asthma: Cause or Modulator?**
J.V. Fahy, MD, San Francisco, CA

9:28 **Endotoxin and Its Protective Effect Against Allergy in Lung Epithelial Cells**
B. Lambrecht, PhD, Gent, Belgium

9:51 **Unjamming and Cell Shape in the Asthmatic Airway Epithelium**
J. Park, PhD, Boston, MA

10:14 **Asthma, 'Omics, and Airway Cell Phenotypes**
M. Seibold, PhD, Denver, CO

10:37 **Developing New Drugs for Asthma Therapy**
J. Solway, MD, Chicago, IL

There will be a 5-minute discussion after each talk.

*This session and the International Conference are supported by an educational grant from **AstraZeneca LP.***

All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

BASIC • CLINICAL • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 2.0

B11 SCIENTIFIC BREAKTHROUGHS IN SARCOIDOSIS RESEARCH AND PHENOTYPING: THE NHLBI GRADS CONSORTIUM

Assemblies on Allergy, Immunology and Inflammation; Clinical Problems; Environmental, Occupational and Population Health; Respiratory Cell and Molecular Biology

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**
Room 2002/2004 (West Building, Level 2)

Target Audience
Those with clinical and research responsibilities, clinical providers of lung health, those needing instruction in areas of medicine outside their speciality, those serving patients with sarcoidosis.

Objectives
At the conclusion of this session, the participant will be able to:

- apply our current understanding of common sarcoidosis phenotypes and the clinical data that defines them to better care for sarcoidosis patients;
- learn new findings regarding immunophenotypes, immune dysregulation and microbiome;
- understand the role of clinical, immune and microbiome phenotyping on sarcoidosis pathogenesis, prognosis and treatment paradigms.

This session will provide exciting new integrative study results that have arisen from the latest NHLBI consortium on sarcoidosis, the Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS). The GRADS study is an observational translational study evaluating the relationship between sarcoidosis phenotypes, immune networks, and gene expression and the microbiome patterns. The data generated by the multi-center and site specific studies expands our understanding of the clinical manifestations, and cellular and molecular mechanisms of disease to help define the biological basis of the clinical heterogeneity in sarcoidosis.

Chairing: L.A. Maier, MD, Denver, CO
E. Chen, MD, Baltimore, MD
N. Kaminski, MD, New Haven, CT

9:00 **A Patient's Perspective**
B. Clark, Emeryville, CA

9:05 **A New Phenotypic Paradigm and the Clinical Data Supporting the GRADS Approach**
N. Hamzeh, MD, Denver, CO

9:25 **Is Sarcoidosis a Th17 Disease? Revisiting T Cell Phenotyping**
L. Koth, MD, San Francisco, CA

9:45 **Programmed Death-1 Inhibition of Sarcoidosis T Cell Proliferation: Potential Therapeutic Option?**
W. Drake, MD, Nashville, TN

10:05 **Neuroimmune Molecules and Innate Immunity in Pulmonary Sarcoidosis**
E. Herzog, MD, PhD, New Haven, CT

10:25 **Sarcoidosis BAL and Lung Tissue Microbiome: Closely Related or Distant Relatives**
R.G. Collman, MD, Philadelphia, PA

10:45 **Panel Discussion**
E. Chen, MD, Baltimore, MD

BEHAVIORAL • CLINICAL • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 2.0

B12 GLOBAL HEALTH: THE WHAT, WHERE AND WHY IN THE 21ST CENTURY

Membership Committee and International Health Committee; Assemblies on Allergy, Immunology and Inflammation; Behavioral Science and Health Services Research; Clinical Problems; Environmental, Occupational and Population Health; Microbiology, Tuberculosis and Pulmonary Infections; Nursing; Pediatrics

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**
Room 130-132 (North Building, Lower Level)

Target Audience
Clinicians, nurses, behavioral and translational scientists seeking to practice in a global community, addressing health inequalities; those seeking to develop or participate in research in global health communities.

Objectives
At the conclusion of this session, the participant will be able to:

- define the current pathways in international respiratory health and outlining approaches to developing expertise and continuing scholarship in those areas;
- identify career goals and plan accordingly for success in international respiratory health;
- identify major obstacles broadly defined in 3 categories: financial challenges, personal mentoring and academic skills acquisition.

This symposium will present practical approaches in developing a career in global health in the 21st century as it pertains to Pulmonary, Allergy and Critical Care

Medicine. The symposium will provide the perspective of leaders and future leaders within the field of international respiratory health, identify common obstacles, and provide strategies for career development for early and mid-level career scientists, physicians and other professionals within and outside the United States.

Chairing: Y.N. Mageto, MD, MPH, Burlington, VT
G. Matute-Bello, MD, Seattle, WA

9:00 **Collaborative Team Field Science: Skills and Methodology Required for Success**
A.S. Buist, MD, Portland, OR

9:20 **Translational Research in Low Resource Settings: Skills and Methodology Required for Success**
T.E. West, MD, MPH, Seattle, WA

9:40 **Education and Training Development in Low and Middle Income Countries: The Nuts and Bolts**
E.J. Carter, MD, Providence, RI

10:00 **Capacity Building in Developing Countries: Challenges and Opportunities on the Ground**
D. Obaseki, MD, MPH, Ile-Ife, Nigeria

10:20 **Epidemiology and Implementation Science:Targeting Chronic Respiratory Diseases in Developing Countries**
C.M. Patino, MD, PhD, Los Angeles, CA

10:40 **Challenges and Opportunities on the Ground: Ethics, Language, and Giving Back**
S. Gordon, MA, MD, DTM&H, Blantyre, Malawi

There will be a 5-minute discussion after each talk.

BASIC • CLINICAL

ATS PRESIDENT'S SYMPOSIUM

CME Credits Available: 2.0

B13 APPLIED PHYSIOLOGY IS ALIVE AND WELL

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**
Room 2016/2018 (West Building, Level 2)

Target Audience
Students, clinicians, scientists and educators.

Objectives
At the conclusion of this session, the participant will be able to:

- define the inflammatory reflex;
- apply the concept of driving pressure at the bedside;
- define loop gain and understand its therapeutic importance.

Although some people have suggested that physiology is dead, this session will present the case that physiology is still alive and well. Many of the advances in patient care which have occurred in recent years have been a result of physiology. Even though molecular and cellular biology have made major advances, the importance of function remains critical. Similarly with advances in genetics and genomics in recent years, the importance of these genes is assessed by functional assessments. Terms such as deep phenotyping reflect acknowledgement that physiological function remains crucial.

Chairing: A. Malhotra, MD, La Jolla, CA
T.S. Simonson, PhD, La Jolla, CA

9:00 **Respiration Mechanics: Saving Lives for Nearly a Century**
J.M. Drazen, MD, Boston, MA

9:10 **Applied Physiology in Sleep Apnea and Control of Breathing**
M.K. Younes, MD, PhD, Winnipeg, Canada

9:35 **Unjamming and Cell Shape in the Asthmatic Airway Epithelium**
J.J. Fredberg, PhD, Boston, MA

10:00 **From Sepsis Mechanisms to the Origin of Bioelectronic Medicines**
K.J. Tracey, MD, Manhasset, NY

10:25 **Assessing Regional Lung Strain and Perfusion at the Bedside: The Future Is Now**
M.B.P. Amato, MD, PhD, Sao Paulo, Brazil

10:50 **Young Investigators Presentations**

LATE BREAKING MINI SYMPOSIUM

B14 HIGH IMPACT LATE-BREAKING CLINICAL TRIALS

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**
Room 3010/3012 (West Building, Level 3)

Chairing: R. Kalhan, MD, MS, Chicago, IL
R.K. Albert, MD, Aurora, CO
M.T. Naughton, MBBS, MD, Prahran, Australia

Oral Presentations

9:00 **Use of a Plasma Proteomic Biomarker in Addition to Clinician Pretest Probability in Pulmonary Nodules with Intermediate Risk of Malignancy Improves Nodule Risk Assessment/**N.T. Tanner, G.A. Silvestri, Charleston, SC, p.A2862

9:15 **Surgical and Large Bore Procedures in Malignant Pleural Mesothelioma and Radiotherapy Trial (SMART Trial) - An RCT Evaluating Whether Prophylactic Radiotherapy Reduces the Incidence of Procedure Tract Metastases/**N.A. Maskell, A.O. Clive, Bristol, United Kingdom, p.A2863

9:30 **Lung Injury Prevention Study with Aspirin (LIPS-A): A Multicenter Randomized Clinical Trial/**D.J. Kor, R.E. Carter, P.K. Park, E. Festic, V. Banner-Goodspeed, R.F. Hinds, D.S. Talmor, O. Gajic, M.N. Gong, Rochester, MN, p.A2864

9:45 **Results of a Randomized Controlled Trial Testing if a Bedside Consult that Coordinates Outpatient Services and Adds Automated Follow-Up Helps Hospitalized Smokers Quit/**R.A. Mularski, L.A. Waiwaiole, M.C. Leo, M.C. Francisco, K. Funkhouser, J.L. Fellows, Portland, OR, p.A2865

10:00 **Profound Antitussive Response to P2X3 Blockade with AF-219 Permits Correlation of Objective Measure of Cough with Improvement in Patient Reported Outcomes/**J.A. Smith, M. Kitt, M. Sher, P. Butera, A.P. Ford, Manchester, United Kingdom, p.A2866

10:15 **Adaptive Servo-Ventilation for Central Sleep Apnea in Heart Failure: Results of the SERVE-HF On-Treatment Analysis/**H. Woehrle, M. Cowie, C. Zu Eulenburg, C. Angermann, M.-P. D'Ortho, E. Erdmann, P. Levy, A. Simonds, F. Zannad, H. Teschler, V. Somers, K. Wegscheider, Martinsried, Germany, p.A2867

10:30 **Fluticasone Furoate, Alone or in Combination with Vilanterol, Decreases the Rate of FEV1 Decline in Patients with Moderate Airflow Obstruction: SUMMIT Study/**B. Celli, F.J. Martinez, J. Anderson, R. Brook, C. Crim, S. Kilbride, D.E. Newby, J. Vestbo, J. Yates, P.M.A. Calverley, Boston, MA, p.A2868

10:45 **Efficacy of Endobronchial Coil Implantation in Patients with Advanced Emphysema: Results of the RENEW Trial/**F.C. Sciurba, G. Criner, C.B. Strange, P.L. Shah, G.C. Michaud, A.C. Mehta, D.-J. Slebos, Pittsburgh, PA, p.A2869

MINI SYMPOSIUM

B15 HEALTH EFFECTS OF INDOOR/OUTDOOR POLLUTION IN CHILDHOOD

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 2006/2008 (West Building, Level 2)

Chairing: K.E. Pinkerton, PhD, Davis, CA
R.J. Laumbach, MD, MPH, Piscataway, NJ
I. Jaspers, PhD, Chapel Hill, NC

Oral Presentations

9:00 **Innate Lymphoid Cells Mediate Type-2 Immunity in the Lungs of Ozone-Exposed Mice/**J.R. Harkema, K. Kumagai, D.N. Jackson-Humbles, R.P. Lewandowski, N. Li, J.G. Wagner, East Lansing, MI, p.A2870

9:15 **Proximity to Roadway, Lifetime Pollution Exposure and Asthma Risk in a Pediatric Cohort/**M.B. Rice, S.L. Rifas-Shiman, A.A. Litonjua, E. Oken, M.W. Gillman, I. Kloog, H. Gibson, B. Coull, J. Schwartz, P. Koutrakis, M.A. Mittleman, D.R. Gold, Boston, MA, p.A2871

9:30 **Effects of Wood Smoke Exposure on Nasal Mucosal Host Defense Responses After Infection with Live-Attenuated Influenza Virus/**I. Jaspers, E.P. Pawlak, K. Addo, C. Diamond, A. Speen, C. Robinette, T.L. Noah, Chapel Hill, NC, p.A2872

9:45 **Exposure to Transition Metals in Particulate Matter Air Pollution and Children's Lung Function in the Southern California Children's Health Study/**R. Urman, R. Habre, S. Fruin, J. Gauderman, F. Lurmann, F. Gilliland, R. McConnell, Los Angeles, CA, p.A2873

10:00 **Dung Biomass Smoke Attenuates Innate Immune Responses to a Viral Mimetic and Influenza A Virus in Human Small Airway Epithelial Cells/**C.E. McCarthy, P.F. Duffney, T.H. Thatcher, R.P. Phipps, P.J. Sime, Rochester, NY, p.A2874

10:15 **Short-Term Nitrogen Dioxide Exposure Increases Rescue Medication Use in Children with Asthma/**L.M. Paulin, E. Matsui, J. Curtin-Brosnan, R. Peng, G. Diette, M.C. McCormack, P. Breysse, D. Williams, N.N. Hansel, Baltimore, MD, p.A2875

10:30 **Inhaled Diesel Exhaust Alters Allergen-Induced Bronchial Secretome in Humans/**N. Mookherjee, P. Ezzati, V. Spicer, J.A. Hirota, C. Carlsten, Winnepeg, Canada, p.A2876

10:45 **Early Life Indoor Inflammatory Exposures and Asthma Risk at Three Years of Age in the Canadian Healthy Infant Longitudinal Development (CHILD) Birth Cohort/**T.K. Takaro, Y. Joffres, H. Shu, J. Brook, A.B. Becker, K. McLean, A.J. Wheeler, J.A. Scott, D.L. Lefebvre, H. Sbihi, P.J. Mandhane, P. Subbarao, S.E. Turvey, M.R. Sears, Burnaby, Canada, p.A2877

MINI SYMPOSIUM

B16 CYSTIC FIBROSIS (CF) AND NON-CF BRONCHIECTASIS

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 3016/3018 (West Building, Level 3)

Chairing: M.L. Metersky, MD, Farmington, CT
A. O'Donnell, MD, Washington, DC

Oral Presentations

9:00 **Identifying Modifiable Risk Factors for Rapid Lung Function Decline in Bronchiectasis/**T. Fardon, S.M. Finch, M. Crichton, A.J. Dicker, S. Marshall, J.D. Chalmers, Dundee, United Kingdom, p.A2878

9:15 **Altered Lung Microbiota Profiles Are Associated with Disease Severity, Exacerbation Frequency and Neutrophilic Inflammation in Bronchiectasis/**A.J. Dicker, C. Fong, M. Crichton, A. Cassidy, G. Suarez-Cuartin, O. Sibila, G.G. Einarsson, W. Ibrahim, J.S. Elborn, C.N.A. Palmer, T. Fardon, S. Marshall, J.D. Chalmers, Dundee, United Kingdom, p.A2879

9:30 **Neutrophil Elastase Activity During Episodes of Pseudomonas Infection in Early Cystic Fibrosis/**L.W. Garratt, A. Kicic, S. Ranganathan, S. Stick, Subiaco, Australia, p.A2880

9:45 **SPLUNC1 Dysregulation in the Sputum of Stable Adult Cystic Fibrosis Subjects/**C.J. Britto, N. Niu, E. Bruscia, C. Barone, M. Egan, L.E. Cohn, New Haven, CT, p.A2881

10:00 **Anti-Pseudomonas Aeruginosa IgG Antibodies and Chronic Airway Infection in Non-Cystic Fibrosis Bronchiectasis/**G. Suarez-Cuartin, O. Sibila, A. Smith, H. Abo-Leyah, A. Rodrigo-Troyano, S. Vidal, V. Plaza, T.C. Fardon, J.D. Chalmers, Barcelona, Spain, p.A2882

10:15 **Erythromycin Inhibits Expression of P. Aeruginosa Quorum Sensing Genes in the Airways of Non-CF Bronchiectasis Subjects Recruited to the BLESS Randomised Controlled Trial/**L.D. Burr, G.B. Rogers, A.C.-H. Chen, S. Taylor, S. Bowler, D. Serisier, M. McGuckin, South Brisbane, Australia, p.A2883

10:30 **Gentamicin Induces the Formation and Alters the Composition of Gram Negative Rod Biofilms. This Process is Blocked by Erythromycin Co-Treatment/**Y.E. Wang, N. Gonella, R. Devries, D. Witt, S. Prasad, Stanford, CA, p.A2884

10:45 **Short-Term and Long-term Effects of Ivacaftor Treatment on Sputum Microbiota in CF Patients with the G551D CFTR Mutation/**L. Hoffman, C. Pope, P. Jorth, K.B. Hisert, M. Welsh, P.K. Singh, E.F. McKone, Seattle, WA, p.A2885

MINI SYMPOSIUM

B17 TUBERCULOSIS: SUSCEPTIBILITY AND IMMUNE RESPONSE

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 3020/3022 (West Building, Level 3)

Chairing: S. Schwander, MD, PhD, Piscataway, NJ
P.C. Karakousis, MD, Baltimore, MD
H. Koziel, MD, Boston, MA
R.N. van Zyl-Smit, MBChB, PhD, Cape Town, South Africa

Featured Speaker

9:00 **Impact of Smoke on TB Pathogenesis/**R.N. van Zyl-Smit, MBChB, PhD, Cape Town, South Africa,

Oral Presentations

9:15 **Comparison of Bronchoalveolar Lavage (BAL) Cells in Human Subjects and Cynomolgus Macaques Prior to and Following Infection with Mycobacterium Tuberculosis/**R.F. Silver, A. Fraser, J.R. Jarvela, T.L. Bonfield, T. Rutledge, J. Flynn, P.L. Ling, Cleveland, OH, p.A2886

9:30 **Histone H3K14 Hypoacetylation and H3K27 Hyermethylation Along with HDAC1 Up-Regulation and KDM6B Down-Regulation Are Associated with Active Pulmonary Tuberculosis Disease/**Y.-C. Chen, M.-C. Lin, T.-Y. Chao, S.-Y. Leung, C.-C. Wu, W.-F. Fang, Kaohsiung, Taiwan, p.A2887

9:45 **Up Regulation of TLR4 Expression in Leukocytes of Co-Infected HIV/TB Patients/**E. Mortaz, J. Garssen, M. Marjani, M. Varahram, A.A. Velayati, I.M. Adcock, P. Tabarsi, Utrecht, Netherlands, p.A2888

10:00 **Serum Short Chain Fatty Acids Increase the Risk of Tuberculosis in HIV Patients on Antiretroviral Therapy and Inhibit Th1 and Th17 Immune Response/**M.D. Weiden, J.C. Clemente, Y. Li, E. Friedman, C. Ruan, J. Cao, A. Pooran, M. Davids, G. Calligaro, R. Dawson, R.N. Van Zyl-Smit, K. Dheda, W.N. Rom, L. Segal, New York, NY, p.A2889

10:15 **Cigarette Smoke Impairs Alveolar Macrophage Migration to Mycobacterium Tuberculosis/**S.M. O'Leary, S. Levitte, L. Ramakrishnan, M.P. O'Sullivan, J.M. Keane, Dublin, Ireland, p.A2890

10:30 **Smokers' Alveolar Macrophages Demonstrate Impaired Glycolytic Reprogramming in Response to Mycobacterium Tuberculosis Infection/**L.E. Gleeson, F.J. Sheedy, D. Triglia, S.M. O'Leary, J.M. Keane, Dublin, Ireland, p.A2891

10:45 **Nicotine Impairs Macrophage Control of Mycobacterium Tuberculosis by Binding to Nicotinic Acetylcholine Receptor, Activating Nfkappab and Inhibiting Autophagy/**E.D. Chan, J. Stitzel, A. Bai, M. Phillips, X. Bai, Denver, CO, p.A2892

MINI SYMPOSIUM

B18 SYMPTOM ASSESSMENT: THE PRACTICAL REALITY

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 307 (South Building, Esplanade Level)

Chairing: V.M. McDonald, PhD, RN, New Lambton Heights, Australia
M. Hodson, MSC, RN, London, United Kingdom

Oral Presentations

9:00 **Routine Dyspnea Assessment Every Shift: Feasibility and Acceptance of by Nurses/**K. Baker, S. Desanto-Madeya, M. Gauthier, M. Mahoney, R. Martinez, R. Banzett, Boston, MA, p.A2893

9:15 **Use of Validated Dyspnea Scales Increases Nurses' Confidence in Their Assessment and Treatment of Dyspnea in Palliative Care Patients/**M. Yannacone, V. Carrieri-Kohlman, S. Barbour, San Francisco, CA, p.A2894

9:30 **Daily Measure of Quality and Intensity of Dyspnea Throughout Acute Hospitalizations/**J.P. Stevens, K. Baker, C.R. O'Donnell, R. Lansing, R. Schwartzstein, R. Banzett, Boston, MA, p.A2895

9:45 **Patients with COPD Prioritise Symptoms Experience Differently to Respiratory Nurse Specialists/**S. Prigmore, A. Caress, J. Yorke, Manchester, United Kingdom, p.A2896

10:00 **Dyspnoea-12 Scores Reported "These Days" Are Greater than Those Reported "Today": Differences in People with COPD, Asthma and ILD/**A.-M. Russell, K.N. Johnston, J. Yorke, M.T. Williams, London, United Kingdom, p.A2897

10:15 **Evaluation of Individual Activity Descriptors of the MRC Dyspnoea Scale: Do They Add Up?/**J. Yorke, C. Gibons, A. Garrow, S. Tyson, J. Vestbo, D. Singh, N. Khan, P.W. Jones, Manchester, United Kingdom, p.A2898

10:30 **A Structural Equation Modeling Analysis of the Relationships Between Symptoms and Physical Performance in Patients with COPD/**J. Lee, V.S. Fan, S. Borson, K.C. Pike, M.E. Jarrett, H.Q. Nguyen, Seattle, WA, p.A2899

10:45 **Fear of Dyspnea Independently Predicts ER Visits and Self-Management Abilities in COPD Patients/**B. Abascal-Bolado, R.P. Benzo, Santander, Spain, p.A2900

MINI SYMPOSIUM

B19 BEST OF PEDIATRICS

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 3006/3008 (West Building, Level 3)

Chairing: M. Rosenfeld, MD, MPH, Seattle, WA
A.C. Koumbourlis, MD, MPH, Washington, DC

Oral Presentations

9:00 **Does Cardiopulmonary Fitness and Pulmonary Function Differ Between Age Matched Groups of Children with Primary Ciliary Dyskinesia (PCD) and Cystic Fibrosis (CF) During One Year?/**A.M. Ring, K. Green, F.F. Buchvald, K.G. Nielsen, Copenhagen, Denmark, p.A2901

9:15 **Novel Technology Demonstrates Apical Release of S-Nitrosothiols and F508Del CFTR Maturation in Response to Airflow in the Human Airway Epithelium/**J. Seckler, N. Marozkina, L. Smith, S.J. Lewis, C.U. Cotton, B. Gaston, Cleveland, OH, p.A2902

9:30 **Are Staphylococcus Aureus Infections Causally Related to More Rapid Disease Progression in Children with Cystic Fibrosis?/**D. Caudri, L. Turkovic, J. Ng, N. De Klerk, T. Rosenow, G. Hall, S. Ranganathan, S. Stick, Subiaco, Australia, p.A2903

9:45 **Sleeping chILD: Neuroendocrine Cell Hyperplasia of Infancy and Polysomnography/**S.M.M. Hawkins, M.E. Kroehl, R.R. Deterding, D.R. Liptzin, Aurora, CO, p.A2904

10:00 **Sex Associated Differences in Gene Expression in Neonates with BPD/**D. Chhabra, C. Espinoza, J. Hagood, San Diego, CA, p.A2905

10:15 **Lung Parenchyma on CT Scans of Premature Infants Normalizes with Age/**D.R. Spielberg, J. Stein, L.L. Walkup, A. Brody, J.C. Woods, Cincinnati, OH, p.A2906

10:30 **Long-Term Respiratory Morbidity in Recipients of Pediatric Solid Organ Transplants: A Retrospective Review/**M.F.A. Wright, M. Chilvers, T. Blydt-Hansen, Vancouver, Canada, p.A2907

Featured Speaker

10:45 **Accidental Career/**A.C. Koumbourlis, MD, MPH, Washington, DC

MINI SYMPOSIUM

B20 HOOKED ON PH'OMICS

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 3003/3005 (West Building, Level 3)

Chairing: C.E. Ventetuolo, MD, MS, Providence, RI
A.A. Desai, MD, Tucson, AZ
A.R. Hemnes, MD, Nashville, TN

Oral Presentations

9:00 **Utility of Deep Phenotyping in the Identification and Validation of Novel Causal Whole Genome Sequencing Variation in Patients with Pulmonary Arterial Hypertension/**C. Hadinnapola, M. Bleda, M. Haimel, H.J. Bogaard, G. Coghlan, P.A. Corris, J.S. Gibbs, D.G. Kiely, A. Lawrie, A.J. Peacock, R.D. Machado, J. Pepke-Zaba, A. Vonk-Noordegraaf, R.C. Trembath, J. Wharton, M.R. Wilkins, S.J. Wort, S. Graf, N.W. Morrell, Cambr, p.A2908

9:15 **Abnormal Transpulmonary Metabolite Flux In Exercise Induced Pulmonary Arterial Vasculopathy/**A.B. Waxman, C. Bennett, A.J. Janocha, S.A.A. Comhair, S.C. Kalhan, J.A. Leopold, S.C. Erzurum, D.M. Systrom, Boston, MA, p.A2909

9:30 **Genome Wide Association Studies in Chronic Thromboembolic Pulmonary Hypertension/**M. Toshner, M. Bleda, M. Newnham, I. Lang, M. Delcroix, J. Cannon, K. Sheares, G. Coghlan, P.A. Corris, S. Gibbs, D. Kiely, A. Peacock, M. Simpson, R.C. Trembath, M.R. Wilkins, S.J. Wort, C. Ng, J. Dunning, N. Screaton, S. Tsui, D. Jenkins, S. Graf, J. Pepke-Zaba, N.W. Morrell, Cambridge, United Kingdom, p.A2910

9:45 **Plasma Proteome Analysis in Idiopathic Pulmonary Arterial Hypertension Identifies a Panel of Prognostic Proteins/**C. Rhodes, J. Wharton, P. Ghataorhe, G. Watson, B. Girerd, L.S. Howard, S. Gibbs, R. Condliffe, C.A. Elliot, D. Kiely, G. Simonneau, D. Montani, O. Sitbon, H. Gall, R.T. Schermuly, H.A. Ghofrani, A. Lawrie, M. Humbert, M. Wilkins, London, United Kingdom, p.A2911

10:00 **Whole Exome Sequencing Reveals CES1 as a Novel Gene in Methamphetamine Induced Pulmonary Arterial Hypertension/**V. De Jesus Perez, M. Orcholski, A. Khurshudyan, K. Yuan, R.T. Zamanian, Palo Alto, CA, p.A2912

10:15 **Genetic Analysis of 1738 WHO Group 1 PAH Patients Enrolled in the PAH Biobank/**M. Pauciulo, K. Lutz, C. Winslow, A. Walsworth, A. Gygi, M. Barve, A. Reponen, L. Martin, H. He, W. Nichols, Cincinnati, OH, p.A2913

10:30 **Metabonomic Phenotype Analysis in Patients with Pulmonary Hypertension/**P. Ghataorhe, C. Rhodes, J. Wharton, V. Horneffer-van Der Sluis, B. Jimenez, M. Lewis, J. Pearce, M. Kyriakides, G. Watson, L.S. Howard, S. Gibbs, H. Gall, H.A. Ghofrani, R.T. Schermuly, Z. Takats, I. Wilson, J. Nicholson, M. Wilkins, London, United Kingd, p.A2914

Featured Speaker

10:45 **More Data, More Problems/**M.W. Geraci, MD, Indianapolis, IN,

POSTER DISCUSSION SESSION

B21 GENETICS, GENOMICS, AND GENE EXPRESSION IN ASTHMA AND COPD

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 2024 (West Building, Level 2)

Poster Viewing **9:00-9:45**

Discussion **9:45-11:00**

Chairing: D. Vercelli, MD, Tucson, AZ
C.P. Hersh, MD, MPH, Boston, MA
S. Sharma, MD, MPH, Aurora, CO

601 **Whole Blood MicroRNA Biomarkers in Acute Respiratory Distress Syndrome/**Z. Zhu, Y. Wei, L. Su, R. Zhang, P. Tejera, Z. Wang, Q. Lu, L. Liang, A. Baccarelli, D.C. Christiani, Boston, MA, p.A2915

602 **Quantitative Genetic Analysis of MUC5AC and MUC5B in a Mouse Model of Asthma/**S. Kelada, A. Livraghi-Butrico, K. McFadden, J. Thomas, W.K. O'Neal, R.C. Boucher, Chapel Hill, NC, p.A2916

603 **Asthma Susceptibility IL33 SNP rs4742165 Is an eQTL for Asthmatic Serum sST2/**O. Li, G. Jia, A. Dressen, B. Yaspan, R. Beasley, J. Fingleton, C. Holweg, J. Matthews, J. Harris, H. Scheerens, J. Arron, D. Choy, T. Staton, South San Francisco, CA, p.A2917

604 **Reduced Pulmonary Function Growth in Childhood Asthmatics Shows High Additive Genetic Heritability/**M. McGeachie, G.L. Clemmer, D.C. Croteau-Chonka, P.J. Castaldi, M.H. Cho, J.E. Sordillo, J. Lasky-Su, B.A. Raby, K. Tantisira, S.T. Weiss, Boston, MA, p.A2918

605 **Association of CD14 C-159t Promoter Polymorphism with Regulatory Cytokine Response in Indian Children with Atopic Asthma/**A. Agarwal, M. Singh, A. Chauhan, N. Paul, Chandigarh, India, p.A2919

606 **Polymorphisms of IL4RA and ADAM33, Risk Variants in Patients with Asthma Exacerbations with Type 2-Predominant Condition/**H. Sunadome, H. Matsumoto, G. Petrova, Y. Kanemitsu, Y. Izuhara, Y. Tohda, T. Horiguchi, H. Kita, K. Kuwabara, K. Tomii, K. Otsuka, M. Fujimura, N. Ohkura, K. Tomita, A. Yokoyama, H. Ohnishi, Y. Nakano, T. Oguma, S. Hozawa, T. Nagasaki, I. Ito, H. Inoue, T. Tajiri, T. Iwata, J. Ono, S. Ohta, M. Tamari, T. Hirota, T. Yokoyama, A. Niimi, K. Izuhara, M. Mishima, Kyoto, Japan, p.A2920

607 **Genome Wide Association Study of Lung Function and Allergy Related Traits in Subjects with Asthma/**M.A. Portelli, N.D. Bennett, I. Ntalla, A. Henry, C.K. Billington, D. Shaw, Z.E.K. Pogson, A. Fogarty, T. McKeever, L. Jonker, A. Singapuri, L. Heaney, A. Mansur, N.C. Thomson, R. Chaudhuri, J. Holloway, G. Lockett, P. Howarth, J. Hankinson, R. Niven, A. Simpson, M.D. Tobin, L.V. Wain, I.P. Hall, C.E. Brightling, I. Sayers, Nottingham, United Kingdom, p.A2921

608 **Determining the Contribution of IL33 and IL1RL1 Polymorphisms to Clinical and Immunological Features of Asthma/**M.A. Portelli, N.D. Bennett, J. Hankinson, I. Ntalla, A. Henry, C.K. Billington, D. Shaw, Z.E.K. Pogson, A. Fogarty, T. McKeever, L. Jonker, A. Singapuri, L. Heaney, A. Mansur, N.C. Thomson, R. Chaudhuri, J. Holloway, G. Lockett, P. Howarth, R. Niven, M.D. Tobin, L.V. Wain, I.P. Hall, C.E. Brightling, A. Simpson, I. Sayers, Nottingham, United Kingdom, p.A2922

609 **Where Next in Asthma Research? A Review of Current Understanding and Future Focus to Prevent and Cure Asthma/**S. Johnston, M.R. Edwards, J. Schwarze, C. Skevaki, S. Saglani, E.J. Kennington, J.L. Edwards, S. Walker, London, United Kingdom, p.A2923

610 **Exome Array Analysis Identifies IL27 as a Susceptibility Locus for Chronic Obstructive Pulmonary Disease/**B.D. Hobbs, M.M. Parker, H. Chen, T. Lao, M.E. Hardin, D. Qiao, I. Hawrylkiewicz, P. Sliwinski, J.J. Yim, W.J. Kim, D.K. Kim, P.J. Castaldi, C.P. Hersh, J.D. Morrow, B.R. Celli, V. Pinto-Plata, G.J. Criner, N. Marchetti, R. Bueno, A. Agusti, B.J. Make, J.D. Crapo, P. Calverley, C.F. Donner, D.A. Lomas, E.F. Wouters, J. Vestbo, P.D. Pare, R.D. Levy, S.I. Rennard, X. Zhou, N.M. Laird, X. Lin, T.H. Beaty, E.K. Silverman, M.H. Cho, Boston, MA, p.A2924

611 **DNA Co-Methylation Modules Associate with COPD in African Americans/**R. Busch, J.D. Morrow, J. Lasky-Su, W. Qiu, G.J. Criner, D.L. DeMeo, Boston, MA, p.A2925

612 **The Effect of Smoke Exposure on Gene Expression: From Fetal Development to COPD/**L.P. Hayden, S. Sharma, J.D. Morrow, D. Chhabra, A. Kho, C.A. Vyhlidal, R. Gaedigk, J.S. Leeder, G.J. Criner, R. Bueno, B. Celli, K. Tantisira, D.L. DeMeo, S.T. Weiss, E.K. Silverman, C.P. Hersh, Boston, MA, p.A2926

613 **Exome Array Analysis of Quantitative Lung Function Measurements in the COPDGene Study/**M.M. Parker, B.D. Hobbs, R.A. Mathias, I. Ruczinski, S.M. Lutz, J.E. Hokanson, P.J. Castaldi, J.D. Crapo, E.K. Silverman, M.H. Cho, T.H. Beaty, Boston, MA, p.A2927

614 **Genetic and Epigenetic Regulation of Myosin Light Chain Kinase by Inflammatory Lung Disease Associated Polymorphisms/**X. Sun, V.R. Elangovan, Y. Shimizu, S.-F. Ma, T. Wang, J.G.N. Garcia, Tucson, AZ, p.A2928

615 **Greater Urban Tree Canopy Exposure May Be Linked to Asthma and DNA Methylation of the IL4 Gene Promoter/**S. Lovinsky-Desir, G.S. Lovasi, X. Liu, D. Torrone, K.H. Jung, J. Jezioro, F.P. Perera, A. Rundle, R.L. Miller, New York, NY, p.A2929

616 **Risk Factors Associated with Irreversible Airway Obstruction in Asthma: A Meta-Analysis and Systematic Review/**L. Zhang, Sichuan, China, p.A2930

617 **The Role of Genes Identified in Genome-Wide Association Studies of Asthma Susceptibility in the Developmental Origin of Asthma/**S. Sharma, A. Kho, C. Vyhlidal, R. Gaedigk, J.S. Leeder, K. Tantisira, S.T. Weiss, Aurora, CO, p.A2931

618 **Gene Expression Networks of Allergic Asthma as Characterized by IgE Levels Among Costa Rican Children/**J.L.-S.A. Lasky-Su, Y. Virkud, R.S. Kelly, M. McGeachie, D.C. Croteau-Chonka, S.T. Weiss, Boston, MA, p.A2932

619 **Flow Cytometry to Generate Transcriptional Profiles from Individual Myeloid Populations Isolated from Human Lung Tissues/**J. Walter, A.V. Misharin, A.C. Argento, A.C. McQuattie-Pimentel, M. Chi, F.J. Gonzalez-Gonzalez, S. Soberanes, P.A. Reyfman, V. Morgan, A. Bharat, S. Bhorade, H.R. Perlman, J.I. Sznajder, N. Chandel, K.M. Ridge, G.S. Budinger, Chicago, IL, p.A2933

620 **Gene Expression Networks of Adult Asthma Modified by Childhood Obesity/**D.C. Croteau-Chonka, K. Tantisira, V.J. Carey, S.T. Weiss, J. Lasky-Su, B.A. Raby, Boston, MA, p.A2934

621 **Genome-wide Association Study of Asthma Susceptibility in African American Children and Youth: The SAGE II Study/**J. Adams, M. White, O. Risse-Adams, S.S. Oh, P. Goddard, J. Magana, M. Spear, D. Hu, S. Huntsman, C. Eng, E.G. Burchard, San Francisco, CA, p.A2935

622 **Children with an Acute Respiratory Illness Infected with Human Rhinovirus (RV) Species C, that Have a CDHR3 rs6967330 A Allele, Are More Likely to Have a Recurrent Wheezing Hospital Presentation/**I.A. Laing, S.-K. Khoo, K.M. Franks, F. Prastanti, J.E. Everard, S. Oo, J. Bizzintino, P.N. Le Souef, Subiaco, Australia, p.A2936

623 **Smoking-Associated Changes in DNA Methylation Are Widely Abolished by Vitamin C Supplementation to Pregnant Smokers/**L.E. Shorey-Kendrick, C.T. McEvoy, L.J. Wilhelm, B.H. Vuylsteke, K.F. Milner, E.R. Spindel, Beaverton, OR, p.A2937

624 **Neonatal SMAD3 Promoter Hypermethylation Predicts Asthma in Children of Asthmatic Mothers from Three Birth Cohorts/** A. DeVries, G. Wlasiuk, S.J. Miller, A. Bosco, D.A. Stern, I.C. Lohman, J. Rothers, A.C. Jones, J. Nicodemus-Johnson, J.A. Curtin, A. Simpson, A. Custovic, D.J. Jackson, J.E. Gern, R.F. Lemanske, Jr., S. Guerra, A.L. Wright, C. Ober, M. Halonen, D. Vercelli, Tucson, AZ p.A2938

625 **Large-Scale Genome-Wide Association Study of Asthma in the Kaiser Permanente Northern California's Genetic Epidemiology Research on Adult Health and Aging (KPNC-GERA) Cohort/**A. Dahlin, J. Ziniti, C. Iribarren, M. Lu, K. Tantisira, S.T. Weiss, A.C. Wu, Boston, MA, p.A7938

POSTER DISCUSSION SESSION

B22 BURDEN OF PULMONARY AND CRITICAL CARE MEDICINE: COST AND UTILIZATION

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 304 (South Building, Esplanade Level)

Poster Viewing **9:00-9:45**

Discussion **9:45-11:00**

Chairing: S.S. Carson, MD, Chapel Hill, NC
J.K. Gerald, MD, PhD, Tucson, AZ
M.P. Kerlin, MD, Philadelphia, PA

201 **Healthcare Use and Costs Among Patients with Non-Cystic Fibrosis Bronchiectasis in the US/**C.M. Blanchette, J.M. Noone, G. Stone, E. Zacherle, M.C. Runken, R. Howden, Charlotte, NC, p.A2939

202 **Inpatient Trend for Adult Cystic Fibrosis in the United States from 1998-2013: A 15 Year Analysis/**A. Agrawal, I.A. Lalani, S.S. Alagusundaramoorthy, D. Du, Long Branch, NJ, p.A2940

203 **Trends in Inpatient Admissions of Pulmonary Hypertension in the United States from 2000-2013/**A. Agrawal, D. Mehta, I.A. Lalani, A. Agarwal, A. Talwar, Long Branch, NJ, p.A2941

204 **Excess Economic Burden in Asthma Patients and the Impact of Comorbidities/**W. Chen, L.D. Lynd, M.J. Fitzgerald, C. Marra, R. Balshaw, T. To, H. Tavakoli, M. Sadatsafavi, Vancouver, Canada, p.A2942

205 **Occurrence of Severe Asthma Events and Exacerbations by Level of Controller Therapy in Patients with Asthma in the United States/**M. DePietro, E. Durden, K.M. Fox, M. Brouillette, J.R. Davis, M. Bonafede, Wilmington, DE, p.A2943

206 **What Is the Cost of Asthma in the States?/**T. Nurmagambetov, O.A. Khavjou, L. Murphy, D. Orenstein, Atlanta, GA, p.A2944

207 **Prevalence and Features of Asthma. Results of a Population-Based Nationwide Survey in Argentina/**A.J. Videla, S. Arias, J.C. Bossio, C.A. Calabrese, G. Armando, H. Neffen, Buenos Aires, Argentina, p.A2945

208 **Medical Service Utilization Among Australian Older Women with Asthma/**P. Eftekhari, P.M. Forder, J.E. Byles, Callaghan, Australia, p.A2946

209 **The Economic Burden of Asthma, Allergic Rhinitis, COPD and Rhinosinusitis in Korea/**K.-H. Yoo, H.-R. Ahn, J.-K. Park, J.-W. Kim, G.-H. Nam, S.-K. Hong, M.-J. Kim, A. Ghoshal, A.R.B.A. Muttalif, H.C. Lin, S. Thanaviratananich, S. Bagga, R. Faruqi, S. Baidya, C. Taylor, D.Y. Wang, S.-H. Cho, Seoul, Korea, Republic of, p.A2947

210 **The Association of Depression with Emergency Department Use in Chronic Obstructive Pulmonary Disease/**H. Weerahandi, J.P. Wisnivesky, M.S. Kale, M. Martynenko, M. Wolf, A. Federman, New York, NY, p.A2948

211 **The Burden of Illness Related to COPD Exacerbations in Quebec, Canada/**R. Tavares, T. Dang-Tan, S. Zhang, M. Stutz, A. Ismaila, J. Vaillancourt, D. Corriveau, R.H. Stanford, X. Lin, G. Nadeau, A. Simidchiev, D. Parsons, J.S. Sampalis, Mississauga, Canada, p.A2949

212 **Economic Burden of Chronic Obstructive Pulmonary Disease (COPD) in Patients with and Without Co-Morbid Cardiovascular Disease (CVD) in the United States/**R.H. Stanford, M.R. Bogart, Research Triangle Park, NC, p.A2950

213 **Economic Surveillance for Chronic Obstructive Pulmonary Disease (COPD) in Alberta, Canada/**A. Waye, P. Jacobs, M. Stickland, M.B. Ospina, I. Mayers, Edmonton, Canada, p.A2951

214 **Sarcoidosis-Associated Hospitalizations in the United States, 2002-2012/**A.B. Wills, J.R. Fontana, C.A. Steiner, H.C. Ackerman, A.P. Ruhl, K.N. Olivier, D.R. Prevots, Bethesda, MD, p.A2952

215 **Cost Consequences of Initial Combination Treatment of PAH with Ambrisentan and Tadalafil/**R.J. Oudiz, S.C. Mathai, R.J. White, M. Jacobsen, D. Weycker, C.D. Burger, Torrance, CA, p.A2953

216 **Healthcare Utilization and Direct Costs Among Pulmonary Arterial Hypertension Patients Before and After Treatment Initiation in the United States/**C.D. Burger, B. Ozbay, E. Riehle, L.B. Montejano, R.J. White, Jacksonville, FL, p.A2954

217 **The Incidence of ICU Admissions in a Privately Insured Population Across the United States/**G.E. Weissman, N.B. Gabler, M.P. Kerlin, S.D. Halpern, Philadelphia, PA, p.A2955

218 **Effect of Hospital Characteristics and Quality Metrics on ICU Utilization Practices: A Multi-State Cross-Sectional Analysis/**K.S. Mathews, J. Zhou, M. Mazumdar, G.N. Stock, C.M. McDermott, New York, NY, p.A2956

219 **Male Predominance in Admission to Intensive Care Units (ICU) Disappears After Surviving One ICU Admission/**C.D. Ramsey, A. Hill, P. Dodek, R. Fowler, J. Kozak, H. Wong, R. Fransoo, M. Doupe, M. Yogendran, A. Garland, Winnipeg, Canada, p.A2957

220 **Identifying the Organizational and Process Factors Driving Treatment Intensity at the End of Life Within and Upstream of the Intensive Care Unit: A Positive Deviance Study/**C. Lin, J. Jopling, K. Vranas, M. Ramsey, M. Simons, D. Zionts, H. Chiou, T. Wagner, A. Milstein, Stanford, CA, p.A2958

221 **Methamphetamine Abuse and Health Care Burden of a Single Tertiary Referral Center in the Central Valley of California/**P. Doddamreddy, J. Tulyagankhodjaev, C. Ives, J. Rosario, V. Balasubramanian, P. Armenian, R. Vohra, Fresno, CA, p.A2959

222 **Trends in Heroin- and Prescription Opioid-Related Intensive Care Unit Admissions Between 2008-2014/**D. Hsu, A. Law, J. Marshall, S. O'Donoghue, J. Bertone, J.P. Stevens, Boston, MA, p.A2960

223 **Trends in Hospital Admissions and Costs associated with Heroin and Prescription Opioid Overdoses: Analysis of National Inpatient Sample Data 2001-2012/**D. Hsu, E. McCarthy, J.P. Stevens, K. Mukamal, Boston, MA, p.A2961

224 **Intermediate Care Resource Utilization Among Patients Hospitalized with Pneumonia/**A.J. Admon, H. Wunsch, T.J. Iwashyna, C.R. Cooke, Ann Arbor, MI, p.A2962

225 **Patterns of Non-Invasive Home Ventilation Usage in the Province of Alberta, Canada: A Retrospective Population-Based Cohort Study/**E.J. MacIntyre, K. Rimmer, C. Cyr, D.A. McKim, M. Chan, M. Heule, A. Massia, L. Rose, S.M. Bagshaw, Edmonton, Canada, p.A2963

POSTER DISCUSSION SESSION

B23 CARDIOVASCULAR AND RESPIRATORY INTERACTIONS IN COPD

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 133 (North Building, Lower Level)

Poster Viewing **9:00-9:45**

Discussion **9:45-11:00**

Chairing: R.G. Barr, MD, DrPH, New York, NY
M.J. Cuttica, MD, Chicago, IL
J.M. Wells, MD, Birmingham, AL

101 **Airflow Limitation and Endothelial Dysfunction: Unrelated and Independent Predictors of Atherosclerosis/**D. Chandra, A. Gupta, P.J. Strollo, C. Fuhrman, J.K. Leader, J.M. Bon, W.A. Slivka, K.E. Kip, S. Reis, F.C. Sciurba, Pittsburgh, PA, p.A2964

102 **Tricuspid Annular Plane Systolic Excursion (TAPSE) as a Predictor of Long Term Survival in Hospitalized Patients with Chronic Obstructive Pulmonary Disease/**M. Diamond, J. Barry, V. Lakhter, K. Shenoy, M. Keane, G.J. Criner, Philadelphia, PA, p.A2965

103 **Growth Differentiation Factor-15 (GDF-15) Levels in Chronic Obstructive Pulmonary Disease Are Independently Associated with Subclinical Coronary Atherosclerosis: An Analysis of the COPDGene Cohort/**C.H. Martinez, C.M. Freeman, J.D. Nelson, M.J. Budoff, S. Murray, X. Wang, S.P. Bhatt, R.P. Bowler, M.T. Dransfield, L. Guo, J. Hokanson, G.L. Kinney, F.J. Martinez, E.A. Regan, J.M. Wells, M.K. Han, J.L. Curtis, Ann Arbor, MI, p.A2966

104 **Impact of Cardiovascular Co-Morbidities on FEV1 Change in Smokers: An Analysis of the COPDGene Cohort/**D.J. Maselli, A.A. Diaz, V. Kim, N. Putcha, M.J. Budoff, E.J. Van Beek, M.G. Foreman, G.L. Kinney, J. Hokanson, J.L. Curtis, F.J. Martinez, A. Tadashi, R.P. Bowler, E.A. Regan, B.J. Make, N.A. Hanania, M.K. Han, C.H. Martinez, San Antonio, TX, p.A2967

105 **Heart-Lung Interaction in a Model of COPD: The Importance of Lung Volume/**W.S. Cheyne, A.M. Williams, M.I. Harper, N.D. Eves, Kelowna, Canada, p.A2968

106 **Volume Loading Exacerbates Adverse Heart-Lung Interaction in a Model of COPD/**W.S. Cheyne, A.M. Williams, M.I. Harper, N.D. Eves, Kelowna, Canada, p.A2969

107 **Lack of Change in Arterial Stiffness and Vascular Function in Chronic Obstructive Pulmonary Disease Patients Admitted to Hospital/**I.J. Andresson, D. Fuhr, M. Bhutani, R. Damant, B.H. Rowe, R. Leigh, M. Stickland, Edmonton, Canada, p.A2970

108 **A Randomized Trial of Once-Daily Fluticasone Furoate/Vilanterol or Vilanterol Versus Placebo to Determine Their Effects on Arterial Stiffness in COPD/**S.P. Bhatt, M.T. Dransfield, J.R. Cockcroft, J. Wang-Jairaj, D.A. Midwinter, D.B. Rubin, C.A. Scott-Wilson, C. Crim, Birmingham, AL, p.A2971

109 **The Relationship Between Airflow Obstruction and Severity of Coronary Arterial Disease in Smokers and Non-Smokers/**S. Ruickbie, A. Prasad, P.W. Jones, E.H. Baker, London, United Kingdom, p.A2972

110 **Effect of Nasal High Flow on Digital Vascular Tone During Sleep in COPD Patients/**K. Fricke, H. Schneider, L. Grote, Baltimore, MD, p.A2973

111 **Atrial Arrhythmia and Diastolic Dysfunction Are Associated with Acute Exacerbation of COPD/**P. Schroff, J.M. Wells, Y.-I. Kim, J.E. Blalock, W.C. Bailey, M.T. Dransfield, S.P. Bhatt, Birmingham, AL, p.A2974

112 **Eligibility for the STATCOPE Trial: A Review of Statin Use in a Hospital-Based Cohort of COPD Patients/**R.P. Young, C. Chen, R.J. Hopkins, G.D. Gamble, Auckland, New Zealand, p.A2975

113 **Pulmonary Hypertension in COPD from Exposure to Biomass Fuel/**M. Gholamnejad, Y. Roosta, Urmia, Iran, p.A2976

114 **Evaluation of T Peak-T End Interval in Patients with Chronic Obstructive Pulmonary Disease (COPD)/**G. Karadeniz, F. Ucsular, M. Demir, S. Bulac Kir, S. Doruk, Izmir, Turkey, p.A2977

115 **Plasma von Willebrand Factor and Longitudinal Change in Percent Emphysema: The MESA Lung Study/**C.P. Aaron, E.A. Hoffman, M.F. Doyle, J.E. Schwartz, E.C. Oelsner, N.B. Larson, S.J. Bielinski, S.M. Kawut, R.G. Barr, New York, NY, p.A2978

116 **Association of Airflow Limitation with Carotid Atherosclerosis in a Japanese Community: The Hisayama Study/**K. Kunihiro, K. Matsumoto, J. Hata, Y. Shundo, S. Fukuyama, H. Inoue, Y. Kiyohara, T. Ninomiya, Y. Nakanishi, Fukuoka, Japan, p.A2979

117 **Association of Chronic Obstructive Pulmonary Disease (COPD) and Diabetes Mellitus with Cardiovascular Diseases; and Review of Health-Care Associated Costs' for COPD Patients from the Medical Expenditure Panel Survey (MEPS) Dataset/**I.A. Lalani, L. Liu, Long Branch, NJ, p.A2980

118 **Comparison of the Prognostic Impact of Chronic Versus Paroxysmal Atrial Fibrillation in Patients with Chronic Obstructive Pulmonary Disease/**T. Tomioka, S. Miyata, K. Inoue, H. Shimokawa, Miyagi, Japan, p.A2981

119 **Occult Cardiac Disease Can Be Identified by Dynamic 256-Slice CT During Chronic Obstructive Pulmonary Disease Exacerbation/**M.I. MacDonald, A.-M. Wong, P. King, S. Lockwood, J. Troupis, P.G. Bardin, Melbourne, Australia, p.A2982

120 **Higher Plasma Myostatin Levels in Cor Pulmonale Secondary to Chronic Obstructive Pulmonary Disease/**C. Ju, J. Zhang, M. Chen, R. Chen, Guangzhou, China, p.A2983

121 **COPD Related Lung Pathophysiology, Aortic Stiffening and Altered Brain Structure: A Magnetic Resonance Neuroimaging Pilot Study/**K.F. Hoth, G.L. Pierce, A.P. Comellas, P. Nopoulos, E.A. Hoffman, V. Magnotta, K. Warner, A. Croghan, L.E. DuBose, E. Harlynn, F. Wamboldt, D.J. Moser, J.D. Newell, Iowa City, IA, p.A2984

122 **Effects of Losmapimod, a Novel p38 Mitogen-Activated Protein Kinase (MAPK) Inhibitor on Vascular Inflammation in Chronic Obstructive Pulmonary Disease (COPD) Subjects Stratified by Fibrinogen: EVOLUTION Trial/**M. Fisk, D. Mohan, J. Cheriyan, J. Forman, J. Fuld, C. McEniery, J.R. Cockcroft, J. Rudd, R. Tal-Singer, M.I. Polkey, I.B. Wilkinson, Cambridge, United Kingdom, p.A2985

123 **The Early Effectiveness of Noninvasive Positive Pressure Ventilation on Right Ventricular Function in Chronic Obstructive Pulmonary Disease Patients with Acute Hypercapnic Respiratory Failure/**H. Feiz Disfani, S. M.Lari, D. Attaran, F. Vakilian, M. Kamandi, Mashhad, Iran, p.A2986

124 **Lung Function Impairment Linked to Coronary Atherosclerotic Lesions in Patients with Chronic Obstructive Pulmonary Disease - Data from COPDGene Study/**D. Li, C. Tan, R.H. Casaburi, J.D. Crapo, E.K. Silverman, G. Washko, B.J. Make, D.A. Lynch, J. Hokanson, M.J. Budoff, Torrance, CA, p.A2987

125 **Spirometric and Bodyplethysmographic Lung Function is Associated with Echocardiography-Derived Ventricular Wall Stress in COPD/**P. Alter, H. Watz, T. Welte, S. Glaser, H. Schulz, R. Bals, S. Sohler, A. Karch, C. Vogelmeier, R.A. Jorres, Marburg, Germany, p.A2988

POSTER DISCUSSION SESSION

B24 OCCUPATIONAL MEDICINE

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 2010/2012 (West Building, Level 2)

Poster Viewing **9:00-9:45**

Discussion **9:45-11:00**

Chairing: P.K. Henneberger, MPH, ScD, Morgantown, WV
N. Suganuma, MD, PhD, Kochi, Japan
K. Cummings, MD, MPH, Morgantown, WV

401 **Lifetime Occupational Exposure to Vapor, Gases/Fumes, Dust and Risk of COPD at 45 Years: The Tasmanian Longitudinal Health Study (TAHS)/**S.M. Alif, S.C. Dharmage, G. Benke, M. Dennekamp, J. Burgess, J.L. Perret, C.J. Lodge, S. Morrison, D.P. Johns, G.G. Giles, P.S. Thomas, R. Vermeulen, H. Kromhout, M. Abramson, E.H. Walters, M.C. Matheson, Melbourne, Australia, p.A2989

402 **Serum IgE Levels Among U.S. Workers - National Health and Nutrition Examination Survey (NHANES), 2005-2006/** J.M. Mazurek, D.N. Weissman, Morgantown, WV, p.A2990

403 **Ambient Air Pollution Exposure and Chronic Bronchitis in a Cohort of U. S. Women/**L.G. Hooper, M.T. Young, J.P. Keller, A. Szpiro, K.M. O'Brien, D.P. Sandler, S. Vedal, J. Kaufman, S. London, Seattle, WA, p.A2991

404 **Influence of Exposure Times on Pollution Related Mortality in the NIH-AARP Cohort/**C. Lim, L. Yinon, R. Hayes, K.R. Cromar, Y. Shao, J. Ahn, G.D. Thurston, Tuxedo, NY, p.A2992

405 **Aging Induces a Hyperinflammatory Response to Organic Dust Stimulation of Peripheral Leukocytes/**K.L. Bailey, L. Smith, A.J. Heires, D.J. Romberger, T.D. LeVan, Omaha, NE, p.A2993

406 **Spectrum of Longitudinal Lung Abnormalities in Microwave Popcorn Workers /**R.L. Bailey, J.M. Cox-Ganser, K.B. Fedan, S.K. White, D.A. Lynch, K. Kreiss, Morgantown, WV, p.A2994

407 **Prospective Study of Processed Meat Intake and the Risk of Chronic Obstructive Pulmonary Disease/**R. Varraso, O. Dumas, K.M. Boogs, W.C. Willett, F.E. Speizer, C.A. Camargo, Villejuif, France, p.A2995

408 **Spirometry and Chest Radiographs in US Coal Miners: Analysis of Data from the Federal Black Lung Program/**R.A. Cohen, J. Graber, G. Harris, K. Almberg, L.H. Go, E.L. Petsonk, C. Rose, Chicago, IL, p.A2996

409 **Among All Miners, Coal Miners Demonstrate a Disproportionately High Prevalence of Obstructive Spirometric Abnormality/**A. Sood, T.W. Boyce, E. Kocher, D. Kesler, O. Myers, K. Evans, L. Cook, Albuquerque, NM, p.A2997

410 **Uranium Miners Demonstrate Lower Lobe Predominant Irregular Pneumoconiotic Opacities on Chest Radiographs/**K.J. Rendon, E. Kocher, T. Wilson, O. Myers, K. Evans, L. Cook, A. Sood, D. Kesler, Albuquerque, NM, p.A2998

411 **Underground Semi-Precious Stones Mining: Risk Factors for Silicosis/**M.M. Knorst, T.P. Souza, J.A. Souza, A.M. Gusso, J.D.S. Moreira, Porto Alegre, Brazil, p.A2999

412 **Lung Transplantation Is Increasingly Common Among Patients with Coal Workers' Pneumoconiosis/**D.J. Blackley, C.N. Halldin, K. Cummings, A.S. Laney, Morgantown, WV, p.A3000

413 **The Association Between Occupational Exposure to Vapor, Gas, Dust and Fume and Different Definitions of COPD, Emphysema and Chronic Bronchitis: The Swedish CArdioPulmonary BioImage Study (SCAPIS)/**K. Toren, N. Murgia, A.-C. Olin, J. Vikgren, G. Bergstrom, Gothenburg, Sweden, p.A3001

414 **Spirometric Trajectories in Lung Disease Longitudinal Surveillance of Former Workers and Volunteers at the World Trade Center Disaster Site/**R.E. de la Hoz, L.A. Bienenfeld, J.T. Doucette, S. Zafar, D.A. Carson, S. Luna-Sanchez, New York, NY, p.A3002

415 **Is the Cardiopulmonary Exercise Testing Better than Spirometry to Detect Early Ventilatory Changes Related to Occupational Exposure to Particulate Matter?/**V.Z. Dourado, E.F. Sperandio, C.T. Ping, M. Romiti, A. Gagliardi, R. Arantes, Santos, Brazil, p.A3003

416 **Occupational Microbial Exposures of Animal Care Workers Measured by 16S rDNA Sequencing/**P.S. Lai, J.G. Allen, T. Winters, C.M. North, C. Hug, J. Vallarino, D.C. Christiani, Boston, MA, p.A3004

417 **Exposure to High Endotoxin Concentration Increases Wheezing Prevalence Among Laboratory Animal Workers/**E.O. Vianna, A.S. Freitas, C.S. Simoneti, E. Ferraz, M.C. Borges, Ribeirao Preto, Brazil, p.A3005

418 **The Effects of Pulmonary Clearance Associated with Radiation Injury to the Lung: Comparison of Newborn Mice and Adult Mice/**C. Johnston, J.P. Williams, R. Gelein, E. Hernady, C. Reed, J.N. Finkelstein, Rochester, NY, p.A3006

419 **Reduced Lung Function in Children Associated with 137Cesium Body Burden/**E.R. Svendsen, I.E. Kolpakov, W.J.J. Karmaus, L. Mohr, V.Y. Vdovenko, D.M. McMahon, B.A. Jelin, Y.I. Stepanova, Charleston, SC, p.A3007

420 **Comparing Plasma, Serum, and Whole Blood Indium Concentrations from Workers at an Indium-Tin Oxide (ITO) Production Facility/**R.R. Harvey, M.A. Virji, N.T. Edwards, K. Cummings, Morgantown, WV, p.A3008

421 **5-ASA Treatment in Chronic Beryllium Disease/**L.A. Maier, B. Barkes, M. Gillespie, J. Elliott, G. Mondello, J. Huang, B. Day, Denver, CO, p.A3009

422 **The Role of JAK2 in Chronic Beryllium Disease/**L. Li, N. Hamzeh, M. Gillespie, G. Mondello, P.M. Mroz, L. Maier, Denver, CO, p.A3010

423 **Particle Matter (PM) Accumulation in Airways of Dental Technicians (DT) Exposed to Beryllium Is a Sensitive Biomarker to Reveal Early Cellular and Molecular Changes/**E.M. Fireman, Y. Lerman, L.A. Maier, L. Newman, M. Stark, Tel Aviv, Israel, p.A3011

424 **Development of Pulmonary Fibrosis Following Bromine Inhalation Injury/**A. Lam, S. Aggarwal, M.A. Carlisle, N. Vetal, A. Agarwal, S. Matalon, Birmingham, AL, p.A3012

425 **Increased Risk of Pneumonia in Residents Living near Poultry Farms: Does the Upper Respiratory Tract Microbiota Play a Role?/**L.A.M. Smit, G.J. Boender, W.A.A. De Steenhuijsen Piters, T.J. Hagenaars, E.G.W. Huijskens, J.W.A. Rossen, M. Koopmans, G. Nodelijk, E.A.M. Sanders, J. Yzermans, D. Bogaert, D. Heederik, Utrecht, Netherlands, p.A7806

POSTER DISCUSSION SESSION

B25 NON-TUBERCULOUS MYCOBACTERIA: EPIDEMIOLOGY, DIAGNOSIS, AND TREATMENT

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 3014 (West Building, Level 3)

Poster Viewing **9:00-9:45**

Discussion **9:45-11:00**

Chairing: K.L. Winthrop, MD, MPH, Portland, OR
T.R. Aksamit, MD, Rochester, MN
C. Swenson, MD, Atlanta, GA

901 **Epidemiology of Nontuberculous Mycobacterial Lung Disease in Hawaii/**J. Adjemian, T.B. Frankland, Y.G. Daida, J.R. Honda, K.N. Olivier, A. Zelazny, S. Honda, D.R. Prevots, Bethesda, MD, p.A3013

902 **Prevalence of Nontuberculous Mycobacterial Infections Among Patients at 151 US Hospitals, 2009-2013/**A.B. Spaulding, Y.L. Lai, K.N. Olivier, A. Zelazny, S.S. Kadri, D.R. Prevots, J. Adjemian, Bethesda, MD, p.A3014

903 **Prevalence of Nontuberculous Mycobacterium in HIV Patients Admitted with Pneumonia/**N.C. Lapinel, S.E. Jolley, J. Ali, D.A. Welsh, New Orleans, LA, p.A3015

904 **Clinical Significance of Nontuberculous Mycobacteria Isolated from Respiratory Specimens in a Chinese Tuberculosis Tertiary Care Center/**H. Duan, N. Chu, Beijing, China, p.A3016

905 **Circulating Exosome and Sputum Pofiling of Women with Nontuberculous Mycobacterial Disease and Breast Cancer/**J.V. Philley, A. Kannan, J.L. Benwill, D.E. Griffith, B.A. Brown-Elliott, F. Thakkar, H.K. Bains, M.S. Devine, R.J. Wallace, S. Dasgupta, Tyler, TX, p.A3017

906 **Northwest Biorepository of Nontuberculous Mycobacteria Patients- Baseline Characteristics/**E. Henkle, S. Novosad, S.A.R. Siegel, C.D. Varley, A. Stadnik, K.L. Winthrop, Portland, OR, p.A3018

907 **Long Term Quality of Life After Nontuberculous Mycobacteria Infection/**E. Henkle, S. Novosad, S.A.R. Siegel, K.L. Winthrop, Portland, OR, p.A3019

908 **Nontuberculous Mycobacterial Lung Infections After Allogenic Hematopoietic Stem Cell Transplantation: Incidence, Characteristics and Outcomes/**J. Beswick, D. Kim, T.K. Marras, Toronto, Canada, p.A3020

909 **Nontuberculous Mycobacteria Drug Susceptibilities in Ontario, Canada, 2010 - 2015/**F.B. Jamieson, E. Andrews, A. Marchand-Austin, M. Sharma, S.K. Brode, T.K. Marras, Toronto, Canada, p.A3021

910 **Macrolide Susceptible Mycobacterium Abscessus Lung Infections/**J.L. Benwill, J.V. Philley, B.A. Brown-Elliott, D.E. Griffith, R.J. Wallace, Tyler, TX, p.A3022

911 **The Usefulness of Radiological Severity Score in Patients with Mycobacterium Avium Complex Lung Disease/**K. Furuuchi, A. Ito, T. Hashimoto, S. Kumagai, T. Ishida, Kurashiki, Okayama, Japan, p.A3023

912 **Should Patients Aged 85 Years and Older Be Treated for Nontuberculous Mycobacterial Lung Disease?**/B.A. Buchcic, T.T. Yamanaka, D.R. Fraidenburg, I. Rubinstein, Chicago, IL, p.A3024

913 **Mycobacterium Avium Complex Disease Treated with Standard Treatment Combined with Amikacin and Clofazimine: A Retrospective Cohort Study**/S. Kops, S. Zweijpfenning, J. Van Ingen, M. Boeree, S. Kuipers, W. Hoefsloot, C. Magis-Escurra, Nijmegen, Netherlands, p.A3025

914 **Symptomatic Outcomes in Patients with Non-Tuberculous Mycobacteria Managed with Chest Physical Therapy**/ A. Basavaraj, J. Samuels, J. Feintuch, K. Alter, D. Addrizzo-Harris, L. Segal, D. Kamelhar, New York, NY, p.A3026

915 **Geographic Diversity of Non-Tuberculous Mycobacteria Species Among NTM Patients in the USA**/M. Mirsaeidi, P. Leitman, S. Wisliceny, E.I. Diaz, A. Leitman, A. Schmid, J.O. Falkinham, M. Campos, M. Salathe, Miami, FL, p.A7807

POSTER DISCUSSION SESSION

B26 UPDATES IN PEDIATRIC LUNG INFECTIONS

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**
Room 3011 (West Building, Level 3)

Poster Viewing **9:00-9:45**

Discussion **9:45-11:00**

Chairing: A. Colin, MD, Miami, FL
T. Moraes, MD, Toronto, Canada
O. Herrera, MD, Santiago, Chile

801 **Repurposing of a Cancer Drug in Clinical Trials for RSV Prophylaxis**/P. Mastrangelo, T. Moraes, W. Duan, M.J. Norris, R.G. Hegele, Toronto, Canada, p.A3027

802 **Cyclic AMP Activation Regulates Respiratory Syncytial Virus-Induced Airway Barrier Dysfunction and Viral Replication by Modulating Occludin**/F. Rezaee, T.J. Harford, P.M. Brown, A. Belkadi, G. Piedimonte, Cleveland, OH, p.A3028

803 **Effectiveness of Respiratory Syncytial Virus Immunoprophylaxis on Bronchiolitis Hospitalization Among High-Risk Infants**/P. Wu, G.J. Escobar, T. Gebretsadik, K. Carroll, S. Li, E. Walsh, E. Mitchel, C. Sloan, W. Dupont, C. Yu, T.V. Hartert, Nashville, TN, p.A3029

804 **Real World Effectiveness of Palivizumab in Reducing Risk for Respiratory Illness for Otherwise Healthy Infants 29 to 36 Weeks Gestation**/H.J. Farber, B. Lachman, F. Buckwold, E. Buck, M. Arun, J.S. Simpson, A.M. Valadez, Houston, TX, p.A3030

805 **Determinants of Persistent Respiratory Symptoms in Early Childhood and Adolescence Following Severe RSV Bronchiolitis in Infancy**/M. Kitcharoensakkul, W. Li, L.B. Bacharier, T.L. Schweiger, C.W. Goss, K.B. Schechtman, M. Castro, St. Louis, MO, p.A3031

806 **Bronchiolitis During Peak and Non-Peak Months: Analysis of 10 Consecutive Epidemics**/R. Nenna, A. Frassanito, L. Petrarca, G. Cangiano, S. Sirianni, E. Mancino, C. Di Mario, C. Scagnolari, A. Pierangeli, P. Papoff, C. Moretti, F. Midulla, Rome, Italy, p.A3032

807 **Metabolic Changes in Airway Epithelial Cells Following Human Metapneumovirus Infection**/A. Casola, Y. Zhao, M. Sinha, R.P. Garofalo, Galveston, TX, p.A3033

808 **Is Capnometry Helpful in Children with Bronchiolitis?**/F. Hakim, R. Jacob, R. Brik, I. Shavit, L. Bentur, Haifa, Israel, p.A3034

809 **Validation of a Strain-Specific Real-Time Enterovirus D68 (EV-D68) Test in Children Hospitalized with Severe Respiratory Syndrome**/P.M. Brown, R. Coelho, S. Cardenas, B.E. Gonzalez, D. Kohn, B. Yen-Lieberman, F. Rezaee, C. Sabella, S. Vogel, C.B. Foster, G. Piedimonte, Cleveland, OH, p.A3035

810 **A Validated Clinical Score for Infants with Acute Bronchiolitis Predicts Length of Oxygen Requirement and Length of Stay**/I. Golan-Tripto, A.D. Goldbart, K. Akel, Y. Dizitzer, M. Yitshak-Sade, A. Tal, Beer-Sheva, Israel, p.A3036

811 **Human Bocavirus and Respiratory Tract Infection in Children**/L. Petrarca, R. Nenna, A. Frassanito, G. Cangiano, C. Scagnolari, R. Tuccinardi, A. Pierangeli, G. Faiola, G. Di Mattia, C. Moretti, F. Midulla, Rome, Italy, p.A3037

812 **Comparison of Severity of Respiratory Disease in Children Testing Positive for Enterovirus D68 and Rhinovirus Subtypes**/E. Caylan, J. Welter, E. Weinblatt, S. Nolan, A. Dozor, Valhalla, NY, p.A3038

813 **Trp Channel Activation in Response to Hypertonic Saline Differs Between Human Pediatric Primary Bronchial Epithelial Cells and Airway Smooth Muscle Cells**/T.J. Harford, P.M. Brown, F. Rezaee, G. Piedimonte, Cleveland, OH, p.A3039

814 **Building a Prediction Model for Radiographically-Confirmed Pneumonia in Children: From Symptoms to Imaging**/M.A. Chavez, L.E. Ellington, R.H. Gilman, D. Figueroa-Quintanilla, J. Marin-Concha, W. Checkley, Lima, Peru, p.A3040

815 **Children with Empyema Have Exercise Limitation at Least Four Years After Admission- A Pilot Study**/B. Jeyaratnam, B. Kennedy, J. McBride, P. Field, P.D. Robinson, Y. Belessis, J. Widger, L. Plush, E. Coward, A. Jaffe, H. Selvadurai, Kensington, Australia, p.A3041

816 **Pediatric Empyema: Yield of Blood and Pleural Fluid Cultures**/C. Stankey, K.E.S. Hamre, W. Wheeler, A. Doucette, W. Pomputius III, S. Kurachek, Minneapolis, MN, p.A3042

817 **The Characteristics and Reliability of Pediatric Digital Lung Sound Examinations in Six African and Asian Countries Participating in the Pneumonia Etiology Research for Child Health (PERCH) Project**/E.D. McCollum, D.E. Park, N. Watson, W.C. Buck, C. Bunthi, A. Devendra, B.E. Ebruke, M. Elhilali, D. Emmanouilidou, A.J. Garcia-Prats, L.N. Githinji, M.L. Hossain, D.P. Moore, A. Mudau, J.M. Mulindwa, D. Olson, J. Otieno Awori, W.P. Vandepitte, C. Verwey, J.E. West, K.L. O'Brien, D. Feikin, L. Hammitt, Baltimore, MD, p.A3043

818 **Microbial Diversity and Abundance in Respiratory Disease and HIV in Children from Mozambique**/A. Annamalay, P. James, M. Lanaspa, J. Bizzintino, S. Acacio, L. Madrid, M. Cox, Q. Bassat, M. Moffatt, P. Le Souef, W.O. Cookson, Subiaco, Australia, p.A3044

819 **Association Between Chronic Aspiration and Chronic Airway Infection with Pseudomonas Aeruginosa and Other Gram-Negative Bacteria in Children with Cerebral Palsy/**C.A. Gerdung, A. Tsang, A.S. Yasseen, K. Armstrong, H.J. McMillan, T. Kovesi, Calgary, Canada, p.A3045

820 **Experiences with the Finger Prick Method for Dried Blot Spot Analysis of Anti-Tuberculosis Drugs in Paraguayan Children/**N.F. Martinez, C. Magis-Escurra, Asuncion, Paraguay, p.A3046

821 **Viral Lower Respiratory Tract Infection with Respiratory Insufficiency/Respiratory Failure Is Associated with an Increased Risk for Dysphagia and Pulmonary Aspiration/**K. McBeth, K.G. Smith, A. Yadav, R.A. Mosquera, C.K. Jon, W. DeJesus Rojas, T.R. Gonzales, J.M. Stark, Houston, TX, p.A3047

822 **Factors that Negatively Affect the Prognosis of Community-Acquired Pneumonia in a Country with Limited Resources (Itigi - Tanzania)/**N. Ullmann, S. Caggiano, M. Mkwambe, E. Verrillo, R. Cutrera, Rome, Italy, p.A3048

823 **Incidence, Characteristics, and Outcomes of Bacterial Tracheitis in Children with an Artificial Airway/**A.M. Gomez-Rubio, R.A. Mosquera, A. Yadav, C.K. Jon, J.M. Stark, K. McBeth, W. DeJesus Rojas, S. Hashmi, G. Colasurdo, T.R. Gonzales, K.G. Smith, Houston, TX, p.A3049

824 **The Practical Implementation of the WHO Integrated Management of Childhood Illnesses (IMCI) Guidelines in the Assessment of Pneumonia in the Under 5s in Malawi/**N.O. Kalu, N. Lufesi, D. Havens, K. Mortimer, Liverpool, United Kingdom, p.A3050

825 **Clinical Presentations of Chlamydia Pneumoniae in Children Hospitalized with Acute Respiratory Infections: A Comparison with Mycoplasma Pneumoniae/**Y. Sun, Incheon, Korea, Republic of, p.A3051

POSTER DISCUSSION SESSION

B27 HYPOXIA AND THE PULMONARY VASCULATURE: BREATHLESS IN SAN FRANCISCO

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 3024 (West Building, Level 3)

Poster Viewing **9:00-9:45**

Discussion **9:45-11:00**

Chairing: L. Shimoda, PhD, Baltimore, MD
C. Guignabert, PhD, Le Plessis Robinson, France
C.M. Hart, MD, Atlanta, GA

1001 **GADD45a Deficiency Protects from Hypoxic Pulmonary Hypertension Via Down-Regulation of UCHL1/**A. Gupta, G. Gupta, H. Tang, O. Rafikova, R. Rafikov, S.M. Black, R.F. Machado, J.R. Jacobson, B. Mathew, S. Mitra, J. Yuan, J.G.N. Garcia, A.A. Desai, Tucson, AZ, p.A3052

1002 **T Helper 17 Cells Contribute to Chronic Hypoxia-Induced Pulmonary Hypertension/**L.D. Maston, D.T. Jones, J.L. Cannon, W. Wang, Y. Wei, W. Xuan, T.C. Resta, L. Gonzalez Bosc, Albuquerque, NM, p.A3053

1003 **MicroRNA-1 Is Decreased by Hypoxia and Contributes to the Development of Experimental Pulmonary Hypertension via Regulation of Sphingosine Kinase 1 (SphK1)/**J.R. Sysol, J. Chen, S. Singla, V. Natarajan, R.F. Machado, Chicago, IL, p.A3054

1004 **Deficiency of Toll-Like Receptor 3 (TLR3) Exacerbates Pulmonary Hypertension in Mice/**A.A.R. Thompson, N.D. Arnold, A.T. Braithwaite, H.L. Casbolt, J.A. Pickworth, J.E. Cole, C. Monaco, D. Kiely, I. Sabroe, A. Lawrie, Sheffield, United Kingdom, p.A3055

1005 **Transcriptomic Profiling of Lung Macrophage Subsets in Hypoxic Pulmonary Hypertension Reveals a Time and Compartment Specific Activation/**S. Pugliese, W. Janssen, K. El Kasmi, K.R. Stenmark, Aurora, CO, p.A3056

1006 **Epoxyeicosatrienoic Acids (EETs) and 20-Hydroxyeicosatetraenoic Acid (20-HETE) Reduce Hypoxic Pulmonary Vasoconstriction in Isolated Ventilated and Perfused Mouse Lungs/**A. Erb, N. Sommer, R.T. Schermuly, J. Bier, M. Heipel, D. Peters, K. Quanz, W. Seeger, F. Grimminger, N. Weissmann, L. Kiss, Giessen, Germany, p.A3057

1007 **Molecular Mechanisms of Classical Transient Receptor Potential 1 (TRPC1) Dysregulation in Chronic Hypoxia-Induced Pulmonary Vascular Remodeling/**M. Malczyk, B. Fuchs, R.T. Schermuly, K. Ahlbrecht, W. Seeger, T. Gudermann, A. Dietrich, N. Weissmann, C. Veith, Giessen, Germany, p.A3058

1008 **The Effects of Chronic Cigarette Smoke Exposure on Cardiovascular Function in Mice/**G. Vanderstocken, M.A. Allwood, M.R. Stampfli, J.A. Simpson, Hamilton, Canada, p.A3059

1009 **Pathologic Matrix Stiffening Results in Vascular Remodeling Phenotypes and Altered COX2 Expression in Pulmonary Artery Endothelial Cells Via a YAP/TAZ Dependent Mechanism/**P. Dieffenbach, T. Boyd, C. Mallarino-Haeger, A. Coronata, D.J. Tschumperlin, L. Fredenburgh, Boston, MA, p.A3060

1010 **Lack of PDGF-B Retention Ameliorates Hypoxia-Induced Pulmonary Hypertension/**P. Tannenberg, E. Folestad, Y.-T. Chang, H. Gladh, L. Muhl, B. Lavina, G. Genove, C. Betsholtz, K. Tran-Lundmark, Stockholm, Sweden, p.A3061

1011 **Altered Interleukin-15 Signalling Complex and Lymphocyte Homeostasis in Hypoxic Pulmonary Hypertension/**S. Jafri, S. Moore, N.W. Morrell, M.L. Ormiston, Cambridge, United Kingdom, p.A3062

1012 **Maturation, Hypoxia, and α-Adrenergic Dependent Pulmonary Contractility in Sheep/**D. Moretta, Loma Linda, CA, p.A3063

1013 **The Role of the Mitochondrial Proteins p66shc and Cyclophilin D in Hypoxic Pulmonary Vasoconstriction and Chronic Hypoxia Induced Pulmonary Hypertension/**M. Gierhardt, N. Sommer, O. Pak, A. Sydykov, K. Quanz, A. Esfandiary, H.A. Ghofrani, R.T. Schermuly, W. Seeger, R. Schulz, N. Weissmann, Giessen, Germany, p.A3064

1014 **Chronic Hypoxia Does not Cause Wall Thickening of Intra-Acinar Pulmonary Supernumerary Arteries/**K. Oshima, J.M. McLendon, W.W. Wagner, Jr., I.F. McMurtry, M. Oka, Mobile, AL, p.A3065

1015 **Resveratrol Can Improve Chronic Hypoxia Induced Pulmonary Hypertension Only in Absence of Sirtuin 1 Catalytic Activity/** M. Taha, Y. Deng, M. McBurney, D.J. Stewart, Ottawa, Canada, p.A3066

1016 **Endosomal Proteins p18 and Rab4 Are Differentially Regulated in Pulmonary Hypertension and COPD/Emphysema/**H. Chichger, A. Vang, Q. Lu, G. Choudhary, E.O. Harrington, Cambridge, United Kingdom, p.A3067

1017 **Epigenetic Regulation of the Anti-Proliferative Transient Receptor Potential Melastatin 8 (TRPM8) Channels of Pulmonary Arterial Smooth Muscle Cells in Hypoxic Pulmonary Hypertension/**J.S.K. Sham, O. Paudel, W.-Y. Tang, Baltimore, MD, p.A3068

1018 **Plasma Levels of Angiopoietin-2 in COPD: Effects of Smoking and Pulmonary Hypertension/**V.I. Peinado, J. Garcia-Lucio, T. Paul, O. Tura, I. Blanco, J.A. Barbera, Barcelona, Spain, p.A3069

1019 **RASSF1A Regulates ROS-HIF Axis in Hypoxia Driven Pulmonary Hypertension/**S. Dabral, C. Muecke, M. Schmoranzer, C. Valsarajan, A. Weitelmann, R. Savai, W. Seeger, R. Dammann, S.S. Pullamsetti, Bad Nauheim, Germany, p.A7808

POSTER DISCUSSION SESSION

B28 ADVANCES IN STEM CELLS IN INJURY AND REPAIR FOR 2016

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 2014 (West Building, Level 2)

Poster Viewing **9:00-9:45**

Discussion **9:45-11:00**

501 **Human Bone Marrow Derived Mesenchymal Stem Cells and Their Released Microvesicles May Promote the Resolution of Acute Lung Injury in Mice in Part Through Inhibition of Multidrug Resistance-Associated Protein 1/**Q. Hao, V. Gudapati, A. Monsel, H. Lim, J.-W. Lee, San Francisco, CA, p.A3070

502 **Generation of Purified Human Type II Alveolar Cells from Gene-Edited Pluripotent Stem Cells/**A. Jacob, F. Hawkins, K. Benson, M. Serra, D.N. Kotton, Boston, MA, p.A3071

503 **Mesenchymal Stem Cells Drive Cell Repopulation In an In Vivo Model of Lung Regeneration/**J. Sembrat, C. Caufield, N. Cardenes, R.R. Vanderpool, M. Bennewitz, S. Snovida, P. Sundd, M. Rojas, Pittsburgh, PA, p.A3072

504 **The Role of BMP Signaling in Deriving Endothelial Cells from Human Pluripotent Stem Cells/**M. Jamal, N. Ruopp, N. Prasain, J.C. Jean, E.D. Austin, S. Majka, M. Yoder, D.N. Kotton, Boston, MA, p.A3073

505 **Human Umbilical Cord Mesenchymal Stromal/Stem Cells Reduce Lung Injury in Rodent E. Coli Pneumonia by Modulating Innate Immunity/**M. Jerkic, A. Wolchuk, S. Dixon, G. Hogan, X. Xu, C. Masterson, G.F. Curley, J.G. Laffey, Toronto, Canada, p.A3074

506 **Bone Marrow Derived Human Mesenchymal Stem Cells Exposed to Pro-Inflammatory Cytokines Lose their Mesenchymal Marker Expression and Transform into Cells with Antigen Presenting Cell Gene Expression Patterns/**M. Schwede, E.M. Wilfong, C.S. Calfee, M. Matthay, San Francisco, CA, p.A3075

507 **Characterizing Embryonic Stem Cell Derived Multipotent Lung Stem Cells/**A. Kidiyoor, S. Murphy, A. Atala, Winston Salem, NC, p.A3076

508 **Human Bone Marrow-Derived Mesenchymal Stem Cells May Modulate TLR4 Signaling to Favorably Affect Human Alveolar Type II Cell Function in an In Vitro Model of Acute Lung Injury/**E.M. Wilfong, M. Schwede, X. Fang, J.W. Lee, C.S. Calfee, M.A. Matthay, San Francisco, CA, p.A3077

509 **Patient-Derived Airway Stem Cells in Human Lung Bio-Engineering/**S.E. Gilpin, J.M. Charest, L.F. Tapias, X. Ren, T. Wu, D.J. Mathisen, H.C. Ott, Boston, MA, p.A3078

510 **Mesenchymal Stem Cells Attenuate Hypoxia-Induced Pulmonary Epithelial Injury Via an NF-κB Dependent Paracrine Mechanism/**N. Shologu, D. O'Toole, M. Scully, J. Laffey, Galway, Ireland, p.A3079

511 **Forkhead BOX F1 Is a Novel Regulator of Autotaxin and Modulates Migration of Human Lung-Resident Mesenchymal Stem Cells/**P. Cao, N. Walker, S. Mazzoni, Y. Aoki, V. Lama, Ann Arbor, MI, p.A3080

512 **Modified Mesenchymal Stem Cells Using miRNA Transfection Could Modify Lung Fibrosis Progression/**J. Sellares, L. Huleihel, N. Cardenes, D. Alvarez, K. Sakamoto, G. Yu, M. Kapetanaki, N. Kaminski, M. Rojas, Pittsburgh, PA, p.A3081

513 **Characteristics of Mesenchymal Stem Cells from Swine with and Without Acute Respiratory Distress Syndrome/**B. Antebi, R.K. Montgomery, K.P. Walker, J.S. McDaniel, A.T. Dixon, A.P. Cap, L.C. Cancio, A.I. Batchinsky, Fort Sam Houston, TX, p.A3082

514 **Polyunsaturated Fatty Acids Potentiate the Effects of Mesenchymal Stromal Cells in Sepsis-Induced Acute Respiratory Distress Syndrome/**J.D. Silva, J.Z. Kitoko, L.L. Castro, S.A.A. Trivelin, B.L. Diaz, P. Olsen, M.M. Morales, P.R.M. Rocco, Rio de Janeiro, Brazil, p.A3083

515 **Deficiencies in Mesenchymal Stem Cells from Idiopathic Pulmonary Fibrosis Patients Result in Lower Capacity to Protect the Lung from Injury/**N. Cardenes, D. Alvarez, C. Corey, S. Wecht, J. Sembrat, V.S. Hanumanthu, M. Bueno, J.S. Nine, S. Shiva, M. Armanios, A.L. Mora, M. Rojas, Pittsburgh, PA, p.A3084

516 **A Role for Mesenchymal Cell Telomerase Reverse Transcriptase in Pulmonary Fibrosis/**T. Liu, H. Yu, L. Ding, Z. Wu, F. Gonzalez De Los Santos, J. Liu, M. Ullenbruch, B. Hu, V. Martins, S.H. Phan, Ann Arbor, MI, p.A3085

517 **Dependence of Lung Epithelial Stem Cell Proliferation and Differentiation on Fibroblast-Specific FGF2 Signaling/**M. Ozaki, A. Hegab, R. Guzy, D. Ornitz, T. Betsuyaku, Tokyo, Japan, p.A3086

518 **Alveolar Epithelial Type II Cell-Specific Deletion of Foxo1 Results in Increased Stem/Progenitor Cell Proliferation In Vitro/**Y. Yeragunta, D.R. Castillo, M. Rieger, J.M. Liebler, P. Flodby, B. Zhou, E.D. Crandall, Z. Borok, Los Angeles, CA, p.A3087

519 **Runt-Related Transcription Factor 2 (Runx2) Regulates Mesenchymal Cell Differentiation and Extracellular Matrix Production in Pulmonary Fibrosis/**C. Mummler, S. Vierkotten, K. Mutze, A. Gunther, M. Konigshoff, Munich, Germany, p.A3088

520 **Human Bone Marrow-Derived Mesenchymal Stem Cell Conditioned Medium Enhance Autophagy to Reduce the Severity of Lipopolysaccharide-Induced Acute Lung Injury/**J. Li, D. Zhang, J. Zhou, C. Bai, Shanghai, China, p.A3089

521 **Mesenchymal Stem Cell Microvesicles Restore Protein Permeability Across Primary Cultures of Injured Human Lung Microvascular Endothelial Cells/**S. Hu, J. Park, H. Lim, Q. Hao, J.W. Lee, San Francisco, CA, p.A3090

522 **The Fate and Function of Mesenchymal Stromal Cells in a Septic Model of ARDS/**C. Masterson, A. Tabuchi, W.M. Kuebler, J.G. Laffey, G.F. Curley, Toronto, Canada, p.A3091

523 **Enhancing the Efficacy of Mesenchymal Stromal Cell Therapy for ARDS/**S. Horie, D. O'Toole, J.G. Laffey, Galway, Ireland, p.A3092

524 **CRISPR-Directed Editing Of Patient-iPSCs To Determine Genetic Contributors To ZAAT-Driven Proteotoxicity/**J. Kaserman, F.J. Molina Estevez, G.C. Lonza, G. Mostoslavsky, D.N. Kotton, A. Wilson, Boston, MA, p.A3093

525 **TALEN-Targeted NKX2-1-GFP iPSC Define a Gene and Surface Marker Signature of iPSC-Derived Lung Progenitors/**F. Hawkins, P. Kramer, A. Jacob, I. Driver, J.R. Rock, J. Shannon, B. Davis, D.N. Kotton, Boston, MA, p.A7809

POSTER DISCUSSION SESSION

B29 A STATE OF UNREST: SLEEP/SDB IN THE ICU AND HOSPITAL

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**
Room 3001 (West Building, Level 3)

Poster Viewing **9:00-9:45**

Discussion **9:45-11:00**

Chairing: R.L. Owens, MD, La Jolla, CA
S. Sharma, MD, Philadelphia, PA
J.S. Balachandran, MD, Mequon, WI

701 **Sleep-Disordered Breathing Is of High Prevalence in Patients with Acute Cardiac Decompensation/**H. Fox, T. Bitter, D. Horstkotte, O. Oldenburg, Bad Oeynhausen, Germany, p.A3094

702 **Can Disrupted Sleep Affect Mortality in the Mechanically Ventilated Critically Ill?/**P.C. Shah, E. Yudelevich, F. Genese, M. Martillo, I.B. Ventura, K. Fuhrmann, M. Mortel, D. Levendowski, C.D. Gibson, P. Ochieng, R. Jean, New York, NY, p.A3095

703 **Day-Night Activity Rhythms Are Disrupted in Children Admitted to the Pediatric ICU After Major Surgery/** S.R. Kudchadkar, N. Shata, O.A. Aljohani, A. AlHarbi, E. Jastaniah, A. Nadkarni, J. Johns, C. Crainiceanu, N. Punjabi, Baltimore, MD, p.A3096

704 **Impact of Light on Sleep Fragmentation in Patients Being Weaned from Prolonged Mechanical Ventilation/**F. Ghods, Y. Park, F. Laghi, M. Tobin, A. Jubran, H. Shaikh, Hines, IL, p.A3097

705 **The Challenges of Sleep in the ICU: The Significance of Sedatives on Sleep Architecture/**K.A. Fuhrmann, M. Martillo, F. Genese, I.B. Ventura, E. Yudelevich, P.C. Shah, A. Basu, C.D. Gibson, P. Ochieng, R. Jean, New York, NY, p.A3098

706 **SOLAR: A Quality Improvement Project to Enhance Sound, Light, And Circadian Rhythms in the ICU/**L. Barnes, R. Barr, K. Mallen, E. Rockafellow, T. Hamieh, S. Jain, K. Crawford, T. Peters, B.K. Gehlbach, Iowa City, IA, p.A3099

707 **Provider and Patient Perceptions to a Quality Improvement Intervention (SOLAR) to Improve Sleep in the ICU/**S. Jain, L. Barnes, C. Bombei, L. Comried, K. Doerschug, B.K. Gehlbach, Iowa City, p.A3100

708 **Sleep Quality and the Use of Sleep Promoting Interventions in Intensive Care Patients/**A. Datt, R. Elliott, S. McKinley, Sydney, Australia, p.A3101

709 **Impact of Earplugs and Eye Mask on Sleep in Critically Ill Patients: A Prospective Randomized Study/**A. Demoule, S. Carreira, S. Lavault, O. Palancca, E. Morawiec, J. Mayaux, I. Arnulf, T. Similowski, Paris, France, p.A3102

710 **Circadian Rhythms in Survivors of Critical Illness Is Related to Acuity of Illness/**R. Daulat, R. DeArmond, D. Combs, S. Shetty, S. Parthasarathy, Tucson, AZ, p.A3103

711 **Adherence of Heart Failure Patients Diagnosed with Sleep Disordered Breathing During Hospitalization/**A. Chakraborty, A. Chowdhury, P.J. Mather, S. Sharma, L. Willes, Philadelphia, PA, p.A3104

712 **The Effectiveness of Early Postoperative Noninvasive Ventilation in Patients Undergoing Bariatric Surgery/**M.S. Stefan, P.K. Lindenauer, X. Liu, P. Pekow, N. Hill, S. Memtsoudis, K. Raghunathan, S. Ramachandran, Springfield, MA, p.A3105

713 **Comparisons of a Home-Based Approach Versus the Hospital-Based Approach in Managing Patients with Suspected Obstructive Sleep Apnea Syndrome/**D.S.C. Hui, S. Ng, K.W. To, F. Ko, J. Ngai, K. Yiu, T.O. Chan, W.W. S. Tam, Shatin, Hong Kong Prc, p.A3106

714 **High-Resolution Pulse Oximetry as a Cost Effective Method to Screen Sleep Apnea in Hospitalized Patients/**D.A. Kahn, U. Mukhtar, U. Shaukat, P.J. Mather, L. Willes, S. Sharma, Philadelphia, PA, p.A3107

715 **Sleep Apnea Screening Program in the Hospital Increases Awareness Among House Staff/**M. Tan, A. Adams, K. Flemmings, L. Willes, S. Sharma, Philadelphia, PA, p.A3108

716 **CPAP Non-Compliance Increases Risk for 30-Day Readmission in Obstructive Sleep Apnea Patients/**K.K. Truong, M. Ross, N. Massoudi, M. Hashemzadeh, B. Jafari, Orange, CA, p.A3109

717 **CPAP Issues: A Factor in Excessive Pulmonary Readmissions/**N. Kotecha, A. Diaz Chavez, M. O'Sullivan, D. Fortune, J. Podell, P. Loveday Casey, G. Burke, E. Eden, New York, NY, p.A3110

718 **Health Resource Utilization of Asthma Hospitalizations with Comorbid Sleep Apnea and Obesity: Results from the Nationwide Inpatient Sample/**M.B. Becerra, B.J. Becerra, M. Teodorescu, San Bernardino, CA, p.A3111

719 **Does Sleep Quantity and Quality Differ in ICU Patient with and Without Delirium?/**K.J. Bosma, D. Ovakim, M. Sen, G.K. Dresser, P. Jones, London, Canada, p.A3112

POSTER DISCUSSION SESSION

B30 MOLECULAR AND IMMUNOLOGICAL ASPECTS OF LUNG CANCER

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 309 (South Building, Esplanade Level)

Author Summaries **9:00-9:30**

Poster Viewing/Discussion **9:30-11:00**

Chairing: C.A. Powell, MD, New York, NY

301 **Low Density Deutrophils (LDN) - a Newly Described Subset of Tumor-Permissive Circulating Neutrophils in Advanced Lung Cancer/**Z.G. Fridlender, O. Eyal, J. Michaeli, P. Damti, J.Y. Sagiv, I. Mishalian, M. Shaul, Z. Granot, Jerusalem, Israel, p.A3113

302 **Suppression of B Lymphopoiesis by Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice/**J.S. Deshane, Y. Wang, C.C. Schafer, J.F. Kearney, H.-C. Hsu, Birmingham, AL, p.A3114

303 **Highly Exhausted T Cell Subsets in Human NSCLC Are Co-Defined by the Predominant Expression of Distinct Inhibitory Receptors/**W.A. Moersig, D.S. Thommen, F. Uhlenbrock, P. Herzig, S. Savic Prince, A. Zippelius, D. Lardinois, Basel, Switzerland, p.A3115

304 **Potential of Autoimmune Response Against Tumor-Associated Antigens to Predict Risk of Developing Lung Cancer/**J.J. Tsay, L. Dai, T.-A. Yie, J. Munger, H. Pass, E. Tan, J. Zhang, W.N. Rom, New York, NY, p.A3116

305 **Characterizing the Role of Immune Cells in the FGF9-Induced Lung Adenocarcinoma Mouse Model/**A.E.M. Hegab, T. Kinoshita, T. Yaguchi, Y. Kawakami, D. Ornitz, T. Betsuyaku, Tokyo, Japan, p.A3117

306 **Cytotoxic T Lymphocyte Antigen 4 (CTLA4) in Non-Small Cell Lung Cancer/**J. Li, H. Zhang, P. Dutta, N. Sabri, W.X. Li, La Jolla, CA, p.A3118

307 **Impact Of Interleukin-22 On K-ras Mutant Lung Cancer Promotion And Stemness Properties/**N. Khosravi, A.M. Cumpian, S. Daliri, M.S. Caetano, S.J. Moghaddam, Houston, TX, p.A3119

308 **IL-17-Mediated Inflammation Promotes Cigarette Smoke-Induced Genomic Instability/**C. Cao, H. Zhou, B. Tian, Z. Chen, W. Li, S. Ying, H. Shen, Hangzhou, China, p.A3120

309 **Tumor-Suppressive microRNAs Modulate Oncogenic Signaling Pathways in Lung Squamous Cell Carcinoma/**H. Mataki, A. Uchida, T. Kumamoto, K. Kamikawaji, K. Mizuno, H. Inoue, Kagoshima, Japan, p.A3121

310 **Deep Sequencing Reveals Unique MicroRNA Profile Alterations in Serum of Lung Cancer Patients that Depends on Cigarette Smoking/**B. Ortiz-Quintero, L.V. Gayosso-Gomez, R. Falfan-Valencia, P. Castillo-Gonzalez, R. Sansores, A. Ramirez-Venegas, M.E. Vazquez-Manriquez, Mexico City, Mexico, p.A3122

311 **Expression of MiR-200c Associates with Overall Survival and Progression Free Survival Under Epidermal Growth Factor Receptor- Tyrosine Kinase Inhibitor (EGFR-TKI) of Non Small Cell Lung Cancer (NSCLC) Patient Harboring EGFR Common Mutation/**H.-Y. Wang, J.-Y. Shih, Yunlin County, Taiwan, p.A3123

312 **Intracellular Redox Active Metal Ions Mediate the Differential Susceptibility of NSCLC Cells to Pharmacological Ascorbate/**J.D. Schoenfeld, Z.A. Sibenaller, K. Cramer-Morales, C.M. Doskey, K.A. Mapuskar, K.R. Parekh, J.C. Keech, J.J. Cullen, G.R. Buettner, F.R. Domann, D.R. Spitz, B.G. Allen, Iowa City, IA, p.A3124

313 **Lung Cancer Associations Are Enriched for Regulatory Variants in Non-Tumor Lung Tissue/**M. Obeidat, Y. Nie, Y. Bosse, M. Laviolette, K. Hao, D.C. Nickle, D.S. Postma, W. Timens, R.J. Hung, W.L. Lam, E.A. Vucic, P.D. Pare, D.D. Sin, Vancouver, Canada, p.A3125

314 **Novel Regulators of Metastases in Lung Squamous Carcinoma/**A. Belanger, A. Porrello, S. Azam, S. Ghosh, T. Waugh, M. Smith, C. Pecot, Chapel Hill, NC, p.A3126

315 **Overexpression of Slug Drives Malignant Phenotypes in Models of Lung Premalignancy and Cancer/**B.S. Grimes, T.C. Walser, R. Li, Z. Jing, L. Tran, S.M. Dubinett, Los Angeles, CA, p.A3127

316 **LincRNA-p21 Impacts Prognosis in Non-Small Cell Lung Cancer Adenocarcinoma Patients/**J. Moises, J. Castellano, J. Ramirez, A. Cordeiro, N. Vinolas, A. Saco, M. Ruiz, S. Santasusagna, F. Aya, L. Molins, A. Navarro, M. Monzo, R.M. Marrades, Barcelona, Spain, p.A3128

317 **Ciz1b Variant as a Surrogate Marker in Surveillance of Lung Cancer Recurrence/**V. Ifeacho, M. Risco, A. Ryazantsev, O. James, G. Rubiaco, K. Almodovar, D. Upadhyay, Fresno, CA, p.A3129

318 **Long Non-Coding RNA FAM83H-AS1 Promotes Tumor Progression and Related to Disease Free Survival in Lung Adenocarcinomas/**J. Zhang, Xi'an, China, p.A3130

319 **MARCKS-Inhibitory Peptides Synergize with Cisplatin to Inhibit Metastasis and Primary Tumor Growth in Mouse Orthotopic Lung Cancer Models/**Q. Yin, S. Fang, J. Park, A. Crews, I. Parikh, B. Dickson, K. Adler, Raleigh, NC, p.A3131

320 **Cancer Associated Fibroblast Promotes Non-Small Cell Lung Cancer Invasiveness by Activating GRP78 Expression on an Integreated Bionic Microfluidic Device/**Q. Wang, T. Yu, Z. Guo, Dalian, China, p.A3132

321 **Folylpoly-γ-Glutamate Synthase (FPGS) Single Nucleotide Polymorphism (SNP) Is Associated with Response to Pemetrexed Treatment for Non-Small Cell Lung Cancer/**S. Fukuda, T. Oguri, T. Uemura, Y. Kanemitsu, O. Takakuwa, H. Ohkubo, M. Takemura, K. Maeno, A. Niimi, Nagoya City, Japan, p.A3133

322 **Arsenic Trioxide Inhibits Cancer Stem Cells Via Down-Regulation of Hedgehog Pathway in Lung Cancer/**B. Li, M.-H. Yang, K.-J. Chang, Shanghai, China, p.A3134

323 **Synergy Between Anti-MARCKS Peptides and Chemotherapeutic Agents in Attenuation of NSCLC Metastasis and Tumor Growth Could Be Based on MARCKS Cell Cycle Regulation/**S. Fang, Q. Yin, J. Park, A. Crews, B. Dickson, K. Adler, Raleigh, NC, p.A3135

324 **p16 Controls Lung Epithelial Cell Growth and Suppresses Transformation Through Mechanisms that Do Not Require Retinoblastoma (Rb) Function/**M. Sen, N. Akeno, A. Reece, D.S. Simpson, K.A. Wikenheiser-Brokamp, Cincinnati, OH, p.A3136

325 **Cigarette Smoke Extract Exposure Induces EGFR-TKI Resistance in EGFR-Mutated NSCLC Via Mediating Src Activation and EMT/**H. Chen, D. Li, L. Zhang, J. Zhou, Chongqing, China, p.A3137

THEMATIC POSTER SESSION

B31 ALPHA-1 ANTITRYPSIN DEFICIENCY

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area B, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: C.E. Cross, MD, Sacramento, CA

P135 **The Clinical Associations of Aα-Val360 in Alpha 1-Antitrypsin Deficiency/**E.V. Low, P.R. Newby, R.G. Edgar, R.A. Stockley, A.M. Turner, Birmingham, United Kingdom, p.A3138

P136 **A Comparison of the Inflammatory Immune Cell Infiltration Associated with Lung Tissue Destruction in Panlobular Emphysema in Alpha-1 Antitrypsin Deficiency and Centrilobular Emphysema Associated with Smoking/**D. Kinose, D.M. Vasilescu, T.-L. Hackett, W.M. Elliott, F. Chu, S. Verleden, B.M. Vanaudenaerde, J.D. Cooper, J.C. Hogg, Vancouver, Canada, p.A3139

P137 **PRMT6 Mediates Inflammation, Apoptosis and Oxidative Stress in a Cigarette Smoke Extract-Induced Mouse Emphysema Model/**X. He, Y. Chen, N. Kang, T. Li, H. Zeng, Z. Chen, Changsha, Hunan, China, p.A3140

P138 **Longitudinal Three-Year Decline in Alpha-1 Antitrypsin Deficiency: Regional Worsening in Emphysema and Ventilation/**E. Lessard, A. Ouriadov, D. Pike, D.G. McCormack, G. Parraga, London, Canada, p.A3141

P139 **Cela1 Promotes Postnatal Alveolar Enlargement and Its Expression and Binding to Elastin Is Regulated by Stretch/**B. Varisco, S. Liu, R. Joshi, Cincinnati, OH, p.A3142

P140 **Overview of Multicenter Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) and Biorepository/**T. Adams, T. Woolard, G. DeIuliis, M. Vukmirovic, X. Yan, N. Aurelien, H. Buqu, H. Lynn, S. O'Neal, M. Becich, H. Hochheiser, D.R. Moller, K. Gibson, C.B. Strange, R.A. Sandhaus, R.M. Senior, E.S. Chen, A. Wyllie, A.M. Morris, B. Methe, E. Ghedin, J.K. Leader, N. Petro, Y. Zhang, L. Silfies, D. Protivnak, M. Martinez, S.R. Wisniewski, N. Kaminski, New Haven, CT, p.A3143

P141 **The Role of Glycosylation of Alpha-1 Antitrypsin in Inflammation Resolution/**D.M. Dunlea, O.J. McElvaney, N. Lacey, M. White, C. McCarthy, P. Hawkins, E. Reeves, N.G. McElvaney, Dublin, Ireland, p.A3144

P142 **Characterization of the Lung Microbiota of Alpha-1 Antitrypsin Deficient Individuals/**M.E. Kirst, J. Nolte, J. Lascano, F. Rouhani, M.L. Brantly, Gainesville, FL, p.A3145

THEMATIC POSTER SESSION

B32 ALVEOLAR MACROPHAGE BIOLOGY

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area B, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: R. Vlahos, PhD, Bundoora, Australia

P146 **cFLIP Is Required for the Maintenance of Embryonic-Derived Alveolar Macrophages/**A.L. McCubbrey, L. Barthel, W. Janssen, Denver, CO, p.A3146

P147 **Autoantibody Against GM-CSF Presented by MHC Class II in Autoimmune Pulmonary Alveolar Proteinosis/**Y. Hamano, H. Kida, M. Hirose, A. Matsumuro, T. Suenaga, H. Sarashina, T. Hamasaki, Y. Inoue, H. Arase, A. Kumanogoh, Suita, Japan, p.A3147

P148 **Recruitment and Proliferation of Macrophage Polarization States During Allergic Lung Inflammation/**C. Draijer, C.E. Boorsma, E. Post, F. Van Dijk, B.N. Melgert, Groningen, Netherlands, p.A3148

P149 **Rac2 Promotes Alternative Macrophage Activation in Bleomycin Induced Pulmonary Fibrosis/**S. Joshi, A. Singh, S. Wong, M. Zulcic, V. Craig, J. Hagood, D. Durden, San Diego, CA, p.A3149

P150 **FoxO1 Mediates Asthmatic Lung Inflammation by Promoting Alternative Activation of Pulmonary Macrophages/**S. Chung, B. Reader, J.Y. Kim, Y.G. Lee, M. Karpurapu, M.N. Ballinger, G.Y. Park, J. Christman, Columbus, OH, p.A3150

P151 **Effect of Nintedanib on Pro-Fibrotic and Anti-Fibrotic Cytokine Release from Alveolar Macrophages in Interstitial Lung Diseases/**F. Bonella, X. Long, X. He, D. Theegarten, T.E. Wessendorf, J. Guzman, U. Costabel, Essen, Germany, p.A3151

P152 **Ghrelin Treatment Decreases Lung Inflammation and Fibrogenesis by Inducing M2 Macrophage Polarization/**N.N. Rocha, M.D.O. Vasconcellos, C.B. Lisboa, G. Guimaraes, G.D.A. Padilha, L.A. Maia, J.D. Silva, C.M. Takiya, V. Capelozzi, P.L. Silva, P.R.M. Rocco, Rio de Janeiro, Brazil, p.A3152

Facilitator: A.M. Manicone, MD, Seattle, WA

P153 **BRD9 Is a Novel Epigenetic Regulator for Human Alveolar Macrophages Polarization/**Y. Morias, A. Schinwald, T. Naessens, H. Boyd, D. Cunoosamy, Molndal, Sweden, p.A3153

P154 **Induction of IL-17Rb and IL-25 in Human Monocytes and Macrophages Through the Action of Th2 Cytokine IL-4/**N. Weathington, S.M. Kanth, J.S. Bednash, Q. Gong, R. Mallampalli, Pittsburgh, PA, p.A3154

P155 **The Effect of Tiotropium Bromide in Development of M2 Macrophages in Murine Model of Asthma/**M. Jinno, S. Ohta, A. Tanaka, A. Fujiwara, Y. Uchida, R. Manabe, H. Furukawa, N. Kuwahara, Y. Fukuda, T. Kimura, K. Hirai, Y. Miyata, T. Homma, M. Yamamoto, Y. Watanabe, T. Yokoe, H. Sagara, Tokyo, Japan, p.A3155

P156 **Decellularized Wild Type and α-Galactosyltransferase Knockout Pig Lungs Stimulate M2 Phenotype in Human Monocyte/Macrophages/**S. Wrenn, A. Coffey, F.E. Uhl, J. Bianchi, B. Dacken, T. Petersen, D.E. Wagner, J.E. Boyson, D.J. Weiss, Burlington, VT, p.A3156

P157 **Distinct Profiles of M2 Macrophage Markers Among Idiopathic Interstitial Pneumonias/**M. Yamashita, R. Saito, M. Ogasawara, Y. Fukuda, H. Sasano, T. Sugai, K. Yamauchi, Morioka, Japan, p.A3157

P158 **SP-R210 (Myo18A) Isoforms as Intrinsic Modulators of Macrophage Priming and Activation/**Z.C. Chroneos, L. Yang, M. Carrillo, Y. Wu, S. Diangelo, P. Silveyra, T.M. Umstead, E.S. Halstead, M. Davies, S. Hu, J. Floros, F.X. McCormack, N.D. Christensen, Hershey, PA, p.A3158

P159 **Critical Role of the Class A Scavenger Receptor on Alveolar Macrophages in Chronic Obstructive Pulmonary Disease Airway Inflammation/**R. Dong, L. Xie, M. Zhou, Shanghai, China, p.A3159

Facilitator: S. Sengupta, MD, MPH, Philadelphia, PA

P160 **Ethanol-Induced Oxidative Stress and Altered AMPK Signaling in Human Alveolar Macrophages/**L. Kaphalia, B.S. Kaphalia, W.J. Calhoun, Galveston, TX, p.A3160

P161 **S-nitrosoglutathione Reductase (GSNOR) Deficiency Impairs Macrophage Phenotypic Differentiation/**C. Guo, J. Gow, M. Govendraj, A.J. Gow, Piscataway, NJ, p.A3161

P162 **Ursolic Acid Inhibits Cigarette Smoke-Induced Alveolar Macrophages Activity Injury Via ERK Signaling Pathway/**Y. Yin, G. Hou, Q. Wang, E. Li, J. Kang, Shen Yang City, China, p.A3162

P163 **Increased Number of Macrophages in the Induced Sputum for Patients with Acute Myocardial Infarction/**N. Kononova, G. Einvik, A. Hoiseth, A. Neukamm, T. Omland, V. Søyseth, Oslo, Norway, p.A3163

P164 **Alveolar Macrophage-Mediated Efferocytosis in Alpha-1 Antitrypsin Deficiency/**U. Parthasarathy, K. Krotova, M. Brantly, Gainesville, FL, p.A3164

P165 **miR-451 Regulates Allergic Lung Inflammation Via Sirt2-Mediated Alternative Macrophage Activation/**Y.G. Lee, S. Chung, M. Karpurapu, M.N. Ballinger, B.F. Reader, J. Deng, Q. Feng, J. Christman, Columbus, OH, p.A3165

THEMATIC POSTER SESSION

B33 ANTIOXIDANTS, VITAMINS AND RELATED PATHWAYS IN AIRWAYS DISEASE

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area B, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: J.S. Deshane, PhD, Birmingham, AL

P169 **Vitamin E Isoform γ-Tocotrienol Attenuates Cigarette Smoke-Induced Chronic Obstructive Pulmonary Disease/** H.Y. Peh, W.D. Tan, T.K. Chan, C.N. Ong, W.F. Wong, Singapore, Singapore, p.A3166

P170 **Impact of Vitamin D3 Deficiency on Airway Vitamin D Metabolism and Inflammation in a Murine Model of Atopic Chronic Rhinosinusitis/**J.K. Mulligan, R. Schlosser, W. Pasquini, B.P. O'Connell, C. Atkinson, Charleston, SC, p.A3167

P171 **Cord Blood Vitamin D Levels and Gene Expression Profiles at Birth Are Associated with Wheezing in the First Year of Life: Results from the Vitamin D Antenatal Asthma Reduction Trial (VDAART)/**A. Al Garawi, V.J. Carey, W. Qiu, H. Mirzakhani, A.A. Litonjua, S.T. Weiss, Boston, MA, p.A3168

P172 **Vitamin D Supplementation in Pregnant Women of Different Races and the Risk of Asthma/Recurrent Wheeze in the Child: Findings from the Vitamin D Antenatal Asthma Reduction Trial (VDAART)/**H.M. Wolsk, B.J. Harshfield, N. Laranjo, V.J. Carey, G.T. O'Connor, M. Sandel, R.C. Strunk, L.B. Bacharier, R.S. Zeiger, M. Schatz, B.W. Hollis, S.T. Weiss, A.A. Litonjua, Boston, MA, p.A3169

P173 **Effect of Vitamin D on Cytokines Gene Expression and Corticosteroid Receptors of Asthmatic Patients in the United Arab Emirates/**B. Mahboub, A. Alzaabi, R.M. Seliem, L.I. Salameh, S.M. Toor, F.S. Shendi, O.M. Al Ali, B.K. Saffarini, W.T. Erabia, A. Mogas, S. Audusseau, V. Narayanan, Q. Hamid, Sharjah, United Arab Emirates, p.A3170

P174 **Age and Gender-Specific Protective Effects of Superoxide Dismutase in Asthma Severity/**S.A.A. Comhair, S.M. Baicker-McKee, E. Bleeker, M. Castro, J.V. Fahy, E. Israel, N. Jarour, B.D. Levy, D. Mauger, S.E. Wenzel, W.G. Teague, B. Gaston, S.C. Erzurum, Cleveland, OH, p.A3171

Facilitator: C. Taube, MD, Leiden, Netherlands

P175 **Superoxide Dismutase Activity, Oxidative DNA Damage, and Nitric Oxide in Ethiopian High Altitude Populations/**A.J. Janocha, A. Gebremedhin, A. Khan, K.S. Ricci, L. Monocello, R. Zhang, S.A.A. Comhair, S.C. Erzurum, C.M. Beall, Cleveland, OH, p.A3172

P176 **Airway Adaptation in a Murine Model of Irritant-Induced Asthma Is Dependent on the Foxp3 Pathway but Not on Regulatory T Cells/**B. Allard, S. Farahnak, A. Panariti, J. Downey, T. McGovern, S. Ano, G. Kaufman, B. Mazer, W. Powell, M. Divangahi, J.G. Martin, Montreal, Canada, p.A3173

P177 **Effects of Aqueous and Hydroethanolic Pyrostegia Venusta Extracts in an Experimental Model of Allergic Asthma/**A.C. Balestra, C. Sandy, A.M.S. Pereira, F. Carmona, M.C. Borges, Ribeirao Preto, Brazil, p.A3174

P178 **The Process of Development of Lung Fibrosis in the Rheumatoid Arthritis Lung Model and the Effect of H2 Treatment in D1CC Mice/**Y. Terasaki, N. Kokuho, M. Terasaki, S. Kunugi, H. Urushiyama, M. Maruyama, T. Akimoto, S. Kanazawa, Tokyo, Japan, p.A3175

P179 **Nrf2 Mediates the Antioxidant Response to Organic Dust-Induced Oxidative Stress In Vivo and In Vitro/**T. McGovern, M. Chen, S. Farahnak, M. O'Sullivan, S. Ano, B. Allard, K. Larsson, J.G. Martin, M. Adner, Montreal, Canada, p.A3176

P180 **The Antioxidant Transcription Factor Nrf2 Is an Important Regulator of Th17 Development/**T.J. Chapman, S. Hillman, S. Knowlden, S. Georas, Rochester, NY, p.A3177

P181 **Rapid Vs Slow Supplementation of Vitamin D-Deficient Asthmatic Children: A Randomized Study/**B.L. Davidson, K. Alansari, K.I. Yousef, I. Alattar, Burien, WA, p.A7810

THEMATIC POSTER SESSION

B34 CASE REPORTS IN IMMUNODEFICIENCES AND ALLERGY

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area B, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: N.A. Parada, MD, New Orleans, LA

P184 **Interstitial Lung Disease Associated with HIV/**J. Lee, N. Ali, H. Nazir, H. Seethamraju, Newark, NJ, p.A3178

P185 **A Japanese Patient Diagnosed Good Syndrome with Prolonged Time After Thymectomy/**T. Nishizawa, D. Kurai, T. Saraya, H. Ishii, H. Takizawa, Mitaka Tokyo, Japan, p.A3179

P186 **Ground Glass Nodules and Cough in an Individual with Common Variable Immunodeficiency/**P. Vishwasrao, K. Yaddanapudi, J. Davis, T. Gabig, A. Desai, Stony Brook, NY, p.A3180

P187 **Not Every Wheezing Is Asthma: A Case of Hypersensitivity Pneumonitis/**H. Bhartee, A.V. Chandran, J. Devasahayam, Y. Oba, Columbia, MO, p.A3181

P188 **Intravenous Immunoglobulin as a Steroid-Sparing Agent to Treat Refractory Bronchiolitis Obliterans in a Patient Without Sinopulmonary Infections/**C. Halpin, E. McGovern, J. Hoag, Philadelphia, PA, p.A3182

P189 **To Steroid, or Not to Steroid: A Case Study Reviewing Controversial Corticosteroid Treatment in Levamisole-Induced Leukocytoclastic Vasculitis/**K. Gupta, P. Aleksiejuk, A. Kalakonda, P. Kohlitz, Syracuse, NY, p.A3183

P190 **Anaphylaxis to Vancomycin in Setting of IL-2 Induced Eosinophilia/**D. Mann, M. Wong, B. Schneider, B. Modena, R. Sell, La Jolla, CA, p.A3184

P191 **Two Tumours, Neuropathy, Infections/**K. Bhaskar, G. Paramjyothi, A.K. Meena, N. Narendra Kumar, N. Ismail, B. Rajendra Prasad, S. Laxma Reddy, K. Vara Prasad, Hyderabad, India, p.A3185

Facilitator: R. Sehmi, PhD, Hamilton, Canada

P192 **Primary Effusion Lymphoma and Initiation of HAART in a Critically Ill Patient with AIDS/**A. McCambridge, C. Zhang, J. O'Horo, P. Escalante, Rochester, MN, p.A3186

P193 **Rare Presentation of Selective Immunoglobin M Deficiency in Patient with Recurrent Pneumonia/**R. Hsiao, M. McCarra, T. Sharma, San Diego, CA, p.A3187

P194 **E Cigarettes - 'Harmless Vapor' or 'Life Threatening Inhaled Toxin? A Case of Potential Laryngeal Edema Due to Electronic Cigarette Vapor Exposure Necessitating Intubation in a Young Woman/**Y. Naidu, A. Croake, N. Mehta, M. Jawish, D. Lingutla, Rochester, NY, p.A3188

P195 **Allergic Bronchopulmonary Aspergillosis Treated with Omalizumab/**A. Reyes Esteves, L.A. Soto, H. Bhatti, Orlando, FL, p.A3189

P196 **A Unique Presentation of DRESS/**M. Yaqoob, A. Alkhatib, C. Nader, Brighton, MA, p.A3190

P197 **A Case of Life Threatening Acute Isolated Uvular Edema/**S.M. Eikermann, G. Shanmuganatha, R.R. Holmes, C. Bulathsinghala, Corpus Christi, TX, p.A3191

P198 **The Interaction of Pulmonary and Extrapulmonary Complications of Common Variable Immunodeficiency Resulting in Severe Respiratory Failure/**A. Damodaran, D.E. Schraufnagel, Chicago, IL, p.A3192

P199 **A Rare Case of Angioedema/**R. Chugh, L. Gross, K. Keshava, A. Mahjoub, A.Y. Huang, Brooklyn, NY, p.A3193

THEMATIC POSTER SESSION

B35 INNOVATIONS IN MEDICAL EDUCATION

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area J, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: T.S. Wang, MD, Los Angeles, CA

P1049 **Development and Implementation of a Program to Train Critical Care Fellows in the Use of Point of Care Ultrasound in the Care of Critically Ill Patients/**S.P. Keller, D.J. Wallace, C.K. Schott, Pittsburgh, PA, p.A3194

P1050 **Standard Vs. Intensive Training in Critical Care Ultrasonography: Prospective Study at a Teaching Institution/**R. Suzuki, M. Kanai, K. Oya, Y. Harada, R. Horie, M.R. Obey, O. Gajic, S.V. Mankad, H. Sekiguchi, Rochester, MN, p.A3195

P1051 **Feasibility and Effectiveness of a Hands on Critical Care Ultrasound Training Course for Pulmonary Critical Fellows/**M. Nusrat, N. Pastis, T. Huggins, Charleston, SC, p.A3196

P1052 **Pilot Study: Implementation of a Comprehensive Bedside Ultrasound Curriculum for Internal Medicine Residents/**J. Keller, M. Wemple, B. Palen, Seattle, WA, p.A3197

P1053 **Applying Learning Theory to Develop a Course on Hemodynamic Monitoring of the Critically Ill Patient/**N.F. Chaisson, A. Kapoor, R. Ashton, A. Duggal, S. Krishnan, R.L. Chatburn, D. Rathz, A. Moghekar, C. Alviar-Restrepo, E. Mireles-Cabodevila, Cleveland, OH, p.A3198

P1054 **Using a Teaching Electronic Medical Record for Assessing Medicine Residents in the Care of Critically Ill Patients: A Pilot Study/**J. Smith, W.G. Carlos, D. Litzelman, Madison, WI, p.A3199

Facilitator: G.R. Connors, MD, New Haven, CT

P1055 **Pulmonary Fellows' Intubation Experience Outside of a Formal Airway Management Rotation/**A.K. Brady, T.V. Poon, R. Adamson, P.A. Kritek, Seattle, WA, p.A3200

P1056 **Medicine Housestaff and Nursing Knowledge of Tracheostomy Management and Complications/**K.G. Lazo, O. Ishikawa, D.M. Wisa, D.I. Zapata, K.-D. Lessnau, B. Mina, New York, NY, p.A3201

P1057 **Knowledge in Mechanical Ventilation Among Internal Medicine Residents Before and After a Respiratory ICU Rotation/**P.P.M.R. Ayres, A. Miethke-Morais, E.L.V. Costa, P. Caruso, C.S.V. Barbas, C.R.R. Carvalho, J.C. Ferreira, Sao Paulo, Brazil, p.A3202

P1058 **Baseline Knowledge of Mechanical Ventilation Among Incoming Interns Participating in a Boot Camp Training Prior to Starting an Internal Medicine Residency Program in Brazil/**R.B.M. Lima, E.M. Zeni, G.D.P. Lauterbach, L.G. Herbst, P.P.M.R. Ayres, A. Miethke-Morais, M.P.T. Nunes, J.C. Ferreira, Sao Paulo, Brazil, p.A3203

P1059 **Nutrition in Critical Care: Addressing the Need for Training and Improving Quality in Education/**L. Yuhico, M. Rath, R. Wehner, E. Mireles, Cleveland, OH, p.A3204

Facilitator: C.J. Schroedl, MD, Chicago, IL

P1060 **Overcoming Time and Room Limitations During In-Situ Simulations in the Intensive Care Unit/**J. Charnin, C. Arsenault, L. Mark, S. Muse, E. Eromo, Boston, MA, p.A3205

P1061 **Using High Fidelity Simulation to Integrate Fellow and Nursing Education to Improve Team Based Learning and Performance in the ICU/**J.A. Gold, R. Dottin, N. McCully, S.N. Nonas, Portland, OR, p.A3206

P1062 **The Effects of Structural Crew Resource Management (CRM)/Medical Team Work (MTW) Training in the ICU, the MTW Impact and Evaluation Study/**P.A. Katinakis, P.E. Spronk, Apeldoorn, Netherlands, p.A3207

P1063 **Analysis of Recording Methods to Facilitate Debriefing After Cardiac Arrest Resuscitation/**S.M. Kassutto, J.B. Kayser, M.P. Kerlin, G. Lipschik, M. Upton, W.D. Schweickert, Philadelphia, PA, p.A3208

P1064 **The Perceptions and Effects of Intern Duty Hour Changes in an Intensive Care Unit Rotation at a Community Teaching Hospital/**S. Thapa, R.D. Chow, Baltimore, MD, p.A3209

Facilitator: J.W. McAllister, MD, Columbus, OH

P1065 **Mobility in the ICU: A Fellowship Quality Improvement Educational Initiative/**V. Esguerra, C. Risaliti, A. Fee-Mulhearn, E. Jackson, Y. Negatu, A. Mahoney, D. Khabbaza, M. Exline, J. Kynyk, Columbus, OH, p.A3210

P1066 **Training Fellows to Triage Effectively/**V.K. Holden, A. Verceles, M.T. McCurdy, N.G. Shah, K. Robinett, Baltimore, MD, p.A3211

P1067 **"O Horror!" Similarities and Differences in Medical and Nursing Students' Identification of Hazards of Hospitalization in an Interprofessional Patient Safety Collaboration/**A.S. Clay, S.M. Chudgar, K. Turner, J. Farnan, J. Vaugh, M. Molloy, Durham, NC, p.A3212

P1068 **A Longitudinal Interprofessional Curriculum for Pediatric Critical Care Fellows Using Situated Cognition as a Theoretical Framework/**D. Castro, K. Roy, E.A. Williams, J. Lawrence, T. Thomas, K. Abela, S. Thammasitboon, M.H. Tcharmtchi, Houston, TX, p.A3213

P1069 **Innovation in Interprofessional Education: A Quality Improvement Project in a Pulmonary Care Unit/**T. Siddharthan, P. Galiatsatos, A. Lambert, H.E. Fessler, R. Sidhaye, Baltimore, MD, p.A3214

P1070 **Building a Pediatric Pulmonary Nursing Curriculum for Thailand/**S.S. Kun, Los Angeles, CA, p.A3215

Facilitator: P.H. Lenz, MD, MEd, Cincinnati, OH

P1071 **Improving Pediatric Pulmonary Training Curricula, SITE Scores, and Board Success/**G. Burg, S. Bales, G. McPhail, B. Chini, Cincinnati, OH, p.A3216

P1072 **Innovative Intervention to Improve Pulmonary and Critical Medicine Fellows' Research Training/**K. Ramar, R. Vassallo, D.R. Nelson, J. Ryu, Rochester, MN, p.A3217

P1073 **Introduction of a Novel Physiology Discussion Series in a Post-Graduate Critical Care Curriculum/**R.M. Shah, V.K. Holden, R. Shrestha, A. Verceles, K. Robinett, N.G. Shah, M.T. McCurdy, Baltimore, MD, p.A3218

P1074 **Physiology "Flipped Classroom"/**L.M. Sarzynski, E.D. Allen, Columbus, OH, p.A3219

P1075 **An Alternative Curriculum for Basic Physiology Education Using Meaningful Engaged Learning/**F.W. Lam, D. Bashir, N. Borges, S. Thammasitboon, Houston, TX, p.A3220

Facilitator: G. Garrison, MD, Burlington, VT

P1076 **Implementation and Evaluation of an Outpatient Pulmonary Curriculum iBook/**A.G. Manko, K. Wood, J.W. McCallister, Columbus, OH, p.A3221

P1077 **A Case-Based, Fellow-Led Approach to Resident Pulmonary Education/**S.G. Bickel, N. Eid, A. O'Hagan, R.L. Morton, Louisville, KY, p.A3222

P1078 **Evaluation of the Perception Capacity of Radiological Imaging Lesions Among Medical Students: Correlation Study Between a Standard Subjective Visual Assessment and an Automated Measure of Concordance of Delimitation of Lesions/**J. Levesque, D. Kazitani, C. Lafond, Montreal, Canada, p.A3223

P1079 **The Study of Learning Curve of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration/**Z.W. Chao, Shanghai, China, p.A3224

P1080 **EBUS-STAT Subscores Analysis to Assess the Validity and Efficacy of Virtual Reality Simulation for EBUS-TBNA Training/**L. Corbetta, S. Scarlata, A. Tofani, P. Palermo, Firenze, Italy, p.A3225

P1081 **Evaluating the Efficiency of ICU Rounds at a Tertiary Academic Medical Center/**M. Vankineni, N. Navuluri, L. DiCola, H. Lumish, I.K. Louh, D. Brodie, N. Yip, New York, NY, p.A7811

THEMATIC POSTER SESSION

B36 PLEURAL DISEASE: CLINICAL STUDIES

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area C, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: D.H. Sterman, MD, New York, NY

P237 **Management of Non-Communicating Multiloculated Pleural Space Infection with Sequential Fibrinolytic Augmented Multiple Chest Tube Drainage: A Single Center Experience/**A. Biswas, M. Jantz, H.J. Mehta, Gainesville, FL, p.A3226

P238 **Medical Thoracoscopy in the Treatment of Complicated Parapneumonic Effusions/**R. Ramanjaneya, M.M. B.V, M. Zuhaib, Bangalore, India, p.A3227

P239 **Utilizing Once Daily Use of Tissue Plasminogen Activator (Tpa) and Deoxyribonuclease (Dnase) for Management of Intrapleural Sepsis/**H.J. Mehta, A. Biswas, A.M. Penley, M. Jantz, Gainesville, FL, p.A3228

P240 **Gravity Mode on Electronic Chest Drainage Systems Better Preserves Chest Wall Motion Compared to Higher Levels of Suction Following Thoracic Surgery/**G. Elshafie, N. Oswald, A. Aliverti, P. Kumar, M. Kalkat, E. Bishay, R. Steyn, P. Rajesh, B. Naidu, Birmingham, United Kingdom, p.A3229

P241 **Exploration Beyond the Thorax/**K. Chatterjee, C. Colaco, B. Colaco, S. Sampath, N. Meena, Little Rock, AR, p.A3230

P242 **Outcomes of Percutaneous Lung Parenchymal Abscess Drainage with Microbiologic Correlation/**C.T. Duncan, T. Gade, G. Nadolski, S. Hunt, Philadelphia, PA, p.A3231

P243 **Predictors of Pneumothorax Following Endoscopic Valve Therapy/**D. Gompelmann, H.-J. Lim, V. Gerovasili, R. Eberhardt, M. Eichinger, C.-P. Heussel, F.J. Herth, Heidelberg, Germany, p.A3232

P244 **Preliminary Cost-Effectiveness Analysis of Intrapleural Therapies for Pleural Infection from the MIST2 Randomised Controlled Trial/**J.M. Wrightson, R. Luengo-Fernandez, R. Hallifax, J.P. Corcoran, N.A. Maskell, I. Psallidas, N.M. Rahman, Oxford, United Kingdom, p.A3233

P245 **Factors Affecting Success of Intrapleural Treatment Using Combination tPA and DNase for Pleural Infection/**J.M. Wrightson, J.P. Corcoran, R. Hallifax, N.A. Maskell, I. Psallidas, N.M. Rahman, Oxford, United Kingdom, p.A3234

P246 **Mixing It Up: Concurrent Administration of TPA and DNase in Complex Parapneumonic Effusions/**R. Bishwakarma, S.K. Shah, W. Zhang, J. Valle, J. Terasaki, S.P. Nishi, Galveston, TX, p.A3235

P247 **Prevalence and Types of Radiographic Thoracic Manifestations in Patients with Primary Klebsiella Liver Abscess/**A. Gupta, E. Yoo, O. Epelbaum, Queens, NY, p.A3236

P248 **Prognostic Factors of 30-Day Mortality in Patients with Pleural Empyema/**F.C. Abrao, F.D. Munhoz, I.R. Abreu, J. Da Silva Alves, M.C. Janini, M. Aldegheri, Sao Paulo, Brazil, p.A3237

Facilitator: K.T. Bramley, MD, New Haven, CT

P249 **Intrapleural tPA 5mg (with DNase) Is an Effective Alternative to the Recommended tPA 10mg (with DNase) Dose for Treatment of Pleural Infection/**N. Popowicz, O. Bintcliffe, F. Piccolo, D. Wong, A. Edey, N.A. Maskell, Y.C.G. Lee, Perth, Australia, p.A3238

P250 **A New Diagnostic Approach for Bilious Pleural Effusion/**T. Saraya, R.W. Light, S. Sakuma, Y. Nakamoto, S. Wada, M. Shimoda, K. Ohkuma, M. Ishida, I. Hirukawa, M. Oda, T. Inui, Y. Ogawa, T. Koide, S. Takata, M. Watanabe, T. Yokoyama, D. Kurai, H. Ishii, H. Takizawa, Mitaka, Japan, p.A3239

P251 **The Minimum Fluid Volume Adequacy to Diagnose Malignant Pleural Effusion: A Retrospective Study/**H. Wu, R. Khosla, S. Chauhan, E. Paal, W. Chen, Washington, DC, p.A3240

P252 **Prevalence of Sjogren's Syndrome in Patients with Nonspecific Pleuritis on Thoracoscopic Pleural Biopsies: A Retrospective Study/**H. Takizawa, Y. Ishii, K. Kurasawa, Tochigi, Japan, p.A3241

P253 **Intrapleural Target Therapies (Anti-VEGF and Anti-EGFR) Reduce Malignant Pleural Effusion and Morbidity in an Experimental Model/**L.R. Teixeira, M.M.P. Acencio, V.A. Alvarenga, J. Puka, H.F.Z. Leite, P.F. Milsoni, S.M. Fernezlian, A.B.G. Santos, M.C.R. Medeiros, E. Marchi, V.L. Capelozzi, Sao Paulo, Brazil, p.A3242

P254 **Combination US-Guided Cutting-Needle Biopsy and Standard Pleural Biopsy for Diagnosis of Unilateral Pleural Effusions: An Effective Approach/**J. Wang, X. Xie, D. Zhou, Y. Zeng, Guangzhou, China, p.A3243

P255 **Why Fibrinolysis Is Recommended in our Local Standards of Empyema Management/**J. Plutinsky, Z. Taligova, R. Sabova, M. Plutinsky, Levice, Slovak Republic, p.A3244

P256 **Retrospective Review of Patients Undergoing Talc Pleurodesis for Management of Symptomatic Pleural Effusions/**D.K. Duong, E.I. Hsiao, C.M. Kirsch, San Jose, CA, p.A3245

P257 **Organizing and Promoting a Dedicated Pleural Service at an Academic Medical Center/**A. Ajakumar Menon, F. Chen, A.C. Theodore, F.M. Schembri, Boston, MA, p.A3246

P258 **Is a Dedicated Pleural Procedures List Justified Within a District General Hospital?/**R. Aslam, E. Bedawi, I. Aslam, Wakefield, United Kingdom, p.A3247

P259 **Flexible Thoracoscopy: Shining a Light on Pleural Effusions/**A. Hufton, C.T. Pantin, M. Babores, J. Gallagher, S. Iyer, Cheshire, United Kingdom, p.A3248

Facilitator: C. Gilbert, DO, MS, Seattle, WA

P260 **A Prospective Assessment of the Clinical Utility of Intercostal Artery Identification in Pleural Intervention/**A. Talwar, J.P. Corcoran, R. Hallifax, I. Psallidas, A. Yousuf, N.M. Rahman, Oxford, United Kingdom, p.A3249

P261 **Comparision of Cell Block and Cytology Techniques in Diagnosis of Malignant Pleural Effusion/**S.S. Comert, B. Caglayan, F. Karatas, C. Dogan, D. Ece, F. Erkek, Istanbul, Turkey, p.A3250

P262 **Time to Reconsider Light's Criteria for Pleural Effusion/**P.-A. Lepine, S. Nguyen, S. Martel, A. Delage, Quebec, Canada, p.A3251

P263 **Does Chest Tube Size Matter?: A Comparison with British Thoracic Society Pleural Disease Guidelines/**D. Das, P. Vishwasrao, S. Ahmad, Stony Brook, NY, p.A3252

P264 **Anatomy of a Specialist Pleural Service: Eight Years' Experience in a Tertiary Hospital/**R. Hallifax, R. Tazi Mezalek, J.P. Corcoran, A. Yousuf, A. Talwar, I. Psallidas, J.M. Wrightson, N.M. Rahman, Oxford, United Kingdom, p.A3253

P265 **The Epidemiology of Pneumothorax in England (1968-2011)/**R. Hallifax, R. Goldacre, M. Goldacre, N.M. Rahman, Oxford, United Kingdom, p.A3254

P266 **Comparison of Pleural Investigation on a Specialist Vs. Non Specialist Ward/**A. Simons, B. Maccarthy, C. Amafili, M. Khandaker, M. Gautam, Liverpool, United Kingdom, p.A3255

P267 **'Reducing Tube Thoracostomy Associated Complications in a South West England Tertiary Trauma Center'/**A. Arora, K. Hejazi, I. Thomas, Chicago, IL, p.A3256

P268 **Post-Pneumonectomy Empyemas: Microbiology, Management and Prognosis/**J.-B. Stern, L. Fournel, P. Girard, M. Al-Nakib, R. Caliandro, D. Gossot, Paris, France, p.A3257

P269 **Feasibility of Early Postoperative Pleurodesis in the Treatment of Air Leak After Lobectomy/**I. Sakanoue, H. Hamakawa, Y. Okubo, T. Saito, K. Minami, Y. Takahashi, Kobe, Japan, p.A3258

P270 **Thrombin Correlates with Inflammation and Fibrosis in Infectious Pleural Effusions/**C.-L. Chung, W.-L. Chen, K.-L. Lee, Taipei, Taiwan, p.A3259

P271 **Australasian Malignant Pleural Effusion (AMPLE) Trial: A Multicentre Randomised Study Comparing Indwelling Pleural Catheter Versus Talc Pleurodesis/**Y.C.G. Lee, E.T.H. Fysh, R. Thomas, N.A. Smith, P. Lee, B.C.H. Kwan, E. Yap, F.C. Horwood, F. Piccolo, D.C.L. Lam, L.A. Garske, R. Shrestha, C. Kosky, C.A. Read, K. Murray, Perth, Australia, p.A7812

P272 **The SEAL-MPE Trial: A Phase I Safety Evaluation of a Novel Silver Nitrate Coated Indwelling Pleural Catheter/**R. Bhatnagar, N. Zahan-Evans, C. Kearney, A. Tremblay, N. Maskell, Bristol, United Kingdom, p.A7813

THEMATIC POSTER SESSION

B37 INTERVENTIONAL PULMONARY MEDICINE: COOL CASES

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area D, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: A.C. Mehta, MBBS, Cleveland, OH

P371 **Utility of Therapeutic Lobar Lung Lavage in Four Patients of Pulmonary Alveolar Proteinosis/**H.R. Iyer, A. Athavale, L. Menon, Mumbai, India, p.A3260

P372 **Delayed Hemothorax Following Bronchoscopic Cryobiopsy: Possible Intercostal Arterial Thermal Injury/**H.C. Sasieta, E.S. Edell, Rochester, MN, p.A3261

P373 **Hemoptysis Associated with Endobronchial Leech/**X.-Q. Xing, Z.-C. Yang, Y.-H. Liu, Y.-L. Li, L.-Q. Liu, X.-W. Wu, Kunming, China, p.A3262

P374 **Fatal Air Embolism Following Lung Biopsy: Does Needle Size Really Matter?/**F. Khalid, K. Alluri, S. Rehman, K. Fernainy, S. Gupta, McKeesport, PA, p.A3263

P375 **Simultaneous Endobronchial Gluing with Blood Patch Pleurodesis for Persistent Alveolar Pleural Fistula/**J.P. Wynne, H.J. Mehta, M. Barnes, M. Jantz, Gainesville, FL, p.A3264

P376 **Postoperative False Alarm: Tunneled Pleural Catheter Crossing the Midline Due to an Enlarged Azygoesophageal Recess/**M. Teixeira, D. White, J.H. Skalski, A.I. Saeed, J.J. Mullon, R.M. Kern, Rochester, MN, p.A3265

P377 **Endobronchial Ultrasound Bronchoscopy in the Diagnosis of Mediastinal Solitary Fibrous Tumor/**A. Webb, H. Yadav, A.I. Saeed, J. Utz, Rochester, MN, p.A3266

P378 **A Not so Fine Needle Aspiration/**J.D. Johnson, J. Lubawski, R. Hargrove, A. Goyal, Maywood, IL, p.A3267

P379 **Mediastinitis Complicating Endobronchial Ultrasound Guided Biopsy of Subcarinal Melanoma/**J.L.-Y. Wong, L. Bashoura, C. Jimenez, R. Miller, Houston, TX, p.A3268

P380 **Amplatzer Placement for Closure of a Large Central Bronchopleural Fistula/**K.Z. Kremens, R. Coursey, Fargo, ND, p.A3269

Facilitator: C.T. Phan, DO, Chicago, IL

P381 **3-D Ultrasound Imaging of Lung Lesions/**W. Warren, S.C. Parrish, R. Browning, P. Malafronte, J. Nations, Bethesda, MD, p.A3270

P382 **Severe Bilateral Airway Ischemic Necrosis in a Lung Transplant Patient Treated with Sequential Balloon Dilation/**H. Inaty, A.H. Alraiyes, A. Kumar, M. Machuzak, Cleveland, OH, p.A3271

P383 **Bronchial Stenosis Distal to the Anastomosis in a Patient with Bilateral Lung Transplantation: A Case Report/**L. Fernandez, L.F. Sua, W. Martinez, F. Sanabria, C. Garcia, M. Velasquez, Cali, Colombia, p.A3272

P384 **Necrotizing Fasciitis: A Rare Complication of Transthoracic Needle Aspiration/**A. Chada, N. Meena, C. Colaco, B. Colaco, K. Kakkera, D. Raghavan, Little Rock, AR, p.A3273

P385 **Bronchogenic Cyst Rupture/**E.M. Rakowski, R. Rajmane, R. Pillai, New York, NY, p.A3274

P386 **Simultaneous Use of Endobronchial Suture Sling and Valve in the Management of a Postoperative Bronchopleural Fistula: A Multimodality and Multidisciplinary Approach/**A.I. Saeed, S. Blackmon, D.E. Midthun, D.R. Nelson, E.S. Edell, Rochester, MN, p.A3275

P387 **Simultaneous Electromagnetic Navigation Bronchoscopy and Computed Tomography of Chest for Precise Localization of a Peripheral Pulmonary Nodule/**A.I. Saeed, R.M. Kern, J.J. Mullon, D.E. Midthun, S. Blackmon, Rochester, MN, p.A3276

P388 **Endobronchial Ultrasound Bronchoscope Damage: Two Unusual Cases/**A. Krishnan, M. Patil, K. Harris, A.H. Alraiyes, S. Dhillon, Buffalo, NY, p.A3277

P389 **Massive Hemoptysis Associated with Aberrant Blood Supply and Left Lower Lobe Cystic Mass in a Patient on Prasugel/**A. Singh, J.F. Turner, T. Dudney, G. Sneed, T. Gaines, J. Snidow, Knoxville, TN, p.A3278

P390 **A Rare Case of Massive Hemoptysis Due to Pulmonary Artery Aneurysm/**K.L. Niehaus, R. Balestra, T. Sriprasart, A. Aragaki-Nakahodo, S. Benzaquen, Cincinnati, OH, p.A3279

Facilitator: N.A. Ninan, MD, New Orleans, LA

P391 **Placement of Fiducial Markers by Electromagnetic Navigational Bronchoscopy to Facilitate Video-Assisted Thoracoscopic Wedge Resection of a Peripheral Lung Nodule/**C. Martinez-Balzano, C. Bielick, C. Stock, P. Oliveira, A. Sosa, Worcester, MA, p.A3280

P392 **An Uncommon Congenital Anomaly Mimicking Mediastinal Carcinoma/**A. Rajagopal, A.P. Maskey, Lexington, KY, p.A3281

P393 **Tracheal Stenosis as a Complication from Transtracheal Oxygen Therapy/**G. Pierson, C. Shapiro, Pueblo, CO, p.A3282

P394 **Nailed It! Fiberoptic Bronchoscopy for Retrieval of an Unusual Pulmonary Foreign Body/**G. Pierson, J. Gordon, J.A. Stienecker, Pueblo, CO, p.A3283

P395 **All that Glitters Is Not Gold/**A.D. Schenone, B.A. Reichardt, V. Kanchustambham, D. Stoeckel, N. Poddar, St. Louis, MO, p.A3284

P396 **Localized Tracheobronchial Amyloidosis Presenting with Massive Hemoptysis in an Intubated, Critically Ill Patient/**S.S. Rao, C.M. Goodson, R. Semaan, S. Arias, T. Kolb, Baltimore, MD, p.A3285

P397 **Thumbtack Aspiration: A Unique Bronchoscopic Challenge/** S.W. Copeland, M. Sigler, R. Alalawi, Lubbock, TX, p.A3286

P398 **Subconjunctival Hemorrhage, an Unusual Complication of Flexible Bronchoscopy/**T. Abdo, A.C. Porter, Oklahoma City, OK, p.A3287

P399 **Pneumothorax and Subcutaneous Emphysema in the Setting of Malignant Effusion and Tunneled Pleural Catheter/**M. Senitko, J.T. Puchalski, K.T. Bramley, New Haven, CT, p.A3288

P400 **Coin Aspiration: An Underappreciated Hazard of Metered Dose Inhalers/**J. Tsui, G. Caughey, B.M. Elicker, M. Lafemina, San Francisco, CA, p.A3289

Facilitator: K. Mahmood, MD, Durham, NC

P401 **A Piece of Broken Metal from Intubation Stylet Retained in Tracheobronchial Tree: A Case Report and a Brief Review of the Literature/**M. Fathi, B. Farzanegan, Tehran, Iran, p.A3290

P402 **Endobronchial Leiomyoma Successfully Treated with Flexible Bronchoscopic Cryotherapy: A Case Report/**S.K. Nepal, M. Cirino, E.R. Rubio, Roanoke, VA, p.A3291

P403 **A Lost Lobe: A Case of Large Endobronchial Hamartoma/** C. Ghattas, A. Andoh-Duku, M. Hundal, S. Rafeq, Boston, MA, p.A3292

P404 **Blame It on the Dog: A Rare Case of Disseminated Blastomycosis Diagnosed Via Endobronchial Ultrasound Guided Transbronchial Needle Aspiration (EBUS-TBNA)/**C.X. Giovacchini, K. Mahmood, Durham, NC, p.A3293

P405 **Typical Carcinoid Tumor in Pregnant Woman Treated with Cryotherapy: An Alternative to Surgery/**T.R. Gogireddy, A. Niroula, S. Katari, R. Friedenheim, Abington, PA, p.A3294

P406 **Use of Navigational Bronchoscopy for Removal of Fractured Balloon Catheter Tip After Peanut Aspiration/**S. Till, N. Shamsid-Deen, A. Thomas, Phoenix, AZ, p.A3295

P407 **Cryotherapy Extraction of Endobronchial Aspergilloma/**A. Singhal, A. Sachdeva, E. Pickering, Baltimore, p.A3296

P408 **Novel Combination of Bronchoscopic and Endoscopic Tools for Retrieval of Aspirated Foreign Bodies/**S. Sears, W. Palmer, J.L. Garland, A. Sharp, D. Riegert-Johnson, Jacksonville, FL, p.A3297

P409 **Bronchial Atresia and Tracheal Web, Rare Association with Successful Endobronchial Argon Plasma Coagulation Dilatation/**Y.A. Al Ahwel, A. Ali, A. Kubbara, S.U. Rehman, D.A. Hernandez, Toledo, OH, p.A3298

P410 **Temporal Tracheobronchial Stenting for Airway Obstruction Caused by a Lung Abscess/**J. Kebbe, A.H. Alraiyes, S.S. Dhillon, K. Harris, Buffalo, NY, p.A3299

Facilitator: L. Fernandez, MD, Cali, Colombia

P411 **Diagnosis and Staging of Malignant Pleural Mesothelioma by Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Biopsy/**J.P. Sta.Cruz, B. Sharma, D. Jarrar, J. Mora, Upland, PA, p.A3300

P412 **Against the Odds- An Interesting Case of Foreign Body Aspiration/**C. Tan, A. Teh, A. Ng, J. Abisheganaden, Singapore, Singapore, p.A3301

P413 **Tracheal Stenosis: A Previously Unreported Complication of Photodynamic Therapy for Tracheal Papillomatosis/**E.L. Scholten, M.M. Magana, S.M. Makani, La Jolla, CA, p.A3302

P414 **An Unusual Case of Fatal Hemoptysis/**H. Alvey, H. Bedi, Y. Chen, C. Ray, M. Simoff, J. Diaz-Mendoza, Detroit, MI, p.A3303

P415 **Removal of Metallic Endobronchial Stents Placed for Malignancy/**A. Agarwal, E. Guzman Suarez, A. Agrawal, N. Meena, Camden, NJ, p.A3304

P416 **Tu(be) or Not Tu(be): Should Patients with Malignant Central Airway Obstruction be Emergently Intubated for Bronchoscopic Interventions?/**E. Soon, S. Biddie, S. Chatterji, P. Bradley, M. Trivedi, R. Mahroof, K. Fife, P. Sivasothy, Cambridge, United Kingdom, p.A3305

P417 **Stent-in-Stent Technique for the Treatment of Proximal Restenosis After Insertion of Bronchial Metallic Stents: A Report of Two Cases/**B. Bondue, P. Schlossmacher, Y. Sokolow, S. Luce, C. Knoop, D. Leduc, Brussels, Belgium, p.A3306

P418 **Circumferential Fire Argon Plasma Coagulation in Endobronchial Obstruction/**C. Oberg, T.J. Harkin, New York, NY, p.A3307

P419 **Laser Therapy in Patients with Suprastomal Tracheal Stenosis After Tracheostomy/**K. Seo, J. Lyu, H. Lee, J. Choi, J. Na, Y. Kim, Cheonan City, Korea, Republic of, p.A3308

P420 **Invaders of the Slithering Kind/**P. De Hoyos Zambrano, A. Malave, San Antonio, TX, p.A3309

THEMATIC POSTER SESSION

B38 PLEURAL DISEASE: CASE REPORTS

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area C, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: F. Maldonado, MD, Nashville, TN

P273 **Transjugular Intrahepatic Portosystemic Shunt (TIPS) in Chylothorax Due to Portal Hypertension/**R.E. Cagnina, K.B. Enfield, Charlottesville, VA, p.A3310

P274 **Bedside Lung Ultrasound: When the Barcode Sign Does Not Necessarily Mean Pneumothorax/**F. Al-Saffar, M. Cerda, R. Louli, W. Cullinane, S. Ibrahim, Jacksonville, FL, p.A3311

P275 **Malignancy Unmasked - A Rare Primary Pleural Angiosarcoma Presenting as a Complex Empyema/**D. Terrington, R. Tabbara, A. Craig-McQuaide, A. Arya, King's Lynn, United Kingdom, p.A3312

P276 **Spontaneous Hemothorax as an Adverse Effect of Rivaroxaban Treatment/**S.J. Lee, S.H. Kim, S. Ju, J.W. Yu, Y.J. Cho, Y.Y. Jeong, H.C. Kim, J.D. Lee, Gyeongsang, Korea, Republic of, p.A3313

P277 **A Case of Catamenial Pneumothorax Complicated by Large Diaphragmatic Fenestration with Hepatic Herniation/**I. Wong, A.T. Reyes, A. Afzal, I. Gulkarov, B. Worku, Brooklyn, NY, p.A3314

P278 **Pleural Extramedullary Hematopoiesis: A Rare Cause of Bloody Pleural Effusion/**D.J. Pepper, E. Delbecq, O. Ioffe, C. White, E.J. Britt, Bethesda, MD, p.A3315

P279 **Rapidly Progressive Parapneumonic Effusion: A Case of Explosive Pleuritis/**N. Abi Hatem, K. Matthews, M. Foroozesh, Roanoke, VA, p.A3316

P280 **Replasing Pleural Effusion in a Patient on Automated Peritoneal Dialysis/**B. Mustafa, F. Ahmed, A.H. Alraiyes, Buffalo, NY, p.A3317

P281 **An Unfortunate Manifestation of HHV-8/**W. Richter, R. Sonti, R. Gross, Washington, DC, p.A3318

P282 **Localized Tension Pneumothorax Following Talc Pleurodesis/** M. Basunia, C. Agu, D. Salhan, S. Kandel, F. Schmidt, D. Enriquez, J. Quist, O. Abdulfattah, S. Roy, Brooklyn, NY, p.A3319

Facilitator: J.A. Akulian, MD, MPH, Chapel Hill, NC

P283 **Massive Subcutaneous Emphysema Following Pleurodesis for Intractable Secondary Pneumothorax Using UniTalcr/** N. Tanaka, M. Okuda, K. Fukuda, M. Tanaka, R. Nohara, Osaka, Japan, p.A3320

P284 **Acquired Hydrothorax After a Laparoscopic Surgery in a Patient on Peritoneal Dialysis/**M. Buni, Houston, TX, p.A3321

P285 **A Rare Case of Pleural Effusion in a 92-Year-Old Man/** S.M. Kanth, E.S. Baker, A.L. Van Dyke, M. Donahoe, Pittsburgh, PA, p.A3322

P286 **Unusual Cause of Left Neck Swelling and Right Pleural Effusion/**M. Senitko, J.T. Puchalski, New Haven, CT, p.A3323

P287 **Sirolimus for Management of Spontaneous Chylothorax/**K. Walker, C. Fanta, Boston, MA, p.A3324

P288 **Pirfenidone-Induced Eosinophilic Pleurisy/**I. Hase, H. Arakawa, B. Yamaguchi, H. Takizawa, K. Fujiu, H. Miyamoto, Y. Ishii, Koriyama-shi, Japan, p.A3325

P289 **Salmonella Vertebral Osteomyelitis Presenting as a Loculated Exudative Pleural Effusion/**S.M. Iosifescu, T. Amass, M. Jankowich, Providence, RI, p.A3326

P290 **Bilateral Chylothorax as Initial Presentation of Chronic Lymphocytic Leukemia (CLL)/**A. Abu Homoud, G. Al-Saoudi, M. El Sawaf, E. Costanzo, Neptune City, NJ, p.A3327

P291 **A Case of Relapsed IgG4-Related Disease Presenting as Chylothorax and Chylous Ascites/**J.J. Shim, K.H. Min, J. Choi, S. Chung, J.Y. Oh, J.K. Sim, G.Y. Hur, S.Y. Lee, K.H. Kang, Seoul, Korea, Republic of, p.A3328

P292 **Spontaneous Pneumohemothorax: An Unusual Presentation with a Concealed Bleeder/**J.M. D'souza, J. Venkatachalam, C.T. Lim, L.L. Phoa, Singapore, Singapore, p.A3329

Facilitator: S. Shojaee, MD, Richmond, VA

P293 **Malignancy Mimic: An Unexpected Consequence of an Abdominal Gun Shot Wound/**V. Esguerra, P. Diaz, Columbus, OH, p.A3330

P294 **Pleural Noduarity in a Vietnam Veteran/**J.C. Mallen, L. Morrow, N. Dewan, Omaha, NE, p.A3331

P295 **Massive Right Sided Pleural Effusion in Chronic Pancreatitis with Hidden Fistula: Is Elevated Pleural Fluid Amylase Alone Sufficient to Diagnose Pancreaticopleural Fistula (PPF) in Proper Clinical Context?/**M. Ghosh, A. Sinha Ray, S. Ghosh, O. Obi, J.Q. Henkle, Springfield, IL, p.A3332

P296 **Pleural Involvement in Extensive Bilateral Primary Nodular Parenchymal Amyloidosis: An Incidentaloma/**P. Kanagarajah, H. Pang, J. Capote, Miami Beach, FL, p.A3333

P297 **Recurrent Pneumothorax in Patient Waiting for Lung Transplant: A Treatment Dilemma/**R. Shrestha, O.D. Adejorin, M. Zaman, Memphis, TN, p.A3334

P298 **Unilateral Obstructive Urinothorax Secondary to Invasive Vaginal Squamous Cell Carcinoma/**A. Abou Yassine, W. Mansour, B. Kfoury, M. Chalhoub, Staten Island, NY, p.A3335

P299 **Pleural Hemorrhage Secondary to Intrapleural Alteplase for Treatment of Loculated Empyema in a Patient on Therapeutic Anticoagulation/**A.A. Ahmed, G. Huss, I.G. Berim, Omaha, NE, p.A3336

P300 **Nuclear Imaging to Confirm an Unusual Hepatic Hydrothorax/** A. Karki, K. Sherani, V. Patel, U. Kulsum, J. Raynor, M. Babury, Jamaica, NY, p.A3337

P301 **One Lung Ventilation: A Patient with Pulmonary Agenesis Undergoing a VATS Procedure/**Y. Vilnits, E. Stevens, E. Nishanian, T. Johnston, New York, NY, p.A3338

P302 **Rapid Development of a Bloody Pleural Effusion from a Kidney Hamartoma/**R. Prakobkit, Stanford, CA, p.A3339

Facilitator: A.C. Argento, MD, Chicago, IL

P303 **Cautionary Tale of Lung Entrapment: Does Drainage Do More Harm than Good?/**B. Alam, G. Johri, A. Olarewaju, T. George, Syracuse, NY, p.A3340

P304 **An Unfortunate Series of Events: The Modified Eloesser Flap and Its Complications/**R. Wu, B. Juthani, J. Mendez, Danbury, CT, p.A3341

P305 **Rapidly Recurring Large Pleural Effusion in the Setting of Chronic Pancreatitis: A Documented Pancreaticopleural Fistula/**S. Kobrossi, J. Ferretti, P. Kohlitz, Syracuse, NY, p.A3342

P306 **Chylothorax: The Milky Truth of Cirrhosis/**J. Lau, A. Usmani, Chicago, IL, p.A3343

P307 **Medical Thoracoscopy Images of a Rare Case of Melanoma with Pleural Metastasis/**A.I. Saeed, R.M. Kern, J.J. Mullon, E.S. Edell, K.G. Lim, Rochester, MN, p.A3344

P308 **Management of Pneumothorax Exvacuo in a Stage IV Lung Cancer Patient/**J.G. Bustamante Alvarez, J. Lai, P. Prassad, D. Brito, C. Arevalo, G.A. Fernandez, C. Nieves, Philadelphia, PA, p.A3345

P309 **Kaposiform Lymphangiomatosis: An Unforeseen Cause of Spontaneous Hemothorax and Episodic Hemoptysis/**A.J. Sweatt, K. Regalia, Stanford, CA, p.A3346

P310 **Post-emetic Rupture of The Esophagus Presenting as Rapidly Progressing Hydropneumothorax: A Case Report/**L.H. Nguyen, V. Le Thuong, N.V. Tran, Ho Chi Minh, Viet Nam, p.A3347

P311 **Pneumothorax, a Rare but Serious Complication of Acupuncture Therapy/**T. Abdo, V.H. Kha, H. Bhardwaj, H. Youness, Oklahoma City, OK, p.A3348

P312 **Foreign Body with Secondary Empyema/**J.A. Williams, F. Lhote, Swansea, United Kingdom, p.A3349

Facilitator: N.A. Maskell, MD, Bristol, United Kingdom

P313 **Pleural Based Masses in a Man with Occupational Exposure: A Case of Pseudomesotheliomatous Carcinoma/**V.B. Nannaka, M. Adrish, Bronx, NY, p.A3350

P314 **Iatrogenic Bilothorax and Gall Bladder Perforation Secondary to Abdominal Liposuction/**A. Husari, N. El Kara, Beirut, Lebanon, p.A3351

P315 **Mediastinal Hematoma: An Unusual Complication from Internal Jugular Central Venous Line/**A. Shahmohammadi, L. McCullough, A. Ataya, I. Faruqi, Gainesville, FL, p.A3352

P316 **Lung Trapped by Malignant Pleural Effusion: A Proposed Treatment/**C.A. Iberico, F. Romero, E. Cuenca, H.B. Lavado, L.N. Herrera, Y. Montenegro, F. Hinojosa, Callao, Peru, p.A3353

P317 **Successful Factor XIII Treatment of Chylothorax in Tuberous Sclerosis/**K.B. Sreter, B. Barisic, Zagreb, Croatia, p.A3354

P318 **Warfarin, Hemothorax and Thrombolytics/**S.J.A. Naqvi, K.S. Allen, Oklahoma City, OK, p.A3355

P319 **Intrapleural Benign Mature Cystic Teratoma/**A. Goizueta, R. Almadi, J. Meharg, Providence, RI, p.A3356

P320 **Bilateral Chylous Effusion Related to Goiter/**S.S. Palakuru, A. Sharma, R. Lodato, Houston, TX, p.A3357

P321 **Pleural Involvement in Waldenstrom Macroglobulinemia/**H. Chen, A. Velasquez, Atlanta, GA, p.A3358

THEMATIC POSTER SESSION

B39 INTERVENTIONAL PULMONARY MEDICINE: RECENT ADVANCES

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area D, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: F.J. Herth, MD, Heidelberg, Germany

P422 **Bronchoscopic Transparenchymal Approach to Lung Nodules/**D.A. Nader, K.L. Mitchell Hervert, Tulsa, OK, p.A3359

P423 **Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration of Hilar and Mediastinal Lymph Nodes Detected on 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography/**D. Minami, N. Takigawa, Y. Kato, T. Ninomiya, T. Kubo, K. Ohashi, K. Hotta, T. Shibayama, N. Miyahara, M. Tabata, A. Kanehiro, M. Tanimoto, K. Kiura, Okayama City, Japan, p.A3360

P424 **Error Introduced into a Virtual Airway Map Created from an Inspiratory Planning CT Scan for Electromagnetic Navigational Bronchoscopy Performed During Tidal Breathing/**B.S. Furukawa, G.A. Silvestri, N. Pastis, Charleston, SC, p.A3361

P425 **The Role of Endobronchial Ultasound Guided Transbronchial Needle Aspiration for the Diagnosis of Peribronchial Lesions/**S.S. Comert, B. Caglayan, C. Dogan, D. Ece, R. Demirhan, Istanbul, Turkey, p.A3362

P426 **Role of Fiberoptic Bronchoscopy in the Diagnosis of Pulmonary Infiltrates in Patients with Hematological Malignancies/**A.K.M. Hanna, Y.M.K. Akl, H.M. Zawam, R.I.M. ElKorashy, M. Said, Cairo, Egypt, p.A3363

P427 **Indications, Results and Complications of Flexible Bronchoscopy in the Intensive Care Unit of Fundacion Valle del Lili, a University Hospital of Reference in Latin America/** L. Fernandez, C.A. Munoz, L.F. Sua, M. Granados, Cali, Colombia, p.A3364

P428 **Therapeutic Bronchoscopy in the Management of Central Airway Obstruction: Experience in Fundacion Valle del Lili, a University Hospital of Reference in Latin America/**L. Fernandez, M. Velasquez, L.F. Sua, Cali, Colombia, p.A3365

P429 **Therapeutic Rigid Bronchoscopy for Patients with Airway Stenosis Due to Small Cell Lung Cancer/**M. Oki, H. Saka, C. Kitagawa, Y. Kogure, S. Oka, M. Nakahata, K. Hori, Y. Murakami, Y. Ise, A. Ishida, Nagoya, Japan, p.A3366

P430 **The Efficacy of Bronchial Artery Embolization for Repeated Hemoptysis: A Retrospective Cohort Study/**T. Niwa, C. Komaki, T. Mori, Hashima-gun, Japan, p.A3368

Facilitator: K.L. Kovitz, MD, MBA, Chicago, IL

P431 **Comparison of Cross-Sectional Area of Tissue Biopsies Obtained with Two Different Forceps/**A. Folch, P. VanderLaan, S.E. Higgins, A. Majid, P. Barcos, D. Alape, E. Folch, Boston, MA, p.A3369

P432 **Diagnostic Yield and Safety of Electromagnetic Navigational Bronchoscopy: A Single Center Experience/**M. Al-Jaghbeer, I.H. Iftikhar, M. Marcus, M. Durkin, Columbia, SC, p.A3370

P433 **Bronchial Thermoplasty in Asthmatic Patients with Severe Fixed Airflow Obstruction: Safety and Following for One Year/** T. Aguirre Perez, J.L. Miguel Reyes, E. Lopez Estrada, S. Cid Juarez, C. Ortega, M.A. Iniguez, E. Dante, Distrito Federal, Mexico, p.A3371

P434 **A Retrospective Analysis of Bronchoscopy in Obese Patients/**A.J. Gangemi, N. Mills, B.D. Wind, R.V. Patel, A. Kasarabada, Philadelphia, PA, p.A3372

P435 **The Use of Brachytherapy for the Treatment of Airway Obstruction/**C. Parks, R. Bechara, S. Cavenaugh, Newnan, GA, p.A3373

P436 **Safety of Airway TruFreezer Spray Cryotherapy for Benign Proximal Tracheal Stenosis with Flexible Bronchoscopy and Laryngeal Mask Airway/**D.H. Yu, S.S. Oh, I. Susanto, Los Angeles, CA, p.A3374

P437 **Diagnostic Role of Fiberbronchoscopy in Patients with Hemoptysis/**F. Fioretti, V. D'Emilio, C. Massaccesi, G.L. Primomo, G. Panella, R. Pela, Ascoli Piceno, Italy, p.A3375

P438 **Initial Experience with Use of High Flow Nasal Cannula (HFNC) During Diagnostic and Therapeutic Bronchoscopy/**W. He, T.J. Harkin, New York City, NY, p.A3376

P439 **Topical Infusion of Tranexamic Acid (TA) for Prevention of Bronchoscopic Biopsy Related Bleeding/**R. Kuint, L. Levy, S. Fishberg, A. Abutbul, P. Cohen Goichman, Z.G. Fridlender, U. Laxer, N. Berkman, Jerusalem, Israel, p.A3377

P440 **Bronchial Artery Embolization for Hemoptysis in Patients with Chronic Pulmonary Aspergillosis/**T. Ando, M. Kawashima, K. Masuda, K. Takeda, J. Suzuki, N. Ohshima, H. Matsui, A. Tamura, H. Nagai, S. Akagawa, K. Ohta, Kiyose-shi, Tokyo, Japan, p.A3378

Facilitator: C.L. Channick, MD, Boston, MA

P441 **Custom Montgomery T-Tubes- Initial Clinical Experience and Outcomes/**G.Z. Cheng, D. Alape, E. Folch, S. Gangadharan, P. Mallur, A. Folch, A. Majid, Boston, MA, p.A3379

P442 **Comparison Between Bronchoscopy Under General Anesthesia Using Laryngeal Mask Airway and Local Anesthesia with Conscious Sedation, a Patient and Operator Centered Outcome/** H.H. Raafat, M.K. Abbass, S.T. Salem, Cairo, Egypt, p.A3380

P443 **Outcomes of Tracheobronchial Stenting in Benign Airway Disease/**L. Frye, F. Almeida, T. Gildea, Cleveland, OH, p.A3381

P444 **3D CT Airway Analysis to Indirectly Assess Smooth Muscle Mass in Patients Undergoing Bronchial Thermoplasty: A Proof of Concept Study/**M. Barry, R. San Jose Estepar, E. Folch, G.Z. Cheng, A. Majid, Boston, MA, p.A3382

P445 **Mediastinal Lymphadenopathy in Acute Congestive Heart Failure/**J.D. Perry III, Y. Shweihat, R. Garciaorr, R. Gerkin, Phoenix, AZ, p.A3383

P446 **Investigating the Complication Rates of Rigid Bronchoscopy and Large Airways Intervention/**L.E. Loewenthal, E.J. Shaw, B.P. Madden, London, United Kingdom, p.A3384

P447 **Mediastinal Granuloma Superinfection Following Ultrasound-Guided Transbronchial Needle Aspiration: A Case Series/**R.J. Lentz, E.S. Lambright, F. Maldonado, J. Loyd, E.L. Grogan, O.B. Rickman, Nashville, TN, p.A3385

P448 **Tracheobronchoplasty for Severe Tracheobronchomalacia: Short and Long-Term Outcomes/**D.E. Alape, S. Gangadharan, E. Folch, A. Folch, S. Ochoa, A. Majid, Boston, MA, p.A3386

P449 **Bronchial Thermoplasty (BT) Global Registry: Trial Design and Current Patient Profile/**F.J. Herth, R. Niven, A. Torrego, L. Puente, N. Facciolongo, M. Novali, S. Bicknell, S. Gasparini, F. Andreo, K. Dheda, J. Vortuba, E. McMullen, F. Nolan, Heidelberg, Germany, p.A3387

Facilitator: D.W. Hsia, MD, Torrance, CA

P450 **Quantitative CT Measurement of Tracheal Cross-Sectional Areas in Relapsing Polychondritis: Correlations with Spirometric Values/**A. Usuba, T. Yamashiro, M. Mineshita, H. Handa, Y. Yamano, S. Matsuoka, T. Miyazawa, Kawasaki, Japan, p.A3388

P451 **Identification and Quantification of Airway Wall Layers with Optical Coherence Tomography: A Histology Based Validation Study/**J.N.S. D'Hooghe, D.M. De Bruin, J.J.T.H. Roelofs, J.T. Annema, P.I. Bonta, Amsterdam, Netherlands, p.A3389

P452 **Endobronchial Ultrasound Transbronchial Needle Aspiration for the Diagnosis of Lymphoma/**C. Bellinger, G. Parks, Z. Lamar, T. Dotson, Winston-Salem, NC, p.A3390

P453 **Fiducial Placement in Peripheral Lung Lesions Using the Veran Spinperc Electromagnetic Navigational Bronchoscopy System: A Case Series/**A. Belanger, T. Zagar, J. Akulian, Chapel Hill, NC, p.A3391

P454 **Six Month Experience of Endobronchial Ultrasound Sampling (EBUS) in a Large Tertiary Centre in the United Kingdom (UK)/** C. Dong, R.A. Mustafa, Middlesbrough, United Kingdom, p.A3392

P455 **Semi-Automated Assessment of Fissure Integrity and Shape and Volume Reduction After One-Way Valve Treatment/**H.G. De Oliveira, R. Rambo, S.M. De Oliveira, A.V. De Macedo Neto, Porto Alegre, Brazil, p.A3393

P456 **New EBUS Bronchoscopy Programs: Predicting Procedure Volume/**B.P. Young, F. Almeida, Cleveland, OH, p.A3394

P457 **Higher Price of Bronchoscopy - Comparison of Repair Rates and Costs Between Older and Newer Generation Bronchoscopes/**B.P. Young, K. Barclay, N. Shah, A.C. Mehta, T. Gildea, Cleveland, OH, p.A3395

P458 **Computed Tomography Prediction of Collateral Ventilation/**Y. Yin, P. Raffy, M. Schuhmann, D. Gompelmann, R. Eberhardt, S. Wood, F.J.F. Herth, Minneapolis, MN, p.A3396

Facilitator: K. Van Nostrand, MD, Atlanta, GA

P459 **Impact of Bronchoscopy After First-Line Chemotherapy in Patients with Stage IV Non Small Cell Lung Cancer on Overall Survival/**C. Dayen, C. Trouve, C. Poulet, B. Gubler, H. Sevestre, R. Suguenot, H. Bentayeb, I. Rault, E. Lecuyer, E. Hoguet, F. Le Meunier, V. Jounieaux, N. Benzerdjeb, C. Andrejak, Y. Douadi, Saint Quentin, France, p.A3397

P460 **Hyperspectral Imaging of Lung Autofluorescence/**J. Dean, P. Favreau, J. Deal, C. Lopez, M. Wheeler, C. Williams, T. Baker, D. Weber, T. Rich, S. Leavesley, Mobile, AL, p.A3398

P461 **Evaluation of Bronchoscopy and Radiographic Imaging in Respiratory Syncytial Virus Infection in Hematologic Malignancy and Hematopoietic Stem Cell Transplant Patients/**E. Vakil, S.A. Faiz, D. Shah, J. Kmeid, F. El Chaer, L. Bashoura, E. Ariza-Heredia, R. Chemaly, Houston, TX, p.A3399

P462 **Airways Tumors and Endoscopic Electrocautery - Curative and Palliative Benefits/**R. Ulmeanu, R.E. Nedelcu, D.I. Ulmeanu, F.D. Mihaltan, Bucharest, Romania, p.A3400

P463 **Evaluation of Appropriate Staging Among EBUS Bronchoscopists/**R. Miller, L. Mudambi, M. Hernandez, G. Eapen, Houston, TX, p.A3401

P464 **Recurrent Respiratory Papillomatosis Involving the Lower Airways Treated with Argon Plasma Coagulation and Cidofovir Intralesional Injection/**S. Umekawa, R. Horie, S.J. Evans, Honolulu, HI, p.A3402

P465 **Diagnosing Post-Operative Pulmonary Complications (PPC) Via Its Effect of Chest Wall Mechanics/**G. Elshafie, P. Kumar, R. Wilson, M. Kalkat, E. Bishay, P. Rajesh, R. Steyn, B. Naidu, Birmingham, United Kingdom, p.A3403

P466 **Cost-Effectiveness Analysis of the Fiberoptic Bronchoscope and the Disposable Bronchoscope for Bedside Bronchoscopy/**H. Sharifi, B.D. Shaller, D. Free, R. Abel, R. Van Wert, A. Sung, Stanford, CA, p.A3404

P467 **Powered Stapler Device Reduces the Incidence of Prolonged Air Leak and Duration of Chest Tube Drainage After Lung Volume Reduction Surgery. A Prospective Randomized Blinded Study/**K. Furrer, S. Dackam, M. Wiese, D. Schumann, D. Lardinois, Basel, Switzerland, p.A7814

P468 **Transbronchial Cryobiopsy Is a Safe Alternative to Surgical Lung Biopsy for the Diagnosis of Diffuse Parenchymal Lung Disease/**R.J. Lentz, T.M. Taylor, J.A. Kropski, F. Maldonado, J.E. Johnson, T.S. Blackwell, O.B. Rickman, Nashville, TN, p.A7815

THEMATIC POSTER SESSION

B40 DYSPNEA: CASE REPORTS

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area C, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: A.F. Dimmock, BA, Hersey, PA

P323 **An Isolated Extramedullary Plasmacytoma of the Trachea Presenting as Progressive Dyspnea on Exertion/**D. Kruse, K. Trujillo, C. Huebert, Omaha, NE, p.A3405

P324 **Bilateral Spontaneous Pneumothoraxes in a Patient with Right Lung Agenesis/**H. Upadhyay, V. Vasudevan, Z. Hashemi, J. Contreras Jr, A. Khokar, L. Gerolemou, F. Arjomand, Brooklyn, NY, p.A3406

P325 **Rhinovirus Associated to Severe Stridor/**S.M. Castillo, B. Forbes, L. Satterwhite, Kansas Cty, KS, p.A3407

P326 **Post Radiofrequency Ablation Dyspnea: An Unusual Cause/**A.M. Jobanputra, J. Sunderram, New Brunswick, NJ, p.A3408

P327 **A New Laryngeal Signs in a Patient with Ehler Danlos Syndrome/**A. Ali, Y.A. Al Ahwel, A. Milad, S.U. Rehman, F. Safi, R. Assaly, Toledo, OH, p.A3409

P328 **Diaphragm Paralysis After Atrial Fibrillation Ablation/**D. Chandra, M. Quast, A.B. Thompson, Omaha, NE, p.A3410

P329 **Unusual Cause of Pneumothorax/**N. Tipirneni, N. Safaie, A. Close, J. Catalanotti, M. Delaney, Washington, DC, p.A3411

P330 **Intra-Lobar Pulmonary Sequestration: A Unique and Potentially Fatal Cause of Hemoptysis/**C. Di Felice, S. Ansari, P. Patel, J. Flemming, S. Patri, Kalamazoo, MI, p.A3412

P331 **Spirometry as the First Clue of Achalasia Causing Upper Airway Obstruction in a World Trade Center Disaster Responder/**G.S. Schneider, G.S. Skloot, New York, NY, p.A3413

P332 **A Fork in the Road: Assessment of Multiple Competing Etiologies for Hypercapnea/**J.S. Mendelson, R.M. Goldring, K.I. Berger, New York, NY, p.A3414

P333 **Dangers of Flying High and Diving Low! An Unusual Case of Dyspnea/**P. Ramadas, P. Krishnan, R. Chakravarty, A. Nadkarni, Syracuse, NY, p.A3415

P334 **Segmental Airway Collapse Associated with Dyspnea and Localized Wheezing/**C. McLaughlin, D. Forbes, A. Skabelund, M.J. Morris, Fort Sam Houston, TX, p.A3416

P335 **Rare Case of ANCA Vasculitis with Alveolar Hemorrhage in Non-Hodgkin Lymphoma/**A. Surana, R. Bansal, Upland, PA, p.A3417

P336 **Treatment of Acute Dyspnea with Morphine to Avert Respiratory Failure/**A. Rose, R.M. Schwartzstein, Boston, MA, p.A3418

P337 **Unexplained Dyspnea in a Non-Smoker: Think Outside the Box/**N. Junaid, K. Chiapaikeo-poco, H. Seethamraju, Newark, NJ, p.A3419

Facilitator: K.F. Gibson, MD, Pittsburgh, PA

P338 **Endo-Bronchial Blood Cast in a Post Cardiac Surgery Patient Without Hemoptysis/**S. Alewan, S. Qanash, S. Mink, Winnipeg, Canada, p.A3420

P339 **Dyspnea: An Unusual Presentation of Hiatal Hernia/**A.K. Jaiswal, J. Yeager, S. Miro, B.R. Madhira, Syracuse, NY, p.A3421

P340 **A Rare Case of Massive Bilateral Chylothorax/**Y. Agrawal, S. Aggarwal, M. Schauer, Kalamazoo, MI, p.A3422

P341 **An Elderly Man with Shortness of Breath: A Case of Primary Pulmonary Amyloidosis/**M. Forte, J.A. Stienecker, J. Gordon, Pueblo, CO, p.A3423

P342 **A Case of Right Heart Thrombus and Acute Pulmonary Embolism - Successful Treatment with Ultrasound-Accelerated Catheter-Directed Thrombolysis/**R. Kim, V. Nidadavolu, K. El-Kersh, J.S. Smith, Louisville, KY, p.A3424

P343 **Everything that Wheezes Is Not Asthma!/**H. Grewal, S. Khatri, Cleveland, OH, p.A3425

P344 **Mounier-Kuhn Syndrome: An Unusual Cause of Dyspnea/**M.R. Chang, G.W. Soo Hoo, Los Angeles, CA, p.A3426

P345 **A Rare Presentation of Isolated Pulmonary Amyloidosis Mimicking Malignancy/**A. Karki, V. Patel, K. Sherani, U. Kulsum, J. Raynor, K. Mandal, A. Shalonov, Jamaica, NY, p.A3427

P346 **"Doc! I Can't Breathe After My Shoulder Surgery"- A Case of Phrenic Nerve Paralysis Post Cervical Paravertebral Nerve Block/**H.A.M. Fakih, S. Daouk, D. Urbine, Gainesville, FL, p.A3428

P347 **Do Not Count Out the Importance of a Tracheal Bronchus/**D. Shiu, M. Lindner, H. Seethamraju, Newark, NJ, p.A3429

P348 **A Rare Case of Pulmonary Sequestration Presenting with Post Prandial Epigastric Pain/**R. Gupta, A. Kim, P. Belligund, Brooklyn, NY, p.A3430

P349 **Improvement of the Pulmonary Function After Weight Gain in a Patient with Anorexia Nervosa/**E.-J. Park, M.-A. Park, J.J. Hwang, I.K. Hwang, S.-H. Kim, J.H. Yoo, H.M. Kang, M.J. Park, Seoul, Korea, Republic of, p.A3431

P350 **Broncholithiasis: One Case Report/**L. Ying, Zhengzhou, China, p.A3432

P351 **Wheezes and Dispnea: Atypical Symptoms of Osler-Weber-Rendu Syndrome/**B.M. Piloto, M.A. Castro, S.Z. Rached, R.M.D.C. Pinto, R. Stelmach, Sao Paulo, Brazil, p.A3433

Facilitator: L.I. Noriega, MD, Panama City, Panama

P352 **Pulmonary Embolism: An Unrelenting Culprit in a Case of Refractory Respiratory Failure/**S. Mookherjee, B. Changlai, Syracuse, NY, p.A3434

P353 **Respiratory Arrest from Dynamic Tracheal Obstruction in Parkinson's Disease/**J. Hadfield, E. Kuo, M. Teh, I. Ling, Perth, Australia, p.A3435

P354 **Dyspnea and the Hidden Crisis/**J.J.B.J. Williams, S. Abdelhadi, F. Munir, Newark, NJ, p.A3436

P355 **Pulmonary Embolism as the Initial Presentation of Membranous Nephropathy/**R. Buckley, J. Trost, S. Patel, Tucson, AZ, p.A3437

P356 **Delayed Negative Pressure Edema in a Young Athletic Man/**Y. Habtegebriel, J. Nfonoyim, A. Mehari, Staten Island, NY, p.A3438

P357 **A Case of Cryptogenic Hypoxia/**C. Colaco, B. Colaco, K. Ayoub, N. Meena, T. Bartter, R. Jagana, Little Rock, AR, p.A3439

P358 **A Curious Case of the Misbehaving Pancreatico-Pleural Fistula/**M. Ignaszewski, R. Asterita, P. Kohlitz, Syracuse, NY, p.A3440

P359 **"Making the 'Connection': A Case of Abnormal Connective Tissue"/**K. Mahan, M. Prekker, Minneapolis, MN, p.A3441

P360 **Are All Left Sided Pleural Effusions Caused by Congestive Heart Failure?/**R. Arancibia, K. Chokshi, S. Kumanovsky, P. Krishnan, Brooklyn, NY, p.A3442

P361 **Giant Thoracic Meningocele Causing Respiratory Failure in a Patient with Neurofibromatosis I/**L.M. Sanso, A. Sanders, K. Gudi, K. Rajwani, New York, NY, p.A3443

P362 **An "Ancient" Cause of an Anterior Mediastinal Mass/**M. Stefanski, N. Rassaei, Hershey, PA, p.A3444

P363 **Patient Suffering from Acute Chest Syndrome with Respiratory Failure Treated Successfully with Extracorporeal Membrane Oxygenation/**H. Nazir, N. Ali, J. Lee, N. Holder, T. Agarwal, S. Jacoby, T. Anandarangam, Newark, NJ, p.A3445

P364 **'PCA for Refractory Dyspnea: Old technology, Novel Strategy'/**N. Panneerselvam, A. Engle, C. Beechy, C. Jastremski, K. Gunasekaran, E. Bravin, Cooperstown, NY, p.A3446

P365 **Cosmetic Gluteal Silicone Injection as a Cause of Unexplained Diffuse Alveolar Hemorrhage and Respiratory Failure/**M. Holub, A. Berman, Newark, NJ, p.A3447

THEMATIC POSTER SESSION

B41 LUNG TRANSPLANTATION: CLINICAL AND TRANSLATIONAL STUDIES

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area E, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: J.M. Diamond, MD, MSCE, Philadelphia, PA

P513 **The Prevalence and Significance of Esophageal Dysfunction in Lung Transplant Recipients with Systemic Sclerosis, A Single-Center Experience/**J. Johannes, F. Abtin, C.H. Miele, K. Schwab, E. Lee, R. Saggar, Los Angeles, CA, p.A3448

P514 **Lung Transplantation in Scleroderma-Related Lung Disease: A Single-Center Experience/**A. Goodarzi, N. Sinha, T. Kaleekal, J.G. Youssef, B. Bruckner, S. Scheinin, Houston, TX, p.A3449

P515 **Impact of Posaconazol Liquid vs. Tablet Formulation on Plasma Trough Levels in Lung Transplant Recipients/**D. Stelzer, F. Ihle, A. Weber, N. Kneidinger, G. Zimmermann, F. Ceelen, R. Schramm, H. Winter, L. Frey, M. Andraschko, M. Vogeser, J. Behr, C. Neurohr, Munich, Germany, p.A3450

P516 **Donor Lung-Derived T Cells Differentiate into IL-17A-Producing T Cells After Lung Transplant into Lymphodeplete Recipients/**Q. Wu, P. Gupta, S. Wagner, R.A. Shilling, Chicago, IL, p.A3451

P517 **The Role of Hyaluronan-CD44 Biology During Primary Graft Dysfunction in Lung Transplant Recipients/**A. DerHovanessian, V. Palchevskiy, S. Weigt, M. Shino, A. Gregson, D. Sayah, J.P. Lynch, R. Saggar, D. Ross, A. Ardehali, R.M. Elashoff, J.A. Belperio, Los Angeles, CA, p.A3452

P518 **Decreased Telomere Lengths in Lung Transplant Recipients Relative to Donors/**H.E. Faust, R. Rajalingam, P.J. Wolters, J.P. Singer, A. Wang, G. Green, J.A. Golden, S. Hays, J. Kukreja, J.R. Greenland, San Francisco, CA, p.A3453

P519 **Severely Shortened Telomeres in Lung Transplant Recipients with Idiopathic Pulmonary Fibrosis Are Associated with Impaired Cytomegalovirus Immunity and Viral Control/**H. Mannem, I. Popescu, A. Hoji, S. Gulati, S. Kilaru, M. Crespo, J.M. Pilewski, M.R. Morrell, C. Ensor, M. Armanios, J.F. McDyer, Pittsburgh, PA, p.A3454

P520 **Characteristics of Donor Specific Antibody Characteristics Associated with Antibody Mediated Rejection in Lung Transplantation/**A. Roux, C. Suberbielle- Boissel, I. Bendib- Lelan, A.M. Hamid, F. Parquin, Suresnes, France, p.A3455

Facilitator: A. Bharat, MD, Chicago, IL

P521 **Association of Tacrolimus Levels During Index Hospitalization for Lung Transplant with Development of Bronchiolitis Obliterans Syndrome/**S. Ahmad, S. Ambardar, A.W. Brown, O.A. Shlobin, C.S. King, A.B. Cochrane, M. Fregoso, K. Germano, A.J. Rongione, L.J. Bogar, N. Weir, S.D. Nathan, Falls Church, VA, p.A3456

P522 **Alemtuzumab for the Treatment of Chronic Lung Allograft Dysfunction/**D. Owen, E. Lushin, D. Gutteridge, M. Latran, D. Roe, C. Hage, Indianapolis, IN, p.A3457

P523 **Effect of Rituximab on Pulmonary Function in Graft-Versus-Host-Disease Following Allogeneic Hematopoietic Stem Cell Transplantation/**L.A. Thomas, J.P. McGuirk, S. Ganguly, O. Aljitawi, A. Singh, T.L. Lin, S. Abhyankar, K.R. Brownback, Kansas City, KS, p.A3458

P524 **The Relationship Between Alveolar Wall Thickness and Lung Function in Orthotopic Lung Grafts/**A. Moskowitz, T. Astor, M. Selig, G. Cheng, R.L. Kradin, Boston, MA, p.A3459

P525 **Torque Teno Virus-DNA Load and Lung Transplant Rejection/**B.C. Frye, S. Bierbaum, I. Hettich, G. Zissel, M. Idzko, H. Hengel, J. Muller-Quernheim, Freiburg, Germany, p.A3460

P526 **A Clinico-Pathologic and Radiologic Correlation Study of Extracorporeal Membrane Oxygenation Associated Acute Lung Injury Among Patients with Advanced Lung Disease/**E. Batchelor, M. Mohanka, S. Bollineni, V. Kaza, F. Torres, J. Mullins, M. Wait, J. Bland, D. Douglass, A. Banga, Dallas, TX, p.A3461

P527 **Extracorporeal Membrane Oxygenation as a Bridge to Lung Transplantation - Impact of Mechanical Ventilation on Mid-Term Outcomes/**M.L. Gabner, D. Kemper, C. Schwarz, M. Deja, R. Yeter, D. Staab, C. Pille, M. Menk, V. Falk, S. Weber-Carstens, C. Knosalla, Berlin, Germany, p.A3462

P528 **An Optimized Viscosity Solution Can Better Preserve Physiological Lung Function Ex Vivo, During Extended Ventilation and Perfusion, Prior to Transplantation/**J. Cornwell, S.C. Rowan, K. Rochfort, P. McLoughlin, Dublin, Ireland, p.A3463

P529 **Mechanism of Death and Relationship to Systemic and Airway Inflammation in Brain Dead Organ Donors/**E.M. Lowery, M. Yong, S. Kliethermes, E.J. Kovacs, Maywood, IL, p.A3464

Facilitator: P.M. Shah, MD, Baltimore, MD

P530 **Inhibition of Connective Tissue Growth Factor Promotes Healthy Revascularization and Ameliorates Fibrosis in Orthotopic Tracheal Transplantation/**Y.-C. Lin, X. Jiang, M. Nicolls, Palo Alto, CA, p.A3465

P531 **Domiciliary Non-Invasive Ventilation Post Lung Transplantation/**S. Kotecha, C. Buchan, K. Parker, J. Toghill, B. Miller, M.T. Naughton, G.I. Snell, E. Dabscheck, Melbourne, Australia, p.A3466

P532 **Long Term Kinetics of CD19+CD24highCD38high Breg Cells in Lung Transplant Recipients/**F. Meloni, M. Morosini, D. Piloni, S. Magni, A. Balderacchi, L. Scudeller, E. Cova, G.M. Stella, F. Antonacci, T. Oggionni, Pavia, Italy, p.A3467

P533 **Translational Potential for Mass Cytometry in Lung Transplantation with Limitations from Medicinal Iodine/** B.C. Keller, D.G. Kelley, R.M. Senior, D.E. Byers, J.J. Atkinson, St. Louis, MO, p.A3468

P534 **Carbon Monoxide Modulates Leukocyte Recruitment/Infiltration in a Murine Orthotopic Single Lung Transplantation Model of Bronchiolitis Obliterans/**Y. Aoki, N. Walker, D. Pinsky, V. Lama, Ann Arbor, MI, p.A3469

P535 **Role of Mitomycin C Application in Lung Transplantation Related Airway Stenosis/**K. Mahmood, M. Elmasri, M.M. Wahidi, L. Snyder, S.L. Shofer, Durham, NC, p.A3470

P536 **Double Trouble: Massive Pulmonary Embolism and Arterial Stenosis in a Lung Transplant Recipient/**J.A. Brenes-Salazar, T. Behrenbeck, Rochester, MN, p.A3471

P537 **Systemic Thrombolysis and Endovascular Clot Retrieval to Treat Massive PE in Recent Lung Transplant Recipient with HIT/**M. Michaelson, A. Kafi, A. Weinberg, S. Alamro, V. Tapson, D. Ramzy, S. Ghandehari, G. Chaux, J. Falk, Los Angeles, CA, p.A3472

Facilitator: R.J. Shah, MD, MSCE, San Francisco, CA

P538 **Peri-Engraftment Respiratory Distress Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation Progressed to Interstitial Lung Fibrosis: A Case Report/**P. Promsin, R. Ruangchira-urai, P. Thomrongpairoj, A. Poompichet, S. Tongyoo, R. Ratanarat, C. Permpikul, Bangkok, Thailand, p.A3473

P539 **Recurrent Shock in Fresh Lung Transplant Patient: History Solves the Mystery/**T. Thaniyavarn, Atlanta, GA, p.A3474

P540 **Safe Utilization of Hydrogen Gas in Clinical Setting After Lung Transplantation/**T. Kawamura, J. Yoshida, T. Kimura, S. Funaki, Y. Shintani, M. Minami, A. Uchiyama, Y. Fujino, A. Nakao, M. Okumura, Suita, Japan, p.A3475

P541 **Pulmonary Allograft Kaposi's Sarcoma After Lung Transplantation/**S.M. Shadly Ahmed, I. Nizami, W. Saleh, Riyadh, Saudi Arabia, p.A3476

P542 **Expanding Bronchial Cyst as an Indicator of Chronic Lung Allograft Rejection/**P. Mulhall, J. Mamary, G. Criner, Phildelphia, PA, p.A3477

P543 **Donor-Derived Disseminated Toxoplasmosis in Lung Transplant Recipient /**D. Gutteridge, L. Zaffiri, M. Duncan, D. Roe, C. Hage, Indianapolis, IN, p.A3478

P544 **A Case of Tacrolimus Associated Posterior Reversible Encephalopathy Syndrome (PRES) with Hemorrhage - A Rare but Major Complication in Post Lung Transplant Patients/**K. Bagavathy, S. Ganesh, Los Angeles, CA, p.A3479

P545 **A Case of Fluctuating Mentation in a Lung Transplant Recipient/**K. Walsma, W. Chou, S. Ganesh, R. Barbers, Los Angeles, CA, p.A3480

P546 **Imatinib Protects Against Ischemia-Reperfusion Injury in an Ex Vivo Rabbit Model of Primary Graft Dysfunction/**J.T. Magruder, J.C. Grimm, L. Johnston, L. Santhanam, R.S. Stephens, D.E. Berkowitz, M. Damarla, R.L. Damico, P.M. Hassoun, A.S. Shah, B.S. Kim, Baltimore, MD, p.A3481

THEMATIC POSTER SESSION

B42 COPD: BIOMARKERS

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area H, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: V.M. Pinto-Plata, MD, Boston, MA

P897 **The BODE Index and BODE Plus Biomarkers as Predictors of Long-Term Survival in COPD/**N. Locantore, B. Celli, A. Agusti, D. Lomas, E.K. Silverman, E.F.M. Wouters, H. Coxson, J. Vestbo, L. Edwards, P.S. Bakke, P.M.A. Calverley, S.I. Rennard, W. MacNee, B.E. Miller, C. Crim, H. Mullerova, J. Yates, R. Tal-Singer, King of Prussia, PA, p.A3482

P898 **Greater Walking Distance Is Associated with Lower Levels of Growth Differentiation Factor-15 in COPD: An Analysis of the COPDGene Cohort/**L. Guo, C.M. Freeman, M.J. Budoff, M.T. Dransfield, M.K. Han, J.E. Hokanson, G.L. Kinney, E.A. Regan, J.M. Wells, J.L. Curtis, C.H. Martinez, Chengdu, China, p.A3483

P899 **Comparison of Oxidant/Antioxidant Balance in COPD and Non-COPD Smokers/**Y. Aydemir, O. Aydemir, A. Sengul, H. Çoban, A.C. Güngen, C. Tasdemir, H. Duzenli, Sakarya, Turkey, p.A3484

P900 **Increased MMP-12 and Decreased Surfactant Protein A in the Airways of Individuals with COPD - Report from a Bronchoscopy Investigation Based on the Obstructive Lung Disease in Northern Sweden (OLIN) Studies/**A.F. Behndig, R. Linder, J. Pourazar, A. Lindberg, A. Blomberg, Umea, Sweden, p.A3485

P901 **Lactate Is a Routinely Available Biomarker in COPD Exacerbation of Prognostic and Therapeutic Significance/**M.I. MacDonald, K. Polkinghorne, I. Laska, M. Qiu, A. Barberi, C. MacDonald, P. King, P.G. Bardin, Melbourne, Australia, p.A3486

P902 **Bacterial Colonization Is Associated with Abnormal Bronchial Structure In Severe Chronic Obstructive Pulmonary Disease (COPD) Patients/**A. Rodrigo-Troyano, O. Sibila, G. Suarez-Cuartin, S. Sjoqvist, N. Keune, L. Garcia-Bellmunt, A. Torrego, V. Plaza, R. Faner, A. Agusti, P. Macchiarini, M.L. Lim, P. Jungebluth, Barcelona, Spain, p.A3487

P903 **α1-Antitrypsin (A1AT) Serum Levels as Marker of Systemic Inflammation in Non-A1AT-Deficient Patients with COPD/** B. Waschki, A.-M. Kirsten, O. Holz, T. Meyer, R. Lichtinghagen, K.F. Rabe, H. Magnussen, T. Welte, H. Watz, S. Janciauskiene, Grosshansdorf, Germany, p.A3488

P904 **SUV39H1 Reduction Is Implicated in Abnormal Inflammation of COPD/**T. Chen, S. Ho, H. Chuang, P. Feng, W. Liu, K. Chen, K. Lee, New Taipei City, Taiwan, p.A3489

P905 **Blood Inflammatory Patterns in Chronic Obstructive Pulmonary Disease: Relationship with Clinical Phenotypes/**S. Nayci, E.S. Ozgur, C. Ozge, Mersin, Turkey, p.A3490

Facilitator: C.P. Aaron, MD, New York, NY

P906 **The Relationship Between COPD Assessment Test and C-Reactive Protein/**H. Lee, H.K. Kang, K. Kim, I.A. Jeong, H.Y. Park, Lee, D.G., Seoul, Korea, Republic of, p.A3491

P907 **Urinary Desmosines Are Associated with Emphysema Severity in Patients with Chronic Obstructive Pulmonary Disease/**C. Kim, Y. Ko, Y.B. Park, Jeju-si, Korea, Republic of, p.A3492

P908 **Elevated Circulating PAI-1 Levels Are Relatd to Disease Severity, Systematic Inflammation and Small Airway Obstruction in Chronic Obstructive Pulmonary Disease/**H. Wang, T. Yang, T. Wang, F. Wen, Chengdu, China, p.A3493

P909 **Correlation Between Plasma Ghrelin Levels and Breathlessness in Patients with Chronic Obstructive Pulmonary Disease/**N. Takeda, A. Sakai, H. Shibata, K. Oka, H. Kitagawa, N. Yoshida, T. Katoh, M. Iwata, Kariya, Japan, p.A3494

P910 **Is the Seropositivity of Helicobacter Pylori Associated with the COPD?; A Cross Sectional Association Study in an Asian Country with High Prevalence of H. Pylori/**H.Y. Lee, J.W. Kim, J.K. Lee, E.Y. Heo, H.S. Chung, D.K. Kim, Seoul, Korea, Republic of, p.A3495

P911 **The Association Between Vitamin D and COPD Risk, Severity and Exacerbation: A Systematic Review and Meta-Analysis Update/**M. Zhu, Y. Ji, Chengdu, China, p.A3496

P912 **Ultrafine Particles (UFPs) Content in Exhaled Breath Condensate (EBC) of COPD Patients Is Decreased by Active Smoking/**E. Fireman Klein, E. Schiff, Y. Adir, A. Amital, A. Jacobi, S. Schneer, M. Shteinberg, E. Fireman, A. Kessel, Haifa, Israel, p.A3497

P913 **Rating the Value of COPD Related Breath VOCs in Models Created by Linear Discriminant Analysis/**O. Holz, A. Gaida, C. Nell, M. Allers, S. Schuchardt, S. Zimmermann, R. Koczulla, J.M. Hohlfeld, Hannover, Germany, p.A3498

P914 **The Relationship Between Pulmonary Function, HRCT Image, Pulmonary Arterial Pressure and Urine Desmosine of COPD Patients/**M. Kato, Kishiwada, Osaka, Japan, p.A3499

Facilitator: S. Rosenberg, MD, Chicago, IL

P915 **Sputum-Plasma Ratio of Soluble Receptor for Advanced Glycation End-Products in Patients with Chronic Obstructive Pulmonary Disease/**A.I. Baess, E.G. Hassanein, A.A. Elganady, Y.A. Issa, E.M.A. Elakhtel, Alexandria, Egypt, p.A3500

P916 **Vitamin D Levels in Patients of COPD and Its Relation with FEV1/FVC/**V. Chopra, P. Kaur, H. Jain, V. Bamrah, K. N, Patiala, India, p.A3501

P917 **Cystatin C Is Associated with Decline in Lung Function and Incident Exacerbations of Chronic Obstructive Pulmonary Disease: The Multi-Ethnic Study of Atherosclerosis (MESA) Lung Study/**S.R. Viola, H. Mattix-Kramer, I. De Boer, B. Kestenbaum, S. Mohan, J.E. Schwartz, M. Schlipak, R.G. Barr, E.C. Oelsner, New York, NY, p.A3502

P918 **Association Between Serum Bilirubin and Risk of COPD Exacerbations/**K.E. Brown, D.D. Sin, H. Voelker, J.E. Connett, K.M. Kunisaki, Minneapolis, MN, p.A3503

P919 **Adiponectin Is Associated with Lower Lung Function in Never Smokers in a General Population-Based Sample/**N.F. Caspersen, A. Flyvbjerg, J. Frystyk, A. Randby, H. Hrubos-Strom, S.K. Namtvedt, T. Omland, G. Einvik, Lorenskog, Norway, p.A3504

P920 **Metabolite Profiles of COPD and Pulmonary Function in the Framingham Heart Study/**D. Ngo, J. Latourelle, J. Dupuis, C. Clish, T.J. Wang, G.T. O'Connor, R.E. Gerszten, Boston, MA, p.A3505

P921 **Systemic Inflammation and Decline in Lung Function in Older People: A Prospective Nationally-Representative from the English Longitudinal Study of Ageing from 2004-2013/**A.M. Yohannes, G. Tampubolon, Manchester, United Kingdom, p.A3506

P922 **The Comparison of Proteases and Antiproteases in Neutrophilic Asthma and Chronic Obstructive Pulmonary Disease (COPD)/**L. Jing, Z. Shi, C. Hua-ping, Y. Xu, D. Li-ping, W. Chang-zheng, Chongqing, China, p.A3507

P923 **The Ideal Biomarker to Predict COPD Exacerbations/**Z. Zafari, D.D. Sin, S. Bryan, M. Sadatsafavi, Vancouver, Canada, p.A3508

THEMATIC POSTER SESSION

B43 COPD: PHENOTYPES AND CLINICAL OUTCOMES

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area H, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: M. Miravitlles, MD, PhD, Barcelona, Spain

P925 **Cluster Analysis of Chronic Obstructive Pulmonary Disease (COPD) Related Phenotypes in the SubPopulations and InteRmediate Outcome Measures in COPD Study (SPIROMICS)/**X. Li, M.K. Han, V.E. Ortega, M.T. Dransfield, H. Li, R.G. Barr, D.J. Couper, E.A. Hoffman, R. Kanner, E. Kleerup, F.J. Martinez, P.G. Woodruff, D.A. Meyers, E.R. Bleecker, Winston-Salem, NC, p.A3509

P926 **Chronic Bronchitis and Airway Thickening Are Associated with Higher Levels of Growth Differentiation Factor-15 (GDF-15) in Smokers Without Airflow Obstruction: An Analysis of the SPIROMICS Cohort/**C.H. Martinez, C.M. Freeman, J.D. Nelson, W.H. Anderson, R.P. Bowler, C.B. Cooper, D.J. Couper, M.K. Han, F.J. Martinez, W.K. O'Neal, V.E. Ortega, R. Paine, III, P.G. Woodruff, J.L. Curtis, Ann Arbor, MI, p.A3510

P927 **Small Airway Disease Is Associated with Patient-Centered Outcomes Among Smokers with Moderate Obstructive Lung Disease. An Analysis of the SPIROMICS Cohort/**C.H. Martinez, A.A. Diaz, J.L. Curtis, C.B. Cooper, C. Pirozzi, R. Kanner, R. Paine, III, P.G. Woodruff, E. Bleecker, N.N. Hansel, R.G. Barr, E. Kazerooni, E.A. Hoffman, B.D. Ross, C. Galban, F.J. Martinez, M.K. Han, Ann Arbor, MI, p.A3511

P928 **A Higher Dysanapsis-Ratio Is Associated with a Lower Risk for COPD Exacerbations: The Obesity-Chest Wall Strapping Analogy/**E. Abston, A.P. Comellas, R.M. Reed, V. Kim, R.A. Wise, R.G. Brower, J.D. Newell, E.A. Hoffman, M. Eberlein, Iowa City, IA, p.A3512

P929 **Macrophage Phenotype Changes Within the Small Airway Wall in Smokers and Chronic Obstructive Pulmonary Disease (COPD)/**S.S. Sohal, K.D. McAlinden, S. Weston, M.Q. Mahmood, M.S. Eapen, E.H. Walters, Launceston, Australia, p.A3513

P930 **Defining Inflammatory Groups Within a COPD Cohort/**K. Hambleton, R. Shrimanker, R. Russell, C.E. Brightling, I. Pavord, M. Bafadhel, Oxford, United Kingdom, p.A3514

P931 **Short-Term Stability of Pulmonary Function and Clinical Measures in COPD Using a Cohort from SPIROMICS (Subpopulations and Intermediate Outcome Measures in COPD Study)/**W.H. Anderson, W.K. O'Neal, C.M. Doerschuk, E.E. Carretta, D.J. Couper, D. Tashkin, R. Paine, III, C.B. Cooper, E.R. Bleecker, R.G. Barr, N.N. Hansel, M.K. Han, F.J. Martinez, J.L. Curtis, P.G. Woodruff, E. Kleerup, R. Kanner, Chapel Hill, NC, p.A3515

P932 **Reduction of Interferon-Stimulated Genes in COPD Prone to Exacerbation/**C. Hilzendeger, J. Da Silva, F.N. Schleich, J.-L. Corhay, M.R. Edwards, S.L. Johnston, R. Louis, Liege, Belgium, p.A3516

P933 **Angiotensin Converting Enzyme (ACE) Gene Polymorphism Is Associated with Chronic Obstructive Pulmonary Disease (COPD), and Pulmonary Hypertension in Patients with COPD/**Y. Ma, H. Fan, X. Tong, Chengdu, China, p.A3517

Facilitator: C.E. Come, MD, Boston, MA

P934 **Mucin Hypersecretion Associated with Chronic Bronchitis and Not Emphysema in Sputum from COPD Patients from the SPIROMICS Cohort/**A.A. Ford, G. Radicioni, R. Cao, A. Ceppe, C.M. Doerschuk, W.K. O'Neal, W.H. Anderson, R.C. Boucher, M. Kesimer, Chapel Hill, NC, p.A3518

P935 **Identification of a Debilitated Phenotype in SPIROMICS/**I. Barjaktarevic, C.H. Martinez, J.L. Curtis, E.A. Hoffman, E.E. Carretta, R.P. Bowler, W.K. O'Neal, M. Quibrera, R.G. Barr, F.J. Martinez, D.J. Couper, G.J. Criner, M.T. Dransfield, M.K. Han, N.N. Hansel, R. Kanner, S.C. Lazarus, E.R. Bleecker, R. Paine, III, D.P. Tashkin, P.G. Woodruff, C.B. Cooper, Los Angeles, CA,p.A3519

P936 **Comparison of Clinical Characteristics and Treatment Outcomes Between Eosinophilic and Neutrophilic COPD Patients with Severe Acute Exacerbation/**H.S. Kang, C.K. Rhee, S.K. Kim, J.W. Kim, S.H. Lee, H.K. Yoon, J.H. Ahn, Y.H. Kim, Seoul, Korea, Republic of, p.A3520

P937 **Gender Phenotyping of COPD Patients Using Complex Network Analysis/**S. Mihaicuta, M. Udrescu, A. Topirceanu, L. Sbarcea, L. Udrescu, Timisoara, Romania, p.A3521

P938 **Exploratory Study of Clinical Phenotype of Airways Disease by Two-Step Cluster Analysis/**Y. Guo, P. Ning, T. Sun, Beijing, China, p.A3522

P939 **The Frequent Exacerbator Phenotype of Chronic Obstructive Pulmonary Disease and Lipid Metabolism/**J. Liuqun, L. Qi, C. Zhe, Zhengzhou, China, p.A3523

P940 **Analysis of Severity Staging of Chronic Bronchitis Reveals Frequent Instability of Diagnosis/**A. Sood, H. Petersen, C. Qualls, P.M. Meek, R. Vasquez-Guillamet, B.R. Celli, Y. Tesfaigzi, Albuquerque, NM, p.A3524

P941 **Factors Describing Chronic Obstructive Pulmonary Disease Predict All-Cause Mortality in Smokers/**G.L. Kinney, S. Santorico, M.H. Cho, K.A. Young, P.J. Castaldi, J. Black-Shinn, B.J. Make, E.A. Regan, R.P. Bowler, S.M. Lutz, E.K. Silverman, J.D. Crapo, J. Hokanson, Aurora, CO, p.A3525

P942 **Factors Associated with COPD Mortality, 2 Year Follow-Up Data from the ARCADE Study/**N. Gale, A. Albarrati, M. Munnery, R. Tal-Singer, J. Cockcroft, D. Shale, Cardiff, United Kingdom, p.A3526

Facilitator: A. Lambert, MD, MHS, Baltimore, MD

P943 **How 'Stable' Is Stable COPD? Daily Symptom Variability of Subjects Enrolled in the SPIROMICS Exacerbation Sub-Study/**K.M. Ancy, N.K. Leidy, K.G. Malley, W.H. Anderson, R.G. Barr, E. Bleeker, R.P. Bowler, E.E. Carretta, C.B. Cooper, D.J. Couper, C.M. Doerschuk, M.T. Dransfield, N.N. Hansel, E.A. Hoffman, R. Kanner, W.K. O'Neal, R. Paine, III, S.P. Peters, MD, PhD, M.B. Scholand, P.G. Woodruff, M.K. Han, F.J. Martinez, New York, NY, p.A3527

P944 **Association Between the Presence of Objective Evidence of COPD on the Presentation and Outcome of Patients Hospitalized with COPD Exacerbation/**C.Y. Pu, R. Nunez, K. Aryal, A. Tulaimat, N. Quesada, Chicago, IL, p.A3528

P945 **Airway Microbiome Dynamics in Chronic Obstructive Pulmonary Disease Patients with Acute Exacerbation and Respiratory Failure and Its Association with Weaning Outcomes- A Preliminary Report/**W.-C. Huang, H.-C. Chen, S.-Y. Liu, C.-C. Huang, Taichung, Taiwan, p.A3529

P946 **Mortality and Exacerbation Risk by Body Mass Index in the (TIOSPIRr) Trial/**N. Putcha, D. Dusser, A. Anzueto, N. Metzdorf, A. Mueller, R.A. Wise, Baltimore, MD, p.A3530

P947 **The Relationship Among Pulmonary Function, Exacerbation and ICU Admission Rate and Pulmonary Artery Enlargement in Patients with Advanced Chronic Obstructive Pulmonary Disease/**A. Sadigov, I. Isayev, A. Bagirzadeh, Baku, Azerbaijan, p.A3531

P948 **Longitudinal Changes in FEV1, Hyperinflation, and 6-Minute Walk Distance in Patients with COPD Associated with Non-Cystic Fibrosis Bronchiectasis/**A. Sadigov, K. Bakhshaliyeva, S. Guliyeva, Baku, Azerbaijan, p.A3532

P949 **Decreased Exacerbation Risk in COPD Correlates with Therapeutic Improvement in FEV1: A Meta-Analysis of Randomized, Controlled Trials/**A.D. Zider, R.G. Buhr, X. Wang, W. Sirichana, I. Barjaktarevic, C.B. Cooper, Los Angeles, CA, p.A3533

P950 **Clinically Significant Impact of Tiotropium and Indacaterol on Six-Minute Walking Test and Inspiratory Capacity in Women with Chronic Obstructive Pulmonary Disease Associated to Biomass Exposure/**M. Velazquez-Uncal, A. Ramirez-Venegas, R.H. Sansores, O. Perez-Bautista, R. Hernandez-Zenteno, A. Velazquez, F. Flores, C. Sanchez, C. Espinosa De Los Monteros, A. Aranda-Chavez, Mexico, Mexico, p.A3534

P951 **Response of Respiratory Symptoms in Outpatient Chronic Obstructive Pulmonary Disease Patients to Administration of Prednisone Therapy/**P. Mulhall, A.J. Criner, M.R. Jacobs, G.J. Criner, Phildelphia, PA, p.A3535

Facilitator: A.P. Comellas, MD, Iowa City, IA

P952 **The Relationship Between the Number of Natural Teeth and Airflow Obstruction: A Cross-Sectional Study Using Data from KNHANES/**S.W. Kim, C.K. Rhee, Y.H. Kim, H.K. Yoon, Seoul, Korea, Republic of, p.A3536

P953 **Health Related Quality of Life in Indian Patients of Chronic Obstructive Pulmonary Disease/**D.P. Bhadoria, V.P. Ghilley, L. Kumar, T. Raghuvanshi, P. Bhadoria, New Delhi, India, p.A3537

P954 **Clinical and Functional Characteristics of Elderly Chronic Obstructive Pulmonary Disease Patients/**S. Nayci, E.S. Ozgur, C. Ozge, E. Tas?tekin, A. Ilvan, Mersin, Turkey, p.A3538

P955 **Prognostic Factors of Patients Who Hospitalized for COPD Exacerbation; a Single Institutional Study/**M. Sato, S. Inoue, A. Igarashi, Y. Tokairin, T. Nemoto, K. Sato, M. Kobayashi, Y. Abe, I. Kubota, Y. Shibata, Yamagata, Japan, p.A3539

P956 **The Development and Application of a Number-Axis System for Diagnosis, Treatment and Prediction of Outcome on Bronchial Asthma, Chronic Obstructive Pulmonary Disease (COPD) and Overlap Syndrome/**J.-Z. Cao, H.-W. Lin, Tianjin, China, p.A3540

P957 **Incident Opioid Drug Use and Adverse Respiratory Outcomes Among Older Adults with COPD/**N.T. Vozoris, X. Wang, H. Fischer, C. Bell, D.E. O'Donnell, P. Austin, A.L. Stephenson, S.S. Gill, P.A. Rochon, Toronto, Canada, p.A3541

P958 **Characteristics of Daily Physical Activity in Patients with Chronic Obstructive Pulmonary Disease and Association with Acute Exacerbations/**N. Yee, H.Q. Nguyen, K.C. Pike, Z. Chen, J. Lee, V.S. Fan, Seattle, WA, p.A3542

P959 **Mild COPD Patients with a High Symptom Load: A Subgroup Analysis from the DACCORD Registry/**P. Kardos, R. Buhl, C.-P. Criee, C. Vogelmeier, N. Lossi, C. Mailaender, H. Worth, Frankfurt, Germany, p.A3543

P960 **Ten Years' Mortality Data of Patients with Chronic Obstructive Pulmonary Disease from the Hokkaido COPD Cohort Study/**H. Makita, M. Suzuki, S. Konno, K. Shimizu, Y.M. Ito, M. Nishimura, Sapporo, Japan, p.A3544

Facilitator: A.A. Diaz, MD, Boston, MA

P961 **Adverse Events Among COPD Patients Treated with Long-Acting Anticholinergics and β2-Agonists in an Outpatient Respiratory Clinic/**C. Rodrigue, M.-F. Beauchesne, F. Savaria, A. Forget, C. Lemiere, P. Larivee, L. Blais, Montreal, Canada, p.A3545

P962 **Chronic Obstructive Pulmonary Disease (COPD) and Pneumonia (PN) Related Risk Variables and Ultimate Mortality Outcome/**J.B. Glaser, D. Pau, N.K. Mobarakai, M. Castellano, Staten Island, NY, p.A3546

P963 **BODEx Index and Multidimensional Evaluation of COPD Patients at the Altitude of Bogota (2640 m)/**C.A. Celis Preciado, A. Canas-Arboleda, J. Lasso, C. Villaquiran-Torres, J.R. Lutz, Bogota, Colombia, p.A3547

P964 **Sedation and Physiological Response to Intranasal Dexmedetomidine (IN-DEX) in Patients with Severe Chronic Obstructive Pulmonary Disease (COPD)/**J.C. Rojas-Gomez, P. Nystrom, Dayton, OH, p.A3548

P965 **Facial Wrinkling Is Associated with Emphysema Independent of Airflow Obstruction: The Pittsburgh SCCOR Cohort/**R.C. Wilson, D. Chandra, J.M. Bon, C.M. Karoleski, C. Fuhrman, J.K. Leader, Y. Zhang, A.M. Morris, Z. Urban, F.C. Sciurba, Pittsburgh, PA, p.A3549

P966 **The Relationship Between Serum Ferritin Concentration and Lung Function in Korean People/**S. Myung Jin, E.K. Goag, S.Y. Kim, Y.S. Kim, Seodaemun-gu, Seoul, Korea, Republic of, p.A3550

P967 **Clinical Characteristics of COPD Patients with Robust Emphysema Progression/**A. Tsutsumi, S. Chubachi, M. Sasaki, M. Sato, N. Kameyama, T. Shirahata, H. Koh, Y. Oyamada, T. Inoue, H. Nakamura, K. Asano, T. Betsuyaku, Tokyo, Japan, p.A3551

P968 **Association of Respiratory Muscle Weakness with Cardiac Autonomic Modulation in Patients with Chronic Obstructive Pulmonary Disease/**R. Trimer, C.L. Goulart, J.C. Simon, N.A. Da Fonseca Miranda, P.D.B. Schneiders, E.A. San Martin, A. Borghi-Silva, A.L.G. Da Silva, Sao Carlos, Brazil, p.A3552

P969 **Results of a Pulmonologist Survey Regarding Attitudes and Practices with Inhalation Devices for COPD/**S.S. Braman, B.W. Carlin, R. Dhand, N.A. Hanania, D.A. Mahler, J.A. Ohar, V. Pinto-Plata, T. Shah, M. Turenne, D. Eubanks, New York, NY, p.A7816

P970 **Efficiency of Neural Respiratory Drive for the Assessment of Bronchodilator Responsiveness in Patients with Chronic Obstructive Pulmonary Disease: An Exploratory Study/**X. Chen, Y. Li, Y.-H. Li, Y.-W. Luo, K. Wang, Y.-T. Chen, Guangzhou, China, p.A7817

THEMATIC POSTER SESSION

B44 COPD: COMORBIDITIES

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area H, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: J.M. Bon, MD, MS, Pittsburgh, PA

P972 **Fibrinogen Is Not Associated with Cardiovascular and Muscular Co-Morbidities in Chronic Obstructive Pulmonary Disease: The ERICA Study/**D. Mohan, M.I. Polkey, J.R. Forman, C.M. McEniery, C.E. Bolton, J.R. Cockcroft, W. MacNee, J. Fuld, M. Marchong, N.S. Gale, M. Fisk, S. Nagarajan, J. Cheriyan, D.A. Lomas, P. Calverley, B.E. Miller, R. Tal-Singer, I.B. Wilkinson, King of Prussia, PA, p.A3553

P973 **Factors Determining the Presence of Osteoporosis in Active and Former Smokers with and Without Chronic Obstructive Pulmonary Disease/**P. Rivera-Ortega, J. Gonzalez-Gutierrez, P. Restituto, N. Varo, I. Colina, A. Calleja, M. Rodriguez, G. Bastarrika, A.B. Alcaide, A. Campo, J.J. Zulueta, J.P. De Torres, Pamplona, Spain, p.A3554

P974 **Risk Factors for Subclinical Osteopenia/Osteoporosis in Patients with Chronic Obstructive Pulmonary Disease/** H. Suzuki, Y. Yamamoto, S. Fujiuchi, A. Takeda, K. Doshita, H. Kuroda, M. Takahashi, T. Tsuji, Y. Fujita, Y. Yamazaki, T. Fujikane, Asahikawa, Japan, p.A3555

P975 **Sarcopenia and Osteopenia/Osteoporosis in Korean Men with COPD Based on KNHANES 2008-2011/**J.Y. Jung, J.A. Hwang, K.S. Jung, S.Y. Kim, S.K. Kim, J. Chang, C.M. Ahn, A.Y. Leem, J.H. Shin, Seoul, Korea, Republic of, p.A3556

P976 **Chest Subcutaneous and Mediastinal Fat and Their Associations with Emphysema and Bone Mineral Density/**J. Grace, J.K. Leader, J. Pu, D. Chandra, Y. Zhang, F.C. Sciurba, J.M. Bon, Pittsburgh, PA, p.A3557

P977 **Frequent Exacerbations of COPD Cause Loss of Antigravity Muscles -Quantitative and Longitudinal Analysis Using Chest CT/**K. Tanimura, S. Sato, A. Sato, K. Hasegawa, K. Uemasu, Y. Hamakawa, T. Oguma, T. Hirai, M. Mishima, S. Muro, Shogoin, Sakyo-ku, Japan, p.A3558

P978 **Anabolic Treatment of COPD-Associated Skeletal Muscle Wasting with Bimagrumab; Results of a Phase IIa Double-Blind RCT/** M.I. Polkey, D. Rooks, F. Franssen, D. Singh, M. Steiner, R. Casaburi, D. Laurent, R. Roubenoff, London, United Kingdom, p.A3559

P979 **Relationship of HMG CoA Reductase Inhibitors and Pulmonary Function in Individuals with HIV/**M. McLaughlin, M. Nouraie, N. Leo, C. Kessinger, M.E. Fitzpatrick, A. Morris, Pittsburgh, PA, p.A3560

P980 **Chronotropic Incompetence and Its Relation to Exercise Intolerance in Chronic Obstructive Pulmonary Disease/**J.-M. Liu, H. Liu, J. Guo, Q. Zhao, W. Yang, L. Wang, S. Gong, Shanghai, China, p.A3561

Facilitator: M.J. Divo, MD, Boston, MA

P981 **Effect of Unrecognized Emphysema on Re-Admission and Survival in Patients with Congestive Heart Failure/**P. Kohli, P. Staziaki, D. Addison, O. Hennessy, R. Takx, S. Janjua, T. Hallett, M. Lu, F. Fintelmann, U. Hoffmann, B. Celli, R.S. Harris, T. Neilan, Boston, MA, p.A3562

P982 **Effect of Emphysema on Re-Admission Rates and Survival in Individuals with Heart Failure/**P. Kohli, P. Staziaki, S. Janjua, T. Hallett, O. Hennessy, R. Takx, D. Addison, M. Lu, F. Fintelmann, U. Hoffmann, B. Celli, R.S. Harris, T. Neilan, Boston, MA, p.A3563

P983 **Perioperative Administration of Long-Acting β2 -Adrenoceptor Agonists Do Not Increase the Risk of Postoperative Atrial Arrhythmias After Pulmonary Resection for Non-Small Cell Lung Cancer in Patients with Chronic Obstructive Pulmonary Disease: A Propensi/**S. Marumo, K. Yamanashi, T. Fukui, R. Sumitomo, Y. Ohtake, M. Fukui, C.-L. Huang, Osaka, Japan, p.A3564

P984 **Prevalence and Predictors of Pulmonary Embolism in Severe Acute Exacerbation of COPD: A Systematic Review/**A. Shujaat, S. Sethi, Buffalo, NY, p.A3565

P985 **Impact of Sleep Quality on the Health Related Quality of Life of Patients with Chronic Obstructive Pulmonary Disease (COPD) in Ile-Ife, Nigeria/**A.O. Adetiloye, G.E. Erhabor, O.O. Adewole, O.F. Awopeju, D.O. Obaseki, B.O. Adeniyi, Ile-Ife, Nigeria, p.A3566

P986 **The Prevalence of Poor Sleep Quality in Patients with Chronic Obstructive Pulmonary Disease Referred for Pulmonary Rehabilitation/**M.M. Roberts, J.-G. Cho, J.R. Wheatley, Westmead, Australia, p.A3567

P987 **Impact of Diabetes in Patients with Chronic Obstructive Pulmonary Disease (COPD) in Developing Countries; Exploring Bidirectional Relationship and Complexities Beyond Co-Morbidity/**N. Bhatta, R. Maskey, P. Koirala, N. Baral, N.R. Karki, R.H. Ghimire, D. Mishra, B. Bista, M. Lamsal, Dharan, Nepal, p.A3568

P988 **Non-Hyperinflated Lungs in COPD Patients with Diabetes Mellitus/**R. Edahiro, S. Nishina, Y. Tamura, Y. Utsu, S. Ishii, A. Kogetsu, K. Okuro, M. Suzuki, M. Koseto, S. Sumitani, B. Sato, S. Kasayama, I. Tachibana, Osaka, Japan, p.A3569

Facilitator: P.M. Calverley, MBChB, Liverpool, United Kingdom

P989 **External Validation of the COTE Index/**Y. Abdou, V.G. Rodrigo, Albuquerque, NM, p.A3570

P990 **Validation of CODEX Index on Patients with Chronic Obstructive Pulmonary Disease in Hong Kong/**K.P. Chan, W.H. Yip, S.S. Ng, J. Ngai, K.W. To, F.W. Ko, D.S. Hui, Hong Kong, Hong Kong Prc, p.A3571

P991 **Factors Associated with Low-Level Physical Activity in Elderly Patients with Chronic Obstructive Pulmonary Disease/**K.U. Kim, S.H. Lee, Y.S. Kim, H.G. Lee, M.K. Lee, H.-K. Park, Busan, Korea, Republic of, p.A3572

P992 **Cluster Analysis Based on Comorbidities for Japanese COPD Patients/**S. Chubachi, A. Tsutsumi, N. Kameyama, M. Sato, M. Sasaki, M. Miyazaki, M. Nakamura, S. Takahashi, H. Nakamura, T. Terashima, K. Asano, T. Betsuyaku, Tokyo, Japan, p.A3573

P993 **The Impact of Depressive Symptoms on Acute Exacerbations in Patients with COPD: Results from a 3-Year Longitudinal Follow- Up of the ECLIPSE Cohort/**A.M. Yohannes, H. Mulerova, K. Lavoie, S. Rennard, J. Vestbo, E. Wouters, N.A. Hanania, Manchester, United Kingdom, p.A3574

P994 **Reported Pneumonia Events in the SUMMIT Trial/**C. Crim, J.A. Anderson, R.D. Brook, P.M.A. Calverley, B. Celli, S. Kilbride, F.J. Martinez, D.E. Newby, J. Yates, J. Vestbo, Research Triangle Park, NC, p.A3575

P995 **Depression Is a Significant Predictor in Both Disease-Specific and Generic Health Related Quality of Life in Patients with Severe Chronic Obstructive Pulmonary Disease/**H.G. Lee, S.M. Jang, S.E. Song, J.H. Mok, E.J. Jo, W.H. Cho, D. Jeon, K.U. Kim, Busan, Korea, Republic of, p.A3576

P996 **Exertional Hypoxemia in Stable COPD Is Common and Predicted by Co-Existing Non-Systic FibrosisBronchiectasis/**A. Sadigov, S. Akhundov, Baku, Azerbaijan, p.A3577

Facilitator: S.P. Bhatt, MD, Birmingham, AL

P997 **The Frequency of Comorbidities in Patients with COPD/**T. Akinci, O.E. Tunces, S. Keserci, V. Embel, M. Aydogan, S. Gumus, Ankara, Turkey, p.A3578

P998 **Comorbidities and One-Year Survival in Chronic Obstructive Pulmonary Disease/**Z. Alacam, N. Dursunoglu, N. Kokturk, H. Senol, Denizli, Turkey, p.A3579

P999 **Concordance Between Self-Reported and Chart-Based Assessment of Comorbidities in Veterans with COPD/** M. Teylan, D. Homsy, O. Okunbur, J. Gao, E. Garshick, M.L. Moy, Boston, MA, p.A3580

P1000 **Chronic Obstructive Pulmonary Disease, Cognitive Function and Mortality in a US National Cohort: NHANES-III/**Y. Odeyemi, F.T. Ogundipe, R. Gillum, A. Mehari, Washington, DC, p.A3581

P1001 **Spirometry and Cognitive Funtion in a US Natonal Cohort/**Y. Odeyemi, O. Lewis, A. Mehari, R. Gillum, Washington, DC, p.A3583

P1002 **Frequency of Community Acquired Pneumonia and Associated Risk Factors in a Primary Care Population of COPD Patients/**N. Williams, N.A. Coombs, L. Rigge, L. Josephs, M. Johnson, M. Thomas, T.M.A. Wilkinson, Southampton, United Kingdom, p.A3582

P1003 **Co-Morbidities Among COPD GOLD-U Are Higher Compared to Those with or Without Obstruction in NHANES/**S.D. Kumbhare, T. Beiko, C.B. Strange, Charleston, SC, p.A3584

P1004 **Evaluation of Fat Infiltration in the Quadriceps of Patients with Chronic Obstructive Pulmonary Disease/**S. Martineau, D. Patoine, A. Dube, V. Coats, S. Bonnet, F. Maltais, Quebec, Canada, p.A3585

THEMATIC POSTER SESSION

B45 OBSTRUCTIVE LUNG DISEASE: INTERESTING CASES

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area D, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: J.H. Hansen-Flaschen, MD, Philadelphia, PA

P470 **A Rheumatologic Disorder Mimicking Asthma/**M. Ferrada, D. Sufredini, A.J. Mazer, J. Katz, Bethesda, MD, p.A3586

P471 **Cough Syncope, an Unusual Presentation of Asthma in Adults/**O.T. Ojo, O. Ozoh, Lagos, Nigeria, p.A3587

P472 **Fixed Focal Stenosis Due to Airway Remodelling from Severe Asthma/**E.M. Rakowski, A.S. Lubinsky, New York, NY, p.A3588

P473 **Nine Cases of Bronchial Asthma Associated with Pulmonary Thromboembolism/**A. Ono, Y. Komase, H. Yamaguchi, N. Hida, T. Yamamoto, Yokohama-shi,, Japan, p.A3589

P474 **Paraneoplastic Hypereosinophilia Presenting with Non-Allergic Asthma and Rhinitis/**D.A. Kruse, K.L. Bailey, Omaha, p.A3590

P475 **Tracheobronchial-Esophageal Fistula in a 23 Year Old with "Asthma"/**U.S. Adil, M. Prekker, Minneapolis, MN, p.A3591

P476 **Allergic Bronchopulmonary Aspergillosis Masquerading as Repetitive Bacterial Pneumonia: A Case Report/**V. Le Thuong, L.H. Nguyen, Ho Chi Minh, Viet Nam, p.A3592

P477 **Successfully Managing a Potentially Near Fatal Asthma by Home Monitoring - A Case Report/**L. Maugeri, A. Gobbi, E. Mellano, E. Gatti, R.L. Dellaca, C. Gulotta, Orbassano, Italy, p.A3593

P478 **All that Wheezes Is Not Asthma but More so if Chest CT Shows Lung Nodules/**A. Aljaafareh, S. Daouk, N. Moguillansky, Gainesville, FL, p.A3594

Facilitator: K.A. Provost, DO, PhD, Buffalo, NY

P479 **Status Asthmaticus Treated with V-V ECMO in Less than 24 Hours/**N. Ali, H. Nazir, J. Lee, H. Seethamraju, Newark, NJ, p.A3595

P480 **Lung Placental Transmogrification/**A. Renno, A. Ali, A. Vasuki, R. Assaly, Toledo, OH, p.A3596

P481 **Alteration of Respiratory Reactance Before and After Bullectomy: A Case Study of the Patient with Bilateral Giant Bullae/**H. Hamakawa, K. Minami, I. Sakanoue, Y. Okubo, T. Saito, H. Date, Y. Takahashi, Kobe, Japan, p.A3597

P482 **More than Meets the Eye: A Previously Undescribed Cause of Horner's Syndrome/**S.B. Ahuja, R. Smith, New York, NY, p.A3598

P483 **A Rare Cause of Abdominal Compartment Syndrome; Tension Pneumothorax-Related Tension Pneumoperitoneum in a Patient with Bullous Emphysema/**M. Bergman, S. Thomas, Y.I. Lee, New York, NY, p.A3599

P484 **Nasal High-Flow Oxygen Therapy System for Improving Sleep-Related Hypoventilation in Chronic Obstructive Pulmonary Disease/**M. Okuda, N. Tanaka, K. Fukuda, R. Nohara, Osaka, Japan, p.A3600

P485 **Severe Bullous Emphysema with Tension Pneumothorax from an Unusual Underlying Etiology/**A.V. Chandran, J. Devasahayam, D. Chairman, Columbia, MO, p.A3601

P486 **Anomalous Brachiocephalic Artery as a Cause of Stridor in an Adult During an Acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)/**E. Jabbour, S. Morais, J. MacLeod, A. Goizueta, J. Meharg, Providence, RI, p.A3602

P487 **Swyer-James-MacLeod Syndrome Misdiagnosed as COPD/**Y.S. Intepe, B. Metin, F. Gundogdu, A. Okur, Yozgat, Turkey, p.A3603

Facilitator: G.E. Westney, MD, Atlanta, GA

P488 **Yellow Nail Syndrome/**M.S. Switzer, W.A. Lewis, J. Nations, Bethesda, MD, p.A3604

P489 **Late Diagnosis of Primary Ciliary Dyskinesia in a Kuwaiti 38-Year-Old Male/**R. Peterson, R. Boente, S. Peterson-Carmichael, S.D. Davis, K. Diab, C.D. Brown, Indianapolis, IN, p.A3605

P490 **Evaluation for Primary Immunodeficiency in a Patient with a Historical Diagnosis of Primary Ciliary Dyskinesia/**J. Zibert, S. Hayat, D. Polineni, Kansas City, KS, p.A3606

P491 **New Diagnosis of Swyer-James-Macleod Syndrome in An Adult: A Case Report/**J. Patel, C.-F. Chang, Los Angeles, CA, p.A3607

P492 **Pneumatocele in an Adult: Case Report and a Review of the Literature/**M. Splittgerber, B. Pancholy, Tampa, FL, p.A3608

P493 **Unexplained Hypokalemia in Atypical Host for Allergic Bronchopulmonary Aspergillosis/**A. Ali, Y.A. Al Ahwel, A. Milad, A. Renno, H. Simo, F. Safi, R. Assaly, Toledo, OH, p.A3609

P494 **Direct Bronchoscopic Instillation of Dornase Alfa for Treatment of Cystic Fibrosis-Related Atelectasis/**A. Rothman, C. Peng, M. Berdella, P. Walker, New York, NY, p.A3610

P495 **ECMO for Respiratory Failure Complicating Bronchial Artery Embolization for Hemoptysis in Cystic Fibrosis/**J.P. Wynne, J. Salgado, J. Lascano, Gainesville, FL, p.A3611

Facilitator: C.L. Kuntz, MD, MS, Wynnewood, PA

P496 **Successful Treatment of Acute Respiratory Distress Syndrome in a Cystic Fibrosis Patient with Multi-Drug Resistant Burkholderia Pneumonia and Cepacia Syndrome/**C.S. Tsai, C.T. Shoff, J. Stamm, Danville, PA, p.A3612

P497 **Mounier-Kuhn Syndrome and Cystic Fibrosis Coexist in the Same Patient with Chronic Respiratory Failure/**Y. Beddawi, M. Khosravi, Lexington, KY, p.A3613

P498 **New Diagnosis of Cystic Fribrosis in an Elderly Patient/**V.D.A. Mangulabnan, A. Rao, Los Angeles, CA, p.A3614

P499 **3-D Reconstruction of Low-Dose Dynamic CT Imaging as a Decision Aid in Tracheobronchomalacia/**M. Shafiq, H. Guo, A. Sung, Stanford, CA, p.A3615

P500 **Facial Burns from an E-Cigarette Explosion/**L. Carrasco, K. Win, O. Adesuyi, E. Wilson, G. Pesola, New York, NY, p.A3616

P501 **E-cigarettes, Mineral Oil and Familial Mediterranean Fever- The Perfect Mix/**N. Ramesh, M. Lau, J. Filopei, M. Harris, New York, NY, p.A3617

P502 **Lung Age with Ex-Smokers and Non-Smokers at Annual Medical Checkup/**M. Fukakusa, Y. Ichikawa, Y. Ishida, K. Masuda, Tokyo, Japan, p.A3618

P503 **Causes of Smoking Cessation in Former Smokers Hospitalized Patients/**E.J. Soto Hurtado, M.D. Almenara Escribano, A. Rodriguez Sanchez, L. Garcia Aranguena, Ronda, Spain, p.A3619

THEMATIC POSTER SESSION

B46 CRITICAL CARE: ICU EPIDEMIOLOGY AND OUTCOMES

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area K, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitators: H. Wunsch, MD, MSc, Toronto, Canada
G.L. Anesi, MD, MBE, Philadelphia, PA

P1127 **External Validation of a Claims-Based ICU Risk-Adjustment Methodology/**K.R. Courtright, E. Raneses, M.O. Harhay, P. Kipnis, G.J. Escobar, S.D. Halpern, M.P. Kerlin, Philadelphia, PA, p.A3620

P1128 **Identification of Mechanically Ventilated Patients Using Administrative Data/**K. Wonneberger, V. Madden, S. Kent, V. Liu, S.D. Halpern, M.P. Kerlin, Philadelphia, PA, p.A3621

P1129 **Patient Recruitment Rate in Multi-Centered Randomized Trials in Critical Care/**S.R. Nalamalapu, D.M. Needham, R.D. Stapleton, Baltimore, MD, p.A3622

P1130 **Benchmarking the Demand for Critical Care Services Among Hospitalizations with Cirrhosis in Texas 2001-2010/**L. Oud, Odessa, TX, p.A3623

P1131 **Signs Associated with the Clinical Decision to Institute Mechanical Ventilation in Patients with Acute Respiratory Failure: A Case-Control Study/**S. Sukhal, A. Tulaimat, Chicago, IL, p.A3624

P1132 **Quantifying the Number of Key Elements to Be Displayed in a Health History Timeline for ICU Patients/**M.E. Nolan, B.W. Pickering, V. Herasevich, Rochester, MN, p.A3625

P1133 **Physician-Written Blogs and the People Who Write Them/**T.D. Walker, D.A. Schwartz, J. Swigris, Aurora, CO, p.A3626

P1134 **Publication Bias in Critical Care Animal Research Presented at the 2008 SCCM Conference/**U. Conradi, A.R. Joffe, Edmonton, Canada, p.A3627

P1135 **Heparin-Induced Thrombocytopenia: Low Yield and Diagnostic Complexity in Critically Ill Patients/**I. Kourouni, S.F. Noronha, M. Varma, J. Shapiro, New York, NY, p.A3628

P1136 **Severe Acute Pancreatitis in Critically Ill Patients Admitted to a High Acuity Tertiary Referral Centre in Australia/**K. Sundararajan, T. Schoeman, L. Hughes, M. Rushton, S. Edwards, B.A.J. Reddi, Adelaide, Australia, p.A3629

Facilitators: W. Checkley, MD, PhD, Baltimore, MD
A.C. Long, MD, MS, Seattle, WA

P1137 **Prevalence of Unrecognized Pre-Diabetes Among Critically Ill Patients Without Stress Hyperglycemia/**S. Arfaie, C. Aguilar, K. Parekh, S. Atlas, A. Sharma, J. Fine, Norwalk, CT, p.A3630

P1138 **Sorry, You're Too Big for Our Scanners: Frequency of Diagnostic Imaging Deferment Due to Weight or Body Habitus in Obese ICU Patients/**S. Shek, M. Duttuluri, D. Teplitsky Nes, R. Jean, New York, NY, p.A3631

P1139 **Estimating the Proportion of Patients "Too Well" to Benefit from Critical Care: A Machine Learning Approach/**K. Vranas, J. Jopling, M. Ramsey, T.E. Sweeney, G.J. Escobar, V. Liu, Portland, OR, p.A3632

P1140 **A Retrospective Review of Admissions to an Obstetric ICU/**D.K. Narendra, V. Bandi, N. Hall, S.L. Clark, M.A. Belfort, K.K. Guntupalli, Houston, TX, p.A3633

P1141 **A Case-Control Study on Risk Factors of Acquired Swallowing Disorders Among Patients After Cardiac Surgery in China/**M. Zhou, T. Liang, Beijing, China, p.A3634

P1142 **Pain Assessment in Cardiothoracic Intensive Care Units: A Snapshot Audit of Practice in London Intensive Care Units/**K.C. Tatham, H. Laycock, H. Wordsworth, London, United Kingdom, p.A3635

P1143 **Factors Associated with Poor Functional Outcome in Patients with Aneurysmal SAH in a Community Hospital/**L. Gupta, A. Vivek, K. Hassan, San Jose, CA, p.A3636

P1144 **Developing Guidelines for Post Traumatic Stress Disorder Symptoms Associated with Critical Illness/**J.J.B.J. Williams, L. Ting, Newark, NJ, p.A3637

P1145 **Value of Serial Neutrophil Gelatinase-Associated Lipocalin (NGAL) Measurement to Predict Renal Outcomes of Intensive Care Unit Patients/**Y.H. Choe, M.Y. Lee, S.H. Kim, J.Y. Lee, S.Y. Park, S.R. Kim, S.J. Park, Y.C. Lee, H.B. Lee, Jeonju, Korea, Republic of, p.A3638

P1146 **High Fluoride Levels with Isoflurane Critical Care Sedation Does Not Cause Nephrotoxicity/**A. Jerath, A. Steel, N. Ferguson, M. Wasowicz, Toronto, Canada, p.A3639

Facilitators: M.A. Tidswell, MD, Springfield, MA
L.E. Ferrante, MD, New Haven, CT

P1147 **Predictors and Outcomes of Prolonged Weaning Among Intubated Patients on Mechanical Ventilation Admitted to the Intensive Care Unit/**A.S. Awaloei, C. Uy, Davao City, Philippines, p.A3640

P1148 **The New Score Made by Combination of Delta Neutrophil Index and Thrombotic Microangiopathic Score as Prognostic Marker in the Critically Ill Patients/**E.K. Goag, J.H. Song, Y.S. Lee, M.S. Park, Y.S. Kim, S.K. Kim, J. Chang, K.S. Chung, Seodaemun-gu, Seoul, Korea, Republic of, p.A3641

P1149 **Marital Status Does Not Explain the Male Predominance of ICU Admission Among Home Care Clients/**A. Hill, C.D. Ramsey, P. Dodek, J. Kozak, M. Doupe, R. Fowler, H. Wong, R. Fransoo, D.C. Scales, A. Garland, Toronto, Canada, p.A3642

P1150 **Is There a Correlation Between Admitting Diagnosis and the Development of Ventilator Associated Events VAEs?/**R. Nakity, A. Kubbara, W. Barnett, F. Khateeb, N. Almeshal, M. Ruzieh, O. Dasa, S.U. Rehman, R. Assaly, Toledo, OH, p.A3643

P1151 **Low T3 Syndrome as a Predictor of Mortality in Critically Ill Patients, a Meta-Analysis and Review/**T. Salim, S. Fakhran, V. Ravi, Chicago, IL, p.A3644

P1152 **Acute Kidney Injury Sub-Phenotypes Based on Creatinine Trajectory Identifies Critically Ill Patients at Increased Risk of Death/**P. Bhatraju, P. Mukherjee, C. Robinson-Cohen, J.D. Christie, N.J. Meyer, M. Matthay, C.S. Calfee, G. O'Keefe, D.C. Christiani, J. Himmelfarb, M.M. Wurfel, Seattle, WA, p.A3645

P1153 **Mortality Predictors in Patients with Diabetic Ketoacidosis and Respiratory Failure/**T. Pandya, R. Sekhon, Z. Ghazarian, M. Labban, M. Hanna, M.A. Khan, Paterson, NJ, p.A3646

P1154 **Neurological and Survival Outcome After Therapeutic Hypothermia at a Large Community Hospital/**L. Premachandra, K. Abed, G. Singh, E. Hamaty, Atlantic City, NJ, p.A3647

P1155 **The Effect of Low Phosphate Levels on Respiratory Failure and Mortality in Critically Ill Patients/**C.K. Federspiel, T.S. Itenov, K.M. Thormar, M. Bestle, Hillerod, Denmark, p.A3648

P1156 **Association Between Vitamin D Deficiency and In-Hospital Mortality in Intensive Care Unit: A Systematic Review and Meta-Analysis/**S. Upala, A. Sanguankeo, Cooperstown, NY, p.A3649

Facilitators: T.W. Rice, MD, MSc, Nashville, TN
P.D. Sottile, MD, Aurora, CO

P1157 **Hypomagnesemia and Mortality in Patients Admitted to Intensive Care Unit: A Systematic Review and Meta-Analysis/**S. Upala, A. Sanguankeo, Cooperstown, NY, p.A3650

P1158 **Mortality Predictors in Intubated African American Patients in a Community Hospital: A Retrospective Study/**S. Kandel, F. Schmidt, P. Kharel, P. Datar, O. Abdulfattah, S. Pandey, S. Ghosh, S. Roy, M. Khalid, C. Agu, M. Basunia, D. Salhan, D. Enriquez, J. Quist, Brooklyn, NY, p.A3651

P1159 **Increased Time of Blood Glucose in Range 70-139 mg/dL Is Strongly Associated with Decreased Mortality in Critically Ill Adults/**M.J. Lanspa, E. Hirshberg, A.M. Hersh, J. Holmen, J. Orme, A. Morris, J.S. Krinsley, Murray, UT, p.A3652

P1160 **Incidence, Risk Factors and Outcomes of Acute Kidney Injury in Two Rwandan Intensive Care Units/**E. Buregeya, E. D Riviello, M.L. Beach, T. Twagirumugabe, Kigali City, Rwanda, p.A3653

P1161 **Long Term Outcomes from a Single Chronic Ventilator Unit: A 5-Year Assessment/**P. Galiatsatos, D. Dababneh, T. Friedlander, D.J. Feller-Kopman, D. Kelly, T. Finucane, M. Bellantoni, D.B. Pearse, W. Greenough, Bethesda, MD, p.A3654

P1162 **The Association Between Pro B- Type Natriuretic Peptide Levels and Mortality in Pneumonia Cases with Acute Respiratory Failure/**Z. Karakurt, I. Ozmen, C. Salturk, F. Kargin, H. Takir, E. Aksoy, R. Sari, E. Celik, E. Acarturk, E. Yildirim, O. Mocin, N. Adiguzel, G. Gungor, S. Oztas, S. Gungor, O. Sogukpinar, P. Atagun, Istanbul, Turkey, p.A3655

P1163 **The Ability of Acute Physiology and Chronic Health Evaluation (APACHE) IV Score for Mortality Prediction in Patients Admitted to The ICU; a Single Center Study/**J.W. Choi, Y.H. Park, I.S. Kwon, Y.S. Park, D.I. Park, C.-U. Chae-Uk Chung, M.R. Park, S.M. Hwang, C.U. Jung, H.S. Park, J.E. Lee, S.S. Jung, J.O. Kim, S.Y. Kim, J.Y. Moon, Daejeon, Korea, Republic of, p.A3656

P1164 **Predictors of Mortality in Patients with Hematologic Malignancies Admitted to the ICU - A Prospective Observational Study/**N. Al-Zubaidi, A. Soubani, Detroit, MI, p.A3657

P1165 **Variables of Two Intensive Care Units in Puerto Rico Compared with Studies Done in United States/**J.E. Nieves-Scharon, G.J. Gonzalez Astacio, P. Torrellas Ruiz, H.J. Maldonado Quintana, M. Cruz Caliz, R.A. Hernandez, R. Fernandez Gonzalez, A. Rodriguez, C. Martinez, San Juan, PR, p.A3658

P1166 **Real-Time Automated Continuous Sampling of Electronic Medical Records Predicts Hospital Mortality/**H.S. Khurana, R.H. Groves, M.P. Simmons, M. Martin, B. Stoffer, S. Kou, R. Gerkin, E. Reiman, S. Parthasarathy, Mesa, AZ, p.A7818

P1167 **A Comparison of Insulin Resistance in Patients Enrolled in a Randomized Controlled Trial of Early Mobilization/**S. Giovanni, B.K. Patel, K.S. Wolfe, A.S. Pohlman, J.B. Hall, J.P. Kress, Chicago, IL, p.A7819

P1168 **Does Mechanical Ventilation During Critical Illness Affect Long Term Cognitive Decline After Intensive Care Unit (ICU) Discharge/** A. Sakusic, J.C. O'Horo, T.D. Singh, R.O. Rosebud, G. Jenkins, R. Petersen, A.A. Rabinstein, O. Gajic, Rochester, MN, p.A7820

P1169 **Perceived Severity of Illness of Interhospital Critically Ill Transfers Impacts Data Utilized by Healthcare Providers/**K. Pennington, A. Kogan, J. Jensen, O. Gajic, J. O'Horo, Rochester, MN, p.A7821

THEMATIC POSTER SESSION

B47 CRITICAL CARE: CLINICAL RESEARCH DISCOVERIES, EPIDEMIOLOGY, AND HEALTH SERVICES FOR SEPSIS

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area K, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitators: G.S. Martin, MD, MSc, Atlanta, GA
C.M. Shaver, MD, PhD, Nashville, TN

P1171 **The Use of Procalcitonin Test in Patients with Sepsis: A Systematic Review and Meta-Analysis/**H.J. Lee, S. Cho, J.K. Suh, B. Jang, S.-M. Lee, J. Kim, S.-B. Hong, S. Na, H. Ryu, K. Jeon, M. Ko, E. Jang, Seoul, Korea, Republic of, p.A3659

P1172 **Improving Time to Antibiotics for Medical Intensive Care Unit Patients with Septic Shock: Risk Factor Prediction/**S.M. Lemieux, J.J. Heavner, J.M. Siner, G.E. Morris, L. Devaux, J.E. Topal, A.D. Anderson, S. Bagwell, M.S. Heavner, New Haven, CT, p.A3660

P1173 **Factors Associated with Delays in Antibiotic Therapy in Patients with Septic Shock/**S. Arora, H. Taha, R. Nanchal, Wauwatosa, WI, p.A3661

P1174 **Factors Associated with Appropriateness of Initial Antibiotic Therapy in Culture Positive Patients with Septic Shock/**S. Arora, R. Nanchal, Milwaukee, WI, p.A3662

P1175 **L-Carnitine Utilization Reflects Acyl-Carnitine Metabolism in Septic Shock Patients/**K.A. Stringer, C. Evans, M. Puskarich, A. Karnovsky, A.E. Jones, Ann Arbor, MI, p.A3663

P1176 **Clinical Significance of Serum Developmental Endothelial Locus-1 (Del-1) in Patients with Severe Sepsis/**G.R. Chon, Y. Koh, C.-M. Lim, J.W. Huh, E.Y. Choi, Y.Y. Park, S.-B. Hong, Chungju, Korea, Republic of, p.A3664

P1177 **Validation of Rapid Ultrafiltration-Immunoassay Method to Measure Free Cortisol in Critically Ill Septic Patients/**A.R. Mitra, J. Mackenzie-Feder, D. Li, D. Sweet, W. Henderson, D. Griesdale, M. Pudek, V. Dhingra, Vancouver, Canada, p.A3665

P1178 **Human Chitinases and Chitinase-Like Protein (C/CLP) as Predictors of Sepsis Due to Pneumonia/**C.R. Marion, N. Andrews, J. Herazo-Maya, A. Losier, L. Sharma, T. Tolbert, W. Liu, C. Dela Cruz, New Haven, CT, p.A3666

P1179 **Use of a Novel Modified Aptamer-Based Assay in a Pilot Evaluation of Plasma from Subjects with Alcohol Use Disorders/**A. Kaur, T.L. Phang, A. McNally, J. Gaydos, E.L. Burnham, Aurora, CO, p.A3667

Facilitators: K.A. Hibbert, MD, Boston, MA
S. Beesley, MD, Salt Lake City, UT

P1180 **Microvascular Metastasis and High Tumor Burden: Independent Risk Factors to Cause Malignancy Related Shock-An Autopsy Study/**M.A. Farooq, M.M. Adnan, C. Deel, A. Awab, Oklahoma City, OK, p.A3668

P1181 **Performance of Diastolic Based Shock Indices in Adults with Sepsis/**A. Otekeiwebia, Lexington, KY, p.A3669

P1182 **Sepsis Differentially Increases Protein Synthesis in Circulating Human Platelets/**E.A. Middleton, R.A. Campbell, H.D. Major, E.S. Harris, A.S. Weyrich, N.D. Tolley, G.A. Zimmerman, Salt Lake City, UT, p.A3670

P1183 **Searching for New Approaches to Recognizing Hemophagocytic Lymphohistiocytosis (HLH): A Meta-Analysis on Characteristics and Significant Laboratory Data of 628 HLH Patients/**Y.C. Yeh, R.A. Quintana-Quezada, S. Sahay, Houston, TX, p.A3671

P1184 **Effectiveness of Computerized Check Points in Reducing Inappropriate Use of Stress Ulcer Prophylaxis: Benefits and Unintended Consequences/**J. Danley, M. Calder, S. Penna, C.P. Farrell, K.C. Blenner, C.L. Kuntz, Media, PA, p.A3672

P1185 **Time Is It! Before and After Standardizing the Controversial Sepsis Resuscitation Bundle in a Large Hybrid Academic Center/**T. Ferreira, W. Sneij, R. Beg, Y. Brito, Y. Buryk, A. Wawrzyniak, L. Abbo, J. Falise, L. Lupe, S. Soorus, D. Ashley, D. Lang, Y. Diaz, Miami, FL, p.A3673

P1186 **Initial Management of Severe Sepsis in Adults Admitted to a Thai Regional Referral Hospital: A Prospective Observational Study/**K.E. Rudd, V. Hantrakun, P. Teparrukkul, S. Booraphun, N.P. Day, D. Limmathurotsakul, T.E. West, Seattle, WA, p.A3674

P1187 **Comparison of a Novel Coding Algorithm Versus the American Burn Association Sepsis Definition to Examine the Epidemiology of Sepsis in Burn-Injured Adults/**M.A. Rech, M.J. Mosier, S. Zelisko, R.S. Cooper, G. Netzer, E.J. Kovacs, M. Afshar, Maywood, IL, p.A3675

P1188 **Risk Factors for Thirty-Day Readmissions Among Sepsis Survivors at a Safety Net Hospital/**K. Styrvoky, M. Weinreich, C.E. Girod, R.M. Ruggiero, Dallas, TX, p.A3676

Facilitators: A. Amaral, MD, Toronto, Canada
H.C. Prescott, MD, MA, Ann Arbor, MI

P1189 **The Relationship Between Sepsis and Adverse Hospital Readmission Outcomes/**B.W. Dietz, T.K. Jones, D.S. Small, D.F. Gaieski, M.E. Mikkelsen, Philadelphia, PA, p.A3677

P1190 **Assessing the Accuracy of UHC Calculated Predicted Sepsis Mortality at Parkland Hospital/**S.E. Prieto, M. Leveno, R.M. Ruggiero, T. Chung, M. Bartlett, Dallas, TX, p.A3678

P1191 **To Determine the Risk Factors Associated with Mortality in Patients with Vancomycin Resistant Enterococci Bacteremia/**N.E. Mathew, J. Benavidez, W. Aslam, Y. MunozMaldonaldo, Y. Liu, R. Fader, V. Brito, S. Ghamande, Temple, TX, p.A3679

P1192 **Increased Ratio of Visceral to Subcutaneous Adipose Tissue in Septic Patients Is Associated with Adverse Outcome/**C. Pisitsak, J.G.H. Lee, J.H. Boyd, H.O. Coxon, J.A. Russell, K. Walley, Vancouver, Canada, p.A3680

P1193 **The CURB-65 Score Used as a Predictor of Mortality in Critically Ill Patients with Non Respiratory Sepsis/**S.D. Leiva, G. Vaca Ruiz, C.M. Luna, Buenos Aires, Argentina, p.A3681

P1194 **Exploring an Association of QT-Dispersion and Sepsis Outcomes in the Critically Ill/**P. Agarwal, M.B. Warner, M.J. Sanley, A.G. Vinayak, Washington, DC, p.A3682

P1195 **Association Between the Abdominal Adiposity and Mortality in Septic Shock/**Y.-J. Jeong, Y.-S. Kang, Y.-S. Yoon, J.Y. Oh, Koyang-city, Korea, Republic of, p.A3683

P1196 **Risk Factors for Mortality in Critically Ill Patients Requiring New Renal Replacement Therapy/**F. Sun, A. Cui, S. Lokhandwala, P. Tyler, M. Shen, D. Paul, T. Pollard, Boston, MA, p.A3684

P1197 **The Effectiveness of Early Goal-Directed Therapy in Patients with Septic Shock: A Meta-Analysis of Randomized Controlled Trials and Prospective Cohort Studies/**Y.-W. Kuo, S.-Y. Ruan, J.-S. Jerng, K.A. Chan, Douliou City, Taiwan, p.A3685

Facilitators: D.C. Scales, MD, PhD, Toronto, Canada
D.W. Ford, MD, MSCR, Charleston, SC

P1198 **Prognostic Value of Serum Vitamin D Binding Protein, 25-Hydroxyvitamin D3 and 1,25-Dihydroxyvitamin D3 in Sepsis Patients/**D. Zhang, P. Yan, X. Liu, H. Gu, L. Xie, Beijing, China, p.A3686

P1199 **The Adjusted Effect of Increased Body Mass Index on Mortality in Patients Requiring ICU Admission for Severe Sepsis and Septic Shock or Influenza: A Systematic Review and Meta-Analysis/**D.J. Pepper, J. Sun, J. Welsh, X. Cui, A. Suffredini, P. Eichacker, Bethesda, MD, p.A3687

P1200 **Epidemiology and Predictors of Outcome in Patients with Sepsis and Related Syndromes Admitted to a Medical Intensive Care Unit: A Prospective Study/**A. Mohan, J. Harikrishna, S.N. Challa, K.V.S. Sarma, B.S. Kumar, Tirupati, India, p.A3688

P1201 **Etomidate in Critically Ill Surgical Patients Is Not Associated with Adrenal Insufficiency or Mortality/**O. Szereszowiec, L. Hansen, A. Baig, J. Nicastro, C. Smith, R. Barrera, Manhasset, NY, p.A3689

P1202 **Is Troponin Elevation in Pre-Existing Cardiovascular Disease Prognostic in Sepsis Survival?/**A. Mora, G. Tsai-Nguyen, R. Gardner, T. Endicott-Yazdani, T.K. Ynosencio, A.L. Smith, Dallas, TX, p.A3690

P1203 **Epidemiology and Outcomes of Sepsis in Two Intensive Care Units in Rwanda/**J. Nzarora, M.L. Beach, E.D. Riviello, T. Twagirumugabe, Kigali, Rwanda, p.A3691

P1204 **Shock in an Ethiopian Medical Intensive Care Unit: Characteristics and Outcomes at Tikur Anbessa Specialized Hospital (TASH) in Addis Ababa, Ethiopia/**N. Navuluri, A. Worku, A. Sultan, L. Selassie, A. Shumet, K. G/Selassie, A. Bekele, C. Sherman, M. Parekh, N.W. Schluger, New York, NY, p.A3692

P1205 **Association Lactate Reduction in Severe Sepsis Hospital Outcomes/**A. Vengerovsky, R. Kashyap, L. Garcia Aguello, J.G. Park, Rochester, MN, p.A3693

P1206 **Implementation of a Tetanus Treatment Protocol in A Sub-Saharan African Intensive Care Unit Improves Patient Mortality And Increases Length Of Stay/**R. Aziz, J.R. Kingery, P. Moschovis, Bugando, Tanzania, p.A7822

P1207 **Impact of Severe Sepsis and Septic Shock Early Management Bundle (SEP-1) on Ward Patients/**X. Han, A.M. Snyder, C. Barc, S. Sokol, N. Pettit, M.D. Howell, D.P. Edelson, M.M. Churpek, Chicago, IL, p.A7823

P1208 **Decreasing Trend of In-hospital Mortality for Sepsis, Severe Sepsis, and Septic Shock: A US Nationwide In-Patient Database Analysis from 2007-2011/**C.-P. Wu, Y.-W. Chen, V. Reddy, A. Hafiz, M.-J. Wang, New York, NY, p.A7824

THEMATIC POSTER SESSION

B48 ASTHMA: INSIGHTS FROM THE BENCH, GENETICS, AND EPIDEMIOLOGY

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area B, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: S.M. Tarlo, MBBS, Toronto, Canada

P203 **Assessment of Asthma and COPD Prevalence: A Comparison Between Three Different Data Sources/**F. Borlee, J. Yzermans, E. Krop, B. Aalders, J.-P. Zock, C. Van Dijk, K. Maassen, F. Schellevis, D. Heederik, L.A.M. Smit, Utrecht, Netherlands, p.A3694

P204 **Prevalence and Risk Factors of Asthma and Asthma Symptoms Among Children Aged 5 -15 Years in Esmeraldas Province, Ecuador: A Cross-Sectional Study Analysis/**E.O. Evbuomwan, C. Ardura-Garcia, L. Melani, J. Blakey, Liverpool, United Kingdom, p.A3695

P205 **Amish Settlements Have Similar Rates of Asthma Despite Differing Exposures/**R. Bascom, K. Miller, A.E.F. Dimmock, K.H.G. Walters, D.R. Gold, Z.E. Adams, S. Thompson, D. Draguljic, C. Abbott, B. Yost, Hershey, PA, p.A3696

P206 **Socioeconomic Position and Asthma Control in a French Elderly Women Population/**S. Temam, S. Chanoine, A. Bedard, F. Clavel-Chapelon, O. Dumas, M. Sanchez, V. Siroux, S. Rican, R. Varraso, N. Le Moual, VilleJuif, France, p.A3697

P207 **Household Food Insecurity Access and Asthma Control Association in Peruvian Children/**C.E. Tarazona-Meza, K.M. Romero Rivero, S.L. Pollard, R. Galvez, P. Breysse, N.N. Hansel, W. Checkley, Lima, Peru, p.A3698

P208 **Short-Term Effects of Airport-Associated Ultrafine Particle Exposure on Lung Function and Inflammation/**R. Habre, S.P. Eckel, S. Fruin, T. Enebish, E. Rappaport, F. Gilliland, Los Angeles, CA, p.A3699

P209 **Immunologic Effect of Ozone and PM2.5 from Mexico City in a Guinea Pig Asthma Model/**L.I. Garcia-Alonso, C.I. Falcon-Rodriguez, A. Osornio-Vargas, N. Manzano-Leon, I. Rosas-Perez, A. De Vizcaya-Ruiz, P. Segura-Medina, Mexico City, Mexico, p.A3700

Facilitator: K.G. Tantisira, MD, Boston, MA

P210 **Western Environments/Lifestyles Have Changed Upper Airway Microbiota in Chinese Immigrants/**X. Zhang, C. Peacock, E. Filipovska-Naumovska, A. Saiganesh, S. Chen, S.-K. Khoo, B.J. Hales, P. Le Souef, G. Zhang, Perth, Australia, p.A3701

P211 **Work-Related Respiratory Symptoms and Self-Reported Asthma in British Woodworkers/**R.E. Wiggans, J. Sumner, E. Robinson, C.M. Barber, Buxton, United Kingdom, p.A3702

P212 **The Usefulness of a Questionnaire in a Preliminary Diagnosis of Work-Related Asthma/**A.A. Lipinska-Ojrzanowska, M. Wiszniewska, J.M. Walusiak-Skorupa, Lodz, Poland, p.A3703

P213 **Asthma and Asthma-Like Symptoms Among Veterans' Administration Healthcare Workers/**A.S. Laney, L.M. Kurth, M.A. Virji, E. Storey, S. Framberg, C. Kallio, J. Fink, Morgantown, WV, p.A3704

P214 **Prognosis of Diisocyanate-Induced Occupational Asthma: A Systematic Review/**N. Uppal, S. Bhinder, M. Ribeiro, S. Chaudhry, M.B. Stanbrook, G. Liss, S.M. Tarlo, Toronto, Canada, p.A3705

P215 **Characteristics of Work Aggravated Asthma in the United Kingdom (UK)/**L. Bradshaw, J. Sumner, P.K. Henneberger, D. Fishwick, Buxton, United Kingdom, p.A3706

Facilitator: L. Avila, MD, San Jose, Costa Rica

P216 **An Epidemiological Study of Bronchial Asthma in Greenhouse Farmers in Liaoning Province from 2006 to 2009/**S. Liu, G.X. Wang, Shenyang, China, p.A3707

P217 **An Evaluation of Nonresponse and Bias in a Study of Asthma in Healthcare Workers/**P.K. Henneberger, M.J. Humann, X. Liang, A.B. Stefaniak, R.F. LeBouf, M.L. Stanton, M.A. Virji, Morgantown, WV, p.A3708

P218 **Whole Genome Sequencing to Identify Genetic Variation Associated with Bronchodilator Response in Minority Children with Asthma/**A.C. Mak, M.J. White, C. Eng, D. Hu, S. Huntsman, S. Oh, M.A. Seibold, P.-Y. Kwok, D.G. Torgerson, R. Hernandez, E.G. Burchard, San Francisco, CA, p.A3709

P219 **Post-Traumatic Stress Disorder Dimensions and Asthma Morbidity in World Trade Center Rescue and Recovery Workers/**I. Mindlis, E. Morales, E.R. Goodman, K. Xu, C. Vilacastelar, K. Keller, G. Crawford, S. James, C.L. Katz, L.E. Crowley, R.E. de la Hoz, S. Markowitz, J.P. Wisnivesky, New York, NY, p.A3710

P220 **Mouse Model of Adult-Onset Allergic Asthma/**Y.M. Ahn, J.H. Shin, K.E. Pinkerton, Davis, CA, p.A3711

P221 **Seasonal Alterations of Respiratory Symptoms and the Health Status Among Mongolian Patients with Chronic Obstructive Pulmonary Disease and Bronchial Asthma: The Pilot Study/**M. Nakao, K. Yamauchi, Y. Ishihara, B. Solongo, D. Ichinnorov, Kurume, Japan, p.A3712

Facilitator: E. Brigham, MD, Baltimore, MD

P222 **Airway C-Reactive Protein Levels Correlate Positively with Body Mass Index/**M.H. Almond, E. Bakhsoliani, M.R. Edwards, S.L. Johnston, London, United Kingdom, p.A3713

P223 **Identification of a Sub-Group of Asthma Patients Prone to Exacerbations Due to Common Colds Using a Novel Epidemiological Method/**C. McCrae, L. Ekerljung, R. Mincheva, P. Gustafson, J. Lotvall, Molndal, Sweden, p.A3714

P224 **Adherence to Guideline-Recommended Asthma Medication Has no Impact on Healthcare Resource Utilization and Costs in Inadequately Controlled Asthma Patients/**J. Casciano, Z. Dotiwala, C. Li, S. Sun, White Plains, NY, p.A3715

P225 **Direct Cost-of-Illness Study of Asthma in Quebec/**L. Blais, C. Lemiere, A. Forget, F.-Z. Kettani, T. Dang-Tan, S. Zhang, D. Corriveau, A. Ismaila, Montreal, Canada, p.A3716

P226 **Psychosocial, Quality of Life and Socioeconomic Outcomes of Patients with Work-Related Asthma and Relationships to Different Models of Clinic Organization/**J.C. Lipszyc, F. Silverman, D.L. Holness, G.M. Liss, K.L. Lavoie, S.M. Tarlo, Toronto, Canada, p.A3717

P227 **The Effect of Co-Morbidities on Productivity Loss in Patients with Asthma/**S. Ehteshami-Afshar, J.M. FitzGerald, C. Carlsten, R. Rousseau, W.C. Tan, J.D. Rolf, M. Sadatsafavi, Vancouver, Canada, p.A3718

P228 **Asthma Triggered by Wildfires Can Be Measured Via Smartphone App: The Asthma Mobile Health Study/**I. Gowda, N. Genes, N. Tignor, P. Wang, Y.-F.Y. Chan, S. Hershman, M. Zweig, S. Violante, E. Schadt, L. Rogers, C.A. Powell, New York, NY, p.A7825

THEMATIC POSTER SESSION

B49 NON-TUBERCULOUS MYCOBACTERIAL DISEASE AND CASE REPORTS

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area L, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: T.K. Marras, MD, Toronto, Canada

P1219 **Laboratory Based Survey for Pulmonary Non-Tuberculous Mycobacteriosis in Japan: 2012-213/**K. Morimoto, N. Hasegawa, K. Izumi, H. Namkoong, K. Uchimura, Y. Hoshino, A. Kurashima, J. Sokunaga, S. Shibuya, M. Shimojima, M. Ato, S. Mitarai, Tokyo, Japan, p.A3719

P1220 **Updated 4th Generation QuantiFERONr-TB Testing in Individuals with Nontuberculous Mycobacteria Infection/**S.A. Siegel, M. Cavanaugh, J.H. Ku, A. Knights, L.M. Kawamura, K.L. Winthrop, Portland, OR, p.A3720

P1221 **Lung Function Decline Based on Clinical Course in Patients with Non-Tuberculous Mycobacterial Lung Disease/**H.Y. Park, B.-H. Jeong, H.R. Chon, H. Lee, K. Jeon, W.-J. Koh, Seoul, Korea, Republic of, p.A3721

P1222 **12-Month Follow-Up Data from a Phase 2 Trial of Liposomal Amikacin for Inhalation (LAI) in Patients with Refractory Nontuberculous Mycobacterial (NTM) Lung Infection/**K.N. Olivier, D.E. Griffith, K.L. Winthrop, B.A. Brown-Elliott, G. Eagle, J. McGinnis, R.J. Wallace, Bethesda, MD, p.A3722

P1223 **Progression of Mycobacterium Avium Complex Infection to Extensive Structural Disease and Hydropneumothorax in an Otherwise Healthy Adult Male/**C.J. VanHook, B. Warner, E.J. McManus, Longmont, CO, p.A3723

P1224 **An Unusual Case of Mycobacterium Avium Complex/**B.-C. Tran, Baltimore, MD, p.A3724

P1225 **Unusual Presentation of Mycobacterium Avium Complex Lung Infection/**V. Trivedi, T.R. Aksamit, L. Karnatovskaia, Rochester, MN, p.A3725

P1226 **In Sickness and In Health: Distinct Presentations of Mycobacterium Avium Complex in a Married Couple/**T.L. Griffiths, S.L. Schmidt, Grand Rapids, MI, p.A3726

P1227 **Mycobacterial Avium Complex Presenting with Fever and Large Necrotizing Lung Mass in Immunocompetent HIV Patient/**F. Aldaas, A.A. Mitma, D.J. Rudolph, S. Zane, Bridgeport, CT, p.A3727

P1228 **TB, or Not TB: A Case of Concomitant Tuberbulosis Pleurisy and Parenchymal Mycobacterium Avium Complex/**E. Nadler, M. Ordoveza, J. Ivanaviciene, Farmington, CT, p.A3728

P1229 **An Endobronchial Mass in a Patient Post Bilateral Lung Transplant/**L.A. Cohen, W.R. Hunt, Atlanta, GA, p.A3729

P1230 **Eosinophilic Pneumonia and Mycobacterial Infection/**J.E. Hines, A. Mohamed Hosni, Ypsilanti, MI, p.A3730

P1231 **Nontuberculous Mycobacterial Hypersensitivity Pneumonitis Secondary to Hot Tub Exposure/**G.Y. Liu, N. Sirikonda, K. Hussain, Morgantown, WV, p.A3731

Facilitator: J. Philley, MD, Tyler, TX

P1232 **Airway Deposition and Retention of Liposomal Amikacin for Inhalation in Patients with Pulmonary Nontuberculous Mycobacterial Disease/**K.N. Olivier, R. Maas-Moreno, M. Whatley, K. Cheng, J.-H. Lee, C. Fiorentino, R. Shaffer, S. Macdonald, R. Gupta, T.E. Corcoran, V.S. Malinin, G. Eagle, W. Perkins, C. Paik, C. Chen, Bethesda, MD, p.A3732

P1233 **CaMoMy Trial: A Prospective Randomized Clinical Trial to Compare Six-Months Sputum Conversion Rate with a Clarithromycin or Moxifloxacin Containing Regimen in Patients with a M. Xenopi Pulmonary Infection: Intermediate Analysis/**C. Andrejak, N. Veziris, F.-X. Lescure, H. Mal, D. Bouvry, L. Bassinet, F.-X. Blanc, J. Camuset, F. Couturaud, J.-F. Bervar, C.-H. Marquette, L. Thiberville, H. Vallerand, J.-C. Dalphin, H. Morel, J. Andrejak, J. Cadranel, V. Jounieaux, Amiens, France, p.A3733

P1234 **Liposome-Ciprofloxacin Inhibits Mycobacterium avium subs hominissuis (MAH) Microaggregate Formation in a Dose and Time Dependent Manner/**L.E. Bermudez, J. Blanchard, L. Babrak, I. Gonda, Corvallis, OR, p.A3734

P1235 **Preliminary Evaluation of a Sitafloxacin - Containing Regimen for Relapsed or Refractory Pulmonary Mycobacterium Avium Complex Disease/**K. Fujita, M. Fujita, Y. Ito, T. Hirai, T. Mio, K. Watanabe, M. Mishima, Kyoto, Japan, p.A3735

P1236 **Nontuberculous Mycobacteria Infection in a Case Diagnosed with Ankylosing Spondylitis/**N. Dirican, M. Pinar, S. Erturk, A. Aynali, S. Atalay, M. Cakir, Isparta, Turkey, p.A3736

P1237 **Mounier-Kuhn Syndrome Presenting with Dysphagia and Weight Loss/**D. Becnel, J.J. Barretto, P.S. Sriram, Gainesville, FL, p.A3737

P1238 **Immune Profiling in a Patient with Treated Mycobacterium Marinum Deep-Tissue Infection and Positive Interferon-γ Release Assay Results/**H.C. Sasieta, T. Peikert, V. Van Keulen, C. Erskine, P. Escalante, Rochester, MN, p.A3738

P1239 **A Case of Complicated Mycobacterium Abscessus Infection in a Lung Transplant Recipient/**N. Hsu, D. Ross, Los Angeles, CA, p.A3739

P1240 **A Rare Case of Severe Recurrent Hemoptysis, Gastropulmonar Fistula Associated with Mycobacterium Abscessus Infection: A Case Report/**L. Fernandez, L.F. Sua, N.A. Romero, F. Rosso, C.A. Munoz, Cali, Colombia, p.A3740

P1241 **Successful Use of Inhaled Antibiotics for Primary Treatment of Mycobacterial Abscessus Infection/**B. Hayward, D. Addrizzo-Harris, New York, NY, p.A3741

P1242 **Resolution of Sequential Mycobacterial Infections Associated with Alpha-1-Antiprotease Therapy/**K.P. Fennelly, M. Brantly, Rockville, MD, p.A3742

P1243 **Rapidly Growing Mycobacterial Sepsis with Septic Pulmonary Emboli/**A. Vasudevan, S. Vanaik, B. Sharma, K.S. Sandhu, Philadelphia, PA, p.A3743

Facilitator: S.J. Ruoss, MD, Palo Alto, CA

P1244 **Attenuation of Pulmonary Mycobacterium Avium-Intracellulare Complex Disease by Active Hexose Correlated Compound (AHCC) in Mice/**M. Fujita, T. Matsumoto, R. Hirano, J. Uchino, K. Watanabe, Fukuoka, Japan, p.A3744

P1245 **Anti- IFN-γ Autoantibodies Reflect Disease Activities of Disseminated NTM Infection; as a Possible Serum Biomarker/** A. Aoki, T. Sakagami, K. Shima, N. Aoki, H. Moro, Y. Tanabe, T. Koya, T. Hasegawa, T. Kikuchi, Niigata, Japan, p.A3745

P1246 **Relationship Between Interferon-γ/Interleukin-17 Production and Clinical Features of Non-Tuberculous Mycobacterium/** H. Kobayashi, Suzuka, Japan, p.A3746

P1247 **AAT Reduces Burden Of Mycobacterium Intracellulare In Human Macrophages By Inducing Phagosome-Lysosome Fusion/**E. Chan, A. Bai, X. Bai, Denver, CO, p.A3747

P1248 **A Rare Case of Mycobacteria Kansasii Pulmonary Infection Presented with Large Pleural Effusion in an Immunocompetent Patient/**V. Patel, A. Shah, J. Raynor, M. Babury, Jamacia, NY, p.A3748

P1249 **M. Chelonae In An Immunosuppressed Patient/**J. Seashore, E. Awerbuch, Queens, NY, p.A3749

P1250 **Co-Infection of Pulmonary Mycobacterium Kansasii and Invasive Pulmonary Aspergillosis in a HIV-Negative Patient/**H. Luong, C. Peng, Richmond Heights, OH, p.A3750

P1251 **Mycobacterium Celatum - An Uncommon Pulmonary Pathogen Presenting as Fatigue and Cough in an Immunocompetent Host/**P. Patel, G.S. Thind, C. Jacob, C. Difelice, L. Lutwick, Kalamazoo, MI, p.A3751

P1252 **A Case of Respiratory Infection Caused by Mycobacterium Triviale/**A. Okabayashi, M. Hasegawa, A. Sato, N. Yokohori, H. Katsura, Chiba, Japan, p.A3752

P1253 **Rare Case of Pulmonary Infection by Rapidly Growing Mycobacteria in an Immunocompromised Host/**J.P. Sugunaraj, C.S. Greco, Y.B. Mehta, Danville, PA, p.A3753

P1254 **Cavitary Lesions of Lungs: First Reported Case of Mycobacterium Shimoidei Infection in the United States of America/**K. Trivedi, P.M. Patel, S. Tindel, D.K. Payne, Shreveport, LA, p.A3754

P1255 **Mycobacterium Cavitary Pneumonia - Not Your TB Type - A Case of Rare Mycobacterium Szulgai/**D.Y. Pandya, H.P. Shah, N. Dalessandro, Allentown, PA, p.A3755

P1256 **Non Tuberculous Mycobacteria in Cystic Fibrosis: Does Treatment Change Outcome in High Prevalence Areas?/**R. Beg, E. Mendes, C. Aguiar, A. Wawrzyniak, M. Salathe, A. Schmid, Miami, FL, p.A7826

P1257 **The Epidemiology of Pulmonary Non-Tuberculous Mycobacteria in Southern Taiwan and Non-Tuberculous Mycobacteria Infection Increase Tuberculosis Risk/** M.-H. Cheng, H.-L. Huang, P.-L. Lu, J.-Y. Wang, C.-C. Shu, J.-Y. Hung, I.-W. Chong, Kaohsiung, Taiwan, p.A7827

THEMATIC POSTER SESSION

B50 TUBERCULOSIS: CASE REPORTS

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area L, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: J. Bernardo, MD, Boston, MA

P1259 **Evaluation of Latent TB: CT Is More than Skin Deep/**S. Iyer, C.T. Pantin, E. Tyler, M. Babores, A. Hufton, Cheshire, United Kingdom, p.A3756

P1260 **The Delayed Diagnosis of Acid-Fast Bacilli Biopsy-Negative Pulmonary Mycobacterium Tuberculosis/**L. Krowl, A. Kahlon, Syracuse, NY, p.A3757

P1261 **Increasing Pulmonary Nodules, Which Gave Us a Delayed Surprise/**C. Meenakshisundaram, H. Friedman, Evanston, IL, p.A3758

P1262 **Tuberculous Necrotizing Granulomata Masqueraded as an Infected Congenital Lung Mass in an Infant/**J.Y. Wong, P. Fitzgerald, Y.D. Wang, R. Bozanovic, J. Arredondo Marin, J. Pernica, F.B. Jamieson, J. Gubbay, Hamilton, Canada, p.A3759

P1263 **Pulmonary Tuberculosis in Immunocompetent Host Presenting with Complete Right Lower Lobe Consolidation/**P. Pirompanich, P. Damronglerd, C. SriAroon, Pathumthani, Thailand, p.A3760

P1264 **"Right Upper Lobe Syndrome" a Rare Presentation of Endobronchial Tuberculosis/**J.M. Chowdhury, M. Kosa, A. Mohammed, J.S. Chowdhury, V. Sheth, M. Korman, Darby, PA, p.A3761

P1265 **An Unusual Presentation of Mycobacterium Tuberculosis in a Patient with Immortal Lymphocytes/**R. Gupta, M. Cutaia, M.R. Al-Ajam, Brooklyn, NY, p.A3762

P1266 **Mycobacterium Tuberculosis and Hemophagocytic Lymphohistiocytosis/**H.K. Gonuguntla, Kochi, India, p.A3763

P1267 **TB or Not TB: A Missed Case of Pulmonary Tuberculosis Presenting as Bronchial Anthracofibrosis/**R. Sengupta, B. Small, B.A. Kelly, C. Ray, D. Ouellette, Detroit, MI, p.A3764

P1268 **Chronic Weakness in the Elderly: It's Not All Cancer/**N. Huprikar, N. Boyer, A. Skabelund, Fort Sam Houston, TX, p.A3765

Facilitator: E.J. Carter, MD, Providence, RI

P1269 **Invasive Endotracheal Tuberculosis/**R.V. Dy, K. Harris, S. Dhillon, A.H. Alraiyes, Buffalo, NY, p.A3766

P1270 **Persistent Dysphonia: A Rare Extrapulmonary Complication of Tuberculosis/**M. Chopra, M. Abidali, B. Ali, S. Rehman, Phoenix, AZ, p.A3767

P1271 **Benign Superior Vena Cava Syndrome Due to Mediastinal Tubercular Mass: A Unique and Rare Presentation/**R.K. Chopra, A. Takale, N. Bhargava, V. Pandharkar, Pune, India, p.A3768

P1272 **Pulmonary Tuberculosis-Induced Central Vein Thrombosis of the Upper Extremity: A Case Report/**K. Najma, T.M. Hassan, F.A. Hamid, Cheras, Malaysia, p.A3769

P1273 **Broncho-Esophageal Fistula from Broncholithiasis/**A. Rajabalan, B.E. Bat, M. Aladin, A. Cutrona, Youngstown, OH, p.A3770

P1274 **Mycobacterium Africanum Lymphadenitis in an Asian Patient with M. Tuberculosis Pulmonary Infection/**A.L. Yang, A. McCambridge, P. Escalante, Rochester, MN, p.A3771

P1275 **An Unusual Cause of Pleural Effusion Following Immunotherapy for Bladder Cancer/**T. Rachakonda, J. Boltax, A.M. Spivak, B. Kendall, Salt Lake City, UT, p.A3772

P1276 **Pleurectomy and Nerve Block: A Treatment Option for Refractory Pain Secondary to Tuberculous Pleurisy/**V.H. Kha, K.S. Allen, S.J. Deb, Oklahoma City, OK, p.A3773

P1277 **VATS - Decortication in a Patient with Primary Tuberculous Pleural Peel/**T. Schneider, T. Jahn, G. Faller, H. Geddert, Karlsruhe, Germany, p.A3774

P1278 **Gone, but Not Forgotten: Oleothorax/**M.A. Shenoy, V. Ponnusamy, P.K. Gorukanti, P. Chandar, K. Chawla, W. Pascal, Brooklyn, NY, p.A3775

Facilitator: D.M. Nilsen, MD, Long Island City, NY

P1279 **Extrapulmonary Tuberculosis as a Mimicker of Metastatic Disease/**P. Doddamreddy, K. Van Gundy, Fresno, CA, p.A3776

P1280 **Cardiomyopathy Secondary to Tuberculosis: A Case Series and Review of Literatures/**N.A. Sherbini, H. Al Hayaan, A. Al-Harbi, H. Al-Jahdali, Riyadh, Saudi Arabia, p.A3777

P1281 **Miliary Tuberculosis in an IGRA Negative Patient After Adalimumab Treatment: A Case Report and Literature Review/**D.F. Condon, T. Cheng, J. Bernardo, Boston, MA, p.A3778

P1282 **Late Disseminated Tuberculosis Relapse After Treatment for Fully Sensitive Pleuro-Pulmonary Tuberculosis in a Patient Receiving Biologic Therapy/**H. Owles, H. Farne, D. Fink, K. Tang, M.C.I. Lipman, D. Creer, London, United Kingdom, p.A3779

P1283 **A Bovine Surprise: A Tale of Immunosuppresion/**A.K.A. Abi Musa Asa'ari, S.Y. Lee, S. Mathew, Stoke-On-Trent, United Kingdom, p.A3780

P1284 **Mycobacterium Bovis Mycotic Aneurysm/**S. Nandavaram, R. Lenox, Syracuse, NY, p.A3781

P1285 **Defying Diagnosis: A Case of Disseminated Tuberculosis, an Expanding Chest Wall Mass, and a Rapid Molecular Test/**M.B. Lesko, C.C. Shaw, New York, NY, p.A3782

P1286 **A 40-Year-Old Patient with Autoimmune Hepatitis and Portopulmonary Hypertension with Miliary Tuberculosis. Challenges of Drug Treatment: A Case Report/**L. Fernandez, J.F. Garcia, K. Monroy, C.A. Munoz, Cali, Colombia, p.A3783

P1287 **Tuberculomas in the Spinal Cord/**P.S. Pandya, London, United Kingdom, p.A3784

P1288 **Pott's Disease, a Diagnosis that Should Not Be Missed/** K. Jessamy, V. Kaul, F. Ojevwe, O. Anozie, Z. Shepherd, Syracuse, NY, p.A3785

Facilitator: M.R. O'Donnell, MD, MPH, New York, NY

P1289 **Tuberculosis of Prosthetic Knee with Simultaneous Nontuberculous Mycobacteria in Lungs/**J.H. Ku, C.D. Varley, E. Epson, A. Deodhar, K.L. Winthrop, Portland, OR, p.A3786

P1290 **A Gut Wrenching Case of MDR-TB/**S.B. Ahuja, K. Doo, B.G. Wu, E. Leibert, R. Condos, New York, NY, p.A3787

P1291 **Discrepancies of the DNA Profiles and Phenotypic Resistance in HIV-MDR Tuberculosis Patients/**P.A. Sitompul, H. Agustin, Jakarta Utara, Indonesia, p.A3788

P1292 **Six-Month Anti-Tuberculosis Drug Regimen Is Not Effective Enough in Treatment of Mediastinal Tuberculosis Lymphadenitis - Possible Role of 18F Fluorodeoxyglucose Positron Emission Tomography in Disease Detection and Treatment Monitoring/**D. Pesut, D. Sobic-Saranovic, J. Jankovic, S. Odalovic, V. Artiko, Belgrade, Serbia, p.A3789

P1293 **Management Challenge: Absorption of Antituberculous Medications After Gastrectomy/**N.H. Ahmed, S.B. Brosnahan, D. Pradhan, C. Caplan-Shaw, E. Leibert, R. Condos, New York, NY, p.A3790

P1294 **Tackling a Challenging Case of Hyperbilirubinemia: Which Is the Culprit?/**N.H. Ahmed, S.B. Brosnahan, C. Caplan-Shaw, New York, NY, p.A3796

P1295 **Challenges in Management of Tuberculosis in the Postpartum Period. A Case Report/**V. Kodadhala, S. Ahmed, A. Thomas, J. Gajjala, Washington, DC, p.A3791

P1296 **Neuropsychiatric Toxicity of Cycloserine in Multidrug-Resistant Tuberculosis Patient with Reversible MRI Changes/**M. Jain, C. Lewis, M. Moriarty, S. Hussain, Auckland, New Zealand, p.A3792

P1297 **Anti-Tuberculosis Drug Related Drug Reaction with Eosinophilia and Systemic Symptoms Syndrome/**H.-C. Chen, Y.-P. Chang, C.-Y. Lin, Y.-C. Chang, K.-T. Huang, W.-F. Fang, Kaohsiung, Taiwan, p.A3793

P1298 **A Case of Rifampicin-Induced Aseptic Meningitis/**L.E. Gleeson, K. Sharma, C. McDonald, N. Conlon, A.M. McLaughlin, J. Keane, Dublin, Ireland, p.A3794

P1299 **A Case of Adrenal Insufficiency Associated with Antituberculosis Treatment/**H. Arikan, S. Olgun Yildizeli, E. Eryuksel, B. Bagci Ceyhan, Istanbul, Turkey, p.A3795

THEMATIC POSTER SESSION

B51 PEDIATRIC ASTHMA: EVALUATION AND TREATMENT

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area F, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: A.G. Vicencio, MD, New York, NY

P609 **Spirometry-Induced Bronchoconstriction: A Sign of Severe Asthma in Children?/**H. AlSaleh, D. Wilson, S.D.M. Dell, Toronto, Canada, p.A3801

P610 **Clinical Assessment and Respiratory Impedance Plethysmography in Predicting Admission in Patients with Status Asthmaticus Presenting to the Pediatric Emergency Department/**A.R. Strang, R. Heinle, L. Xie, K. Giordano, M. Attia, T.H. Shaffer, Wilmington, DE, p.A3806

P611 **Bronchodilator Response Measured by Interrupter Resistance (Rint) Predicts which Wheezy Preschool Children will Respond to Inhaled Corticosteroid/**P. Seddon, R. Willson, C. Olden, L. Symes, N. Beydon, E. Lombardi, D. Wertheim, Brighton, United Kingdom, p.A3808

P612 **Once-Daily Tiotropium Respimatr Add-on Therapy Improves FEF25-75% in Children and Adolescent Patients with Persistent Symptomatic Asthma/**S. Goldstein, S.J. Szefler, C. Vogelberg, G. Bensch, J. Given, G. El Azzi, P. Moroni-Zentgraf, M. Engel, R. Sigmund, E. Hamelmann, New York, NY, p.A3817

P613 **Once-daily Tiotropium Respimatr Add-on Therapy Improves Lung Function in Children with Severe Symptomatic Asthma/**S.J. Szefler, T. Harper, I. Laki, A. Boner, G. El Azzi, P. Moroni-Zentgraf, M. Engel, A. Hayman, E. Hamelmann, Aurora, CO, p.A3818

P614 **Safety and Tolerability of Once-daily Tiotropium Respimatr Add-on Therapy in Children with Severe Symptomatic Asthma/**S.J. Szefler, N. Rupp, A. Boner, G. El Azzi, P. Moroni-Zentgraf, M. Engel, E. Hamelmann, Aurora, CO, p.A3819

P615 **Obesity and Pulmonary Function in School-Age Children with Asthma/**S. Krishnan, D. Hettiaracchi, M. Scharbach, A.J. Dozor, Valhalla, NY, p.A3797

Facilitator: A.Y. Joshi, MD, Rochester, MN

P616 **Impact of Late Use Magnesium Sulfate Administration in Inner City Children Hospitalized for Asthma Exacerbation/**P.J. Shukla, E. Aragona, J.M. Wang, R. Megalaa, S. Kilaikode, G. Phull, D.K. Pillai, Washington, DC, p.A3807

P617 **Sino-Nasal 5 Questionnaire Predicts Poor Asthma Control in Children with Persistent Asthma/**G. Phull, P.J. Shukla, R. Megalaa, D. Prue, C. Martinez, K. Scheffey, S. Kilaikode, D.K. Pillai, Washington, DC, p.A3815

P618 **Establishing the Reliability and Validity of the Pediatric Acute Asthma Score/**T. Wolfe, D. Angst, C.A. Lefaiver, Oak Lawn, IL, p.A3816

P619 **Effectiveness of Tiotropium in Children with Difficult-to-Control Asthma/**N.A. Jabre, M. Gondor, St. Petersburg, FL, p.A3820

P620 **Comparison of InspiraChamberr with InspiraMaskT and Optichamber Diamond with LiteTouch Mask - Aerosol Characteristics and Mask Volume/**M. Newhouse, R. Toddywala, V. Shukla, Somerset, NJ, p.A3824

P621 **Obesity and Airway Dysanapsis in Children and Adolescents with and Without Asthma/**E. Forno, D. Weiner, J. Mullen, G. Kurland, G.S. Sawicki, E. Acosta-Perez, A. Colon-Semidey, M. Alvarez, G. Canino, J.C. Celedon, Pittsburgh, PA, p.A3828

P622 **Effects of a Respiratory Therapist-Driven Asthma Protocol on Pediatric Patients Admitted with Status Asthmaticus: A Quality Improvement Project/**S. Perry, A. O'Hagan, S. Bickel, A. Truman, A. Krause, R. Fauth, T. Murray, Louisville, KY, p.A3800

Facilitator: D.K. Radhakrishnan, MD, Ottawa, Canada

P623 **Clinical Manifestations and Asthma Related Outcomes of Hospitalized Children Infected with Enterovirus D68 Versus Rhinovirus/**R. Coelho, P.M. Brown, A. Wadhwa, A. Dossul, B.E. Gonzalez, S. Cardenas, J. Carl, D. Kohn, N. Kraynack, C. Sabella, C. Starkey, S. Vogel, B. Yen-Lieberman, C.B. Foster, G. Piedimonte, Cleveland, OH, p.A3802

P624 **Bedroom HEPA Air Filters Can Improve Respiratory Health of Children with Asthma in Detroit/**T.C. Lewis, E.A. Parker, T.G. Robins, S.A. Batterman, B. Mukherjee, G.B. Mentz, X. Ren, C. Godwin, B.A. Israel, Ann Arbor, MI, p.A3805

P625 **Evaluation of Asthma Control Test (ACT) in Association with Peak Expiratory Flow Rate (PEFR) in Indian Children/**A. Chauhan, M. Singh, K. Thumburu, Chandigarh, India, p.A3812

P626 **Lack of Inhaled Steroid Use in Children Following Hospitalization with a Severe Acute Wheezing Illness/**J. Bizzintino, S.-K. Khoo, K. Franks, F. Prastanti, J. Everard, S. Oo, I. Laing, P. Le Souef, Subiaco, Australia, p.A3823

P627 **Cost-Utility Analysis of Once-Daily Vs. Twice-Daily Inhaled Corticosteroid Dosing for Maintenance Treatment of Asthma in Pediatric Patients/**C.E. Rodriguez-Martinez, M.P. Sossa-Briceno, J.A. Castro-Rodriguez, Bogota, Colombia, p.A3826

P628 **Lack of HPA-Axis Suppression After 12 Weeks of Flunisolide HFA (AerospanTM) in Patients 4 and Older/**D.P. Skoner, J. Corren, Pittsburg, PA, p.A3804

P629 **Preventing Severe Exacerbations in Preschool Children with Recurrent Wheeze: A Systematic Review and Meta-Analysis/**S.V. Kaiser, T. Huynh, L.B. Bacharier, P. Parkin, J. Rosenthal, L.A. Bakel, M.D. Cabana, San Francisco, CA, p.A3798

Facilitator: I.R. Sami, MD, Washington, DC

P630 **Resistant Airway Obstruction in Children/**S. Krishnan, A.J. Dozor, J. Holbrook, R.A. Wise, L.B. Bacharier, D.A. Kaminsky, C.G. Irvin, H.J. Farber, J.E. Lang, D. Shade, D. Green, L.B. Gerald, J. Ryu, M.A. Brown, S. Bose, J. Saams, R. Yasin, W.G. Teague, Valhalla, NY, p.A3803

P631 **Duration of Response and Time to Response of Albuterol Multidose Dry Powder Inhaler Vs Albuterol Hydrofluoroalkane and Placebo in Children with Asthma/**P.Y. Qaqundah, H. Taveras, H. Iverson, Huntington Beach, CA, p.A3809

P632 **What Represents a Meaningful Improvement in Symptom-Free Days (SFD) and Rescue-Free Days (RFD) for Children? Perspectives from Children and Caregivers/**L.M. Nelsen, H. Staunton, K. Sully, S.K. Khindri, H. Svedsater, R. Arbuckle, Collegeville, PA, p.A3814

P633 **Phenotype and Medication Use of Preschool Children Seen in a Tertiary Care Asthma Program/**C.E. Canessa, X.J. Wu, K.J. Hildebrand, C.L. Yang, Vancouver, Canada, p.A3822

P634 **Structural Lung Abnormalities on CT Correlate to Asthma Inflammation in BAL/**D.J. Roach, K. Ruangnapa, R.J. Fleck, M. Rattan, T.W. Guilbert, J.C. Woods, Cincinnati, OH, p.A3825

P635 **Prevalence of Asthma and Allergic Rhinitis in Children with Celiac Disease/**S. Ozdogan, N. Urganci, M. Usta, N.U. Kizilkan, Istanbul, Turkey, p.A3829

P636 **Pediatric Asthma Patients and Providers Prefer Color-Coded Labeling of Metered Dose Inhalers (MDIs)/**P.-Y. Tsou, J. Ronayne, H. Kumar, Chicago, p.A3799

Facilitator: O. Herrera, MD, Santiago, Chile

P637 **No Tachyphylaxis Following Chronic Use of Albuterol Multidose Dry Powder Inhaler in Children With Asthma Over 3 Weeks/**C. LaForce, H. Taveras, H. Iverson, Raleigh, NC, p.A3810

P638 **Comparison of Two Training Methods to Optimize the Pressurized Metered Dose Inhaler Technique in Children with Asthma Attending Outpatient Clinics/**W.G. Ammari, N. Al-Hyari, N. Obeidat, M. Khater, A. Sabouba, M. Sanders, Amman, Jordan, p.A3811

P639 **What Represents a Meaningful Improvement in Asthma Control as Measured Using the Childhood Asthma Control Test (cACT)? Perspectives from Qualitative Interviews with Children and Caregivers/**L.M. Nelsen, H. Staunton, K. Sully, S.K. Khindri, H. Svedsater, R. Arbuckle, Collegeville, PA, p.A3813

P640 **Metered-Dose Inhaler Compared to Nebulizer for Bronchodilator Treatment of Inpatients with Asthma Exacerbation/**N.M. Pajor, M.A. Nevin, Chicago, IL, p.A3821

P641 **Effect of Childhood Asthma on Lung Function at 21 Years/**S. Suresh, M. O'Callaghan, A.A. Mamun, P.D. Sly, South Brisbane, Australia, p.A3827

P642 **Building Bridges Transforms the Approach to School-Centered Asthma Care and Improves Outcomes for Children with Asthma/**M.C. Gleason, M. Villarreal, J.P. Hollenbach, C. Haas-Howard, M.M. Cloutier, M. McGinn, L. Cicutto, C. Langton, H. Mitchell, S.J. Szefler, Aurora, CO, p.A7828

P643 **From the Frontline: What's Really Happening with Asthma Care at School?/**A. Volerman, A. Hull, S. Ignoffo, G. Chisum, P. Dominguez, S. Hanshaw, S. Taylor, V.G. Press, Chicago, IL, p.A7829

THEMATIC POSTER SESSION

B52 NEONATAL LUNG DISEASE: FROM BENCH TO BABIES

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area F, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: R.M. Ryan, MD, Charleston, SC

P644 **Airway Smooth Muscle Tone and Hyper-Reactivity Are Both Decreased by S-Nitrosoglutathione Reductase Inhibition in a Murine Bronchopulmonary Dysplasia Model/**B. Gaston, H. Einisman, T. Raffay, C. Wijers, S.J. Lewis, Cleveland, OH, p.A3848

P645 **Extracellular Adenosine in Hyperoxic Lung Injury Regulates Inflammation in a Newborn Murine Model of Bronchopulmonary Dysplasia/**J. Davies, H. Li, H. Karmouty-Quintana, N.-Y. Chen, T. Weng, J. Molina, M.R. Blackburn, Houston, TX, p.A3849

P646 **NADPH Oxidase 2 Regulates Sepsis-Induced Lung Inflammation and Alveolar Remodeling in Neonatal Mice/**V. Sampath, H. Menden, Kansas City, MO, p.A3862

P647 **Extracellular Adenosine Is Detrimental in Lung Recovery Following Hyperoxic Lung Injury in a Murine Model of Bronchopulmonary Dysplasia/**J. Davies, H. Li, H. Karmouty-Quintana, N.-Y. Chen, T. Weng, J. Molina, M.R. Blackburn, Houston, TX, p.A3850

P648 **An Attenuated TGF-β Type II Receptor Expressed in Conditional TβRII Knock-Out Mice Initiates Shc but Not SMAD Signaling/**M.K. Lee, S.M. Smith, C. Li, P. Minoo, R. Bajpai, Los Angeles, CA, p.A3856

P649 **Postnatal Growth Restriction Augments Oxygen-Induced Pulmonary Hypertension in a Neonatal Rat Model of Bronchopulmonary Dysplasia/**S. Wedgwood, C. Warford, S. Agvateesiri, S. Berkelhamer, M. Perez, M. Underwood, R. Steinhorn, Sacramento, CA, p.A3865

P650 **Resident Lung Mesenchymal Stromal Cells Are Perturbed In Neonatal Ventilator-Induced Lung Injury/**K. Atkins, J. Collins, A. Vadivel, A. Chu, R. Van Gaal, S. Zhong, M. O'Reilly, M. Brand, B. Thebaud, Ottawa, Canada, p.A3859

Facilitator: T.E. Tipple, MD, Birmingham, AL

P651 **Feasibility of Continuous Oximetry Recording in Home Oxygen Management of Premature Infants with Bronchopulmonary Dysplasia/**L. Frain, H. Suchy, K. Gaukler, E. Moran, L.M. Rhein, Boston, MA, p.A3832

P652 **Breath-by-Breath Analysis of Respiratory Sinus Arrhythmia in Preterm Infants/**W. Shalish, S. Rao, G. Sant'Anna, J. Mortola, Montreal, Canada, p.A3835

P653 **Improving Indoor Air: The Feasibility of Deploying Indoor HEPA Air Filters in Homes of Inner City Non-Smoking Pregnant Women and Infants Who Live with a Smoker/**J. Rice, M.C. McCormack, S. Bose, S. Muqueeth, N.N. Hansel, G. Diette, Baltimore, MD, p.A3836

P654 **Home Apnea Monitoring Program, 10 Years of Experience at a Large Tertiary Children Hospital/**C. Wiggins, K. Laning, G.F. Perez, Washington, DC, p.A3837

P655 **Maternal Alcohol Use and Associated BPD/Death in the Very Low Birthweight Newborn/**T.W. Gauthier, D.M. Guidot, C.E. McCracken, M.S. Kelleman, L.A.S. Brown, Atlanta, GA, p.A3851

P656 **Maternal Pre-Pregnancy Weight as a Risk Factor for Bronchopulmonary Dysplasia in Preterm Infants/** S. Jordan-Crowe, S.L. Simpson, M. Alejandro-Rodriguez, M.J. Allen, W.L. Spencer, S. Worley, A.S. Tang, J.H. Peterson, G. Piedimonte, Cleveland, OH, p.A3852

P657 **Chest CT Volume Acquisition and Comparison of Quantitative CT Airway Measurements in Young Children with Chronic Lung Disease/**E. Cohen, D. Savage, T.E. Robinson, Palo Alto, CA, p.A3870

Facilitator: L.C. Eldredge, MD, PhD, Seattle, WA

P658 **Deficiency of Lysophosphatidic Acid Receptor 1 Protects Against LPS-Induced Lung Injury in Adult Rats with Hyperoxia-Induced Neonatal Lung Injury/**G.T.M. Wagenaar, X. Chen, E.H. Laghmani, R.M.A. Sengers, E. Cuppen, F.J. Walther, Leiden, Netherlands, p.A3833

P659 **Neonatal Hyperoxia Exposure Enhances Alveolar Infection of Influenza A Virus in Adult Mice/**W. Domm, M. Yee, A. Nogales, L. Martinez-Sobrido, M. O'Reilly, Rochester, NY, p.A3846

P660 **Alteration in Asporin Expression of Developing Mouse Lung with Bronchopulmonary Dysplasia Phenotypes Induced by Hyperoxia/**S. Srisuma, N. Chaiyawong, J. Thongam, K. Chusamer, L. Wongkhat, S. Thorsuwan, Bangkok, Thailand, p.A3839

P661 **Protective Effect of Human Umbilical Cord Mesenchymal Stromal Cell-Derived Exosomes on Multifactorial Lung Injury in Neonatal Mice/**L. Strueby, M. O'Reilly, M. Moebius, F. Eaton, M. Fung, C. Suen, J. Collins, B. Thebaud, Saskatoon, Canada, p.A3840

P662 **Angiopoietin2-Induced Lung Injury Is Mediated by miR-207-EphrinB2 Pathway in Developing Lungs/**M.A. Syed, V. Bhandari, Philadelphia, PA, p.A3841

P663 **Enhanced Effects of Hyperoxia on Vessel Development in Newborn Mice Heterozygote for the BMP Receptor 2/**M. Koschlig, X. Tian, D. Sudheendra, E.F. Spiekerkoetter, A. Hilgendorff, Munich, Germany, p.A3847

Facilitator: V. Bhandari, MD, DrMed, Philadelphia, PA

P664 **The Role of Transglutaminase 2 in Normal and Aberrant Late Lung Development/**I. Mizikova, D.M.G. Silva, W. Seeger, R.E. Morty, Bad Nauheim, Germany, p.A3860

P665 **Resident Lung Mesenchymal Stromal Cells (L-MSCs) and Enhanced Healing Capacity in Neonatally Injured Lungs of MRL/MPJ Mice/**M. O'Reilly, J. Collins, A. Vadivel, S. Zhong, F. Eaton, J.J. Greer, B. Thebaud, Edmonton, Canada, p.A3861

P666 **Spatial Molecular Atlas of Normal Lung Development in Mouse/**J. Carson, M.C. Ljungberg, J. Laskin, S. Nguyen, R. Sontag, T. Umrod, C. Ansong, R. Corley, Austin, TX, p.A3868

P667 **Emc3 Regulates Surfactant Protein Processing and ABCA3 Biosynthesis and Is Required for Surfactant Function at Birth/**X. Tang, C.-L. Na, J. Bridges, X. Lin, J.A. Whitsett, Cincinnati, OH, p.A3869

P668 **The p66Shc Adapter Protein Is Necessary to Maintain Pluripotency/**M.K. Lee, S.M. Smith, R. Bajpai, P. Minoo, Los Angeles, CA, p.A3857

P669 **Brain-Derived Neurotrophic Factor (BDNF) Treatment Alters Transient Receptor Potential Vanilloid 1 (TRPV1) mRNA Expression in A-Delta Nodose Airway Neurons During a Critical Period of Development/**D. Hunter, R. Dey, T. Batchelor, Morgantown, WV, p.A3867

Facilitator: H.J. Rozycki, MD, Richmond, VA

P670 **Late Gestation Lung1 (LGL1/CRISPLD2) Suppresses Proinflammatory Mediators in Human Fetal, Adult, and COPD Lung Fibroblasts and Epithelial Cells/**H. Zhang, Q. Wu, K. Detillieux, A.J. Halayko, N. Sweezey, F. Kaplan, Montreal, Canada, p.A3838

P671 **Male Gender Associates with Distinctive Gene Expression Pattern in Neonatal Lung Mesenchymal Stromal Cells from Infants Developing Bronchopulmonary Dysplasia/**A.P. Popova, T. Cui, M. Linn, A.M. Goldsmith, Ann Arbor, MI, p.A3842

P672 **Sex-Specific Differences in Neonatal Hyperoxic Lung Injury/**K. Lingappan, W. Jiang, L. Wang, B. Moorthy, Houston, TX, p.A3855

P673 **sRAGE in the Lungs of Ventilated Very Low Birthweight Infants Is Associated with Bronchopulmonary Dysplasia/**H.J. Rozycki, J.L. Bradley, S. Karam, Richmond, VA, p.A3863

P674 **Sulforaphane Protects Against Hyperoxic Toxicity Via NF-E2 Related Factor (Nrf2) Pathway: Implications for Bronchopulmonary Dysplasia/**R. Kalikkot Thekkeveedu, C. Chu, B. Moorthy, Houston, TX, p.A3864

P675 **Protein Expression in the Pathogenesis of Bronchopulmonary Dysplasia and Pulmonary Hypertension in Preterm Infants/** R. Siddaiah, E. Ndifreke, S. Diangelo, P. Silveyra, Hershey, PA, p.A3854

Facilitator: R. Keller, MD, San Francisco, CA

P676 **Surfactant Protein-D Serum Levels as an Indicator of Lung Injury in Infants with Congenital Diaphragmatic Hernia/**K. Marks, M. Landis, F.Y. Lim, B.E. Haberman, P.S. Kingma, Cincinnati, OH, p.A3830

P677 **Correlation Between Pulmonary Function Test and Quantitative CT Assessment in Infants with Postinfectious Bronchiolitis Obliterans/**M. Sohn, Y.H. Kim, K.W. Kim, K.-E. Kim, Seoul, Korea, Republic of, p.A3831

P678 **The Effects of Bethanechol on Patients with Tracheomalacia/**C. Quinlan, M. Santiago, L. Smith, E. Fiorino, K. Tsirilakis, Y.L. Liu, New Hyde Park, NY, p.A3843

P679 **Bethanechol Improves Respiratory Symptoms in Young Children with Tracheomalacia/**J. Piccione, E. Kofmehl, H. Facey, T. Giordano, H.B. Panitch, Philadelphia, PA, p.A3845

P680 **Respiratory Complications in Children with Esophageal Atresia and/or Tracheoesophageal Fistula/**P.B. Llaque, Lima, Peru, p.A3844

P681 **IPA Analysis of Proteomic and miRNA Profiles in Tracheal Aspirates of Preterm Infants with Pulmonary Hypertension/**R. Siddaiah, T. Gowda, P. Silveyra, Hershey, PA, p.A3853

P682 **Cord Blood-Derived Endothelial Colony-Forming Cell Function Is Disrupted in Congenital Diaphragmatic Hernia/**H. Fujinaga, Y. Ito, A. Umezawa, M. Kuroda, Tokyo, Japan, p.A3858

P683 **Rapamycin Reverses Lymphatic Abnormalities in a Transgenic Mouse Model of Pulmonary Lymphangiectasia/**P. Baluk, L.-C. Yao, J. Flores, D. McDonald, San Francisco, CA, p.A3866

P684 **Efficacy of Pulmonary Macrophage Transplantation (PMT) Therapy Is Mediated by Mature Macrophages Without Requirement of Myeloid Progenitor Expansion/**T. Suzuki, P. Arumugam, A. Sallese, C. Chalk, D. Black, B. Carey, R.E. Wood, B.C. Trapnell, Cincinnati, OH, p.A3834

P685 **Developmental Regulation of IL-22R1 in Infant Airway Epithelium Is Dependent Upon Interferon-λ and Enhanced By TLR3 Signaling/**D.T. Dugger, L.A. Miller, Davis, CA, p.A7830

P686 **Does Nasal CPAP or High-Flow Nasal Cannula Interfere with Sucking, Swallowing and Breathing During Bottle-Feeding?/**N. Samson, C. Nadeau, L. Vincent, D. Cantin, C. Catelin, J.-P. Praud, Sherbrooke, Canada, p.A7831

THEMATIC POSTER SESSION

B53 PHOUND IN TRANSLATION

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area A, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: E. Brittain, MD, Nashville, TN

P1 **The Role of Tissue Factor and Autophagy in Pulmonary Vascular Remodeling in a Rat Model for Chronic Pulmonary Thromboembolic Hypertension/**C. Deng, D. Wu, M. Yang, Y. Chen, H. Ding, Z. Zhong, N. Lian, Q. Zhang, S. Wu, K. Liu, Fuzhou, China, p.A3871

P2 **Gene Expression and Proteomic Analysis of Pulmonary Artery in a Rabbit Model of Pulmonary Thromboembolism/**S. Ni, Nantong City, Jiangsu Province, China, p.A3872

P3 **Time-Dependent Effect of VEGF Blockade on PAH Progression/** Z. Wang, T.A. Hacker, N. Chesler, Madison, WI, p.A3873

P4 **The Role of Exosomes in Pulmonary Arterial Hypertension/**J. Badlam, M. Yarnell, T.M. Bull, S. Flores, Aurora, CO, p.A3874

P5 **Targeting a Novel BMPR2 Modifier Gene, FHIT, with a Repurposed Drug to Improve Pulmonary Hypertension/**D. Sudheendra, X. Tian, J. Kuang, D. Solow-Cordero, J. Saldivar, E. Austin, J. Loyd, K. Huebner, P. Khatri, E.F. Spiekerkoetter, Stanford, CA, p.A3875

P6 **Heterozygote BMPR2 Mutation in Rat: A New Strategy to Understand PAH Pathobiology/**A. Hautefort, C. Rucker-Martin, V. Capuano, F. Lercef, P. Dorfmuller, B. Girerd, D. Montani, M. Humbert, F. Antigny, F. Perros, Le Plessis-Robinson, France, p.A3876

P7 **Metabolic Syndrome Exacerbates Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction/**F. Potus, B. Ranchoux, E. Tremblay, S. Provencher, S. Bonnet, Quebec City, Canada, p.A3877

P8 **Parasympathetic Nervous System Stimulation by Pyridostigmine Improves Survival and Cardiac Function in Experimental Pulmonary Arterial Hypertension/**D. Da Silva Goncalves Bos, X. Sun, A. Vonk-Noordegraaf, F.S. de Man, L. Handoko, Amsterdam, Netherlands, p.A3878

P9 **Endothelial-Specific Deletion of Hypoxia-Inducible Factor 2α Completely Protect Mice Against Hypoxia-Induce Pulmonary Hypertension/**H. Tang, H. Gong, Y. Gu, R.J. Ayon, S. Song, A. Babicheva, S. Vinjamuri, A.B. Malik, J.G.N. Garcia, A. Makino, J. Yuan, Tucson, AZ, p.A3879

P10 **Postnatal Hyperoxia Exposure Durably Impairs Right Ventricular Function in Aged Male Rats/**K. Goss, L.H. Tetri, K. Haraldsdottir, R.K. Braun, T.A. Hacker, M.W. Eldridge, Madison, WI, p.A3880

P11 **Serotonin Signaling Through Nox1 in Human Pulmonary Artery Smooth Muscle Cells - Implications in Vascular Remodeling in Pulmonary Arterial Hypertension/**K.Y. Hood, I. Morecroft, A.P. Harvey, A.C. Montezano, R.M. Touyz, M. MacLean, Glasgow, United Kingdom, p.A3881

P12 **Immunomodulatory Therapy with Synthetic Double Stranded RNA Prevents Pulmonary Hypertension/**D. Farkas, D. Kraskauskas, V. Kraskauskiene, A.A. Fowler, S. Spiegel, L. Farkas, Richmond, VA, p.A3882

Facilitator: S.Y. Chan, MD, PhD, Pittsburgh, PA

P13 **Acute Effects of Cell Free Hemoglobin on Pulmonary Vascular Impedance/**D.A. Schreier, T.A. Hacker, D.M. Tabima Martinez, M.O. Platt, N. Chesler, Madison, WI, p.A3883

P14 **Role of Pulmonary Arterial Smooth Muscle and Endothelial Mitochondrial Complex III in Chronic Hypoxia-Induced Pulmonary Hypertension/**G.B. Waypa, V.J. Dudley, P.T. Schumacker, Chicago, IL, p.A3884

P15 **Reductive Stress in Pulmonary Arterial Hypertension/**O. Rafikova, V. Nair, A.A. Desai, S.M. Black, R. Rafikov, Tucson, AZ, p.A3885

P16 **HDAC6-Hsp90: A Shock Duo Implicated in Pulmonary Arterial Hypertension/**S. Chabot, O. Boucherat, G. Ruffenach, S. Breuils-Bonnet, E. Tremblay, S. Provencher, S. Bonnet, Quebec, Canada, p.A3886

P17 **Isolated Heart Model Demonstrates Evidence of Contractile and Diastolic Dysfunction in Right Ventricles from Rats with Sugen/Hypoxia-Induced Pulmonary Hypertension (SuHx-PH)/**E. Nevo-Netes, A. Vayl, A. Frump, J.A. Kline, T. Lahm, Indianapolis, IN, p.A3887

P18 **Evaluation of the Therapeutic Effects of Nitrite and Metformin in a Mouse Model of Pulmonary Hypertension Associated with Heart Failure and Preserved Ejection Fraction /**Q. Meng, M. Bueno, N. Kelly, Y.C. Lai, A.L. Mora, M.T. Gladwin, Pittsburgh, PA, p.A3888

P19 **Left Ventricular Function Measured by Speckle-Tracking Based Strain and Strain Rate Echocardiography in Experimental Pressure Overload-Induced Right Ventricular Hypertrophy/**B. Kojonazarov, M. Boehm, T. Novoyatleva, C. Lu, F. Grimminger, N. Weissmann, H.A. Ghofrani, W. Seeger, R.T. Schermuly, Giessen, Germany, p.A3889

P20 **New Mouse Model of Pulmonary Hypertension Induced by Respiratory Syncytial Virus Bronchiolitis/**D. Kimura, J. Saravia, I. McNamara, R.D. Sullivan, D. You, S.A. Cormier, Memphis, TN, p.A3890

P21 **Carbonic Anhydrase Is Not a Relevant Nitrite Reductase in the Lung/**P.A. Pickerodt, S. Kronfeldt, M. Russ, K. Vorbrodt, P. Lother, T. Busch, W. Boemke, E.R. Swenson, R.C.E. Francis, Berlin, Germany, p.A3891

P22 **Combination Ambrisentan and Tadalafil Preserve Vascular Volume Quantified by Micro CT Better than Either Monotherapy/**D. Lachant, D. Haight, S.R. Glickman, S. Akers, R.D. Ambrosini, S. Staicu, R.J. White, Rochester, NY, p.A3892

P23 **Gap Junction Connexin-43 Mislocalization and a-Actinin Expressional Changes in the Right Ventricle: Potential Contributors to Right Heart Failure in Pulmonary Hypertension/**O. Lohani, Aurora, CO, p.A3893

P24 **Urocortin-2 Improves Right Ventricular Function in Pulmonary Arterial Hypertension/**R. Adao, P. Mendes-Ferreira, D. Santos-Ribeiro, C. Maia-Rocha, F. Potus, S. Breuils-Bonnet, S. Provencher, S. Bonnet, A. Leite-Moreira, C. Bras-Silva, Porto, Portugal, p.A3894

Facilitator: F. Potus, PhD, Quebec, Canada

P25 **Using Genetics, Epigenetics and Small Molecules to Reverse Metabolic Reprogramming in Adventitia Fibroblasts for Pulmonary Hypertension Therapy/**H. Zhang, D. Wang, M. Li, L. Plecita, A. D'alessandro, S. Riddle, B.A. McKeon, A. Flockton, M. Frid, P. Petr Jezek, K. El Kasmi, K.R. Stenmark, Aurora, CO, p.A3895

P26 **Chronic Right Ventricular Pressure Overload May Be Protective in Patients with Large Acute Pulmonary Emboli/**A.S. Witkin, J. Rodriguez-Lopez, Y. Chang, F. Huang, M. Jaff, B.A. Parry, K. Rosenfield, R. Rosovsky, R.N. Channick, C. Kabrhel, Boston, MA, p.A3896

P27 **Angiotensin-II (AngII) Induced AngII Type 1 Receptor Activation Upregulates Alpha-2-Antiplasmin Expression in Experimental Pulmonary Hypertension Model/**S.M. Malik, A.K. Baidya, V. Chhabra, S.B. Singh, P. Reddy, New Delhi, India, p.A3897

P28 **The Lung Origin of Coronary Artery Diseases in Pulmonary Hypertension Patients: Role for the DNA damage/BRD4 Axis/**J. Meloche, V. Nadeau, E. Tremblay, F. Potus, S. Chabot, E. Charbonneau, S. Provencher, S. Bonnet, Quebec City, Canada, p.A3898

P29 **Combination Ambrisentan and Tadalafil Prevents Right Ventricular Enlargement Better than Either Monotherapy/**S.R. Glickman, D. Lachant, S. Akers, S. Staicu, D. Haight, R.J. White, Rochester, NY, p.A3899

P30 **Distinct Effects of Phosphodiesterase-5 and Fibroblast Growth Factor Receptor-1 Inhibitors in Monocrotaline-Induced Pulmonary Arterial Hypertension/**N.S. Felix, L. Mendonca, J.S. Da Silva, C.L. Braga, C.S. Samary, F.F. Cruz, N.N. Rocha, G. Zapata-Sudo, P.R.M. Rocco, P.L. Silva, Rio de Janeiro, Brazil, p.A3900

P31 **Early Hemodynamic and Echocardiographic Indicators of Right Ventricular Dysfunction in Neonatal Calves with Pulmonary Hypertension/**R.D. Brown, K.S. Hunter, K. Bartels, K.R. Stenmark, Aurora, CO, p.A3901

P32 **MicroRNA and Gene Dysregulation in Pulmonary Hypertension: Experimental Findings in a Large Animal Model Compared to Predictions by a Systems Biology Approach/**A. Rothman, H. Restrepo, V. Sarukhanov, W.N. Evans, R. Williams, K. Anderson, N. Hamburger, D. Mann, Las Vegas, NV, p.A3902

P33 **CARSKNKDC (CAR) Selective Enhancement of Fasudil-Induced Pulmonary Vasodilation in a Porcine Model of Chronic Pulmonary Hypertension/**A. Rothman, H. Restrepo, W.N. Evans, V. Sarukhanov, D. Mann, Las Vegas, NV, p.A3903

P34 **The Orally Available p110α Selective PI3K Inhibitor BYL719 Reduces Hypoxia-Induced PH in Mice/**E.M. Berghausen, A. Behringer, M. Vantler, S. Baldus, S. Rosenkranz, Cologne, Germany, p.A3904

P35 **Inflammation and Obesity in Fattening Steers at Low Elevations: A Natural Animal Model of Irreversible Hypoxic Pulmonary Hypertension, Pulmonary Arterio-Venous Remodeling, and Heart Failure/**G. Krafsur, R.D. Brown, S. Riddle, M. Frid, J. Poth, D. Gould, J. Neary, T. Holt, F. Garry, K.R. Stenmark, Aurora, CO, p.A3905

Facilitator: L. Zhao, MD, PhD, London, United Kingdom

P36 **Inhibition of Fibrotic and Hypoxia Gene Response in a Pulmonary Vascular Surrogate System with a Small Molecule Stimulator of Soluble Guanylate Cyclase/**D.P. Zimmer, B.K. Cole, P. Ge, K. Tang, G.T. Milne, M. Simmers, R. Feaver, M.S. Collado, S. Hoang, M. Lawson, A. Mackey, D. Manka, B.R. Blackman, M. Ribadeneira, Cambridge, MA, p.A3906

P37 **Endostatin and Right Ventricular Remodeling in PAH**/R.L. Damico, A. Goyanes, L. Varela, C.P. Corona-Villalobos, S.L. Zimmerman, S.C. Mathai, T. Kolb, P.M. Hassoun, Baltimore, MD, p.A3907

P38 **Examination of the CXCL11/CXCR3 Biological Axis in the Hypoxic Lung**/C. Hughes, M. Paterson, P. McLoughlin, C. Costello, Dublin, Ireland, p.A3908

P39 **HIV-Nef-Induced Apoptosis in Lung Microvascular Endothelial Cells Correlates with the Upregulation of EMAPII**/S. Chelvanambi, M. Clauss, R.B. Day, H. Twigg, Indianapolis, IN, p.A3909

P40 **Reversal of Pulmonary Arterial Hypertension by a Taxane Anti-Tumor Drug**/Y.F. Ibrahim, Y.J. Suzuki, Washington, DC, p.A3910

P41 **Kinetic Analysis of 3'-Deoxy-3'-[18F]-Fluorothymidine (FLT) Positron Emission Tomography (PET) in Monocrotaline-Induced Pulmonary Hypertension Rat**/A. Ashek, O. Dubois, M. Wilkins, L. Zhao, London, United Kingdom, p.A3911

P42 **IW-1973, a Clinical-Stage Soluble Guanylate Cyclase Stimulator, Affects Pulmonary Hemodynamics and Attenuates Inflammation and Vascular Damage to the Lungs in a Monocrotaline-Induced Pulmonary Arterial Hypertension Rat Model**/S. Jacobson, D.P. Zimmer, C. Shea, M. Currie, J. Masferrer, Cambridge, MA, p.A3912

P43 **Effects of Inhaled Nitric Oxide on Pulmonary Artery Smooth Muscle Cells (PASMC) Exposed to Positive Pressure Ventilation and Hyperoxia**/D. Alapati, S.L. Balasubramaniam, J. Hossain, S. Soundar, P. Fawcett, T.H. Shaffer, Wilmington, DE, p.A3913

P44 **Hydrogen Sulfide (H2S) Prevents the Monocrotaline Induced Pulmonary Hypertension by Regulating Inflammasome Signaling**/A.K. Baidya, A. Chhabra, V. Chhabra, S.M. Malik, S.B. Singh, M. Sharma, P. Reddy, New Delhi, India, p.A3914

P45 **Abrogation of Endothelial Mef2c Results in Exacerbation of Pulmonary Hypertension: Implicating the Histone Deacetylase (HDAC) IIa-MEF2 Signaling Axis**/A. Sofer, C. Hwangbo, I. Papangeli, X. Hu, S. Park, J. Schwarz, H. Chun, New Haven, CT, p.A3915

P46 **Investigation of Neutrophil Function in IPAH Patients**/M.-H. Ruchaud-Sparagano, J. Grant, L. Thirugnanasothy, S. Sithamparanathan, J. Simpson, P. Corris, Newcastle upon Tyne, United Kingdom, p.A3916

P47 **S100A12 is Elevated in Patients with Pulmonary Hypertension and Predicts Mortality**/C. Ryu, A.E. Tzouvelekis, J. Herazo-Maya, H. Pan, P. Adonteng-Boateng, Q. Li, N. Kaminski, H.J. Ford, F. Ahmad, E. Herzog, W.H. Fares, New Haven, CT, p.A7832

THEMATIC POSTER SESSION

B54 CASE REPORTS IN THE PULMONARY CIRCULATION

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area A, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: H.I. Palevsky, MD, Philadelphia, PA

P49 **Pulmonary Arterial Hypertension Caused by Congenital Portosystemic Venous Shunt: A Case Report**/X. Cheng, C. Xiong, Beijing, China, p.A3917

P50 **Pulmonary Thromboembolism with Right Heart Thrombus-in-Transit: Vital Bedside Diagnosis Using Goal Directed Echocardiography to Guide Emergent Management**/I. Kourouni, S.R. Dudekonda, J. Mathew, N. Gopal, J. Shapiro, New York, NY, p.A3918

P51 **Pulmonary Capillary Hemangiomatosis: A Rare Cause of Pulmonary Hypertension**/E. Demirer, T. Caliskan, F. Ciftci, Z. Kucukodaci, M. Yalcin, E. Ozturk, K. Kara, I. Yilmaz, Istanbul, Turkey, p.A3919

P52 **Hereditary Hemorrhagic Telangiectasia (Rendu-Osler-Weber Syndrome): Unusual Presentation and Follow Up with CPET**/C.A. Celis Preciado, J. Lasso, D. Ballen, C. Zuluaga, A. Romero, D. Valencia, Bogota, Colombia, p.A3920

P53 **Hepatopulmonary Syndrome in Hereditary Hemorrhagic Telangiectasia (HHT): Not All Right-to-Left Shunting in HHT Is Due to Pulmonary Arteriovenous Malformations**/S. Krishnan, T. Lahm, Indianapolis, IN, p.A3921

P54 **What Really Came First, the Disease or the Manifestations?**/I. Valle, R. Fernandez-Gonzalez, M. Cruz Caliz, A. Dones, Rio Piedras, PR, p.A3922

P55 **Paradoxical Embolism Due to Pulmonary Arteriovenous Malformation (PAVM) Causing Acute Ischemic Stroke During Systemic Thrombolytic Therapy for a Massive Pulmonary Embolism (PE)**/M. Ijaz, M. Hasan, H. Khaleel, J.-T. Chen, Bronx, NY, p.A3923

P56 **Systemic Vascular Invasion Causing Hemoptysis**/T. Cheng, V. Chen, San Jose, CA, p.A3924

P57 **A Rare Case of a Primary Sarcoma of the Pulmonary Artery in a 56 Year Old Female: A Case Report**/E. Leung, M. Salih, N. Ettinger, Chesterfield, MO, p.A3925

P58 **A Case of Pulmonary Artery Aneurysm - A Rare and Dangerous Entity**/G.F. Shaughnessy, B.P. Shapiro, Jacksonville, FL, p.A3926

P59 **Acute Pulmonary Embolism Presenting as a Lung Mass**/M. Yaqoob, M. Hundal, C. Ghattas, J. Unterborn, Brighton, MA, p.A3927

Facilitator: Z. Safdar, MD, Houston, TX

P60 **Pulmonary Vein Varix: A Rare Incidental Finding/**Y. Eslaamizaad, H. Kalatoudis, I. Kaiser, G. Apergis, Brooklyn, NY, p.A3928

P61 **When Ventilation-Perfusion Scan Falters: A Rare Cause of Chronic Pleuritic Chest Pain, Hypoxia, and Pulmonary Hypertension/**C. Liu, R. Hilton, R. Sharma, S. Hussain, New Brunswick, NJ, p.A3929

P62 **An Unusual Cause of Hypoxia/**L. Alghothani, D. Chui, N. Sood, Columbus, OH, p.A3930

P63 **Pulmonary Hypertension Due to Unilateral Pulmonary Agenesis/**T.J.K. Vossler, S. Ganesh, Los Angeles, CA, p.A3931

P64 **Jod-Basedow Phenomenon Precipitating Fatal Right Heart Failure/**A. Palkar, A. Tsegaye, S. Sahni, A. Talwar, New Hyde Park, NY, p.A3932

P65 **Unusual Cause of Dyspnea/**P. Ochieng, T. Flick, D. Johnson, Willimasport, PA, p.A3933

P66 **Atypical Hemolytic Uremic Syndrome (HUS) and Pulmonary Veno-Occlusive Disease (PVOD)/**M.J.S. Farmer, I. Preston, R.N. Channick, Springfield, MA, p.A3934

P67 **Regional Differences in Pulmonary Hemodynamics Due to a Left Atrial Mass/**A. Bhardwaj, G. Chang, R.R. Zimmer, H. Palevsky, Philadelphia, PA, p.A3935

P68 **Is It Efficacious to Switch from Infusion to Oral Therapy for Pulmonary Arterial Hypertension?/**D. Khabbaza, N. Sood, Columbus, OH, p.A3936

P69 **Chronic Thromboembolism Pulmonary Hypertension in a Patient with Klinefelter and Antiphospholipid Syndrome/**S.S. Sanchez, A.S. Herrera, G. Delgado, M. Hinojosa, J.F. Moreno, R. Mercado, Monterrey, Mexico, p.A3937

Facilitator: S.P. Gaine, MD, PhD, Dublin, Ireland

P70 **Pulmonary Embolism and Deep Venous Thrombosis Associated with Diindolylmethane/**P.V. Bui, M. Moualla, D.J. Upson, Albuquerque, NM, p.A3938

P71 **Diagnostic Challenges of Pulmonary Nodules-Thromboembolic Pulmonary Infarcts as a Differential on the Horizon/**B. Muthuswamy, N. Victor, A. Tikotekar, Dover, DE, p.A3939

P72 **Bronchial Artery Aneurysm: An Unusual Cause of Intermittent Hemoptysis/**S. Ahmad, K.R. Jones, Oklahoma City, OK, p.A3940

P73 **Idiopathic Pulmonary Artery Aneurysm/**R.G. Sangani, S. Devabhktuni, S. Hadique, P. Jain, Morgantown, WV, p.A3941

P74 **The Devastating Pulmonary Complications of Sickle Cell Disease: Fat Emboli Associated Acute Chest Syndrome Mimicking Massive Pulmonary Embolism/**R. Sengupta, J. Veljanovski, D. Sudasena, A. Michaels, T. Jain, M. Rahman, B. DiGiovine, Detroit, MI, p.A3942

P75 **Imatinib is Effective for Treating Pulmonary Hypertension Induced by Pulmonary Tumor Thrombotic Microangiopathy with Gastric Cancer/**K. Kubota, Shimotsuke, Tochigi, Japan, p.A3943

P76 **An Incidental Pulmonary Vein thrombosis - Resolution with Watchful Waiting/**P. Rattner, A. Sutherland, Newark, NJ, p.A3944

P77 **Complimentary Role of Extracorporeal Membrane Oxygenation Therapy and Ultrasound Assisted Catheter Directed Thrombolysis in Management of Cardiac Arrest Due to Massive Pulmonary Embolism: A Report of 2 Cases/**R. Desai, M. Calder, R. Reber, T. Meyer, S. Gregory, E. Gnall, L. Samuels, E. Casanova-Ghosh, L. Greenspon, Wynnewood, PA, p.A3945

P78 **Catheter-Directed Low-Dose Alteplase in the Management of Pulmonary Embolism (PE) Resulting in Fatal Intracranial Hemorrhage (ICH): A Case Report/**J.S. Mendelson, T. Lewis, J. Papadopoulos, D.R. Schwartz, New York, NY, p.A3946

P79 **Pneumonectomy for the Management of Unilateral Pulmonary Artery Agenesis/**A. O'Reilly, K. Sharma, A. Franciosi, J.D. Dodd, A. Fabre, D. Healy, E.F. McKone, C.G. Gallagher, Dublin, Ireland, p.A3947

THEMATIC POSTER SESSION

B55 REASON TO BELIEVE: CLINICAL PH STUDIES

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area A, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: H. Olschewski, MD, Graz, Austria

P81 **Maternal Ancestry and Risk of Pulmonary Arterial Hypertension/**S.Y. Farha, B. Hu, S. Comhair, J.G. Zein, R. Dweik, S.C. Erzurum, M. Aldred, Cleveland, OH, p.A3948

P82 **Helicity Is a Marker of Pulmonary Vascular Stiffness in Pulmonary Arterial Hypertension/**D.S. Reisner, C. Zheng, M. Schafer, J.K. Buckner, B. Notzold, J. Browning, J. Hertzberg, V. Kheyfets, K. Hunter, B. Fenster, Denver, CO, p.A3949

P83 **Oscillatory Shear Stress Is Associated with Main Pulmonary Artery Stiffness in COPD/**R. Brody, M. Schafer, R. Volpe, R. Arce, A. Rocker, K.S. Hunter, K. Buckner, B.E. Fenster, Denver, CO, p.A3950

P84 **MicroRNA-146a Expression Is Increased in Human PAH/**P. Mendes-Ferreira, F. Potus, D. Santos-Ribeiro, C. Maia-Rocha, R. Adao, A. Leite-Moreira, S. Provencher, S. Bonnet, C. Bras-Silva, Porto, Portugal, p.A3951

P85 **Characteristics of Severe Pulmonary Hypertension Associated with COPD in a French Multicenter Study/**G. Dauriat, A. Kanagaratnam, O. Sitbon, B. Lamia, M. CANUET, V. Cottin, M. Reynaud-Gaubert, A. Bourdin, C. Viacroze, E. Bergot, A. Chaouat, C. Pison, Y. Costa, G. Thabut, H. Mal, Paris, France, p.A3952

P86 **A Positive Vasodilator Response to Inhaled Nitric Oxide Does Not Predict Survival in Pulmonary Arterial Hypertension: A National Single Centre Experience/**G. Jayasekera, C. Church, A. Mackenzie, M. Johnson, A. Peacock, West Dunbartonshire, United Kingdom, p.A3953

P87 **Cytokine Levels as Predictors of Pulmonary Arterial Hypertension in Human Immunodeficiency Virus Seropositive Subjects/**M. Henriques-Forsythe, T. Tewolde, M.B. Huang, H.W. Farber, A. Quarshie, V.C. Bond, Atlanta, GA, p.A3954

P88 **Higher Prevalence of Pulmonary Hypertension Among an African American HIV-Infected Cohort/**M. Henriques-Forsythe, T. Tewolde, R. Lapu-Bula, H.W. Farber, A. Onwuanyi, Atlanta, GA, p.A3955

P89 **Efficacy and Safety of Inhaled Sodium Nitrite in Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction/**M.A. Simon, R.R. Vanderpool, T.N. Bachman, P. White, E.L. Parsley, M.T. Gladwin, Pittsburgh, PA, p.A3956

P90 **Neutrophil- to-Lymphocyte Ratio Predicts Survival in Pulmonary Arterial Hypertension Patients/**V. Foris, G. Kovacs, P. Douschan, A. Avian, A. Olschewski, H. Olschewski, Graz, Austria, p.A3957

P91 **Characteristics of Precapillary Pulmonary Hypertension in Elderly and Very Elderly Patients/**M. Ginoux, S. Turquier, J.C. Glerant, J. Traclet, C. Khouatra, F. Philit, A. Senechal, J.-F. Mornex, V. Cottin, Bron, France, p.A3958

P92 **Is Right Heart Catheterization Justified in Very Elderly Patients?/**M. Ginoux, V. Cottin, J.C. Glerant, J. Traclet, C. Khouatra, F. Philit, A. Senechal, J.-F. Mornex, S. Turquier, Bron, France, p.A3959

P93 **Circulating RNA as Potential Biomarkers in Pulmonary Hypertension/**I. Singh, K. Max, D. Berger, K. Bogardus, T. Tuschl, E. Horn, K. Akat, New York, NY, p.A3960

P94 **Using Near-Infrared Spectroscopy to Characterize the Effects of Inhaled Nitric Oxide on Skeletal Muscle Oxygen Saturation in Adults with Pulmonary Arterial Hypertension/**B.D. Shaller, C. Kholdani, H. Hedlin, A.J. Sweatt, A. Hsi, E.F. Spiekerkoetter, R.T. Zamanian, Stanford, CA, p.A3961

Facilitator: N. Al-Naamani, MD, Boston, MA

P95 **The Spatial Distribution of Pulmonary Blood Flow in Adults Who Have Undergone Fontan Procedure/**S.R. Hopkins, B.F. Printz, R.C. Sa, H.G. El-Said, C.K. Davis, R.J. Theilmann, La Jolla, CA, p.A3962

P96 **Pulmonary Arterial Hypertension: Effect of Online CME on Improving Treatment Decisions/**J. Spyropoulos, C.C. Kearns, R.J. White, New York, NY, p.A3963

P97 **Pulmonary Arterial Hypertension (PAH) Associated with Interferon Therapy: A Population Based Study/**R. Papani, A. Duarte, Y.L. Lin, G. Sharma, Galveston, TX, p.A3964

P98 **Portopulmonary Hypertension Following Splenectomy: A Mayo Clinic Experience/**J.M. Segraves, R. Cartin-Ceba, M.J. Krowka, Rochester, MN, p.A3965

P99 **Interstitial Lung Disease Associated Pulmonary Hypertension in China/**L. Wang, Q.-H. Zhao, R. Jiang, S.-G. Gong, J. He, P. Yuan, J.-M. Liu, Shanghai, China, p.A3966

P100 **Pulmonary Function Test Parameters in Patients with Scleroderma-Associated Pulmonary Arterial Hypertension and Correlation with Mean Pulmonary Artery Pressure and Pulmonary Vascular Resistance/**V. Yap, A. Selvachandran, M. Zantah, R. Foley, D. Datta, Farmington, CT, p.A3967

P101 **Does Riociguat Provide Clinical Improvement in Pulmonary Hypertension? - A Meta Analysis/**M. Anantha Narayanan, A. Kanmanthareddy, H. Devineni, J. Baskaran, L.E. Morrow, T.O. Wichman, Omaha, NE, p.A3968

P102 **Characteristics and Diagnoses of Elderly Patients Referred to a Pulmonary Vascular Clinic for Evaluation of Possible Pulmonary Arterial Hypertension/**H. Edriss, K. Selvan, T. Denega, T. Rodrigues, K. Nugent, Lubbock, TX, p.A3969

P103 **Safety and Tolerability of Outpatient Transition of Parenteral and Inhaled Treprostinil to Oral Treprostinil in Patients with Pulmonary Arterial Hypertension/**A.A. Khan, K. Ackerbauer, R. Tandon, Chicago, IL, p.A3970

P104 **A Comparison of Safety and Pharmacokinetics of Esuberaprost (BPS-314d-MR) in Subjects with Normal, Mild and Moderate Hepatic Impairment/**K.R.B.V. Kessler, T. Marbury, K. Lasseter, J. Berg, G. Patel, X. Chen, S. Peychal, J. Shin, P. Sista, Silver Spring, MD, p.A3971

P105 **Connective Tissue Disease Associated Pulmonary Arterial Hypertension (CTD-PAH) - Prognosis, Predictors and Outcomes (PROPOS) Study/**R. Ronaghi, B. Doremus, A.I. Khan, V. Balasubramanian, Fresno, CA, p.A3972

P106 **Diabetes and Group III Pulmonary Hypertension: A Matched Case-Control Study/**V.K. Singh, A.M. Morris, P. George, Monroeville, PA, p.A3973

P107 **Pulmonary Capillary Wedge Pressure (PCWP) and Its Role in Determining Outcomes in Pulmonary Arterial Hypertension (PAH)/**S. Venepally, R. Ronaghi, A.I. Khan, V. Balasubramanian, Fresno, CA, p.A3974

P108 **Evaluating the Role of a Pulmonary Hypertension Specialist Nurse in Early Referral/**L.E. Loewenthal, E.J. Shaw, B.P. Brendan, London, United Kingdom, p.A3975

Facilitator: H.J. Ford, MD, Chapel Hill, NC

P109 **Clinical Significance of Detecting Pulmonary Arterio-Venous Malformations with Chest Radiographs/**K. Yamamoto, T. Sugiura, Y. Kasahara, S. Sakao, N. Tanabe, K. Tatsumi, Chiba, Japan, p.A3976

P110 **TRANSIT-1: Evaluation of Transition from Inhaled Treprostinil to Oral Selexipag/**A. Frost, R.L. Benza, H. Farber, N.H. Kim, B.K. Hartline, T. Pfister, Y. Shiraga, V. McLaughlin, Houston, TX, p.A3977

P111 **Low Rate of Adverse Events Associated with Inpatient Parenteral Prostacyclins/**K. Albujoq, R. Awdish, L. Yessayan, M. Mendez, J. Jennings, N. MacDonald, H. Cajigas, S. Hegab, Detroit, MI, p.A3978

P112 **Patients with Pulmonary Arterial Hypertension Less Represented in Clinical Trials - Who Are They and How Are They?/**G. Kovacs, A. Avian, P. Douschan, V. Foris, A. Olschewski, H. Olschewski, Graz, Austria, p.A3979

P113 **Novel PET Vascular Biomarkers in Pulmonary Arterial Hypertension/**V.J. Kelly, P. Kohli, T. Winkler, E. Kehl, J. Rodriguez-Lopez, K.A. Hibbert, M. Kone, J.G. Venegas, R.N. Channick, R.S. Harris, Boston, MA, p.A3980

P114 **DLCO or NT-proBNP as a Screening Tool for PAH in Subjects with COPD/**R.R. Vanderpool, M.G. Risbano, N. Leo, C. Kessinger, L. Kingsley, Y. Zhang, T.N. Bachman, M.A. Simon, M.T. Gladwin, F.C. Sciurba, A.M. Morris, Pittsburgh, PA, p.A3981

P115 **Diagnostic Performance of PA:A Ratio Combined with Contrast Reflux Grade on CT for Pulmonary Hypertension/**A. Palkar, A. Agrawal, S. Sahni, N. Kohn, R. Shah, L. Bacchus, A. Talwar, New Hyde Park, NY, p.A3982

P116 **Lung Perfusion Evaluation in Patients with Stable Granulomatosis with Polyangiitis/**J. Pinaffi, E.P. Oliveira, M.S. Tavares, L.K. Dourado, Sao Paulo, Brazil, p.A3983

P117 **Baseline Characteristics of Patients Enrolled in a Prospective Study of Riociguat for Pulmonary Hypertension Associated with Idiopathic Interstitial Pneumonia (RISE-IIP Study)/**S.D. Nathan, H.R. Collard, V. Cottin, M.M. Hoeper, F.J. Martinez, S. Malcolm, C. DiCasoli, M. Yao, A. Wells, Falls Church, VA, p.A3984

P118 **Guidance on the Registration and Reporting of Drug-Induced Pulmonary Hypertension/**C. O'Connell, D. Montani, L. Savale, O. Sitbon, X. Jais, G. Simonneau, M. Humbert, M.-C. Chaumais, Le Plessis Robinson, France, p.A3985

P119 **Examining SES Factors and Symptom Burden in Patients with PAH/**C. Brown, D.D. Ralph, S. Nolley, E. Tomas, P.J. Leary, Seattle, WA, p.A3986

P120 **Treatment Patterns After Initial Therapy Among Pulmonary Arterial Hypertension Patients in the United States/**C.D. Burger, B. Ozbay, E. Riehle, G. Lenhart, R.J. White, Jacksonville, FL, p.A3987

P121 **Diagnostic Accuracy of 12-Lead EKG and Chest CT in PH/**W.R. Cullinane, Jr., M. Faisal, F. Al-Saffar, A.A. Bajwa, A. Shujaat, Jacksonville, FL, p.A3988

THEMATIC POSTER SESSION

B56 THE ART AND SCIENCE OF REHABILITATION: NOVEL TREATMENTS AND OUTCOMES IN PULMONARY REHABILITATION

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area J, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: M.A. Spruit, PhD, Horn, Netherlands

P1083 **Evidence-Based Rehabilitation for COPD by Neuromuscular Electric Stimulation/**K.-Y. Chen, Luodong Township, Taiwan, p.A3989

P1084 **The Effects of High and Low Frequency Transcutaneous Electrical Muscle Stimulation (TCEMS) on Exercise in Patients with COPD: A Pilot Study/**T.E. Dolmage, D. Brooks, R.S. Goldstein, Toronto, Canada, p.A3990

P1085 **Emotional State Associated with Self-Management Behaviour in People with COPD/**F.C. Blackstock, K.E. Webster, C.F. McDonald, C.J. Hill, Campbelltown, Australia, p.A3991

P1086 **How Should Mindfulness Be Delivered to Individuals with Chronic Obstructive Pulmonary Disease (COPD)? The Views of Healthcare Professionals' and Patients/**S.L. Harrison, A.L. Lee, R.S. Goldstein, D. Brooks, Middlesbrough, United Kingdom, p.A3992

P1087 **Conceptualizing Pulmonary Telerehabilitation with Healthcare Professionals/**J. Inskip, H. Novak-Lauscher, L. Li, M. Ansermino, G. Dumont, A. Garde, K. Ho, A. Hoens, J. Road, C.J. Ryerson, P. Camp, Vancouver, Canada, p.A3993

P1088 **A Physician-Led Intervention to Prevent COPD Re-Admissions/**N. Csikesz, L. Nici, Providence, RI, p.A3994

P1089 **Reduction in the Number of COPD-Related Hospitalization by Low-Intensity Low-Frequency Outpatient Pulmonary Rehabilitation - KORCH Intervention/**Y. Sano, J. Ueki, N. Tamura, K. Obata, Tokyo, Japan, p.A3995

Facilitator: R. Evans, MBChB, PhD, Leicester, United Kingdom

P1090 **Impact of Pulmonary Rehabilitation on Heart Rate Variability Following COPD Exacerbation:A Pilot Study Using a Novel Activity Monitor/**R.S. Novitch, J. Kelly, B. Dehbandi, C. Semper, D. Putrino, White Plains, NY, p.A3996

P1091 **Home-Based Exercise Training Improves Functional Capacity in COPD Patients: A Cross-Sectional Study in Low Income Country/**O.F. Awopeju, R. Adedoyin, Ile-Ife, Nigeria, p.A3997

P1092 **Pulmonary Rehabilitation: A Retrospective Study in Eastern North Carolina/**S.N. Chalise, H. Shaheen, M.Z. Rizwan, K. O'Brien, R. Shaw, Greenville, NC, p.A3998

P1093 **The American Association of Cardiovascular and Pulmonary Rehabilitation (PR) Registry/**C. Garvey, G.S. Bauldoff, M. Vitcenda, C. Paladenech, C. Teneback, D. Donesky, K. Eichenauer, M. Corbett, San Francisco, CA, p.A3999

P1094 **Application of Upper Airway Manometry to Measure the Efficacy of Positive Expiratory Pressure Breathing Techniques in Excessive Dynamic Airway Collapse (EDAC)/**M.A. Zafar, A.M. Mulhall, W. Eschenbacher, A. Kaul, S. Benzaquen, R.J. Panos, Cincinnati, OH, p.A4000

P1095 **The Contribution of Ventilatory Capacity, Gas Transfer Capacity and the Presence of Airflow Obstruction to Limitations in Maximum Power Output/**G.L. Jones, N.L. Jones, K.J. Killian, Hamilton, Canada, p.A4001

P1096 **Pulmonary Rehabilitation in a Lung Transplant Patient with Bilateral Pneumothorax and Severe Thinness Malnutrition: A Case Report/**J. Li, B. Sun, G. Jing, Chicago, IL, p.A4002

Facilitator: H.B. Rossiter, PhD, Torrance, CA

P1097 **Inter-Operator Reliability of Quadriceps Force Elicited by Magnetic Stimulation of the Femoral Nerve/**N. Khan, T. Schnell, D. Aleksonis, D. Radovanovic, A. Jubran, E.G. Collins, M.J. Tobin, C. McBurney, F. Laghi, Hines, IL, p.A4003

P1098 **Longitudinal Follow-Up of a Chronic Obstructive Pulmonary Disease Cohort After 3 Years: Changes in Quadriceps Strength, Aortic Pulse Wave Velocity and Blood Biomarkers/**S.C. Buttery, D. Mohan, M. Fisk, N.S. Hopkinson, I.B. Wilkinson, R. Tal-Singer, M.I. Polkey, London, United Kingdom, p.A4004

P1099 **Impact of Pulmonary Rehabilitation on Rectus Femoris Dimension in COPD/**S. Kolli, A. Kirkpatrick, D. Radovanovic, J. Aguilera, J. Butler, C. Jelinek, S. O'Connell, F. Laghi, M.J. Tobin, E.G. Collins, Hines, IL, p.A4005

P1100 **Interobserver Reliability of Quadriceps Evaluation by Ultrasound in Mechanically Ventilated Polytrauma Patients/**L.V. Santana, N. Pinto, A. Xavier, V. Maldaner, P. Melo, P.E. Silva, G. Cipriano Jr, J. Durigan, L. Vieira, R. Zille,Brasilia, Brazil, p.A4006

P1101 **Effects of a Program of Pulmonary Rehabilitation with Emphasis on the Training of the Respiratory Muscles and Recreational Activities in COPD Patients/**J.R. Jimenez, D.F. Ugas, C.R. Rojas, Talca, Chile, p.A4007

P1102 **Neuromuscular Electrical Stimulation in Obese Patients with Obstructive Sleep Apnea (OSA): A Pilot Study/**I. Vivodtzev, N. Maffiuletti, A.-L. Borel, A. Grangier, B. Wuyam, R. Tamisier, J.L. Pepin, Grenoble, France, p.A4008

P1103 **Effectiveness of Elastic Tube Resistance Training on 6-Minute Walk Test and Muscle Force in Patients with COPD: A Randomized Control Trial/**C.A. Camillo, B.S. Silva, F. Lima, A.P. Freire, L.A. Gobbo, F. Lira, D. Ramos, E.M. Ramos, Leuven, Belgium, p.A4009

P1104 **Catabolic-Anabolic Status and Peripheral Muscle Wasting Detected by Ultrasound Imaging in COPD/**A. Kirkpatrick, A. Goyal, D. Radovanovic, S. Kolli, J. Butler, C. Jelinek, E.G. Collins, M.J. Tobin, F. Laghi, Hines, IL, p.A4010

P1105 **The Glittre ADL-Test Learning Effect - Pilot Study/**C.L.P. De Araujo, B. Foscarini, G. Reinaldo, V. Menezes, P. Dal Lago, Porto Alegre, Brazil, p.A7833

THEMATIC POSTER SESSION

B57 FIBROSIS BIOLOGY

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area M, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

P1393 **Proteasome Activator 200 (PA200) Is Dysregulated in Fibrotic Remodeling of the Lung/**V. Welk, N. Semren, M. Korfei, A. Gunther, O. Eickelberg, Munich, Germany, p.A4011

P1394 **Endoplasmic Reticulum (ER) Stress Exacerbates Pulmonary Fibrosis in Inducible Alveolar Epithelial Type II Cell-Specific Grp78 Knockout Mice/**P. Flodby, C. Li, H. Wang, Y. Liu, M. Rieger, M. Kahn, M.F. Beers, A.S. Lee, P. Minoo, E.D. Crandall, Z. Borok, B. Zhou, Los Angeles, CA, p.A4012

P1395 **Evaluation of Hedgehog and Wnt Developmental Pathway Inhibitors Using BioMAPr Systems In Vitro Models of Pulmonary Fibrosis/**J.I. Drake, S. Velichko, S. Privat, D. Nguyen, E. Berg, A. O'Mahony, South San Francisco, CA, p.A4013

P1396 **Effect of Chronic Intermittent Hypoxia in a Murine Model of Bleomycin-Induced Pulmonary Fibrosis/**T.F. Gille, M. Didier, C. Rotenberg, D. Marchant, A. Sutton, D. Valeyre, H. Nunes, E. Boncoeur, C. Planes, Bobigny, France, p.A4014

P1397 **Lung Epithelium Overexpressed Noncoding RNA (LEON): Role of a Novel Long Intergenic Noncoding RNA in Idiopathic Pulmonary Fibrosis/**B. Juan-Guardela, J. Herazo-Maya, A.E. Tzouvelekis, K. Sakamoto, G. Yu, A. Prasse, Z. Borok, N. Kaminski, New Haven, CT, p.A4015

P1398 **Autophagy Deficiency Increases Endoplasmic Reticulum Stress and Pulmonary Fibrosis Susceptibility in Atg4b Knockout Mice/**M. Maciel, M. Gaxiola, C. Lopez-Otin, M. Selman, A. Pardo, S. Cabrera, Mexico City, Mexico, p.A4016

P1399 **Idiopathic Pulmonary Fibrosis Fibroblasts Utilize Decoy Receptor 3 to Evade the Fas Ligand-Dependent Apoptosis/**J. Im, P. Hergert, R.S. Nho, Minneapolis, MN, p.A4017

P1400 **Decreased Expression of the Cell Cycle Inhibitor CDKN2B Promotes Pulmonary Fibrosis Through Increased Myofibroblast Differentiation Rather Than Increased Proliferation/**A.M. Scruggs, H. Koh, N.J. Leeper, L.R.K. Penke, S. Huang, Ann Arbor, MI, p.A4018

P1401 **SIRT3 Regulates Senescence and Secretory Phenotype of Lung Fibroblasts/**D. Kurundkar, A. Kurundkar, V.J. Thannickal, Birmingham, AL, p.A4019

P1402 **Nox4 Negatively Regulates Metabolic Reprogramming In Lung Fibroblasts/**K. Bernard, V. Miguel, N.J. Logsdon, G.A. Benavides, V.M. Darley-Usmar, V.J. Thannickal, Birmingham, AL, p.A4020

P1403 **Kruppel-Like Factor 4 (KLF4) Negatively Regulates Forkhead Box Protein M1 (FOXM1) Expression and FOXM1-Mediated Fibroblast Activation/**L.R.K. Penke, M. Peters-Golden, Ann Arbor, MI, p.A4021

P1404 **Regulation of IL-33 by Oncostatin M in Mouse Lung Epithelial Cells/**C.D. Richards, L. Izakelian, A. Dubey, A. Quershi, G. Zhang, K. Kwofie, S. Wong, F. Botelho, Hamilton, Canada, p.A4022

P1405 **TNS1 Is Upregulated During Pulmonary Fibrosis and Is Essential for Myofibroblast Differentiation and Extracellular Matrix Formation/**N. Sandbo, E.E. Torr, K. Bernau, Madison, WI, p.A4023

P1406 **Expression and Regulation of Glutathione Peroxidase 3 in Interstitial Lung Disease/**C.A. Staab-Weijnitz, A.C. Schamberger, I.E. Fernandez, H. Schiller, K. Heinzelmann, M. Sterclova, M. Vasakova, M. Mann, O. Eickelberg, Munich, Germany, p.A4024

P1407 **IPF BALF Cells Show Reduced Expression of PINK1 Coupled to Elevated Oxidized Mitochondria Levels/**E. Vasarmidi, E. Tsitoura, G. Margaritopoulos, C. Koutoulaki, S. Michelakis, I. Charalambous, N. Tzanakis, D. Georgopoulos, K. Antoniou, Heraklion, Greece, p.A4025

P1408 **Enhanced Spontaneous TGFβ1 Production and Defective LPS Responses in Monocytes from Patients with Scleroderma Related Interstitial Lung Disease/**H. Pan, H. Ding, M. Gulati, W.H. Fares, Y. Gan, D. Carrano, P. Adonteng-Boateng, X. Peng, E. Herzog, New Haven, CT, p.A4026

P1409 **Increased Expression of Plasminogen Activator Inhibitor 1 Contributes to Alveolar Type II Cell Senescence in IPF Lung/**C. Jiang, G. Liu, Q. Ding, V.B. Antony, V.J. Thannickal, R.-M. Liu, Birmingham, AL, p.A4027

P1410 **Effect of Blockade of Fibroblast Growth Factor Receptor Signaling in Experimental Pulmonary Fibrosis in Mice/**S. Sato, H. Goto, S. Morizumi, H. Okazaki, Y. Chen, H. Kawano, Y. Toyoda, M. Hanibuchi, M. Azuma, Y. Nishioka, Tokushima, Japan, p.A4028

P1411 **Hypoxia Induces Endoplasmic Reticulum Stress in Alveolar Epithelial Cells: Potential Implication in Idiopathic Pulmonary Fibrosis/**E. Boncoeur, A. Naguez, R. Label, A. Soumare, O. Bernard, D. Marchant, Y. Uzunhan, T.F. Gille, C. Planes, Bobigny, France, p.A4029

P1412 **Connective Tissue Growth Factor Is Associated with Pulmonary Hypertension Complicating Idiopathic Pulmonary Fibrosis/**A. Biswas, C. Fu, G. Brown, B. Amador, M. Wallet, S. Wallet, E. Scott, A.J. Bryant, Gainesville, FL, p.A4030

P1413 **Potential Role of Altered Clusterin Expression and Localization in IPF to Limit Fibroproliferation/**L. Peix, I.C. Evans, D.R. Pearce, J.K. Simpson, T.M. Maher, R.J. McAnulty, London, United Kingdom, p.A4031

P1414 **Tranilast Inhibits Pulmonary Fibrosis in Mice/**M. Kato, F. Takahashi, H. Ihara, H. Baskoro, Y. Koinuma, K. Suina, T. Asao, Y. Fujimoto, R. Kanemaru, K. Muraki, T. Sato, N. Shimada, M. Takahashi, K. Takahashi, Tokyo, Japan, p.A4032

P1415 **Adenylate Cyclase Pathway and Progression of Fibrosis/**S. Mukherjee, L. Janssen, Hamilton, Canada, p.A4033

P1416 **A Synthetic Cannabinoid that Exerts a Potent Anti-Fibrotic Effect During the Fibrogenic Phase of Bleomycin Lung/** M. Lucattelli, S. Fineschi, E. Selvi, E. Garcia Gonzalez, B. Bartalesi, G. De Cunto, S. Lorenzini, M. Galeazzi, G. Lungarella, Siena, Italy, p.A4034

P1417 **Epitopes of Anti-Fibrotic mAbs Against Integrin αδβ1 Reveal Complete Aminoacid Conservation Within Mammalian Species/**Y. Yokosaki, N. Kawashima, N. Nishimichi, Hiroshima, Japan, p.A4035

P1418 **Identification of a New Specific Auto-Antibody of Idiopathic Pulmonary Fibrosis/**M. Hikichi, Y. Gon, S. Maruoka, T. Morisawa, K. Mizumura, T. Ooki, R. Ito, H. Hiranuma, F. Kumasawa, Y. Kozu, E. Tsuboi, S. Hashimoto, Tokyo, Japan, p.A4036

P1419 **Study on the Mechanism of Action of Polymyxin B Hemoperfusion Therapy in Acute Exacerbation of Interstitial Pneumonias/**T. Utsunomiya, M. Yuka, T. Yamamoto, K. Aoe, K. Oishi, T. Matsumoto, H. Ueoka, M. Yano, Y. Mimura, Ube, Japan, p.A4037

P1420 **Light Chain Genotype Analysis of GM-CSF Autoantibody in Autoimmune Pulmonary Alveolar Proteinosis by Next Generation Sequencing/**A. Hashimoto, T. Tanaka, A. Hayakawa, Y. Itoh, T. Nei, K. Shiiya, M. Higuchi, K. Nakagaki, T. Takada, K. Akasaka, R. Tazawa, K. Nakata, Niigata, Japan, p.A4038

P1421 **Activation of Adenylyl Cyclase/cAMP Pathway Inhibits Glycolysis and Collagen Production in Human Lung Fibroblasts/**L.J. Witt, R. Nigdelioglu, D.D.-W. Wu, A.Y. Meliton, N.O. Dulin, R.B. Hamanaka, G.M. Mutlu, Chicago, IL, p.A4039

P1422 **Revisiting Pulmonary Ossification/**S.G. Ramos, L.B. Rocha, M.R. Celes, A.C. Freitas, C. Tefe-Silva, K.M. Mata, L.G.B.V. Santoro, M.A. Abreu, E.M. Floriano, J. Baddini-Martinez, Ribeirao Preto, Sao Paulo, Brazil, p.A4040

P1423 **OPG May Protect Bleomycin-Induced Pulmonary Fibrosis by Inhibiting SMAD2/3 Dependent TGF-β1 Activation/**D. Weng, H. Li, Shanghai, China, p.A4041

P1424 **The Palliative Effect of Amniotic Membrane Derived Cells (AMDC) and Conditioned Media on Lung Fibrosis/**A.C. Zamora-Martinez, D.M. Hebrink, P.E. Jenson, T.J. Kottom, A.H. Limper, Rochester, MN, p.A4042

P1425 **Phosphatidylethanolamine Induces Apoptosis in Primary Cultures of Normal Human Lung Fibroblasts/**B. Tlatelpa Romero, C. Mendoza Milla, J.M. Justo Janeiro, L.G. Vazquez De Lara, Puebla, Mexico, p.A4043

P1426 **Metformin Attenuates Pulmonary Fibrosis on the Established Mouse Model Induced by Bleomycin/**S.H. Jeong, Y.J. Kim, J.W. Park, E.S. Son, S.Y. Kyung, S.M. Kang, Incheon, Korea, Republic of, p.A4044

P1427 **Pirfenidone Inhibits p38 Mediated Generation of Procoagulant Microparticels by Human Alveolar Epithelial Cells/**T. Neri, S. Lombardi, F. Faita, S. Petrini, C. Balia, V. Scalise, R. Pedrinelli, P. Paggiaro, A. Celi, Pisa, Italy, p.A4045

P1428 **Influenza-Induced Collagen Deposition and Peribronchial Fibrosis Occurs Independent of Gq/11-Mediated TGFβ Generation in the Alveolar Epithelium/**A.E. John, A. Habgood, A.L. Tatler, J. Porte, S. Offermanns, R.G. Jenkins, Nottingham, United Kingdom, p.A7834

P1429 **Characterizing the Maturation of TGF-β Induced Pulmonary Fibrotic Scar: Quantitation of Extracellular Matrix Protein Synthesis, Remodeling and Crosslinking Rates/**M. Decaris, C. Shimbori, S. Liu, M. Gatmaitan, E. Nyangau, K. Ask, K. Li, M. Hellerstein, P.-S. Bellaye, J. Gauldie, S. Turner, M. Kolb, Emeryville, CA, p.A7835

P1430 **RNA Sequencing of Alveolar Epithelial Cells Derived from Human Lung Explants/**Y. Sakairi, J.A. Villalba, J.C. Osorio, S.G. Chu, K. Tsoyi, H.J. Goldberg, S. El-Chemaly, P. Camp, G. Washko, M.A. Perrella, I.O. Rosas, Boston, MA, p.A7836

P1431 **Stearoyl CoA Desaturase-1 Activity Is Required for Resolving Endoplasmic Reticulum Stress and Suppressing Fibrotic Responses in the Lung/**F. Romero, D. Shah, G. George, R. Summer, Philadelphia, PA, p.A7837

P1432 **Detection of CFTR Function and Modulation in Primary Human Nasal Cell Spheres/**J.J. Brewington, E. Filbrandt, C.-S. Moon, A. Ostmann, A. Naren, J.P. Clancy, Cincinnati, OH, p.A7838

P1433 **The Role of Endocannabinoid System in Regulation of Radiation-Induced Pulmonary Fibrogenesis/**E. Berdyshev, I. Bronova, K. Erdelyi, A. Makriyannis, P. Pacher, Denver, CO, p.A7839

THEMATIC POSTER SESSION

B58 BIG AND BIGGER (DATA): OMICS AND BIOMARKERS OF COPD AND OTHER CHRONIC LUNG DISEASES

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area M, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

P1434 **Senescence-Associated MicroRNA Expression in Serum Exsosomes and Vastus Lateralis Muscle Samples from COPD Patients with Low and Normal Fat Free Mass Index/**R. Lakhdar, D. McGuinness, L. Monaghan, E. Drost, P. Sheils, B. MacNee, R. Rabinovich, Edinburgh, United Kingdom, p.A4046

P1435 **Identification of MicroRNAs that Potentially Regulate Chronic Mucus Hypersecretion in COPD/**H. Tasena, M. Van Den Berge, A. Faiz, D.S. Postma, W. Timens, M. Hylkema, P.S. Hiemstra, P.J. Sterk, I.H. Heijink, C.-A. Brandsma, Groningen, Netherlands, p.A4047

P1436 **Differential Expression of microRNAs After Acute Smoke Exposure in Primary Human Bronchial Epithelial Cells from Smokers with and Without COPD/**G.E. Holt, M. Mirsaeidi, M. Campos, M. Salathe, Miami, FL, p.A4048

P1437 **MicroRNA-218-5p Is Implicated in the Pathogenesis of Chronic Obstructive Pulmonary Disease/**G. Conickx, P. Mestdagh, F. Avila Cobos, F.M. Verhamme, T. Maes, B.M. Vanaudenaerde, L. Lahousse, G.F. Joos, J. Vandesompele, K.R. Bracke, G.G. Brusselle, Ghent, Belgium, p.A4049

P1438 **Effect of Electronic Cigarettes on Oxidative Stress Gene and microRNA Expression from Lung Epithelial Cells In Vitro/**S.K. Solleti, A. Ahmad, S. Bhattacharya, Q. Wang, J. Mereness, C. Slaunwhite, T. Rangasamy, T.J. Mariani, Rochester, NY, p.A4050

P1439 **Isolation and Characterization of Extracellular Vesicles from Plasma of Patients with Chronic Obstructive Pulmonary Disease/**I.K. Sundar, I. Rahman, Rochester, NY, p.A4052

P1440 **Altered Gene Expression Profiles in Human Bronchial Epithelial Cells Exposed to E-Cigarette Liquid: Results from a Genome-Wide Monitoring/**S. Altraja, M. Mitt, A. Altraja, Tartu, Estonia, p.A4053

P1441 **Genetic Regulation of Gene Expression Changes in COPD/**C.A. Brandsma, A. Faiz, D.S. Postma, P.D. Pare, D.D. Sin, Y. Bosse, M. Laviolette, D.C. Nickle, K. Hao, W. Timens, M. Van Den Berge, Groningen, Netherlands, p.A4054

P1442 **Quantitative Analysis of the Soluble Proteome of Airway Epithelial Cells in COPD/**T. Heyder, M. Yang, M. Kohler, C. Sihlbom, R. Karimi, A. Eklund, J. Grunewald, M.C. Skold, A.M. Wheelock, Stockholm, Sweden, p.A4055

P1443 **Inducible Expression Quantitative Trait Loci: A Novel Method to Identifying Genetic Variants Associated with Corticosteroid Responsiveness in COPD/**A. Faiz, D.S. Postma, G.H. Koppelman, P.S. Hiemstra, P.J. Sterk, W. Timens, K. Steiling, A. Spira, I.H. Heijink, M. Van Den Berge, Groningen, Netherlands, p.A4056

P1444 **Lipidomic Analysis of Human Lung Fibroblasts from Ex-Smokers with and Without COPD/**A.D. Desautels, M.H. Ryu, T.H. Mahood, A. Jha, K. Limbert Rempel, G.L. Stelmack, R. Chaudhary, H. Unruh, A. Ravandi, A.J. Halayko, Winnipeg, Canada, p.A4057

P1445 **Proteomic Profiling of Peripheral Exosomes Leads to the Identification of Novel Biomarker Candidates for Emphysema/**Y. Takeda, H. Kume, K. Takafuji, H. Hirata, T. Kijima, T. Tomonaga, A. Kumanogoh, Osaka, Japan, p.A4058

P1446 **TAILS Proteomics in Two Species Identifies New Complement Components and Protease Inhibitors as MMP-12 Substrates During Exacerbations of COPD/**B. Mallia-Millanes, A. Dufour, C.J. Philp, C.E. Bolton, S.D. Shapiro, C.M. Overall, S.R. Johnson, Nottingham, United Kingdom, p.A4059

P1447 **Comprehensive Molecular Profiling of the Lung Using Mass Spectrometry Based Omics Technologies/**C. Ansong, G. Clair, J. Kyle, Y.-M. Kim, S. Dautel, R. Sontag, E. Zink, J. Carson, R. Corley, Richland, WA, p.A4060

P1448 **Valosin Containing Protein Is a Novel Plasma Marker to Indicate Cigarette Smoking Response and Chronic Obstructive Pulmonary Disease (COPD)/**C. Song, W. Chatila, T.J. Rogers, Philadelphia, PA, p.A4061

P1449 **Integration of Molecular Interactome and Targeted Interaction Analysis to Identify a COPD Disease Network Module/**A. Sharma, M. Kitsak, M. Cho, E.K. Silverman, Boston, MA, p.A4062

P1450 **Genome-Wide Association Study Identifies Novel Loci Associated with FEV1 Decline Over 11 Years in Individuals with Chronic Obstructive Pulmonary Disease from the Lung Health Study/**N. Fishbane, M. Obeidat, N.N. Hansel, N. Rafaels, R.A. Mathias, I. Ruczinski, T.H. Beaty, K. Barnes, P.D. Pare, D.D. Sin, Vancouver, Canada, p.A4063

P1451 **Using Lung Gene Expression Profiles of Murine Emphysema Models to Understand Human COPD Susceptibility/**J.H. Yun, J. Morrow, W. Qiu, T. Lao, Z. Jiang, C.A. Owen, M.A. Perrella, A.M.K. Choi, E.K. Silverman, X. Zhou, C.P. Hersh, Boston, MA, p.A4064

P1452 **Analysis of Changes in the Lung Microbiome and Host Parameters in Current and Former Smokers with and Without COPD in the SPIROMICS Cohort/**J.R. Erb-Downward, M.K. Han, C.M. Freeman, J.P. Brown, S. Christenson, C.B. Cooper, R.G. Barr, N.N. Hansel, R. Kanner, M. Zeidler, W. Moore, E. Bleecker, N. Falkowski, D. Farr, R. Paine, III, P.G. Woodruff, F.J. Martinez, J.L. Curtis, G.B. Huffnagle, Arbor, MI, p.A4065

P1453 **Association Between Blood Biomarkers, CT Phenotype and COPD Stage in SPIROMICS/**J. Taylor, I. Degtiar, S. Murray, X. Wang, C.H. Martinez, J.R. Erb-Downward, N. Marchetti, G.J. Criner, W.K. O'Neal, D.J. Couper, R.P. Bowler, M.B. Scholand, C. Pirozzi, C.B. Cooper, R. Kanner, R. Paine, III, R.G. Barr, E. Bleecker, N.N. Hansel, P.G. Woodruff, E.A. Hoffman, C. Galban, B.D. Ross, E. Kazerooni, F.J. Martinez, M.K. Han, Ann Arbor, MI, p.A4066

P1454 **Using Multiple Reaction Monitoring Mass Spectrometry to Identify Biological Pathways and Networks Involved in COPD Exacerbations/**J. Leung, V. Chen, Z. Hollander, J.M. FitzGerald, C. Borchers, B.M. McManus, R.T. Ng, D.D. Sin, Vancouver, Canada, p.A4067

P1455 **Support Vector Machine Identifies a Set of Metabolites in Plasma that Predict Rapid FEV1 Decline in Humans and Mice/** H. Petersen, J. Sui, S. Plis, Y. Tesfaigzi, Albuquerque, NM, p.A4068

P1456 **Association of Plasma Levels of sRAGE with 2-Year Radiographic Emphysema Progression/**Y. Zhang, J.M. Bon, J.K. Leader, D. Chandra, P. An, Y. Chu, D.O. Wilson, C. Fuhrman, F.C. Sciurba, Pittsburgh, PA, p.A4069

P1457 **Gender Differences in the Alteration of the Bronchoalveolar Lavage Cell Proteome in Response to Smoking and COPD/**M. Yang, M. Kohler, H.K. Garberg, J. Grunewald, R. Karimi, F.S. Berven, M.C. Skold, A.M. Wheelock, Stockholm, Sweden, p.A4070

P1458 **Endothelial Function and Endothelial-Derived Microparticles After Exercise in Patients with Chronic Obstructive Pulmonary Disease/**D. Nieri, T. Neri, L. Malagrina, D. Guarino, S. Santerini, S. Antonelli, C. De Simone, G. De Cusatis, C. Spanu, C. Palombo, B. Vagaggini, A. Celi, P. Paggiaro, Pisa, Italy, p.A4071

P1459 **Airway Inflammatory Mediator Determinants of COPD Exacerbation Severity and Resolution/**R.V. Dy, C. Wrona, T. Murphy, S. Sethi, Buffalo, NY, p.A4072

P1460 **Genomic Profiling of DNA-Damage Response in Lung Tissue Identifies Clinical Phenotypes of COPD/**M. Sauler, J. Tedrow, J. Herazo-Maya, F.C. Sciurba, N. Kaminski, P.J. Lee, J.L. Gomez, New Haven, CT, p.A4073

P1461 **Age, Sex and Genetic Factors Are Associated with Response to Ipratropium Among Individuals with Mild COPD in the Lung Health Study/**M. Obeidat, N. Fishbane, N.N. Hansel, N. Rafaels, R.A. Mathias, I. Ruczinski, T.H. Beaty, K. Barnes, P.D. Pare, D.D. Sin, Vancouver, Canada, p.A4074

P1462 **Transcriptomic Alterations Associated with Emphysematous Lung Destruction in Centrilobular and Panlobular Emphysema/**J.J. Kantrowitz, D. Kinose, D.M. Vasilescu, T.-L. Hackett, C. Stevenson, J.C. Hogg, M. Lenburg, A. Spira, Boston, MA, p.A4075

P1463 **Proteomics of Laser Capture Micro-Dissected Alveolar Tissue During Lung Development/**G. Clair, P. Piehowski, T. Nicola, J.A. Kitzmiller, N. Ambalavanan, J. Carson, R. Corley, C. Ansong, Richland, WA, p.A4076

P1464 **Enhanced Mass Spectrometry-Based Proteomics Can Be Used to Distinguish Differences in Protein Compositions of Acellular Emphysematous Versus Normal Lungs/**F.E. Uhl, B. Zvarova, J.G. Fields, B. Deng, Y.W. Lam, D.J. Weiss, D.E. Wagner, Burlington, VT, p.A4077

P1465 **Mouse Lung Developmental Gene Expression Profiling Study Identifies Novel Candidate Genes for Pulmonary Function/**K. Ganguly, L. George, M. Irmler, A. Mitra, T.A. Thimraj, J. Beckers, S. Upadhyay, H. Schulz, G.D. Leikauf, Chennai, India, p.A4078

P1466 **The Lung Connectivity Map: Characterizing Lung Specific Responses to Compound Perturbation/**S. Corbett, E. Moses, T. Wang, J.D. Campbell, C. Perdomo, X. Lu, T. Natoli, R. Narayan, J. Rosains, A. Subramanian, M.E. Lenberg, A. Spira, Boston, MA, p.A4079

P1467 **Proteomic Analysis Reveals Significant Epithelial Remodeling After In Vitro Exposure to Diacetyl Vapor/**M.W. Foster, W.M. Gwinn, F.L. Kelly, D.M. Brass, J.W. Thompson, M.A. Moseley, D.L. Morgan, S.M. Palmer, Durham, NC, p.A4080

P1468 **SENP1 and Polycythemia: A Human Experiment in Nature at High Altitude/**P. Azad, G.G. Haddad, La Jolla, CA, p.A7840

P1469 **Epigenetic Modifications in Peripheral Blood of Human Infants Born and Raised at High Altitude/**S. Krishnan, K. Nephew, M. Ivan, M.R. Martinez, F. Bonilla, C. Cabana, C.J. Llapur, R.S. Tepper, Indianapolis, IN, p.A7841

THEMATIC POSTER SESSION

B59 NOVEL GENES AND GENE EFFECTS IN COPD

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area H, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

P1006 **Association of XRCC5 Polymorphisms with COPD and COPD-Related Phenotypes in Han Chinese: A Case-Control Cohort Study/**B. Wang, J. Yang, J. Xiao, B. Liang, H. Zhou, X. Ou, Y. Feng, Chengdu, China, p.A4081

P1007 **Molecular Characterization of Novel Rare Variants of SERPINA1 Gene in Alpha-1 Antitrypsin Deficiency Patients from Spain/**B. Martinez-Delgado, N. Matamala, B. Lara, R. Saez, S. Castillo, M. Molina, A. Texido, D. Retana, T. Fernandez, A. Otero, L. Lopez, I. Blanco, Madrid, Spain, p.A4082

P1008 **Linking the COPD Susceptibility Gene Iron-Responsive Element Binding Protein 2 (IRP2) with Pathological Outcomes in Experimental COPD/**S.M. Cloonan, K. Glass, M. Laucho-Contreras, A.R. Bhashyam, M. Cervo, M. Pabon, C. Konrad, F. Polverino, I.I. Siempos, E. Perez, K. Mizumura, M. Ghosh, H. Parameswaran, N. Williams, K.T. Rooney, Z.-H. Chen, M.P. Goldklang, G.-C. Yuan, S. Moore, D.L. DeMeo, T.A. Rouault, J.M. D'Armiento, E. Schon, G. Manfredi, J. Quackenbush, A. Mahmood, E.K. Silverman, C.A. Owen, A.M.K. Choi, New York City, NY, p.A4083

P1009 **Decreased Histone Deacetylase 2 in Peripheral Blood Monocytes of Patients with Chronic Obstructive Pulmonary Disease/**C. Tan, L. Xuan, S. Cao, G. Yu, H. Qi, H. Wang, Beijing, China, p.A4084

P1010 **Role of R213G Polymorphism in Cigarette Smoke-Induced Acute Lung Injury/**R. Gaurav, G.C. Mouradian, B.C. Hartman, J. Varasteh, C. Fratelli, E. Grayck, R.P. Bowler, Denver, CO, p.A4085

P1011 **Non-Canonical WNT-5A Compromises Endogenous Lung Repair in COPD/**H.A. Baarsma, W. Skronska-Wasek, K. Mutze, F. Ciolek, G. John-Schuster, M. Dagouassat, A. Gunther, J. Boczkowski, R. Smits, A.O. Yildirim, M. Konigshoff, Munich, Germany, p.A4086

P1012 **Reduced Expression of the Epigenetic Regulator HMGN5 Enhances Susceptibility to Emphysema/**T.M. Conlon, L. Merthan, V. Gailus-Durner, H. Fuchs, M. Hrabe De Angelis, T. Furusawa, M. Bustin, O. Eickelberg, A.O. Yildirim, Munich, Germany, p.A4087

P1013 **Excessive Rac2 Activity in ZZ-Alpha-1 Antitrypsin Deficient Individuals and the Beneficial Effect of Alpha-1 Augmentation Therapy on Aberrant Neutrophil Degranulation/**S.A. Landers, F. Gargoum, N. Lacey, M. White, E. Reeves, N.G. McElvaney, Dublin, Ireland, p.A4088

P1014 **Differential Association of Macrophage Migration Inhibitory Factor (MIF) Promoter Polymorphism with Emphysema in HIV-Infected Compared to Uninfected Patients/**A. Berical, K.A. McGinnis, L. Yu, C. Zhang, L. Leng, R. Bucala, K.A. Crothers, P.J. Lee, M. Sauler, New Haven, CT, p.A4089

P1015 **Cytoskeletal and Mitochondrial Genes as New Targets in the Protection of Airway Epithelial Cells Against Cigarette Smoke/**C. Kliment, Y. Liu, S. Claypool, R. Sihaye, D. Robinson, Baltimore, MD, p.A4090

P1016 **Transforming Growth Factor Beta Affects MiRNA Expression in Control and COPD Fibroblasts/**J. Ong, W. Timens, V. Rajendran, A. Algra, A. Spira, M. Lenburg, J. Campbell, D.S. Postma, A. Van Den Berg, J.L. Kluiver, C.A. Brandsma, Groningen, Netherlands, p.A4091

P1017 **miR-199a-5p, miR-598 and miR-320a Are Regulated by NκB and Decreased in Monocytes of ZZ Individuals Receiving Alpha-1 Antitrypsin Augmentation Therapy/**T.M. Hassan, T. Carroll, S. O'Neill, N.G. McElvaney, C.M. Greene, Dublin, Ireland, p.A4092

P1018 **Muc5b Deficiency Worsens Airway Hyperreactivity in Allergen Challenged Mice/**C.M. Evans, D. Raclawska, A. Stefanski, B.S. Bochner, W. Janssen, Aurora, CO, p.A7842

THEMATIC POSTER SESSION

B60 SMOKING AND PARTICULATES IMPACT ON LUNG HEALTH

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area M, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

P1471 **Identification of IGSF3, a Previously Uncharacterized Gene Linked to an Unusually Severe Case of Emphysema that Is Decreased Both In Vivo and In Vitro in Response to Cigarette Smoke/**K. Schweitzer, N. Rush, N. Jinawath, R. Yonescu, A. Panoskaltsis-Moratori, C.A. Griffin, D.B. Pearse, I. Petrache, Denver, CO, p.A4093

P1472 **Total Particulate Matter Concentration Skews the Gene Expression Pattern in Cigarette Smoke-Exposed Mice Towards an Inflammatory Phenotype: A Gene-Expression Study/** G. Vanderstocken, A. Dvorkin-Gheva, A.O. Yildirim, C.-A. Brandsma, M. Obeidat, Y. Bosse, J.A. Hassell, M.R. Stampfli, Hamilton, Canada, p.A4094

P1473 **Effects of Straw Burning Particulate Matters to Pulmonary Fibrosis Mice Model and the Intervention of NAC/**Y. Li, D. Weng, Shanghai, China, p.A4095

P1474 **Effects of Repeated Carbon Black Nanoparticle Exposures on Healthy and Nitrogen Dioxide Pre-Damaged Mice Lungs/**N. Schreiber, E. Kotte, B. Muller, Marburg, Germany, p.A4096

P1475 **Targeting Sphingosine-1-Phosphate Lyase to Enhance Lung S1P and Reduce Experimental Cigarette Smoke-Induced Chronic Lung Injury and Remodeling/**E. Beatman, C. Poirier, K.A. Serban, E. Berdyshev, J. Saliba, M. Justice, T. Ovarecz, D.J. Zambrowicz, K. Schweitzer, I. Petrache, Denver, CO, p.A4097

P1476 **Cigarette Smoke Induces Human Airway Epithelial Senescence Via Growth Differentiation Factor 15 (GDF15) Production/** Q. Wu, D. Jiang, J.L. Matsuda, K. Ternyak, B. Zhang, H.W. Chu, Denver, CO, p.A4098

P1477 **The Presence of Serotonin in Cigarette Smoke - A Possible Mechanism in Cigarette Smoke-Induced Airway Inflammation/**Y. Cui, W.K.W. Lau, K.W.K. Liu, M.S.M. Ip, J.C.W. Mak, Hong Kong, Hong Kong Prc, p.A4099

P1478 **Pathophysiologic Implications of E-Cigarette Exposure on Airway Epithelial Ion Transport and Mucociliary Clearance/**M.D. Fain, V.Y. Lin, S.V. Raju, L. Tang, C. Fernandez, M. Mazur, J.E. Blalock, P.L. Jackson, S. Rowe, Birmingham, AL, p.A4100

P1479 **Cigarette Smoke-Induced Downregulation of the Epithelial Cell Enriched WNT Receptor Fzd4 Contributes to Reduced Wnt/β-Catenin Signaling and Alveolar Epithelial Cell Proliferation in COPD/**W. Skronska-Wasek, K. Mutze, H.A. Baarsma, D.E. Wagner, M. Stornaiuolo, M. Konigshoff, Munich, Germany, p.A4101

P1480 **Impact of Tobacco Smoke on Upper Airway Dendritic Cell Accumulation and Their Regulation by Human Sinonasal Epithelial Cells/**J.K. Mulligan, B.P. O'Connell, W. Pasquini, R. Mulligan, C. Atkinson, R. Schlosser, Charleston, SC, p.A4102

P1481 **Differential and Tissue Specific Autophagic Responses to Cigarette Smoke Exposure/**M.A. Pabon, F. Malick, K.C. Ma, K. Mizumura, S. Hisata, H.C. Lam, M. Choi, A.M.K. Choi, S.M. Cloonan, New York, NY, p.A4103

P1482 **Hexadimethrine Bromide Prevents Acute Mortality in Rats After Inhalation of Sulfur Mustard Analog, 2-Chloroethyl Ethyl Sulfide (CEES)/**N. Mariappan, M. Husain, I. Zafar, S. Ahmad, A. Ahmad, Birmingham, AL, p.A4104

P1483 **Secondhand Smoke Diminishes Airway Epithelial Ion Transport In Vitro and In Vivo and Is Partially Blocked by Antioxidant Therapy/**L.W. Rasmussen, H. Fortinberry, S. Byzek, L. Tang, S. Rowe, S.V. Raju, Birmingham, AL, p.A4105

P1484 **Hydrogen Therapy Attenuates Bronchial Inflammation After Smoke Inhalation Injury in Sheep/**B. Enkhataivan, S. Jacob, E. Lopez, S. Fukuda, K. Ihara, H. Hawkins, P. Enkhbaatar, R. Cox, Galveston, TX, p.A4106

P1485 **Cigarette Smoke Alters the Biomechanical Properties of Airway Eithelial Cells/**K. Brune, H. Lam, M. Wang, H.M. Yong, S.S. An, D.N. Robinson, V.K. Sidhaye, Baltimore, MD, p.A4107

P1486 **Cadmium in the Peripheral Airways of Tobacco Smokers with and Without COPD/**B. Levänen, B.-M. Sundblad, J. Ji, K. Midander, A. Julander, K.F. Che, K. Larsson, L. Palmberg, A. Linden, Stockholm, Sweden, p.A4108

P1487 **The Imbanlance of Oxidant/Antioxidant Caused by Nitrate in Particulate of Cigarette Smoke May Influence the Progress of Chronic Obstructive Pulmonary Disease/**L. Wang, Y. Hu, H. Li, Hangzhou, China, p.A4109

P1488 **Proteasome-Dependent MHC I Antigen Presentation Is Altered by Cigarette Smoke/**I.E. Keller, A. Dann, C. Lukas, D. Brech, O. Vosyka, E. Noessner, O. Eickelberg, S. Meiners, Munchen, Germany, p.A4110

P1489 **Quercetogetin Protects Cigarette Smoke Extract (CSE)-Induced Mitophagic Cell Death in Pulmonary Epithelial Cells/**J.-W. Park, S. Eun Sook, Incheon, Korea, Republic of, p.A4111

P1490 **Cigarette Smoke-Induced Accumulation of Oxidized Phosphatidylcholine in COPD Primary Human Lung Fibroblasts: Inhibition by Simvastatin/**M.H. Ryu, A.D. Desautels, A. Jha, T.H. Mahood, R. Chaudhary, H. Unruh, C. Carlsten, A. Ravandi, A.J. Halayko, Vancouver, Canada, p.A4112

P1491 **Cigarette Smoke Decreases NALP3 Protein Levels/**S. Han, J. Jerome, R. Mallampalli, Pittsburgh, PA, p.A4113

P1492 **Mechanisms of Uptake/Egress and Intracellular Fate of Nanoparticles in Primary Rat Alveolar Epithelial Cell Monolayers (RAECM)/**E.D. Crandall, A. Sipos, J. Peti-Peterdi, R.H. Chow, Z. Borok, K.-J. Kim, Los Angeles, CA, p.A4114

P1493 **Toxicants, Salicylic Acid and Toluene Diisocyanate, Enhance Carbachol-Induced Bronchoconstriction in Human Precision-Cut Lung Slices (hPCLS)/**J.A. Jude, C. Koziol-White, G. Cao, D. Botelho, W. Jester, R.A. Panettieri, Jr., Philadelphia, PA, p.A4115

P1494 **Determination of Asbestos Body-Associated Proteins by Laser Scanning Micro-Dissection and Mass Spectrometry/**T.N. Perkins, E. Toftgaard Poulsen, J.J. Enghild, A. Ghio, V. Roggli, T.D. Oury, Pittsburgh, PA, p.A4116

P1495 **Synthesis of a Cross-Linked Hyaluronan Matrix by the Airway Epithelium in Experimental Bronchiolitis Obliterans/**D.M. Brass, F.L. Kelly, W.M. Gwinn, C. Brinkley, A. Nagler, D.L. Morgan, M.W. Foster, S.M. Palmer, Durham, NC, p.A4117

P1496 **Preclinical Development of an Antibody Against EMAP II to Treat Cigarette-Smoke (CS)-Induced Emphysema/**K. Koike, E. Beatman, M. Justice, B. Johnstone, M. Clauss, K. Schweitzer, I. Petrache, Denver, CO, p.A7843

THEMATIC POSTER SESSION

B61 FIBROBLASTS AND MATRIX IN COPD

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area H, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

P1019 **Combination of Glycopyrronium and Indacaterol Suppressed Carbachol-Induced Fibrotic Responses in Lung Fibroblasts/**Y. Namba, S. Togo, M. Traf, K. Kadoya, K.Y. Nagahama, H. Taka, N. Kaga, A. Orimo, X. Liu, K. Takahashi, Tokyo, Japan, p.A4118

P1020 **Role of Growth Differentiation Factor 11 in the Pathogenesis of Chronic Obstructive Pulmonary Disease/**K. Onodera, H. Sugiura, M. Yamada, A. Koarai, S. Togo, T. Numakura, R. Tanaka, K. Sato, Y. Hashimoto, K. Abe, Y. Kyogoku, M. Ichinose, Sendai, Japan, p.A4119

P1021 **The Association Between Emphysema and Genetic Variations of LTBP4, a Protein Related to the Formation of Elastic Fiber Assembly/**T. Ishii, S. Chubachi, M. Sasaki, T. Arai, T. Betsuyaku, A. Gemma, K. Kida, Tokyo, Japan, p.A4120

P1022 **Fibroblast Growth Factor 23-Mediated FGF Receptor 4 Signaling in Bronchial Epithelial Cells Contributes to Inflammation in COPD Patients/**S. Krick, N. Baumlin, S. Dennis, M. Campos, C. Faul, M. Salathe, Miami, FL, p.A4121

P1023 **Extracellular Matrix Components Affect Myoblast Proliferation and Differentiation/**X. Liu, Z. Song, J. Ren, A. Nelson, F. Makino, H. Basma, S. Swanson, I. Pipinos, S.I. Rennard, Omaha, NE, p.A4122

P1024 **Extracellular Vesicles (EVs) from Normal Human Lung Fibroblasts Cells (NHLF) and COPD/Pulmonary Emphysema Cells Stimulated by IL-β/TNF-α Mediate Divergent Effects/** F. Makino, J. Ikari, M. Makino, A. Nelson, H. Basma, X. Liu, S.I. Rennard, Omaha, NE, p.A4123

P1025 **Prenyltransferase Expression and Function in Lung Fibroblasts from Moderate COPD Patients/**T.H. Mahood, M.H. Ryu, A. Desautels, O.O. Ojo, G.L. Stelmack, H. Unruh, A.J. Halayko, Winnipeg, Canada, p.A4124

P1026 **Role of Transforming Growth Factor -β1 and Smad Signaling Pathways in EMT Associated COPD Pathegenesis in Smokers/**M.Q. Mahmood, D. Reid, H.K. Muller, D.A. Knight, S.S. Sohal, E.H. Walters, Hobart, Australia, p.A4125

P1027 **Differential Expression of mRNAs in COPD Lung Fibroblasts Varies with Cell Passage and Inflammatory Stimulation In Vitro/**J. Ikari, A. Nelson, L. Smith, T.D. LeVan, S. Iwasawa, Y. Gunji, F. Makino, K. Ikari, M. Farid, X. Wang, H. Basma, X. Liu, D.L. DeMeo, C. Feghali-Bostwick, K. Tatsumi, S.I. Rennard, Omaha, NE, p.A4126

P1028 **Regulation of Non-Canonical WNT-5A by Primary Human Lung Fibroblasts/**F. Ciolek, M. Konigshoff, H.A. Baarsma, Munich, Germany, p.A4127

P1029 **Priming Adipose Stromal Cells for Enhanced Paracrine Anti-Elastase Activity/**K. Ni, M.U. Mukhtar, C. Meador, D. Cao, M. Justice, K. Schweitzer, K.L. March, I. Petrache, Denver, CO, p.A4128

P1030 **Elastin Degradation of Lung Matrix in Advanced COPD Compared to Normal Lung/**Y.Y. Lin, J. He, S. Ma, J. Cantor, T. Usuki, G.M. Turino, New York, NY, p.A4129

P1031 **PPARg and TGF-β1 Signaling Are Involved in Airway Repair in Cigarette Smoke-Associated Chronic Bronchitis/**J. Sailland, N. Baumlin, S. Dennis, S. Krick, M. Salathe, A. Schmid, Miami, FL, p.A4130

P1032 **Epigenetic Changes in CSE-Exposed Human Lung Fibroblasts/** H. Basma, G. Blankenau, A. Nelson, F. Makino, X. Liu, L. Smith, S.I. Rennard, Omaha, NE, p.A4131

P1033 **Connective Tissue Growth Factor that Promotes Pulmonary Epithelial Cell Senescence Is a Severity-Dependent Biomarker for COPD/**J.-H. Jang, H. Chand, S. Bruse, M. Doyle-Eisele, C. Royer, J. McDonald, Y. Lin, Y. Tesfaigzi, T. Nyunoya, Albuquerque, NM, p.A4132

P1034 **Little Evidence for Epithelial-Mesenchymal Transition in a Murine Model of Airway Fibrosis Induced by Repeated Naphthalene Exposure/**T. Tsuji, M. Itoh, R. Kikuchi, T. Uruma, H. Watanabe, K. Yamaguchi, H. Nakamura, K. Aoshiba, Tokyo, Japan, p.A4133

P1035 **Low Vitamin K Status Is Associated with COPD and Accelerated Degradation of Mature Elastin/**B. De Brouwer, M. Spanbroek, N. Drummen, J. Van Den Ouweland, P. Zanen, C. Vermeer, R. Janssen, Nijmegen, Netherlands, p.A4134

P1036 **Relationship Between Pulmonary Matrix Metalloproteinases and Emphysema Sub-Types/**K. Ostridge, S. Harden, S. Bourne, N. Coombes, R.S.J. Estepar, G. Washko, P. Elkington, K.J. Staples, T.M.A. Wilkinson, Southampton Hampshire, United Kingdom, p.A4135

P1037 **Matrix Metalloproteinase 10 (MMP10) Is Highly Up-Regulated in M2 Macrophages and Lymphoid Aggregates in Idiopathic Pulmonary Fibrosis/**C. Chima-Melton, H.D. Jones, W. Parks, Los Angeles, CA, p.A7844

THEMATIC POSTER SESSION

B62 THE BIOLOGY OF SCARRING. WHERE ARE WE NOW

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area M, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

P1498 **Hypoxia Worsens Pulmonary Fibrosis Through Expression of C/EBP Homologous Protein (CHOP)/**A. Burman, W.E. Lawson, T.S. Blackwell, H. Tanjore, Nashville, TN, p.A4136

P1499 **Expression of the Relaxin Receptor RXFP1 Is Decreased in Idiopathic Pulmonary Fibrosis: Implications for Relaxin-Based Therapies in Fibrotic Lung Disease/**J. Tan, J. Tedrow, Y. Chu, K. Veraldi, Y. Zhang, D. Kass, Pittsburgh, PA, p.A4137

P1500 **Low Input Ion Torrent RNA-Sequencing of Formalin-Fixed, Paraffin-Embedded (FFPE) Lung Tissue from Patients with Idiopathic Pulmonary Fibrosis/**M. Vukmirovic, X. Yan, B. Hu, R. Homer, G. Deluliis, K. Gibson, K.O. Lindell, S.A. Yousem, J.H. Maya, N. Kaminski, New Haven, CT, p.A4138

P1501 **Integrin-α6 Regulates Cellular Senescence and Pro-fibrotic Gene Expression in IPF Fibroblasts/**A.R. Kurundkar, J.S. Deshane, Y. Zhou, D. Kurundkar, L. Hecker, S. Rangarajan, V.J. Thannickal, Birmingham, AL, p.A4139

P1502 **An Antagonistically Pleiotropic Role of miR-34a in the Pathogenesis of Lung Fibrosis in Young and Aged Mice/**H. Cui, S. Banerjee, J. Ge, N. Xie, R.-M. Liu, V.B. Antony, V.J. Thannickal, G. Liu, Birmingham, AL, p.A4140

P1503 **Elderly-Onset Hereditary Pulmonary Alveolar Proteinosis and CSF2RA Mutation/**R. Tazawa, M. Ito, K. Nakagome, K. Akasaka, H. Ohta, Y. Uchida, A. Shiono, T. Takada, M. Nagata, J. Tohyama, K. Hagiwara, M. Kanazawa, K. Nakata, Niigata, Japan, p.A4141

P1504 **FENDRR Is an Epigenetic Regulator of Cellular Senescence in Pulmonary Fibroblasts/**K. Sakamoto, B. Juan Guardela, G. Yu, J. Herazo-Maya, F. Ahangari, A.E. Tzouvelekis, R. Homer, N. Kaminski, New Haven, CT, p.A4142

P1505 **Analysis of Long Non-Coding RNA Expression Profiles in the Mouse Model of Pulmonary Fibrosis/**H. Sun, J. Chen, W. Qian, J. Kang, J. Wang, L. Jiang, L. Qiao, J. Zhang, Nanjing, China, p.A4143

P1506 **Identification of Paraquat Aerosolization-Induced Lung Injury and Related Fibrosis in Mice/**H. Sun, J. Kang, P. Huang, C.E. Hennessy, L.A. Warg, S.K. Mathai, M.I. Schwarz, C.M. Evans, I.V. Yang, D.A. Schwartz, J. Zhang, Nanjing, China, p.A4144

P1507 **NEU1 Sialidase Is Elevated in the Lungs of Patients with IPF and Contributes to Fibrosis/**I.G. Luzina, V. Lockatell, S.W. Hyun, Z. Noor, A. Liu, E.P. Lillehoj, C. Lee, A. Miranda-Ribera, N.W. Todd, S.E. Goldblum, S.P. Atamas, Baltimore, MD, p.A4145

P1508 **Interstitial Smooth Muscle Bundles Rather than Activated Myofibroblasts Are Associated with Poor Clinical Outcomes in Patients with Histologic Areas of Organization/**I.G. Luzina, A.E. Wyman, A.P. Burke, S.P. Atamas, N.W. Todd, Baltimore, MD, p.A4146

P1509 **Increased Alveolar Epithelial Cell Senescence in Pulmonary Fibrosis/**M. Lehmann, K. Mutze, H.B. Schiller, D.E. Wagner, M. Konigshoff, Munich, Germany, p.A4147

P1510 **Gene Expression Profiling in End-Stage IPF Lung Fibrotic Microenvironment/**J.E. McDonough, F. Ahangari, M. Vukmirovic, G. Deluliis, N. Tanabe, S. Verleden, J. Herazo-Maya, X. Yang, B. Hu, N. Aurelien, G.M. Verleden, B.M. Vanaudenaerde, W. Wuyts, J.C. Hogg, N. Kaminski, Leuven, Belgium, p.A4148

P1511 **Role of MAP Kinase Phosphatase 5 (MKP5) in Pulmonary Fibrosis/**A.E. Tzouvelekis, G. Yu, M. Kisuk, J. Herazo-Maya, T. Woolard, N. Aurelien, M. Vukmirovic, K. Sakamoto, T. Adams, G. DeIuliis, F. Ahangari, A. Bennett, N. Kaminski, New Haven, CT, p.A4149

P1512 **Disruption of Proximal-Peripheral Epithelial Differentiation and Activation of Hippo/YAP Signaling in Idiopathic Pulmonary Fibrosis/**A. Sridharan, A.W. Lange, K.A. Wikenheiser-Brokamp, B. Stripp, J.A. Whitsett, Cincinnati, OH, p.A4150

P1513 **STAT3 IS a Critical Regulator of Myofibroblast Function and Pulmonary Fibrosis/**K.M. Choi, A.J. Haak, K.J. Smith, P.R. Walters, M.A. Thompson, M.R. Freeman, L.J. Manlove, Y.S. Prakash, R. Vassallo, D.J. Tschumperlin, Rochester, MN, p.A4151

P1514 **Proinflammatory Cytokines and Bronchoalveolar Lavage from Idiopathic Pulmonary Fibrosis Patients Are Promoting the Expression of Fibrogenic Factors Through the Stimulation of Subepithelial Pneumonic Myofibroblasts. A Possible Role for the Novel Fibrogenic Factor TL1A/c/**E. Bouros, E. Filidou, K. Arvanitidis, D. Mikroulis, P. Steiropoulos, G. Bamias, D. Bouros, G. Kolios, Alexandroupolis, Greece, p.A4152

P1515 **Cadmium Induces Vimentin Phosphorylation Through Both AKT and Cdc2 Signaling in Lung Cells/**F.J. Li, H. Li, R. Surolia, Z. Wang, T. Kulkarni, G. Liu, V.J. Thannickal, V.B. Antony, Birmingham, AL, p.A4153

P1516 **Idiopathic Pulmonary Fibrosis Fibroblasts Exhibit Matrix-Autonomous Upregulation in Non-Muscle Myosin II/** B.D. Southern, L.M. Grove, R.G. Scheraga, S. Abraham, K.A. Niese, T.T. Egelhoff, M.A. Olman, Cleveland, OH, p.A4154

P1517 **Evidence of Mesenchymal to Epithelial Transition in Human Fibroblasts Obtained from Normal Lungs and from Idiopathic Interstitial Pneumonias/**C. Becerril, M. Montano, C. Ramos, J. Cisneros, C. Mendoza-Milla, M. Checa, A. Pardo, M. Selman, Mexico City, Mexico, p.A4155

P1518 **Danaparoid Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice/**X. Wang, Y. Tanino, T. Nikaido, M. Kikuchi, Y. Sato, N. Fukuhara, K. Misa, R. Togawa, Y. Suzuki, M. Uematsu, A. Fukuhara, S. Sato, J. Saito, H. Yokouchi, M. Munakata, Fukushima, Japan, p.A4156

P1519 **The Role of p22phox-Dependent NADPH Oxidases in Bleomycin-Induced Interstitial Lung Disease/**B.M. Nagy, C. Nagaraj, H. Olschewski, A. Olschewski, Graz, Austria, p.A4157

P1520 **The Role of Bronchiolar Epithelial Cell Migration in Idiopathic Pulmonary Fibrosis (IPF)/**J. Fukumoto, R. Soundararajan, R.F. Lockey, N. Kolliputi, Tampa, FL, p.A4158

P1521 **Alveolar Epithelial Cells Release Pro-Fibrotic Mediators in Response to Endoplasmic Reticulum Stress/**K.E. Black, V.A. Pace, A.M. Tager, Boston, MA, p.A4159

P1522 **Whole Genome Sequencing Identifies Susceptibility Loci for DPB/**Y. Jin, D. Weng, Shanghai, China, p.A4160

P1523 **Proteasome-Dependent Degradation of IL-33 in Primary Human Pulmonary Fibroblasts/**A. Clerman, Z. Noor, I.G. Luzina, S.P. Atamas, Baltimore, MD, p.A4161

P1524 **Analysis of Lung Injury Models by Using Human MUC1 Transgenic Mice/**T. Kubota, M. Sakai, S. Akita, S. Kawase, H. Ohnishi, A. Yokoyama, Nankoku City, Japan, p.A4162

P1525 **Rapamycin Insensitive mTOR Signalling Promotes TGF-ß Induced Pro-Fibrotic Gene Expression in Human Lung Fibroblasts/**H. Woodcock, J. Eley, S. Peace, C. Nanthakumar, T.M. Maher, P. Mercer, R. Chambers, London, United Kingdom, p.A4163

P1526 **Lung Fibroblasts Derived from Patients with Idiopathic Pulmonary Fibrosis Are Resistant to Alternaria Alternata-Mediated Cell Death/**J. Im, R.S. Nho, Minneapolis, MN, p.A4164

P1527 **The Role of Histone Deacetylase 8 in Fibroblast-Myofibroblast Differentiation/**S. Saito, Y. Zhuang, G. Morris, J. Lasky, New Orleans, LA, p.A4165

P1528 **Electrophysiological and Pharmacological Characterization of Primary K+-, Cl— and Ca2+-Conductances in Human Pulmonary Fibroblasts/**M. Rahman, S. Mukherjee, V. Sheng, L. Janssen, Hamilton, Canada, p.A4166

P1529 **Establishment of Non-Infectious Exacerbation Pulmonary Fibrosis Model in Rat/**S. Chen, D. Weng, Shanghai, China, p.A4167

P1530 **Identification of Novel Mediators in Lung Fibrosis/**J. Verneau, London, United Kingdom, p.A4168

P1531 **Melatonin Attenuates TGFß1-Induced Epithelial-Mesenchymal Transition in Lung Alveolar Epithelial Cells/**Y. Na, J. Kang, Shenyang City, China, p.A4169

P1532 **Nintedanib Reduces Pulmonary Fibrosis in a Model of Rheumatoid Arthritis Associated Interstitial Lung Disease/**E.F. Redente, M.A. Aguilar, L.P. Lalire, B.L. Edelman, L. Wollin, D.W.H. Riches, Denver, CO, p.A4170

P1533 **Involvement of PARK2-Mediated Mitophagy in Idiopathic Pulmonary Fibrosis Pathogenesis/**K. Kobayashi, J. Araya, H. Hara, S. Minagawa, M. Yoshida, K. Tsubouchi, T. Kadota, N. Saito, N. Sato, Y. Kurita, S. Ito, J. Kojima, T. Numata, Y. Kaneko, H. Asano, M. Yamashita, M. Odaka, T. Morikawa, K. Nakayama, K. Kuwano, Tokyo, Japan, p.A4171

P1534 **Functional, Histological and Biochemical Endpoints for Assessing Antifibrotic Efficacy in a Rat Model of Pulmonary Fibrosis/**H.G. Hoymann, D. Schaudien, T. Hansen, M. Niehof, A. Braun, Hannover, Germany, p.A4172

P1535 **Urokinase Plasminogen Activator (uPA) Is Increased in Interstitial Lung Disease (ILD): A Potential Fibrogenic Mediator and Biomarker in ILD/**M. Schuliga, J. Jaffar, A. Berhan, S. Langenbach, T. Harris, G. Westall, A.G. Stewart, Parkville, Australia, p.A4173

P1536 **Necroptosis Is Involved in Bleomycin Induced Experimental Lung Injury/Fibrosis/**S.W. Park, J.-M. Lee, M.W. Lee, H.J. Seo, J.-H. Lee, A.S. Jang, D.-J. Kim, S.T. Uh, Y.H. Kim, C.-S. Park, Bucheon, Korea, Republic of, p.A4174

P1537 **How Basic Science Methodology Has Changed in the Context of the Bleomycin Model of Pulmonary Fibrosis/**P.S. Kolb, D. Miller, J. Lee, C. Shimbori, P.-S. Bellaye, K. Ask, M.R.J. Kolb, Hamilton, Canada, p.A4175

P1538 **SFTPA1 Mutation in Familial Idiopathic Interstitial Pneumonia and Lung Cancer/**N. Nathan, V. Giraud, C. Picard, H. Nunes, F. Dastot Le Moal, P. Duquesnoy, B. Copin, M. Reynaud-Gaubert, D. Valeyre, L.-J. Couderc, T. Chinet, R. Borie, B. Crestani, V. Nau, S. Tissier, L. Galeron, A. De Ligniville, N. Kuziner, M. Simansour, L. Mansour Hendili, M. Legendre, C. Kannengiesser, A. Coulomb, L. Gouya, S. Amselem, A. Clement, Paris, France, p.A7845

THEMATIC POSTER SESSION

B63 MY WAY: OSA OUTPATIENT MODELS OF CARE

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area N, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitators: C. Chai-Coetzer, MBBS, PhD, Adelaide, Australia
J.P. Bakker, PhD, Boston, MA

P1539 **Are Partner-Completed Epworth Sleepiness Scale Scores Useful in the Evaluation of Patients with Suspected Obstructive Sleep Apnea?/**H. Upadhyay, S. Bhat, V. DeBari, M. Ahmad, P. Polos, S. Chokroverty, Edison, NJ, p.A4176

P1540 **Stop- Bang Questionnaire in Obstructive Sleep Apnea: A Severity Predictor/**D. Polano Alonso, T. Martin, S. Garcia Marin, A.L. Figueredo Cacacho, C. Vinado Manes, C. Panadero Paz, S. Garcia Saez, J.M. Marin Trigo, E. Chacon Valles, S. Bello Dronda, Zaragoza, Spain, p.A4177

P1541 **Should the Epworth Sleepiness Score Be Used to Prioritize Services for Suspected Obstructive Sleep Apnoea?/**A. Neill, A. Campbell, D. Scott, Wellington, New Zealand, p.A4178

P1542 **Racial Disparities in Referral for Sleep Apnea Evaluation/**S. Thomas, K.A. Dudley, S.R. Patel, Boston, MA, p.A4179

P1543 **Role of Nocturnal Oxygen Desaturation for the Diagnosis of Coexistent Obstructive Sleep Apnea in Patients with COPD/**D. Dhingani, A.S. Copur, V. Khatri, A. Fulambarker, North Chicago, IL, p.A4180

P1544 **Romanian Lesson from a Screening of Sleep Apnea and Patients with Obesity-Hypoventilation Syndrome/**F.D. Mihaltan, E.C. Jeler, Bucharest, Romania, p.A4181

P1545 **Sleep Apnea and Prescription Opioid Use in U.S. Veterans: Results from a National Database/**S. Chowdhuri, W. Wiitala, D. Ratz, J. Davis, Detroit, MI, p.A4182

P1546 **Sleep Disorders in Breast Cancer Patients Based on Polysomnographic Data/**A. Knox, D. Balachandran, V.C. Murphy, L. Bashoura, S.A. Faiz, Houston, TX, p.A4183

Facilitators: S. Mukherjee, MBBS, PhD, Toronto, Canada
A. Neill, MBChB, MD, Wellington, New Zealand

P1547 **Effectiveness of Positive Airway Pressure in Type 2 Diabetes and Obstructive Sleep Apnea/**L.M. Donovan, M. Rueschman, N.A. Basu, J. Weng, K.A. Dudley, J.P. Bakker, R. Wang, S. Bertisch, S.R. Patel, Seattle, WA, p.A4184

P1548 **Effect of Mobile Health Technology on Positive Airway Pressure Adherence in Patients with Sleep Apnea/**K.J. Pak, L. Seoane, J.P. Bakker, S. Bertisch, C. Pham, N. McNaughton, J. Park, K. Severensin, L.A. Bazzano, New Orleans, LA, p.A4185

P1549 **Impact of Interactive Web-Based Education and Automated Feedback Program on CPAP Adherence for the Treatment of Obstructive Sleep Apnea/**D. Hwang, J. Chang, J. Liang, K. Becker, J.B. Kim, R.R. Woodrum, D.T. Vega, J. DeWitte, M. Crocker, A. Benjafield, S. Derose, Fontana, CA, p.A4186

P1550 **The Impact of Group Versis Individual PAP Therapy Set-Up on OSA Treatment Compliance- A Pilot Study/**M. Stanchina, J. Lincoln, W. Donat, W. Corrao, A. Malhotra, East Greenwich, RI, p.A4187

P1551 **Impact of the Purchase of Continuous Positive Airway Pressure Therapy on Acceptance and Long Term Adherence: A Belgian Model/**G.B. Mwenge, J. Leemans, J. Bousata, D. Rodenstein, Bruxelles, Belgium, p.A4188

P1552 **Evaluation of a "Fast Track" Alternative Care Provider Clinic for Patients with Severe Sleep Disordered Breathing/**S.R. Pendharkar, W.H. Tsai, K.L. Fraser, J. Kelly, A. Ip, M.J. Santana, E.D. Penz, W. Flemons, P.J. Hanly, Calgary, Canada, p.A4189

P1553 **Adherence and Patients' Competencies in the Use of Home Non-Invasive Ventilation/**M. Patout, G. Arbane, L. Castaldi, P. Marino, J. Owusu-Afriyie, J. Steier, N. Hart, P.B. Murphy, London, United Kingdom, p.A4190

THEMATIC POSTER SESSION

B64 BOP GOES THE HEART: CARDIOVASCULAR CONSEQUENCES OF SDB

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area N, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: S.R. Patel, MD, Pittsburgh, PA

P1555 **Effects of JAG1 Gene Polymorphism on Systemic Blood Pressure in Patients with Obstructive Sleep Apnea/**R. Tkacova, I. Paranicova, V. Habalova, I. Trojova, P. Joppa, I. Tkac, Kosice, Slovak Republic, p.A4191

P1556 **Prevalence and Effect of Obstructive Sleep Apnea in Erectile Dysfunction/**C. Limsuwat, P. Aswanetmanee, E. Onate, I. Klair, S. Thammasitboon, New Orleans, LA, p.A4192

P1557 **The Interaction of Obesity and Nocturnal Hypoxemia on Cardio-Vascular Consequences in Adults with Obstructive Sleep Apnea: A Historical Observational Study/**T. Kendzerska, N. Ayas, A.S. Gershon, G. Tomlinson, R.S. Leung, Toronto, Canada, p.A4193

P1558 **Sleep-Disordered Breathing Is Associated with Macrovascular Complications in Patients with Diabetes Mellitus Type 2/**S. Stadler, S. Jalili, C. Boger, M. Arzt, Regensburg, Germany, p.A4194

P1559 **Relationship Between Severity of Sleep Apnea and Extent of Coronary Atherosclerosis/**Y. Tomita, T. Kasai, S. Ishiwata, M. Ohno, K. Narui, Tokyo, Japan, p.A4195

Facilitator: J.C. Borel, PhD, La Tronche, France

P1560 **IGF-1: A Marker of Cardio-Metabolic Risk in Sleep Apnea Syndrome?/**L.-M. Galerneau, J.L. Pepin, A.-L. Borel, O. Chabre, M. Sapene, B. Stach, J. Girey-Rannaud, R. Tamisier, P. Caron, Grenoble, France, p.A4196

P1561 **Characteristics of Arterial Stiffness in Young Male Patients with Arterial Hypertension, Obesity and Severe Sleep Apnea Syndrome/**E. Elfimova, A. Zairova, M. Andreevskaya, A. Litvin, A. Rogoza, I. Chazova, Moscow, Russian Federation, p.A4197

P1562 **Slow Wave Sleep and Incident Hypertension/**S. Javaheri, Y.Y. Zhao, N. Punjabi, S. Quan, D.J. Gottlieb, S. Redline, Boston, MA, p.A4198

P1563 **Purinergic P2X3 Receptor Signalling in the Carotid Body (CB) Accounts for Its Aberrant Discharge in Pathology Revealing New Therapeutic Target for Hypertension/**J.F. Paton, D.J. Moraes, M.P. Da Silva, B.H. Machado, A.P. Ford, Bristol, United Kingdom, p.A7846

P1564 **Prevalence of OSA in a Hypertensive Cohort: Comparison of Dipping Vs Nondipping Status/**S.J. Crinion, S. Ryan, G. Nolan, L. Hayes, K. McDonald, W.T. McNicholas, Dublin, Ireland, p.A4199

Facilitator: R. Tamisier, MD, PhD, Grenoble, France

P1565 **Association Between Nocturnal Blood Pressure Dipping and Arterial Stiffness in Patients with Mild Obstructive Sleep Apnea/**L.R.A. Bittencourt, Sao Paulo, Brazil, p.A4200

P1566 **The Prevalence of Obstructive Sleep Apnea in Patients with Type B Aortic Dissection/**W. Ling, L.J. Fang, G. Li, C.P. Yan, W. Rui, C.J. Yan, Guangzhou, China, p.A4201

P1567 **Impact of Pulmonary Hypertension on Reduction of Right Ventricular Longitudinal Strain in Patients with Obstructive Sleep Apnea Syndrome/**A. Canora, S. Castaldo, C. Santoro, A. Buonauro, R. Esposito, B. Trimarco, A. Sanduzzi Zamparelli, M. Galderisi, M. Bocchino, Naples, Italy, p.A4202

P1568 **Obstructive Sleep Apnea and the Risk of Recurrent Venous Thromboembolism/**N. Toledo Pons, E. Nervo, A. Alonso Fernandez, A. Garcia-Suquia, M. De La Pena, A. Barcelo, J. Pierola, M. Carrera Lamarca, D. Romero, C. Fernandez-Capitan, A. Lorenzo, J. Soriano, F. Garcia-Rio, Palma de Mallorca, Spain, p.A4203

P1569 **Prevalence and Outcomes of Sleep Disordered Breathing in Heart Failure/**S. Kotecha, K. Kee, T. Roebuck, E. Dabscheck, B. Miller, P. Bergin, M.T. Naughton, Melbourne, Australia, p.A4204

Facilitator: C.M. Hoyos, MPH, PhD, Glebe, Australia

P1570 **Exercise in Normobaric Hypoxia Compared to Sham Hypoxia Improves Cardiovascular Rehabilitation in Geriatric Patients/**S. Pramsohler, S. Wimmer, M. Burtscher, M. Faulhaber, H. Gatterer, N. Netzer, Bad Aibling, Germany, p.A4205

P1571 **Risk of Obstructive Sleep Apnea in Patients with Pacemakers and Implantable Cardioverter Defibrillators and Inicidence of Ventricular Arrhythmia/**R. Clay, V.K. Kapur, J.M. Gronquist, L.G. Tereshchenko, A. Khan, Portland, OR, p.A4206

P1572 **6-Month Follow Up of Sleep Disordered Breathing in Congestive Heart Failure in Maputo, Mozambique/**J.E. Orr, I. Mbanze, P.N. DeYoung, G. Valerio, G. Muchanga, R. Banze, E. Nunes, A. Malhotra, A. Damasceno, La Jolla, CA, p.A4207

P1573 **Predictors of Sleep Disordered Breathing in Heart Failure Patients in Mozambique/**P.N. DeYoung, J. Flatt, I. Mbanze, G. Valerio, E. Nunes, R. Banze, E.T. Smales, A. Damasceno, A. Malhotra, La Jolla, CA, p.A4208

P1574 **Sleep Overnight Monitoring for Apnea in Heart Failure (SOMA-HF Study)/**A. Chowdhury, A. Adams, S. Gupta, K. Flemming, L. Willes, P.J. Mather, S. Sharma, Philadelphia, PA, p.A4209

P1575 **Cardiovascular Improvements with Adaptive Servo-Ventilation in Heart Failure: Insights from the CAT-HF Trial/**N. Punjabi, D. Whellan, M. Fiuzat, A. Benjafield, H. Woehrle, K.J. Anstrom, A. Blase, J. Lindenfeld, O. Oldenburg, C. O'Connor, Baltimore, MD, p.A4210

THEMATIC POSTER SESSION

B65 THINGS THAT GO BUMP IN THE NIGHT: SLEEP CASE STUDIES AND NON-OSA SLEEP

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area N, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: B. Mokhlesi, MD, MS, Chicago, IL

P1576 **Learn Targets for Bi-Level Ventilation Intelligent Volume-Assured Pressured Support (iVAPS) Mode Successfully Predicts Bi-Level Ventilation Settings After Polysomnogram in an Adolescent with Duchenne Muscular Dystrophy (DMD)/**A. Khayat, S. Al-Saleh, A. Hamilton, I. Narang, C. Daniels, F. Syed, R. Amin, Toronto, Canada, p.A4211

P1577 **Successful Management of Breathing-Related Sleep Disorder Associated with an Orphan Syndrome, Rapid-Onset Obesity with Hypothalamic Dysfunction, Hypoventilation, and Autonomic Dysregulation (ROHHAD)/**M.I. Saadi, M.A. Tablizo, Fresno, CA, p.A4212

P1578 **A Rare Case of Persistent Hypersomnia of Central Origin After Pneumococcal Meningitis/**M.I. Saadi, L. Keenan, Fresno, CA, p.A4213

P1579 **Parkinson's Disease as a Contributing Cause of Obstructive Sleep Apnea, Treatable with Controlled Release Levodopa/**M. Kaminska, A.-L. Lafontaine, V. Mery, A. Robinson, R.J. Kimoff, Montreal, Canada, p.A4214

P1580 **A Case of Idiopathic Bilateral Diaphragmatic Paralysis Presenting in a Young Man with Orthopnea and Sleep Disruption/**T. Sahai, A. Goizueta, N. Hauser, M. Stanchina, D. Rosen, M. Keuroghlian, Providence, RI, p.A4215

Facilitator: R. Arens, MD, Bronx, NY

P1581 **Obstructive Sleep Apnea in Bardet-Biedl Syndrome/**S.S. Hahn, H. Greenberg, H. Steinberg, New Hyde Park, NY, p.A4216

P1582 **Low Pulse Oximeter Reading Caused by Rare Hemoglobinopathy /**L.M. Sarzynski, S.J. Khalfoun, T. Turner, Columbus, OH, p.A4217

P1583 **Resolution of Polycythemia with Treatment of Obstructive Sleep Apnea/**A. Chakraborty, S. Sharma, Philadelphia, PA, p.A4218

P1584 **Two Cases of a Rare Cause of Hypersomnia with Characteristic Similarities and Distinct Differences/**B. Colaco, M.C. Lipford, M. Junna, Rochester, MN, p.A4219

P1585 **"I See Horses in the Room"- An Intriguing Case of Neuro Degenerative Disease in an Elderly Male/**R. Radhakrishna, Syracuse, NY, p.A4220

Facilitator: S. Chowdhuri, MD, MS, Detroit, MI

P1586 **Ventricular Peritoneal Shunt Malfunction Presenting as Central Sleep Apnea/**C.M. Papantonakis, R.F. Brown, M. Fazili, Nashville, TN, p.A4221

P1587 **Opioids Cause Central Sleep Apnea in Humans/**S. Javaheri, S. Patel, Cincinnati, OH, p.A4222

P1588 **Willis-Ekbom, a Conundrum in Hemochromatosis/**D. Smith, S. Ie, E.R. Rubio, Roanoke, VA, p.A4223

P1589 **Biomarkers of Restless Leg Syndrome Among US Adults in NHANES/**S.D. Kumbhare, M. Fall, C.B. Strange, C. Lal, Charleston, SC, p.A4224

P1590 **The Prevalence and Severity of Restless Legs Syndrome Among Pregnant Women in Saudi Arabia/**M.I. Alangari, A.K. Aldubayan, A.M. Alsharidah, Y. Saber, A.H. Olaish, A. Taki, A. BaHammam, Riyadh, Saudi Arabia, p.A4225

Facilitator: R. Bhattacharjee, MD, San Diego, CA

P1591 **The Prevalence and Associated Risk Factors of Restless Legs Syndrome Among Saudi Adults/**N.A. Sherbini, A. Ahmad, A. Fatani, K. Al-Otaibi, S. Al-Jahdali, Y. Ali, A. Al-Harbi, M. Khan, S. Baharoon, H. Al-Jahdali, Riyadh, Saudi Arabia, p.A4226

P1592 **A 7-Year Old Boy with Polysomnographic Characteristics of High Frequency Leg Movements/**P. Aswanetmanee, C. Limsuwat, I. Klair, D. Sharon, S. Thammasitboon, New Orleans, LA, p.A4227

P1593 **The Impact of Whole Brain and Bone Radiation Therapy on Sleep Quality Measures/**I.C. Forde, D. Connolly, K. Meleveedu, A. Geeti, B. McGibbon, J. Kwon, Bridgeport, CT, p.A4228

P1594 **Sleep Duration and Its Impact on the Nutritional Status. Results from the Chilean National Health Survey/**P.E. Brockmann, F. Damiani, G. Valdivia, Santiago, Chile, p.A4229

P1595 **Screen Hours and Sleep Disturbances: In the 2005-2006 National Health and Nutrition Examination Survey/**O. Lewis, Y. Odeyemi, A. Mehari, V. Joseph, R. Gillum, Washington, DC, p.A4230

P1596 **The Effect of Sleep Duration on Exhaled Nitric Oxide Levels in U.S. Adults/**J. Hyde, R. Qayyum, Chattanooga, TN, p.A4231

THEMATIC POSTER SESSION

B66 LUNG CANCER SCREENING AND NODULE EVALUATION

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area E, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: M.P. Rivera, MD, Chapel Hill, NC

P548 **Lung Cancer Screening with Low-Dose CT in "Real-Life": Preliminary Results of the First-Round CT in the Setting of Routine Practice at a Public Pulmonology Service in Brazil/**F.M. Svartman, M.M.R. Leite, A.P.G. Sartori, R.S. Gutierrez, R.D. Marques, C.B. Heidtmann, R.S. Coelho, C.T. De Oliveira, R.L.T. Ferreira, M.M. Tedesco, F.V. Scornavacca, Porto Alegre, Brazil, p.A4232

P549 **Identifying Lung Cancer in Patients with Current or Previous Pulmonary Tuberculosis/**C. Parker, C. Siracuse, E. Pinjic, A. Rebello, F.C. Hiran, V. Litle, Boston, MA, p.A4233

P550 **The Diagnostic Value of 18F-FDG PET-CT for Early Lung Occupying Lesion/**Y. Li, W. Luo, W. Li, Sichuan, China, p.A4234

P551 **Frequency of Surveillance Imaging Following Diagnostic Chest CT Imaging/**S. Dawadi, S.B. Zeliadt, E.H. Pham, L.C. Feemster, J.E. Takasugi, P.A. Greene, L.G. Kessler, N. Seixas, D.H. Au, Seattle, WA, p.A4235

P552 **Lung Cancer Screening in Community Based Practice in Puerto Rico: A Survey of Puerto Rico Pulmonologists/**J. Martinez-Gonzalez, W. Rodriguez-Cintron, J. Albors-Sanchez, Y. Rodriguez-Sepulveda, San Juan, PR, p.A4236

P553 **Lung Cancer Screening Program in Public Primary Care Health System in the Southern of Brazil/**M.M.R. Leite, R.S. Gutierrez, F.M. Svartman, A.P.G. Sartori, Porto Alegre, Brazil, p.A4237

P554 **An Automated Tracking System Improves Management of Lung Nodules/**J.D. Shelver, K.L. Rice, M. McClure, A. Fabbrini, C. Wendt, Minneapolis, MN, p.A4238

P555 **Outcome of Incidentally Detected Airway Nodules/**H.-J. Kim, D.K. Kim, Y.W. Kim, Y.J. Lee, J.S. Park, Y.-J. Cho, S.J. Kim, H.I. Yoon, J.H. Lee, C.-T. Lee, Seongnam-si, Gyeonggi-do, Korea, Republic of, p.A4239

Facilitator: C.M. Kinsey, MD, MPH, Burlington, VT/

P556 **FEV1 and DLCO as an Additional Risk Stratifying Parameter in Lung Screening Programs/**V. Le, Y. Lei, A. Jimenez, A. Campagna, S. Regis, B. McKee, C. Lamb, Burlington, MA, p.A4240

P557 **A Graphical User Interface for Comparison of Lung Cancer Risk Prediction Models/**S.K.N. Dilger, M. Muralidharan, J. Uthoff, J.C. Sieren, Iowa City, IA, p.A4241

P558 **Diffuse Pulmonary Nodules: A Tale of Two Diagnoses/**A. Krishna, G.L. Rampon, S.K. Patolia, St. Louis, MO, p.A4242

P559 **Unusual Cause of Peripheral Lung Nodules in a Patient with Idiopathic Pulmonary Fibrosis(IPF)/**J. Deepak, A.E. Wyman, A. Striegel, E. Pickering, Baltimore, MD, p.A4243

P560 **A Rare and Interesting Cause of Pulmonary Nodules: A Case of Epithelioid Hemangioendothelioma/**L. Harper, G. Dominell, J. English, J. Johnston, Vancouver, Canada, p.A4244

P561 **Suspicious Positron Emission Tomography (PET) Positive Lung Nodule - Is It Cancer?/**D. Albano, T. Bilfinger, B. Nemesure, Stony Brook, NY, p.A4245

P562 **An Eccentric Solitary Pulmonary Nodule/**Z. Hashemi, P. Nangrani, J. Contreras Jr, A. Khokar, K.A. Nangrani, H. Upadhyay, L. Gerolemou, F. Arjomand, V. Vasudevan, Brooklyn, NY, p.A4246

P563 **Multiple Calcified Pulmonary Nodules: Not Always Granulomatous!/**S.G. Arif, T. Barnes, Grand Rapids, MI, p.A4247

Facilitator: C.G. Slatore, MD, Portland, OR

P564 **An Unusual Cause for Multiple Pulmonary Nodules/**M. Kadri, R.R. Katpally, S. Safdar, M.H. Azzam, J. Dabu, R. Miller, Newark, NJ, p.A4248

P565 **Squamous Cell Cancer Masquerading as Aspergilloma/**G.S. Sidhu, D. Collins, J. Joseph, Fresno, CA, p.A4249

P566 **A PET Artifact Masquerading as a PET Positive Lung Mass/**P. Tunsupon, M.J. Mador, Buffalo, NY, p.A4250

P567 **Cannonballs in Disguise/**G. Thompson, K. Sharain, R. Cartin-Ceba, Rochester, MN, p.A4251

P568 **Transthoracic Needle Biopsy- A Cautionary Tale/**S. Dhungana, K. Buch, Lexington, KY, p.A4252

P569 **Case of Esophageal Cancer Diagnosed on a Lung Cancer Screening Low-Dose Computed Tomography/**A. Khachane, S. Chiba, I. Brichkov, J. Shaw, Brooklyn, NY, p.A4253

P570 **Performance of Natural Language Processing in Identifying Lung Nodule Characteristics After Low-Dose CT Lung Cancer Screening/**D.P. Ritzwoller, N.M. Carroll, A. Burnett-Hartman,, H.S. Feigelson, E.E. Lyons, Denver, CO, p.A7847

THEMATIC POSTER SESSION

B67 THORACIC ONCOLOGY: GENERAL ASPECTS

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area E, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: W.A. Bulman, MD, New York, NY

P573 **The Incidence of Brain Metastasis at the Initial Diagnosis of Lung Squamous Cell Carcinoma Based on Stage Excluding Brain Metastasis/**S.H. Jeong, H. Lee, S.H. Shin, M.P. Chung, B.-H. Jeong, K.-J. Lee, S.-W. Um, O.J. Kwon, H. Kim, Seoul, Korea, Republic of, p.A4254

P574 **Ventilation Heterogeneity and Its Association with Lung Cancer/**L. Mikulic, C.M. Kinsey, G. Garrison, G. Gentchos, D.G. Chapman, D.A. Kaminsky, Burlington, VT, p.A4255

P575 **Lung Cancer Fast Track Referrals: Evaluation of a New Referral Form in East Dorset/**R. Punwani, M. Brown, W. Denehan, S. Crowther, Poole, United Kingdom, p.A4256

P576 **Sarcoid-Like Reaction in Regional Lymph Nodes in Patients with Lung Cancer: Incidence and Racial Disparities/**M. Senitko, G.E. Abraham 3rd, M.F. Petrini, D. Haynes, Jackson, MS, p.A4257

P577 **A Noninvasive, Simple-to-Perform and Transcutaneous Measurement for Lung Cancer/**J. Li, J. Zhou, Y. Song, C. Bai, Shanghai, China, p.A4258

P578 **Lung Cancer in Young Patients - 10-Year Study in a Portuguese Hospital/**M. Vargas-Castanho, T. Martin, F. Menezes, J. Roldao-Vieira, Almada, Portugal, p.A4259

P579 **Prevalence and Characteristics of Primary Lung Cancer Among Large Lung Masses/**K. Chatterjee, N. Shah, Y. Rochlani, N. Meena, Little Rock, AR, p.A4260

P580 **The Lung Cancer Database Map in Australia: Overview of a Descriptive Study Protocol/**E. Stone, N. Rankin, J. Phillips, K. Fong, T. Shaw, Darlinghurst, Australia, p.A4261

P581 **Clinical Characteristics of Lung Cancer Diagnosed During Follow-Up of Interstitial Pneumonia/**M. Sema, H. Sakashita, Y. Miyazaki, N. Inase, Tokyo, Japan, p.A4262

Facilitator: T. Aoki, MD, PhD, Isehara City, Japan

P582 **Clinico-Radio-Pathological Profile of 174 Patients of Bronchogenic Carcinoma in Udaipur Region/**R.K. Sharma, G. Chhabra, Udaipur, India, p.A4263

P583 **Effect of PET-CT on Staging of the Patients with Small Cell Lung Cancer Who Had Been Determined as Limited Stage with Conventional Methods/**U. Yilmaz, B. Yalcin, F. Coskun, H. Arik, F. Cansun, Izmir, Turkey, p.A4264

P584 **Quantitative False Positive Positron Emission Tomography (PET) Scan Following Endobronchial Ultrasound Guided Transbronchial Aspiration (EBUS-TBNA): A Retrospective Study/**S. Jasra, C.L. Roche, S. Dhillon, K. Harris, A.H. Alraiyes, Buffalo, NY, p.A4265

P585 **Outcomes of Stage I Non Small Cell Lung Cancer at the Princess Alexandra Hospital, Australia, 2008-2012/**R. Sheehy, C. Hukins, M. Murphy, Brisbane, Australia, p.A4266

P586 **Can Progression-Free Survival and Objective Response Rate Predict Overall Survival in a Phase III Randomized Controlled Trial Evaluating the First-Line Chemotherapy for Advanced Non-Small Cell Lung Carcinoma? Systematic Review/**K. Nakashima, N. Horita, A. Narita, M. Ikeda, R. Ushio, H. Watanabe, K. Nagai, Y. Shibata, K. Tashiro, H. Nagakura, T. Tsukahara, M. Yamamoto, T. Sato, T. Kaneko, Yokohama, Japan, p.A4267

P587 **Chronic Kidney Disease Is Associated with Mortality Risk in Patients with Lung Cancer: A Nationwide Population-Based Cohort Study/**Y.-F. Wei, J.-T. Wu, J.-Y. Chen, C.-K. Hsu, H.-S. Lee, Y.-C. Hsu, Kaohsiung City, Taiwan, p.A4268

P588 **High Neutropil-Lymphocyte Ratio Confers Poor Prognosis in Patients with Small Cell Lung Cancer/**D. Liu, W. Li, Chengdu, China, p.A4269

P589 **The Difference of Survival Time of the Patients with Thoracic Malignancy According to Timing of Consultation to Palliative Care Doctor/**T. Okimoto, Y. Tsubata, R. Tanino, Y. Mori, Y. Amano, M. Nakao, T. Hotta, N. Koba, M. Hamaguchi, S. Hamaguchi, T. Hoshino, A. Sutani, Y. Awaya, H. Takeyama, T. Isobe, Izumo, Japan, p.A4270

Facilitator: T. Peikert, MD, Rochester, MN

P590 **Evaluation of the Clinical Outcomes of Advanced Non-Small Cell Lung Cancer Patients with Actionable Mutations Treated with Molecular Targeted Therapy in the Intensive Care Unit/**K.C. Kerrigan, G. Otterson, Columbus, OH, p.A4271

P591 **Impact of Chronic Hepatitis C Infectionand Liver Metastasis on Survival Outcome of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer (NSCLC) Patient Treated with First-Line Gefetinib in Real-World Practice/**Z.-H. Yao, W.-Y. Liao, C.-C. Ho, K.-Y. Chen, J.-Y. Shih, J.-S. Chen, Z.-Z. Lin, C.-C. Lin, J.C.-H. Yang, C.-J. Yu, Taipei, Taiwan, p.A4272

P592 **Influence of Diagnosis and Treatment Delays on Survival of Lung Cancer/**M.A. Solis, J. Falco, A.R. Garcia, M. Heres, S. Lamot, M. Hernandez, S. Quadrelli, Buenos Aires, Argentina, p.A4273

P593 **Does Smoking Status After a Diagnosis of Lung Cancer Matter? The Effect of Quitting on Patient Outcomes/**R.E. Roberts, K. Lewis, R. Ghosal, G. Collier, Llanelli, United Kingdom, p.A4274

P594 **The Efficacy of Bevacizumab for Patients with Malignant Pleural Effusion or Ascites: A Meta-Analysis from 6 Randomized Controlled Clinical Trials/**J. Zhang, Shanghai, China, p.A4275

P595 **The Degree of Emphysema and Air Trapping Detected by Quantitative Computed Tomography Predicts Lung Cancer Survival/**M.A. Moughrabieh, W. Chen, C. Lusk, A. Wenzlaff, H. Jang, C. Neslund-Dudas, D.L. Spizarny, T. Song, M. Flynn, A. Soubani, S. Gadgeel, A. Schwartz, Detroit, MI, p.A7848

P596 **Moderate Centrilobular Emphysema Is the Lung Parenchymal Morphology Associated with A Risk for Lung Cancer/**C.M. Kinsey, C. Mendoza, B. Cole, J.H.T. Bates, R.P. Bowler, G. Washko, R.S.J. Estepar, Burlington, VT, p.A7849

P597 **The Impact of Mental Health Comorbidities on Timeliness of Care in Veterans with Lung Cancer/**S.S. Khatami, S. Takemoto, S. Wang, N. Trivedi, San Francisco, CA, p.A7850

11:45 a.m. - 1:15 p.m.

S3 ATS WOMEN'S FORUM

SAN FRANCISCO MARRIOTT MARQUIS
Yerba Buena Salon 7 (Lower B2 Level)

The annual ATS Women's Forum recognizes the achievements and supports the advancement of women in pulmonary, critical care, and sleep medicine and research. At the forum **Catherine R. Lucey, MD**, Professor of Medicine, Vice Dean for Education, University of California San Francisco School of Medicine will discuss issues that are relevant to female medical professionals followed by a question and answer period.

In addition, the 2016 Elizabeth A. Rich, MD Award, which has honored the work and memory of Elizabeth Rich, MD since 2000, will be presented. The award is given to a woman who has made significant achievements in the practice or science of pulmonary, critical care, or sleep medicine; demonstrated leadership in her field; and has shown dedicated mentorship of junior colleagues. The 2016 award recipient is **Irina Petrache, MD**, Professor, Department of Medicine, Chief, Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, CO. Dr. Petrache will also address the audience.

The forum provides a valuable opportunity for women to meet new colleagues and ATS leaders. Men are also welcome to attend the forum. Attendees will find value in the inspirational messages and career insights that the speakers share as well as vibrant networking opportunities.

The forum is organized and presented by the ATS Membership Committee, and will be hosted by **Yolanda Mageto, MD, MPH,** chair of the committee.

Conference badges are required for admission.
Space is limited and admittance is on a first-come, first-served basis. There is no additional fee. A plated lunch will be served.

CLINICAL

WORKSHOP

CME Credits Available: 1.5

Nursing Contact Hours Available: 1.8

WS3 PULMONARY REHABILITATION FOR INTERSTITIAL LUNG DISEASE: OPTIMIZING THE MODEL

Registration Fee: $75.00 (includes box lunch)
Attendance is limited. Pre-registration is required.

Assemblies on Pulmonary Rehabilitation; Clinical Problems; Nursing

11:45 a.m. - 1:15 p.m. **MOSCONE CENTER**

Room 301 (South Building, Esplanade Level)

Target Audience
Providers of care to people with interstitial lung disease; providers of pulmonary rehabilitation.

Objectives
At the conclusion of this session, the participant will be able to:

- learn about the state of the science underpinning ILD rehabilitation;
- prescribe effective exercise training for people with ILD;
- gain new strategies for comprehensive rehabilitation in ILD.

This workshop will define the state of the evidence for pulmonary rehabilitation in interstitial lung disease (ILD) and explore strategies to optimize rehabilitation outcomes for patients with these diverse and disabling respiratory conditions.

Chairing: A.E. Holland, PhD, Melbourne, Australia
L.P. Cahalin, PhD, Miami, FL

11:45 **Rehabilitation for ILD: State of the Evidence**
A.E. Holland, PhD, Melbourne, Australia

12:00 **Peripheral Muscle in ILD: Does it Matter?**
S. Mathur, PhD, PT, Toronto, Canada

12:15 **Exercise Training Strategies for ILD: Meeting the Physiological Challenge**
B. Vainshelboim, PhD, Petach Tikva, Israel

12:35 **Beyond Exercise Training: What is Comprehensive Rehabilitation for ILD?**
J.J. Swigris, DO, MS, Denver, CO

12:55 **Capturing Important Changes: Measurement of Outcomes in Rehabilitation for ILD**
L. Dowman, MAppSc, Heidelberg, Australia

BASIC • CLINICAL • TRANSLATIONAL

WORKSHOP

CME Credits Available: 1.5

WS4 PATIENT-DERIVED MODELS OF HUMAN LUNG DISEASE: A LAB MEETING

Registration Fee: $75.00 (includes box lunch)
Attendance is limited. Pre-registration is required.

Assemblies on Respiratory Cell and Molecular Biology; Allergy, Immunology and Inflammation; Clinical Problems; Critical Care; Environmental, Occupational and Population Health; Microbiology, Tuberculosis and Pulmonary Infections; Pediatrics; Pulmonary Circulation; Pulmonary Rehabilitation; Respiratory Structure and Function; Sleep and Respiratory Neurobiology; Thoracic Oncology

11:45 a.m. - 1:15 p.m. **MOSCONE CENTER**

Room 302 (South Building, Esplanade Level)

Target Audience
Lung health care providers, scientists and investigators interested or involved in basic, translational and clinical research related to the pathogenesis, pathology and clinical aspects of COPD and related human lung diseases, research and care providers engaged in pulmonary and critical care medicine.

Objectives
At the conclusion of this session, the participant will be able to:

- learn about state of the art in vivo, ex vivo and in vitro patient-derived models of human lung biology and disease;
- implement patient-derived models to study the pathogenesis, phenotype and candidate therapies for human lung diseases;
- understand how to translate information derived from patient-derived models into innovative clinically relevant approaches to study, diagnose, prevent and treat human lung diseases in a personalized manner ("precision medicine").

This workshop will discuss state of the art methods to study chronic human lung diseases (asthma, cystic fibrosis, COPD, and pulmonary fibrosis) in a personalized manner by modeling complex interaction between different cell types and tissue components (epithelial cells, extracellular matrix, fibroblasts, blood vessels, immune cells etc) using patient-derived human samples. In addition to talks by leading experts in the field, during this session, participants will have an opportunity to discuss their own research problems, ideas and questions with the faculty in a "lab meeting format" and learn how to translate discoveries derived from studies using patient-derived models into novel personalized approaches to prevent and treat human lung diseases (targeted "precision medicine" strategies).

Chairing: R. Shaykhiev, MD, PhD, New York, NY
S.D. Reynolds, PhD, Columbus, OH
D.J. Weiss, MD, PhD, Burlington, VT

11:45 **"Personalized" In Vitro and Ex Vivo Models of Human Airway Disease**
S.H. Randell, PhD, Chapel Hill, NC

12:00 **Patient-Derived 3D-Models of COPD and Emphysema**
M. Konigshoff, MD, PhD, Munich, Germany

12:15 **Preclinical Humanized Models of Airway Remodeling in Asthma**
R. Freishtat, MD, MPH, Washington, DC

12:30 **Modeling Lung Disease Using iPS Cells: Towards Precision Medicine**
D.N. Kotton, MD, Boston, MA

12:45 **"Lab Meeting" Discussion**
Z. Borok, MD, Los Angeles, CA
C. Coraux, PhD, Reims, France

CLINICAL

ADULT CLINICAL CORE CURRICULUM

CME Credits Available: 1.5

CC2 SLEEP MEDICINE CLINICAL CORE CURRICULUM I

Adult Core Curriculum Working Group

11:45 a.m. - 1:15 p.m. **MOSCONE CENTER**

Gateway Ballroom 102-104 (South Building, Lower Level)

Target Audience
Internists and subspecialists in pulmonary, critical care, and sleep medicine who work in a clinical setting and are currently engaged in maintenance of certification.

Objectives
At the conclusion of this session, the participant will be able to:

- remain current with medical knowledge relevant to their practice in pulmonary, critical care, and sleep medicine;
- evaluate their understanding of key skills and content areas in pulmonary, critical care and sleep medicine, as well as receive feedback on their comprehension of a result of a pre-test/post-test comparison;
- support clinicians who are engaged in maintenance of certification activities by providing updates on subjects included in recertification requirements.

The ATS Clinical Core Curriculum Symposia focus on a 3-year content cycle of key medical content in the areas of pulmonary, critical care, and sleep medicine. The topics are also aligned with corresponding MOC Medical Knowledge modules. This symposium is intended to assist clinicians with staying current with the growth of information relevant to their medical practice, as well as provide an opportunity to evaluate individual knowledge and skills while earning MOC Medical Knowledge points.

Chairing: J.S. Balachandran, MD, Chicago, IL
T.S. Wang, MD, Los Angeles, CA

11:45 **Sleep Testing/Staging/Scoring: Staging and Scoring**
C. Lal, MD, Charleston, SC

12:05 **Sleep Testing/Staging/Scoring: In-Lab Diagnostics**
N.A. Shah, MD, MPH, New York, NY

12:45 **Sleep Testing/Staging/Scoring: Ambulatory Diagnostics**
K.F. Sarmiento, MD, MPH, La Jolla, CA

CENTER FOR TOBACCO PRODUCTS, U.S. FOOD AND DRUG ADMINISTRATION

L11 FDA REGULATION OF TOBACCO PRODUCTS IN THE U.S.: 2016 UPDATE

12:15 p.m. - 1:15 p.m. **MOSCONE CENTER**

Room 3016/3018 (West Building, Level 3)

Target Audience
Any attendees interested in reducing tobacco related deaths.

Objectives
At the conclusion of this session, the participant will be able to:

- understand the FDA's Center for Tobacco Products' (CTP) strategic priorities and CTP's vision for the regulation of tobacco products to help reduce the death and disease toll caused by tobacco use;
- discuss the Deeming Proposed Rule and how it will affect the way CTP evaluates the newly regulated products;
- understand CTP's research portfolio and how the Office of Science uses this information to inform tobacco product regulation.

The 2009 Tobacco Control Act gave FDA regulatory authority over cigarettes, cigarette tobacco, roll-your-own tobacco, and smokeless tobacco. Newly "deemed" products in a proposed rule include electronic cigarettes, cigars, pipe tobacco, certain dissolvables that are not "smokeless tobacco," gels, and waterpipe tobacco. Once the proposed rule becomes final, FDA will be able to use regulatory tools, such as age restrictions and rigorous scientific review of new tobacco products and claims to reduce tobacco-related disease and death. Youth use of certain unregulated tobacco products, such as e-cigarettes and cigars, is on the rise. FDA oversight of tobacco products can provide important information about proposed deemed tobacco products and help limit youth exposure to these products. Once final, the rule will also enable FDA to explore whether different products pose different levels of risk, and will help the Agency develop policies to improve public health. This session will help the medical, research, and public health communities understand the authority granted to the FDA to regulate tobacco and tobacco products and how science is used to make the most effective regulatory decisions.

Chairing: P. Callahan-Lyon, MD, Silver Spring, MD

12:15 **FDA Regulation of Tobacco Products in the U.S.**
P. Callahan-Lyon, MD, Silver Spring, MD

12:55 **CTP Research Portfolio**
C. Dresler, MD, Silver Spring, MD

NATIONAL AERONAUTICS AND SPACE ADMINISTRATION

L12 NASA'S SATELLITES AND MODELS TO STUDY THE ENVIRONMENT AND DISEASES

12:15 p.m. - 1:15 p.m. **MOSCONE CENTER**

Room 3010/3012 (West Building, Level 3)

Target Audience
Pulmonary health researchers and clinicians needing environmental data to study and understand the geographic, environmental, and meteorological differences in pulmonary disease. The researcher will hear from public health researchers new research and models that can be used to study the environment and related diseases.

Objectives
At the conclusion of this session, the participant will be able to:

- inform clinicians and researchers about ongoing NASA projects related to lung performance and cardiac disease;
- provide a synopsis of a project using observations of earth's environment and public health applications that are of interest to pulmonary clinicians and researchers;
- provide an overview of the NASA Health and Air Quality Program relating to public health applications that are of interest to pulmonary clinicians and researchers.

Satellite earth observations present a unique vantage point of the earth's environment from space which offers a wealth of health applications for researchers. The session will show results of the remote sensing observations of earth and health applications. This session will detail on-going projects within NASA and specifically related to incorporating satellite remote sensing for studying dust, forest fires and their relationship to diseases such as asthma, and other environmentally-induced lung and cardiac diseases.

Chairing: S.M. Estes, MS, Huntsville, AL
J.A. Haynes, MS, Washington, DC

12:15 **Using NASA's Remote Sensing Data to Improve Research in Respiratory Health**
J.A. Haynes, MS, Washington, DC

12:25 **Downwind of the Flames: Assessing and Predicting Wildfire Smoke Related Morbidity Using Satellites, In-Situ Measurements and Models**
R. Gan, PhD, Ft. Collins, CO

12:40 **Utilization of Satellite Observation for Improved Air Quality Simulations**
A.P. Biazar, PhD, Huntsville, AL

12:55 **Tracking African and Asian Dust to North America Using NASA's CALIPSO Satellite**
A. Omar, PhD, Hampton, VA

VETERANS ADMINISTRATION

L13 SLEEP RESEARCH IN THE VA: GENES, COMORBIDITIES, AND GENDER

12:15 p.m. - 1:15 p.m. **MOSCONE CENTER**
Room 3020/3022 (West Building, Level 3)

Target Audience
Providers serving patients with sleep disorders; those treating central sleep apnea in heart failure; those engaged in research related to sleep disorders; pulmonary providers or investigators in the VA.

Objectives
At the conclusion of this session, the participant will be able to:

- understand potential roles of genetic factors in sleep disorders;
- treat central sleep apnea in heart failure patients;
- recognize and treat sleep disorders among women.

Complexity in the manifestations of sleep disorders may relate to heterogeneity in genetic and gender related factors and variable impacts of co-morbid conditions including heart failure and mental illnesses. Because sleep disorders are exceedingly common among veterans, the VA Research and Development Program supports broad-based investigation into these disorders. This session will include presentations from investigators in the VA on their research related to (1) genetic causes of sleep disorders using mouse models; (2) optimal treatments for central sleep apnea in patients with heart failure; and (3) prevalence and nature of sleep disorders, including insomnia, among women and their preferences for treatment.

Chairing: J.K. Brown, MD, San Francisco, CA
M.S. Badr, MD, Detroit, MI
L. Nici, MD, Providence, RI

12:15 **Respiratory Rhythmogenesis in Mouse Models**
K.P. Strohl, MD, Cleveland, OH

12:35 **Heart Failure and Central Sleep Apnea: Beyond ASV**
D.J. Gottlieb, MD, MPH, Boston, MA

12:55 **Sleep Disorders Among Women Veterans**
J.L. Martin, PhD, North Hills, CA

NATIONAL CENTER FOR ENVIRONMENTAL HEALTH, CDC

L14 UPDATE FROM CDC'S NATIONAL ASTHMA CONTROL PROGRAM

12:15 p.m. - 1:15 p.m. **MOSCONE CENTER**
Room 3006/3008 (West Building, Level 3)

Target Audience
Clinicians, physicians, nurses, respiratory therapists, asthma educators.

Objectives
At the conclusion of this session, the participant will be able to:

- recognize the role of state health departments in asthma control;
- improve quality of asthma care provided to patients;
- understand the importance of public health/clinical care partnerships for asthma control.

Asthma is an ideal model to demonstrate public health/health care collaboration. Moreover, asthma is highly associated with disparities across racial, ethnic and socioeconomic groups. Multi-component interventions are available to address asthma, including guidelines-based medical management, self-management education, indoor and outdoor trigger reduction interventions, and linkages to social services. A strong evidence base has documented the feasibility and effectiveness of asthma interventions and the ability of asthma efforts to generate a short-term return on investment. CDC works with state and federal partners to advance public health/healthcare collaboration to maximize the reach, impact, efficiency and sustainability of comprehensive asthma control services.

Chairing: P.L. Garbe, DVM, MPH, Atlanta, GA

12:15 **State Asthma Control Programs**
P.L. Garbe, DVM, MPH, Atlanta, GA

12:35 **Quality Measures for Asthma Care**
S.F. Beavers, MD, Atlanta, GA

12:55 **Insurance Reimbursement for Comprehensive Asthma Care**
J. Hsu, MD, Atlanta, GA

NATIONAL HEART, LUNG, AND BLOOD INSTITUTE, DIVISION OF LUNG DISEASES, NIH

L15 ENDOTYPES AND PHENOTYPES: A BASIS FOR PRECISION-BASED MEDICINE IN COPD, THE SUBPOPULATIONS AND INTERMEDIATE OUTCOME MEASURES IN COPD STUDY (SPIROMICS)

12:15 p.m. - 1:15 p.m. **MOSCONE CENTER**

Room 2006/2008 (West Building, Level 2)

Target Audience
Those with clinical or research responsibilities.

Objectives
At the conclusion of this session, the participant will be able to:

- understand and learn about imaging phenotyping of COPD;
- learn about molecular phenotyping of COPD;
- learn about clinical pheontyping of COPD.

SPIROMICS is an NHLBI sponsored study that supports the prospective collection and analysis of phenotypic, biomarker, genetic, genomic, and clinical data from subjects with COPD for the purpose of identifying subpopulations and intermediate outcome measures. Participants in this session will learn about new results from the SPIROMICS study that define new clinical subpopulations related to COPD, clinically relevant endotypes that affect risk, and potential intermediate markers that predict disease progression. The session will also provide information for early stage investigators and the investigative community on how to get involved with the study and access data.

Chairing: R.G. Barr, MD, DrPH, New York, NY
L. Postow, PhD, Bethesda, MD

12:15 **Overview of SPIROMICS Design**
R.G. Barr, MD, DrPH, New York, NY

12:25 **Signficance of Large and Small Airway Phenotypes**
M.K. Han, MD, MS, Ann Arbor, MI

12:40 **Identifying COPD Subpopulations Based on Symptoms and Molecular Signatures**
P.G. Woodruff, MD, MPH, San Francisco, CA

12:55 **SPIROMICS Imaging Phenotyping**
E.A. Hoffman, PhD, Iowa City, IA

1:05 **Identified Subpopulations Based on Unbiased Clustering**
E. Bleecker, MD, Winston-Salem, NC

NATIONAL HEART, LUNG, AND BLOOD INSTITUTE, DIVISION OF LUNG DISEASES, NIH

L16 VIRUSES AND BACTERIA IN ASTHMA ACROSS THE AGES

12:15 p.m. - 1:15 p.m. **MOSCONE CENTER**

Room 2002/2004 (West Building, Level 2)

Target Audience
Providers of lung health, medical fellows in training, graduate, post-doctoral fellows and established scientists in basic research on lung biology, and infectious disease.

Objectives
At the conclusion of this session, the participant will be able to:

- understand and learn new findings about the impact of nasal bacteria and viruses on respiratory illness severity and response to azithromycin therapy in preschool children with recurrent severe episodes of lower respiratory tract symptoms;
- gain knowledge about differences in the bronchial bacterial microbiome in patients with allergies and asthma and characterize modifications in the microbiome associated with the use of inhaled corticosteroids in adults with asthma;
- describe how treatment with inhaled corticosteroids alters the bronchial virome in adults with asthma.

This session highlights findings from two AsthmaNet studies that investigated effects of inhaled corticosteroids (ICS) on bacterial microbiome and virome in adults and effects of the virome on respiratory illness severity and response to azithromycin therapy in children. Findings elucidate how two components of the microbiome - bacterial and viral - are impacted by treatment and how viruses influence severity of respiratory illness and treatment response. Management insights might emerge during the panel-audience discussion, e.g., composition of the baseline airway bacterial microbiome may shape the response to viral respiratory infection,as frequently one of the treatments prescribed is an ICS.

Chairing: W.W. Busse, MD, Madison, WI
J.P. Kiley, PhD, Bethesda, MD

12:15 **Viral and Bacterial Determinants of Illness Severity and Response to Azithromycin Therapy in Preschool Children**
D.J. Jackson, MD, Madison, WI

12:30 **Bronchial Bacterial Microbiome: Relationships to Allergy, Asthma, and Inhaled Corticosteroid Treatment**
Y.J. Huang, MD, Ann Arbor, MI

12:45 **Bronchial Virome: Effects of Inhaled Corticosteroid Treatment in Adults with Asthma**
A. Shifren, MD, St. Louis, MO

1:00 **General Discussion**
W.W. Busse, MD, Madison, WI

NATIONAL HEART, LUNG, AND BLOOD INSTITUTE, DIVISION OF LUNG DISEASES, NIH

L17 EDUCATION RESEARCH IN SLEEP HEALTH AND SLEEP-CIRCADIAN BIOLOGY

12:15 p.m. - 1:15 p.m. **MOSCONE CENTER**

Room 2016/2018 (West Building, Level 2)

Target Audience
Health care providers, researchers, educators, and public stakeholders interested in innovative education tools, programs and platforms that will transfer health information and scientific advances in sleep and circadian biology to medical education, health care, and community-based settings.

Objectives
At the conclusion of this session, the participant will be able to:

- describe findings from innovative educational research programs;
- understand and describe strategies for effective transfer of sleep and circadian scientific knowledge;
- describe communication goals and methods of implementation in health care and communities settings.

This session will present data-based findings and progress from an NHLBI initiative that aims to develop educational strategies for the dissemination of sleep and circadian biology based health information to health care providers and minority communities. The presentations will focus on improving sleep apnea health literacy through community-based engagement, improving sleep/circadian rhythms and the detection of sleep disorders in the inpatient setting, and enhanced sleep/circadian medical education via telemedicine for residents and primary care physicians.

Chairing M. Twery, PhD, Bethesda, MD
J. Girardin, PhD, New York, NY

12:15 **Tailored Sleep Health Education: A Community-Engaged Approach**
J. Girardin, PhD, New York, NY

12:35 **Tackling the Elephant in the Room: Educating Hospital Staff About Sleep Medicine**
A. Vineet, MD,Chicago, IL

12:55 **Use of Telemedicine to Promote Sleep Medicine Education in Health Care**
I. Rosen, MD, MS, Philadelphia, PA

NATIONAL HEART, LUNG, AND BLOOD INSTITUTE, DIVISION OF LUNG DISEASES, NIH

L18 HOW THE NHLBI K12 PROGRAM IS ADVANCING OUR KNOWLEDGE IN THE OMICS OF LUNG DISEASE

12:15 p.m. - 1:15 p.m. **MOSCONE CENTER**
Room 2001/2003 (West Building, Level 2)

Target Audience
Those interested in the application of omics technologies to the diagnosis and therapy of all lung diseases; those interested in training young investigators in lung research, providers of lung health; those with clinical or research responsibility.

Objectives
At the conclusion of this session, the participant will be able to:

- gain new strategies for training young investigators;
- learn new ways to apply omics to questions about lung disease;
- gain new strategies for diagnosing, treating and predicting the course of specific lung diseases.

The K12 in omics of lung diseases is an NHLBI sponsored career development program with the objective to develop an interdisciplinary program that will educate young pulmonary investigators in methods of integrative "omics" technologies including genomics, proteomics, metabolomics, bioinformatics, computational modeling and system biology. Participants in this session will learn about the structure and organization of the different programs and how the elements of each program interconnect to create an integrated and multidisciplinary learning experience

Chairing: C.M. Doerschuk, MD, Chapel Hill, NC
S. Colombini-Hatch, MD, Bethesda, MD

12:15 **Computational Skill Building**
J.A. Whitsett, MD, Cincinnati, OH

12:35 **High Through Proteomics**
M. Rabinovitch, MD, Stanford, CA

12:55 **Discussion**
S. Colombini-Hatch, MD, Bethesda, MD
C.M. Doerschuk, MD, Chapel Hill, NC

NATIONAL HEART, LUNG, AND BLOOD INSTITUTE, DIVISION OF LUNG DISEASES, NIH

L19 GENETIC BASIS OF IDIOPATHIC PULMONARY FIBROSIS

12:15 p.m. - 1:15 p.m. **MOSCONE CENTER**
Room 2020/2022 (West Building, Level 2)

Target Audience
Health care providers, researchers and patients.

Objectives
At the conclusion of this session, the participant will be able to:

- explain our current understanding of IPF pathogenesis;
- refer patients for future studies in IPF;
- plan gene-to-function studies to fill knowledge gaps in IPF and identify novel therapeutic targets.

There have been substantial advances in our understanding of the pathogenesis of idiopathic pulmonary fibrosis (IPF) through several genome-wide association studies (GWAS) of and linkage studies of families that have two or more family members with this disease. GWAS have identified many candidate genes that may contribute to disease risk. Linkage studies of families have identified causal mutations of surfactant protein or telomerase complex genes that are also found in certain sporadic cases of IPF. Thus, rather than existing as distinct syndromes, sporadic and familial cases of IPF probably reflect a continuum of genetic risk. The presenters will 1) present the latest research results, 2) discuss a novel hypothesis of IPF pathogenesis based on GWAS studies, 3) describe how cutting-edge bioinformatic and next-generation sequencing techniques could allow an integrated approach to defining IPF pathogenesis and 4) how to apply these advances to achieve personalized medicine in IPF.

Chairing: C.K. Garcia, MD, PhD, Dallas, TX
J. Eu, MD, Bethesda, MD

12:15 **Mechanisms of Pulmonary Fibrosis**
T.S. Blackwell, MD, Nashville, TN

12:30 **Genetics of Pulmonary Fibrosis: New Genes, New Mutations, Same Pathway**
C.K. Garcia, MD, PhD, Dallas, TX

12:45 **IPF: A Mucociliary Disease of the Peripheral Airways?**
D.A. Schwartz, MD, Aurora, CO

1:00 **Personalized Medicine in IPF: How Genetics May Inform Us**
I. Noth, MD, Chicago, IL

MEET THE PROFESSOR SEMINARS

CME Credits Available: 1.0

Registration Fee: $70.00 (includes box lunch.)
Attendance is limited. Pre-registration is required.

12:15 p.m. - 1:15 p.m. **INTERCONTINENTAL HOTEL**

MP501 **PRIMARY IMMUNE DEFICIENCY AND PULMONARY DISEASE**
A. Dosanjh, MD, San Diego, CA
Union Square (Third Floor)

MP502 **ELECTRONIC CIGARETTES: POTENTIAL HARMS AND BENEFITS, PERSONAL AND PUBLIC**
D.J. Upson, MA, MD, Albuquerque, NM
SoMa (Third Floor)

MP503 **LUNG TRANSPLANTATION FOR CONNECTIVE TISSUE DISEASE-RELATED INTERSTITIAL LUNG DISEASE**
J.A. Golden, MD, San Francisco, CA
Mission (Third Floor)

MP504 **CURRENT STRATEGIES FOR MANAGING THE PATIENT WITH CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION**
K.M. Wille, MD, MSPH, Birmingham, AL
Marina (Third Floor)

MP505 **NEW DRUGS AND BEYOND: PRACTICAL STRATEGIES FOR TOTAL CARE OF THE IPF PATIENT**
D.E. Antin-Ozerkis, MD, New Haven, CT
Grand Ballroom C (Third Floor)

MP506 **TREATMENT OF BRONCHIECTASIS: WHAT SHOULD I DO?**
G. Tino, MD, Philadelphia, PA
Grand Ballroom B (Third Floor)

MP507 **TREATMENT OF VENOUS THROMBOEMBOLISM WITH TARGET-SPECIFIC NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS**
R.D. Yusen, MD, MPH, St. Louis, MO
Grand Ballroom A (Third Floor)

MP508 **TIMING OF REFERRAL FOR LUNG TRANSPLANT IN CYSTIC FIBROSIS**
D. Hadjiliadis, MD, MHS, Philadelphia, PA
Twin Peaks (Fourth Floor)

MP509 **HOW I DO IT: STRATEGIES OF SUCCESSFUL WOMEN IN CRITICAL CARE**
E.L. Burnham, MD, Aurora, CO
P.A. Kritek, MD, Seattle, WA
L. Ware, MD, Nashville, TN
M.S. Herridge, MD, MPH, Toronto, Canada
Telegraph Hill (Fourth Floor)

MP510 **AIR POLLUTION AND LUNG CANCER: ROLE OF AIRWAY EPITHELIAL CELLS**
H. Bayram, MD, PhD, Gaziantep, Turkey
Potrero Hill (Fourth Floor)

MP511 **THE USE OF ANTIBIOTICS AND ADJUNCTIVE THERAPIES IN CRITICALLY ILL PATIENTS WITH CAP**
C. Feldman, MBBCh, DSc, PhD, Johannesburg, South Africa
Nob Hill (Fourth Floor)

MP512 **IMPAIRED SLEEP AND SYMPTOMS MANAGEMENT IN ACUTE AND CHRONIC ILLNESS**
E.R. Chasens, PhD, RN, Pittsburgh, PA
Laurel Hill (Fourth Floor)

MP513 **BRONCHIOLITIS OBLITERANS IN CHILDREN: CONSENSUS AND CONTROVERSY**
G. Kurland, MD, Pittsburgh, PA
A.M.H. Casey, MD, Boston, MA
Cathedral Hill (Fourth Floor)

MP514 **IMAGING IN CHRONIC THROMBOEMBOLIC DISEASE: V/Q AND CT SCAN INTERPRETATION FOR THE PULMONOLOGIST**
R.N. Channick, MD, Boston, MA
Sutter (Fifth Floor)

MP515 **NEW ROLES FOR APOLIPOPROTEINS IN THE PATHOGENESIS AND TREATMENT OF ASTHMA**
S.J. Levine, MD, Bethesda, MD
Stockton (Fifth Floor)

MP516 **ASTHMA AND WOMEN'S HEALTH. REPRODUCTIVE HORMONES: FRIEND OR FOE?**
Y.S. Prakash, MD, PhD, Rochester, MN
Howard (Fifth Floor)

MP517 **THE ROLE OF POLYSOMNOGRAPHY IN TECHNOLOGY DEPENDENT CHILDREN**
N. Simakajornboon, MD, Cincinnati, OH
J. Brockbank, MD, Richmond, VA
Fremont (Fifth Floor)

MEDICAL EDUCATION SEMINAR

CME Credits Available: 1.0

ME2 DELIVERING TIMELY RELEVANT FEEDBACK IN CLINICAL SETTINGS

Registration Fee: $70.00 (includes box lunch)
Attendance is limited. Pre-registration is required.

12:15 p.m. - 1:15 p.m. **INTERCONTINENTAL HOTEL**

InterContinental Ballroom A (Fifth Floor)

Target Audience
This session is aimed at faculty and trainees involved clinical training.

Objectives
At the conclusion of this session, the participant will be able to:

- reiterate the importance of feedback in daily clinical teaching;
- provide clinicians with the tools to create an environment for delivery of effective and timely feedback;
- equip training clinicians with the means to plan and implement feedback sessions in a clinical setting.

Feedback is a cornerstone of medical training. In our daily role as clinician educators, feedback is a key component, facilitating opportunities to improve and

encourage trainees to reach their maximum potential. Acknowledging that the provision of meaningful feedback is a skill that can be taught, we approach this session with a literature review of relevance to working clinicians, and follow with an interactive approach to a set of scenarios, illustrated by video case studies.

Speakers: E. Kelly, MD, Dublin, Ireland
J.B. Richards, MD, MA, Charleston, SC

THEMATIC SEMINAR SERIES

CME Credits Available: 1.0

TSS1 CONTEMPORARY CONTROVERSIES IN THE DIAGNOSIS AND MANAGEMENT OF IDIOPATHIC PULMONARY FIBROSIS: A PRO/CON DEBATE

Registration Fee: $140.00 for full series (includes box lunch)
Attendance is limited. Pre-registration is required.

This is part 2 of a 3-part series. Those registering for this seminar series will be registered for all 3 parts. The program for the full series is included with the Sunday, May 15, 12:15 p.m. program.

Monday 12:15 p.m. - 1:15 p.m. **INTERCONTINENTAL HOTEL**
InterContinental Ballroom C (Fifth Floor)

PRO: Bronchoalveolar Lavage Should Routinely be Performed in the Diagnostic Work-Up of IPF
A.U. Wells, MD, London, United Kingdom

CON: Bronchoalveolar Lavage Should Routinely be Performed in the Diagnostic Work-Up of IPF
H.R. Collard, MD, San Francisco, CA

THEMATIC SEMINAR SERIES

CME Credits Available:1.0

TSS2 REDUCING HOSPITAL READMISSIONS

Registration Fee: $140.00 for full series (includes box lunch)
Attendance is limited. Pre-registration is required.

This is part 2 of a 3-part series. Those registering for this seminar series will be registered for all 3 parts. The program for the full series is included with the Sunday, May 15, 12:15 p.m. program.

Monday 12:15 p.m. - 1:15 p.m. **INTERCONTINENTAL HOTEL**
InterContinental Ballroom B (Fifth Floor)

Approaches to Reduce Hospital Readmissions

Effective Components of a Readmission Reduction Program
S.S. Braman, MD, New York, NY

Novel Interventions to Reduce Readmissions
V.G. Press, MD, MPH, Chicago, IL

Partnering with Patient Navigators and Peer Advocates
J.A. Krishnan, MD, PhD, Chicago, IL

AMERICAN THORACIC SOCIETY · 1905 ·

ATS 2016

Where today's science meets tomorrow's care™

International Conference

San Francisco
CALIFORNIA

Monday Afternoon, May 16

1:15 p.m. - 2:15 p.m.

VISIT THE EXHIBIT HALL

Take this opportunity between sessions to visit the Exhibit Hall to gain practical knowledge to advance care and research. Exhibitors will be on hand to provide information on pharmaceutical products, medical equipment, publications and research services.

2:15 p.m. - 4:15 p.m.

2016 RECOGNITION AWARDS FOR SCIENTIFIC ACCOMPLISHMENTS

MOSCONE CENTER
Room 3010/3012 (West Building, Level 3)

The Recognition Award for Scientific Accomplishments is given to individuals for outstanding scientific contributions in basic or clinical research to the understanding, prevention and treatment of lung disease. Those considered for the award are recognized for either scientific contributions throughout their careers or for major contributions at a particular point in their careers.

Chairing: A.J. Halayko, PhD, Winnipeg, Canada
T.W. Ferkol, MD, St. Louis, MO

Awardees:

2:15 **Cellular and Molecular Mechanisms in Pulmonary Hypertension**
Serpil Erzurum, MD, Cleveland, OH

2:45 **Asthma and Its Regulation Through the Lens of the Immune System**
Anuradha Ray, PhD, Pittsburgh, PA

3:15 **COPD: From Genetics to Networks**
Edwin K. Silverman, MD, PhD, Boston, MA

3:45 **Reactive Oxygen, Aging and Fibrotic Lung Disease**
Victor J. Thannickal, MD, Birmingham, AL

CLINICAL

ADULT CLINICAL CORE CURRICULUM

CME Credits Available: 2.0

CC3 PULMONARY CLINICAL CORE CURRICULUM II

Adult Core Curriculum Working Group

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Gateway Ballroom 102-104 (South Building, Lower Level)

Target Audience
Internists and subspecialists in pulmonary, critical care, and sleep medicine who work in a clinical setting and are currently engaged in maintenance of certification.

Objectives
At the conclusion of this session, the participant will be able to:

- remain current with medical knowledge relevant to their practice in pulmonary, critical care, and sleep medicine;
- evaluate their understanding of key skills and content areas in pulmonary, critical care and sleep medicine, as well as receive feedback on their comprehension of a result of a pre-test/post-test comparison;
- support clinicians who are engaged in maintenance of certification activities by providing updates on subjects included in recertification requirements.

The ATS Clinical Core Curriculum Symposia focus on a 3-year content cycle of key medical content in the areas of pulmonary, critical care, and sleep medicine. The topics are also aligned with corresponding MOC Medical Knowledge modules. This symposium is intended to assist clinicians with staying current with the growth of information relevant to their medical practice, as well as provide an opportunity to evaluate individual knowledge and skills while earning MOC Medical Knowledge points.

Chairing: G.C. Michaud, MD, New Haven, CT
C.L. Channick, MD, Boston, MA

2:15 **Interstitial Lung Disease: Therapeutic Options**
D. Sayah, MD, PhD, Los Angeles, CA

2:45 **Sarcoid/HP**
R. Adamson, MBBS, Seattle, WA

3:15 **Opportunistic Pulmonary Infections in HIV and Non-HIV Patients**
B. Coruh, MD, Seattle, WA

3:45 **Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia**
C.S. Dela Cruz, MD, PhD, New Haven, CT

This session and the International Conference are supported by an educational grant from ***Boehringer Ingelheim Pharmaceuticals, Inc.***
All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

BEHAVIORAL • CLINICAL • TRANSLATIONAL

YEAR IN REVIEW

CME Credits Available: 2.0

Nursing Contact Hours Available: 2.4

B81 NURSING YEAR IN REVIEW

Assembly on Nursing

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 307 (South Building, Esplanade Level)

Target Audience
Registered nurses, advanced practice nurses, and any other ATS members involved in lung health, clinical research and practice and with a particular interest in global perspectives.

Objectives
At the conclusion of this session, the participant will be able to:

- compare the similarities and differences in international pulmonary clinical care and research;
- identify gaps in the international evidence base;
- discuss future international research considerations.

The session will cover key research advances in patient centered care from different international perspectives. Each presenter will present country specific advances and challenges in nursing practice and research whilst offering comparisons with international work.

Chairing: J. Yorke, PhD, RN, Manchester, United Kingdom
J. Choi, PhD, RN, Pittsburgh, PA

2:15 **Control of TB in High Burden Countries: The China Experience**
Y. Jin, PhD, Changsha, China

2:35 **Control of TB in Low Burden Settings: The UK Experience**
A. Story, PhD, RN, London, United Kingdom

2:55 **Novel Approaches to Self-Management in Australian Adults with Severe Asthma**
V. McDonald, PhD, RN, New Lambton Heights, Australia

3:15 **Delivery System Research: Highlights in Pulmonary Nursing Care in the USA and Beyond**
H.Q. Nguyen, PhD, RN, Pasadena, CA

3:35 **Integrated Care Services for Chronic Pulmonary Patients**
C. Hernandez, PhD, MSc, RN, Barcelona, Spain

3:55 **General Discussion**

BEHAVIORAL • CLINICAL • TRANSLATIONAL

CLINICAL TOPICS IN PULMONARY MEDICINE

CME Credits Available: 2.0

B82 SEEING BEYOND THE VAPORS: CURRENT TOPICS ON ELECTRONIC CIGARETTE USE

Assemblies on Clinical Problems; Behavioral Science and Health Services Research; Environmental, Occupational and Population Health; Nursing

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 135 (North Building, Lower Level)

Target Audience
Pulmonologists, internists/hospitalists, trainees and researchers, clinical supervisors, nurses, respiratory therapists, pharmacists, attendees interested in electronic cigarettes, tobacco use and addiction, smoking cessation and tobacco regulation.

Objectives
At the conclusion of this session, the participant will be able to:

- describe the use patterns and health perceptions by e-cigarette users nationally and internationally;
- learn the current status of regulation of e-cigarettes;
- counsel patients regarding the role of e-cigarettes in smoking cessation.

Electronic cigarette (e-cigarette) use is increasing at an exponential rate in the U.S. and internationally. This symposium will provide a contemporaneous update on key topics surrounding e-cigarettes. The speakers will review prevalence and use patterns within the U.S. as well as internationally. To ensure relevance to conference attendees, additional topics will cover the diverse issues surrounding e-cigarettes including lung harms and second-hand exposure, FDA and governmental regulatory update and the role of e-cigarettes in smoking cessation. The symposium will conclude with a panel discussion on e-cigarettes.

Chairing: M.B. Drummond, MD, MHS, Baltimore, MD
M.N. Eakin, PhD, Baltimore, MD

2:15 **E-Cigarette Use in the United States: What, Who and Why?**
K.F. Harrington, PhD, MPH, Birmingham, AL

2:35 **Effect of E-Cigarettes on Pulmonary Host Defense Responses**
I. Jaspers, PhD, Chapel Hill, NC

2:55 **Update on State and Federal E-Cigarette Regulations**
D.J. Upson, MA, MD, Albuquerque, NM

3:15 **E-Cigarette Use: An International Perspective**
K. Carlsen, MD, PhD, Oslo, Norway

3:35 **E-Cigarettes as a Smoking Cessation Tool**
F.T. Leone, MD, MS, Philadelphia, PA

3:55 **Panel Discussion**

There will be a 5-minute discussion after each talk.

CLINICAL

CLINICAL TOPICS IN PULMONARY MEDICINE

CME Credits Available: 2.0

B83 PEDIATRIC CLINICAL CHEST ROUNDS

Assemblies on Pediatrics; Allergy, Immunology and Inflammation; Clinical Problems; Critical Care; Nursing; Sleep and Respiratory Neurobiology

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 134 (North Building, Lower Level)

Target Audience
Pediatric pulmonologists, intensivists, neonatologists, nurse practitioners, nurses, respiratory therapists, others who provide care to children with lung diseases.

Objectives
At the conclusion of this session, the participant will be able to:

- diagnose a variety of complex respiratory disorders;
- develop new strategies to manage the care of infants and children with complex or confusing respiratory disorders;
- apply appropriate diagnostic tests in complex cases.

This session discusses interesting clinical cases related to Pediatric Pulmonology. The focus is to choose cases from submitted abstracts that are unique, but also have a clear story to tell that will be of educational benefit to the audience. Duplication of cases presented in previous years are avoided by reviewing previous years' topics. Cases are presented by fellows or junior faculty and then subsequently discussed by an expert in the field. While the case presentation will be of interest to all Pediatric Pulmonologists; special focus is given to make this session of interests for trainees. Interactive questions are included in all case presentation to engage and involve the audience actively in the process of solving the clinical dilemma to encourage interactive learning.

Chairing: J.S. Debley, MD, MPH, Seattle, WA
S. Goldfarb, MD, Philadelphia, PA
J. Harrison, MBChB, MRCP, MRCPCH, Melbourne, Australia

2:15 **14 Year Old Boy with a Chronic Productive Cough**
A. Taylor, BA, Denver, CO

2:30 **Expert Discussant**
A. Chang , MD, Brisbane, Australia

2:45 **Persistent Tachypnea in a Term Infant**
M. Mathew, MD, Mineola, NY

3:00 **Expert Discussant**
V. Balasubramaniam , MD, Madison, WI

3:15 **14 Year Old Girl with Progressive Dry Cough and Dyspnea**
P. Phinizy, MD, New York, NY

3:30 **Expert Discussant**
L. Young, MD, Nashville, TN

3:45 **Two Month Old Boy with Noisy Breathing and Hypoxemia**
G. Rulong, MD, Cincinnati, OH

4:00 **Expert Discussant**
M.L. Chen, MD, Seattle, WA

CLINICAL

CRITICAL CARE TRACK

CME Credits Available: 2.0

B84 AT THE EDGE OF THE EVIDENCE: MAKING DECISIONS IN THE REAL WORLD

Assemblies on Critical Care; Nursing

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 3000/3002/3004 (West Building, Level 3)

Target Audience
Practitioners in critical care including staff physicians, fellows, medical students, nursing professionals and respiratory therapists.

Objectives
At the conclusion of this session, the participant will be able to:

- more appropriately transfuse blood products in hemorrhagic shock;
- understand and apply available evidence to determine family presence for CPR;
- apply available evidence in deciding whether to place invasive monitoring catheters in critically ill patients.

This session will present expert review of evidence in many topics within critical care and will provide strategies for making decisions "at the edge of the evidence," where the data do not provide a clear answer. Subjects will range from when to allow family to witness resuscitation attempts to assessing neurologic prognosis after arrest to transfusion guidelines in hemorrhagic shock.

Chairing: K.A. Hibbert, MD, Boston, MA
H.B. Gershengorn, MD, Bronx, NY
M. Hua, MD, MSc, New York, NY

2:15 **Introduction**
K.A. Hibbert, MD, Boston, MA

2:20 **The Cold Truth: Can You Accurately Determine Neurologic Prognosis After Cooling?**
D. Greer, MD, New Haven, CT

2:35 **Witness to the End: Family Presence During Resuscitation Attempts**
K. O'Connell, MD, Washington, DC

2:50 **1:1:What? Which Blood Products Should We Transfuse in Hemorrhagic Shock?**
D. Yeh, MD, Boston, MA

3:05 **The Drier the Better? When Should you Diurese a Critically Ill Patient?**
M.J. Lanspa, MD, MS, Salt Lake City, UT

3:20 **Poking Holes in Practice: Can Intensive Care be Less Invasive?**
A. Garland, MD, MA, Winnipeg, Canada

3:35 **Wake Up and Breathe**
N.E. Brummel, MS, MSCI, MD, Nashville, TN

3:50 **A Lingering Question: When is ECMO the Answer in Adult ARDS?**
A. Combes, MD, PhD, Paris, France

4:05 **Question and Answer**
H.B. Gershengorn, MD, Bronx, NY

BASIC • TRANSLATIONAL

BASIC SCIENCE CORE

CME Credits Available: 2.0

B85 LUNGS CAN TELL TIME: CLOCK GENES, INFLAMMATION, IMMUNOLOGY AND SLEEP

Assemblies on Allergy, Immunology and Inflammation; Respiratory Cell and Molecular Biology; Respiratory Structure and Function; Sleep and Respiratory Neurobiology

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 2009/2011 (West Building, Level 2)

Target Audience
Basic and translational Investigators studying Inflammatory conditions of the lung, sepsis, sleep medicine, and metabolism. Systems biologists interested in genome-wide analyses of complex airway diseases. Clinicians interested in the genetic basis for time sensitive symptoms in airway disease such as nocturnal asthma and COPD.

Objectives
At the conclusion of this session, the participant will be able to:

- describe the organization of the circadian clock at the whole organism level and specifically within the lung;
- learn new findings about how clock genes regulate the lung antimicrobial responses and inflammation;
- learn new findings about the relationships between sleep, clock genes and the ill health effects competence of shift work.

Discussions will cover complex airway diseases. This session will also cover inflammatory conditions of the lung, sepsis, sleep medicine, and metabolism.

Chairing: J. Haspel, MD, PhD, St. Louis, MO
I. Rahman, PhD, Rochester, NY
S.P. Shea, PhD, Portland, OR

2:15 **If You Give The Lung a Watch: Introduction to Circadian Rhythms in the Lung**
J. Haspel, MD, PhD, St. Louis, MO

2:25 **Circadian Rhythms in Lung Physiology and Sleep**
S.P. Shea, PhD, Portland, OR

2:40 **The Lung Epithelial Clock and Its Role in Inflammation**
A. Loudon, PhD, Manchester, United Kingdom

3:10 **How Much Sleep or When? Teasing Apart the Health Effects of Sleep Deprivation and Circadian Disruption**
K. Gamble, PhD, Birmingham, AL

3:40 **Role of Clock Genes in COPD Pathogenesis**
I. Rahman, PhD, Rochester, NY

3:55 **Clock Genes, Viral Bronchiolitis and Childhood Asthma**
J.Haspel, MD, PhD, St. Louis, MO

There will be a 5-minute discussion after each talk.

BASIC • CLINICAL • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 2.0

B86 IMMUNOTHERAPY FOR LUNG CANCER: POWER TO THE HOST

Assemblies on Thoracic Oncology; Allergy, Immunology and Inflammation

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 303/305 (South Building, Esplanade Level)

Target Audience
Providers of lung health, pulmonary oncologists and/or practitioners of all health specialties participating in tumor boards, researchers in cancer and immunology, nursing (all subspecialties), pulmonary trainees.

Objectives
At the conclusion of this session, the participant will be able to:

- learn and apply new FDA approved agents for immunotherapy in lung cancer to correct subsets with the disease;
- understand new strategies to manage the care of advanced-stage lung cancer patients;
- improve current treatments through translational development and improve basic biological understanding of the immune system in lung cancer.

This scientific symposium will focus on both existing and promising translational approaches to immunotherapy in the treatment of lung cancer. It will cover both biological mechanisms that mediate baseline immunosuppression in lung cancer along with rational and state of the art use of existing (FDA approved) and highly promising approaches to achieve immune-mediated regression and/or cures in advanced-stage lung cancer. Developments in adjuvant immune-checkpoint and whole cell-based as well as vaccine approaches together with basic science concepts in immunologic signaling and host microenvironment will also be included. The science will cover novel genetic and epigenetic concepts as well.

Chairing: M.M. Fuster, MD, San Diego, CA
Z.G. Fridlender, MD, Jerusalem, Israel

2:15 **State of PD1/PDL1 Targeting in Lung Cancer**
R.M. Huber, MD, PhD, Munich, Germany

2:35 **Immunity Biomarkers and the Mutational Landscape in Lung Cancer**
E.B. Garon, MD, Los Angeles, CA

2:55 **Novel Immune Checkpoint Blockade Approaches**
S. Patel, MD, La Jolla, CA

3:15 **Immunosuppression and the Tumor Microenvironment**
A.M. Houghton, MD, Seattle, WA

3:35 **Treating Thoracic Malignancies with Adoptive T Cell Transfer: Successes and Challenges**
S. Albelda, MD, Philadelphia, PA

3:55 **Immune Considerations and Therapy for Mesothelioma**
D.H. Sterman, MD, New York, NY

*This session and the International Conference are supported by an educational grant from **AstraZeneca LP.***

All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

BASIC • CLINICAL • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 2.0

B87 BEYOND BMPR2: EMERGING ROLES OF DNA DAMAGE AND SOMATIC MUTATION IN PULMONARY ARTERIAL HYPERTENSION

Assemblies on Pulmonary Circulation; Respiratory Cell and Molecular Biology

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 3007/3009 (West Building, Level 3)

Target Audience
Basic research scientists and clinician scientists.

Objectives
At the conclusion of this session, the participant will be able to:

- learn new findings about how BMPR2 mutations impact the redox state and signaling environment of pulmonary arterial cells and impose a mutagenic risk on the mitochondrial genome;
- learn new concepts about mitochondria retrograde signaling to the nucleus and how this process is impacted by mtDNA mutations;
- learn new concepts about DNA damage and somatic mutation in pulmonary arterial hypertension.

Like cancer, pulmonary artery hypertension (PAH) has a prominent genetic component. For example, in familial as well as a proportion of sporadic PAH, germline mutations in the BMPR2 gene are a documented risk factor for the disease. In addition, hypertensive pulmonary cells also display an array of somatic mutations, but little is known about mechanisms of their formation, their functional consequences, and the potential that such somatic mutations could serve as diagnostic or prognostic biomarkers or therapeutic targets. Accordingly, the goal of this Scientific Symposium is to highlight emerging roles of DNA damage and somatic mutation in pulmonary arterial hypertension.

Chairing: M. Aldred, PhD, Cleveland, OH
M.N. Gillespie, PhD, Mobile, AL

2:15 **The Link Between BMPR2, Mitochondrial Dysfunction and Vulnerability to DNA Damage in Pulmonary Hypertension**
M. Rabinovitch, MD, Stanford, CA

2:35 **Mitochondrial DNA Mutations and Their Impact on Nuclear Gene Expression**
D. Wallace, PhD, Philadelphia, PA

2:55 **Transcriptional Regulation in Hypoxic Cells by Controlled DNA "Damage" and Repair**
M.N. Gillespie, PhD, Mobile, AL

3:15 **The DNA Damage Response in PAH**
S. Bonnet, PhD, Quebec, Canada

3:35 **DNA Damage and Repair and Somatic Mutation in PAH**
M. Aldred, PhD, Cleveland, OH

3:55 **The Cancer Paradigm for Pulmonary Arterial Hypertension: An Update**
M.J.C. Humbert, MD, PhD, Le Kremlin Bicetre, France

BEHAVIORAL • CLINICAL • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 2.0

B88 IMPROVING REAL WORLD CARE THROUGH INNOVATIVE TRIAL DESIGNS

Assemblies on Behavioral Science and Health Services Research; Critical Care; Thoracic Oncology

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 306/308 (South Building, Esplanade Level)

Target Audience
Pulmonary and critical care clinicians, trainees, clinical researchers.

Objectives
At the conclusion of this session, the participant will be able to:

- understand and learn about novel techniques in clinical trial design;
- learn new findings about management of respiratory infection, lung cancer, and pulmonary nodules;
- better apply clinical trial findings to making decisions for individual patients.

Pulmonary, sleep, and critical care medicine are plagued with expensive negative clinical trials that do not change clinical practice. To advance patient care in an increasingly resource constrained research environment, innovative, creative study designs have evolved. These designs move beyond traditional approaches that largely explore one intervention in one disease in a single population to monitoring multiple treatments and combinations of treatments in real world populations. In this symposium, we will use exemplars from recent and ongoing high profile trials across the fields of pulmonary and critical care medicine to show how novel designs can greatly improve efficiency, value, and translatability of findings to individual patients.

Chairing: H.C. Prescott, MD, MA, Ann Arbor, MI
V. Liu, MD, MS, Oakland, CA
S.J. Bartlett, PhD, Montreal, Canada

2:15 **Novel Trial Designs to Optimize Efficiency and Real World Impact**
S.J. Bartlett, PhD, Montreal, Canada

2:20 **PREPAREing for Future Epidemics: Platform Trial with Adaptive Randomization**
A. Nichol, MD, Dublin, Ireland

2:40 **Personalizing Care for Lung Cancer: Testing 10 Treatments All at Once**
J. Kern, MD, Denver, CO

3:00 **Real World Management of Lung Nodules: Large Pragmatic Trials**
M.K. Gould, MD, MS, Pasadena, CA

3:20 **Making Trials More Useful by Analyzing RCTs for Heterogeneity of Treatment Effects**
T.J. Iwashyna, MD, PhD, Ann Arbor, MI

3:35 **Evaluative Frameworks to Confirm Research Paradigms Work as Intended**
D. Hickam, MD, MPH, Washington, DC

3:50 **Panel Discussion**
W.M. Vollmer, PhD, Portland, OR
S.D. Halpern, MD, PhD, Philadelphia, PA
L. Reineck, MD, Bethesda, MD

*This session and the International Conference are supported by an educational grant from **AstraZeneca LP.***
All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

BASIC • CLINICAL • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 2.0

B89 HEALTH EFFECTS OF INHALED TOXINS: FROM THE BENCH TO THE TRENCHES: A GLOBAL PERSPECTIVE

Assemblies on Environmental, Occupational and Population Health; Clinical Problems

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 2006/2008 (West Building, Level 2)

Target Audience
Basic scientists and translational researchers interested in mechanisms of inhalation injury and emerging therapies; clinicians treating patients acutely exposed to inhalational toxins; clinicians, public health physicians, and epidemiologists involved in long term care of these patients.

Objectives
At the conclusion of this session, the participant will be able to:

- learn new findings regarding lung injury due to inhalational toxins;
- apply this knowledge to the care of individuals presenting with inhalational lung injury;
- discuss emerging new potential strategies for the treatment of the acute and chronic effects of lung injury due to inhalational toxins.

The symposium will provide a venue for basic, scientific, clinical, and epidemiologic researchers to present an overview of our current understanding of the underlying biology of inhalational lung injury as well as recent advances in the medical management of specific inhalational toxins. Within this broad field, we plan to focus on recent global events, which either have affected or are putting at risk local populations for injury secondary to tear and chlorine gas. Following mass-inhalational events, those with underlying lung disease are at increased risk for short and long-term pulmonary and systemic effects, including increased susceptibility to infections, increased airway hyperreactivity, development of restrictive lung diseases as well as cardiac abnormalities. With this session, we aim to improve knowledge of pulmonary and critical care specialists caring for victims of acute lung injury secondary to inhalational toxins, as well as providing care for those with chronic respiratory disease following inhalational injury. Further, we will provide updates and pave the way for future collaborative endeavors and studies to assess the effectiveness of countermeasures. We are very fortunate to have a number of outstanding speakers including the Scientific Committee Chair for the Turkish Thoracic Society, with direct involvement of patients exposed to massive amounts of tear gas in Turkey; the Deputy Medical Director of Medecins Sans Frontieres (MSF); and a disaster epidemiologist, who performed ground-breaking epidemiological studies on persons exposed to chlorine during the Graniteville train derailment

and a number of basic and translational scientists who contributed greatly in our understanding of basic mechanisms by which tear gas and chlorine damage the cardiopulmonary systems.

Chairing: S. Matalon, PhD, Birmingham, AL

2:15 **Introduction**
E. Summerhill, MD, Pawtucket, RI

2:20 **Pulmonary and Systemic Consequences of Tear Gas Exposure in an Urban Turkish Population**
E. Dagli, MD, Istabul, Turkey

2:40 **Chemosensation and Reflex Control in Inhalational Exposures**
S.E. Jordt, PhD, Durham, NC

3:00 **Mechanisms and Modification of Chlorine and Other Halogen Gas Induced Injury**
S. Matalon, PhD, Birmingham, AL

3:15 **Graniteville, SC Railway Derailment: Acute and Chronic Effects of Chlorine Gas Exposure**
E.R. Svendsen, PhD, Charleston, SC

3:35 **Managing Chemical Disasters Across the Globe: A Doctor Without Borders Perspective**
F. Baud, MD, Paris, France

3:55 **Novel Countermeasures for Inhalational Exposures: Is There Hope on the Horizon?**
C.W. White, MD, Denver, CO

BASIC

SCIENTIFIC SYMPOSIUM

CME Credits Available: 2.0

B90 NEW INSIGHTS INTO THE PREDISPOSITION, PATHOGENESIS, AND MANAGEMENT OF FUNGAL PNEUMONIA

Assemblies on Microbiology, Tuberculosis and Pulmonary Infections; Allergy, Immunology and Inflammation; Critical Care; Respiratory Cell and Molecular Biology

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 3016/3018 (West Building, Level 3)

Target Audience
Basic or clinical translational scientists interested in learning about the latest advances in the field of respiratory fungal diseases; clinicians seeking to update their knowledge on the management of immune suppressed or immune competent patients with endemic or opportunistic fungal pneumonia.

Objectives
At the conclusion of this session, the participant will be able to:

- learn new findings about the genetic defects and other immune factors that predispose the host to develop fungal pneumonia;
- apply new knowledge about the molecular and cellular mechanisms that underlie the pathophysiology of fungal pneumonia;
- diagnose and integrate new treatment options for fungal pneumonia.

This session will provide attendees with a state of the art review of emerging scientific principles and clinically relevant advances that are pertinent to the understanding of invasive fungal infection of the respiratory system. Individual speakers will describe novel primary immune deficiencies that predispose certain individuals to fungal pneumonia as well as the systems biology approach to comprehensively understand fungal-host cell interactions. Recent insights molecular and cellular pathogenesis of endemic and opportunistic fungal pneumonias will then be considered. Finally, the latest advances in clinical diagnostic strategies and therapeutic approaches for respiratory fungal diseases will be reviewed.

Chairing: S. Qureshi, MD, Montreal, Canada
S.E. Evans, MD, Houston, TX
C.S. Dela Cruz, MD, PhD, New Haven, CT

2:15 **Primary Immunodeficiencies Underlying Respiratory Fungal Infection**
A. Puel, PhD, Paris, France

2:35 **Systems Biology Analysis of the Fungal-Host Cell Interaction**
L. Romani, MD, PhD, Perugia, Italy

2:55 **Pathogenesis of Opportunistic Fungal Pneumonia**
A.H. Limper, MD, Rochester, MN

3:15 **Subversion of Host Immunity by Endemic Fungal Pathogens**
S. Qureshi, MD, Montreal, Canada

3:35 **Novel Diagnostic Tools and Approaches to Fungal Pneumonia**
C.A. Hage, MD, Indianapolis, IN

3:55 **Current Therapeutic Approaches for Fungal Pneumonia**
S.E. Evans, MD, Houston, TX

There will be a 5-minute discussion after each talk.

BASIC • BEHAVIORAL • CLINICAL • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 2.0

B91 AJRCCM: LEADING JOURNAL IN RESPIRATORY, CRITICAL CARE AND SLEEP MEDICINE. KEY PAPERS, PUBLICATION ETHICS, NEW INITIATIVES

AJRCCM; Assemblies on Allergy, Immunology and Inflammation; Behavioral Science and Health Services Research; Clinical Problems; Critical Care; Environmental, Occupational and Population Health; Microbiology, Tuberculosis and Pulmonary Infections; Nursing; Pediatrics; Pulmonary Circulation; Pulmonary Rehabilitation; Respiratory Cell and Molecular Biology; Respiratory Structure and Function; Sleep and Respiratory Neurobiology; Thoracic Oncology

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 2002/2004 (West Building, Level 2)

Target Audience
All readers and potential authors of AJRCCM, and early career researchers in particular.

Objectives
At the conclusion of this session, the participant will be able to:

- understand the scope of the ATS family of journals and what makes a good and acceptable paper;

- highlight main papers in airways disease asthma and COPD including critical care;
- describe major issues in publication ethics.

AJRCCM (Blue Journal) is the premier respiratory journal with the high impact factor for respiratory journals. The aim of this session is to showcase key papers on airways disease from AJRCCM issues over the past year with examples of papers accepted and summarize key findings. Also the session will be organized on issues in publication ethics and the role of the early career AJRCCM group. Time for discussion will be very valuable.

Chairing: L.J. Brochard, MD, Toronto, Canada
J.A. Wedzicha, MD, PhD, London, United Kingdom

2:15 **Introduction: ATS Family of Journals**
J.A. Wedzicha, MD, PhD, London, United Kingdom

2:25 **Highlights in Critical Care in AJRCCM**
L.J. Brochard, MD, Toronto, Canada

2:50 **Progress in COPD in AJRCCM**
F.J. Martinez, MD, New York, NY

3:15 **Asthma Papers in AJRCCM: Children and Adults**
F.D. Martinez, MD, Tucson, AZ

3:40 **Early Career Researchers: How Can You Help?**
A.J. Mackay, MBBS, London, United Kingdom

3:55 **Publication Ethics: How to Navigate the Issues**
J.A. Wedzicha, MD, PhD, London, United Kingdom

There will be a 5-minute discussion after each talk.

MINI SYMPOSIUM

B93 THINKING ABOUT LUNG HEALTH AND DEFINING EARLY COPD

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**
Room 130-132 (North Building, Lower Level)

Chairing: R. Kalhan, MD, MS, Chicago, IL
M.T. Dransfield, MD, Birmingham, AL
C.E. Berry, MD, Tucson, AZ

Featured Speaker

2:15 **Shifting Focus: The Study of Lung Health Versus Lung Disease/**R.A. Wise, MD, Baltimore, MD,

Oral Presentations

2:30 **Characterization of Smokers with COPD Exacerbations Despite Preserved Spirometry in the SubPopulations and Intermediate Outcome Measures In COPD Study (SPIROMICS)/**S.A. Christenson, R.G. Barr, E.R. Bleecker, R.P. Bowler, C.B. Cooper, G.J. Criner, M.T. Dransfield, N.N. Hansel, M.K. Han, E.A. Hoffman, R. Kanner, S.C. Lazarus, F.J. Martinez, R. Paine, III, J.M. Wells, P.G. Woodruff, San Francisco, CA, p.A4276

2:45 **Functional Small Airway Abnormalities Increase with Age Among Never and Ever-Smokers Without Airflow Obstruction. An Analysis of the SPIROMICS Cohort/**C.H. Martinez, A.A. Diaz, J.L. Curtis, C.B. Cooper, C. Pirozzi, R. Kanner, R. Paine, III, P.G. Woodruff, E. Bleecker, N.N. Hansel, R.G. Barr, E. Kazerooni, E.A. Hoffman, B.D. Ross, C. Galban, C.T. Cigolle, F.J. Martinez, M.K. Han, Ann Arbor, MI, p.A4277

3:00 **Effect of Acute Respiratory Events on Lung Function Decline in Current and Former Smokers with and Without COPD/**K.M. Kunisaki, M.T. Dransfield, M. Strand, S.P. Bhatt, R.P. Bowler, G.J. Criner, J.L. Curtis, N.A. Hanania, H. Nath, N. Putcha, S.E. Roark, E.S. Wan, G. Washko, J.M. Wells, C. Wendt, B.J. Make, Minneapolis, MN, p.A4278

3:15 **The Relative Contribution of a Low Baseline FEV1 Versus Rapid Decline in Lung Function Over Time on Incident COPD/**W.C. Tan, L. Zheng, S.D. Aaron, D.D. Sin, J. Road, D.E. O'Donnell, F. Maltais, P. Hernandez, K.R. Chapman, J.M. FitzGerald, D. Marciniuk, J. Leipsic, C. Hague, H. Coxson, M. Kirby, J.C. Hogg, J. Bourbeau, Vancouver, Canada, p.A4279

3:30 **The Utility of Chronic Respiratory Symptoms During Middle-Age in Identifying Smokers Who Developed COPD by Their Early Sixties Within a Nationally Representative Birth Cohort Study/**J.P. Allinson, R. Hardy, G.C. Donaldson, S.O. Shaheen, D. Kuh, J.A. Wedzicha, London, United Kingdom, p.A4280

3:45 **Sustained or Relative Increases in Cardiopulmonary Fitness Are Associated with Preserved Lung Health from Young Adulthood to Middle Age/**L. Benck, M. Cuttica, L. Colangelo, S. Sidney, M.T. Dransfield, C. Lewis, D.R. Jacobs, Jr., N. Zhu, D. Mannino, M. Carnethon, K. Liu, R. Kalhan, Chicago, IL, p.A4281

4:00 **Lung Function Decline and Related Biological and Environmental Risk Factors: Longitudinal Follow-Up of the CRONICAS Study/**C.H. Miele, R.H. Gilman, J.J. Miranda, A. Bernade-Ortiz, D. Antiporta, R.A. Wise, W. Checkley, Baltimore, MD, p.A4282

MINI SYMPOSIUM

B94 PREDICTORS OF OUTCOME IN ILD

2:15 p.m. - 4:00 p.m. **MOSCONE CENTER**
Room 3020/3022 (West Building, Level 3)

Chairing: S.K. Danoff, MD, PhD, Baltimore, MD
B.J. Ley, MD, San Francisco, CA
A.W. Brown, MD, Falls Church, VA

Oral Presentations

2:15 **Development and Progression of Interstitial Lung Abnormalities in the Framingham Heart Study /**R.K. Putman, T. Araki, H. Hatabu, W. Gao, J. Dupuis, J. Latourelle, M. Nishino, O. Zazueta, S. Kurugol, J.C. Ross, R. San Jose Estepar, D.A. Schwartz, I.O. Rosas, G. Washko, G.T. O'Connor, G.M. Hunninghake, Boston, MA, p.A4283

2:30 **Mortality and Undiagnosed Interstitial Lung Abnormalities/** R.K. Putman, H. Hatabu, T. Araki, G. Gudmundsson, W. Gao, M. Nishino, Y. Okajima, J. Dupuis, J. Latourelle, M.H. Cho, S. El-Chemaly, H. Coxson, B.R. Celli, I.E. Fernandez, O.E. Zazueta, J.C. Ross, R. Harmouche, R. San Jose Estepar, A.A. Diaz, S. Sigurdsson, E. Gudmundsson, G. Eiriksdottir, T. Aspelund, M.J. Budoff, G.L. Kinney, J. Hokanson, M.C. Williams, J.T. Murchison, W. MacNee, U. Hoffmann, C.J. O'Donnell, L.J. Launer, T.B. Harris, V. Gudnason, E.K. Silverman, G.T. O'Connor, G. Washko, I.O. Rosas, G.M. Hunninghake, Boston, MA, p.A4284

2:45 **Predictors of Mortality in Patients with Idiopathic Pulmonary Fibrosis Under Clinical Practice Conditions: INSIGHTS-IPF Registry/**J. Behr, H. Wirtz, A. Prasse, D. Pittrow, J. Klotsche, D. Koschel, S. Andreas, M. Claussen, C. Grohe, M. Kreuter, Gauting, Germany, p.A4285

3:00 **Mortality, Costs, and Length of Stay in Patients with Idiopathic Pulmonary Fibrosis/**J. Mooney, K. Raimundo, E. Chang, M.S. Broder, Stanford, CA, p.A4286

3:15 **High Attenuation Areas on Computed Tomography, Subclinical Interstitial Lung Disease, and Mortality in Community Dwelling Adults/**A. Podolanczuk, E.C. Oelsner, R.G. Barr, E.A. Hoffman, H.F. Armstrong, J.H.M. Austin, R.C. Basner, M.N. Bartels, J.D. Christie, P.L. Enright, B. Gochuico, K. Hinckley Stukovsky, J. Kaufman, H. Nath, J.D. Newell, S.M. Palmer, D. Rabinowitz, G. Raghu, J. Sell, J.P. Sieren, S.K. Sonavane, R.P. Tracy, J.R. Watts, K. Williams, S.M. Kawut, D.J. Lederer, New York, NY, p.A4287

3:30 **Predicting Mortality in Patients with Rheumatoid Arthritis Related Interstitial Lung Disease: Expanding The GAP Model/**J. Morisset, E. Vittinghoff, B.Y. Lee, R. Tonelli, X. Hu, B.M. Elicker, J.H. Ryu, K.D. Jones, S. Cerri, A. Manfredi, M. Sebastiani, B.J. Ley, P.J. Wolters, T.E. King, D.S. Kim, H.R. Collard, J.S. Lee, San Francisco, CA, p.A4288

3:45 **A Multicentre Evaluation of Inter-Multidisciplinary Team Agreement for Predicted Disease Behaviour and Management Strategy in Diffuse Lung Disease/**A.U. Wells, S.L. Walsh, V. Poletti, A. Dubini, S. Piciucchi, E. Bendstrup, L.B. Madsen, F. Rasmussen, D. Valeyre, H. Nunes, P.Y. Brillet, M. Kambouchner, H. Taniguchi, J. Fukuoka, T. Johkoh, K.R. Flaherty, J.L. Myers, S. Desai, B. Gooptu, S. Pomplun, J.C. Grutters, K. Seldenrijk, D.A.F. Van Den Heuval, H.W. Van Es, M.F. Van Oosterhout, A. Morais, C.S. Moura, J. Pereira, C. Sayer, J. Jacob, D. Hansell, London, United Kingdom, p.A4289

MINI SYMPOSIUM

B95 CRITICAL CARE: NEW CLINICAL TRIALS

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 3006/3008 (West Building, Level 3)

Chairing: I.S. Douglas, MD, Denver, CO
R.D. Stapleton, MD, PhD, Burlington, VT

Oral Presentations

2:15 **Effect of Saline Versus Balanced Crystalloids on Major Adverse Kidney Events in the Medical Intensive Care Unit: The SALT Randomized Trial/**M.W. Semler, M.J. Noto, J.L. Stollings, J.M. Ehrenfeld, J.P. Wanderer, M. Plante, D.P. Mulherin, S. Strawbridge, A. Wheeler, T.W. Rice, Nashville, TN, p.A4290

2:30 **A Randomized Controlled Trial of a Fresh Frozen Plasma Transfusion Dosing Algorithm for Cirrhotic Patients/**S.C. Berngard, S. Biggins, A. Benson, J. Gralla, M. Moss, La Jolla, CA, p.A4291

2:45 **READS - Randomized Educational ARDS Diagnosis Study: A LUNG-SAFE Sub-Study/**S. Goddard, E. Fan, V. Manoharan, G.D. Rubenfeld, Toronto, Canada, p.A4292

3:00 **Effect of Sevoflurane Inhalation on Gas Exchange and Inflammation in Patients with Acute Respiratory Distress Syndrome: A Monocenter, Prospective Randomized Controlled Trial/**M. Jabaudon, P. Boucher, E. Imhoff, R. Chabanne, J.-S. Faure, L. Roszyk, G. Clairefond, R. Blondonnet, R. Guerin, S. Perbet, S. Cayot, V. Sapin, J.-E. Bazin, E. Futier, J.-M. Constantin, Clermont-Ferrand, France, p.A4293

3:15 **Noninvasive Ventilation in Acute Respiratory Failure: A Comparison of Facemask Versus Helmet Interface/**B.K. Patel, K.S. Wolfe, A.S. Pohlman, J.B. Hall, J.P. Kress, Chicago, IL, p.A4294

3:30 **A Randomized Trial of Video-Augmented Verbal Consent Versus Verbal Consent for Substitute Decision Makers in an Early ICU Cycling Clinical Trial/**M.E. Kho, F. Clarke, M. Duffett, M. Shears, D. Cook, Hamilton, Canada, p.A4295

3:45 **A Multicenter Randomized Controlled Trial of Palliative Care-Led Informational/Emotional Support Meetings for Family Decision Makers of Patients with Chronic Critical Illness/**S.S. Carson, C.E. Cox, S. Wallenstein, L. Hanson, M. Danis, J.A. Tulsky, E. Chai, J. Nelson, Chapel Hill, NC, p.A4296

4:00 **Lung Injury Prevention Study with Budesonide and Beta Agonist, Formoterol (LIPS-B): A Multicenter Randomized Clinical Trial/**E. Festic, G. Carr, R. Cartin-Ceba, R.F. Hinds, V. Bansal, V. Banner-Goodspeed, D.S. Talmor, G. Rajagopalan, R.D. Frank, O. Gajic, M. Matthay, J.E. Levitt, Jacksonville, FL, p.A7851

MINI SYMPOSIUM

B96 HUNGRY HEART: RV FUNCTION IN PH

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 3003/3005 (West Building, Level 3)

Chairing: F. De Man, PhD, Amsterdam, Netherlands
D.G. Kiely, MD, Sheffield, United Kingdom
L. Dewachter, MD, Brussels, Belgium

Oral Presentations

2:15 **Role of Lymphatics in Right Ventricular Edema and Pericardial Effusion in Pulmonary Hypertension/**M.E. Yeager, O. Lohani, K.L. Colvin, Aurora, CO, p.A4297

2:30 **FK506 Reduces Right Ventricular Cardiac Fibrosis in a BMP Dependent Manner/**X. Tian, J. Kuang, D. Sudheendra, S. Reddy, M. Zhao, D. Bernstein, E.F. Spiekerkoetter, Stanford, CA, p.A4298

2:45 **Influence of Sex on Estrogenic System in the Right Ventricle/**M. MacLean, E. Wallace, M. Nilsen, D. Morales-Cano, Glasgow, United Kingdom, p.A4299

3:00 **Effects of Pharmacological Aldosterone Antagonism by Eplerenone on Pressure Overload-Induced Right Ventricular Dysfunction/**M. Boehm, C. Lu, T. Novoyatleva, N.D. Arnold, A.T. Braithwaite, F. Grimminger, H.A. Ghofrani, N. Weissmann, W. Seeger, A. Lawrie, R.T. Schermuly, B. Kojonazarov, Giessen, Germany, p.A4300

3:15 **Altered Insulin Signaling in Mutant BMPR2 Cardiomyocytes Associated with Mitochondrial Dysfunction/**M. Talati, J.P. Fessel, S. Zhu, C. Jetter, N. Penner, J. West, A.R. Hemnes, Nashville, TN, p.A4301

3:30 **A Cardioprotective Estrogen Receptor α-Apelin Axis Mediates Salutary Effects of 17β-Estradiol (E2) on Right Ventricular Function in Pulmonary Hypertension/**A. Frump, M. Albrecht, S. Breulis Bonnet, F. Potus, S. Provencher, S. Bonnet, M.B. Brown, T. Lahm, Indianapolis, IN, p.A4302

3:45 **Right Ventricular End-Systolic Regional Wall Stress is Associated with Invasive Measures of Right Ventricular Afterload/**C.J. Mullin, R. Tedford, C.P. Corona-Villalobos, S.L. Zimmerman, I.R. Kamel, T. Kolb, R.L. Damico, D.A. Kass, P.M. Hassoun, S.C. Mathai, Baltimore, MD, p.A4303

4:00 **Pulmonary Arterial Hypertension Improvement by Macitentan is Associated with an Increase in Right Ventricle, Peripheral Muscle and Lungs Angiogenesis/**V. Nadeau, S. Bonnet, R. Paradis, F. Potus, E. Tremblay, C. Lambert, M. Iglarz, S. Provencher, Quebec City, Canada, p.A4304

MINI SYMPOSIUM

B97 MITOCHONDRIA DYSFUNCTION IN THE DEVELOPMENT OF LUNG DISEASE

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 2016/2018 (West Building, Level 2)

Chairing: N. Chandel, PhD, Chicago, IL
R. Guzy, MD, PhD, Chicago, IL

Oral Presentations

2:15 **Staphylococcus Aureus Causes Mitochondrial Injury in Lung Alveoli/**J. Hook, J. Bhattacharya, New York, NY, p.A4305

2:30 **Role of Mitochondrial (Dys-)Function for Cell Death and Immune Activation in Influenza and Pneumococcal Infection/**E. Pappe, M. Mieth, J. Ruckert, J. Neudecker, T. Bauer, M. Tonnies, N. Suttorp, T. Wolff, S. Hippenstiel, A. Hocke, A. Nerlich, Berlin, Germany, p.A4306

2:45 **Mice Lacking the Genes for Cytochrome P450 (CYP)1A Enzymes Display Increased Susceptibility to Hyperoxic Lung Injury, Oxidative DNA damage, and Oxidative Stress: Implications for ALI/ARDS in Humans/**B. Moorthy, W. Jiang, L. Wang, X. Couroucli, K. Lingappan, Houston, TX, p.A4307

3:00 **Metabolomic Profiling of Acutely Injured Human Alveolar Epithelial Type 2 Cells Reveals Key Role of Tryptophan Metabolism/**A.J. Rogers, X. Fang, M. Wu, M. Zheng, G. Peltz, M.A. Matthay, Stanford, CA, p.A4308

3:15 **Mitochondrial DNA Released Following Necroptosis Accumulates on RBCs/**J. Mei, D. Qing, M. Hotz, D.L. Siegel, N. Sondheimer, N.S. Mangalmurti, Philadelphia, PA, p.A4309

3:30 **SIRT3, The Anti-Aging Major Mitochondrial Deacetylase, Is Important for Preventing Pulmonary Fibrosis/**R.P. Jablonski, S.-J. Kim, P. Cheresh, D. Williams, L. Morales-Nebreda, M. Chi, Y. Cheng, A. Yeldandi, A. Pardo, M. Selman, K.M. Ridge, D. Guis, G.S. Budinger, D. Kamp, Chicago, IL, p.A4310

3:45 **SH2 Domain-Containing Phosphatase-(SHP)-2 Attenuates Fibrotic Responses Through Regulation of Fibroblast Mitochondrial Metabolism and Autophagy/**A.E. Tzouvelekis, G. Yu, H. Lee, J.-S. Yi, J. Herazo-Maya, T. Woolard, A. Munivar, A. Srivastava, P. Mannam, K. Sakamoto, G. DeIuliis, F. Ahangari, A. Bennett, N. Kaminski, New Haven, CT, p.A4311

4:00 **Macrophage Mitophagy and Fibrosis Development Requires the Mevalonate Pathway/**M. Vaid, J.L.L. Casey, L. Gu, A.B. Carter, Birmingham, AL, p.A4312

MINI SYMPOSIUM

B98 SIGNALING, REMODELING AND CONTRACTION IN THE AIRWAY

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 2020/2022 (West Building, Level 2)

Chairing: C.J. Koziol-White, PhD, New Brunswick, NJ
J.K. Burgess, PhD, Groningen, Netherlands

Oral Presentations

2:15 **Premature Infants Have an Intrinsic Airway Secretory Signature Characterized by Enhanced Production of Airway Remodeling Growth Factors/**R. Megalaa, S. Huseni, K. Pancham, G.F. Perez, C.E. Rodriguez-Martinez, S. Kilaikode, M.C. Rose, S. Wolf, G.R. Nino, Washington, DC, p.A4313

2:30 **Mast Cell Activation by Hyperosmolar Mannitol-Challenge in Isolated Human Small Airways/**J. Safholm, J. Bood, S.-E. Dahlen, M. Adner, Stockholm, Sweden, p.A4314

2:45 **Impaired Crosstalk Between Airway Epithelium and Human Bronchial Smooth Muscle Cells in COPD/**E. Ahmed, A. Fort, L. Knabe, I. Vachier, A. Virsolvy, S. Richard, P. Chanez, A. Bourdin, Montpellier, France, p.A4315

3:00 **Simultaneous 2-Photon Imaging of Ca2+ Signaling in Airway Smooth Muscle Cells, T-Cells and Mast Cells in Precision-Cut Lung Slices from a House Dust Mite Allergic Mouse Model/**J. Chen, J.F. Perez-Zoghbi, M.J. Sanderson, Worcester, MA, p.A4316

3:15 **SOCS1 and SOC3 Modulate Immune Response in the Airway Smooth Muscle/**B.E. Himes, C. Koziol-White, M. Johnson, W. Jester, R.A. Panettieri, Jr., Philadelphia, PA, p.A4317

3:30 **Free Fatty Acid 4/GPR120 Receptor Agonist TUG891 - a Novel Potent Bronchodilator of Small Airways/**J.E. Bourke, J. Chen, M. Simoons, J. Micallef, M. Lam, B. Shimpukade, T. Ulven, M.J. Sanderson, C. Donovan, Clayton, Australia, p.A4318

3:45 **Neutrophil Elastase Promotes the Activation of Signaling Pathways that Mediate the Inflammatory Phenotype in Airway Smooth Muscle/**A.D. Lockett, S.J. Gunst, Indianapolis, IN, p.A4319

4:00 **Deep Inspiration, Fluidization and the Actin Binding Protein Cofilin/**B. Lan, C.Y. Park, K. Jae Hun, R. Krishnan, J.J. Fredberg, Boston, MA, p.A4320

MINI SYMPOSIUM

B99 THE BEST OF EVERYTHING: HOT TOPICS IN SLEEP

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 2001/2003 (West Building, Level 2)

Chairing: M. Teodorescu, MD, MS, Madison, WI
N.A. Antic, MBBS, PhD, Adelaide, Australia
S.P. Patil, MD, PhD, Baltimore, MD

Oral Presentations

2:15 **Identifying Obstructive Sleep Apnea Patients Vulnerable to Opioid-Induced Respiratory Depression - A Randomized Double-Blind Placebo-Controlled Crossover Trial/**D. Wang, L. Rowsell, K. Wong, B. Yee, D.J. Eckert, A. Somogyi, J. Duffin, R. Grunstein, Camperdown, Australia, p.A4321

2:30 **Transgenic Approach to Selectively Modulate Hypoglossal Motoneurons/**T.A. Fleury Curado, H. Pho, L.U. Sennes, A.R. Schwartz, V.Y. Polotsky, Baltimore, MD, p.A4322

2:45 **Relationship Between Sleep-Disordered Breathing and Aggressiveness Markers of Malignant Cutaneous Melanoma. A Multicentric Study/**M.A. Martinez-Garcia, A. Martorell, E. Nagore, J.L. Rodriguez-Peralto, M. Sanchez De La Torre, L. Hernandez, J. Diaz De Atauri, E. Chiner, J.M. Montserrat, R. Farre, F. Campos-Rodriguez, J. Abad, O. Mediano, F.-B. Illa, V. Cabriada, J. Corral, I. Cano, F. Troncoso-Acevedo, A. Fortuna, M. De La Pena, M. Somoza-Gonzalez, M. Gonzalez, M. LLombart, F. Del Campo, C. Navarro, M.J. Selma, A. Munoz, Valencia, Spain, p.A4323

3:00 **Genetic Associations with Obstructive Sleep Apnea Traits in Hispanic/Latino Americans/**B.E. Cade, H. Chen, A.M. Stilp, K.J. Gleason, T. Sofer, R. Arens, G.I. Bell, J.E. Below, A.C. Bjonnes, S.G. Chun, M.P. Conomos, W.C. Johnson, A.C. Frazier-Wood, J.M. Lane, E.K. Larkin, J.S. Loredo, W.S. Post, A.R. Ramos, K. Rice, J.I. Rotter, N.A. Shah, K.D. Taylor, T.A. Thornton, C. Wang, P.C. Zee, C.L. Hanis, S.R. Sunyaev, S.R. Patel, C.C. Laurie, X. Zhu, R. Saxena, X. Lin, S. Redline, Boston, MA, p.A4324

3:15 **Sleep-Disordered Breathing Severity and Cognitive Performance in Community Young School-Aged Children/**L. Kheirandish-Gozal, S.J. Hunter, D.L. Smith, M.F. Philby, J. Kaylegian, D. Gozal, Chicago, IL, p.A4325

3:30 **Effects of Nox2 Activity on Murine Gut Microbiota Alterations Induced by Sleep Fragmentation and Intermittent Hypoxia/**V. Poroyko, Z. Qiao, A. Khalyfa, A. Gileles-Hillel, R. Farre, D. Gozal, Chicago, IL, p.A4326

3:45 **Mortality Patterns in a Large Series of Patients with Obstructive Sleep Apnea on Treatment with Continuous Positive Airway Pressure/**J. Valls, G. Castella, R. Boix, C. Colls, A. Garcia-Altes, I. Teixido, J. Mateo, F. Solsona, J. Escarrabill, M. Sanchez De La Torre, F. Barbé, Lleida, Spain, p.A4327

4:00 **Obstructive Sleep Apnea and Cardiovascular Events After Percutaneous Coronary Intervention/**C.-H. Lee, R. Sethi, R. Li, H.-H. Ho, T. Hein, M.-H. Jim, G. Loo, C.-Y. Koo, X.-F. Gao, S. Chandra, X.-X. Yang, S.F. Furlan, Z. Ge, A. Mundhekar, W.-W. Zhang, C.H.G. Uchoa, R.B. Kharwar, P.-F. Chan, S.-L. Chen, M.Y. Chan, A.M. Richards, H.-C. Tan, T.-H. Ong, G. Roldan, B.-C. Tai, L.F. Drager, J.-J. Zhang, Singapore, Singapore, p.A4328

POSTER DISCUSSION SESSION

B101 PHENOTYPING OF ASTHMA IN THE ERA OF BIOMARKERS AND OMICS

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 2014 (West Building, Level 2)

Poster Viewing **2:15-3:00**

Discussion **3:00-4:15**

Chairing: A.N. Gerber, MD, PhD, Denver, CO
C. Taube, MD, Leiden, Netherlands
G.M. Gauvreau, PhD, Hamilton, Canada

501 **Longitudinal Replication of Severe Asthma Exhaled Breath Phenotypes by the U-BIOPRED Electronic Nose Platform/** P. Brinkman, A.H. Wagener, P.-P. Hekking, A.T. Bansal, Y. Wang, H. Weda, H.H. Knobel, T.J. Vink, N.J. Rattray, A. D'Amico, G. Pennazza, M. Santonico, P.S. Bakke, M. Caruso, K.F. Chung, J. Corfield, S.-E. Dahlen, R. Djukanovic, T. Geiser, I. Horvath, N. Krug, J. Musial, D.E. Shaw, I. Pandis, T. Sandstrom, A.R. Sousa, P. Montuschi, S.J. Fowler, P.J. Sterk, Amsterdam, Netherlands, p.A4329

502 **Characterization of a Severe Asthma Patient Population with and Without Eosinophilic Inflammation and Frequent Exacerbations by Multiple PROs (IDEAL)**/L.M. Nelsen, R. Suruki, F. Albers, E. Bradford, N. Gunsoy, S. Cockle, J.-Y. Shin, Collegeville, PA, p.A4330

503 **Transcriptomic Fingerprints of Fixed Airflow Limitation in Adult Severe Asthma Patients from the U-BIOPRED Cohort**/P.-P. Hekking, M. Loza, B. De Meulder, S. Pavlidis, F. Baribaud, C. Auffray, A.H. Wagener, P. Brinkman, D. Lefaudeux, A.T. Bansal, A.R. Sousa, J. Corfield, E.H. Bel, I. Adcock, R. Djukanovic, K.F. Chung, P.J. Sterk, Amsterdam, Netherlands, p.A4331

504 **Dipeptidyl Peptidase-4 (DPP-4) Is a Novel Predictive Biomarker for the Investigational Anti-IL-13 Targeted Therapy Tralokinumab**/ K. Ranade, T.-H. Pham, G. Damera, P.Z. Brohawn, F. Pilataxi, M. Kuziora, K. Streicher, S. Manetz, I. Vainshtein, M. Liang, D. She, E. Piper, C.E. Brightling, R.J. Martin, Gaithersburg, MD, p.A4332

505 **Collective Clinical and Inflammatory Phenotyping of Asthma and COPD by Breathomics**/R. De Vries, P. Brinkman, J.W.F. Dagelet, E. Dijkers, F.H.C. De Jongh, P.J. Sterk, Amsterdam, Netherlands, p.A4333

506 **Peripheral Blood CRTH2 Positive Cells in Patients with Severe Asthma**/L. Xue, B. Hilvering, R. Shrimanker, L. Stoeger, S. Go, C. Borg, C. Connolly, S. Thulborm, S. Pahlke, M. Bafadhel, I. Pavord, Oxford, United Kingdom, p.A4334

507 **Predictive Performance of Non-Invasive Type 2 Biomarkers for Asthmatic Sputum Eosinophilia in BOBCAT and U-BIOPRED Studies**/D.F. Choy, F. Cai, R.G. Knowles, R. Djukanovic, D.E. Shaw, P.J. Sterk, K.F. Chung, I. Adcock, S.-E. Dahlen, J. Harris, J. Matthews, J. Arron, H. Scheerens, C.T.J. Holweg, South San Francisco, CA, p.A4335

508 **The Lung Microbiota in Stable Adult Asthma Differs According to Inflammatory Phenotype, Sex, and Atopy**/G.B. Rogers, L.E. Leong, P.G. Gibson, I.A. Yang, S.J. Hodge, P.N. Reynolds, A.L. James, J.W. Upham, C. Jenkins, M. Peters, M. Baraket, J.L. Simpsons, Bedford Park, Australia, p.A4336

509 **Paths to ACOS: Evaluation of Persistent Airflow Limitation in an Urban Population with Asthma**/K. Doo, N. Xu, Y. Shao, M. Liu, M.-E. Fernandez-Beros, G. Schattner, S. Garafano, L. Rogers, G. Grunig, B. Bleck, J. Reibman, New York, NY, p.A4337

510 **A Blood Eosinophil Count of Greater Than 150 Cells/uL Predicts Sputum Eosinophilia â?¥ 3% in Patients with Severe Asthma with Other Markers of Inflammatory Lung Disease**/D. Austin, I. Pouliquen, S. Yancey, E. Bleeker, Stockley Park, United Kingdom, p.A4338

511 **Relationship Between Th2 Gene Mean Expression in Sputum Cells, Mast Cell Infiltration of the Airway Wall, and Airway Hyperresponsiveness in Asthma**/S. Long, Y. Lai, J.D. Nolin, M.C. Altman, C.W. Frevert, M. Larmore, M. Peters, T.S. Hallstrand, Seattle, WA, p.A4339

512 **Analysis of T Helper Cell Gene Regulation in Asthma by Genome-Wide Chromatin Accessibility Profiling in Monozygotic Twins**/R.N. Bauer, A.T. Satpathy, K. Qu, T. Ho, R.S. Chinthrajah, R.L. Miller, H.Y. Chang, K.C. Nadeau, Stanford, CA, p.A4340

513 **Sputum Eosinophils but not Neutrophils Are Associated with a Very Frequent Exacerbator Phenotype in Asthma**/M.T.D. Opina, A.T. Hastie, H. Li, D.A. Meyers, E.R. Bleecker, W.C. Moore, Winston-Salem, NC, p.A4342

514 **Two IL1RL1 Asthma Risk Variants Function as Expression Quantitative Trait Loci Through Different Promoter Usage**/E. Gordon, A. Wesolowska-Andersen, C. Urbanek, M.E. Lachowicz-Scroggins, M. Peters, J.V. Fahy, M. Seibold, San Francisco, CA, p.A4342

515 **Circulating MicroRNAs and Association with Methacholine PC20 in the Childhood Asthma Management Program (CAMP) Cohort**/J.S. Davis, A. Kho, K. Moore, J. Sylvia, S.T. Weiss, K. Tantisira, Boston, MA, p.A4343

516 **Novel Mechanisms of Steroid Function in Airway Smooth Muscle Defined Through ChIP-seq**/A.N. Gerber, V. Kadiyala, R.A. Panettieri, Jr., S. Sasse, Denver, CO, p.A4344

517 **A Single Dose of Inhaled Budesonide Induces Expression of Genes Involved in Cell Signaling, Migration, Proliferation and Anti-Inflammatory Effects in the Human Airways**/R. Newton, M.M. Mostafa, C.F. Rider, E.M. King, S. Shah, C. Dumonceaux, S. Traves, M.M. Kelly, A. Miller-Larsson, R. Leigh, Calgary, Canada, p.A4345

518 **Clinical and Molecular Characterization of the CHI3L1/YKL-40 Severe Asthma Endotypes**/J.L. Gomez, G. Crisafi, C. Holm, N.N. Jarjour, G.A. Hawkins, D.A. Meyers, E. Bleecker, J. Reibman, L.E. Cohn, G.L. Chupp, New Haven, CT, p.A4346

519 **M1 M2 Sputum Macrophage Profiles in Healthy Individuals, Airway Disease, Tobacco Smokers and Alternative Tobacco Users**/N.E. Alexis, H.B. Wells, S. Miller, B. Goldstein, Y. Saini, S. Donaldson, D. Peden, Chapel Hill, NC, p.A4347

520 **Day-Time Variation of Periostin in Adults With and Without Asthma**/I. Braithwaite, R. Caswell-Smith, T. Cripps, T. Charles, A. Hosking, M. Handigol, C. Holweg, J. Matthews, M. Holliday, C. Maillot, J. Fingleton, M. Weatherall, R. Beasley, Wellington, New Zealand, p.A4348

521 **Longitudinal Study of Serum Periostin Levels in Stable Adult Asthma**/I. Braithwaite, R.A.C. Semprini, R. Caswell-Smith, J. Fingleton, C. Holweg, J. Matthews, M. Weatherall, R. Beasley, Wellington, New Zealand, p.A4349

522 **Polymorphisms in Duffy Antigen Receptor for Chemokines Are Associated with Clinical Severity During Treatment Adjustment in Asthmatics**/D.G. Chapman, E.B. Mougey, K. George, J.J. Lima, C.G. Irvin, Burlington, VT, p.A4350

523 **High Blood Eosinophil Concentrations and Serum Biomarkers of Low IL-13 Pathway Activation at Baseline Predict Exacerbation Rate Reduction by Benralizumab for Patients with Moderate to Severe Asthma**/P. Newbold, Y. Wu, V. Shih, M. Liang, I. Vainshtein, K. Ranade, Gaithersburg, MD, p.A4351

524 **Cigarette Smoke Modifies the IL-13-Induced Th2 Gene Signature in Primary Human Bronchial Epithelial Cells**/T.C.J. Mertens, A.M. Van Der Does, D.K. Ninaber, P.S. Hiemstra, C. Taube, Leiden, Netherlands, p.A4352

525 **Clinical Cluster Phenotypes from the Severe Asthma Research Program (SARP1/2): Reproducibility in SARP 3 and the Importance of Baseline Lung Function in Disease Stability and Progression/**W.C. Moore, X. Li, H. Li, M. Castro, S.C. Erzurum, J.V. Fahy, E. Israel, N.N. Jarjour, B.D. Levy, L.B. Bacharier, A.M. Fitzpatrick, B. Gaston, N. Ly, R.E. Myers, S. Ramratnam, W. Phipatanakul, W.G. Teague, D. Mauger, S.E. Wenzel, D.A. Meyers, E.R. Bleecker, Winston-Salem, NC, p.A7852

POSTER DISCUSSION SESSION

B102 STRATEGIES TO IMPROVE CARE QUALITY IN PULMONARY AND CRITICAL ILLNESS

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 304 (South Building, Esplanade Level)

Poster Viewing **2:15-3:00**

Discussion **3:00-4:15**

Chairing: B. Patel, MD, Houston, TX
K.A. Sloan, MD, Boston, MA
R.C. Hyzy, MD, Ann Arbor, MI

201 **Communication and Framing Effects on Reduction of Pneumonia Readmissions/**A.P. Halpin, Orange, CA, p.A4353

202 **Variation in Perceptions of Inpatient Consultation Quality in the Intensive Care Unit/**J.P. Stevens, S.D. Roche, N. Demosthenes, K. O'Reilly, M. Cocchi, M.D. Howell, B. Landon, Boston, MA, p.A4354

203 **A Quality Improvement Project to Implement Validated Alcohol Screening in the Medical Intensive Care Unit/**J. Williams, A. Thomson, A.R. Hassell, E.L. Burnham, M. Moss, B. Clark, Denver, CO, p.A4355

204 **A Continuous Protocolized Educational Intervention Optimizes the Utilization of Arterial Blood Gases and Decreases Their Associated Costs in the ICU/**C. Martinez-Balzano, P. Oliveira, M. O'Rourke, L. Hills, A. Sosa, Worcester, MA, p.A4356

205 **Awakening and Breathing Coordination, Delirium Monitoring/Management and Early Mobilization (ABCDE) Bundle Reduces Hospital Costs/**O.T. Otusanya, S.J. Hsieh, M.N. Gong, H.B. Gershengorn, Bronx, NY, p.A4357

206 **Linked Do-Not-Resuscitate (DNR) and Do-Not-Intubate (DNI) Orders and Factors Associated with DNI Orders: A Retrospective Chart Review at an Urban Tertiary Care Center/**S. Stream, A. Nolan, S. Kwon, C. Constable, New York, NY, p.A4358

207 **A Multidisciplinary Initiative to Reduce Alarm Fatigue from Unnecessary Pulse Oximetry Alarms/**A.R. Stephens, J. Piepenbrink, D. Whalen, K.A. Sloan, Boston, MA, p.A4359

208 **Sepsis Now a Priority: A Quality Improvement Initiative for Early Sepsis Recognition and Care/**C.M. McDonald, S. West, C. Soong, D. Dushenski, S.E. Lapinsky, M. Ashby, K. Van Den Broek, G. Wilde-Friel, C. Kan, M. McIntyre, A.M. Morris, Toronto, Canada, p.A4360

209 **Application of Interventions that Maximize Compliance with Patient Care Checklists in the Academic Intensive Care Unit Setting/**J. Caraballo, A. Pezzulo, Iowa City, IA, p.A4361

210 **Bi-Level Non-Invasive Ventilation for Acute Respiratory Failure: A Quality Improvement Review of Local Health Region Practice and Management/**J.C.D. Hasmatali, K. Whittemore, D. Marciniuk, Saskatoon, Canada, p.A4362

211 **Improving Patient and Physician Comfort with Code Status/**S.L. Rhoads, A. Charles, Providence, RI, p.A4363

212 **Are We Calling Palliative Care On Time? A Retrospective Study of Advanced Stage Non Small Cell Lung Cancer, Pancreatic and Colon Cancer at an Academic Hospital/**M. Kang, N. Duma, S. Kothadia, K. Patel, M. Gonzalez Velez, B.L. Gladney, C.C. Ezeonu, H. Kim, M. Gutierrez, Newark, NJ, p.A4364

213 **Identification of Targets to Improve 30-Day Returns to Emergency Department and Inpatient Care Among Thoracotomy Procedure Patients/**R. Shaffer, C.Y. Tsai, L. Backhus, C. Curtin, T. Hernandez-Boussard, Stanford, CA, p.A4365

214 **Implementation of Ontario's Emergency Department Asthma Care Pathway: Determinants of Uptake/**C. Kwok, L. Levesque, G. Liu, J. Olajos-Clow, C. Madeley, S. Athron, G. Styling, T. To, M.D. Lougheed, Kingston, Canada, p.A4366

215 **Pilot Data from a Comprehensive Respiratory Therapist Driven COPD Care Management Program/**R.A. Mularski, G. Callison, B. Wartell, M. Wackford, S. Sobiesczyk, W.R. Hu, S. Mikkelsen, J.A. Rettmann, H.E. Vanni, D.M. Mosen, Portland, OR, p.A4367

216 **Evaluation and Documentation of Oxygen Requirements in Patients Hospitalized with COPD: Time for Oxygen Reconciliation?/**F. Zaidi, B.A. Buchcic, V. Prieto-Centurion, N.I. Ramey, N.E. Bracken, J.A. Krishnan, Chicago, IL, p.A4368

217 **Cystic Fibrosis Patients Benefit from CF Legal Hotline/**B. Sufian, J. Passamano, A. Sopchak, Houston, TX, p.A4369

218 **No Pain! Great Gain!! Improving Pain Management at Howard University Hospital/**J.I. Obi, A. Mehari, A. Deonarine, Alexandria, DC, p.A4370

219 **Pneumococcal Vaccination in a Cancer Center/**A.J. Larson, K. MacKenney, C. Jimenez, E. Ariza-Heredia, A. Knox, V. Murphy, D. Balachandran, D.E. Ost, N. Immanivong, V.R. Shannon, H.B. Grosu, G.A. Eapen, S.A. Faiz, L. Bashoura, Houston, TX, p.A4371

220 **Quality Improvement in a Fellows Clinic: Implementation of a Patient Centered Inhaler Education Program/**A.G. Cole, P. Lenz, Cincinnati, OH, p.A4372

221 **Pre-Discharge Airway Evaluation in Tracheostomy-Dependent Children: A Quality Improvement Safety Initiative/**J.J. Soares, A. Striegl, K. Johnson, S. Parikh, L. Elder, T. Ong, Seattle, WA, p.A4373

222 **Influence of 'Out of Network' Pulmonary Hypertension Care and VA Pharmacy Consultation on Potentially Inappropriate Prescribing of Phosphodiesterase-5-Inhibitors in the VA/**M.R. Freiman, A.J. Rose, D. Miller, R.S. Wiener, Boston, MA, p.A4374

223 **Could Current Methods of Sputum Analysis Be Improved in Non-CF Bronchiectasis? A Health Service Review/**M.A. Dimitrov, J. Salgado, L. Turnbull, J. Pungur, J. Yeyha, M. Kattar, W. Leung, G. Tyrrell, D. Vethanayagam, Edmonton, Canada, p.A4375

224 **Importance of Rapid Diagnostic Tests in the Management of Uncomplicated Malaria Among Under-Five Children in a Semi-Urban Hospital in Nigeria/**B.I. Awokola, G.A. Amusa, E.A. Abioye-Kuteyi, S.B.A. Oseni, C.A. Fayomi, I.S. Bello, A.O. Fadugbagbe, O.O. Ajayi, O.P. Ilesanmi, E.O. Awokola, Warri, Nigeria, p.A4376

225 **Low Lung Function and Lung Transplant Referral for Cystic Fibrosis/**K.J. Ramos, B. Quon, E.D. Lease, M.L. Aitken, C.H. Goss, Seattle, WA, p.A7853

POSTER DISCUSSION SESSION

B103 ADVANCES IN DIAGNOSTIC BRONCHOSCOPY

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 309 (South Building, Esplanade Level)

Poster Viewing **2:15-3:00**

Discussion **3:00-4:15**

Chairing: A.C. Mehta, MBBS, Cleveland, OH
M.M. Wahidi, MD, Durham, NC
S. Shojaee, MD, Richmond, VA

301 **A Clinical Prediction Model of Malignant N2 or Higher Disease by Endobronchial Ultrasound Guided Transbronchial Needle Aspiration in Non-Small Cell Lung Cancer Staging/**O.J. O'Connell, R. Lazarus, T. Saettele, M. Rodriguez Vial, L. Noor, X.B. Tian, H. Grosu, R. Morice, C. Jimenez, G. Eapen, D. Ost, Houston, TX, p.A4377

302 **Endobronchial Ultrasound (EBUS) Taken to the Next Level: EBUS Guided Mediastinal Lymph Node Forceps Biopsy (EBFB)- A Novel Technique/**R.M. Mehta, R.K. Aurangabadwalla, C.L. Gowda, Bangalore, India, p.A4378

303 **Transbronchial Cryobiopsy in Diffuse Parenchymal Lung Disease: Retrospective Analysis of 75 Cases/**K. Ussavarungsi, J.H. Ryu, E.S. Edell, Rochester, MN, p.A4379

304 **Computer Tomography Guided Lung Biopsy Using Interactive Breath-Hold Control: A Randomized Study/**H. Ashraf, S. Krag-Andersen, M. Naqibullah, V. Minddal, A. Norgaard, T.M.H. Naur, P.S. Myschetzky, P.F. Clementsen, Hellerup, Denmark, p.A4380

305 **Ultrasound-Guided Percutaneous Biopsy Performed in the Outpatient Pulmonary Clinic: An Opportunity to Expedite and Improve the Diagnosis and Staging of Thoracic Malignancies/**W. Warren, R. Browning, J. Nations, S.C. Parrish, Bethesda, MD, p.A4381

306 **System for Multimodal Image-Guided Endobronchial Ultrasound: Human Pilot Study/**W.E. Higgins, X. Zang, R. Cheirsilp, P. Byrnes, T. Kuhlengel, J. Toth, R. Bascom, University Park, PA, p.A4382

307 **PET/CT Image Registration for Multimodal Bronchoscopic Procedure Planning and Guidance/**W.E. Higgins, R. Cheirsilp, X. Zang, P. Byrnes, T. Kuhlengel, T. Allen, J. Toth, R. Bascom, University Park, PA, p.A4383

308 **Does Endobronchial Ultrasound Guided Transbronchial Needle Aspiration of Mediastinal Lymph Nodes Contribute to False Positive Findings on PET-CT Imaging?/**J.M. Ramsahai, M.S. Rose, C. Molnar, A.C. Chee, P. MacEachern, C.A. Hergott, E. Dumoulin, N. Strilchuk, M. Fortin, N. Taghizadeh, A. Tremblay, Calgary, Canada, p.A4384

309 **The Addition of Endobronchial Ultrasound-Guided Core Needle Biopsy (EBUS-CNB) to Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration (EBUS-TBNA) Increases Diagnostic Yield/**T.R. Leclair, G. Garrison, H. Nsour, K. Butnor, S. Anderson, C.M. Kinsey, Burlington, VT, p.A4385

310 **Improved Diagnostic Yield of Bronchoscopy in Peripheral Pulmonary Lesions: Combination of Radial Probe EBUS and Rapid On-Site Evaluation/**W.-C. Cheng, C.-H. Chen, B.-R. Wu, C.-Y. Chen, W.-C. Chen, W.-C. Liao, C.-Y. Tu, Taichung, Taiwan, p.A4386

311 **Granulomatous Inflammation Found by Endobronchial Ultrasound Transbronchial Needle Aspiration (EBUS-TBNA) in Patients with Malignancy - A Quaternary Referral Centre Experience/**A. Fon, A. Baumann, H. Jersmann, P. Robinson, P. Nguyen, Adelaide, Australia, p.A4387

312 **Utility of Probe Based Confocal Laser Endomicroscopy to Aid in Transbronchial Cryobiospy for Diagnosis of Diffuse Interstitial Lung Diseases/**K. Trivedi, A. Wellikoff, R.C. Holladay, Shreveport, LA, p.A4388

313 **Transbronchial Cryobiopsy for Diagnosis of Diffuse Interstitial Lung Diseases: Experience at the Louisiana State University (Shreveport) Hospital/**K. Trivedi, A. Wellikoff, R.C. Holladay, Shreveport, LA, p.A4389

314 **Transbronchial Cryobiopsies: Are They the Future of Bronchoscopic Lung Biopsies?/**N. Al Nasrallah, K. Diab, Indianapolis, IN, p.A4390

315 **EBUS-TBNA in a Community Hospital: Does Formal Fellowship Training Improve Diagnostic Yield?/**R. Gamarallage, T. Chandak, C. Joseph, Pittsfield, MA, p.A4391

316 **Interobserver Variability of Sonographic Features of Mediastinal Lymph Nodes by EBUS: Need for Qualitative or Quantitative Measurements?/**N. Ozcelik, Y. Abul, Y. Bulbul, I. Eyuboglu, S. Ozsu, F. Oztuna, T. Ozlu, Trabzon, Turkey, p.A4392

317 **Sensitivity of Different Sampling Modalities with Electromagnetic Navigational Bronchoscopy and Effect of Radial EBUS on Yield/**D. Sharma, C. Bellinger, Winston Salem, NC, p.A4393

318 **Diagnostic Utility of Conventional Transbronchial Needle Aspiration for Evaluation of Lung Cancer Staging and Diagnosis/**B. Yaghmour, S. Giri, N. Tashtish, M. Zaman, Los Angeles, CA, p.A4394

319 **The Effect of Obtaining Positron Emission Tomography Scan Prior to the Endobronchial Ultrasound Guided Transbronchial Needle Aspiration on Its Diagnostic Yield/**M.R. Mourad, E. Reda, L. Satterwhite, L.R. Pitts, F.R. Quijano, K.R. Brownback, Kansas City, KS, p.A4395

320 **Sensitivity and Specificity of Endobronchial Ultrasound with Transbronchial Needle Aspiration in Suspected Non-Malignant Lymphadenopathy/**L. Eickhoff, H. Suhling, T. Welte, J. Gottlieb, T. Fuehner, Hannover, Germany, p.A4396

321 **The Effect of Body Mass Index on the Diagnostic Yield of Endobronchial Ultrasound Guided Transbronchial Needle Aspiration of Hilar-Mediastinal Lymphadenopathy and Masses/**A. Andoh-Duku, J.L. Breeze, P. Lacamera, S. Rafeq, M. Agustin, Boston, MA, p.A4397

322 **Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration for Nodal Staging in Non-Small Cell Lung Carcinoma (NSCLC)/**D. Coutinho, A. Oliveira, S. Campainha, S. Neves, J. Miranda, A. Furtado, D. Tente, A. Sanches, J. Almeida, J. Moura E Sa, Vila Nova de Gaia, Portugal, p.A4398

323 **EBUS TBNA - A Feasible, Efficacious and Safe Procedure at Non-Tertiary Regional Health Centres/**T.M. Baird, M. Bint, S. Erigadoo, M. Putt, C. Wright, Nambour, Australia, p.A4399

324 **Endobronchial Ultrasound and Transbronchial Needle Aspiration EBUS-TBNA: Experience in Fundacion Valle del Lili, a University Hospital of Reference in Latin America/**L. Fernandez, L.F. Sua, M. Velasquez, C.A. Munoz, Cali, Colombia, p.A4400

325 **CT Guided Core Biopsy of Pulmonary Nodules: Safety and Efficacy When Performed by Pulmonologists/**G. Trikha, S.M. Eckardt, Syracuse, NY, p.A4401

POSTER DISCUSSION SESSION

B104 RESPIRATORY FAILURE: LUNG REGIONAL AND TRANSLATIONAL MECHANISMS IN ARDS

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**
Room 3001 (West Building, Level 3)

Poster Viewing **2:15-3:00**

Discussion **3:00-4:15**

Chairing: J.H.T. Bates, DSc, PhD, Burlington, VT
J.A. Bastarache, MD, Nashville, TN

701 **Heterogeneity in Regional Gene Expression in a 24-Hour Sheep Model of Mild Septic ARDS/**S. Hashimoto, L.F.S.C. Paula, T. Winkler, A.S. Oviedo, L. Le, J. Brandao, G. Musch, R.M. Baron, M.F. Vidal Melo, Boston, MA, p.A4402

702 **Functional Analysis of Regionally Differentially Expressed Genes in a Sheep Model of Lung Injury Due to Endotoxemia and Mechanical Ventilation/**M.A. Lessa, T. Wellman, N. De Prost, M.R. Tucci, T. Winkler, G. Musch, J.H. Chung, R.M. Baron, B.A. Raby, M. Vidal-Melo, Boston, MA, p.A4403

703 **Differentially Expressed MicroRNAs in ARDS Target Genes Associated with the Disease/**A.J. Goodwin, C. Wilson, L. Felton, C. Guo, J. Buie, L.M. Schnapp, P.V. Halushka, J.A. Cook, H. Fan, Charleston, SC, p.A4404

704 **Using RNA-Seq Profiling to Identify Biomarkers for the Acute Respiratory Distress Syndrome (ARDS)/**C. Molnar, L. Schultz, Z. Ma, J.R. Broach, J.A. Howrylak, Hershey, PA, p.A4405

705 **Gene Expression Changes in Response to Lung Injury Reveal Importance of the ERK Pathway in Human and Animal Models of ARDS/**T.E. Sweeney, S. Lofgren, P. Khatri, A.J. Rogers, Stanford, CA, p.A4406

706 **High-Resolution Metabolomics Reveals Distinct Pathways in Septic Patients that Developed Acute Respiratory Distress Syndrome/**K. Uppal, V. Tran, D. Jones, S. Li, A.M. Esper, Atlanta, GA, p.A4407

707 **Regional Pulmonary Metabolic Activation in the First 24h of Lung Injury Due to Mild Endotoxemia and Mechanical Ventilation/**G.C. Motta Ribeiro, S. Hashimoto, T. Winkler, K. Grogg, L.F.S.C. Paula, A.S. Oviedo, J. Brandao, M. Vidal-Melo, Rio de Janeiro, Brazil, p.A4408

708 **Simultaneous Measurement of pH and Metabolism in Injured Rat Lungs Using Hyperpolarized 13Carbon MRI/**N. Drachman, S. Kadlecek, M. Pourfathi, Y. Xin, H. Profka, R.R. Rizi, Philadelphia, PA, p.A4409

709 **Distribution of Regional Lung Perfusion in Experimental ARDS: A Comparison Between Ex-Vivo Fluorescence-Labeled and In-Vivo Radionuclide-Labeled Microspheres Measurements/**A. Braune, T. Bluth, T. Kiss, A. Gueldner, M. Andreeff, J. Kotzerke, M.G.D. Abreu, Dresden, Germany, p.A4410

710 **Parametric Response Mapping for the Analysis of Regional Inflation in the Prone Position/**M. Cereda, Y. Xin, N. Meeder, J. Zeng, A. Rodriguez, H. Staroba, Q. Bey, H. Profka, S. Kadlecek, B.P. Kavanagh, J. Wu, J.C. Gee, R.R. Rizi, Philadelphia, PA, p.A4411

711 **Imaging the Progression of Ventilator Induced Lung Injury/**Y. Xin, M. Cereda, H. Hamedani, J. Wu, J. Clapp, S. Kadlecek, J. Zeng, N. Meeder, H. Staroba, A. Rodriguez, Q. Bey, H. Profka, B.P. Kavanagh, J.C. Gee, R.R. Rizi, Philadelphia, PA, p.A4412

712 **The Spatial Heterogeneity of Acute Lung Injury Strongly Affects Drug Delivery to Damaged Alveoli/**J.S. Brenner, D. Jiang, K. Bhamidipati, E. Hood, V.R. Muzykantov, Philadelphia, PA, p.A4413

713 **Hyaluronic Acid Levels of Plasma and Bronchoalveolar Lavage Fluid Are Associated with Severity of Organ Dysfunction in Acute Respiratory Distress Syndrome/**A.J. Esposito, C. Mikacenic, N. Jones, P.L. Bollyky, R.D. Stapleton, M.M. Wurfel, Seattle, WA, p.A4414

714 **Time Course of Increased Secretory Phospholipase Group IIA in Human ARDS from Pneumonia or Aspiration/**M.V. Novotny, A. Chakrabarti, M.C. Seeds, C. Ruppert, J. Wagner, A. Guenther, R.D. Hite, Cleveland, OH, p.A4415

715 **Angiotensin Levels in Acute Respiratory Distress Syndrome Correlate with Clinical Outcomes: A Pilot Study/**R. Reddy, A. Baydur, S. Liu, S. Louie, K. Rodgers, Los Angeles, CA, p.A4416

716 **Circulating Nucleosomes Discriminate Mortality in Pediatric Acute Respiratory Distress Syndrome/**N. Yehya, N.J. Thomas, S.S. Margulies, Philadelphia, PA, p.A4417

717 **Biomarkers of Endothelial and Epithelial Dysfunction in Adult and Pediatric Acute Respiratory Distress Syndrome/**N. Yehya, T. Dolinay, N.J. Thomas, J.A. Howrylak, S.S. Margulies, Philadelphia, PA, p.A4418

718 **Oxylipin Profiling in the Acute Respiratory Distress Syndrome/**N. Larsson, S. Gouveia-Figueira, J. Claesson, S. Lehtipalo, A.F. Behndig, J. Tyden, J. Johansson, R. Pinto, M.L. Nording, Umea, Sweden, p.A4419

719 **Inhibition of Phospholipase-Mediated Phoshatidylglycerol Depletion and Replacement of Surfactant Improve Surfactant Function in a Murine ARDS Model/**R.D. Hite, A. Chakrabarti, M.V. Novotny, M. Waite, M.C. Seeds, Cleveland, OH, p.A4420

720 **Transpulmonary Pressure Based on Absolute Esophageal Pressure Measurement Predicts Morphological Changes of Lung Parenchyma in an Experimental Animal Model/**J. Fumagalli, C. Zhang, V. Torsani, M. Pirrone, S. Gomez, S.R.R. De Santis, M.R. Tucci, O.P. Ramos, C. Lima, G. Bento, L. Berra, R. Kacmarek, M.B.P. Amato, Boston, MA, p.A4421

721 **Net Alveolar Fluid Clearance Is Associated with Phenotypes of Lung Morphology in Acute Respiratory Distress Syndrome/**R. Blondonnet, J. Lutz, L. Roszyk, D. Bouvier, R. Guerin, S. Perbet, S. Cayot, T. Godet, L. Blanchon, J.-E. Bazin, E. Futier, V. Sapin, J.-M. Constantin, M. Jabaudon, Clermont-Ferrand, France, p.A4422

722 **Lung Inflammation in ARDS and Heart Failure is Not Related to the Degree of Regional Strain/**K.A. Hibbert, T. Winkler, L.F. Cruz, V.J. Kelly, C.A. Holland, K.L. Brait, J.G. Venegas, M. Vidal-Melo, R.S. Harris, E.K. Bajwa, Boston, MA, p.A4423

723 **Non-Invasive Assessment of Regional Respiratory Airflow in Acute Respiratory Failure Patients/**T. Mauri, C. Turrini, N. Eronia, B. Cambiaghi, G. Grasselli, P. Tagliabue, T. Sasso, G. Bellani, L. Gattinoni, A. Pesenti, Milan, Italy, p.A4424

724 **Cell Therapy for the Treatment of Acute Lung Injury: Alveolar type II Cells or Mesenchymal Stem Cells?/**R. Guillamat-Prats, M. Camprubi-Rimblas, F. Puig, R. Herrero, A. Serrano-Mollar, J. Tijero, M.N. Gomez, L. Blanch, A. Artigas, Sabadell, Spain, p.A4425

725 **The Composition of the Oral, Lung and Gut Microbiome in Adult Critically Ill Patients with or at Risk for the Acute Respiratory Distress Syndrome/**G.D. Kitsios, A. Fitch, S. Rapport, M.J. Morowitz, A.M. Morris, B.J. McVerry, Pittsburgh, PA, p.A4426

POSTER DISCUSSION SESSION

B105 COPD: EPIDEMIOLOGY AND GENETICS

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 133 (North Building, Lower Level)

Poster Viewing **2:15-3:00**

Discussion **3:00-4:15**

Chairing: C.P. Hersh, MD, MPH, Boston, MA
I. Pavord, MD, Oxford, United Kingdom
M.C. McCormack, MD, MHS, Baltimore, MD

101 **Identification of Novel Genes Related to Two Definitions of Airway Obstruction in Never-Smokers/**D.A. Van Der Plaat, K. De Jong, A. Faiz, J.M. Vonk, C.C. Van Diemen, I. Nedeljkovic, N. Amin, C.A. Brandsma, Y. Bosse, D.D. Sin, D.C. Nickle, C.M. Van Duijn, D.S. Postma, H.M. Boezen, Groningen, Netherlands, p.A4427

102 **Identification of Novel Genes Related to Obstruction of the Small Airways in Adult Never-Smokers/**D.A. Van Der Plaat, K. De Jong, A. Faiz, J.M. Vonk, C.C. Van Diemen, I. Nedeljkovic, N. Amin, C.A. Brandsma, Y. Bosse, D.D. Sin, D.C. Nickle, C.M. Van Duijn, H.M. Boezen, D.S. Postma, Groningen, Netherlands, p.A4428

103 **Variants in the Nicotine Acetylcholine Receptor (CHRNA 3/5) Locus May Play a Role in COPD Development Via Smoking Status/**D.A. Van Der Plaat, K. De Jong, J.M. Vonk, C.C. Van Diemen, I. Nedeljkovic, N. Amin, C.M. Van Duijn, D.S. Postma, H.M. Boezen, Groningen, Netherlands, p.A4429

104 **Genome-Wide Association Analysis of Pulmonary Disease Factors Reveals Different Genetic Variation for Emphysema and Airway Disease/**K.A. Young, G.L. Kinney, M.H. Cho, P.J. Castaldi, T.H. Beaty, J.D. Crapo, E.K. Silverman, J. Hokanson, S.M. Lutz, Aurora, CO, p.A4430

105 **Genome-Wide Association Identifies rs28929474 (Glu342Lys) in SERPINA1 Associated with Post-Bronchodilator FEV1/FVC and Percent Predicted FEV1 in SPIROMICS/**X. Li, V.E. Ortega, E.J. Ampleford, R.G. Barr, D.J. Couper, M.K. Han, E.A. Hoffman, R. Kanner, E. Kleerup, F.J. Martinez, P.G. Woodruff, G.A. Hawkins, E.R. Bleecker, D.A. Meyers, Winston-Salem, NC, p.A4431

106 **Association of CHRNA3 and CYP26A with Pulmonary Function Is Partially Mediated by Smoking/**S.M. Lutz, M.H. Cho, G.L. Kinney, K.A. Young, T. Fingerlin, C. Lange, T.H. Beaty, E.K. Silverman, J. Hokanson, Denver, CO, p.A4432

107 **Rare SERPINA1 Variants in the Multi-Ethnic SPIROMICS Population/**V.E. Ortega, X. Li, W.K. O'Neal, E.J. Pennington, R.G. Barr, D.J. Couper, M.K. Han, R. Kanner, E. Kleerup, F.J. Martinez, S.P. Peters, MD, PhD, S.I. Rennard, P.G. Woodruff, E.A. Hoffman, D.A. Meyers, E.R. Bleecker, Winston-Salem, NC, p.A4433

108 **TLR4 Asp2999Gly (rs4986790) Is Associated with Chronic Bronchitis and Decreased LPS-Induced IL-6 Production in Agricultural Workers/**L.A. Weissenburger-Moser, L. Smith, A.J. Heires, K.M. Kelly, J.A. Merchant, J. Meza, D.J. Romberger, T.D. LeVan, Omaha, NE, p.A4434

109 **RGS6 Contribution to Chronic Obstructive Pulmonary Disease and Lung Cancer/**J. She, L. Zhu, C. Bai, P. Yang, Shanghai, China, p.A4435

110 **Epigenome-Wide Association Study in Blood DNA from a Cohort of Chronic Obstructive Pulmonary Disease/**W.J. Kim, J. Park, H.-K. Koo, Chuncheon, Korea, Republic of, p.A4436

111 **Genome-Wide Pathway Analysis of Chronic Bronchitis in the Framingham Heart Study/**S.-Y. Liao, D.C. Christiani, Riverside, CA, p.A4437

112 **Interaction of CD14 Haplotypes and Soluble CD14 on Pulmonary Function in Agricultural Workers/**T.D. LeVan, L. Smith, A.J. Heires, J. Meza, L.A. Weissenburger-Moser, D.J. Romberger, Omaha, NE, p.A4438

113 **COPD Subtype Identification in the International COPD Genetics Consortium: Collaborative Subtyping Results Across Ten Cohorts/**P.J. Castaldi, M. Benet-Mora, H. Petersen, M. Preethi Boorgula, J. Finigan, M. Paoletti, M. Boezen, J.M. Vonk, R.P. Bowler, A. Agusti, M. Pistolesi, M.A. Puhan, G. Ter Riet, E. Wauters, J. Anto, M.H. Cho, C.P. Hersh, K. Barnes, S.I. Rennard, N. Rafaels, J.D. Crapo, Y. Tesfaigzi, E.K. Silverman, J. Garcia-Aymerich, Boston, MA, p.A4439

114 **TH17 Cytokine Expression Within the First 6 Months Post WTC Exposure Is Associated with Accelerated FEV1 Decline Over the Subsequent 13 Years/**J. Weakley, C.B. Hall, R. Zeig-Owens, T. Schwartz, M.P. Webber, M. Vossbrinck, H.W. Cohen, T.K. Aldrich, A. Nolan, D.J. Prezant, M.D. Weiden, Brooklyn, NY, p.A4440

115 **Validation of Metabolic Syndrome Biomarkers of Particulate Induced Lung Injury in World Trade Center Exposed Firefighters/** S. Kwon, E.J. Caraher, S.H. Haider, T. Schwartz, R. Zeig-Owens, M.P. Webber, D. Prezant, A. Nolan, New York, NY, p.A4441

116 **Traffic Related Particulate Matter and Elevated CRP in COPD/**E. Garshick, S. Grady, J.E. Hart, M.L. Moy, B. Coull, J. Schwartz, F. Laden, P. Koutrakis, West Roxbury, MA, p.A4442

117 **Smoking Duration Alone Predicts Emphysema and Lung Function Better than Pack-Years/**S.P. Bhatt, Y.-I. Kim, K.F. Harrington, J.M. Wells, J.E. Hokanson, S.M. Lutz, M.H. Cho, D.L. DeMeo, B.J. Make, S.I. Rennard, D.P. Tashkin, R.A. Wise, M.T. Dransfield, W.C. Bailey, Birmingham, AL, p.A4443

118 **A Population Based Assessment of Asthma and the Asthma Chronic Obstructive Pulmonary Disease Overlap Syndrome (ACOS): A Canadian Perspective/**R. Nantel-Smith, R. Olivenstein, J.G. Martin, J.M. FitzGerald, W.C. Tan, S.D. Aaron, J. Road, D.E. O'Donnell, F. Maltais, P. Hernandez, R. Cowie, K.R. Chapman, D. Marciniuk, J. Bourbeau, Montreal, Canada, p.A4444

119 **Inflammatory Bowel Disease and Risk of Mortality in Chronic Obstructive Pulmonary Disease (COPD) and Asthma-COPD Overlap Syndrome (ACOS)/**P. Brassard, M. Vutcovici, P. Ernst, A. Kezouh, S. Suissa, A. Bitton, Montreal, Canada, p.A4445

120 **Associations Between Household Air Pollution and Cardiopulmonary Outcomes May Differ by Type of Pollutant/**B. Wills, E. Klasen, N. Naithani, R.H. Gilman, J.M. Tielsch, M. Chiang, S. Khatry, P. N Breysse, D. Menya, C. Apaka, J. Carter, C. B Sherman, W. Checkley, Baltimore, MD, p.A4447

121 **Gender Differences by Age In Symptoms, Airflow Limitation, Exacerbation Risk and GOLD Combined Assessment Among Subjects with COPD in COPDGene Cohort/**D.L. DeMeo, M.K. Han, E.A. Regan, A. Yadao, A. Kavati, A. Vegesna, D. Keininger, T.K. Wilcox, S. Ramagopalan, M. Pereira, B.J. Make, Boston, MA, p.A4448

122 **Reproductive and Hormone-Related Factors Are Associated with Lower Lung Function in COPDGene/**D.L. DeMeo, M.G. Foreman, E.A. Regan, S.P. Bhatt, M.K. Han, J. Hokanson, J.D. Crapo, E.K. Silverman, B.J. Make, Boston, MA, p.A4449

123 **Morbidity, Mortality and Lung Function in 14 Extracellular Superoxide Dismutase R213G Homozygotes Among 95,873 Individuals from the General Population/**C.J. Kobylecki, S. Afzal, B. Nordestgaard, Herlev, Denmark, p.A4450

124 **Circulating Biomarkers of Smoking and Lung Function Deficits/**M.M. Vasquez, M. Zhou, M. Imboden, D. Keidel, M.W. Gerbase, N.M. Probst-Hensch, D.L. Sherrill, F.D. Martinez, M. Halonen, S. Guerra, Tucson, AZ, p.A7854

POSTER DISCUSSION SESSION

B106 CELLULAR/MOLECULAR MECHANISMS AND TRANSLATIONAL ASPECTS OF RESPIRATORY TRACT INFECTIONS

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 3014 (West Building, Level 3)

Poster Viewing **2:15-3:00**

Discussion **3:00-4:15**

Chairing: J.P. Mizgerd, ScD, Boston, MA
D.J. Marchant, PhD, Edmonton, Canada
S. Awasthi, PhD, Oklahoma City, OK

901 **Peroxisome Proliferator-Activated Receptor Gamma Activation Attenuates Alcohol-Induced Alveolar Macrophage Mitochondrial Derangements and Phagocytic Dysfunction via miR-92a/b Up-Regulation/**S.M. Yeligar, F.L. Harris, L.A.S. Brown, C.M. Hart, Decatur, GA, p.A4451

902 **Next Generation Sequencing of Respiratory Fluids Accurately Distinguishes Bacterial from Viral Lower Respiratory Tract Infection by Both Microbial and Host Transcriptional Profiling/**C. Langelier, S. Christenson, B. O'Donovan, S. Nerella, M.K. Sontag, K. Harris, P.M. Mourani, J. DeRisi, San Francisco, CA, p.A4452

903 **Use of Bronchoalveolar Lavage Fluid as Culture Medium: Bacterial Growth is Enhanced in Lavage Fluid Acquired from Patients with Advanced Lung Disease/**D.G. Dunlap, N. Falkowski, E. Hunter, J.R. Erb-Downward, N. Walker, V. Lama, G.B. Huffnagle, R.P. Dickson, Ann Arbor, MI, p.A4453

904 **Synergistic Toll-Like Receptor Signaling-Induced Resistance Protects Mice Against Pneumonia in the Presence of Acute Leukemia and Cytotoxic Chemotherapy/**M.M. Leiva-Juarez, H.H. Ware, V.V. Kulkarni, C.T. Kirkpatrick, Y. Wang, S.E. Evans, Houston, TX, p.A4454

905 **The Role of Pellino-1 in Modulating Signalling Pathways Controlling the Inflammatory Response to Viral Stimuli in Airway Epithelial Cells/**E.K. Marsh, E.C. Prestwich, H.M. Marriott, C. Paiva, J.A. Bennett, M.R. Jonker, W. Timens, I.H. Heijink, L.C. Parker, D.H. Dockrell, I. Sabroe, Sheffield, United Kingdom, p.A4455

906 **Lung Epithelial Cell Mitochondrial Reactive Oxygen Species Are Required for Antiviral Resistance Induced by Synergistic Toll-Like Receptor Signaling/**C.T. Kirkpatrick, Y. Wang, V.V. Kulkarni, H.H. Ware, A.K. Plumer, M.M. Leiva-Juarez, S.E. Evans, Houston, TX, p.A4456

907 **The Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Exhibits Bilateral Entry and Exclusively Apical Egress in Well-Differentiated Human Airway Epithelial Cells/**K. Li, C.L. Wohlford-Lenane, P.B. McCray, Iowa City, IA, p.A4457

908 **Mouse Models to Study Middle East Respiratory Syndrome Disease Pathogenesis and Treatment/**C.L. Wohlford-Lenane, K. Li, D.K. Meyerholz, S. Perlman, P.B. McCray, Iowa City, IA, p.A4458

909 **RIPK3 Regulates Type I IFN Mediated Immunity to Pulmonary Influenza A Virus Infection/**J. Downey, E. Pernet, F. Coulombe, B. Allard, J. Jaworska, S. Qureshi, J.G. Martin, P. Joubert, M. Divangahi, Montreal, Canada, p.A4459

910 **Influenza A Infection Is Exacerbated in a Mouse Model of Lung-Specific Transforming Growth Factor-A? Over-Expression/**B.J. Thomas, K. Kan-o, M. Tate, A. Mansell, J.A. Elias, P.G. Bardin, Clayton, Australia, p.A4460

911 **Severity of Type II Cell Depletion Influences the Recruitment of Krt5+ Epithelial Cells Following Influenza A Virus Infection/**M. Yee, W. Domm, R.M. Kottmann, P.J. Sime, M. O'Reilly, Rochester, NY, p.A4461

912 **Interferons Suppress IL-1ß Dependent GM-CSF in Post-Influenza Pneumococcal Infection of Human Lungs/**K. Zscheppang, J. Berg, D. Fatykhova, M. Tonnies, T. Bauer, P. Schneider, J. Neudecker, J. Ruckert, S. Eggeling, M. Schimek, A. Gruber, N. Suttorp, S. Hippenstiel, A. Hocke, Berlin, Germany, p.A4462

913 **Characterisation of the Neutrophil in Respiratory Syncytial Virus Bronchiolitis/**G.L. Saint, R. Smyth, B.F. Flanagan, P.S. McNamara, Liverpool, United Kingdom, p.A4463

914 **Host Gene Expression Patterns Distinguish Disease Severity in Respiratory Syncytial Virus Infected Infants/**C.-Y. Chu, X. Qiu, L. Wang, S. Bhattacharya, C. Slaunwhite, B. Tesini, D. Francis, J. McGrath, G. Lofthus, A. Murphy, M.A. Formica, L. Denmark, K. Schnabel, L. Shelley, J. Carnahan, A. Corbett, J. Holden-Wiltse, D. Topham, A. Falsey, M. Caserta, T.J. Mariani, E. Walsh, Rochester, NY, p.A4464

915 **Respiratory Syncytial Virus Recruits Its Receptor, Nucleolin, to the Cell Surface Prior to Viral Fusion and Mediates Viral Entry by Toll-Like Receptor-4 Signaling/**C. Griffiths, L. Bilawchuk, L. Jensen, D.J. Marchant, Edmonton, Canada, p.A4465

916 **RSV Pulmonary Infection Induces Human Anti-RSV Immune Responses and Pathology in Humanized Mice/**A. Sharma, B. Sung, W. Wu, J. Huang, T. Tsao, X. Li, R. Gomi, M. Tsuji, S. Worgall, New York, NY, p.A4466

917 **Targeting Intracellular Potassium for the Control of Respiratory Syncytial Virus/**T. Moraes, W. Duan, M. Malhi, J. Maynes, M.J. Norris, Toronto, Canada, p.A4467

918 **Enterovirus D68 Lower Respiratory Tract Infection Causes Elevated Airway Hyperreactivity in Fischer-344 Rats/**P.M. Brown, T.J. Harford, A. Belkadi, V. Agrawal, F. Rezaee, G. Piedimonte, Cleveland, OH, p.A4468

919 **Dendritic Cell-Mediated Lung Injury in Response to Aspergillus in Chronic Granulomatous Disease: Protective Role of Neutrophil-Derived Reactive Oxygen Species/**R.E. Cagnina, K.R. Michels, A. Bettina, Z. Zhang, M. Burdick, B. Mehrad, Charlottesville, VA, p.A4469

920 **Inter-Relationships Between Regulatory T Cells, Effector T Cells, the PD-1 Signaling Pathway, and Immunomodulatory Lung Dendritic Cells in Mice with Persistent Cryptococcal Lung Infection/**J.A. Roussey, S. Teitz-Tennenbaum, M.A. Olszewski, J.J. Osterholzer, Ann Arbor, MI, p.A4470

921 **Inhaled Corticosteroids Alter Pathogenicity Profile of Airway Pathogens Pseudomonas Aeruginosa and Staphylococcus Aureus/**J. Joshua, A. Vyas, L.E. Crotty Alexander, San Diego, CA, p.A4471

922 **IFITM3 Regulatory SNP Increases Severe Human Influenza Risk by Shifting Transcription Factor Occupancy/**E.K. Allen, T. Bhangale, P. Dogra, M. Ohlson, C. Oshansky, D. Finkelstein, B. Youngblood, A.G. Randolph, C. Rosenberger, P.G. Thomas, Memphis, TN, p.A7855

923 **First Successful Expression of a Trimeric Human Fragment of SP-A and Demonstration of Its Increased Efficacy in Neutralisation of RSV Compared with Native Human SP-A/**A. Watson, C.M. Spalluto, N. Kronqvist, K. Staples, J. Johansson, T.M.A. Wilkinson, J. Madsen, H. Clark, Southampton, United Kingdom, p.A7856

924 **Targeting Bruton's Tyrosine Kinase Protects Mice from Adverse Effects of Streptococcus Pneumoniae Induced Pneumonia/**A. Kurdowska, J.M. Florence, A. Jeffers, A. Krupa, T.A. Tucker, Tyler, TX, p.A7857

925 **Dissecting the Role of Macrophage-Mediated Killing of Pneumocystis Murina/**K.M. Dischert, D.R. Samuelson, T. Charles, N.M. De La Rua, J.E. Shellito, New Orleans, LA, p.A7858

POSTER DISCUSSION SESSION

B107 TUBERCULOSIS: ISSUES DURING TREATMENT

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 3024 (West Building, Level 3)

Poster Viewing	**2:15-3:00**
Discussion	**3:00-4:15**

Chairing: M.C. Lipman, MD, London, United Kingdom
N.D. Walter, MD, Denver, CO
W.O. Worodria, MBChB, MMeD, PhD, Kampala, Uganda

1001 **Sputum Is a Surrogate for Bronchoalveolar Lavage for Monitoring Mycobacterium Tuberculosis Transcriptional Profiles in TB Patients/**B.J. Garcia, A.G. Loxton, G.M. Dolganov, J.L. Davis, M.I. Voskuil, M. Strong, S. Leach, G. Walzl, G.K. Schoolnik, N.D. Walter, Denver, CO, p.A4472

1002 **Role of Tobacco Cessation as an Adjunct to Anti-Tuberculosis Treatment in Pulmonary Tuberculosis: An Open-Label, Randomized, Controlled Clinical Trial/**S.K. Sharma, A. Mohan, H. Mishra, A.D. Singh, S. Jhanhi, R.M. Pandey, P.B. Pallipamu, B.K. Singh, R.N. Yadav, K. Dheda, G. Theron, A. Sengupta, New Delhi, India, p.A4473

1003 **Prediction of Post-Tuberculosis Lung Function Impairment/** E.W. Pefura-Yone, B. Moifo, F. Kouna, A.D. Balkissou, A.P. Kengne, Yaounde, Cameroon, p.A4474

1004 **Health Care System and Patient Determinants of Loss to Follow-Up During Tuberculosis Treatment in Capital City of Cameroon/**E.W. Pefura-Yone, P.T. Enono-Edende, H.K. Fatime-Abaicho, A.D. Balkissou, A.P. Kengne, E. Afane-Ze, Yaounde, Cameroon, p.A4475

1005 **Treatment Outcomes of Hospitalised Adults Tuberculosis and HIV Co-Infected Patients in a Suburban Centre in Nigeria/**T.A. Salami, Irrua, Nigeria, p.A4476

1006 **Age, Dehydration, Respiratory Failure, Orientation Disturbance, and Blood Pressure (A-DROP) Score Predicts In-Hospital Mortality in HIV-Negative Non-Multidrug-Resistant Smear-Positive Pulmonary Tuberculosis Patients/**K. Nagai, N. Horita, A. Narita, M. Ikeda, K. Nakashima, R. Ushio, H. Watanabe, Y. Shibata, K. Tashiro, H. Nagakura, T. Tsukahara, M. Yamamoto, T. Sato, T. Kaneko, Yokohama, Japan, p.A4477

1007 **Mortality of Patients with Sensitive Tuberculosis in the Tuberculosis Department of the Machava General Hospital in Maputo, Mozambique/**P.M. Zindoga, O. Augusto, S. Peleve, S. Amade, A. Hassane, J. Pondo, A. Daniel, E. Nunes, Maputo, Mozambique, p.A4478

1008 **Negative Interaction of Diabetes Mellitus with Clinical Characteristics and Treatment Success of Tuberculosis in Indonesia/**D. Arlinda, A. Yulianto, A.K. Syarif, A.D. Harso, R.I. Sugiyono, M. Karyana, Jakarta Pusat, Indonesia, p.A4479

1009 **What Is the Best Treatment Regimen for Isoniazid-Resistant Tuberculosis? A Network Meta-Analysis/**H.R. Stagg, R.J. Harris, H.-A. Hatherell, M.C.I. Lipman, I. Abubakar, London, United Kingdom, p.A4480

1010 **An Evaluation of Factors Associated with Mortality Among Drug Resistant Tuberculosis Patients /**M. Seifert, S.B. Georghiou, D. Catanzaro, C.S. Rodrigues, V. Crudu, T.C. Victor, R.S. Garfein, A. Catanzaro, T.C. Rodwell, La Jolla, CA, p.A4481

1011 **Association of Previously Treated Tuberculosis Using Second Line TB Drugs with Conversion Rate of Multi Drugs Resistance (MDR-TB) Patients in Indonesia/**D. Handayani, N. Librianty, P.Z. Soepandi, Dki Jakarta, Indonesia, p.A4482

1012 **Role of Nutrition Status in Multidrug Resistant Tuberculosis (MDR-TB) Conversion/**N. Librianty, P. Soepandi, D. Handayani, A. Fuady, Jakarta Timur, Indonesia, p.A4483

1013 **Association of NFE2L2 Polymorphisms and Anti-Tuberculosis Drug-Induced Hepatotoxicity/**G. Ji, A.J. Sandford, J. He, Chengdu, China, p.A4484

1014 **An Updated Meta-Analysis on CYP2E1 RsaI/PstI and DraI Polymorphisms and Risk of Anti-Tuberculosis Induced Hepatotoxicity: Evidence from 26 Studies/**J. He, F.-J. Wang, Y. Wang, T. Niu, Chengdu, China, p.A4485

1015 **Pregnancy Safety Assessment of 3 Months of Once-Weekly Rifapentine and Isoniazid and 9 Months of Daily Isoniazid: A Post-Hoc Analysis of the PREVENT TB and the iAdhere Trials/**R.N. Moro, N.A. Scott, A. Vernon, S.V. Goldberg, K. Schwartzman, M. Narita, E.S. Machado, N.W. Schluger, M. Lopez, C.C. Leung, R.E. Chaisson, R.W. Belknap, J. Sanchez, M.E. Villarino, T. Sterling, Atlanta, GA, p.A7859

1016 **Statin Adjunctive Therapy Enhances the Activity of the First-Line Regimen Against TB in Mice/**P.C. Karakousis, N. Bruiners, M. Pinn, M. Zimmerman, B. Prideaux, V. Dartois, M.L. Gennaro, N. Dutta, Baltimore, MD, p.A7860

1017 **Treatment-Shortening Activity of Clofazimine, Administered at a Range of Doses, in Combination with the First-Line Regimen for Tuberculosis in the Mouse Model/**N.C. Ammerman, R.V. Swanson, E.M. Bautista, H. Guo, D.V. Almeida, S.-Y. Li, F. Betoudji, S. Tyagi, E. Nuermberger, J.H. Grosset, Baltimore, MD, p.A7861

POSTER DISCUSSION SESSION

B108 ADVANCES IN PEDIATRIC LUNG FUNCTION TESTING

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 3011 (West Building, Level 3)

Poster Viewing **2:15-3:00**

Discussion **3:00-4:15**

Chairing: P.D. Sly, DSc, MBBS, MD, Herston, Australia
P. Subbarao, MD, Toronto, Canada
G. Hall, PhD, Subiaco, Australia
M.H. Jones, MD, PhD, Porto Alegre, Brazil

801 **Dynamic Volumes, Diffusing Capacity and Multiple Breath Nitrogen Washout Indices in Ex-Premature Danish School Children/**J.K. Sorensen, A.K. Berg, A. Henriksen, F.F. Buchvald, K.G. Nielsen, Copenhagen, Denmark, p.A4486

802 **Multiple Breath Nitrogen Washout (MBWN2) and Fractional Exhaled Nitric Oxide (FeNO) in Healthy and Asthmatic Preschool Children/**L. Vilmann, F.F. Buchvald, K.G. Nielsen, Copenhagen, Denmark, p.A4487

803 **Correlation of Lung Clearance Index (LCI) with Hyperpolarized 129Xe Pulmonary Magnetic Resonance Imaging (MRI): A Preliminary Study of Well-Controlled Asthmatics/**N. Kanhere, J. Zheng, K. Kowalik, B. Zanette, B.P. Kavanagh, P. Subbarao, G.E. Santyr, Toronto, Canada, p.A4488

804 **Ventilation Inhomogeneity in Severe Acute Wheezing Preschool Children as Measured by Nitrogen Based Multiple Breath Washout/**K. Kowalik, M. Schaap, C. Lepine, A. Dubeau, Z. Lu, C. Racette, T. Moraes, K. Boutis, F.A. Ratjen, P. Subbarao, Toronto, Canada, p.A4489

805 **Monitoring Allograft Function in Post Lung Transplant Children by Multiple Breath Washout Demonstrates Peripheral Lung Ventilation Inhomogeneity/**J.E. Kao, J.M. Zirbes, C. Conrad, C. Milla, Stanford, CA, p.A4490

806 **Effect of Tissue Nitrogen Excretion on Multiple Breath Washout Measurements/**M. Kane, S. Stanojevic, R. Jensen, F.A. Ratjen, Toronto, Canada, p.A4491

807 **Comparison of Reporting Two Versus Three Trials of the Lung Clearance Index/**M. Klingel, S. Stanojevic, R. Jensen, H. Webster, S.D. Davis, G. Retsch-Bogart, F.A. Ratjen, Toronto, Canada, p.A4492

808 **Bronchodilator Responsiveness Assessed by the Forced Oscillometry (FO) and Multiple Breath Washout (MBW) Techniques in Preschool Children with Asthma/**N.L. Friedman, J.M. McDonough, E.B. Hysinger, J.L. Allen, Philadelphia, PA, p.A4493

809 **Relationships Between Lung Clearance Index and Clinical Markers of Early Cystic Fibrosis Lung Disease Are Unchanged When Only Two Trials Are Assessed/**K.A. Ramsey, R.E. Foong, A.J. Harper, S. Stick, G. Hall, Chapel Hill, NC, p.A4494

810 **Ventilation Distribution Is Altered in the Presence of Respiratory Symptoms in Young Children with Cystic Fibrosis/**R.E. Foong, K.A. Ramsey, B. Skoric, A.J. Harper, C.C. Clem, M. Davis, L. Turkovic, S. Stick, S. Ranganathan, S.D. Davis, G. Hall, Perth, Australia, p.A4495

811 **Utility of Adding Impulse Oscillometry to Standard Spirometry for Pulmonary Function Evaluation in Pediatric Asthmatic Patients: A Cross Sectional Study/**S. Tagliati, E. Cristofaro, F. Bonetti, M. Cottini, D.G. Peroni, Ferrara, Italy, p.A4496

812 **Calculated Maximum Voluntary Ventilation (MVV) Vs. Measured MVV- A Better Predictor of Maximum Ventilatory Capacity in Children During CPET?/**R. Bhatia, K.L. Colwell, Akron, OH, p.A4497

813 **A New Challenge to Measure Cardiac Output and Stroke Volume During Exercise in Cystic Fibrosis Patients/**C. Lambiase, A. Favoriti, M.E. Di Cicco, M. Unolt, F. Occasi, V. Rizzo, R. Lanzano, S. Papasso, G. De Castro, G. Tancredi, Rome, Italy, p.A4498

814 **Functional Capacity Tests: 6mwt and Swt in Children with Cerebral Palsy/**N.P. Silva, L.P. Cahalin, I. Peres Costa, S. Dal Corso, R. Arena, L.M.M. Sampaio, Sao Paulo, Brazil, p.A4499

815 **Assessing Bronchodilator Response (BDR) in Preschool Children Using Spirometry/**L.E. Busi, P.D. Sly, S.A. Restuccia, R.D. Tourres, Buenos Aires, Argentina, p.A4500

816 **Expert vs. Automatic Assessment of the Flow-Volume Curve Configuration/**E. Forno, D. Weiner, G.A. Weiner, L. Sullivan, G. Kurland, Pittsburgh, PA, p.A4501

817 **Applicability of the Global Lung Function Initiative (GLI) 2012 Reference Equations in Sicilian Children/**G. Viegi, S. Fasola, G. Cilluffo, L. Montalbano, V. Malizia, G. Ferrante, F. Cibella, S. La Grutta, Palermo, Italy, p.A4502

818 **Clinical Implications of Gas Exchange Results Measured During Routine Lung Function in Asthmatic Children/**N. Beydon, F. Lacin, Paris, France, p.A4503

819 **Inspiratory and Expiratory Impedance Reference Values in 6-11 Year Old Italian Children/**E. Lombardi, G. Abbati, G. Biadene, R.L. Dellaca, A. Gobbi, G. Fenu, C. Calogero, Florence, Italy, p.A4504

820 **IE50 Measured by Structured Light Plethysmography (SLP) Can Differentiate Between Children With and Without Asthma, and Can Detect Response to a Bronchodilator/**H. Hmeidi, E. Chadwick, W. Lenney, F. Gilchrist, S. Motamedi-Fakhr, R. Wilson, R. Iles, J. Alexander, Stoke-on-Trent, United Kingdom, p.A4505

821 **Structured Light Plethysmography (SLP) Can Quantify Abnormal Breathing in Children Aged 2-12 Admitted With Acute Asthma/**H. Hmeidi, E. Chadwick, W. Lenney, F. Gilchrist, S. Motamedi-Fakhr, R. Wilson, R. Iles, J. Alexander, Stoke-on-Trent, United Kingdom, p.A4506

822 **The Effects of Birth Weight on Infant Pulmonary Function/**A. Dubeau, Z. Lu, S. Balkovec, K. Kowalik, P. Gustafsson, F.A. Ratjen, M.R. Sears, P. Subbarao, Toronto, Canada, p.A4507

823 **Improving Adherence in Children with Cystic Fibrosis Through Home Spirometry: Results of a Feasibility Study/**A. Shakkottai, S.Z. Nasr, Ann Arbor, MI, p.A4508

POSTER DISCUSSION SESSION

B109 HIGHLIGHTS AND ADVANCES IN PULMONARY REHABILITATION

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**
Room 2024 (West Building, Level 2)

Poster Viewing **2:15-3:00**

Discussion **3:00-4:15**

Chairing: R.S. Goldstein, MD, Toronto, Canada
W. Man, MD, PhD, Harefield, United Kingdom
J. Bourbeau, MD, Montreal, Canada

601 **Cardiopulmonary Requirements and Factors Limiting Exercise Performance During Limb Muscle Endurance Training in Patients with COPD and Healthy Controls/**A. Nyberg, D. Saey, M. Martin, F. Maltais, Quebec, Canada, p.A4509

602 **Reproducibility and Quality Control of Near-Infrared Spectroscopic Determination of Muscle Oxidative Capacity in Chronic Obstructive Pulmonary Disease/**A. Adami, R. Cao, J. Porszasz, R. Casaburi, H.B. Rossiter, Torrance, CA, p.A4510

603 **Longitudinal Changes in Peak Oxygen Uptake in Chronic Obstructive Pulmonary Disease (COPD) Patients with Dynamic Hyperinflation and/or Tidal Expiratory Flow Limitation/**B.B. Aarli, P. Calverley, X. Soler, F.L. Powell, A. Malhotra, B. Frisk, T.M.L. Eagan, P. Bakke, J.A. Hardie, Bergen, Norway, p.A4511

604 **Longitudinal Changes in Skeletal Muscle Size, Strength and Physical Function After Lung Transplantation/**S. Mathur, P. Mendes, T. Janaudis-Ferreira, L. Wickerson, D. Helm, J. Sykes, D. Brooks, L. Singer, Toronto, Canada, p.A4512

605 **Effect of Obesity-Classification on Dyspnea on Exertion in Obese Women/**T.G. Babb, V. Bernhardt, D. Bhammar, J. Stickford, J.T. Basset, R. Marines-Price, M. Roman, Dallas, TX, p.A4513

606 **The Effect of Different Interventions on the Sensory and Affective Dimensions of Exertional Dyspnea in Patients with Chronic Obstructive Pulmonary Disease (COPD)/**S.E. Perry, G. Koelwyn, B. Melzer, D. Rolf, N. Eves, Kelowna, Canada, p.A4514

607 **Clinical Outcomes of Pulmonary Rehabilitation. Results for the UK National COPD Audit/**M. Steiner, J. Holzhauer-Barrie, D. Lowe, L. Searle, E. Skipper, S. Welham, M. Roberts, Leicester, United Kingdom, p.A4515

608 **Visceral Adipose Tissue and Muscle Lipids Predict Comorbidities in COPD. An ECLIPSE Substudy/**M. Martin, N. Almeras, J. Desprès, H. Coxson, G. Washko, I. Vivodtzev, E.F. Wouters, E. Rutten, M.C. Williams, J.T. Murchison, J. Yates, W. MacNee, D.D. Sin, F. Maltais, Quebec, Canada, p.A4516

609 **Skeletal Muscle Atrophy Occurs Early and Rapidly in the First 5 Days After Emergency Admission in Mechanically Ventilated Polytrauma Patients/**L. Vieira, P. Melo, V. Maldaner, A. Xavier, V.C. Souza, P.E. Silva, S. Mathur, G. Cipriano Jr, Brasilia, Brazil, p.A4517

610 **Early Neuromuscular Electrical Stimulation Preserves Skeletal Muscle Size and Echogenicity in Mechanically Ventilated Polytrauma Patients/**L. Vieira, P. Melo, V. Maldaner, L.V. Santana, O.T. Nobrega, J. Durigan, S. Mathur, G. Cipriano Jr, Brasilia, Brazil, p.A4518

611 **Understanding the Unmet Educational Needs of Patients with Interstitial Lung Disease: Setting the Stage for a Tailored Pulmonary Rehabilitation Program/**J. Morisset, B.-P. Dube, C. Garvey, J.J. Swigris, J. Bourbeau, H.R. Collard, J.S. Lee, San Francisco, CA, p.A4519

612 **High Intensity Interval Versus Moderate Intensity Continuous Training in a Pulmonary Rehabilitation Programme for Patients with Interstitial Lung Disease/**D. Nikoletou, C. Lech, I. McNaughton, R. Aul, I. Chis-Ster, P.W. Jones, London, United Kingdom, p.A4520

613 **Effect of Supplemental Oxygen on Exercise Response in Patients with Idiopathic Pulmonary Fibrosis/**L. Dowman, C.F. McDonald, D. Pouniotis, C.J. Hill, N. Goh, R. Vlahos, S. Bozinovski, A.E. Holland, Melbourne, Australia, p.A4521

614 **Short-Term and Long-Term Changes in Chronic Respiratory Questionnaire Domains and Total Scores From Different Exercise-Training Protocols in Chronic Obstructive Pulmonary Disease/**A. Milot, G. Moullec, K.A. Duckworth, V. Pepin, Montreal, Canada, p.A4522

615 **Self-Reported Daily Physical Activity Complements Objectively Measured Physical Activity in Veterans with COPD/**E.S. Wan, A. Kantorowski, M. Teylan, D. Homsy, E. Garshick, M.L. Moy, West Roxbury, MA, p.A4523

616 **The Impact of Social Support on Changes in Physical Activity Over 2-Years in Patients with COPD/**Z. Chen, V.S. Fan, K.C. Pike, J. Lee, N. Yee, S. Borson, S.G. Adams, R. Kohen, G. Matute-Bello, H.Q. Nguyen, Seattle, WA, p.A4524

617 **An Exploration of the Relationship Between Physical Activity, Mortality and Time to First Admission in Subjects Admitted into Hospital with an Acute Exacerbation of Chronic Respiratory Disease (CRD)/**T.C. Harvey-Dunstan, N. Greening, S.F. Hussain, E. Chaplin, R. Chimera, M.D.L. Morgan, M. Steiner, S.J. Singh, Leicester, United Kingdom, p.A4525

618 **Physical Activity Performed in Intervals of More than 10 Minutes Is Associated with Better Lung Function Over 3-Years in Adults with Cystic Fibrosis/**N.S. Cox, J.A. Alison, B.M. Button, J.W. Wilson, J.M. Morton, A.E. Holland, Melbourne, Australia, p.A4526

619 **Use of a Home-Based Manual to Help the Patients to Maintain the Gains of Pulmonary Rehabilitation/**Y. De Souza, K.M. Da Silva, B. Figueira, D. Condesso, A.J. Noronha Filho, R. Rufino, C.H.D. Costa, Rio de Janeiro, Brazil, p.A4527

620 **How Smart Are These Socks? Using Smart Socks to Detect Slow Walking Speeds During Overground Walking in Healthy Adults/**N.R. Morris, K. Cheng, J. Houlihan, J. Wootherspoon, N. Tuttle, Southport, Australia, p.A4528

621 **Patient Perspectives on Pulmonary Rehabilitation Using Telehealth/**J. Inskip, H. Novak-Lauscher, L. Li, M. Ansermino, G. Dumont, A. Garde, K. Ho, A. Hoens, J. Road, C.J. Ryerson, P.G. Camp, Vancouver, Canada, p.A4529

622 **A Randomized Controlled Pilot Study Using a Virtual Game System (VGS) as a Home-Based Exercise Modality Following Pulmonary Rehabilitation (PR) in Patients with COPD/**H. Kotrach, E. Dajczman, M.A. Baltzan, R. Wardini, S. Levitz, M. Rotaple, F. Abcarius, M. Stathatos, D. Lynch, N. Wolkove, C. Sounan, Montreal, Canada, p.A4530

623 **Pedometer-Directed Step Count Targets as an Adjunct to Pulmonary Rehabilitation in COPD: A Randomized Controlled Trial/**C.M. Nolan, M. Maddocks, J.L. Canavan, S.E. Jones, S.S.-C. Kon, D. Kaliaraju, M. Polkey, W.D.-C. Man, Harefield, United Kingdom, p.A7862

624 **Impact of Multidisciplinary Self-Management Education Program in Patients with Chronic Obstructive Pulmonary Disease: Self-Efficacy, Exercise Tolerance, and Quality of Life/**C.-L. Chien, Y.-F. Liu, W.-T. Liu, C.-C. Lu, P.-C. Wang, L.-L. Chiang, New Taipei City, Taiwan, p.A7863

625 **Physical Frailty and Pulmonary Rehabilitation in COPD/** W.D.-C. Man, M. Maddocks, S.S.-C. Kon, J.L. Canavan, S.E. Jones, C.M. Nolan, A. Labey, M.I. Polkey, Harefield, United Kingdom, p.A7864

POSTER DISCUSSION SESSION

B110 NOVEL THERAPIES AND TARGETS IN FIBROSIS

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 2010/2012 (West Building, Level 2)

Author Summaries **2:15-2:45**

Poster Viewing/Discussion **2:45-4:15**

401 **Myofibroblast Differentiation Mechanotransduction Depends on the Plasma Membrane Translocation of a Transient Receptor Potential Vanilloid 4 (TRPV4)/Phosphoinositide 3-Kinase Gamma (PI3Kγ) Complex/**L.M. Grove, M.L. Mohan, S. Abraham, K.A. Niese, B.D. Southern, R.G. Scheraga, S.V. Naga Prasad, M.A. Olman, Cleveland, OH, p.A4531

402 **Pharmacological Profile and Efficacy of GLPG1690, a Novel Autotaxin Inhibitor for the Treatment of Idiopathic Pulmonary Fibrosis/**E.M. Van Der Aar, B. Heckmann, R. Blanque, N. Desroy, S. Dupont, C. Cottereaux, A. Monjardet, E. Wakselman, D. Dirven, T. Christophe, B. Hrvacic, J. Ralic, F. Marsais, R. Brys, Mechelen, Belgium, p.A4532

403 **TLK117-Induced GSTP Inhibition Attenuates TGF-ß-Induced Lung Fibrosis/**Y. Janssen-Heininger, D.H. McMillan, K.G. Lahue, R.W. Schneider, X. Qian, J. Van Der Velden, S. Abdalla, A. Van Der Vliet, S. Flemer, V. Anathy, Burlington, VT, p.A4533

404 **Metformin Suppresses Myofibroblast Differentiation by Inhibition of NOX4-Mediated SMAD Signaling/**N. Sato, N. Takasaka, M. Yoshida, S. Minagawa, J. Araya, N. Saito, K. Tsubouchi, Y. Kurita, K. Kobayashi, H. Hara, J. Kojima, T. Numata, Y. Kaneko, K. Nakayama, T. Morikawa, K. Kuwano, Tokyo, Japan, p.A4534

405 **The Proteome Signature of Disease Progression in Idiopathic Pulmonary Fibrosis/**D.N. O'Dwyer, S. Ashley, M. Xia, S. Murray, E. Grant, E.S. White, K.R. Flaherty, F.J. Martinez, B.B. Moore, Ann Arbor, MI, p.A4535

406 **Alveolar Type II Cell Transplantation Improves Alveolar Dynamics and Structure in Bleomycin Induced Lung Fibrosis/**G. Gay-Jordi, E. Lopez-Rodriguez, M. Ochs, A. Serrano-Mollar, Barcelona, Spain, p.A4536

407 **Thyroid Hormone as a Novel Therapeutic Agent in Lung Fibrosis Through Restoration of AECs Mitochondrial Homeostasis/**G. Yu, A. Tzouvelekis, R. Wang, J. Herazo-Maya, J.P. Castro, G. DeIuliis, T. Woolard, R. Drigo, R. Homer, A. Srivastava, Y. Gan, M. Graham, X. Liu, P. Mannam, E. Herzog, A. Antonio C. Bianco, N. Kaminski, New Haven, CT, p.A4537

408 **Disease Progression in Idiopathic Pulmonary Fibrosis Is Associated with an Increased Subpopulation of Resident Pulmonary Monocyte Like Cells in Bronchoalveolar Lavage/**L.M. Nicol, M. Brittan, J.A. Marwick, A.C. MacKinnon, R. Mills, P.A. McFarlane, W.A. Wallace, G. Stewart, J. Simpson, A. Rossi, S.E. Howie, J.T. Murchison, N. Hirani, Edinburgh, United Kingdom, p.A4538

409 **Azithromycin Suppresses TGF-ß-Induced Myofibroblast Differentiation by Promoting Proteasomal Degradation of NOX4/**K. Tsubouchi, J. Araya, H. Hara, S. Minagawa, N. Saito, N. Sato, M. Yoshida, Y. Kurita, K. Kobayashi, J. Kojima, T. Numata, Y. Kaneko, K. Nakayama, T. Morikawa, K. Kuwano, Tokyo, Japan, p.A4539

410 **miR338-3p, a Target of Lactate Dehydrogenase, Is Differentially Regulated in Pulmonary Fibrosis/**J.L. Judge, C.F. Woeller, T.H. Thatcher, R.P. Phipps, P.J. Sime, R.M. Kottmann, Rochester, NY, p.A4540

411 **Self-Assembled Micelle RNAi for Effective and Safe Targeting of Dysregulated Genes in Pulmonary Fibrosis/**P.O. Yoon, J.W. Park, C.-M. Lee, S.H. Kim, J.-S. Yang, H.-O. Park, K. Lee, Q. Lu, J.A. Elias, C.G. Lee, Daejeon, Korea, Republic of, p.A4541

412 **The Effect of Inhaled Low Dose Carbon Monoxide on Cytokine/Chemokine Production in Idiopathic Pulmonary Fibrosis/**K.T. Rooney, H.J. Goldberg, G.M. Hunninghake, K. Nakahira, I.I. Siempos, K.R. Flaherty, F.J. Martinez, J.G.N. Garcia, D.J. Lederer, J.C. Osorio, G. Raghu, J.A. Villalba, J. Lasky, H.R. Collard, I. Noth, R.F. Machado, C. Steele, I.O. Rosas, A.M.K. Choi, New York City, NY, p.A4542

413 **Pathogenesis of Pulmonary Fibrosis - The Role of Extracellular Heat Shock Protein-90 (HSP90) in Myofibroblast Differentiation and Persistence/**P.-S. Bellaye, N. Wheildon, C. Shimbori, M.R.J. Kolb, Hamilton, Canada, p.A4543

414 **De Novo Analysis of Human Idiopathic Pulmonary Fibrosis Lungs Reveals Dysregulated Canonical A-to-G Editing Events at 3' UTRs and microRNA Target Sites/**R. Soundararajan, T.M. Stearns, A.L. Griswold, A. Mehta, A. Czachor, J. Fukumoto, R.F. Lockey, B.L. King, N. Kolliputi, Tampa, FL, p.A4544

415 **Effects of Nintedanib and Pirfenidone on Expression and Maturation of Collagen -a Comprehensive Analysis/**L. Knuppel, Y. Ishikawa, K. Heinzelmann, R. Hatz, J. Behr, H.P. Bachinger, O. Eickelberg, C.A. Staab-Weijnitz, Munchen, Germany, p.A4545

416 **Critical Importance of the ROCK Isoforms ROCK1 and ROCK2 for Vascular Leak and Dendritic Cell Recruitment in Pulmonary Fibrosis/**R.S. Knipe, C.K. Probst, J.W. Griffith, B.S. Shea, J.K. Liao, A.M. Tager, Boston, MA, p.A4546

417 **MUC5B And TOLLIP Variants: Association with Disease Progression And Survival in an IPF Cohort/**C. Stock, M. Bonini, S. Kingston, G.E. Lindahl, A.-M. Russell, P.L. Molyneaux, P. Saunders, M.A. Kokosi, P. Sestini, A.U. Wells, T.M. Maher, E.A. Renzoni, London, United Kingdom, p.A4547

418 **Oral Treatment with PBI-4050 Reduces Serum and Lung Anti-Inflammatory/Fibrotic Biomarkers/**L. Gagnon, B. Grouix, M. Tremblay, A. Laverdure, L. Gervais, F. Sarra-Bournet, L. Geerts, K. Hince, M.-P. Cloutier, M. Leduc, S. Abbott, J.-S. Duceppe, B. Zacharie, P. Laurin, Laval, Canada, p.A4548

419 **Amelioration of Pulmonary Fibrosis by Targeting the Unfolded Protein Response/**M. Thamsen, B.J. Backes, F.R. Papa, San Francisco, CA, p.A4549

420 **MUC5B Promoter Polymorphism rs35705950 Enhances the Risk of Asymptomatic Fibrotic Interstitial Lung Disease/**S.K. Mathai, A.D. Walts, J. Powers, D.A. Lynch, J.H. Chung, K. Smith, J. Woodward, J. Loyd, K.K. Brown, M.P. Steele, M.I. Schwarz, T. Fingerlin, I.V. Yang, D.A. Schwartz, Aurora, CO, p.A4550

421 **Treatment with a Selective KCa3.1 Ion Channel-Inhibitor Attenuates Established Pulmonary Fibrosis in a Segmental Bleomycin Challenge Model in Sheep/**L. Organ, E. Koumoundouros, B. Bacci, C. Samuel, W. Kimpton, K. Snibson, Parkville, Australia, p.A4551

422 **Administration of Sphingosine Kinase 1 Inhibitor Post-Bleomycin Challenge Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice: Role of YAP1/**L.S. Huang, V. Natarajan, Chicago, IL, p.A4552

423 **Non Circulating Pulmonary Resident Memory T Cells Can Be Identified And Demonstrate Activated Phenotypes in Idiopathic Pulmonary Fibrosis/**C. Bonham, C.L. Hrusch, M. Jaffery, A. Adegunsoye, K. Blaine, M.E. Strek, I. Noth, A.I. Sperling, Chicago, IL, p.A4553

424 **XBP1 Deficiency in Type II Alveolar Epithelial Cells Protects Against Lung Fibrosis/**J. Brands, M. Bueno, M. Rojas, A.L. Mora, Pittsburgh, PA, p.A4554

425 **Targeting Fibroblastoid-Like Cells by Drug Loaded Engineered Gold Nanoparticles as Novel Approach for ILD-SSc Treatment/**F. Meloni, E. Cova, S. Inghilleri, V. Codullo, L. Pandolfi, D. Piloni, M. Colombo, M. Morosini, V. Barzon, S. Magni, D. Prosperi, C. Montecucco, Pavia, Italy, p.A4555

5:00 p.m. - 7:00 p.m.

ASSEMBLY MEMBERSHIP MEETINGS

The fourteen Assemblies are the primary groups of the American Thoracic Society. Each Assembly holds an annual Membership Meeting at the International Conference. All Assembly members and other interested individuals are invited to attend.

The Assembly Membership Meetings provide an update on the Assembly's activities via the Assembly's Leadership and provide Assembly members the chance to have input on future directions, information on how to get involved and networking opportunities. Voting results for the Assembly's future leaders will also be announced.

The Assembly Membership Meetings will be held on Monday, May 16, 2016, 5:00 p.m. - 7:00 p.m., with the exception of the Assemblies on Behavioral Science and Health Services Research and Pediatrics (see below.)

ALLERGY, IMMUNOLOGY AND INFLAMMATION
SAN FRANCISCO MARRIOTT MARQUIS
Golden Gate A (B2 Level)
Chairing: M.A. Olman, MA, MD, Cleveland, OH

BEHAVIORAL SCIENCE AND HEALTH SERVICES RESEARCH
SAN FRANCISCO MARRIOTT MARQUIS
Yerba Buena Salon 10-12 (Lower B2 Level)
Chairing: K.A. Riekert, PhD, Baltimore, MD
This Assembly will meet on
Sunday, May 15, 2016
6:30 p.m. - 8:30 p.m.

CLINICAL PROBLEMS
HILTON SAN FRANCISCO UNION SQUARE
Continental Ballroom 6 (Ballroom Level)
Chairing: G. Tino, MD, Philadelphia, PA

CRITICAL CARE
SAN FRANCISCO MARRIOTT MARQUIS
Yerba Buena Salon 8 (Lower B2 Level)
Chairing: C.S. Calfee, MD, San Francisco, CA

ENVIRONMENTAL OCCUPATIONAL AND POPULATION HEALTH
HILTON SAN FRANCISCO UNION SQUARE
Continental Ballroom 4 (Ballroom Level)
Chairing: J.R. Harkema, DVM, PhD, East Lansing, MI

MICROBIOLOGY, TUBERCULOSIS AND PULMONARY INFECTIONS
SAN FRANCISCO MARRIOTT MARQUIS
Yerba Buena Salon 4-6 (Lower B2 Level)
Chairing: R.G. Wunderink, MD, Chicago, IL

NURSING
SAN FRANCISCO MARRIOTT MARQUIS
Yerba Buena Salon 10-12 (Lower B2 Level)
Chairing: D.M. Donesky, PhD, San Francisco, CA

PEDIATRICS
SAN FRANCISCO MARRIOTT MARQUIS
Yerba Buena Salon 8 (Lower B2 Level)
Chairing: J.F. Chmiel, MD, MPH, Cleveland, OH
This Assembly will meet on
Sunday, May 15, 2016
6:30 p.m. - 8:30 p.m.

PULMONARY CIRCULATION
HILTON SAN FRANCISCO UNION SQUARE
Continental Ballroom 5 (Ballroom Level)
Chairing: T. Stevens, PhD, Mobile, AL

PULMONARY REHABILITATION
SAN FRANCISCO MARRIOTT MARQUIS
Yerba Buena Salon 13-15 (Lower B2 Level)
Chairing: C.L. Rochester, MD, New Haven, CT

RESPIRATORY CELL AND MOLECULAR BIOLOGY
SAN FRANCISCO MARRIOTT MARQUIS
Golden Gate B (B2 Level)
Chairing: N. Kaminski, MD, New Haven, CT

RESPIRATORY STRUCTURE AND FUNCTION
SAN FRANCISCO MARRIOTT MARQUIS
Yerba Buena Salon 9 (Lower B2 Level)
Chairing: R.A. Panettieri, MD, New Brunswick, NJ

SLEEP AND RESPIRATORY NEUROBIOLOGY
SAN FRANCISCO MARRIOTT MARQUIS
Yerba Buena Salon 7 (Lower B2 Level)
Chairing: S.P. Patil, MD, PhD, Baltimore, MD

THORACIC ONCOLOGY
SAN FRANCISCO MARRIOTT MARQUIS
Club Room (Second Level)
Chairing: M.K. Gould, MD, MS, Pasadena, CA

7:00 p.m. - 10:00 p.m.

ASSEMBLY DINNERS AND RECEPTIONS

Assembly members and non-members, students and fellows are invited to join us for an evening of good food, great company, camaraderie and a very entertaining program. This is a wonderful opportunity to introduce young members and trainees to Assembly leaders, to connect with old friends and to set up new interactions and collaborations.

Pre-registration and an additional fee are required. Seating is limited.

The following Assemblies will hold a dinner or reception on Monday May 16, 2016 from 7:00 p.m. - 10:00 p.m. immediately following the Assembly Membership Meetings.

Assembly on Allergy, Immunology and Inflammation & Assembly on Respiratory Cell and Molecular Biology Joint Reception
SAN FRANCISCO MARRIOTT MARQUIS
Golden Gate C (B2 Level)
$27.00 - For all

Assembly on Clinical Problems Reception
HILTON SAN FRANCISCO UNION SQUARE
Continental Ballroom 7 (Ballroom Level)
$17.00 - Fellow
$37.00 - Member
$47.00 - Non Member

Assembly on Critical Care Reception
SAN FRANCISCO MARRIOTT MARQUIS
Yerba Buena Salon 8 (Lower B2 Level)
$17.00 - Fellow
$37.00 - Member
$47.00 - Non Member

Assembly on Microbiology, Tuberculosis and Pulmonary Infections Reception
SAN FRANCISCO MARRIOTT MARQUIS
Yerba Buena Salon 1-3 (Lower B2 Level)
$17.00 - Fellow
$37.00 - Member
$47.00 - Non Member

Assembly on Pediatrics Dinner
SAN FRANCISCO MARRIOTT MARQUIS
Atrium (Second Level)
$80.00 - Fellow
$100.00 - Member
$110.00 - Non Member

Assembly on Respiratory Structure and Function Reception
SAN FRANCISCO MARRIOTT MARQUIS
Yerba Buena Salon 9 (Lower B2 Level)
$80.00 - Fellow
$100.00 - Member
$110.00 - Non Member

Assembly on Sleep, Respiratory and Neurobiology Reception
SAN FRANCISCO MARRIOTT MARQUIS
Yerba Buena Salon 7 (Lower B2 Level)
$50.00 - Fellow
$90.00 - Member
$110.00 - Non Member

Assembly on Thoracic Oncology Reception
SAN FRANCISCO MARRIOTT MARQUIS
Foothill G (Second Level)
$17.00 - Fellow
$37.00 - Member
$47.00 - Non Member

Dinner/Reception Disclaimer – Event prices reflect menu selections.
For more information on the Assembly Dinners and Receptions please visit the ATS Assembly home page at: http://www.thoracic.org/members/assemblies/about/

CLINICAL

PEDIATRIC CLINICAL CORE CURRICULUM

CME Credits Available: 1.0

PCC3 PEDIATRIC CLINICAL CORE CURRICULUM

Pediatric Core Curriculum Working Group

6:45 a.m. - 7:45 a.m. **MOSCONE CENTER**

Room 3007/3009 (West Building, Level 3)

Target Audience
Pediatric pulmonary and critical care physicians who work in a clinical setting and are currently engaged in maintenance of certification.

Objectives
At the conclusion of this session, the participant will be able to:

- remain current with medical knowledge relevant to their practice in pediatric pulmonology;
- evaluate their understanding of key skills and content areas in pediatric pulmonology as well as receive feedback on their comprehension of a result of a pre-test/post-test comparison;
- support clinicians who are engaged in maintenance of certification activities by providing updates on subjects included in recertification requirements.

The Pediatric Core Curriculum symposia promotes lifelong learning and the enhancement of the clinical judgment and skills essential for practicing pediatricians. The symposia will address topics that have been identified by an ATS pediatric working group, which is comprised of members of the ATS Education Committee and the International Conference Committee, who have identified important areas within pediatric medicine (including vasculitic pulmonary diseases, lung defense mechanism, congenital abnormalities of the airways, and respiratory failure). Attendees will increase their medical knowledge as a result of attending this symposium, and this will be measured by a comparison of pre-test vs. post-test results on the corresponding maintenance of certification module. The ATS Pediatric Core Curriculum will focus on a 3-year content cycle of key medical content in the area of pediatric medicine.

Chairing: D.M. Boyer, MD, Boston, MA
P.E. Moore, MD, Nashville, TN

6:45 **Congenital Abnormalities of the Upper Airways**
D. Simon, MD, Atlanta, GA

7:15 **Congenital Abnormalities of the Lower Airways**
C.M. Oermann, MD, Kansas City, MO

SUNRISE SEMINARS

CME Credits Available: 1.0

Registration Fee: $65.00 (includes continental breakfast.)
Attendance is limited. Pre-registration is required.

6:45 a.m. - 7:45 a.m. **INTERCONTINENTAL HOTEL**

SS201 **INNOVATIONS IN ASTHMA THERAPY: INHALED STATINS?**
A.A. Zeki, MD, MAS, Sacramento, CA
Union Square (Third Floor)

SS202 **BEHAVIORAL ECONOMICS AND PATIENT DECISION-MAKING IN THE AFFORDABLE CARE ACT ERA**
M.R. Patel, PhD, MPH, Ann Arbor, MI
N. Thakur, MD, MPH, San Francisco, CA
SoMa (Third Floor)

SS203 **NEW DEVELOPMENTS IN CYSTIC FIBROSIS**
B. Quon, MD, MBA, Vancouver, Canada
Mission (Third Floor)

SS204 **LUNG TRANSPLANTATION: UPDATE IN PATIENT REFERRAL, SELECTION, AND EVALUATION**
J.C. Lee, MD, Philadelphia, PA
Marina (Third Floor)

SS205 **RISK PREDICTION IN IDIOPATHIC PULMONARY FIBROSIS**
B.J. Ley, MD, San Francisco, CA
Grand Ballroom C (Third Floor)

SS206 **IDENTITY THEFT: IS IT REALLY SARCOID?**
E.M. Carmona, MD, PhD, Rochester, MN
Grand Ballroom B (Third Floor)

SS207 **NEW ADVANCES IN INTERSTITIAL LUNG DISEASE**
C.J. Ryerson, MD, Vancouver, Canada
Grand Ballroom A (Third Floor)

SS208 **APPROACH TO THE DIAGNOSTIC WORKUP AND INITIAL MANAGEMENT OF PULMONARY VASCULITIS**
M. Baqir, MBBS, Rochester, MN
Twin Peaks (Fourth Floor)

SS209 **ANTICOAGULATION AND PROCEDURES: OIL AND WATER?**
A.C. Argento, MD, Chicago, IL
K. Mahmood, MD, Durham, NC
Telegraph Hill (Fourth Floor)

SS210 **REBOOTING CODE STATUS: GUIDING PATIENTS AND FAMILIES THROUGH LIFE-THREATENING ILLNESS**
S.M. Brown, MD, MS, Murray, UT
Potrero Hill (Fourth Floor)

SS211 **PHYSIOLOGIC EVALUATION OF PATIENTS WITH OCCUPATIONAL LUNG DISEASE FOR DIAGNOSIS, IMPAIRMENT, AND DISABILITY**
C.J. Schroedl, MD, Chicago, IL
Nob Hill (Fourth Floor)

SS212 **TREATMENT OF NTM: ALTERNATIVES TO CURRENT ANTIMICROBIALS**
J. Cook, MD, Maywood, IL
M. Prickett, MD, MPH, Chicago, IL
Laurel Hill (Fourth Floor)

SS213 **MANAGEMENT OF PARAPNEUMONIC EFFUSION IN CHILDREN: AN UPDATE**
R.E. Myers, MD, Cleveland, OH
K.R. Ross, MD, Cleveland, OH
Cathedral Hill (Fourth Floor)

SS214 **DIAGNOSING PULMONARY HYPERTENSION: TRICKS OF THE TRADE**
A. Vaidya, MD, Philadelphia, PA
Sutter (Fifth Floor)

SS215 **INSPIRATORY MUSCLE TRAINING IN COPD**
D. Langer, PhD, PT, Leuven, Belgium
Stockton (Fifth Floor)

SS216 **OPTIMIZATION OF THE 3D IN VITRO ASSAY TO STUDY LUNG STEM/PROGENITOR CELLS**
A.E.M. Hegab, MD, PhD, Tokyo, Japan
Howard (Fifth Floor)

SS217 **UPDATE IN HYPERBARIC MEDICINE**
J. Evangelista, MD, Detroit, MI
Fremont (Fifth Floor)

SS218 **SLEEP DISORDERED BREATHING IN ADULTS WITH NEUROMUSCULAR DISEASE**
J.E. Orr, MD, La Jolla, CA
InterContinental Ballroom C (Fifth Floor)

SS219 **LUNG CANCER IN ASIANS: A DIFFERENT BEAST ALTOGETHER?**
C. Chang, MD, Los Angeles, CA
InterContinental Ballroom B (Fifth Floor)

FACULTY DEVELOPMENT SEMINAR

FD2 NUTS AND BOLTS IN NEGOTIATING A JOB

Pre-registration is required. There is no additional fee. Attendance is limited.

6:45 a.m. - 7:45 a.m. **INTERCONTINENTAL HOTEL**
InterContinental Ballroom A (Fifth Floor)

Target Audience
Early career clinical and/or research faculty, clinical and post doctoral fellows, graduate students, residents, nurses, and allied health professionals already involved in or seeking a career in academic pulmonary, allergy, critical care, and/or sleep medicine.

Objectives
At the conclusion of this session, the participant will be able to:

- identify how their success is gauged.
- understand basic elements needed for advancement in their ideal job.
- learn strategies to negotiate for key items to support their career development.

As a junior faculty member, are you unsure of how to prepare a CV, how to prepare for an interview and how to negotiate what you want when applying for a job? This seminar will provide helpful tips on how to best prepare for and negotiate your ideal job.

Chairing: C.C. Thomson, MD, MPH, Cambridge, MA

Speakers: M. Moss, MD, Aurora, CO
S.S. Carson, MD, Chapel Hill, NC
J.M. Beck, MD, Denver, CO
C.S. Rand, PhD, Baltimore, MD

BASIC • CLINICAL • TRANSLATIONAL

ATS KEYNOTE SERIES

CME Credits Available: .75

The ATS Keynote Series provides state of the art lectures on selected topics in an unopposed format to showcase major discoveries in pulmonary, critical care and sleep medicine. The speakers have been chosen by input from the members and various ATS committees with consensus built via the ATS executive committee.

Two sessions are presented each morning during the conference. Below are the topics for the Tuesday,May 17th series.

K5 THE CHANGING NATURAL COURSE OF COPD

8:00 a.m. - 8:45 a.m. **MOSCONE CENTER**
Room 134 (North Building, Lower Level)

Speaker: Bartolome R. Celli, MD, Boston, MA

*This session and the International Conference are supported by an educational grant from **AstraZeneca LP.***
All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

K6 STRUCTURAL INSIGHTS INTO GPCR SIGNALING: IMPLICATIONS FOR DRUG DISCOVERY

8:00 a.m. - 8:45 a.m. **MOSCONE CENTER**
Room 135 (North Building, Lower Level)

Speaker: Brian Kobilka, MD, Stanford, CA

*This session and the International Conference are supported by an educational grant from **AstraZeneca LP.***
All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests

CLINICAL

YEAR IN REVIEW

CME Credits Available: 2.0

C1 CLINICAL YEAR IN REVIEW 3

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Gateway Ballroom 102-104 (South Building, Lower Level)

Target Audience
Providers including physicians, nurses, respiratory therapists, nurse practitioners, physician assistants. Trainees including residents and fellows; clinical researchers.

Objectives
At the conclusion of this session, the participant will be able to:

- apply new clinical research knowledge to clinical practice;
- learn new findings about key conditions in pulmonary, critical care and sleep;
- have new strategies to manage the care of common conditions in pulmonary, critical care, and sleep.

The annual Clinical Year in Review symposia topic reviews of the key clinical research publications over the last year. Each speaker is asked to review the 5-7 most important and influential publications on their topic in the prior year.

Chairing: J.L. Taylor-Cousar, MD, Denver, CO
D.J. Lederer, MD, MS, New York, NY
D.W. Ford, MD, MSCR, Charleston, SC

9:00 **Palliative Care**
C.E. Cox, MD, MPH, Durham, NC

9:30 **Lung Cancer**
N.T. Tanner, MD, MSCR, Charleston, SC

10:00 **Sleep in Critical Illness**
R.L. Owens, MD, La Jolla, CA

10:30 **Sleep Disordered Breathing**
J.L. Pepin, MD, PhD, Grenoble, France

*This session and the International Conference are supported by an educational grant from **AstraZeneca LP.***

All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

CLINICAL

CLINICAL TOPICS IN PULMONARY MEDICINE

CME Credits Available: 2.0

C2 TOBACCO SMOKING AND CESSATION IN VULNERABLE POPULATIONS

Assemblies on Clinical Problems; Behavioral Science and Health Services Research

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 135 (North Building, Lower Level)

Target Audience
Physicians, nurses, public health officials, physicians in training.

Objectives
At the conclusion of this session, the participant will be able to:

- enhance the knowledge of smoking behaviors and smoking cessation therapies in different subpopulations;
- become aware of targeted or customized treatment options for smoking cessation;
- understand and become aware of the risks of light or moderate smoking.

Tobacco smoking is a major risk factor for a variety of diseases. Tobacco smoking substantially impacts respiratory, cardiac, and vascular health resulting in excess health care costs and premature loss of life. Some ethnic groups and communities are disproportionately impacted, manifesting greater risk of smoking-related lung cancer and death. This session explores the state of the knowledge on the genetics of tobacco smoking and smoking cessation; tobacco use in several ethnic groups; and targeted smoking cessation programs.

Chairing: M.G. Foreman, MD, Atlanta, GA
D.J. Upson, MA, MD, Albuquerque, NM

9:00 **Tobacco Use in African Americans**
E.R. Neptune, MD, Baltimore, MD

9:25 **Tobacco Use in Latinos**
F. Holguin, MD, MPH, Pittsburgh, PA

9:50 **Ethnic Variation in Lung Cancer Among Smokers**
M.P. Rivera, MD, Chapel Hill, NC

10:15 **Best Approaches to Smoking Cessation in Targeted Groups**
M. Castro, MD, MPH, St. Louis, MO

10:40 **Genetics of Tobacco Addiction and Smoking Cessation**
M.G. Foreman, MD, Atlanta, GA

CLINICAL • TRANSLATIONAL

CLINICAL TOPICS IN PULMONARY MEDICINE

CME Credits Available: 2.0

C3 KEY MANAGEMENT CONSIDERATIONS IN SARCOIDOSIS

Assemblies on Clinical Problems; Allergy, Immunology and Inflammation

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 134 (North Building, Lower Level)

Target Audience
Practitioners who actively care for patients with sarcoidosis, as well as investigators involved in clinical or translational sarcoidosis studies.

Objectives
At the conclusion of this session, the participant will be able to:

- screen for and diagnose cardiac sarcoidosis;
- understand when to start immunosuppression for pulmonary sarcoidosis and for other “dangerous” sarcoidosis phenotypes;
- devise a steroid sparing treatment regimen, and know better how to counsel patients on the rationale for the various options.

We begin this session by a review of the pathophysiology of sarcoidosis from the perspective of providing rationale for treatment strategies. We then highlight

management of cardiac sarcoidosis, fibrotic pulmonary sarcoidosis, and pulmonary hypertension - the phenotypes of sarcoidosis most associated with poor outcomes and increased mortality. Following this, we review indications and use of currently available immunosuppressive agents, and introduce potential new therapies for sarcoidosis by summarizing the status of current clinical trials.

Chairing: K.C. Patterson, MD, Philadelphia, PA
A.S. Morgenthau, MD, New York, NY

9:00 **A Patient's Perspective**
J. Ploudre, St. Louis, MO

9:05 **Etiology and Immunopathogenesis of Sarcoidosis**
D.R. Moller, MD, Baltimore, MD

9:20 **When Is a Sarcoidosis Patient in Danger from Their Disease and in Need of Treatment?**
A.U. Wells, MD, London, United Kingdom

9:35 **When Should We Move on from Prednisone and What Should We Give?**
J.C. Grutters, MD, PhD, Nieuwegein, Netherlands

9:50 **What Is the Role of Immunosuppression in Preventing Pulmonary Fibrosis in Sarcoidosis?**
K.C. Patterson, MD, Philadelphia, PA

10:05 **Should Sarcoidosis-Associated Pulmonary Hypertension be Treated?**
R.P. Baughman, MD, Cincinnati, OH

10:20 **How Should We Diagnose and Treat Cardiac Sarcoidosis?**
D.A. Culver, DO, Cleveland, OH

10:35 **What Are the Potential New Treatments for Sarcoidosis? An Update on Clinical Trials**
A.S. Morgenthau, MD, New York, NY

CLINICAL

CRITICAL CARE TRACK

CME Credits Available: 2.0

C4 SEPSIS CARE FROM START TO FINISH

Assemblies on Critical Care; Clinical Problems; Nursing

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**
Room 3000/3002/3004 (West Building, Level 3)

Target Audience
Clinicians and researchers who seek to improve the care of sepsis patients.

Objectives
At the conclusion of this session, the participant will be able to:

- understand methods of improving the early identification of sepsis, including public awareness campaigns, EMS identification, and SOFA score in ER/hospital ward;
- deliver evidence-based care, including fluid-resuscitation, use of e-ICU;
- improve health system approaches to quality improvement and addressing long-term sequelae of sepsis.

Sepsis is the single most expensive cause of hospitalization and the largest contributor to hospital death. Despite its staggering impact, almost nothing is known about how to treat sepsis patients outside of the six "golden hours" immediately after presentation. In this session, leading experts will review the emerging evidence to inform clinicians about improving sepsis treatment across different time windows and discuss critical knowledge gaps that require future research. In the process, attendees will gain new insight into the intersection of sepsis with pre-hospital care, sepsis care on the wards, sepsis related hospital readmission, and systems-level sepsis quality improvement.

Chairing: V. Liu, MD, MS, Oakland, CA
H.C. Prescott, MD, MA, Ann Arbor, MI

9:00 **Sepsis Screening in the Community: How Do We Inform the Public?**
S. Simpson, MD, Kansas City, KS

9:18 **Pre-Hospital Care of Sepsis: Leveraging Emergency Medical Service Providers**
C.W. Seymour, MD, MSc, Pittsburgh, PA

9:35 **Life After Rivers: Neither EGDT Nor Neglect**
S. Peake, PhD, Victoria, Australia

9:52 **Identifying Sepsis Outside the ICU: SIRS or qSOFA?**
D.C. Angus, MD, MPH, Pittsburgh, PA

10:09 **Enabling Best Sepsis Care Through Tele-Medicine**
D.W. Ford, MD, MSCR, Charleston, SC

10:26 **The Long Tail of Sepsis: Readmissions and Beyond**
H.C. Prescott, MD, MA, Ann Arbor, MI

10:43 **Optimizing Learning Health Care Systems to Address Sepsis**
V. Liu, MD, MS, Oakland, CA

BASIC • CLINICAL • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 2.0

C5 THE BRAIN AFTER CRITICAL ILLNESS: POPULATIONS, PATIENTS, AND PATHWAYS

Assemblies on Critical Care; Behavioral Science and Health Services Research

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**
Room 3006/3008 (West Building, Level 3)

Target Audience
Critical care providers; those with research or clinical interest in long term outcomes after hospitalization or critical illness.

Objectives
At the conclusion of this session, the participant will be able to:

- define the severity and frequency of long-term brain disorders after critical illness;
- improve quality of life for patients by discussing long term outcomes after critical illness and informing patients and families about the impact of treatment decisions;
- understand the role of the critical care community in leveraging existing studies to improve our understanding of survivorship after critical illness.

This session will describe the emerging understanding of chronic cognitive and affective disorders complicating critical illness survivorship from a multiscale perspective, from population level data to animal models.

Chairing: B.H. Singer, MD, PhD, Ann Arbor, MI
W.J. Ehlenbach, MD, Madison, WI
R.O. Hopkins, PhD, Murray, UT

9:00 **A Patient's Perspective**
P. Popp, Evergreen, CO

9:05 **Cognitive and Affective Disorders in Survivors of ICU Hospitalization**
R.O. Hopkins, PhD, Murray, UT

9:30 **Survivorship After Sepsis: A Population Perspective**
T.J. Iwashyna, MD, PhD, Ann Arbor, MI

9:55 **Neuropathology in Long Term Survivors of Sepsis**
W.J. Ehlenbach, MD, Madison, WI

10:15 **Mechanisms of Long Term Brain Dysfunction After Critical Illness**
B.H. Singer, MD, PhD, Ann Arbor, MI

10:35 **Neuroinflammation and Cognitive Decline After Stroke**
M. Buckwalter, MD, PhD, Stanford, CA

There will be a 5-minute discussion after each talk.

CLINICAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 2.0

Nursing Contact Hours Available: 2.4

C6 A REPORT CARD ON EDUCATION DURING PULMONARY REHABILITATION: HOW ARE WE DOING?

Assemblies on Pulmonary Rehabilitation; Behavioral Science and Health Services Research; Nursing

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**
Room 130-132 (North Building, Lower Level)

Target Audience
Individuals engaged in the education of pulmonary patients; physicians, nurses, physical/physiotherapists and respiratory therapists.

Objectives
At the conclusion of this session, the participant will be able to:

- outline the current approach to patient education in pulmonary rehabilitation and present the evidence illustrating the effects of patient education on outcomes such as knowledge, quality of life, self-efficacy, healthcare utilization;
- describe the challenges with eliciting health behavior change and how education and learning new information is only one component of changing, while detailing other factors that impact behavioral change;
- formulate ideas for future directions in education in pulmonary rehabilitation.

The objectives of this symposium are to explore our current approaches to engaging people with COPD in educational activities, using pulmonary rehabilitation education programs as a model. We will explore current educational approaches (didactic and interactive self-management education), their successes and failures in our current communities of practice, and how we might adapt these approaches to modernize educational activities and meet the learning needs of people with COPD in 2015. Participants will be involved in a discussion on the complexity of facilitating health behavior change in people with COPD, how education may be a component of this and what future directions may be in the digital learning world.

Chairing: S. Lareau, MS, RN, Aurora, CO
R. ZuWallack, MD, Hartford, CT
L. Nici, MD, Providence, RI
F.C. Blackstock, PhD, BPhysio(Hons), Melbourne, Australia

9:00 **Historical Approach to Education in Pulmonary Rehabilitation for People with COPD**
S. Lareau, MS, RN, Aurora, CO

9:15 **A Patient Perspective on Education in Pulmonary Rehabilitation**
E. Egbert, San Francisco, CA

9:20 **Current Educational Models in Pulmonary Rehabilitation: Do They Pass or Fail?**
F.C. Blackstock, PhD, BPhysio(Hons), Melbourne, Australia

9:50 **Health Literacy: "I Don't Understand, So How Can I Learn?" Moving Towards Patient Tailored Education**
M.R. George, AE-C, PhD, RN, New York, NY

10:15 **Challenges of Changing Behavior: Education Is Only One Component**
J. Bourbeau, MD, Montreal, Canada

10:40 **Education in Pulmonary Rehabilitation: Where Do We Need to Go Next?**
L. Nici, MD, Providence, RI

There will be a 5-minute discussion after each talk

*This session and the International Conference are supported by an educational grant from **AstraZeneca LP.***
All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

CLINICAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 2.0

C7 UNDERSTANDING CLINICAL TRIALS DATA IN PULMONARY ARTERIAL HYPERTENSION AND USING THOSE DATA IN PRACTICE

Assemblies on Pulmonary Circulation; Clinical Problems

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**
Room 3020/3022 (West Building, Level 3)

Target Audience
Clinicians and clinical researchers in pulmonary disease

Objectives
At the conclusion of this session, the participant will be able to:

- understand how PAH trials are designed and the basics of statistical interpretation (e.g.-what is a hazard ratio?);
- understand the data emerging in PAH and how it applies to patients;
- outline the importance of various endpoints in PAH trials and why they are important to patient care.

This session will focus on the wealth of clinical trials data in pulmonary hypertension. Starting with a discussion of how such trials are designed and then covering specific trials and endpoints will give the audience an overview that they can apply to the care of patients with pulmonary arterial hypertension.

Chairing: R.N. Channick, MD, Boston, MA
V. McLaughlin, MD, Ann Arbor, MI

9:00 **How Are Clinical Trials in PAH Designed: The Basics**
Speaker to be Announced

9:30 **Comparing Endpoints in PAH Trials: Surrogate, Correlate, or Something Else?**
S.M. Kawut, MD, MS, Philadelphia, PA

9:50 **PRO: Long-Term Morbidity Mortality Trials Are the Way to Go in PAH**
V. McLaughlin, MD, Ann Arbor, MI

10:05 **CON: Event Driven Trials Are of Limited Value. Trials Need to Be Designed to Determine if a Drug Actually Improves Patients' Lives**
V. Tapson, MD, West Hollywood, CA

10:20 **PRO: Upfront Combination Therapy Should Now Be the Standard of Care in PAH**
M.J.C. Humbert, MD, PhD, Le Kremlin Bicetre, France

10:35 **CON: Upfront Combination Therapy Has Not Been Proven to Be Superior to Sequential Combination Therapy**
R.N. Channick, MD, Boston, MA

10:50 **Panel Discussion**
R.N. Channick, MD, Boston, MA

BASIC • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 2.0

C8 BREACHING BARRIERS: TARGETED DELIVERY OF THERAPEUTICS TO THE LUNG

Assemblies on Respiratory Cell and Molecular Biology; Allergy, Immunology and Inflammation; Clinical Problems; Critical Care; Pediatrics; Pulmonary Circulation; Respiratory Structure and Function; Thoracic Oncology

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**
Room 3010/3012 (West Building, Level 3)

Target Audience
Pulmonary and critical care clinicians (adult, pediatric, neonatal) and lung researchers.

Objectives
At the conclusion of this session, the participant will be able to:

- learn the latest findings about overcoming barriers to delivery of therapeutic agents to the lungs;
- learn the advantages and limitations of endothelial vs epithelial targeting for a variety of molecular entities in a range of lung diseases;
- apply knowledge regarding lung-specific delivery to overcome current limitations in treatment of both rare and common lung diseases.

Many therapeutics which show promise in vitro are abandoned because of systemic toxicity or inability to effectively penetrate lung tissue via airways or vasculature. Emerging knowledge and technology is improving lung-specific delivery, eliminating critical barriers in treatment of many lung diseases.

Chairing: J. Hagood, MD, La Jolla, CA
Z. Borok, MD, Los Angeles, CA

9:00 **Caveolar Pumping for Lung Specific Delivery**
J. Schnitzer, MD, La Jolla, CA

9:25 **Mucus Penetrating Nanoparticles for Drug Delivery**
J.S. Suk, PhD, Baltimore, MD

9:50 **Using Nanocarriers to Target the Lung Endothelium**
V.R. Muzykantov, MD, PhD, Philadelphia, PA

10:15 **Mesenchymal Stem Cell Exosomes Target the Acutely Injured Lung**
M.A. Matthay, MD, San Francisco, CA

10:40 **Panel Discussion**
J. Hagood, MD, La Jolla, CA

CLINICAL • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 2.0

C9 THE LINK BETWEEN CILIARY ASSEMBLY DEFECTS, NEONATAL RESPIRATORY DISTRESS AND BRONCHIECTASIS IN ADULTHOOD: A PRIMER ON PRIMARY CILIARY DYSKINESIA

Assemblies on Pediatrics; Clinical Problems; Microbiology, Tuberculosis and Pulmonary Infections; Respiratory Cell and Molecular Biology

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**
Room 3007/3009 (West Building, Level 3)

Target Audience
Pulmonologists, nurses, allied health professionals, clinical trainees, translational scientists.

Objectives
At the conclusion of this session, the participant will be able to:

- acquire an understanding of how inherited defects in ciliary assembly mechanisms lead to impaired ciliary structure and function;
- learn how to diagnose PCD with ciliary ultrastructural studies, genetic studies and nasal nitric oxide measurement;
- understand the adverse health consequences of impaired ciliary function from fetal development to adult life.

PCD is an inherited disease in which defects of the motile cilia lining the respiratory tract cause impaired mucociliary clearance, resulting in progressive

bronchiectasis that may cause end-stage lung disease by adulthood. This session will highlight new insights into pathomechanisms of disease that have come from both model systems and human gene discovery studies, as well as clinical insights that have arisen from multi-center efforts in North America and Europe to study PCD cohorts over the past decade. Clinical insights will include genotype-phenotype associations, new diagnostic tests and an update on clinical trials that are currently being conducted around the world.

Chairing: S.D.M. Dell, MD, Toronto, Canada
T.W. Ferkol, MD, St. Louis, MO

9:00 **A Patient's Perspective**
M. Kitlowski, Baltimore, MD
R. Giannokos, Silver Spring, MD

9:05 **Mechanisms of Ciliary Assembly Defects in PCD**
S. Brody, MD, St. Louis, MO

9:30 **Phenotype-Genotype Relationships in Children and Adults**
S. Davis, MD, Indianapolis, IN

9:50 **Incorporating Emerging Genetic Testing into Diagnostic Strategies**
M. Leigh, MD, Chapel Hill, NC

10:10 **Airway Microbiology and Inflammation in PCD**
K.N. Olivier, MD, MPH, Bethesda, MD

10:30 **The Impact of Disease Management Strategies on Long-Term Prognosis**
J. Lucas, PhD, Southampton, United Kingdom

There will be a 5-minute discussion after each talk.

BEHAVIORAL • CLINICAL • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 2.0

C10 ACHIEVING "ENVIRONMENTAL JUSTICE": A MAJOR STEP TOWARD RESPIRATORY HEALTH EQUALITY

Assemblies on Environmental, Occupational and Population Health; Allergy, Immunology and Inflammation; Behavioral Science and Health Services Research; Clinical Problems; Critical Care; Microbiology, Tuberculosis and Pulmonary Infections; Nursing; Pediatrics; Sleep and Respiratory Neurobiology; Health Equality Sub-Committee

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**
Room 2002/2004 (West Building, Level 2)

Target Audience
Clinicians, researchers and public health practitioners focusing on the prevention and treatment of respiratory diseases.

Objectives
At the conclusion of this session, the participant will be able to:

- learn new findings about the impact of major environmental risk factors on respiratory health disparities;
- apply new strategies to advocate for environmental justice as means to achieve respiratory health equality;
- discuss feasible and necessary policies to achieve environmental justice and thus move toward respiratory health equality.

Because the frequency of major environmental risk factors for respiratory diseases differs across demographic groups (defined by socioeconomic status, race/ethnicity, sexual orientation, health care access, occupation, or other characteristics), respiratory health disparities are commonly encountered in pediatric and adult pulmonary medicine. Attainment of respiratory health equality requires the ending of respiratory health disparities, which can be achieved only through multidisciplinary efforts to eliminate detrimental environmental exposures. This symposium will review and discuss the current challenges posed by key environmental risk factors for health disparities (smoking, air pollution and occupation), focusing on knowledge gaps and health policy needs.

Chairing: J.C. Celedon, MD, DrPH, Pittsburgh, PA
J.M. Samet, MD, MS, Los Angeles, CA
E.G. Burchard, MD, MPH, San Francisco, CA

9:00 **Environmental Justice and Health Equality: Conceptual Framework**
J.C. Celedon, MD, DrPH, Pittsburgh, PA

9:20 **Tobacco Use and Respiratory Health Disparities**
P. Ling, MD, San Francisco, CA

9:40 **Traffic-Related Air Pollution: Who Lives Closer to Major Highways?**
J.R. Balmes, MD, San Francisco, CA

10:00 **Countering Targeted Campaigns Against Vulnerable Populations: Menthol Cigarettes as a Case Study**
E.R. Neptune, MD, Baltimore, MD

10:20 **Not All Occupations Are Equal: Migrant Workers as a Case Study**
M.B. Schenker, MD, MPH, Davis, CA

10:40 **Short and Long Term Policies to Achieve Environmental Justice**
M.B. Rice, MD, MPH, Boston, MA

BASIC • CLINICAL • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 2.0

C11 PATHOGENESIS AND TREATMENT OF OBSTRUCTIVE LUNG DISEASES: NEW INSIGHTS

Assemblies on Respiratory Structure and Function; Allergy, Immunology and Inflammation; Microbiology, Tuberculosis and Pulmonary Infections; Respiratory Cell and Molecular Biology

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**
Room 2006/2008 (West Building, Level 2)

Target Audience
Allergists, pulmonologists, basic scientists, physiologists, translational researchers, fellows and residents, and graduate trainees interested in the pathophysiology and emerging treatment options for obstructive lung diseases.

Objectives
At the conclusion of this session, the participant will be able to:

- describe factors contributing to the onset and progression of obstructive lung diseases;

- understand the role of genetics, epigenetics and the microbiome on lung function in obstructive lung diseases;
- learn about new findings on potential therapeutic strategies and research endeavors in obstructive lung diseases.

The factors responsible for the initiation, maintenance, progression, and exacerbations of obstructive lung diseases are incompletely understood. Airway remodeling, acute and chronic inflammation and airway hyperresponsiveness are well known established hallmarks of these syndromes. However, the contributions of microbial and environmental exposures as well as the influence of genetic and epigenetic changes to disease risk and treatment are being actively investigated, elucidated and appreciated. This integrated symposium will present insights into the impact of these diverse factors to the development and progression of asthma and COPD, and how this knowledge is being applied to identify novel targets for therapy.

Chairing: B. Camoretti-Mercado, PhD, Tampa, FL
T. Pera, PhD, Philadelphia, PA
J.E. Bourke, PhD, Clayton, Australia

9:00 **Obstructive Pulmonary Disease: What Went Wrong and How to Fix It**
M. Kraft, MD, Tucson, AZ
Parker B. Francis Speaker

9:20 **Detection of Early Stages of Pulmonary Obstructive Disease: An Ambitious Goal**
S.I. Rennard, MD, Melbourn, United Kingdom

9:40 **Genomics of Obstructive Lung Diseases: New and Old Players**
P.G. Woodruff, MD, MPH, San Francisco, CA

10:00 **Epigenetic Control of Smooth Muscle Phenotype**
W. Gerthoffer, PhD, Mobile, AL

10:20 **Significance and Interactions of the Lung Microbiome in Obstructive Lung Diseases**
S.V. Lynch, PhD, San Francisco, CA

10:40 **Searching New Interventions for Obstructive Lung Diseases: Promises and Challenges**
S.R. White, MD, Chicago, IL

There will be a 5-minute discussion after each talk.

*This session and the International Conference are supported by an educational grant from **AstraZeneca LP.***
All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

BASIC • CLINICAL • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 2.0

C12 BIOMARKERS: GUIDEPOSTS IN THE ROADMAP TO IMPROVED PERSONALIZED AND PRECISION MEDICINE

Drug and Device Discovery and Development Committee; Assembly on Thoracic Oncology

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**
Room 2005/2007 (West Building, Level 2)

Target Audience
Basic, translational and clinical investigators in academia, industry and government; individuals involved in drug and device discovery and early/late development, clinical trials and regulatory approval.

Objectives
At the conclusion of this session, the participant will be able to:

- understand what is meant by biomarkers;
- understand the utility of biomarkers in clinical trials,development of therapeutic innovations, and in health sciences broadly;
- use practical examples of biomarkers in medicine.

This symposium will discuss the importance of Biomarkers in basic, translational and clinical studies. The advent of personalized and precision medicine requires an improved ability to distinguish among patients to better diagnose and treat disease. Biomarkers provide a means to first diagnose disease then subdivide patient cohorts into categories based on differences in clinical presentation, disease progression, histopathology, physiology and genetics/genomics. Biomarkers may serve as surrogate endpoints in clinical trials and a means to measure the response to therapeutic interventions. Additionally, biomarkers play critical roles as evidence of target engagement and biological effects in early development, and early markers of toxicity or harms and patient risk stratification. The session will define biomarkers, their clinical utility and provide a development and regulatory perspective on their use in clinical trials.

Chairing: T.F. Reiss, MD, New Hope, PA
J. Moss, MD, PhD, Bethesda, MD
P. Mazzone, MD, MPH, Cleveland, OH

9:00 **How to Identify a Biomarker**
J.A. Wagner, MD, PhD, Cambridge, MA

9:24 **Cross-Talk Among Medical Subspecialties Facilitates Biomarker Discovery and Use in Clinical Trial Design**
R. Vessey, MA, BM, BCh, Summit, NJ

9:48 **Biomarkers: Here, There and Everywhere: Lessons from a Longitudinal Study of LAM**
J. Moss, MD, PhD, Bethesda, MD

10:12 **Molecular Testing as a Guide to Lung Cancer Therapeutics**
C.A. Powell, MD, New York, NY

10:36 **The Regulatory Perspective: Acceptability of Biomarkers as Surrogate Endpoints in Clinical Trials**
R. Meyer, MD, Silver Spring, MD

*This session and the International Conference are supported by an educational grant from **AstraZeneca LP.***
All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

BASIC

SCIENTIFIC SYMPOSIUM

CME Credits Available: 2.0

C13 PROGRESS IN STEM CELL BIOLOGY AND DISEASE APPLICATIONS

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**
Room 2016/2018 (West Building, Level 2)

Target Audience
All clinicians, basic researchers, and other lung health care professionals looking to learn about state of the art developments in stem cell biology and their applications to lung diseases

Objectives
At the conclusion of this session, the participant will be able to:

- appreciate the current state of the art with respect to stem cell biology;
- appreciate the current state of the art with respect to cancer stem cells;
- appreciate applications of stem cell and cancer stem cell biology to respiratory diseases and critical illnesses.

The potential for use of stem cells to prevent or treat human disease has led to unprecedented growth of the field of regenerative medicine. Moreover, increasing evidence demonstrates the feasibility of utilizing an individual's own cells in developing potential stem cell-based therapeutic approaches: the ultimate in personalized medicine. This symposium will provide a strong basic scientific and clinical rationale and current state of the art in this rapidly developing area. The speakers are all accomplished stem cell investigators from outside the respiratory field who will bring new knowledge and perspective that will help guide future developments in lung regenerative medicine.

Chairing: D.J. Weiss, MD, PhD, Burlington, VT
D.N. Kotton, MD, Boston, MA

9:00 **Normal and Neoplastic Stem Cells**
I. Weissman, MD, Stanford, CA

9:30 **Imaging Cancer Heterogeneity and Therapy Resistance in Real Time**
T. Reya, PhD, La Jolla, CA

10:00 **Interspecific Blastocyst Complementation: A Novel Approach to Generate Functional Organs**
T. Rashid, MD, London United Kingdom

10:30 **Defining the Lung Cell By Cell**
M. Krasnow, PhD, Palo Alto, CA

MINI SYMPOSIUM

C14 FINDING THE SWEET SPOT BETWEEN TOO MUCH AND TOO LITTLE CARE

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**
Room 307 (South Building, Esplanade Level)

Chairing: R.S. Wiener, MD, MPH, Boston, MA
A. Garland, MD, MA, Winnipeg, Canada

Oral Presentations

9:00 **ICU Admission Does Not Confer a Survival Benefit for COPD, CHF, and AMI/**T.S. Valley, M.W. Sjoding, A.M. Ryan, T.J. Iwashyna, C.R. Cooke, Ann Arbor, MI, p.A4556

9:15 **Adoption and De-Adoption of Adjuvant Treatments for Acute Respiratory Failure/**L. Munshi, E. Fan, H. Wunsch, H. Gershengorn, N.D. Ferguson, T. Stukel, G.D. Rubenfeld, Toronto, Canada, p.A4557

9:30 **Hospital Volume and Outcomes of Noninvasive Ventilation in Patients Hospitalized with an Acute Exacerbation of COPD/**M.S. Stefan, P.K. Lindenauer, M.-S. Shieh, P. Pekow, K. Fisher, N. Hill, Springfield, MA, p.A4558

9:45 **Associations Between Hospital Non-Invasive and Invasive Mechanical Ventilation Utilization in Acute Exacerbations of Chronic Obstructive Pulmonary Disease/**A.B. Mehta, A.J. Walkey, Boston, MA, p.A4559

10:00 **Gender Differences in Appropriate Treatment for Chronic Obstructive Pulmonary Disease/**S. Rinne, A.H. Gerity, L.M. Thayer, C.-F. Liu, M.A. Cook, L.A. Bastian, New Haven, CT, p.A4560

10:15 **Diagnosis and Over-Diagnosis of Asthma in Canadian Adults/**S.D. Aaron, K. Vandemheen, L.-P. Boulet, J.M. FitzGerald, M. Ainslie, S. Gupta, C. Lemiere, S. Field, A. McIvor, P. Hernandez, I. Mayers, Ottawa, Canada, p.A4561

10:30 **Evaluating the Costs of IMRT vs 3D-RT in Stage III Non-Small Cell Lung Cancer/**M.S. Kale, G. Mhango, M. Bonomi, A. Federman, K. Sigel, K. Rosenzweig, J.P. Wisnivesky, New York, NY, p.A4562

10:45 **Procedural Aggressiveness in Veterans with Stage IV Non-Small Cell Lung Cancer at End of Life/**M.H. Tukey, R. Youssef, K. Faricy-Anderson, V. Mor, Providence, RI, p.A4563

MINI SYMPOSIUM

C15 TB GAME CHANGERS: DIAGNOSTICS, HIV, DRUG-RESISTANCE, AND TREATMENT

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**
Room 3016/3018 (West Building, Level 3)

Chairing: R. Reves, MD, MSc, Denver, CO
P. Nahid, MD, MPH, San Francisco, CA
C. Daley, MD, Denver, CO

Oral Presentations

9:00 **Tuberculosis Screening in People Living with HIV Based on Plasma Cytokine and Chemokine Levels/**L.C. Strnad, E. Chang, L. Chaisson, R.K. Ravindran, P.A. Luciw, I.H. Khan, A. Cattamanchi, San Francisco, CA, p.A4564

9:15 **Intensified Tuberculosis Case-Finding Among People Living with HIV: Diagnostic Yield of Xpert MTB/RIF, Urine Lipoarabinomannan and Liquid Culture/**C. Yoon, F. Semitala, E. Atuhumuza, L. Asege, S. Mwebe, J. Katende, A. Andama, D. Armstrong, D. Dowdy, M. Kamya, A. Cattamanchi, San Francisco, CA, p.A4565

9:30 **Modifiers to the Infectiousness of HIV Seropositive Tuberculosis Patients: A Household Contact Study from Sub-Saharan Africa/**L. Martinez, J.N. Sekandi, M.E. Castellanos, S. Zalwango, C.C. Whalen, Athens, GA, p.A4566

9:45 **Frequency and Distribution of Tuberculosis Resistance-Associated Mutations in a Multisite Study/**S.B. Georghiou, D. Catanzaro, R.S. Garfein, V. Crudu, C. Rodrigues, T.C. Victor, A. Catanzaro, T.C. Rodwell, La Jolla, CA, p.A4567

10:00 **Whole Genome Analysis of 5,310 Globally Diverse Mycobacterium Tuberculosis Isolates Reveals Consistent Ordering in the Emergence of Drug Resistance/**K.A. Cohen, A. Manson McGuire, T. Abeel, C. Desjardins, A.S. Pym, A.M. Earl, Boston, MA, p.A4568

10:15 **Feasibility of a Streamlined SIngle-saMPLE (SIMPLE) TB Diagnosis and Treatment Initiation Strategy in Uganda/**P.B. Shete, T. Nalugwa, K. Farr, C. Ojok, M. Nantale, L. Chaisson, D. Dowdy, A. Katamba, D. Moore, A. Cattamanchi, San Francisco, CA, p.A4569

10:30 **High Dose Moxifloxacin for Drug Resistant Tuberculosis; is 600mg the Optimal Dose in High Resistance Settings?/**S.R. Ganatra, Z.F. Udwadia, J.B. Mullerpattan, R.A. Banka, A.R. Gandhare, M.A. Sadani, C.S. Rodrigues, Mumbai, India, p.A4570

10:45 **Prospective Study of Extensively Drug Resistant Tuberculosis and HIV Co-Infection (PROX) in KwaZulu-Natal, South Africa/**K. Yuengling, N. Padayatchi, A. Wolf, C.R. Horsburgh, M. O'Donnell, New York, NY, p.A4571

MINI SYMPOSIUM

C16 PEDIATRIC IMAGING: WHAT'S NEW

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 3003/3005 (West Building, Level 3)

Chairing: T.E. Robinson, MD, Palo Alto, CA
M.O. Wielpuetz, MD, Heidelberg, Germany

Oral Presentations

9:00 **Pulmonary MRI to Evaluate Neonatal Lung Growth in Congenital Diaphragmatic Hernia/**M.A. Schopper, L.L. Walkup, J.A. Tkach, N.S. Higano, F.Y. Lim, B.E. Haberman, J.C. Woods, P.S. Kingma, Cincinnati, OH, p.A4572

9:15 **Dependence of MRI-Determined Lung Volume on Gestational Age: A Comparison between Healthy and IUGR Fetuses/**E. Stirrat, J. Zheng, R. Ramroop, C. Macgowan, M. Seed, G.E. Santyr, Toronto, Canada, p.A4573

9:30 **Quantification of Neonatal Lung Parenchymal Density Via Ultra-Short Echo-Time (UTE) Magnetic Resonance Imaging (MRI)/**N.S. Higano, L.L. Walkup, A. Hahn, R. Thomen, S. Merhar, P.S. Kingma, J.A. Tkach, S. Fain, J.C. Woods, Cincinnati, OH, p.A4574

9:45 **Automated Lung Segmentation and Longitudinal Air Trapping Quantification in Chronic Lung Disease of Prematurity/**A. Mansoor, G.F. Perez, K. Pancham, A. Jain, K. Okada, M.G. Linguraru, G.R. Nino, Washington, DC, p.A4575

10:00 **The Relationship of Lung Function in Cystic Fibrosis to Volume of Hypo Perfused Lung Volume and Systemic Arterial Blood Flow to the Lung/**M. Alexander, K. Eaton, R.J. Fleck, J.C. Woods, A. Brody, J.P. Clancy, Cincinnati, OH, p.A4576

10:15 **Hyperpolarized 129Xe MRI Is Sensitive to Impaired Ventilation in Pediatric Cystic Fibrosis Patients with Normal Spirometry/**L.L. Walkup, R. Thomen, T. Akinyi, K. Ruppert, Z.I. Cleveland, J.P. Clancy, J.C. Woods, Cincinnati, OH, p.A4577

10:30 **Stationary Digital Chest Tomosynthesis of Cystic Fibrosis/**Y.Z. Lee, J.L. Goralski, A. Hartman, G. Wu, S. Donaldson, R.C. Boucher, O. Zhou, Chapel Hill, NC, p.A4578

10:45 **Longitudinal Automated Airway and Air-Trapping Analysis on CT in School Age Children with Mild Cystic Fibrosis Lung Disease/**M.O. Wielpuetz, T.E. Robinson, P. Konietzke, C.-P. Heussel, H.-U. Kauczor, C. Galban, D.N. Cornfield, D. Savage, B. Newman, O. Weinheimer, Heidelberg, Germany, p.A4579

MINI SYMPOSIUM

C17 FASCINATING MECHANISMS IN LUNG FIBROSIS

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 2020/2022 (West Building, Level 2)

Oral Presentations

9:00 **TAZ Activation Promotes Fibroblast-Mediated Matrix Stiffening in the Lung/**D. Sicard, Q. Tan, K.M. Choi, D. Mehra, D. Lagares, C. Probst, A.M. Tager, D.J. Tschumperlin, Rochester, MN, p.A4580

9:15 **Expression of the Surfactant Protein C Mutant SP-CI73T in Mice Results in Dose Dependent Disruption of Lung Development and Age Related Diffuse Parenchymal Lung Remodeling In Adults/**S.-I. Nureki, Y. Tomer, S.J. Russo, V. Nguyen, S. Mulugeta, M.F. Beers, Philadelphia, PA, p.A4581

9:30 **Therapeutic Targeting of Fibroblast Durotaxis: A Novel Class of Anti-Fibrotic Therapies for IPF/**D. Lagares, P. Grasberger, C. Probst, A. Engler, A.M. Tager, Charlestown, MA, p.A4582

9:45 **Impaired Myofibroblast Dedifferentiation Contributes to Non-Resolving Fibrosis in Aging/**L. Hecker, N.J. Logsdon, Y.-J. Shin, J.G.N. Garcia, V.J. Thannickal, Tucson, AZ, p.A4583

10:00 **Characterizing the Diversity of Pathologic Fibroblasts Across Solid Organs Using Single Cell RNAseq/**K.-H. Sun, Y. Chang, I. Driver, A. King, M. Fricano, N.I. Reed, J.R. Rock, D. Sheppard, San Francisco, CA, p.A4584

10:15 **RTEL1 Regulates Cell Cycle and DNA Repair Mechanisms in Alveolar Epithelial Cells/**J.A. Kropski, J. Cogan, D.B. Mitchell, C.L. Calvi, C. Markin, E.T. Garnett, D.A. Schwartz, L.R. Young, W.E. Lawson, M.P. Steele, J. Loyd, Z. Zhao, J.A. Phillips, III, T.S. Blackwell, Nashville, TN, p.A4585

10:30 **Hippo Signaling is Deranged in Idiopathic Pulmonary Fibrosis and Correlates with Disease Severity/**D.E. Wagner, K. Mutze, H.B. Schiller, R. Costa, N. Kaminski, M. Konigshoff, Munich, Germany, p.A4586

10:45 **The Host Response to the Lung Microbiome in Idiopathic Pulmonary Fibrosis/**N. Tanabe, J.E. McDonough, M. Sze, S. Verleden, D. Kinose, D.M. Vasilescu, R. Ng, B.T. Jin, N. Kaminski, W. Wuyts, B.M. Vanaudenaerde, J.C. Hogg, Vancouver, Canada, p.A4587

MINI SYMPOSIUM

C18 ADVANCES IN MEASURING LUNG FUNCTION: SMALL AIRWAYS AND UP

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 2009/2011 (West Building, Level 2)

Chairing: D.A. Kaminsky, MD, Burlington, VT
M.J. Hegewald, MD, Murray, UT
C. Thamrin, PhD, Glebe, Australia

Oral Presentations

9:00 **Prevalence of Increased Airway Closure in Response to Methacholine Among Asthmatic Participants in the American Lung Association's Airways Clinical Research Centers (ALA-ACRC)/**D.A. Kaminsky, J. Holbrook, J. Mastronade, W.G. Teague, M.F. Busk, K. Sumino, D.G. Chapman, A.E. Dixon, R.A. Wise, C.G. Irvin, Burlington, VT, p.A4588

9:15 **Age and Sex Influences on Dynamic Air-Trapping in Asthma/**R. Sorkness, C. Kienert, M. O'Brien, S. Fain, N.N. Jarjour, Madison, WI, p.A4589

9:30 **Low Dynamic Compliance May Indicate Expiratory Flow Limitation in Healthy Infants/**D. Czovek, L. Willemse, B. Radics, G. Makan, A. Visagie, Z. Gingl, G. Hall, P.D. Sly, H.J. Zar, Z. Hantos, D. Gray, South Brisbane, Australia, p.A4590

9:45 **Intra-Breath Assessment of Respiratory Impedance Reveals Unique Pattern of Bronchodilator Response in Wheezy Children/**C. Shackleton, Z. Hantos, A. Kumar, K. Grimwood, B. Radics, Z. Gingl, P.D. Sly, D. Czovek, South Brisbane, Australia, p.A4591

10:00 **Breath-To-Breath and Day-To-Day Variability of Respiratory Impedance in Asthma Patients/**C.D. Nguyen, A. Gobbi, R.L. Dellaca, G.G. King, C. Thamrin, Sydney, Australia, p.A4592

10:15 **Bronchodilator Responses of Forced Oscillation Technique and Spirometry in Adults with and Without Airflow Obstruction in an Australian Community/**K. Jetmalani, C. Thamrin, C.S. Farah, C. Diba, B. Toelle, G.G. King, Sydney, Australia, p.A4593

10:30 **Dysfunction of the Distal Airway and Alveolar Capillary Membrane (Distal Lung Unit) During Steady State Exercise/** I. Soghier, D. Smith, K.I. Berger, R.M. Goldring, B.W. Oppenheimer, New York, NY, p.A4594

10:45 **Impact of Hematocrit on Airway Properties and Lung Tissue Viscoelasticity/**G.H. Fodor, F. Petak, B. Babik, W. Habre, Szeged, Hungary, p.A4595

MINI SYMPOSIUM

C19 FROM GENES TO MOTOR NEURONS: ADVANCES IN CONTROL OF BREATHING

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 2001/2003 (West Building, Level 2)

Chairing: E.B. Gauda, MD, Baltimore, MD
N. Nichols, PhD, Columbia, MO
F.J. Jacono, MD, Cleveland, OH

Oral Presentations

9:00 **Localizing Effects of Leptin on Upper Airway and Respiratory Control During Sleep/**Q. Yao, H. Pho, J.P. Kirkness, E.E. Ladenheim, S. Bi, T.H. Moran, D.D. Fuller, D.C. Bloom, A.R. Schwartz, V.Y. Polotsky, Baltimore, MD, p.A4596

9:15 **Acute Cervical Spinal Cord Injury Exhibits Sleep Disordered Breathing in a Rat Model/**Z. Minic, M. Shanidze, D.R. Wahlstrom, H. Goshgarian, A. Sankari, Detroit, MI, p.A4597

9:30 **5HT Modulation of Arousal and Chemoreflex Responses in Intact and SCI Mice/**D. Komnenov, J.Z. Solarewicz, F. Afzal, D. Kuhn, J. Mateika, Detroit, MI, p.A4598

9:45 **Effect of Acute Intermittent Hypoxia on Ventilation in Patients with Chronic Spinal Cord Injury During Sleep/**A. Sankari, A.T. Bascom, M.S. Badr, Detroit, MI, p.A4599

10:00 **Determination of Optimal Supplemental Oxygen Flow Rate for Treatment of Infants with Obstructive Sleep Apnea (OSA)/**J. Brockbank, M. Dixon, N. Simakajornboon, Richmond, VA, p.A4600

10:15 **Does High Altitude Cause Hypoventilation in Patients with Congenital Central Hypoventilation Syndrome?/**L. Kang, S.S. Kun, N. Vajda, T.G. Keens, I.A. Perez, Los Angeles, CA, p.A4601

10:30 **Analysis of Hypoxic and Hypercapnic Ventilatory Response in Healthy Volunteers/**H. Sharifi, S. Goldberg, H. Ollila, L. Lin, T. Rico, O. Andlauer, A. Aran, E. Bloom-Rosen, J. Faraco, F. Han, E. Mignot, Stanford, CA, p.A4602

Featured Speaker

10:45 **The Latest and Greatest in Neural Control of Breathing/**J.M. Ramirez, PhD, Seattle, WA

MINI SYMPOSIUM

C20 ADVANCES IN THE CELLULAR AND MOLECULAR UNDERSTANDING OF LUNG CANCER

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 306/308 (South Building, Esplanade Level)

Chairing: S. Albelda, MD, Philadelphia, PA
V.C. Broaddus, MD, San Francisco, CA

Featured Speaker

9:00 **Learning from Within: The Role of the Microenviroment in Lung Cancer/**S. Dubinett, MD, Los Angeles, CA,

Oral Presentations

9:15 **Non-Small Cell Lung Cancer (NSCLC) Tumor Progression is Inhibited in an Inducible Vascular-Specific MicroRNA-1 (miR-1) Transgenic Model/**A. Korde, L. Jin, M. Haslip, S. Takyar, New Haven, CT, p.A4603

9:30 **In Utero Second-Hand Smoke Exposure Accelerates Urethane-Induced Lung Tumor Growth and Malignancy in Male Mice/**A. Noel, R. Xiao, L.R. Peterson, Z. Perveen, V. Le Donne, D.B. Paulsen, A.L. Penn, Baton Rouge, LA, p.A4604

9:45 **Mouse Models of Lung Cancer Initiated by Adenovirus Expressing Cre Recombinase Also Target Alveolar Macrophages/**D. Tippimanchai, J. Poczobutt, K. Nolan, G. Verzosa, H. Li, R. Nemenoff, S. Malkoski, Aurora, CO, p.A4605

10:00 **The Autocrine and Paracrine Roles of Epithelial STAT3 in K-ras Mutant Lung Cancer/**M.S. Caetano, H.T. Van, E. Bugarin, A.M. Cumpian, H. Zhang, S.E. Evans, I.I. Wistuba, C. Behrens, H. Kadara, S.S. Watowich, S.J. Moghaddam, Houston, TX, p.A4606

10:15 **Glycan Sulfation Modulates Dendritic Cell Biology and Carcinoma Growth/**M.M. Fuster, R. El Ghazal, X. Yin, S. Johns, M. Macal, E. Zuniga, San Diego, CA, p.A4607

10:30 **The Examination of CD47 and Its Potential Therapy Target Study on the Migration and Invasion in Non-Small Cell Lung Cancer/**Q. Wang, H. Zhao, J. Wang, X. Du, E. Li, Dalian, China, p.A4608

10:45 **Comprehensive Assessment of the Human Lung Cancer Tumor Immune Microenvironment Via a Novel Immunohistochemistry Method/**K.T. Meinhof, R. Remark, C.A. Powell, M. Merad, S. Gnjatic, C.D. Becker, New York, NY, p.A4609

BASIC SCIENCE CORE POSTER DISCUSSION SESSION

C21 APPLYING 'OMICS TECHNOLOGIES TO REVEAL GENE REGULATORS AND BIOMARKERS IN LUNG DEVELOPMENT AND DISEASE

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 2010/2012 (West Building, Level 2)

Poster Viewing **9:00-9:45**

Discussion **9:45-11:00**

Chairing: N. Kaminski, MD, New Haven, CT
M.W. Geraci, MD, Indianapolis, IN
C.E. Wheelock, PhD, Stockholm Sweden

401 **Transcriptomic Changes Common to Diverse Chronic Lung Diseases Indicate a Core Lung Response to Chronic Injury/**B.M. Cherry, B. Juan-Guardela, K. Sakamoto, N. Kaminski, J. Herazo-Maya, New Haven, CT, p.A4610

402 **Vascular Cell-Specific Genome-Wide Profiling of Epigenetic Landscape Reveals Gene Regulatory Signatures in Human Pulmonary Arterial Hypertension/**P. Chelladurai, C. Kunne, C. Weber, M. Schmoranzer, R.R. Notzold, W. Seeger, M. Looso, U.-M. Bauer, S.S. Pullamsetti, Bad Nauheim, Germany, p.A4611

403 **Circulating Exosomal MicroRNA Signature in Young Healthy Adults Subjects Exposed to Intermittent Hypoxia and Following Normoxic Recovery/**A. Khalyfa, C. Zhang, A.A. Khalyfa, A. Beaudin, A. Andrade, M.J. Poulin, D. Gozal, Chicago, IL, p.A4612

404 **Metabolomics Approach to Understanding the Pathogenesis of Respiratory Syncytial Virus (RSV) Infection/**K.N. Turi, M. Steinhoff, M. Watanabe, L. Romick-Rosendale, M.L. Moore, L.J. Anderson, E.K. Larkin, T. Gebretsadik, T.V. Harter, Nashville, TN, p.A4613

405 **A Systems-Biology Approach to Identify a YAP/TAZ-miR-130/301 Molecular Circuit Controlling Pulmonary Fibrosis/**J.H. Yoon, T. Bertero, K.A. Cottrill, S. Annis, B. Bhat, B. Gochuico, J.C. Osorio, I.O. Rosas, K.J. Haley, B.N. Chau, S.Y. Chan, Pittsburgh, PA, p.A4614

406 **Metabolic Reprogramming in Pulmonary Hypertension as Gleaned Through Mass Spectrometry-Based Metabolomics/**A. D'Alessandro, S. Riddle, H. Zhang, M. Li, A. Flockton, K.C. Hansen, M.A. Fini, S. Pullamsetti, K.C. El Kasmi, K.R. Stenmark, Aurora, CO, p.A4615

407 **Desmoplakin (DSP) Variants Are Associated with Idiopathic Pulmonary Fibrosis and with Differential Gene Expression in Lung Tissue/**S.K. Mathai, B.S. Pedersen, K. Smith, P. Russell, M.I. Schwarz, K.K. Brown, M.P. Steele, J. Loyd, J.D. Crapo, E.K. Silverman, D. Nickerson, T. Fingerlin, I.V. Yang, D.A. Schwartz, Aurora, CO, p.A4616

408 **Genome-Wide Assessment Reveals Marked Differences in the Transcriptomes of Mononuclear Phagocytes in the Developing Lung/**E. Sajti, V. Link, C. Romanoski, G. Fonseca, T. Troutman, L. Prince, C. Glass, La Jolla, CA, p.A4617

409 **Automated Cell Type Prediction in Single Cell RNA-Seq Analysis of the Lung/**M. Guo, J.A. Whitsett, S.S. Potter, Y. Xu, Cincinnati, OH, p.A4618

410 **Meta-Analysis of Peripheral Blood Mononuclear Cell Genome-Wide Expression Profiling in Pulmonary Arterial Hypertension/**A.J. Mazer, R. Cai, J. Sun, G. Graninger, B. Harper, G. Ferreyra, R.L. Danner, M.A. Solomon, J.M. Elinoff, Bethesda, MD, p.A4619

411 **Precision Transcriptomes: Among a Population of Healthy Smokers, What Are the Shared Vs Individual Smoking-Responsive Genes in the Small Airway Epithelium and Alveolar Macrophages?/**Y. Strulovici-Barel, M.R. Staudt, J. Salit, R.J. Kaner, A.E. Tilley, A.M. Rogalski, C. Hollmann, H. Bitter, S.G. Pillai, H. Hilton, G. Wolff, C.S. Stevenson, S. Visvanathan, J.S. Fine, J.G. Mezey, R.G. Crystal, New York, NY, p.A4620

412 **Single Cell RNA-Seq Analysis of Fibrosis in Mouse Pulmonary Fibrosis Models/**A. Munivar, X. Yan, A. Tzouvelekis, T. Woolard, K. Sakamoto, G. Deluliis, J. Herazo-Maya, Q. Li, M. Vukmirovic, N. Aurelien, T. Adams, N. Kaminski, F. Ahangari, New Haven, CT, p.A4621

413 **Investigating the Diagnostic Potential of Circulating miRNA Signatures in Pulmonary Arterial Hypertension/**J. Iremonger, A.M. Rothman, C. Rhodes, R. Condliffe, C.A. Elliot, D. Kiely, L.S. Howard, S. Gibbs, J. Wharton, M.R. Wilkins, A. Lawrie, Sheffield, United Kingdom, p.A4622

414 **Sputum Transcriptomics Identifies Co-Expressed Network Signatures Associated with FEV1 and Sputum Neutrophilia in Severe Asthmatics on Oral Corticosteroids/**C.H.S. Kuo, S. Pavlidis, M. Loza, F. Baribaud, A. Rowe, I. Pandis, C. Rossios, R. Lutter, R. Djukanovic, P.J. Sterk, K.F. Chung, I. Adcock, Y. Kuo, London, United Kingdom, p.A4623

415 **Investigating mRNA and miRNA Alterations Induced by Asthma-associated Cytokine Stimulation in a Human Airway Model Using RNASeq/**L.R. Bonser, S.A. Christenson, J. Pollack, R. Barbeau, A. Barczak, L. Zlock, W. Finkbeiner, P.G. Woodruff, D. Erle, San Francisco, CA, p.A4624

416 **Lung Gene Expression Analysis: An Integrative Web Portal for Comprehensive Gene Expression Data Analysis in Lung Development/**Y. Du, J.A. Kitzmiller, A. Sridharan, A.K. Perl, J. Bridges, R.S. Misra, G.S. Pryhuber, T.J. Mariani, S. Bhattacharya, M. Guo, S.S. Potter, P. Dexheimer, B. Aronow, J.A. Whitsett, Y. Xu, Cincinnati, OH, p.A4625

417 **A Comparative Transcriptomic Approach to Identify Transcriptional Programs Regulating Primate Lung Maturation/**Y. Xu, Y. Du, J.A. Kitzmiller, A. Sridharan, S.S. Potter, S.E. Wert, M. Guo, A. Jobe, S.G. Kallapur, C.A. Chougnet, J.A. Whitsett, Cincinnati, OH, p.A4626

418 **MicroRNA Array Analysis of Microvesicles (MVs) Derived from Broncho-Alveolar Lavage Fluid (BALF) Indicates Potential Novel Regulators of Lipopolysaccharide (LPS) Induced Alveolar Macrophage Activation/**D. Zhang, H. Lee, Y. Jin, Boston, MA, p.A4627

419 **Gene Expression Profiles Using RNA-Sequencing of Formalin-Fixed, Paraffin-Embedded (FFPE) Lung Tissue Predict Poor Outcomes in Idiopathic Pulmonary Fibrosis/**J. Herazo-Maya, M. Vukmirovic, X. Yan, B. Hu, R. Homer, B. Juan-Guardela, Q. Li, A.E. Tzouvelekis, G. Yu, F. Ahangari, N. Aurelien, G. Deluliis, K. Gibson, K.O. Lindell, S.A. Yousem, N. Kaminski, New Haven, CT, p.A4628

420 **Single Cell RNA Sequencing Reveals Smoking-Associated Alterations in Bronchial Epithelial Subpopulations/**G.E. Duclos, J.D. Campbell, P. Autissier, Y.M. Dumas, R. Terrano, G. Liu, M.E. Lenburg, A. Spira, J. Beane, Boston, MA, p.A4629

421 **Obese Adipocyte-Derived Exosomal miRNAs Targeting TGF-ß Signaling Are Associated with Poor Asthma Control/**S.C. Ferrante, S. Epstein, E. Nadler, M. Barberio, M. Goldberg, L. Maltz, M. Hubal, R.J. Freishtat, Washington, DC, p.A4630

422 **Corticosteroid Effects on Transcriptional Programs Regulating Lung Maturation in the Fetal Primate/**D.D. Lipps, A. Schmidt, A. Jobe, J.A. Whitsett, Y. Xu, Cincinnati, OH, p.A4631

423 **Non-Invasive Sub-Phenotyping of Asthma in the U-BIOPRED Study by Analysis of Urinary Lipid Mediator Excretion Patterns/**C.E. Wheelock, J. Kolmert, D. Lefaudeux, M. Sjodin, D. Balgoma, A.R. Sousa, J. Corfield, I. Pandis, R. Djukanovic, S.-E. Dahlen, Stockholm, Sweden, p.A4632

424 **Interrogation of an Exhaled microRNA Panel to Develop Risk Biomarkers for Lung Cancer/**S.D. Spivack, M. Shi, W. Han, L. Rosa, Bronx, NY, p.A4633

POSTER DISCUSSION SESSION

C22 AIRWAY EPITHELIUM: MOLECULAR REGULATION OF INFLAMMATION

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 133 (North Building, Lower Level)

Poster Viewing **9:00-9:45**

Discussion **9:45-11:00**

Chairing: R. Wu, PhD, Davis, CA
A. Haczku, MD, PhD, Davis, CA
A. Van Der Vliet, PhD, Burlington, VT

101 **Allergen-Induced Unfolded Protein Response Regulates Lung Inflammation and Fibrosis/**V. Anathy, S. Mariswamy, E. Nakada, B. Mihavics, S.M. Hoffman, D.G. Chapman, N.R. Bhakta, P.G. Woodruff, C.G. Irvin, A.E. Dixon, M.E. Poynter, Burlington, VT, p.A4634

102 **Adaptive and Innate Lymphocytes Are Dispensable for House Dust Mite Induced Airways Epithelial Endoplasmic Reticulum (ER) Stress and Fibrosis in Mice/**V. Anathy, S.M. Hoffman, J. Ather, B. Mihavics, E. Nakada, K. Fortner, M.E. Poynter, Burlington, VT, p.A4635

103 **Proteome Profiling Reveals Cofilin-1 as a Candidate Mediator of TGF-Beta1-Induced Glucocorticoid Resistance/**A.G. Stewart, C.R. Keenan, Y.C. Xia, S. Langenbach, M. Li, Parkville, Australia, p.A4636

104 **Respiratory Syncytial Virus or the TLR3 Ligand, Double Stranded RNA, Induce Glucocorticoid Resistance in Human Bronchial Epithelial Cells/**A.G. Stewart, A. Radwan, Y.C. Xia, S. Langenbach, R.C. Gualano, Parkville, Australia, p.A4637

105 **Respiratory Syncytial Virus or the TLR3 Ligand Double Stranded RNA Induce Glucocorticoid Resistance in Human Bronchial Epithelial Cells/**A. Radwan, Y.C. Xia, S. Langenbach, R.C. Gualano, A.G. Stewart, Parkville, Australia, p.A4638

106 **Distinct MUC5AC-Rich Domains in Mucus Tether to the Epithelium and Impair Mucociliary Transport in Asthma/**L.R. Bonser, L. Zlock, W. Finkbeiner, D. Erle, San Francisco, CA, p.A4639

107 **Insulin Mediated Airway Remodeling Via ß Catenin Signaling/** P. Kolumam Parameswaran, M. Bodas, S. Singh, M.R. Freeman, M.A. Thompson, N. Bhatraju, B. Patnaik, A. Gheware, U. Mahabalirajan, R. Gosens, B. Ghosh, C. Pabelick, A. Linneberg, Y.S. Prakash, A. Agarwal, Rochester, MN, p.A4640

108 **An In Vivo Model of Human Airways for Investigating Fibrosis/**S.C. Ferrante, T.-L. Hackett, C.E. Hoptay, J. Engelhardt, J.L. Ingram, S. Alcala, Y. Zhang, F. Shaheen, E. Matz, D.K. Pillai, R.J. Freishtat, Washington, DC, p.A4641

109 **SPLUNC1 Modulates Calcium Influx in Airway Smooth Muscle/**T. Wu, W. Walton, M. Redinbo, N.E. Alexis, R. Tarran, Chapel Hill, NC, p.A4642

110 **Surfactant Protein A2 Alleles Differentially Alter IL-13-Induced Mucin Production/**A.S. Buntzman, S. Sasipa Tanyaratsrisakul, Y. Wang, D. Francisco, K. Addison, A. Manne, J.G. Ledford, D.R. Voelker, M. Kraft, Tucson, AZ, p.A4643

111 **Mitochondrial Arginine Metabolism in Bioenergetics of Asthma/**W. Xu, S. Ghosh, S.A.A. Comhair, K. Asosingh, A.J. Janocha, L.A. Mavrakis, C. Bennett, L. Gruca, B.B. Graham, K. Queisser, C.C. Kao, S.H. Wedes, J. Petrich, R. Tuder, S.C. Kalhan, S.C. Erzurum, Cleveland, OH, p.A4644

112 **Primary Airway Epithelial Cells that Are Conditionally Reprogrammed Maintain Lineage, Phenotypic and Functional Characteristics/**A. Kicic, K.M. Martinovich, T. Iosifidis, K.-M. Ling, E. Kicic-Starcevich, K. Looi, L.W. Garratt, N.C. Shaw, A.G. Buckley, S.T. Montgomery, F.J. Lannigan, E.N. Sutanto, D.A. Knight, S. Stick, Perth, Australia, p.A4645

113 **Differential Migration Responses to Wounding Between Asthmatic and Non-Asthmatic Primary Airway Epithelial Cells/**T. Iosifidis, A.G. Buckley, E.N. Sutanto, K.-M. Ling, L.W. Garratt, K. Looi, E. Kicic-Starcevich, K.M. Martinovich, N.C. Shaw, S.T. Montgomery, S. Vijayasekaran, F.J. Lannigan, P.J. Rigby, D.A. Knight, S. Stick, A. Kicic, Perth, Australia, p.A4646

114 **Increased Nuclear Factor-κB Activation in Airway Epithelial Cells in a Mouse Model of Allergic Airways Disease Promotes Pathophysiology Consistent with Asthma and COPD/**D.G. Chapman, R.W. Schneider, N. Daphtary, M. Aliyeva, K.G. Lahue, J.L.J. Van Der Velden, Y. Janssen-Heininger, C.G. Irvin, Burlington, VT, p.A4647

115 **The Regulation of Interleukin-13 Receptor Subunits in Response to Mechanical Wounding and IL-13 Exposure/**S.-Y.J. Yang, G.K. Singhera, D.R. Dorscheid, Vancouver, Canada, p.A4648

116 **Bronchial Epithelial Expression of IL33/ST2: Stratification on Known Risk Genotypes/**M.A. Portelli, S.K. Bhaker, S.R. Johnson, D. Shaw, C.E. Brightling, I. Sayers, Nottingham, United Kingdom, p.A4649

117 **Airway Epithelial Cell Peroxisome Proliferator-Activated Receptor l3 (PPARγ) Is a Crucial Regulator of Allergic Airway Disease/** A.T. Reddy, S.P. Lakshmi, R.C. Reddy, Pittsburgh, PA, p.A4650

118 **SDF-1/CXCR4 Signaling Regulates Bone Marrow Mesenchymal Stem Cell Trafficking to Promote Airway Remodeling in Asthmatic Rats/**B. Mo, Z. Wang, C. Wang, J. Wei, L. Ma, D. Yao, J. Wang, G. Huang, J. Huang, Q. Xu, Guilin, China, p.A4651

119 **Maintenance of IRF1 by IL1B and Dexamethasone in Human Pulmonary Epithelial Cells: Role of the Mitogen-Activated Protein Kinase Phosphatase, DUSP1/**S.V. Shah, M.M. Mostafa, R. Newton, Calgary, Canada, p.A4652

120 **Airway Epithelial Exosomes Play a Major Role in Intercellular Communication and Pathophysiology of Asthma/**R. Gupta, G. Radicioni, H. Dang, P. Mieczkowski, S.H. Randell, M. Kesimer, Chapel Hill, NC, p.A4653

121 **KIF3A Regulates Lung Morphogenesis, Airway Epithelial Cell Repair and Inflammation/**P. Vummidi Giridhar, S.M. Bell, A. Sridharan, J.B. Myers, H. Johansson, M. Lisa, P. Rajavelu, J.A. Kitzmiller, M. Kofron, N. Cheng-Lun, E. Brandt, M. Ericksen, N. Anjaparavanda, M. Chang.Suk, H. Hua, L. Mark, G.K. Hershey, J. Whitsett, Cincinnati, OH, p.A4654

122 **DUOX2 and its Product Hydrogen Peroxide Enhance MUC5AC Expression in Human Bronchial Epithelial Cells/**J. Milosevic, T. Zhang, E.B. Etling, S.E. Wenzel, Pittsburgh, PA, p.A4655

123 **Normal Autophagy Activity Is Maintained in Human Airway Epithelial Cells from Severe Asthmatics/**A.C. Burks, A.D. Naylor, J. Haspel, M. Castro, J.D. Dickinson, T.S. Stappenbeck, M.J. Holtzman, S.L. Brody, St. Louis, MO, p.A4656

124 **IL-33 Increases IL1F9 (IL36γ) Expression in Human Airway Epithelial Cells/**S.R. White, B. Laxman, R. Stern, Chicago, IL, p.A4657

125 **Phosphatidylethanolamine-Binding Protein 1 Modulates 15-Lipoxygenase 1 Pathway in Human Airway Epithelial Cells/** E.B. Etling, S. Lauder, V. Tyrrell, E.B. Yecies, J.B. Trudeau, V.B. O'Donnell, J. Zhao, S.E. Wenzel, Pittsburgh, PA, p.A4658

POSTER DISCUSSION SESSION

C23 CONTEMPORARY QUESTIONS IN LUNG TRANSPLANTATION

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 304 (South Building, Esplanade Level)

Poster Viewing **9:00-9:45**

Discussion **9:45-11:00**

Chairing: J.D. Christie, MD, MSCE, Philadelphia, PA
S.M. Bhorade, MD, Chicago, IL
R.D. Yusen, MD, MPH, St. Louis, MO

201 **Multiple Listing in Lung Transplant Candidates: A Cohort Study/**J.J. Mooney, H. Hedlin, R. McKenzie, P. Mohabir, L. Chhatwani, R. Ha, J. Boyd, K. Patel, J. Bhattacharya, G. Dhillon, Stanford, CA, p.A4659

202 **Effect of Broader Geographic Sharing of Donor Lungs on Lung Transplant Candidate Outcomes/**J.J. Mooney, L. Chhatwani, K. Patel, P. Chiu, R. Ha, J. Boyd, G. Dhillon, Stanford, CA, p.A4660

203 **Predictors And Outcomes of Unplanned Early Rehospitalization in The First Year Following Lung Transplantation/**A. Courtwright, S. Salomon, M.J. Divo, I.O. Rosas, P. Camp, H. Mallidi, P. Burkett, S. El-Chemaly, A.L. Fuhlbrigge, D. Wolfe, H.J. Goldberg, Boston, MA, p.A4661

204 **Management of Viral Respiratory Tract Infections in Lung Transplant Recipients: Current Practice in Northern Europe/**E. Lhuillier, M. Patout, P. Marino, O. Brugiere, G. Dauriat, G. Jebrak, G. Thabut, A.-C. Metivier, H. Mal, Paris, France, p.A4662

205 **Suicidal Ideation in Lung Transplant Recipients: An Assessment of Pre-Transplant Risk Factors Through 4 Case Studies/**M. Samsi, L. Zaluda, D.F. Dilling, Chicago, IL, p.A4663

206 **Body Composition Phenotypes in Adults Awaiting Lung Transplantation/**P. Madahar, J.P. Singer, J. Sell, P. Katz, J.A. Golden, H.Y. Robbins, L. Shah, K. Raza, J. Hook, M. Bacchetta, F. D'Ovidio, J.R. Sonett, J. Kukreja, L. Leard, S. Hays, S. Arcasoy, J.M. Diamond, J.D. Christie, D.J. Lederer, New York, NY, p.A4664

207 **Survival of Lung Transplant Candidates with COPD: BODE Reconsidered/**M.J. Mulligan, M. Eberlein, M.T. Dransfield, G. Netzer, P.G. Sanchez, S.M. Scharf, D.D. Sin, B.R. Celli, R.M. Reed, Baltimore, MD, p.A4665

208 **Changes in Quality of Life After Lung Transplantation in Recipients with Connective Tissue Related ILD (CTD-ILD)/**R.J. Shah, H.R. Collard, A. Soong, P. Shrestha, S. Hays, L. Leard, J.A. Golden, J. Kukreja, A.V. Estrada, P. Blanc, J.P. Singer, San Francisco, CA, p.A4666

209 **Safety and Change in Management of Surveillance Versus Clinically Indicated Bronchoscopy in Lung Transplant Recipients/**Z. Haupt, H.C. Prescott, Ann Arbor, MI, p.A4667

210 **Questioning the Role of Surveillance Transbronchial Biopsies Beyond Six Months Post Lung Transplant: A Single Institution Experience/**H. Inaty, A. Jawad, J. Cicenia, S. Sethi, F. Almeida, A.C. Mehta, T. Gildea, M. Valapour, M. Machuzak, Cleveland, OH, p.A4668

211 **Circulating Elastase Confers a High Risk for the Development of Bronchiolitis Obliterans Syndrome/**C.E. Milla, J.M. Zirbes, A. Yacob, L. Tian, R.T. Zamanian, M. Bental-Roof, R. Bland, M. Rabinovitch, G. Dhillon, M. Nicolls, Stanford, CA, p.A4669

212 **Lung Transplantation Improves Health-Related Quality of Life for Most, but Not All, with Advanced Lung Disease/**J.P. Singer, A. Soong, P. Shrestha, D. Huang, M. Mindo, P. Katz, L. Leard, S. Hays, J.A. Golden, J. Kukreja, J.R. Greenland, M.E. Kleinhenz, R.J. Shah, P.D. Blanc, San Francisco, CA, p.A4670

213 **Impact of Body Fat Composition on Hospital Length of Stay and One Year Readmission Rate in Patients Post Bilateral Lung Transplantation/**O. Ahmad, M. Browning, M. Baz, C. Hage, J. Wu, M. Duncan, D. Roe, Indianapolis, IN, p.A4671

214 **Neuron Specific Enolase Is an Early Marker of Delirium Following Lung Transplantation/**B.J. Anderson, C. Christie, R. Tino, K. Ramphal, A. Wysoczanski, M. Theodore, N. Blumenthal, J. Golato, E. Hobson, K. Carney, J. Mendez, C.A. Bermudez, E. Cantu, J.M. Diamond, Philadelphia, PA, p.A4672

215 **Poor Outcomes for Bronchiectasis Patients Post Lung Transplantation/**J.L. Kennedy, C. Ellender, K. Steinfort, A. Walker, H. Whitford, Prahran, Australia, p.A4673

216 **Outcomes in Allosensitized Lung Transplant Recipients: A Single Center Experience/**A. Mayalall, E. Reed, A. DerHovanessian, M. Shino, D. Sayah, J.P. Lynch, R. Saggar, D. Ross, A. Ardehali, J.A. Belperio, S. Weigt, Los Angeles, CA, p.A4674

217 **The Diagnostic Value of Quantitative End-Inspiratory Chest-CT in Bronchiolitis Obliterans Syndrome (BOS)/**M. Horger, S. Wirths, S.D. Ioanoviciu, W. Thaiss, M. Haentschel, C. Kloth, W. Spengler, J. Hetzel, Tuebingen, Germany, p.A4675

218 **Early Nosocomial Adenovirus Infection Is Associated with Worse Outcomes Following Lung Transplantation/**O.H. Mohamedaly, A.L. Gray, C.R. Wolfe, Durham, NC, p.A4676

219 **Ventilation Heterogeneity Early Post Lung Transplant Predicts Rejection and Mortality/**B.R. Thompson, M. Ellis, S. Verbanck, T. Kotsimbos, P. Liakakos, G.I. Snell, Melbourne, Australia, p.A4677

220 **Axial Visceral Fat-to-Skeletal Muscle Ratio Is Associated with Six Minute Walk Distance Performance Following Lung Transplantation/**L. Debiane, C. DiPerna, A. Perkins, B. Khan, M. Asare-Sawiri, D. Roe, M. Tann, C. Hage, Indianapolis, IN, p.A4678

221 **Associations Between Pre-Transplant Body Mass Index, Pectoralis Muscle Area, and Underlying Disease in Patients Undergoing Lung Transplantation/**G.W. Li, V. Hoang, N.L. Capuano, C.C. Kao, G. Dronavalli, A.D. Parulekar, Houston, TX, p.A4679

222 **Adipose Gene Expression Profile Changes with Lung Allograft Reperfusion/**J.M. Diamond, S. Arcasoy, J. McDonnough, E. Cantu, J.R. Sonett, M. Bacchetta, F. D'Ovidio, C.A. Bermudez, A. McBurnie, M. Rushefski, Y. Suzuki, J. Giles, M. Oyster, C. D'Errico, A. Ferrante, M. Lippel, G. Singh, J.D. Christie, D.J. Lederer, Philadelphia, , p.A4680

223 **Assessment of FEV1 Decline After Lung Transplantation Using Functional Respiratory Imaging/**E.M. Barbosa, F. Ferreira, W. Vos, C. Van Holsbeke, L. Nuyttens, W. De Backer, J. De Backer, J.C. Lee, Philadelphia, PA, p.A4681

224 **Time Course of Postoperative Changes of Anti-Gravity Muscle in Patients Undergoing Lung Transplantation. -Quantitative Analysis Using Chest CT-/**Y. Oshima, S. Sato, S. Hasegawa, F. Chen, H. Date, S. Matsuda, Kyoto, Japan, p.A4682

225 **Change in the Lung Allocation Score and Survival of Candidates Awaiting Lung Transplantation/**D.R. Nunley, L.A. Szalacha, G.S. Bauldoff, Louisville, KY, p.A4683

POSTER DISCUSSION SESSION

C24 CRITICAL CARE: CAN ICU DESIGN IMPROVE ICU CARE?

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 3001 (West Building, Level 3)

Poster Viewing **9:00-9:45**

Discussion **9:45-11:00**

Poster Discussion Session

Chairing: C.N. Sessler, MD, Richmond, VA
T.S. Valley, MD, Ann Arbor, MI
D.K. Costa, PhD, RN, Ann Arbor, MI

701 **Impact of Transfer to Tertiary Care Center in Severely Ill Medical ICU Population/**D. Raval, J.L. Breeze, P. LaCamera, Boston, MA, p.A4684

702 **The Impact of Longer Wait Times for Admission on Intensive Care Unit Mortality/**M. Acho, M. Durst, A.D. Olson, M. Mazumdar, K.S. Mathews, New York, NY, p.A4685

703 **Duration of Mechanical Ventilation in the ED: Impact on Length of Mechanical Ventilation, Hospital Length of Stay and In-Hospital Mortality/**L.B. Angotti, S. Wilcox, J.B. Richards, Charleston, SC, p.A4686

704 **Journey Isomorphism Among Patients Admitted to an Intensive Care Unit/**C.M. Quill, R. White, M. Trayhan, D. Pinto, P. Ng, D. Krusch, M. Zand, Rochester, NY, p.A4687

705 **Inter-Hospital Transport of Critically Ill Adults During a Hospital Relocation is Not Associated with Clinical Deterioration or In-Hospital Mortality (The ICU MOVE Study)/**Y.A. Khan, J.L. Johnson, J.L. Mooney, R.H. Barnes, J. MacMahon, V.L. Holloway, M.W. Semler, T.W. Rice, B. DeBoisblanc, D.R. Janz, New Orleans, LA, p.A4688

706 **Impact of Outlier Status on Patient Outcomes in a Medical Intensive Care Unit/**D. Ahmad, K. Moeller, J. Chowdhury, V. Patel, E.J. Yoo, Philadelphia, PA, p.A4689

707 **Does ICU Design Affect Delirium Incidence or Prevalence Among Critically Ill Patients?/**H. Oueini, B. Khan, Indianapolis, IN, p.A4690

708 **Reduction of Catheter-Associated Urinary Tract Infections (CAUTI) Acquired in the ICUs by Combining Lean Quality Improvement Methodology and Prevention Bundle/**S. Leung, J. Huffaker, A. Adams, Bronx, NY, p.A4691

709 **Utility of Lean Daily Management System as an Organized Approach to Address Catheter-Associated Urinary Tract Infection in Intensive Care/**S. Zulqarnain, S. Chennadi, S. Fahmy, G. Jamaleddine, Brooklyn, NY, p.A4692

710 **Central Venous Catheter Patient Safety: A Quality Improvement Initiative/**A. Rajagopal, A.A. Montgomery-Yates, Lexington, KY, p.A4693

711 **Who Really Needs the ICU in Sepsis? An Examination of Intensive Care Unit Interventions in Patients Admitted from the Emergency Department Under a Severe Sepsis Protocol/**J. Hsieh, E. Len, G. Wigger, J. Madara, D. Oxman, Philadelphia, PA, p.A4694

712 **Impact of Intensive Care Unit Discharge Delays/**S. Bose, A. Moskowitz, L. Jalilian, L.A. Celi, A.E.W. Johnson, Boston, MA, p.A4695

713 **Does the Application of Operational Research Methods to Intensive Care Patient Flow Data Provide Solutions to Capacity Constraints?/**G. O'Callaghan, M. MacKay, Adelaide, Australia, p.A4696

714 **How the Nurse Work Environment and ICU Physician Staffing Influence Risk of Ventilator-Associated Pneumonia/**D.K. Costa, J. Yang, M. Manojlovich, Ann Arbor, MI, p.A4697

715 **Variation in Intensive Care Unit Organizational Patterns: A State-Wide Analysis/**R. Kohn, V. Madden, J.M. Kahn, D.A. Asch, S.D. Halpern, M.P. Kerlin, Philadelphia, PA, p.A4698

716 **The Impact of an Overnight Intensivist on Resident Perceptions of Patient Care, Clinical Competency and Education/**R. Holden, J. Maguire, T. Bice, S.S. Carson, Chapel Hill, NC, p.A4699

717 **Medical Compared to Surgical Intensive Care Units (ICU) - Can ICU Cultures Differ Within Walls of a Hospital/**A.A. Mitma, R. Vazquez, R. Scatena, C. Vazquez Guillamet, I. Naqvi, Y.A. Adjepong, C.A. Manthous, N. Montayar, Bridgeport, CT, p.A4700

718 **Implementation of Formal Multidisciplinary Rounds in a Medical Intensive Care Unit/**T.E. Hwalek, W.D. Schweickert, L. Dixon, W. Butcher, J.E. Strickland, J. Bishop, M. Young, D.C. Files, P. Morris, R.N. Bakhru, Winston Salem, NC, p.A4701

719 **Team Behavioral Variables and Administration of Evidence-Based Critical Care/**R. Scatena, R. Vasquez-Guillamet, C. Vazquez Guillamet, A.A. Mitma, I. Naqvi, N. Motayar, Y.A. Adjepong, Z. Bham, C.A. Manthous, Norwalk, CT, p.A4702

720 **Critical Care Team Composition and Processes of Care/**N. Motayar, I. Naqvi, C.A. Manthous, R. Scatena, A.A. Mitma, R. Vazquez, Y.A. Adjepong, C. Vazquez Guillamet, Cincinnati, OH, p.A4703

721 **Perceptions of Nurses and Physicians Regarding Team Leadership/**C. Vazquez Guillamet, R. Vazquez, N. Montayar, I. Naqvi, A.A. Mitma, R. Scatena, Y.A. Adjepong, C.A. Manthous, Albuquerque, NM, p.A4704

POSTER DISCUSSION SESSION

C25 HIV-ASSOCIATED LUNG INFECTIONS/DISORDERS - FROM BASIC TO CLINICAL

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**
Room 3014 (West Building, Level 3)

Poster Viewing **9:00-9:45**

Discussion **9:45-11:00**

Chairing: K.A. Crothers, MD, Seattle, WA
M.R. Gingo, MD, MS, Pittsburgh, PA
J.E. Shellito, MD, New Orleans, LA

901 **Up-Regulation of Human Alveolar Macrophage Prostaglandin E Synthase Gene Expression by HIV1 Infection/**R.J. Kaner, M.R. Staudt, J. Salit, F. Agosto-Perez, J.G. Mezey, R.G. Crystal, New York, NY, p.A4705

902 **Has the Highly Active Anti-Retroviral Therapy (HAART) Era Altered the Utility of Bronchoscopy in Human Immunodeficiency Virus (HIV) Infected Patients Who Undergo Bronchoscopy?/**J. Sethi, R. Lenhardt, Chicago, IL, p.A4706

903 **Predictors of Mortality Among Hospitalized Pneumonia Patients in a High HIV Burden Setting/**W.O. Worodria, E. Chang, A. Andama, I. Sanyu, P. Byanyima, J. Zawedde, I. Ayakaka, A. Sessolo, L. Davis, L. Huang, Kampala, Uganda, p.A4707

904 **Human Immunodeficiency Virus and Pneumocystis Jirovecii Pneumonia: Clinical and Radiological Characteristics/**M. Fielli, A. Gonzalez, M. Heres, C. Tummino, M. Bigot, O. Garcia, P. Capece, A. Zapata, L. Cristaldo, A. Avila, J. Burgos, Buenos Aires, Argentina, p.A4708

905 **Risk Factors for Pneumocystis Jirovecii Pneumonia (PCP) in Kidney Transplantation Recipients/**S.H. Lee, D.J. Joo, M.S. Kim, Y.S. Kim, M.S. Park, S.K. Kim, J. Chang, S.Y. Kim, Seoul, Korea, Republic of, p.A4709

906 **Phenotypic Characteristics and Differentiation of Th9 Cells in Pneumocystis Pneumonia/**F. Guo, Z.-H. Tong, S.-L. Yang, Y. Hu, D. Wang, Beijing, China, p.A4710

907 **Pneumocystis Pneumonia Alters the Intestinal Microbial Communities and Inferred Functional Capacities/**D.R. Samuelson, T. Charles, N.M. De La Rua, C.M. Taylor, E.E. Blanchard, M. Luo, J.E. Shellito, D.A. Welsh, New Orleans, LA, p.A4711

908 **Efficacy of Caspofungin in the Treatment for Pneumocystis Pneumonia in Immunocompromised Patients Without HIV Infection/**T. Li, Z.-H. Tong, Beijing, China, p.A4712

909 **Assessing the Role of Natural Killer Cells in Pneumocystis Murina Pneumonia/**T. Charles, D.R. Samuelson, J.E. Shellito, New Orleans, LA, p.A4713

910 **Alterations Of CD11c+CD11b+ Dendritic Cells During Host Defense Against Pneumocystis Murina Infection/**S. Yang, Z. Tong, Beijing, China, p.A4714

911 **HIV-Related Viral Proteins Impair Nrf2 Function and Increase Oxidative Stress in Alveolar Macrophages/**E. Egea, X. Fan, B. Staitieh, D.M. Guidot, Atlanta, GA, p.A4715

912 **HIV-Related Viral Proteins Reversibly Impair GM-CSF Receptor ß Expression in Alveolar Macrophages/**B. Staitieh, X. Fan, E. Egea, W.A. Neveu, D.M. Guidot, Atlanta, GA, p.A4716

913 **Dietary Supplementation with S-Adenosylmethionine and Zinc Attenuates HIV-Induced Alveolar Macrophage Phagocytic Dysfunction/**S.M. Yeligar, S.K. Cribbs, D.M. Guidot, L.A.S. Brown, Decatur, GA, p.A4717

914 **The Microbiome of Small Airway Epithelial Cells in HIV-Infected and Uninfected Individuals/**S.Y. Xu, J. Leung, M. Sze, E.A. Vucic, T. Shaipanich, S. Sinha, C. Nislow, W.L. Lam, S. Lam, P. Man, D.D. Sin, Vancouver, Canada, p.A4718

915 **The Association Between Emphysema and Non-Calcified Lung Nodules in HIV-Infected and Uninfected Individuals and Implications for Lung Cancer Screening/**M. Triplette, K. Sigel, A.M. Morris, A. Petraglia, J.P. Wisnivesky, C.Y. Kong, P. Diaz, K.A. Crothers, Seattle, WA, p.A4719

916 **Emphysema Severity, Distribution, and Diffusion Capacity Predict Emphysema Progression in HIV/**J. Leung, A. Malagoli, A. Santoro, G. Besutti, G. Ligabue, D. Dai, C. Hague, J. Leipsic, D.D. Sin, S.F.P. Man, G. Guaraldi, Vancouver, Canada, p.A4720

917 **Projected Burden of Lung Cancer Among People with HIV in the United States/**K.P. Reddy, R.A. Parker, E. Losina, T.P. Baggett, A.D. Paltiel, N.A. Rigotti, M.C. Weinstein, K.A. Freedberg, R.P. Walensky, Boston, MA, p.A4721

918 **Characteristics of HIV-Associated Pulmonary Hypertension/**S. Rehman, V.K. Singh, M.A. Simon, M.L. Saul, R.R. Vanderpool, M.T. Gladwin, A.M. Morris, McKeesport, PA, p.A4722

919 **HIV Infection Is Associated with Increased Lung Density on CT Scan/**A. Lambert, M.B. Drummond, C. Merlo, R.A. Wise, G. Kirk, R. Brown, Baltimore, MD, p.A4723

920 **Determinants of Decline in Lung Function in an HIV-Infected Cohort/**S. Maximous, M.E. Fitzpatrick, M. Nouraie, C. Kessinger, N. Leo, A.M. Morris, Pittsburgh, PA, p.A4724

921 **Sensitivity and Specificity of Respiratory Symptoms and Clinical Signs for Abnormal Spirometry among HIV+ Individuals in Kenya/**E.F. Attia, E. Maleche-Obimbo, N. Yatich, L. Ndukwe, S. Sakr, N.G. El Antouny, M.H. Chung, K.A. Crothers, Seattle, WA, p.A4725

922 **Associations Between Lymphocyte Activation, Senescence, and Memory Subset Expression with Pulmonary Function in HIV-Infected and HIV-Uninfected Individuals/**M.B. Lawani, M.E. Fitzpatrick, C. Kessinger, N. Leo, L. Huang, L. Kingsley, A. Vallejo, K. Norris, A. Landay, A. Morris, Pittsburgh, PA, p.A4726

923 **Association Between Inflammation, Immune Senescence, HIV-Infection, and Pulmonary Dysfunction/**S. Qin, M.E. Fitzpatrick, M.B. Lawani, E. Kleerup, L. Kingsley, A.M. Morris, Pittsburgh, PA, p.A4727

924 **Associations Between Persistent HIV-1 Viremia on Antiretroviral Therapy and Pulmonary Dysfunction in An HIV-Infected Cohort/**H. Michael, M.E. Fitzpatrick, F.F. Hong, L. Kingsley, C. Kessinger, N. Leo, D. McMahon, J.W. Mellors, A.M. Morris, Pittsburgh, PA, p.A4728

925 **Lower Diffusing Capacity Is Associated with Mortality in HIV-Infected Individuals/**M.R. Gingo, S.M. Nouraie, C. Kessinger, N. Leo, R. Greenblatt, L. Huang, E. Kleerup, L. Kingsley, D. McMahon, A.M. Morris, Pittsburgh, PA, p.A4729

POSTER DISCUSSION SESSION

C26 FAMILY CENTERED CRITICAL CARE WITHIN AND BEYOND THE ICU

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 309 (South Building, Esplanade Level)

Poster Viewing	**9:00-9:45**
Discussion	**9:45-11:00**
Discussion	**Poster Discussion Session**

Chairing: J.A. Tate, PhD, RN, Columbus, OH
S.M. Brown, MD, MS, Murray, UT

301 **Family Experiences with ICU Bedside Rounds: A Qualitative Descriptive Study/**S.E. Cody, Worcester, MA, p.A4730

302 **ICU Clinician Perspectives on Involvement of Family Members in the Care of Critically Ill Patients/**K. Turner, W.G. Anderson, A. Lipshutz, J. Cimino, K. Liu, C. Pathak, H. Schell-Chaple, M. Gropper, San Francisco, CA, p.A4731

303 **Family Care Rituals (FCR) in the Intensive Care Unit (ICU)/**T. Amass, G. Villa, L. Tomasi, A. Palmisciano, M.-E. Yeow, R. De Gaudio, S. O'Mahony, J.R. Curtis, M.M. Levy, Providence, RI, p.A4732

304 **How Much Do Family Members Satisfy with the Intensive Care Unit in South Korea?**/G. Lim, J. Min, G. Park, J. Yoon, J. Shin, S. Park, S. Kim, J. Park, H. Yoon, J. Lee, C. Lee, Y. Cho, Y. Lee, Seoul, Korea, Republic of, p.A4733

305 **Predictors of Patient and Family Ratings of Overall Satisfaction with Care in the Intensive Care Unit**/S. Lah, E. Wilson, R. Rozenblum, E. Hirshberg, J. Orme, R. Hopkins, S.M. Brown, Murray, UT, p.A4734

306 **Measuring the Quality of Consultations in the Intensive Care Unit: Family and Nursing Perspectives on Communication**/S.D. Roche, N. Demosthenes, A. Reichheld, A. Johansson, M.D. Howell, B. Landon, M. Cocchi, J.P. Stevens, Boston, MA, p.A4735

307 **Development of a Novel, Scalable Digital Psychosocial Intervention Platform for Intensive Care Unit Survivors and Their Family Members**/C.E. Cox, J.M. Greeson, L.S. Porter, D.M. Jones, M.K. Olsen, W. Reagan, B. Walton, A. Ungar, C.L. Hough, Durham, NC, p.A4736

308 **Incidence and Predictors of Anxiety and Depression in Caregivers of Critically Ill Patients and Comparison of These Symptoms at the Time of Admission and Discharge from the Intensive Care Unit (ICU): A Prospective Study**/D. Chaudhry, N. Jain, A. Singh, S. Sethi, S. Virdi, Rohatk, India, p.A4737

309 **Caregiver Priorities During a Child's Recovery from Critical Illness**/K. Choong, S. Al-Harbi, D. Fraser, J. Cameron, M. Tarnopolsky, H. Clark, J.W. Gorter, L. Thabane, M. Khetani, M.S. Herridge, S. Cameron, R. Simpson, L. Chiu, M. Wakim, N. Fayed, Hamilton, Canada, p.A4738

310 **Caregivers to ICU Patients and Burden of Caregiving Prior to ICU Admission**/S. Beesley, E. Hirshberg, E. Wilson, J. Butler, K. Kuttler, J. Holt-Lunstad, J. Orme, R.O. Hopkins, S.M. Brown, Salt Lake City, UT, p.A4739

311 **The Association Between Acute Perceived Stress and Long-Term Anxiety Among Family Members of Critically Ill Patients**/S. Beesley, R.O. Hopkins, E. Wilson, J. Bulter, J. Holt-Lunstad, K. Kuttler, J. Orme, S.M. Brown, E. Hirshberg, Salt Lake City, UT, p.A4740

312 **What About the Caregivers? Psychosocial Outcomes in Informal Caregivers of the Critically Ill - Preliminary Results**/K.J. Haines, S. Berney, J. Jones, E. Skinner, S. Warrillow, L. Remedios, L. Denehy, Heidelberg, Australia, p.A4741

313 **Decisional Support Guide for Families of ICU Patients: A Multicenter Feasibility Study**/P. Chiarolanzio, J. Kraft, C. Kim, J. Reading, L.J. Van Scoy, D. Heyland, Hershey, PA, p.A4742

314 **The Experience of Conducting Family Conferences Via Telemedicine for Critically Ill Patients Transferring to a Tertiary Care Center**/P.R. Menon, T. Rabinowitz, P. Prelock, R.D. Stapleton, Burlington, VT, p.A4743

315 **Approaching Psychological Trauma of the Critically Ill: Patient and Family Perspectives**/V. Dziadzko, M.A. Dziadzko, O. Gajic, L. Karnatovskaia, Rochester, MN, p.A4744

316 **Intensive Care: Life After Leaving the Hospital - Experiences of Family and Friends**/K. Rowan, S. Prinhja, London, United Kingdom, p.A4745

317 **Measuring Adaptive Coping of Hospitalized Patients with a Severe Medical Condition: The Sickness Insight in Coping Questionnaire (SICQ)**/P.E. Spronk, E. Boezeman, J.G.M. Hofhuis, A. Hovingh, C.E. Cox, R.E. De Vries, Apeldoorn, Netherlands, p.A4746

318 **Coping as a Multi-Level Construct: Associations with Psychological Outcomes Among Family Members of Mechanical Ventilation Survivors**/N.R. Nadig, N.G. Huff, C.E. Cox, D.W. Ford, Charleston, SC, p.A4747

319 **Barriers and Facilitators to the Conduct of Interdisciplinary Family Meetings in the ICU: Preliminary Findings from a Qualitative Exploration**/J.B. Seaman, R. Arnold, M. Nilsen, A. Argenas, A.-M. Shields, D. White, Pittsburgh, PA, p.A4748

320 **Developing a Framework for Implementing Intensive Care Unit Diaries: A Focused Review of the Literature**/M. Beg, E.A. Scruth, V. Liu, Santa Clara, CA, p.A4749

POSTER DISCUSSION SESSION

C27 NEWS FROM THE NICU AND PICU

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 3011 (West Building, Level 3)

Poster Viewing **9:00-9:45**

Discussion **9:45-11:00**

Chairing: J.K. McGuire, MD, Seattle, WA
V. Ackerman, MD, Indianapolis, IN

801 **Nasal Continuous Positive Airway Pressure Increases the Efficiency of Bottle-Feeding in Preterm Lambs**/N. Samson, A. Michaud, S. Nault, R. Othman, D. Cantin, M. Sage, C. Nadeau, J.-P. Praud, Sherbrooke, Canada, p.A4750

802 **Effect of Nasal Continuous Positive Airway Pressure (NCPAP) on the Pharyngeal Swallow in Neonates**/A.A. Bidiwala, L. Ferrara, S. Islam, M. Pirzada, D. Barlev, I. Sher, N. Hanna, Bronx, NY, p.A4751

803 **Mechanical Ventilation (NIPPV)-Induced Lung Recruitment Assessed by Electrical Impedance Tomography (EIT) Persists After Its Withdrawal in Duchenne Muscular Dystrophy**/L. Appendini, M. Vinci, G. Ferreyra, S. Dal Farra, M. Goia, E. Bignamini, Saluzzo, Italy, p.A4752

804 **The Reliability of Invasive and Non-invasive Blood Pressure Measurements in Critically Ill Children**/R. Joffe, G. Garcia Guerra, J. Duff, J. Pugh, A.R. Joffe, Edmonton, Canada, p.A4753

805 **Risk Factors for Pediatric Noninvasive Ventilation Failure Using Physiologic and Clinical Measures**/M.C. Lafortune, A. Kamerkar, J. Hotz, R. Morzov, C.J. Newth, R.G. Khemani, Los Angeles, CA, p.A4754

806 **Heart Rate Variability in Extremely Preterm Infants While Receiving Nasal Intermittent Positive Pressure Ventilation (NIPPV) and Continuous Positive Airway Pressure (CPAP) Immediately After Extubation**/S. Latremouille, L. Kanbar, P. Lamer, A. Al-Jabri, W. Shalish, R. Kearney, G. Sant'Anna, Montreal, Canada, p.A4755

807 **The Validity of Ultrasound Cardiac Output Monitor (USCOMr) Measurements in Hemodynamically Stable and Unstable Pediatric Patients/**K. Choong, N. Al Rahbi, F. Alanzi, D. Zorko, M.H. Alhasani, C.L. De Almeida, T. Mondal, J. Cheng, L. Thabane, Hamilton, Canada, p.A4756

808 **Ventilation Reconciliation: Improving the Accuracy of Documented Home Ventilator Settings in a Pediatric Home Ventilator Clinic/**D. Benscoter, M. Kaiser, E. Koch, D. Leonard, R. Bessenbach, Y. Zou, R. Szczesniak, R.S. Amin, Cincinnati, OH, p.A4757

809 **Physiological Benefits of Variable Ventilation Over Conventional and High Frequency Ventilation in a Preterm Lamb Model of Surfactant Deficiency/**B. Suki, P.B. Noble, S.B. Jawde, Z. King, S. Ahmadi-Norrbakhsh, E. Bartolak-Suki, J.J. Pillow, Boston, MA, p.A4758

810 **Trends in Patient Characteristics and Outcomes for Children Requiring Invasive Mechanical Ventilation in the Intensive Care Unit/**A.M. Cartron, V. Shankar, W. Pastor, Washington, DC, p.A4759

811 **BAL Culture Results Are Not Specific to VAP Signs and Symptoms in Mechanically Ventilated Children/**A.L. Beardsley, M.E. Nitu, Indianapolis, IN, p.A4760

812 **Characteristics of the Lower Airway Microbiome in Mechanically Ventilated Children Differ by Reason for Admission and Day of Intubation/**K.M. Burgess, J.K. Harris, J.I. Miller, B. Wagner, M.K. Sontag, P.M. Mourani, Aurora, CO, p.A4761

813 **Physiological Biomarkers of Autonomic Dysfunction in Premature Infants Are Linked to High Risk of Hospital Readmission Due to Acute Life-Threatening Events (ALTE)/**G.R. Nino, R. Govindan, T. Al-Shargabi, M. Metzler, R. Joshi, G.F. Perez, A. Massaro, R. McCarter, A. DuPlessis, Washington, DC, p.A4762

814 **Predictors of Unreliable Pulse Oximetry Among Young Children with Sepsis in Uganda/**P.P. Moschovis, M.O. Wiens, J.P. Kiwanuka, E. Kumbakumba, A. Ndamira, O. Keneema, D. Hayden, D.R. Hess, J.M. Ansermino, P.L. Hibberd, Boston, MA, p.A4763

815 **Usefulness of Polysomnography for Evaluation and Management of Chronic Mechanical Ventilation in Children/**N. Gurbani, D. Benscoter, N. Simakajornboon, Cincinnati, OH, p.A4764

816 **Airway Endoscopy for Critically Ill Children in a High-Volume Pediatric Flexible Bronchoscopy Service/**J.J. Brewington, D.R. Spielberg, D. Benscoter, Cincinnati, OH, p.A4765

817 **The Feasability of Probe-Based Confocal Endomicroscopy (pCLE) in Children/**C. McHendry, C. Towe, S. Moore, J. Shannon, M.G. Schecter, Cincinnati, OH, p.A4766

818 **Rates of Clinical Improvement Following Therapeutic Flexible Bronchoscopy in Critically Ill Children/**D.R. Spielberg, J.J. Brewington, D. Benscoter, Cincinnati, OH, p.A4767

819 **Complete Weaning from Ventilatory Support After Whole Therapeutic Lung Lavage Using Total Liquid Ventilation in Severe Meconium Aspiration Syndrome/**M. Sage, M. Nadeau, J. Mousseau, E. Gullickson-Larouche, R. Dunfield, R. Robert, J.-P. Praud, P. Micheau, H. Walti, Sherbrooke, Canada, p.A4768

820 **Predicting Height in a Pediatric Intensive Care Unit Using Ulnar Length/**M.A. Rasouli, C.J. Newth, R.G. Khemani, P.A. Ross, Los Angeles, CA, p.A4769

821 **Toward Understanding Bedside Communication in the Pediatric Intensive Care Unit/**K. Von Zychlin, E. Bourget, H. Starks, M. Lewis-Newby, Seattle, WA, p.A4770

POSTER DISCUSSION SESSION

C28 THE TIES THAT BIND: BASIC STUDIES IN ALI AND BARRIER FUNCTION

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 3024 (West Building, Level 3)

Poster Viewing **9:00-9:45**

Discussion **9:45-11:00**

Chairing: E.P. Schmidt, MD, Aurora, CO
S.M. Dudek, MD, Chicago, IL
E.O. Harrington, PhD, Providence, RI

1001 **The Extent of Endothelial Glycocalyx Degradation Is Different in Direct Compared to Indirect Acute Respiratory Distress Syndrome (ARDS) and Is Associated with Non-Pulmonary Organ Dysfunction in Severe Sepsis/**L. Murphy, N. Wickersham, J.B. McNeil, C.M. Shaver, J.A. Bastarache, L. Ware, Nashville, TN, p.A4771

1002 **The Tyrosine Kinase Abl-Related Gene (Arg/ABL2) Mediates Vascular Leak by Internalizing α5ß1 Integrin/**J. Aman, E.T. Valent, J. Amado-Azevedo, J. Bezu, Van, E.C. Eringa, R. Krishnan, P.L. Hordijk, V.W.M. Van Hinsbergh, G.P. Van Nieuw Amerongen, Amsterdam, Netherlands, p.A4772

1003 **Role of Phospholipase D2 in Focal Adhesions and Cell Spreading in Human Lung Microvascular Endothelial Cells/**M. Shaaya, P. Fu, Y. Komarova, A. Karginov, V. Natarajan, Chicago, IL, p.A4773

1004 **Integrin ß4 Splice Variant Expression Is Altered by VILI and SNPs/**G. Kelly, J.B. Mascarenhas, W. Chen, J.R. Jacobson, A. Cress, T. Wang, J.G.N. Garcia, Tucson, AZ, p.A4775

1005 **Artificial Sweetener Sucralose Protects the Pulmonary Endothelium from LPS-Induced Permeability/**H. Chichger, E.O. Harrington, Cambridge, United Kingdom, p.A4776

1006 **Cell-Free Hemoglobin Causes Oxidative Stress, Mitochondrial Dysfunction, and Increased Endothelial Permeability in Human Pulmonary Microvascular Endothelial Cells/**J.L. Kuck, S.I. Dikalov, J.P. Fessel, C.M. Shaver, J.A. Bastarache, L. Ware, Nashville, TN, p.A4777

1007 **Acid Injury to Alveolar Epithelium Causes Depolarization of Endothelial Mitochondria/**R.F. Hough, G.A. Gusarova, M.N. Islam, J. Bhattacharya, New York, NY, p.A4778

1008 **Cingulin Is a Novel Regulator of Endothelial Permeability and RhoA Signaling at Tight Junctions/**A. Sitikov, A.S. Shah, Y. Tian, G. Gawlak, A.A. Birukova, Chicago, IL, p.A4779

1009 **Intravascular Delivery of Purified Focal Adhesion Kinase Protects Against Acute Lung Injury/**S.K. Quadri, S. Das, M. Wei, J. Bhattacharya, New York, NY, p.A4780

1010 **Cell-Free Hemoglobin Causes Acute Lung Injury and Increases Mortality in a Mouse Model of Polymicrobial Sepsis/**J.A. Bastarache, C.M. Shaver, N.D. Putz, J.L. Kuck, M.G. Paul, J.L. Wynn, L.B. Ware, Nashville, TN, p.A4781

1011 **Role of TRPM2 in Sphingolipid-Mediated Radiation-Induced Lung Injury/**Y. Epshtein, H. Wang, A.B. Malik, J. Jacobson, Chicago, IL, p.A4782

1012 **The Importance of Ext1 to Lung Recovery After Pulmonary Endothelial Glycocalyx Degradation/**Y. Yang, S.M. Haeger, J.A. Ford, J.F. Colbert, K.L. Dailey, R.S. Stearman, F. Zhang, R.J. Linhardt, E.P. Schmidt, Aurora, CO, p.A4783

1013 **Impaired Hypoxic Pulmonary Vasoconstriction After Acute Lung Injury Is Mediated Through Activation Nuclear Factor of Activated T-Cells and Epigenetic Mechanisms in Pulmonary Artery Smooth Muscle Cells/**D.R. Fraidenburg, J. Yuan, R.F. Machado, S.M. Dudek, Chicago, IL, p.A4784

1014 **Soluble Epoxide Hydrolase Deficiency or Inhibition Enhances Murine Hypoxic Pulmonary Vasoconstriction After Lipopolysaccharide Challenge/**M. Wepler, A. Beloiartsev, D. Panigrahy, D.B. Bloch, F. Ichinose, W.M. Zapol, Boston, MA, p.A4785

1015 **Trefoil Factor 2 Is a Novel Regulator of Vascular Barrier Dysfunction in Lung Injury/**X. Wu, S. Sammani, G.A. Infusino, S.M. Dudek, J.G.N. Garcia, T. Wang, Tucson, AZ, p.A4786

1016 **Inhibition of Murine Pulmonary Microvascular Endothelial Cell Apoptosis Promotes Repair and Rescues Barrier Function Under Septic Conditions/**S.E. Gill, L. Wang, S. Mehta, London, Canada, p.A4787

1017 **Role of Syndecan-1 in Mechanical Stress-Induced Lung Endothelial Cell Inflammatory Responses Mediated by Integrin ß4/**W. Chen, R.O. Dull, J.R. Jacobson, Chicago, IL, p.A4788

POSTER DISCUSSION SESSION

C29 PROTECTORS OF THE LUNG: INNATE IMMUNE RESPONSES IN ACUTE LUNG INJURY

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 2014 (West Building, Level 2)

Poster Viewing **9:00-9:45**

Discussion **9:45-11:00**

Chairing: C.M. Waters, PhD, Memphis, TN
E. Herzog, MD, PhD, New Haven, CT
J.A. Bastarache, MD, Nashville, TN
H. Garn, PhD, Marburg, Germany
R. Paine, MD, Salt Lake City, UT
J. Liu, PhD, Chicago, IL
N.V. Kolliputi, PhD, Tampa, FL

501 **IL-36R Blockade Attenuates Lung Injury and Mortality After H1N1 Influenza Virus Infection in Mice/**T. Aoyagi, M.W. Newstead, X. Zeng, M. Kaku, T.J. Standiford, Ann Arbor, MI, p.A4789

502 **Dnase2a Deficiency Suppresses NLRP3 Inflammasome Activation and Improves the Survival of Mice Subjected to Cecal Ligation and Puncture Induced Sepsis/**K. Nakahira, K.T. Rooney, S. Hisata, A.M.K. Choi, New York, NY, p.A4790

503 **The Two-Pore Potassium Channel TREK-1 Alters Inflammasome Activation in Alveolar Macrophages/**C.N. Immanuel, J.A. Kennedy, B. Teng, C. Luellen, S.A. Cormier, E.A. Fitzpatrick, A. Schwingshackl, C.M. Waters, Memphis, TN, p.A4791

504 **IL-22 / IL-22 Binding Protein (IL-22ra2) Balance Is Critical for the Resolution of Influenza Induced Lung Pathology/**D. Pociask, J. Kolls, New Orleans, LA, p.A4792

505 **SPLUNC1 Regulates LPS-Induced Innate Immune Activation and Lung Neutrophilic Inflammation/**C.J. Britto, N. Niu, L.E. Cohn, New Haven, CT, p.A4793

506 **The Assembly of NLRP3 Inflammasome Is via PI3K-δ Signaling Pathway in Bronchial Epithelium of HDM-Induced Allergic Asthma/**S.R. Kim, Y.C. Lee, K.B. Lee, H.J. Kim, D.I. Kim, Y.H. Choe, Jeonju, Korea, Republic of, p.A4794

507 **HO-1 Mediates the Cytoprotective Effects of NLRP3 Deficiency Via Autophagy/**Y. Zhang, P.J. Lee, New Haven, CT, p.A4795

508 **Toll-Like Receptor 4 Mediates the Protective Effects of VEGF in Lung Endothelium/**Y. Zhang, S. Takyar, P. Shan, P.J. Lee, New Haven, CT, p.A4796

509 **Distinct Effects of Cell-Free Hemoglobin and Heme on Lung Permeability and Inflammation During Acute Lung Injury/** C.M. Shaver, C.P. Upchurch, D. Janz, B.S. Grove, N.D. Putz, N. Wickersham, S.I. Dikalov, L. Ware, J.A. Bastarache, Nashville, TN, p.A4797

510 **Midkine Deficiency Attenuates Lipopolysaccharide-Induced Lung Inflammation in Mice/**Y. Tanino, X. Wang, T. Nikaido, M. Kikuchi, Y. Sato, K. Misa, R. Togawa, Y. Suzuki, M. Uematsu, A. Fukuhara, S. Sato, J. Saito, H. Yokouchi, M. Munakata, Fukushima, Japan, p.A4798

511 **Lipoteichoic Acid Upregulates Plasminogen Activator Inhibitor-1 Expression in Human Pleural Mesothelial Cells Via TLR2/JNK/AP-1 Pathway/**K.L. Lee, W.L. Chen, K.S. Lai, C.L. Chung, Taipei City, Taiwan, p.A4799

512 **Effects of Ethanol's on Pulmonary Expression of Inflammatory Cytokines and Activation of Anti-Microbial Peptides Via Vitamin D Pathway/**O. Ogunsakin, New Orleans, LA, p.A4800

513 **Innate Memory of Airway Epithelial Cells Augments LPS-Induced Mucous Secretory Response/**H.S. Chand, Y. Mebratu, Y. Tesfaigzi, Albuquerque, NM, p.A4801

514 **Aberrant TLR9 Responses in Scleroderma Fibrocytes and Bleomycin Induced Lung Fibrosis/**H. Sun, H. Pan, H. Ding, M. Gulati, W.H. Fares, P. Adonteng-Boateng, D.A. Carrano, C. Ryu, X. Peng, C. Dela Cruz, H. Bai, E. Herzog, New Haven, CT, p.A4802

515 **Roles of RAGE and TXNIP in NLRP3-Inflammasome Activation in Human Macrophages/**M. Jabaudon, J. Lutz, R. Blondonnet, C. Belville, G. Clairefond, D. Bouvier, L. Blanchon, J.-L. Couderc, V. Sapin, J.-M. Constantin, Clermont-Ferrand, France, p.A4803

516 **Differential Effects of Antimicrobial Regimens in the Regulation of Ventilator Induced Lung Injury Associated Inflammasome Activation./**D.S. Jones, I.I. Siempos, A.M.K. Choi, New York, NY, p.A4804

517 **Hypoxia Suppresses Innate Immune Function in Primary Murine Alveolar Epithelial Cells Through Effects on the Redox-Sensitive Factor, NFκB/**A. Sturrock, D. Woller, R. Paine, Salt Lake City, p.A4805

518 **Redox Imbalance Induced by Angiotensin II Aggravated Pulmonary Fibrosis Via Activating NALP3 Inflammasomes/** Y. Meng, Y. Chen, M. Pan, Q. Yang, Z. Zheng, Guangzhou, China, p.A4806

519 **RING Finger E3 Ligase PPP1R11 Regulates TLR2 Signaling and Innate Immunity/**B.B. Chen, A. Mckelvey, S. Dunn, T. Lear, Y. Liu, Pittsburgh, PA, p.A4807

520 **Asian Sand Dust Increases MUC8 and MUC5B Expressions Via TLR4-Dependent ERK2 and p38 MAPK in Human Airway Epithelial Cells/**Y.-D. Kim, Y.S. Choi, H.G. Na, C.H. Bae, S.-Y. Song, Daegu, Korea, Republic of, p.A4808

521 **Lung WWOX Knockdown Causes Neutrophilic Inflammation Associated with Increased Epithelial IL-8 Secretion/**S. Singla, J. Chen, J.R. Sysol, R.F. Machado, Chicago, IL, p.A4809

522 **Notch Signaling in the Differentiation of Alveolar Type II to Type I Cells After Pseudomonas Aeruginosa Induced Lung Injury/**J. Finn, Y. Liu, Chicago, IL, p.A7865

523 **Functional Role of Pericytes in Lung Homeostasis and Acute Lung Injury/**C.F. Hung, Y.-H. Chow, W.A. Altemeier, L.M. Schnapp, Seattle, WA, p.A7866

524 **Duox2 Overexpression Can Control and Prevent Influenza A Virus-Induced Acute Lung Infection/**H.J. Kim, S.N. Hong, J.Y. Kim, J.W. Lee, Seoul, Korea, Republic of, p.A7867

525 **Diet-Induced Obesity Induces Endoplasmic Reticulum Stress in the Lung Endothelium and Predispose to LPS Induced Acute Lung Injury/**D. Shah, F. Romero, R. Summer, Philadelphia, PA, p.A7868

POSTER DISCUSSION SESSION

C30 ACUTE LUNG INJURY: CELL FUNCTION, SIGNALING AND STRETCH

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 2024 (West Building, Level 2)

Poster Viewing **9:00-9:45**

Discussion **9:45-11:00**

Chairing: R.D. Hubmayr, MD, Rochester, MN
L.M. Schnapp, MD, Charleston, SC
D.W. Kaczka, MD, PhD, Iowa City, IA

601 **Resident and Recruited Alveolar Macrophages Exhibit Distinct and Dynamic Programming States Following Acute Lung Injury/**K.J. Mould, L. Barthel, M.P. Mohning, S. Leach, T. Danhorn, P.M. Henson, W. Janssen, Aurora, CO, p.A4810

602 **Deletion of c-FLIP in CD11b+ Macrophages Protects Against Bleomycin Induced Lung Fibrosis/**A.L. McCubbrey, L. Barthel, W. Janssen, Denver, CO, p.A4811

603 **High Fat Feeding Protects Mice from Ventilator-Induced Lung Injury Via a Neutrophil-Independent Mechanism/**M. Wilson, J. Petrie, M. Shaw, C. Oakley, B.V. Patel, K.P. O'Dea, M. Takata, London, United Kingdom, p.A4812

604 **Pressure Dependent Alveolar Derecruitment Is Linked with Surfactant Dysfunction in Bleomycin-Induced Acute Lung Injury/**L. Knudsen, E. Lopez-Rodriguez, L. Berndt, C. Boden, C. Ruppert, J.H.T. Bates, M. Ochs, B.J. Smith, Hannover, Germany, p.A4813

605 **AMPing Up Lung Repair: The Interplay of Hypercapnia, Adenylate Cyclase and AMP Kinase/**R.A. Oeckler, S. Wang, D.N. Schiavo, R. Stroetz, B. Walters, Rochester, MN, p.A4814

606 **Lipopolysaccharide-Induced Lung Injury Is More Severe in Old Compared to Young Mice/**C. Brandenberger, K.M. Kling, E. Lopez-Rodriguez, C. Pfarrer, C. Muhlfeld, Hannover, Germany, p.A4815

607 **Effects of Bacterial LPS on the Biomechanics of Alveolar Epithelial Cells Measured by Atomic Force Microscopy/** V.R. Oliveira, J.J. Uriarte, W. Zin, R. Farre, D. Navajas, I. Almendros, Barcelona, Spain, p.A4816

608 **Lung Microenvironment Profiles in Mouse Models of Acute Respiratory Distress Syndrome (ARDS)/**A.A. Luo, D. Islam, A. Grassi, D. Toumpanakis, B. Han, J.G. Laffey, M. Liu, A.S. Slutsky, H. Zhang, Toronto, Canada, p.A4817

609 **Rapid Quantification of Lung Inflation and Recruitment with Automatic Lung Segmentation of Chest Computed Tomography in a Variable Lung Collapse Model/**J. Graf, A. Santos, C. Silva, A. Salazar, P. Formenti, J.J. Marini, Santiago, Chile, p.A4818

610 **The Effects of Chest Wall Strapping in a Porcine Model of ARDS/**E. Abston, J. Herrmann, P. Taft, M. Eberlein, D.W. Kaczka, D.A. Stoltz#, J. Zabner, Iowa City, IA, p.A4819

611 **Multi-Frequency Oscillatory Ventilation (MFOV): Impact on Eucapnic Ventilation Distribution in Simulated Lung Injury/**J. Herrmann, M.H. Tawhai, D.W. Kaczka, Iowa City, IA, p.A4820

612 **Arginase Upregulation And Airway Hyperreactivity in Neonatal Mice Exposed to Moderate Hyperoxia/**I. Kuipers, M.A. Thompson, M.R. Freeman, L.J. Manlove, R.D. Britt Jr., P.W. MacFarlane, R.J. Martin, C.M. Pabelick, Y.S. Prakash, Rochester, MN, p.A4821

613 **Alpha-Klotho Protects Zucker Diabetic Fatty Rat Lung Against Hyperoxic Injury/**P. Ravikumar, E.V. Wechsler, O.W. Moe, C.C.W. Hsia, Dallas, TX, p.A4822

614 **Solubilized Lung-Derived Extracellular Matrix Mitigates Hyperoxic Lung Injury/**P. Ravikumar, C.T. Atkins, J. Wu, Y. Hong, C.C.W. Hsia, Dallas, TX, p.A4823

615 **Real-Time Imaging of Stretch-Induced ATP Release in Rat Pulmonary Epithelial Cells/**J.J. Tan, E. Brochiero, R. Grygorczyk, Montreal, Canada, p.A4824

616 **The Role of Surfactant Dysfunction in Ventilator Induced Lung Injury Pathogenesis/**B.J. Smith, S.A. Seong, G.S. Roy, J.H.T. Bates, Burlington, VT, p.A4825

617 **Linking Alveolar Epithelial Barrier Disruption to Function in Ventilator-Induced Lung Injury/**K.L. Hamlington, C.M. Dunn, G.S. Roy, B.J. Smith, J.H.T. Bates, Burlington, VT, p.A4826

618 **Calculating an Injury Cost Function for Ventilator-Induced Lung Injury/**J.H.T. Bates, B.J. Smith, K.L. Hamlington, G.B. Allen, Burlington, VT, p.A4827

619 **Pathophysiological Consequences of Lobar Unilateral Perfusion Block in a 8-Hour Large Animal Model of Ventilator Induced Lung Injury (VILI)/**B. Cambiaghi, O. Moerer, G. Hahn, T. Mauri, E.A. Schulze Kalthoff, A.M. Pesenti, M. Quintel, Monza, Italy, p.A4828

620 **Effects of Ventilatory Settings on a Pendelluft Phenomenon During Mechanical Ventilation - A Lung Model Study/**Y. Enokidani, A. Uchiyama, T. Yoshida, R. Abe, Y. Fujino, Osaka, Japan, p.A4829

621 **Activation of the ß2-Adrenergic Receptors on Monocytes Negatively Regulates Their Recruitment to the Injured Lung/**L. Morales-Nebreda, R.B. Hamanaka, A. McQuattie-Pimentel, M. Chi, S. Soberanes, R. Nigdelioglu, T. Cho, A.V. Misharin, G.S. Budinger, G.M. Mutlu, Chicago, IL, p.A4830

622 **Inhibition of Prolyl Hydroxylase Attenuates Fas Ligand-Induced Apoptosis and Lung Injury in Mice/**Y. Nagamine, K. Tojo, T. Yazawa, S. Takaki, Y. Baba, T. Goto, K. Kurahashi, Yokohama, Japan, p.A4831

623 **Impact of Ca2+ Signalling on Volume Regulated Anion Channel in A549 Alveolar Cells: Implication for Alveolar Fluid Clearance/**O.O. Ponomarchuk, F. Boudreault, R. Grygorczyk, S.N. Orlov, Moscow, Russian Federation, p.A4832

624 **Optimal Variability Maintains Surfactant Metabolism During Ventilation of Preterm Sheep/**E. Bartolak-Suki, J.J. Pillow, B. Suki, Boston, MA, p.A4833

625 **Variable Ventilation Minimizes Cyclical Overdistension and Pulmonary Inflammation in Lung-Healthy Anesthetized Rats/** W. Zin, L. Camilo, M. Avila, L.F. Cruz, G. Motta-Ribeiro, M. Abreu, A. Cardozo, A. Carvalho, Rio de Janeiro, Brazil, p.A4834

THEMATIC POSTER SESSION

C31 EXPERIMENTAL ASTHMA THERAPIES

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area D, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: J.F. Alcorn, PhD, Pittsburgh, PA

P371 **In Vivo Dual PI3κγδ Inhibition in a Rat Model of Pulmonary Inflammation - Evidence of Local Therapeutic Activity/**S.R. Blomqvist, T. Andreasson, S. Arlbrandt, P. Bold, K. Bjorhall, M. Brulls, P. Cygan, M. Karlsson, M. Mogemark, M. Perry, V. Morrison, C. Goodyear, K. Karabelas, M. Thomas, Molndal, Sweden, p.A4835

P372 **Targeting the Immunological Drivers of Asthma with Inhaled Delivery of a JAK1 Inhibitor/**M.C. Catley, A. Smailagic, M. Rhedin, N. Parker, M. Nilsson, A. Aurell Holmberg, R. Hendrickx, K. Johansson, Gothenburg, Sweden, p.A4836

P373 **Depletion of Blood Eosinophils and Basophils After Administration of an Anti-CRTh2 Antibody in Cynomolgus Monkeys/**T. Staton, F. Fuh, S. Klabunde, A. Reyes, T. Huang, Y. Shang, J. Payandeh, M. Matsumoto, I. Hotzel, H. Wang, J. Wang, K. Reif, H. Scheerens, South San francisco, CA, p.A4837

P374 **TLR7/8 Ligand (Resiquimod, S28463) Protects Non-Human Primates from Ascaris Suum Extract Induced Model of Allergic Asthma/**C. Kanagaratham, P. Camateros, J. Henri, F. Kopriva, M. Hajduch, D. Radzioch, Montreal, Canada, p.A4838

P375 **Phosphoinositide-3 Kinase Inhibition in Th17-Dominant Allergic Airway Disease in Mice/**M.L. Manni, M.E. Clay, K.J. McHugh, M. Salmon, J.K. Kolls, J.F. Alcorn, Pittsburgh, PA, p.A4839

P376 **Leukotriene Receptor Blockade Decreases Mucin Production Triggered by Acute Ethanol Ingestion in Allergen-Sensitized Mice/**B. Lussier, T. Hsieh, D. Remick, Boston, MA, p.A4840

P377 **The Effect of Statin on Alternaria-Induced Asthma in Mice/**T. Kamatani, M. Matsuzaka, K. Fukunaga, H. Kabata, T. Tanosaki, S. Kagawa, T. Mochimaru, R. Baba, K. Otsuka, S. Ueda, K. Tanaka, T. Betsuyaku, Tokyo, Japan, p.A4841

P378 **Effects of Chronic Treatment with CAPE, a Specific NF Kappa-B Inhibitor, Compared to Rho Quinase Inhibitor or Corticosteroid on Airway Hyperresponsiveness in Mice with Chronic Allergic Pulmonary Inflammation/**I.F. Tiberio, F.C.R. Souza, T.M. Santos, L.R. Aristoteles, R.F. Righetti, B. Saraiva-Romanholo, C.M. Prado, F.M.A. Costa, E.A. Leick, M.A. Martins, Brazil, p.A4842

P379 **Acetaminophen Attenuates House Dust Mite Induced Allergic Airway Disease in Mice/**G.J. Smith, R.S. Thrall, M.M. Cloutier, J.E. Manautou, J.B. Morris, Storrs, CT, p.A4843

Facilitator: A. Haczku, MD, PhD, Davis, CA

P380 **Electronic Cigarette Inhalation Promotes Inflammatory Cytokines Within the Airways and Systemic Inflammation in Mice/**D. Mathew, J.H. Hwang, L.E. Crotty Alexander, San Diego, CA, p.A4844

P381 **PGE2-Treated Macrophages Inhibit Development of Allergic Lung Inflammation in Mice/**C. Draijer, C.E. Boorsma, C. Reker-Smit, E. Post, K. Poelstra, B.N. Melgert, Groningen, Netherlands, p.A4845

P382 **Treatment with a Lysate of Helicobacter Pylori Prevents Allergic Airway Inflammation in Mice/**Y. Van Wijck, S. De Kleijn, P.S. Hiemstra, A. Muller, H.H. Smits, C. Taube, Leiden, Netherlands, p.A4846

P383 **The Group Which Elevated Exhaled Nitric Oxide Exists in Normal Population/**M. Itoga, S. Takanashi, Y. Tanaka, H. Tanaka, K. Taima, T. Morimoto, K. Okumura, Hirosaki, Japan, p.A4847

P384 **Identification of a Spleen Tyrosine Kinase (Syk) Inhibitor from Screening Brusatol Derivatives and Investigation of Its Anti-Airway Inflammatory Mechanisms/**Q. Hou, Y. Ding, J. Bai, M. Lin, China, p.A4848

P385 **Dermatophagoides Pteronyssinus 1 and Dermatophagoides Pteronyssinus 2 Specific Immunoblobulins E Curative Effect Evaluation for Specific Immunotherapy/**P. Zheng, B. Sun, Guangzhou, China, p.A4849

P386 **The Cardiomyocyte Protein Alpha-T-Catenin Contributes to Asthma Through Regulating Pulmonary Vein Inflammation/**C.J. Gottardi, G.R.S. Budinger, P. Bryce, S.S. Folmsbee, Chicago, IL, p.A4850

P387 **Preventative Administration of IL-27 Improves Airway Inflammation of Ovalbumin -Induced Asthma Mice Model Via Both STAT1 and GADD45γ/p38MAPK Pathways/**Z. Chen, X. Su, K. Xu, J. Pan, X. Wang, Shanghai, China, p.A4851

P388 **A Microfluidic Small Airway-on-Chip Enables Analysis of Human Lung Inflammation and Therapeutic Responses In Vitro/**R. Villenave, K. Benam, C. Lucchesi, A. Varone, C. Hubeau, H.H. Lee, S. Alves, M. Salmon, T. Ferrante, J. Weaver, A. Bahinski, G. Hamilton, D.E. Ingber, Boston, MA, p.A7869

THEMATIC POSTER SESSION

C32 IMAGING INFLAMMATION IN THE LUNG

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area B, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: A.J. Gow, PhD, Piscataway, NJ

P135 **Use of Radiolabelled Autologous Neutrophils to Measure Neutrophil Clearance in the Lung in Patients with COPD and in Healthy Subjects Following Lipopolysaccharide/**N.C. Tregay, N. Farahi, R. Simmonds, C. Loutsios, I. Cullum, D. Gillett, D. Carroll, K. McGlashan, L. Griffiths, S. Madhavan, M. Begg, A. Cahn, E. Hessell, K. Povey, C. Solanki, J. Buscombe, A.M. Peters, E.R. Chilvers, Cambridge, United Kingdom, p.A4852

P136 **Mapping and Analysis of Human and Mouse Esophageal Nerve Plexuses Using Whole Mount Immunofluorence Imaging Reveals Differences in Neuropeptide Expression/**B.J. Marsh, M.G. Drake, A.D. Fryer, D.B. Jacoby, Portland, OR, p.A4853

P137 **Static 18F-FDG-PET Scans and Patlak Analysis of Dynamic 18F-FDG-PET Scans for Quantification of Lung Inflammation in Experimental ARDS/**A. Braune, L. Oehme, T. Kiss, T. Bluth, J. Kotzerke, M.G.D. Abreu, Dresden, Germany, p.A4854

P138 **Ultrastructural Changes and Mitochondrial Dysfunction in Primary Human Airway Epithelial Cells (HBECs) from Subjects with Asthma/**D.E. Winnica, M. Bueno, M. Sullivan, C. Corey, A.L. Mora, D. Stolz, S. Shiva, F. Holguin, Pittsburgh, PA, p.A4855

P139 **Nitrogen Mustard-Induced Lung Fibrosis Visualized by MRI and CT Imaging Is Accompanied by Accumulation of Foamy Macrophages/**A.J. Gow, A. Venosa, D. Adler, J. Laskin, E. Yurkow, D. Laskin, Piscataway, NJ, p.A4856

P140 **Hyperleukocytic Acute Myeloid Leukemia: Radiographic Findings and Clinico-Radiological Correlation in a Large Series of Patients/**M. Stefanski, C. Jamis-Dow, A. Van De Louw, Hershey, PA, p.A4857

THEMATIC POSTER SESSION

C33 IMMUNE PATHOLOGY OF VIRAL INFECTIONS

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area B, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: B.Y. Besecker, MD, Columbus, OH

P144 **Role of Endogenous Hydrogen Sulfide in Airway Hyperresponsiveness (AHR) and Inflammation in a Mouse Model of Cigarette Smoke Exposure and Respiratory Syncytial Virus (RSV) Infection/**R.P. Garofalo, Galveston, TX, p.A4858

P145 **The Role of BRP-39 in RSV-Induced Airway Inflammation in Mice/**M.J. Kim, D.H. Shim, I.S. Seol, S.H. Yoon, Y.H. Kim, M.N. Kim, J.Y. Hong, K.E. Lee, K.W. Kim, M.H. Sohn, K.-E. Kim, J.M. Lee, Seoul, Korea, Republic of, p.A4859

P146 **Silver Nanoparticles Down-Regulate Retinoic Acid-Inducible Gen 1 (RIG-I) Signalling Pathway During Influenza Infection Resulting in Lower Activation of TANK-Binding Kinase 1 (TBK1) and Reduced CCL5 Production/**I. Garcia-Verdugo, A. Dieu, B. Villeret, B. Solhonne, J.-M. Sallenave, Paris, France, p.A4860

P147 **HIV Infection Model of COPD in Mice/**P. Geraghty, E. Hadas, B.-H. Kim, D. Volsky, R. Foronjy, New York, NY, p.A4861

P148 **Immunopathology of the Airways in Severe Influenza A (H1N1)pdm Infection/**M. Buttignol, R.C. Pires-Neto, R.C. Rossi E Silva, M. Ballarin, M. Dolhnikoff, T. Mauad, Sao Paulo, Brazil, p.A4862

P149 **Cigarette Smoke Dampens Anti-Viral Responses in Human Small Airway Epithelial Cells Increasing Susceptibility to Influenza Viral Infections/**P.F. Duffney, C.E. McCarthy, A. Nogales, T.H. Thatcher, L. Martinez-Sobrido, R.P. Phipps, P.J. Sime, Rochester, NY, p.A4863

P150 **Detrimental Role of IL-1ß in a Mouse Model of Cigarette Smoke and H1N1 Influenza Infection/**G. Vanderstocken, M.C. Morissette, P. Shen, A.B. Roos, A.J. Beaulieu, A. Tabuchi, W.M. Kuebler, M.R. Stampfli, Hamilton, Canada, p.A4864

Facilitator: S.A. Cormier, PhD, Memphis, TN

P151 **Novel Insights into the H1N1 Pandemic: Mice Sensitized with House Dust Mite Extract Demonstrate Increased Morbidity from H1N1 Infection/**H.H.R. Chen, D.A. Ngan, Y. Oh, D.A. Knight, T.-L. Hackett, D.R. Dorscheid, P. Man, M. Niikura, D.D. Sin, J.A. Hirota, Vancouver, Canada, p.A4865

P152 **The Effects of Depleting Peripheral Monocytes on Pulmonary Inflammation in Juvenile-Model of Influenza A Virus Infection/**K.L. Staricha, K.M. Ridge, B.M. Coates, Chicago, IL, p.A4866

P153 **The Proliferative State of Alveolar Type II Cells Determines Susceptibility to Influenza Pneumonia/**N.M. Nikolaidis, J.G. Noel, L. Pitstick, J.C. Gardner, Y. Uehara, M.A. Nashu, A. Saito, H. Wu, F.X. McCormack, Cincinnati, OH, p.A4867

P154 **Chronic Pulmonary Inflammation in HIV Positive Subjects on Long Term Antiretroviral Therapy/**M.A. McInerney, P.A. Smith, R.B. Day, I. Robey, H. Erickson, V. Pulko, B.P. Katz, K.S. Knox, H. Twigg, Indianapolis, IN, p.A4868

P155 **Parainfluenza 3 Virus Induces Increased Cough Sensitivity, BDNF Expression, and Vagal Sensory TRPV1 Expression in the Airways/**E.J. Zaccone, Y. Muroi, L. Han, B.J. Canning, P. Gao, B.J. Undem, Baltimore, MD, p.A4869

P156 **Plasmacytoid Dendritic Cells Play a Critical Role in Regulating Gene Expression Patterns Induced by Human Rhinoviruses/** J. Upham, C. Xi, O. Pena, A. Bosco, Brisbane, Australia, p.A4870

P157 **Trp Channel Activation in Response to Respiratory Syncytial Virus Differs Between Human Pediatric Primary Bronchial Epithelial Cells and Airway Smooth Muscle Cells/**T.J. Harford, P.M. Brown, F. Rezaee, G. Piedimonte, Cleveland, OH, p.A4871

Facilitator: S. Konno, MD, Sapporo, Japan

P158 **Toll Like Receptor 7 Regulates the Electrolytes Secretion from Airway Submucosal Gland/**S. Gamo, S. Muramatsu, K. Murakami, T. Tamada, M. Nara, H. Sugiura, M. Ichinose, Sendai city, Miyagi pref, Japan, p.A4872

P159 **Respiratory Syncytial Virus Infection Affects the Survival and Differentiation of Human Neuroprogenitor Cells/**A. Belkadi, P.M. Brown, S. Manti, F. Rezaee, G. Piedimonte, Cleveland, OH, p.A4873

P160 **Rhinovirus Induces CXCL-10 Via IL-33/ST2 Signaling Axis in Human Bronchial Epithelial Cells/**M. Farazuddin, S. Ganesan, M.H. Hudy, B. Unger, A.T. Comstock, D. Proud, U. Sajjan, Ann Arbor, MI, p.A4874

P161 **Rhinovirus Infection Induces Abnormal Repair in a Model of Regenerating Airway Epithelium/**A.N. Faris, S. Ganesan, A. Chattoraj, S.S. Chattoraj, A.T. Comstock, B.L. Unger, M.B. Hershenson, U. Sajjan, Ann Arbor, MI, p.A4875

P162 **The Potential Roles of IFIT Genes and Interferon Induction for Antiviral Immune Response to Influenza Virus Infection in Nasal Mucosa/**H.J. Kim, S.N. Hong, W.H. Lee, Seoul, Korea, Republic of, p.A4876

P163 **Azithromycin Therapy During Severe RSV Bronchiolitis: Upper Airway Microbiome Alterations and Subsequent Recurrent Wheeze/**A. Beigelman, L.B. Bacharier, M. Isaacson-Schmid, J. Baty, K.B. Schechtman, G. Sajol, K. Wylie, G.A. Storch, M. Castro, Y. Zhou, St. Louis, MO, p.A4877

P164 **The Nasopharyngeal Microbiome During Acute RSV Infection Resembles the Bacterial Profile Associated with Increased Risk of Childhood Asthma/**C. Rosas-Salazar, M.H. Shilts, S. Yooseph, J.D. Chappell, E.K. Larkin, R.A. Halpin, K.E. Nelson, M.L. Moore, L.J. Anderson, R.S. Peebles, S. Das, T.V. Hartert, Nashville, TN, p.A4878

P165 **Phenotyping Immune Responses in Asthma and Respiratory Infections/**L. Lin, D. Belgrave, E. Bakhsoliani, A. Hirsman, M.R. Edwards, R.P. Walton, R. Solari, J.A. Curtin, A. Simpson, M. Rattray, A. Custovic, S.L. Johnston, Manchester, United Kingdom, p.A7870

THEMATIC POSTER SESSION

C34 IMMUNE REGULATION OF TRANSPLANT REJECTION

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area B, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: R.A. Shilling, MD, Chicago, IL

P168 **IL-17A Blockade Attenuates Lung Transplant Obliterative Bronchiolitis/**P.K. Gupta, Q. Wu, S. Wagner, R.A. Shilling, Chicago, IL, p.A4880

P169 **Foxp3+ Regulatory T Cells Are Critical for CD154/CD40 Costimulation Blockade-Induced Lung Allograft Acceptance/**E.A. Lendermon, J. Dodd-o, T.A. Coon, F.R. D'Alessio, J.F. McDyer, Pittsburgh, PA, p.A4881

P170 **Endothelial HIF-2α Deficiency Disrupts Airway Microvascular Structure and Impairs the Repair of Vessels of Transplanted Airways/**X. Jiang, W. Tian, A. Tu, M. Nicolls, Palo Alto, CA, p.A4882

P171 **Innate-like B1 B Cells Recognize Type V Collagen as A Danger Signal and Initiate Humoral Immune Response/**L. Zaffiri, K. Rothhaar, A.J. Fisher, E.A. Mickler, M. Yoshimoto, D.S. Wilkes, Indianapolis, IN, p.A4883

P172 **Immunoregulation of Human T-bet/IFN-γ Type-1 T Cell Responses by the E3 Ligase Fbxl2 and Novel Drug BC1261/**T.A. Coon, R. Mallampalli, B.B. Chen, J.F. McDyer, Pittsburgh, PA, p.A4884

P173 **Mesenchymal Stem Cells Reduce Obliterative Bronchiolitis Via IDO/**M. Ge, G. Zheng, G. Qiu, Q. Shu, J. Xu, Shaoxing, China, p.A4885

P174 **Acute Microvascular Rejection Increases Graft Iron, Promoting Aspergillus Fumigatus Allograft Invasion/**J.L. Hsu, M. Inayathulla, A.B. Tu, K.V. Clemons, J. Rajadas, D.A. Stevens, M. Nicolls, Stanford, CA, p.A4886

Facilitator: P. Burkett, MD, PhD, Boston, MA

P175 **Levels of Surfactant Protein D in Bronchial Aspirates Within Six Hours of Lung Transplantation Are Associated with Clinical Outcomes/**J. Madsen, S. Rideout, L. Thakuria, R. Romano, A. Simon, A. Popov, F. De Robertis, S. Soresi, M. Carby, A. Reed, N. Marczin, H. Clark, M. Griffiths, Southampton, United Kingdom, p.A4887

P176 **Prospective Molecular Profiling In Human Lung Allografts/**F. Laenger, N. Izykowski, J. Rische, P. Braubach, J. Gottlieb, T. Welte, A. Haverich, G. Warnecke, H. Kreipe, M.P. Kuehnel, D. Jonigk, Hannover, Germany, p.A4888

P177 **Ischemia Reperfusion-Induced Genetic Expression Profiles in the Human Lung/**B.S. Kim, L. Johnston, J.T. Magruder, J.C. Grimm, C. Talbot, R.S. Stephens, M. Damarla, R.L. Damico, P.M. Hassoun, A.S. Shah, Baltimore, MD, p.A4889

P178 **Retention and Activation of Donor Vascular Monocytes in Transplanted Lungs Suggests a Central Role in Primary Graft Dysfunction/**K.C. Tatham, K.P. O'Dea, R. Romano, H. Donaldson, L. Thakuria, K. Wakabayashi, B.V. Patel, A. Reed, A. Simon, N. Marczin, M. Takata, London, United Kingdom, p.A4890

P179 **Remodelling-Related Molecular Profiles in Different Subforms of Chronic Lung Allograft Dysfunction/**D. Jonigk, B. Rath, L. Maegel, H. Golpon, N. Izykowski, T. Welte, S. Janciauskene, J. Gottlieb, G. Warnecke, A. Haverich, H. Kreipe, M.P. Kuehnel, F. Laenger, Hannover, Germany, p.A4891

P180 **Coordinated Immune Activation by Distinct Mononuclear Phagocytes Subtypes Against the Mismatch of Minor Antigens/**C. Jakubzick, S. Atif, S. Gibbings, R. Gill, T. Grazia, R. Torres, P.M. Henson, G. Randolph, Denver, CO, p.A7871

THEMATIC POSTER SESSION

C35 INNATE IMMUNE MECHANISMS IN COPD

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area L, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: S. Garantziotis, MD, Research Triangle Park, NC

P1219 **Inflammatory Airway Diseases Are Characterized by a Microenvironment-Induced Sliding of Mast Cells into a Gradually Increasing Chymase+, CPA3+, and Cathepsin+ Phenotype/**P. Siddhuraj, M. Mori, A. Bergqvist, H.-J. Hoffman, L. Bjermer, J. Erjefalt, Lund, Sweden, p.A4892

P1220 **Expression and Function of Growth Differentiation Factor-15 in Cigarette Smoke-Induced Inflammation and COPD/**F.M. Verhamme, L.J. Seys, E.G. De Smet, S. Provoost, D. Elewaut, G.F. Joos, G.G. Brusselle, K.R. Bracke, Ghent, Belgium, p.A4893

P1221 **Elevated Levels of BPIFA1 (SPLUNC1) and BPIFB1 (LPLUNC1) in Lungs of Patients with COPD/**E.G. De Smet, L.J. Seys, F.M. Verhamme, B.M. Vanaudenaerde, G.F. Joos, G.G. Brusselle, C.D. Bingle, K.R. Bracke, Ghent, Belgium, p.A4894

P1222 **Inflammation Paradox - A Detailed Analysis of Inflammatory Profile in the Large and Small Airway Wall in Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD) Patients/**M.S. Eapen, K.D. McAlinden, D. Tan, H.K. Muller, S.S. Sohal, E.H. Walters, Hobart, Australia, p.A4895

P1223 **The High-Affinity IgE Receptor Is Upregulated on Plasmacytoid Dendritic Cells in Patients with Severe COPD/**P. Stoll, A. Baehker, M. Ulrich, K. Bratke, K. Garbe, J.C. Virchow, M. Lommatzsch, Rostock, Germany, p.A4896

P1224 **Platelets of COPD Patients Are Hyper-Responsive/**F. Aleva, Q. De Mast, K. Van Bragt, P. De Groot, Y. Heijdra, A. Van Der Ven, Nijmegen, Netherlands, p.A4897

Facilitator: M. Divangahi, PhD, Montreal, Canada

P1225 **Longitudinal Analysis Better Characterized Asthma-COPD Overlap Syndrome (ACOS): Finding from the Korean Asthma Cohort, COREA** /S.-Y. Park, J. Lee, J.-H. Kim, H.-J. Kim, H.-S. Kwon, Y.S. Cho, H.-B. Moon, T.-B. Kim, Seoul, Korea, Republic of, p.A4898

P1226 **Inhibition of p38 MAPK in Human Skeletal Muscle Cells Attenuates the SAA1 Secretion Initiated by Inflammatory Stimulation and Could Be Helpful Against Muscle Targeted Inflammation in COPD/**D. Patoine, A. Dube, M.-E. ThAcriault, S. Bonnet, F. Maltais, Quebec, Canada, p.A4899

P1227 **Sputum Bacterial and Fungal Dynamics During Exacerbations of Severe COPD/**J. Su, H. Zhou, GuangZhou, China, p.A4900

P1228 **Highly Selective Inhibitors of PI3Kγ for the Oral Treatment of COPD/**K. Karabelas, S. Arlbrandt, P. Bold, A. Butcher, J.F. Carlsson, P. Cygan, J. Ehnebom, C. Goodyear, L. MacLellan, M. Nordberg, H. Lindmark, M. Mogemark, R. Pehrson, M. Perry, S.R. Blomqvist, A. Stern, M. Thomas, Gothenburg, Sweden, p.A4901

P1229 **Plasma Cytokines and Chemokines Are Associated with Airflow Obstruction and Exacerbations in The COPDGene Cohort/**E.P. Bradford, S. Jacobson, B.C. Hartman, J. Keene, R.P. Bowler, Denver, CO, p.A4902

P1230 **An Impaired Innate Immune Response in Airway Smooth Muscle Cells from Chronic Cough Patients/**C. Rossios, S. Pavlidis, D. Gibeon, D. Horowitz, P. Branigan, M. Loza, F. Baribaud, N. Rao, F. Chung, I.M. Adcock, London, United Kingdom, p.A4903

Facilitator: R. Shaykhiev, MD, PhD, New York, NY

P1231 **IL17 Is Increased in Diseased Lung Tissue as Well as During Respiratory Disease Exacerbations and Increases Airway Contraction in Normal Human Lung Tissue/**D. Mohn, L. Sherman, K. Miner, C. Vezina, J.A. Johnston, Thousand Oaks, CA, p.A4904

P1232 **Complement Therapeutics Ameliorate Cigarette Smoke Induced Emphysema Development and Progression/**S. Stephenson, A. Kirst, A. Alawieh, J.K. Mulligan, T. Williamson, N. Reaves, S. Tomlinson, C. Atkinson, Charleston, SC, p.A4905

P1233 **Marco Regulates the In Vivo Response to Low Molecular Weight Hyaluronan Fragments/**A. Birukova, Z. Li, J.W. Hollingsworth, R.M. Tighe, Durham, NC, p.A4906

P1234 **Cigarette Smoke-Induced Lung Inflammation in Chronic Obstructive Pulmonary Disease Mediated Via LTB4/BLT1/SOCS1 Pathway/**R. Dong, K. Zhao, L. Xie, M. Zhou, Shanghai, China, p.A4907

P1235 **The Effect of MDR1 Polymorphisms on the Development of COPD/**E. Atahan, B. Batar, M. Guven, B. Tutluoglu, Istanbul, Turkey, p.A4908

P1236 **Type 1 Innate Lymphoid Cells Are Increased in COPD and May Contribute to Pathogen-Induced Exacerbations of Disease/**A.A. Humbles, J. Kearley, A. Copenhaver, C. Sanden, M. Mori, L. Yu, G. Harms Pritchard, A. Berlin, C. Hunter, R.P. Bowler, J.S. Erjefalt, R. Kolbeck, J.S. Silver, Gaithersburg, MD, p.A7872

P1237 **Serum Type 2 Chemokines in Chronic Obstructive Pulmonary Disease (COPD) Subjects in the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS)/**W. Tew, C. Chung, P. Manser, C. Holweg, S.A. Christenson, C. Rosenberger, W.K. O'Neal, P.G. Woodruff, M. Neighbors, South San Francisco, CA, p.A7873

P1238 **Mice with a Selectively Disrupted Phosphatase Shp2 Exhibit Age-Dependent CPFE-Like Alveolar Injury/**J. Xu, B. Tao, S. Zhou, X. Guo, X. Zhang, Y. Ke, Hanghou, China, p.A7874

THEMATIC POSTER SESSION

C36 NOVEL MECHANISMS OF ALLERGIC AIRWAY INFLAMMATION IN ANIMAL MODELS

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area B, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: L.A. Miller, PhD, Davis, CA

P183 **Effects of Concurrent Exposure of Diesel Exhaust Particles and House Dust Mite on Development of Allergen-Induced Airways Inflammation/**Y. Zhang, A. Hin, X. Wang, S. Salehi, J.A. Scott, C. Carlsten, C.-W. Chow, Toronto, Canada, p.A4909

P184 **A Phosphatidylinositol 3-Kinase Inhibitor(PI3K) Strongly Suppressed Inflammation and Pulmonary Vascular Remodeling in a Murine Model of Allergic Vasculitis/**Y. Oikawa, N. Sasaki, Y. Nakamura, K. Yamauchi, Morioka, Japan, p.A4910

P185 **Wogonin Attenuates Allergic Neutrophilic Airway Inflammation by Inducing Neutrophil Apoptosis/**F.-F. Bai, L. Han, Z. Chen, X.-N. Zeng, J. Zhu, M. Huang, T. Zheng, Z. Zhu, L.-F. Zhou, Nanjing, China, p.A4911

P186 **SplD- a Novel Inhalant Allergen from S. Aureus Causes Th2 Bias in Mice/**O. Krysko, A. Teufelberger, S. Stenzel, K. De Grove, T. Maes, G. Holtappels, B. Broker, C. Bachert, Gent, Belgium, p.A4912

P187 **Prior Chronic Exposure to Diesel Exhaust Particles Enhances Airways Hyperresponsiveness and Inflammation in an Acute Model of House Dust Mite-Induced Airways Inflammation/**X. Wang, A. Hin, Y. Zhang, S. Salehi, J.A. Scott, C. Carlsten, C.-W. Chow, Toronto, Canada, p.A4913

P188 **Defining Allergic Airways Disease Severity in a Colony of Allergic Dogs/**K. Rudolph, C.M. Royer, E.G. Barrett, Albuquerque, NM, p.A4914

P189 **Glucocorticoid Induced Leucine Zipper Protein (GILZ) Deficient Mice Show a Similar Response as Wild Type Mice in Allergic Airway Disease Whereas Mice with GILZ Deficiency in Just the Bronchial Epithelial Cells Show an Enhanced Response in a Murine Asthma /**A. Doerner, J. Eddleston, M. Miller, D. Broide, B. Zuraw, La Jolla, CA, p.A4915

Facilitator: I.P. Lewkowich, PhD, Cincinnati, OH

P190 **Thrombocytopaenia at Time of Allergen Sensitization Regulates Subsequent Allergen Induced Airway Inflammation in Mice/**S.C. Pitchford, R.T. Amison, S.J. Cleary, C.P. Page, London, United Kingdom, p.A4916

P191 **Maternal Allergen Exposure Reveals an Early Atopic Phenotype and Unique Developmental Transcriptome in Innately Hyperresponsive Rat Pups/**F. Kaplan, A. Kho, N. Carpe, H. Mirzakhani, K. Tantisira, J.G. Martin, S.T. Weiss, Montreal, Canada, p.A4917

P192 **Chronic Ovalbumin Sensitization Enhances Cough and Expiratory Reflexes Elicited by Inhaled Irritant Gases in Awake Mice/**C. Zhang, R.-L. Lin, M. Khosravi, L.-Y. Lee, Guiyang, China, p.A4918

P193 **Marmoset Monkeys as a Model for Human Allergic Asthma/**C. Curths, S. Jimenez-Delgado, J. Wichmann, Y.S. Kap, F.-J. Kaup, A. Braun, K. Sewald, S. Knauf, F. Dahlmann, Göttingen, Germany, p.A4919

P194 **Elimination of IL-33 Inhibits Airways Hyperresponsiveness/**C.M. Frodella, B.J. Smith, L.T. Hellman, M.E. Poynter, A. Van Der Vliet, M. Aliyeva, N. Daphtary, M. Hristova, L.K.A. Lundblad, Burlington, VT, p.A4920

P195 **A Rat Model of Severe Allergic Asthma/**P.W. Andreotta, M. Rosado, S. Rogers, A. Kury, S.T. Sonis, G.D. Lyng, Watertown, MA, p.A4921

P196 **Effects of Diesel Exhaust Particles Exposure in a Murine Model of Asthma Due to Soybean/**M.-J. Cruz, D. Alvarez-Simon, S. Gomez-Olles, M.-D. Untoria-Corral, J. Yllera-Retegui, M. Olle-Monge, X. Munoz, Barcelona, Spain, p.A4922

Facilitator: A.I. Sperling, PhD, Chicago, IL

P197 **Chronic Mouse Model of Chemical-Induced Asthma/**L. Pollaris, F. Devos, S. Seys, B. Nemery, P.H.M. Hoet, J. Vanoirbeek, Leuven, Belgium, p.A4923

P198 **Comparison of the Pharmacokinetics and Efficacy of Fluticasone Propionate in a Canine Inflammation Model/**K. Rudolph, C.M. Royer, R. Chand, R.P. Sheeler, D.T. Vodak, P.J. Kuehl, B.C. Moeller, E.G. Barrett, Albuquerque, NM, p.A4924

P199 **IL5 and IL13 -Antibodies Specifically Inhibit Asthma Features in a Cytokine Induced Mouse Model/**H. Beckert, S. Reuter, H. Meyer-Martin, S. Korn, R. Buhl, Mainz, Germany, p.A4925

P200 **IL-33 from Inflammatory Monocytes Recruited to Lung Contributes to HDM-Induced Airway Inflammation/**H. Tashiro, K. Takahashi, G. Kato, S. Hayashi, S. Kimura, N. Sueoka-Aragane, Saga, Japan, p.A4926

P201 **Saccharomyces Cerevisiae UFMG 905 Modulates Cytokine Production in the Cecum and Inhibits Lung Inflammation in an Animal Model of Asthma/**M.C. Borges, V.M. Fonseca, C. Sandy, F.S. Martins, E.O. Vianna, Ribeirao Preto, Brazil, p.A4927

P202 **Nerve Growth Factor Promotes the Maturation and Cytokine Release of Dendritic Cells Induced by Ovalbumin with Low-Dose Lipopolysaccharide Via the NF-kB Pathway/**P. Pan, H. Tan, H. Li, ChangSha, China, p.A4928

P203 **Epsi-gam Attenuates Aeroallergen-Induced Early Phase Bronchoconstriction and Late Phase Inflammation in House Dust Mite-Sensitive Non-Human Primates /**R.L. Wardle, K.M. Gowdy, J.H. Chandler, S.W. Reece, G. Sperinde, K. Von Loehneysen, K.B. Holley, A.F. Reid, N. Sigal, M.R. Van Scott, Greenville, NC, p.A7875

P204 **Innate Immunity Activation via Toll-Like Receptors-2/6 and -9 Agonists Suppress Viral Replication, Airway Hyperreactivity, Mucous Metaplasia, and Eosinophilic Inflammation Associated with Chronic Lung Disease in Mice/**D.L. Goldblatt, S. Tkachman, M. Tuvim, B.F. Dickey, Houston, TX, p.A7876

THEMATIC POSTER SESSION

C37 PULMONARY FIBROSIS

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area B, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: R.G. Scheraga, MD, Cleveland, OH

P206 **5'Ectonucleotidase (CD73) Impacts on Radiation-Induced Immune Changes/**S. De Leve, F. Wirsdorfer, F. Cappuccini, M. Stuschke, V. Jendrossek, Essen, Germany, p.A4929

P207 **A Retrospective Cohort Analysis of Anti-Jo Associated Lung Disease/**P.D. Jackson, C. Hutchinson, T. Siddharthan, Portland, OR, p.A4930

P208 **Clinical and Imaging Features of Anti-Aminoacyl-tRNA Synthetase Antibody-Positive Interstitial Lung Disease/** M. Takahashi, K. Mizumura, T. Shimizu, S. Maruoka, T. Morisawa, N. Takahashi, Y. Gon, S. Hashimoto, Tokyo, Japan, p.A4931

P209 **Hypoxia and Macrophage Differentiation Contribute to Pulmonary Fibrosis Through Regulation of ADORA2B/** K.M. Philip, H. Karmouty-Quintana, T.W. Mills, N.-Y. Chen, J. Davies, F. Luo, J. Molina, M.R. Blackburn, Houston, TX, p.A4932

P210 **Relationship Baseline Fibrosis Score to Lung Function in a Clinical Trial Population with Idiopathic Pulmonary Fibrosis/** S.M. Humphries, T.G. O'Riordan, J.J. Zhang, S. Bayly, R. Sood, A. Hayden, D.A. Lynch, Denver, CO, p.A4933

P211 **CT-Derived Textural Analysis Score Predicts Physiologic Progression in IPF/**S.M. Humphries, M. Strand, K.R. Flaherty, M.I. Schwarz, E. Kazerooni, E.J.R. Van Beek, D.A. Lynch, Denver, CO, p.A4934

P212 **Inhibition of Glutamine Metabolism Arrests the Development of Pulmonary Fibrosis/**C.L. Vigeland, Y. Chan-Li, S.L. Collins, A.H. Hughes, M.-H. Oh, J.D. Powell, M.R. Horton, Baltimore, MD, p.A4935

Facilitator: M.N. Ballinger, PhD, Columbus, OH

P213 **Insights from a Multi-Centre Real Life Experience in Germany with Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis/**F. Bonella, M. Kreuter, L. Hagmeyer, C. Neurohr, C. Keller, M. Kohlhaeufl, J. Muller-Quernheim, K. Milger, A. Prasse, Essen, Germany, p.A4936

P214 **Combination Potential of Pirfenidone and Silymarin for Treatment of Idiopathic Pulmonary Fibrosis/**S. Dasari, R. Alluri, K.V. Routhu, Hyderabad, India, p.A4937

P215 **Aspirin-Triggered Resolvin D1, ATRvD1, Reverts Chronic Pulmonary Fibrosis in a Murine Model/**C.F. Benjamim, R.D.F. Guilherme, T.D.O. Nogueira, J.S. Neves, C.D.A. Canetti, Rio de Janeiro, Brazil, p.A4938

P216 **A Novel Approach for Fibrocyte Identification in Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension/**P. Heukels, J. Van Hulst, M. Van Nimwegen, K. Boomars, M. Wijsenbeek, L. Van Den Toorn, H.C. Hoogsteden, R. Hendriks, M. Kool, B. Van Den Blink, Rotterdam, Netherlands, p.A4939

P217 **Proteomic and Transcriptomic Signatures of Hypoxic Lung Epithelial Cells Reveal a Central Relationship Between Focal Adhesion Kinase 1 and Galectin-1 Driving Fibrosis/** J.J. Kathiriya, N. Nakra, J. Nixon, P. Patel, V. Vaghasiya, V. Dave, Tampa, FL, p.A4940

P218 **Resident Memory T Cells Arrest and Reverse Pulmonary Fibrosis/**A.H. Hughes, Y. Chan-Li, C.L. Vigeland, S.L. Collins, M.R. Horton, Baltimore, MD, p.A4941

P219 **Performance Characteristic of Six Minute Walk Test in Scleroderma Patients with Interstitial Lung Disease/**C. Ghattas, A. Gadre, O.A. Minai, K.B. Highland, Boston, MA, p.A4942

Facilitator: R. Guzy, MD, PhD, Chicago, IL

P220 **Beta-Catenin Upregulates Fibrosis Associated Genes Through mRNA Synthesis and Stabilization in Human Lung-Resident Mesenchymal Cells/**P. Cao, N. Walker, Y. Aoki, S. Mazzoni, L. Badri, E. Fearon, V. Lama, Ann Arbor, MI, p.A4943

P221 **Idiopathic Interstitial Pneumonia with Autoimmune Features: Clinical Characteristics and Prognosis in a French Cohort/** K. Ahmad, T. Barba, J. Traclet, C. Khouatra, V. Cottin, Bron, France, p.A4944

P222 **Simtuzumab in Idiopathic Pulmonary Fibrosis (IPF): Baseline Demographic and Lung Function Data from a Clinical Trial/** G. Raghu, K.K. Brown, H.R. Collard, D.J. Lederer, F.J. Martinez, P.W. Noble, J.W. Song, A.U. Wells, T.P. Whalen, L. Lambert, J.W. Chien, J.J. Zhang, T.G. O'Riordan, Seattle, WA, p.A4945

P223 **Analysis of Serum Ferritin in Patients with Acute Exacerbation of Idiopathic Pulmonary Fibrosis/**N. Enomoto, Y. Enomoto, Y. Oyama, M. Kono, Y. Suzuki, K. Furuhashi, T. Fujisawa, N. Inui, Y. Nakamura, T. Suda, Hamamatsu, Japan, p.A4946

P224 **The Effect of N-Acetylcysteine on Idiopathic Pulmonary Fibrosis: A Meta-Analysis/**W. Luo, Y.L. Li, Chongqing, China, p.A4947

P225 **Development of Pulmonary Fibrosis Is Dependent on Transcription Factors that Control T Cell Identity and Effector Function/**K.J. Lorentsen, C. Fu, V. Shenoy, M.L. Brantly, E. Scott, D. Avram, A.J. Bryant, Gainesville, FL, p.A4948

P226 **CCP Antibodies in Idiopathic Interstitial Lung Disease/**S.M. Matson, R. Keith, K. Demoruelle, Z. Yunt, J.J. Swigris, J.J. Solomon, Aurora, CO, p.A4949

Facilitator: R. Vij, MD, Chicago, IL

P227 **Eotaxin-2 in Lung Tissue Is Associated with Disease Severity and Progression of IPF/**O.O. Amubieya, G.H.J. Kim, R. Huynh, M. Shino, A. DerHovanessian, D. Sayah, R. Saggar, A. Ardehali, D. Ross, J.P. Lynch, J.A. Belperio, S. Weigt, Los Angeles, CA, p.A4950

P228 **Comparison of Two Murine Models of Acute and Chronic Hypersensitivity Pneumonitis Due to Pigeon Serum Exposure/**M.-J. Cruz, M. Sanchez-Ortiz, M.-D. Untoria-Corral, A. Villar, S. Gomez-Olles, F. Morell, X. Munoz, Barcelona, Spain, p.A4951

P229 **Lymphocyte Subset Expression and Disease Severity in Systemic Sclerosis/**J. Gagermeier, S. Qazi, R. Tehrani, Maywood, IL, p.A4952

P230 **Endogenous Semaphorin-7A Impedes Human Airway Primary Fibroblast Proliferation, Migration and Differentiation/**S. Esnault, E.E. Torr, M.W. Johansson, N. Sandbo, N.N. Jarjour, Madison, WI, p.A4953

P231 **Effects of Endotoxin Injection on Diaphragm Muscle Contractile Properties in MyD88KO Mice/**K. Yamaguchi, Y. Kato, M. Miura, C. Shindoh, Sendai, Japan, p.A4954

P232 **Dexamethasone Therapy Does Not Prevent the Recruitment of Monocyte-Derived Alveolar Macrophages During Lung Fibrosis/**F.J. Gonzalez-Gonzalez, L. Morales-Nebreda, A.C. Mc Quattie-Pimentel, R. Piseaux, M. Chi, K.A. Radigan, M. Jain, A.V. Misharin, H.R. Perlman, G.S. Budinger, Chicago, IL, p.A4955

P233 **Therapeutic Efficacy of a Novel LPA1 Receptor Antagonist, UD-009, in a Bleomycin-Induced Pulmonary Fibrosis Model/**K. Nishikawa, E. Okanari, Y. Shinohara, H. Matsunaga, H. Nishida, N. Iwase, S. Ushiyama, Yamaguchi, Japan, p.A7877

THEMATIC POSTER SESSION

C38 NEW DEVELOPMENTS IN ASTHMA CARE, METHODS, AND OUTCOMES

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area F, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: K.A. Riekert, PhD, Baltimore, MD

P609 **Barriers to Asthma Self-Management: Results from the SAMBA Screening Instrument/**I. Mindlis, M. Martynenko, R.M. O'Conor, J.P. Wisnivesky, M. Wolf, A. Federman, New York, NY, p.A4956

P610 **Age at Onset and Adherence to ICS Controller Therapy Among Severe Asthmatics (Keio-SARP)/**K. Masaki, K. Fukunaga, T. Kamatani, R. Baba, T. Tanosaki, K. Ohtsuka, M. Matsusaka, T. Mochimaru, H. Kabata, S. Ueda, Y. Suzuki, K. Asano, T. Betsuyaku, Tokyo, Japan, p.A4957

P611 **The Missing Link in Asthma Adherence: First-Fill Prescription Rates/**S.G. Bickel, S. Eid, N. Eid, Louisville, KY, p.A4958

P612 **Medication Adherence Among Difficult-to-Treat Asthmatics Managed in a Specialist Asthma Clinic/**A. Yii, T. Lapperre, W.T. Lim, A. Chan, M. Koh, Singapore, Singapore, p.A4959

P613 **'Sitting It Out and Keeping Calm': Results of a Population Survey on How and When Asthma Patients Use Rescue Treatment/**H.K. Reddel, J.M. Foster, Sydney, Australia, p.A4960

P614 **Knowledge of Inhaler Technique Among Health Care Providers: An Evaluation of Doctors and Nurses/**B.O. Adeniyi, A.M. Adebayo, O. Ilesanmi, D. Obaseki, G.E. Erhabor, Owo, Nigeria, p.A4961

Facilitator: L.B. Gerald, MSPH, PhD, Tucson, AZ

P615 **What Is Needed to Speed Up the Development of New Asthma Treatments in Europe: A Pan-European Perspective/**R. Djukanovic, J. Varkonyi-Sepp, B. Varkonyi, J.L. Edwards, E.J. Kennington, S. Walker, Southampton, United Kingdom, p.A4962

P616 **The Comparison of Three Asthma Control Questionnaires and Peak Expiratory Flow Variability/**P. Ruchiwit, A. Kanitsap, W. Petvipusit, Pathumthani, Thailand, p.A4963

P617 **Do Asthma or COPD Cost-Effectiveness Models Have Similar Structures and Inputs?/**J.D. Campbell, C.H. Kim, P. Dilokthornsakul, Aurora, CO, p.A4964

P618 **A Longitudinal Claims Analysis of 90-Day Asthma Treatment Step Patterns/**J.D. Campbell, A.M. Thompson, P. Dilokthornsakul, Aurora, CO, p.A4965

P619 **A Survey of Asthma Management Practices and Implementation of Global Initiative for Asthma (GINA) Guidelines Among Doctors in a Resource-Limited Setting in Nigeria/**M. Iroezindu, E. Chima, N. Uchenna, G. Mbata, C. Okwuonu, Enugu, Nigeria, p.A4966

P620 **Access to Methacholine Challenges in Northern Alberta; A Quality Assurance Project/**M. Peters, D. Pawluski, E. James, D. Stollery, E. Wong, D.W. Cockcroft, D. Vethanayagam, Edmonton, Canada, p.A4967

Facilitator: S.B. Khatri, MD, MSc, Cleveland, OH

P621 **Phone Interventions Reduce ED Visits in Moderate Persistent Asthma in a Resident Run Community Hospital/**K. Gopalratnam, A. Geeti, Y.A. Adjepong, M.J. Smith, D. Lindahl, Bridgeport, CT, p.A4968

P622 **Patient Characteristics and Health Outcomes Among Patients with Allergic Asthma Treated with Inhaled Corticosteroids and Long-Acting Beta Agonists Combination Therapy/**L.K. Lee, S. Gabriel, E. Obi, B. Paknis, B.E. Chipps, Foster City, CA, p.A4969

P623 **Allergic Status Is Associated with Increased Number of Asthma Exacerbations/**W.J. Calhoun, T.A. Omachi, S.R. Reddy, E. Chang, M.S. Broder, J. Antonova, Galveston, TX, p.A4970

P624 **Clinical Characteristics of Asthmatic Patients with Influenza-Like Illness and Risk for Severe Exacerbations in Mexico/**P. Paulin-Prado, K. Nishimura, L. Freimanis-Hance, S. Hunsberger, J. Beigel, A. Galindo-Fraga, A.A. Ortiz-Hernandez, B. Llamosas-Gallardo, S. Moreno-Espinosa, R. Valdez-Vazquez, M. Magana-Aquino, G.M. Ruiz-Palacios, A. Ramirez-Venegas, Mexico, Mexico, p.A4971

P625 **A Cluster Analysis of Bronchial Asthma Patients with Depressive Symptoms/**Y. Seino, N. Shimizu, I. Mashima, T. Sakagami, T. Koya, F. Yoshimine, T. Hasegawa, Y. Muramatsu, K. Muramatsu, E. Suzuki, T. Kikuchi, Niigata, Japan, p.A4972

P626 **Overuse of Antibiotics Among Patients Hospitalized for Exacerbations of Asthma/**P.K. Lindenauer, M.S. Stefan, L.C. Feemster, M.-S. Shieh, S.S. Carson, D.H. Au, J.A. Krishnan, Springfield, MA, p.A7878

P627 **Asthma Care Paths in Urban Settings: Identifying Local Barriers to Care to Pilot Targeted Solutions/**J. Chang, M. Latifi, M. Ferrari, R. Engineer, S. Podolsky, S.B. Khatri, Cleveland, OH, p.A7879

THEMATIC POSTER SESSION

C39 IPF: MORE ON DIAGNOSIS AND THERAPY

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area D, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: G. Raghu, MD, Seattle, WA

P391 **Using Hyperpolarized 129Xe Imaging to Quantify Apical Vs. Basal and Central Vs. Peripheral Gas Exchange Impairment in Idiopathic Pulmonary Fibrosis/**J.M. Wang, S.H. Robertson, M. He, R.S. Virgincar, G.M. Schrank, R.M. Smigla, T. O'Riordan, J. Sundy, L. Ebner, C.R. Rackley, H.P. McAdams, B. Driehuys, Durham, NC, p.A4973

P392 **Quantitative Image Analysis of Spirometry-Guided HRCT in a Phase 2 Study of PRM-151 in Patients with Idiopathic Pulmonary Fibrosis/**B. Van Den Blink, B. Bartholmai, J.R. Miedema, C.J. Lammering, E.E. Van Der Wall, M.Y. Gerrits-Boeye, M. Wapenaar, K.M. Carroll, R. Chamberlain, H.C. Hoogsteden, G. Raghu, Rotterdam, Netherlands, p.A4974

P393 **The Changes and Clinical Significance of Serum Laminin, Type IV Collagen, Type III Procollagen N-Terminal Peptide and Hyaluronic Acid in Pulmonary Fibrosis Patients/**Y. Su, D. Weng, Shanghai, China, p.A4975

P394 **Care of Patients with IPF at a Community Hospital in the UK. Adherence to National Institute for Health and Care Excellence (NICE) Guidance and Implications for Network Care/**S. Diver, S. Paterson, T. Gatheral, Lancaster, United Kingdom, p.A4976

P395 **Correlation Between Serum High-Mobility Group Box Protein 1 Level and Prognosis in Acute Exacerbation of Fibrosing Interstitial Pneumonia/**H. Shimizu, S. Sakamoto, K. Furuya, A. Kinoshita, A. Suzuki, K. Koyama, N. Urabe, T. Isshiki, K. Gocho, G. Sano, K. Sugino, K. Isobe, Y. Takai, S. Homma, Ootaku, Japan, p.A4977

P396 **Assessing the Impact of Obstructive Sleep Apnea on Survival in Idiopathic Pulmonary Fibrosis/**K. Janssen, Q. Wang, D. Perlman, R. Tomic, H. Kim, Minneapolis, MN, p.A4978

P397 **Cardiovascular Risk Factors, Comorbidities and Concomitant Medications from Three Phase 3 Trials of Pirfenidone in Idiopathic Pulmonary Fibrosis/**M. Glassberg, S.D. Nathan, C. Lew, K. Raimundo, B.-M. Day, J. Stauffer, W. Chou, P.W. Noble, Miami, FL, p.A4979

P398 **Cardiovascular Events in Phase 3 Trials of Pirfenidone in Idiopathic Pulmonary Fibrosis (IPF)/**M. Glassberg, S.D. Nathan, C.-Y. Lin, C. Lew, K. Raimundo, J. Stauffer, W. Chou, P.W. Noble, Miami, FL, p.A4980

P399 **Prevalence of Basilar Fibrosis on Abdominal Computerized Tomography Imaging/**G. Magda, J.L. Della-Santina, S.A. Stayrook, N. Weir, C.S. King, S. Ahmad, O.A. Shlobin, A.W. Brown, C.P. Della-Santina, S.D. Nathan, Washington, DC, p.A4981

P400 **FAM13A Polymorphism as a Prognostic Factor in Patients with Idiopathic Pulmonary Fibrosis/**C. Hirano, S. Ohshimo, Y. Horimasu, H. Iwamoto, K. Fujitaka, H. Hamada, N. Hattori, F. Bonella, J. Guzman, U. Costabel, N. Kohno, Hiroshima, Japan, p.A4982

P401 **The Importance of Longitudinal Micro-CT-Derived Biomarker Quantification for Therapy Evaluation in Mouse Models of Lung Fibrosis/**G. Vande Velde, E. De Langhe, J. Poelmans, A. Hillen, U. Himmelreich, J. Vanoirbeek, R. Lories, Leuven, Belgium, p.A4983

P402 **The Usefulness of Direct Hemoperfusion with Polymyxin B-Immobilized Fiber (PMX-DHP) Treatment on Acute Exacerbation of Interstitial Pneumonitis/**H. Furusawa, M. Sugiura, Y. Miyazaki, N. Inase, Tokyo, Japan, p.A4984

P403 **Clinical Significance of Thyroid Antibodies and Hormones in Patients with Idiopathic Interstitial Pneumonia/**Y. Sato, Y. Tanino, T. Nikaido, K. Misa, R. Togawa, Y. Suzuki, M. Uematsu, A. Fukuhara, S. Sato, J. Saito, X. Wang, M. Munakata, Fukushima, Japan, p.A4985

P404 **MUC5B Genotype Does Not Affect Cough Severity In Fibrotic Lung Diseases/**P. Saunders, C. Stock, S. Kingston, P.L. Molyneaux, M.G. Belvisi, M. Kokosi, A.U. Wells, E. Renzoni, T.M. Maher, London, United Kingdom, p.A4986

P405 **Relationship of Serum Sodium Level to Outcomes in Patients with Interstitial Lung Disease/**P.R. Yeturu, D. Kurbanov, C. Cherian, J. Pang, M.J. Fazzari, G. Nair, Mineola, NY, p.A4987

P406 **Functional Respiratory Imaging (FRI) in IPF: Regional Information Matters/**W. Vos, C. Van Holsbeke, F. Ferreira, J. De Backer, J.G. Goldin, S. Porter, W. De Backer, Kontich, Belgium, p.A4988

P407 **Survival in Interstitial Lung Disease with Possible Usual Interstitial Pneumonia by High Resolution Computed Tomography/**C.T. Lee, J.M. Oldham, J.H. Chung, S. Montner, E. Valenzi, L.J. Witt, L.W. Chen, S. Hsu, M.E. Strek, I. Noth, R. Vij, Chicago, IL, p.A4989

P408 **Correlation of DLCO Components (Dm and Vc) with High Resolution Computed Tomography and Their Prognostic Impact in Idiopathic Pulmonary Fibrosis/**T.F. Gille, L. Moya, M. Boubaya, G. Bertrand, D. Valeyre, P.Y. Brillet, C. Lamberto, C. Planes, H. Nunes, Bobigny, France, p.A4990

P409 **Progression of Pulmonary Hypertension in Idiopathic Pulmonary Fibrosis with Mostly Mild to Moderate Restriction/**R. Teramachi, H. Taniguchi, Y. Kondoh, T. Kimura, K. Kataoka, T. Matsuda, T. Yokoyama, A. Suzuki, T. Furukawa, Seto, Japan, p.A4991

P410 **Diagnosis by Multi Disciplinary Discussion of Idiopathic Interstitial Pneumonias in a Real World; Japanese Multi Center Cohort Study/**Y. Inoue, M. Kitaichi, M. Akira, T. Johkoh, A. Hebisawa, I. Yamadori, T. Arai, C. Sugimoto, A. Matsumuro, M. Hirose, K. Tachibana, T. Kasai, W.D. Wallace, D.M. Hansell, W.D. Travis, Osaka, Japan, p.A4992

P411 **Spectrum of Idiopathic Pulmonary Fibrosis Severity in Clinical Practice: Implications for Clinical Trial Feasibility and Design/**D. Macaulay, S.D. Nathan, Y. Yu, E. Terasawa, New York, NY, p.A4993

P412 **Demographic and Clinical Characteristics of Patients Treated with Pirfenidone in the US/**K. Raimundo, A. Farr, W. Chou, South San Francisco, CA, p.A4994

P413 **Effect of Continued Treatment with Pirfenidone Following a ≥ Relative Decline in Percent Predicted Forced Vital Capacity in Patients with Idiopathic Pulmonary Fibrosis (IPF)/**S.D. Nathan, C. Albera, U. Costabel, I. Glaspole, M. Glassberg, L. Lancaster, D.J. Lederer, C.A. Pereira, J. Swigris, B.-M. Day, W. Chou, A.U. Wells, Falls Church, VA, p.A4995

P414 **Residual Volume-Corrected Forced Vital Capacity Change: A More Accurate Indicator of Outcomes in IPF?/**S.D. Nathan, N. Weir, S.A. Stayrook, C.S. King, S. Ahmad, O.A. Shlobin, A.W. Brown, Falls Church, VA, p.A4996

P415 **CPI and DLCO Parameters Identifying Patients at Risk of Acute Exacerbation of IPF/**E. Fraser, R. Hoyles, L.P. Ho, Oxford, United Kingdom, p.A4997

Facilitator: K.K. Brown, MD, Denver, CO

P416 **Benefits of Young Donor Adipose-Derived Mesenchymal Stem Cell Therapy in the Rescue of Bleomycin-Induced Pulmonary Fibrosis in an Aged Mouse Model/**G.A. Rubio, X. Xia, S. Pereira-Simon, S.J. Elliot, M. Glassberg, Miami, FL, p.A4998

P417 **Diagnostic Significance of Biomarkers for Chronic Fibrosing Idiopathic Interstitial Pneumonias (Usual Interstitial Pneumonia Vs Non-Specific Interstitial Pneumonia)/**M. Kato, S. Sasaki, K. Nakamura, N. Arano, T. Takeshige, S. Kuriyama, K. Muraki, O. Nagashima, Y. Yoshioka, S. Tominaga, K. Takahashi, Chiba, Japan, p.A4999

P418 **Relationship Between Nintedanib Exposure, Patient Characteristics and Clinical Efficacy in Patients with Idiopathic Pulmonary Fibrosis/**U. Schmid, B. Weber, C. Dallinger, L. Richeldi, C. Hallmann, G. Raghu, M. Freiwald, Biberach an der Riss, Germany, p.A5000

P419 **Serum Decorin as a Possible Prognostic Biomarker in Patients with Acute Exacerbation of Idiopathic Pulmonary Fibrosis/**T. Nikaido, Y. Tanino, N. Fukuhara, K. Misa, Y. Sato, R. Togawa, Y. Suzuki, M. Uematsu, A. Fukuhara, S. Sato, J. Saito, X. Wang, M. Munakata, Fukushima, Japan, p.A5001

P420 **Implications of Pulmonary Physiology and Exercise Testing Results in Idiopathic Pulmonary Fibrosis (IPF) in a Real World Cohort/**C. Sharp, G. Dixon, A. Edwards, H. Adamali, A.B. Millar, Bristol, United Kingdom, p.A5002

P421 **Characteristics and Accuracy of Internet Health Information for Idiopathic Pulmonary Fibrosis/**J.H. Fisher, D. O'Connor, A.M. Flexman, S. Shapera, C.J. Ryerson, Toronto, Canada, p.A5003

P422 **Baseline Pulmonary Function Test Predicts Survival: Analysis from the Australian IPF Registry/**H. Jo, I. Glaspole, N. Goh, P. Hopkins, Y. Moodley, P. Reynolds, H. Walters, C. Zappala, H. Allan, S. Chapman, W. Cooper, S. Ellis, C. Grainge, G. Keir, A. Mahar, T.J. Corte, Camperdown, Australia, p.A5004

P423 **Human Epididymis Protein 4 Is a Novel Biomarker for Chronic Fibrosing Interstitial Pneumonias/**M. Masuo, Y. Miyazaki, T. Fujie, N. Inase, M. Nakamura, K. Ohbo, Tokyo, Japan, p.A5005

P424 **Digital Clubbing Is Associated with Higher Serum KL-6 Levels and Lower Pulmonary Function in Patients with Interstitial Lung Disease/**K. Shiraishi, T. Jinta, N. Nishimura, R. Tsugitomi, T. Tanigawa, H. Nakaoka, K. Okafuji, A. Kitamura, Y. Tomishima, T. Tamura, G.A. Deshpande, N. Chohnabayashi, Tokyo, Japan, p.A5006

P425 **Airway Expression of Transient Receptor Potential Channels in Idiopathic Pulmonary Fibrosis/**N.X. Hutchinson, S. Wozniak, A. Gibbs, A.J. Tonks, B. Hope-Gill, Cardiff, United Kingdom, p.A5007

P426 **Using microCT to Quantify the Compliance of Lungs in a Bleomycin-Induced Pulmonary Fibrosis Rat Model/**S. Siddiqui, Y. Xin, H. Profka, S. Kadlecek, R.R. Rizi, Philadelphia, PA, p.A5008

P427 **Comparative Analysis Between Pulmonary Fibrosis Idiopathic and Systemic Sclerosis Regarding Six-Minute Walk Test and Respiratory Function Test/**M. Pimentel, L. Valentine, K.M. Da Silva, A. Maiworm, R. Rufino, C.H.D. Costa, Rio de Janeiro, Brazil, p.A5009

P428 **The Preliminary Evaluation of the Effectiveness and Safety of <Pulmonary Fibrosis Rehabilitation Exercise>**/L. Shen, Q.H. Li, D. Weng, Shanghai, China, p.A5010

P429 **Phase 1 LPS Challenge Study of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics of Multi-Day Inhaled (IH) Dosing of the MAPKAP Kinase II (MK2) Inhibitor, MMI-0100, in Subjects Who Smoke**/W. Bradford, C. Peterson, C.M. Brophy, P.W. Noble, A. Panitch, C. Lander, A.D. Luber, G. Nicolson, B. Leaker, Morristown, NJ, p.A5011

P430 **A Retrospective Analysis to Assess the Clinical Significance of an Isolated Reduction in Residual Volume**/A. Kumar, J.D. Lopez, T. Salim, A. Sahni, A. Tulaimat, S.S. Fakhran, Chicago, IL, p.A5012

P431 **Relationship Between Systemic and Localized Inflammatory Protein Expression in Combined Pulmonary Fibrosis and Emphysema (CPFE), Interstitial Pulmonary Fibrosis, and Emphysema**/W. Cornwell, C. Kim, A.C. Lastra, C. Dass, S. Bolla, H. Wang, N. Marchetti, T.J. Rogers, G.J. Criner, Philadelphia, PA, p.A5013

P432 **Correlation of Clinical Characteristics by the Grade of Pulmonary Emphysema in Combined Pulmonary Fibrosis and Emphysema**/K. Sugino, Y. Nakamura, K. Gocho, G. Sano, K. Isobe, S. Sakamoto, Y. Takai, S. Homma, Tokyo, Japan, p.A5014

P433 **Combined Pulmonary Fibrosis and Emphysema: A Novel Evaluation of Lung Tissue Proteins**/A.C. Lastra, C. Kim, W.D. Cornwell, C. Dass, S. Bolla, T.J. Rogers, H. Wang, N. Marchetti, G.J. Criner, Philadelphia, PA, p.A5015

P434 **Different Genetic Characteristic Profiles of Combined Pulmonary Fibrosis and Emphysema**/H. Qiu, D. Weng, Shanghai, China, p.A5016

P435 **Computed Tomograpy Findings of Pleuroparenchymal Fibroelastosis Patients After Single Lung Transplantation**/Y. Waseda, C. Halder, H. Prosch, C. Herold, K. Kasahara, C. Lambers, Kanazawa, Japan, p.A5017

P436 **Efficacy of Concurrent Treatments in Rapidly Progressive Idiopathic Pulmonary Fibrosis**/K. Oda, K. Yatera, H. Ishimoto, H. Mukae, Japan, p.A5018

P437 **Dietary Patterns and Subclinical Interstitial Lung Disease: The MESA Lung Fibrosis Study**/J. Sell, S.M. Kawut, A. Podolanczuk, G. Raghu, W. Karmally, E.D. Michos, R.G. Barr, D.R. Jacobs, Jr., D.J. Lederer, New York, NY, p.A5019

P438 **Cardiovascular Medication Use and Subclinical Interstitial Lung Disease: The MESA Lung Fibrosis Study**/M.D. Restivo, J. Sell, A. Podolanczuk, S.M. Kawut, G. Raghu, E.D. Michos, R.G. Barr, D.J. Lederer, New York, NY, p.A5020

P439 **Evaluation of the Healthcare Burden of Idiopathic Pulmonary Fibrosis (IPF) in Fife, Scotland**/D.J. Dhasmana, F. Harrison, T. Hartley, D. Szapiro, United Kingdom, p.A5021

THEMATIC POSTER SESSION

C40 SARCOIDOSIS: UNDERSTANDING THIS MULTI-SYSTEM DISORDER

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area C, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: G.E. Westney, MD, Atlanta, GA

P237 **Lung Function Tests in Patients with Sarcoidosis Related Pulmonary Hypertension**/V. Kouranos, A.U. Wells, J.B. Barney, D.A. Culver, M.B. Scholand, E.M. Carmona, E. Alhamad, O.A. Shlobin, F. Cordova, B. Van Den Blink, R.P. Baughman, United Kingdom, p.A5022

P238 **Serum Chitotriosidase as Indicator of Disease Activity in Sarcoidosis Patients**/S. Filipovic-Stepic, V. Vucinic-Mihailovic, Z. Sumarac, J. Videnovic-Ivanov, M. Stjepanovic, M. Omcikus, Belgrade, Serbia, p.A5023

P239 **Implementation of Electronic Medical Record (EMR) Checklist to Improve Compliance with Chronic Steroid Management Recommendations of Pulmonary Patients**/O. Nadeem, S.K. Avasarala, F. Cheema, L. Yessayan, K. Thavarajah, Detroit, MI, p.A5024

P240 **Resolution of Cardiac Magnetic Resonance T2 Signal Following Immune Suppression for Cardiac Sarcoidosis: A Case Series**/E. Ruden, E. Jackson, S. Raman, E.D. Crouser, Columbus, OH, p.A5025

P241 **Impact of Metabolic Disorders on Pulmonary Sarcoidosis**/N. Durairajan, B. Thapa, H. Bokaie, L. Samavati, Detroit, MI, p.A5026

P242 **Assessment of Myocardial Inflammation by FDG-PET as a Guide to Immunosuppressive Therapy of Cardiac Sarcoidosis**/S.R. Russell, A.E. Pender, A.B. Chicos, P.H. Sporn, Chicago, IL, p.A5027

P243 **Association of Calcified Lymph Nodes on Thoracic Computed Tomography and Severity of Pulmonary Disease in Sarcoidosis**/Y. Kawar, V. Ortiz, J. Jennings, L. Yessayan, K. Thavarajah, Detroit, MI, p.A5028

Facilitator: R.P. Baughman, MD, Cincinnati, OH

P244 **Using Impulse Oscillation to Detect Airflow Limitation in Pulmonary Sarcoidosis**/P.W. Kicker, K. Sheikh, S.C. Parrish, A. Holley, Bethesda, MD, p.A5029

P245 **Castleman Disease Associated Diffuse Parenchymal Lung Disease: A Retrospective Analysis of 21 Cases in a Tertiary Chinese Hospital**/H. Huang, X. Song, S. Li, K. Xu, Y. Bi, R. Feng, Z. Xu, Beijing, China, p.A5030

P246 **Is the Neutrophil-to-Lympocyte Ratio Different in Sarcoidosis and Interstitial Lung Diseases?**/Z. Karakurt, U. Aka Akturk, N. Durmus Kocak, M. Yalcinsoy, S. Gungor, E. Aksoy, B. Gundogus, L. Sertcelik, M. Coban Agca, D. Duman, S. Oztas, D. Yavuz, H. Ozgen, T. Sevim, E. Akkaya, Istanbul, Turkey, p.A5031

P247 **Sarcoidosis Clinical Features and Diagnosis/**M. Amano, H. Nunokawa, N. Fujiwara, T. Ohba, R. Kawabe, K. Honda, S. Satoh, R. Okuda, K. Matsushima, Saitama, Japan, p.A5032

P248 **Diagnostic Utility of Angiotensin Converting Enzyme in Sarcoidosis: A Population-Based Study/**P. Ungprasert, E.M. Carmona, C.S. Crowson, E.L. Matteson, Rochester, MN, p.A5033

P249 **Infliximab for Cardiac Sarcoidosis: A Case Series/**L. Harper, K. Pearson, B. Bonnano, J. Shaiah, R. Brunken, D.A. Culver, Cleveland, OH, p.A5034

THEMATIC POSTER SESSION

C41 SARCOIDOSIS: CASE REPORTS

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area C, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: S.R. Russell, MD, Chicago, IL

P251 **A Diagnostic Challenge: A Rare Case of Cavitary Pulmonary Sarcoidosis/**L.-P. Nguyen, A. Zeki, R. Harper, Sacramento, CA, p.A5035

P252 **Case Report of Non-Caseating Granulomas in Bronchial Washings of Patient with Sarcoidosis/**J. Leap, T. Cheema, Pittsburgh, PA, p.A5036

P253 **Vanishing Hepatic Sarcoidosis Preceding Miliary Sarcoidosis/**F. Afridi, H. Bhatti, Orlando, FL, p.A5037

P254 **Necrotizing Sarcoid Granulomatosis (NSG), a Rare Form of Granulomatous Lung Disease /**A.-M. Edwards, Kalamazoo, MI, p.A5038

P255 **Unusual Subcutaneous Swelling of the Extremities as the Presenting Manifestation of Sarcoidosis/**S. Farooq, C. Chhakchhuak, N. Gupta, Cincinnati, OH, p.A5039

P256 **Concurrent Birt-Hogg-Dube Syndrome and Sarcoidosis/**B.T. Kuhn, R. Harper, Sacramento, CA, p.A5040

P257 **Lofgren's Syndrome: Acute Onset of Sarcoidosis/**A. Gandhi, Abington, PA, p.A5041

P258 **Ectopic Thyroid: A Novel Location for Sarcoidosis/**A. Keenan, R. Tomic, H.E. Dincer, H. Kim, Minneapolis, MN, p.A5042

P259 **Hip Pain - Unusual Presentation of Sarcoidosis/**K. Gunasekaran, S. Murthi, N. Panneerselvam, L.C. Edmonds, Cooperstown, NY, p.A5043

P260 **Hypercalcemia, Acute Kidney Injury and Atrial Fibrillation: A Rare Presentation of Sarcoidosis/**A. Alkhatib, M. Yaqoob, B. Obaidat, J. Strom, O. Shweish, Brighton, MA, p.A5044

P261 **A Rare Presentation of Pulmonary Sarcoidosis as Right Middle Lobe Syndrome/**Y. Habtegebriel, A. Thomas, A. Mehari, V. Poddar, Washington, DC, p.A5045

P262 **Bullous Sarcoidosis/**C. Meenakshisundaram, H. Friedman, Evanston, IL, p.A5046

Facilitator: K. Thavarajah, MD, Detroit, MI

P263 **Extremity Lymphedema Can Be an Initial Presentation of Sarcoidosis/**E. Alkhankan, H. Al Krad, F. Alkhankan, Huntington, WV, p.A5047

P264 **Acute Dyspnea - An Atypical Presentation of Cardiac Sarcoidosis Can Lead to Misguide Diagnosis: Case Report/**M.A.I. Cheema, L. Pawar, S. Sahni, A. Iftikhar, New Hyde Park, NY, p.A5048

P265 **Atypical Presentation of the Skeletal Sarcoidosis/**A.B. Adial, P. Upadhyaya, M.A.I. Cheema, A. Iftikhar, Forest Hills, NY, p.A5049

P266 **Upper Airway Obstruction Requiring Emergent Trachesostomy Secondary to Laryngeal Sarcoidosis/**C. Ryu, E. Herzog, H. Pan, R. Homer, M. Gulati, New Haven, CT, p.A5050

P267 **Can a Leopard Change Its Spots: Metastatic Breast Cancer or Sarcoidosis?/**C. Parker, K. Allen, S. Browning, Oklahoma City, OK, p.A5051

P268 **Non-Caeseating Granulomas Infiltrating the Bone Marrow: A Unique Presentation of Sarcoidosis/**A. Fee-Mulhearn, E. Amin, Columbus, OH, p.A5052

P269 **Case Series of Patients with Testicular Sarcoidosis/**M.M.H.S. Khan, M.A. Judson, Albany, NY, p.A5053

P270 **Sarcoid-Associated with MGUS: An Atypical Presentation/**R. Abdulai, J.A. Englert, Boston, MA, p.A5054

P271 **A Case of Human Adjuvant Disease Complicated with Sarcoidosis/**T. Oishi, H. Koh, J. Kagyo, A. Iwamaru, T. Yamamoto, K. Ota, Tokyo, Japan, p.A5055

P272 **A Rare Presentation of Lofgren Syndrome: A Case Report of a Chinese Patient with Unilateral Lymphadenopathy/**E.A. Yu, J. Wortzman, L.K. Snydman, B.L. Fanburg, Boston, MA, p.A5056

P273 **When Dyspnea Is Not Just Dyspnea/**K. Kakal, R. Lubman, Los Angeles, CA, p.A5057

THEMATIC POSTER SESSION

C42 LAM, CYSTIC LUNG DISEASE, AND MIMICS: CASE REPORTS

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area D, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: C.D. Fell, MD, MSc, Calgary, Canada

P441 **Diffuse Cystic Lung Disease in A Heavy Smoker: A Rare Case of Pulmonary Langerhans' Cell Histiocytosis/**Y.R. Sedhai, R. Parajuli, A. Asija, A. Mohammed, R.S.R. Edara, A.A. Hameed, M. Alauddin, Darby, PA, p.A5058

P442 **A Case of Sporadic Lymphangioleiomyomatosis with Immune Thrombocytopenia/**M.K. Loya, Sayre, PA, p.A5059

P443 **Pulmonary Lymphangioleiomyomatosis and Pregnancy/**Y.-C. Chang, C.-C. Huang, C.-C. Wang, Y.-M. Chen, H.-C. Kao, H.-C. Chen, K.-T. Huang, M.-C. Lin, Kaohsiung, Taiwan, p.A5060

P444 **Cystic Lung Disease in Adult Polycystic Kidney Disease/**E. Espinoza Moscoso, D. Ouellette, Detroit, MI, p.A5061

P445 **Sporadic Lymphangioleiomyomatosis and Pheochromocytoma: A Case of Neural Crest Cells Gone Awry/**E.A. Townsend, P. Rush, D. Buehler, Madison, WI, p.A5062

P446 **A Case of Sporadic Lymphangioleiomyomatosis Confirmed by Thoracentesis/**C.P. Cardenas, C.D. Ochoa, C.E. Girod, Dallas, TX, p.A5063

P447 **A Case of Early Diagnosis of Pulmonary Langerhans Cell Histiocytosis/**K.H. Kang, J.J. Shim, K.H. Min, J. Choi, S. Chung, J.Y. Oh, J.K. Sim, G.Y. Hur, S.Y. Lee, Seoul, Korea, Republic of, p.A5064

Facilitator: N. Gupta, MD, Cincinnati, OH

P448 **Constrictive Bronchiolitis Mimicking Pulmonary Lymphangioleiomyomatosis/**A.P. Toledo, B.N. Endlich, F.E. Arimura, C.S. Freitas, E.C.T. Nascimento, F.D.C. Bernardi, M. Dolhnikoff, R.A. Kairalla, B.G. Baldi, C.R.R. Carvalho, Sao Paulo, Brazil, p.A5065

P449 **Imatinib Treatment of Lymphangiomatosis/**L.J. Libby, N. Narula, H. Fernandes, J. Gruden, D. Wolf, D.M. Libby, New York, NY, p.A5066

P450 **Pulmonary Cavitary Lesions with an Associated Complicated Pleural Space: A Unique Case of Cryptogenic Organizing Pneumonia/**A.D. George, D.J. Bell, E.T. McCann, Fort Sam Houston, TX, p.A5067

P451 **Placental Transmogrification of the Lung Mimicking Lymphangioleiomyomatosis/**J.C. Fernandez Castillo, D.F. Dilling, Maywood, IL, p.A5068

P452 **A Rare Case of Cystic Lung Disease/**S. Alhassan, R. Thirumala, Pittsburgh, PA, p.A5069

P453 **Pulmonary Lymphangioleiomyomatosis in a Female with a Large Ovarian Cyst/**N. Reisman, L. Logue, S. Salama, Brooklyn, NY, p.A5070

THEMATIC POSTER SESSION

C43 PULMONARY ALVEOLAR PROTEINOSIS AND OTHER RARE LUNG DISEASE: CASE REPORTS

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area C, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: C.B. Strange, MD, Charleston, SC

P275 **Pulmonary Alveolar Proteinosis Co-Existing with Underlying Non Specific Interstitial Pneumonia/**J. Lee, H. Nazir, H. Seethamraju, Newark, NJ, p.A5071

P276 **Atypical Langerhans Cell Histiocytosis Masquerading as Hidradenitis Suppurativa/**A. Ataya, R.C.-Y. Teng, M. Jantz, Gainesville, FL, p.A5072

P277 **Hyalinising Granuloma: A Rare Pulmonary Cavitary Pseudotumor, a Case Report/**S. Alhassan, E. Bihler, Pittsburgh, PA, p.A5073

P278 **Pulmonary Hyalinizing Granuloma with Sweet's Syndrome/**V. Trivedi, M. Baqir, Rochester, MN, p.A5074

P279 **Pulmonary Alveolar Microlithiasis/**M.J. Kioka, G. Tatem, Detroit, MI, p.A5075

P280 **Calcium: Great for Bones, Not for Lungs/**P. Krishnan, S. Nandavaram, P. Ramadas, D. Savici, Syracuse, NY, p.A5076

P281 **Unusual Presentation of Erdheim-Chester Disease with Hemoptysis and Dyspnea as the Initial Chief Complaint/**D. Franco-Palacios, J. Arunthamakun, R.N. Aguillard, Memphis, TN, p.A5077

P282 **Nodular Pulmonary Amyloid Presenting with Hemoptysis/**A. Shawkat, L. Pawar, G. Trikha, Syracuse, NY, p.A5078

P283 **Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia Presenting as Usual Interstitial Pneumonia/**K. Chatterjee, J. Jo Kamimoto, A. Dunn, P. Mittadodla, M. Joshi, Little Rock, AR, p.A5079

P284 **Pathological Findings of Removal Lungs from a Patient with Refractory Fibrotic Autoimune Pulmonary Alveolar Proteinosis After Bilateral Lung Transplantation/**S. Ohkouchi, R. Saitou, J. Tominaga, M. Kobayashi, T. Hirano, M. Ichinose, Y. Okada, H. Kurosawa, Sendai, Japan, p.A5080

Facilitator: H. Ishii, MD, PhD, Mitaka, Japan

P285 **A Case of Pulmonary Interstitial Lesions Developed in the Early-Stage of Neuromyelitis Optica Spectrum Disorder/**Y. Asato, T. Kamitani, M. Kuramochi, K. Nakanishi, T. Shimada, T. MIsu, T. Takahashi, M. Aoki, K. Fujihara, Y. Kawabata, Nakano, Japan, p.A5081

P286 **Immunoglobulin Light Chain Amyloidosis Presenting as Supraglottic Mass, Bronchiectasis, and Cystic Lung Disease/**E. Valenzi, J.M. Oldham, A. Husain, J.H. Chung, M.E. Strek, Chicago, IL, p.A5082

P287 **Concurrent Myasthenia Gravis and Autoimmune-Featured Interstitial Lung Disease: A Case Report/**B. Natt, A. Rodriguez, K.S. Knox, G. Carr, Tucson, AZ, p.A5083

P288 **Pulmonary Alveolar Microlithiasis: A Case Report/**S. Garg, N. Panagiotopoulos, D. Lawrence, M. Hayward, S. Kolvekar, London, United Kingdom, p.A5084

P289 **Tracheobronchomegaly in Mounier-Kuhn Syndrome Mimicking the Cystic Lung Disease Seen in Lymphangioleiomyomatosis/**A.M. Taveira-DaSilva, A.M. Jones, P. Julien-Williams, J. Yao, J. Moss, Bethesda, MD, p.A5085

P290 **Granulomatous-Lymphocytic Interstitial Lung Disease as an Early Manifestation of Common Variable Immunodeficiency: A Case Report/**H. Katsura, M. Hasegawa, A. Okabayashi, N. Yokohori, C. Asano, K. Hiroshima, T. Ogura, T. Takemura, Chiba, Japan, p.A5086

P291 **Autoimmune Pulmonary Alveolar Proteinosis with Progressive Fibrosis Refractory to Treatment with Whole Lung Lavage, Inhaled Granulocyte Macrophage Colony-Stimulating Factor and Rituximab/**C.R. Laratta, K.A. Johannson, M.M. Kelly, M. Van Olm, A.G. Lee, C.D. Fell, Edmonton, Canada, p.A5087

P292 **A Case of Acquired Pulmonary Alveolar Proteinosis Successfully Treated with Whole Lung Lavage/**C. Borders, J. Morgan, Fort Sam Houston, TX, p.A5088

P293 **Metastatic Pulmonary Calcification in an End Stage Renal Disease Patient on Hemodialysis: A Case Report/**G. Alrehaili, C. Bolinger, A. Joury, R. Pirouz, A.W. McLean, J. Ahari, P. Rohatgi, Washington, DC, p.A5089

P294 **Putting It All Together-A Challenging Diagnosis of Immunoglobulin G4-Related Lung Disease (IgG4RLD)/**H.A.M. Fakih, Y. Samra, A. Aljaafareh, A. Prasad, E. Papierniak, D. Urbine, Gainesville, FL, p.A5090

Facilitator: K.N. Olivier, MD, MPH, Bethesda, MD

P295 **Self-Induced Pulmonary Granulomatosis: Clinical Vignette/**P.M. Indramohan, S. Curran-Melendez, N. Bhanot, Pittsburgh, PA, p.A5091

P296 **Pulmonary Alveolar Proteinosis with Severe Hypoxemia: A Combined Therapeutic Strategy/**X. Yan, H. Xu, L. Zhang, L. Chao, B. Wang, J. Li, J. Cao, Shi Jiazhuang, China, p.A5092

P297 **Thoracic Air Leak Syndromes as an Early Manifestation of Bronchiolitis Obliterans in Transplant Patients with Graft-Versus-Host Disease/**J.S. Imam, M. Werlang, I. Mira-Avendano, Jacksonville, FL, p.A5093

P298 **A case of Autoimmune Pulmonary Alveolar Proteinosis with Fluctuating Disease Activity in Parallel with Tobacco Smoke Burden/**E. Yamaguchi, A. Takahashi, A. Matsubara, K. Kosaka, M. Nishimura, H. Tanaka, N. Yokoe, A. Kubo, Nagakute, Japan, p.A5094

P299 **Pulmonary Amyloidosis: A Rare Presentation of a Rare Disease/**H.V. Parmar, M. Hegazi, P. Ngo, M.P. Carson, V. Kramer, Neptune, NJ, p.A5095

P300 **Dendriform Pulmonary Ossification: An Atypical Radiologic Presentation of Idiopathic Pulmonary Fibrosis/**M.G. Sperry, E.J. Britt, Baltimore, MD, p.A5096

P301 **Rare Case of Dendriform Pulmonary Ossification/**H. Mehta, D. Mehta, R. Khanna, N. Alappan, Cleveland, OH, p.A5097

P302 **Pulmonary Calcinosis: A Rare Presentation of a Common Complication in a Hemodialysis Patient/**M. Imtiaz, M. Moizuddin, M. Shaukat, Albany, NY, p.A5098

P303 **Osteogenesis Imperfecta Associated with Dendriform Pulmonary Ossification and Emphysematous Change/**M. Morikawa, Y. Fukuda, Y. Demura, H. Itoh, M. Anzai, Y. Umeda, S. Ameshima, T. Ishizuka, Fukui, Japan, p.A5099

P304 **Pulmonary Sequestration: A Case Report/**A. Fidan, E. Torun Parmaksiz,, S. Sener Comert, C. Dogan, B. Salepci, B. Caglayan, Istanbul, Turkey, p.A5100

THEMATIC POSTER SESSION

C44 DIFFUSE PARENCHYMAL LUNG DISEASE: CASE REPORTS

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area C, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: M.L. Salisbury, MD, Ann Arbor, MI

P306 **Eosinophilic Pneumonia Associated with Pirfenidone Therapy/**D. Gomez, B. Mehrad, CHarlottesville, VA, p.A5101

P307 **Severe Pulmonary Hypertension and Lung Fibrosis Associated with Silicone Embolisms in the Pulmonary Vasculature 17 Years After Subcutaneous Silicone Injections/**M.E. Hellemons, M.J. Overbeek, A. Boonstra, K. Grunberg, A. Vonk Noordegraaf, E. Nossent, Amsterdam, Netherlands, p.A5102

P308 **Novel Use of Mycophenolate for Treatment of Progressive, Refractory Respiratory Bronchiolitis Interstitial Lung Disease/**M. Mart, S. Pandey, M. Khosravi, Lexington, KY, p.A5103

P309 **Pet Groomers Lung: A New Addition to the List of Occupation Related Hypersensitivity Pneumonitis Spectrum of Disorders/**C.Y. Pu, V. Sharma, Chicago, IL, p.A5104

P310 **A Novel Use: Aspira Catheter Connected with Heimlich Valve to Manage Bronchopleural Fistula in Lymphocytic Interstitial Pneumonia Induced Recurrent Spontaneous Pneumothorax/**P. Kanagarajah, S. Gottlieb, Miami Beach, FL, p.A5105

P311 **Short Telomere Syndrome a Rare Cause of Familial Idiopathic Pulmonary Fibrosis/**P. Kanagarajah, M. Linares, S. Gottlieb, Miami Beach, FL, p.A5106

P312 **Kikuchi-Fujimoto Disease: A Refractory Case** /L. O'Hare, Birmingham, AL, p.A5107

P313 **Osteonecrosis in a Patient with Cystic Fibrosis/**E.E. Barsky, G.S. Sawicki, T.R. Martin, Boston, MA, p.A5108

P314 **An Unexpected Cause of Radiological Reverse Halo Sign/**N. Reisman, L. Logue, S. Shahzad, Brooklyn, NY, p.A5109

P315 **A Functional Respiratory Imaging View on Idiopathic Pleuroparenchymal Fibroelastosis/**V. Verplancke, F. Ferreira, W. Vos, G. Leemans, C. Van Holsbeke, J. De Backer, M. De Waele, W. De Backer, Edegem, Belgium, p.A5110

P316 **Clinical Dilemma in the Lung Transplant Clinic/**H. Taha, P. Foy, K. Presberg, Milwaukee, WI, p.A5111

P317 **A Case of Hypercalcemia Due to Granulomatous Inflammation in Acute Hypersensitivity Pneumonitis/**O. Bohn, R. Tomic, K. Woerner, H. Kim, M. Bhargava, E. Racila, D. Perlman, Minneapolis, MN, p.A5112

P318 **Eosinophilic Pneumonitis as the Presenting Symptom of Angioimmunoblastic T-Cell Lymphoma/**J.A. Stienecker, J. Gordon, Pueblo, CO, p.A5113

P319 **A Case of Sarcoidosis and Sjogren's Syndrome: Clues Suggesting Overlap Rather than Mimicry/**S. Daouk, S. Hadigal, A. Aljaafareh, D. Patel, Gainesville, FL, p.A5114

P320 **Fever, Rash and Hypoxia: A Rare Case of Organizing Pneumonia Associated with Polyarteritis Nodosa/**N. Al Nasrallah, M. Peregrim, Indianapolis, IN, p.A5115

P321 **Mycoplasma Pneumoniae Infection Associated with Organizing Pneumonia: Steroid-Sparing Treatment Regimen/**F. Omar, A.V. Chandran, J. Devasahayam, H. Hofmann, Columbia, MO, p.A5116

P322 **Erasmus Syndrome in a Patient Evaluated for Pulmonary Hypertension/**J.S. Imam, I. Mira-Avendano, Jacksonville, FL, p.A5117

P323 **Multifocal Micronodular Pneumocyte Hyperplasia in a Patient with Tuberous Sclerosis- Stable Chest CT Findings Over 9 Years of Follow Up/**B.S. Pannu, J.M. Boland Froemming, V.N. Iyer, Rochester, MN, p.A5118

P324 **Pulmonary Blue Bodies: Significant Pathologic Finding or Red Herring?/**S.A. Sellers, D. Henke, Chapel Hill, NC, p.A5119

P325 **Neurofibromatosis Related Interstitial Lung Disease: Is There a True Relationship?/**J.C. Uddeen, M.J. McNamee, Farmington, CT, p.A5120

P326 **Lymphoma and the Lung: A Case of Chronic Consolidation and Multiple Pneumatoceles in Lymphoplasmacytic Lymphoma/**P. Ratanawatkul, C. Wanitpongpun, A. Panitchote, P. Intarawichian, Khon Kaen, Thailand, p.A5121

P327 **Wheezing with Yellow Eyes: A Case of Chronic Eosinophillic Pneumonia/**A. Reyes Esteves, L.A. Soto, H. Bhatti, Orlando, FL, p.A5122

P328 **A Rare Case of Multicentric Castleman's Disease Without Apparent Mediastinal Lymphadenopathy and a Review of the Japanese Literature/**K. Ichikawa, T. Saraya, M. Fujiwara, H. Ishii, T. Mitsuya, M. Karita, R. Kawachi, H. Takizawa, Mitaka, Japan, p.A5123

P329 **Rare Presentation of Richter Syndrome: Choosing Wisely!/**B.C.T. Wong, S. Pakhale, Ottawa, Canada, p.A5124

Facilitator: B.T. Garibaldi, MD, Baltimore, MD

P330 **Miliary Pattern and No Complaints/**J.R. Schroeder, J. Ramirez, F.F. Rahaghi, P. Bejarano, Weston, FL, p.A5125

P331 **Atypical Presentation of Chronic Eosinophilic Pneumonia with Concomitant Mycobacterium Avium Infection/**A. Rajaratnam, O. Ajala, F. Shah, McKeesport, PA, p.A5126

P332 **Unusual Usual Interstitial Pneumonia/**K.A. Nangrani, A. Khokar, J. Contreras Jr, P. Nangrani, M. Dang, H. Upadhyay, Z. Hashemi, F. Arjomand, V. Vasudevan, L. Gerolemou, Brooklyn, NY, p.A5127

P333 **Rare Radiologic Presentation of an Unusual Malignancy in the Lung: Diffuse Large B-Cell Lymphoma Presenting as Diffuse Bilateral Ground-Glass Opacities Diagnosed on Transbronchial Lung Biopsy/**H. Inaty, C. Artiles, R. Yadav, S. Mukhopadhyay, D. Sahoo, Cleveland, OH, p.A5128

P334 **Is Diffuse Panbronchiolitis Ionizing Radiation Related?/**C.-M. Lin, Taipei, Taiwan, p.A5129

P335 **Not so Cryptogenic Organizing Pneumonia: Occult Immunodeficiency as a Cause/**V.S. Ramalingam, S. Montner, E. Valenzi, A. Husain, M.E. Strek, Milwaukee, WI, p.A5130

P336 **A Diagnostic Dilemma with Crazy Paving Pattern/**A. Vasudevan, B. Sharma, S. Khanna, J. Mora, S. Vanaik, K.S. Sandhu, Philadelphia, PA, p.A5131

P337 **Interstitial Lung Disease Due to Histoplasmosis: A Case Report/**C.B. Gulay, A. Albay Jr., Manila, Philippines, p.A5132

P338 **Chronic Cutaneous Lupus Erythematous (CCLE) Associated Interstitial Lung Disease (ILD)/**V.K. Patel, H. Bhatti, S.K. Ali, Orlando, FL, p.A5133

P339 **Ten Year Follow Up of a Middle Aged Female with Pulmonary Amyloidosis Associated with Sjogren's Syndrome/**B.A. Kelly, D. Ouellette, Detroit, MI, p.A5134

P340 **Secondary Organizing Pneumonia: Coexistence of Organizing Pneumonia Adjacent to Metastatic Breast Cancer in the Lung/**D. Hynes, D. Ahmad, E.J. Yoo, Philadelphia, PA, p.A5135

P341 **Organizing Pneumonia Manifesting as Large Nodules/**V.K. Holden, A.P. Burke, W. Burrows, A. Sachdeva, Baltimore, MD, p.A5136

P342 **A Case of Recurrent Post-Operative Hypoxia and Pulmonary Infiltrates/**M. Soffler, J.P. Stevens, Boston, MA, p.A5137

P343 **Cryptogenic Organizing Pneumonia: A New Twist on an Old Disease/**K.A. McPherson, P.H. Hanneman, W.G. Carlos, Indianapolis, IN, p.A5138

P344 **Cryptogenic Organizing Pneumonia - Cocaine, Untreated OSA or Psoriasis?/**P. Kidambi, E. Trayner, Cambridge, MA, p.A5139

P345 **Nonspecific Interstitial Pneumonia with Progression to Diffuse Micronodules in an Individual with a History of Malignancy: What Are the possibilities?/**N. Jagan, N. Khanal, M. Ananthanarayanan, T.O. Wichman, Omaha, NE, p.A5140

P346 **The Mysterious Case of Acute Respiratory Failure and Centrilobular Lung Nodules/**A. Petraglia, L. Corral Guerrero, A. King, N. Dandachi, Mckeesport, PA, p.A5141

P347 **A Sandstorm Lung: A Case of Pulmonary Alveolar Microlithiasis/**H. Hawamdeh, S. Patel, A. Ataya, H. Alnuaimat, Gainesville, FL, p.A5142

P348 **Respiratory Failure Caused by Avian Antigen Exposure Misdiagnosed as Pulmonary Fibrosis/**P. Chandar, S. Kulandaisamy, H. Desoky, A. Rai, Y. Kupfer, C. Seneviratne, Brooklyn, NY, p.A5143

P349 **Case Report: A 70-Year-Old Female with Elevated Creatinine, Hypercalcemia, Lymphadenopathy and Splenomegaly/**J. Yang, X. Xu, T. Sun, Beijing, China, p.A5144

P350 **Chronic Eosinophilic Pneumonia Complicated by Methicillin-Resistant Staphylococcus Aureus/**P.R.M. Evangelista, J.R.V. Gonong, Philippines, p.A5145

P351 **An Interesting Case of Lung Parenchymal Non-Necrotizing Granulomatous Inflammation in an Individual with Chronic Lymphocytic Leukemia/**M. Bender, A. Borczuk, E. Mellow, B.-G. Harvey, New York, NY, p.A5146

P352 **Dyspnea and Steroid Responsive Pulmonary Infiltrates in a Middle Aged Smoker/**S. Zaidi, J. Taillon, S. Milan, A. Saleh, Brooklyn, NY, p.A5147

P353 **A Elderly Asian Lady Presenting with Pulmonary Fibrosis and Ascites/**P.S. Pandya, London, United Kingdom, p.A5148

THEMATIC POSTER SESSION

C45 DYSPNEA: TAKES YOUR BREATH AWAY

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area D, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: A.E. Holland, PhD, Melbourne, Australia

P455 **Impact of Level of Lesion and Spinal Curvature on Pulmonary Function in Spina Bifida/**T.M. Crytzer, B.E. Dicianno, Y.-T. Cheng, M.J. Bryner, R.C. Wilson, F.C. Sciurba, Pittsburgh, PA, p.A5149

P456 **Specialist Pulmonologist Assessment Avoids Unnecessary CT Pulmonary Angiography in Suspected Pulmonary Embolism/**B.A. Shuker, M. Saroka, L. Satterthwaite, D. Parr, Coventry, United Kingdom, p.A5150

P457 **Preliminary Validation Results of the Brazilian Version of the Dyspnoea-12 Scale/**J. Baddini-Martinez, A.A. Simsic, H.B. Rodrigues, V.A.P. Di Lorenzo, E.M.G. Regueiro, J. Yorke, Ribeirao Preto, Brazil, p.A5151

P458 **Controlled Delivery of High Dose Aerosol Furosemide (80mg) Does Not Improve Consistency of Treatment Effect on Laboratory-Induced Dyspnea/**C.R. O'Donnell, R. Banzett, R. Lansing, D. Beach, R.M. Schwartzstein, Boston, MA, p.A5152

P459 **Hyperinflation: A Mechanism to Assess for Dyspnea in Chronic Obstructive Lung Disease?/**M.E. Miller, A. Baydur, Los Angeles, CA, p.A5153

P460 **Clinical Practice of Zhao's Artificial Trachea: 10-Years Experience/**W. Zhao, Beijing, China, p.A5154

Facilitator: M.P. Keane, MD, Dublin, Ireland

P461 **Controlled-Delivery of Aerosol Furosemide (40 mg) Does Not Improve Consistency of Treatment Effect on Laboratory-Induced Dyspnea/**C. MorAclot-Panzini, R. Banzett, C. O'Donnell, R. Lansing, D. Beach, R.M. Schwartzstein, Paris, France, p.A5155

P462 **Comparison of Four Scores for Ultrasound Assessment of Pulmonary Aeration/**B. Grondin Beaudoin, C. Chartrand-Lefebvre, M. Girard, Montreal, Canada, p.A5156

P463 **Progression from Respiratory Dysfunction to Failure in Late-Onset Pompe Disease/**K.I. Berger, Y. Chan, W.N. Rom, R.M. Goldring, New York, NY, p.A5157

P464 **Differences in Respiratory Physiology in Obese Patients with Hypoventilation Syndrome and Obese Patients Without/** T.S. Hynes, S. Saleem, B. Casserly, Limerick, Ireland, p.A5158

P465 **Hydroxyurea Therapy in Adult Nigerian Sickle Cell Disease: A Monocentric Pilot Survey on Pattern of Use, Clinical Effects and Patient's Compliance/**O.S. Oghuvwu, A.S. Adewoyin, Benin-City, Nigeria, p.A5159

P466 **Sickle Cell Trait mutation Is Associated with Higher Storage Hemolysis and Lower Red Blood Cell Post Transfusion Survival/**D. Osei-Hwedieh, T. Kanias, D. Sinchar, C. St. Croix, Z. Xiong, M. Jessup, K.P. Potoka, Q. Xu, J. Franks, J. Sertorio, E. Novelli, R. Binder, D. Triulzi, D. Kim-Shapiro, J.S. Lee, M.T. Gladwin, Pittsburgh, PA, p.A5160

THEMATIC POSTER SESSION

C46 COUGH: EVALUATION AND TREATMENT

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area D, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: M.R. Horton, MD, Baltimore, MD

P468 **The Role of Expiratory Chest Computed Tomography in Patients with Chronic Cough/**Y. Yamamoto, T. Takahashi, D. Naito, K. Shima, Y. Fuseya, K. Takahashi, N. Sakai, Otsu, Shiga, Japan, p.A5161

P469 **Etiologies of Chronic Cough and Prevalence of OSAS in Patients Referred for Chronic Cough in Japan/**N. Yokohori, M. Hasegawa, A. Okabayashi, H. Katsura, Chiba, Japan, p.A5162

P470 **Factors Contributing to Asthmatic Cough Refractory to Inhaled Corticosteroids Are Different Between Daytime and Nighttime/**Y. Kanemitsu, H. Matsumoto, T. Oguma, T. Nagasaki, Y. Izuhara, I. Ito, T. Tajiri, T. Iwata, O. Kusada, N. Aoyama, M. Mishima, A. Niimi, K. Sasaki, Nagoya-shi, Japan, p.A5163

P471 **Expression of Transient Receptor Potential Channels in Pulmonary Epithelial Cells Exposed to Gastric Fluid Constituents/**N.X. Hutchinson, B. Hope-Gill, A.J. Tonks, Cardiff, United Kingdom, p.A5164

P472 **Prevalence of Chronic Cough and Possible Causes in General Population/**H.-K. Koo, I. Jeong, H. Jung, S.-S. Lee, J. Park, Goyang, Korea, Republic of, p.A5165

P473 **Cough Clinical Practice Guidelines: A Critical Review of Scientific Evidence and Recommendations/**M. Jiang, W.J. Guan, Z.F. Fang, Y.Q. Xie, J.X. Xie, K.F. Lai, N.S. Zhong, Guangzhou, China, p.A5166

P474 **The Measurement of Cough Response to Bronchoconstriction Induced by Methacholine: An Examination Using the Astograph Method/**J. Hara, M. Fujimura, T. Sakai, N. Ohkura, A. Okazaki, S. Watanabe, Y. Ishiura, K. Kasahara, Kanazawa, Japan, p.A5167

P475 **Use of Non-Steroidal Infiammatory Drugs (NSAID) in Post-Infectious Cough/**A. Zanasi, F. Saibene, L. Lanata, M. Mazzolini, Bologna, Italy, p.A5168

Facilitator: S. Stowasser, MD, Rhein, Germany

P476 **What Is the Optimum Endpoint for the Capsaicin Cough Challenge?/**R.D. Turner, S.S. Birring, G.H. Bothamley, London, United Kingdom, p.A5169

P477 **Middle Mediastinal Ectopic Thymic Hyperplasia/**K. Hanlon, A. Staricco, Detroit, MI, p.A5170

P478 **An Unfortunate Mimicker of Sarcoidosis in a 36 Year Old Man/**K. Waksmundzki, M. Stefanski, M. Joshi, J.W. Toth, L.J. Van Scoy, Hershey, PA, p.A5171

P479 **Endobronchial Lipoma: A Rare and Benign Lung Tumor/**M.M. Herrera, K.G. Mayhall, S. Dolan, Milwaukee, WI, p.A5172

P480 **Pneumorachis: An Unusual Sequela of Spontaneous Pneumomediastinum/**A. Bhatt, S. Suliman, V. Nidadavolu, K. El-Kersh, Louisville, KY, p.A5173

P481 **Spontaneous Lung Herniation Following Cough/**N. Thiruchelvam, N. Alappan, Cleveland, OH, p.A5174

P482 **An In Vitro Model of Airway Aspiration?/**A.H. Morice, L. Sadofsky, S. Hart, Cottingham, United Kingdom, p.A5175

THEMATIC POSTER SESSION

C47 COPD: EXACERBATIONS

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area L, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: N.A. Hanania, MD, MS, Houston, TX

P1239 **Procalcitonin Level Based Care in Hospitalized Patients with Acute Exacerbations of COPD/**N. Menon, B.M. Walsh, M. Vitunac, C. Francis, D. Francis, R. Evans, P.F. Simonelli, Danville, PA, p.A5176

P1240 **Outcomes Following Virus and Non-Virus Associated Acute Exacerbations of COPD/**B.M. Walsh, N. Menon, D. Francis, C. Francis, P.F. Simonelli, Danville, PA, p.A5177

P1241 **Prevalence of Bacterial and Viral Infections in Acute Exacerbation of Chronic Obstructive Pulmonary Disease in Single Center in South Korea/**J. Choi, K.H. Min, S. Chung, J.Y. Oh, J.K. Sim, G.Y. Hur, S.Y. Lee, K.H. Kang, J.J. Shim, Seoul, Korea, Republic of, p.A5178

P1242 **Lung-Function Profile Before and After the First Moderate to Severe Exacerbation During the WISDOM Study/**E. Wouters, H. Magnussen, R. Rodriguez-Roisin, K. Tetzlaff, S. Bell, P.M. Calverley, Maastricht, Netherlands, p.A5179

P1243 **Roflumilast Initiated at Onset of Acute Exacerbation of COPD Enhances Lung Function Recovery: Results from the Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Trial, Treatment with Roflumilast at ExAcerbaTion (TREAT)/**A.J. Mackay, A.R.C. Patel, R. Singh, R. Sapsford, G.C. Donaldson, N. Prasad, U. Goehring, K. Nip, J.A. Wedzicha, London, United Kingdom, p.A5180

P1244 **Reduction of Airway Inflammation with Roflumilast Initiated at Onset of Acute Exacerbation of COPD: Results from the Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Trial, Treatment with Roflumilast at ExAcerbaTion (TREAT)/**A.J. Mackay, A.R.C. Patel, R. Singh, R. Sapsford, G.C. Donaldson, N. Prasad, U. Goehring, K. Nip, J.A. Wedzicha, London, United Kingdom, p.A5181

P1245 **Role of Osteopontin in Differential Diagnosis of Acute Exacerbations of COPD from Pneumonia/**T. Ozlu, S. Gunaydin, S. Ozsu, Y. Abul, A. Orem, Trabzon, Turkey, p.A5182

P1246 **Clinical Significance of Isolation of Aspergillus spp. During Acute Exacerbation of Chronic Obstructive Lung Disease/**M. Patout, E. Lhuillier, A. Benattia, L. Favennec, L. Thiberville, J.-F. Muir, A. Cuvelier, Bois-Guillaume, France, p.A5183

P1247 **Bronchodilator Response to Anticholinergic Agent Is Associated with Exacerbation in Patients with COPD/**S. Konno, H. Makita, M. Suzuki, K. Shimizu, H. Kimura, M. Nishimura, Sapporo, Japan, p.A5184

Facilitator: S.D. Aaron, MD, Ottawa, Canada

P1248 **Eosinophilia Is Common in COPD Exacerbations and Associated with Non-Infectious Aetiology/**M.I. MacDonald, C.R. Osadnik, M. Qiu, S. Vasanthakumar, P. King, P.G. Bardin, Melbourne, Australia, p.A5185

P1249 **Correlation Between Symptoms Pattern and Future Exacerbations: A Post-Hoc Analysis from The SPARK Study/**J.A. Wedzicha, K. Mezzi, R. Fogel, G. Bader, D. Banerji, London, United Kingdom, p.A5186

P1250 **Are Viral Infections Associated to Severe Exacerbation in Chronic Obstructive Pulmonary Disease (COPD) Due to Biomass Exposure?/**P. Paulin-Prado, N. Bautista-Felix, M. Velazquez-Uncal, O. Perez, A. Nolasco, F. Dueñas, R. Hernandez-Zenteno, F. Flores-Trujillo, A. Velazquez, C. Espinosa De Los Monteros, C. Sanchez, L. Ochoa-Coutino, R.H. Sansores, A. Ramirez-Venegas, Mexico, Mexico, p.A5187

P1251 **Characterisation of Isolates of Streptococcus Pneumoniae in Patients with Chronic Obstructive Pulmonary Disease - Is There a Role for the Pneumococcal Conjugate Vaccine (PCV13)?/**R. Costello, H. McCarthy, M. Jackson, M. Corcoran, M. McElligott, E. MacHale, I. Sulaiman, H. Humphreys, Dublin, Ireland, p.A5188

P1252 **Immunoglobulin G Deficiency Increases the Severity and Frequency of Exacerbations of Chronic Obstructive Pulmonary Disease/**C. Kim, S. Gumus, P. Mulhall, D. Ciccolella, F. Cordova, Philadelphia, PA, p.A5189

P1253 **Nocturnal Hypercapnia and Acidosis Despite Normoxemia in Patients Hospitalized for Exacerbation of Chronic Obstructive Pulmonary Disease/**C. Kim, N. Marchetti, G.J. Criner, Philadelphia, PA, p.A5190

P1254 **Eosinophils in the ER: Effects on Outcomes of Exacerbations of Airways Disease. Data from the Pre-AWARD Study/**R. Russell, S. Beer, R. Pullinger, T. Doggett, I. Pavord, M. Bafadhel, Oxford, United Kingdom, p.A5191

P1255 **Blood Eosinophil Count and Outcomes in Adults Admitted with an Acute Exacerbation of COPD: Data from the Pre-AWARD Study/**R. Russell, R. Pullinger, T. Doggett, S. Beer, I. Pavord, M. Bafadhel, Oxford, United Kingdom, p.A5192

P1256 **Eosinophilic COPD Exacerbation: Is There Any Difference in Readmission, Length of Stay and Mortality in the Hospital/**Z. Karakurt, E. Aksoy, D. Duman, M. Coban Agca, I. Ozmen, S. Atik Gungor, N. Kocak, U. Aka Akturk, C. Salturk, Istanbul, Turkey, p.A5193

Facilitator: A.G. Henderson, MD, Chapel Hill, NC

P1257 **Particulate Matter and Acute Exacerbation of Chronic Obstructive Pulmonary Disease in Chiayi Area/**Y.-C. Lin, Y.-L. Chou, Y.-H. Tsai, S.-L. Huang, S.-E. Guo, M.-C. Chi, C.-T. Chou, C.-M. Lin, Chiayi Hsien, Taiwan, p.A5194

P1258 **Reexamination of a Risk Score for Severity of Acute Exacerbations of Chronic Obstructive Pulmonary Disease and Its Utility in Identifying Low Risk Patients/**H. Baig, L. Alsaleh, K. Rathi, S. Adwani, C. Yuan, I. Gllava, K. Abusaada, Orlando, FL, p.A5195

P1259 **Use of a Positive Expiratory Pressure Device Reduces Hospital Length of Stay for Acute Exacerbation of Chronic Obstructive Pulmonary Disease/**S. Milan, M. Megally, E. Patel, V. Patel, A. Vaidya, E. Bachman, J. Weingarten, Brooklyn, NY, p.A5196

P1260 **Role of Body Mass Index in the Prediction of Exacerbation in Chronic Obstructive Pulmonary Disease/**H. Joo, H.K. Yoon, K.-H. Yoo, K.S. Jung, C.K. Rhee, Seoul, Korea, Republic of, p.A5197

P1261 **Tracheal Collapse as a Risk Factor for Acute Exacerbations of Chronic Obstructive Pulmonary Disease/**A.J. Berglund, K.T. Beam, K.E. Kagy, F.A. Rawlins III, M.J. Morris, Ft. Sam Houston, TX, p.A5198

P1262 **A Study of the Risk Factors Associated with Pulmonary Hypertension Resulting in AECOPD/**Y. Liu, X.Y. Fan, B. Chen, L. Zhang, AnHui/Hefei, China, p.A5199

P1263 **Respiratory Symptom Patterns over One Year in Patients with COPD: Results from the Acute Exacerbation and Respiratory Infections (AERIS) Study/**R. Sung, M. Allinder, E. Aris, S. Bourne, J.-M. Devaster, V. Kim, N. Leidy, N. Locantore, F. Mannino, K. Ostridge, M. Peeters, R. Tal-Singer, L. Welch, V. Weynants, N. Williams, B.E. Miller, T. Wilkinson, King of Prussia, PA, p.A5200

P1264 **Physiological Improvements During an Acute Exacerbation of COPD Are Greater in Those Who Remain Exacerbation-Free Compared with Repeat Exacerbators/**B. Cushen, N. McCormack, I. Sulaiman, M. Mokoka, R. Costello, B. Deering, Dublin, Ireland, p.A5201

THEMATIC POSTER SESSION

C48 COPD: IMAGING

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area L, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: G.R. Washko, MD, Boston, MA

P1266 **CT Total Airway Count Explains Airflow Limitation in COPD Patients Without Emphysema/**M. Kirby, W.C. Tan, C. Hague, J. Leipsic, J. Bourbeau, J.C. Hogg, H. Coxson, Vancouver, Canada, p.A5202

P1267 **Radiological Phenotypes of Smoking and Non-Smoking COPD/**M. Kirby, W.C. Tan, C. Hague, J. Leipsic, D.D. Sin, J. Bourbeau, J. Road, D.E. O'Donnell, F. Maltais, P. Hernadez, K.R. Chapman, D. Marciniuk, J.M. FitzGerald, S.D. Aaron, J.C. Hogg, H. Coxson, Vancouver, Canada, p.A5203

P1268 **Clinical Significance of Visual Evaluation of Emphysema Pattern and Severity on CT in Cigarette Smokers/**D.A. Lynch, M. Al Qaisi, T. Gray, T. Bennett, D. Nevrekar, C. Wilson, M.H. Cho, J.D. Crapo, Denver, CO, p.A5204

P1269 **Morphological Features of Non-Emphysematous Obstruction in COPD/**B.A. Hoff, E. Pompe, D.S. Postma, J.-W.J. Lammers, F.A. Mohamed Hoesein, M. Van Den Berge, N.H.T. Ten Hacken, B.D. Ross, C. Galban, Ann Arbor, MI, p.A5205

P1270 **Continuous Measurement of Lung Density on Dynamic-Ventilation CT: Disconnection in Respiratory Movement Between the Right and Left Lungs in Patients with COPD/**T. Yamashiro, H. Moriya, M. Tsubakimoto, S. Murayama, Okinawa, Japan, p.A5206

P1271 **A Multilobar Visual Scoring System (MLVS) Responsive to Short Term Change in Lung CT Emphysema/**J.M. Bon, S. Perera, J.K. Leader, J. Pu, D. Chandra, Y. Zhang, C. Fuhrman, F.C. Sciurba, Pittsburgh, PA, p.A5207

P1272 **CT Small Airway Dimensions And Emphysema Severity in Surrounding Parenchyma/**B.A. Lutey, J.J. Atkinson, R.M. Senior, D.S. Gierada, St. Louis, MO, p.A5208

P1273 **A Statistical Hypothesis Test for Threshold-Based Emphysema Quantification/**G. Vegas Sanchez-Ferrero, G. Washko, F.N. Rahaghi, M.J. Ledesma Carbayo, R. San Jose Estepar, Boston, MA, p.A5209

P1274 **Three-Dimensional Lobar Evaluation of Pharmacological Volume Reduction Induced by Tiotropium in COPD Patients/**S. Sato, S. Muro, K. Tanimura, T. Oguma, A. Sato, K. Hasegawa, K. Uemasu, Y. Hamakawa, T. Hirai, M. Mishima, Kyoto, Japan, p.A5210

Facilitator: M. Kirby, PhD, Vancouver, Canada

P1275 **Evaluation of Interstitial Abnormalities in the Group B of the 2011 GOLD Classification of COPD/**M. Ohgiya, H. Matsui, A. Tamura, S. Ide, A. Yoshide, M. Saito, E. Inoue, K. Kusaka, H. Tashimo, A. Yamane, H. Nagai, S. Akagawa, K. Ota, Japan, p.A5211

P1276 **Branching Patterns and Automated Labeling of Sub-Segmental Human Airways/**J. Tschirren, M.K. Han, R.G. Barr, E.A. Hoffman, Coralville, IA, p.A5212

P1277 **Combined Airway Disease and Emphysema Is a Poor Prognostic Factor in Chronic Obstructive Pulmonary Disease/**C.K. Rhee, H.K. Yoon, Y.-M. Oh, S.-D. Lee, Seoul, Korea, Republic of, p.A5213

P1278 **Lower Lobe Air Trapping Is Linked to Exacerbation Recovery Rate/**W. Vos, C. Van Holsbeke, W. Van Geffen, H. Kerstjens, M. Pistolesi, O. Usmani, B. Hajian, A. Cahn, J. De Backer, W. De Backer, Kontich, Belgium, p.A5214

P1279 **Correlation Between the Parameters Quantified by Thoracic High-Resolution Computed Tomography and Pulmonary Function Tests in Patients with Chronic Obstructive Pulmonary Disease/**X. Tang, S. Chen, X. Jin, Y. Song, Shanghai, China, p.A5215

P1280 **Various Patterns of Dynamic Deformation of Intra-Mediastinal Airway During Maximum Forced Expiration Visualized by 4D-CT Images Among Respiratory Diseases/**T. Kijima, H. Hirata, H. Kitaoka, Suita, Japan, p.A5216

P1281 **Pulmonary Emphysema Is a Predictor of Decline in Forced Expiratory Volume in One Second Among Visitors with Obstructive Pulmonary Dysfunction Found in Medical Checkup/**N. Nishimura, T. Tanigawa, H. Nakaoka, M. Fukakusa, R. Tsugitomi, K. Okafuji, A. Kitamura, Y. Tomishima, N. Uchiyama, T. Jinta, T. Tamura, N. Chohnabayashi, Tokyo, Japan, p.A5217

P1282 **Accuracy of Pulmonologists and Radiologists in Assessing Abnormalities on Thoracic Imaging/**K. Chatterjee, C. Colaco, T. Raman, B. Colaco, N. Meena, Little Rock, AR, p.A5218

THEMATIC POSTER SESSION

C49 RESPIRATORY FAILURE: CLINICAL AND TRANSLATIONAL ASPECTS OF VILI AND LUNG PROTECTIVE MV

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area G, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitators: I.S. Douglas, MD, Denver, CO
M.B.P. Amato, MD, PhD, Sao Paulo, Brazil

P691 **Variable Ventilation Reduces Lung Damage Without Increasing Bacterial Translocation from the Lung into the Systemic Circulation in a Rat Model of Pneumonia/**R.F. Magalhaes, C.S. Samary, R.S. Santos, M.D.O. Vasconcellos, N.N. Rocha, J.Z. Kitoko, C.A. Silva, C. Hildebrandt, C.F. Albuquerque, C.L. Santos, R. Huhle, H.C. Faria-Neto, V.L. Capelozzi, M.M. Morales, P. Olsen, P. Pelosi, M. Gama De Abreu, P.R.M. Rocco, P.L. Silva, Rio de Janeiro, Brazil, p.A5219

P692 **Spontaneous Breathing with Moderate but Not Low PEEP Is Associated with Reduced Inflammation and Type II Epithelial Cell Damage in Mild Experimental Acute Respiratory Distress Syndrome/**P.L. Silva, P.A. Magalhaes, G.D.A. Padilha, L. Moraes, C.L. Santos, L.A. Maia, C.C. Duarte, L. Andrade, G. Magalhaes, V.L. Capelozzi, P. Pelosi, P.R.M. Rocco, Rio de Janeiro, Brazil, p.A5220

P693 **Variable Ventilation Improves Respiratory System Elastance and Reduces Lung Damage in Experimental Lung Ischemia-Reperfusion/**A. Soluri-Martins, L. Moraes, R.S. Santos, C.L. Santos, R. Huhle, V.L. Capelozzi, P.L. Silva, P. Pelosi, M.G. De Abreu, P.R.M. Rocco, Rio de Janeiro, Brazil, p.A5221

P694 **Effects of 24h Variable Ventilation on Lung Function and Inflammation in Experimental Severe Acute Respiratory Distress Syndrome/**T. Kiss, T. Bluth, A. Gueldner, A. Braune, R. Huhle, L. Ball, F. Simonassi, I. Rentzsch, J. Wittenstein, P.R.M. Rocco, L. Oehme, M. Andreeff, T. Winkler, M. Vidal-Melo, P. Pelosi, J. Kotzerke, M.G. De Abreu, Dresden, Germany, p.A5222

P695 **Pregnancy Exacerbates Acute Lung Injury in a Mouse Model of Ventilator Induced Lung Injury/**L.E. Ring, M.J. Romero, J.M. D'Armiento, New York, NY, p.A5223

P696 **Abdominal Edema and Inflammation in a Ventilator-Induced Lung Injury Model. Comparison Between Spontaneous Breathing and Mechanical Ventilation/**S. Marchesi, A. Hata, A. Larsson, G. Hedenstierna, Uppsala, Sweden, p.A5224

P697 **Therapeutic Hypothermia Attenuates Pulmonary Vascular Permeability and Inflammation in a Mouse Model of Ventilator-Induced Lung Injury/**D. Slack, D. Corwin, N.G. Shah, M. Tulapurkar, J.D. Hasday, Baltimore, MD, p.A5225

P698 **High PEEP Reduces Recruitment/Derecruitment During Neurally Adjusted Ventilatory Assist in Mild Experimental ARDS/**G. Perchiazzi, M. Pellegrini, H. Lantz, G. Hedenstierna, A. Larsson, Uppsala, Sweden, p.A5226

P699 **Distribution of Regional Lung Perfusion Using Fluorescence-Labeled Microspheres in Experimental ARDS: Tissue Mass Cannot Be Used as Surrogate for Tissue Volume/**T. Bluth, A. Braune, A. Gueldner, T. Kiss, M. Andreeff, J. Kotzerke, M.G.D. Abreu, Dresden, Germany, p.A5227

P700 **The Actin Cytoskeleton Determines Alveolar Receptor Trafficking in Lung/**G.A. Gusarova, M.N. Islam, S. Das, J. Bhattacharya, New York, NY, p.A5228

P701 **Functional Role of Receptor-Interacting Protein Kinase 3 (RIPK3) in The Pathogenesis of Ventilator-Induced Lung Injury/**I.I. Siempos, M. Imamura, D.S. Jones, A.M.K. Choi, New York, NY, p.A5229

P702 **Non-Deleterious Effect of High Tidal Volume and Positive End-Expiratory Pressure in Mechanically Ventilated Rats/** H.C. Sasieta, S. Wang, R. Stroetz, B. Walters, R.A. Oeckler, Rochester, MN, p.A5230

Facilitators: L.J. Brochard, MD, Toronto, Canada
E.L. Burnham, MD, Aurora, CO

P703 **The Effects of Prone Positioning on Transpulmonary Pressures and End Expiratory Volumes in Healthy Patients/**A. Kumaresan, M. Garcia, R. Gerber, S. Loring, D.S. Talmor, Boston, MA, p.A5231

P704 **Peak Driving Pressure as a Surrogate to Respiratory System Elastance During Positive End Expiratory Pressure Titration/**G.C. Motta Ribeiro, N. Carvalho, B.C. Bergamini, D.M. Medeiros, F.A. Bozza, A. Beda, A.W. Reske, A.V. Pino, A. Giannella-Neto, W.A. Zin, M.B.P. Amato, H. Wrigge, A.R. Carvalho, Rio de Janeiro, Brazil, p.A5232

P705 **High Frequency Percussive Ventilation Increases Alveolar Recruitment in Patients with Early Acute Respiratory Distress Syndrome. A Physiological CT-Scan Study/**T. Godet, M. Jabaudon, R. Blondonnet, B. Pereira, J.-M. Garcier, E. Futier, J.-M. Constantin, Clermont-Ferrand, France, p.A5233

P706 **Can External Positive End Expiratory Pressure Worsen the Neuromechanical Coupling of the Diaphragm in Patients With COPD?/**D. Radovanovic, T. Schnell, A. McLachlan, H. Shaikh, A. Jubran, M.J. Tobin, F. Laghi, Hines, IL, p.A5234

P707 **Variability of Neurally-Adjusted Ventilatory Assist (NAVA) Compared to Pressure Support Ventilation (PSV) During Protective Mechanical Ventilation in Patients with Acute Respiratory Distress Syndrome (ARDS)/**F. Diniz-Silva, A.M. Alencar, H.T. Moriya, L.C.M. Silva, F.F. Valenzuela, B. Suki, J.C. Ferreira, Sao Paulo, Brazil, p.A5235

P708 **Current Practice in Reducing Peri-Operative Pulmonary Complications in Obese Patients: A Review of London Bariatric Services/**T. Carter, L.E. Loewenthal, London, United Kingdom, p.A5236

P709 **Different Ventilator Strategies Yield Different Biological Effects in Experimental Open Abdominal Surgery/**L.A. Maia, C.S. Samary, M.V. Oliveira, C.L. Santos, R. Huhle, M.G.D. Abreu, P. Pelosi, P.L. Silva, P.R.M. Rocco, Rio de Janeiro, Brazil, p.A5237

P710 **End-Inspiratory Airway Pressures and Patient-Centered Outcomes in the Critical Illness Outcomes Study/**C.M. Mallow, J.E. Sevransky, G.S. Martin, T.D. Girard, R.G. Brower, W. Checkley, Baltimore, MD, p.A5238

P711 **Lower Tidal Volume Is Associated with Favorable Neurologic Outcome Following Out-of-Hospital Cardiac Arrest/**T.B. Ghafouri, L. Hsu, R.J. Anderson, J. Joshua, S. Tyagi, J.R. Beitler, San Diego, CA, p.A5239

P712 **Peak Pressures and PaO2/FiO2 Ratios on Day 2 Predict Outcomes in Patients on Mechanical Ventilators/**H. Edriss, J. Whiting, S. Yang, K. Nugent, Lubbock, TX, p.A5240

P713 **Respiratory System and Transpulmonary Driving Pressures in ARDS/**E.N. Baedorf Kassis, S. Loring, D.S. Talmor, Boston, MA, p.A5241

P714 **Positive End-Expiratory Pressure (PEEP) Titration to Minimize Driving Pressure in Patients with ARDS/**S.K. Sahetya, D.N. Hager, S.V. Desai, T. Kolb, R.S. Stephens, R.G. Brower, Baltimore, MD, p.A5242

Facilitators: J.E. Sevransky, MD, MHS, Atlanta, GA
L. Ware, MD, Nashville, TN

P715 **Driving Pressure and Inflammation in Acute Respiratory Distress Syndrome/**A.C. McKown, M.W. Semler, B.T. Thompson, C.S. Calfee, T.W. Rice, Nashville, TN, p.A5243

P716 **Is Low Stretch APRV Possible?/**E. Hirshberg, M.J. Lanspa, C.K. Grissom, J. Peterson, Salt Lake City, UT, p.A5244

P717 **Relationship of Lower Tidal Volume for One-Lung Ventilation During Lobectomy Surgery with Postoperative Pulmonary Complications in Lung Cancer Patients/**H.J. Kim, S.H. Choi, Daegu, Korea, Republic of, p.A5245

P718 **Interrogation of Bronchoalveolar Lavage Fluid in Acute Respiratory Distress Syndrome Using Multiplexed Proseek Immunoassay/**P. Yadav, K. Viken, V. Kumar, M.S. Steinbach, M. Bhargava, Minneapolis, MN, p.A5246

P719 **The Nitrite Reductase Activity of Red Blood Cell Hemolysates Is Diminished in Critical Illness/**C. Dony, O. Wexler, G. Tsang, T. Bice, B. Maddock, S. Mroczek, D. Oldfield, K. Falkner, M. Apostolakos, A. Pietropaoli, Rochester, NY, p.A5247

P720 **Evaluation of Early Inspiratory Phase Delivery of Nitric Oxide In Vitro/**M.B.T. Hofferberth, P.A. Pickerodt, T. Busch, W. Boemke, M. Deja, Berlin, Germany, p.A5248

P721 **The Implementation of a Lung-Protective Mechanical Ventilation Strategy in the Emergency Department/**B.M. Fuller, I. Ferguson, R.J. Stephens, C.A. Briscoe, R.S. Hotchkiss, M.H. Kollef, St. Louis, MO, p.A5249

P722 **Surfactant Protein-A Nanobody-Conjugated Liposomes Loaded with Methylprednisolone Demonstrate High Lung Targeting and Therapeutic Effect for Acute Lung Injury/**H. Li, D. Weng, Shanghai, China, p.A5250

P723 **Using Electronic Careset to Improve Adherence to Low Tidal Volume Ventilation/**S. Till, R. Garcia-Orr, R. Gerkin, N. Nikhanj, Phoenix, AZ, p.A5251

P724 **End-Tidal CO2 Correlation with PaCO2 in Acute Respiratory Distress Syndrome/**T. Brinton, T. Yousuf, J. Iskandar, R. Nepal, R. Mehta, T. Hanif, Oak Lawn, IL, p.A5252

P725 **Changes in Mechanical Ventilation Settings After Post-Intubation Arterial Blood Gases in a University Hospital Intensive Care Unit/**M.I. Pino, O. Llanos, C. Colaco, N. Meena, Little Rock, AR, p.A5253

P726 **Ventilator Associated Events in Light of the CDC Guidelines, Are We Protecting the Brain and Harming the Lung?/**A. Kubbara, W. Barnett, O. Dasa, N. Almeshal, F. Khateeb, N. Horen, M. Ruzieh, R. Nakity, H. Simo, A. Iqbal, A. Jilwan, R. Parsad, A. Ambati, Y.A. Al Ahwel, M. Taleb, R. Assaly, Toledo, OH, p.A5254

P727 **An Analysis of Reporting According to the ARRIVE (Animal Research: Reporting of In Vivo Experiments) Guidelines for Pre-Clinical Studies of Mesenchymal Stromal Cells for the Treatment of Acute Lung Injury/**M.T. Avey, D. Moher, D. Fergusson, G. Griffin, J.M. Grimshaw, B. Hutton, M.M. Lalu, M. Macleod, J.C. Marshall, S.H. Mei, M. Rudnicki, D.J. Stewart, K. Sullivan, A.F. Turgeon, L. McIntyre, Ottawa, Canada, p.A5255

P728 **Renal Angiopoietin-2 Is Increased After Injurious Mechanical Ventilation in a Murine Model of Sepsis/**M. Hepokoski, J.A. Englert, R.M. Baron, L. Crotty-Alexander, M.M. Fuster, J.R. Beitler, A. Malhotra, P. Singh, San Diego, CA, p.A7880

P729 **Human Umbilical Cord Mesenchymal Stem/Stromal Cells Reduce Inflammation and Injury in Rodent E Coli Pneumonia and in Monocytes from Patients with Severe Sepsis/**G. Hogan, M. Jerkic, S. Gagnon, C. Masterson, J.G. Laffey, G.F. Curley, Toronto, Canada, p.A7881

THEMATIC POSTER SESSION

C50 CRITICAL CARE: DELIRIUM AND SEDATION IN THE ICU

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area G, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitators: R. Clouser, DO, Burlington, VT
A.M. Ahasic, MD, MPH, New Haven, CT
M.P. Goldklang, MD, New York, NY

P731 **Risk Factors Associated with Post ICU Psychiatric Disorders in ICU Delirium Survivors/**C. Mosher, A. Sheikh, D. Gutteridge, G. Gilroy, B. Khan, Indianapolis, IN, p.A5256

P732 **Awareness and Diagnosis of ICU Delirium After Implementing a Formal Assessment Guideline/**T.H. Kyaw, A. Aysenne, J. Palomino, New Orleans, LA, p.A5257

P733 **Concordance Between Bedside Nursing and Protocolized Sedation Assessments in Medical Intensive Care Unit Patients/**C.C. Anderson, S.E. Jolley, J. Johnson, B. DeBoisblanc, New Orleans, LA, p.A5258

P734 **Association Between Pre-ICU Frailty and ICU Delirium/**I.H. Shalom, A.A. Hope, M. Hurtado-Sburdoni, M.N. Gong, S.J. Hsieh, New York, NY, p.A5259

P735 **Variation in the Management of Pain, Agitation, and Delirium in Critically Ill Patients Among ICUs in British Columbia, Canada/**J.A. Chiu, M. Shergill, V. Dhingra, J.J. Ronco, C. Pamplin, S. McKeown, P. Dodek, Vancouver, Canada, p.A5260

P736 **Dose Using Richmond Agitation-Sedation Scale (RASS) Verses Motor Activity Assessment Scale (MAAS) Score Reduce the Amount of Sedation in ICU/**B.M. Abdulmajeed, K. Alghamdi, Jeddah, Saudi Arabia, p.A5261

P737 **Impact of Pharmaceutical Care on Treatment of Pain and Agitation in Medical Intensive Care Unit/**P. Dilokpattanamongkol, T. Suansanae, C. Suthisisang, S. Morakul, C. Karnjanarachata, V. Tangsujaritvijit, Bangkok, Thailand, p.A5262

P738 **Inappropriate Continuation of Atypical Antipsychotics Started in the Intensive Care Unit (ICU) Upon Discharge from the Hospital/**K. Karamchandani, A. Prasad, A. Quintili, Hershey, PA, p.A5263

P739 **Transitioning from Dexmedetomidine to Clonidine Causes Longer Stay in the Intensive Care Unit/**A. Mohammed, A. Maheshwari, J.M. Chowdhury, Y.R. Sedhai, N. Pozzessere, S. Manns, Darby, PA, p.A5264

Facilitators: J.P. Kress, MD, Chicago, IL
B.H. Singer, MD, PhD, Ann Arbor, MI

P740 **High Doses of Dexmedetomidine May Result in Increased Length of Stay and Mortality in the Intensive Care Unit/**J.M. Chowdhury, A. Maheshwari, A. Mohammed, N. Pozzessere, Y. Sedhai, S. Manns, Darby, PA, p.A5265

P741 **Role of Statins in Delirium Prevention in Critically Ill and Cardiovascular Surgery Patients: A Meta-Analysis/**S. Vallabhajosyula, A. Kanmanthareddy, L.E. Morrow, D.J. Esterbrooks, Rochester, MN, p.A5266

P742 **Digital Pupillometry Correlates with Depth of Sedation During Propofol Administration/**J.L. Haddock, J. Breaux, S.E. Jolley, J. Johnson, S. Connolly, R. Paccione, R. Kamat, S. Kantrow, B. DeBoisblanc, New Orleans, LA, p.A5267

P743 **Initial Synchronized Intermittent Mandatory Ventilation Versus Assist/Control Ventilation in Decreasing Delirium in Patients with Moderate Acute Respiratory Distress Syndrome: A Prospective Randomized Controlled Trial/**J. Luo, M.-Y. Wang, B.-M. Liang, H. Yu, Z.-A. Liang, Chengdu, China, p.A5268

P744 **Clonidine for Sedation in the Critically Ill: A Systematic Review and Meta-Analysis/**J.G. Wang, E. Belley-Cote, L. Burry, M. Duffett, T. Karachi, D. Perri, W. Alhazzani, F. D'Aragon, H. Wunsch, B. Rochwerg, Hamilton, Canada, p.A5269

P745 **Dexmedetomidine: Sedative of Choice in Patients with a History of Alcohol/**A. Maheshwari, A. Mohammed, J.M. Chowdhury, Y. Sedhai, N. Pozzessere, S. Manns, Darby, PA, p.A5270

P746 **Identification of a Sedation Threshold Associated with a Reduction in Ventilator Dyssynchrony in the Acute Respiratory Distress Syndrome/**P.D. Sottile, D. Albers, M. Moss, Aurora, CO, p.A5271

P747 **Different Effect of Early Neurocognitive Rehabilitation on Autonomic Nervous System in Critically Ill Patients with and without Delirium/**M. Turon, D. Hernando, S. Fernandez-Gonzalo, R. Bailon, G. Goma, J. Lazaro, J. Montanya, E. Gil, C. De Haro, M. Martinez-Perez, J. Lopez-Aguilar, A. Martinez-Rubio, M. Jodar, P. Laguna, L. Blanch, Madrid, Spain, p.A5272

P748 **Functional Performance Outcomes After ICU Delirium/**T. Huff, B. Khan, Indianapolis, IN, p.A5273

P749 **The Association Between Opioid and Benzodiazepine Use on Clinical Deterioration in Hospitalized Patients on the Wards/**P.G. Lyons, A.M. Snyder, D.P. Edelson, B. Mokhlesi, M.M. Churpek, Chicago, IL, p.A7882

THEMATIC POSTER SESSION

C51 RESPIRATORY FAILURE: HIGH FLOW OXYGEN, LIBERATION, NON-INVASIVE, AND PROLONGED VENTILATION

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area G, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitators: J.R. Beitler, MD, MPH, La Jolla, CA
N.D. Ferguson, MD, MSc, Toronto, Canada

P752 **Continuous Biobehavioral Measures to Identify Patient Ventilator Asynchrony: Methodological and Practice Challenges/**K.G. Mellott, D.J. Jones, S.K. Hanneman, Houston, TX, p.A5274

P753 **Prevalence of Respiratory Alarms in Intensive Care and the Influence of Respiratory Sensitivity Setting Changes/** P.R.E. Harris, Y. Bai, H. Schell-Chaple, D. Donesky, X. Hu, San Rafael, CA, p.A5275

P754 **Accuracy of Invasive and Non-Invasive Criteria to Diagnose Over-Assistance During Pressure Support Ventilation/** R.P. Assuncao, A.L.P. Albuquerque, J.G. Ferreira, P.V. Santana, V.C. Iamonti, L.Z. Cardenas, M.C. Pereira, M.C. Macchione, O.P. Ramos, C.R.R. Carvalho, P. Caruso, Sao Paulo, Brazil, p.A5276

P755 **Leak-Induced Asynchrony in Home Ventilators: A Bench Study/**K. Zhu, C. Rabec, J. Gonzalez, S. Aouf, G. Roisman, P. Escourrou, Gentilly, France, p.A5277

P756 **Intrinsic Positive End Expiratory Pressure (PEEPi) Measurement in Spontaneously Breathing Patients Using Conditioned Central Venous Pressure (CVP) Signal/**P.J.C. Biselli, R.S. Nobrega, Sao Paulo, Brazil, p.A5278

P757 **Asynchronies Evaluation During the First 72 Hours of Mechanical Ventilation/**C. De Haro, J. Montanyà, J. López-Aguilar, R. Fernández, G. Albaiceta, S. Fernández-Gonzalo, M. Turon, G. Gomà, E. Chacón, A. Estruga, C. Subirà, G. Murias, U. Lucangelo, J. Villar, Y. Skrobik, R. Kacmarek, J. Oliva, L. Blanch, Sabadell, Spain, p.A5279

P758 **Asyncrony and Advanced Modes of Mechanical Ventilation: A Brazilian Survey/**A.M. Isola, E.B. Caser, R.G. Rodrigues, C.S.V. Barbas, Sao Paulo, Brazil, p.A5280

P759 **Derivation and Validation of APPROVE: Accurate Prediction of Prolonged Ventilation Score/**M.A. Dziadzko, L.A. Schenck, P. Mirhaji, O. Gajic, E. Festic, V. Herasevich, M.N. Gong, Rochester, MN, p.A5281

P760 **Detecting Noninvasive Ventilation Duration and Causes of Failure in Acute Respiratory Failure Critically ill Patients/**C.S. Silva, G.F.J. Matos, C. Taniguchi, G.P. Schettino, R.C. Eid, C.S.V. Barbas, Sao Paulo, Brazil, p.A5282

P761 **Impact of Anemia and Immunity on Weaning and Survival Outcomes in Patients with Ventilator-Dependent Respiratory Failure/**M. Zantah, V. Yap, P. Scalise, D. Datta, Farmington, CT, p.A5283

P762 **Chronic Critical Illness: Influence of Etiology of Ventilator Dependency on Weaning Outcomes at a Regional Weaning Center/**M. Hassenpflug, J. Steckart, D.R. Nelson, Los Angeles, CA, p.A5284

P763 **Chronic Critical Illness: Updates to Weaning Outcomes at a Regional Weaning Center/**M. Hassenpflug, J. Steckart, D.R. Nelson, Los Angeles, CA, p.A5285

Facilitators: R.G. Brower, MD, Baltimore, MD
K. Karamchandani, MD, Hershey, PA

P764 **Outcome and Predictors in Prolonged Mechanical Ventilation Patients with Heart Failure in Taiwan/**H. Hung-Yu, L. Li-Fu, K. Kuo-Chin, H. Chi-chen, C. Ning-Hung, Taoyuan City, Taiwan, p.A5286

P765 **Patient Characteristics, Feasibility and Outcomes of a Home Mechanical Ventilation Program in a Developing Country/**N. Saiphoklang, A. Kanitsap, P. Ruchiwit, P. Pirompanich, T. Sricharoenchai, C.B. Cooper, Pathumthani, Thailand, p.A5287

P766 **I-TRACH: Validating a Tool for Predicting Prolonged Mechanical Ventilation/**R. Inocencio, P.A. Clark, C. Lettieri, Bethesda, MD, p.A5288

P767 **Identification of Criteria Associated with Extubation Failure in Brain-Injured Patients. Elaboration of a Prognostic Score. GODWEAN Study/**T. Godet, R. Chabanne, J. Marin, S. Kauffmann, B. Pereira, J.-M. Constantin, Clermont-Ferrand, France, p.A5289

P768 **Comparison of Two Weaning Trials of Mechanical Ventilation in Medico-Surgical ICU. Assessment of Pulmonary and Cardiac Parameters. CARWEAN Study/**T. Godet, S. Perbet, A. Soummer, L. Roszyk, B. Pereira, J.-J. Rouby, J.-M. Constantin, Clermont-Ferrand, France, p.A5290

P769 **Effects of Alternative Spontaneous Breathing Trial Techniques on Clinical Outcomes: A Systematic Review and Meta-Analysis/** K.E.A. Burns, I. Soliman, N. Adhikari, A. Zwein, J. Wong, C. Gomez-Builes, L.J. Brochard, L. Chen, N. Rittayamai, M. Sklar, A. Lanys, G. Chen, M. Rauseo, J.O. Friedrich, Toronto, Canada, p.A5291

P770 **Can the Dynamic Evaluation of the Rapid Shallow Breathing Index in Spontaneous Breathing Trial Be a Possible Predictor of Weaning in Tracheostomized Patients?/**K.S.C. Torres, R.M. Mota, M.S. Dias, A.P.P. Silva, V.E.C. Zamora, K.C. Oliveira, M.L.M. Pereira, E.L. Toste, M.R. Cruz, Rio de Janeiro, Brazil, p.A5292

P771 **Characteristics of Unplanned Extubations in an Urban ICU/**M. Salahuddin, G. Eiger, G.A. Fernandez, D. Wheeler, A. Wani, Philadelphia, p.A5293

P772 **Self-Extubation Revisited: A Case-Control Study/**J.L. Morales, R. Gueret, F. Ahmed, A. Tulaimat, Chicago, IL, p.A5294

P773 **Identifying APACHE II and SOFA Threshold Values that Predict Successful Weaning and Extubation from Mechanical Ventilation/**U. Bien, I. Peres Costa, R. Arena, L.M.M. Sampaio, Sao Paulo, Brazil, p.A5295

P774 **Pleural Effusion During Weaning from Mechanical Ventilation/**T. Pham, D. Roux, A. Beurton, J.-D. Ricard, M. Fartoukh, A. Demoule, M. Dres, Paris, France, p.A5296

P775 **Role of Integrated Pulmonary Index in Identifying Extubation Failure/**R. Kaur, D.L. Vines, Chicago, IL, p.A5297

Facilitator: N.S. Hill, MD, Boston, MA

P776 **End-Tidal Carbon Dioxide (EtCO2) as a Surrogate for PaCO2 During Spontaneous Weaning Trials in Patients with Obstructive and Non-Obstructive Lung Disease/**D. Bhanot, S. Simpson, H. Latham, M. Stites, A. Kubo, J. Croy, C. Nydegger, Kansas City, KS, p.A5298

P777 **Interdisciplinary Communication Dashboards to Reduce Ventilator Hours/**S.S. Palakuru, B. Patel, A.A. Aman, Houston, TX, p.A5299

P778 **The Role and Clinical Utility of Ward-Based Respiratory Failure Units: Experience from Three Australian Units/**J. Hadfield, M. Murphy, C. Hukins, J. Douglas, G. Tay, D. Stead, B. Singh, Perth, Australia, p.A5300

P779 **Healthcare Utilization Following Patients with Tracheostomy/** S. Leung, V. Pittignano, V. Kvetan, Bronx, NY, p.A5301

P780 **Patients with Acute Type 2 Respiratory Failure Due to COPD Can Be Successfully Managed in a Ward-Based Respiratory High Dependency Unit (RHDU) Irrespective of Respiratory Failure Severity/**S. Gleeson, C. Hukins, P. McLoed, M. Murphy, Brisbane, Australia, p.A5302

P781 **Impact of Gender on Adherence to Best Practice Mechanical Ventilation Strategies in a Cardiothoracic Surgery ICU/**M. Noland, J.A. Gold, S.N. Nonas, Portland, OR, p.A5303

P782 **Feasibility and Tolerability of Neurally Adjusted Ventilatory Assist in High Cervical Spinal Cord Injury/**J.M. Singh, A. Matte, N. Comtois, D. Chen, J.A. Spahija, Toronto, Canada, p.A5304

P783 **Neurally Adjusted Ventilatory Assist Improves Inspiratory Phase of Patient-Ventilator Interaction During Noninvasive Ventilation/**N. Fujimura, A. Ikeda, K. Nobukuni, J. Yoshino, A. Zaitsu, Kurume, Japan, p.A5305

P784 **The Comparative Effectiveness of Noninvasive and Invasive Ventilation in Pneumonia/**M.S. Stefan, P.K. Lindenauer, T. Lagu, A. Priya, P. Pekow, N.S. Hill, B.H. Nathanson, J. Steingrub, Springfield, MA, p.A5306

P785 **Outcomes of Patients on Noninvasive Ventilation in Acute Respiratory Failure Due to Pneumonia/**A.J. Hayek, K. Lipatov, P. Yau, A. Arroliga, E. Stock, S. Ghamande, Temple, TX, p.A5307

P786 **A Survey of Non-Invasive Ventilation (NIV) Practices in Shandong Province, China/**X. Chen, R. Zhang, A. Qu, B. Zhang, J. Xing, D. Hao, C. Ma, S. Yang, Y. Xie, F. Li, Jinan, China, p.A5308

P787 **Ventilator Settings and Outcome of Noninvasive and Invasive Ventilation for Patients with Acute Respiratory Failure on Chronic Interstitial Lung Disease/**K. Wakabayashi, T. Tateishi, Y.U. Adachi, N. Inase, K. Nakazawa, Tokyo, Japan, p.A5309

Facilitator: E. Fan, MD, PhD, Toronto, Canada

P788 **Short-Term Physiological Effects of Nasal High-Flow in Patients with Respiratory Distress. Impact of Flow Rates on the Work of Breathing/**M. Delorme, P.-A. Bouchard, M. Simon, F. Lellouche, Bordeaux, France, p.A5310

P789 **Short-Term Physiological Effects of Nasal High-Flow in Healthy Subjects. Impact of Flow Rates on the Work of Breathing/**M. Delorme, P.-A. Bouchard, M. Simon, F. Lellouche, Bordeaux, France, p.A5311

P790 **Automated Oxygen Titration During High Flow Oxygen Therapy. Evaluation of the Feasibility in Healthy Subjects/**F. Lellouche, E. L'Her, P.-A. Bouchard, M. Delorme, T. Elfaramawy, M. Morissette, B. Gosselin, Quebec, Canada, p.A5312

P791 **Optimal Delivery of Salbutamol with a Pressurized Metered Dose Inhaler within a High Flow Nasal Therapy Circuit/**F. Reminiac, C. Landel, S. Gensburger, T. Bocar, L. Mordier, M. Philippe, D. Le Pennec, L. Vecellio, S. Ehrmann, Tours, France, p.A5313

P792 **Evaluating Bronchodilator Delivery During Nasal High Flow Therapy: A Bench Study/**F. Reminiac, C. Landel, M. Philippe, L. Vecellio, D. Le Pennec, S. Ehrmann, Tours, France, p.A5314

P793 **Hygrometry of Gas Delivered with Different High Flow Oxygen Humidifiers and Impact on Comfort of the Level of Hygrometry/**P.-A. Bouchard, M. Delorme, F. Lellouche, Quebec, Canada, p.A5315

P794 **Validation of the S/F Ratio in a Non-Intubated Hospitalized Cohort/**T. Deiss, F. Moazed, T. Liu, M. Lippi, K.N. Kangelaris, M. Matthay, K. Liu, C.S. Calfee, San Francisco, CA, p.A5316

P795 **Nasal High Flow Therapy Improves Comfort and Dyspnea during Breaks off Noninvasive Ventilation in the Acute Care Setting Compared to Standard Oxygen/**G. Spoletini, L. Pisani, C. Mega, M. Alotaibi, A. Khoja, F. Blasi, S. Nava, N.S. Hill, Cambridge, United Kingdom, p.A5317

P796 **Short Term Physiological Effects of Nasal High Flow (NHF) on Respiratory Mechanics in Stable Patients with Chronic Obstructive Pulmonary Disease (COPD)/**L. Pisani, N. Corcione, V. Comellini, F. Natali, L. Fasano, S. Nava, Bologna, Italy, p.A5318

P797 **Daytime Breathing Pattern Changes by Nasal High Flow Therapy in Chronic Hypercapnic COPD Patients/**G. Nilius, K.-J. Franke, U. Domanski, M.F. Schroeder, S. Tatkov, Hagen, Germany, p.A5319

P798 **Comparison of Aerosol Deposition with Heated and Unheated High Flow Nasal Cannula (HFNC) in Healthy Adults/** L. Alcoforado, A. Ari, J. De Melo Barcelar, S.C. S. Brandao, J.B. Fink, A. Dornelas De Andrade, Recife, Brazil, p.A5320

P799 **Nasal Highflow (NHF) - Quantitation of CO2-Wash-Out in a Lung Model/**J. Braunlich, H. Wirtz, Leipzig, Germany, p.A5321

P800 **Nasal Highflow (NHF) - Worsening Oxygenation Without FIO2 Adjustment/**J. Braunlich, H. Wirtz, Leipzig, Germany, p.A5322

P801 **Safety of Using a Laryngeal Mask Airway During Bedside Percutaneous Tracheostomy/**M.J. Sanley, M.B. Warner, R. Sonti, A.G. Vinayak, Washington, DC, p.A5323

THEMATIC POSTER SESSION

C52 CRITICAL CARE CASE REPORTS: RESPIRATORY FAILURE/MECHANICAL VENTILATION

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area G, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitators: P. Subedi, MD, Loma Linda, CA
G. Garrison, MD, Burlington, VT

P805 **An Adjunct to Intubation Criteria for Patients with Guillain-Barre Syndrome/**A. Rudkovskaia, J.-P. Ayala, Bridgeport, CT, p.A5324

P806 **Soft Palate Perforation Due to Intubation Using GlideScope® Video Laryngoscope/**J. Berardi, A. Matela, G. Aristide, R. Modayil, J. Mathew, Mineola, NY, p.A5325

P807 **Recurrent Pneumonia Caused by Diffuse Laryngotracheal Stenosis as a Consequence of Prior Prolonged Intubation in a Patient with Systemic Lupus Erythematosus/**M.G. Sperry, J. Deepak, Baltimore, MD, p.A5326

P808 **Urgent Tracheostomy Post tPA Infusion for Ischemic Stroke/**A. Ali, Y.A. Al Ahwel, H. Zughaib, A. Milad, F. Safi, Toledo, OH, p.A5327

P809 **First Reported Case of Successful Use of Diaphragmatic Pacemaker in High Cervical Injury in Long Term Mechanical Ventilation in Rio De Janeiro - Brazil/**R.M. Mota, K.S.C. Torres, M.S. Dias, A.P.P. Silva, K.C. Oliveira, V.E.C. Zamora, M.L.M. Pereira, E.L. Toste, M.R. Cruz, Rio de Janeiro, Brazil, p.A5328

P810 **Effects of Increasing the Slope of Inspiratory Flow on Lung Viscoelasticity and Alveolar Ventilation in a Patient with Status Asthmaticus/**K. Waksmundzki, M. Stefanski, P. Haouzi, Hershey, PA, p.A5329

P811 **The Misadventures of Air: Colitis Versus Barotrauma/**K. Doo, S.B. Ahuja, A. Nolan, New York, NY, p.A5330

P812 **Hypokalemic Paralysis and Respiratory Arrest Due to Sjogren's Syndrome and Systemic Lupus Erythematosus/**K. Doo, K.I. Berger, N. Chitkara, New York, NY, p.A5331

P813 **High Flow Nasal Cannula Induced Subcutaneous Emphysema, Pneumomediastinum and Pneumothorax/**S.I.M. Jafri, I. Ahsan, F.I. Malik, N. Ali, G.C. Christensen, Abington, PA, p.A5332

P814 **"A Case of Complete Bilateral Lung Collapse by Saddle Mucous Plug"/**M. Kashif, D. Lvovsky, Bronx, NY, p.A5333

P815 **Foreign Body Aspiration as Cause of Cardiac Arrest and Its Early Recognition with Better Outcome/**M. Kashif, H.R.T. Hashmi, M. Khaja, Bronx, NY, p.A5334

P816 **Education for ACLS Includes Ultrasound Training/**P. Vishwasrao, S. Ahmad, Stony Brook, NY, p.A5335

P817 **A Fatal Case of Pulmonary Kaposi's Sarcoma - Associated Immune Reconstitution Syndrome After Initiation of ART/**M. Abidali, A. Abidali, A. Bozak, R. Garcia Orr, Phoenix, AZ, p.A5336

P818 **Myeloid Sarcoma Involving the Anterior Mediastinum Causing Hypercapnic-Hypoxemic Respiratory Failure/**N.K. Ahuja, R. Balk, Chicago, IL, p.A5337

Facilitators: K.F. Sarmiento, MD, MPH, La Jolla, CA
N.M. Kanodra, MBBS, Charleston, SC

P819 **Boerhaave Syndrome: A Rare Cause of Tension Hydropneumothorax/**S.E. Richter, P. Nayyar, O. Rojanapairat, D. Chatterjee, A.C. Lucero, A. El-Sherief, G.W. Soo Hoo, J. Betancourt, Los Angeles, CA, p.A5338

P820 **A Case of a Large Traumatic Pneumatocele Treated by Video-Assisted Thoracoscopic Surgery/**K. Minami, H. Hamakawa, T. Saito, Y. Ookubo, I. Sakanoue, Y. Takahashi, Kobe, Japan, p.A5339

P821 **Application of Negative Pressure Wound Vacuum Therapy for Treatment of Severe Air Leak Syndrome in a Critically Ill Pediatric Patient/**D.S. Kriplani, Loma Linda, CA, p.A5340

P822 **Usefulness of a Non-Invasive Minute Ventilation Monitoring in Poly-Substance Overdose/**J. Moss, S.W. Robison, Jacksonville, FL, p.A5341

P823 **Non-Invasive Minute Ventilation Monitoring in a Post-Operative Sternotomy Patient/**S.W. Robison, J. Moss, Jacksonville, FL, p.A5342

P824 **Comparison of Aerosol Delivery During Simulated Adult Noninvasive Positive Pressure Ventilation: Nebulizer Versus Pressurized Metered-Dose Inhaler/**R. Dhand, H. Wang, M.T. McCormack, C.S. Elder, D. Church, J.F. Turner, Knoxville, TN, p.A5343

P825 **Management of Respiratory Depression from Tianeptine Overdose with Naloxone/**R. Pillai, B. Zakhary, V. Mukherjee, New York, NY, p.A5344

P826 **Feeding the Lung/**K. Vadamalai, G. Ogunbayo, Rochester, NY, p.A5345

P827 **Aspiration or AsPEAration?/**R. Doobay, A.J. Shah, U. Masood, A. Kahlon, D. Manta, Syracuse, NY, p.A5346

P828 **Cardiopulmonary Arrest After Choking on a Chewing Gum - An Interesting Case Report/**C. Shekhar, K. Duggal, A. Rajkumar, G. Kefalas, Canton, OH, p.A5347

P829 **Hypercapnic Respiratory Failure: A Late Presentation of Myotonic Dystrophy/**E. Levine, D. Kozhevnikov, B. Mina, New York, NY, p.A5348

P830 **A Wound Leading to Respiratory Failure: A Case Report/**S. Fountain, S. Lee, J. Mand, Phoenix, AZ, p.A5349

P831 **Quadriplegic Man Becomes Ventilator Dependent/**Z. Bhatti, J. Sexton, Syracuse, NY, p.A5350

THEMATIC POSTER SESSION

C53 CRITICAL CARE CASE REPORTS: MULTISYSTEM ORGAN FAILURE

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area G, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: J. Maguire, MD, Chapel Hill, NC

P835 **The Downpour of Zollinger-Ellison Syndrome/**H. Shih, Rochester, MN, p.A5351

P836 **Hypoxia as a Harbinger of a Hematologic Malignancy/**Z.M. Berg, M. Pham, C. Baumann, A. McCambridge, A. Sen, R. Cartin-Ceba, L. Mertz, Scottsdale, AZ, p.A5352

P837 **A Fatal Case of Spontaneous Tumor Lysis Syndrome/**H. Bhartee, A.V. Chandran, J. Devasahayam, H. Sangha, Columbia, MO, p.A5353

P838 **Hide and Seek Cancer/**W. Aye, R. Viggiano, K. Leslie, Phoenix, AZ, p.A5354

P839 **Anakinra as a Novel Treatment in Adult Macrophage Activation Syndrome/**K.J. Henry, V.S. Sambhara, R.A. Raschke, Phoenix, AZ, p.A5355

P840 **A Rare Cause of Pulmonary Edema in Post-Operative Period/**K. Chatterjee, P. Mittadodla, C. Colaco, R. Jagana, Little Rock, AR, p.A5356

P841 **Fatal Case of Pasteurella Multocida Septicemia and Multiorgan System Failure in a Patient with Cryptogenic Cirrhosis/**I. Malhotra, M.A. Shenoy, H. Desoky, Y. Kupfer, A. Rai, P. Chandar, T. Yoon, R. Periut, C. Seneviratne, A. Gajankush, Brooklyn, NY, p.A5357

P842 **When the Bite Is Worse Than the Bark: A Case of Capnocytophaga Canimorsus Meningitis and Multisystem Organ Failure in a Previously Healthy Asplenic Individual/**T.N. Latta, S.R. Gomadam, C.A. Johnson, D.W. Forster, J.A. Ribes, Lexington, KY, p.A5358

P843 **Hemorrhagic Shock Resulting from Invasive Gastric Aspergillosis in a Non-Immunocompromised Patient/**S. Medrek, D. Narendra, Houston, TX, p.A5359

P844 **Pseudomonas Bacteremia in the Setting of Exertional Heat Stoke/**A. Kannappan, H. Bensimhon, S. Hochman, J. Maguire, Chapel Hill, NC, p.A5360

P845 **Rhabdomyolysis Secondary to Influenza A Infection/**M. Fadila, Columbia, MO, p.A5361

P846 **Hickam's Dictum: An Elusive Case of Cytomegalovirus Infection in a Patient with Suspected Vasculitis/**A. Shahmohammadi, L. McCullough, A. Aljaafareh, H.J. Mehta, Gainesville, FL, p.A5362

Facilitators: A.N. Chesnutt, MD, Portland, OR
N. Adhikari, MD, MS, Toronto, Canada

P847 **Fulminant Hepatic Failure Due to Exertional Heat Stroke: Making a Case for Liver Transplantation/**A. Somoracki, L. Cagino, R. Helton, A. Ataya, H. Alnuaimat, Gainesville, FL, p.A5363

P848 **Plasma Exchange for an Acute Sickle Cell Crisis with Thrombotic Thrombocytopenic Purpura-Like Features/**H. Baig, F. Asad Ur Rahman, M. Betancourt-Ramirez, Orlando, FL, p.A5364

P849 **An Unusual Case of Cirrhosis/**R. Helton, I. Faruqi, A. Somoracki, Gainesville, FL, p.A5365

P850 **A Rare Differential to a Familiar Symptom of Exophthalmos/**Y.C. Yeh, J.M. Scoon, Houston, TX, p.A5366

P851 **Improvement of Multi-Organ Dysfunction and Shock with Apheresis in Hypertriglyceridemia Induced Acute Pancreatitis: A Case Report/**M.D. Kaushal, S. Islam, M. Exline, Columbus, OH, p.A5367

P852 **Pain, Paresis, Pulselessness, Disseminated Intravascular Coagulation and Death: Tumultuous Turn of Events After Acute Heroin Intoxication/**K. Duggal, C. Shekhar, A. Rajkumar, J.B. Miller, Canton, OH, p.A5368

P853 **Multi-Organ Failure Following "Worb Water" Ingestion/**M. Jegapragasan, K. Pennington, L. Karnatovskaia, Rochester, MN, p.A5369

P854 **Severe Multiorgan Failure Hours After High Dose Carfilzomib Therapy for Refractory Multiple Myeloma/**A. El-bakush, M. Al-janabi, A. Ismail, M.Z. Rizwan, R. Dietrich, Greenville, NC, p.A5370

P855 **Descending Necrotizing Mediastinitis Presenting with Multisystem Organ Failure in a Bodybuilder Due to Anabolic Steroid Use/**J. Nguyen, B. Garber, N. Barot, Sylmar, CA, p.A5371

P856 **An Atypical Presentation of Acute Febrile Neutrophilic Dermatosis as Drug-Induced Bullous Variant Sweet's Syndrome/**S. Savajiyani, A. Higashi, R. Garcia Orr, Phoenix, AZ, p.A5372

P857 **The Case of the Killer Mocha: Pheochromocytoma Crisis Induced by a Caffeinated Beverage/**A. Pariyadath, G. Gipson, K. Sayball, G. Phan, S. Smith, K. Miller, Richmond, VA, p.A5373

P858 **Capillary Leak Syndrome Related to Clofarabine/**C. Batzlaff, M.M. Dulohery, Rochester, MN, p.A5374

Facilitator: V. Sharma, MD, Chicago, IL

P859 **Hemophagocytic Lymphohistiocytosis Caused by Infection by Ehrlichia Chaffeensis: A Case Report/**L.P. Nguyen, M.K. Ishaq, K.R. Jones, Oklahoma City, OK, p.A5375

P860 **Hemophagocytic Lymphohistiocytosis with Solid Organ Malignancy: A Rare Association/**S.S. Hoskote, A.C. Zamora-Martinez, L.B.M. Liu, A.C. Roden, T. Moua, Rochester, MN, p.A5376

P861 **Multisystem Organ Failure with Unclear Etiology? Consider Hemophagocytic Lymphohistiocytosis/**J.A. Giaccotto, J. Dargin, Burlington, MA, p.A5377

P862 **Two Cases of Hemophagocytic Lymphohistiocytosis: A Fulminant Condition Masquerading as Sepsis/**N.Y. Madisi, A. Manasia, A. Bassilly-Marcus, J. Oropello, R. Kohli-Seth, New York, NY, p.A5378

P863 **Hemophagocytic Lymphohistiocytosis Associated with Systemic Lupus Erythematous/**D. Nualles-Percy, A. Friedenberg, San Jose, CA, p.A5379

P864 **Hemophagocytic Lymphohystiocytosis: A Difficult Diagnosis Confounded by Immune Reconstitution Inflammatory Syndrome/**M. Linares, R. Beg, P. Kanagarajah, K. Imperatore, C. Tuda, D. Kett, Miami Beach, FL, p.A5380

P865 **Acquired Hemophagocytic Lymphohistiocytosis: A Great Mimicker of Sepsis and Ongoing Diagnostic and Therapeutic Dilemma/**M. Abidali, J. Hall, R. Garcia Orr, Phoenix, AZ, p.A5381

P866 **More than Just Multiorgan Dysfunction from Ehrlichia Induced Hemophagocytic Lymphohistiocytosis/**M.A. Disselkamp, M. Tupayachi-Ortiz, Lexington, KY, p.A5382

P867 **Extravascular Fluid Everywhre, but Why?/**G.J. Gonzalez Astacio, K. Rivera Manzano, J.E. Nieves Scharon, H.J. Maldonado Quintana, R. Fernandez Gonzalez, R.A. Hernandez, M. Gonzalez, P. Torrellas Ruiz, San Juan, PR, p.A5383

P868 **Clinical Course and Treatment of Systemic Capillary Leak/**J. Barlow, E. Fagley, Seattle, WA, p.A5384

P869 **A Case of Cyclic Hypotension: Idiopathic Capillary Leak Syndrome/**L. Abushamat, A. Ataya, S. Hadigal, H. Alnuaimat, Gainesville, FL, p.A5385

THEMATIC POSTER SESSION

C54 CRITICAL CARE CASE REPORTS: SEPSIS

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area G, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitators: D.J. Niven, MD, MSc, Calgary, Canada
I.D. Peltan, MD, MSc, Murray, UT

P873 **Pasteurella Multocida Bacteremia Causing Septic Shock in a Cirrhotic Patient/**M. Shahidi, P.V. Dicpinigaitis, Bronx, NY, p.A5386

P874 **Rapid Onset of Pasteurella Multocida Sepsis Secondary to a Dog Bite in an Otherwise Healthy Elderly Male/**A. Laursen, E.J. McManus, C.J. VanHook, Longmont, CO, p.A5387

P875 **A Rare Cause of Morbidity in the Immunocompromised Host/**T.T. Wong, L. Logue, S. Shahzad, A. Leong, Brooklyn, NY, p.A5388

P876 **Klebsiella Liver Abscess/**G.W. Williams, Memphis, TN, p.A5389

P877 **Hypervirulent Klebsiella Pneumoniae Necrotizing Soft Tissue Infection in a Diabetic Patient Following Transcontinental Travel to Southeastern Asia/**N. Shamsid-Deen, V.S. Sambhara, J. Bowers, G. Chu, E.M. Driebe, D.M. Engelthaler, P.S. Keim, Phoenix, AZ, p.A5390

P878 **20 Year Old Healthy Male with Descending Necrotizing Mediastinitis/**A. El-bakush, M. Al-janabi, C. Anciano, R. Dietrich, M. Bowling, Greenville, NC, p.A5391

P879 **Scedosporium Apiospermum Infection: Lethality and Complications in the Process of Treatment with Extracorporeal Membrane Oxygenation (ECMO)/**Y. Mei, X. Chen, K. Sun, H. Sun, J. Zhang, Nanjing, China, p.A5392

P880 **Postanginal Sepsis: An Uncommon Presentation of an Uncommon Disease/**D. LoVerde, J.A. Ohar, Winston-Salem, NC, p.A5393

P881 **Pyogenic Liver Abscess: A Rare Case of Monomicrobial Fusobacterium Nuceatum Liver Abscess with Sepsis in a Immunocompetent Host/**A. Avula, S. Toom, A. Niroula, A. Gandhi, New York, NY, p.A5394

P882 **A Rare Case of Corynebacterium Striatum Endocarditis in an Immunocompromised Patient/**A. Amaraneni, C. Difelice, C. Barrett, A. Surender, Kalamazoo, MI, p.A5395

Facilitators: P.R. Menon, MD, Burlington, VT
G.J. Soto, MD, Bronx, NY

P883 **Sepsis from Too Much Air/**P.H. Patel, W. Krimsky, S.J. Kausik, D.P. Harley, St. Louis, MO, p.A5396

P884 **Bilateral Adrenal Hemorrhage-A Rare Fatal Complication of Pneumonia/**M. Hundal, C. Ghattas, A. Alkhatib, S. Rafeq, Boston, MA, p.A5397

P885 **A Fatal Case of Vibrio Cholerae Bacteremia in a Patient with Stage IIIC Ovarian Carcinoma/**K. Montemayor, S. Raju, S.K. Sahetya, Baltimore, MD, p.A5398

P886 **A Classic Case of a Crustacean Calamity/**L. Kimmig, W. Kareem, Philadelphia, PA, p.A5399

P887 **A Case of Neuroinvasive West Nile Virus(WNV)/**A. Karki, A. Al-Nuaimi, K. Mandal, V. Patel, U. Kulsum, S. Sarkar, J. Raynor, Jamaica, NY, p.A5400

P888 **Scratching the Surface: A Need for a Deeper Look in a Fatal Case of Group F Streptococcal Sepsis/**M. Megally, L. Logue, K. Sury, Brooklyn, NY, p.A5401

P889 **Sepsis Secondary to Streptococcus Agalactiae Mastitis in a Patient with Negative Screening and Without Risk Factors for Severe Disease/**A. Taylor, B. Warner, C.J. VanHook, Longmont, CO, p.A5402

P890 **A Little Toxin Goes a Long Way/**J.L. Newitt, E. Crowley, M. Williams, Indianapolis, IN, p.A5403

P891 **Septicemic Plague Presenting as Shoulder Pain and Weakness/**N. Settergren, A. Patel, Pueblo, CO, p.A5404

P892 **Successful Treatment of Severe Vasodilatory Shock with Methylene Blue: A Case Report/**S. Alhassan, R. Thirumala, Pittsburgh, PA, p.A5405

THEMATIC POSTER SESSION

C55 CARDIOPULMONARY EFFECTS OF AIR POLLUTION

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area J, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: D.C. Christiani, MD, MPH, MS, Boston, MA

P1049 **Comparison of the Biological Effects of Wintertime California and China PM in Healthy Young Mice/**X.L. Sun, H.Y. Wei, K.J. Bein, D.E. Young, Q. Zhang, A.R. Castaneda, K.E. Pinkerton, Jinan, China, p.A5406

P1050 **Repeated Co-Exposure to Diesel Exhaust Particulate and Crystalline Silica in Rats/**B.Y. Farris, J.S. Fedan, R.R. Mercer, B.T. Chen, J.R. Roberts, Morgantown, WV, p.A5407

P1051 **Effects of Simulated Microgravity on JNK/c-Jun/c-Fos Signaling Pathway in Lung of Rhesus Monkey/**H. Li, P. Wang, C. Xu, Y. Cai, Y. Chen, Beijing, China, p.A5408

P1052 **Cx43 Mediates Particulate Matter-Induced Human Lung Endothelial Barrier Disruption/**X. Wu, X. Xu, J.G.N. Garcia, T. Wang, Tucson, AZ, p.A5409

P1053 **Carbonaceous Particulate Matter in the Alveolar Macrophage and Lung Surface Tissue Compartments of Residents from Sao Paulo, Brazil/**M.G. Padovan, P.H.D.N. Saldiva, A.L.F. Braga, A. Whitehouse, J. Grigg, Brazil, p.A5410

P1054 **Air Pollution Particulate Matter (PM) Load in Alveolar Macrophages from Real-World-Exposed Megacity Dwellers and the Impact of Seasonal PM Differences on Phagocytosis of Mycobacterium Tuberculosis in Human Monocyte-Derived Macrophages/**C. Carranza, M. Torres, Y. Gonzalez, C. Gardner, M.D.J. Ramirez, A. Osornio Vargas, J. Zhang, S. Schwander, Mexico City, Mexico, p.A5411

Facilitator: J.A. Hirota, PhD, Vancouver, Canada

P1055 **Pre-Exposure to Particulate Matter Enhances RSV-Induced Barrier Dysfunction/**F. Rezaee, T.J. Harford, P.M. Brown, A. Belkadi, G. Piedimonte, Cleveland, OH, p.A5412

P1056 **Pulmonary Function Response to Exposure to Low Concentration Ozone in Young Adults: Inter-Comparison Among Studies and Meta-Analysis/**C.S. Kim, H. Kehrl, A. Rappold, M. Case, R. Devlin, D. Diaz-Sanchez, Research Triangle Park, NC, p.A5413

P1057 **Effects of Desert Dust Storms and Climatological Factors on Mortality and Morbidity Due to Respiratory Diseases in Gaziantep, South East Turkey/**H. Bayram, S. Kul, M. Bogan, B. Al, Gaziantep, Turkey, p.A5414

P1058 **Effect of Particulate Matter Air Pollution on the Health Status, Respiratory Symptoms, and Lung Function of Mongolian Living in Ger District and Urban Area of Ulaanbaatar/** Y. Ishihara, M. Nakao, K. Yamauchi, H. Oomori, D. Ichinnorov, B. Solongo, Kurume, Japan, p.A5415

P1059 **Indoor Particulate Matter (PM) 2.5 Levels in Elementary School Classrooms in UB Are in Compliance with WHO Standards in the Fall Season/**D. Ulzii, T. Altantuya, G. Khishigmaa, B. Nandin-Erdene, D. Warburton, Ulaanbaatar, Mongolia, p.A5416

P1060 **The Prevalence of Selected Respiratory Diseases and the Exposure to PM10 in the Ambient Air/**A.J. Badyda, P.O. Czechowski, P. Dabrowiecki, G. Majewski, A. Gayer, D. Mucha, L. Adamkiewicz, Warsaw, Poland, p.A5417

Facilitator: M.B. Rice, MD, MPH, Boston, MA

P1061 **Commuting Mode and Cardiovascular Risk Factors in a Shanghai, China/**A. Gaffney, J.-Q. Hang, M.-S. Lee, L. Su, F.-Y. Zhang, D.C. Christiani, Boston, MA, p.A5418

P1062 **Socioeconomic Status and Cardiovascular Health in Shanghai, China/**A. Gaffney, J.-Q. Hang, M.-S. Lee, L. Su, F.-Y. Zhang, D.C. Christiani, Boston, MA, p.A5419

P1063 **Panel Studies on Acute Effects of Air Pollution in Patients with COPD: A Systematic Review and Meta-Analysis/**L.A.M. Smit, L.D. Bloemsma, G. Hoek, Utrecht, Netherlands, p.A5420

P1064 **Ethnic Differences in Effects of Low Birth Weight on Risk for Hypertension Among Healthy Young Japanese, Mongolian and Han Chinese Volunteers/**S. Bao, E. Kanno, H. Tanno, R. Maruyama, Sendai, Japan, p.A5421

P1065 **The Restrictive Spirometry Pattern, Cardiac Structure, and Incident Heart Failure Risk: The Jackson Heart Study/** M. Jankowich, W.-C. Wu, C. Blackshear, W. Wang, M. Godfrey, S. Abbasi, G. Choudhary, Providence, RI, p.A5422

P1066 **Obesity Is Associated with Airspace Lipid Dysregulation/**N. Ubags, M.C. Antkowiak, A. Wallace, E. Dilli, M. Wargo, B.T. Suratt, Burlington, VT, p.A5423

P1067 **Fine Particulate Matter Exposure from Biomass Fuel Use in Rural Uganda/**D. Muyanja, J. Vallarino, J.G. Allen, B. Kakuhikire, D.C. Christiani, A.C. Tsai, P.S. Lai, Mbarara, Uganda, p.A7883

P1068 **Traffic-Related Air Pollution (TRAP) Intervention Study/**S. Vedal, N. Zhang, R. Zhao, B. Han, J. Xu, W. Yang, Z. Bai, Seattle, WA, p.A7884

THEMATIC POSTER SESSION

C56 OCCUPATIONAL MEDICINE AND LUNG FUNCTION

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area J, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: L.A. Maier, MD, Denver, CO

P1070 **Effect of Comorbid Lower Respiratory Symptoms and PTSD on Pulmonary Function and Physical Health Status in Deployed Veterans/**M.J. Falvo, D.R. Litke, D.A. Helmer, O.Y. Osinubi, J.C. Klein, D. Ndirangu, L.A. Patrick-DeLuca, A.M. Sotolongo, East Orange, NJ, p.A5424

P1071 **Small Airway Dysfunction as a Mechanism for Persistence of Lower Respiratory Symptoms Despite Treatment in Patients Exposed to World Trade Center Dust/**K.I. Berger, C. Caplan-Shaw, A. Kazeros, D. Pradhan, R.M. Goldring, J. Reibman, New York, NY, p.A5425

P1072 **Spirometry Quality Control and Intraindividual FEV1 and FVC Variability/**J. Sumner, D. Fishwick, Buxton, United Kingdom, p.A5426

P1073 **Longitudinal Assessment of Spirometry Performed for Occupational Health Surveillance/**J. Sumner, D. Fishwick, Buxton, United Kingdom, p.A5427

P1074 **Impulse Oscillometry in Veterans Exposed to Depleted Uranium/**S.E. Hines, A. Barnes, P. Gucer, J. Gaitens, M. Oliver, M. Condon, T. Roth, K. Squibb, M. McDiarmid, Baltimore, MD, p.A5428

P1075 **Fractional Exhaled Nitric Oxide (FeNO) as a Biomarker for Formaldehyde Inhalation Exposure/**R. Arakawa, T. Irokawa, H. Inomata, H. Ogawa, S. Ohkouchi, E. Nikkuni, K. Kiuchi, E. Miura, H. Kurosawa, Sendai, Japan, p.A5429

P1076 **Pulmonary Function in Military Firefighters Pre and Post Southwest Asia Deployment/**A.D. George, A.J. Skabelund, M.J. Morris, A.N. Young, Fort Sam Houston, TX, p.A5430

P1077 **Selected Results of Polish and World Spirometry Days in 2013-2015/**P. Dabrowiecki, A.J. Badyda, P.O. Czechowski, A. Gayer, D. Mucha, Warsaw, Poland, p.A5431

Facilitator: P.I. Harber, MD, MPH, Tucson, AZ

P1078 **Comparison of the Pulmonary Function Test Between Teaching and Nonteaching Staff in a Public High School in Davao City, Philippines/**M.C. Kasilag, C. Uy, Davao City, Philippines, p.A5432

P1079 **Longitudinal Decline and Spirometric Restriction in Microwave Popcorn and Flavoring Manufacturing Workers/**J.M. Cox-Ganser, R.L. Bailey, S.K. White, K.B. Fedan, K. Kreiss, Morgantown, WV, p.A5433

P1080 **Respiratory Symptoms and Spirometric Indices of Workers in a Nigerian Bottling Factory- A Pilot Survey of a 5-Year Prospective Study/**O.S. Oghuvwu, J.O. Aigbirior, G. Erhabor, Benin-City, Nigeria, p.A5434

P1081 **Utility of Lung Clearance Index as a Noninvasive Marker of Deployment Lung Disease/**S.D. Krefft, M. Robinson, M. Heidel, M. Strand, R. Meehan, C. Rose, Aurora, CO, p.A5435

P1082 **Arizona Hospital Discharge Database: Implications of Primary and Secondary Respiratory Diagnoses for Occupational Respiratory Surveillance and Compensation/**P.I. Harber, J.K. Ha, M. Roach, Tucson, AZ, p.A5436

P1083 **Macrophage and Airway Epithelial Cell Enhanced M1 Expression in Response to Silver Nanoparticle Exposure/**O.K. Kurt, J.J. Zhang, T.N. Kadir, A.K. Pham, J.K. Dhillon, X.L. Sun, K.E. Pinkerton, Ankara, Turkey, p.A5437

P1084 **Silver Nanomaterials: A Comparative Study of Pulmonary Response/**T.N. Kadir, J.J. Zhang, R.M. Silva, D.S. Anderson, L.S. Van Winkle, K.E. Pinkerton, Davis, CA, p.A5438

P1085 **Chest CT Scan Findings Among Former Workers and Volunteers at the World Trade Center Disaster Site/**R.E. de la Hoz, L.A. Bienenfeld, D.A. Carson, J.P. Wisnivesky, D.A. Lynch, J.T. Doucette, New York, NY, p.A5439

Facilitator: C.A. Redlich, MD, MPH, New Haven, CT

P1086 **A Novel Method for Identifying Urine Biomarker Related to Air Pollution/**L. Bian, Y. Wang, W. Song, G. Hou, Z. Wang, H. Li, X. Kang, Z. Jin, L. Li, G. Li, China, p.A5440

P1087 **Survey of a Native American Uranium Mining Community Demonstrates an Interest in Research Participation and in Study of Diseases Beyond the Lung/**M. Laweka, E. Kocher, T.W. Boyce, O. Myers, K. Evans, D. Kesler, L. Cook, A. Sood, Albuquerque, NM, p.A5441

P1088 **Completeness of Respiratory Injury and Illness Reporting in the Illinois Mining Industry: Comparing Workers' Compensation Claims to the MSHA Part 50 Program/**K. Almberg, L. Friedman, D. Swedler, J. Graber, C. Rose, E.L. Petsonk, R.A. Cohen, Chicago, IL, p.A5442

P1089 **Blood Eosinophils and World Trade Center Exposure Predict Surgery in Chronic Rhinosinusitis: A 13.5-Year Longitudinal Study/**S. Kwon, B. Putman, J. Weakley, C.B. Hall, R. Zeig-Owens, T. Schwartz, M.P. Webber, H.W. Cohen, T.K. Aldrich, D. Prezant, A. Nolan, M.D. Weiden, New York, NY, p.A5443

P1090 **Biomarkers of GERD and Barrett's Esophagus in World Trade Center-Exposed Fire Department of New York City Rescue Workers: The Aerodigestive Continuum/**S.H. Haider, S. Kwon, E.J. Caraher, A.K. Lee, T. Schwartz, R. Zeig-Owens, M.P. Webber, D.J. Prezant, A. Nolan, New York, NY, p.A5444

P1091 **Elevation of Serum IgG1 Within 6 Months of WTC Exposure Reduces the Odds of Sinus Surgery Over the Subsequent 13.5 Years/**J. Weakley, C.B. Hall, R. Zeig-Owens, T. Schwartz, M.P. Webber, H.W. Cohen, T.K. Aldrich, M. Huie, D. Morrison, A. Nolan, D.J. Prezant, M.D. Weiden, Brooklyn, NY, p.A5445

P1092 **Carbon Monoxide Exposure and Respiratory Health of Motorcycle Taxi Drivers in an African City/**J. Wanjiku, H. Lawin, A. Kpangon, B. Fayomi, Nakuru, Kenya, p.A5446

Facilitator: S.E. Hines, MD, MPH, Baltimore, MD

P1093 **Heme Oxygenase Activity Increases After Exercise in Healthy Volunteers/**A. Ghio, M. Case, J. Soukup, Chapel Hill, NC, p.A5447

P1094 **Heme Oxygenase Activity Correlates with Serum Indices of Iron Homeostasis in Healthy Non-Smokers/**A. Ghio, D. Schreinemachers, Chapel Hill, NC, p.A5448

P1095 **Expanding a National Program of Respiratory Health Surveillance for Coal Miners—Update on the Implementation of New Requirements for Coal Miner Health Surveillance in the United States/**C.N. Halldin, A.L. Wolfe, L.-A.F. Beeckman-Wagner, D.J. Blackley, A.S. Laney, Morgantown, WV, p.A5449

P1096 **Analysis on the Risk Factors of Greenhouse Farmer Lung in Some Rural Areas of Liaoning Province/**W. Xiaoge, Shenyang, China, p.A5450

P1097 **Environmental and Occupational Health (GEOHealth) Hub for Eastern Africa: Review of Current State and Plans for Research and Training/**K. Berhane, A. Kumie, A. Afullo, L. Atuyambe, E. Rugigana, N. Hundal, J. Samet, Los Angeles, CA, p.A5451

P1098 **Silicon, a Potential Biomarker in Silicosis Research/**H. Liu, X. Hao, W. Tian, Z. Guo, S. Liu, Tangshan, China, p.A5452

P1099 **Building Conceptual Schema for Monitoring and Response System on Occupational and Environmental Lung Disease/**A.E. Ozcelik, N. Ozcelik, Rize, Turkey, p.A5453

P1100 **First-Time Monitoring of Simultaneous Effects of Hypergravity on Heart and Lung by Electrical Impedance Tomography/**J.B. Borges, G. Hedenstierna, J.S. Bergman, C. Dussault, M.B.P. Amato, S. Montmerle-Borgdorff, Uppsala, Sweden, p.A7885

THEMATIC POSTER SESSION

C57 CELLULAR/MOLECULAR MECHANISMS AND TRANSLATIONAL ASPECTS OF RESPIRATORY INFECTIONS

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area K, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: J.P. Mizgerd, ScD, Boston, MA

P1127 **Disruption of Murine Lower Airway Microbiome/**B.G. Wu, B.D. Scaglione, J. Gilani, A. Wang, Y. Li, L. Segal, New York, NY, p.A5454

P1128 **Dectin-1 Mediates the Induction and Processing of Interleukin-1β by the Canonical NLRP3 Inflammasome in B-Lymphocytes/**M.F. Ali, A.G. Kronebusch, A.H. Limper, E.M. Carmona, Rochester, MN, p.A5455

P1129 **Thrombocytopenia and Lung Iron Content in Patients with Pneumonia/**K. Yaqub, K.K. Sakata, K. Williams, H. Vikram, L. Wesselius, Scottsdale, AZ, p.A5456

P1130 **Bacterial Killing of Cultured Pig Tracheal Epithelia Was Not Altered by HCO3—Free Medium/**S. Zhu, J.-H. Chen, Hong Kong Prc, p.A5457

P1131 **The Tie2-Agonist Vasculotide Protects Lungs from Pneumonia-Induced Barrier Disruption/**B. Gutbier, X. Jiang, C. Ehrler, T.J. Mitchell, N. Weissmann, P. Van Slyke, D.J. Dumont, N. Suttorp, M. Witzenrath, Berlin, Germany, p.A5458

P1132 **Treatment with Synergistic TLR Ligands that Protect Against Leukemia-Associated Pneumonias Does Not Worsen Tumor Burden/**H.H. Ware, M.M. Leiva-Juarez, C.T. Kirkpatrick, V.V. Kulkarni, Y. Wang, S.E. Evans, Houston, TX, p.A5459

P1133 **Mechanisms of Pyocyanin Toxicity and Genetic Determinants of Resistance in Staphylococcus Aureus/**M.J. Noto, W.J. Burns, E.P. Skaar, Nashville, TN, p.A5460

Facilitator: C.S. Dela Cruz, MD, PhD, New Haven, CT

P1134 **Comparison of an Anti-Alpha Toxin (AT) and Clumping Factor A (ClfA) mAb Combination and Bi-Specific Antibodies for Protection in S. Aureus Pneumonia/**C. Tkaczyk, S. Kasturirangan, M. Hamilton, A. Sadowska, Y.Y. Shy, G. Rainey, C. Stover, B. Selllman, Gaithersburg, MD, p.A5461

P1135 **Changes in Staphylococcal, Streptococcal and Pseudomonal Growth and Pathogenicity During Fever/**E. McEachern, A. Vyas, J.H. Hwang, J. Joshua, L.E. Crotty Alexander, New York, NY, p.A5462

P1136 **Identification and Replication of Transcriptomic Biomarkers of Bacterial Involvement in Lower Respiratory Tract Infections/**S. Bhattacharya, A. Rosenberg, D. Peterson, K. Grezesik, A. Baran, J.M. Ashton, A. Corbette, J. Holden-Wiltse, T.J. Mariani, A. Falsey, Rochester, NY, p.A5463

P1137 **Celastrol Promotes Granulocyte Differentiation to Protect Against Bacteria/**K.L. Gates, P. Homan, Z. Lu, A.C. McQuattie-Pimentel, F. Gonzalez, A.V. Misharin, N. Chandel, W.E. Balch, R.I. Morimoto, G.S. Budinger, Chicago, IL, p.A5464

P1138 **Obesity Worsens the Outcome of Influenza Virus Infection Via Impaired IFN -Beta Induction and Reduced Expressions of Antimicrobial Peptides in Mice/**H. Namkoong, M. Ishii, H. Fujii, K. Yagi, T. Asakura, S. Suzuki, H. Kamata, N. Hasegawa, T. Betsuyaku, Tokyo, Japan, p.A5465

P1139 **The Pulmonary OX40 Ligand Expression Induced by the Influenza Infection Plays a Potential Role in the Pathogenesis/**T. Hirano, T. Kikuchi, N. Tode, H. Sugiura, M. Ichinose, Sendai, Japan, p.A5466

P1140 **Broccoli Sprout Homogenates and Live Attenuated Influenza Virus: Effect on Peripheral Blood Natural Killer Cells/**L. Muller, M. Meyer, R.N. Bauer, H. Zhou, H. Zhang, S. Jones, C. Robinette, T.L. Noah, I. Jaspers, Basel, Switzerland, p.A5467

Facilitator: Z.C. Chroneos, PhD, Hershey, PA

P1141 **Nucleotide-Binding Oligomerization Domain Containing 2 (NOD2) Heterozygous Knock-Out Mice Are Protected from Influenza A Virus Infection/**K.M. Wiese, K.L. Staricha, K.M. Ridge, Chicago, IL, p.A5468

P1142 **Cyclic GMP-AMP Synthase (cGAS), Stimulator of Interferon Genes (STING) and Interferon Activated Gene 16 (IFI16) Are Essential for Intrinsic Lung Epithelial Responses Against Influenza A Infection, but Not for Therapeutically Induced Antiviral Resistance/**V.V. Kulkarni, Y. Wang, C.T. Kirkpatrick, M.M. Leiva-Juarez, A.K. Plumer, H.H. Ware, S.E. Evans, Houston, TX, p.A5469

P1143 **Mitochondrial Reactive Oxygen Species-Dependent Inducible Antiviral Resistance in Primary Lung Epithelial Cells/** A.K. Plumer, C.T. Kirkpatrick, M.M. Leiva-Juarez, H.H. Ware, V.V. Kulkarni, Y. Wang, J. Pantaleon, S.E. Evans, Houston, TX, p.A5470

P1144 **Toll-Like Receptor 7 Mediated Enhancement of Respiratory Syncytial Virus Replication in Human Bronchial Epithelial Cells/**L. Jensen, C. Griffiths, L. Bilawchuk, D.J. Marchant, Edmonton, Canada, p.A5471

P1145 **Mitochondrial DNA in Bronchoalveolar Lavage Fluid is Associated with Mortality in Patients with Viral Lower Respiratory Tract Infections/**M. Pabon, K.C. Ma, K. Nakahira, M. Salvatore, A.M.K. Choi, New York, NY, p.A5472

P1146 **Alveolar Macrophage Secretion of Suppressor of Cytokine Signaling 3 Is Enhanced During Microbial Infection in the Lung/**J.M. Speth, P. Mancuso, B.B. Moore, J.B. Weinberg, M. Peters-Golden, Ann Arbor, MI, p.A5473

P1147 **Airway Epithelial Production of IL-17C Following Bacteria and Rhinovirus Co-Exposure/**K.C. Jamieson, D. Proud, Calgary, Canada, p.A5474

Facilitator: C.R. Marion, DO, PhD, New Haven, CT

P1148 **Complement Receptor 3 Mediates Aspergillus Fumigatus Internalization into Pulmonary Epithelial Cells Accompanied with an Increase of Intracellular Phosphatidic Acid/**L. HAN, X. Jia, M. Schmidt, X. Han, Beijing, China, p.A5475

P1149 **FleA Expression in Aspergillus Fumigatus Is Recognized by Fucosylated Structures on Mucins and Macrophages to Prevent Lung Infection/**S.C. Kerr, G.J. Fischer, M. Sinha, O. McCabe, J.M. Palmer, M. Wimmerova, S. Carrington, S. Yuan, C.A. Lowell, S. Oscarson, N.P. Keller, J.V. Fahy, San Francisco, CA, p.A5476

P1150 **Dectin-1 Activate NFκB Pathway Via IRAK1 and RIP2 Signalings Besides Syk in Mice Lung Infected with Aspergillus Fumigatus/**J. Liu, L. Yu, J. Zhou, C. Chen, D. Li, Y. Song, C. Shao, Shanghai, China, p.A5477

P1151 **Analysis of Exhaled Volatile Organic Compounds (VOCs) in Cystic Fibrosis with Pulmonary Aspergillosis/**H.-W. Shin, B. Barletta, S. Meinardi, D. Cooper, S. Osborne, P. Tirakitsoontorn, A. Arrieta, D. Blake, Irvine, CA, p.A5478

P1152 **Bacillus Anthracis Spore Movement and Uptake by Cells Resident in the Human Lung Are Not Affected by Anthrax Lethal Toxin/**J.P. Metcalf, J.L. Booth, E.S. Duggan, V.I. Patel, M. Langer, A. Braun, K.M. Coggeshall, Oklahoma City, OK, p.A5479

P1153 **Caracterization of Experimental Pneumonia Model in Mice/**M.B. De Abreu, C.S.M. De Oliveira, A.C. Jardim Neto, R.A. Gaudio, L.M. Camilo, G.C. Motta-Ribeiro, W.A. Zin, A.R. Carvalho, Rio de Janeiro, Brazil, p.A5480

P1154 **Formulation and Aerosol Characterization of Select Aminoglycoside- and Fluoroquinolone-Class Antibiotics in a Proprietary Breath Actuated Nebulizer and In Vivo Pharmacokinetics in a Preclinical Mouse Model/**R. Toddywala, S. Bhardwaj, R. Condos, G. Smaldone, Somerset, NJ, p.A5481

P1155 **Biodistribution and Clearance of Liposomal Amikacin for Inhalation and Free Amikacin After a Single-Dose Inhalation in Rats/**V.S. Malinin, M.E. Neville, W.R. Perkins, Bridgewater, NJ, p.A5482

THEMATIC POSTER SESSION

C58 TUBERCULOSIS INFECTION AND DISEASE

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area K, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: J. Bernardo, MD, Boston, MA

P1157 **Type-1 Polarized Dendritic Cells Pulsed with ESAT-6 Are a Potent Immunogen Against Tuberculosis/**Y. Satake, Y. Nakamura, M. Kono, H. Hozumi, T. Nagata, K. Tsujimura, N. Enomoto, T. Fujisawa, N. Inui, K. Yokomura, H. Hayakawa, T. Suda, Hamamatsu, Japan, p.A5483

P1158 **Mast Cell C57 Activation by Mycobacterium Tuberculosis Lipids and Mycobacterium Bovis Bacille Calmette-Guerin (BCG)/**S. Rosero, I. Torres, A. Goodridge, City of Knowledge, Panama, p.A5484

P1159 **Mycobacterium Tuberculosis Induced Connective Tissue Growth Factor Expression Through JAK2/STAT3/p300 Activation in Human Lung Fibroblasts/**C.-H. Lin, Taipei, Taiwan, p.A5485

P1160 **Use of Antibiotic TB Therapy Inhibits Induction of MMP1: Potential Benefit in Cavity Formation/**T. Shiomi, P. Elkington, S. Kwon, J. Sonnet, J.M. D'Armiento, New York, NY, p.A5486

P1161 **A Phase I Trial Evaluating Aerosol Administration of a Candidate TB Vaccine, MVA85A, as a Way to Induce Potent Local Cellular Immune Responses and Avoid Anti-Vector Immunity/**Z.-R. Manjaly Thomas, I. Satti, M. Wilkie, S. Harris, M. Riste, A. Hamidi, A. Minhinnick, H. Bettinson, H. McShane, Oxford, United Kingdom, p.A5487

P1162 **Association Between Macrophage Migration Inhibitory Factor (MIF) Gene Polymorphisms and Serum MIF with Pulmonary Tuberculosis/**X. Tong, H. Fan, Y. Ma, S. Liu, Chengdu, China, p.A5488

P1163 **Polymorphisms in Mannose Binding Lectin-2 Gene Were Associated with the Risk of Tuberculosis/**J. He, W.C. Li, X.Y. Li, Chengdu, Sichuan, China, p.A5489

P1164 **Association of CYBA Polymorphisms with Tuberculosis Susceptibility in the Chinese Han Population/**Q. Liu, Y. Wang, S. Wu, G. Ji, J.-Q. He, Chengdu, China, p.A5490

Facilitator: P. Escalante, MD, Rochester, MN

P1165 **Association of Interferon-γ +874T/A and Interleukin-10 -1082G/A Gene Polymorphisms with MDR-TB Susceptibility and Culture Conversion/**H.H. Sudarmo, E. Burhan, A.A. Prasetyo, S. Suradi, R. Reviono, Surakarta, Indonesia, p.A5491

P1166 **Updated 4th Generation QuantiFERON®-TB Testing in Individuals with Low Tuberculosis Risk Factors/**S.A. Siegel, M. Cavanaugh, J.H. Ku, A. Knights, L.M. Kawamura, K.L. Winthrop, Portland, OR, p.A5492

P1167 **Is Interferon Gamma Release Assays (IGRAs) Testing Using Dichotomous Cutoff Point Accurate for Contact Tracing In Tuberculosis Investigations?/**Y. Dawod, C. Thao, A. Greenberg, Las Vegas, NV, p.A5493

P1168 **Latent Tuberculosis Infection Screening with Tuberculin Skin Test in High-Risk Healthcare Workers/**Y. Park, S.Y. Kim, M.S. Park, Y.S. Kim, S.K. Kim, J. Chang, Y.A. Kang, Seoul, Korea, Republic of, p.A5494

P1169 **Prevalence of Positive TST in Patients with Rheumatic Diseases Candidates for Biologic Agents in a High Tuberculosis Incidence Setting/**D.R. Silva, G. Garziera, F. Otesbelgue, F.L. Staub, P.E. Palominos, C.V. Brenol, Porto Alegre, Brazil, p.A5495

P1170 **The Comparison of Interferon Gamma Release Assays in CKD Patients Including Renal Transplantation and Hemodialysis for Latent Tuberculosis Infection/**H. Igari, S. Ishikawa, F. Yamagishi, Chiba, Japan, p.A5496

P1171 **Predicting Active Tuberculosis Development in Dialysis Patients by Using Interferon-Gamma Release Assay/**C.-C. Shu, J.-Y. Wang, V.-C. Wu, L.-N. Lee, C.-J. Yu, Taipei, Taiwan, p.A5497

P1172 **Clinical Comparison Study of QFT and T-SPOT in the Detection of LTBI, Early Active Pulmonary TB, and Advanced Pulmonary TB/**K. Fukushima, Y. Kaneko, N. Ehara, R. Nakano, T. Matsutake, T. Kubo, H. Mukae, S. Kohno, Isahaya, Japan, p.A5498

Facilitator: P.L. Hazangwe, MD, PhD, Harare, Zimbabwe

P1173 **QFT®-TB Gold in Tube and T-SPOT®.TB in Patients with Suspected Lung Tuberculosis/**N. Okimoto, Okayama, Japan, p.A5499

P1174 **Effect of Tuberculosis Treatment on Newly Developed QuantiFERON-TB® Gold Plus/**A. Kamada, M. Amishima, T. Inbe, Sapporo, Japan, p.A5500

P1175 **The Relationship Between PTH and PPD in Patients Undergoing Hemodialysis Treatment/**S. Deniz, J.C. Emre, Aydin, Turkey, p.A5501

P1176 **Metabolic Syndrome and Tuberculosis: Is There a Link?/**F. Elvira-Chavez, D. Pedroza-Escobar, S. Lopez-Garcia, M.D.L.L. Sevilla-Gonzalez, J. Luna-Herrera, L.M. Flores-Perea, A. Resendiz-Ramirez, E. Arenaza-Jimenez, L.A. Ibarra-Arriaga, E.I. Villegas-Hernandez, V.R. Ruiz-Roldan, M. Torres-Hernandez, Miguel Hidalgo DF, Mexico, p.A5502

P1177 **Tubercuosis Epidemiological Distribution in the Mountain Area of Taiwan Using Molecular Biology/**Y.-W. Huang, J.-J. Lee, P.-S. Yen, W.W. Chen, Y.-Y. Yu, Pushin Township, Taiwan, p.A5503

P1178 **Associations of Influenza Vaccination with Incident Tuberculosis and All-Cause Mortality Among Elderly Taiwanese Patients: A Nationwide Population-Based Cohort Study/**W.-J. Su, Y.-F. Yen, V.Y.-F. Su, P.-H. Chuang, S.-W. Pan, J.-Y. Feng, Taipei, Taiwan, p.A5504

P1179 **Adherence of Physicians-in-Training to the 2009 International Standards of Tuberculosis Care (ISTC) at the University of the Philippines-Philippine General Hospital/**A.F. Zagala, J. Benedicto, Manila, Philippines, p.A5505

P1180 **Public Private Mixed Implementation Enhanced Pulmonologist Adherence of Using ISTC In Private Sectors in Bogor, Indonesia/**A. Kosasih, D. Handayani, Bogor, Indonesia, p.A5506

Facilitator: O. Hilberg, MD, Aarhus, Denmark

P1181 **The Analysis of Chest Radiology of the National Tuberculosis Prevalence Survey in Mongolia, Phase 1/**Y. Ichimura, P. Bayasgalan, B. Tsolmon, D. Naranzul, S. Tugsdelger, B. Puntsag, K. Tsushima, K. Tatsumi, Chiba, Japan, p.A5507

P1182 **Is There an Added Value of Chest CT in Discriminating Between Latent and Active Mycobacterium Tuberculosis Infection in IGRA Positive Patients?/**S. Bommart, M. Peries, H. Kovacsik, N. Nagot, G. Durand, B. Ghaye, P. Van De Perre, E. Tuaillon, A. Bourdin, Montpellier, France, p.A5508

P1183 **Usefulness of Virtual Bronchoscopy for Endobronchial Tuberculosis/**Y. Shimoda, T. Akamatsu, Y. Tanaka, H. Watanabe, Y. Endo, T. Suzuki, I. Hayashi, S. Sakurai, M. Saigusa, A. Yamamoto, Y. Shishido, T. Akita, S. Morita, K. Asada, T. Shirai, Shizuoka, Japan, p.A5509

P1184 **Value of Laboratory Parameters Used in the Diagnosis of Tuberculous Pleurisy/**A. Arisoy, M.S. Tasbakan, A. Sayiner, Izmir, Turkey, p.A5510

P1185 **Detection of Circulating Mycobacterium Tuberculosis DNA in the Plasma of Smear-Positive Pulmonary TB Patients by Digital PCR Assay/**R. Ushio, M. Yamamoto, K. Nakashima, H. Watanabe, K. Nagai, Y. Shibata, K. Tashiro, T. Tsukahara, H. Nagakura, N. Horita, T. Sato, M. Shinkai, M. Kudo, A. Ueda, T. Kaneko, Yokohama, Japan, p.A5511

P1186 **Expectorated and Induced Sputum Collection in Patients with Tuberculous Pleural Effusion in a High Prevalence Hospital in the United States: an Analysis of Incremental Yield/**A. Gupta, S. Shahabuddin, O. Epelbaum, Queens, NY, p.A5512

P1187 **Unstimulated IFN-γ Can Surrogate ADA for Diagnosis of Pleural Tuberculosis/**A.P. Santos, L. Rodrigues, R. Correa, T. Mafort, M. Ribeiro-Alves, G. Pereira, C.H.D. Costa, R. Rufino, Rio de Janeiro, Brazil, p.A5513

P1188 **Loculated Tuberculous Pleural Effusion: Easily Accessible and Potent Predictor of Mycobacterial Culture in Pleural Fluid/**Y. Ko, C. Kim, J. Song, Seoul, Korea, Republic of, p.A5514

Facilitator: D.M. Nilsen, MD, Long Island City, NY

P1189 **To Study the Diagnostic Yield of Medical Thoracoscopy in Patients with Pleural Effusion of Undetermined Etiology Presented to a Tertiary Care Center Catering to Rural Population in Central India/**A.R. Mishra, R. Swarnakar, B. Vaghani, Nagpur, India, p.A5515

P1190 **Clinical Significance of Peripheral Eosinophilia in Patients with Standard Short Course Chemotherapy for Tuberculosis/**T.-O. Kim, H.-Y. Choi, H.-J. Shin, C.-K. Park, H.-J. Ban, I.-J. Oh, Y.-I. Kim, Y.-C. Kim, S.-C. Lim, Y.-S. Kwon, Gwangju, Korea, Republic of, p.A5516

P1191 **Comparison Acute Respiratory Distress Syndrome Caused by Tuberculosis with Caused by Pneumonia: Propensity Score Matching Analysis/**H.-J. Shin, T.-O. Kim, C.-K. Park, H.-J. Ban, I.-J. Oh, Y.-I. Kim, S.-C. Lim, Y.-C. Kim, Y.-S. Kwon, Y.-C. Ko, Gwangju, Korea, Republic of, p.A5517

P1192 **Extrapulmonary Tuberculosis: A Retrospective Review of 331 Cases at Kocaeli Tuberculosis Dispansary/**A. Sengul, N. Ogan, Y. Aydemir, Kocaeli, Turkey, p.A5518

P1193 **Knowledge of People Living with HIV (PLWH) to Tuberculosis - HIV Coinfection/**R. Nur Febri, R. Wisaksana, B.W. Lestari, Cirebon, Indonesia, p.A5519

P1194 **HIV Infection Among Patients with Tuberculosis Enrolled in Directly Observed Treatment, Short - Course (DOTS) Center in Davao City: A Cross - Sectional Study/**M.J.A. Dalayon, C. Uy, J. Itable, A. Lopez, Davao City, Philippines, p.A5520

P1195 **Tuberculosis Associated with Human Immunodeficiency Virus Infection in Mures County, Romania (10 Years, 2004-2013)/**G. Jimborean, R. Nemes, P. Postolache, O. Popa, E.S. Ianosi, Targu Mures, Romania, p.A5521

P1196 **Assessment of the Role of Bronchoalveolar Lavage Fluid (BALF) and Serum Vitamin D Levels in AIDS Disease Progression and Opportunistic Infections Amongst HIV and Tuberculosis Co-Infected Individuals/**S. Sinha, D. Mandal, P. Kasana, New Delhi, India, p.A5522

Facilitator: P.K. Moonan, DrPH, MPH, Atlanta, GA

P1197 **Clinical Course of Patients who Developed Tuberculosis After Receiving Tumor Necrosis Factor-α Inhibitors/**M.-A. Park, E.-J. Park, S.-H. Kim, I.K. Hwang, J.J. Hwang, H.M. Kang, J.H. Yoo, M.J. Park, Seoul, Korea, Republic of, p.A5523

P1198 **Immunosuppressant Drugs and Tuberculosis: Patient's Features in a University Hospital/**B.M. Pinto, L. Gama, C. Miranda, R. Vargas, A.P. Santos, W. Costa, D. Capone, H.R. Siqueira, C.H.D. Costa, J. Leung, R. Rufino, Rio de Janeiro, Brazil, p.A5524

P1199 **Analysis of Risk Factors for Early and Late Default Among Active Tuberculosis Patients/**J. Kim, J.H. Ahn, A.Y. Shin, H.S. Kang, Y.H. Kim, H.S. Moon, J.H. Ha, H.J. Kim, Korea, Republic of, p.A5525

P1200 **Detainment of Patients with Tuberculosis Under Section 38 of the Health Act, 1947 in Ireland/**L. Khorsheed, M. Murray, T. O'Connor, Cork, Ireland, p.A5526

P1201 **Treatment Outcomes of Tuberculosis Patients: Cohort 2014 in a Private Sector in Cali, Colombia/**L. Fernandez, J.F. Garcia, K. Monroy, C.A. Munoz, Cali, Colombia, p.A5527

P1202 **Sustainability and TB Outcomes of a Community Based Health Service Project: 3 Year Evaluation of a Solok District, Indonesia/**R. Machmud, Z. Zulhendrizon, F. Purba, S. Supriyadi, M. Masrul, D. Delyuzar, Padang, Indonesia, p.A5528

P1203 **Validation of Tuberculosis Outcome and Social Support Questionnaire (TOSQ) Among Nigerian Workers/**G.C. Isiguzo, C.N. Ugwu, K. Ukwaja, M.O. Iroezindu, G.A. Amusa, B.I. Awokola, C.J. Lane, B.C. Ezeokpo, Abakaliki, Nigeria, p.A5529

Facilitator: T.M. O'Connor, MD, Cork, Ireland

P1204 **Cough- and Sputum-Related Quality of Life in Pulmonary Tuberculosis/**T. Suzuki, Y. Tanaka, H. Watanabe, Y. Endo, Y. Shimoda, I. Hayashi, S. Sakurai, M. Saigusa, T. Akamatsu, A. Yamamoto, Y. Shishido, T. Akita, S. Morita, K. Asada, T. Shirai, Shizuoka, Japan, p.A5530

P1205 **Evaluation of Clinic and Radiologic Findings and Side Effect Profiles in Pulmonary Tuberculosis Patients, A Single Center Experience/**A. Sengul, Kocaeli, Turkey, p.A5531

P1206 **Effect of Emergency Liver Transplantation on the Survival of Patients with Antituberculous Therapy-Induced Acute Liver Failure/**J.-Y. Huh, K.-W. Jo, T.S. Shim, Seoul, Korea, Republic of, p.A5532

P1207 **An Update on the Trends and Treatment in Multidrug-Resistant Tuberculosis/**I.R. Reynolds, E.D. Chan, Denver, CO, p.A5533

P1208 **Rifampicin-Sparing Treatment in Pulmonary Tuberculosis Patients with Rifampicin-Mono-Resistance or Rifampicin Adverse Event/**S. Park, K.W. Jo, S.D. Lee, W.S. Kim, T.S. Shim, Seoul, Korea, Republic of, p.A5534

P1209 **Drug Susceptibility of Mycobacteria in Moscow Region/**V.I. Litvinov, M.V. Makarova, M. Krasnova, R. Galkina, L. Krilova, E. Khachaturyants, I. Peretokina, Moscow, Russian Federation, p.A5535

P1210 **The Role of Histone Deacetylases in the Innate Immune Response to Mycobacterium Tuberculosis Infection/**M. Campo, C. Seshadri, C.M. Stein, G.J. Peterson, R.D. Wells, H. Mayanja-Kizza, W.H. Boom, T.R. Hawn, Seattle, WA, p.A7886

P1211 **Evaluation of Optimal Regimens for Treatment of Rifampicin Resistant-Tuberculosis: Multicenter, Randomized Controlled Study in China/**S. Tang, L. Yao, X. Hao, Y. Liu, Beijing, China, p.A7887

P1212 **iAdhere Study: Cost-Effectiveness of Self-Administered Isoniazid/Rifapentine for Treatment of Latent Tuberculosis Infection in the United States/**D.P. Holland, D. Sheehan, A. Wright, N.A. Scott, R.W. Belknap, A.S. Borisov, Atlanta, GA, p.A7888

THEMATIC POSTER SESSION

C59 TOPICS ON SELF-MANAGEMENT AND SUPPORTIVE CARE ACROSS THE SPECTRUM OF CHRONIC RESPIRATORY CONDITIONS

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area F, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: L. Matura, PhD, RN, Philadelphia, PA

P629 **An Exploration of the Transition Readiness Needs of Urban African American Youth with Asthma/**W.M. Gibson-Scipio, K. Kolmodin MacDonell, C. Pearson, Detroit, MI, p.A5537

P630 **General Health Perception in People with Exacerbated COPD/**S.K. Park, Korea, Republic of, p.A5538

P631 **Self Care Behavior in People with Exacerbated COPD/** S.K. Park, Korea, Republic of, p.A5539

P632 **Differences in Perceptual Experiences of Breathlessness and Impairment Between People with Moderate-Severe COPD in Australia and the United Kingdom/**A.-M. Russell, K.N. Johnston, J. Yorke, M.T. Williams, London, United Kingdom, p.A5540

P633 **Impact of a Structured Therapeutic Education Program for COPD Patients on Preventing Readmissions (APRENDEEPOC Program)/**C. Hernandez, N. Seijas, A. Folch, C. Grane, I. Orts, C. Esquinas, J. Aibar, L. Macia, Barcelona, Spain, p.A5541

P634 **Functional Assessment of Patients with COPD, Pulmonary Hypertension and Interstitial Lung Diseases Using the Index Oxygen Desaturation-Distance Ratio (DDR)/**F. Burgos, X. Alsina, C. Gistau, I. Blanco, J. Roca, Barcelona, Spain, p.A5542

P635 **Exercise and Pulmonary Rehabilitation Participation Among Patients with Alpha-1 Antitrypsin Deficiency/**J. Nolte, T. Kurtz, M.L. Brantly, Gainesville, FL, p.A5543

Facilitator: R.T. Disler, PhD, RN, Sydney, Australia

P636 **Correlates of Sleep Quality in Women: Results of the National Sleep Foundation 2013 Poll/**E.R. Chasens, L.M. Baniak, C.E. Kline, Pittsburgh, PA, p.A5544

P637 **Review of Nurse Supported Sodium Oxybate Service for Patients with Narcolepsy/**M.F. Docherty, C. Carlin, C. Livingston, E. Livingston, Glasgow, United Kingdom, p.A5545

P638 **Sleep and Activity as Predictors of Subjective Health Status in Middle-Aged Women/**L.M. Baniak, C.E. Kline, J.L. Morris, E.R. Chasens, Pittsburgh, PA, p.A5546

P639 **Assisting Tobacco Users to Quit with Text Messaging/**P.A. Folan, C. Fardellone, A. Spatarella, N. Kohn, A. Talwar, Great Neck, NY, p.A5547

P640 **Nurse-Conducted Smoking Cessation Program in Patients Admitted in a Respiratory Ward Hospitalization/**D. Macias, C. Florencio, J. Hilares, V. Gomez, N. Reyes, I. Alfageme, Seville, Spain, p.A5548

P641 **Patients' Views About Living and Dying with Pulmonary Arterial Hypertension/**I. Armstrong, J. Yorke, J. Warden, P. Sephton, L. McGowan, Sheffield, United Kingdom, p.A5549

Facilitator: Z. Chen, BSN, Seattle, WA

P642 **The Lived Experience of Idiopathic Pulmonary Fibrosis: A Qualitative Study/**I. Egerod, D. Overgaard, G. Kaldan, K. Marsaa, T.L. Nielsen, S.B. Shaker, Copenhagen, Denmark, p.A5550

P643 **HIV Infection and Comorbidity as Predictors of Palliative Care Consultation in Adults Hospitalized with Heart Failure/**S.L. Feder, S. Jeon, J.P. Tate, J. Womack, M. Funk, N. Redeker, K. Akgun, West Haven, CT, p.A5551

P644 **Patterns of Healthcare Utilization by Patients with Interstitial Lung Disease/**A. Rodriguez, A. Nastase, K.S. Knox, G. Carr, Tucson, AZ, p.A5552

P645 **Having to Get to the End of the Rope to Realize the Existence of Chronic Obstructive Pulmonary Disease- Patients' and Families' Experiences/**H. Jonsdottir, G.H. Bragadottir, B.S. Halldorsdottir, T.S. Ingadottir, Reykjavik, Iceland, p.A5553

P646 **The Relaxation Effects of Hand-Massage Therapy on Autonomic Nervous Function and Emotions among Patients Receiving Palliative Care/**T. Sato, Y. Yamasaki, R. Maruyama, Sendai, Japan, p.A5554

P647 **Pecs that will Leave You Breathless/**K.J. Jackson, San Francisco, CA, p.A5555

THEMATIC POSTER SESSION

C60 ALL ABOUT CYSTIC FIBROSIS

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area E, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: F.A. Ratjen, MD, PhD, Toronto, Canada

P513 **The ATP Binding Cassette C4 (ABCC4) Transporter Regulates Extracellular cAMP Transport, Intracellular PKA Activity, and CFTR Channel Activity in Human Airway Epithelial Cells/** C.F. Rider, R. Newton, C. Bear, C. Carlsten, J.A. Hirota, Vancouver, Canada, p.A5557

P514 **Characterization of an Inhaled Epithelial Sodium Channel (ENaC) Blocker in Mice to Improve Mucociliary Clearance/**J.E. Phillips, B. Bennett, D. Fong, M. Fiorino, X. Zhang, K. Edson, J.A. Johnston, Thousand Oaks, CA, p.A5564

P515 **Nano-Based Autophagy-Induction Rescues ΔF508-CFTR and Pa Infection in CF Cells/**S.M. Brockman, M. Bodas, P. Chandramani, N. Vij, Mount Pleasant, MI, p.A5570

P516 **Bioengineering of Optimal AAV Based Vectors for Effective Gene Therapy for Bronchial Epithelium/**Y.M. Colon-Cortes, E. Martin, M. Abu- Hasan, A. Srivastava, G. Aslanidi, Gainesville, FL, p.A5571

P517 **Airway Therapeutic Discovery Using a Porcine Model of Cystic Fibrosis/**D. Cook, M. Stroik, R.J. Adam, B. Deonovic, L. Reznikov, N. Gansemer, K.F. Au, D. Meyerholz, D. Stoltz, Iowa City, IA, p.A5572

P518 **Losartan Rescues Cystic Fibrosis (CF)-Related Mucociliary Dysfunction in CF Cells In Vitro and in a Novel CF Sheep Model In Vivo/**M. Salathe, N. Baumlin, A. Kis, S. Krick, A. Schmid, J.R. Sabater, W.M. Abraham, Miami, FL, p.A5573

Facilitator: J. Chmiel, MD, MPH, Cleveland, OH

P519 **The Gene Expression Profile of Signal Transducer and Activator of Transcription (STATs) and Suppressor of Cytokine Signaling (SOCS) in Cystic Fibrosis/**S. Sagwal, M. Singh, R. Prasad, Chandigarh, India, p.A5556

P520 **Spdef-Independent Mucin Production During Non-Th2-Dominated Pulmonary Inflammation Revealed in the Scnn1b-Tg Muco-Obstructive Mouse Model/**G. Chen, A. Volmer, K. Wilkinson, K. Terrell, W.K. O'Neal, A. Livraghi-Butrico, R.C. Boucher, Chapel Hill, NC, p.A5558

P521 **Altered Toll-Like Receptor 4 and Histone Deacetylase 2 Expression in CFBE41o- Cells Regulates Hemeoxygenase I Via Nuclear Factor Erythroid 2-Related Factor 2**/S.V. Garapati, P. Mahavadi, M. Henke, A. Guenther, S.P. Chillappagari, Giessen, Germany, p.A5560

P522 **Increased TGFβ1 Alters Cellular Glutathione and Oxidant Stress in Neonatal Alveolar Macrophage with CFTR Mutation**/T.W. Gauthier, X.D. Ping, L.A.S. Brown, Atlanta, GA, p.A5563

P523 **Qualitative and Quantitative Changes of Gel Forming Mucins and Exosomes in Response to Infection and Inflammation in the Airways**/B. Batson, M. Arifuzzaman, P. Haridass, H. Dang, P. Mieczkowski, C. Ribeiro, L. Abdullah, M. Kesimer, Chapel Hill, NC, p.A5565

P524 **2-O, 3-O Desulfated Heparin Blocks High Mobility Group Box1 Release from Macrophages by Inhibition of P300 Acetyltransferase Activity**/S. Zheng, A. Kummarapurugu, D.K. Afosah, N.V. Sankaranarayanan, R. Boothello, Y. Jin, U.R. Desai, T. Kennedy, J.A. Voynow, Richmond, VA, p.A5566

P525 **IL1R1 Regulates MUC5B Production and Inflammatory Responses in the Airway Epithelium**/G. Chen, W.K. O'Neal, Y. Deng, D. Yu, L. Jones, C. Ribeiro, S.H. Randell, R.C. Boucher, Chapel Hill, NC, p.A5559

P526 **Repeated Aerosol Challenge with CFTRinh-172 and Human Neutrophil Elastase Results in Prolonged Dysfunction of Airway Mucus Transport and Loss of β-Adrenergic Responsiveness in Sheep**/W.M. Abraham, J.R. Sabater, D. McClain, R.W. Ball, T. Ahmed, Miami Beach, FL, p.A5569

P527 **High-Dose Ibuprofen Dampens Inflammatory Signaling Via Microtubule Structure and Dynamics in Cystic Fibrosis Epithelial Cells**/S.M. Rymut, C.U. Cotton, T.J. Kelley, Cleveland, OH, p.A5575

P528 **How to Effectively Degrade Neutrophil Extracellular Traps (NETs) by Airway Nucleases**/N. Palaniyar, D.N. Douda, C. Licht, L. Yip, Toronto, Canada, p.A5577

Facilitator: B.T. Kopp, MD, Columbus, OH

P529 **Sustained Effectiveness of Ivacaftor Therapy in Three Sisters with S549N CFTR**/A.R. Strang, K. Peeke, A. Shenoy, A. Chidekel, Wilmington, DE, p.A5583

P530 **Trends in Cystic Fibrosis Hospital Admissions in Ireland: A National Review**/K.N. McCarthy, Co Westmeath, Ireland, p.A5582

P531 **Potentiator Therapy Modifies Inflammatory Induced Neutrophil Activation in Patients with Cystic Fibrosis**/M. White, B. Alfawaz, F. Gargoum, C. McCarthy, E.M. O'Brien, N.G. McElvaney, E. Reeves, Dublin, Ireland, p.A5584

P532 **Characterization of Ivacaftor and Lumacaftor Using BioMAP® Profiling - Implications for Cystic Fibrosis**/S. Velichko, E. Berg, A. Folias, D. Bassoni, A. O'Mahony, South San Francisco, CA, p.A5585

P533 **Improved Homogeneity of Particle Deposition Following Ivacaftor Treatment in Cystic Fibrosis**/W.D. Bennett, K.L. Zeman, B.L. Laube, J. Wu, P.J. Mogayzel, S.H. Donaldson, Chapel Hill, NC, p.A5586

P534 **Acute and Long Term Effects of Ivacaftor on Air Trapping in Adults with Cystic Fibrosis and the G551D Mutation**/R.J. Adam, J.D. Dodd, K.B. Hisert, B. Grogan, J.L. Launspach, C.G. Gallagher, J. Sieren, E.A. Hoffman, M. Welsh, P.K. Singh, E.F. McKone, D.A. Stoltz, Iowa City, IA, p.A5587

P535 **Donor Arterial Partial Pressure of Oxygen and Outcomes After Lung Transplantation in Children with Cystic Fibrosis**/D. Hayes, Jr., D. Tumin, S.D. Reynolds, D. Malleske, J. Tobias, B.T. Kopp, Columbus, OH, p.A5578

Facilitator: E. Eber, MD, Graz, Austria

P536 **Evidence for Reduced Epithelial Cl- Secretion in Primary Human Nasal Epithelial Cells of Patients with Chronic Rhinosinusitis**/J.J. Salomon, T. Albrecht, H. Scheuermann, I. Baumann, M.A. Mall, Heidelberg, Germany, p.A5567

P537 **c.2768C>A CFTR Is a Disease-Causing Mutation**/X. Zhang, J.S. Hothi, C. Gushue, S. Srinivasan, D.C. Stokes, W. Zhang, Memphis, TN, p.A5561

P538 **FAM13A a New Lung Modifier Gene in Cystic Fibrosis Regulates Cytoskeletal Dynamics, RhoA and Enhances TGF-β-induced EMT**/L. Guillot, K. Thompson, C. Hodges, L. Fiette, N. Rousselet, M. Drumm, P.-Y. Boelle, H. Corvol, Paris, France, p.A5562

P539 **The Metabolic Footprint of the Airway Bacterial Community in Cystic Fibrosis**/J.M.C. Sweetnam, D.R. Denner, E.T. Naureckas, S.R. White, Augusta, GA, p.A5568

P540 **Optimization of hMSCs for Therapeutic Impact in Cystic Fibrosis**/T.L. Bonfield, M.T. Sutton, D. Fletcher, R. Van Heeckeren, D. Lennon, A.I. Caplan, Cleveland, OH, p.A5576

P541 **Phenotypic Characterization of Cultured Human Cystic Fibrosis Airway Smooth Muscle Cells**/M. O'Sullivan, A. Panariti, J. Jang, M. Pyrch, A.-M. Lauzon, J.G. Martin, Montreal, Canada, p.A5579

P542 **CFTR Amplifiers: A New Class of CFTR Modulator that Complements the Substrate Limitations of Other CF Therapeutic Modalities**/J.P. Miller, L. Drew, O. Green, A. Villella, B. McEwan, N. Patel, D. Qiu, A. Bhalla, C. Bastos, D. Parks, K. Giuliano, K. Longo, M. Ivarsson, B. Munoz, P.-S. Lee, H. Mehmet, M. Haeberlein, Cambridge, MA, p.A5574

Facilitator: D.B. Sanders, MD, MS, Madison, WI

P543 **Comparison of Quantitative Airway Measurements by 3 CT Algorithms in Children with Mild CF Lung Disease**/D. Savage, O. Weinheimer, M.O. Wielputz, T. Ziyeh, C. Tu, B. Newman, T.E. Robinson, Palo Alto, CA, p.A5588

P544 **Pediatric Hyperpolarized 129Xe MR Imaging: Safety and Tolerability in Healthy Children and Cystic Fibrosis Patients**/L.L. Walkup, R. Thomen, T. Akinyi, K. Ruppert, Z.I. Cleveland, J.P. Clancy, J.C. Woods, Cincinnati, OH, p.A5589

P545 **Comparison of Lung Clearance Index and Quantitative CT Air Trapping in Infant/Toddler/Preschool Children Vs. School Age Children with Cystic Fibrosis (CF)**/T.E. Robinson, M.L. Goris, C.E. Milla, T. Kongstad, K. Green, K.G. Nielsen, Palo Alto, CA, p.A5590

P546 **End-Expiratory Lung Volume Is Not Associated with Gas Trapping on CT in Early Cystic Fibrosis Lung Disease/**T. Rosenow, C. Mok, K.A. Ramsey, C. Murray, G. Hall, S. Stick, Subiaco, Australia, p.A5591

P547 **Using Computational Fluid Dynamics to Measure Ventilation and Airway Resistance in Early CF Lung Disease: A Preliminary Study/**J.S. Kimbell, E.M. DeBoer, T.W. Ferkol, S. Ranganathan, J.E. Hatch, S.D. Davis, Chapel Hill, NC, p.A5592

P548 **Harmful Effects of In Utero Tobacco Smoke Exposure on Development of Early Infection and Structural Lung Disease in Children with Cystic Fibrosis/**L. Turkovic, A. Hutchin, T. Rosenow, G. Hall, S. Stick, I.A. Laing, Subiaco, Australia, p.A5593

P549 **Predicting the Development of Bronchiectasis in Preschool Children with Cystic Fibrosis/**D. Caudri, L. Turkovic, N. De Klerk, T. Rosenow, S. Ranganathan, S. Stick, Subiaco, Australia, p.A5580

P550 **Impact of Socio-Environmental Factors on Initial Pulmonary Function Test (PFT) in Pediatric Patients with Cystic Fibrosis/**G.R. Oates, L. Britton, S. Gamble, C. Mims, R.A. Oster, H.H. Gutierrez, W.T. Harris, Birmingham, AL, p.A5581

THEMATIC POSTER SESSION

C61 PEDIATRIC SLEEP: SCREENING AND OUTCOMES

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area E, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: L. Kheirandish-Gozal, MD, MSc, Chicago, IL

P552 **Cardiovascular and Metabolic Consequences of Habitual Snoring in Adolescent and Younger Adults: Results from a Population-Based Survey/**P.E. Brockmann, A. Castet, F. Nunez, A. Sepulveda, L. Villarroel, F. Damiani, Santiago, Chile, p.A5594

P553 **Prevalence of Childhood Sleep Disordered Breathing and Associated Risk Factors in Urban Compared to Rural Areas/**R. Ersu, E. Civelek, B. Cakir, A. Demir, C.N. Kocabas, B.T. Karadag, Istanbul, Turkey, p.A5595

P554 **Sleep-Disordered Breathing in Children with Current Wheezing and Allergic Rhinoconjunctivitis/**R. Ersu, E. Civelek, Y. Gokdemir, B. Cakir, A. Demir, C.N. Kocabas, B.T. Karadag, F. Karakoc, Istanbul, Turkey, p.A5596

P555 **Pediatric Sleep-Disorder Questionnaire as a Screening Tool for Obstructive Sleep Apnea in Children with Sickle Cell Disease/**W. De Jesús-Rojas, K. Macbeth, F.F. Corrales-Medina, J.M. Stark, M.P. Carroll, K.G. Smith, T.R. Gonzales, D.L. Brown, C.K. Jon, R.A. Mosquera, A. Yadav, Houston, TX, p.A5597

P556 **Quantitative Analysis of Thoracoabdominal Asynchrony in Pediatric Polysomnography/**J.Z. Bronstein, T.H. Shaffer, A. Chidekel, R. Heinle, Wilmington, DE, p.A5598

Facilitator: R. Amin, MD, Toronto, Canada

P557 **Follow-Up of Children with Obstructive Sleep Apnea After Tonsillectomy and Adenoidectomy/**Z.N. Soultan, C.E. Amedro, Syracuse, NY, p.A5599

P558 **Persistent Respiratory Effort in Children with Sleep Disordered Breathing After Adenotonsillectomy/**J.-B. Martinot, J.C. Borel, V. Cuthbert, S. Denison, J.L. Pepin, D. Gozal, Namur, Belgium, p.A5610

P559 **Overnight Pulse Oximetry for the Diagnosis of Obstructive Sleep Apnea Syndrome in Children with Obesity/**A. Sathyaprasad, J. Stoll, N. Al-Hammadi, M. Bird, J.S. Kemp, A. Coverstone, St. Louis, MO, p.A5600

P560 **Sleep and Quality of Life of Adolescents in Ibadan, Nigeria/**A. Alohan, E. Orimadegun, J. Yaria, ibadan, Nigeria, p.A5601

P561 **Bronchoscopic Findings in Infants with Polysomnography/**A. Bandyopadhyay, H.N. Muston, J.E. Slaven, W.A. Engle, A. Daftary, Indianapolis, IN, p.A5602

P562 **Prader-Willi Syndrome and Progression of Obstructive Sleep Apnea with Human Growth Hormone Therapy/**J.Z. Bronstein, A.R. Strang, J. Marriner, J. Gustave, A. Chidekel, Wilmington, DE, p.A5603

Facilitator: H. Tan, MD, London, United Kingdom

P563 **Sleep Patterns in a Cohort of General Population Canadian 1-Year-Old Infants/**S. Gaddipati, P.J. Mandhane, A. Dubeau, T. Moraes, M.R. Sears, P. Subbarao, I. Narang, Toronto, Canada, p.A5604

P564 **Screening for Sleep Disordered Breathing in the Difficult-to-Treat Asthma Population Using the Pediatric Sleep Questionnaire/**A.R. Lopez, C.M. Kercsmar, N. Simakajornboon, Cincinnati, OH, p.A5605

P565 **Pediatric Sleep Questionnaire Detects Sleep Disordered Breathing in Asthmatics with Poor Nighttime Control/**R. Megalaa, G. Phull, D. Prue, C. Martinez, K. Scheffey, S. Kilaikode, P.J. Shukla, D.K. Pillai, Washington, DC, p.A5606

P566 **Impact of Supervised Asthma Medication Use on Sleep Outcomes of Elementary School Children/**E. Oren, D. Combs, J. Fisher, J.L. Goodwin, D. Billheimer, J.K. Gerald, C. Clemens, M.A. Brown, L.B. Gerald, Tucson, AZ, p.A5607

P567 **Sleep-Disordered Breathing and Sympathetic Activity in Obese Children and Adolescents/**A. Van Eyck, K. Van Hoorenbeeck, B. De Winter, L. Van Gaal, W. De Backer, S. Verhulst, Antwerp, Belgium, p.A5608

P568 **Impact of Preterm Birth on Cardiorespiratory Reflexes Originating from the Esophagus/**S. Nault, N. Samson, C. Nadeau, D. Djeddi, J.-P. Praud, Sherbrooke, Canada, p.A5609

THEMATIC POSTER SESSION

C62 PEDIATRIC CASES I

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area E, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: D.M. Boyer, MD, Boston, MA

P570 **A Cervical Case? Improvement in Pulmonary Function Flows from Sitting to Supine/**L.C. Bishay, C. Berde, D. Rosen, Boston, MA, p.A5611

P571 **Pulmonary Function Tests in a 2-Year-Old Male with Prune-Belly Syndrome and Renal Failure Undergoing Peritoneal Dialysis/**A.R. Strang, J.Z. Bronstein, A. Chidekel, T.H. Shaffer, Wilmington, DE, p.A5613

P572 **Rigid and Flexible Bronchoscopy for Meconium Aspiration Syndrome While on Extracorporeal Membrane Oxygenation(ECMO)/**J. Hong, T. Sweberg, K. Tsirilakis, New Hyde Park, NY, p.A5616

P573 **Severe BPD Complicated by PIG/**T. Simoneau, A. McLaughlin, F. Balarezo, C. Lapin, Hartford, CT, p.A5628

P574 **Children Affected by Congenital Central Hypoventilation Syndrome: Decannulation and Non Invasive Ventilation/**V. Caldarelli, M.G. Paglietti, E. Verrillo, R. Cutrera, Reggio Emilia, Italy, p.A5632

P575 **Staph Aureus Sepsis and Acute Respiratory Distress Syndrome Requiring Extracorporeal Life Support in an Adolescent with Cystic Fibrosis/**L.E. Faricy, G. Church, San Francisco, CA, p.A5639

Facilitator: F.O. Ogunlesi, MD, Washington, DC

P576 **When the Nebs Aren't Helping: Paradoxical Bronchoconstriction Due to Preservative in Continuous Albuterol Nebulizer Solution/**M. Currie, C. Jordan, C. Loughlin, Chapel Hill, NC, p.A5614

P577 **Lactic Acidosis in Status Asthmaticus: A Potential Side Effect of Albuterol Treatment/**B.M. Seay, S. Prabhakaran, M. Abu-Hasan, Gainesville, FL, p.A5615

P578 **Pulmonary Interstitial Lymphoid Hyperplasia and Autoimmune Hemolytic Anemia Successfully Responding to Steroid Sparing Agents in a 3 Year Old Boy/**L.C. Bishay, S.O. Vargas, L. Bartnikas, M. Fishman, C. Lillehei, T. Chatila, A.M.H. Casey, Boston, MA, p.A5612

P579 **A Unique Case of Pulmonary Lymphangectasia in a Teenager/**F. Afolabi, Dallas, TX, p.A5622

P580 **Novel Suture-Less Repair of Total Anomalous Pulmonary Venous Connection on a Medical Mission in Peru/**L.R. Gokanapudy, K.E. Remy, M.D. Ruppe, J.D. Tobias, W. Schechter, I. Abdullah, E.V. Melgar, R. Michler, Newark, NJ, p.A5629

P581 **Probable Primary Ciliary Dyskinesia in the Presence of Complex Congenital Heart Disease and Juvenile Dermatomyositis/**J. Cogen, T. Ong, Seattle, WA, p.A5635

P582 **Worsening Hypoxemia in an 11 Year-Old with Hereditary Hemorrhagic Telangiectasia (HHT)/**A.P. Vendittelli, C. Sabogal, Orlando, FL, p.A5640

Facilitator: R. Bhatia, MD, Akron, OH

P583 **A Delayed Diagnosis of Post Infectious Bronchiolitis Obliterans Associated with RSV/**A. Arastu, M. Corden, M. Bansal, Los Angeles, CA, p.A5617

P584 **Histoplasmosis Myocarditis: A Rare Manifestation of Disseminated Disease in an Immunocompetent Host/**B. Scott, J. Sherwin, C. Ozment, Durham, NC, p.A5619

P585 **Longitudinal Profiles of Serum Specific Immunoblobulins E and G4 to Whole and Component Dermatophagoides Pteronyssinus Allergens during Immunotherapy in Southern Chinese Children/**B. Sun, P. Zheng, Guangzhou, China, p.A5623

P586 **Diagnosis and Management of Sporadic Pulmonary Arteriovenous Malformation Not Associated with Hereditary Hemorrhagic Telangiectasia/**C. Okorie, S. Bhargava, Palo Alto, CA, p.A5625

P587 **A Case of Pulmonary Edema at Moderate Altitude: Extending the Spectrum of HAPE?/**N. Breitnauer, D. Bush, P.C. Stillwell, T. Carpenter, Aurora, CO, p.A5627

P588 **Investigating Persistent Fatigue: The Role of Exercise Challenge Testing in Diagnosing Mitochondrial Disorders/**B. Prentice, S. Towns, H. Selvadurai, B. Kennedy, Westmead, Australia, p.A5630

Facilitator: S. Schmitt-Grohe, MD, Bonn, Germany

P589 **Drug-Induced Bronchiolitis Obliterans Organizing Pneumonia (BOOP) in a Pediatric Patient/**E. Sayad, A. Dossul, S. Cardenas, Cleveland, OH, p.A5618

P590 **Neurologic Outcome in Pediatric Traumatic Cardiac Arrest - A Case Report and Review of Literature/**S. Raj, H.M. Ushay, S. Medar, Bronx, NY, p.A5620

P591 **Diffuse Lung Disease with Granulomas in an Infant: Aspiration Lung Injury?/**I. Jain, D.I. Craven, K.R. Ross, G. Luo, Cleveland, OH, p.A5621

P592 **Successful Use of Non Invasive Ventilation in a Child Affected by Congenital Myotonic Dystrophy Syndrome/**V. Caldarelli, M. Lusuardi, L. Spagnolatti, S. Amarri, Reggio Emilia, Italy, p.A5631

P593 **Primary Ciliary Dyskinesia, Hypotrichosis and Macular Dystrophy: Coincidence or a Novel Syndrome?/**E. Basora, C. Miranda, D. Morel, M. Tekin, A. Colin, Miami, FL, p.A5633

P594 **Continuous Renal Replacement Therapy for Profound Hyperammonemia in Pediatric Metabolic Disease/**C. Markham, K. Remy, St. Louis, MO, p.A5634

P595 **Disseminated Adenovirus Treated with Brincidofovir in a Post Liver Transplant Cystic Fibrosis Patient/**A. Carrion, B.K. Haberman, J.K. Eshun, S.R. Arnold, G. Maron, Memphis, TN, p.A5637

Facilitator: E. Belteton, MD, Las Victorias, Guatemala

P596 **Successful Outcome of a Genetic Lethal Condition in a Term Newborn/**A. Baig, C. Burg, H. Thomas, Omaha, NE, p.A5642

P597 **Acute Respiratory Failure Secondary to Bilateral Intra-Tonsillar Abscesses in a Pediatric Patient/**S. Rao, H.S. Agarwal, Albuquerque, NM, p.A5624

P598 **Gorhams-Stout Disease in a Young Pregnant Female-A Management Dilemma/**L. Jalota, K. Bilello, Fresno, CA, p.A5626

P599 **Two Unusual Cases of Cystic Fibrosis/**Y.B. zheng, L. Cao, China, p.A5638

P600 **A Neonatal Presentation of Co-Morbid Maple Syrup Urine Disease and Cystic Fibrosis/**N.L. Friedman, L.M. Grande, J.L. Blair, M. Yudkoff, R.C. Rubenstein, Philadelphia, PA, p.A5636

P601 **A Chinese Girl with Cystic Fibrosis Confirmed by 2 Cystic Fibrosis Transmembrane Regulator (CFTR) Gene Mutations/**A.Y.-F. Yip, Hong Kong, Hong Kong Prc, p.A5641

THEMATIC POSTER SESSION

C63 BORN TO RUN: EXERCISE IN CARDIOPULMONARY DISEASE

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area M, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: I.R. Preston, MD, Boston, MA

P1393 **Breathing Intolerance Index (BIT) in Cardiomyopathy Patients - Understanding Respiratory Muscle Endurance in Response to Exercise with Medical Management/**K. Bagavathy, A. Tran, L. Pallickal, M. Fong, A. Baydur, Los Angeles, CA, p.A5643

P1394 **Slope of 6MWD as a Predictor of Clinical Outcome in PAH/**M.G. Risbano, Y. Rao, J. Cleveland, Pittsburgh, PA, p.A5644

P1395 **Cardiopulmonary Exercise Test in Pulmonary Embolism/**J.-M. Liu, J. Guo, S. Chen, L. Wang, Q. Zhao, W. Yang, S. Gong, China, p.A5645

P1396 **Oxygen Uptake Efficiency Slope, an Objective Submaximal Parameter in Evaluating Exercise Capacity in Pulmonary Thromboembolism/**J.-M. Liu, J. Guo, S. Chen, Q. Zhao, W. Yang, L. Wang, S. Gong, Shanghai, China, p.A5646

P1397 **Difference in Exercise Capacity and Ventilatory Efficiency Between Chronic Obstructive Pulmonary Disease Associated Pulmonary Hypertension and Idiopathic Pulmonary Hypertension/**J.-M. Liu, H. Liu, J. Guo, L. Wang, W. Yang, Q. Zhao, S. Gong, Shanghai, China, p.A5647

P1398 **Improvement of Exercise Capacity and Ventilatory Efficiency in Patients with Pulmonary Embolism After Anticoagulant Therapy/**J.-M. Liu, D. Huang, J. Guo, L. Wang, W. Yang, Q. Zhao, S. Gong, Shanghai, China, p.A5648

P1399 **The Correlation of Decrease of Heart Rate Recovery and Chronotropic Incompetence with Exercise Capacity in Idiopathic Pulmonary Arterial Hypertension Patients/**J.-M. Liu, C. Wu, J. Guo, Q. Zhao, L. Wang, Shanghai, China, p.A5649

P1400 **Exercise-Induced Pulmonary Hypertension: An Expensive "Non-Disease" Entity/**S. Raviv, S. Mahajan, A. Ahmed, K. Kuchta, D. Melgar, A. Johnston, E. Genova, S. Smart, Evanston, IL, p.A5650

P1401 **Noninvasive Calculation of Dead Space in Cardiopulmonary Exercise Testing: Reliability Between and Comparative Sensitivity of Two Methods In Assessment of Pulmonary Vascular Disease/**T. Zaman, M.B. Warner, A.G. Vinayak, Washington, DC, p.A5651

P1402 **End-Tidal CO2 in Patients with Pulmonary Arterial Hypertension/**L. Truong, I. Lee, A. Hugh, S. Ganesh, A.A. Balekian, Los Angeles, CA, p.A5652

P1403 **Cardiopulmonary Exercise Test Correlates to Residual Right-Sided Cardiac Abnormalities in Adults with Surgically Repaired Tetralogy of Fallot/**P. Cejudo, M. Rodriguez-Puras, R. Vazquez, B. Manso, F. Villagra, C. Fernandez-Vivancos, F. Ortega, P. Gallego, L. Gomez-Izquierdo, Sevilla, Spain, p.A5653

Facilitator: P.M. Hassoun, MD, Baltimore, MD

P1404 **Significant Improvement of Oxygen Saturation of Peripheral Artery During Exercise in Patients with CTEPH Treated with Riociguat/**M. Hatano, H. Maki, T. Inaba, S. Minatsuki, I. Komuro, Tokyo, Japan, p.A5654

P1405 **Cardiopulmonary Exercise Testing Improve Diagnostic Accuracy in Patients with Echocardiography Suspected Pulmonary Hypertension/**Q.-H. Zhao, L. Wang, R. Jiang, J.-M. Liu, Shanghai, China, p.A5655

P1406 **Sex-Specific Cardiopulmonary Exercise Testing Parameters as Predictors in Patients with Idiopathic Pulmonary Arterial Hypertension/**P. Yuan, T.-X. Chen, J.-M. Liu, Shanghai, China, p.A5656

P1407 **Sex-Specific Cardiopulmonary Exercise Testing Indexes Related to Hemodynamics in Idiopathic Pulmonary Arterial Hypertension/**T.-X. Chen, P. Yuan, J.-M. Liu, Shanghai, China, p.A5657

P1408 **Exercise Determinants of Ventilatory Efficiency in Heart Failure with Preserved Ejection Fraction/**E.H. Van Iterson, E.M. Snyder, T.P. Olson, Rochester, MN, p.A5658

P1409 **Ventilatory Response to Exercise in Heart Failure with Preserved or Reduced Ejection Fraction/**E.H. Van Iterson, E.M. Snyder, T.P. Olson, Rochester, MN, p.A5659

P1410 **Blood MiRNAs to Monitor Pulmonary Hypertension - Effect of Exercise Training/**G. Grunig, I. Ladran, C.A. Eichstaedt, C. Fischer, G. Krafsur, K.R. Stenmark, E. Grunig, S. Pylawka, New York, NY, p.A5660

P1411 **Effect of Voluntary Exercise on Inflammation, Vascular and Airway Remodeling in a Mouse Model of Pulmonary Hypertension Induced by Exposure to Antigen and Urban Particulate Matter/**N. Durmus, B. Bleck, J. Reibman, G. Grunig, Tuxedo, NY, p.A5661

P1412 **Chronic Endurance Exercise Attenuates Impairments in VO2max in Rats with Pulmonary Arterial Hypertension/**D. McCullough, A. Vang, S. Heo, G. Choudhary, Auburn, AL, p.A5662

P1413 **Dynamic Fluctuations of Circulating Growth Hormone in Patients with Chronic Lung Disease/**S. Sahni, A. Iftikhar, S. Verma, Y.-M. Yang, A. Talwar, P.B. Sehgal, E.J. Miller, New Hyde Park, NY, p.A5663

P1414 **Pyridostigmine for Exercise Intolerance Treatment in Preload Failure/**R.K. Oliveira, J.A. Tracy, A.L. Karin, A. Waxman, D. Systrom, Sao Paulo, Brazil, p.A5664

THEMATIC POSTER SESSION

C64 ALI AND BARRIER FUNCTION

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area M, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: B.J. McVerry, MD, Pittsburgh, PA

P1416 **Spleen Tyrosine Kinase Signaling Mediates Endothelial Barrier Disruption in Acute Lung Injury/**S. Slavin, V. Grose, A. Leonard, A. Pietropaoli, F. Fazal, A. Rahman, Rochester, NY, p.A5665

P1417 **Lung Ischemia-Reperfusion Injury and Endothelial ROS-Induced Ca2+ Influx Are Attenuated by Loss of CD36, a Fatty Acid Transporter/**K. Suresh, L. Servinsky, O. Rentsendorj, J. Dodd-o, D.B. Pearse, L. Shimoda, Baltimore, MD, p.A5666

P1418 **The S1P Transporter, Spns2, Regulates HGF/C-Met-Mediated Lamellipodia Formation and Migration of Human Lung Endothelial Cells/**P. Fu, P.V. Usatyuk, D.L. Ebenezer, V. Natarajan, Chicago, IL, p.A5667

P1419 **Inhibition of Xanthine Oxidoreductase with Febuxostat Promotes Lung Injury Resolution in a Murine Model of Endotoxemia/**L. Johnston, M. Damarla, K. Carino, M. Aladdin, L. Varela, L. Wang, T. Kolb, B.S. Kim, R.L. Damico, N.R. Aggarwal, P.M. Hassoun, Baltimore, MD, p.A5668

P1420 **Hsp90 Inhibitors Prevent NF-κB-Dependent Gene Activation in Human Lung Microvascular Endothelial Cells by Inducing MDM2-Dependent Sirt-2-Promoter Binding/**G.S. Thangjam, B. Charalampos, B. Nektarios, B.W. Gregory, M.A. Clements, J. Newton, J.D. Catravas, Norfolk, VA, p.A5669

P1421 **Equilibrative Nucleoside Transporter 1 Mediates Adenosine-Induced Endothelial Mitochondrial Dysfunction and Contributes to Cigarette Smoke Priming for Acute Lung Injury/**E. Chambers, J. Ko, S.I.S. Rounds, Q. Lu, M.R. Blackburn, Providence, RI, p.A5670

P1422 **Circulatory Microparticles and Lung Endothelial Cell Function in Acute Respiratory Distress Syndrome Patients/**T. Shah, C. Bardita, N. Jeganathan, R. Balk, D. Predescu, S.A. Predescu, Chicago, IL, p.A5671

Facilitator: M. Damarla, MD, Baltimore, MD

P1423 **The Functional Impact of Pulmonary Endothelial Glycocalyx Remodeling After Sepsis/**T.C. Lane, J.F. Colbert, Y. Yang, S.M. Haeger, J.A. Ford, K.L. Dailey, E.P. Schmidt, Aurora, CO, p.A5672

P1424 **Glycocalyx Degradation Differs Between Direct and Indirect Lung Injury/**A.M. DeDent, S.M. Haeger, M.J. Perez, Y. Yang, J.A. Ford, K.L. Dailey, F. Zhang, R.J. Linhardt, E.P. Schmidt, Aurora, CO, p.A5673

P1425 **Dyslipidemia Is Associated with Increased Markers of Endothelial Activation Following Lung Injury/**M.C. Antkowiak, E. Dilli, A. Wallace, D. Distafano, L.P. Lalire, N. Ubags, M.E. Poynter, B.T. Suratt, Burlington, VT, p.A5674

P1426 **Abl Family Kinases Mediate LPS-Induced Lung Vascular Permeability and Inflammation/**A.N. Rizzo, X. Sun, E. Letsiou, J.G.N. Garcia, S.M. Dudek, Chicago, IL, p.A5675

P1427 **Differential Effect of Low and High Magnitude Cyclic Stretch on Endothelial Inflammatory Activation/**A. Sitikov, Y. Tian, I. Mambetsariev, G. Gawlak, J. O'Donnell, A.A. Birukova, Chicago, IL, p.A5676

P1428 **Many Roles of Vinculin in Regulation of Endothelial Monolayer Integrity: Location, Location, Location/**Y. Ke, A.S. Shah, T. Ohmura, N. Sarich, A.A. Birukova, K.G. Birukov, Chicago, IL, p.A5677

P1429 **Multifunctional Regulator of Small GTPases IQGAP1 Mediates Lung Endothelial Response to Barrier Enhancing Oxidized Phospholipids/**Y. Ke, O. Oskolkova, T. Ohmura, N. Sarich, K.G. Birukov, Chicago, IL, p.A5678

Facilitator: E.N. Grayck, MD, Aurora, CO

P1430 **Actin Related Protein 2/3 Complex Regulates Actin Membrane Structures to Determine Endothelial Barrier Function/**P.G. Belvitch, M. Brown, E. Letsiou, A.N. Rizzo, J.G.N. Garcia, S.M. Dudek, Chicago, IL, p.A5679

P1431 **VEGF Receptor-2 Mediates Adherens Junction Remodeling and Endothelial Permeability in Pulmonary EC Exposed to High Magnitude Cyclic Stretch/**Y. Tian, Y. Ke, G. Gawlak, J. O'Donnell, A.A. Birukova, K.G. Birukov, Chicago, IL, p.A5680

P1432 **Inhibition of Hsp90 Repairs the LPS-Induced ALI in Mice/**C. Birmpas, C. Dimitropoulou, N. Barabutis, G.S. Thangjam, B.W. Gregory, J.D. Catravas, Norfolk, VA, p.A5681

P1433 **Cytosolic Active Caspase 3 Plays a Critical Role in Promoting Endothelial Barrier Integrity/**M. Damarla, K. Carino, K. Suresh, L. Johnston, B.S. Kim, T. Kolb, R.L. Damico, C. Machamer, L. Shimoda, P.M. Hassoun, Baltimore, MD, p.A5682

P1434 **Molecular Candidates for Promoting Pulmonary Vascular Endothelial Repair in Endotoxin-Induced Lung Injury/**T. Kawasaki, T. Kinoshita, J. Terada, K. Tatsumi, Chiba, Japan, p.A5683

P1435 **Group V Secretory Phospholipase A2 Is Degraded by Autophagy in Human Lung Endothelial Cells/**L.N. Meliton, X. Zhu, M. Brown, Y. Ephstein, E. Letsiou, S.M. Dudek, Chicago, IL, p.A5684

THEMATIC POSTER SESSION

C65 ONE STEP UP FROM PE TO CTEPH

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area M, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: V. De Jesus Perez, MD, Stanford, CA

P1437 **One-Year Experience After Implementation of a Multidisciplinary Pulmonary Embolism Team/**L.E. Eggert, K. Klipper, D. Kadian-Dodov, R. Reddy, L. DePalo, R. Lookstein, H. Poor, New York, NY, p.A5685

P1438 **D-Dimer in Chronic Thromboembolic Pulmonary Hypertension (CTEPH)/**N. Skoro-Sajer, C. Gerges, S. Taghavi, R. Sadushi-Kolici, W. Klepetko, I. Lang, Vienna, Austria, p.A5686

P1439 **Does Thrombolytic Therapy During the Clinical Course of Acute Pulmonary Embolism Improve Prognosis?/**M. Koslow, A. Osadchy, F. Fanadka, Y. Neumann, D. Shitrit, Givatayim, Israel, p.A5687

P1440 **The Underutilization of Clinical Prediction Scores and D-Dimer Testing in the Age of the CT Pulmonary Angiogram in Patients with Suspected Pulmonary Embolisms/**J. Filopei, G. Bajpayee, Y. Duanmu, B. Lou, M. Islam, E.E. Bondarsky, M. Lau, N. Ramesh, D. Lucido, S. Bergmann, D. Steiger, New York, NY, p.A5688

P1441 **Alternative Diagnosis to Pulmonary Embolism Following a Negative CT Pulmonary Angiogram/**J. Filopei, B. Lou, N. Ramesh, M. Islam, G. Bajpayee, M. Lau, E.E. Bondarsky, D. Steiger, New York, NY, p.A5689

P1442 **Real World Management in the Evolving Landscape of Pulmonary Embolism Management/**J. Filopei, A. Chakravarti, N. Ramesh, S. Acquah, P. Patrawalla, D. Steiger, New York, NY, p.A5690

P1443 **Pulmonary Infarction Secondary to Pulmonary Embolism - Clinical and Radiographic Characteristics/**M. Islam, J. Filopei, N. Ramesh, B. Lou, D. Steiger, New York, NY, p.A5691

P1444 **Expression of Tissue Factor and Forkhead Box Transcription Factor O-1 in a Rat Model for Chronic Thromboembolic Pulmonary Hypertension/**C. Deng, D. Wu, M. Yang, Y. Chen, C. Wang, Z. Zhong, N. Lian, H. Chen, S. Wu, Fuzhou, China, p.A5692

P1445 **Secondary Polycythemia Is an Independent Risk Factor for Acute Respiratory Failure in COPD Patients Hospitalized for Pulmonary Embolism/**L. Guo, H.L. Jiang, L.Y. Gao, C.R. Ju, C.H. Martinez, J.L. Curtis, Chengdu, China, p.A5693

P1446 **Single Drug Approach with Edoxaban Is Effective and Safe for the Patients with Venous Thromboembolism/**Y. Hattori, A. Tsuji, J. Ueda, S. Fukui, T. Ogo, S. Yasuda, H. Ogawa, N. Nakanishi, Suita, Osaka, Japan, p.A5694

P1447 **Improving Utilization of CTA in the Diagnosis of Pulmonary Embolism/**M.N. Saleh, F. Marmoush, F. Ashraf, A. Abdin, F. Hamid, M. Salhab, A. Saeed, S. Imran, T. Minami, E. Summerhill, M. Alqadi, Pawtucket, RI, p.A5695

P1448 **Role of Bedside Chest Ultrasonography and Echocardiography in the Diagnosis of Pulmonary Embolism in Emergency Rooms/**M.K. Ghanem, H. Makhlouf, A. Abd El-Azim, A.A. AlKarn, Assiut, Egypt, p.A5696

Facilitator: S.C. Mathai, MD, MHS, Baltimore, MD

P1449 **Predictors of Hospital Mortality in Patients with Acute Pulmonary Embolism in Intensive Care Units/**T. Salim, C.C. Portillo, J. Sethi, C. Pena Orbea, R. Lenhardt, Chicago, IL, p.A5697

P1450 **Ultrasound-Assisted Catheter Directed Thrombolysis for Pulmonary Embolism: Pulmonary Perspective/**S. Suliman, K. El Kersh, E. McDaniel, J.S. Smith, Louisville, KY, p.A5698

P1451 **An Analysis of Mechanism of Hypoxia in Chronic Thromboembolic Pulmonary Hypertension/**S. Minatsuki, H. Maki, T. Inaba, M. Hatano, I. Komuro, Tokyo, Japan, p.A5699

P1452 **Relationship Between Improved Pulmonary Arterial Pressure and Changes in the Wall Thickness of Right Ventricle Myocardium by 320-Slice CT in Patients Under Pulmonary Endarterectomy/**T. Sugiura, N. Tanabe, A. Sasaki, H. Kasai, Y. Matsuura, N. Kawata, S. Sakao, K. Tatsumi, Chiba, Japan, p.A5700

P1453 **The Age Adjusted D-Dimer: A Real World Experience in Patients with Suspected Pulmonary Embolism/**N. Ramesh, M. Lau, J. Filopei, M. Islam, B. Lou, E.E. Bondarsky, G. Bajpayee, Y. Duanmu, D. Steiger, New York, NY, p.A5701

P1454 **Treatment of Venous Thromboembolism with Parenteral Anticoagulation and Warfarin; A Quality Improvement Project/**A. Desai, R. Calixte, M. Aparnath, A. Hindenberg, J. Mathew, Mineola, NY, p.A5702

P1455 **Thrombolytic Use and in Hospital Mortality from Pulmonary Emboli in an Urban Teaching Hospital/**M. Labban, Z. Ghazarian, R. Sekhon, T. Pandya, M. Hanna, R. Solis, Paterson, NJ, p.A5703

P1456 **D-Dimer Cut-Off Value Adjustment in the Workup of Pulmonary Embolism: Initiative Quality Improvement/**S. Alhassan, K. Patel, S. Lavudi, M. Young, E. Bihler, M. Balaan, Pittsburgh, PA, p.A5704

P1457 **Incidence of Post-Operative ARDS in a Contemporary Pulmonary Endarterectomy Cohort, Undertaken in a High Volume Tertiary Centre/**C. Summers, E.M. Swietlik, J. Pepke-Zaba, N. Jones, M. Newnham, J. Jacob, A. Proudfoot, C. Ng, S. Tsui, J. Dunning, D. Jenkins, A. Vuylsteke, M. Toshner, Cambridge, United Kingdom, p.A5705

P1458 **Chronic Inflammation After Splenectomy Is a Risk Factor for Increased Thrombotic Cardiovascular Events/**M. Gerges, C. Gerges, V. Seidl, B. Eichelberger, K. Lechner, A. Alimohammadi, D. Bonderman, M. Frey, T. Hofbauer, M. Humenberger, J. Jakowitsch, S. Panzer, I. Lang, Vienna, Austria, p.A5706

P1459 **Anticoagulation Therapy for Chronic Thromboembolic Pulmonary Hypertension Referred for Pulmonary Thromboendarterectomy Surgery: A Single Referral Center Experience/**S. Kim, G.V. Pretorius, M.M. Madani, K.M. Kerr, W.R. Auger, P.F. Fedullo, N.H. Kim, Seoul, Korea, Republic of, p.A5707

P1460 **The Association of Pulmonary Arteriopathy with Persistent Hypoxemia After Pulmonary Endarterectomy in Chronic Thromboembolic Pulmonary Hypertension/**T. Jujo, N. Tanabe, S. Sakao, H. Ishibashi-Ueda, K. Ishida, A. Naito, F. Kato, T. Takeuchi, A. Sekine, R. Nishimura, T. Sugiura, A. Shigeta, M. Masuda, K. Tatsumi, Chiba, Japan, p.A5708

Facilitator: J.D. West, PhD, Nashville, TN

P1461 **Isolated Sub-Segmental Pulmonary Embolism Frequently Coincide with Other Significant CT Chest Findings in a High Risk Orthopedic Population: A Retrospective Study/**J.S. Mendelson, V. Mukherjee, D. Steiger, S. Funk, E. Dweck, New York, NY, p.A5709

P1462 **Downward Trend in Inferior Vena Cava (IVC) Filter Use Following a Safety Alert/**H.L. Erickson, J.E. Simmering, R.R. Butler, L.A. Polgreen, A.P. Comellas, P.M. Polgreen, Iowa City, IA, p.A5710

P1463 **Risk of Venous Thromboembolism in Patients with Celiac Disease: A Systematic Review and Meta-Analysis/**P. Ungprasert, K. Wijarnpreecha, N. Srivali, Rochester, MN, p.A5711

P1464 **Improving Turn-Around Time from Requisition to Diagnosis for CT Pulmonary Angiography: Follow-Up at Six Years/**N.A. Avila, S. Zaidi, R. Smith, S. Grimes, A.J. Dwyer, Washington, DC, p.A5712

P1465 **Incidence of Deep Vein Thrombosis Post Cardiac Surgery /**A.H. Siddiqui, M.A. Shariff, K.C. Bowman, R. Aboushe, K. Roy, T.J. Maniatis, S.A. Alhajri, J.T. McGinn, B. Pandya, T.M. Khan, K. Chong, J.P. Nabagiez, Staten Island, NY, p.A5713

P1466 **The Predictive Value of Wells and Revised Geneva Score and D-Dimer for the Diagnosis of Acute Pulmonary Embolism in Critical Care Unit/**D. Li, A. Xu, Shanghai, China, p.A5714

P1467 **Population Demographics of Patients Diagnosed with Pulmonary Embolism with and Without Major Complications: A Study Involving 113,555 Patients/**R. Chandrashekar, M. Konda, Kalamazoo, MI, p.A5715

P1468 **Analysis of Difficulties and Faults of Diagnostics and Treatment of Pulmonary Embolism/**N. Latypova, E. Kim, A. Faizova, Astana, Kazakhstan, p.A5716

P1469 **Appropriate Ordering of Computed Tomography Pulmonary Angiograms to Evaluate for Pulmonary Embolism/**Y. Vayntrub, N. Seam, N.A. Avila, D. Mobarek, Washington, DC, p.A5717

P1470 **Pulmonary Embolism in Post-Operative Orthopedic Patients: Do the Numbers Stack Up?/**R. Postelnicu, V. Mukherjee, E. Dweck, New York, NY, p.A5718

P1471 **Extensive Screening for Occult Malignancy in Unprovoked Venous Thromboembolism: A Meta-Analysis of Randomized Clinical Trials/**M. Salih, M. Gashouta, E. Leung, T. Algarod, M. Ayan, Chesterfield, MO, p.A5719

P1472 **Suboptimal Pharmacological Deep Venous Thrombosis (DVT) Prophylaxis from Missed Doses Can Increase the Risk of Venous Thromboembolism (VTE) in Hospitalized Patients/**S.S. Patil, K. Gopal, M.S. Narat, A.A. Aman, D.D. Jackson, K. Gomez, T. Johnson, B. Patel, Houston, TX, p.A5720

THEMATIC POSTER SESSION

C66 'WALK THIS WAY'- UPDATE ON EXERCISE TESTS AND PULMONARY REHABILITATION

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area F, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: D. Brooks, PhD, Toronto, Canada

P649 **Correlation Between Five Exercise Tests to the COPD Assessment Test (CAT) in Stable COPD/**T.C. Harvey-Dunstan, S.E. Edwards, L. Houchen-Wolloff, R. Tal-Singer, M. Polkey, M.D.L. Morgan, M.C. Steiner, S.J. Singh, Leicester, United Kingdom, p.A5721

P650 **Safety of the Six Minute Walk Test in Chronic Lung Disease/** R. Khair, D. Boyce, E. Pullins, M.C. McCormack, S.C. Mathai, Baltimore, MD, p.A5722

P651 **The Peak Ratios of Pulmonary Gas Exchange to Ventilation (VO2/VE and VCO2/VE) Correlate with but Underestimate Lactate Threshold and Onset of Ventilatory Compensation/**C. Tan, H.B. Rossiter, J. Porszasz, T.S. Bowen, W.W. Stringer, R. Casaburi, J.E. Hansen, Beijing, China, p.A5723

P652 **Six Minute Walk Test Distance: Is It a Good Predictor of Mortality?/**A. Biswas, P. Markey, B. Jacob, West Yorkshire, United Kingdom, p.A5724

P653 **The Reference Equation for 200 Meters Walk Test/**A. Maiworm, K.M. Da Silva, Y. De Souza, J. Parnayba, M. Da Cal, B. Figueira, D. Condesso, C.H.D. Costa, R. Rufino, Rio de Janeiro, Brazil, p.A5725

P654 **The Reference Equation to Six-Minute Step Test: A Benchmark to Evaluate the Functional Capacity in Patients/**K.M. Da Silva, Y. De Souza, J. Parnayba, A. Maiworm, M. Da Cal, B. Figueira, D. Condesso, R. Rufino, C.H.D. Costa, Rio de Janeiro, Brazil, p.A5726

P655 **Comparison of Cardiopulmonary Exercise Test in Smoker and Non-Smoker/**J. Zhang, yinchuan, Ningxia, China, p.A5727

P656 **Cardiopulmonary Exercise Test Differences in Healthy Adults with and Without Anxiety Disorders - Does Activity Level and Fitness Have an Influence?/**L.P. Cahalin, M.L. Wong, K. Allsup, R. Arena, D.E. Forman, Coral Gables, FL, p.A5728

Facilitator: M.N. Bartels, MD, MPH, Bronx, NY

P657 **Long Term Management of COPD Via a Clinical Guidance System: 14 Years of a Continuous Improvement Model/**B. Tiep, M. Barnett, R. Carter, R. Murray, Monrovia, CA, p.A5729

P658 **Serum C-Reactive Protein Levels in COPD Patients After Eight Week Comprehensive Pulmonary Rehabilitation Program/**I. Candemir, P. Ergun, D. Kaymaz, N. Demir, F. Tasdemir, Ankara, Turkey, p.A5730

P659 **Can Information from Cardiopulmonary Exercise Testing Predict Outcome After Pulmonary Rehabilitation in Patients with COPD?/**R.J. Perez, R. ZuWallack, D. Datta, Farmington, CT, p.A5731

P660 **Comorbidities in Patients with Chronic Obstructive Pulmonary Disease and Pulmonary Rehabilitation Outcomes/**P. Tunsupon, A. Lal, M.A. Khamis, M.J. Mador, Buffalo, NY, p.A5732

P661 **Short Duration Dyspnea Challenge Test to Assess Severity of Dyspnea in Patients with Chronic Obstructive Pulmonary Disease/**P. Sharma, N.R. Morris, M. Sabaratnam, L. Adams, Southport, Australia, p.A5733

P662 **Chronic Obstructive Pulmonary Disease (COPD) Patients After Pulmonary Rehab: Psycho-Social Factors/**M. Dekker, P. Saini, R. Priori, C. Barretto, M. Sillen, M. Spruit, Eindhoven, Netherlands, p.A5734

P663 **Clinical, Socio-Demographic and Psychological Characteristics of Participants and Non-Participants to Pulmonary Rehabilitation in Patients with Chronic Obstructive Pulmonary Disease (COPD)/**E.D. Rivard, V. Pepin, F. Beaucage, L. Blais, G. Moullec, RESP Team, Montreal, Canada, p.A5735

P664 **Trends of Symptom Scores in COPD Patients Followed in a Tertiary Care Pulmonology Clinic: Are Patients Feeling Better?/**R. Evans, N. Menon, C.S. Tsai, S.A. Evans, D.W. Drumm, A.L. Berger, P.F. Simonelli, Danville, PA, p.A5736

P665 **Pulmonary Rehabilitation Is Associated with Improvement in Short Physical Performance Battery Scores in COPD/**C. Teneback, P. Savage, Burlington, VT, p.A5737

Facilitator: H. Demeyer, PhD, Leuven, Belgium

P666 **Postural Deviations in People with Chronic Obstructive Pulmonary Disease (COPD)/**A.L. Lee, K. Zabjek, R.S. Goldstein, D. Brooks, Toronto, Canada, p.A5738

P667 **"Who Wants to Hurt?" - A Qualitative Exploration of Pain Experiences and Their Meaning in People with Chronic Obstructive Pulmonary Disease (COPD)/**A.L. Lee, S.L. Harrison, R.S. Goldstein, D. Brooks, Toronto, Canada, p.A5739

P668 **Chronic Pain in Chronic Obstructive Pulmonary Disease (COPD): Prevalence, Clinical Implications and Psychological Responses/**A.L. Lee, R.S. Goldstein, D. Brooks, Toronto, Canada, p.A5740

P669 **Light Intensity Physical Activity (LIPA) Is Associated with Patient Reported Outcomes in People with COPD/**N.S. Cox, A.T. Burge, A. Mahal, C.J. Hill, A.L. Lee, R. Moore, C. Nicolson, A. Lahham, R. Ndongo, C.F. McDonald, A.E. Holland, Melbourne, Australia, p.A5741

P670 **The Minimal Clinically Important Difference for Daily Step Counts in Persons with COPD/**M. Teylan, D. Homsy, O. Okunbur, J. Gao, E. Garshick, M.L. Moy, Boston, MA, p.A5742

P671 **Objectively Measured Sedentary Behavior in People with COPD and Assisted Living Residents/**J.L. Larson, C. Vos, S. Woo, D. Fernandez, D. Buckery, Ann Arbor, MI, p.A5743

P672 **Objectively Measured Physical Activity and Sleep Quality in Chronic Obstructive Pulmonary Disease/**Z. Parwanta, A.T. Burge, V. Pepin, N.S. Cox, A.E. Holland, Montreal, Canada, p.A5744

P673 **A Screening Tool to Predict Obstructive Sleep Apnea in Patients with Chronic Obstructive Pulmonary Disease: A Pilot Study of the UCSD COPD-OSA Questionnaire/**X. Soler, S.-Y. Liao, A.L. Ries, A. Malhotra, San Diego, CA, p.A5745

THEMATIC POSTER SESSION

C67 ACUTE LUNG INJURY

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area M, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: L.G. Dobbs, MD, Oakland, CA

P1475 **Altered Expression of IRF1 and Its Regulatory Genes in Lipopolysaccharide-Induced Acute Lung Injury Mouse Model/**J.-R. Park, H. Lee, S.-R. Yang, Chuncheon, Korea, Republic of, p.A5746

P1476 **F Box Protein FBXO10 Targets the Receptor for Advanced Glycation End Products (RAGE) for Ubiquitination and Degradation in Human Bronchial Epithelial Cells/**J. Evankovich, S. Dunn, A. Mckelvey, T. Lear, B.B. Chen, R. Mallampalli, Pittsburgh, PA, p.A5747

P1477 **Attenuation of Lung Injury by Lung Epithelium Cell Specific Knockdown of Nampt Gene Expression/**G. Bi, N.N. Nsumu, L. Zhang, D. Heruth, S. Ye, Kansas City, MO, p.A5748

P1478 **Epithelial Cells Internalize Macrophage-Derived Microparticles: Mechanisms of Uptake and Modulation by the Extracellular Environment/**D.J. Schneider, J.M. Speth, L.R.K. Penke, M. Peters-Golden, Ann Arbor, MI, p.A5749

P1479 **Deletion of αENaC in Alveolar Type I Cells Demonstrates the Integral Role of Type I Cells in Maintaining Lung Fluid Balance/**M. Johnson, S. Balan, A.M. Gillespie, L. Dobbs, San Francisco, CA, p.A5750

Facilitator: G.M. Mutlu, MD, Chicago, IL

P1480 **AKB-9785, a VE-PTP Inhibitor, Decreases Inflammation and Alters the Angiopoietin/Tie2 System Dynamic Response in a S. Aureus Sepsis Model/**R.R. Bartz, T. McCord, H. Suliman, T. Orr, C.A. Piantadosi, C. Kontos, Durham, NC, p.A5751

P1481 **Differential Pulmonary Gene and Protein Expression in Wild Type, Cyp1a1-Null and Cyp1a2-Null Mice in Acute Hyperoxic Lung Injury: Role of Cytochrome P450 (CYP)1A/**K. Lingappan, S. Maity, W. Jiang, L. Wang, X. Couroucli, C. Coarfa, B. Moorthy, Houston, TX, p.A5752

P1482 **Peptide-Based Activation of GPR116 on Alveolar Epithelial Cells Induces G Protein-Coupled Responses and Modulates Alveolar Surfactant Pool Sizes In Vivo/**J. Bridges, A. Filuta, K. Brown, K. Arora, A. Naren, M.-G. Ludwig, K. Seuwen, J. Jaros, W. Miller, Cincinnati, OH, p.A5753

P1483 **KLF2 Enhances Barrier Protection by Directly Regulating RapGEF3, a GEF Which Activates Rac1/**D.D.-W. Wu, R.-T. Huang, M. Jain, A.A. Birukova, J. Lloyd, K.G. Birukov, G.M. Mutlu, Y. Fang, Chicago, IL, p.A5754

P1484 **G-CSF Promotes Alveolar Epithelial Repair Following Acute Lung Injury/**A.J. Paris, Y. Liu, N. Dai, J. Mei, K. Hudock, G.S. Worthen, Philadelphia, PA, p.A5755

Facilitator: E. Roan, PhD, Memphis, TN

P1485 **A Novel Cytoplasmic Domain in ENaC-Alpha Mediates Activation by the Lectin-Like Domain of TNF/**I. Czikora, Q. Yue, A. Alli, B.J. Duke, T.L. Thai, R. Lemmens-Gruber, B. Fischer, T. Chakraborty, W. Shabbir, D.C. Eaton, R. Lucas, Augusta, GA, p.A5756

P1486 **LPS Relocates Nuclear Resided Fbxo24 into Cytoplasmic Compartment to Augment Histone Acetyltransferase GCN5L2 Medicated Transcriptional Activity in Lung Epithelial Cells/**J. Li, Q. Wu, C. Zou, Pittsburgh, PA, p.A5757

P1487 **Examining the Collapse-Mechanism of the Pulmonary Surfactant/**M.R. Al-Saiedy, S.L. Nelson, A. Tarokh, F.H.Y. Green, M.W. Amrein, Calgary, Canada, p.A5758

P1488 **The EMT Process Occurs in Early Pulmonary Fibroproliferation of LPS-Induced ARDS in Rats/**P. Wang, M. Yu, M. Wang, B. Zhong, J. Li, X. Zhong, P. Zhao, Q. Zhang, J. Yuan, G. Jiao, Chengdu City, China, p.A5759

P1489 **Myosin Phosphatase Protects Against LPS-Induced Pulmonary Endothelial Barrier Dysfunction/**A. Kasa, B.A. Ghorshkov, K.-M. Kim, S. Kumar, S.M. Black, D. Fulton, C. Dimitopolou, J.D. Catravas, A.D. Verin, Augusta, GA, p.A5760

Facilitator: I. Vadasz, MD, Giessen, Germany

P1490 **TGF-β Promotes Ubiquitination, Endocytosis and Degradation of the Protein Transporter Megalin in Alveolar Epithelial Cells/**L.C. Mazzocchi, C. Vohwinkel, W. Seeger, I. Vadasz, Giessen, Germany, p.A5761

P1491 **Destabilization of Lysophosphatidic Acid Receptor 1 Reduces Cytokine Release and Protects Against Lung Injury/**J. Zhao, J. Wei, D. Su, R.K. Bowser, L. Zhang, A.M. Jacko, Y. Zhao, Pittsburgh, PA, p.A5762

P1492 **The O-Glycosylated Ectodomain of FXYD5 Impairs Alveolar Epithelial Integrity by Inhibiting the Intercellular Trans-Dimerization of the Na,K-ATPase/**L.A. Dada, E. Tokhtaeva, P.N. Soni, K.M. Ridge, G. Sachs, J.I. Sznajder, O. Vagin, Chicago, IL, p.A5763

P1493 **Tumor Necrosis Factor Alpha (TNF- α) Increases Strain Field Heterogeneity in Alveolar Epithelial Cells Leading to Monolayer Damage/**J.D. Herwig, C.M. Waters, E. Roan, Memphis, TN, p.A5764

P1494 **Hypercapnia Impairs Cell Junction Formation by Promoting Ubiquitination and Proteasomal Degradation of the Na,K-ATPase β-Subunit in Alveolar Epithelial Cells/**V. Kryvenko, N.M. Gabrielli, L.A. Dada, W. Seeger, J.I. Sznajder, I. Vadasz, Giessen, Germany, p.A5765

Facilitator: D.W. Kamp, MD, Chicago, IL

P1495 **The Effect of PGC-1α on Acute Lung Injury/**J. Wang, Y. Jiao, Chongqing City, China, p.A5766

P1496 **AMP-Activated Protein Kinase and Extracellular Signal-Regulated Kinase 1/2 Mediate Hypercapnia-Induced Polyubiquitination and Endocytosis of ENaC in the Alveolar Epithelium/**P. Gwozdzinska, B.A. Buchbinder, W. Seeger, I. Vadasz, Giessen, Germany, p.A5767

P1497 **Exploring the Distinct Role of the Secreted Form of Nampt for the Regulation of Pro-Survival Mechanisms in Endothelial Cells in the Context of Acute Lung Injury/**R.C. Oita, W. Ma, S. Chiang, T. Wang, S.M. Black, J. Yuan, J.G.N. Garcia, Tucson, AZ, p.A5768

P1498 **GSK3β Stability Is Regulated by Its Activation State and Influences Inflammation in Lung Epithelial Cells/**T. Suber, J. Cai, J. Zhao, Y. Zhao, R. Mallampalli, Pittsburgh, PA, p.A5769

P1499 **The Mitochondrial Calcium Uniporter Is a Therapeutic Target in Acute Lung Injury/**M.N. Islam, G.A. Gusarova, S. Das, J. Bhattacharya, New York, NY, p.A5770

Facilitator: I. Rahman, PhD, Rochester, NY

P1500 **Mitochondrial OXPHOS (Complex III) Is an Important Regulator of Fibroblast Differentiation: Implications in Bioenergetics and Cellular Senescence/**W. Lei, C.A. Lerner, I. Sundar, H. Yao, I. Rahman, Rochester, NY, NY, p.A5771

P1501 **An Antidotal Therapy for Carbon Monoxide Poisoning Improves Survival by Reversing Hemodynamic Collapse and Mitochondrial Dysfunction/**J.J. Rose, L. Wang, Q. Xu, D. Osei-Hwedieh, E.N. Schwoegl, Q. Nguyen, C. Corey, X.Y.N. Huang, C.F. McTiernan, J. Tejero, C.P. O'Donnell, S. Shiva, M.T. Gladwin, Pittsburgh, PA, p.A5772

P1502 **PBMCs from Patients with Limited Systemic Sclerosis Demonstrate Altered Mitochondrial Dynamics/**S. Lenna, G.A. Farina, H.W. Farber, R. Lafyatis, M. Trojanowska, Boston, MA, p.A5773

P1503 **Specificity of Metabolic Stress in the Regulation of Mitochondria Dysfunction Induced mtDNA Release in Lung Epithelial Cells/**J.-S. Moon, M.J. Koo, S.W. Ryter, K. Nakahira, A.M.K. Choi, New York, NY, p.A5774

P1504 **Small Molecule Inhibition of the E3 Ligase Subunit Fbxo7 Prevents Mitochondrial Damage/**Y. Liu, T. Lear, B.B. Chen, R. Mallampalli, Pittsburgh, PA, p.A5775

Facilitator: H. Kubo, MD, PhD, Tokyo, Japan

P1505 **Autophagy Deficient Mesenchymal Stromal Cells Are More Susceptible to Oxidative Injury as a Result of Mitochondrial Dysfunction/**S. Ghanta, K. Tsoyi, C.A. Piantadosi, A.M.K. Choi, M.A. Perrella, Boston, MA, p.A5776

P1506 **Remembering the Ancestral Language: Mammalian Mitochondria Directly Recognize and Respond to Bacterial Quorum Signals/**J.L. Kuck, O. Dougherty, C. Moore, T. Luong, L. Letterman, S. Orfield, J.P. Fessel, E. Brittain, Q.S. Wells, Nashville, TN, p.A5777

P1507 **Macrophage Akt1-Mediated Mitochondrial Biogenesis Regulates Pulmonary Fibrosis/**J. Casey, A.B. Carter, Birmingham, AL, p.A5778

P1508 **Mitochondrial Catalase Enforced Expression (MCAT-EE) Transgenic Mice Are Protected Against Asbestos- and Bleomycin-Induced Lung Fibrosis in Part Via Beneficial Effects on AECs/**P. Cheresh, S.-J. Kim, R.P. Jablonski, A. Yeldandi, L. Morales Nebreda, Y. Cheng, M. Chi, R. Piseaux, K.M. Ridge, C.M. Hart, N. Chandel, G.S. Budinger, D. Kamp, Chicago, IL, p.A5779

P1509 **Mitochondrial ROS Induce Up-Regulation of SIRT1 in LPS-Induced Acute Lung Injury/**Y.C. Lee, S.R. Kim, H.J. Kim, S.H. Kim, S.Y. Park, Jeonju, Korea, Republic of, p.A5780

Facilitator: R. Lucas, PhD, Augusta, GA

P1510 **Bronchial Epithelial Calcium Metabolism Impairment in Smokers: Decreased ORAI3 Signaling Involved in Cilia Beating/**A. Fort, L. Knabe, K. Khelloufi, D. Gras, N. Molinari, S. Richard, P. Chanez, I. Vachier, A. Bourdin, Montpellier, France, p.A5781

P1511 **ASIC1a/αEnac Hybrid Channels Contribute to Alveolar Fluid Clearance/**D.C. Eaton, P. Trac, O. Al-Khalili, M. Greenlee, Atlanta, GA, p.A5782

P1512 **AMP-Activated Protein Kinase Deactivation and Lung Injury in C57BL/6 Mice Fed Chronic-Binge Ethanol/**L. Kaphalia, B.S. Kaphalia, W.J. Calhoun, Galveston, TX, p.A5783

P1513 **Resolution of Acute Lung Injury Induced by Whole Gastric Juice in the Hamster/**G.R. Borzone, J. Araos, M. Meneses, P. Ayala, Santiago, Chile, p.A5784

P1514 **Follistatin Like-1 Aggravates Radiation-Induced Lung Injury/**Y. Fang, L. Wang, Z. Chen, W. Ning, Tianjin, China, p.A5785

Facilitator: S.P. Reddy, PhD, Chicago, IL

P1515 **Overexpression of IL-38 Protein in the Lungs of Drug Induced Lung Injury/**M. Tominaga, M. Okamoto, T. Kawayama, S. Kaieda, M. Matsuoka, Y. Sakazaki, T. Kinoshita, T. Hoshino, Kurume, Japan, p.A5786

P1516 **Acid Sphingomyelinase Is a Novel Regulator of LYNUS and Autophagy/**M. Justice, C. Poirier, K. Schweitzer, J. Saliba, I. Petrache, Denver, CO, p.A5787

P1517 **Low Phosphate Diet Arrests and Reverses Stone Accumulation and Acute Lung Injury in Mice with Pulmonary Alveolar Microlithiasis/**Y. Uehara, N.M. Nikolaidis, A. Saito, L. Pitstick, H. Wu, H. Amlal, K. LaSance, J.C. Woods, J. Guo, F.X. McCormack, Cincinnati, OH, p.A5788

P1518 **Characterize the Lung Extracellular Vesicles in the Presence of Oxidative Stress/**H. Lee, D. Zhang, H.-G. Moon, J.H. Hwang, Y. Jin, Boston, MA, p.A5789

P1519 **Ischemic Lung Injury Following Cardio-Pulmonary Bypass (CPB) Is Associated with Inflammation and Differentiation/**A.L. Durham, E. Al Jaaly, F. Fiorentino, P. Brook, K. Heesom, P. Lavender, G. Angelini, I. Adcock, London, United Kingdom, p.A5790

THEMATIC POSTER SESSION

C68 IMMUNE CELL INTERACTIONS IN COPD

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area L, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

P1284 **Recombinant Human Granulocyte Colony-Stimulating Factor Versus Bone Marrow Mononuclear Cells in Treatment of Pulmonary Emphysema Model/**M.K. El Badrawy, N. Shalabi, M.A. Mohamed, A. Ragab, N. Anber, H.W. Abdelwahab, M.A. Sobh, Y. Khater, A. Abdel Hamid, Mansoura, Egypt, p.A5791

P1285 **GM-CSF Drives Human Lung Tissue Macrophages Towards a More Pro-Inflammatory Phenotype/**J. Tilman, P.J. Barnes, L. Donnelly, London, United Kingdom, p.A5792

P1286 **Differential Effects of Budesonide and Fluticasone Propionate in Human Bronchial Epithelial Cells Exposed to Streptococcus Pneumonia and Viral Mimetic Poly-(I:C)/**I.H. Heijink, M.R. Jonker, D.S. Postma, M. Van Den Berge, Groningen, Netherlands, p.A5793

P1287 **Biology of the Circulating CD45+Col1+ Cells During the Pathogenesis of Pulmonary Emphysema/**Y.M. Shim, M. Burdick, K. Qing, T.A. Altes, J.P. Mugler, B. Mehrad, C.E. Rose, Jr., Charlottesville, VA, p.A5794

P1288 **The Decrease of TRPV2 Expression in Alveolar Macrophage by Cigarette Smoke Exposure Raises Chronic Inflammation in Lung/**H. Masubuchi, M. Ueno, T. Maeno, K. Hara, K. Yamaguchi, T. Suga, M. Kurabayashi, Maebashishi, Japan, p.A5795

P1289 **Aberrant Airway Epithelial Differentiation Resulting from Cigarette Smoke Exposure Leads to Loss of Constitutive Host Defence Protein Expression/**A.M. Van Der Does, G. Amatngalim, F. Dishchekenian, T.C.J. Mertens, D.K. Ninaber, A. Van Der Linden, C. Taube, P.S. Hiemstra, Leiden, Netherlands, p.A5796

P1290 **Smoking Increases Bacterial Growth and Biofilm Formation/**L.G. Vargas Buonfiglio, J.A. Borcherding, R. Fernandez-Ruiz, M. Cano, L. Powers, A.K. Gerke, A.P. Comellas, Iowa City, IA, p.A5797

P1291 **Water Pipe Condense (WPC) Regulates the Expression of TLRs on Human Macrophages Via Reactive Oxygen Species/**E. Mortaz, G.F. Folkerts, J. Garssen, A.K. Kiani, H.R. Jamaati, M. El-Sabbana, A.A. Velayati, I.M. Adcock, Tehran, Iran, p.A5798

P1292 **Neutrophil Death in a Population of Patients with Neutrophilic COPD/**J.L. Cane, K. Hambleton, C. Borg, C. Connolly, T. Powell, L. Xue, I. Pavord, M. Bafadhel, Oxford, United Kingdom, p.A5799

P1293 **Effect of Inhaled Anticholinergics on Pathogenicity of Pseudomonas Aeruginosa and Staphylococcus Aureus/**A. Vyas, J. Joshua, L.E. Crotty Alexander, San Diego, CA, p.A5800

P1294 **Effects of the Novel Pharmacological Compound Sul-121 on LPS-Induced Airway Neutrophilia/**B. Han, W.J. Poppinga, H. Zuo, P. Vogelaar, K. Van Der Graaf, A.J. Halayko, H. Meurs, M. Schmidt, Groningen, Netherlands, p.A5801

P1295 **Alpha-1 Antitrypsin Decreases Pro-Inflammatory Monocyte-Endothelial Cells Interactions Via Fractalkine Axis/**A.M. Mikosz, R.K. Maasa, S. Winfree, M. Justice, K. Dunn, I. Petrache, K.A. Serban, Denver, CO, p.A5802

P1296 **Differences in COPD Blood Monocyte Populations Do Not Affect Maturation to Mature Tissue Macrophage by Ex-Vivo GMCSF/**V. Kraskovsky, M. Smith, S. Sethi, K.A. Provost, Buffalo, NY, p.A5803

P1297 **Increased Neutrophil Gelatinase-Associated Lipocalin (NGAL) Promotes Airway Remodeling in COPD/**X. Yao, Y. Wang, I. Adcock, P.J. Barnes, Nanjing, China, p.A5804

P1298 **Involvement of IL-17A in Development of Airway Fibrosis in Mice/**H. Yanagisawa, M. Hashimoto, S. Minagawa, J. Araya, A. Bondesson, A. Budelsky, S. Nishimura, Tokyo, Japan, p.A5805

P1299 **Characterization of Pulmonary Immunophenotype in Patients with COPD/**N.M. Mark, J.K. Kargl, S. Pipavath, A.M. Houghton, Seattle, WA, p.A5806

P1300 **Langerhans Cells Are Highly and Widely Distributed in Respiratory Bronchiolitis with Smoking-Related Changes of the Lungs in Smokers/**A. Masunaga, T. Takemura, E. Yamaguchi, Y. Horio, S. Saeki, T. Mori, M. Suzuki, H. Kohrogi, Kumamoto City, Japan, p.A5807

THEMATIC POSTER SESSION

C69 HERE'S LOOKING AT YOU: IMAGING STUDIES IN COPD

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area L, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

P1302 **Computational Fluid Dynamics Simulation of Airflow and Gaseous Diffusion in Emphysematous Lung Parenchyma/**A. Dutta, D.M. Vasilescu, J.C. Hogg, A.B. Phillion, J. Brinkerhoff, Kelowna, Canada, p.A5808

P1303 **A MiroCT Based Quantitative Assessment of Preterminal Bronchioles in COPD/**N. Tanabe, D.M. Vasilescu, J.E. McDonough, D. Kinose, M. Suzuki, J.D. Cooper, J.C. Hogg, Vancouver, Canada, p.A5809

P1304 **Dose Modulation in an Anthropomorphic Chest Phantom and Its Relative Effects on Regional CT Densitometry Using QCT Analysis/**J.A. Schirm, E. Stanton, C. Ibsen, J. Tschirren, J.D. Newell, E.A. Hoffman, K.-S. Chan, J.P. Sieren, Coralville, IA, p.A5810

P1305 **In-Silico Assessment of Airway Deposition Using Functional Respiratory Imaging for Mono, Dual and Triple Combination Co-Suspension Metered Dose Inhaler Formulations/**W. Vos, J. De Backer, J. Schroeder, M. Sommerville, S.K. Dwivedi, W. De Backer, Kontich, Belgium, p.A5811

P1306 **Krypton and Xenon Gas Imaging Using Third Generation Dual Energy CT (DECT) Scan Technologies and an Anthropomorphic Test Object/**J.D. Newell, Jr, J. Guo, K.-S. Chan, M. Fuld, J.C. Sieren, W. Kearney, E.A. Hoffman, Iowa City, IA, p.A5812

P1307 **Third Generation Dual Source CT Scanner and Iterative Reconstruction Software Enables Improved Spatial Resolution of Airway Geometry using a 1024 x 1024 CT Reconstruction Matrix/**J.D. Newell, Jr, J. Guo, K.-S. Chan, M.K. Fuld, P.K. Saha, D. Jin, E.A. Hoffman, Iowa City, IA, p.A5813

P1308 **Parenchymal Airspace Profiling Provides an Unbiased Categorization of Parenchymal Compartments and Accurate Quantification of Parenchymal Destruction/**R. Xiao, T. Shiomi, M. Goldklang, J. D'Armiento, New York, NY, p.A5814

P1309 **Investigating the Nature of Small Airways Disease in Mild/Moderate COPD: Micro-CT Analysis of Paraffin Embedded Lung Tissue/**H.-K. Koo, D.M. Vasilescu, S. Booth, A.E. Scott, O. Katsamenis, J. Warner, I. Sinclair, J.C. Hogg, T.-L. Hackett, Vancouver, Canada, p.A5815

P1310 **A Multi-Variable Assessment of Factors Effecting Dual Energy Computed Tomography Assessment of Pulmonary Perfused Blood Volume-Associated Metrics/**T.M. Dougherty, M.K. Han, J.D. Newell, Jr, E. Kazerooni, M. Shirk, N.N. Hansel, R.G. Barr, E.A. Hoffman, Iowa City, IA, p.A5816

P1311 **Fissure Integrity and Rate of Emphysema Progression: SubPopulations and InteRmediate Outcome Measures In COPD Study (SPIROMICS)/**T.M. Dougherty, J.D. Newell, Jr, Y. Yin, J.A. Schirm, J.P. Sieren, R.G. Barr, E. Bleecker, R.P. Bowler, A.P. Comellas, C.B. Cooper, G.J. Criner, M.T. Dransfield, N.N. Hansel, M.K. Han, R. Kanner, S.C. Lazarus, F.J. Martinez, P.G. Woodruff, K.-S. Chan, E.A, Hoffman, Iowa City, IA p.A5817

P1312 **Relative Contributions of Quantitative CT Measures to Airflow Obstruction in Cigarette Smokers/**J.P. Charbonnier, D.A. Lynch, S.M. Humphries, M. Strand, E.M. Van Rikxoort, Nijmegen, Netherlands, p.A5818

P1313 **Progression of CT Quantified Lung Density in the COPDGene Study and Its Relationship to Spirometry/**E.M. Van Rikxoort, M. Strand, S.M. Humphries, D.A. Lynch, Nijmegen, Netherlands, p.A5819

P1314 **In Vivo Imaging of Polymers in α1-Antitrypsin Deficiency/**I. Haq, D.A. Lomas, London, United Kingdom, p.A5820

P1315 **Exploration of Vascular Role in COPD Etiology: Standardization and Validation of Regional Pulmonary Arterial Cross Sectional Area Measures from CT/**D. Jin, T.M. Dougherty, J. Guo, E.A. Hoffman, J.D. Newell, Jr, P.K. Saha, Iowa City, IA, p.A5821

P1316 **In Vivo Imaging of Pathogenic Processes in a Rabbit Model of Emphysema/**M.P. Goldklang, Y. Tekabe, T. Zelonina, J. Trischler, R. Xiao, K. Stearns, A. Romanov, T. Shiomi, L. Johnson, J. D'Armiento, New York, NY, p.A5822

THEMATIC POSTER SESSION

C70 THE NEXT NEW THERAPEUTIC TARGET? TRANSLATIONAL STUDIES OF COPD THERAPIES

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area L, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

P1318 **Acute and Chronic LPS Exposure Models of COPD and Differential Sensitivity to Inhaled and Systemic Corticosteroids/**K.J. Broadley, W.R. Ford, E. Hardaker, D.L. Turner, E.J. Kidd, C.M. Davies, Cardiff, United Kingdom, p.A5823

P1319 **Clinical and Pathologic Evidence of Chronic Bronchitis in a Novel Ferret Model of COPD Exhibiting Acquired CFTR Dysfunction/**S.V. Raju, J.E. Trombley, S. Byzek, L. Tang, V.Y. Lin, T. Schoeb, S. Rowe, Birmingham, AL, p.A5824

P1320 **Compartment-Specific and Time-Dependent Analysis of Mice with Smoke-Induced Pulmonary Hypertension and Emphysema/**M. Bednorz, J. Wilhelm, R.T. Schermuly, H.A. Ghofrani, W. Seeger, N. Weissmann, M. Seimetz, Giessen, Germany, p.A5825

P1321 **The Combined Use of Chronic Waterpipe Smoke Exposure and Sugen 5416 as a Novel Model of Chronic Obstructive Pulmonary Disease/**A.A. Alzoubi, R. Ghazwi, M. Alqudah, M.B. Abdallah, K. Al-Zoubi, K. Abe, Irbid, Jordan, p.A5826

P1322 **Cigarette Smoke Exposure Combined to LPS Instillation: A New Experimental Model of Exacerbation in Chronic Obstructive Pulmonary Disease in Mice/**D.A.B. Cervilha, J.T. Ito, J.D. Lourenco, C.R. Olivo, D.S. Sales, B.M. Saraiva, M.C. Oliveira - Junior, M.A. Martins, R.P. Vieira, F.D.T.Q.S. Lopes, Sao Paulo, Brazil, p.A5827

P1323 **Characterization of a Mouse Model of Emphysema Induced by Multiple Doses of Elastase/**M.D.O. Vasconcellos, G.D.A. Padilha, N.N. Rocha, L.A. Maia, C.M. Takiya, D.G. Xisto, S.C. Abreu, P.L. Silva, P.R.M. Rocco, Rio de Janeiro, Brazil, p.A5828

P1324 **Ununiformed Decrease in Bone Mass During the Development of Emphysema in Rats/**K. Tomoda, K. Kubo, Y. Yamamoto, N. Koyama, M. Yoshikawa, H. Kimura, Kashihara, Japan, p.A5829

P1325 **Chronic Bronchitis Enhancement in Newborn Mice from Exposure to Environmental Tobacco Smoke/**J. Jia, T.M. Conlon, C. Ballester Lopez, O. Eickelberg, M.A. Mall, A.O. Yildirim, Munich, Germany, p.A5830

P1326 **The Effect of an IκB-Kinase-β(IKKβ) Inhibitor on Tobacco Smoke-Induced Pulmonary Inflammation/**S.I. Choi, S.Y. Lee, W.J. Jung, S.H. Lee, E.J. Lee, K.H. Min, G.Y. Hur, J.H. Kim, C. Shin, J.J. Shim, K.H. In, K.H. Kang, M.-G. Lee, Seoul, Korea, Republic of, p.A5831

P1327 **3-Deazaneplanocin A-an Inhibitor of Histone Methyltransferase Ezh2-Exacerbates Elastase-Induced Emphysema in Mice/**T. Asakura, M. Ishii, H. Namkoong, K. Yagi, S. Suzuki, T. Tanosaki, S. Kagawa, T. Kamo, S. Tasaka, N. Hasegawa, T. Betsuyaku, Tokyo, Japan, p.A5832

P1328 **Inhibition of Neutrophil Serine Protease Activation with the Reversible DPP1 Inhibitor AZD7986/**J. Root, J. Bernstrom, S. Clifton, G. Dahl, K. Doyle, P. Gardiner, P. Johannesson, H. Kack, J. Shearer, C. Wikell, K. Stenvall, Gothenburg, Sweden, p.A5833

P1329 **Combination of Theophylline with Long-Acting Beta-2 Adrenergic Receptor Agonist Inhibits Cigarette Smoke Induced Airway Inflammation/**Y.H. Hsiao, C.M. Tseng, Y.C. Wu, Y.R. Kou, D.W. Perng, Taipei, Taiwan, p.A5834

P1330 **Synergistic Effects Between Olodaterol and Tiotropium on Methacholine-Induced Contraction in Guinea Pig Airway Smooth Muscle/**H. Kume, T. Isoya, Y. Tohda, Osakasayama, Japan, p.A5835

P1331 **The Role of Bevacizumab in Vascular Airway Remodelling in a Rat Model of Chronic Obstructive Pulmonary Disease/**F. Chen, X.Z. Bo, W. Lu, C. Bin, Hang Zhou, Zhejiang Province, China, p.A5836

P1332 **SIK Inhibition: A Novel Opportunity to Modulate Disease Phenotype in COPD/**M. Goransson, A. Schinwald, L. Stjernborg, K. Madeyski-Bengtson, L. Jarl, K. Karabelas, Molndal, Sweden, p.A5837

P1333 **Pirfenidone Improves Mucociliary Clearance In Smoking-Associated Airway Epithelial Injury/**J. Sailland, N. Baumlin, S. Dennis, S. Krick, M. Salathe, A. Schmid, Miami, FL, p.A5838

P1334 **Drug Delivery from a Novel LAMA/LABA Co-Suspension Technology of Glycopyrrolate/Formoterol Fixed-Dose Combination MDI: Evidence of Consistency, Robustness and Patient-Use Reliability/**P. Mack, A. Doty, J. Schroeder, K. Vang, S.K. Dwivedi, Durham, NC, p.A5839

P1335 **The β2-Agonist Indacaterol and the Anticholinergic Glycopyrrolate Reduce the Constriction of Large and Small Intrapulmonary Airways Using a Guinea Pig Model of COPD/**M. Schmidt, A. Oldenburger, A. Zuidhof, C. Elzinga, H. Meurs, H. Maarsingh, M. Schmidt, Groningen, Netherlands, p.A5840

P1336 **Inhaled Ipratropium Gives Enhanced Muscarinic Occupancy in the Lung Compared to Intravenous Administration- a Positron Emission Tomography (PET) Study in Non-Human Primates/**P.A. Ewing, Z. Cselenyi, M. Friden, P. Johnstrom, A. Jucaite, L. Farde, M. Schou, Molndal, Sweden, p.A5841

P1337 **Effects of Soluble Guanylate Cyclase (sGC) Stimulation on Extrapulmonary Oxidative Stress in Guinea Pigs Chronically Exposed to Cigarette Smoke/**T. Paul, A. Salazar, V.I. Peinado, M. Cortes, E. Ferrer, E. Puig, O. Tura, I. Blanco, E. Barreiro, J.A. Barbera, Barcelona, Spain, p.A5842

P1338 **Delivery of Inhaled Medication Is Maintained by a Breath-Actuated Nebulizer when Used by Patients with Differing Inhalation/Exhalation Ratios: A Laboratory Study Using Albuterol Sulfate Solution for Nebulization/**J. Suggett, M. Nagel, V. Avvakoumova, V. Wang, D. Coppolo, J.P. Mitchell, London, Canada, p.A5843

P1339 **Erythropoietin Receptor (EPOR)/β-Common Receptor (β-CR) Signalling: A Potential Therapeutic Role in Lung Disease/**K. Rochfort, S. Whelan, E. Coleman, K. Howell, Dublin, Ireland, p.A5844

P1340 **Interleukin-6 Trans-Signaling as a Therapeutic Target in Emphysema/**B. Jenkins, S. Ruwanpura, L. McLeod, A. Lilja, L. Dousha, S. Bozinovski, P. King, P.G. Bardin, R. Vlahos, G. Anderson, S. Rose-John, Clayton, Australia, p.A5845

P1341 **ARA-290, an Erythropoietin Mimetic, Prevents the Development of Emphysema in the Adult Mouse Lung/**S. Whelan, K. Rochfort, E. Coleman, P. McLoughlin, K. Howell, Dublin, Ireland, p.A5846

P1342 **Small-Molecule CFTR Modulators in Pre-Clinical Development for the Treatment of Chronic Obstructive Pulmonary Disease/**L. Drew, J.P. Miller, O. Green, A. Villella, D. Kanmert, B. McEwan, C. Bastos, K. Longo, M. Ivarsson, B. Munoz, P.-S. Lee, H. Mehmet, M. Haeberlein, Cambridge, MA, p.A5847

P1343 **Association of Increased Autophagy in COPD and Dysregulation of Zinc Handling Systems/**E. Roscioli, H. Bac-Tran, R. Hamon, P. Zalewski, S.J. Hodge, Adelaide, Australia, p.A5848

THEMATIC POSTER SESSION

C71 YOU ARE WHAT YOU BREATHE: AIRWAY CELL BIOLOGY IN COPD

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area L, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

P1345 **Cellular Localization of Drug Transporter Protein in Human COPD Lung/**X. Zhou, T. Berg, T. Hegelund-Myrback, M. Nord, L. Gustavsson, Molndal, Sweden, p.A5849

P1346 **Decreased Nuclear Factor Erythroid 2-Related Factor 2 Expression Enhances Apoptosis of Airway Epithelial Cells in Patients with Chronic Obstructive Pulmonary Disease/**K. Yamada, K. Asai, Y. Kubo, Y. Kyomoto, T. Kawamoto, S. Yoshida, K. Sato, N. Yamamoto, N. Yoshii, T. Watanabe, M. Uji, K. Hirata, Osaka, Japan, p.A5850

P1347 **Extracellular ATP Involves in dsRNA-Induced MUC5AC Production Via P2Y2R in Human Airway Epithelium/** Y. Shishikura, A. Koarai, H. Sugiura, H. Aizawa, Y. Hashimoto, T. Numakura, M. Yamada, M. Ichinose, Sendai, Japan, p.A5851

P1348 **Role of Acrolein in Cigarette Smoke-Induced Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Dysfunction/**V.Y. Lin, S.V. Raju, L. Tang, L. Wilson, M. Mazur, K.J. Macon, J.E. Trombley, P.L. Jackson, J.C. Kappes, L.J. DeLucas, S. Barnes, J.E. Blalock, S. Rowe, Birmingham, AL, p.A5852

P1349 **Hydrogen Sulfide Attenuates Bronchial Epithelial Cell Apoptosis by Inhibiting Endoplasmic Reticulum Stress/** Y. Chen, F. Lin, C. Liao, Y. Sun, Y. Bai, Y. Liao, M. Li, Y. Qi, Beijing, China, p.A5853

P1350 **Expression and Function of MTUS1 in a Cell Model of Cigarette Smoke Extract Induced Chronic Obstructive Pulmonary Disease/**X. Gong, J. Zhou, Y. Song, C. Bai, Shanghai, China, p.A5854

P1351 **Role of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 (CEACAM1) in Acute Exacerbation of Chronic Obstructive Pulmonary Disease and the Potential Mechanism/**Y. Zhu, C. Bai, Y. Song, X. Wang, Shanghai, China, p.A5855

P1352 **Localization and Expression of Fam13a and Ireb2 in Mouse Lung Tissue/**M. Sato, S. Inoue, A. Igarashi, Y. Tokairin, T. Nemoto, K. Sato, M. Kobayashi, Y. Abe, I. Kubota, Y. Shibata, Yamagata, Japan, p.A5856

P1353 **Quantification and Characterization of Human Lung Mesenchymal Stem Cells/**T. Cruz, A. Lopez-Giraldo, A. Agusti, R. Faner, Barcelona, Spain, p.A5857

P1354 **Intercellular Adhesion Molecule 1 (ICAM-1) Expression Is Upregulated in Smokers and Patients with Chronic Airflow Limitation (CAL)/**S.D. Shukla, H.K. Muller, R. Latham, S.S. Sohal, H. Walters, Hobart, Australia, p.A5858

P1355 **Induced-Pluripotent Stem Cell-Derived Mesenchymal Stem Cells Attenuate Cigarette Smoke-Induced Mitochondrial Dysfunction And Apoptosis in Airway Smooth Muscle Cells/**X. Li, C. Michaeloudes, Y. Zhang, Q. Lian, J.C.W. Mak, P.K. Bhavsar, K.F. Chung, Hong Kong, Hong Kong Prc, p.A5859

P1356 **In Search of Ckit+ Stem Cells in Lung Tissue/**A. Lopez-Giraldo, T. Cruz, A. Agusti, R. Faner, Barcelona, Spain, p.A5860

P1357 **Effects of Vilanterol and Umeclidinium Alone and in Combination in Human Airway Smooth Muscle Cells/**N. Shaikh, M. Johnson, J. Riley, K.F. Chung, P.K. Bhavsar, London, United Kingdom, p.A5861

P1358 **Flavored E-liquids Alter Cell Proliferation and Calcium Signaling/**T.R. Rowell, S. Sizer, R. Tarran, Chapel Hill, NC, p.A5862

P1359 **HMGA1 Permits Human Airway Basal Stem/Progenitor Cells to Regenerate the Normal Airway Epithelium/**H. Zhang, J. Yang, M.S. Walters, R.G. Crystal, New York, NY, p.A5863

P1360 **The COPD Progression Is Mediated by Up-Regulated RAGE and Nuclear Translocation of Nrf2 Signaling/**H. Lee, J.-R. Park, S.-R. Yang, Korea, Republic of, p.A5864

P1361 **Little Cigars Exert More Severe Effects on Airway Epithelia than Cigarettes/**A. Ghosh, S.L. Reeber, C.M. Jania, A.J. Garrison, S.L. Lee, S.L. Tilley, C.M. Doerschuk, A.H. Herring, G.L. Glish, R. Tarran, Chapel Hill, NC, p.A5865

P1362 **Inhibition of Nephronectin Expression in Human Bronchial Epithelial Cells Using siRNA Knock-Down/**G. Qian, A. Henry, B. Liu, S. Miller, C.K. Billington, I.P. Hall, Nottingham, United Kingdom, p.A5866

P1363 **Generation of Functional Lung Organoids that Resemble the Human Small Airway Epithelia/**K. White, S. Raja, M. Dowling, K. Subramanian, Cambridge, MA, p.A5867

P1364 **p53- and PAI-1-Mediated Induction of C-X-C Chemokines and CXCR2: Importance in Pulmonary Inflammation Due to Cigarette Smoke Exposure/**N. Tiwari, A.S. Marudamuthu, B. Puthusseri, S. Idell, S. Shetty, Tyler, TX, p.A5868

P1365 **Acquired CFTR Dysfunction Is Associated with Bronchiectasis in Smokers and Former Smokers with Chronic Obstructive Pulmonary Disease/**K. Teerapuncharoen, J.M. Wells, S.V. Raju, L. Rasmussen, H. Nath, A.A. Diaz, R. San Jose Estepar, G. Washko, S.P. Bhatt, G.M. Solomon, M.T. Dransfield, S.M. Rowe, Birmingham, AL, p.A5869

P1366 **Monitoring Local Pulmonary cAMP Levels: Combining Precision Cut Lung Slice (PCLS) and Fluorescence Resonance Energy Transfer (FRET) Technologies in Mice/**H. Zuo, W.J. Poppinga, E. Zeisberg, V.O. Nikolaev, M. Schmidt, Groningen, Netherlands, p.A5870

P1367 **Effects of Two Doses of Bone Marrow-Derived Mesenchymal Stromal Cells in a Model of Elastase-Induced Severe Emphysema/**H.A. Poggio, N.N. Rocha, J.Z. Kitoko, M.M. Morales, P.C. Olsen, P.R.M. Rocco, M.A. Antunes, F.F. Cruz, Rio de Janeiro, Brazil, p.A5871

P1368 **Epac1 and Epac2 Regulate Airway Smooth Muscle Tone in Mice/**M. Schmidt, A. Oldenburger, C. Elzinga, H. Maarsingh, Groningen, Netherlands, p.A5872

P1369 **Impact of Tobacco Smoking on Extracellular IL-17A Protein in the Peripheral Airways/**B. Levanen, P. Glader, B. Dahlen, B. Billing, L. Palmberg, I. Qvarfordt, K. Larsson, A. Linden, Stockholm, Sweden, p.A5873

P1370 **Differential Induction of MUC5AC Mucin Gene Expression by Haemophilus spp. Isolated from Patients with COPD/**A. Tariq, C. Wrona, S. Sethi, Buffalo, NY, p.A5874

P1371 **Smoking-Induced Up-Regulation of KLF4 Modulates Partial Somatic Cell- Reprogramming-Like in the Human Airway Epithelium/**G. Wang, X. Ou, H. Zhou, J. Salit, Y. Strulovici-Barel, R.J. Kaner, R.G. Crystal, New York, NY, p.A5875

P1372 **Characterization of the Chloride/Bicarbonate Exchanger Pendrin (SLC26A4) in Airway Epithelia Implicates Pendrin as a Potential Mediator of Mucus Hypersecretion and Airway Surface Liquid Dehydration/**B. Bennett, X. Zhang, J. Whoriskey, M. Fiorino, J. Yu, D. Kaufman, K. Rohrbach, E. Valente, F.-F. Lin, G. Li, S. Matyas, S. Davis, J.A. Johnston, J.E. Phillips, Thousand Oaks, CA, p.A5876

P1373 **Mechanisms of Alveolar Type II Cell Injury in Emphysema/**K. Bahmed, E. Messier, R. Tuder, J. Mitchell, H.W. Chu, R.P. Bowler, R. Mason, B. Kosmider, Philadelphia, PA, p.A5877

P1374 **β-Catenin in COPD - a Role for Both Inhibitors and Activators/**K. Rydell-Tormanen, X.-H. Zhou, O. Hallgren, L. Eriksson, A. Andersson-Sjoland, G. Westergren-Thorsson, Lund, Sweden, p.A5878

P1375 **Oxidant-Induced Autophagy and Ferritin Degradation: A Novel Pathway through Lysosomal Iron to Epithelial-Mesenchymal Transition/**A. Sioutas, L. Vainikka, M. Kentson, S. Dam-Larsen, U. Wennerstrom, P. Jacobson, H.L. Persson, Linkoping, Sweden, p.A5879

P1376 **Altered Redox and Metabolic Status in Airway Smooth Muscle Cells of Patients with COPD/**C. Michaeloudes, C.-H. Kuo, I.M. Adcock, K.F. Chung, London, United Kingdom, p.A5880

THEMATIC POSTER SESSION

C72 EPITHELIAL BIOLOGY

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area H, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: L.A. Dada, PhD, Chicago, IL

P897 **Production of Inflammatory Mediators and Induction of Apoptosis in Pleural Mesothelial Cells, Lung and Breast Cancer Cells Exposed to Talc Particles/**M.M.P. Acencio, L.R. Teixeira, V.A. Alvarenga, C.S.R. Silva, R.K.B. Sales, E. Marchi, Sao Paulo, Brazil, p.A5881

P898 **Glycogen Synthase Kinase-3β Induces Mesenchymal Transition (MesoMT) of Human Pleural Mesothelial Cells/**T.A. Tucker, A. Jeffers, S. Owens, G. Shryock, J. Boren, K. Koenig, S. Idell, Tyler, TX, p.A5882

P899 **Regulatory Roles of cAMP in Epithelial-Mesenchymal Transition in Lung Epithelial Cells/**R. Kikuchi, T. Tsuji, H. Nakamura, K. Aoshiba, Ibaraki, Japan, p.A5883

P900 **Proprotein Convertase Paired Basic Amino Acid-Cleaving Enzyme 4 (PACE4) Is Involved in the Maturation of Integrin AlphaV in Human Nasal Epithelial Cells/**S.-N. Lee, J.-H. Yoon, Seoul, Korea, Republic of, p.A5884

P901 **Airway Smooth Muscle Conditioned Meida Protets Airway Epithelial Cells from Viral-Induced Glucocorticoid Insensitivity/**Y.C. Xia, S. Langenbach, C.R. Keenan, R.C. Gualano, A.G. Stewart, Parkville, Australia, p.A5885

P902 **Viral Infection Induces Airway Epithelial Glucocorticoid-Insensitivity/**Y.C. Xia, S. Langenbach, C.R. Keenan, A. Radwan, S. Londrigan, R.C. Gualano, A.G. Stewart, Parkville, Australia, p.A5886

Facilitator: S. Idell, MD, PhD, Tyler, TX

P903 **Towards Therapeutic Alveolar Regeneration - Characterization of a Novel Wnt-Responsive Subpopulation of Type II Pneumocyte which Exhibits Increased Progenitor Cell Function in the Adult Mammalian Lung/**W.J. Zacharias, D. Frank, J. Zepp, M. Morley, E.E. Morrisey, Philadelphia, PA, p.A5887

P904 **HOIL-1L-Induced PKCζ¶ Degradation Stabilizes Plasma Membrane Na,K-ATPase Levels to Prevent Lung Injury During Hypoxia/**N.D. Magnani, M.A. Queisser, L.A. Dada, L.C. Welch, A.V. Misharin, G.S. Budinger, J.I. Sznajder, Chicago, IL, p.A5888

P905 **Therapeutic Notch2 Neutralization Reverses an Established Goblet Cell Formation in an IL-13 Mouse Model of Mucus Hypersecretion/**J. Coote, H. Danahay, A. Pessotti, D. Xia, P. Capodieci, A. Doelemeyer, A. Jaffe, Cambridge, MA, p.A5889

P906 **TGF-β Induces Alveolar Epithelial Cell Apoptosis Through Activation of a FADD/Caspase 8 Pathway/**A.K. Wheaton, M. Velikoff, M. Agarwal, K.K. Kim, Ann Arbor, MI, p.A5890

P907 **Autophagy Is Required for Basal and ATP-Activated MUC5AC Secretion in Airway Epithelial Cells/**J.D. Dickinson, J.M. Sweeter, S.L. Brody, Omaha, NE, p.A5891

P908 **Autophagy Dependent Superoxide ROS Is Increased in Airway Epithelial Cells During Chronic IL-13 Stimulation/**J.D. Dickinson, J.M. Sweeter, M.C. Zimmerman, S.L. Brody, Omaha, NE, p.A5892

Facilitator: S.L. Brody, MD, St. Louis, MO

P909 **Cadherin-26 (CDH26) Is a Novel Apical Membrane Protein Important to Airway Epithelial Cell Polarity and Differentiation/**M.E. Lachowicz-Scroggins, E. Gordon, H. MacLeod, J.V. Fahy, San Francisco, CA, p.A5893

P910 **Effect of β-Glucan on MUC4 and MUC5B Expression in Human Airway Epithelial Cells/**Y.S. Choi, Y.-D. Kim, J.H. Ahn, C.H. Bae, S.-Y. Song, Daegu, Korea, Republic of, p.A5894

P911 **Immunolocalization of β-ENaC and NKCC1 Reveals Distinct Epithelial Cells with Either Absorptive or Secretory Phenotypesin Porcine Airways/**G. Flores-Delgado, P. Quinton, La Jolla, CA, p.A5895

P912 **Maresin-1 Regulates Epithelial to Mesenchymal Transition and Wound Healing Processes in Bronchial Epithelial Cells/**T.M. Nordgren, A.J. Heires, K.L. Bailey, D.J. Romberger, Omaha, p.A5896

P913 **Role of FOXC2 Gene in Differentiation of Alveolar Type1 Epithelial Cells/**M. Tsuji, M. Morishima, K. Shimizu, M. Kondo, T. Kume, J. Tamaoki, T. Ezaki, Tokyo, Japan, p.A5897

P914 **Effects of the Apical Krebs Solution on Ion Transport of Cultured Pig Tracheal Epithelia/**W. Xu, W.N.F. Li, J.-H. Chen, Hong Kong, Hong Kong Prc, p.A5898

Facilitator: U. Sajjan, PhD, Ann Arbor, MI

P915 **Investigating the Activity of a Rhinovirus Capsid-Binding Compound, AZ13694531, on Rhinovirus-C and Rhinovirus-A Replication in Differentiated Primary Airway Epithelial Cells: New Insights into Rhinovirus Species Coverage and Mechanism of Action/**C. McCrae, J. Horndahl, P. Hazon, R. Svard, P. Svanberg, D. Keeling, Molndal, Sweden, p.A5899

P916 **Effects of Mycoplasma Pneumoniae on Airway Epithelial Culture Morphology/**T. Krunkosky, O. Prince, D. Krause, Athens, GA, p.A5900

P917 **Artificial Butter Flavoring Exposure Causes an Extracellular Matrix Reorganizing Proteomic Signature in Primary Human Airway Epithelial Cells/**D.M. Brass, W.M. Gwinn, A. Valente, F.L. Kelly, C. Brinkley, A. Nagler, A. Moseley, D.L. Morgan, S.M. Palmer, M.W. Foster, Durham, NC, p.A5901

P918 **Nutrition Polarization Promote the Cilia Formation of Epithelial Cell/**L. Deng, Y. Jin, Y. Duan, Changzhou, China, p.A5902

P919 **Expression of Homeodomain-Only Protein (HOPX) in Normal Lung/**J.M. Liebler, C.N. Marconett, H. Wang, Y. Liu, P. Flodby, I.A. Laird-Offringa, P. Minoo, E.D. Crandall, Z. Borok, B. Zhou, Los Angeles, CA, p.A5903

THEMATIC POSTER SESSION

C73 OXIDANTS

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area H, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: R.E. Morty, MD, Giessen, Germany

P921 **Deficiency of Two-Pore-Domain Potassium (K2P) Channels Promotes Hyperoxia-Induced Lung Injury/**A. Schwingshackl, B. Teng, C. Luellen, C.M. Waters, Los Angeles, CA, p.A5904

P922 **Nitration Reversal and Functional Recovery is Oxygenation-Dependent in an Atelectasis Model of Oxidative Stress and Lung Injury/**R.S. Deeb, H. Peprah-Mensah, C. Cheung, D.P. Hajjar, S.S. Gross, P.M. Heerdt, Bridgeport, CT, p.A5905

P923 **The Role of EGFR Inhibition in Hyperoxia-Induced ARDS/**B.J. Clark, Y. Sun, B. D'Amico, P.J. Lee, J. Koff, New Haven, CT, p.A5906

P924 **Modification of CC10 Protein by Reactive Oxygen Species: A Novel Anti-Inflammatory Mechanism/**A.L. Pilon, M.E. Winn, R.S. Clayton, H. Hariprakasha, Rockville, MD, p.A5907

P925 **Refinement of a Hyperoxia-Based Mouse Model of Bronchopulmonary Dysplasia/**C. Nardiello, D.M. Silva, J. Ruiz Camp, I. Mizikova, W. Seeger, R.E. Morty, Bad Nauheim, Germany, p.A5908

P926 **Caveolar Scaffolding Domain Peptide Prevents Hyperoxia-Induced Remodeling in a Neonatal Murine Model/**E. Vogel, L.J. Manlove, I. Kuipers, M. Thompson, Y.-H. Fang, M.R. Freeman, R. Britt, A. Faksh, Y.S. Prakash, C. Pabelick, Rochester, MN, p.A5909

Facilitator: J. Sisson, MD, Omaha, NE

P927 **Gene Expression Profiling Identifies Cell Proliferation and Inflammation as the Predominant Pathways Regulated by Aryl hydrocarbon Receptor in Primary Human Fetal Lung Cells Exposed to Hyperoxia/**B. Shivanna, S. Zhang, A. Patel, S. Maity, J. Belmont, S. Welty, C. Coarfa, B. Moorthy, Houston, TX, p.A5910

P928 **Enhanced Resistance to Reactive Oxygen Species Driven Cell Death in IPF Fibroblasts Is Mediated by AMPK-Dependent Axis/**K. Kim, J. Im, R.S. Nho, St. Paul, MN, p.A5911

P929 **Alcohol Drives Airway Production of Reactive Oxygen Species (ROS) that Alter Cilia Function/**C.L. Gerald, J.A. Pavlik, J.M. DeVasure, M.C. Zimmerman, T.A. Wyatt, J.H. Sisson, Omaha, NE, p.A5912

P930 **Hyperoxia-Compromised Phagocytic Function in Macrophages Is Improved by Salicylates Via Inhibition of HMGB1 Release/**M. Wang, L.L. Mantell, Queens, NY, p.A5913

P931 **Reactive Oxygen Species Are Required for Metabolic Reprogramming in Endothelial Cells Following Loss of Laminar Shear Stress/**D.D.-W. Wu, R.-T. Huang, R.B. Hamanaka, L.J. Witt, A.Y. Meliton, Y. Fang, G.M. Mutlu, Chicago, IL, p.A5914

Facilitator: B. Moorthy, PhD, Houston, TX

P932 **The Effect of the Mitochondria-Targeted Antioxidant MitoQ on Hypoxic Pulmonary Vasoconstriction and Chronic Hypoxia-Induced Pulmonary Hypertension/**O. Pak, S. Scheibe, A. Esfandiary, M. Gierhardt, A. Sydykov, A. Fysikopoulos, F. Veit, F. Kroschel, R.T. Schermuly, H.A. Ghofrani, W. Seeger, M. Murphy, N. Weissmann, N. Sommer, Gießen, Germany, p.A5915

P933 **Diaphragm Abnormalities in Heart Failure Patients: Upregulation of NAD(P)H Oxidase Subunits and Heightened Protein Oxidation/**L.F. Ferreira, B. Ahn, A.W. Beharry, P.D. Coblentz, N. Patel, A.R. Judge, M.R. Bonnell, C.W. Hoopes, Gainesville, FL, p.A5916

P934 **Atrial Natriuretic Peptide Differentially Affects Surfactant Secretion by Human Alveolar Type II Cells According to O2 Concentration/**R.M. Ryan, M.K. Paintlia, D.A. Newton, J.E. Baatz, Charleston, SC, p.A5917

P935 **Lung Epithelial Specific Type II TGFβ Receptor Interacting Protein-1 (TRIP-1) Over-Expression Protects Mice Against Acute Hyperoxia Lung Injury/**M.F. Nyp, V. Sampath, S.M. Mabry, A. Navarro-Olmo, I.I. Ekekezie, Kansas City, MO, p.A5918

P936 **Analysis of Reactive Sulfur Species Production in Lungs of COPD/**T. Numakura, H. Sugiura, T. Ida, K. Sato, R. Tanaka, K. Onodera, Y. Hashimoto, T. Hirano, M. Yamada, A. Koarai, S. Fujii, T. Akaike, M. Ichinose, Sendai, Japan, p.A5919

Facilitator: P.J. Lee, MD, New Haven, CT

P937 **miRNA Arrays of the Apoptotic Bodies Derived from Broncho Alveolar Lavage Fluid (BALF) Suggest Potential Novel Regulators of Hyperoxia-Induced Acute Lung Injury/**H. Lee, D. Zhang, Y. Jin, Boston, MA, p.A5920

P938 **Pro-Inflammatory Function of Circulating Exosome After Hyperoxia Induced Lung Injury/**H.-G. Moon, J.H. Lee, H.S. Choi, Y. Jin, Boston, MA, p.A5921

P939 **Role of Endoplasmic Reticulum Stress in Changes of Insulin Signaling Pathway in HepG2 Cell Exposed to Intermittent Hypoxia/**H.H. Yi, J.C. Gu, M. Li, Y.Q. Li, J. Feng, J. Zhou, J. Du, China, p.A5922

P940 **Intraoperativeoperative Hemidiaphragm Electrical Stimulation Reduces Oxidative Stress and Increases Autophagy Levels in Older Adults/**A.D. Martin, R. Mankowski, T. Beaver, S. Ahmed, B.K. Smith, C. Leeuwenburgh, Gainesville, FL, p.A5923

P941 **Requirement of β-Adrenergic Receptor Activation for Hypoxia-Mediated Signaling/**H. Cheong, J.K.T. Dermawan, K. Asosingh, K. Queisser, W. Xu, O. Stephens, S.V. Naga Prasad, S.C. Erzurum, Cleveland, OH, p.A5924

THEMATIC POSTER SESSION

C74 MODELS AND METHODS IN LUNG BIOLOGY

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area H, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: J.M. D'Armiento, MD, PhD, New York, NY

P943 **Ex Vivo Lung Volume Measurement Using High Resolution Micro-Computerized Tomography/**J. Luo, B. Varghese, T. Skorka, B. Zhou, E.D. Crandall, Z. Borok, Los Angeles, CA, p.A5925

P944 **A Novel Ex Vivo Perfusion System Preserves Morphologic and Functional Integrity of Mouse Tracheal Segments and Is Suitable For Investigating Mucous Metaplasia/**E.Y. Cheah, T.S. Mann, P.J. Henry, Perth, Australia, p.A5926

P945 **Characterization of Club Cell Secretory Protein Producing Cells in an Ex Vivo COPD Culture Model/**L. Knabe, A. Petit, D. Gras, J. Charriot, E. Ahmed, R. Jean, A.-S. Gamez, P. Chanez, I. Vachier, A. Bourdin, Montpellier, France, p.A5927

P946 **Oropharyngeal Aspiration as an Alternative Route of Inhaled Administration in a Mouse Model of IL-13 Induced Goblet Cell Metaplasia/**K. Hulland, K. Wetzel, P. Capodieci, M. Dowling, J. Coote, Cambridge, MA, p.A5928

P947 **Airway Organoid 3D Co-Cultures for Tissue Engineering and Lung Biology/**Q. Tan, K.M. Choi, D. Sicard, D. Mehra, A. Haak, D.J. Tschumperlin, Rochester, MN, p.A5929

P948 **Mouse Alveolar Epithelial Type I Cell Isolation Using Magnetic Sorting/**M. Sunohara, H. Kage, B. Zhou, J.M. Liebler, P. Flodby, E.D. Crandall, Z. Borok, Los Angeles, CA, p.A5930

P949 **Comparative Decellularization and Recellularization of Wild Type and Alpha 1,3 Galactosyltransferase Knockout Pig Lungs: A Model for Ex Vivo Xenogeneic Lung Bioengineering and Transplantation/**J. Platz, N. Bonenfant, F.E. Uhl, A. Coffey, T. McKnight, C. Parsons, D. Sokocevic, Z. Borg, Y.W. Lam, B. Deng, J.G. Fields, M. Desarno, R. Loi, A. Hoffmann, J. Bianchi, B. Dacken, D.E. Wagner, D.J. Weiss, Burlington, VT, p.A5931

P950 **Miniaturizing the Human Alveolar Microenvironment to Study Lung Injury, Repair and Regeneration for Drug Discovery/**S. Daya, J. Marin, M. Ogishi, K. Feldman, M. Dowling, C. Bauer, Cambridge, MA, p.A5932

Facilitator: D.J. Weiss, MD, PhD, Burlington, VT

P951 **Knockout of RAGE Ameliorates Cigarette Smoke-Induced Airway Inflammation in Mice/**M. Chen, T. Wang, L. Liu, D. Xu, F. Wen, L. Chen, Chengdu, China, p.A5933

P952 **A Manufacturing- and Regulatory-Friendly Cell Expansion Technology Allowing for Trillion-Fold Expansion of Primary Airway Epithelial Cells/**C. Zhang, A. Shrivastava, Gaithersburg, MD, p.A5934

P953 **A Comparative Pharmacokinetic (PK) Analysis of Systemic Vs. Inhaled Administration of Therapeutic Biologics/**S. Mowbray, O. Bonneau, J. Coote, Y. Pang, M. Dowling, D.J. Rowlands, M. Rowlands, Cambridge, MA, p.A5935

P954 **Oral Treatment with PBI-4050 Reduces Plasminogen Activator Inhibitor-1 (PAI-1), Alpha-Smooth Muscle Actin (α-SMA) and Collagen Expression in Human Fibroblasts and Mice Fibrotic Lungs/**L. Gagnon, M. Leduc, B. Grouix, M. Tremblay, F. Sarra-Bournet, A. Laverdure, W. Gagnon, L. Geerts, K. Hince, L. Gervais, M.-P. Cloutier, S. Abbott, J.-S. Duceppe, B. Zacharie, P. Laurin, Laval, Canada, p.A5936

P955 **TGFβ and IL-13 Induce Pro-Fibrotic Changes in the 3DBioBarrier™ Airway Epithelial/Fibroblast Model System/** S.J. Wadsworth, C. Overed-Sayers, L. Murray, M.A. Sleeman, D. Clarke, Vancouver, Canada, p.A5937

P956 **Aspiration Pneumonia Induces Atrophy in Respiratory, Skeletal, and Swallowing Muscles in a Mouse Model/**R. Komatsu, T. Okazaki, M. Kobayashi, Y. Tsukita, M. Nihei, H. Sugiura, S. Ebihara, M. Ichinose, sendai miyagi, Japan, p.A5938

P957 **Modeling Environmental Mediated Extracellular Matrix Chemical Modifications in the Lung: Implications in Profibrotic and Inflammatory Responses/**C.A. Lerner, W. Lei, I.K. Sundar, P.A. Kirkham, I. Rahman, Rochester, NY, p.A5939

P958 **Validation of a Novel Rabbit S. Pneumoniae Model of Empyema and Responses to Intrapleural Fibrinolytic Therapy with tPA or scuPA/**G. Florova, A. Komissarov, A.O. Azghani, A. Buchanan, K. Koenig, C. Schaefer, J. Boren, S. Idell, Tyler, TX, p.A5940

Facilitator: P. Chen, MD, Los Angeles, CA

P959 **Establishment of a Novel Nanobody Specific for Anti-Human Pulmonary Surfactant Protein A and Its Targeting Capacity/**X. He, S. Wang, Z. Yin, D. Weng, H. Li, Nantong, China, p.A5941

P960 **Human Lungs Actively Synthesize and Secrete a Range of Phospholipids into the Airspace and Circulation in an Isolated Perfusion Model/**L. Thakuria, R. Romano, V. Goss, G. Koster, P. Townsend, A. Simon, A. Popov, F. De Robertis, T. Pitt, S. Soresi, M. Carby, A. Reed, N. Marczin, M. Griffiths, A.D. Postle, London, United Kingdom, p.A5942

P961 **High Resolution Analysis of Cells Isolated from Developing Human Lung/**R.S. Misra, Y. Xu, S. Bhattacharya, S.K. Solleti, J. Holden-Wiltse, G. Clair, C. Ansong, T.J. Mariani, J.A. Whitsett, G.S. Pryhuber, Rochester, NY, p.A5943

P962 **In Vivo Imaging of Lung Apoptosis in Acute Lung Injury/**A. Gupta, M.P. Goldklang, K. Stearns, Y. Tekabe, R. Xiao, N. Bae, T. Zelonina, L. Johnson, J. D'Armiento, New York, NY, p.A5944

P963 **Ex Vivo Culture of Lung Buds on the Chorioallantoic Membrane of the Avian Embryo/**M.A.J. Selleck, R. Figueroa, R. Lansford, M.E. Bronner, Los Angeles, CA, p.A5945

P964 **The Ethics of Animal Research: A Survey of the Public and Scientists in North America/**A.R. Joffe, M. Bara, N. Anton, N. Nobis, Edmonton, Canada, p.A5946

P965 **Expectations for the Methodology and Translation of Animal Research: A Survey of the Public and Scientists in North America/**A.R. Joffe, M. Bara, N. Anton, N. Nobis, Edmonton, Canada, p.A5947

P966 **Deletion of Rsph1 in a Mouse Model of Primary Ciliary Dyskinesia Results in a Mild Phenotype/**L.E. Ostrowski, A. Livraghi-Butrico, W. Yin, P. Sears, T. Rogers, B. Grubb, Chapel Hill, NC, p.A5948

THEMATIC POSTER SESSION

C75 IMPROVING AND ASSESSING RESPIRATORY FUNCTION

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area H, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: K.I. Berger, MD, New York, NY

P969 **Spirometric Reference Values for Malagasy Healthy Non-Smokers Born and Living in France/**J. Ratomaharo, O.J. Linares, D.S. Callingridge, D. Rakotonanahary, M. Randriantahiry, R. Ranaivoson, M. Hegewald, R.L. Jensen, J. Hankinson, A. Morris, Athis-Mons, France, p.A5950

P970 **A Unique Signature of Disease: Impulse Oscillometry Findings in Constrictive Bronchiolitis/**S.G. Bickel, R.L. Morton, A. O'Hagan, N. Eid, Louisville, KY, p.A5951

P971 **Machanisms for Decrease in Resistance After Bronchodilator Inhalation Without Change in FEV1/**H. Kurosawa, H. Ogawa, T. Irokawa, S. Ohkouchi, R. Arakawa, E. Miura, E. Nikkuni, Y. Shimizu, Sendai, Japan, p.A5952

P972 **Respiratory Impedance Measuring by ®MostGraph-01 Is Affected by Obesity/**Z. Isobe, Fukaya city, Japan, p.A5953

P973 **Effects of Weight Loss Therapy on Respiratory System Impedance in Obese Subjects/**E. Nikkuni, K. Kiuchi, R. Arakawa, D. Kobayasi, E. Miura, S. Ohkouchi, T. Irokawa, H. Ogawa, H. Kurosawa, Sendai, Japan, p.A5954

P974 **The Effect of Spermidine on Obesity-Associated Pathological Changes of the Lung/**J. Schipke, E. Lopez-Rodriguez, C. Muhlfeld, Hannover, Germany, p.A5955

Facilitator: V.J. Kelly, PhD, BS, Boston, MA

P975 **Reference Values to Spirometry in Sample of Brazilian Population: A New Proposal/**R. Rufino, K.M. Da Silva, A. Maiworm, C.H.D. Costa, A.J. Lopes, Rio de Janeiro, Brazil, p.A5956

P976 **Forced Expiratory Volume (FEV) Measurements in Mouse Models of Lung Disease/**J. Vanoirbeek, A. Maaske, C. Aznar Lopez, L. Pollaris, B. Nemery, P.H.M. Hoet, R. Lories, M. Tenbusch, F. Devos, Leuven, Belgium, p.A5957

P977 **Oscillatory Measurements of Upper Airway Casts Reconstructed from CT Images/**B. Radics, T. Coppens, N. Andre, C. Page, L. Degrugilliers, S. Borkowski, K. Bayat, G. Makan, Z. Gingl, Z. Hantos, S. Bayat, Deszk, Hungary, p.A5958

P978 **The Meaning of the Impedance of Respiratory System Measured by Forced Oscillation Technique - Fundamental Analysis Using the Phantom Model -/**T. Ogasa, S. Osanai, Kitami City Hokkaido, Japan, p.A5959

P979 **Ventilation Heterogeneity Is Substantially Decreased When Breathing 5% Carbon Dioxide/**M.J. Emery, J. Anderson, E.R. Swenson, Seattle, WA, p.A5960

Facilitator: D.G. Chapman, PhD, Burlington, VT

P980 **Automated Analysis of Neural Respiratory Drive from Parasternal Intercostal Muscle Electromyography Predicts Safe Discharge in Exacerbations of COPD/**S. Devot, J. Van De Laar, R. Priori, R. Derkx, P.B. Murphy, E.-S. Suh, N. Hart, Cambridge, United Kingdom, p.A5961

P981 **Face Mask Spirometry in Normal Subjects and Motor Neurone Disease Patients/**M.P. Swanney, E.R. Ingram, C. Drennan, J. Yang, Christchurch, New Zealand, p.A5962

P982 **Pneumoperitoneum Inflation with Different Levels of Pressure in Rats Promotes Pulmonary Inflammation with Different Repercussion/**J. Brandao, C.B.N. Andreia Dato, K. Vasconcelos, L. Falcao, I. Oliveira-Junior, Sao Paulo, Brazil, p.A5963

P983 **Exercise Induced Respiratory Insufficiency in a Murine Model of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency/**A.M. Keeler, K.V. Desroshers, L. Xiong, M.K. ElMallah, Worcester, MA, p.A5964

P984 **Inhibition of Neutral Sphingomyelinase Prevents Diaphragm Weakness and Ventilatory Abnormalities in Chronic Heart Failure/**P.D. Coblentz, B. Ahn, N. Patel, L. Hayward, J.-K. Yoo, D. Christou, L.F. Ferreira, Gainesville, FL, p.A5965

THEMATIC POSTER SESSION

C76 VENTILATORY CONTROL: GETTING ON MY NERVES

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area N, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: C.A. Sinderby, PhD, Toronto, Canada

P1539 **The Inspiratory Capacity (IC) Maneuver May Underestimate Dynamic Hyperinflation in Patients with COPD During Exhaustive Exercise/**Y.M. Luo, Z.H. Qiu, B.T. He, H. Qin, Y. Luo, L. Zhou, M.I. Polkey, Guangzhou, China, p.A5966

P1540 **Neural Respiratory Drive Generated by Inspiratory Capacity Maneuver Could Be Further Increased by Inhalation of CO2/**Y. Luo, H. Qin, B. He, M.-H. Su, L. Zhou, Z.-H. Qiu, J. Moxham, M.I. Polkey, Y.M. Luo, Gunagzhou, China, p.A5967

P1541 **Effect of Repetitive Magnetic Cervical Stimulation of Phrenic Roots on Diaphragmayic Function in Healthy Volunteers/**Y. Rebollar, M. Bourgoin-Heck, S. Ragot, F. Petitpas, R. Robert, X. Drouot, V. Diaz, Poitiers, France, p.A5968

P1542 **The Effect of Thoracic Nerve Blocks on Chest Wall Mechanics/**G. Elshafie, P. Kumar, R. Steyn, M. Kalkat, R. Wilson, E. Bishay, P. Rajesh, B. Naidu, Birmingham, United Kingdom, p.A5969

P1543 **The Utility of Impulse Oscillometry (IOS) in Early Detection of Respiratory Impairment in Patients with Amyotrophic Lateral Sclerosis (ALS)/**E.M. Elamin, C. Gutierrez, S.L. Phillips, C. Wilson6, Y. Kang, K. White, W. Anderson, Tampa, FL, p.A5970

Facilitator: M.G. Drake, MD, Portland, OR

P1544 **Resistive Breathing Induced IL-6 Damps the Respiratory Controler Response to Hypercapnic and Hypoxic Stimuli Via the Carotid Body and Augmented It Via the Phrenic Nerve/**F. Perlikos, I. Koutsourelakis, G. Prezerakos, A. Sotiriou, M. Dettoraki, C.E. Giannakopoulou, A. Papalois, T. Vassilakopoulos, Athens, Greece, p.A5971

P1545 **Focal Ischemic Stroke Decreases Ipsilateral Carotid Blood Flow and Modifies Respiratory Pattern in Rats: Role of Inflammation on Lung-Brain Interaction/**C.S. Samary, A.B. Ramos, L.A. Maia, N.N. Rocha, C.L. Santos, R.F. Magalhaes, A.L. Clevelario, R.M. Mendez-Otero, V.L. Capelozzi, T.P. Ferreira, P. Pelosi, M.G.D. Abreu, P.L. Silva, P.R.M. Rocco, Rio de Janeiro, Brazil, p.A5972

P1546 **The Effect of Acrolein on Lung Function and Substance P Release in Mice/**Z. Wu, J.E. Hanson, R.D. Dey, Morgantown, WV, p.A5973

P1547 **Pulmonary Function in Parkinson's Disease/**A. Begeman, M. Luinstra, S. Vroegop, E. Frijlink, Groningen, Netherlands, p.A5974

THEMATIC POSTER SESSION

C77 DIGGING DOWN DEEP: MEASURING SDB PHYSIOLOGICAL TRAITS

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area N, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: A.R. Schwartz, MD, Baltimore, MD

P1549 **Obstructive Sleep Apnea and Airway Structure Characterization During Wakefulness Using Tracheal Breathing Sounds/**A.M. Elwali, Z. Moussavi, Winnipeg, Canada, p.A5975

P1550 **Utility of Acoustic Pharyngometry in the Diagnosis of Obstructive Sleep Apnea/**T. Kendzerska, M. Grewal, C.M. Ryan, Toronto, Canada, p.A5976

P1551 **Differences in Respiratory Rate Variability Among Patients with and Without Obstructive Sleep Apnea/**A.W. McLean, R. Pirouz, G. Alrehaili, C. Bolinger, K. Rider, H. Kaya, S. Kimbro, R. Amdur, V. Jain, J. Ahari, J. Williams, A. Bawa, Washington, DC, p.A5977

P1552 **Development and Validation of an Acoustic Model of the Upper Airway for Snore Sound Generation/**M. Shokrollahi, S. Saha, M. Taheri, Z. Moussavi, A. Yadollahi, Toronto, Canada, p.A5978

Facilitator: P. Catcheside, PhD, Daw Park, Australia

P1553 **Objective Measurements of Snoring Frequency and Intensity Predict Sleep Apnea Severity/**F. Sgambati, M. Guzman, H. Pho, R.S. Arias, T. Otvos, E. Wolfe, I. Hawks, J.P. Kirkness, H. Schneider, P.L. Smith, A.R. Schwartz, Baltimore, MD, p.A5979

P1554 **Accuracy of Portable Devices in Sleep Apnea Using Oximetry-Derived Heart Rate Increases as a Surrogate Arousal Marker: A Prospective Study/**P. Lachapelle, S. Pamidi, A.E. Olha, L. Lavigne, R.J. Kimoff, Montreal, Canada, p.A5980

P1555 **Analysis of CO2 Brainstem Chemoreceptors Sensitivity and the Depth of Sedation During Drug Induced Sleep-Endoscopy Procedure/**N. Zaikina, L. Karnatovskaia, Z. Kaliadzich, G. Gudny, E. Tishkevich, V. Kulchitsky, M.A. Dziadzko, A. Dzyadzko, Minsk, Belarus, p.A5981

Facilitator: J.P. Kirkness, PhD, Baltimore, MD

P1556 **Respiratory Rate Variabiity During Sleep Assessed by Spectral Analysis of Respiratory Flow/**R. Pirouz, A.W. McLean, G. Alrehaili, C. Bolinger, K. Rider, H. Kaya, S. Kimbro, R. Amdur, V. Jain, J. Williams, J. Ahari, A. Bawa, G. Gutierrez, Washington, DC, p.A5982

P1557 **Respiratory Rate Variability During Normal Sleep/**G. Alrehaili, A.W. McLean, R. Pirouz, C. Bolinger, H. Kaya, K. Rider, S. Kimbro, R. Amdur, V. Jain, J. Ahari, J. Williams, A. Bawa, G. Gutierrez, Washington, DC, p.A5983

P1558 **Estimating Critical Collapsing Pressure from Peak Inspiratory Flow During Sleep/**A. Azarbarzin, S.A. Sands, L. Taranto Montemurro, M. Marques, D.P. White, A. Wellman, Boston, MA, p.A5984

THEMATIC POSTER SESSION

C78 NOT STRANGERS IN THE NIGHT: SLEEP AND THORACIC DISEASES

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area N, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: L.F. Wolfe, MD, Chicago, IL

P1560 **Cardiac Function of Preadolescent Young Males with Duchenne Muscular Dystrophy and Early Onset of Sleep Disordered Breathing/**A.R. Lopez, H. Sawnani, J.E. Pascoe, N. Simakajornboon, Cincinnati, OH, p.A5985

P1561 **The Effect of Sleep Disordered Breathing on Heart Rate Variability in Boys with Duchenne Muscular Dystrophy/** J.E. Pascoe, K. McConnell, A.R. Lopez, A. Minkara, H. Sawnani, T.J. Dye, N. Simakajornboon, Cincinnati, OH, p.A5986

P1562 **Evaluation of Respiratory Movements in a Murine Model Mimicking Different Stages of Parkinson's Disease/** P.S.D. Campos, Y. Kumei, K. Hasegawa, L.R. Kawamura, J.L.L. Zeredo, Brasilia, Brazil, p.A5987

P1563 **Obesity Hypoventilation Syndrome: Prevalence in Ambulatory Obese and Validity of Venous Bicarbonates for Improving Diagnosis Capabilities/**J.C. Borel, F. Guerber, I. Jullian-Desayes, M. Joyeux-Faure, N. Arnol, N. Taleux, R. Tamisier, J.L. Pepin, Grenoble, France, p.A5988

P1564 **Simple Strategy to Recognize Obesity Hypoventilation Syndrome in Hospitalized Patients/**Z. Fast, S. Sharma, Philadelphia, PA, p.A5989

Facilitator: M. Macrea, MD, MPH, PhD, Salem, VA

P1565 **Descriptive Characteristics of Obstructive Sleep Apnea Patients at Risk of Extended Stay in the Post-Operative Care Unit/**E. Lee, J. Daugherty, San Diego, CA, p.A5990

P1566 **Peri-Operative Risk Following Bariatric Surgery Is Not Increased in Untreated Patients with Moderate Obstructive Sleep Apnea Selected by an Innovative Decisional Algorithm/**M. Martin, C. Minville, F. Series, I. Boutin, F. Maltais, S. Marceau, J. Bussieres, Quebec, Canada, p.A5991

P1567 **Fluid Shifts in Pulmonary Hypertension in Those with and Without Sleep Apnea/**C.G. Carvalho, M. Minic, J.T. Granton, C.M. Ryan, Toronto, Canada, p.A5992

P1568 **Evaluation of Right Ventricular Remodeling and Expansion of Extracellular Volume (ECV) Using Cardiac Magnetic Resonance Imaging in Co-Existent Chronic Obstructive Pulmonary Disease and Obstructive Sleep Apnea/**R. Jen, J.R. Wilson, R.L. Owens, Y. Li, P.N. DeYoung, E.T. Smales, A. Malhotra, La Jolla, CA, p.A5993

Facilitator: X. Soler, MD, PhD, San Diego, CA

P1569 **Microalbuminuria in Patients with Overlap Syndrome/**T. Matsumoto, K. Murase, T. Minami, R. Tachikawa, S. Hamada, K. Tanizawa, M. Inouchi, T. Handa, T. Oga, M. Yanagita, M. Mishima, K. Chin, Kyoto, Japan, p.A5994

P1570 **A Population Based Study of Sleep Disorders in Chronic Obstructive Pulmonary Disease: Sleep Quality and Acute Exacerbations of COPD/**M. Shorofsky, J. Bourbeau, R.J. Kimoff, N. Ayas, W.C. Tan, S.D. Aaron, D.D. Sin, J. Road, D. O'Donnell, F. Maltais, K.R. Chapman, J.M. FitzGerald, D. Marciniuk, H. Coxson, M. Kaminska, Montreal, Canada, p.A5995

P1571 **The Chronic Obstructive Pulmonary Disease and Obstructive Sleep Apnea/**L. Oliveira, J.C. Mendes, J.J. Urbano, A.S. Silva, E.F. De Oliveira, N.T. Fonseca, E.A. Perez, Sao Paulo, Brazil, p.A5996

P1572 **Increased Neural Respiratory Drive Due to Upper Airway Resistance; a Possible Protective Mechanism in COPD?/**B. He, L. Zhou, S. Xiao, J. Steier, J. Moxham, M.I. Polkey, Y. Luo, Guangzhou, China, p.A5997

Facilitator: J.E. Orr, MD, La Jolla, CA

P1573 **High Prevalence of Obstructive Sleep Apnea in Patients with Asthma/**Y. Miura, H. Nakamura, T. Mio, T. Miyashita, S. Miyauchi, T. Uchida, S. Yamazaki, S. Minezaki, S. Shinomiya, Y. Uchida, A. Kaga, K. Komiyama, H. Ota, K. Nakagome, T. Soma, M. Nagata, M. Kanazawa, Saitama, Japan, p.A5998

P1574 **Association Between Asthma Control and Sleep Condition/**Y. Watanabe, T. Yokoe, A. Fujiwara, Y. Uchida, T. Kimura, Y. Fukuda, N. Kuwahara, R. Manabe, H. Furukawa, M. Jinno, K. Hirai, Y. Miyata, H. Mizuma, M. Yamaguchi, Y. Kishino, Y. Murata, T. Honma, S. Ohta, M. Yamamoto, A. Tanaka, T. Onishi, H. Sagara, Tokyo, p.A5999

P1575 **Cardiorespiratory Responses and Acute Mountain Sickness in Humans During Aerobic Exercise While Exposed to Hypobaric and Normobaric Hypoxia/**L. Rausch, S. Pramsohler, S. Wimmer, M. Faulhaber, Innsbruck, Austria, p.A6000

P1576 **Spiroergomety in Normobaric and Hypobaric Hypoxia/**M. Frieb, S. Pramsohler, M. Koop, H. Gatterer, M. Faulhaber, M. Burtscher, N. Netzer, Innsbruck, Austria, p.A6001

Facilitator: A. Sankari, MD, PhD, Detroit, MI

P1577 **Making Sense of Sensory Nerves: An In Vitro Characterisation of Gene Expression Profiles of Airway-Innervating Guinea-Pig Airway Neurons Using Single-Cell Analysis/**M.A. Wortley, E. Dubuis, S.J. Bonvini, S. Wong, F. Shala, S.A. Maher, J.J. Adcock, J.A. Smith, M.A. Birrell, M.G. Belvisi, London, United Kingdom, p.A6002

P1578 **The A1 Adenosine Receptor Is a Novel Inhibitory Receptor That Regulates the Cough Reflex Via a Central Mechanism of Action/**A.Z. El-Hashim, S. Mathew, D. Spina, Kuwait, Kuwait, p.A6003

P1579 **Autonomic Function During REM Sleep in COPD Associated to OSA/**R. Trimer, R. Cabiddu, V. Trimer, R.G. Mendes, F.S.M. Costa, A.D. Oliveira Junior, A. Borghi-Silva, Sao Carlos, Brazil, p.A6004

P1580 **Systemic Inflammation in Patients with Severe COPD Who Desaturate Only Nocturnally: A Possible Indication for Long-Term Nocturnal Supplemental Oxygen Therapy?/**S.K. Nepal, R.D. Mantilla, M. Thomas, M.M. Macrea, Roanoke, VA, p.A6005

THEMATIC POSTER SESSION

C79 MULTIMODALITY APPROACHES TO DIAGNOSIS AND TREATMENT OF LUNG CANCER

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area A, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: I. Barjaktarevic, MD, MSc, Los Angeles, CA

P1 **Analysis of Efficiency in Bronchoscopic and Interventional Pulmonary Procedures in a Mixed Endoscopy Suite: Increasing Quality in the Delivery of Pulmonary Medicine/**D.I. Zapata, M. Walczyszyn, D.M. Wisa, B. Mina, B. Husta, New York, NY, p.A6006

P2 **Endobronchial Ultrasound-Transbronchial Needle Aspiration as a Modality for Safely Obtaining High Yield Rates for EGFR and ALK Mutations in Non-Small Cell Cancers/**S. Ganesh, H.T. Saman, K. Ibrahim, S.Y. Lee, B. Samarasekera, D. Petkova, Sutton Colfield, United Kingdom, p.A6007

P3 **In Times When Tissue Is Still the Issue, This Is How We Do It: Methodology for Handling Endobronchial Ultrasound Guided Transbronchial Needle Aspiration Samples/**E. Martinez, G. Diaz-Fuentes, S. Venkatram, Bronx, NY, p.A6008

P4 **Mediastinal Lymph Node Lung Adenocarcinoma Without a Known Primary Lesion Diagnosed by EBUS-TBNA Histology/**E. Martinez, G. Diaz-Fuentes, S. Venkatram, Bronx, NY, p.A6009

P5 **The Usefulness of High-Flow Nasal Cannula for Maintaining Oxygenation During Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration/**H. Ichikawa, O. Takakuwa, N. Takeda, K. Fukumitsu, Y. Kanemitsu, T. Uemura, H. Ohkubo, M. Takemura, K. Maeno, Y. Ito, T. Oguri, A. Niimi, Nagoya, Japan, p.A6010

P6 **A Case of Lymph Node Tuberculosis Diagnosed During Lung Cancer Staging/**A. Sengul, S. Arslan, O. Kapıcıbasi, F.E. Tasolar, Kocaeli, Turkey, p.A6011

P7 **Enlarging Pulmonary Anthracosis: Is an Excellent Biopsy Enough?/**D. Baral, A. Shawkat, M. Paul, Syracuse, NY, p.A6012

P8 **The Utility of Endobronchial Ultrasound in the Diagnosis of Recurrent Pleuropulmonary Synovial Sarcoma/**J. MacLeod, A. Caraganis, S. Katz, G.R. Bourjeily, R. El-Bizri, Providence, RI, p.A6013

P9 **Utilization of In Vivo Imaging of a Ground Glass Opacity Using Navigational Bronchoscopy and Confocal Laser Microendoscopy/**M.J. Sobieszczyk, S.C. Parrish, M.S. Switzer, Bethesda, MD, p.A6014

P10 **Large Cell Neuroendocrine Carcinoma of the Lung: A Rare Cancer by EBUS Guided Core Needle Biopsy/**D. Mabe, S.C. Parrish, A. Lazarus, Gaithersburg, MD, p.A6015

P11 **Combined Endobronchial and Endoscopic Ultrasound-Guided Fine-Needle Aspiration (EBUS/EUS-FNA): A One-Stop Approach in Diagnosing and Staging Lung Cancer/**K. Sharma, P. Nadarajan, D. O'Toole, F. O'Connell, Dublin, Ireland, p.A6016

P12 **Painless Jaundice as the Initial Presentation of a High Grade Neuro-endocrine Tumor: Utility of Endoscopic Ultrasound Guided Trucut Biopsy (EUS-TCB)/**D. Nesheim, N. Ramesh, J. Filopei, E.E. Bondarsky, P. Walker, D. Steiger, New York, NY, p.A6017

P13 **Our Trans-Thoracic Biopsy Practices Accompanied by The Imaging Process: The Contribution of Positron Emission Tomography Usage to Accurate Diagnosis/**Y.S. Intepe, B. Metin, S. Sahin, B. Kaya, A. Okur, Yozgat, Turkey, p.A6018

P14 **Characterization of a Bronchoscopic Thermal Ablation Catheter in Porcine Lung/**K. Howk, W. Dickhans, K. Rooks, F.D.M. Nonalaya, K. Haley, Mansfield, MA, p.A6019

P15 **Bronchoscopic Management of a Pulmonary Tumorcavity After First-Line Therapy with Afatinib/**R.M. Huber, K. Kahnert, Z. Syunyaeva, P. Mertsch, Munich, Germany, p.A6020

P16 **Single Port Video Assisted Lobectomy and Mediastinal Lymph Node Dissection for Pulmonary Cancer Surgical Treatment - Experience of a Surgical Center/**R. Ferreira, A. Sena, J. Cruz, Lisboa, Portugal, p.A6021

Facilitator: M.H. Tukey, MD, Providence, RI

P17 **Robotic Video-Assisted Thoracoscopic Lung Resection: Comparison of Outcomes and Learning Curve from a Single Surgeon in a Tertiary Care Center/**P. Kanagarajah, A. Torres, A. Bacigalupo, S. Shaukat, F.A. Myslicki, R. Williams, Miami Beach, FL, p.A6022

P18 **Outcomes of Patients with Incomplete Interlobar Fissure After Pulmonary Lobectomy for Non-Small-Cell Lung Cancer/**C. Menna, M. Ibrahim, C. Andreetti, A.M. Ciccone, A. D'Andrilli, E.A. Rendina, Teramo, Italy, p.A6023

P19 **Hypocapnea at Rest Predicts Outcome in Patients Undergoing Lung Resection/**K. Brat, Z. Tothova, J. Skrickova, V. Sramek, M. Vasakova, Z. Merta, P. Homolka, I. Cundrle Jr, Brno, Czech Republic, p.A6024

P20 **Visceral Pleural Invasion Decreased Overall Survival in Resected Non-Small Lung Cancer Patients with Tumor Size Ranged 3 to 5cm Rather than 3cm or Less/**P. Zhou, Chengdu Shi, China, p.A6025

P21 **Left Lung Torsion: Complication of Lobar Resection for an Early Stage Lung Adenocarcinoma/**W. Mansour, E. Moussaly, A. Abou Yassine, J. Nabigiez, R. Maroun, Staten Island, NY, p.A6026

P22 **Successful Treatment of Early Stage Monophasic Pulmonary Synovial Sarcoma with Minimally Invasive Robotic Video-Assisted Lobectomy/**D. Saha, A. Maiti, F. Khan, E. Rodriguez, Pittsburgh, PA, p.A6027

P23 **Primary Lung Cystic Adenoid Tumor with Extensive Involvement of the Right Lung and Distal Trachea treated with Tracheal Sleeve Pneumonectomy: A Case Report/**L. Fernandez, L.F. Sua, J.D. Victoria, M. Velasquez, C.A. Munoz, Cali, Colombia, p.A6028

P24 **Comparison of Icotinib, Erlotinib and Gefitinib in Treating Non-Small Cell Lung Cancer/**X. Si, H. Wang, X. Zhang, M. Wang, L. Zhang, Beijing, China, p.A6029

P25 **Chemotherapy with Pemetrexed and Platinums Provided Better Outcome in Stage IV Lung Adenocarcinoma Patients with Susceptible EGFR Mutations and Acquired Resistance to the First-Line Gefitinib/**H.-L. Huang, C.-J. Yang, M.-J. Tsai, W.-A. Chang, J.-Y. Hung, M.-S. Huang, I.-W. Chong, Kaohsiung, Taiwan, p.A6030

P26 **100 Months Surviving Rate Without Progression, the Best Answer in the Literature to Erlotibin in Wild Type EGFR Adenocarcinoma/**Y. Rosati, G. Mattioli, A. Re, G. Riccioni, M. Serafini, T. Pieramici, T. Taccari, A. Tubaldi, Macerata, Italy, p.A6031

P27 **Octreotide as Bridging Therapy to Erlotinib in Bronchorrhea-Induced Respiratory Failure/**N. Bournival, J.D. Marshall, C.J. Britto, New Haven, CT, p.A6032

P28 **Recurrent Pneumothorax as a Complication of Treatment with Pazopanib: First Case Report in Metastatic Renal Cell Carcinoma/**C.R. Towns, B.D. Brockway, Wellington, New Zealand, p.A6033

P29 **Vasculitis Like Eruption Associated with Erolotinib Therapy/**H.-Y. Fang, W.-C. Liao, C.-J. Hsu, P.-Y. Wu, T.-C. Hsia, C.-Y. Tu, Taichung City, Taiwan, p.A6034

P30 **Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) Abnormalities Years After Talc Pleurodesis as a Confounding Factor in Subsequent Lung Cancer Evaluation/**W. Warren, W. Londeree, S. Cantrell, W. Kelly, Bethesda, MD, p.A6035

P31 **New Dosimetric Parameter Predicts the Onset of Radiation Pneumonitis/**Y. Uchida, T. Tsugawa, K. Aoki, K. Noma, S. Tanaka, W. Shigemori, R. Seto, M. Yamaguchi, E. Ogawa, Y. Nakano, Otsu City,Shiga,, Japan, p.A6036

P32 **Effects of Proton Therapy on Pulmonary Function in Hodgkin Lymphoma Patients/**J.A. Bellardini, A. Bajwa, V. Seeram, J. Cury, L. Jones, N. Mendenhall, B. Hoppe, Jacksonville, FL, p.A6037

THEMATIC POSTER SESSION

C80 THORACIC ONCOLOGY: CASE REPORTS

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area A, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: P. Nana-Sinkam, MD, Columbus, OH

P36 **A Case of Primary Pulmonary Extranodal Zone Lymphoma Mimicking Pneumonia/**A. Ciledag, A. Gurun Kaya, S. Enon, S. Civriz Bozdag, A. Kaya, Ankara, Turkey, p.A6038

P37 **Lymphomatoid Granulomatosis Presenting as Multiple Lung Masses/**C.-Y.R. Teng, H. Mehta, Gainesville, FL, p.A6039

P38 **Rare Presentation of Systemic Anaplastic T Cell Lymphoma as a Lung Mass with Endobronchial Invasion and Obstructive Atelectasis/**A. Aljaafareh, S. Daouk, C. Carter, H.J. Mehta, Gainesville, FL, p.A6040

P39 **Localized Pulmonary Crystal-Storing Histiocytosis Complicating Pulmonary Mucosa-Associated Lymphoid Tissue Lymphoma - Transbronchial Lung Biopsy Study was Key Step for Final Diagnosis/**N. Kokuho, S. Kunugi, N. Onda, H. Urushiyama, M. Terasaki, A. Azuma, H. Mitunori, A. Gemma, Y. Terasaki, Tokyo, Japan, p.A6041

P40 **Rare and Aggressive Lymphocyte-Depleted Hodgkin Lymphoma Resulting in Extensive Lung Infiltration and Respiratory Failure/**M.G. Sperry, Y. Zhang, N.W. Todd, Baltimore, MD, p.A6042

P41 **Chyloptysis, Hemoptysis, and Chylothorax in a Fifty Year Old Woman/**S.D. Levy, E. Bajwa, W. O'Donnell, Boston, MA, p.A6043

P42 **Synchronus Primary Lung Adenocarcinoma and Lymphoma: A Case Report/**H. Taha, S. Arora, A. Taneja, Milwaukee, WI, p.A6044

P43 **Spontaneous Tumor Lysis: An Unusual Complication of a Rare Case of Plasmablastic Lymphoma with Lung Involvement/**L. Khalid, R. Parajuli, G.E. Holt, A. Vosiughi, Miami, FL, p.A6045

P44 **Primary Pulmonary Anaplastic Large Cell Lymphoma Masquerading as Asthma in a Young Woman/**N. Abi Hatem, M. Carter, D. Kuchelan, J. Goyos, Roanoke, VA, p.A6046

P45 **From MALT to B Cell Lymphoma Via Granulicatella Adiacens in the Lungs/**V. Shah, M. Rives-Sanchez, J. Maizes, Atlantis, FL, p.A6047

P46 **An Unusual Way to Diagnose Intravascular Large B-Cell Lymphoma/**J. Mikhail, S. Hussain, New Brunswick, NJ, p.A6048

P47 **Pulmonary Diffuse Large B-Cell Lymphoma Initially Presenting as Asthma/**S. Kim, A.I. Ritchie, D. Adeboyeku, London, United Kingdom, p.A6049

P48 **Extramedullary Dissemination of Multiple Myeloma to the Lung/**P. Malie, A. Mahmood, C. Bulathsinghala, Corpus Christi, TX, p.A6050

Facilitator: S.S. Oh, DO, Los Angeles, CA

P49 **Solitary Extramedullary Plasmacytoma of the Trachea: A Case Report and Review of the Literature/**Y. Xiong, Q. Li, J. Xu, Shanghai, China, p.A6051

P50 **Bilateral Myelomatous Pleural Effusions/**A. Amaraneni, C. Difelice, C. Barrett, A. Surender, Kalamazoo, MI, p.A6052

P51 **Inflammatory Myofibroblastic Tumor of the Lung: A Rare Case Report/**M. Imtiaz, M. Moizuddin, Albany, NY, p.A6053

P52 **Leiomyosarcoma of the Innominate Vein; A Smooth Muscle Criminal/**H. Arshad, M. Young, P. Rali, R. Adurty, Pittsburgh, PA, p.A6054

P53 **Benign Metastasizing Leiomyoma/**V. Angirekula, J. Finley, Cleveland, OH, p.A6055

P54 **Pulmonary Benign Metastasizing Leiomyoma, Why Metastasizes if Benign/**Y. Usman, O. Iftikhar, M.K. Ishaq, A. Awab, Oklahoma City, OK, p.A6056

P55 **Metastatic Epithelioid Trophoblastic Tumor to the Lungs/**P.R.M. Evangelista, G.E.I.R. Ladrera, Philippines, p.A6057

P56 **A Case of Non-Gestational Choriocarcinoma in a Postmenopausal Woman Presenting with Pulmonary Metastatic Disease/**M.J. Sobieszczyk, S.C. Parrish, Bethesda, MD, p.A6058

P57 **Pulmonary Artery Sarcoma: The Retrospective Study of Clinical Presentation and Course/**N. Srivali, E.S. Yi, J.H. Ryu, Rochester, MN, p.A6059

P58 **Pulmonary Kaposi Sarcoma in the Era of HAART Therapy: A Case Report/**K. Trivedi, P.M. Patel, S.C. Adams, D.K. Payne, Shreveport, LA, p.A6060

P59 **Primary Pulmonary Synovial Sarcoma- A Rare Aggressive Tumor and a Diagnostic Challenge/**A.V. Chandran, J. Devasahayam, F. Omar, A. Parker, Columbia, MO, p.A6061

P60 **Metastatic Epithelioid Sarcoma: A Rare Cause of Recurrent Hypoxic Respiratory Failure/**S. Morais, E. Jabbour, M. Marsh, R. El-Bizri, Providence, RI, p.A6062

Facilitator: A.A. Balekian, MD, MS, Los Angeles, CA

P61 **Missed Case of Rare High-Grade Lung Sarcoma Presenting as Cavitary Pneumonia with Unusual Cutaneous Lesions/**M. Rahman, R. Sengupta, Detroit, MI, p.A6063

P62 **A Case of Sarcomatoid Malignant Mesothelioma with Prominent Osteosarcomatous Element of the Pleura: High Expression of Receptor Activator of Nuclear Factor κB Ligand (RANKL)/**M. Terasaki, Y. Terasaki, N. Kokuho, H. Urushiyama, K. Wakamatsu, S. Kunugi, Tokyo, Japan, p.A6064

P63 **A Rare Tumor in a Rare Location: A Case of Mediastinal Liposarcoma/**C. Cano Portillo, A. Sahni, Chicago, IL, p.A6065

P64 **The Potential Malignancy of a Solitary Fibrous Tumour of the Pleura/**D. Patrini, M. Hayward, U. Ekeowa, P. Russell, D. Lawrence, N. Panagiotopoulos, United Kingdom, p.A6066

P65 **A Case of Malignant Mesothelioma Who Survived 9 Years Without Proper Treatment/**H. Arikan, S. Olgun Yildizeli, E. Eryuksel, B. Bagci Ceyhan, Istanbul, Turkey, p.A6067

P66 **Rapid Onset and Progression of Mesothelioma Within Six Months Leaves Patient Without Surgical Options/**H. Nazir, J. Lee, N. Ali, H. Seethamraju, Newark, NJ, p.A6068

P67 **Endobronchial Neurogenic Tumor: A Combination of Traumatic Neuroma and Neurofibroma/**A.K. Tandon, E. Pina, Cincinnati, OH, p.A6069

P68 **Middle Mediastinal Schwannoma a Case Report and Literature Review/**C.M.D.L. Lajom, Manila, Philippines, p.A6070

P69 **An Anterior Mediastinal Adenocarcinoma in CREST Syndrome/**E. Male, M. Fernandez, S. Ghamande, A. Arroliga, Temple, TX, p.A6071

P70 **Bronchogenic Cyst in the Thymus: A Rare Anterior Mediastinal Mass/**R. Supakul, G. Valaulikar, I. Romero Legro, Memphis, TN, p.A6072

P71 **Thymoma- a Common Cause of Adult Anterior Medistinal Mass/**U. Kulsum, S. Podder, K. Sherani, A. Shalonov, J. Raynor, Jamaica, NY, p.A6073

P72 **Ectopic Thryroid Masquerading as Lung Cancer/**P.S. Pandya, London, United Kingdom, p.A6074

Facilitator: L.C. Moses, MD, Richmond, VA

P73 **Granular Cell Tumor: A Case of a Rare Tumor with an Unusual Location and Presentation/**A. Rudkovskaia, I.C. Forde, J.-P. Ayala, P.J. Cohen, Bridgeport, CT, p.A6075

P74 **Esophageal Malignancy with Esophagorespiratory Fistula Masquerading as Pneumonia/**K. Ohkuma, T. Saraya, H. Ishii, H. Takizawa, Mitaka, Japan, p.A6076

P75 **Endobronchial Metastasis in a Patient with Adenocarcinoma of the Prostate/**R. Kim, V. Nidadavolu, G. Pfister, K. El-Kersh, U. Gauhar, Louisville, KY, p.A6077

P76 **A Rare Case of Tracheal Hamartoma/**O.D. Adejorin, R. Shrestha, M.P. Muthiah, M. Zaman, Memphis, TN, p.A6078

P77 **Peribronchial Sclerosing Hemangioma with 68Ga Uptakeof DOTATOC PET-CT/**J. Kelly-Garcia, B.B. Cano Vargas, J.L. Criales-Cortes, H. Santiago-Payan, C. Canales-Ibarra, Mexico, Mexico, p.A6079

P78 **Poorly Differentiated Adenocarcinoma Mimicking Paraspinal Abscess/**M.A. Dziadzko, W.P. Holland, L. Karnatovskaia, Rochester, MN, p.A6080

P79 **An Unusual Endobronchial Lesion/**J. Martinez, J. Albors-Sanchez, W. Rodriguez-Cintron, San Juan, PR, p.A6081

P80 **A Series of Unfortunate Events: A Case of True Spontaneous Lung Herniation Resulting in Multiple Rib Fractures/**K. Downey, Y.B. Mehta, Z. Mehta, Danville, PA, p.A6082

P81 **An Unusual Source of Endobronchial Metastases/**L. Cruz, R. Mutneja, B. Lahiri, Farmington, CT, p.A6083

P82 **An Embolic Quandary/**A. Giri, P. Bansal, M. Kosters, P. Kohlitz, Syracuse, NY, p.A6084

P83 **More than a Hemidiaphragm Elevation - An Unusual Pleural Tumor/**C.J. Scallan, R. Jesudoss, M. Duran-Castillo, Cleveland, OH, p.A6085

P84 **Appearances Are Deceptive: An Unusual Presentation of a Rare Primary Lung Tumor!!/**D. Dhingani, I. Waheed, L. Srinivasan, U. Sagheer, S. Sivaraman, North Chicago, IL, p.A6086

THEMATIC POSTER SESSION

C81 UNUSUAL PRESENTATIONS OF LUNG CANCER: CASE REPORTS

9:00 a.m. - 4:15 p.m. **MOSCONE CENTER**

Area A, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: D.W. Hsia, MD, Torrance, CA

P88 **DIPNECH a Rare Cause of Obstructive Airway Disease/**P. Vishwasrao, J. Davis, L. Palmer, Stony Brook, NY, p.A6087

P89 **A Narrow Escape from Bilateral Adrenalectomy: A Case of Unrecognized Ectopic Adrenocorticotropic Hormone Production/**B.S. Grimes, I. Barjaktarevic, Los Angeles, CA, p.A6088

P90 **Atypical Presentation of Primary Small Cell Lung Carcinoma/**C. Kobe, A.G. Manko, K. Wood, Minneapolis, MN, p.A6089

P91 **Spontaneous Tumor Lysis Syndrome (TLS) in Small Cell Carcinoma of the Lung (SCLC)/**W. Ezegbunam, K. Ayinapudi, E. Kupferstein, Brooklyn, NY, p.A6090

P92 **Imitating the Great Masquerader/**A.R. Peralta, N.M. Vasquez, D. Chairman, Columbia, MO, p.A6091

P93 **Cystic Adenocarcinoma of the Lung/**Z. Ghazarian, M. Alziadat, R. Sekhon, M. Ismail, Paterson, NJ, p.A6092

P94 **Spontaneous Regression Of Non-Small Cell Lung Cancer After Biopsy/**F. Elmufdi, R. Andrade, A. Begnaud, Minneapolis, MN, p.A6093

P95 **A Case of Remitting Seronegative Symmetrical Synovitis with Pitting Edema (RS3PE) Syndrome Presenting as a Para-Neoplastic Syndrome/**D. Dhingani, A.S. Copur, A. Fulambarker, North Chicago, IL, p.A6094

P96 **A Young Man with Back Pain/**H. Enuh, P. Sharma, B. Pulluri, J. Sprague, P. Gibson, D.A. Kaminsky, Burlington, VT, p.A6095

P97 **When Lightening Strikes Twice. A Case of Dual Diagnosis of Non Hodgkin Lymphoma and Small Cell Cancer of Esophagus/**H. Arshad, M. Young, P. Rali, R. Adurty, Pittsburgh, PA, p.A6096

P98 **Synchronous Intralobar Pulmonary Sequestration and Poorly Differentiated Adenocarcinoma in the Right Lower Lung Lobe/**H. Baig, H. Chohan, A. Lewis, Orlando, FL, p.A6097

P99 **Stroke and a Valvular Lesion in a Patient with Stage IV Non-Small Cell Lung Cancer/**A.A. Mitma, S. Zarich, D. Witt, Bridgeport, CT, p.A6098

P100 **Spindle Cell Carcinoma Masquerading as Metastatic Renal Cell Carcinoma/**B. Lou, C. Peng, N. Rohs, R. Sulica, New York, NY, p.A6099

P101 **A Case of Hepatoid Adenocarcinoma of the Lung/**L. Shiekh Sroujieh, S. Jassim, M.N. Iqbal, E. Sivak, J. Tomashefski, Cleveland, OH, p.A6100

P102 **Coexistent Pulmonary Granular Cell Tumor and Adenocarcinoma of the Lung with Pulmonary Tuberculosis/**S. Uslu, C.E. Dagli, H. Erdem, M. Karaoglanoglu, Ordu, Turkey, p.A6101

P103 **Lung Nodule- Thoracic Endometriosis/**V. Angirekula, Z. Shaman, Cleveland, OH, p.A6102

P104 **A Rare Cause of Hemoptysis: Mucoepidermoid Carcinoma of the Bronchus/**K. Lam, A. Gohil, Palo Alto, CA, p.A6103

P105 **Metastasis to the Colon from Lung Adenocarcinoma Manifesting as Tarry Stool/**S. Yi-Cheng, C.-Y. Tu, W.-C. Liao, Taichung, Taiwan, p.A6104

P106 **A Lung Mass, Orthopnea, and Syncope: Tissue Diagnosis Should Wait/**K.R. Courtright, J. Fritz, A. Haas, Philadelphia, PA, p.A6105

P107 **Jaundice in a Patient with Advanced Lung Cancer/**W.-C. Liao, C.-C. Li, C.-H. Chen, C.-Y. Chen, C.-Y. Tu, Taichung, Taiwan, p.A6106

P108 **Bilateral Vocal Cord Paralysis from Tonsillar Cancer/**H.J. Son, San Francisco, CA, p.A6107

P109 **Pulmonary Adenocarcinoma: A Case of False Identity/**N. Mehta, Y. Naidu, S. Sharma, D. Lingutla, Rochester, NY, p.A6108

P110 **Diagnosis of an Unusual Case of Metastatic Non-Small Cell Lung Cancer/**E. Levine, G. Romaka, D.M. Wisa, B. Mina, New York, NY, p.A6109

P111 **Lung Cancer Presenting with Acute Onset Severe Chest Pain/**C. Sutton, C. McCartney, R. Nayak, St. Louis, MO, p.A6110

P112 **Adenocarcinoma of the Anus: An Extremely Rare Presentation of a Primary Lung Malignancy/**J.A. Riggs, K. Carson, St. Louis, MO, p.A6111

P113 **"I am superman" - Psychiatric Symptoms as an Initial Manifestation of Lung Cancer, an Interesting Case!/**P.K. Gorukanti, A. Agarwal, M.A. Shenoy, A. Rai, T. Yoon, W. Pascal, K. Chawla, Brooklyn, NY, p.A6112

P114 **A Case of Scant Hemoptysis that Lead to the Discovery of a Rare Mid-Tracheal Tumor/**I.E. Alwine, T. Smith, M. Shamiyia, R. Duff, Myrtle Beach, SC, p.A6113

P115 **Small Cell Lung Cancer Presenting as Painful Obstructive Jaundice: Case Report/**J.M. Scoon, Y.C. Yeh, A.E. Sagar, Houston, TX, p.A6114

P116 **A Pathologic Rarity/**C.J. Ezekiel, S. Kosuri, Harrisburg, PA, p.A6115

P117 **Multicenter Adenocarcinoma in Young Female Patient/**R.K.R. Leal, C.A. Barros Franco, G. Kissmann, R. Haddad, H. Paiva, Rio de Janeiro, Brazil, p.A6116

P118 **Unusual Presentation of Metastatic Lung Cancer in a Young Patient/**P.S. Vayalil, C. Brown, B. Bumgarner, M. Mirza, J. Murray, A. Theertham, J. Lambrecht, Omaha, NE, p.A6117

P119 **First Order Horner Syndrome: Atypical Presentation of Primary Adenocarcinoma of Lung with Brainstem Metastasis/**A. Gandhi, C. Hilton, A. Avula, R. Rampure, S. Bhutani, Abington, PA, p.A6118

P120 **Small Cell Lung Cancer Presenting as Cystic Brain Metastases: An uncommon Presentation/**A. Mohammed, J.M. Chowdhury, E. Green, Darby, PA, p.A6119

P121 **Shoulder Pain Masquerading a Tumor: Pancoast Tumor/**J. Aleman-Ortiz, W. Rodriguez-Cintron, San Juan, PR, p.A6120

P122 **Development of Lung Adenocarcinoma with Epidermal Growth Factor Receptor Mutation in Patients with Breast Cancer History: Case Report/**L. Fernandez, D.A. Vargas, L.F. Sua, L.I. Gomez, L.X. Rodriguez, Cali, Colombia, p.A6121

P123 **Seizure and a Solitary Brain Metastasis in a Non-Smoker - A Rare and Unusual Initial Presentation of Occult Asymptomatic Non-Small Cell Lung Cancer/**D. Terrington, A. Craig-McQuaide, R. Tabbara, A. Arya, King's Lynn, United Kingdom, p.A6122

P124 **Adenocarcinoma of the Lung Presenting as a Lung Abscess/**C. Agu, M. Basunia, S. Kandel, D. Salhan, F. Schmidt, D. Enriquez, J. Quist, Brooklyn, NY, p.A6123

P125 **Three Cases of Pulmonary Adenocarcinoma in Which Epidermal Growth Factor Receptor (EGFR) Exon 20 T790M Resistance Mutations in Pleural Fluids Disappeared/**T. Kodama, K. Watanabe, K. Nagai, M. Shinoda, M. Shinkai, T. Kaneko, Yokohama Kanagawa Prefecture, Japan, p.A6124

P126 **A Rare Type of Synchronous Multiple Primary Lung Cancer: Staging and Treatment Dilemma/**C. Ghattas, M. Hundal, M. Agustin, J. Unterborn, Boston, MA, p.A6125

P127 **Lung Cancer Presenting as a PET Negative Cystic Lung Lesion: Colloid Adenocarcinoma of the Lung with Cystic Changes and Enteric Differentiation/**P. Dammert, R. Sawhney, D. Brenner, Dover, DE, p.A6126

P128 **A Case of FDG-PET Uptake Heterogeneity in a Pulmonary Neuroendocrine Tumor/**D.G. Washburn, D. Chooljian, Loma Linda, CA, p.A6127

P129 **A Case of Sarcomatoid Carcinoma of the Lung in a Young Female/**D.G. Venkat, G. Lyles, R. Elliot, C. Teba, Cleveland, OH, p.A6128

P130 **Chylous Pleural and Pericardial Effusions in Adenocarcinoma of the Lung/**L.M. Sanso, L. Lief, K. Rajwani, New York, NY, p.A6129

11:45 a.m. – 1:15 p.m

ATS PLENARY SESSION
MOSCONE CENTER
Room 303/305 (South Building, Esplanade Level)

The Plenary Session features a discussion with **Katie Meyler**, founder of the More than Me Academy, which is a tuition-free girls school in Monrovia, Liberia established to help girls get off the streets and into school. When Ebola broke out in the area, Meyler turned the school into a disaster-response center and organized meetings, food distribution, and ambulance service. Among the many honors she has received, Meyler was one of the "Ebola Fighters" collectively recognized by TIME magazine as the 2014 Person of the Year.

The ATS Outstanding Educator Award will be presented to **Robert Kotloff, MD.**

The Plenary Session will also feature the introduction of the ATS slate of officers for 2016-2017, the current state of the Society, and plans for the Society's future.

BASIC • CLINICAL • TRANSLATIONAL

WORKSHOP

CME Credits Available: 1.5

WS5 LATEST ADVANCES IN THE LUNG MICROBIOME

Registration Fee: $75.00 (includes box lunch)
Attendance is limited. Pre-registration is required.

Assemblies on Microbiology, Tuberculosis and Pulmonary Infections; Allergy, Immunology and Inflammation

11:45 a.m. - 1:15 p.m. **MOSCONE CENTER**
Room 301 (South Building, Esplanade Level)

Target Audience
Clinical and laboratory investigators and health care professionals interested in microbiome research and application of microbiome to patient care in the outpatient, hospital and/or critical care setting, including physicians, trainees, early career investigators.

Objectives
At the conclusion of this session, the participant will be able to:

- learn recent advances in our understanding of the host-microbe interactions on disease and maintenance of lung health;
- appreciate the vast emerging information on microbial communities in specific disease states and how the dynamic host-microbe interaction affects disease progression and treatment decisions, allowing attendees the ability to apply this knowledge to their own areas of interest;
- understand the functional significance of the lung microbiome and how these microbes can alter the lung environment in specific disease states. Attendees will be able to critically examine microbiome research and further investigate how these organisms can affect the lung mileu.

Understanding the composition of various aspects of what makes us who we are and how we develop disease is paramount to understanding disease pathogenesis, treatment responses, and personalizing medical care. The lung microbiome is not only an area of emerging research interest, but also one that has considerable clinical impact. Improved knowledge about microbial communities in the lung will ultimately contribute to development of innovative approaches and therapies to diagnose and treat chronic respiratory diseases. This workshop will highlight the latest findings on lung microbiome investigations in gut-lung interactions, disease states such as asthma and HIV, and the potential for novel therapeutic strategies.

Chairing: M.R. Gingo, MD, MS, Pittsburgh, PA
H.L. Twigg, MD, Indianapolis, IN

11:45 **Normal Lung Micriobiome and Lung Pneumotypes**
L. Segal, MD, New York, NY

12:07 **Microbiome and Asthma**
Y.J. Huang, MD, Ann Arbor, MI

12:29 **Gut-Lung Microbial Interaction**
S.V. Lynch, PhD, San Francisco, CA

12:51 **Correlation of the Lung Microbiome with Metabolome in HIV**
S.K. Cribbs, MD, MSc, Decatur, GA

BEHAVIORAL • CLINICAL

WORKSHOP

CME Credits Available: 1.5

WS6 TO TWEET OR NOT TO TWEET: SOCIAL MEDIA IN HEALTH CARE AND EDUCATION

Registration Fee: $75.00 (includes box lunch)
Attendance is limited. Pre-registration is required.

Assemblies on Behavioral Science and Health Services Research; Allergy, Immunology and Inflammation; Clinical Problems; Pediatrics; Respiratory Cell and Molecular Biology

11:45 a.m. - 1:15 p.m. **MOSCONE CENTER**
Room 302 (South Building, Esplanade Level)

Target Audience
Health care providers, educators, and researchers at all levels of digital fluency, from beginner to expert; individuals interested in learning about how these digital platforms are being used in health care and for research.

Objectives
At the conclusion of this session, the participant will be able to:

- become acquainted with and review different types of social media and web-based information sharing platforms;
- discover how patients and providers are using digital and social media to transform the way health care is delivered and taught worldwide;
- develop strategies to integrate social media into clinical practice, academic research, and education.

Social media and digital communication are dramatically changing the way patients and health care providers communicate and interact. Cell phones allow 63% of cell phone owners to use mobile internet where social media has empowered patients to expand their health care knowledge and participate in research. Social media provides practitioners with new ways to learn about real-time information about relevant topics, lead discussions, promote causes, and build relationships with patients. In this session, five social media experts will discuss how to navigate social media platforms and review how others are using digital tools and social media platforms to improve communication, increase knowledge acquisition, and improve patient care. With a combined following of over 13,000 Twitter followers, these four experts demonstrate how both junior and senior faculty, individuals with MDs and PhDs, can incorporate Twitter into their daily lives to discuss the results of studies, promote studies, ask questions, and network. This workshop includes a hands-on component as participants who sign up for a Twitter account prior to the workshop will have the opportunity to tweet questions to the speakers using a predesignated workshop hashtag. The speakers will answer questions at the end of the session and also tweet responses during the workshop. This interactive component will have two purposes. First, participants will get their questions answered. Secondly, participants will learn some of the basics of tweeting, retweeting, marking favorites, using hashtags and more. Finally, we will discuss how to leverage social media to improve the health education of students, patients, and providers.

Chairing: W.G. Carlos, MD, MSCR, Indianapolis, IN
A.C. Wu, MD, MPH, Boston, MA

11:45 **To Thine Own Self Be True: What to Expect**
W.G. Carlos, MD, MSCR, Indianapolis, IN

11:50 **Much Ado About Something: Introduction to Social Media**
B.E. Himes, PhD, Philadelphia, PA

12:05 **The Taming of Social Media: #ATS2016**
C.L. Carroll, MD, Hartford, CT

12:20 **All of Health Care Research is a Stage: The Role of Social Media**
A.C. Wu, MD, MPH, Boston, MA
N. Kaminski, MD, New Haven, CT

12:40 **The Merchant of Medical Education**
A.S. Clay, MD, Durham, NC

12:50 **As You Tweet It: The Perils of a Social Media Presence**
E. Skinner, PhD, PT, Melbourne, Australia

1:00 **All's Well That Ends Well**
A.C. Wu, MD, MPH, Boston, MA
W.G. Carlos, MD, MSCR, Indianapolis, IN

MEET THE PROFESSOR SEMINARS

CME Credits Available: 1.0

Registration Fee: $70.00 (includes box lunch.)
Attendance is limited. Pre-registration is required.

12:15 p.m - 1:15 p.m. **INTERCONTINENTAL HOTEL**

MP601 **ROLE OF VITAMIN D IN ASTHMA AND ABPA**
M. Singh, MD, Chandigarh, India
Union Square (Third Floor)

MP602 **A GUIDE TO SUBMITTING A SUCCESSFUL APPLICATION TO PCORI**
J.A. Krishnan, MD, PhD, Chicago, IL
SoMa (Third Floor)

MP603 **FLEISCHNER SOCIETY GUIDELINES FOR PULMONARY NODULES**
A.C. Mehta, MBBS, Cleveland, OH
Mission (Third Floor)

MP604 **PULMONARY VASCULITIS: CONCEPTUAL APPROACH TO MANAGEMENT**
U. Specks, MD, Rochester, MN
Marina (Third Floor)

MP605 **INTERSTITIAL LUNG PATHOLOGY FOR NON-PATHOLOGISTS**
K.D. Jones, MD, San Francisco, CA
Grand Ballroom C (Third Floor)

MP606 **APPROACH TO THE PATIENT WITH REFRACTORY CHRONIC COUGH**
P.V. Dicpinigaitis, MD, Bronx, NY
Grand Ballroom B (Third Floor)

MP607 **ADVANCES IN THE MANAGEMENT OF PULMONAY ARTERIAL HYPERTENSION: A CASE-BASED DISCUSSION OF APPLYING THE LATEST GUIDELINES AND CLINICAL RESEARCH**
M.M. Chakinala, MD, St. Louis, MO
Grand Ballroom A (Third Floor)

MP608 **LIFE AFTER DEATH: ENHANCING TRANSPLANTATION VIA OPTIMAL MANAGEMENT OF THE ORGAN DONOR**
D.R. Nunley, MD, Louisville, KY
Twin Peaks (Fourth Floor)

MP609 **AIR POLLUTION DOESN'T RECOGNIZE THE BORDER: GLOBAL PERSPECTIVE OF AIR POLLUTION**
M. Akpinar-Elci, MD, MPH, Norfolk, VA
Telegraph Hill (Fourth Floor)

MP610 **DIAGNOSTIC ALGORITHMS FOR SUSPECTED PNEUMONIA IN VENTILATED PATIENTS**
R.G. Wunderink, MD, Chicago, IL
Potrero Hill (Fourth Floor)

MP611 **A DIFFICULT CONVERSATION: TALKING TO YOUR PATIENT ABOUT SEX**
G.S. Bauldoff, PhD, RN, Powell, OH
E.G. Collins, PhD, RN, Chicago, IL
Nob Hill (Fourth Floor)

MP612 **A SYSTEMATIC APPROACH TO PULMONARY DISEASE IN CHILDREN WITH COMPLEX CARDIAC DISEASE**
R.R. Deterding, MD, Aurora, CO
Laurel Hill (Fourth Floor)

MP613 **DELIVERING EFFECTIVE PULMONARY REHABILITATION WITH MINIMAL RESOURCES**
J. Alison, PhD, MSc, PT, Lidcombe, Australia
Cathedral Hill (Fourth Floor)

MP614 **DAY/NIGHT AND CLOCK IN LUNG PATHOPHYSIOLOGY**
I. Rahman, PhD, Rochester, NY
Sutter (Fifth Floor)

MP615 **PERSONALIZED MEDICINE FOR ASTHMA: WHAT'S THE HYPE ABOUT PHENOTYPE?**
G.S. Skloot, MD, New York, NY
Stockton (Fifth Floor)

MP616 **IMPACT OF MILD OSA ON CARDIOVASCULAR OUTCOMES: A REPORT FROM THE ATS SRN TASK FORCE**
S. Chowdhuri, MD, MS, Detroit, MI
Howard (Fifth Floor)

MP617 **INSIGHTS ON RUNNING A MULTIDISCIPLINARY TEAM DISCUSSION FOR LUNG NODULES**
D. Upadhyay, MD, Fresno, CA
Fremont (Fifth Floor)

MEDICAL EDUCATION SEMINAR

CME Credits Available: 1.0

ME3 PRACTICAL SKILLS FOR TEACHING IN SMALL GROUPS

Registration Fee: $70.00 (includes box lunch)
Attendance is limited. Pre-registration is required.

12:15 p.m. - 1:15 p.m. **INTERCONTINENTAL HOTEL**
InterContinental Ballroom A (Fifth Floor)

Target Audience
Providers, including physicians, nurses and advanced practice providers, within pulmonary, critical care and sleep medicine who seek to expand their teaching repertoire and, in particular, improve their skills in small group setting.

Objectives
At the conclusion of this session, the participant will be able to:

- describe strategies that can be employed before entering the classroom to ensure a productive small group learning environment;
- delineate an approach to manage challenging learners in the small group setting;
- describe the appropriate balance of speech between students and teacher and tools for managing the white board effectively during small group teaching.

The small group is one of the primary settings in which medical educators may be asked to interact with learners. While often a highly rewarding experience, it can be a challenging environment in which to teach due to the small number of learners, the emphasis on interaction and active participation and the less structured nature of the teaching encounter. This session will use an interactive format to impart strategies for managing these and other challenges and ensuring successful small group teaching encounters.

Speaker: A.M. Luks, MD, Seattle,WA

THEMATIC SEMINAR SERIES

CME Credits Available: 1.0

TSS1 CONTEMPORARY CONTROVERSIES IN THE DIAGNOSIS AND MANAGEMENT OF IDIOPATHIC PULMONARY FIBROSIS: A PRO/CON DEBATE

Registration Fee: $140.00 for full series (includes box lunch)
Attendance is limited. Pre-registration is required.

This is part 3 of a 3-part series. Those registering for this seminar series will be registered for all 3 parts. The program for the full series is included with the Sunday, May 15, 12:15 p.m. program.

Tuesday 12:15 p.m. - 1:15 p.m. **INTERCONTINENTAL HOTEL**
InterContinental Ballroom C (Fifth Floor)

PRO: Decline of 10% or Greater in FVC Should be Regarded as Treatment Failure in IPF
V. Cottin, MD, PhD, Lyon, France

CON: Decline of 10% or Greater in FVC Should be Regarded as Treatment Failure in IPF
P.W. Noble, MD, Los Angeles, CA

THEMATIC SEMINAR SERIES

CME Credits Available: 1.0

TSS2 REDUCING HOSPITAL READMISSIONS

Registration Fee: $140.00 for full series (includes box lunch)
Attendance is limited. Pre-registration is required.

This is part 3 of a 3-part series. Those registering for this seminar series will be registered for all 3 parts. The program for the full series is included with the Sunday, May 15, 12:15 p.m. program.

Tuesday 12:15 p.m. - 1:15 p.m. **INTERCONTINENTAL HOTEL**
InterContinental Ballroom B (Fifth Floor)

PRO: Medications Are the Key to Reducing Readmissions in COPD
G.T. Ferguson, MD, Livonia, MI

CON: Medications Are the Key to Reducing Readmissions in COPD
R.A. Wise, MD, Baltimore, MD

1:15 p.m. - 2:15 p.m.

VISIT THE EXHIBIT HALL

Take this opportunity between sessions to visit the Exhibit Hall to gain practical knowledge to advance care and research. Exhibitors will be on hand to provide information on pharmaceutical products, medical equipment, publications and research services.

CLINICAL

ADULT CLINICAL CORE CURRICULUM

CME Credits Available: 2.0

CC4 SLEEP MEDICINE CLINICAL CORE CURRICULUM II

Adult Core Curriculum Working Group

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Gateway Ballroom 102-104 (South Building, Lower Level)

Target Audience

Internists and subspecialists in pulmonary, critical care, and sleep medicine who work in a clinical setting and are currently engaged in maintenance of certification.

Objectives

At the conclusion of this session, the participant will be able to:

- remain current with medical knowledge relevant to their practice in pulmonary, critical care, and sleep medicine;
- evaluate their understanding of key skills and content areas in pulmonary, critical care and sleep medicine, as well as receive feedback on their comprehension of a result of a pre-test/post-test comparison;
- support clinicians who are engaged in maintenance of certification activities by providing updates on subjects included in recertification requirements.

The ATS Clinical Core Curriculum Symposia focus on a 3-year content cycle of key medical content in the areas of pulmonary, critical care, and sleep medicine. The topics are also aligned with corresponding MOC Medical Knowledge modules. This symposium is intended to assist clinicians with staying current with the growth of information relevant to their medical practice, as well as provide an opportunity to evaluate individual knowledge and skills while earning MOC Medical Knowledge points.

Chairing: J.S. Balachandran, MD, Chicago, IL
T.S. Wang, MD, Los Angeles, CA

2:15 **Circadian Disorders: Overview of Biology**
S.P. Shea, PhD, Portland, OR

2:45 **Circadian Disorders: Shift Work, Advanced, Jet Lag**
K.M. Sharkey, MD, PhD, Providence, RI

3:15 **Parasomnias: REM**
S. Pamidi, MD, Montreal, Canada

3:45 **Parasomnias: NREM**
A.V. Shelgikar, MD, Ann Arbor, MI

BASIC • TRANSLATIONAL

CLINICAL TOPICS IN PULMONARY MEDICINE

CME Credits Available: 2.0

C82 INFECTION AND EXACERBATIONS: LEARNING ACROSS PULMONOLOGY

Assemblies on Clinical Problems; Microbiology, Tuberculosis and Pulmonary Infections

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 135 (North Building, Lower Level)

Target Audience

Clinicians and researchers interested in infection as applied to exacerbations and progression of chronic respiratory disease.

Objectives

At the conclusion of this session, the participant will be able to:

- describe new findings about infection as applied to disease progression and exacerbations across the major chronic respiratory diseases;
- understand novel strategies to manage infection in the context of chronic lung diseases;
- apply learning from different disease areas in relation to infection, exacerbations, and the healthy human airway microbiome.

We believe that clinicians and scientists in one discipline can learn much from the experience of those working in others, even within a specialty such as pulmonology. This symposium unites the areas of infection and clinical problems across disease areas, to discuss the role of infection and exacerbations in chronic respiratory disease. The Symposium will be of interest to a wide range of clinicians, scientists and industry professionals from across our Society.

Chairing: J.R. Hurst, MBChB, PhD, London, United Kingdom
K.L. Gates, MD, Chicago, IL
S. Sethi, MD, Buffalo, NY

2:15 **The Healthy Human Airway Microbiome**
R.P. Dickson, MD, Ann Arbor, MI

2:35 **Infection and Exacerbations of Asthma**
Y.J. Huang, MD, Ann Arbor, MI

3:00 **Respiratory Infection and COPD**
J.R. Hurst, MBChB, PhD, London, United Kingdom

3:25 **Microbial Dysbiosis and Exacerbations of Bronchiectasis**
J.D. Chalmers, MBChB, PhD, Dundee, United Kingdom

3:50 **The Role of Infection in the Progression of ILD**
H.R. Collard, MD, San Francisco, CA

There will be a 5-minute discussion after each talk.

CLINICAL • TRANSLATIONAL

CLINICAL TOPICS IN PULMONARY MEDICINE

CME Credits Available: 2.0

C83 NEW CONCEPTS REGARDING LUNG TRANSPLANT ALLOGRAFT DYSFUNCTION

Assemblies on Clinical Problems; Allergy, Immunology and Inflammation

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 134 (North Building, Lower Level)

Target Audience
Physicians and surgeons, nurses, respiratory therapists, pharmacists, trainees, industry.

Objectives
At the conclusion of this session, the participant will be able to:

- gain an understanding of changes in the definitions of PDG, AMR, and CLAD;
- improve diagnostic approaches to lung allograft dysfunction that include HLA monitoring and pathology assessment;
- develop new strategies for diagnosing PGD, AMR, and CLAD.

Lung allograft dysfunction definitions and diagnoses have evolved over time. Speakers will address reassessment of primary graft dysfunction definition and grading, diagnosis of antibody mediated rejection of the lung allograft, the pros and cons of HLA antibody monitoring, and recognition of new subtypes of chronic lung allograft dysfunction.

Chairing: D.J. Levine, MD, San Antonio, TX

2:15 **Redefining Primary Graft Dysfunction**
J.D. Christie, MD, MSCE, Philadelphia, PA

2:39 **Definition and Diagnosis of Lung Allograft Antibody Mediated Rejection**
R.D. Yusen, MD, MPH, St. Louis, MO

3:03 **HLA Antibody Monitoring in Lung Transplantation**
D.B. Tyan, PhD, Palo Alto, CA

3:27 **Chronic Lung Allograft Dysfunction (CLAD) Classification Update**
A.R. Glanville, MBBS, MD, Sydney, Australia

3:51 **Pathology of Pulmonary Allograft Dysfunction**
G.J. Berry, MD, Palo Alto, CA

There will be a 5-minute discussion after each talk.

BEHAVIORAL • CLINICAL

CRITICAL CARE TRACK

CME Credits Available: 2.0

C84 THE NEW ICU RECOVERY TOOLKIT: 5 HAMMERS LOOKING FOR THE RIGHT NAIL

Assemblies on Critical Care; Behavioral Science and Health Services Research; Clinical Problems

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 3000/3002/3004 (West Building, Level 3)

Target Audience
Clinicians working in the ICU or dealing with patients in its aftermath.

Objectives
At the conclusion of this session, the participant will be able to:

- more appropriately evaluate proposals for what post-ICU interventions their program should find;
- recommend resources to their patients on ICU discharge more selectively and with increased effectiveness;
- understand the strengths and limitations of existing data on ICU recovery interventions.

While we all know that problems are common after the ICU, nobody really knows what to do to make those problems better. Some people are worried enough that they seem ready to jump on any potential solution. Five approaches seem to garner the most excitement. In this session, we step back from the individual solutions to ask emerging leaders in the field: Why should this approach work? What are the data so far? (And why might they have been negative despite the approach still being hopeful?) How do we pick the right patient and system for that intervention?

Chairing: T.J. Iwashyna, MD, PhD, Ann Arbor, MI
C. Hodgson, PT, PhD, Melbourne, Australia
N. Pinto, MD, Chicago, IL

2:15 **Fix the Brain**
J.C. Jackson, PsyD, Nashville, TN

2:35 **Move the Body**
C. Hodgson, PT, PhD, Melbourne, Australia

2:55 **Recruit the General Practitioners**
J. Gensichen, MD, MSc, MPH, Jena, Germany

3:15 **Do it Ourselves (with a Post-ICU Clinic)**
E. Wilcox, MD, MPH, Toronto, Canada

3:35 **Help Survivors Help Each Other**
M.E. Mikkelsen, MD, Philadelphia, PA

3:55 **Not if, but Which: Selecting the Right Follow-Up for the Right Patient**
H.C. Prescott, MD, MA, Ann Arbor, MI

BASIC • CLINICAL • TRANSLATIONAL

BASIC SCIENCE CORE

CME Credits Available: 2.0

C85 SCIENTIFIC BREAKTHROUGHS IN RNA BIOLOGY: WHAT'S NEW, EXCITING AND THERAPEUTIC!

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 2009/2011 (West Building, Level 2)

Assemblies on Allergy, Immunology and Inflammation; Clinical Problems; Pulmonary Circulation; Respiratory Cell and Molecular Biology; Respiratory Structure and Function; Thoracic Oncology

Target Audience
Providers and trainees interested in clinical, basic and translational lung physiology, development and disease and molecular biology.

Objectives
At the conclusion of this session, the participant will be able to:

- understand and improve knowledge of the role of Linc RNA in lung development;
- understand the potential use of MicroRNAs as therapeutic targets.

This session will focus on some of the recently identified and novel roles of RNA species in regulating lung development and in treating lung disease. Speakers will discuss the role of long non-coding RNA in lung development and the potential for micro RNA as therapies for lung cancer. Thus the session will span basic biology and development to cutting edge therapeutics. It will synergize with the 2016 Scientific Core theme. Presentations from experts in the field will be complemented by abstract related to the topic being discussed.

Chairing: N. Kaminski, MD, New Haven, CT
P.J. Sime, MD, Rochester, NY
D. Erle, MD, San Francisco, CA

2:15 **Talk and Speaker to be Announced**

2:45 **FENDRR is an Epigenetic Regulator of Cellular Senescence in Pulmonary Fibroblasts**
K. Sakamoto, MD, New Haven, CT

3:00 **Identification of Novel MicroRNA Targets in Neonatal Lungs of CTGF-Transgenic Mice**
C. Miranda, MD, Nashville, TN

3:15 **Monocyte-Derived Alveolar Macrophages Contribute to the Development of Lung Fibrosis and Persist in the Lung Over the Lifespan**
A. Misharin, PhD, Evanston, IL

3:30 **MicroRNA Regulation of Allergic Inflammation and Asthma**
K.M. Ansel, PhD, San Francisco, CA

*This session and the International Conference are supported by an educational grant from **AstraZeneca LP.***

All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

BEHAVIORAL • CLINICAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 2.0

Nursing Contact Hours Available: 2.4

C86 SELF-MANAGEMENT AND RISK REDUCTION CHALLENGES IN VULNERABLE POPULATIONS

Assemblies on Nursing; Behavioral Science and Health Services Research; Clinical Problems

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 307 (South Building, Esplanade Level)

Target Audience
Nurses, physicians, physician assistants, respiratory therapists, respiratory care practitioners, pharmacists, physical therapists involved in providing or directing care in underserved populations in developed countries.

Objectives
At the conclusion of this session, the participant will be able to:

- identify current disparities in health delivery in underserved, disenfranchised and vulnerable populations.
- foster health professional attitudes to promote and frame actions to reduce disparities through identification and management of key risk factors;
- look to the future of greater equity in the delivery and access to health care for all communities.

This session will identify vulnerable populations across the world and discuss the unique challenges of modifying risk in these groups.

Chairing: R.T. Disler, PhD, RN, Sydney, Australia
L.B. Gerald, MSPH, PhD, Tucson, AZ

2:15 **A Patient's Perspective**
D. Breslawsky, La Quinta, CA

2:20 **Differences in Self-Management Preferences Increases Risk of Uncontrolled Asthma in Urban Black Adults**
M.R. George, AE-C, PhD, RN, New York, NY

2:40 **Disparities in Respiratory Health in Indigenous Australians**
E. Tikoft, CNC, Alice Springs, Australia

3:00 **Tuberculosis Among Homeless People in London, United Kingdom**
A. Story, PhD, RN, London, United Kingdom

3:20 **Sexual Orientation, Respiratory Disease Risk Factors and Access to Health Care**
N. Sitkin, BS, New Haven, CT

3:40 **Children with Asthma Living in Rural Settings**
L. Cicutto, PhD, RN, Denver, CO

4:00 **Panel Discussion**

*This session and the International Conference are supported by an educational grant from **AstraZeneca LP.***

All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

BASIC

PUBLIC ADVISORY ROUNDTABLE

CME Credits Available: 2.0

C87 NEW INSIGHTS INTO THE GENETIC BASIS OF PEDIATRIC LUNG DISEASE

Public Advisory Roundtable; Assembly on Pediatrics

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 3007/3009 (West Building, Level 3)

Target Audience
Physicians, basic and translational scientists, clinician-investigators, nurses, patients, and parents.

Objectives
At the conclusion of this session, the participant will be able to:

- understand the genetics of interstitial lung diseases in neonates and children, and how this information is providing new insights into pathogenesis, improved diagnostic tests, and potential therapeutic targets;
- appreciate the emerging genetics of primary ciliary dyskinesia and importance as a diagnostic approach, and understand genotype-phenotype relationships in this disease;
- recognize the importance of genetics in the pathophysiology of cystic fibrosis lung disease, and how this knowledge has led to the development of precision medicine.

The emergence of powerful, more affordable genomic technologies have advanced our knowledge of lung diseases at a rapid pace, providing greater insights into the genetics and pathophysiology of pulmonary diseases in children and adults. The progress made in genomics will increasingly translate into improved patient health, with improved diagnostic tests and personalized therapies. This session will highlight the progress made in genomics of lung diseases, focusing on the genetic and cellular bases of four childhood diseases, which will serve as a roadmap for other conditions.

Chairing: G.R. Porta, BS, Mason, OH
T.W. Ferkol, MD, St. Louis, MO

2:15 **Annual PAR Awards**
G.R. Porta, BS, Mason, OH

2:30 **Introduction**
T.W. Ferkol, MD, St. Louis, MO

2:35 **Neonatal Lung Diseases**
F.S. Cole, MD, St. Louis, MO

3:00 **Cystic Fibrosis**
G.R. Cutting, MD, Baltimore, MD

3:25 **Primary Ciliary Dyskinesia**
M. Knowles, MD, Chapel Hill, NC

3:50 **Childhood Interstitial Lung Diseases**
L.M. Nogee, MD, Baltimore, MD

CLINICAL • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 2.0

C88 VIRAL COMMUNITY-ACQUIRED PNEUMONIA

Assemblies on Microbiology, Tuberculosis and Pulmonary Infections; Clinical Problems; Critical Care; Pediatrics

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 3016/3018 (West Building, Level 3)

Target Audience
Pulmonologists, critical care specialists, pediatricians, scientists, hospital administrators, medical providers, trainees, fellows, and advanced practice providers.

Objectives
At the conclusion of this session, the participant will be able to:

- understand and learn about recent epidemiological data on respiratory viruses as etiology of community acquired pneumonia;
- learn new diagnostics tools to detect viral infection, including understanding the utility of procalcitonin in clinical medicine;
- understand how to integrate new information on respiratory viruses into clinical practice.

This session will provide the learner a comprehensive overview on how respiratory viruses contribute to current causes of community acquired pneumonia (CAP) and acute lung injuries in the ICU especially in the setting of the increasing use of genetic-based diagnostic approaches to detect viruses. Speakers in this symposium will highlight the current epidemiology of viral CAP and review the existing diagnostics of viral CAP including a pro/con debate on the role of procalcitonin in viral pneumonia. The role of viral pneumonia as cause of ARDS, and how RSV contributes to the disease in children and the elderly will be explored. And finally, given the increased use of molecular diagnostics to detect respiratory viruses, there will be a timely and careful discussion on what to do with a positive respiratory virus panel, including an analysis of whether rhinovirus ever causes pneumonia. These series of talks will update the audience on the recent information on viral pneumonia in clinical medicine with the goal of improving not only understanding of this topic but better implementation of current knowledge on viral pneumonia into practice.

Chairing: C.S. Dela Cruz, MD, PhD, New Haven, CT
R.D. Shah, MD, Chicago, IL

2:15 **Epidemiology of Viral CAP**
W. Self, MD, MPH, Nashville, TN

2:35 **Pro/Con Debate: Procalcitonin for Viral Pneumonia (Con)**
G.W. Waterer, MBBS, PhD, MBA, Perth, Australia

2:50 **Pro/Con Debate: Procalcitonin for Viral Pneumonia (Pro)**
T. File, MD, Akron, OH

3:05 **RSV in the Young and Old Patients**
J. Devincenzo, MD, Memphis, TN

3:25 **Viral Pneumonia and ARDS: A Lethal Combination**
J.E. Chastre, MD, Paris, France

3:45 **What to Do with a Positive Respiratory Virus Panel (RVP)?**
R.G. Wunderink, MD, Chicago, IL

4:05 **Discussion**
C.S. Dela Cruz, MD, PhD, New Haven, CT

There will be a 5-minute discussion after each talk.

BASIC • CLINICAL • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 2.0

C89 EMERGING IMMUNE FUNCTIONS OF THE PULMONARY EPITHELIUM IN INFECTION, ASTHMA, AND CHRONIC LUNG DISEASE

Assemblies on Allergy, Immunology and Inflammation; Microbiology, Tuberculosis and Pulmonary Infections; Respiratory Cell and Molecular Biology; Respiratory Structure and Function

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 2005/2007 (West Building, Level 2)

Target Audience
Basic, translational, and clinical researchers interested in advancing their understanding of how the respiratory epithelium contributes to immunity, inflammation, and disease.

Objectives
At the conclusion of this session, the participant will be able to:

- learn cutting edge findings on how airway and alveolar epithelia coordinate inflammatory and immune responses in the lung;
- learn new techniques for targeted study of epithelial cells in the lung;
- appreciate the role of the airway epithelial basal cell in lung repair and regeneration in health and disease.

Emerging literature has begun to reveal a remarkable number of roles for the respiratory epithelium, from conducting airway to alveolus, in innate and adaptive immunity. Far from housekeeping cells that form a simple mechanical barrier, epithelial cells are increasingly recognized in a new light as professional immune sentinels that instruct hematopoietic cells and also promote repair during infection, asthma, fibrosis, and other disorders. This session brings together leading experts to discuss recent paradigm shifting findings on the respiratory epithelium as a master regulator of the inflammatory, immune, fibrotic, and repair processes that underlie both acute and chronic lung disease.

Chairing: M.B. Fessler, MD, Research Triangle Park, NC
A.A. Humbles, PhD, Gaithersburg, MD

2:15 **Transcriptional Regulation of Epithelial Biology and Its Contributions to Lung Disease**
J.A. Whitsett, MD, Cincinnati, OH

2:35 **Novel Immune Functions of the Alveolar Epithelium During Pneumonia**
J.P. Mizgerd, ScD, Boston, MA

2:55 **Role of MUC5B in Pulmonary Fibrosis and Beyond**
D.A. Schwartz, MD, Aurora, CO

3:15 **Epithelial Cytokines in Allergic Pulmonary Inflammation**
C.M. Lloyd, PhD, London, United Kingdom

3:35 **Regulation of Airway Basal Stem Cell Self-Renewal in Health and Disease**
B. Gomperts, MD, Los Angeles, CA

3:55 **Running Interference: The Lung Epithelium as Orchestrator of the Interferon Response**
A.S. Prince, MD, New York, NY

There will be a 5-minute discussion after each talk.

BASIC • CLINICAL • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 2.0

C90 IT TAKES TWO TO TANGO: RIGHT AND LEFT VENTRICLE INTERACTIONS IN PULMONARY VASCULAR DISEASE

Assemblies on Pulmonary Circulation; Clinical Problems; Critical Care; Respiratory Cell and Molecular Biology

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 3010/3012 (West Building, Level 3)

Target Audience
Basic, translational and clinical researchers interested in right and left ventricular function in health and disease.
Clinicians (especially internists, pulmonologists/ intensivists, and cardiologists) interested in RV and LV function as well as in RV-directed therapies in pulmonary vascular diseases.

Objectives
At the conclusion of this session, the participant will be able to:

- understand differences and similarities between the RV and LV
- identify the interplay between RV and LV function in health and disease
- understand how research and therapeutic approaches to LV disease can be translated to RV disease

This session will focus on interactions between the right ventricle (RV) and left ventricle (LV) in pulmonary hypertension (PH). While it has long been known that the RV is at risk for failing in PH, little is known about how PH and RV dysfunction affect the LV. Similarly, the potential effect of PH-specific therapies on LV function has been poorly understood. Lastly, the exact mechanisms of RV dysfunction in LV disease are only incompletely understood. This session will address these knowledge gaps by providing novel evidence indicating that complex RV and LV interactions
underlie the pathophysiology of decreased cardiac output in PH. Novel and emerging approaches in LV research and their implications for the study of the RV will be discussed.

Chairing: T. Lahm, MD, Indianapolis, IN
C.E. Ventetuolo, MD, MS, Providence, RI
W.M. Kuebler, MD, PhD, Toronto, Canada

2:15 **RV and LV: Twins or Strangers?**
T. Lahm, MD, Indianapolis, IN

2:39 **RV Involvement in LV Disease: What Makes the RV Fail in the Setting of LV Failure?**
R. Tedford, MD, Baltimore, MD

3:03 **Relax! RV and LV Diastology in Pulmonary Hypertension**
F. De Man, PhD, Amsterdam, Netherlands

3:27 **Left, Right, or Both? Is There a Role for Beta Blockers, ACE Inhibitors, or Neurohormonal Modulators in RV Failure?**
C.E. Ventetuolo, MD, MS, Providence, RI

3:51 **Lessons Learned from Left Heart Failure: Which Novel Approaches and Directions in LV Research Can Be Applied to the RV?**
M. Bristow, MD, PhD, Denver, CO

BEHAVIORAL • CLINICAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 2.0

Nursing Contact Hours Available: 2.4

C91 OPTIMIZING ICU ROUNDS: EVIDENCE-BASED APPROACHES FOR IMPROVING PATIENT CARE AND TEACHING

Assemblies on Behavioral Science and Health Services Research; Clinical Problems; Critical Care; Nursing; Sleep and Respiratory Neurobiology

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 3006/3008 (West Building, Level 3)

Target Audience
Families of critically ill patients, critical care providers, and those with clinical, teaching, research, or administrative responsibilities.

Objectives
At the conclusion of this session, the participant will be able to:

- become familiar with evidence based interventions designed to improve patient care and teaching during ICU rounds;
- integrate effective strategies regarding communication with patients and their families while rounding in the ICU;
- understand the importance of incorporating multidisciplinary teams (nursing, respiratory therapists, pharmacists, and other providers) into ICU rounds.

The scientific symposium aims to provide the attendee with complementary tools leading to organized and efficient ICU rounds that also excel in delivering high value patient care and quality resident and fellow teaching. Attendees will gain a better understanding of the forces influencing change in the current rounding structure. Attendees will then learn about seminal work in the development and evaluation of interventions to improve the rounding structure. Gaps in our current understanding and areas for further exploration will be emphasized.

Chairing: A. Amaral, MD, Toronto, Canada
D.K. Costa, PhD, RN, Ann Arbor, MI

2:15 **The Challenge of Competing Priorities in ICU Rounding in 2016**
H.T. Stelfox, MD, PhD, Calgary, Canada

2:25 **Pre-Rounding in the ICU: The Effects of Disrupted Patient and Provider Sleep on ICU Outcomes**
B.K. Gehlbach, MD, Iowa City, IA

2:45 **Beyond Pimping: Teaching Effectively While Rounding Efficiently**
A.S. Clay, MD, Durham, NC

3:05 **Choosing Wisely in the ICU: Integrating Principles of High Value Care into Rounds**
J. Wagner, MD, MSHP, Philadelphia, PA

3:25 **Speak Up: Incorporating Patients and Their Families into Daily Rounds**
M. Happ, PhD, RN, Columbus, OH

3:45 **Embracing Multidisciplinary Team Rounding in the ICU**
D.K. Costa, PhD, RN, Ann Arbor, MI

4:05 **Integrating the Evidence for Effective Rounding in the ICU**
A. Amaral, MD, Toronto, Canada

There will be a 5-minute discussion after each talk.

BEHAVIORAL • CLINICAL • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 2.0

C92 ATS CLINICAL PRACTICE GUIDELINES: CLINICAL PRACTICE ON THE CUTTING EDGE

Documents Development and Implementation Committee; International Conference Committee; Education Committee; Assemblies on Behavioral Science and Health Services Research; Critical Care; Microbiology, Tuberculosis and Pulmonary Infections; Nursing; Pediatrics; Pulmonary Circulation

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 2006/2008 (West Building, Level 2)

Target Audience
Physicians, nurses, respiratory therapists, and others who care for children who require flexible bronchoscopy or have pulmonary hypertension, or for adults or children with acute respiratory distress syndrome, hospital-acquired pneumonia, ventilator-associated pneumonia or tuberculosis.

Objectives
At the conclusion of this session, the participant will be able to:

- understand how evidence is used to inform diagnostic and treatment recommendations;
- apply clinical recommendations from recently published guidelines and technical standards in clinical practice, improving patient outcomes;
- obtain new strategies to manage exercise induced bronchoconstriction, pulmonary hypertension of sickle cell disease, Bronchiolitis Obliterans Syndrome.

This session is the second annual scientific symposium highlighting recently approved or published ATS evidence-based clinical practice guidelines and technical standards. This year's symposium will highlight guidelines on hospital-acquired and ventilator-associated pneumonia, diagnosis of tuberculosis, treatment of tuberculosis, and pediatric pulmonary hypertension, as well as technical standards on pediatric flexible bronchoscopy. Speakers will describe the clinical recommendations formulated by the guideline panels, discuss the rationale for each, and critically review the evidence supporting each recommendation. Speakers will also describe how the guidelines provide the foundation for improving care. Speakers include the chairs of the panels that developed the guidelines and technical standards.

Chairing: K.C. Wilson, MD, New York, NY
C.C. Thomson, MD, MPH, Cambridge, MA

2:15 **Implementation of ATS Clinical Practice Guidelines**
C.C. Thomson, MD, MPH, Cambridge, MA

2:25 **Strength of Recommendations and Quality of Evidence**
K.C. Wilson, MD, New York, NY

2:35 **Hospital Acquired Pneumonia/Ventilator-Associated Pneumonia Guidelines**
M.L. Metersky, MD, Farmington, CT

2:50 **Diagnosis of Tuberculosis Guidelines**
D.M. Lewinsohn, MD, PhD, Portland, OR

3:05 **Treatment of Drug Sensitive Tuberculosis Guidelines**
P. Nahid, MD, MPH, San Francisco, CA

3:20 **Pediatric Pulmonary Hypertension Guidelines**
S.H. Abman, MD, Aurora, CO

3:35 **Pediatric Bronchoscopy Technical Standards**
A. Faro, MD, St. Louis, MO

3:50 **Late Breaking Guidelines**
K.C. Wilson, MD, New York, NY

There will be a 5-minute discussion after each talk.

MINI SYMPOSIUM

C93 IMMUNE REGULATION OF INFECTION: BUILT IN PROTECTION

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 3020/3022 (West Building, Level 3)

Chairing: M.A. Olman, MA MD, Cleveland, OH
J.K. Kolls, MD, Pittsburgh, PA
J.C. Deng, MD, Los Angeles, CA

Oral Presentations

2:15 **Resolvin D1 Promotes Nontypeable Haemophilus Influenzae Clearance and Improves Respiratory Health/**A. Croasdell, S.H. Lacy, K. Owens, T.H. Thatcher, P.J. Sime, R.P. Phipps, Rochester, NY, p.A6130

2:30 **Circadian Regulation of Lung Injury and Inflammation in Influenza A Infection/**S. Sengupta, J. Xue, C.B. Lopez, G.A. FitzGerald, Philadelphia, PA, p.A6131

2:45 **Transient Receptor Potential Vanilloid 4 (TRPV4) Mediates Macrophage Phagocytosis, Cytokine Production, and Infection-Associated Lung Injury/Resolution in a Stiffness Dependent Manner/**R.G. Scheraga, S. Abraham, K.A. Niese, L.M. Grove, B.D. Southern, T.L. Bonfield, C. Zhao, T.A. Hamilton, M.A. Olman, Cleveland, OH, p.A6132

3:00 **Viral Infection Induces Development of a Distinct Neutrophil Phenotype with Impaired Ability to Clear Bacterial Pathogens/**J.E. Prasso, W. Lung, C. Yuen, Y. Tarabichi, Q. Cheng, J.C. Deng, Los Angeles, CA, p.A6133

3:15 **Impaired Dendritic Cell Recruitment and Anti-viral Function in Asthmatic Patients Following Rhinovirus Infection/**A. Cameron, J. Dhariwal, S.L. Johnston, R.P. Walton, London, United Kingdom, p.A6134

3:30 **Resistin-Like Molecules as Antiviral Mediators Against Influenza A Virus Infection/**A.E. Samarasinghe, Y. Lin, K. LeMessurier, J.A. McCullers, Memphis, TN, p.A6135

3:45 **Resolution of Respiratory Pneumococcal Infection Seeds the Local Lung Tissue with CD4+ TRM Cells that Prevent Future Pneumonias/**N.M.S. Stauffer, F.T. Coleman, K.L. Hilliard, K. Yamamoto, G. Wasserman, H. Dooms, M. Jones, L.J. Quinton, J.P. Mizgerd, Boston, MA, p.A6136

4:00 **IL-33 Protects Against Influenza-Associated Bacterial Super-Infection/**K.M. Robinson, M.E. Clay, K. Ramanan, K.J. McHugh, J.F. Alcorn, Pittsburgh, PA, p.A6137

MINI SYMPOSIUM

C94 LUNG INJURY, INFLAMMATION AND REPAIR: INNATE IMMUNE REGULATION

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 2020/2022 (West Building, Level 2)

Chairing: R. Vlahos, PhD, Bundoora, Australia
R.L. Zemans, MD, Denver, CO

Oral Presentations

2:15 **Pannexin-1 Channels on Endothelial Cells Regulate Lung Ischemia-Reperfusion Injury/**A.K. Sharma, E. Charles, Y. Zhao, I. Kron, K.S. Ravichandran, B. Isakson, V. Laubach, Charlottesville, VA, p.A6138

2:30 **Epithelial β1 Integrin is Required for Maintenance of Alveolar Homeostasis in the Adult Lung/**E.J. Plosa, L.R. Young, T.S. Blackwell, R. Zent, Nashville, TN, p.A6139

2:45 **Increased Expression of microRNA-155-5p by Alveolar Type II Cells Contributes to Development of ARDS in H1N1 Influenza A Virus-Infected Mice/**I.C. Davis, P. Woods, E. Tili, L. Martinez-Sobrido, Columbus, OH, p.A6140

3:00 **Group-2 Innate Lymphoid Cells Mediate Ozone Induced Neutrophilia and Airway Hyperresponsiveness/**C.H. Flayer, M.Q. Ge, C.E. Jereb, S. Ott, Q. Yang, A. Haczku, Davis, CA, p.A6141

3:15 **Type-2 Immune Responses Protect Against Bleomycin-Induced Lung Injury Through an ICOS-Dependent Mechanism/**C.L. Hrusch, D. Bryaska, M. Jaffery, C. Bonham, K. Blaine, J. Casaos, S. Takahashi-Manns, A.I. Sperling, Chicago, IL, p.A6142

3:30 **Foxp3+ Regulatory T Cell Expression of Keratinocyte Growth Factor During Acute Lung Injury Resolution/**J.R. Mock, C.F. Dial, F.R. D'Alessio, C.M. Doerschuk, Chapel Hill, NC, p.A6143

3:45 **Ozone Suppresses Pulmonary Dendritic Cell Migration to Regional Lymph Nodes Via SP-D and NKp46 Dependent Pathways/**M.Q. Ge, B. Kokalari, C.H. Flayer, S.S. Killingbeck, I. Redai, A. Macfarlane, J.W. Hwang, A. Kolupoti, D.M. Kemeny, K.S. Campbell, A. Haczku, Davis, CA, p.A6144

4:00 **Human Ex-Vivo Ventilated and Perfused Lungs: A Relevant Pre-Clinical Model for Therapeutic Testing of the Small Molecule Anti-Inflammatory FBXO3 Inhibitor BC1215/**N. Weathington, D. Alvarez, J. Sembrat, N. Cardenes, K. Noda, Q. Gong, N. Shigemura, J. D'Cunha, B. Chen, R. Mallampalli, M. Rojas, Pittsburgh, PA, p.A6145

MINI SYMPOSIUM

C95 OUTSTANDING EPIDEMIOLOGY AND HEALTH SERVICES RESEARCH IN CRITICAL CARE

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 3003/3005 (West Building, Level 3)

Chairing: H. Wunsch, MD, MSc, Toronto, Canada
A.J. Walkey, MD, MSc, Boston, MA

Oral Presentations

2:15 **The Critical Care Crisis of Opioid Overdoses in the U.S.**/J.P. Stevens, M.J. Wall, D. Hsu, J. Marshall, M.D. Howell, Boston, MA, p.A6146

2:30 **Healthcare Utilization Patterns 12 Months Pre- and Post-ICU Admission**/E. Hirshberg, K. Kuttler, V. Standfield, R.O. Hopkins, S.M. Brown, Salt Lake City, UT, p.A6147

2:45 **Epidemiology of Vasopressin Use Among Adults with Septic Shock in the United States**/E.A. Vail, H.B. Gershengorn, M. Hua, A.J. Walkey, H. Wunsch, New York, NY, p.A6148

3:00 **Modeling Patient Subpopulations Improves Sepsis Mortality Prediction**/A.P. Sales, M.B. Mayhew, J.D. Greene, J.M. Baker, A. Santucci, G.J. Escobar, T. Wasson, V. Liu, Livermore, CA, p.A6149

3:15 **Nighttime Extubations Are Associated with Worse Outcomes for U.S. Intensive Care Unit Patients**/H.B. Gershengorn, D.C. Scales, A. Kramer, H. Wunsch, Bronx, NY, p.A6150

3:30 **Racial and Socioeconomic Disparities in Mortality Among Older Survivors of Critical Illness**/M.R. Baldwin, J. Sell, W.C. Gonzalez, N. Hayden, A. Javaid, D. Berlin, D.J. Lederer, New York, NY, p.A6151

3:45 **Clinical and Sociocultural Factors Causing In-Hospital Medical Emergencies: A Qualitative Study**/F. Elmufdi, S. Burton, N. Sahni, C. Weinert, Minneapolis, MN, p.A6152

4:00 **Reversal of Scientific Evidence and Identifying Opportunities for De-Adoption in Critical Care: A Scoping Review**/D.J. Niven, T.J. McCormick, S. Straus, B. Hemmelgarn, L. Jeffs, T. Barnes, H.T. Stelfox, Calgary, Canada, p.A6153

MINI SYMPOSIUM

C96 GLOBAL PERSPECTIVES ON COPD BURDEN AND CARE DELIVERY

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**
Room 130-132 (North Building, Lower Level)

Chairing: J. Bourbeau, MD, Montreal, Canada
J.A. Ohar, MD, Winston-Salem, NC
S.R. Russell, MD, Chicago, IL

Featured Speaker

2:15 **COPD Care in the U.S.: A Special Report on Behalf of the Lancet Respiratory Medicine Commission**/M.K. Han, MD, MS, Ann Arbor, MI,

Oral Presentations

2:30 **Organizational Factors Associated with Length of Stay for Veterans with Chronic Obstructive Pulmonary Disease**/S. Rinne, L.A. Bastian, P.K. Lindenauer, P. Kaboli, M.A. Cook, E.S. Wong, C.-F. Liu, New Haven, CT, p.A6154

2:45 **The Morbidity, Mortality, and Healthcare Utilization Attributed to Cardiovascular Disease in COPD Patients in Quebec, Canada**/R. Tavares, T. Dang-Tan, S. Zhang, A. Ismaila, M. Stutz, E.C. Goodall, D. Corriveau, R.H. Stanford, J. Vaillancourt, D. Parsons, X. Lin, A. Simidchiev, G. Nadeau, A.C. Lindsay, J.S. Sampalis, Mississauga, Canada, p.A6155

3:00 **A Cross-Sectional Assessment of the Burden of Chronic Obstructive Pulmonary Disease (COPD) Symptoms in the United States and Europe using the National Health and Wellness Survey**/B. Ding, M. DiBonaventura, N. Karlsson, G. Bergstrom, U. Holmgren, Gothenburg, Sweden, p.A6156

3:15 **Evaluation of the Newly Developed Assessment of Burden COPD (ABC)-Tool: A Tool to Measure and Visualize the Experienced Burden of COPD Patients**/A.H.M. Slok, D. Kotz, G. Van Breukelen, N.H. Chavannes, M.P.M.H. Rutten-van Molken, H. Kerstjens, T. Van Der Molen, G.M. Asijee, R.P. Dekhuijzen, S. Holverda, P.L. Salome, L.M. Goossens, J.C.C.M. In 't Veen, O.C.P. Van Schayck, Maastricht, Netherlands, p.A6157

3:30 **Regional, Gender and Racial Variation in COPD Medication Prescribing Patterns in the US**/A. Pandya, A. Kaur, J. Mamary, H. Zhao, M.R. Jacobs, G.J. Criner, Philadelphia, PA, p.A6158

3:45 **Forecasting Health Services Use in Individuals with Chronic Obstructive Pulmonary Disease (COPD): A Time-Series Analysis**/A.S. Gershon, D. Thiruchelvam, R. Moineddin, X.Y. Zhao, J. Hwee, T. To, Toronto, Canada, p.A6159

4:00 **Optimizing Spirometric Assessment of COPD Classification and Prognosis**/W. Checkley, R.A. Wise, J. Garcia-Aymerich, P. Sobradillo, G. Barr, P. Lange, N.N. Hansel, A. Agusti, R. Rodriguez-Roisin, J. Anto, A. Menezes, M.A. Puhan, Baltimore, MD, p.A6160

MINI SYMPOSIUM

C97 COPD: EPIDEMIOLOGY, RISK FACTORS, AND BIOMARKERS

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**
Room 2002/2004 (West Building, Level 2)

Chairing: R.G. Barr, MD, DrPH, New York, NY
M.G. Foreman, MD, Atlanta, GA
J.M. Brehm, MD, MPH, Pittsburgh, PA

Oral Presentations

2:15 **Prevalence and Mortality of the Asthma-COPD Overlap Syndrome (ACOS) in Denmark: A Long-Term Follow-Up Study of a Large Random Population Sample**/C.B. Barnes, Z.J. Andersen, K. Overvad, A. Tjonneland, C.S. Ulrik, Hvidovre, Denmark, p.A6161

2:30 **Socioeconomic Status and Chronic Obstructive Pulmonary Disease Among Low- and Middle-Income Countries: The GRAND South Study**/M. Grigsby, T. Siddharthan, W. Checkley, Baltimore, MD, p.A6162

2:45 **Long-Term Exposure to Ozone and Accelerated Progression of Percent Emphysema and Decline in Lung Function: The MESA Air and Lung Studies/**M. Wang, R.G. Barr, E.A. Hoffman, J. Madrigano, C.P. Aaron, P.D. Sampson, L. Sheppard, S. Vedal, J. Kaufman, Seattle, WA, p.A6163

3:00 **Genetic Ancestry is Associated with Baseline Lung Function, CT-Scan Emphysema, and COPD Risk in African Americans and Hispanics from SPIROMICS/**V.E. Ortega, E.A. Hoffman, E.J. Ampleford, G.A. Hawkins, R.G. Barr, D.J. Couper, M.K. Han, R. Kanner, E. Kleerup, F.J. Martinez, S.I. Rennard, P.G. Woodruff, D.A. Meyers, E.R. Bleecker, Winston-Salem, NC, p.A6164

3:15 **Associations Between Smoking, Telomere Length and Lung Function Decline: Findings from a Population-Based Longitudinal Study/**P. Andujar, D. Courbon, E. Bizard, E. Marcos, S. Adnot, P. Demoly, I. Pin, G. Thabut, J. Boczkowski, B. Leynaert, Creteil, France, p.A6165

3:30 **Lung Cancer-Specific Mortality Reduction With CT Screening: Outcomes According to Airflow Limitation in the ACRIN NLST Sub-Study (N=18,475)/**R.P. Young, F. Duan, E. Greco, R.J. Hopkins, C. Chiles, G.D. Gamble, D. Aberle, Auckland, New Zealand, p.A6166

3:45 **Microalbuminuria Predicts the Incidence of Severe Chronic Lower Respiratory Disease Exacerbations in Older Adults: The Multi-Ethnic Study of Atherosclerosis (MESA)-Lung Study/**E.C. Oelsner, M.E. Grams, D.R. Jacobs, Jr., R. Kronmal, G.T. O'Connor, D. Rabinowitz, R.P. Tracy, R.G. Barr, New York, NY, p.A6167

4:00 **Blood Eosinophils Poorly Correlate with Sputum Eosinophils, and Have Few Associations with Spirometry, Clinical and Quantitated Computed Tomography Measures Compared to Sputum Eosinophils in the SPIROMICS Cohort/**A.T. Hastie, N.E. Alexis, C. Doerschuk, N.N. Hansel, S. Christenson, N. Putcha, V.E. Ortega, S.P. Peters, MD, PhD, R.G. Barr, D.J. Couper, E.A. Hoffman, R. Kanner, E. Kleerup, F.J. Martinez, P.G. Woodruff, M.K. Han, D.A. Meyers, J.L. Curtis, E.R. Bleecker, Winston-Salem, NC, p.A6168

MINI SYMPOSIUM

C98 AIRWAY REMODELING IN COPD AND ASTHMA

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 2016/2018 (West Building, Level 2)

Chairing: T. Hackett, PhD, Vancouver, Canada
H. Meurs, PhD, Groningen, Netherlands
A.L. James, MD, MBBS, PhD, Nedlands, Australia

Oral Presentations

2:15 **Investigating the Features of Small Airway Obstruction in COPD: Obstructed Small Airways Are an Early Feature of Mild and Moderate Disease/**S. Booth, H.-K. Koo, D.M. Vasilescu, L. Mostaco-Guidolin, J.C. Hogg, T.-L. Hackett, Vancouver, Canada, p.A6169

2:30 **Brain Derived Neurotrophic Factor Effects on Asthmatic Airway Smooth Muscle: A Profile of Epigenetic Regulation/** L.J. Manlove, G.R. Saint-Croix, M. Freeman, M.A. Thompson, C. Pabelick, Y.S. Prakash, Rochester, MN, p.A6170

2:45 **Quantitative Assessment of Airway Remodeling with Birefringence Microscopy: Phenotyping Asthma/**M.J. Suter, D.C. Adams, L.P. Hariri, A.J. Miller, J.A. Holz, M.V. Szabari, R.S. Harris, J.L. Cho, J.W. Griffith, D.L. Hamilos, A.D. Luster, B.D. Medoff, Boston, MA, p.A6171

3:00 **Heterogeneity of Airway Remodeling Contributes to Airway Hyperresponsiveness in Asthma/**C.D. Pascoe, P.D. Pare, G.M. Donovan, Winnipeg, Canada, p.A6172

3:15 **Novel Non-Linear Optical Imaging to Understand the Composition of Fibrilar Collagen and Elastin in Remodeled Asthmatic Airways/**L.B. Mostaco-Guidolin, E.T. Osei, S. Hajimohammadi, J. Ullah, T.-L. Hackett, Vancouver, Canada, p.A6173

3:30 **Mast Cell Tryptase Activates Matrix Metalloproteinase-1 Causing Matrix Remodelling, Airway Smooth Muscle Growth and Airway Obstruction During Asthma Exacerbations/**S. Naveed, D.J. Jackson, D. Clements, C. Reynolds, D. Shaw, S.L. Johnston, S.R. Johnson, Nottingham, United Kingdom, p.A6174

3:45 **Fibulin-1 Plays Critical Roles in the Pathogenesis of Pulmonary Diseases/**P.M. Hansbro, G. Liu, M.A. Cooley, A.G. Jarnicki, A.C.-Y. Hsu, P.M. Nair, T.J. Haw, M. Fricker, S.L. Gellatly, R.Y. Kim, M.D. Inman, G. Tjin, P.A. Wark, J.C. Horvat, B.G. Oliver, W.S. Argraves, D.A. Knight, J.K. Burgess, New Lambton Heights, Australia, p.A6175

4:00 **MMP-13 is a Critical Driver of Lung Destruction in a Viral Exacerbation Model of COPD/**M.P. Goldklang, F. Cvetkovski, D. Turner, R. Xiao, T. Zelonina, K. Stearns, J. Trischler, P. Sklepkiewicz, P. Elkington, D. Farber, J. D'Armiento, New York, NY, p.A6176

MINI SYMPOSIUM

C99 BEYOND THE NATIONAL LUNG SCREENING TRIAL

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 306/308 (South Building, Esplanade Level)

Chairing: C.G. Slatore, MD, Portland, OR
M.K. Gould, MD, MS, Pasadena, CA

Featured Speaker

2:15 **The Future of Lung Cancer Screening/**R.S. Wiener, MD, MPH, Boston, MA,

Oral Presentations

2:30 **Using Electronic Health Records to Assess Eligibility for Lung Cancer Screening: An Examination of Capture and Reliability of Smoking History Data/**L. Sakoda, G. Minowada, G. Mogel, V. Lee, N. Gordon, P. Doria-Rose, L. Kushi, L. Habel, Oakland, CA, p.A6177

2:45 **Airflow Limitation and Lung Cancer Risk in a Large Prospective Screening Study (NLST-ACRIN Cohort Analysis, N=18, 714)/**R.J. Hopkins, R.P. Young, F. Duan, C. Chiles, E. Greco, G.D. Gamble, D. Aberle, Auckland, New Zealand, p.A6178

3:00 **Racial and Gender Disparities for Curative Lung Cancer Surgery in the National Lung Screening Trial/**A.A. Balekian, Los Angeles, CA, p.A6179

3:15 **Estimating the Benefit of CT Screening for Metachronous Lung Cancer/**K.L. Hamlington, C.M. Kinsey, J.C. O'Toole, R.D. Stapleton, J.H.T. Bates, Burlington, VT, p.A6180

3:30 **Impact of a Bronchial Genomic Classifier on Clinical Decision Making in Patients Undergoing Diagnostic Evaluation for Lung Cancer/**J.S. Ferguson, R. Van Wert, Y. Choi, M. Rosenbluth, J. Huang, A. Spira, Madison, WI, p.A6181

3:45 **Cost-Effectiveness of the Percepta Bronchial Genomic Classifier for the Diagnostic Evaluation of Lung Cancer: An Analytical Framework Based on the AEGIS Studies/**D.J. Feller-Kopman, S. Liu, A.M. Garner, M. Decamp, J.B. Pietzsch, Baltimore, MD, p.A6182

4:00 **Diagnostic Evaluation of the Indeterminate Pulmonary Nodule Among Military and Veteran Personnel with Suspect Lung Cancer: The DECAMP Consortium/**E. Billatos, M. Muse, A. Jiwani, I. Mahon, E. Maple, C.W. Atwood, C. Apgar, J.T. Battaile, R. Browning, E. Garshick, R.H. Goldstein, R.L. Keith, K. More, M. Morris, J.S. Parrish, M. Reid, C. Gatsonis, D. Elashoff, F. Duan, S.M. Dubinett, M. Lenburg, P.P. Massion, D. Remick, I.I. Wistuba, M. Schnall, A. Vachani, A. Spira, Boston, MA, p.A6183

POSTER DISCUSSION SESSION

C101 SARCOIDOSIS

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 3014 (West Building, Level 3)

Poster Viewing **2:15-3:00**

Discussion **3:00-4:15**

Chairing: M.A. Judson, MD, Albany, NY
A.S. Morgenthau, MD, New York, NY
E.S. Chen, MD, Baltimore, MD

901 **The Foundation for Sarcoidosis Research Sarcoidosis Advanced Registry for Cures/**L. Serchuck, G. Spitzer, M. Rossman, R.P. Baughman, D.A. Culver, M. Drent, C. Lipset, B. Stern, Chicago, IL, p.A6184

902 **Comparison of Cardiac Magnetic Resonance Imaging and 18F-Fluoro-2-Deoxyglucose Positron Emission Tomography Used for Diagnostic Assessment of Cardiac Involvement in Suspected Cardiac Sarcoidosis Patients/**V. Kouranos, R. Sharma, M. Kokosi, J. Baksi, S. Prasad, R. Khattar, K. Wechalekar, A.U. Wells, London, United Kingdom, p.A6185

903 **Pulmonary Sarcoidosis Phenotypes: Using Cluster Analysis/**M.M. Banoei, N. Sweiss, R.P. Baughman, B.W. Winston, Calgary, Canada, p.A6186

904 **The Impact of Age and Left Ventricular Function on Survival in Cardiac Sarcoidosis/**Y. Zhou, H. Li, E. Lower, A. Costea, M. Attari, R.P. Baughman, Shanghai, China, p.A6187

905 **Clinical Characteristics of Sarcoidosis Patients in America and China/**Y. Zhou, H. Li, E. Lower, Shanghai, China, p.A6188

906 **A Novel In Vitro Human Model of Sarcoidosis/**E.D. Crouser, E. Guirado, M.W. Julian, W. Sadee, A. Papp, A. Friedman, P. White, L. Schlesinger, Columbus, OH, p.A6189

907 **Stepwise Approach to Bronchoscopic Diagnosis of Sarcoidosis in Patients with Intrathoracic Adenopathy Employing EBUS, ROSE, and Histology Needles/**C. Oberg, T.J. Harkin, New York, NY, p.A6190

908 **The Complimentary Role of Transbronchial Cryobiopsy Versus Endobronchial Utrasound (EBUS) for Diagnosing Pulmonary Sarcoidosis/**S. Benzaquen, A. Aragaki, T.S. Sripasart, D. Tanase, G. Khana, M. Kirschner, R.P. Baughman, Cincinnati, UT, p.A6191

909 **Predicting the Course of Sarcoidosis in the Initial Evaluation/**M. Castro, P. Gomes, R.C. Tibana, B. Beraldo, A. Gimenez, C. Fukuda, R. Ferreira, M.R. Soares, C.A. Pereira, Sao Paulo, Brazil, p.A6192

910 **The Use of Registry for Sarcoidosis Associated Pulmonary Hypertension (ReSAPH) in the Design of the Riociguat for Sarcoidosis Associated Pulmonary Hypertension (RioSAPH)/**R.P. Baughman, S.D. Nathan, P. Engel, J.B. Barney, M.B. Scholand, D.A. Culver, Cincinnati, OH, p.A6193

911 **Can the Sarcoidosis Health Questionnaire Predict the Short- and Long-Term Outcomes of Patients with Chronic Sarcoidosis?/**K. Tanizawa, T. Handa, S. Nagai, T. Oga, T. Kubo, Y. Ito, K. Aihara, K. Ikezoe, A. Sokai, Y. Nakatsuka, T. Hirai, K. Chin, M. Mishima, T. Izumi, Kyoto, Japan, p.A6194

912 **Quality of Life Impairment and Fatigue Are Not Correlated with Mean Pulmonary Artery Pressure in Patients with Sarcoidosis Associated Pulmonary Hypertension/**E.M. Carmona, S. Kalra, J.B. Barney, O.A. Shlobin, D.A. Culver, M.B. Scholand, K. Vasilis, E.H. Alhamad, F. Cordova, B. Van Den Blink, R.P. Baughman, Rochester, MN, p.A6195

913 **Correlation Between Serum Biomarkers (ACE and Chitotriosidase) and 18F-FDG PET/CT)-Follow Up Study/**V. Mihailovic-Vucinic, S. Filipovic-Stepic, J.L. Videnovic Ivanov, M. Stjepanovic, B. Gvozdenovic, Z. Sumarac, Belgrade, Serbia, p.A6196

914 **Relation of Neutrophil/Lymphocyte Ratio with Radiological Extent in Pulmonary Sarcoidosis/**N. Ocal, D. Dogan, R. Ocal, E. Tozkoparan, O. Deniz, E. Ucar, S. Gumus, C. Tasci, A. Taskin, U. Turhan, Ankara, Turkey, p.A6197

915 **The Morphological Feature of Alveolar Macrophage Form on Bronchoalveolar Lavage Fluid in Patients with Sarcoidosis/**M. Ishida, H. Ishii, S. Wada, T. Koide, T. Saraya, R. Tazawa, K. Nakata, H. Takizawa, Mikata, Japan, p.A6198

916 **Sarcoidosis in Patients with Previous Malignancy/**R. Kuint, N. Arish, E. Sapir, L. Levy, A. Abutbul, Z.G. Fridlender, U. Laxer, N. Berkman, Jerusalem, Israel, p.A6199

917 **A Novel Method to Quantitate Fluorodeoxyglucose by Positron Emission Tomography (PET) in the Lung Parenchyma of Sarcoidosis Patients/**R. Keijsers, N. Sweiss, L.A. Saketkoo, E. Lower, R.P. Baughman, Utrecht, Netherlands, p.A6200

918 **Sarcoidosis Associated Pulmonary Hypertension Across the World: Results of a Registry of Sarcoidosis Associated Pulmonary Hypertension (ReSAPH)/**J.B. Barney, O.A. Shlobin, D.A. Culver, M.B. Scholand, E.M. Carmona, V. Kouroanos, E. Alhamad, F. Cordova, B. Van Den Blink, R.P. Baughman, Birmingham, AL, p.A6201

919 **Scalp Hair Cortisol and Testosterone; Related to Psychological Distress in Patients with Sarcoidosis?/**M.J.G. Van Manen, V.L. Wester, E.F.C. Van Rossum, L.M. Van Den Toorn, B. Van Den Blink, K.Y. Dorst, Y.B. De Rijke, H.C. Hoogsteden, M.S. Wijsenbeek, Rotterdam, Netherlands, p.A6202

920 **Diagnostic Yield of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration for the Diagnosis of Sarcoidosis: A Preliminary Comparison of Sensitivity in Black versus White Patients/**E.S. Rains, M. Calder, T. Meyer, V. Ciocca, L. Lande, Wynnewood, PA, p.A6203

921 **Proprosal for a Neurosarcoidosis Classification System/**D. Perlman, A. Johnson, M. Bhargava, M. Fiol, Minneapolis, MN, p.A6204

922 **Prevalence and Risk Factor of Proteinuria in Sarcoidosis/**A. Chopra, P. Brasher, R. Zhang, H. Chaudhry, A. Asif, M.A. Judson, Albany, NY, p.A6205

923 **Evolution of EBUS in the Diagnosis of Sarcoidosis in Ireland/**K. Sharma, A. O'Regan, Dublin, Ireland, p.A6206

924 **Study on Staging of Sarcoidosis Using the Combination of Chest Computed Tomography Scan and Radiography/**Y. Zhang, D. Weng, Shanghai, China, p.A6207

925 **The Importance of Diagnostic Metabolic Syndrome During the Course of Sarcoidosis/**J.L. Videnovic Ivanov, V.V. Vucinic-Mihailovic, S. Filipovic-Stepic, D. Gostiljac, M. Stjepanovic, Belgrade, Serbia, p.A6208

POSTER DISCUSSION SESSION

C102 STATEGIES TO UNDERSTAND ILD: REGISTRIES, PROGNOSTIC INDICATORS AND MORE

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 304 (South Building, Esplanade Level)

Poster Viewing **2:15-3:00**

Discussion **3:00-4:15**

Chairing: T. Corte, MD, PhD, Sydney, Australia
R. Bascom, MD, MPH, Hershey, PA
G.P. Cosgrove, MD, Denver, CO

201 **Detecting and Treatment Pulmonary Thromboembolism in Patients with Rapidly Progressive Interstitial Pneumonias Improve the Prognosis/**S. Hamada, H. Ichiyasu, H. Ideguchi, H. Okabayashi, S. Okamoto, M. Inaba, S. Ushijima, N. Hirata, T. Yoshinaga, H. Kohrogi, Kumamoto City, Japan, p.A6209

202 **Establishment of a National Registry for Pulmonary Alveolar Proteinosis in the United States/**B. Carey, C. Chalk, A. Toth, M. Nowell-Bostic, K. Uchida, T. Suzuki, B.C. Trapnell, Cincinnati, OH, p.A6210

203 **A Multicentre Evaluation of Inter-Multidisciplinary Team Agreement for Diagnosis in Diffuse Lung Disease/**S.L. Walsh, A.U. Wells, V. Poletti, A. Dubini, S. Piciucchi, E. Bendstrup, L.B. Madsen, F. Rasmussen, J.C. Grutters, K. Seldenrijk, M. Van Oosterhout, H.W. Van Es, D. Valeyre, H. Nunes, P. Yves Brillet, M. Kambouchner, A. Morais, J. Pereira, C.S. Moura, B. Gooptu, S. Desai, S. Pomplun, T. Johkoh, J. Fukuoka, H. Taniguchi, J. Jacob, C. Sayer, K. Flaherty, J.L. Myers, M.A. Kokosi, D. Hansell, London, United Kingdom, p.A6211

204 **Mortality and Comorbidity Among Danish ILD Patients 1998-2010/**O. Hilberg, A. Lokke, C. Hyldgaard, E. Bendstrup, Aarhus, Denmark, p.A6212

205 **Quality and Bias of Internet Health Information for Idiopathic Pulmonary Fibrosis/**J.H. Fisher, D. O'Connor, A.M. Flexman, S. Shapera, C.J. Ryerson, Toronto, Canada, p.A6213

206 **Patients with Both Possible UIP Pattern on High-Resolution CT and Consistent with UIP Pattern on Histopathological Criteria Could Include Those of Interstitial Lung Diseases with Known Causes Rather than Idiopathic Pulmonary Fibrosis ~a Retrospective Anal/**S. Hashimoto, M. Ueyama, S. Terada, T. Nakanishi, N. Hamao, T. Inao, Y. Yasuda, C. Morimoto, S. Okamori, Y. Kaji, T. Yasuda, T. Hajiro, E. Tanaka, Y. Nishimoto, S. Noma, G. Honjo, Y. Kobashi, Y. Taguchi, Tenri, Japan, p.A6214

207 **Differentiating Early Stage and Later Stage IPF Using Hyperpolarized 129Xe Ventilation MRI/**M. He, S.H. Robertson, J.M. Wang, C.R. Rackley, H.P. McAdams, B. Driehuys, Durham, NC, p.A6215

208 **Longitudinal Change in Lung Function in Patients with Non-Usual Interstitial Pneumonia Fibrotic Interstitial Lung Disease/**J.S. Sheth, M. Xia, S. Murray, K.R. Flaherty, Ann Arbor, MI, p.A6216

209 **Changes in Body Mass Index as a Prognostic Tool for Patients with Idiopathic Pulmonary Fibrosis/**T. Kulkarni, P. Acosta-Lara, T. Luckhardt, J.A. De Andrade, D. Kass, K. Gibson, V.J. Thannickal, S.R. Duncan, Birmingham, AL, p.A6217

210 **Morbidity and Mortality of Surgical Lung Biopsy in Interstitial Lung Disease/**T. Lee, M. Brijbassi, T.K. Marras, S. Shapera, J.H. Fisher, Toronto, Canada, p.A6218

211 **MUC5B and Radiologic Subtypes of Interstitial Lung Abnormalities in the AGES-Reykjavik Study/**G. Gudmundsson, R.K. Putman, T. Araki, E.F. Gudmundsson, M. Nishino, S. Sigurdsson, G. Eiriksdottir, T. Aspelund, L.J. Launer, T.B. Harris, I.O. Rosas, D.A. Schwartz, H. Hatabu, V. Gudnason, G.M. Hunninghake, Reykjavik, Iceland, p.A6219

212 **Using a Clinical Data Research Network-Derived Idiopathic Pulmonary FIbrosis Cohort to Estimate Recruitment Bias in Clinical Pharmaceutical Trials/**A.E.F. Dimmock, R. Bascom, F. Cordova, K.O. Lindell, K. Gibson, C. Chuang, S.K. Danoff, Hershey, PA, p.A6220

213 **Trajectory of Symptom Burden, Impact and survival in an Idiopathic Pulmonary Fibrosis Population/**A.-M. Russell, M.B. Scholand, E.A. Snyder, A.-M. Doyle, A.D. Russell, C. Burdett, J. Lasky, L.A. Saketkoo, London, United Kingdom, p.A6221

214 **Impact, Survival, Symptoms and Management: US and UK Patient Perceptions of Living with Idiopathic Pulmonary Fibrosis/**A.-M. Russell, M.B. Scholand, E.A. Snyder, A. Russell, C. Burdett, A.-M. Doyle, J. Lasky, E. Renzoni, A. Wells, L.A. Saketkoo, London, United Kingdom, p.A6222

215 **The Value of a Systematic Assessment of Medication Use and Polypharmacy in Patients with IPF/**S. Maharaj, P.S. Kolb, N. Hambly, G. Cox, M.R.J. Kolb, Hamilton, Canada, p.A6223

216 **A Multicenter, Prospective, Blinded Comparison of Local Histopathology and Expert Pathology Panel Diagnoses in ILD/**U. Imtiaz, T. Colby, J.L. Myers, K. Cleveland, S. Edejer, P. Bianchi, Y. Choi, D. Pankratz, J. Huang, G.C. Kennedy, South San Francisco, CA, p.A6224

217 **Association Between Clinical Characteristics and In-Hospital Mortality in Patients with Idiopathic Pulmonary Fibrosis/**J. Mooney, K. Raimundo, E. Chang, M.S. Broder, Stanford, CA, p.A6225

218 **The Diagnosis of Idiopathic Non-Specific Interstitial Pneumonia (NSIP): Are International Multidisciplinary Team Discussions Feasible?/**J. Moller, A. Altraja, T. Sjaheim, L.B. Madsen, F. Rasmussen, E. Bendstrup, Aarhus, Denmark, p.A6226

219 **The Clinical Utility of a Genomic Diagnostic Test in Differentiating Usual Interstitial Pneumonia from Other Interstitial Lung Disease Pathologies/**X. Wu, E.A. Belloli, M. Rosenbluth, Y. Choi, S. Danese, K.R. Flaherty, F.J. Martinez, New York, NY, p.A6227

220 **Prevalence and Determinants of Frailty in Fibrotic Interstitial Lung Disease/**K.M. Milne, J.M. Kwan, S. Guler, T.A. Winstone, A. Le, P.G. Wilcox, C.J. Ryerson, Vancouver, Canada, p.A6228

221 **Quantitative CT Analysis of Honeycombing Area Predicts Survival in Idiopathic Pulmonary Fibrosis/**H. Nakagawa, Y. Higami, K. Fukunaga, Y. Kashiwagi, M. Osawa, T. Nagao, E. Ogawa, Y. Nakano, Otsu, Japan, p.A6229

222 **Low Sensitivity of Trans Bronchial Biopsies in Diagnosing Interstitial Lung Diseases/**W. Thijs, R. Snooks, S. Fletcher, Hoofddorp, Netherlands, p.A6230

223 **Validation of a Method for Automatic Detection of Lung Sounds in Fibrotic Interstitial Lung Disease/**G. Sgalla, D. Nikolic, S.L. Walsh, S. Fletcher, S. Cerri, F. Luppi, M.G. Jones, D.E. Davies, N. Sverzellati, D. Hansell, A. Barney, L. Richeldi, Southampton, United Kingdom, p.A6231

224 **Optimal Low Dose Computed Tomography Parameters for Evaluating Interstitial Lung Disease: A Systematic Simulation Study/**L. Fidler, S. Ley, H. Schenk, M. Durand, N. Paul, T.K. Marras, S. Shapera, S. Mittoo, Toronto, Canada, p.A6232

225 **Population Demographics of Patients Diagnosed with Interstitial Lung Disease with Major Complications: A Study Involving 14,015 Patients/**R. Chandrashekar, M. Konda, Kalamazoo, MI, p.A6233

POSTER DISCUSSION SESSION

C103 EOSINOPHILS IN COPD AND THE ASTHMA-COPD OVERLAP SYNDROME: SORTING THROUGH THE CHAOS OF ACOS

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 2010/2012 (West Building, Level 2)

Poster Viewing **2:15-3:00**

Discussion **3:00-4:15**

Chairing: D.D. Sin, MD, Vancouver, Canada
P.G. Woodruff, MD, MPH, San Francisco, CA
M.E. Hardin, MD, Boston, MA

401 **Is Blood Eosinophil Count a Predictor of Disease Worsening After ICS Withdrawal?/**H. Watz, H. Magnussen, K. Tetzlaff, L. Gronke, H. Finnigan, P.M. Calverley, Grosshansdorf, Germany, p.A6234

402 **The Stability of Blood Eosinophils in Stable COPD Patients and Validity of Using Baseline Eosinophil Values to Determine Eosinophilia in Epidemiological Studies/**E.R.C. Millett, C.E. Brightling, I. Pavord, R. Russell, M. Bafadhel, Oxford, United Kingdom, p.A6235

403 **The Blood Eosinophil Trajectory of Patients with COPD Through Stable State, Exacerbation and Recovery/**E.R.C. Millett, C.E. Brightling, I. Pavord, R. Russell, M. Bafadhel, Oxford, United Kingdom, p.A6236

404 **Phenotypic/Genetic Characteristics of COPD, Asthma, and Asthma-COPD Overlap Syndrome (ACOS) in SPIROMICS and SARP/**X. Li, V.E. Ortega, H. Nadia, S. Christenson, W.C. Moore, H. Li, R.G. Barr, D.J. Couper, E.A. Hoffman, M.K. Han, R. Kanner, E. Kleerup, F.J. Martinez, G.A. Hawkins, P.G. Woodruff, E.R. Bleecker, D.A. Meyers, Winston-Salem, NC, p.A6237

405 **Fractional Exhaled Nitric Oxide Levels in Asthma-COPD Overlap Syndrome: Analysis of the NHANES, 2007-2012/**T. Goto, C.A. Camargo, K. Hasegawa, Boston, MA, p.A6238

406 **Blood Eosinophil Levels in COPD Patients in the UK Clinical Practice Research Datalink (CPRD)/**S. Landis, R. Suruki, K. Bonar, E. Hilton, C. Compton, Uxbridge, United Kingdom, p.A6239

407 **Does Eosinophilia and Neutrophil-to-Lymphocyte Ratio Effect Hospital Re-Admission in Cases of COPD Exacerbation?/**M. Agca, E. Aksoy, D. Duman, I. Ozmen, E. Yildirim, S. Gungor, N.D. Kocak, U. Akturk, C. Salturk, Z. Karakurt, Istanbul, Turkey, p.A6240

408 **Clinical Outcomes and Disease Progression in Patients with Asthma-COPD Overlap Syndrome/**J. Cosentino, H. Zhao, M.E. Hardin, C.P. Hersh, J.D. Crapo, V. Kim, G. Criner, Philadelphia, PA, p.A6241

409 **Asthma-Like Features and Clinical Course in COPD: An Analysis from the Hokkaido COPD Cohort Study/**M. Suzuki, H. Makita, S. Konno, K. Shimizu, H. Kimura, M. Nishimura, Sapporo, Japan, p.A6242

410 **Effectiveness Using Higher ICS Dosage in Patients with COPD by Different Blood Eosinophilic Counts/**S.-L. Cheng, Taipei, Taiwan, p.A6243

411 **Airway Hyperresponsiveness in COPD: A Marker of Asthma-COPD Overlap Syndrome? /**R. Tkacova, D. Dai, J.M. Vonk, J. Leung, P.S. Hiemstra, M. Van Den Berge, L. Kunz, Z. Hollander, D.P. Tashkin, R.A. Wise, J.E. Connett, R.T. Ng, B.M. McManus, S.F.P. Man, D.S. Postma, D.D. Sin, Vancouver, Canada, p.A6244

412 **Clinical Characteristics of Asthma—COPD Overlap Syndrome Patients with Fungal Sensitization/**T. Tanosaki, K. Fukunaga, M. Miyazaki, M. Haraguchi, M. Sasaki, S. Kagawa, K. Otsuka, T. Mochimaru, M. Matsusaka, K. Masaki, H. Kabata, S. Ueda, Y. Suzuki, K. Asano, T. Betsuyaku, Tokyo, Japan, p.A6245

413 **Omalizumab in Patients with COPD and Atopic Phenotype: A Case Series/**P. Dammert, D. Jawahar, Dover, DE, p.A6246

414 **Evaluating Serum Periostin as a Biomarker in Chronic Obstructive Pulmonary Disease During Stable State and Exacerbations/**R. Shrimanker, K. Hambleton, W. Tew, C.E. Brightling, C. Holweg, M. Bafadhel, Oxford, United Kingdom, p.A6247

415 **Relationship Between Serum Eosinophil Levels and COPD Exacerbations/**H. Inoue, M. Ichinose, K. Tatsumi, Y. Sakata, K. Shibata, H. Miyagishi, Y. Fukuchi, Kagoshima, Japan, p.A6248

416 **Blood Eosinophil Count to Predict Bronchial Eosinophilic Inflammation in Chronic Obstructive Pulmonary Disease (COPD)/**F.N. Schleich, J.-L. Corhay, R. Louis, Liege, Belgium, p.A6249

417 **Peripheral Blood Eosinophil Levels at the Time of Hospitalization in COPD Patients/**A. Kaur, E. Dominguez, S. Duffy, R. Marron, H. Zhao, G.J. Criner, Philadelphia, PA, p.A6250

418 **Clinical Characteristics in COPD Patients with Eosinophilia/**H. Meteran, V. Gottlieb, C. Porsbjerg, V. Backer, Copenhagen, Denmark, p.A6251

419 **Is Inhaled Corticoid Steroid Therapy One of Keywords for Overlap Syndrome Between Asthma and COPD Management?/**Y. Nozaki, H. Wakayama, M. Yamamoto, S. Gen, M. Morosawa, S. Katoh, K. Noda, Y. Ryuge, Nagoya, Aichi, Japan, p.A6252

420 **Characterization of the Asthma-COPD Overlap Syndrome: A Qualitative Analysis of Focus Groups With Pulmonologists/**C. Rodrigue, M.-F. Beauchesne, V. Mallette, C. Lemiere, P. Larivee, L. Blais, Montreal, Canada, p.A6253

421 **Proportion and Characteristics of Asthma-Chronic Obstructive Pulmonary Disease (COPD) Overlap Syndrome Among COPD Patients in Japan/**H. Inoue, T. Nagase, S. Morita, A. Yoshida, T. Jinnai, M. Ichinose, Kagoshima, Japan, p.A7889

POSTER DISCUSSION SESSION

C104 RARE INTERSTITIAL LUNG DISEASE: LAM, CYSTIC LUNG DISEASE, AND MORE

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 133 (North Building, Lower Level)

Poster Viewing **2:15-3:00**

Discussion **3:00-4:15**

Chairing: V. Cottin, MD, PhD, Lyon, France
B.C. Trapnell, MD, Cincinnati, OH

101 **Early and Late Onset Adverse Events in LAM Patients Treated with Sirolimus for Two Years/**K. Nakata, Y. Inoue, K. Seyama, R. Tazawa, T. Tamada, A. Mikami, H. Nakayama, M. Suzuki, M. Ebina, M. Hanaoka, N. Hattori, T. Hirai, T. Arai, C. Sugimoto, N. Kitamura, T. Tanaka, K. Akazawa, M. Mishima, Niigata, Japan, p.A6254

102 **Early Intervention with Sirolimus Benefits Mild Lymphangioleiomyomatosis-Related Lung Disease/**T. Takada, K. Seyama, Y. Inoue, K. Nagai, M. Suzuki, H. Moriyama, K. Akasaka, R. Tazawa, T. Hirai, M. Mishima, M. Hayashida, M. Hirose, C. Sugimoto, T. Arai, N. Hattori, K. Watanabe, A. Mikami, T. Tamada, H. Yoshizawa, K. Akazawa, T. Tanaka, N. Kitamura, K. Nakata, Niigata, Japan, p.A6255

103 **Impact of Pleural Disease on Pulmonary Function Test Results in Patients with Lymphangioleiomyomatosis/**R. Kanaan, C.B. Strange, Charleston, SC, p.A6256

104 **Reproducibility of FEV1 Measurements in Patients with Lymphangioleiomyomatosis/**A.M. Taveira-DaSilva, P. Julien-Williams, A.M. Jones, M. Haughey, M. Stylianou, J. Moss, Bethesda, MD, p.A6257

105 **Serum Autoantibodies and Comorbid Collagen Vascular Diseases in Lymphangioleiomyomatosis/**S. Futami, T. Arai, C. Sugimoto, K. Tachibana, N. Takeuchi, Y. Sasaki, A. Hirooka, K. Nakao, T. Koba, M. Hirose, A. Matsumuro, T. Honma, S. Hayashi, M. Akira, M. Kitaichi, Y. Inoue, Osaka, Japan, p.A6258

106 **A Rare Cause of Nodular Cystic Disease: Report of Three Cases/**V. Lopez Rodriguez, X. Lopez Contreras, A. Panizo, B. Fernandez, P. Cebollero, J. Cascante, J. Hueto, Pamplona, Spain, p.A6259

107 **Lung Ultrasound Has Limited Diagnostic Value in Rare Cystic Lung Diseases/**J.R. Davidsen, E. Bendstrup, D.P. Henriksen, O. Graumann, C.B. Laursen, Odense, Denmark, p.A6260

108 **HRCT Screening for Diffuse Cystic Lung Diseases in Patients Presenting with Spontaneous Pneumothorax is Cost Effective/**N. Gupta, D. Langenderfer, F.X. McCormack, D.P. Schauer, M.H. Eckman, Cincinnati, OH, p.A6261

109 **Clinico-Radiologocal-Pathologic Characteristics of Idiopathic Unclassifiable Interstitial Pneumonia/**Y. Nakamura, K. Sugino, K. Matsumoto, M. Kitani, A. Hebisawa, K. Shibuya, S. Homma, Tokyo, Japan, p.A6262

110 **Pulmonary Talcosis in a Community Based HIV Clinic/**B.J. Saczek, Z. Belak, G. Kraushaar, M. Pandey, J. St Onge, Saskatoon, Canada, p.A6263

111 **Total Covering Technique for Recurrent Pneumothorax in Patients of Birt-Hogg-Dube Syndrome/**T. Mizobuchi, M. Kurihara, S. Yamanaka, H. Ebana, K. Seyama, Tokyo, Japan, p.A6264

112 **Pulmonary Alveolar Proteinosis: A Case Series from a Reference Center in Brazil/**R.A.B. De Athayde, J.R.B. De Oliveira Filho, R.S. Tartaglia, F.E. Arimura, G.I. Heiden, R.A. Kairalla, C.R.R. De Carvalho, B.G. Baldi, Sao Paulo, Brazil, p.A6265

113 **Organizing Pneumonia in Myelodysplastic Syndrome: A Case Series/**S.S. Hoskote, V. Trivedi, B.S. Pannu, V.N. Iyer, Rochester, MN, p.A6266

114 **Clinical Course of Patients with Bronchiolitis Obliterans After Hematologic Stem Cell Transplantation/**M. Yomota, M. Nagamata, O. Tasuru, K. Ohashi, T. Hishima, Tokyo, Japan, p.A6267

115 **Parenchymal Lung Diseases Associated with Chronic Lymphocytic Leukemia/**S. Khanijo, P. Tandon, S. Koenig, New Hyde Park, NY, p.A6268

116 **Pulmonary Amyloidosis: Clinicopathologic Correlation in an Autopsy Series of Amyloidosis/**K. Ussavarungsi, J.E. Yi, J.H. Ryu, Rochester, MN, p.A6269

117 **Elements of Diagnosis in Hypersensitivity Pneumonitis/**K. Ussavarungsi, A. Arcadu, T. Moua, Rochester, MN, p.A6270

118 **Respiratory Manifestations of IgG4 Related Disease: A Retrospective Analysis of 97 Cases in a Single Chinese Hospital/**H. Huang, X. Song, S. Li, K. Xu, Y. Bi, R. Feng, Z. Xu, Beijing, China, p.A6271

119 **A Case Series of Lung Chronic Graft-Versus-Host Disease in a Pulmonary Reference Center in Brazil/**J.R.B.D.O. Filho, R.S. Tartaglia, R.A.B. De Athayde, F.E. Arimura, B.G. Baldi, R.A. Kairalla, C.R.R. De Carvalho, A.D.M. Kawassaki, Sao Paulo, Brazil, p.A6272

120 **Inhalation Antigens Sensitisation in Czech Hypersensitivity Pneumonitis Patients/**M. Sterclova, M. Paulik, J. Skibova, M. Vasakova, Prague, Czech Republic, p.A6273

121 **Outcomes in Chronic Hypersensitivity Pneumonitis Treated with Immunosuppression/**A. Adegunsoye, J.M. Oldham, L.W. Chen, S. Hsu, C. Demchuk, S. Montner, J.H. Chung, M.E. Strek, R. Vij, Chicago, IL, p.A6274

122 **A Retrospective Review of Age Related change in Percent Predicted Forced Vital Capacity in Chronic Hypersensitivity Pneumonitis/**D. Bhanot, D. Polineni, L.R. Pitts, M. Hamblin, Kansas City, KS, p.A6275

123 **Proapototic Protein Bim Mediates Estrogen-Enhanced Survival in Lymphangioleiomyomatosis/**J.J. Yu, C. Li, X. Li, Y. Sun, E.Y. Zhang, E.P. Henske, F.X. McCormack, Cincinnati, OH, p.A6276

124 **Cell-Cell Communication in Lymphangioleiomyomatosis: Microarray Analysis Shows Induction of Chemokines and Fibroblast Growth Factors in LAM Associated Fibroblasts/** A. Dongre, D. Clements, M. Castellanos-Uribe, S.T. May, S.R. Johnson, Nottingham, United Kingdom, p.A6277

125 **CA-125 in Lymphangioleiomyomatosis Correlates with Disease Progression and Sirolimus Therapy/**C.G. Glasgow, G. Pacheco-Rodriguez, W.K. Steagall, P. Julien-Williams, M. Stylianou, J. Moss, Bethesda, MD, p.A6278

POSTER DISCUSSION SESSION

C105 RESPIRATORY FAILURE: MECHANISTIC INSIGHTS FROM LUNG INJURY MODELS

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 3001 (West Building, Level 3)

Poster Viewing **2:15-3:00**

Discussion **3:00-4:15**

Chairing: C.S. Calfee, MD, San Francisco, CA
J.M. Liebler, MD, Los Angeles, CA

701 **MicroRNA Found in Human Airway Secretions Modulate the NFkB Pathway/**P. Narute, R. Cai, J. Sun, A. Suffredini, Bethesda, MD, p.A6279

702 **Dysregulated MicroRNAs (miRNAs) in Pediatric Acute Respiratory Distress Syndrome (ARDS) and Animal Models of Acute Lung Injury: Focus on miR-26a and EphA2/**R. Good, C. Sucharov, L. Hernandez-Lagunas, C. Vohwinkel, U. Kompella, T. Carpenter, E. Grayck, Aurora, CO, p.A6280

703 **MicroRNA-223 Mediates Kidney Injury During Experimental Sepsis./**J.F. Colbert, J.A. Ford, Y. Yang, S.M. Haeger, K. Brodsky, H. Eltzschig, E.P. Schmidt, A. Ginde, Aurora, CO, p.A6281

704 **Differential immunomodulatory effects of mitochondria and its components on lung inflammation in vivo/**S. Hisata, S.W. Ryter, A.M.K. Choi, K. Nakahira, New York, NY, p.A6282

705 **Parkin Mediates Endothelial Inflammatory Responses in Acute Lung Injury/**E. Letsiou, S. Sammani, H. Wang, P.G. Belvitch, S.M. Dudek, Chicago, IL, p.A6283

706 **Cigarette Smoke Exposure Worsens Endotoxin-Induced Lung Injury in Mice/**J.E. Gotts, J. Abbott, X. Fang, H. Yanagisawa, S. Nishimura, C.S. Calfee, M.A. Matthay, San Francisco, CA, p.A6284

707 **Critical Role of the Prostaglandin D2 Receptor CRTH2 in Acute Lung Injury Caused by Lipopolysaccharide (LPS)-Induced Shock in Mice/**S. Suzuki, M. Ishii, T. Asami, H. Namkoong, K. Yagi, T. Asakura, H. Kamata, S. Tasaka, S. Kagawa, T. Kamo, K. Asano, M. Nakamura, H. Hirai, K. Nagata, N. Hasegawa, T. Betsuyaku, Tokyo, Japan, p.A6285

708 **Protective Role o of Aspirin-Triggered (17R) Resolvin D2 in Sepsis-Induced Lung Injury/**H. Gao, Y. Liu, J. Li, R. Qin, S.-K. Zhang, X. Wang, Boston, MA, p.A6286

709 **Peritoneal sepsis impairs efficient recruitment of neutrophils into the alveolar space and augment lung injury after nosocomial infection/**T. Hiruma, K. Uchida, B.C. Trapnell, Y. Kusakabe, Y. Yamamura, T. Totsu, K. Chang, K. Nakamura, K. Doi, S. Nakajima, N. Yahagi, Y. Yamada, Tokyo, Japan, p.A6287

710 **Follistatin-like Protein-1 Limits Inflammation in Acute Lung Injury/**B. Campfield, M. Majewski, T.J. Eddens, R. Hirsch, J.K. Kolls, Pittsburgh, PA, p.A6288

711 **Therapeutic Effects of Microvesicles Derived From A Mouse Macrophage Cell Line (RAW264.7) in Severe Pneumonia in Mice/**H. Lim, S. Hu, J. Park, Q. Hao, J.W. Lee, San Francisco, CA, p.A6289

712 **Human Neutrophil-derived Microvesicles Activate Pulmonary Endothelial Cells In an In Vitro Model of Pulmonary Microvascular Inflammation/**N. Tirlapur, K.P. O'Dea, M. Takata, London, United Kingdom, p.A6290

713 **Murine Bone Marrow-derived Mesenchymal Stem Cells Exert Anti-viral and Barrier-protective Properties in Influenza Virus Infection/**L. Jankauskaite, C. Schmoldt, J. Wilhelm, J. Lohmeyer, S. Herold, Giessen, Germany, p.A6291

714 **Human mesenchymal stem/stromal cells produce distinct M1- and M2-like macrophage phenotypes, enhance reactive oxygen species production and augment phagocytosis and bacterial killing in macrophage from healthy volunteers and from patients with severe seps/**G.F. Curley, A. Volchuk, M. Jerkic, C. Masterson, K. Szaszi, J.G. Laffey, S. Grinstein, Toronto, Canada, p.A6292

715 **Carbon Monoxide Exposure Increases the therapeutic effect of Mesenchymal Stromal Cells in Sepsis via Specialized Pro-resolving Lipid Mediators/**K. Tsoyi, S. Hall, J. Dalli, R. Colas, S. Ghanta, A. Coronata, L. Fredenburgh, R.M. Baron, A.M.K. Choi, C. Serhan, X. Liu, M.A. Perrella, Boston, MA, p.A6293

716 **Effect of Antithrombin in an in-vitro Model of Acute Respiratory Distress Syndrome/**R. Guillamat-Prats, F. Puig, M. Camprubi-Rimblas, T. Lebouvier, A. Artigas, Sabadell, Spain, p.A6294

717 **Heparin effect in alveolar macrophages in acute lung injury model/**M. Camprubi-Rimblas, L. Chimenti, R. Guillamat-Prats, T. Lebouvier, J. Tijero, M.N. Gomez, L. Blanch, A. Artigas, Sabadell, Spain, p.A6295

718 **GBT1118, a Drug that Increases Oxygen Affinity of Hemoglobin, Improved Survival During Murine Hypoxic Acute Lung Injury/**N.D. Putz, C.M. Shaver, K. Dufu, C.-M. Li, Q. Xu, A. Hutchaleelaha, J. Lehrer-Graiwer, J.A. Bastarache, L.B. Ware, Nashville, TN, p.A6296

719 **Methotrexate Reduces Acute Lung Injury in a Murine Model of Sepsis /**J. Bringue, R. Guillamat-Prats, E. Torrents, M.L. Martinez, M.N. Gomez, L. Blanch, A. Artigas, Sabadell, Spain, p.A6297

720 **Neutral Microporous Resin Column Hemoperfusion Found Effective for Lipopolysaccharide-induced Acute Lung Injury/Acute Respiratory Distress Syndrome in Porcine Models/**S. Luo, X. Xu, C. Jia, F. Xiao, Y. Li, H. Dai, C. Wang, Beijing, China, p.A6298

721 **R-107 Attenuates Severity of Acute Respiratory Distress Syndrome Induced by Chlorine Gas Inhalation in Ovine Model/**S. Fukuda, K. Ihara, E. Lopez, R. Cox, G. Southan, A. Salzman, J.R. Salsbury, D.S. Prough, P. Enkhbaatar, Galveston, TX, p.A6299

722 **A Comparison of Four Different Models of Acute Respiratory Distress Syndrome in Sheep/**R. Nowacki, M. Engel, E. Jonker, D. Ophelders, M. Nikiforou, B. Kramer, Maastricht, Netherlands, p.A6300

723 **Bacterial Dissemination to the Brain in a Murine Model of Treated Sepsis/**B.H. Singer, R.P. Dickson, M. Newstead, N. Falkowski, K. Kim, J.R. Sieber, T. Schmidt, G.B. Huffnagle, T.J. Standiford, Ann Arbor, MI, p.A6301

724 **Moderate Running Reduces Septic Pulmonary Inflammation in Aged Mice/**S.E. Gill, S. Swarbreck, C. Pape, R. Veldhuizen, J. Koropatnick, K. Tyml, London, Canada, p.A6302

725 **Development of a Mini-Oxygenator - a Step Toward an Artificial Lung/**A. Dharia, E. Abada, T. Yeager, W. Moses, J. Park, C. Blaha, N. Wright, B. Padilla, S. Roy, San Francisco, CA, p.A6303

POSTER DISCUSSION SESSION

C106 WRECKING BALL: NEW PARADIGMS IN UNDERSTANDING AND TREATMENT OF PH

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 3024 (West Building, Level 3)

Poster Viewing **2:15-3:00**

Discussion **3:00-4:15**

Chairing: A.W. Trammell, MD, Atlanta, GA
P.J. Leary, MD, MS, Seattle, WA
P. Corris, MD, Newcastle, United Kingdom

1001 **Benchmarking Quality Initiatives in the Care of Pulmonary Arterial Hypertension Patients at an Academic Medical Center/**C. Kholdani, H. Hedlin, A. Hsi, K. Kudelko, Y. Sung, V. De Jesus Perez, E.F. Spiekerkoetter, J. Liu, R.T. Zamanian, Stanford, CA, p.A6304

1002 **The Clinical Impact of Intrapulmonary Vascular Dilation in Liver Disease/**H.M. DuBrock, M.J. Krowka, K. Forde, K. Krok, M. Patel, T.E. Sharkoski, S. Batra, G. Lin, J. Oh, C.D. Mottram, P.D. Scanlon, M. Fallon, S.M. Kawut, Boston, MA, p.A6305

1003 **Macrophage Migration Inhibitory Factor (MIF): A Novel Biomarker of Portopulmonary Hypertension/**H.M. DuBrock, J. Rodriguez-Lopez, B.L. LeVarge, M.P. Curry, I.R. Preston, R.N. Channick, S.A. Karumanchi, Boston, MA, p.A6306

1004 **Evidence of Shared Genetic Architecture Between Combined Pulmonary Hypertension and Pulmonary Arterial Hypertension/**T.R. Assad, A.R. Hemnes, E.K. Larkin, A.M. Glazer, Q.S. Wells, E.H. Farber-Eger, M. Xu, E. Brittain, Nashville, TN, p.A6307

1005 **Pulmonary Vascular Resistance and Compliance Relationship in Pulmonary Hypertension: Direct Measurements Versus Empiric Formulae/**C. Gerges, M. Gerges, P. Fesler, N.P. Konowitz, N. Skoro-Sajer, I. Lang, Wien, Austria, p.A6308

1006 **Subclinical Albuminuria as a Prognostic Indicator in Group 1 Pulmonary Arterial Hypertension/**N.P. Nickel, J.P. Fessel, A.R. Hemnes, J. Rand, L. Wheeler, J. Loyd, E.D. Austin, Nashville, TN, p.A6309

1007 **Perioperative Morbidity and Mortality in Patients with Pulmonary Hypertension Undergoing Non-Cardiac Surgery: An Analysis of Admission Records from the Nationwide Inpatient Sample from 2005-2009/**K. Dudley, R. Lobato, J. Wong, B. Maxwell, K. Rhoads, R.T. Zamanian, Stanford, CA, p.A6310

1008 **Identification of Plasma Biomarkers Associated with the Development of Scleroderma-Associated Pulmonary Arterial Hypertension/**D. Fox, C. Meadows, C. Abbott, R. Kumar, J.C. Robinson, J.W. Anderson, A. Fischer, K.R. Stenmark, B.B. Graham, T.M. Bull, Aurora, CO, p.A6311

1009 **A Randomized Clinical Trial of Anastrozole in Pulmonary Arterial Hypertension/**S.M. Kawut, C. Archer-Chicko, A. DeMichele, D. Dubow, J. Fritz, B. Ky, H. Palevsky, A. Palmisciano, M. Patel, D. Pinder, K. Propert, K.A. Smith, F. Stanczyk, A. Vaidya, C.E. Ventetuolo, Philadelphia, PA, p.A6312

1010 **Borderline Pulmonary Pressure Is Associated with Worse Survival in Patients at Risk for Pulmonary Hypertension - A Retrospective Single Center Analysis/**P. Douschan, G. Kovacs, V. Foris, A. Avian, A. Olschewski, H. Olschewski, Graz, Austria, p.A6313

1011 **Characterization of Cardiopulmonary Exercise Testing Parameters in Patients with Borderline Pulmonary Arterial Pressure/**R. Jiang, H. Liu, L. Wang, Q.-H. Zhao, S.-G. Gong, J. He, J.-M. Liu, Z.-C. Jing, Shanghai, China, p.A6314

1012 **The RESPITE Study: Riociguat in Patients with PAH and an Inadequate Response to Phosphodiesterase 5 Inhibitors/**M.M. Hoeper, P.A. Corris, J. Klinger, D. Langleben, R. Naeije, G. Simonneau, R.L. Benza, Hannover, Germany, p.A6315

1013 **Predicting Outcomes in Pulmonary Arterial Hypertension Based on Estimated Glomerular Filtration Rate/**M.M. Chakinala, D.W. Coyne, R.L. Benza, A.E. Frost, M.D. McGoon, B.K. Hartline, R.P. Frantz, M. Selej, D.R. Mink, H.W. Farber, St. Louis, MO, p.A6316

1014 **Initial Combination with Bosentan and Sildenafil as Compared with Initial Monotherapy with the Same Drugs in Patients with Pulmonary Arterial Hypertension: A Case-Control, Multicenter Study/**M. Palazzini, N. Hirani, F. Dardi, J. Weatherald, C. Bachetti, M.V. Thakrar, G. Mazzanti, D. Helmersen, A. Manes, E. Gotti, A. Rinaldi, A. Albini, E. Monti, S. Fukui, D. Guarino, N. Galie, Bologna, Italy, p.A6317

1015 **Comparative Outcome of Incident Patients with Pulmonary Hypertension Due to Left Heart Disease According with the Haemodynamic Classification of the 2015 ESC-ERS Pulmonary Hypertension Guidelines/**A. Rinaldi, M. Palazzini, C. Bachetti, E. Gotti, G. Mazzanti, F. Dardi, A. Albini, E. Monti, S. Fukui, D. Guarino, N. Galie, A. Manes, Bologna, Italy, p.A6318

1016 **Genomics and Survival in PAH: Results of a GWAS/**R.L. Benza, M. Gomberg-Maitland, H. Wiener, A. Frost, D. Langleban, T. Pulido, A. Torbicki, P. Correa-Jaque, T. Demarco, M. Tamari, T. Hirota, M. Kubo, M. Passineau, H.K. Tiwari, Pittsburgh, PA, p.A6319

1017 **EIF2AK4 Mutation-Carriers with PVOD Present Distinct Features Within the Remodeled Lung Vasculature/**E. Nossent, D. Montani, B. Girerd, F. Perros, F. Soubrier, E. Fadel, K. Grunberg, H.J. Bogaard, G. Simonneau, A. Vonk Noordegraaf, M.J.C. Humbert, P. Dorfmuller, Amsterdam, Netherlands, p.A6320

1018 **Pulmonary Arterial Capacitance Predicts Survival in Pulmonary Arterial Hypertension/**N. Al-Naamani, S. Muthukuru, N.S. Hill, I.R. Preston, K.E. Roberts, Boston, MA, p.A6321

POSTER DISCUSSION SESSION

C107 IMMUNITY, EXACERBATION AND IMMUNE CELL FUNCTION IN COPD

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 2014 (West Building, Level 2)

Poster Viewing **2:15-3:00**

Discussion **3:00-4:15**

501 **Defective Phagocytosis of Aspergillus Fumigatus by COPD Macrophages/**K.B.R. Belchamber, A. Shah, P.J. Barnes, D. Armstrong-James, L. Donnelly, London, United Kingdom, p.A6322

502 **Airway Glucose in Virus-Induced COPD Exacerbations/**R. Hewitt, J. Webber, H. Farne, M.-B. Trujillo-Torralbo, J. Footitt, P.L. Molyneaux, S.L. Johnston, J. Tregoning, P. Mallia, London, United Kingdom, p.A6323

503 **Toll-Like Receptor 9, a Key to Attenuation of Disease Progression in a Mouse Model of Chronic Obstructive Pulmonary Disease/**T. Sato, K. Nakashima, Y. Shibata, R. Ushio, M. Ikeda, H. Watanabe, K. Nagai, K. Tashiro, H. Nagakura, N. Horita, M. Yamamoto, M. Shinkai, M. Kudo, D. Klinman, T. Kaneko, Yokohama, Japan, p.A6324

504 **Combination Effect of p38 MAPK Inhibition and Corticosteroid on Haemophilus Influenzae Stimulated Alveolar Macrophages from COPD Patients/**S. Lea, R. Khalaf, H. Metcalfe, D. Singh, Manchester, United Kingdom, p.A6325

505 **Lung Eosinophils and GATA3+ Cells Accumulate in Draining Lymph Nodes in Chronic Obstructive Pulmonary Disease/**P. Jogdand-Sathe, M. Mori, A. Walls, T. Mauad, C. Sanden, J.S. Erjefalt, Lund, Sweden, p.A6326

506 **Identification and Functional Characterization of Novel Dendritic Cell Subsets in Chronic Obstructive Pulmonary Disease (COPD) Lung/**T. Naessens, Y. Morias, B. Lambrecht, D. Cunoosamy, Molndal, Sweden, p.A6327

507 **Differences in Neutrophil Chemotactic Responses in COPD and Health, in the Stable State and During Exacerbations/**G.M. Walton, A. Culliford, H. Greenwood, J. Patel, A.J.A. McGuinness, R.A. Stockley, E. Sapey, Birmingham, United Kingdom, p.A6328

508 **Regulation of IL-22-Producing Human Lung Natural Killer Cells by the Dendritic Cell Inhibitory Receptor, IL-22 Binding Protein, Is Decreased in COPD/**C. Peng, V.R. Stolberg, B.L. Saxton, J.P. Brown, L. McCloskey, J.L. Curtis, C.M. Freeman, Guiyang, China, p.A6329

509 **A Mechanistic Role for Autoantibodies in Emphysema Development/**S.E. Stephenson, A. Alawieh, S. Tomlinson, C. Atkinson, Charleston, SC, p.A6330

510 **Sputum Secretory Immunoglobulin A1 (SIgA1) from Patients with COPD Enhances Opsonophagocytosis of Nontypeable Haemophilus influenzae and Moraxella catarrhalis/**P. Tunsupon, M. Smith, C. Wrona, S. Sethi, Buffalo, NY, p.A6331

511 **Importance of Tregs and IL-10 in COPD Progression Induced by Cigarette Smoke Exposure/**J.T. Ito, D.A.B. Cervilha, D.S. Sales, J.D. Lourenco, J.J. Simao, C.R. Olivo, M.A. Martins, F.D.T.Q.S. Lopes, Sao Paulo, Brazil, p.A6332

512 **Effects of Statins on Innate Immune Cells in Lung Tissues of Mild to Moderate COPD/**S.F. Van Eeden, S. Miller, K. Hiraiwa, E. Lin, D. Ng, J.C. Hogg, Vancouver, Canada, p.A6333

513 **Human Beta Defensin 2 Levels Are Reduced in the Sputum of Chronic Obstructive Pulmonary Disease (COPD) Patients and Are Associated with the Occurrence of Exacerbations/**C. McCrae, Y. Zhou, J. Qian, J. Zheng, R. Tang, A. Nilsson, M. Zhang, P. Bruijnzeel, J. Saltzman, O. Vaarala, R. Chen, N. Zhong, Molndal, Sweden, p.A6334

514 **Bacterial Regulation of Pathogen Recognition Receptors in Macrophages in COPD Are Differentially Modified by Budesonide and Fluticasone Propionate Ex Vivo/**K.A. Provost, M. Smith, A. Miller-Larsson, G.D. Gudleski, S. Sethi, Buffalo, NY, p.A6335

515 **Rhinovirus Impairs Phagocytosis of Bacteria by Monocyte Derived Macrophages in Chronic Obstructive Pulmonary Disease/**L.J. Finney, K.B.R. Belchamber, M.R. Edwards, P. Mallia, S.L. Johnston, L. Donnelly, J.A. Wedzicha, London, United Kingdom, p.A6336

516 **Change in Titer of Serum Antibodies Directed at the Bacterial Surface Reflect the Frequency of Lower Airway Bacterial Carriage and Infection in COPD/**B. Mustafa, C. Wrona, T. Murphy, S. Sethi, Buffalo, NY, p.A6337

517 **IRF-3 Involved in Pathogenesis of Pulmonary Emphysema/**T. Ishii, K. Hosoki, Y. Nikura, T. Nagase, N. Yamashita, Tokyo, Japan, p.A6338

518 **Streptococcus Pneumoniae Colonization in Lower Airways Accelerates the Progression of Cigarette Smoke-Induced Chronic Obstructive Pulmonary Disease/**X. Gou, Q. Zhang, S. More, G. Bamunuarachchi, Y. Liang, F. Khan, C. Wang, L. Liu, Stillwater, OK, p.A6339

519 **Inefficiency of Influenza Vaccination in COPD Patients Is Associated with Defect of B Cell Differentiation and Decrease of IFNγ CD4+ T Cells Production/**A. Parpaleix, L. Boyer, A. Wiedemann, C. Lacabaratz, A. Lino, A. Covali-Noroc, C. Chouaid, B. Maitre, Y. Levy, L. Jean-Daniel, S. Adnot, Creteil, France, p.A6340

520 **Secretory IgA Deficiency in Individual Small Airways in COPD Correlates with Local Activation of Adaptive Immunity/**V.V. Polosukhin, B.W. Richmond, R.-H. Du, J.M. Cates, L.B. Ware, J.W. Lee, A.V. Kononov, T.S. Blackwell, Nashville, TN, p.A6341

521 **Smoke Exposure Drives Lung Disease Progression by Reducing Protein Tyrosine Phosphatase 1B Activity Via Toll-Like Receptor-9 Signaling/**P. Geraghty, N. Baumlin, M. Salathe, R. Foronjy, New York, NY, p.A6342

522 **Macrophages from Patients with Z Mutation in Antitrypsin Have Increased Proteolytic Activity on Extracellular Matrix Through Matriptase-MMP-14/**K. Krotova, G.W. Marek, L. Wang, N. Khodayari, F. Rouhani, M.L. Brantly, Gainesville, FL, p.A6343

523 **Severe Reduction of Peripheral T Cells Does Not Afford Protection Toward Emphysema and Bronchial Remodelling Induced in Mice By Cigarette Smoke/**G. Lungarella, G. De Cunto, B. Lunghi, B. Bartalesi, E. Cavarra, S. Fineschi, C. Ulivieri, M. Lucattelli, Siena, Italy, p.A6344

524 **Active Smoking is Associated with Increased Eosinophils in Bronchoalveolar Lavage but Not in Sputum or Peripheral Blood: SPIROMICS Immunophenotyping Sub-Study/**S.X. Li, A.J. Hirzel, C.M. Freeman, S.W. Crudgington, V.R. Stolberg, J. Sonstein, N.E. Alexis, P.V. Basta, E.E. Carretta, S.A. Christenson, D.J. Couper, C.M. Doerschuk, M.K. Han, N.N. Hansel, A.T. Hastie, R.J. Kaner, F.J. Martinez, W.K. O'Neal, R. Paine, III, S.I. Rennard, D. Shimbo, P.G. Woodruff, M. Zeidler, J.L. Curtis, Ann Arbor, MI, p.A6345

525 **M2 Macrophages Promote the Chronic Progression of Experimental Emphysema/**J.M. Craig, N. Limjunyawong, H.A.D. Lagasse, A. Poupore, A. Scott, W. Mitzner, Baltimore, MD, p.A6346

POSTER DISCUSSION SESSION

C108 ADVANCES IN LUNG FUNCTION ASSESSMENT

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 2024 (West Building, Level 2)

Poster Viewing **2:15-3:00**

Discussion **3:00-4:15**

Chairing: C.G. Irvin, PhD, Burlington, VT
B. Oppenheimer, MD, New York, NY

601 **High-Flow Nasal Cannula Offers Greater Reduction of Effort of Breathing in Children of Lower Weight/**T.W. Weiler, A. Kamerkar, J. Hotz, P.A. Ross, C.J. Newth, R.G. Khemani, Los Angeles, CA, p.A6347

602 **Does Passive Expiratory Volume Detect Bronchodilator Responsiveness in Infants with Bronchopulmonary Dysplasia?/**B.J. Clouse, S. Sitaram, L. Wei, S.R. Jadcherla, Columbus, OH, p.A6348

603 **Diffusion-perfusion Relationship Measured by a Rebreathing Technique in Mice with Bleomycin Induced Lung Injury/**D.M. Dane, H. Lu, E. Wechsler, P. Ravikumar, C.C.W. Hsia, Dallas, TX, p.A6349

604 **Residual Volume and Expiratory Flow Distinguishes Interstitial Lung Disease from Other Causes of Lung Restriction/**B. Singh, K. Raj, S.S. Dhaliwal, W. Noffsinger, Nedlands, Australia, p.A6350

605 **Clinical Significance of Isolated Decrease in Single Breath Lung Volume-Total Lung Capacity Ratio (VA/TLC)**/Y.-C. Huang, L.G. Que, Durham, NC, p.A6351

606 **Automated Full-Range Pressure-Volume Curves in Mice**/A. Robichaud, L. Fereydoonzad, N. Limjunyawong, R. Rabold, W. Mitzner, Montreal, Canada, p.A6352

607 **Expiratory Flow Limitation Is Related to Symptoms and Predicts Outcomes of Pulmonary Rehabilitation in Chronic Obstructive Pulmonary Disease**/S.C. Zimmermann, L. Ganderton, A. Fraser, L. Scott, A. Bertolin, J. Watts, A. Chan, C. Thamrin, G.G. King, Glebe, Australia, p.A6353

608 **A Possibility to Characterize the Primary Level of Bronchial Obstruction in Asthma and COPD Patients by Means of Analysis of Forced Expiratory Tracheal Noise Time and Band Pass Energy**/I. Pochekutova, V. Korenbaum, V. Malaeva, A. Kostiv, Vladivostok, Russian Federation, p.A6354

609 **No Effect of the Measurement Duration on the Within-Session Repeatability of Respiratory Impedance in Adults**/E. Oostveen, K. Leemans, W. De Backer, K. De Soomer, Antwerp, Belgium, p.A6355

610 **The Effect of Inspired Oxygen Fraction on Ventilation Heterogeneity in the Healthy Lung**/S.R. Hopkins, A.R. Elliott, G.K. Prisk, C. Darquenne, La Jolla, CA, p.A6356

611 **Changes in Peripheral Airway Function with Pulmonary Graft Vs. Host Disease in a Longitudinal Study of Paediatric Bone Marrow Transplant Patients**/P.D. Robinson, K.M. Hardaker, G. Jayasuriya, M. Gabriel, B. Kennedy, S. Keogh, P. Shaw, I. Twist, H. Selvadurai, Westmead, Australia, p.A6357

612 **Forced Oscillation Technique Measurements Relate to Hyperinflation and Lung Volume Improvements Following Long-Acting Bronchodilator in Chronic Obstructive Pulmonary Disease**/S. Milne, C. Hammans, S. Watson, C.S. Farah, C. Thamrin, G.G. King, Glebe, Australia, p.A6358

613 **Are Variations of Impedance in Time Contributing to Frequency Dependence of Resistance?**/H. Hanafi, K. El-Sankary, G.N. Maksym, Halifax, Canada, p.A6359

614 **Effects of Rostral Fluid Shifts on Airway Narrowing in Asthma**/S.A. Bhatawadekar, L. Jung, O. Lyons, M.D. Inman, J.J. Fredberg, S.M. Tarlo, A. Yadollahi, Toronto, Canada, p.A6360

615 **Lung Clearance Index (LCI) as a Potential Indicator of Pulmonary Impairment in Adolescent Idiopathic Scoliosis (AIS)**/A.K.B. Blyme, B. Hanel, M. Gehrchen, K.G. Nielsen, B. Dahl, Copenhagen, Denmark, p.A6361

616 **Comparison of Two Methods for Automatic Multiple Breath Washout Phase-III Analysis**/C. Buess, K. Nilsen, B.R. Thompson, Zurich, Switzerland, p.A6362

617 **Normative Values for the Test of Incremental Respiratory Endurance (TIRE)**/L.P. Cahalin, C. Garcia, T.S. Denis, S. Colas-Salgado, B. Eisenhardt, M.F. Formiga, M. Cohen, Coral Gables, FL, p.A6363

618 **Characterizing Respiratory Muscle Weakness in Amyotrophic Lateral Sclerosis with the Combined Use of Lung volumes, Spirometry and Muscle Strength**/F.M. Pais, T. Tyner, V.V. Jain, J.J. Vempilly, Fresno, CA, p.A6364

619 **Improved Diaphragm Contractile Function Following Intramyocardial Injection of Cardiosphere-Derived Cells in the mdx Mouse Cardiomyopathy Model**/M.A. Aminzadeh, M. Fournier, P. Durvasula, M.I. Lewis, E. Marban, Los Angeles, CA, p.A6365

620 **Technique and Validity of Sniff Airway Pressure and Sniff Diaphragm Thickening to Assess Diaphragm Function**/S.L. Vorona, C. Urrea, A. Lanys, N.D. Ferguson, L.J. Brochard, E.C. Goligher, Toronto, Canada, p.A6366

621 **Correlation of Diaphragm Thickness and NIF**/A. Pavlov, S. Ahmad, Stony Brook, NY, p.A6367

622 **Lung Clearance Index in Children with Asthma and Different Degree of Control at Ages 5 to 14 Years-Old**/L.G. Gochicoa-Rangel, R. Del Rio Hidalgo, M.E. Urbina-Munguia, U. Mora-Romero, S. Guerrero-Zuniga, R. Benitez-Perez, L. Rodriguez-Moreno, R. Fernandez-Plata, N. Villca-Ala, S. Cid Juarez, L. Torre-Bouscoulet, Ciudad De Mexico, Mexico, p.A7890

POSTER DISCUSSION SESSION

C109 PATHOGENESIS OF SDB: DOES IT MATTER?

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 3011 (West Building, Level 3)

Poster Viewing	**2:15-3:00**
Discussion	**3:00-4:15**

Chairing: P. Eastwood, PhD, Nedlands, Australia
A. Jordan, PhD, Parkville, Australia
P. Genta, MD, Sao Paolo, Brazil

801 **Hypocapnia Induced Via Mechanical Hyperventilation Does Not Reduce Upper Airway Dilator Muscle Activity Following Arousal from Sleep**/J. Cori, F. O'Donoghue, P. Rochford, J. Trinder, A. Jordan, Parkville, Australia, p.A6368

802 **Arousal Induced Hypocapnia Does Not Reduce Genioglossus Muscle Activity Following the Return to Sleep in Obstructive Sleep Apnea (OSA)**/J. Cori, T. Thornton, F. O'Donoghue, P. Rochford, J. Trinder, A. Jordan, Parkville, Australia, p.A6369

803 **Comparison of Peri-Pharyngeal Muscle Recruitment During Wakefulness and Sleep in Healthy Subjects During Upper Airway Obstruction**/A. Oliven, G. Cohen, Y. Dotan, A.R. Schwartz, Haifa, Israel, p.A6370

804 **Genioglossus Reflex Responses to Negative Upper Airway Pressure Are Impaired in People with Tetraplegia and Obstructive Sleep Apnoea**/N. Wijesuriya, L. Gainche, A. Jordan, D.J. Berlowitz, M. LeGuen, P. Rochford, F. O'Donoghue, W. Rhueland, J. Butler, J. Carberry, D.J. Eckert, Randwick, Australia, p.A6371

805 **Day-to-Day Variability and Blunted Perception of High Nasal Resistance in People with Tetraplegia and Obstructive Sleep Apnoea**/N. Wijesuriya, C. Lewis, J. Butler, A. Jordan, D.J. Berlowitz, D.J. Eckert, Randwick, Australia, p.A6372

806 **Upper Airway Dynamics During Wakefulness and Natural Sleep in OSA Subjects: Preliminary Results/**C. Darquenne, A.R. Elliott, R.J. Theilmann, E.T. Smales, P.N. DeYoung, A. Malhotra, La Jolla, CA, p.A6373

807 **Negative Effort Dependence in a Starling Resistor Bench Model of the Upper Airway: Role of Surrounding Chamber Pressure/**K. Kairaitis, C. Lambeth, B. Kolevski, T. Amis, Westmead, Australia, p.A6374

808 **Estimation of Airway Stiffness and Collapsibility in Children with Down Syndrome and Persistent Obstructive Sleep Apnea/**R.N. Prasad, G. Mylavarapu, D.R. Subramaniam, R. Sczcesniak, M. Mahmoud, S.L. Ishamn, S.R. Shott, R.J. Fleck, E.J. Gutmark, R.S. Amin, Cincinnati, OH, p.A6375

809 **Influence of Ventilatory Drive and Inspiratory Mechanics on Genioglossus Movement Under Ultrasound Imaging/**B. Kwan, L. Bilston, R. McBain, J. Butler, S. Gandevia, Randwick, Australia, p.A6376

810 **Assessment Of Genioglossus Fatigue Using Different Contraction Tasks/**W. Li, S. Gakwaya, F. Series, Quebec, Canada, p.A6377

811 **Phenotyping Sleep Apnea Using Polysomnography: Upper Airway Collapsibility and Responsiveness/**S.A. Sands, B.A. Edwards, P. Terrill, L. Taranto Montemurro, A. Azarbarzin, M. Marques, S. Loring, J.P. Butler, D.P. White, A. Wellman, Boston, MA, p.A6378

812 **Pathophysiologic Factors Mediating Obstructive Sleep Apnea Syndrome in Adolescents/**R.J. Schwab, B.T. Keenan, J. Huang, H. Yuan, R.M. Bradford, S. Bagchi, S.H.C. Wang, I.E. Tapia, C. Cielo, C. Marcus, Philadelphia, PA, p.A6379

813 **Clinically Relevant Phenotypes of Obstructive Sleep Apnea/**A. Zinchuk, S. Jeon, B. Koo, N. Redeker, B. Selim, J. Concato, K.H. Yaggi, New Haven, CT, p.A6380

814 **Obstructive Sleep Apnea Phenotypes: A Cluster Analysis/**R. Tamisier, S. Bailly, M. Destors, Y. Grillet, P. Richard, B. Stach, I. Vivodtzev, J.-F. Timsit, P. Levy, J.L. Pepin, Grenoble, France, p.A6381

815 **Does Norepinephrine Participated in the Central Regulation of Genioglossus During CIH in Rats?/**L. Zhou, W. Wang, A. Wang, J. Kang, Shenyang, China, p.A6382

816 **Desipramine Increases Genioglossus Activity and Reduces Upper Airway Collapsibility During Non-REM Sleep in Healthy Subjects/**L. Taranto Montemurro, B.A. Edwards, S.A. Sands, M. Marques, D.J. Eckert, D.P. White, A. Wellman, Boston, MA, p.A6383

817 **Effect of Sustained Hyperoxia on Breathing Stability in Older Adults During NREM Sleep/**S. Pranathiageswaran, M.S. Badr, K. Ross, A. Ahmed, S. Chowdhuri, Detroit, MI, p.A6384

818 **The Effect of Body Position on Dynamic Loop Gain in Obstructive Sleep Apnea Patients/**S.A. Joosten, D. Mann, S. Landry, S.A. Sands, P. Terrill, G.S. Hamilton, B.A. Edwards, Clayton, Australia, p.A6385

819 **Mild Intermittent Hypoxia with Sustained Hypercapnia Reduces Therapeutic Continuous Positive Airway Pressure and Upper Airway Resistance in Participants with Obstructive Sleep Apnea/**M. El-Chami, D. Shaheen, S. Sudan, H.-S. Lin, J. Mateika, Detroit, MI, p.A6386

820 **Lowered Metabolic Rate as a Potential Avenue for Stabilizing Breathing in Obstructive Sleep Apnea: An Observational Study/**C.M. De Melo, L. Taranto Montemurro, J. Butler, D.P. White, A. Wellman, S.A. Sands, Boston, MA, p.A6387

821 **The Central Nervous System in Breathing Disturbances of Prematurity/**S.C. Ramirez, T.M. Anderson, N.A. Baertsch, J.E. Koschnitzky, C.V. Smith, J.-M. Ramirez, Seattle, WA, p.A6388

822 **Neural Lineages That Control Inspiration In Intact Animals/**N.A. Baertsch, J.-M. Ramirez, Seattle, WA, p.A6389

823 **How Opioids Suppress Breathing/**A.D. Wei, A.J. Garcia, J.-M. Ramirez, Seattle, WA, p.A6390

POSTER DISCUSSION SESSION

C110 MESOTHELIOMA AND MALIGNANT PLEURAL DISEASE: FROM BENCH TO BEDSIDE TO COMMUNITY

2:15 p.m. - 4:15 p.m. **MOSCONE CENTER**

Room 309 (South Building, Esplanade Level)

Poster Viewing **2:15-3:00**

Discussion **3:00-4:15**

Chairing: D.H. Sterman, MD, New York, NY
Y. Aelony, MD, Harbor City, CA

301 **A Model to Predict Pleural Effusion Recurrence/**H. Grosu, S. Molina, R. Casal, J. Diaz-Mendoza, C. Reddy, L. Yarmus, D. Schiavo, M. Simoff, J. Johnstun, C. Ray, A. Raid, D. Feller-Kopman, H. Lee, S. Sahetya, F. Foley, F. Maldonado, B. Xian, L. Noor, R. Miller, L. Mudambi, T. Saettele, M. Vial-Rodriguez, C. Jimenez, G. Eapen, D. Ost, Houston, TX, p.A6391

302 **Real-Life' Diagnostic Peformance and Subjectivity of Computed Tomography (CT) Imaging in Pleural Malignancy/**S. Tsim, K.G. Blyth, Glasgow, United Kingdom, p.A6392

303 **Malignant Pleural Effusion (MPE) Management with Aseptr Tunneled Pleural Catheter: Feasibility and Effects on Quality of Life (QoL)/**M. Mahdavian, B. Wong, S. Asghari, K. Amjadi, Ottawa, Canada, p.A6393

304 **An Update in the Epidemiology of Malignant Pleural Effusions/**C.T. Phan, S.B. Smith, A.C. Argento, C.T. Gillespie, Chicago, IL, p.A6394

305 **Outcomes of a Dedicated Pleural Service in a Healthcare System/**S.R. Mummadi, L. Bettencourt, P.Y. Hahn, Chicago, IL, p.A6395

306 **Concomitant Existence of Interstitial Pneumonia Is a Risk Factor of Unexpected Pleural Invasion and Malignant Pleurisy in Surgical Cases of Non-Small Cell Lung Cancer/**A. Hata, H. Suzuki, T. Oshima, Y. Sata, T. Toyoda, T. Inage, T. Yamamoto, K. Tanaka, T. Fujiwara, H. Wada, T. Nakajima, T. Iwata, S. Yoshida, I. Yoshino, Chiba, Japan, p.A6396

307 **Prognostic Factors of Mortality After Palliative Procedures in Patients with Malignant Pleural Effusion/**F.C. Abrao, M.C. De Oliveira, G.G. Viana, I.R. Abreu, Sao Paulo, Brazil, p.A6397

308 **Relationship Between Pleural Fluid Volume and Mortality/**C. Parks, R. Bechara, W. Dev, Newnan, GA, p.A6398

309 **Role of Chest Ultrasound in Detecting Successful Pleurodesis/**E.K. Ibrahim, K.M. Kamel, A.A.A.K. Abo Zaid, H.E.S.H. Fayiad, Cairo, Egypt, p.A6399

310 **Predicting Autopleurodesis After Placement of an Indwelling Pleural Catheter for Symptomatic Malignant Pleural Effusions/**J. Johnstun, C. Reddy, Salt Lake City, UT, p.A6400

311 **A Novel Combination of Calprotectin and CXCL12 for Predicting Malignancy in Patients with Exudative Pleural Effusion/**D. Liu, J. Luo, C.-T. Li, Z.-A. Liang, Chengdu, China, p.A6402

312 **Diagnosing Mesothelioma Via Its Effect on Chest Wall Mechanics/**G. Elshafie, A. Aliverti, P. Kumar, P. Rajesh, R. Steyn, M. Kalkat, E. Bishay, B. Naidu, Birmingham, United Kingdom, p.A6402

313 **Quality of Life in Patients with Malignant Pleural Mesothelioma is Influenced by Histological Differentiation/**D.Y. Kircheva, S. Watson, A. Husain, S. Jacob, K. Todd, B. Rose, H. Kindler, A. Durkin, W.T. Vigneswaran, Chicago, IL, p.A6403

314 **Radiological Aspects Could Influence the Survival in Patients with Malignant Pleural Effusion After Palliative Procedure/**F. Abrao, J.H. Godoy Rodrigues, F.D. Munhoz, G.G. Viana, M.C. De Oliveira, I.R. Abreu, Sao Paulo, Brazil, p.A6404

315 **Malignant Pleural Mesothelioma in Southern Portugal/**C. Guerreiro, M. Lopes, J. Santos Silva, F. Freitas, A. Mayer, R. Sotto Mayor, J. Duro Da Costa, M.T. Almodovar, Faro, Portugal, p.A6405

316 **Is Malignant Pleural Mesothelioma in Southern Portugal Increasing?/**M. Lopes, C. Guerreiro, F. Freitas, J. Santos Silva, R. Sotto Mayor, A. Mayer, J. Duro Da Costa, M.T. Almodovar, Almada, Portugal, p.A6406

317 **Role Of Ebus - TBNA in Ganglional Staging of Malignant Pleural Mesothelioma/**T. Aguirre Perez, R. Baez Saldana, L. Martinez, E. Guzman, E. Pena Miraval, P. Castillo, U. Rumbo, M.A. Iniguez, J. Alatorre, R. Jeronimo, O. Arrieta, J.R. Perez Padilla, Distrito Federal, Mexico, p.A6407

318 **Morbimortality of Radical Panpleuropneumonectomy for Malignant Pleural Mesothelioma in a Single Cancer Center at the Health Mexican System/**J. Kelly-Garcia, E.M. Garcia-Bazan, D. Zamora-Lemus, H. Arias-Cevallos, H.K. Mandujano-Law, E. Lascano-Hernandez, Mexico, Mexico, p.A6408

319 **Malignant Pleural Mesothelioma Revisited- A Descriptive Case Series/**J.M. D'souza, S.K. Tan, J.E. Seet, Singapore, Singapore, p.A6409

320 **Targeting EphA2 Using miR-302b Encapsulated-eprhin-A1 Conjugated Liposomal Nanoparticles Inhibits Malignant Pleural Mesothelioma Tumor Growth/**N. Nasreen, H. Lee, K. Mohammed, F. Kaye, P. Sharma, B. Moudgil, W. Clapp, Gainesville, FL, p.A6410

321 **Anti-Tumor Effect of MT95-4, a Fully Humanized Anti-Aminopeptidase N Monoclonal Antibody, on Tumor Progression in an Animal Model of Malignant Pleural Mesothelioma/**T. Otsuki, N. Hattori, H. Hamada, Y. Takayama, Y. Horimasu, T. Masuda, S. Miyamoto, T. Nakashima, H. Iwamoto, K. Fujitaka, N. Kohno, Hiroshima, Japan, p.A6411

322 **Autophagy Correlates with Patient Outcome in Mesothelioma/**C. Follo, D. Barbone, W.G. Richards, R. Bueno, V.C. Broaddus, San Francisco, CA, p.A6412

323 **Analysis of Gene-Expression Changes in 3D Spheroids Highlights a Survival Role for ASS1 in Mesothelioma/**D. Barbone, C. Follo, L. Van Dam, P.V. Jithesh, S.D. Zhang, W.G. Richards, R. Bueno, D.A. Fennell, V.C. Broaddus, San Francisco, CA, p.A6413

324 **Receptor Tyrosine Kinase-Like Orphan Receptor 2, ROR2, Regulates the Proliferation of Malignant Pleural Mesothelioma Cells/**H. Ogino, H. Goto, S. Kakiuchi, A. Saijo, S. Sakaguchi, M. Tobiume, K. Otsuka, H. Yoneda, M. Hanibuchi, Y. Nishioka, Tokushima, Japan, p.A6414

325 **The Mutational Burden of Pleural Mesothelioma with a History of Smoking and Asbestos Exposure/**M. Ginsburg, R. Friedman, G.E. Bates, A. Borczuk, R.N. Taub, J.R. Sonett, New York, NY, p.A6415

CLINICAL

PEDIATRIC CLINICAL CORE CURRICULUM

CME Credits Available: 1.0

PCC4 PEDIATRIC CLINICAL CORE CURRICULUM

Pediatric Core Curriculum Working Group

6:45 a.m. - 7:45 a.m. **MOSCONE CENTER**

Room 3007/3009 (West Building, Level 3)

Target Audience
Pediatric pulmonary and critical care physicians who work in a clinical setting and are currently engaged in maintenance of certification.

Objectives
At the conclusion of this session, the participant will be able to:

- remain current with medical knowledge relevant to their practice in pediatric pulmonology;
- evaluate their understanding of key skills and content areas in pediatric pulmonology as well as receive feedback on their comprehension of a result of a pre-test/post-test comparison;
- support clinicians who are engaged in maintenance of certification activities by providing updates on subjects included in recertification requirements.

The Pediatric Core Curriculum symposia promote lifelong learning and the enhancement of the clinical judgment and skills essential for practicing pediatricians. The symposia will address topics that have been identified by an ATS pediatric working group, which is comprised of members of the ATS Education Committee and the International Conference Committee, who have identified important areas within pediatric medicine (including vasculitic pulmonary diseases, lung defense mechanism, congenital abnormalities of the airways, and respiratory failure). Attendees will increase their medical knowledge as a result of attending this symposium, and this will be measured by a comparison of pre-test vs. post-test results on the corresponding maintenance of certification module. The ATS Pediatric Core Curriculum will focus on a 3-year content cycle of key medical content in the area of pediatric medicine.

Chairing: D.M. Boyer, MD, Boston, MA
P.E. Moore, MD, Nashville, TN

6:45 **Acute Respiratory Failure**
J. Rettig, MD, Boston, MA

7:15 **Chronic Respiratory Failure**
C.D. Baker, MD, Aurora, CO

SUNRISE SEMINARS

CME Credits Available: 1.0

Rgistration Fee: $65.00 (includes continental breakfast.)
Attendance is limited. Pre-registration is required.

6:45 a.m. - 7:45 a.m. **INTERCONTINENTAL HOTEL**

SS301 **ROLE OF THE MICROENVIRONMENT IN CELL FATE: MACROPHAGES MEET MECHANOBIOLOGY**
R.G. Scheraga, MD, Cleveland, OH
Union Square (Third Floor)

SS302 **HEME OXYGENASE ACTIVITY IN PULMONARY DISEASE MEASURED BY TRANSCUTANEOUS CARBOXYHEMOGLOBIN**
L.E. Kurlandsky, MD, Fayetteville, NY
SoMa (Third Floor)

SS303 **CHRONIC LUNG DISEASE IN HIV**
J. Leung, MD, Vancouver, Canada
Mission (Third Floor)

SS304 **DIFFUSE CYSTIC LUNG DISEASE**
N. Gupta, MD, Cincinnati, OH
Marina (Third Floor)

SS305 **APPROACH TO PATIENTS WITHOUT DEFINITE UIP ON HRCT: LESSONS LEARNED FROM DIFFICULT CASES**
M. Porteous, MD, Philadelphia, PA
Grand Ballroom C (Third Floor)

SS306 **ADVANCES IN NON-CF BRONCHIECTASIS THROUGH THE LENS OF PRIMARY CILIARY DYSKINESIA**
M. Prickett, MD, MPH, Chicago, IL
Grand Ballroom B (Third Floor)

SS307 **COPD PHENOTYPES: DO THEY MAKE A DIFFERENCE?**
T. Beiko, Dr., Charleston, SC
Grand Ballroom A (Third Floor)

SS308 **EVALUATION AND MANAGEMENT OF PATIENTS WITH CTD-ILD FOR LUNG TRANSPLANTATION**
R.J. Shah, MD, San Francisco, CA
Twin Peaks (Fourth Floor)

SS309 **A SECOND LUNG TRANSPLANT: WHO AND UNDER WHAT CIRCUMSTANCES?**
A.L. Gray, MD, Durham, NC
Telegraph Hill (Fourth Floor)

SS310 **RACIAL AND ETHNIC HEALTH DISPARITIES IN SEPSIS**
G.J. Soto, MD, Bronx, NY
Potrero Hill (Fourth Floor)

SS311 **VITAMIN D AND ASTHMA**
J.M. Brehm, MD, MPH, Pittsburgh, PA
Nob Hill (Fourth Floor)

SS312 **TREATMENT OF DRUG RESISTANT INFECTIONS IN INDIVIDUALS WITH BRONCHIECTASIS**
E.C. Dasenbrook, MD, Cleveland, OH
Laurel Hill (Fourth Floor)

SS313 **UNTANGLING PATIENT REPORTED OUTCOME AND EXPERIENCE MEASURES**
M. Hodson, MSC, RN, London, United Kingdom
J. Yorke, PhD, RN, Manchester, United Kingdom
Cathedral Hill (Fourth Floor)

SS314 **NON-INVASIVE POSITIVE PRESSURE VENTILATION FOR THE PEDIATRIC PULMONOLOGIST**
R. Amin, MD, Toronto, Canada
Sutter (Fifth Floor)

SS315 **ACUTE RIGHT HEART FAILURE: THE PRACTICAL NUTS AND BOLTS OF ASSESSMENT AND MANAGEMENT**
W.H. Fares, MD, MSc, New Haven, CT
Stockton (Fifth Floor)

SS316 **"MIND THE GAP": USE OF NATIVE TISSUE SLICES AND DECELLULARIZED HUMAN MATRICES AS EX VIVO MODELS OF REGENERATION AND DISEASE**
D.E. Wagner, PhD, Munich, Germany
Howard (Fifth Floor)

SS317 **THE MODERN APPROACH TO THE MANAGEMENT OF PNEUMOTHORAX AND AIR LEAK**
A. Chopra, MD, Albany, NY
Fremont (Fifth Floor)

SS318 **EXERCISE TRAINING IN SLEEP DISORDERED BREATHING: TIME TO MAKE A NEW FRIEND**
M. Macrea, MD, MPH, PhD, Salem, VA
InterContinental Ballroom C (Fifth Floor)

SS319 **MANAGEMENT OF MALIGNANT PLEURAL EFFUSION BY THE PULMONOLOGIST: UPDATES**
S. Shojaee, MD, Richmond, VA
A.C. Argento, MD, Chicago, IL
InterContinental Ballroom B (Fifth Floor)

FACULTY DEVELOPMENT SEMINAR

FD3 THE ROADMAP TO SUCCESS IN EARLY ACADEMIC CAREER DEVELOPMENT: YOUR FIRST FIVE YEARS

Pre-registration is required. There is no additional fee. Attendance is limited.

6:45 a.m. - 7:45 a.m. **INTERCONTINENTAL HOTEL**
InterContinental Ballroom A (Fifth Floor)

Target Audience
Early career clinical and/or research faculty, clinical and post doctoral fellows, graduate students, residents, nurses, and allied health professionals already involved in or seeking a career in academic pulmonary, allergy, critical care, and/or sleep medicine.

Objectives
At the conclusion of this session, the participant will be able to:

- able to identify components necessary for success in their career path;
- understand how to balance various expectations and interests needed for career advancement;
- gain strategies to protect their time from competing obligations.

As a junior faculty member, are you confronted with numerous, potentially competing, obligations on your time and effort? The first five years of your faculty appointment is crucial for establishing the proper trajectory of your career. This seminar will provide valuable insights and strategies on balancing professional activities while developing a successful academic career.

Chairing: J.C. Horowitz, MD, Ann Arbor, MI

Speakers: L.E. Crotty Alexander, MD, San Diego, CA
M. Peters-Golden, MD, Ann Arbor, MI
J.B. Richards, MD, MA, Charleston, SC
M. Ballinger, PhD, Columbus, OH
C.M. Waters, PhD, Memphis, TN

BASIC • CLINICAL • TRANSLATIONAL

ATS KEYNOTE SERIES

CME Credits Available: .75

The ATS Keynote Series provides state of the art lectures on selected topics in an unopposed format to showcase major discoveries in pulmonary, critical care and sleep medicine. The speakers have been chosen by input from the members and various ATS committees with consensus built via the ATS executive committee.

Two sessions are presented each morning during the conference. Below are the topics for the Wednesday, May 18th series.

K7 BIOMARKERS FOR PRECISION MEDICINE IN ASTHMA

8:00 a.m. - 8:45 a.m. **MOSCONE CENTER**
Room 134 (North Building, Lower Level)

Speaker: Serpil C. Erzurum, MD, Cleveland, OH

*This session and the International Conference are supported by an educational grant from **AstraZeneca LP.***
All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

K8 ARDS: MECHANISMS AND PROFESSIONAL SOCIETIES

8:00 a.m. - 8:45 a.m. **MOSCONE CENTER**
Room 135 (North Building, Lower Level)

Speaker: Brian P. Kavanagh, MD, Toronto, Canada

CLINICAL

YEAR IN REVIEW

CME Credits Available: 2.0

D1 CLINICAL YEAR IN REVIEW 4

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Gateway Ballroom 102-104 (South Building, Lower Level)

Target Audience
Providers including physicians, nurses, respiratory therapists, nurse practitioners, physician assistants. Trainees including residents and fellows; clinical researchers.

Objectives
At the conclusion of this session, the participant will be able to:

- apply new clinical research knowledge to clinical practice;
- learn new findings about key conditions in pulmonary, critical care and sleep;
- have new strategies to manage the care of common conditions in pulmonary, critical care, and sleep.

The annual Clinical Year in Review symposia topic reviews of the key clinical research publications over the last year. Each speaker is asked to review the 5-7 most important and influential publications on their topic in the prior year.

Chairing: J.L. Taylor-Cousar, MD, Denver, CO
D.J. Lederer, MD, MS, New York, NY
D.W. Ford, MD, MSCR, Charleston, SC

9:00 **Asthma**
A. Sood, MD, MPH, Albuquerque, NM

9:30 **Medical Education**
J.W. McCallister, MD, Columbus, OH

10:00 **Pulmonary Vascular Disease**
H.J. Bogaard, MD, PhD, Amsterdam, Netherlands

10:30 **ILD**
D.J. Lederer, MD, MS, New York, NY

This session and the International Conference are supported by educational grants from ***AstraZeneca LP, Boehringer Ingelheim Pharmaceuticals, Inc.***
All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

CLINICAL • TRANSLATIONAL

CLINICAL TOPICS IN PULMONARY MEDICINE

CME Credits Available: 2.0

D2 WHAT, WHEN, WHERE: CLEARING THE AIR ON STEM CELL THERAPIES IN PULMONARY DISEASES

Assemblies on Clinical Problems; Respiratory Cell and Molecular Biology

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 135 (North Building, Lower Level)

Target Audience
Providers of lung health; patients victimized by biotourism; researchers; clinicians.

Objectives
At the conclusion of this session, the participant will be able to:

- understand the terminology surrounding stem cell therapies;
- recognize the lack of efficacy data surrounding cell based therapies at this time;
- discuss future areas of investigation and application of cell based therapies in lung disease.

This session will highlight seminal basic science information and recent advances in the application of cell based therapeutics to the treatment of lung disease (IPF, COPD, and ARDS). For patients and physicians who search for treatments for incurable lung diseases, stem cell therapies have drawn increasing attention. Unfortunately, patients become victims of biotourism. Several well designed and completed phase 1 clinical trials have now been completed with mesenchymal stem cells (MSCs) that demonstrate patient safety. The results of these trials will be reviewed as they are paving the way for productive phase 2 and 3 studies and ultimately new therapeutic modalities. Controversies and cautions will be addressed.

Chairing: M. Glassberg, MD, Miami, FL
V. Lama, MD, MS, Ann Arbor, MI
M. Rojas, MD, Pittsburgh, PA

9:00 **Introduction and Overview**
M. Glassberg, MD, Miami, FL

9:05 **Vocabulary Check: Let's All Talk the Same Language**
V. Lama, MD, MS, Ann Arbor, MI

9:25 **The Journey from Bench to Bedside: Deciphering How MSCs Work**
D.J. Weiss, MD, PhD, Burlington, VT
B. Thebaud, MD, PhD, Ottawa, Canada

9:45 **Moving Stem Cell Therapies to Patients with IPF**
M. Glassberg, MD, Miami, FL

10:05 **The Stem Cells for ARDS Treatment Trial: What Lies Ahead**
M.A. Matthay, MD, San Francisco, CA

10:25 **A Note of Caution in Stem Cell Therapies: Separating the Wheat from the Chaff**
Speaker To Be Announced

10:45 **Panel Discussion: Conclusions and Questions**
V. Lama, MD, MS, Ann Arbor, MI

BASIC • CLINICAL • TRANSLATIONAL

CLINICAL TOPICS IN PULMONARY MEDICINE

CME Credits Available: 2.0

D3 TRANSLATIONAL ADVANCES IN PLEURAL DISEASES: WHAT CLINICIANS NEED TO KNOW

Assembly on Clinical Problems

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 134 (North Building, Lower Level)

Target Audience
Clinicians and allied health professionals with clinical and research responsibilities in respiratory diseases; especially chest physicians, interventional pulmonologists, respiratory nurses, thoracic surgeons, internists, general physicians and junior

Objectives
At the conclusion of this session, the participant will be able to:

- understand and learn the rationale of gene therapy, stem cell treatment and phenotyping of malignant effusion patients;
- describe the interactions between bacteria and the pleura, and its therapeutic potentials;
- learn new technologies being applied in pleural diagnosis and management;

This symposium will provide learners with up to date information and evidence on several exciting developments in translational research of pleural diseases which have impacted clinical care, or are likely to do so in the future. The session will provide leading translational research on pleural disease, including pleural malignancy and infection, and novel investigative technologies. The session will cover cutting edge approaches of using stem cell therapy in the pleura and the role of mesothelial cells in lung fibrosis.

Chairing: N.M. Rahman, MSc, PhD, Oxford, United Kingdom
M.M. Wahidi, MD, Durham, NC

9:00 **Gene Therapy for Pleural Cancers: Hurdles and Progresses**
D.H. Sterman, MD, New York, NY

9:20 **Phenotyping Malignant Pleural Effusions: Why and What for?**
N.A. Maskell, MD, Bristol, United Kingdom

9:40 **Stem Cell Therapy in Pleural Diseases: Fact or Fiction**
S. Janes, MD, PhD, London, United Kingdom

10:00 **The Pleura: A New Co-Conspirator in Pulmonary Fibrosis**
V.B. Antony, MD, Birmingham, AL

10:20 **Bacteria, Fibrinolytics and Pleural Space: Exciting New Lessons**
Y.C.G. Lee, MBChB, PhD, Perth, Australia

10:40 **Novel Interventional Technologies in Pleural Diseases**
D.J. Feller-Kopman, MD, Baltimore, MD

CLINICAL • TRANSLATIONAL

CRITICAL CARE TRACK

CME Credits Available: 2.0

D4 CRITICAL CARE MEETS SILICON VALLEY: TECH SOLUTIONS FOR RESEARCH AND PRACTICE

Assemblies on Critical Care; Behavioral Science and Health Services Research

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**
Room 3000/3002/3004 (West Building, Level 3)

Target Audience
Practicing clinicians who care for critically ill adults, researchers studying critical illness, health system administrators and trainees.

Objectives
At the conclusion of this session, the participant will be able to:

- understand how apps may be developed and used to improve clinical research and bedside critical care;
- describe how real-time analytics can be leveraged to improve critical care delivery;
- understand how a re-engineered electronic health records system will improve the delivery of critical care.

Silicon Valley companies like Google, Apple, and Uber create simple tech solutions to enhance our everyday lives. These innovations also have pertinent applications in critical care, and this session will detail technological solutions that can enhance clinical research and care for patients with critical illness. Examples highlighted in the session will include developing apps to improve patient care tasks, crowd-sourcing research communities for solutions to complex problems in critical care, gathering data from wearable devices to monitor critical illness, utilizing real-time analytics to identify critical illness and improve hospital efficiency, and re-engineering EHR's to improve bedside critical care.

Chairing: M.W. Sjoding, MD, Ann Arbor, MI
M.M. Churpek, MD, MPH, PhD, Chicago, IL
C.E. Cox, MD, MPH, Durham, NC

9:00 **Learning from Silicon Valley: Safer, Efficient, Patient-Centered Care with Technology**
M.W. Sjoding, MD, Ann Arbor, MI

9:10 **Mapping Real-Time Alerts to Identify Critical Illness**
M.M. Churpek, MD, MPH, PhD, Chicago, IL

9:28 **Crowdsourcing Research Communities to Solve Problems in Critical Care**
T.J. Pollard, PhD, Cambridge, MA

9:46 **Building EHR-Integrated Apps for More "Meaningful" Use in Critical Care**
C.E. Cox, MD, MPH, Durham, NC

10:04 **Next Generation Wearable Technologies for Monitoring Critical Illness**
G.S. Martin, MD, MSc, Atlanta, GA

10:22 **Bringing the "Sharing Economy" to Hospitals**
V. Liu, MD, MS, Oakland, CA

10:40 **Engineering Electronic Health Record Systems of the Future**
M.N. Gong, MD, MS, Bronx, NY

BEHAVIORAL • CLINICAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 2.0

Nursing Contact Hours Available: 2.4

D5 IMPROVING OUR UNDERSTANDING OF RESPIRATORY SYMPTOMS, REFRACTORY CHRONIC COUGH AND INTERPROFESSIONAL MANAGEMENT

Assemblies on Nursing; Behavioral Science and Health Services Research; Clinical Problems; Pulmonary Rehabilitation

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**
Room 307 (South Building, Esplanade Level)

Target Audience
Anyone involved in the provision of care for those with respiratory problems and specifically with chronic cough.

Objectives
At the conclusion of this session, the participant will be able to:

- explore issues related to respiratory symptom managment and respiratory symptom clusters with a focus on cough;
- identify a theoretical understanding of the relationship of psychologic symptoms and chronic cough and to understand the role of speech pathology in the managment of chronic cough;
- become aware of recent finding of systematic reviews and guidelines related to the diagnosis and management of chronic refractory cough.

This session will use interprofessional inquiry and recent findings from the literature to broaden the attendees understanding of the symptom of chronic cough and refractory chronic cough and its management in 2016.

Chairing: P.M. Meek, RN, PhD, Denver, CO
A.M. Russell, MSc, London, United Kingdom

9:00 **Reflections from Symptom Management**
P.M. Meek, RN, PhD, Denver, CO

9:15 **Respiratory Symptom Clusters**
J. Yorke, PhD, RN, Manchester, United Kingdom

9:30 **Examining Change in Symptoms of Depression, Anxiety, and Stress in Adults After Treatment of Chronic Cough**
C.L. French, PhD, RN, Worcester, MA

9:45 **Update Refractory Chronic Cough and Management**
P.G. Gibson, MBBS, Newcastle, Australia

10:00 **The Role of the Speech Pathologist and Speech Pathology in the Management of Chronic Cough**
A.E. Vertigan, PhD, MBA, BAppSc(Sp.Path), Newcastle, Australia

10:15 **Is the Refractory Cough of a Psychogenic Nature a Habit or an Undiagnosed Tic Cough?**
R.S. Irwin, MD, Worcester, MA

10:30 **Panel Discussion**

CLINICAL • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 2.0

D6 CANNABIS, CANNABIMIMETICS, AND OPIATES IN SLEEP AND BREATHING

Assemblies on Sleep and Respiratory Neurobiology; Behavioral Science and Health Services Research; Pediatrics

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**
Room 2001/2003 (West Building, Level 2)

Target Audience
Pulmonologists, pediatricians, respiratory therapists, nurses practitioners, sleep medicine research scientists, epidemiologists, public health providers and health services researchers.

Objectives
At the conclusion of this session, the participant will be able to:

- discuss neurodevelopmental and respiratory effects of cannabis use in adolescents and young adults;
- learn emerging data on effects of cannabis on sleep and novel therapeutic applications of cannabimetic drugs in sleep related breathing;
- review effects of opioids on sleep related breathing and discuss ampakines; a novel therapy for opioid induced respiratory depression.

Legalization of cannabis in the U.S. and other countries has led to increasing medicinal and recreational use of cannabis. This symposium will describe the known effects of cannabis on neurodevelopment of adolescents and its effects on sleep. Current and potential therapeutic uses of cannabis and cannabimimetics in sleep and breathing disorders will be discussed. Acute and chronic use of opioids in hospitalized patients, perioperative settings and for opioid use disorders is increasingly prevalent. Effects of opioids on sleep related breathing and novel preclinical pharmacologic interventions to reverse opioid effects on breathing will be reviewed.

Chairing: B. Prasad, MD, MS, Chicago, IL
L. Kheirandish-Gozal, MD, MSc, Chicago, IL

9:00 **A Patient's Perspective**
J. Jorgensen, Vista, CA

9:05 **Opioid-Induced Sleep Apnea: Precursor to Periodicity**
S. Chowdhuri, MD, MS, Detroit, MI

9:25 **Ampakine Therapy for Alleviating Opioid-Induced Respiratory Depression**
J.J. Greer, PhD, Edmonton, Canada

9:50 **Cannabis and Human Sleep: What Have We Learned So Far?**
K. Babson, PhD, Menlo Park, CA

10:10 **Neurodevelopmental and Respiratory Effects of Cannabis in Adolescents and Adults**
R. Bhattacharjee, MD, San Diego, CA

10:25 **Cannabinoids: Novel Translational Potential for Sleep Apnea Therapy?**
D.W. Carley, PhD, Chicago, IL

There will be a 5-minute discussion after each talk.

BASIC • CLINICAL • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 2.0

D7 EXPLOITING GPCRS FOR NEW AND IMPROVED ASTHMA MEDICINE

Assemblies on Respiratory Structure and Function; Allergy, Immunology and Inflammation; Respiratory Cell and Molecular Biology

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**
Room 2002/2004 (West Building, Level 2)

Target Audience
Basic, translational and clinical scientists who wish to learn about the exciting discoveries of new targets for asthma therapy, and how these targets are being validated both in vitro and in vivo.

Objectives
At the conclusion of this session, the participant will be able to:

- learn new findings about the identification and validation of new asthma drug targets;
- screen drug candidates that improve lung function;
- gain knowledge on GPCR signaling in the lung.

There is still an urgent need to develop new and improved therapy for asthma. G-protein coupled receptors (GPCRs) are the targets of more than 50% of all known pharmaceuticals. Current mainstay asthma therapies including beta-agonists, anticholinergics, and leukotriene inhibitors, all directly target GPCRs. Recent studies have identified several GPCRs and many of them unexpectedly as new potential targets for asthma therapy. In this session, we will bring a high-caliber list of experts to discuss the latest developments in this exciting area that promises to change the face of asthma medicine in the coming decades.

Chairing: Q. Lu, PhD, Boston, MA
R. Penn, PhD, Philadelphia, PA

9:00 **Targeting Calcium Sensing Receptor (CaSR) in Allergic Asthma**
D. Riccardi, PhD, Cardiff, United Kingdom

9:20 **Function and Targeting of Proton-Sensing GPCR OGR1 in ASM**
R. Penn, PhD, Philadelphia, PA

9:40 **Bitter Taste Receptors as Targets for Novel Bronchodilators**
D.A. Deshpande, PhD, Philadelphia, PA

10:00 **Screening GPCR Targets with Force**
R. Krishnan, PhD, Boston, MA

10:20 **Structural Insights into ß2-Adrenergic Receptor Signaling**
R. Sunahara, PhD, La Jolla, CA

10:40 **Cholecystokinin (CCK) and Its Receptor CCKAR as Novel Therapeutic Targets for Asthma**
Q. Lu, PhD, Boston, MA

*This session and the International Conference are supported by an educational grant from **AstraZeneca LP.***
All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

BASIC • CLINICAL • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 2.0

D8 ATS MYTHBUSTERS: ABERRANT TISSUE REGENERATION IS A PRIMARY DRIVER OF COPD PATHOGENESIS

Assemblies on Respiratory Cell and Molecular Biology; Allergy, Immunology and Inflammation; Clinical Problems; Critical Care; Environmental, Occupational and Population Health; Microbiology, Tuberculosis and Pulmonary Infections; Pulmonary Circulation; Pulmonary Rehabilitation; Respiratory Structure and Function; Thoracic Oncology

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**
Room 2016/2018 (West Building, Level 2)

Target Audience
Lung health care providers, scientists and investigators interested or involved in basic, translational and clinical research related to lung biology and clinical aspects of COPD and related human lung diseases. Research and care providers engaged in pulmonary and critical care medicine.

Objectives
At the conclusion of this session, the participant will be able to:

- understand how aberrant airway and alveolar regeneration contributes to the pathogenesis of airway remodeling, emphysema and inflammation in COPD;
- learn how aberrant tissue repair mechanisms interact with other components of COPD pathogenesis (oxidative stress, inflammation, altered innate immunity and host-microbe interactions);
- understand how to translate the novel knowledge about the role of aberrant tissue regeneration in COPD pathogenesis into clinically relevant "personalized" (precision medicine) approaches to better prevent, diagnose and treat COPD.

This session continues the "ATS Mythbusters" series focused on emerging areas of translational lung biology and medicine. The central theme of the current ATS Mythbuster session is recently evolved concept of abnormal airway and alveolar structural maintenance and regeneration as the driving force of COPD pathogenesis and progression. Recently developed data supporting this novel concept ("myth") will be presented by the investigators who contributed to these discoveries and then discussed by internationally recognized leading scientists ("busters") in the COPD field.

Chairing: R. Shaykhiev, MD, PhD, New York, NY
I. Petrache, MD, Denver, CO
J.C. Hogg, MD, PhD, Vancouver, Canada

9:00 **Introduction to the Myth: Emerging Non-inflammatory Origins of COPD**
I. Petrache, MD, Denver, CO

9:15 **Altered Epithelial Barrier Function in COPD Airways**
I.H. Heijink, PhD, Groningen, Netherlands

9:30 **Pathologic Programming of Airway Basal Stem Cells in COPD**
R. Shaykhiev, MD, PhD, New York, NY

9:45 **Epithelial-Mesenchymal Interactions and Airway Fibrosis in COPD**
S. Nishimura, MD, San Francisco, CA

10:00 **Wnt Signaling Shift in COPD and Aging**
M. Konigshoff, MD, PhD, Munich, Germany

10:15 **Telomere Dysfunction and Alveolar Stem Cell Failure in Emphysema**
M. Armanios, MD, Baltimore, MD

10:30 **"Mythbusters" Discussion**
L.M. Fabbri, MD, Modena, Italy
M. Saetta, MD, Padova, Italy
S.I. Rennard, MD, Melbourn, United Kingdom
P.J. Barnes, MD, DSc, London, United Kingdom

BASIC • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 2.0

D9 CRACKING THE CELL CODE: UNDERSTANDING THE CONTRIBUTION OF CELLS TO PULMONARY VASCULAR DISEASES

Assemblies on Pulmonary Circulation; Respiratory Cell and Molecular Biology

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 3020/3022 (West Building, Level 3)

Target Audience
Pulmonary and critical care physicians, nurse practitioners, pulmonary vascular biologists and trainees who conduct research in diseases of the pulmonary circulation.

Objectives
At the conclusion of this session, the participant will be able to:

- review the state of the art knowledge regarding normal development of the pulmonary circulation and how these cellular mechanisms are recapitulated in adult disease;
- discuss how interactions between components of the vessel wall (endothelial cells, pericytes, fibroblasts and smooth muscle cells) serve to respond to vascular injury and how their dysregulation can result in disease;
- establish relevance of abnormal cell to cell interactions in the setting of specific pulmonary vascular diseases such as pulmonary arterial hypertension, lung fibrosis and ARDS.

As a vital part of the cardiovascular system, the pulmonary circulation is dependent on its cell components to coordinate adequate responses in both health and disease. While much focus has been devoted to understanding the work of individual cells, limited attention has been given to how these cells interact with each other to preserve the balance required for adequate gas exchange. This symposium will summarize seminal findings regarding how cell behavior is organized during development and how these actions are recapitulated as part of the pulmonary vasculature's efforts to preserve homeostasis in response to injury and disease.

Chairing: V. De Jesus Perez, MD, Stanford, CA
K. Birukov, MD, PhD, Chicago, IL
C. Guignabert, PhD, Le Plessis Robinson, France

9:00 **Development of the Pulmonary Circulation: A Blueprint for Understanding Pulmonary Vascular Diseases**
D. Greif, MD, Guilford, CT

9:20 **Pulmonary Angiogenesis in Health and Disease**
V. De Jesus Perez, MD, Stanford, CA

9:40 **Endothelial-Pericyte Interactions in Health and Disease**
C. Guignabert, PhD, Le Plessis Robinson, France

10:00 **Exosomes, Microparticles in Cell-Cell Communication Within the Pulmonary Circulation**
J.R. Klinger, MD, Providence, RI

10:20 **The Pulmonary Circulation Under Attack: Endothelial-Leukocyte Communication During Lung Injury**
K. Birukov, MD, PhD, Chicago, IL

10:40 **Epithelial-Mesenchymal Crosstalk During Lung Tissue Remodeling**
O. Eickelberg, MD, Munchen, Germany

BASIC • CLINICAL • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 2.0

D10 NEW CONCEPTS IN TB IMMUNITY AND TARGETS FOR TREATMENT

Assemblies on Allergy, Immunology and Inflammation; Microbiology, Tuberculosis and Pulmonary Infections

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 3016/3018 (West Building, Level 3)

Target Audience
Providers of care for tuberculosis, those with clinical and research interests in TB drug development and immune responses, and those who research the immune response to other intracellular pathogens and treatment of those infections.

Objectives
At the conclusion of this session, the participant will be able to:

- learn new findings and developments about host response and susceptibility to TB and other intracellular infections;
- apply knowledge gained from the session to new diagnostic and biomarker strategies for patients with TB or other infections;
- utilize knowledge gained to help form new strategies for treatment or prevention of TB and other intracellular infections.

This session will provide an update on developments in innate and acquired immunity on tuberculosis, seeking lessons that may be gleaned from the host responses to other intracellular pathogens. This sessions will seek cross fertilization of knowledge of the host response between TB and non-TB infections. The session will discuss new developments in TB biomarkers and diagnostics, consider host susceptibilities, present TB strain differences in pathogenicity, TB lineage and co-evolution, and conclude with therapeutic targets for MTB treatment utilized in new treatment.

Chairing: J.J. Saukkonen, MD, Boston, MA
J.M. Keane, MD, Dublin, Ireland
A. Haczku, MD, PhD, Davis, CA

9:00 **Developments in Innate Immunity of Tuberculosis**
J.M. Keane, MD, Dublin, Ireland

9:20 **Developments in Acquired Immunity of Tuberculosis and Other Intracellular Pathogens**
S.A. Khader, PhD, St. Louis, MO

9:40 **TB Lineage, Host Response and Biomarkers**
P. Nahid, MD, MPH, San Francisco, CA

10:00 **New Developments in TB Diagnostics**
C. Boehme, MD, Geneva, Switzerland

10:20 **TB Treatment Targets, Vaccines, and Host-Directed Therapies**
R. Wallis, MD, Johannesburg, South Africa

10:40 **Panel Discussion**

BASIC • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 2.0

D11 ARDS AND INFLAMMATORY INJURY

Assemblies on Allergy, Immunology and Inflammation; Critical Care; Respiratory Cell and Molecular Biology; Respiratory Structure and Function

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**
Room 3006/3008 (West Building, Level 3)

Target Audience
Clinical researchers, basic scientists and clinicians interested in understanding the inter-dependence between the innate immune response, excessive inflammation, and acute lung injury/ARDS.

Objectives
At the conclusion of this session, the participant will be able to:

- understand the mechanisms which lead to differing outcomes in ARDS;
- learn and understand the mechanisms contributing to inflammatory response following ALI.

Acute respiratory distress syndrome (ARDS), the most severe form of ALI, has a mortality rate of approximately 40%, despite modern ICU care. The importance of inflammation in initiation and progression of acute lung injury has been previously established. Inflammasome signaling is critical in the host defense response to infectious and non-infectious agents known to contribute to lung pathology. Inflammatory responses are typically initiated by the innate immune system, leading to the production of IL-1ß and IL-18, which recruit neutrophils and monocytes to the site of infection. However, these same cytokines and cells can damage the alveolus and impair respiratory function. An important goal of this session is to illustrate how data derived from patient samples and clinically relevant animal models points to a common pathway(s) and helps to define the basic mechanisms which impacts disease outcomes in patients

Chairing: C. Hardin, MD, PhD, Boston, MA
T. Cohen, PhD, Gaithersburg, MD

9:00 **Bridging Human, Animal and In-Vitro Data**
M.A. Matthay, MD, San Francisco, CA

9:20 **Airway Responses to Bacterial Pathogens**
A.S. Prince, MD, New York, NY

9:40 **Regulation of Nod-Like Receptors in Acute Lung Injury**
K.M. Ridge, PhD, Chicago, IL

10:00 **RAGE and Acute Lung Injury**
J. Constantin, MD, PhD, Clermont-Ferrand, France

10:20 **Alveolar Epithelial Repair After Inflammatory Injury**
R.L. Zemans, MD, Denver, CO

10:40 **The Transcription Factor Miz1 in the Lung: Good or Bad?**
J. Liu, PhD, Chicago, IL

CLINICAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 2.0

D12 ADVANCES IN TOBACCO DEPENDENCE TREATMENT FOR THE HOSPITALIZED PATIENT

Tobacco Action Committee

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**
Room 130-132 (North Building, Lower Level)

Target Audience
Health care workers treating tobacco dependence and tobacco related disease.

Objectives
At the conclusion of this session, the participant will be able to:

- gain new strategies to initiate a quit attempt for hospitalized smokers;
- become familiar with the tools available to implement a hospital-based smoking cessation program that includes post-discharge follow up;
- improve smoking cessation rates among hospitalized patients.

Hospitalization marks a unique opportunity to impact the tobacco epidemic. The effective health care system must consider a number of variables in devising interventions for promoting abstinence and facilitating transition to outpatient care. In this session various aspects of tobacco dependence treatment in hospitalized smokers will be explored. Common obstacles including initial counseling of resistant patients, personalizing treatment plans, use of technology, and effective discharge planning will be reviewed.

Chairing: F.T. Leone, MD, MS, Philadelphia, PA

9:00 **The Inpatient Tobacco Treatment Consultation**
F.T. Leone, MD, MS, Philadelphia, PA

9:25 **Implementing Hospital Cessation: The Ottawa Model**
S. Gilman, MD, Montreal, Canada

9:50 **Initiating NRT and Other Treatments**
D. Sachs, MD, Palo Alto, CA

10:15 **Transitioning into Post-Discharge Care**
S. Pakhale, MD, Ottowa, Canada

10:35 **Should We Allow E-Cigarette Use in Hospitals?**
D.J. Upson, MA, MD, Albuquerque, NM

There will be a 5-minute discussion after each talk.

MINI SYMPOSIUM

D13 VIRAL INFECTIONS AND ASTHMA: HOST DEFENSE AND SELF DEFEAT

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**
Room 2005/2007 (West Building, Level 2)

Chairing: J.E. Gern, MD, Madison, WI
M.M. Wurfel, MD, PhD, Seattle, WA
T.S. Hallstrand, MD, MPH, Seattle, WA

Oral Presentations

9:00 **Gene Expression Underlying Altered Immune Responses to Human Rhinovirus Species in Children with Acute Wheezing Illnesses/**L.A. Coleman, S.-K. Khoo, K. Franks, J. Bizzintino, F. Prastanti, J.E. Everard, S. Oo, R. Maciewicz, C. McCrae, L. Oberg, P. Le Souef, I.A. Laing, A. Bosco, Crawley, Australia, p.A6416

9:15 **Regulation of Airway Inflammation and Immunity by Toll-Interacting Protein/**C. Huang, J.G. Ledford, D. Jiang, Q. Wu, R. Berman, L. Li, M. Kraft, H.W. Chu, Denver, CO, p.A6417

9:30 **Nasal Aspirate CXCL10, CXCL8 and IFN-Λ Correlate with Symptoms and Lung Function in Inner-City Asthmatic Children with Respiratory Viral Infection/**T.C. Lewis, E.E. Metitiri, I.H. Winer, A.T. Comstock, A.M. Goldsmith, X. Ren, G.B. Mentz, T.G. Robins, S.A. Batterman, B. Mukherjee, M.B. Hershenson, Ann Arbor, MI, p.A6418

9:45 **The Relevance of Humoral and Cellular Innate Responses in Virus-Induced Exacerbation of Experimental Asthma/**L. Ravanetti, A. Dijkhuis, Y.S. Sabogal Pineros, S.M. Bal, R. Lutter, Amsterdam, Netherlands, p.A6419

10:00 **Interferon-Gamma Reduces Type 2 Innate Lymphoid Cell Expansion and IL-13 Production, Mucous Metaplasia and Airways Hyperresponsiveness in Rhinovirus-Infected Immature Mice/**M. Han, J. Young Hong, J.K. Bentley, C. Rajput, S. Jaipalli, J. Lei, M.B. Hershenson, Ann Arbor, MI, p.A6420

10:15 **Azithromycin Augments RV-Induced Type I and Type III Interferon Production Via Interaction with MAVS/**M.R. Edwards, J.D. Porter, M. Khaitov, S. Moshkovski, L. Jones, L. Roberts, K.K.N. Anandamma, I. Kilty, E. Tate, S.L. Johnston, London, United Kingdom, p.A6421

10:30 **The Role of IL-17A in the Pathogenesis of Early Infection with RSV Breaking Immune Tolerance in Mice/**Z. Jie, Y. He, W. Sun, T. Shi, J. Shi, X. Su, Shanghai, China, p.A6422

10:45 **Among Asthmatic Children, Low Expression Patterns of TLR Pathway Genes by Bronchial Epithelial Cells in Response to In Vitro RSV Infection Are Associated with a History of Acute Exacerbations/**M.C. Altman, E. Whalen, K. Misura, T.K. Kolstad, J.A. Rosenthal, S.R. Reeves, S.F. Ziegler, J.S. Debley, Seattle, WA, p.A6423

MINI SYMPOSIUM

D14 IMPROVING CARE AND REDUCING DISPARITIES IN ASTHMA AND SLEEP

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 303/305 (South Building, Esplanade Level)

Chairing: A.J. Apter, MD, MSc, MA, Philadelphia, PA
M.A. Valerio, MPH, PhD, San Antonio, TX

Oral Presentations

9:00 **Demographic and Socioeconomic Determinants of Asthma in the US/**B.E. Himes, O. Mansour, R. Greenblatt, M. Ross, Philadelphia, PA, p.A6424

9:15 **Barriers for Adult Asthmatics Living in Low-Income Communities/**T. Bryant-Stephens, A.J. Apter, S. Hardy, S. Reed-Wells, N. Mak, X. Han, L. Perez, A.R. Localio, Philadelphia, PA, p.A6425

9:30 **Aspects of Asthma Self-Management: Inhaler Technique, Ability to Access (Navigate) Health Care , and Inhaled Steroid Knowledge Are Correlated/**L. Perez, K. Morales, J. Huang, G. Ndicu, X. Han, H. Klusaritz, A. Localio, A.J. Apter, Philadelphia, PA, p.A6426

9:45 **Mobile Telemedicine Programs in School Could Increase Clinician Efficiency and Improve Access to Health Care Among Children with Asthma/**A.A. Lowe, J.K. Gerald, C. Clemens, M.A. Brown, M. Moore, T.F. Carr, M. Goforth, J. Fisher, D. Billheimer, L.B. Gerald, Tucson, AZ, p.A6427

10:00 **Efficacy of a School-Based Behavioral Intervention for Urban Adolescents with Undiagnosed Asthma: A Controlled Trial/**J.-M. Bruzzese, B.J. Sheares, Y. Zhao, S. Kingston, A. Cespedes, H. Sadeghi, M. Kattan, D. Evans, New York, NY, p.A6428

10:15 **Impact of Comorbid Insomnia on Asthma Control and Asthma-Related Healthcare Utilization/**F.S. Luyster, P.J. Strollo, F. Holguin, E. Bleecker, M. Castro, J.V. Fahy, B. Gaston, E. Israel, N.N. Jarjour, D. Mauger, S.E. Wenzel, Pittsburgh, PA, p.A6429

10:30 **Asthma-Related Co-Morbidities in Urban Children with Persistent Asthma: Contributors to Disparities in Asthma, Sleep and Academic Outcomes/**D. Koinis Mitchell, S.J. Kopel, E.L. McQuaid, J. Boergers, C. Esteban, R. Seifer, G.K. Fritz, R.B. Klein, Providence, RI, p.A6430

10:45 **Efficacy of an Educational and Behavioral Intervention to Increase Nightly Sleep Duration in Urban Latino and African American Early School-Aged Children: A Randomized Controlled Trial /**B.J. Sheares, C.I. Lamm, C.-S. Leu, D. Bai, K.B. Dorsey, M. Kattan, D. Evans, New York, NY, p.A6431

MINI SYMPOSIUM

D15 NEW THERAPIES IN ILD

9:00 a.m. - 10:45 a.m. **MOSCONE CENTER**

Room 306/308 (South Building, Esplanade Level)

Chairing: L. Richeldi, MD, PhD, Southampton, United Kingdom
D.E. Antin-Ozerkis, MD, New Haven, CT
C. Johnson, MD, MHS, Baltimore, MD

Oral Presentations

9:00 **Scleroderma Lung Study II: Comparison of Therapy with Mycophenolate Mofetil Versus Oral Cyclophosphamide in Patients with Symptomatic Scleroderma Interstitial Lung Disease/**D.P. Tashkin, M.D. Roth, D.E. Furst, P. Clements, D. Khanna, E. Volkmann, S. Kalafa, J. Goldin, G.H.J. Kim, E. Arriola, C.-H. Tseng, R.E. Elashoff, Los Angeles, CA, p.A6432

9:15 **Safety and Tolerability of Intravenous Bone Marrow-Derived Human Mesenchymal Stem Cells for Patients with Idiopathic Pulmonary Fibrosis- The AETHER Study (NCT 2013700)/** R.L. Toonkel, P. Bejarano, D.L. DiFede, S.J. Elliot, J.E. Fishman, J.M. Hare, A. Khan, V. LaRussa, Y.N. Mageto, A. Mendizabal, M. Mushtaq, M.V. Pujol, G.A. Rubio, E. Simonet, S. Shafazand, M. Glassberg, Miami, FL, p.A6433

9:30 **N-Acetylcysteine Response Among Anti-Nuclear Antibody Seropositive Patients with Idiopathic Pulmonary Fibrosis/**J.M. Oldham, C. Lee, E. Valenzi, L.J. Witt, A. Adegunsoye, L.W. Chen, S. Hsu, S. Montner, J.H. Chung, R. Vij, M.E. Strek, I. Noth, Chicago, IL, p.A6434

9:45 **Impact of Statins on Lung Function Decline in Idiopathic Pulmonary Fibrosis (IPF)/**M. Kreuter, F. Bonella, T.M. Maher, U. Costabel, P. Spagnolo, D. Weycker, K.-U. Kirchgassler, M. Kolb, Heidelberg, Germany, p.A6435

10:00 **Azathioprine for Antisynthetase-Associated Interstitial Lung Disease/**L.L. Silhan, J.A. Huapaya, S.K. Danoff, Baltimore, MD, p.A6436

10:15 **Functional Improvement in Patients with Lymphangioleiomyomatosis (LAM) After Sirolimus/**K.-F. Xu, Y. Zhan, X. Tian, J. Wang, W. Xu, H. Cui, X. Li, Beijing, China, p.A6437

10:30 **Whole Lung Lavage Followed by Inhaled Sargramostim as Therapy of Autoimmune Pulmonary Alveolar Proteinosis/**I. Campo, F. Mariani, E. Paracchini, Z. Kadija, M. Zorzetto, C. Tinelli, G. Rodi, F. Meloni, M. Griese, B.C. Trapnell, G. Scheuch, B. Muellinger, M. Luisetti, Pavia, Italy, p.A6438

MINI SYMPOSIUM

D16 CRITICAL CARE: REDUCING VARIATION IN USUAL CARE

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 3003/3005 (West Building, Level 3)

Chairing: G.D. Rubenfeld, MD, MSc, Toronto, Canada
H.B. Gershengorn, MD, Bronx, NY
A.J. Walkey, MD, MSc, Boston, MA

Oral Presentations

9:00 **Out of Sight: Lack of Geographic Co-Localization of Intensive Care Unit Patients and Care Teams Is Associated with Increased Mortality/**R. Stretch, N. Della Penna, L.A. Celi, Boston, MA, p.A6439

9:15 **Variation in Tracheostomy Utilization for Mechanically Ventilated Adults by Diagnosis: an Analysis of National Trends/**J.M. Kruser, S.B. Smith, R.D. Shah, C.H. Weiss, R.G. Wunderink, Chicago, IL, p.A6440

9:30 **Provider Variability in Time to Antibiotics in Patients Presenting to the Emergency Department with Severe Sepsis/**I.D. Peltan, K.H. Mitchell, K.E. Rudd, B.A. Mann, D.J. Carlbom, T.D. Rea, C.T.L. Hough, S.M. Brown, Seattle, WA, p.A6441

9:45 **Practice Patterns and Utilization of Procalcitonin in Critically Ill Patients with Sepsis/**D.C. Chu, A.B. Mehta, A.J. Walkey, Boston, MA, p.A6442

10:00 **Sepsis Case Volume and Evidence-Based Processes of Care/**A. Fawzy, A.J. Walkey, Boston, MA, p.A6443

10:15 **Potential Harm Associated with Severity-Adjusted Treatment Variability in Fluid Resuscitation of Critically Ill Septic Patients/**J.N. Mansoori, W.T. Linde-Zwirble, P.C. Hou, E. Havranek, I.S. Douglas, Aurora, CO, p.A6444

10:30 **Is a Fluid-Conservative Strategy Optimal for All Patients with Acute Respiratory Distress Syndrome (ARDS)? Latent Class Analysis Indicates that ARDS Endotypes Have a Differential Response to Fluid-Management Strategy in the NHLBI ARDS Network Fluid and C/**K.R. Famous, K. Delucchi, L.B. Ware, K. Liu, K.N. Kangelaris, B.T. Thompson, M. Matthay, C.S. Calfee, San Francisco, CA, p.A6445

10:45 **Impact of a Physician-Based Pay-For-Performance Program on Use of Spontaneous Breathing Trials in Mechanically Ventilated Patients/**I.J. Barbash, C.W. Seymour, S.R. Gunn, J.M. Kahn, Pittsburgh, PA, p.A6446

MINI SYMPOSIUM

D17 "OMICS" OF ENVIRONMENTAL LUNG DISEASE

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 2006/2008 (West Building, Level 2)

Chairing: A.A. Litonjua, MD, MPH, Boston, MA
E. Forno, MD, MPH, Pittsburgh, PA
V.E. Ortega, MD, Winston Salem, NC

Oral Presentations

9:00 **Exposure to Manufactured Nanoparticles During Gestation: Impact on the Respiratory Tract of the Offspring in a Mouse Model/**E. Paul, M.-L. Franco-Montoya, J. Rose, J. Boczkowski, S. Lanone, C. Delacourt, J.-C. Pairon, Creteil, France, p.A6447

9:15 **Effects of Controlled Diesel Exhaust and Allergen Co-Exposure on miRNA and Gene Expression in Humans: Modulation of Lung Inflammatory Markers Associated with Asthma/**C.F. Rider, M. Yamamoto, O.P. Gunther, A. Singh, J.A. Hirota, S.J. Tebbutt, C. Carlsten, Vancouver, Canada, p.A6448

9:30 **Genetic and Epigenetic Regulation of MUC5B Expression in Idiopathic Pulmonary Fibrosis/**B.A. Helling, B. Pedersen, K.K. Brown, M.P. Steele, J. Loyd, G. Cosgrove, M.I. Schwarz, S. Groshong, C.M. Evans, T. Fingerlin, I.V. Yang, D.A. Schwartz, Aurora, CO, p.A6449

9:45 **Effect of Little Cigar Exposure on the Airway Epithelial Mucus Barrier and Exosomal miRNA Profile/**S. Abdelwahab, A. Ghosh, B. Reidel, P. Haridass, R. Gupta, H. Dang, P. Mieczkowski, R. Tarran, M. Kesimer, Chapel Hill, NC, p.A6450

10:00 **Recent Second-Hand Smoke Exposure Is Associated with Altered CpG Methylation Between Monozygotic Twins/** J.C.A. Lawrence, R.N. Bauer, K.C. Nadeau, R.L. Miller, New York, NY, p.A6451

10:15 **Plasma Metabolomics Analysis Identifies Candidate Biomarkers of Flavoring-Induced Bronchiolitis Obliterans/**M.W. Foster, J.W. Thompson, D.M. Brass, M.A. Moseley, D.L. Morgan, S.M. Palmer, Durham, NC, p.A6452

10:30 **Metabolomic Profiling of Childhood Asthma Severity in a Costa-Rican Population: Insights into Disease Pathogenesis/**R.S. Kelly, A. Dahlin, A.C. Wu, M. McGeachie, D.C. Croteau-Chonka, S.T. Weiss, J. Lasky-Su, Boston, MA, p.A6453

10:45 **Varying Effects of PM2.5, Genetic and Epigenetic Variations in iNOS Promoter on FeNO in Children/**Y. Zhang, M. Salam, K. Berhane, S. Eckel, E. Rappaport, W. Linn, R. Habre, T. Bastain, F. Gilliland, Salt Lake City, UT, p.A6454

MINI SYMPOSIUM

D18 CYSTIC FIBROSIS AND PRIMARY CILIARY DYSKINESIA: TWO SIDES OF THE SAME COIN?

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 3007/3009 (West Building, Level 3)

Chairing: A.J. Shapiro, MD, Montreal, Canada
D. Hayes, MD, Columbus, OH

Oral Presentations

9:00 **Respiratory Microbiology in Primary Ciliary Dyskinesia: Comparisons to a Pediatric Cystic Fibrosis Cohort/**M.C. Tracy, J.M. Zirbes, C. Hernandez, D.N. Cornfield, C.E. Milla, Palo Alto, CA, p.A6455

9:15 **Comparison of the Microbiota of the Airway in Children with Cystic Fibrosis and Non-Cystic Fibrosis Bronchiectasis/**R.J. Green, S. Vosloo, R. Masekela, S. De Beer, F. Venter, Pretoria, South Africa, p.A6456

9:30 **A Comparison of Anaerobic to Aerobic Power Ratio in Children with Primary Ciliary Dyskinesia and Healthy Controls/**S. Simsek, D. Inal-Ince, A. Cakmak, E. Calik-Kutukcu, M. Saglam, N. Vardar-Yagli, N. Emiralioglu, H.U. Ozcelik, H. Sonbahar-Ulu, C. Bozdemir-Ozel, H. Arikan, N. Kiper, Ankara, Turkey, p.A6457

9:45 **In Vivo Cystic Fibrosis (CF) Nasal Epithelial Transcriptomic Studies Reveal non-CFTR Differential Gene Expression Associated with CF Lung Disease Severity/**D. Polineni, H. Dang, R.G. Pace, J.R. Stonebraker, X.G. Guo, L.C. Jones, C.R. Esther, M.P. Boyle, J.F. Chmiel, P.R. Durie, P.J. Gallins, F.A. Wright, W.K. O'Neal, M. Knowles, Kansas City, KS, p.A6458

10:00 **The Influence of Secondhand Smoke Exposure on Arachidonic Acid Metabolism and Outcomes in Infants and Young Children with Cystic Fibrosis/**B.T. Kopp, L.K. Rogers, A. Mejias, D. Hayes, Jr., D. Tumin, F. Woodley, R. Thompson, J. Groner, Columbus, OH, p.A6459

10:15 **Minorities with Cystic Fibrosis Are Underrepresented in Pharmacology Clinical Trials/**M.E. McGarry, S.A. McColley, San Francisco, CA, p.A6460

10:30 **Age-Related Survival Disparity Associated with Lung Transplantation in Cystic Fibrosis: An International Study/** D. Hayes, Jr., A.R. Glanville, D. McGiffin, J.D. Tobias, D. Tumin, Columbus, OH, p.A6461

Featured Speaker

10:45 **Contrasting the CF and PCD Phenotypes/**S.D. Davis, MD, Indianapolis, IN,

MINI SYMPOSIUM

D19 CLINICAL STUDIES IN PH

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 3010/3012 (West Building, Level 3)

Chairing: R.T. Zamanian, MD, Stanford, CA
R. Souza, MD, PhD, Sao Paulo, Brazil
I. Lang, MD, Vienna, Austria

Oral Presentations

9:00 **Comprehensive Characterization of Insulin Resistance and Its Association with Ventricular Function in Pulmonary Arterial Hypertension/**R.E. Wells, M. Cuttica, R. Dash, F. Abbasi, M. Van De Veerdonk, I.R. Preston, A.R. Hemnes, A.J. Sweatt, M. Gomberg-Maitland, R.T. Zamanian, Stanford, CA, p.A6462

9:15 **Sarcoidosis-Associated Pulmonary Hypertension in the Modern PAH-Targeted Therapy Era: Experience from the French Registry/**A. Boucly, H. Nunes, X. Jais, V. Cottin, A. Tazi, O. Sanchez, G. Prevot, M. Reynaud Gaubert, C. Dromer, C. Viacroze, D. Horeau Langlard, C. Pison, E. Bergot, D. Montani, G. Simonneau, M. Humbert, O. Sitbon, L. Savale, Le Kremlin Bicêtre, France, p.A6463

9:30 **Serial Vasoreactivity Reassessment Is a Prognostic Tool in Pulmonary Arterial Hypertension/**A.J. Sweatt, E.F. Spiekerkoetter, A. Hsi, Y. Sung, V. De Jesus Perez, K. Kudelko, R.T. Zamanian, Stanford, CA, p.A6464

9:45 **Extended Evaluation of emPHasis-10 Quality of Life Questionnaire in PH/**I. Smith, C. Billings, D. Kiely, J. Yorke, I. Armstrong, Sheffield, United Kingdom, p.A6465

10:00 **Targeting the Prostacyclin Pathway in the Treatment of Connective Tissue Disease Associated Pulmonary Arterial Hypertension (PAH): Insights from the Randomized Controlled GRIPHON Trial with Selexipag/**S.P. Gaine, R.N. Channick, L. Di Scala, N. Galie, H.-A. Ghofrani, M.M. Hoeper, I. Lang, V. McLaughlin, R. Preiss, L.J. Rubin, G. Simonneau, O. Sitbon, V. Tapson, K.M. Chin, Dublin, Ireland, p.A6466

10:15 **Comparative Effectiveness of Pharmacological Interventions for Pulmonary Arterial Hypertension: A Systematic Review and Network Meta-Analysis/**S. Jain, R. Khera, Z. Wang, M.H. Murad, A. Blevins, G.A. Schmidt, S. Singh, A.K. Gerke, Iowa City, IA, p.A6467

10:30 **A Randomized Open Label Study Comparing First-Line Treatment with Bosentan or Sildenafil in Chronic Thromboembolic Pulmonary Hypertension/**E. Gotti, M. Palazzini, A. Manes, C. Bachetti, G. Mazzanti, A. Rinaldi, F. Dardi, A. Albini, E. Monti, S. Fukui, D. Guarino, N. Galie, Bologna, Italy, p.A6468

10:45 **Comparing Patient-Reported Outcomes to Functional, Hemodynamic, Echocardiographic, and Cardiac MRI Parameters in Scleroderma-Associated Pulmonary Arterial Hypertension/**R. Khair, T. Kolb, R.L. Damico, P.M. Hassoun, R.T. Zamanian, R. Tedford, T. Housten Harris, T. Sato, E. Pullins, C. Corona-Villalobos, S.L. Zimmerman, O. Minai, F. Torres, R.E. Girgis, K.M. Chin, S.C. Mathai, Baltimore, MD, p.A6469

POSTER DISCUSSION SESSION

D21 ASTHMA TREATMENT: GLUCOCORTICOIDS, BIOLOGICALS AND BEYOND

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 2010/2012 (West Building, Level 2)

Poster Viewing **9:00-9:45**

Discussion **9:45-11:00**

Chairing: S.E. Wenzel, MD, Pittsburgh, PA
L.E. Cohn, MD, New Haven, CT
N.J. Kenyon, MD, Sacramento, CA

401 **Effect of Mepolizumab in Severe Eosinophilic Asthma Patients Eligible for Omalizumab Treatment/**F.C. Albers, R. Price, S. Yancey, E. Bradford, Research Triangle Park, NC, p.A6470

402 **Burden of Disease in Severe Asthma Mepolizumab Population Stratified by Blood Eosinophil Count/**E. Bradford, R. Follows, R. Price, S. Yancey, Research Triangle Park, NC, p.A6471

403 **Utility of Serum Periostin and Free IgE Levels in Evaluating Responsiveness to Omalizumab in Patients with Severe Asthma/**T. Tajiri, H. Matsumoto, Y. Gon, R. Ito, S. Hashimoto, K. Izuhara, M. Suzukawa, K. Ohta, J. Ono, S. Ohta, I. Ito, T. Oguma, H. Inoue, T. Iwata, T. Nagasaki, Y. Kanemitsu, A. Niimi, M. Mishima, Kyoto, Japan, p.A6472

404 **Baseline IgE Levels as a Marker of Type 2 Asthma Among Patients Enrolled in the Prospective Observational Study to Evaluate Predictors of Clinical Effectiveness in Response to Omalizumab (PROSPERO)/**B.E. Chipps, W.W. Busse, A.T. Luskin, R.S. Zeiger, B. Trzaskoma, N.M. Griffin, T.A. Omachi, T.B. Casale, Sacramento, CA, p.A6473

405 **Omalizumab - Response in Patients with Severe Allergic Asthma in a Real Life Setting/**L. Zierau, E.S. Walsted, V. Backer, Copenhagen, Denmark, p.A6474

406 **Regulating Goblet Cell Formation and Mucus Production with Inhaled Sam Pointed Domain Containing ETS Transcription Factor (SPDEF) Antisense Oligonucleotides/**J. Crosby, C. Zhao, D. Bai, M. McCaleb, S. Guo, B.P. Monia, Carlsbad, CA, p.A6475

407 **A Randomized, Double-Blinded, Placebo-Controlled, Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of XmAbr7195/**A. Gershman, R. Goldwater, P. Foster, San Diego, CA, p.A6476

408 **L-Arginine and Glucagon-Like Peptide 1, a Novel Pathway to Asthma Control/**D.-V. Nguyen, A.L. Linderholm, L. Franzi, N.J. Kenyon, Sacramento, CA, p.A6477

409 **The Effect of the 15-Lipoxygenase 1 (15LO1) Inhibitor BLX2477 on IL-13-Induced Periostin mRNA Expression in Human Airway Epithelial Cells (HAECs)/**Y. Minami, E.B. Etling, V.B. O'Donnell, E.B. Yecies, J.B. Trudeau, H.E. Claesson, J. Zhao, S.E. Wenzel, Pittsburgh, PA, p.A6478

410 **Inhibition of Asthma Phenotype Through Aerobic Exercise: Involvement of P2X7 Receptor and CD73 Signaling in Airway Epithelium and in Peribronchial Leukocytes/**R.P. Vieira, M.C. De Oliveira Junior, A.R. Almeida-Oliveira, J.C.J. Aquino-Junior, A.S. Andrade-Sousa, E. Assumpcao-Neto, A. Aparecida-Brito, N.C. Rigonato-Oliveira, A.S. Renno, M.A.R. Brandao-Rangel, A.P.L. Oliveira, Sao Paulo, Brazil, p.A6479

411 **Aerobic Exercise Reduces Asthma Phenotype Through Modulation of SOCS-JAK-STAT Signaling/**R.P. Vieira, A.R. Almeida-Oliveira, J.C.J. Aquino-Junior, M.C. Oliveira-Junior, A.S. Andrade-Sousa, E. Assumpcao-Neto, A. Aparecida-Brito, N.C. Rigonato-Oliveira, A. Silva-Renno, M.A.R. Brandao-Rangel, A.P.L. Oliveira, Sao Paulo, Brazil, p.A6480

412 **Anti-Inflammatory Effect of an Eicosapentaenoic Acid Metabolite on Airway Inflammation in a Murine Model of Ovalbumin-Induced Asthma/**T. Mochimaru, K. Fukunaga, J. Miyata, M. Matsusaka, K. Masaki, H. Kabata, Y. Suzuki, Y. Isobe, M. Arita, T. Betsuyaku, Tokyo, Japan, p.A6481

413 **Selective Targeting of STAT6 at Antigen Priming Reduces OX40L and TH2-Biased Airway Inflammatory Responses/**S. Lee, J. Shan, B.T. Srinivasa, M. Jin, E.D. Fixman, Montrea, Canada, p.A6482

414 **Pre-Clinical Evaluation of a Potent Janus Kinase (JAK) Inhibitor Designed for Topical Delivery in Severe Asthma/**H.-H. Lee, M.A. Gil, J. Woodhouse, M. Caniga, A. Byford, R. McLeod, Y. Jia, R. Fernandes, J. Naber, D. Witter, M. Cicmil, M. Salmon, Boston, MA, p.A6483

415 **Developing FOXM1 Inhibitors to Suppress Goblet Cell Metaplasia and Airways Hyperresponsiveness/**V. Kalinichenko, L. Sun, X. Ren, I.-C. Wang, A. Pradhan, Y. Zhang, B. Han, J.A. Whitsett, T.V. Kalin, Cincinnati, OH, p.A6484

416 **A Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Oral Azithromycin (500 Mg OD) as a Supplement to Standard Care for Adult Patients with Acute Exacerbations of Asthma (the AZALEA Trial)/**S.L. Johnston, M. Szigeti, M. Cross, C.E. Brightling, R. Chaudhuri, T. Harrison, A.H. Mansur, L. Robinson, Z. Sattar, D.J. Jackson, P. Mallia, E.H.C. Wong, C. Corrigan, B. Higgins, P. Ind, D. Singh, N.C. Thomson, D. Ashby, A. Chauhan, London, United Kingdom, p.A6485

417 **Effect of Dupilumab on FEV1 and Severe Exacerbations in Patients with Uncontrolled Persistent Asthma: A Subgroup Analysis Defined According to Early-Onset and Late-Onset Asthma/**S.F. Weinstein, L.B. Ford, B. Zhang, G. Pirozzi, H. Staudinger, R.R. Evans, N.M.H. Graham, M. Louis-Tisserand, A. Teper, Huntington Beach, CA, p.A6486

418 **Roflumilast Ameliorates Airway Hyper-Responsiveness Caused by Diet-Induced Obesity in a Murine Model/**H.J. Park, J.-H. Lee, Y.H. Park, H. Han, D.W. Sim, K.H. Park, J.-W. Park, Seoul, Korea, Republic of, p.A6487

419 **A Novel and Safe Inhaled Asthma Drug: A Phase I/II Randomised Placebo Controlled Trial/**F.H.Y. Green, R. Leigh, V. Swystun, G. Shrestha, S. Galal, M. Fadayomi, A. Chiu, C. Pieron, T. El-Mays, D.E. Nelson, J. Dennis, Calgary, Canada, p.A6488

420 **Dupilumab Improves Lung Function Inclusive of Small Airways in Patients with Uncontrolled Persistent Asthma: Results from a Phase 2b Clinical Trial/**M. Castro, S.E. Wenzel, J. Corren, J. Maspero, B. Zhang, G. Pirozzi, R.R. Evans, N.M.H. Graham, M. Louis-Tisserand, A. Teper, St. Louis, MO, p.A6489

421 **Thymulin Gene Therapy Delivered by a New Biodegradable DNA Nanoparticle in Experimental Chronic Allergic Asthma/**A.L. Da Silva, G.P. Oliveira, J.Z. Kitoko, N.G. Blanco, J.S. Suk, J. Hanes, P.C. Olsen, M.M. Morales, P.R.M. Rocco, Rio de Janeiro, Brazil, p.A6490

422 **Dupilumab Improves Patient-Reported Outcomes in Uncontrolled Persistent Asthma: Results from a Phase 2b Clinical Trial/**P. Chanez, J. Corren, M. Castro, L. Fabbri, V.N. Joish, R.E. Evans, N.M.H. Graham, V. Mastey, A. Abbe, C. Taniou, S. Mahajan, A. Teper, G. Pirozzi, L. Eckert, Marseille, France, p.A6491

423 **Exploring the Safety and Efficacy of CRD007, an Oral Mast Cell Inhibitor, on Responsiveness to Inhaled Mannitol in Adults with Asthma: A Double-Blind, Placebo-Controlled, Cross-Over Phase II Trial/**V. Backer, S.-E. Dahlen, G. Tornling, C.B. Barnes, E.S. Walsted, C. Porsbjerg, C.S. Ulrik, Copenhagen, Denmark, p.A6492

424 **The Effect of Lebrikizumab Therapy on Key Type 2 Biomarkers in Moderate-to-Severe, Uncontrolled Asthma Patients: A Pooled Analysis from Phase 2 Trials/**N.A. Hanania, P. Korenblat, J. Corren, J. Olsson, N. Kamath, S. Gray, N. Martin, C.T.J. Holweg, J.G. Matthews, H. Scheerens, S.L. Limb, S. Korom, Houston, TX, p.A6493

425 **Mast Cell Inhibition by Imatinib Reduces Airway Reactivity and Improves FEV1 in Severe Asthma/**K.N. Cahill, H. Katz, J. Cui, S. Kazani, A. Crosby-Thompson, D. Garofalo, M. Castro, N.N. Jarjour, E. Dimango, S.C. Erzurum, J. Trevor, K. Shenoy, V.M. Chinchilli, M. Wechsler, J. Boyce, E. Israel, Boston, MA, p.A7892

POSTER DISCUSSION SESSION

D22 REDUCING HARMS OF TOBACCO USE

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 133 (North Building, Lower Level)

Poster Viewing **9:00-9:45**

Discussion **9:45-11:00**

Chairing: H.J. Farber, MD, Houston, TX
H. Kathuria, MD, Boston, MA
A. Vachani, MD, MS, Philadelphia, PA

101 **Internal Medicine Resident Perceptions and Knowledge Regarding Smoking Cessation/**R. Sedhom, S. Parikh, A. Sarkar, M. Steinberg, New Brunswick, NJ, p.A6494

102 **Do Physicians Address Smoking Status in Patients Admitted to the Hospital?/**R. Sedhom, A. Sarkar, S. Parikh, M. Yacoub, New Brunswick, NJ, p.A6495

103 **Resident Physician Perceptions and Knowledge of Electronic Cigarettes/**R. Sedhom, C. Malaty, New Brunswick, NJ, p.A6496

104 **Community Pharmacy Personnel Interventions for Smoking Cessation: A Cochrane Systematic Review and Meta-Analysis/**K.V. Carson, R. To-A-Nan, M. Roberts, C. King, J. Van Agteren, B.J. Smith, Adelaide, Australia, p.A6497

105 **Effects of Deep Breathing in Smoking Cessation of Smoking Outpatients of Pulmonology Clinic of Santa Casa de Sao Paulo/**I.B. Polonio, K. Kamiya, A. Borghi, D. Ryuichi, M. Leao, V. Alves, R. Stirbulov, Sao Paulo, Brazil, p.A6498

106 **Effectiveness of Deep Breathing, a Self-Help Book and Additive Effects of the Two Interventions in Cigarette Consumption, Anxiety and Depression and Motivation to Stop Smoking in Students of the Anhembi Morumbi University/**I.B. Polonio, I. Ueda, J. Carvalho, R. Amaral, Sao Paulo, Brazil, p.A6499

107 **Efficacy and Safety of β-Adrenoceptor Inverse Agonist and Biased Ligand, Nadolol, in Smoking Cessation of Patients with Chronic Cough with or Without Airflow Obstruction/**M. Castro, G. Sajol, D. Ksiazek, T. Koch, H. Yin-Declue, N. Oleka, C. Pitts, M. Glass, St. Louis, MO, p.A6500

108 **Factors Associated with Effective Outpatient Smoking Cessation Counseling/**T.B. Lumpkin, D. Ksiazek, K. Scholl, K. Schechtman, M. Castro, St. Louis, MO, p.A6501

109 **The Outcomes of Interdisciplinary Approach in Smoking Cessation Clinic at Thammasat University Hospital, Thailand/**P. Pirompanich, T. Jirapramukpitak, N. Saiphoklang, T. Sricharoenchai, P. Ruchiwit, P. Takizawa, N. Sennoi, A. Kanitsap, Pathumthani, Thailand, p.A6502

110 **Factors Affecting Smoking Cessation Interventions in Pulmonary Clinic/**L. Shiekh Sroujieh, M.N. Iqbal, C. Castro, M. Elrifai, S. Dixon Williams, J.D. Thornton, Cleveland, OH, p.A6503

111 **Identifying Clinician Barriers to Improve Smoking Cessation Integration Within a Lung Cancer Screening Program at an Urban Safety-Net Hospital/**L. Swamy, K.A. Sloan, C. Fitzgerald, G. Millien, C. O'Donnell, C.C. Reardon, K. Steiling, R.S. Wiener, H. Kathuria, Boston, MA, p.A6504

112 **Varenicline for Smoking Cessation: Be Alone or Together?/**Y. Yu, Y. Ni, G. Shi, T. Chen, J. Hao, Shanghai, China, p.A6505

113 **Psychiatric Comorbidity, Gender and Treatment Success in a Tobacco Cessation Unit (TCU) in Albacete University Hospital During 2011/**R. Godoy Mayoral, F.J. Callejas Gonzalez, J. Cruz Ruiz, M. Genoves Crespo, F.J. Agustin Martinez, J.A. Garcia Guerra, A.J. Martinez Garcia, A. Molina Cano, W.M. Mayoris Almonte, A.I. Tornero Molina, Albacete, Spain, p.A6506

114 **Continuous Abstinence Rates at 3, 6, 9 and 12 Months for Males in a Tobacco Cessation Unit (TCU) in Albacete University Hospital During 2011/**F.J. Callejas Gonzalez, R. Godoy Mayoral, J. Cruz Ruiz, M. Genoves Crespo, F.J. Agustin Martinez, J.A. Garcia Guerra, A.J. Martinez Garcia, A. Boldova Loscertales, F. Gonzalez Torralba, A.I. Tornero Molina, Albacete, Spain, p.A6507

115 **The Important of Partner Support in Smoking Cessation**/O. Turan, P.A. Turan, A. Mirici, Canakkale, Turkey, p.A6508

116 **Evaluation of Electronic-Cigarette and Nicotine Alone Effect in Comparison to Tobacco Cigarette Smoke**/V. Reinikovaite, A. Rau, F. Deleyiannis, L. Taraseviciene-Stewart, Aurora, CO, p.A6509

117 **Electronic Cigarette Advertising Encourages Conventional Cigarette Smoking Within a London Student Cohort: A Cross-Sectional Survey**/C. Ratneswaran, M. Colquhoun, R. Judge, J. Steier, T.K. Khong, London, United Kingdom, p.A6510

118 **Electronic Cigarettes for Adults with Tobacco Dependence Undergoing a Tobacco Treatment Program: A Pilot Prospective Study**/S.R. Baldassarri, S.L. Bernstein, G.L. Chupp, B.A. Toll, New Haven, CT, p.A6511

119 **A Qualitative Study of Discourse from Proponents and Opponents of Electronic Cigarettes on Twitter**/S.A. Spence, M.B. Stanbrook, Toronto, Canada, p.A6512

120 **Vapor Lung: Bronchiolitis Obliterans Organizing Pneumonia (BOOP) in Patient with E-Cigarette Use**/R.D. Mantilla, R.T. Darnell, U. Sofi, Roanoke, VA, p.A6513

121 **The Adverse Effects of Waterpipe Smoking: A Systematic Review**/M.H. Khan, R. Al-Lehebi, M.B. Stanbrook, Toronto, Canada, p.A6514

122 **Respiratory Symptoms Predict Motivation to Quit Smoking Among Smokers with and Without COPD**/A.C. Melzer, L.C. Feemster, K.A. Crothers, S.E. Gillespie, A.G. Henderson, J.A. Krishnan, P.K. Lindenauer, M.A. McBurnie, R.A. Mularski, E.T. Naureckas, S. Pickard, D.H. Au, Seattle, WA, p.A6515

123 **Use and Perceived Risk of E-cigarettes Among North Carolina Middle and High School Students**/C.X. Giovacchini, L.R. Pacek, F.J. McClernon, L.G. Que, Durham, NC, p.A7893

POSTER DISCUSSION SESSION

D23 SYMPTOMS MATTER: COUGH, DYSPNEA, FATIGUE AND QUALITY OF LIFE

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 304 (South Building, Esplanade Level)

Poster Viewing **9:00-9:45**

Discussion **9:45-11:00**

Chairing: K. Lindell, PhD, RN, Pittsburgh, PA
J.J. Swigris, DO, MS, Denver, CO
S. Mittoo, MD, MHS, Toronto, Canada

201 **Acute Worsening Events in Fibrotic Sarcoidosis: Effect on Quality of Life, Pulmonary Function, and Cough**/T. Tully, S.S. Birring, M.A. Judson, D.A. Culver, R.P. Baughman, London, United Kingdom, p.A6516

202 **Disease Severity and Quality of Life in Newly Diagnosed Idiopathic Pulmonary Fibrosis Patients**/E.C. O'Brien, P. Shrader, M.T. Durheim, L.D. Snyder, J.L. Todd, V. Gamerman, K.J. Anstrom, J.A. Belperio, D.A. Culver, J.A.M. De Andrade, J. Roman, T.P.M. Whelan, C.S. Conoscenti, S.M. Palmer, Durham, NC, p.A6517

203 **Frailty Is Common and Associated with Dyspnea Severity in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease**/T.A. Winstone, J.M. Kwan, K.M. Milne, F. Schooley, J. Dunne, P.G. Wilcox, C.J. Ryerson, Vancouver, Canada, p.A6518

204 **A Multi-Platform Recruitment Approach to Establishing an Idiopathic Pulmonary Fibrosis Cohort for Patient-Centered Research**/A.E.F. Dimmock, B.L. Johannes, S.K. Danoff, K.O. Lindell, K. Gibson, J. McCullough, F. Cordova, C.D. Dobi, M.E. Gauvey-Kern, B. Mahler, J. Uhrig, J.E. Carns, C. Chuang, R. Bascom, Hershey, PA, p.A6519

205 **Supplemental Oxygen Improves Sleep Disordered Breathing but Not Quality of Life in Patients with Interstitial Lung Disease**/L. Troy, J. Al Aghbari, K. Wong, E. Lau, N. Taylor, S. Webster, B. Yee, P. Corte, P. Torzillo, R. Grunstein, T. Corte, Camperdown, Sydney, Australia, p.A6520

206 **Exercise Limitation in Idiopatic Pulmonary Fibrosis - Back to Basics**/Y. Shostak, B. Vainshelboim, I. Terner, M.R. Kramer, B.D. Fox, Petah Tikva, Israel, p.A6521

207 **Patients' Perspectives on the Use of Domiciliary Oxygen Therapy in Interstitial Lung Disease**/Y.H. Khor, A.E. Holland, N. Goh, C.F. McDonald, Heidelberg, Australia, p.A6522

208 **SF-36 Questionnaire in Patients with Interstitial Lung Disease**/B.M. Pinto, R.M.F. Marques, B.V. Jordaim, R. Vargas, C. Miranda, N. Pimentel, V. Monteiro, C.H.D. Costa, R. Rufino, Rio de Janeiro, Brazil, p.A6523

209 **A Phase 2 Dose-Escalation Study with AF-219, a P2X3 Antagonist for the Treatment of Chronic Cough**/J.A. Smith, M. Kitt, M. Sher, P. Butera, A.P. Ford, Manchester, United Kingdom, p.A6524

210 **Treatment Effect of Combination of NSAID and Antitussives in Patients with URTI Related Cough**/A. Zanasi, L. Lanata, F. Saibene, F. De Blasio, Bologna, Italy, p.A6525

211 **Identification of Prolonged Cough Phenotypes Using Cluster Analysis**/T. Jinta, S. Ohyama, Y. Ohtani, W. Furuie, M. Akaza, T. Sasano, Y. Sakakibara, K. Tsuchiya, M. Tamaoka, N. Inase, Y. Sumi, Tokyo, Japan, p.A6526

212 **A Randomized Clinical Trial of Levodropropizine Effect on Respiratory Centre Output in Patients with Intractable Chronic Cough**/C. Mannini, F. Lavorini, F. Saibene, L. Lanata, G. Fontana, Florence, Italy, p.A6527

213 **A Predictor of Cough-Related Quality of Life in Patients with Lung Cancer**/T. Shirai, S. Sakurai, Y. Tanaka, H. Watanabe, Y. Endo, Y. Shimoda, T. Suzuki, I. Hayashi, M. Saigusa, T. Akamatsu, A. Yamamoto, Y. Shishido, T. Akita, S. Morita, K. Asada, T. Suda, Shizuoka, Japan, p.A6528

214 **Treatment of Dyspnea in Do-Not-Intubate (DNI) Patients: Preliminary Results of a Multi-Center Observational Study**/G. Spoletini, L. Pisani, T. Trung, C. Mega, A. Khoja, M. Mantero, F. Blasi, S. Nava, A. Chi, N.S. Hill, Cambridge, United Kingdom, p.A6529

215 **Predicted Probability of Dyspnea in Community-Dwelling Older Persons**/B. Miner, C.A. Vaz Fragoso, New Haven, CT, p.A6530

216 **Simplifying the Cardiopulmonary Exercise Test Enables Pattern Recognition and Differentiation Between Diseases Causing Exertional Dyspnea/**K.H. Melamed, B. Dolezal, X. Wang, C.B. Cooper, Los Angeles, CA, p.A6531

217 **Absolute Lung Volume and Breathlessness in Men and Women in the General Population/**M. Ekstrom, L. Schioler, R. Gronseth, A. Johannessen, C. Janson, C. Svanes, B. Leynaert, D. Jarvis, K. Toren, Lund, Sweden, p.A6532

218 **Validation of the Objective Simplified Wells Score and Comparison with Clinical Judgement/**J. Seashore, M. Farokhi, J.P. Wisnivesky, O. Epelbaum, Queens, NY, p.A6533

219 **Patient Reported Dyspnea on Standardized Questionnaires Does Not Correlate with Measurement Of maxVO2 During Cardio-Pulmonary Exercise Testing/**D. Gaspard, S. Akers, J. Kass, M. Pratter, Camden, NJ, p.A6534

220 **Correlation of Self Reported Breathlessness with Post Exercise Dyspnea in Obesity/**M. Agustin, H. Chang, J. Unterborn, A. Andoh-Duku, Boston, MA, p.A6535

221 **Interstitial Lung Disease Patient Diagnostic Journey (INTENSITY) Survey/**P. Bianchi, D.J. Lederer, S. Danese, J. Loboda, G. Cosgrove, South San Francisco, CA, p.A7894

POSTER DISCUSSION SESSION

D24 GRAM NEGATIVE PNEUMONIAS: FROM BENCH TO BEDSIDE

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 3014 (West Building, Level 3)

Poster Viewing **9:00-9:45**

Discussion **9:45-11:00**

Chairing: J.E. Chastre, MD, Paris, France
C.S. Dela Cruz, MD, PhD, New Haven, CT
M.S. Niederman, MD, New York, NY

901 **Alterations in Pseudomonas Aeruginosa Pathogenicity in Response to Cigarette Smoke Exposure/**M. Ahn, J.H. Hwang, E. McEachern, L.E. Crotty Alexander, San Diego, CA, p.A6536

902 **The Fermentation Product 2,3-butanediol Alters P. aeruginosa Virulence and the Lung Microbiome/**A. Sharma, M. Nguyen, W. Wu, R. Gomi, L. Angenent, S. Worgall, New York, NY, p.A6537

903 **Chitinase 3-Like 1 (Chil1) Regulates Pseudomonas-Induced Inflammasome Activation Independent of the Inflammasome Nlrc4 Highlights Importance of Nlrp3 Mediated Lung Pathology/**C.R. Marion, W. Liu, L. Sharma, R. Singh, J. Wang, C.G. Lee, J.A. Elias, B. Kazmierczak, C. Dela Cruz, New Haven, CT, p.A6538

904 **The Signaling Pathway Involved in MUC1 Mucin Upregulation in Macrophages During Pseudomonas Aeruginosa Infection/**K. Kato, A. Hanss, N. Morgan, K.S. Knox, E.P. Lillehoj, K.C. Kim, Tucson, AZ, p.A6539

905 **Thrombocytopenia Impairs Host Defence in a Murine Model of Pulmonary Infection with Psuedomonas Aeruginosa/**R.T. Amison, A. Rossi, S. Ranucci, S. Arnold, S.C. Pitchford, A. Bragonzi, C.P. Page, London, United Kingdom, p.A6540

906 **Interleukin 7 Immunotherapy Improves Survival in Sepsis Followed by Secondary Pseudomonas Aeruginosa Pneumonia/**Y. Shindo, A.G. Fuchs, C.G. Davis, J. Unsinger, T. Eitas, C.-A. Burnham, J.M. Green, G.V. Bochicchio, R.S. Hotchkiss, St. Louis, MO, p.A6541

907 **Severity-of-Illness Scores Predict Failure of Antibiotic Therapy in Pseudomonas Aeruginosa Pneumonia/**R.D. Shah, R.G. Wunderink, Chicago, IL, p.A6542

908 **Molecular Characteristics and Epidemiology of Clinically Tested Non-Extended-Spectrum β-Lactamase (ESBL)-Producing Klebsiella Pneumoniae Isolates in China/**Z. Zhang, Y. Zhai, Y. Guo, D. Li, Z. Wang, Y. Chen, J. Wang, Q. Wang, Z. Gao, Beijing, China, p.A6543

909 **Promoter-Associated blaSHV Extended-Spectrum Beta-Lactamases (ESBLs) Phenotypic Silencing in Klebsiella Pneumoniae/**Y. Zhai, Z. Zhang, Y. Guo, Y. Lv, Z. Wang, L. Liu, L. Xu, D. Yang, R. Li, Y. Xu, J. Yang, Y. Chen, Q. Wang, Z. Gao, Beijing, China, p.A6544

910 **Interleukin (IL)-1α and IL-1β Contribute to Host Defense Against Pulmonary Klebsiella Infection Via Different Mechanisms/**S. Cai, P. Baral, L. Jin, S. Jeyaseelan, Baton Rouge, LA, p.A6545

911 **Diet-Induced Obesity Impairs Pulmonary Bacterial Clearance in Klebsiella Pneumonia/**P. Mancuso, J.B. Weinberg, K. Singer, Ann Arbor, MI, p.A6546

912 **Epithelial IL-17R Is Required for Pulmonary Host Defense Against K. Pneumonaie/**K. Chen, G. Trevejo-Nunez, E.E. Way, W. Elsegeiny, D.M. Ricks, A.V. Garg, S.L. Gaffen, J.K. Kolls, Pittsburgh, PA, p.A6547

913 **Effects of Carbapenemase-Producing K. Pneumoniae ST258 on the Components of the Airway Epithelial Barrier/**M. Wickersham, A.S. Prince, D. Ahn, New York, NY, p.A6548

914 **ST191 Belonging to CC92 Became Dominate Carbapenem-Resistant Acinetobacter Baumannii that Cause Nosocomial Pneumonia in Intensive Care Units in a Teaching Hospital in Central China/**P. Pan, H. Tan, M. Li, X. Su, C. Hu, ChangSha, China, p.A6549

915 **Outcome and Prognostic Factors of Pneumonia Patients with Acinetobacter Baumannii Bacteremia/**W.-C. Liao, C.-H. Chen, W.-C. Chen, B.-R. Wu, C.-Y. Chen, W.-C. Cheng, T.-C. Hsia, C.-Y. Tu, Taichung, Taiwan, p.A6550

916 **Multidrug Resistance in Acinetobacter Baumannii Pneumonia and Sepsis Increases the Risk of Receiving Inappropriate Empiric Treatment/**M. Zilberberg, B.H. Nathanson, K. Sulham, W. Fan, A.F. Shorr, Goshen, MA, p.A6551

917 **Effectiveness of High Dose Sulbactam for the Treatment of Ventilator Associated Pneumonia Caused by Carbapenem Resistant Acinetobacter Baumanii/**I. Jeong, J.W. Son, M.J. Na, S.J. Kwon, Daejeon, Korea, Republic of, p.A6552

918 **Intranasal Treatment with Bacteriophage Rescue Mice from Acinetobacter Baumannii-Mediated Pneumonia/**C.Q. Bai, Z.Q. Mi, Y. Wang, X.P. An, X. Yuan, W.K. Niu, H.Y. Liu, P.Y. Li, Y.N. Liu, Y.Z. Feng, Y. Huang, X. Zhang, Z. Zhang, H. Fan, F. Peng, Y.G. Tong, Beijing, China, p.A6553

919 **Relationship of Mucosal Antibodies to Non-Typeable Haemophilus influenzae (NTHi) Colonisation of the COPD Airway/**K.J. Staples, S. Thomas, S. Taylor, K. Ostridge, K. Cox, A. Richardson, A.C. Tuck, S.C. Clarke, A. Gorringe, T.M.A. Wilkinson, Southampton, United Kingdom, p.A6554

920 **Macrophage Galactose-Type Lectin-1 (MGL1) Deficiency Is Associated with Increased Lung Pathology and Hyperinflammation in Gram-Negative Pneumonia/**J. Sharma, C.N. Jondle, A. Sharma, T.J. Simonson, B.B. Mishra, Grand Forks, ND, p.A6555

921 **Macrophage-Colony Stimulating Factor in Gram-Negative Pneumonia: Dynamic Protection of Lung and Liver Mononuclear Phagocytes/**B. Mehrad, A. Bettina, Z. Zhang, K.R. Michels, R.E. Cagnina, A. Kadl, M. Burdick, Charlottesville, VA, p.A6556

922 **Carbapenem Resistent K. Pneumoniae ST258 Evade Calcium and Calpain Dependent Neutrophil Killing/**H. Penaloza, D. Ahn, M. Wickersham, D. Parker, S. Bueno, A.S. Prince, Santiago, Chile, p.A7895

923 **Recruited Monocytic-Myeloid Derived Suppressor Cells (M-MDSCs) Dominate the Immune Response to Klebsiella pneumoniae ST258 in Bacterial Pneumonia/**D. Ahn, H. Penaloza, M. Wickersham, A.S. Prince, New York, NY, p.A7896

924 **Flagellin Within Pseudomonas Aeruginosa Induce Neutrophil Pyroptosis Through NLRC4 Inflammasome Activation/**J.-H. Ryu, Seoul, Korea, Republic of, p.A7897

925 **DNA-Delivery of Monospecific and Bispecific Monoclonal Antibodies Targeting Pseudomonas Aeruginosa Protect Mice from Lethal Pneumonia/**A. DiGiandomenico, A. Patel, T. Smith, A. Keller, S.T.C. Elliot, L. Wachter, J. McAuliffe, S. Ramos, K. Broderick, J. Yan, A. Khan, D.H. Park, M. Wise, M. Karuppiah, S. Flingai, L. Humeau, N. Sardesai, C. Stover, D. Weiner, Gaithersburg, MD, p.A7898

POSTER DISCUSSION SESSION

D25 NEONATAL AND CONGENITAL LUNG DISEASES

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**
Room 3011 (West Building, Level 3)

Poster Viewing **9:00-9:45**

Discussion **9:45-11:00**

Chairing: L.M. Nogee, MD, Baltimore, MD
J. Wambach, MD, St. Louis, MO
C.V. Lal, MD, Birmingham, AL

801 **Treatment of Neonatal Hyperoxia Lung Injury with Differentiated hiPSCs/**C.T. Drinnan, T.J. Jensen, A. Mitchell, S. Vadasz, C.M. Finck, Farmington, CT, p.A6557

802 **Pulmonary Vasculature in Infants with Down Syndrome Is Underdeveloped/**D. Bush, C. Galambos, S.H. Abman, Aurora, CO, p.A6558

803 **Identification of Vitamin D Sensitive Pathways During Lung Development/**L. Chen, R. Wilson, E. Bennett, G. Zosky, Hobart, Australia, p.A6559

804 **Temporal, Spatial and Functional Changes Characterize PDGFRa Expressing Fibroblasts During Sacculation and Alveolarization/**A.-K. Perl, Cincinnati, OH, p.A6560

805 **Identification of Optimal Time Points and Proteomic Profiling During Murine Lung Alveolar Septation/**T. Nicola, E. Sefer, C.R. Espinoza, F. Ahangari, D. Chhabra, J. Hagood, N. Kaminski, Z. Bar-Joseph, N. Ambalavanan, Birmingham, AL, p.A6561

806 **IL-1Ra Protects Against Impaired Alveolar Development and Airway Fibrosis but Not Airway Hyperresponsiveness in a Mouse Model of Bronchopulmonary Dysplasia/**J.E. Bourke, S.G. Royce, E. Lamanna, M. Lam, C. Donovan, C. Bui, M. Nold, C. Nold, Clayton, Australia, p.A6562

807 **Inflammation Downregulates Fibulin-5 Expression and Disrupts Elastic Fiber Assembly During Saccular Stage Lung Development/**J.T. Benjamin, R. Van Der Meer, L.R. Young, T.S. Blackwell, Nashville, TN, p.A6563

808 **A Role for the Accessory Type III Transforming Growth Factor-β Receptor in Post-Natal Lung Alveolarization/**A.E. Pozarska, G. Niess, W. Seeger, R.E. Morty, Bad Nauheim, Germany, p.A6564

809 **Monocyte-Centred Inflammatory Response Characterizing Early Stages of BPD Development in the Preterm Infant/**P. Oak, M. Koschlig, A. Windhorst, N. Jain, T. Reicherzer, H. Ehrhardt, M. Frankenberger, C.M. Alvira, M. Schwarz, O. Eickelberg, A. Hilgendorff, Munich, Germany, p.A6565

810 **Echocardiographic and Catheterization Patterns in Pediatric Patients with Secondary Pulmonary Arterial Hypertension Due to Bronchopulmonary Dysplasia/**A. Singh, B. Feingold, B. Rivera-Lebron, S. Drant, Pittsburgh, PA, p.A6566

811 **Determining the Dose-Response Curve Needed to Translate Pulmonary Macrophage Transplantation (PMT) Therapy to Children with Hereditary Pulmonary Alveolar Proteinosis/**P.I. Arumugam, T. Suzuki, A. Sallese, C. Chalk, D. Black, B. Carey, B.C. Trapnell, Cinicnnati, OH, p.A6567

812 **Quantitative Measures of Ground Glass Opacities Correlate with Use of Daytime Oxygen in Neuroendocrine Cell Hyperplasia of Infancy/**D.R. Spielberg, A. Brody, J.C. Woods, C. Towe, Cincinnati, OH, p.A6568

813 **A Novel Role for Transforming Growth Factor Beta-Induced Protein in Promoting Pulmonary Endothelial Migration in the Alveolar Lung/**M. Liu, S.P. Rao, C. Husted, G. Umbach, C.M. Alvira, Stanford, CA, p.A6569

814 **Muring Lung Lipofibroblast Lineage Tracing/**A. Ntokou, R.E. Morty, W. Seeger, K. Ahlbrecht, Bad Nauheim, Germany, p.A6570

815 **Multiplexed Direct Genomic Selection Identifies Exonic, Intronic, and Copy Number Variation in Surfactant-Associated Genes Among Infants with Respiratory Distress Syndrome (RDS) and Children with Interstitial lung Disease (chILD)/**J.B. Tam-Williams, W. Eldridge, D. Wegner, D. Alvarado, L. Nogee, A. Hamvas, F.S. Cole, J. Wambach, St. Louis, MO, p.A6571

816 **The Impact of Mesenchymal Stem Cell Therapy in Bronchopulmonary Dysplasia: The Interaction Between Inflammation and Oxidative Stress/**C.R. Nitkin, T.L. Bonfield, Cleveland, OH, p.A6572

817 **Airway Reactivity in Preterm Infants Is Associated with Increased Respiratory Morbidity in The First Year of Life/**C.L. Ren, R. Feng, S.D. Davis, E. Eichenwald, H.B. Panitch, J.K. Sharp, J.S. Kemp, Indianapolis, IN, p.A6573

818 **Imaging-Based Pulmonary Functional Measurements from Self-Gated Neonatal Ultra-Short Echo-Time (UTE) Magnetic Resonance Imaging (MRI)/**N.S. Higano, A. Hahn, L.L. Walkup, R. Thomen, S. Merhar, P.S. Kingma, J.A. Tkach, S. Fain, J.C. Woods, Cincinnati, OH, p.A6574

819 **Serum Brain-Derived Neurotrophic Factor (BDNF) Levels Can Predict Bronchopulmonary Dysplasia in Neonates/**S.L. Simpson, M. Alejandro-Rodriguez, M.J. Allen, W.L. Spencer, S. Worley, A.S. Tang, J.H. Peterson, G. Piedimonte, Cleveland, OH, p.A6575

820 **Outcomes in Neonates with Bronchopulmonary Dysplasia and Tracheobronchomalacia/**E.B. Hysinger, R. Shinohara, N.L. Friedman, H. Zhang, H.B. Panitch, S.M. Kawut, Philadelphia, PA, p.A6576

821 **Factors Associated with Spontaeous Closure of the Patent Ductus Arteriosus in the Premature Neonate/**D. McCurnin, A. Quinn, C. Blanco, L. McGill-Vargas, S.R. Seidner, San Antonio, TX, p.A6577

822 **Nutritional Follow-Up of Congenital Diaphragmatic Hernia Survivors - The Sydney Children's Hospital Experience/**J. Mui, A. Numa, A. Jaffe, S. Chuang, Randwick, Australia, p.A6578

823 **Novel NPY-Mediated Effect on Proliferation, Migration and IL-6 Expression in Neonatal Pulmonary Fibroblasts Is Related to Lung Growth After Intrauterine Growth Restriction/**C. Thangaratnarajah, K. Dinger, C. Vohlen, J. Nawabi, C. Klaudt, E. Lopez, J. Dobner, K.-D. Nuesken, S. V. Hoersten, J. Doetsch, M.A. Alejandre Alcazar, Cologne, Germany, p.A7899

POSTER DISCUSSION SESSION

D26 I'M ON FIRE- INFLAMMATION IN PULMONARY VASCULAR DISEASE

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 3024 (West Building, Level 3)

Poster Viewing **9:00-9:45**

Discussion **9:45-11:00**

Chairing: F. Perros, PhD, Le Plessis Robinson, France
M.R. Nicolls, MD, Palo Alto, CA
L.C. Price, MBBS, London, United Kingdom

1001 **Evidence of Dysregulated Humoral Immunity in Idiopathic Pulmonary Arterial Hypertension/**E. Groves, K. Zalewska, A. Crosby, R.M. Salmon, Z. Wei, P.D. Upton, C. Hadinnapola, E.F. McKinney, M. Southwood, H. Baxendale, J. Pepke-Zaba, N.W. Morrell, M. Toshner, Cambridge, United Kingdom, p.A6579

1002 **Elucidating the Role of Inflammation and Endothelial Dysfunction in Chronic Thromboembolic Pulmonary Hypertension and their Clinical Significance/**C. Hadinnapola, M. Southwood, J. HernA¡ndez - SA¡nchez, J. Cannon, D. Jenkins, S.D. Preston, N. Screaton, K. Sheares, N.W. Morrell, M. Toshner, J. Pepke-Zaba, Cambridge, United Kingdom, p.A6580

1003 **Plasma 12- and 15-HETE Are Predictors of Survival in Pulmonary Arterial Hypertension/**N. Al-Naamani, K.D. Sagliani, G.G. Dolnikowski, R. Warburton, D. Toksoz, U. Kayyali, N.S. Hill, B.L. Fanburg, K.E. Roberts, I.R. Preston, Boston, MA, p.A6581

1004 **Elevated Pulmonary Arterial Pressures Are Associated with Changes in the Oral Microbiome and Reduction in Predicted Nitrate and Nitrite Metabolism/**C.D. Koch, A. Fitch, M.A. Simon, R.R. Vanderpool, H. Spallek, S. Rehman, M.L. Saul, M.T. Gladwin, A.R. Vieira, A.M. Morris, Pittsburgh, PA, p.A6582

1005 **Hemodynamic Unloading Rapidly Reverses Perivascular Inflammation in a Rat Model of PAH/**K. Abe, I.F. McMurtry, M. Oka, Fukuoka, Japan, p.A6583

1006 **Pulmonary Adventitial Remodeling in Pulmonary Hypertension: Fibroblast Responses to Changes in Matrix and Interstitial Fluid/**M.E. Yeager, K.L. Colvin, Aurora, CO, p.A6584

1007 **Functional Reprogramming of Macrophages Through Targeted Inhibition of Metabolic Pathways as a Strategy to Promote Anti-Inflammatory Signaling in Pulmonary Hypertension/**K. EL Kasmi, S. Riddle, M. Li, A. D'Alessandro, H. Zhang, B.A. McKeon, A. Flockton, M. Frid, K.C. Hansen, S. Pullamsetti, Q. Zhang, K.R. Stenmark, Aurora, CO, p.A6585

1008 **Adventitial Fibroblasts Shape the Local Microenvironment to Induce and Sustain Alterations in Macrophage Metabolism as a Critical Adaptation to Promote a Pro-Inflammatory and Pro-Remodeling Phenotype/**K. EL Kasmi, A. D'Alessandro, S. Riddle, H. Zhang, M. Li, A. Anderson, K. Rawlinson, A. Flockton, B.A. McKeon, K.C. Hansen, M. Frid, K.R. Stenmark, Aurora, CO, p.A6586

1009 **Patients with Exercise Induced Pulmonary Arterial Hypertension Exhibit Coagulation System and Endothelial Activation/**A.B. Waxman, L.M. Grove, D.M. Systrom, J.A. Leopold, R. Dweik, G.A. Heresi, S.C. Erzurum, M.A. Olman, Boston, MA, p.A6587

1010 **4-Methylthio-2-Oxobutyric Acid (MTOB), a Novel Small Molecule and Inhibitor of CtBP1, Inhibits the Proliferative and Pro-inflammatory Phenotype of Adventitial Fibroblast in Pulmonary Hypertension/**M. Li, B.A. McKeon, S. Kumar, M. Frid, A. Flockton, S. Riddle, A. D'Alessandro, H. Zhang, M.A. Fini, K. El Kasmi, Q. Zhang, K.R. Stenmark, Aurora, CO, p.A6588

1011 **The Role of the Bone Morphogenetic Protein 9 in Endothelial Inflammation/**C.G. Mitrofan, S. Appebly, N. Morrell, Cambridge, United Kingdom, p.A6589

1012 **The NF-κB Pathway Is Important for Phenotype and Proliferation of Pulmonary Microvascular Endothelial Cells and Lung Endothelial Progenitor Cells/**D. Farkas, V. Kraskauskiene, A.A. Fowler, K. Islam, R. Natarajan, L. Farkas, Richmond, VA, p.A6590

1013 **Autocrine Regulation of Interleukin 33 Expression in Human Pulmonary Artery Endothelial Cells/**T.C. Tsui, S. Boeder, E.C. Breen, T.D. Bigby, La Jolla, CA, p.A6591

1014 **TNFα Stimulates an Inflammatory Response in Human Pulmonary Microvascular Endothelial Cells (HPMECs): The Role of NF-κB and BET Proteins/**A. Natsuki, J. Wort, F. Chung, I.M. Adcock, S. Mumby, London, United Kingdom, p.A6592

POSTER DISCUSSION SESSION

D27 MACROPHAGES: RESOLVERS, RESPONDERS OR BOTH?

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 2014 (West Building, Level 2)

Poster Viewing **9:00-9:45**

Discussion **9:45-11:00**

501 **Requirement of IL-6 for Maximal M2 Macrophage Accumulation, and Growth of Ectopically Delivered B16 Melanoma, in Mouse Lungs Upon Oncostatin M Overexpression/**L. Izakelian, E. Ayaub, A. Dubey, S. Wong, F. Botelho, K. Ask, C.D. Richards, Hamilton, Canada, p.A6593

502 **Tumor-Associated Macrophages Induces Activation of STAT3 on Small Cell Lung Cancer Cells/**T. Iriki, K. Ohnishi, Y. Komohara, Y. Fujiwara, M. Takeya, H. Kohrogi, Kumamoto, Japan, p.A6594

503 **Modulation of Alveolar Macrophage Immune Function by Fatty Acid Ethyl Esters/**T.W. Gauthier, X.D. Ping, L.A.S. Brown, Atlanta, GA, p.A6595

504 **Tissue-Resident Alveolar Macrophages Persist Over the Lifespan with Minimal Input from the Bone Marrow but Are Replaced by Monocyte-Derived Cells Upon Depletion/**A.C. Mc Quattie-Pimentel, F.J. Gonzalez, C.-I. Chen, J.M. Walter, M. Chi, S. Soberanes, R. Piseaux, K.M. Ridge, H.R. Perlman, G.S. Budinger, A.V. Misharin, Chicago, IL, p.A6596

505 **Apoptosis Signal Regulating Kinase-1 Promotes Inflammasome Priming in Alveolar Macrophages/**J.A. Kennedy, C.N. Immanuel, C. Luellen, B. Teng, E.A. Fitzpatrick, C.M. Waters, Memphis, TN, p.A6597

506 **Pulmonary Alveolar Proteinosis Is Driven by Reduced GM-CSF-Dependent Cholesterol Clearance by Alveolar Macrophages, Not an Inability to Catabolize Surfactant Phospholipids/**A. Sallese, T. Suzuki, J. Bridges, A. Filuta, D. Black, C. Chalk, B. Carey, B.C. Trapnell, Cincinnati, OH, p.A6598

507 **TGFb1 Induced Mammalian Lung Fibrosis Requires TGFBR2 Expression on Macrophages/**X. Peng, R. Homer, J.A. Elias, E. Herzog, New Haven, CT, p.A6599

508 **Alveolar Macrophage Activation Pattern in Idiopathic Pulmonary Fibrosis (IPF): Bronchoalveolar Lavage (BAL) Transcriptome Analysis/**C.M. Swaisgood, I. Arisi, F. Mariani, E. Puxeddu, M. Amicosante, D. Giovannini, M. Pallante, G. Paone, T. Flagg, M.L. Brantly, C. Saltini, Gainesville, FL, p.A6600

509 **Macrophage Mitochondrial Calcium Content Is Required for Pulmonary Fibrosis Development/**L. Gu, A.J. Ryan, J.L. Larson-Casey, A.B. Carter, Birmingham, AL, p.A6601

510 **IL-6 Mediated Hyperpolarization of Profibrotic Macrophages Is Dependent on Spliced XBP1/**E. Ayaub, K. Tandon, P. Parthasarathy, J. Murphy, P.S. Kolb, S. Lhotak, M.R.J. Kolb, M.D. Inman, R.C. Austin, C.D. Richards, K. Ask, Hamilton, Canada, p.A6602

511 **A Unique Human Alveolar Macrophage Polarization Phenotype Is Associated with Disease Progression in Idiopathic Pulmonary Fibrosis/**L.M. Nicol, M. Brittan, J.A. Marwick, A.C. MacKinnon, R. Mills, P.A. McFarlane, W.A. Wallace, G. Stewart, J. Simpson, A.G. Rossi, S.E. Howie, J.T. Murchison, N. Hirani, Edinburgh, United Kingdom, p.A6603

512 **Transcriptional Signatures of Alveolar Macrophages in a Murine Model of Chronic Granulomatous Disease: Similarities to Sarcoidosis/**A. Mohan, S.A. Gharib, A. Malur, M. McPeek, B.P. Barna, L.M. Schnapp, M.J. Thomassen, Greenville, NC, p.A6604

513 **Expression of CD71 on Alveolar Macrophages Reveals Distinct Cell Populations in Human Bronchoalveolar Lavage from Patients with Interstitial Lung Disease/**S.J. Allden, R.J. Toshner, A.J. Byrne, C.M. Lloyd, T. Maher, Slough, United Kingdom, p.A6605

514 **Hypercapnia Increases Mortality of Influenza A Virus Infection in Mice and Viral Replication in Macrophages by a RIG-1- and MDA5-dependent Mechanism/**M. Casalino Matsuda, A. Nair, M. Chi, K.L. Gates, G.S. Budinger, P.H. Sporn, Chicago, IL, p.A6606

515 **Mitochondrial Transfer Via Tunnelling Nanotubes (TNT) Is a Novel Mechanism by Which Mesenchymal Stromal Cells Enhance Macrophage Phagocytosis in In Vivo Models of Acute Lung Injury/**M.V. Jackson, T.J. Morrison, D.F. McAuley, M. Matthay, C.M. O'Kane, A.D. Krasnodembskaya, Belfast, United Kingdom, p.A6607

516 **Monocyte-Derived Alveolar Macrophages Contribute to the Development of Lung Fibrosis and Persist in the Lung Over the Lifespan/**A.V. Misharin, L. Morales-Nebreda, C.M. Cuda, P.A. Reyfman, S. Berdnikovs, A.C. McQuattie-Pimentel, F.J. Gonzalez-Gonzalez, R. Saber, C.-I. Chen, H.R. Perlman, G.S. Budinger, Chicago, IL, p.A6608

517 **Influenza A Virus Infection Leads to Excess Monocyte Recruitment and Severe Lung Injury in Juvenile Mice/** B.M. Coates, K.L. Staricha, K.M. Ridge, Chicago, IL, p.A6609

518 **Opposing Heme Oxygenase-1 Expression Pattern in Macrophages Cause Different Cell Behaviors/**C. Canetti, C. Freitas-Oliveira, A. Brogliato, M.M. Chaves, G. Sodre, C.F. Benjamim, R. Coutinho-Silva, Rio de Janeiro, Brazil, p.A6610

POSTER DISCUSSION SESSION

D28 NOVEL IMAGING METHODS TO STUDY LUNG DISEASE

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 2024 (West Building, Level 2)

Poster Viewing **9:00-9:45**

Discussion **9:45-11:00**

Chairing: E.A. Hoffman, PhD, Iowa City, IA
M.F. Vidal Melo, MD, PhD, Boston, MA
M. Kirby, PhD, Vancouver, Canada

601 **Common Airway Variants and Risk of Chronic Obstructive Pulmonary Disease. The Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS)**/B.M. Smith, E.A. Hoffman, E.R. Bleecker, D.J. Couper, M.K. Han, N.N. Hansel, R. Kanner, E. Kleerup, F.J. Martinez, S.I. Rennard, P.G. Woodruff, R.G. Barr, Montreal, Canada, p.A6611

602 **Multiscale Imaging-Based Clusters in the COPD Cohort Associates with Clinical Characteristics: The SubPopulations and InteRmediate Outcome Measures in COPD Study (SPIROMICS)**/B. Haghighi, S. Choi, E.A. Hoffman, J. Newell, R.G. Barr, M.K. Han, C.B. Cooper, W.K. O'Neal, P.G. Woodruff, E.R. Bleecker, F.J. Martinez, C.-L. Lin, Iowa City, IA, p.A6612

603 **Computer-Aided Lung Informatics for Pathology Evaluation and Rating (CALIPER) Analysis of Chest CT to Detect Histologically Proven Emphysema**/F. Foley, S. Raghunath, S. Rajagopalan, R. Karwoski, F. Maldonado, B. Bartholmai, T. Peikert, Rochester, MN, p.A6613

604 **Hyperpolarized Xenon-129 Spectroscopy Measures in Smokers, COPD Patients and Normals Are Correlated with DLCO and 6 MW Test**/K. Ruppert, K. Qing, T.A. Altes, J.P. Mugler, Cincinnati, OH, p.A6614

605 **Imaging Carbon Monoxide Diffusion with Positron Emission Tomography**/D.L. Chen, M.M. Chakinala, C. McEvoy, J.J. Atkinson, F.J. Brooks, St. Louis, MO, p.A6615

606 **MRI Biomarker Using Pulmonary Blood Flow and Tissue Density in IPF and COPD**/A. Caprihan, J. Ming, D. Kuethe, Y. Tesfaigzi, G. Washko, Albuquerque, NM, p.A6616

607 **Diaphragm Morphology Assessed by Computed Tomography in Chronic Obstructive Pulmonary Disease**/A. Donovan, D. Jensen, H. Coxson, S. Gottfried, B.J. Petrof, J. Bourbeau, B.M. Smith, Montreal, Canada, p.A6617

608 **3D Morphology Meets Molecular Pathology: Chronic Lung Alveolar Dysfunction Revisited**/M.P. Kuehnel, J. Wehling, M. Kellner, G. Warnecke, N. Izykowski, R. Grothausmann, L. Knudsen, T. Welte, A. Haverich, F. LA¤nger, H. Kreipe, D. Jonigk, Hanover, Germany, p.A6618

609 **Imaging Alveolar Dynamics with 4D Optical Coherence Tomography (OCT) and Time-Resolved Intravital Microscopy (IVM) During Uninterrupted Mechanical Ventilation of Rats**/C. Schnabel, E. Koch, Dresden, Germany, p.A6619

610 **In Vivo-Quantitative Assessment of Lung Injury Using Carbon-13 HP-MRI in a Two-Hit Model of Acid Aspiration and VILI**/M. Pourfathi, S. Kadlecek, Y. Xin, S. Siddiqui, M. Cereda, H. Profka, H. Hamedani, R.R. Rizi, Philadelphia, PA, p.A6620

611 **Imaging-Based Measurement of the Risk of Lung Injury Progression**/H. Hamedani, M. Cereda, Y. Xin, J. Wu, J. Clapp, S. Kadlecek, J. Zeng, N. Meeder, H. Staroba, A. Rodriguez, Q. Bey, H. Profka, B.P. Kavanagh, J.C. Gee, R.R. Rizi, Philadelphia, PA, p.A6621

612 **Magnetic Resonance Imaging of Radiation-Induced Lung Injury with Correlation to Histology**/B. Zanette, E. Stirrat, S. Shojaie, O. Doganay, G.E. Santyr, Toronto, Canada, p.A6622

613 **Is the Lung in Obesity Also Obese?: Lung Tissue Volume Is Elevated in Obesity and Reduced by Bariatric Surgery**/A. Santos, E. Rivas, R. Rodriguez-Roisin, M. Sanchez, J. Ruiz-Cabello, E. Arismendi, J.G. Venegas, Boston, MA, p.A6623

614 **Peri-Bronchial Parenchyma Expands Less than Segmental After Bronchoconstriction, a Difference that Increases with Lung Volume**/J.S. Osorio-Valencia, V.J. Kelly, R.S. Harris, T. Winkler, J.G. Venegas, Boston, MA, p.A6624

615 **Clinical Computer-Aided Diagnosis Tool for Pulmonary Nodule Characterizations Shows Improved Performance with the Inclusion of Nodule-Associated Parenchymal Features**/S.K.N. Dilger, J. Uthoff, E. Hammond, S.L. Mott, B.J. Smith, M. Ahuja, M. Gailey, A. McGruder, J.D. Newell, E.A. Hoffman, J.C. Sieren, Iowa City, IA, p.A6625

616 **Identifying Longitudinal Computed Tomography Biomarkers of Malignancy to Improve Noninvasive Lung Cancer Diagnosis**/S.K.N. Dilger, J. Uthoff, E. Hammond, M. Ahuja, M. Gailey, A. McGruder, J.D. Newell, E.A. Hoffman, J.C. Sieren, Iowa City, IA, p.A6626

617 **Heterogeneity and Diversity of Pulmonary Cells in Human Lung Assessed by Immunofluorescence Confocal Imaging**/J.A. Kitzmiller, S.E. Wert, A.-K. Perl, K. Srivastava, C. Stockman, B. Webster, J.A. Whitsett, Cincinnati, OH, p.A6627

618 **Micro-Computed Tomography Imaging of Frozen Human Lung Tissue Samples**/D.M. Vasilescu, A.B. Phillion, D. Kinose, D.F. Paige, S. Verleden, B.M. Vanaudenaerde, J.D. Cooper, T.-L. Hackett, J.C. Hogg, Vancouver, Canada, p.A6628

619 **Multi-Level Registration of Multi-Modality and Longitudinally Acquired Thoracic Images for Lung Assessment in a Swine Exposure Model**/E. Hammond, F. De Stefano, S.K.N. Dilger, E.A. Hoffman, J.D. Newell, J.C. Sieren, Iowa City, IA, p.A6629

620 **Reversal of Airflow Limitation Post-Albuterol Is Not Accompanied by Improved Xenon-129 Gas Exchange in Adults with Asthma**/K. Qing, W.G. Teague, J.P. Mugler, K. Ruppert, J.F. Mata, Y.M. Shim, C.E. Rose, Jr., B. Mehrad, G.W. Miller, I.C. Ruset, F.W. Hersman, T.A. Altes, Charlottesville, VA, p.A6630

621 **The Abnormal Airways that Dominate Asthma Attack: New Clues Using Ventilation MRI During Exercise- and Methacholine-Challenge**/M. Fennema, D.P. Capaldi, K. Sheikh, S. Svenningsen, R.L. Eddy, C. Licskai, D.G. McCormack, G. Parraga, London, Canada, p.A6631

622 **What do MRI Ventilation Defects Reveal About Asthma Control?/**S. Svenningsen, P. Nair, D.G. McCormack, G. Parraga, London, Canada, p.A6632

623 **Towards Image-Guided Asthma Therapy: A Clinical Pipeline to Generate MRI Sub-Segmental Ventilation Measurements/**F. Guo, S. Svenningsen, R.L. Eddy, M. Fennema, D.G. McCormack, G. Parraga, London, Canada, p.A6633

624 **Pulmonary Physiologic Response to Segmental Allergen Challenge Differs in Allergic Adults with and Without Asthma/**V.J. Kelly, T. Winkler, M. Kone, D.L. Hamilos, R. Afshar, J.L. Cho, L.L. Liang, J.W. Griffith, J.G. Venegas, A.D. Luster, B.D. Medoff, R.S. Harris, Boston, MA, p.A6634

625 **Unstable Size of Ventilation Defects (VDefs) in an Animal Model of Bronchoconstriction Using Continuous Methacholine (MCh) Infusion/**T. Winkler, A. Braune, V.J. Kelly, R.S. Harris, G. Musch, A. Rashid, J.G. Venegas, Boston, MA, p.A6635

POSTER DISCUSSION SESSION

D29 BENCH TO BEDSIDE: TRANSLATIONAL SCIENCE IN SDB

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 3001 (West Building, Level 3)

Poster Viewing **9:00-9:45**

Discussion **9:45-11:00**

Chairing: D. Gozal, MD, Chicago, IL
J.C. Jun, MD, Baltimore, MD
A. Goldbart, MD, Beer Sheva, Israel
S.P. Patil, MD, PhD, Baltimore, MD

701 **Sleep Characteristics, Insulin Resistance and Cortisol Levels in Pregnant Women with Gestational Diabetes Mellitus/**J. MacLeod, A. Caraganis, F. Monteiro, S. Martin, L. Larson, R. El-Bizri, G.R. Bourjeily, Providence, RI, p.A6636

702 **Obstructive Sleep Apnea, Insulin Resistance and Cortisol Levels in Pregnant Women with Gestational Diabetes Mellitus/**A. Caraganis, J. MacLeod, M. Kao, F. Monteiro, S. Martin, L. Larson, R. El-Bizri, G.R. Bourjeily, Providence, RI, p.A6637

703 **Oxidative and Carbonyl Stress in Pregnant Women with Obstructive Sleep Apnea/**N. Khan, G. Messerlian, F. Monteiro, E. Eklund, J. Hodosy, P. Celec, P. Curran, G.R. Bourjeily, Providence, RI, p.A6638

704 **Obstructive Sleep Apnea Features, Lower Airway Obstruction and Inflammation in Patients with Asthma/**M. Teshome, T. Denman, M. Teodorescu, Madison, WI, p.A6639

705 **CPAP Withdrawal Induces Lipolysis During Sleep/**J.C. Jun, S. Chopra, L. Pham, O. Mesarwi, A.R. Schwartz, V.Y. Polotsky, Baltimore, MD, p.A6640

706 **Time Course of Cardiac Troponin in Patients with Acute Coronary Syndrome and Sleep Apnea/**A. Sanchez-de-la-Torre, M. Sanchez-de-la-Torre, J. Valls, M. Flores, A. Maisel, A. Malhotra, F. Barbe, X. Soler, Lleida, Spain, p.A6641

707 **Contributing Factors to Arterial Stiffness in Patients with Obstructive Sleep Apnea Syndrome: An Individual Meta-Analysis/**R. Tamisier, J.C. Borel, S. Millasseau, L.-M. Galerneau, M. Destors, M. Perrin, J.L. Pepin, Grenoble, France, p.A6642

708 **Evening Versus Morning Administration of an ACE-inhibitor and Its Effects on 24 Hour Blood Pressure Control in Patients with Obstructive Sleep Apnoea and Hypertension: A Double Blind Randomised Controlled Trial/**Y. Djavadkhani, B. Yee, R. Grunstein, K. Wong, P.A. Cistulli, H. Arima, C.L. Phillips, Sydney, Australia, p.A6643

709 **Carotid Body Involvement in a Translational Ovine Model of Renovascular Hypertension: Sensitivity to Purinergic P2X3 Receptor Antagonism with AF-130/**J.F. Paton, R. Ramchandra, F.D. McBryde, A.P. Ford, Bristol, United Kingdom, p.A7900

710 **Effectiveness of Two Maintenance Diets Following a Very Low Energy Diet to Reduce Cardio-Metabolic Risk in Obese Sleep Apnea Patients: A Randomized Controlled Trial/**C.M. Hoyos, E.A. Cayanan, N. Marhsall, B. Yee, K. Wong, Y. Djavadkhani, R. Grunstein, Glebe, Australia, p.A6644

711 **Risk Factors Analysis for Disorders of Glucose Metabolism of Newly Diagnosed Adult OSAS Patients/**F. Jiang, Z.-A. Liang, Sichuan, China, p.A6645

712 **A Randomized Controlled Study on the Effects of CPAP on Visceral Fat Thickness, Carotid Intima-Media Thickness and Adipokines in Patients with Obstructive Sleep Apnea/**S.S. Ng, E.K. Liu, R.C. Ma, T.-O. Chan, K.-W. To, K.K. Chan, J. Ngai, W.-H. Yip, F.W. Ko, C.-K. Wong, D.S. Hui, Hong Kong, Hong Kong Prc, p.A6646

713 **Forkhead Box P3 Overexpression in Adults with Obstructive Sleep Apnoea/**I. Martin-Burriel, A. Sanz, D. Sanz-Rubio, V. Gil, L. Varona, R. Bolea, J. Godino, M. Andres, A.L. Simon, M. Forner, J.M. Marin, Zaragoza, Spain, p.A6647

714 **Telomere Shortening in Middle-Aged Men with Sleep-Disordered Breathing/**L. Boyer, E. Audureau, L. Margarit, E. Marcos, E. Bizard, P. Le Corvoisier, I. Macquin-Mavier, G. Derumeaux, T. Damy, X. Drouot, A. Covali-Noroc, J. Boczkowski, S. Bastuji-Garin, S. Adnot, Creteil, France, p.A6648

715 **The Role of Complement in Obstructive Sleep Apnea/**A. Daggan, M. Emin, F. Castagna, S. Jelic, New York, NY, p.A6649

716 **Effect of Sleep-Deprivation on Cytokines Level, Neutrophils Functions and Lymphocyte Populations/**M.A. Al-Abri, I. Al-Saidi, E. Said, S. Hasson, A. Al-Jabri, M. Al-Belushi, J. Al-Busaidi, O. Habbal, Al-Khoudh, Oman, p.A6650

717 **Low Integrated Area of Desaturation Index After Adaptive Servo Ventilation Therapy Is Strong Indicator to Predict Fatal Cardiovascular Events in Patients with Heart Failure/**A. Umeyama, N. Takama, M. Kurabayashi, Isesaki, Japan, p.A6651

718 **Is Periodic Breathing During Exercise Controlled by Chemical Feedback Signals?/**P. Haouzi, D. Kim, Hershey, PA, p.A6652

719 **Sleep Amplifies Hypoxemia at Altitude in the Cronicas Cohort/**L. Pham, C.H. Miele, R.S. Arias, N. Schwartz, A. Rattner, C. Meinzen, J.J. Miranda, R.H. Gilman, W. Checkley, A.R. Schwartz, Baltimore, MD, p.A6653

720 **Repeated Short-Term Exposures to Normobaric Hypoxia Do Not Prevent Acute Mountain Sickness in Susceptible Individuals/**M. Faulhaber, E. Pocecco, H. Gatterer, T. Duennwald, N. Netzer, M. Burtscher, Innsbruck, Austria, p.A6654

721 **Sleep and Breathing of Healthy Young Adults in Normobaric Hypoxia Equivalent to 3500m, 4500m and 5500m Altitude: Physiologic Analysis and Description of Sex Differences/**N. Netzer, S. Wimmer, M. Faulhaber, H. Gatterer, M. Burtscher, S. Pramsohler, Bad Aibling, Germany, p.A6655

POSTER DISCUSSION SESSION

D30 NOVEL CLINICAL APPROACHES TO THORACIC MALIGNANCIES

9:00 a.m. - 11:00 a.m. **MOSCONE CENTER**

Room 309 (South Building, Esplanade Level)

Poster Viewing **9:00-9:45**

Discussion **9:45-11:00**

Chairing: G.L. Narsavage, APRN, PhD, RN, Morgantown, WV
T.J. Harkin, MD, New York, NY

301 **Clinical Contributions of Exhaled Volatile Organic Compounds in the Diagnosis of Lung Cancer/**T. Oguma, T. Nagaoka, M. Kurahashi, N. Kobayashi, H. Takiguchi, K. Niimi, H. Tomomatsu, K. Tomomatsu, N. Hayama, T. Aoki, T. Urano, T. Abe, K. Asano, Kanagawa, Japan, p.A6656

302 **Is There an Association of One's Clinical Phenotype with the Lung Cancer Phenotype They Are Most Likely to Develop?/**P. Mazzone, X.-F. Wang, H. Choi, D. Ha, C. Chevalier, E. Shen, B. Huang, M.K. Gould, Cleveland, OH, p.A6657

303 **A Comparison of Lung Cancer in New Zealand Europeans and Maori: Are Maori More Susceptible to Smoking?/**R.J. Hopkins, C. Kendall, G.D. Gamble, R.P. Young, Auckland, New Zealand, p.A6658

304 **Circulating Stanniocalcin-1 in the Diagnosis of Lung Cancer/**V. Ifeacho, A. Ryazantsev, G. Rubiaco, M. Risco, O. James, K. Almodovar, D. Upadhyay, Fresno, CA, p.A6659

305 **Comorbidities Are Associated with Stage I Lung Cancer Diagnosis/**M.C. Aldrich, H.M. Munro, E.L. Grogan, P.P. Massion, W.J. Blot, Nashville, TN, p.A6660

306 **Defining the Lung Cancer Comorbidome and Its Effect on Survival/**M.K. Gould, E.E. Hahn, C.E. Munoz-Plaza, J.S. Lee, C. Parry, E. Shen, Pasadena, CA, p.A6661

307 **The Effect of Statins on Survival in Patients with Stage IV Lung Cancer/**J.J. Lin, N. Ezer, K. Sigel, G. Mhango, J.P. Wisnivesky, New York, NY, p.A6662

308 **Lepidic Growth Component and Nodal Metastasis of Invasive Pulmonary Adenocarcinoma/**J. Kim, K.W. Lee, Seongnam-si, Korea, Republic of, p.A6663

309 **Unique Clinical and Survival Characteristics of Clinically N0 on 18F-FDG PET/CT in Stage IV Non-Small Cell Lung Cancer/**J.H. Mok, S.M. Jang, H.J. Na, J.S. Eom, E.J. Jo, M.H. Kim, K. Lee, K.U. Kim, H.-K. Park, M.K. Lee, 602-739, Busan, Korea, Republic of, p.A6664

310 **Predictor of Mortality in Patients with Solid Malignancy Admitted to the ICU - A Prospective Observational Study/**P.L. Kingah, Houston, TX, p.A6665

311 **Characterization and Prognosis of Non-Small Cell Lung Cancer (NSCLC) Patients with Secondary and Multiple Malignant Neoplasms/**A.B. Schulze, L.H. Schmidt, A. Kuemmel, L.C. Baie, C. Albers, M. Mohr, A. Faldum, D. Goerlich, R. Wiewrodt, Muenster, Germany, p.A6666

312 **Napsin A Levels in Epithelial Lining Fluids in Patients with Primary Lung Adenocarcinoma/**A. Uchida, T. Samukawa, T. Kumamoto, H. Mataki, K. Mizuno, I. Higashimoto, H. Inoue, Kagoshima, Japan, p.A6667

313 **The Accuracy of Quantitative CT Scan Based Prediction of Post-Lung Resection FEV1 and DLCO** /H. Choi, D. Teeters, D. Raymond, P. Raffy, X. Wang, P. Mazzone, Cleveland, OH, p.A6668

314 **High Temperature Requirement A3 (HtrA3) Inhibits Cell Migration and Predicts Survival in Resected Non-Small-Cell Lung Cancer/**J. Zhao, J. Zhang, M. Feng, J. Qu, Shanghai, China, p.A6669

315 **Analysis of Postoperative Survival in Patients with Resected Lung Adenocarcinoma According to the Tumor-Associated Macrophages/**Y. Machida, N. Motono, M. Tanaka, S. Maeda, K. Usuda, M. Sagawa, Ishikawa, Japan, p.A6670

316 **Video-Assisted Thoracoscopic Surgery Vs Surgical Lobectomy: A Propensity Matched Study of Data from 2008-2012/**H.H. Desai, B. Natt, C. Bime, Tucson, AZ, p.A6671

317 **Use of 4DCT in the Measurement of Respiration-Induced Catheter Motion in Endobronchial High Dose Rate Brachytherapy/**C. Parks, S. Cavanaugh, A. Vidovic, T. Law, S. Crawford, J. Wei, Newnan, GA, p.A6672

318 **Radiological Changes After Stereotactic Ablative Radiotherapy for Early Stage Lung Cancer: Observed Features of Fibrosis and Tumour Recurrence/**A. Talwar, N. Panakis, N.M. Rahman, F. Gleeson, Oxford, United Kingdom, p.A6673

319 **Amrubicin for Relapsed Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of 803 Patients/**K. Nakashima, N. Horita, A. Narita, M. Ikeda, R. Ushio, H. Watanabe, K. Nagai, Y. Shibata, K. Tashiro, H. Nagakura, T. Tsukahara, M. Yamamoto, T. Sato, T. Kaneko, Yokohama, Japan, p.A6674

320 **Does EGFR Mutation or Younger Age (Age≤50 Years) Affect EGFR TKI Treatment Outcome? - A Cohort Study Among Lung Adenocarcinoma Patients in Taiwan/**S.-G. Wu, C.-J. Yu, J.C.-H. Yang, J.-Y. Shih, P.-C. Yang, Douliou City, Taiwan, p.A6675

321 **Efficacy, Safety and Dosage of Afatinib in Patients with Non-Small Cell Lung Cancer After Failure of Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI)/**C. Park, T. Kim, H. Shin, H. Ban, J. Lim, Y. Kwon, I. Oh, S. Lim, Y. Kim, Hawsun, Jeonnam, Korea, Republic of, p.A6676

322 **Evaluation of a Bronchoscopic Thermal Ablation Device in a Live Porcine Model using Electromagnetic Navigation and Cone-beam CT Follow-up/**J. Mattingley, K. Howk, W. Dickhans, K. Maranjian, K. Rooks, K. Haley, La Crosse, WI, p.A6677

323 **Treatment of Isolated Mediastinal and Hilar Recurrence of Lung Cancer with Bronchoscopic Endobronchial Ultrasound Guided Intratumoral Injection of Chemotherapy with Cisplatin/**J.P. Wynne, H.J. Mehta, M. Jantz, A. Begnaud, A.M. Penley, P. Malhotra, S. Fernandez-Bussy, J. Cope, J. Shuster, Gainesville, FL, p.A6678

324 **The European Initiative for Quality in Thoracic Oncology (EIQTOC): A Comprehensive Snapshot on Lung Cancer Care in Europe/**T.G. Blum, M. Gaga, A. Rich, N. Schonfeld, A.-P. Meert, B. Grigoriu, J.-P. Sculier, Berlin, Germany, p.A6679

325 **MDM2 Gene Copy Number Gain Distinguishes Aggressive from Indolent Lung Adenocarcinomas** /Y. Zou, A. Borczuk, C.A. Powell, P.P. Massion, Nashville, TN, p.A7901

THEMATIC POSTER SESSION

D31 NOVEL MECHANISMS OF ALLERGY AND AIRWAY INFLAMMATION

9:00 a.m. - 3:30 p.m. **MOSCONE CENTER**

Area D, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: N.J. Kenyon, MD, Sacramento, CA

P371 **Increased Vascularity of the Bronchial Mucosa in Patients with Severe Asthma and the Role of IL-17A in Angiogenesis and Vascular Remodeling/**A. Panariti, V. Narayanan, C. Baglole, D.H. Eidelman, S. Hussain, J.G. Martin, Q. Hamid, Montreal, Canada, p.A6680

P372 **The Bitter Taste Receptor Gene TAS2R42 Is a Novel Asthma Severity Gene/**G.A. Hawkins, D.A. Deshpande, E.J. Ampleford, X. Li, H. Li, W.C. Moore, D.A. Meyers, E.R. Bleecker, Winston-Salem, NC, p.A6681

P373 **Using Anatomically-Correct Models to Predict Deposition of Inhaled Allergens in the Upper and Lower Airways of Young Children/**B. Laube, K. Koehler, A. Rule, M. Ghosh, E. Matsui, P. Breysse, Baltimore, MD, p.A6682

P374 **Dysregulation of Gel-Forming Mucins in Asthma/**M.E. Lachowicz-Scroggins, S. Yuan, E. Dunican, S.C. Kerr, M. Yu, S. Carrington, J.V. Fahy, San Francisco, CA, p.A6683

P375 **Efficacy Assessment of a Novel Disruptive IgE Inhibitor in Non-Human Primate and Human Precision-Cut Lung Slices/**J. Wichmann, S. Jimenez-Delgado, C. Curths, A. Schmitt, S. Dunker, D. Jonigk, P. Braubach, F.-J. Kaup, A. Braun, A. Eggel, F. Dahlmann, K. Sewald, S. Knauf, Gottingen, Germany, p.A6684

P376 **Western Environment/Lifestyles Reduce Cytokine Production Capacities in Most Toll-Like Receptor Pathways in Chinese Immigrants/**A. Saiganesh, B. Hales, S. Chen, E. Filipovska-Naumovska, G. Pareira, M. Garand, T. Kollmann, A. Currie, P. Le Souef, G. Zhang, Perth, Australia, p.A6685

P377 **Sensitization to Perennial Inhalant Allergens in Adolescents and Children in a Sub-Saharan Africa Country: Prevalence and Correlates/**A.D. Balkissou, E.W. Pefura-Yone, C.L. Mbele-Onana, A.P. Kengne, C. Kuaban, Yaounde, Cameroon, p.A6686

P378 **Association Between the CDHR3 rs6867330 Risk Allele and Chronic Rhinosinusitis/**E. Chang, A. Willis, J. Calton, C. Thompson, A. Chiu, F.D. Martinez, Tucson, AZ, p.A6687

P379 **Enhanced Thrombin Formation and Impaired Fibrinolysis in Persistent Asthma/**S. Bazan-Socha, L. Mastalerz, A. Cybulska, L. Zareba, R. Kremers, M. Zabczyk, G. Pulka, T. Iwaniec, C. Hemker, A. Undas, Krakow, Poland, p.A6688

P380 **Impact of Early Life Interferon Gamma Levels on Lung Development in Childhood: A Birth Cohort Analysis/**B. Shutes, D.A. Stern, A. Wright, W.J. Morgan, M. Halonen, Tucson, AZ, p.A6689

Facilitator: P. Akuthota, MD, La Jolla, CA

P381 **Low IgE and Eosinophils Allergic Asthma Is Characterized by Altered Levels of Circulating Apoptotic Endothelial Microparticles/**S.L. O'Beirne, M.R. Staudt, J. Salit, G. Wang, R.J. Kaner, H. Hilton, H. Bitter, S.G. Pillai, C.S. Stevenson, G. Wolff, S. Visvanathan, J.S. Fine, R.G. Crystal, New York, NY, p.A6690

P382 **Production of Human Monoclonal IgE from Patients with Allergic Bronchopulmonary Mycosis/**M.A. Wurth, D.J. Horvath, R.F. Brown, Y. Khan, S. Smith, Nashville, TN, p.A6691

P383 **Increased Mucosal Responses to Allergen in Obese Compared with Lean Asthmatics/**A.E. Dixon, M. Subramanian, K.E. Black, M. Van Der Vliet, V. Anathy, D.A. Kaminsky, M.E. Poynter, A. Van Der Vliet, Burlington, VT, p.A6692

P384 **The Receptor for Advanced Glycation End-Products Mediates VCAM-1 Expression in Pulmonary Endothelial Cells: Implications for Asthma and Allergic Airway Disease/**T.N. Perkins, E.A. Oczypok, G.E. Dutz, T.D. Oury, Pittsburgh, PA, p.A6693

P385 **The Effects of Infant Feeding Practices on Food Sensitization in a Canadian Birth Cohort/**M.M. Tran, W.H. Dai, D.L. Lefebvre, P. Subbarao, A.B. Becker, P.J. Mandhane, S.E. Turvey, W.-Y. Lou, M.R. Sears, Hamilton, Canada, p.A6694

P386 **Early-Life Farming Exposures and Adult Atopy: The Agricultural Lung Health Study/**J.S. House, A.B. Wyss, J.A. Hoppin, D.M. Umbach, S. London, Research Triangle Park, NC, p.A6695

P387 **Human IgE Plasma Cells in the Blood, Nasal Polyp, and the Bone Marrow Long Lived Plasma Cell Subset/**A. Corrado, C. Tipton, S. Wise, K.-Y.C. Chiang, E. Waller, I. Sanz, F.E.-H. Lee, Atlanta, GA, p.A6696

P388 **Expression of Arginase in Children with Allergic Bronchopulmonary Aspergillosis: Regulation of Nitric Oxide Synthesis/**N. Paul, M. Singh, J. Kaur, A. Chakrabarti, Chandigarh, India, p.A6697

P389 **Extracellular Signal-Regulated Kinase1/2 Signaling Pathway Regulates the Phenotype Transition of Human Bronchial Smooth Muscle Cells Passively Sensitized by Asthmatic Serum/**M. Xie, X. Liu, Y. Xu, Wuhan, China, p.A6698

Facilitator: S.F. Ma, PhD, Chicago, IL

P390 **Plasma von Willebrand Factor (VWF) Is Elevated in Asthmatic Patients with Metabolic Syndrome (MetS)/**M.W. Johansson, C.C. Chow, M.D. Evans, R. Sorkness, L.C. Denlinger, S. Fain, N.N. Jarjour, D.F. Mosher, M.L. Schiebler, Madison, WI, p.A6699

P391 **Is There a Mediation Effect of Systemic Inflammatory Mediators for Obesity Contributing to Poor Asthma Control?/**X. Zhang, J. Zheng, L. Zhang, H.P. Zhang, L. Wang, G. Wang, Chengdu, China, p.A6700

P392 **PIM2 Can Induce Asthma Pathogenesis Through IL-10/**W. Du, G. Shi, 200032, China, p.A6701

P393 **Galangin Attenuates Airway Remodeling by Inhibiting TGF-β1-Mediated ROS Generation and MAPK/Akt Phosphorylation in Asthma/**Y.-N. Liu, W.-J. Zha, X.-N. Zeng, M. Huang, Nanjing, Jiangsu, China, p.A6702

P394 **Oligomeric Proanthocyanidins Attenuates Airway Chronic Inflammation and Remodeling Via TGF-β1-ROS-MAPK Pathway/**X. Zeng, Y. Ma, H. Gu, M. Huang, Nanjing, Jiangsu, China, p.A6703

P395 **Phosphodiesterase III Plays a Crucial Role in the Pathophysiology of Asthma/**A. KleinJan, E. Koekoek, M. Lukkes, M. De Bruijn, M. Van Nimwegen, J. Beute, V. Manganiello, R. Hendriks, Rotterdam, Netherlands, p.A6704

P396 **Airway Exposure to Staphylococcus Aureus Particles Promotes Development of Antigen-Specific Th2-Type Immunity to Inhaled Antigens Through Production of Interleukin-1α(IL-1α)/**K. Hara, Z. Isobe, H. Masubuchi, M. Ueno, T. Maeno, T. Hisada, M. Kurabayashi, Maebashi,Gunma, Japan, p.A6705

P397 **Characterization of Airway Immune and Physiological Changes in Response to Inhalational Exposure in Non-Human Primates/**S.S. Killingbeck, S. Ott, M.Q. Ge, C.H. Flayer, L. Olsen, C. Jereb, K. Chun, L.A. Miller, A.A. Zeki, A. Haczku, Davis, CA, p.A6706

P398 **IL-17A Has a Synergistic Effect on Smooth Muscle Contaction with TNF-a/**M. Kudo, M. Masuda, Y. Moriyama, M. Yamamoto, T. Sato, M. Shinkai, T. Kaneko, D. Sheppard, Yokohama, Japan, p.A6707

Facilitator: A. Haczku, MD, PhD, Davis, CA

P399 **A Change in Frequency and Function of Regulatory T Cells in Asthmatic Patients/**T. Chen, J. Hao, Y. Ni, Y. Yu, W. Du, G. Shi, Shanghai, China, p.A6708

P400 **Characterization of Human Innate Lymphoid Cell Type 2 (ILC2) Responses to TSLP, IL-33 and IL-25/**C. Vissinga, M. Comeau, South San Francisco, CA, p.A6709

P401 **Development of A Novel Atmospheric Aerosol Simulate Permits Chronic Exposure to Atmospheric Secondary Organic Particulate Matter and Shows Dose Response Effect on Airway Responsiveness to Methacholine/**S. Salehi, J. Ye, A. Portelli, M. North, A. Chan, C.-W. Chow, Toronto, Canada, p.A6710

P402 **Chlorpyrifos-Induced Airway Hyperreactivity Is Mediated by Different Inflammatory Cells Dependent Upon Sensitization Status/**B. Proskocil, D. Bruun, P. Lein, D.B. Jacoby, A.D. Fryer, Portland, OR, p.A6711

P403 **Regulation of Immune Response by TSLP in Children with Atopic Diseases/**A. Chauhan, M. Singh, A. Agarwal, Chandigarh, India, p.A6712

P404 **Induction of Neutrophil Apoptosis by a Novel Monoclonal Antibody Against the Sialic Acid-Binding Immunoglobulin-Like Lectin 9 (Siglec-9)/**Z. Chen, F.-F. Bai, L. Han, J. Zhu, T. Zheng, Z. Zhu, L.-F. Zhou, Nanjing, China, p.A6713

P405 **Targeted Treatment Allergic Rhinitis with CpG Oligodeoxynucleotides Reduces Lower Airway Inflammation of Combined Allergic Rhinitis and Asthma Syndrome Via Down-Regulation Thymic Stromal Lymphopoietin/**H.-T. Li, Z.-G. Chen, H. Liu, J. Ye, X.-L. Zou, Y.-H. Wang, H.-L. Yang, P. Meng, T.-T. Zhang, Guangzhou, China, p.A6714

P406 **Effect of Neurotrophin-4 and Repulsive Guidance Molecule B on Phagocytosis of TiO2 Particles/**A. Fedulov, Y. Zhang, J. Barrios, X. Ai, Boston, MA, p.A6715

P407 **Role of Acetylcholine on Fibroblast-Driven Remodelling in Asthma/**F.L.M. Ricciardolo, I. Leone, V. Sorbello, M.P. Pieper, Orbassano (Turin), Italy, p.A6716

P408 **Interleukin-17 and Leptin Contribute to Airway Fibrosis and Altered Interleukin-13 Receptor Expression in Obese Asthma/**J.L. Ingram, M. Ghio, R.W. Sigmon, J. Wong, B. Theriot, A. Hegde, J.K.L. Walker, M. Kraft, Durham, NC, p.A7902

P409 **Novel Anti-βc Receptor Antibody Targets Multiple Effector Cell Populations in Human Nasal Polyps Transplanted into Immunodeficient Transgenic Human Interleukin-3 (IL-3)/Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Knock-in Mice/**C.M. Owczarek, M. Grimbaldeston, U. Dhagat, C. Panousis, G.M. Gauvreau, R. Sehmi, S.G. Smith, C. Brown, K.-H. Yip, H. Pant, G. Vairo, A. Lopez, A. Nash, M. Wilson, N. Wilson, Parkville, Australia, p.A7903

P410 **Specialized Proresolving Mediators (SPMs) Reduce Human B Cell IgE Production from Asthma Patients/**N. Kim, P.J. Sime, R.P. Phipps, Rochester, NY, p.A7904

THEMATIC POSTER SESSION

D32 PNEUMONIA

9:00 a.m. - 3:30 p.m. **MOSCONE CENTER**

Area D, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: L.J. Quinton, PhD, Boston, MA

P411 **Role of STAT2 Signaling in Influenza and Bacterial Super-Infection/**R. Gopal, B. Lee, K.J. McHugh, S. Mandalapu, M.E. Clay, K. Ramanan, J.F. Alcorn, Pittsburgh, PA, p.A6717

P412 **Interleukin 22 Controls Streptococcus Pneumoniae Extrapulmonary Dissemination by Signaling Through the Liver/**G. Trevejo-Nunez, K. Chen, J. Kolls, M. Zheng, Pittsburgh, PA, p.A6718

P413 **The Low Density Lipoprotein Receptor-Related Protein 1 Mediates Bacterial Phagocytosis in Alveolar Macrophages/**T.F. Olonisakin, M. Yu, M. Jessup, Z. Xiong, M. Hulver, C. St. Croix, S. Watkins, R. Shanks, P. Ray, J.S. Lee, Pittsburgh, PA, p.A6719

P414 **Pleiotropic Signaling of Type I Interferon (IFN) Receptor Is a Master Regulator of Host Susceptibility to Post-Influenza Bacterial Super-Infection/**A. Rynda-Apple, K.M. Shepardson, K. Larson, R. Morton, Bozeman, MT, p.A6720

P415 **Differential Cell Source and Regulation of IL-6 Family Cytokines during Pneumonia/**K.E. Traber, K. Hilliard, E. Allen, Y. Kim, E.M. Symer, M.R. Jones, J.P. Mizgerd, L.J. Quinton, Boston, MA, p.A6721

P416 **The Histone Deacetylase Inhibitor Trichostatin A Protects Mice Against Lethal Post-Influenza Pneumococcal Infection/**K. Yagi, M. Ishii, H. Namkoong, T. Asami, T. Asakura, S. Suzuki, H. Fujiwara, T. Nishimura, T. Kamo, S. Tasaka, N. Hasegawa, T. Betsuyaku, Tokyo, Japan, p.A6722

P417 **Methicillin-Resistant S. aureus (MRSA) Induced Pleural Mesothelial Barrier Dysfunction is Dependent on EphA2 Signaling/**K. Mohammed, T. Ganguly, S. Gehlot, V. Verma, W. Clapp, N. Nasreen, Gainesville, FL, p.A6723

P418 **Scavenger Receptor B-I Protects the Lung from Influenza Induced Inflammation/**K.M. Gowdy, M. McPeek, M.J. Yaeger, B. Luo, A. Malur, M.J. Thomassen, M.B. Fessler, Greenville, NC, p.A6724

P419 **CCR2 Promotes Increased Bacterial Burden Via IL-27 Upregulation Which Inhibits IL-17 Production in Post-Influenza Bacterial Pneumonia/**N. Nathani, A. Podsiad, B.H. Singer, N. Lukacs, T.J. Standiford, B.B. Moore, U. Bhan, Ann Arbor, MI, p.A6725

P420 **The Effect of Corticosteroids on Neutrophil Recruitment and Interferon-Gamma Production in the Lungs After S. Pneumoniae Pneumonia/**O.K. Giddings, J. Martin, J. Gomez, C.M. Doerschuk, Chapel Hill, NC, p.A6726

P421 **The Synthetic Antimicrobial Peptide WLBU2 Promotes Staphylococcus aureus Clearance in the Mouse Lung/**H. Rich, B. Deslouches, K.J. McHugh, R. Montelaro, K.M. Robinson, J.F. Alcorn, Pittsburgh, PA, p.A6727

P422 **GM-CSF Confers Protection from Severe Influenza Pneumonia through Accelerated Recovery of Lung Homeostasis/** E.S. Halstead, M. Davies, T.M. Umstead, W. Guo, S. Hu, L. Yang, R. Myers, T. Cooper, Z.C. Chroneos, Hershey, PA, p.A6728

Facilitator: M. Divangahi, PhD, Montreal, Canada

P423 **Autocrine Interleukin-10-Mediated Immune Modulation of CD11b+ Dendritic Cells in Mice with Persistent Cryptococcal Lung Infection/**S. Teitz-Tennenbaum, S. Vigliante, S. Levitz, M.A. Olszewski, J.J. Osterholzer, Ann Arbor, MI, p.A6729

P424 **Immunity Status of IPA Patients with Structural Lung Diseases in Chinese Adults/**S. Liang, F.J. Xu, 200433, China, p.A6730

P425 **Multiple Abnormal Gene Mutation Identified in Patients with H7N9 Influenza Pneumonia/**C. Chen, M. Wang, Z. Zhu, X. Lao, X. Fan, Y. Song, Shanghai, China, p.A6731

P426 **LPS-Activated Conditioned Medium from Human Mesenchymal Stromal Cells Ameliorates E.coli Induced Pneumonia in the Rat/**J. Devaney, S. Horie, J. Chao, S. Elliman, D. O'Toole, R. MacLoughlin, J.G. Laffey, Galway, Ireland, p.A6732

P427 **Glucocorticoids Treatment Induces B Lymphocytes Depletion in Hosts with Pneumocystis Pneumonia/**D. Wang, Y. Hu, K. Zhai, Z.-H. Tong, 100020, China, p.A6733

P428 **Severity of Bronchiolitis Associated with Atypical Pathogens in Hospitalized Infants in Georgia/**I. Chkhaidze, D. Zirakishvili, N. Barnabishvili, K. Gogvadze, Tbilisi, Georgia, p.A6734

P429 **The Clinical Value of Serum Albumin and Prealbumin Levels in Children with Lobar Pneumonia Caused by Mycoplasma Pneumonia/**S.L. Hua, X.J. Jiang, Putuo District, China, p.A6735

P430 **The Effects of Fluticasone Propionate on Growth of Stenotrophomonas Maltophilia and Klebsiella Pneumoniae/**S. Nariya, J. Durack, R. Singh, Y.J. Huang, Ann Arbor, MI, p.A6736

P431 **Possible Systemic Immune Paralysis in Patients Undergoing Aseptic, Limited Surgical Stress/**Y. Tamai, K. Uchida, Y. Kusakabe, K. Chang, S. Taketomi, H. Inui, S. Tanaka, Y. Yamada, Tokyo, Japan, p.A6737

P432 **The Protective Effect of N-Acetylcysteine on Streptococcus Pneumonia Model of Simulated Weightlessness Rats/**P. Wang, M.H. Li, Beijing, China, p.A6738

P433 **HSF1 Mediates Hypercapnia-Induced Immunosuppression in Murine Pseudomonas Pneumonia/**K.L. Gates, Z. Lu, M. Casalino Matsuda, A. Nair, G.S. Budinger, P.H. Sporn, Chicago, IL, p.A6739

THEMATIC POSTER SESSION

D33 ROLE OF OXIDATIVE STRESS IN INFLAMMATION

9:00 a.m. - 3:30 p.m. **MOSCONE CENTER**

Area D, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: Y. Fang, PhD, Chicago, IL

P437 **Evidence of Renal and Pulmonary Endothelial Dysfunction in Chronic Obstructive Pulmonary Disease (COPD)/**F. Polverino, M. Laucho-Contreras, V. Bijol, V. Pinto-Plata, M.J. Divo, M. Choi, L.M. Sholl, Y. Tesfaigzi, H. Petersen, B.R. Celli, C.A. Owen, Boston, MA, p.A6740

P438 **Neutrophil Activity Markers Are Reduced Following a High, Versus a Low, Fruit and Vegetable Diet, in Overweight and Obese Adults with Asthma/**M.E. Jensen, P.G. Gibson, M. Garg, L.G. Wood, New Lambton Heights, Australia, p.A6741

P439 **Oxidative Stress Is Associated with Airway Hyperresponsiveness Induced by Increased Osmolality in Patients with Asthma/**D. Naumov, E. Borodin, A. Prikhodko, J.M. Perelman, V. Kolosov, Blagoveshchensk, Russian Federation, p.A6742

P440 **Lipid Oxidation and Apoptotic Response Associated with ATP8B1 Deficiency in Lung Epithelial Cells/**A.J. Cooke, J. Fukumoto, T. Herrin, A. Rajan, L.C. Tan, N. Kolliputi, R.F. Lockey, Tampa, FL, p.A6743

P441 **Profiling the Effects of PI3K-Inhibitors on Ozone-Induced Airway Inflammation, Cytokine Secretion and Oxidative Stress/**M.A. Gil, S. Shah, D. Chen, A. Cabal, J. Katz, M. Cicmil, M. Salmon, H.-H. Lee, H. Houshyar, A. Bass, H. Yu, S. Alves, P. Gardiner, I. Knowles, R. McLeod, Boston, MA, p.A6744

P442 **Role of High Mobility Group Box 1 Protein in Respiratory Syncytial Virus Pathogenesis/**Y.M. Hosakote, A. Kurosky, Galveston, TX, p.A6745

Facilitator: M. Christofidou-Solomidou, PhD, Philadelphia, PA

P443 **GSTP Modulates NF-κB Activation and Pro-Inflammatory Responses in Lung Epithelial Cells/**Y. Janssen-Heininger, J.T. Jones, D.H. McMillan, X. Qian, K.G. Lahue, J. Van Der Velden, Burlington, VT, p.A6746

P444 **The Activity of Myeloperoxidase and Cytolysis of Bronchial Neutrophils in Asthmatics with Airway Hyperresponsiveness to Hyperosmolar Stimulus/**J.M. Perelman, A.B. Pirogov, A. Prikhodko, S.V. Zinovyev, E. Borodin, E. Afanas'eva, V. Kolosov, Blagoveshchensk, Russian Federation, p.A6747

P445 **Caffeic Acid Phenethyl Ester Attenuates Allergic Airway Inflammation and Remodeling by Inhibiting ROS Generation and MAPK/Akt Phosphorylation in Asthma/**Y. Ma, J.-X. Zhang, X.-N. Zeng, M. Huang, 210029, China, p.A6748

P446 **The Role of Mitochondrial Fusion in the Pathogenesis of Fungus-Induced Severe Asthma/**S.R. Kim, Y.C. Lee, H.J. Park, D.I. Kim, S.H. Kim, Jeonju, Korea, Republic of, p.A6749

P447 **Morphological Changes and Contact of Mitochondria with Endoplasmic Reticulum Contributes to Severe Bronchial Asthma/**Y.C. Lee, S.R. Kim, D.I. Kim, H.J. Park, Jeonju, Korea, Republic of, p.A6750

THEMATIC POSTER SESSION

D34 SARCOIDOSIS

9:00 a.m. - 3:30 p.m. **MOSCONE CENTER**

Area D, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: K.C. Patterson, MD, Philadelphia, PA

P451 **Circulating Fibrocytes as Biomarkers of End-Organ Fibrotic Complications in Sarcoidosis/**D. Gomez, A.R. Vranic, M. Burdick, B. Mehrad, Charlottesville, VA, p.A6751

P452 **The Role of CXCL9 and Monocytes in Sarcoidosis/**B.S. Benn, S.A. Sun, M.E. Ho, J. Ramstein, R. Su, S. Garudadri, N.R. Bhakta, L. Koth, San Francisco, CA, p.A6752

P453 **The Annexin A11 Genetic Variation is Associated with Pulmonary Fibrosis in African Americans with Sarcoidosis/**B.S. Sarmento, M. Mirsaeidi, W. Zhang, T. Abbasi, A. Hakim, D. Schraufnagel, N. Sweiss, J.G.N. Garcia, R.F. Machado, Miami, FL, p.A6753

P454 **Computational Systems Genetics Identifies Genetic Variants Contributing to Sarcoidosis Progression in African Americans/**N. Pouladi, K. Batai, H. Li, N.G. Casanova, T. Zhou, W. Zhang, T. Wang, I. Achour, R. Kittles, Y. Lussier, J.G.N. Garcia, Tucson, AZ, p.A6754

P455 **Evaluation of the Lower Airway Microbiome and Immunological Response in Rheumatoid Arthritis/**L. Segal, B.G. Wu, C. Ubeda, A. Artacho, R. Condos, W. Wikoff, A. Catrina, J. Scher, New York, NY, p.A6755

P456 **Exosomal MicroRNA for Detection of Cardiac Sarcoidosis/** E.D. Crouser, N. Hamzeh, P. Nana-Sinkam, L. Maier, M.W. Julian, M. Gillespie, E. Jackson, M. Rahman, K. Wang, Columbus, OH, p.A6756

Facilitator: R.W. Harper, MD, Sacramento, CA

P457 **Resolution of Propionibacterium Acnes-Induced Granulomatous Pulmonary Inflammation and Fibrosis in C57BL/6 Mice Despite Continued Antigen Exposure/** N. Fouladpour, M. Moyer, D. Nethery, J.R. Jarvela, J. Tomashefski, R.F. Silver, Cleveland, OH, p.A6757

P458 **BNP, 6MWD Test, DLCO% and the Severity of Sarcoidosis-Associated Pulmonary Hypertension/**A. Vu, H.R. Omar, R.P. Baughman, R.F. Machado, N. Sweiss, M. Mirsaeidi, Miami, FL, p.A6758

P459 **Gene Expression Profiling of African Americans with Fibrosing Pulmonary Sarcoidosis/**M.A. Pardinas Gutierrez, R.F. Machado, N. Sweiss, D. Schraufnagel, R.P. Baughman, M. Mirsaeidi, Miami, FL, p.A6759

P460 **Association of Neutrophil to Lymphocyte Ratio and Pulmonary Hypertension in Sarcoidosis Patients/**A.S. Calzadilla, H.R. Omar, E. Camporesi, N. Sweiss, R.P. Baughman, M. Mirsaeidi, Miami, FL, p.A6760

P461 **The Interleukine-10 and Interferon-γmRNA Expression of Peripheral Blood Mononuclear Cells in Patients with Sarcoidosis/**M. Ando, M. Yamasue, H. Yoshikawa, S. Toba, K. Umeki, S.-I. Nureki, J.-I. Kadota, Yufu-City, Japan, p.A6761

P462 **Increased PP2A Expression in Sarcoidosis CD4+ T-Cells May Reduce Proliferation and Induce Apoptosis/**J. Rotsinger, R. Wang, L. Celada, W. Drake, Nashville, TN, p.A6762

P463 **Prevalence of Autoimmune Diseases in Sarcoidosis - A Decade Analysis of National Hospital Discharge Survey/**S. Annangi, D. Tirumala Rao, S. Nutalapati, M. Henriques-Forsythe, E.L. Flenaugh, M.G. Foreman, G. Westney, Atlanta, GA, p.A7905

THEMATIC POSTER SESSION

D35 SEPSIS: INNATE IMMUNE MECHANISMS

9:00 a.m. - 3:30 p.m. **MOSCONE CENTER**

Area D, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: P.A. Verhoef, MD, PhD, Chicago, IL

P466 **Peritoneal CD49d+CD4+ T Cells Have a Role of Early Sepsis Development in an Intra-Abdominal Polymicrobial Sepsis Mice Model/**K.W. Seo, J. Kim, U.J. Moon, Y.J. Jegal, S.S. Yang, J.B. Jeon, B.J. Kang, T.-H. Lee, S.W. Ra, J.-J. Ahn, H.R. Cho, B. Kwon, Ulsan, Korea, Republic of, p.A6763

P467 **Bacterial Lipopeptides and Heat-Killed Staphylococcus Aureus Modulate Lung Vascular Endothelial Permeability Through Toll-like Receptor 2/**J. Hellman, F. Xu, San Francisco, CA, p.A6764

P468 **Mesenchymal Stem Cells Decrease CD14++CD16+ Monocytes of Sepsis Patients Via Prostaglandin E2/**G. Qiu, L. Huang, G. Zheng, M. Ge, D. Lai, Q. Shu, J. Xu, Hangzhou, China, p.A6765

P469 **Use of Radiolabelled Autologous Neutrophils to Establish the Early Bio-Distribution of Neutrophils in COPD and Healthy Volunteers Following Lipopolysaccharide Challenge/**N.C. Tregay, N. Farahi, R. Simmonds, C. Loutsios, D. Gillett, I. Cullum, D. Carroll, K. McGlashan, L. Griffiths, S. Madhavan, M. Begg, A. Cahn, E. Hessell, K. Povey, C. Solanki, J. Buscombe, A.M. Peters, E.R. Chilvers, Cambridge, United Kingdom, p.A6766

P470 **Platelets Are Recruited to Lipopolysaccharide-Challenged Lungs of Neutrophil Replete and Depleted Mice/**S.J. Cleary, C. Hobbs, C.P. Page, S.C. Pitchford, London, United Kingdom, p.A6767

P471 **Evaluation of Lecithinized Superoxide Dismutase as a Drug for Acute Respiratory Distress Syndrome/**K.-I. Tanaka, T. Mizushima, Tokyo, Japan, p.A6768

P472 **Immunological Mechanism of Lung Inflammation by Lipopolysaccharide (LPS)/**M. Takeuchi, A. Kawazoe, M. Takasaki, N. Miwa, Y. Tanaka, K.E. Pinkerton, Kyoto, Japan, p.A6769

P473 **Hepatic NF-κB RelA Limits Systemic Consequences of Pneumonia, Sepsis, or NKT Cell Activation/**Y. Kim, K.L. Hilliard, E. Allen, K.E. Traber, E.M. Symer, M.R. Jones, J.P. Mizgerd, L.J. Quinton, Boston, MA, p.A6770

THEMATIC POSTER SESSION

D36 COPD: LABA, LAMA, ICS, AND COMBINATIONS

9:00 a.m. - 3:30 p.m. **MOSCONE CENTER**

Area A, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: A. Anzueto, MD, San Antonio, TX

P1 **Reduction in Clinically Important Deterioration in Chronic Obstructive Pulmonary Disease in Patients Treated with Aclidinium/Formoterol Combination/**D. Singh, A. DUrzo, F. Chuecos, A. Munoz, E. Garcia Gil, Manchester, United Kingdom, p.A6771

P2 **Comparison of Extrafine Beclometasone Dipropionate/Formoterol Fumarate (BDP/FF) Versus Other Double Combinations on Reduction of Moderate/Severe Exacerbations/**D. Singh, A. Bizzi, M. Spinola, S. Petruzzelli, A. Papi, Manchester, United Kingdom, p.A6772

P3 **Efficacy of Aclidinium/Formoterol on Bronchodilation and Symptoms in Symptomatic and Asymptomatic Patients with COPD: Pooled Analysis of Two Phase III Studies/**M. Miravitlles, K.R. Chapman, F. Chuecos, A. Ribera, E. Garcia Gil, Barcelona, Spain, p.A6773

P4 **Efficacy of Inhaled Glycopyrrolate for Moderate-to-Severe COPD: A Subgroup Analysis by Gender from the Pooled GEM1 and GEM2 Studies/**D.A. Mahler, A. Satti, S. Spangenthal, A. Yadao, P. D'Andrea, A. Uddin, B. Franke-Bray, Hanover, NH, p.A6774

P5 **Effect of Glycopyrrolate on Lung Function, Health Status and Dyspnea in Age Subgroups: A Pooled Analysis from the GEM1 and GEM2 Studies/**D.A. Mahler, E. Kerwin, A.H. Gifford, A. Yadao, P. D'Andrea, A. Uddin, B. Franke Bray, Hanover, NH, p.A6775

P6 **Indacaterol/Glycopyrrolate Improves Dyspnea in US Patients with Moderate-to-Severe COPD: A Subgroup Analysis of the Pooled FLIGHT1 and FLIGHT2 Studies/**D.A. Mahler, S. Maitra, R. Fogel, D. Banerji, Hanover, NH, p.A6776

P7 **Indacaterol/Glycopyrrolate Improves Health Related Quality of Life in US Patients with COPD: A Subgroup Analysis from the Pooled FLIGHT1 and FLIGHT2 Studies/**D.A. Mahler, T. Ayers, F. Patalano, S. Maitra, D. Banerji, Hanover, NH, p.A6777

P8 **1-Year Follow-Up of COPD Patients After Withdrawal of Inhaled Corticosteroid Maintenance Therapy: A Subgroup Analysis of the DACCORD Study/**R. Buhl, C.-P. Criee, P. Kardos, C. Vogelmeier, C. Mailaender, N. Lossi, H. Worth, Mainz, Germany, p.A6778

P9 **Benefits of Tiotropium + Olodaterol Over Tiotropium at Delaying Clinically Significant Events in Patients with COPD Classified as GOLD B/**R. Buhl, L. McGarvey, S. Korn, G.T. Ferguson, L. Gronke, C. Hallmann, F. Vob, K.F. Rabe, F. Maltais, Mainz, Germany, p.A6779

P10 **Treatment Persistence in a German Real-Life COPD Cohort (DACCORD)**/C.-P. Criee, R. Buhl, P. Kardos, C. Vogelmeier, C. Mailaender, N. Lossi, H. Worth, Bovenden, Germany, p.A6780

P11 **Gender Differences in Baseline Characteristics of Patients with COPD: A Pooled Analysis of Pivotal Trials of Indacaterol/Glycopyrronium from the IGNITE Program**/S. Fucile, I. Tsiligianni, K. Mezzi, K. Kostikas, R. Fogel, East Hanover, NJ, p.A6781

P12 **Pooled Analyses from PINNACLE-1 and -2: The Novel LAMA/LABA Co-Suspension Technology Glycopyrrolate/Formoterol Fixed-Dose Combination Delivered by MDI Shows Improvement Versus Monocomponents in Patients with COPD**/F.J. Martinez, K.F. Rabe, R. Rodriguez-Roisin, L.M. Fabbri, G.T. Ferguson, P.W. Jones, S.I. Rennard, S. Siddiqui, C. Orevillo, P. Darken, C. Reisner, New York, NY, p.A6782

P13 **Cardiovascular Safety Profile of a Novel LAMA/LABA Co-Suspension Technology Fixed-Dose Combination of Glycopyrrolate/Formoterol Delivered by Metered Dose Inhaler in Patients with COPD: 24-Hour Holter Monitoring Study**/F.J. Martinez, L.M. Fabbri, S.I. Rennard, S. Sethi, G. Gottschlich, S. Arora, P. Darken, C. Orevillo, S. Siddiqui, C. Reisner, New York, NY, p.A6783

P14 **The Novel LAMA/LABA Co-Suspension Technology of Glycopyrrolate/Formoterol Fixed-Dose Combination MDI Significantly Improves Health Status in Symptomatic Patients with COPD**/F.J. Martinez, L.M. Fabbri, G.T. Ferguson, C. Orevillo, P. Darken, C. Reisner, New York, NY, p.A6784

Facilitator: S.C. Lazarus, MD, San Francisco, CA

P15 **Beneficial Effect of the Novel LAMA/LABA Co-Suspension Technology of Glycopyrrolate/Formoterol Fixed-Dose Combination Delivered by MDI in GOLD A and B COPD Patients: Pooled Analyses from PINNACLE-1 and -2**/F.J. Martinez, K.F. Rabe, R. Rodriguez-Roisin, L.M. Fabbri, G.T. Ferguson, P.W. Jones, S.I. Rennard, S. Siddiqui, C. Orevillo, P. Darken, C. Reisner, New York, NY, p.A6785

P16 **Impact of Vilanterol, Fluticasone Furoate, or Their Combination on Exacerbations in COPD Patients with Moderate Airflow Obstruction: The SUMMIT Trial**/F.J. Martinez, J. Anderson, R. Brook, B. Celli, C. Crim, S. Kilbride, D. Newby, J. Vestbo, J. Yates, P. Calverley, New York, NY, p.A6786

P17 **Effects of Symptom Severity at Baseline on Lung-Function and SGRQ Responses in the OTEMTOr Studies**/F.J. Martinez, R. Abrahams, G.T. Ferguson, L. Bjermer, L. Gronke, F. Vob, D. Singh, New York, NY, p.A6787

P18 **Long-Term Safety and Tolerability of Indacaterol/Glycopyrrolate in Moderate-to-Severe COPD Patients from the US: A Subgroup Analysis from the FLIGHT3 Study**/G.T. Ferguson, A.A. Schubert-Tennigkeit, C. Thach, D. Banerji, Farmington Hills, MI, p.A6788

P19 **Benefits of Tiotropium + Olodaterol on Symptoms and Health-Related Quality of Life in Patients with Moderate to Severe COPD with Chronic Bronchitis and/or Emphysema**/G.T. Ferguson, R. Abrahams, L. Bjermer, L. Gronke, F. Vob, D. Singh, Farmington Hills, MI, p.A6789

P20 **Pooled Analyses from PINNACLE-1 and -2: Safety Profile of the Novel LAMA/LABA Co-Suspension Technology Fixed-Dose Combination (Glycopyrrolate/Formoterol) Delivered by MDI, in Patients with Chronic Obstructive Pulmonary Disease (COPD)**/G.T. Ferguson, K.F. Rabe, F.J. Martinez, R. Rodriguez-Roisin, L.M. Fabbri, P.W. Jones, S.I. Rennard, S. Siddiqui, C. Orevillo, P. Darken, C. Reisner, Farmington Hills, MI, p.A6790

P21 **Safety and Efficacy of a Novel LAMA/LABA Co-Suspension Technology Glycopyrrolate/Formoterol Fixed-Dose Combination Delivered by MDI: Results of a One-Year Extension Study in Patients with COPD (PINNACLE-3)**/N.A. Hanania, D.P. Tashkin, E. Kerwin, J. Donohue, M. Denenberg, D. O'Donnell, D. Quinn, S. Siddiqui, C. Orevillo, A. Maes, C. Reisner, Houston, TX, p.A6791

P22 **24-Hour Lung Function Following the Novel LAMA/LABA Co-Suspension Technology of Glycopyrrolate/Formoterol Fixed-Dose Combination MDI, in Patients with Moderate-to-Very-Severe COPD**/S. Arora, L. Delacruz, G. Feldman, K. Pudi, S. Siddiqui, C. Orevillo, A. Maes, C. Reisner, Columbus, OH, p.A6792

P23 **Safety of Inhaled Glycopyrrolate in Patients with Moderate-to-Severe COPD: Subgroup Analysis from the Pooled Data of Four Clinical Trials**/P. D'Andrea, C. LaForce, A. Pedinoff, S.D. Miller, A. Yadao, A. Uddin, B. Franke-Bray, East Hanover, NJ, p.A6793

P24 **Cardiovascular Safety of Twice-Daily Inhaled Glycopyrrolate in Subgroups of Patients with Moderate-to-Severe COPD: Pooled Analysis from the GEM1, GEM2, FLIGHT1 and FLIGHT2 Studies**/E. Kerwin, C. LaForce, A. Pedinoff, A. Yadao, P. D'Andrea, A. Uddin, B. Franke-Bray, Medford, OR, p.A6794

P25 **Improvement in Lung Function with Indacaterol/Glycopyrrolate (IND/GLY) in Patients with Moderate to Severe COPD from the US: A Subgroup Analysis from the FLIGHT1 and FLIGHT2 Studies**/E. Kerwin, D.A. Mahler, A. FowlerTaylor, S. Maitra, D. Banerji, Medford, OR, p.A6795

P26 **Safety of Indacaterol/Glycopyrrolate Versus Its Monocomponents and Placebo in US Patients with Moderate-to-Severe COPD: A Subgroup Analysis from the FLIGHT1 and FLIGHT2**/E. Kerwin, A. FowlerTaylor, C. Thach, M. Larbig, D. Banerji, Medford, OR, p.A6796

P27 **UMEC/VI as Step-Up Therapy from Tiotropium in Moderate Symptomatic COPD: a Randomized, 12-Week Study**/E. Kerwin, C.J. Kalberg, D. Galkin, C.-Q. Zhu, A. Church, W. Fahy, Medford, OR, p.A6797

Facilitator: V. Kim, MD, Philadelphia, PA

P28 **Efficacy and Safety of Indacaterol/Glycopyrrolate in the US Versus non-US Population: Comparison of Clinical Data from a Pooled Analysis of FLIGHT1 and FLIGHT2**/D. Banerji, A. FowlerTaylor, C. Thach, F. Patalano, East Honover, NJ, p.A6798

P29 **Efficacy and Safety of Indacaterol/Glycopyrrolate Versus Its Monocomponents and Placebo in Symptomatic Patients (GOLD B and GOLD D) with COPD: FLIGHT1/FLIGHT2 Pooled Analysis in the US Subgroup/**T. Ayers, S. Maitra, M. Larbig, D. Banerji, East Hanover, NJ, p.A6799

P30 **Indacaterol/Glycopyrrolate Improves Lung Function, Dyspnea and Health Status in Symptomatic Patients with COPD Using Prior LAMA, LABA or LABA/ICS: Post-Hoc Analysis from Pooled FLIGHT1 and FLIGHT2 Studies/**T. Ayers, S. Maitra, R. Fogel, D. Banerji, East Hanover, NJ, p.A6800

P31 **Indacaterol/Glycopyrrolate Significantly Improves COPD Assessment Test (CAT) Scores in US Patients with Moderate-to-Severe COPD: Subgroup Analysis from Pooled FLIGHT1 and FLIGHT2 Studies/**R. Fogel, S. Maitra, F. Patalano, D. Banerji, East Hanover, NJ, p.A6801

P32 **Impact of a Long-Acting Beta Agonist and an Inhaled Corticosteroid in COPD Patients with Moderate Airflow Obstruction and CV Disease or Risk: A Factorial Analysis of the SUMMIT Trial/**P.M.A. Calverley, J.A. Anderson, R.D. Brook, C. Crim, S. Kilbride, F.J. Martinez, D.E. Newby, J. Vestbo, J.C. Yates, B. Celli, Liverpool, United Kingdom, p.A6802

P33 **Using Different Sets of Patient-Relevant Outcomes in Chronic Obstructive Pulmonary Disease to Evaluate Efficacy of Tiotropium Respimatr - a Post-Hoc Analysis/**R. Dahl, A. Anzueto, N. Metzdorf, A. Mueller, P.M. Calverley, Odense C., Denmark, p.A6803

P34 **Efficacy and Safety of Tiotropium + Olodaterol in Patients with COPD by ATS Category/**F. Maltais, E. Pizzichini, L. Gronke, F. Vob, E. Derom, Quebec, Canada, p.A6804

P35 **Effect of Tiotropium + Olodaterol Therapy on COPD Exacerbations in the TONADOr Studies/**E. Derom, M. Flezar, L. Gronke, F. Vob, R. Buhl, Ghent, Belgium, p.A6805

P36 **Tiotropium + Olodaterol Therapy Provides Lung-Function Benefits Over Salmeterol + Fluticasone Propionate Irrespective of Prior ICS Treatment: Post Hoc Analyses of the ENERGITOr Study/**E. Derom, E. Clerisme-Beaty, L. Gronke, F. Voss, D. Zhai, L. Bjermer, Gent, Belgium, p.A6806

P37 **Analysis of Rescue Medication Use Over 1 Year in Patients Receiving LAMA, LABA, or Combination Maintenance Treatment for COPD in the TONADOr Studies/**C.B. Cooper, R. Abrahams, G.T. Ferguson, E. Clerisme-Beaty, F. Vob, R. Buhl, Los Angeles, CA, p.A6807

P38 **Lung-Function Response to Tiotropium + Olodaterol in Patients with COPD with β-Agonist Reversibility/**D.P. Tashkin, G.T. Ferguson, E. Clerisme-Beaty, F. Vob, R. Buhl, Los Angeles, CA, p.A6808

P39 **Tiotropium + Olodaterol Therapy Provides Symptomatic Benefits Irrespective of Prior Maintenance Treatment: Post Hoc Analyses of the OTEMTOr Studies/**R. Abrahams, G.T. Ferguson, L. Bjermer, L. Gronke, F. Vob, D. Singh, Morgantown, WV, p.A6809

P40 **Treatment with Tiotropium Plus Olodaterol Respimat Improves Physical Functioning of COPD Patients in a Real Life Setting/**M. Haensel, T. Glaab, R. Sauer, R. Rubin, R. Buhl, Ingelheim am Rhein, Germany, p.A6810

Facilitator: C.B. Cooper, MD, Los Angeles, CA

P41 **Inhaler Errors After Reading the Patient Information Leaflet in Patients with COPD: A Comparison of Elliptar with Five Inhaler Devices/**J. Van Der Palen, M. Thomas, H. Chrystyn, R. Sharma, V. Imber, C.-Q. Zhu, N. Barnes, Enschede, Netherlands, p.A6811

P42 **Training and Time to Achieve Correct Inhaler Use: A Comparison Between Inhalers in Patients with COPD/**J. Van Der Palen, M. Thomas, H. Chrystyn, R. Sharma, V. Imber, C.-Q. Zhu, H. Svedsater, Enschede, Netherlands, p.A6812

P43 **Inhaler Preference in Patients with COPD: A Comparison of Elliptar with Five Inhaler Devices/**J. Van Der Palen, M. Thomas, H. Chrystyn, R. Sharma, H. Svedsater, C.-Q. Zhu, N. Barnes, Enschede, Netherlands, p.A6813

P44 **Benefits of Tiotropium Versus Placebo for Delaying Clinically Significant Events in Patients with Moderate COPD (GOLD 2)/**K. Rabe, N. Metzdorf, F. Vob, C. Hallmann, L. Gronke, D. Tashkin, Grosshansdorf, Germany, p.A6814

P45 **Comparative Efficacy of Umeclidinium Versus Other Long-Acting Muscarinic Antagonist in Combination with ICS/LABA/**V. Chounta, E. Huisman, A.S. Ismaila, A. Karabis, Y.S. Punekar, Brentford, United Kingdom, p.A6815

P46 **Treatment Satisfaction and Preference with Indacaterol/Glycopyrronium Fixed-Dose Combination Therapy in Comparison to Tiotropium Monotherapy - Results of the FAVOR Study/**P. Kardos, I. Hagedorn, Frankfurt, Germany, p.A6816

P47 **Improvement in Lung Function and Symptom Control with Aclidinium Bromide Versus Tiotropium and Placebo in Symptomatic Patients with COPD: Post-Hoc Analysis of a Phase IIIb Study/**J. Beier, R. Mroz, A.-M. Kirsten, F. Chuecos, E. Garcia Gil, Wiesbaden, Germany, p.A6817

P48 **Improvement in Symptom Severity and Quality of Life in Patients with COPD Treated with Aclidinium Bromide: Results of a Non-Interventional Study/**J. Beier, T. Plate, A. Prechtl, Wiesbaden, Germany, p.A6818

P49 **Risk of Pneumonia with Budesonide-Containing Treatments in COPD: An Individual Patient-Level Pooled Analysis of Interventional Studies/**C. Jorup, S. Hollis, D. Lythgoe, G. Martensson, P. Regnell, G. Eckerwall, Molndal, Sweden, p.A6819

P50 **The Effect of Aclidinium Bromide 400 µg on Lung Function, Sleep Quality and Physical Activity in Patients with Chronic Obstructive Pulmonary Disease: Results of a Phase IV Pilot Study/**H. Magnussen, M. Arzt, S. Andreas, T. Plate, A. Ribera, B. Seoane, H. Watz, A.-M. Kirsten, Grosshansdorf, Germany, p.A6820

P51 **Should Inhaled Corticosteroids Be Considered in Group A and B COPD Patients with Marked Post-Bronchodilator Reversibility of FEV1/**J. Balachandran, 691009, India, p.A6821

P52 **Assessing Treatment Success with Tiotropium Respimatr by Combining Responder Rates of Different Patient-Relevant Outcomes - a Post-Hoc Analysis/**A. Anzueto, P.M. Calverley, N. Metzdorf, A. Mueller, R. Dahl, San Antonio, TX, p.A6822

P53 **24-Hour Lung Function Profile of Novel Co-Suspension Technology Glycopyrrolate/Formoterol Metered Dose Inhaler Versus Placebo and Spirivar Respimatr, in Patients with Moderate-To-Very-Severe Chronic Obstructive Pulmonary Disease/**C. Reisner, G. Gottschlich, F. Fakih, A. Koser, J. Krainson, L. Delacruz, S. Arora, G. Feldman, K. Pudi, S. Siddiqui, C. Orevillo, A. Maes, Morristown, NJ, p.A6823

Facilitator: N.R. Bhakta, MD, PhD, San Francisco, CA

P54 **A Novel Biophysical Model to Investigate Regional and Total Lung Delivery of QVA149 (IND/GLY) Delivered Via the Neohalerr Device/**A. Kuttler, T. Dimke, Basel, Switzerland, p.A6824

P55 **Comparative Efficacy of Umeclidinium with Other Once-Daily Long-Acting Muscarinic Antagonists in Moderate-to-Severe Chronic Obstructive Pulmonary Disease/**I. Naya, P. Shah, M. Vahdati-Bolouri, W. Fahy, Uxbridge, United Kingdom, p.A6825

P56 **The Effect of Indacaterol/ Glycopyrronium on Lung Function and Physical Activity in More Severe COPD - A Posthoc Subgroup Analysis of the MOVE Study/**H. Watz, C. Mailaender, A.-M. Kirsten, Grosshansdorf, Germany, p.A6826

P57 **Pharmacokinetic and Safety Profile of a Novel Co-Suspension Technology Fixed-Dose Combination of Budesonide/Glycopyrrolate/Formoterol Delivered by Metered Dose Inhaler in Healthy Adult Subjects/**C. Orevillo, J. Miller, P. DePetrillo, S. Siddiqui, S. Ballal, C. Reisner, Morristown, NJ, p.A6827

P58 **Pharmacokinetic and Safety Profile of the Novel LAMA/LABA Co-Suspension Technology Glycopyrrolate/Formoterol Fumarate Fixed-Dose Combination MDI, in Japanese Healthy Subjects/**C. Orevillo, J. Miller, P. DePetrillo, A. Maes, S. Siddiqui, C. Reisner, Morristown, NJ, p.A6828

P59 **Effect of Organic Cation Transport Inhibition on the Pharmacokinetics of Glycopyrronium Bromide in Fixed Combination with Beclomethasone Dipropionate and Formoterol Fumarate/**D. Cuomo, F. Mariotti, G. Ciurlia, L. Spaccapelo, M. Scuri, A. Muraro, D. Acerbi, Parma, Italy, p.A6829

P60 **Pharmacokinetics of a Novel Triple Fixed Dose Combination Metered Dose Inhaler: Comparison with the Free Combination and the Single Components/**D. Cuomo, F. Mariotti, S. Collarini, A. Muraro, D. Acerbi, Parma, Italy, p.A6830

P61 **Umeclidinium Dose-Response in Patients with Fixed Airflow Obstruction and Reversibility to Albuterol Irrespective of a Primary Diagnosis of Asthma or COPD/**L. Lee, E. Kerwin, K. Collison, W. Wu, S. Yang, S. Pascoe, Stevenage, United Kingdom, p.A6831

P62 **Comparative Assessment of Umeclidinium/Vilanterol (UMEC/VI) Combination Therapy Among Symptomatic Patients with COPD/**E. Huisman, A. Ismaila, I. Naya, A. Karabis, Y.S. Punekar, Houten, Netherlands, p.A6832

P63 **Health-Related Quality of Life Among Patients Who Experienced Prior COPD-Related Exacerbations: Post Hoc Analysis of a 52-Week Randomized Placebo-Controlled Trial of Nebulized Arformoterol Tartrate/**J. Donohue, V. Ganapathy, L. Nelson, X. Zhou, Chapel Hill, NC, p.A6833

P64 **Tudorza PRESSAIRr Patient Satisfaction and Preference Study/**J.R. Davis, R.S. Epstein, M. Leone-Perkins, S. Dixit, K.M. Fox, F. Trudo, Willmington, DE, p.A6834

P65 **Impact of Adherence to ICS/LABA Therapy on the Rate of COPD Exacerbations/**J.R. Davis, F. Trudo, B. Wu, O. Tunceli, J. Horton, D.M. Kern, K.M. Fox, Wilmington, DE, p.A6835

P66 **SURF-COPD: The Recording of Cardiovascular Risk in Patients With Chronic Lung Disease/**A. Dudina, S. Lane, M. Butler, M.-T. Cooney, I. Graham, Dublin, Ireland, p.A6836

P67 **COPD Symptom Based Management and Optimize Treatment Strategy in Japan (The COSMOS-J Trial)/**P.W. Jones, M. Kato, K. Fujimoto, A. Kobayashi, T. Hayamizu, H. Hitosugi, M. James, G. Hagan, T. Betsuyaku, Brentford, United Kingdom, p.A7906

P68 **A Randomized Trial of Once-Daily Fluticasone Furoate/Vilanterol 100/25 Versus Vilanterol 25 to Evaluate the Contribution on Lung Function of Fluticasone Furoate in the Combination in Subjects with COPD/**T. Siler, A. Nagai, C.A. Scott-Wilson, D.A. Midwinter, C. Crim, St Charles, MO, p.A7907

THEMATIC POSTER SESSION

D37 COPD: DEVELOPMENTAL THERAPEUTICS

9:00 a.m. - 3:30 p.m. **MOSCONE CENTER**

Area A, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: R.C. Balkissoon, MD, Denver, CO

P70 **Assessment of the Effect of Pulsed Inhaled Nitric Oxide in COPD Patients with Pulmonary Hypertension using Functional Respiratory Imaging (FRI)/**F. Ferreira, B. Hajian, W. Vos, J. De Backer, C. Van Holsbeke, L. Nuyttens, D. Quinn, W. De Backer, Kontich, Belgium, p.A6837

P71 **A Phase I, Randomised, Double Blind, Placebo Controlled, Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Inhaled Doses of RPL554 Administered by Nebuliser to Healthy Male Subjects and Stable COPD Patients/**D. Singh, K.H. Abbott-Banner, F. Reid, K. Newman, Manchester, United Kingdom, p.A6838

P72 **A Phase I, Randomised, Double Blind, Placebo Controlled, Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Inhaled Doses of the Dual Phosphodiesterase 3/4 (PDE3/4) Inhibitor RPL554 Administered by Nebuliser to Healthy Male Subjects/**D. Singh, K.H. Abbott-Banner, F. Reid, K. Newman, Manchester, United Kingdom, p.A6839

P73 **Inhibition of Soluble Epoxide Hydrolase Does Not Augment Hypoxic Pulmonary Vasoconstriction in Healthy Subjects/**A. Lazaar, A. Baines, M. Ahmed, R. Boardley, A. Hussaini, King of Prussia, PA, p.A6840

P74 **Narrow Spectrum Kinase Inhibitors: The Efficacy of a Novel Class of Inhaled Anti-Inflammatory Molecules in Chronic Obstructive Pulmonary Disease (COPD) Patients/**P. Russell, C. Charron, C. Robinson, K. Xia, T. Kosoglou, L. O'Dowd, L. Cass, G. Dines, A. Brindley, C. Stevenson, London, United Kingdom, p.A6841

P75 **Safety and Efficacy of AQX-1125 in Chronic Obstructive Pulmonary Disease (COPD) - Results of the Phase 2 Flagship Study/**D. Scholl, J. Vestbo, P. Tam, L. Mackenzie, C. Harwig, J. Toews, S. Shrewsbury, Vancouver, Canada, p.A6842

P76 **A 12 Week, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy of RV568 (JNJ49095397), a Narrow Spectrum Kinase Inhibitor, in COPD Patients/**C. Robinson, K. Xia, P. Russell, C. Stevenson, M. Loza, T. Kosoglou, A. Brindley, F. Baribaud, P. Silkoff, E. Barnathan, L. O'Dowd, G. Dines, Spring House, PA, p.A6843

Facilitator: S.A. Christenson, MD, San Francisco, CA

P77 **A Novel COPD Exacerbation Trial Design/**M. Fageras, B.J. Make, N. Patel, P.M. Calverley, Molndal, Sweden, p.A6844

P78 **Safety, Tolerability and Pharmacokinetic Profile of CHF6001, a Novel Selective Inhaled PDE4 Inhibitor, in Healthy Volunteers/**M.-A. Nandeuil, F. Mariotti, G. Lucci, D. Santoro, G. Poli, D. Acerbi, Courbevoie Cedex, France, p.A6845

P79 **Genes or Dose, East or West What Makes N Acetyl Cysteine Work? Meta-Analysis of NAC Low Dose Vs High Dose Comparing Trials Done in Asian Population Vs European Population /**S.U. Rehman, T. Vacek, A. Ali, Y. Alahwal, N.S. Khan, A. Kubbara, N. Kozodoi, A. Flora, S. Khudder, J. Hammersely, D. Olson, Toledo, OH, p.A6846

P80 **Too Much or Not Enough? Natural Products for Chronic Obstructive Pulmonary Disease (COPD) and Asthma/**J. Shergis, L. Wu, A. Zhang, X. Guo, C. Lu, C. Xue, Bundoora, Australia, p.A6847

P81 **Effects of Carbocysteine Lysine Salt in Patients with COPD/**D. Lacedonia, G. Patricelli, G.E. Carpagnano, M.P. Foschino Barbaro, Foggia, Italy, p.A6848

P82 **Frequency of Exacerbations in Chronic Obstructive Pulmonary Disease: The Efficacy of Carbocysteine Lysine Salt with or Without Inhaled Steroids/**G. Paone, L. Lanata, F. Saibene, R. Delli Colli, B. Moscatelli, G. Puglisi, Rome, Italy, p.A6849

THEMATIC POSTER SESSION

D38 COPD: PHYSIOLOGIC EVALUATION

9:00 a.m. - 3:30 p.m. **MOSCONE CENTER**

Area A, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: F.C. Sciurba, MD, Pittsburgh, PA

P84 **A Comparison Between the Metronome-Paced Tachypnea Test and Cardiopulmonary Exercise Testing in Detecting Dynamic Hyperinflation in an Average COPD Population/**E. Vis, A. Hoekstra - Kuik, N. Veeger, A. Ten Brinke, J. Van Der Maten, Leeuwarden, Netherlands, p.A6850

P85 **Second Order Transfer Function of Specific Resistance Loops to Detect Presence of COPD/**M. Topalovic, R. Zonanashvili, V. Exadaktylos, D. Berckmans, J.-M. Aerts, T. Troosters, W. Janssens, Leuven, Belgium, p.A6851

P86 **The Effect of Lung Cancer Resection on Chest Wall Mechanics of COPD Patients/**G. Elshafie, A. Aliverti, P. Kumar, R. Steyn, M. Kalkat, E. Bishay, P. Rajesh, B. Naidu, Birmingham, United Kingdom, p.A6852

P87 **The Inverse Relationship Between Volume and Expiratory Flow Identifies Chronic Obstructive Pulmonary Disease/**A. Oh, T.A. Morris, I.T. Yoshii, T. Morris, San Diego, CA, p.A6853

P88 **Oscillometry Small Airways Phenotypes Are Predictive of GOLD Classification, Lung Function and Emphysema but Not Chronic Bronchitis in Community Practice COPD/**R.J. Dandurand, M. Dandurand, R.S.J. Estepar, J. Bourbeau, D.H. Eidelman, Montreal, Canada, p.A6854

P89 **Residual Volume Responsiveness to Bronchodilators Over Time/**C. Sutton, C. McCartney, S.K. Patolia, S. Naydenov, R. Nayak, St. Louis, MO, p.A6855

P90 **Daily Peak Expiratory Flow Rate Measured at Home Reflects Laboratory Measurement of Peak Expiratory Flow Rate in Chronic Obstructive Pulmonary Disease (COPD)/**R.N. Criner, K.M. Criner, A.J. Criner, N. Marchetti, F. Jaffe, M.J. Markus, S.L. Krachman, A. Rastogi, H.S. Smith, G.J. Criner, Philadelphia, PA, p.A6856

P91 **Influenza Vaccination in COPD Patients - No Detectable Changes in Lung Function, Systemic or Airway Inflammatory Markers/**G.C. Donaldson, B. Kowlessar, R. Sapsford, A.R.C. Patel, A.J. Mackay, R. Singh, J.A. Wedzicha, United Kingdom, p.A6857

P92 **Effects of Age, Gender, Race, and Degree of Baseline Airflow Obstruction on Daily Peak Expiratory Flow Rate (PEFR) Variability in Moderate to Severe COPD/**K.M. Criner, R.N. Criner, A.J. Criner, H.S. Smith, D. Yu, N. Marchetti, F. Jaffe, S.L. Krachman, A. Rastogi, M.J. Markus, G.J. Criner, Philadelphia, PA, p.A6858

P93 **Exercise Ventilatory Mechanics by Optoelectronic Plethysmography Before and After Lung Volume Reduction Surgery: A Case Series/**A.M. Layton, B.M. Thomashow, J. Guenette, W. Bulman, P.A. Jellen, B.A. Whippo, A.D. Ramlogan, M. Ginsburg, New York, NY, p.A6859

Facilitator: C. Bime, MD, Tucson, AZ

P94 **Efficacy and Safety of Novel 4-Grade Devices for Simulation Experience of Effort Breathing in Healthy Subjects/**Y. Tokunaga, T. Kawayama, T. Kinoshita, H. Oda, A. Yorita, H. Imaoka, T. Hoshino, Japan, p.A6860

P95 **Relationship of Bronchodilator Response Patterns with Severity of Airflow Limitation and Forced Expiratory Volume After First Second in COPD/**M. Basunia, C. Agu, S. Kandel, D. Salhan, F. Schmidt, D. Enriquez, J. Quist, O. Abdulfattah, S. Roy, Brooklyn, NY, p.A6861

P96 **The Significance of Low FEF25-75 as an Indicator of Obstructive Airway Disease in the Presence of Normal FEV1/FVC Ratio/**Z. Ghazarian, F.D. Ponce, M.B. Naranjo, R. Sekhon, M. Hanna, T. Pandya, M. Labban, M. Ismail, M.A. Khan, Paterson, NJ, p.A6862

P97 **Validation of Structured Light Plethysmography (SLP) Generated Respiratory Rate (RR) Against Clinician Over-Scored Capnography/**S. Motamedi-Fakhr, R. Wilson, R. Iles, Ely, United Kingdom, p.A6863

P98 **Validity Evaluation of Impulse Oscillometry(IOS) in Obstructive Lung Diseases Among Filipinos/**A. Quing, R. Zotomayor, M. Ang, B.E. Macaraig, Quezon City, Philippines, p.A6864

P99 **Chest Wall Strapping Improves Expiratory Airflow and Reduces Air Trapping and Hyperinflation in Mild to Moderate COPD/**H. Taher, H. Winnike, R. Beichel, J. Zabner, M. Eberlein, Iowa City, IA, p.A6865

P100 **Application of Impulse Oscillometry and Bronchial Dilation Test for Analysis in Patients with Asthma and Chronic Obstructive Pulmonary Disease/**P. Wang, Beijing, China, p.A6866

P101 **Stops During the Six-Minute Walk Test and Its Correlation with New Measurements in Patients with Chronic Obstructive Pulmonary Disease (COPD)/**M.J. Fernandez Sanchez, C.A. Celis Preciado, X. Correa Rios, O.M. Garcia, A. Canas-Arboleda, J.I. Lasso, C. Villaquiran-Torres, J.R. Lutz, Bogota, Colombia, p.A6867

P102 **Correlation Between Percent Predicted of Forced Expiratory Volume in First Second (FEV1 % Predicted) and Six Minute Walk Distance (6MWD) in Patients of Chronic Obstructive Pulmonary Disease/**N.K. Chauhan, S. Kumar, L.K. Saini, N. Dutt, P. Sanwaria, Jodhpur, India, p.A6868

P103 **Resistance and Reactance of Respiratory System in Healthy Subjects and COPD Patients: Literature Values/**A.C. Gastaldi, I.M.E. Silva, J.A.B. Martinez, B.P.X.A. Silva, D.O.D. Santos, L.P. Nascimento, M.H.D. Paula, Brazil, p.A6869

Facilitator: C.H. Martinez, MD, MS, MPH, Ann Arbor, MI

P104 **Correlation of Current Classification of Severity of Chronic Obstructive Pulmonary Disease in Global Initiative for Chronic Obstructive Lung Disease (GOLD 2015) with the 6 Minute Walk Test (6MWT) and 6 Minute Work (6MWORK) Among Filipino Patients/**M.M.J. Jampayas, C.A. Uy, R.F. Cabahug, Davao, Philippines, p.A6870

P105 **The Accuracy of Venous Blood Gas in Severe Lung Disease/**M. Weir, N. Marchetti, G.J. Criner, Philadelphia, PA, p.A6871

P106 **Changes in Lung Volume Over Time in Patients with Chronic Obstructive Pulmonary Disease/**J. Park, Y.J. Lee, J.S. Park, S.J. Kim, Y.-J. Cho, J.H. Lee, C.-T. Lee, H.I. Yoon, Seongnam-si, Gyeonggi-do, Korea, Republic of, p.A6872

P107 **Clinical Risk Factors of Decline in Forced Expiratory Volume in One Second Among Visitors with Obstructive Pulmonary Dysfunction Found in Medical Checkup/**T. Tanigawa, N. Nishimura, H. Nakaoka, R. Tsugitomi, K. Okafuji, A. Kitamura, Y. Tomishima, N. Uchiyama, T. Jinta, T. Tamura, N. Chohnabayashi, Chuo-ku, Tokyo, Japan, p.A6873

P108 **Pulmonary Function Test Abnormalities in Patients Undergoing Liver Transplant Evaluation: Single Center Retrospective Study/**A. Miller, G. Ruppel, J. Taylor, R. Nayak, St. Louis, MO, p.A6874

P109 **Forced Vital Capacity Is Associated with Exercise Capacity in Liver Transplant Candidates/**T.E. Sharkoski, K. Forde, M.J. Krowka, C.D. Mottram, P.D. Scanlon, K. Krok, M. Patel, M. Fallon, S.M. Kawut, Philadelphia, PA, p.A6875

P110 **Effects of Lung Function and Anthropometric Features on Inhaler Inhalation Sounds: A Step Towards Personalizing Acoustic Monitoring of Inhalation Technique/**T.E. Taylor, C. De Looze, P. MacHale, M.S. Holmes, I. Sulaiman, R. Costello, R. Reilly, Dublin, Ireland, p.A6876

P111 **Visualization of Inhalation Flow Profile and Drug Dispersion from a Dry Powder Inhaler Using a Handy Analyzer/**T. Kondo, T. Tanigaki, H. Yokoyama, M. Hibino, S.M. Cassan, S. Tajiri, K. Akazawa, Y. Yamada, Fujisawa, Japan, p.A6877

P112 **Exercise-Induced Oxygen Desaturation in Severe COPD Patients/**M.C. Pereira, S.M.S. Doria, I.A. Paschoal, M.M. Moreira, L.C. Palhares, E.D.M. Capitani, Campinas, Brazil, p.A6878

THEMATIC POSTER SESSION

D39 COPD: NON-PHARMACOLOGIC THERAPIES

9:00 a.m. - 3:30 p.m. **MOSCONE CENTER**

Area A, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: B.J. Make, MD, Denver, CO

P114 **Does Long-Term Oxygen Therapy 24 h/Day Improve Survival Compared to 15 h/Day in Hypoxemic Chronic Obstructive Pulmonary Disease?/**Z. Ahmadi, J. Sundh, A.B. Hermansson, M. Ekstrom, Lund, Sweden, p.A6879

P115 **Long-Term Effects of Non-Invasive Ventilation at Home in Hypercapnic Patients with COPD/**R. Rogiers, N. Van De Voorde, G. Leemans, J. Aerts, W. Vos, J. De Backer, W. De Backer, Edegem, Belgium, p.A6880

P116 **Impact of Non Invasive Open Ventilation (NIOV) on Dyspnea and Quality of Life in Patients with Chronic Obstructive Pulmonary Disease (COPD) and Idiopathic Pulmonary Fibrosis (IPF)/**A. Breiburg, K. Lam, G. Dhillon, C. Zone, M. Nicolls, W. Kuschner, Palo Alto, CA, p.A6881

P117 **The Effect of Age, Gender, Body Mass Index (BMI), Emphysema Lobe Predominance, and Exercise Capacity on Inspiratory Muscle Strength After Lung Volume Reduction Surgery (LVRS)**/R.N. Criner, D. Yu, G.J. Criner, Philadelphia, PA, p.A6882

P118 **Endoscopic Lung Volume Reduction: Can Valves be safely removed?**/R.-H. Hubner, C. Grah, C. Thieme, C. Pizarro, B. Temmesfeld-Wollbrueck, S. Hippenstiel, N. Suttorp, D. Skowasch, Berlin, Germany, p.A6883

P119 **A Prospective Study of RejuvenAirT System Radial Spray Cryotherapy to Determine Safety and Histological Effect in the Lung**/D. Breen, J. Coad, D.-J. Slebos, Galway, Ireland, p.A6884

P120 **Bronchoscopic Lung Volume Reduction: Proof of Original Concept with New Image Technique**/S.W. Lee, S.M. Lee, S.Y. Shin, T.S. Park, J.S. Lee, Y.-M. Oh, S.-D. Lee, J.B. Seo, Seoul, Korea, Republic of, p.A6885

P121 **The Role of Pulmonary Lobe Deflation Measurements in COPD Patients Planned for Lung Volume Reduction**/J. Hetzel, M. Haentschel, W. Spengler, A. Ehab, S.D. Ioanoviciu, M. Horger, Tuebingen, Germany, p.A6886

Facilitator: J. Porszasz, MD, PhD, Torrace, CA

P122 **Bronchoscopic Decompression for Severe Emphysema**/A. Kumar, L. Lam, T. Gildea, Y. Meli, X. Wang, A.C. Mehta, Cleveland, OH, p.A6887

P123 **Review of Quality of Life Outcomes Following Use of an Oscillating Positive Expiratory Pressure (OPEP) Device for Chronic Obstructive Pulmonary Disease (COPD): 8 Weeks Field Study Using the COPD Assessment Test (CAT)**/J. Suggett, 5G4, Canada, p.A6888

P124 **A Placebo-Controlled, Randomized Trial of Mesenchymal Stem Cells Associated with One-Way Endo-Bronchial Valves in Severe COPD Patients**/F.F. Cruz, H.G. De Oliveira, M.A.A. Almeida, A.V.D.M. Neto, G.A. Oliveira, F.M. Svartman, C.L.K. Rebelatto, D.J. Weiss, P.R.S. Brofman, P.R.M. Rocco, Rio de Janeiro, Brazil, p.A6889

P125 **Preoperative Predictors of Improvement with Lung Volume Reduction Surgery**/B.A. Whippo, P.A. Jellen, B.M. Thomashow, M. Ginsburg, C. Chiuzan, Y. Zhang, W. Bulman, New York, NY, p.A6890

P126 **STEP-UP Randomized Controlled Trial of Segmental Vapor Ablation in Patients with Severe Emphysema: 6 Month Results**/C.B. Strange, F.J.F. Herth, A. Valipour, P.L. Shah, R. Eberhardt, C. Grah, J. Egan, J.H. Ficker, M. Wagner, C. Witt, U. Liebers, P. Hopkins, W. Gesierich, M. Phillips, F. Stanzel, W. McNulty, C. Petermann, G.I. Snell, D. Gompelmann, Charleston, SC, p.A7908

P127 **Positive Airway Pressure Therapies and Hospitalization Risk in Chronic Obstructive Pulmonary Disease**/M.M. Vasquez, L.A. McClure, D.L. Sherrill, S. Guerra, S. Parthasarathy, Tucson, AZ, p.A7909

P128 **One Year Follow-Up After Endobronchial Valve Treatment in Patients with Emphysema Without Interlobar Collateral Ventilation**/K. Klooster, J.E. Hartman, N.H.T. Ten Hacken, D.-J. Slebos, Groningen, Netherlands, p.A7910

P129 **Effect of Yoga Breathing (Pranayama) on Exercise Tolerance and Dynamic Hyperinflation in Patients with COPD**/D.A. Kaminsky, N.A. Hanania, K.K. Guntupalli, J. Lippman, S. Burns, M. Brock, A. Mohsin, C. LaRock-McMahon, H. Pecott-Grimm, J. Skelly, M. Desarno, P. Warren, M. Whitney, Burlington, VT, p.A7911

THEMATIC POSTER SESSION

D40 CRITICAL CARE: DIAGNOSING AND TREATING BACTERIAL AND VIRAL INFECTIONS IN THE ICU

9:00 a.m. - 3:30 p.m. **MOSCONE CENTER**

Area G, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitators: M.H. Kollef, MD, St. Louis, MO
K. Akrami, MD, Bethesda, MD

P691 **Critically Ill Patients with the Middle East Respiratory Syndrome (MERS): A Multicenter Study**/Y.M. Arabi, A. ALOmari, Y. Mandourah, F. Al-Hameed, A. Sindi, B. Al-Raddadi, S. Shalhoub, A. Almotairi, I. Qushmaq, K. Alkhatib, A. Mady, O. Solaiman, A. Abdulmomen, A. Alaithan, R. Alradadi, A. Rajab, G. Almekhlafi, A. Alharthy, M. Alahmadi, M. Sadat, H. Almutairi, S. Abdukahil, E. Alqasim, A. Toledo, M. Nasim, F. Bafqeeh, O. Alshankeety, A. Anwar, A.S. Aldawood, L. Merson, R. Fowler, F. Hayden, H. Balkhy, Riyadh, Saudi Arabia, p.A6891

P692 **Critically Ill Healthcare Workers with the Middle East Respiratory Syndrome (MERS)**/Y.M. Arabi, A. ALOmari, Y. Mandourah, F. Al-Hameed, A. Sindi, B. Al-Raddadi, S. Shalhoub, A. AlMotairi, K. Alkhatib, A. Abdulmomen, I. Qushmaq, A. Mady, O. Solaiman, A. Alaithan, R. Alradadi, A. Rajab, G. Almekhlafi, A. Alharthy, M. Alahmadi, M. Sadat, S. Abdukahil, A. Toledo, H. Almutairi, E. Alqasim, A.S. Aldawood, L. Merson, R. Fowler, F. Hayden, H. Balkhy, Riyadh, Saudi Arabia, p.A6982

P693 **Factors Associated with Recurrence and Mortality in Central Line-Associated Bloodstream Infections**/L.E. Huerta, G. Nelson, T.W. Rice, Nashville, TN, p.A6893

P694 **Anatomic Site-Specific Complication Rates for Central Venous Catheter Insertions**/J.H. Garfinkel, S. Long, M. Goyal, J. Bell, J.M. Friedrich, A. Kumar, K. Blythe, J. Keyloun, S. Chung, R. Molyneaux, K. Yusuf, S. Fitzgibbons, Washington, DC, p.A6894

P695 **Comparison Between Chlorhexidine Gluconate Impregnated Dressings and Skin Antisepsis in the Prevention of Catheter Related Blood Stream Infections in the Intensive Care Unit: A Prospective Randomized Controlled Trial**/K. Rivera Manzano, C. Betancourt, R. Fernandez Gonzalez, R.A. Hernandez, R. Fernandez, R. Reyes, San Juan, PR, p.A6895

P696 **CLABSI Data and Numeracy Among Clinicians: Results of a Twitter-Based International Survey**/S. Govindan, V. Chopra, T.J. Iwashyna, Ann Arbor, MI, p.A6896

P697 **Ascorbic Acid Attenuates Hyperoxia-Compromised Host Defense Against Pulmonary Bacterial Infection**/V. Patel, V. Sampat, M.G. Espey, R. Sitapara, H. Wang, X. Yang, C.R. Ashby, D.D. Thomas, L.L. Mantell, Jamaica, NY, p.A6897

P698 **Clinical Outcomes Following Early Versus Late Vancomycin Discontinuation in Patients with Negative Bronchoalveolar Lavage Culture Samples/**D.G. Singhvi, M.W. Landmeier, C. Ononye, R.D. Shah, B. Lizza, S.B. Smith, C.H. Weiss, R.G. Wunderink, Chicago, IL, p.A6898

P699 **Characteristics of Patients Receiving Prolonged Empiric Vancomycin for Clinically Suspected Pneumonia But Negative Respiratory Cultures/**C. Ononye, M.W. Landmeier, D. Gupta, R.G. Wunderink, R.D. Shah, Chicago, IL, p.A6899

Facilitators: R.G. Wunderink, MD, Chicago, IL
A. Leligdowicz, MD, PhD, Toronto, Canada

P700 **Procalcitonin Based Algorithm and Cost Effectiveness for Acute Hypoxic Respiratory Failure with Infiltrates/**R. Pattison, D. Ashbaker, A. Birdwell, S. Westbrook, R. Fader, C. McCormick-Baw, J. Pruszynski, H.D. White, A. Arroliga, S. Ghamande, Temple, TX, p.A6900

P701 **Appropriateness of Procalcitonin Guided Antimicrobial Therapy Utilization in Hospitalized Veteran Patients/**M.K. Ellis, H.A. Kindermann, W. Blaser, J. Alegro, K. Gussert, D. Lans, Milwaukee, WI, p.A6901

P702 **Clinical Experience with Aerosolized Polymyxin B for the Treatment of Pneumonia/**B. Lizza, R.D. Shah, M.H. Scheetz, R.G. Wunderink, Chicago, IL, p.A6902

P703 **Enhanced Culturing Techniques Identify Unexpected Pathogens in Patients with Suspected Ventilator-Associated Infections: The Fast Identification of Pathogens (FindPath) Pilot Study/**S. Rotella, M. Xu, C. Wardell, M. Rieger, L. Rossi, E. McDonald, C. Main, M. Surette, A. Fox-Robichaud, Hamilton, Canada, p.A6903

P704 **Incidence of Ventilator Associated Pneumonia in Patients Undergoing Heart Surgery/**M. Fathi, B. Farzanegan, S. Salarian, Tehran, Iran, p.A6904

P705 **Standard Versus Prolonged Duration of Oseltamivir for Treatment of Influenza in Critically Ill Adults/**S. Chauv, J. Sorensen, N.B. Grossman, G.V. Fontaine, M.R. Hunter, A.R. Jephson, P. Crossno, Murray, UT, p.A6905

P706 **Myocarditis in Severe Influenza Infection: A Review of the Literature/**S.A. Sellers, W.A. Fischer, Chapel Hill, NC, p.A6906

P707 **miR-150 Is Associated with Fatal Outcome in Patients with Pandemic 2009/H1N1 Influenza Virus/**G. Ramirez-Martinez, S. Mendez-Flores, J. Moran, L. Jimenez-Alvarez, M.C. Garcia-Sancho, D. Martinez-Briseno, E. Marquez-Garcia, A. Cruz-Lagunas, R. Perez-Padilla, J. Zuniga, Mexico City, Mexico, p.A6907

P708 **Five-Year Review of Right-Sided Infective Endocarditis in an Indian Intensive Care Unit/**S. Vallabhajosyula, M.D. Varma, Rochester, MN, p.A6908

Facilitator: K.N. Kangelaris, MD, MAS, San Francisco, CA

P709 **Association of Hyponatremia with In-Hospital Outcomes in Infective Endocarditis: A Five-Year Review from an Indian Intensive Care Unit/**S. Vallabhajosyula, M.D. Varma, Rochester, MN, p.A6909

P710 **Incidence, Risk Factors, Microbiological Profile and Outcome of Intensive Care Unit (ICU) Acquired Infections in Critically Ill Patients in a Multidisciplinary ICU: A Prospective Study/**N. Jain, A. Kumar, N. Goel, S. Virdi, D. Chaudhry, Rohatk, India, p.A6910

P711 **Five-Year Trends in Difficult to Treat Antimicrobial-Resistant Gram-Negative Bloodstream Infections Among Inpatients at 180 US Hospitals/**S.S. Kadri, A.B. Spaulding, Y.L. Lai, J. Adjemian, D.R. Prevots, T. Palmore, H. Masur, C. Rhee, M. Klompas, J. Dekker, A. Suffredini, D.C. Hooper, S. Fridkin, R.L. Danner, Bethesda, MD, p.A6911

P712 **Modeling Risk for Developing Multidrug Resistant (MDR) Infections in an at Risk, MDR-Naive, Critically Ill Population/**R. Sonti, M. Conroy, E. Welt, Y. Hu, G. Luta, D. Jamieson, Washington, DC, p.A6912

P713 **Risk Factors Associated with Mortality in Critically Ill Patients with Candidemia/**V. Mayor, G. Ortiz, A. Franco, J. Osorio, Bogota, Colombia, p.A6913

P714 **Outcomes for HIV Patients Admitted to an Urban Academic ICU in the Era of HAART/**D. Nesheim, N. Ramesh, J. Paralkar, J. Filopei, S. Acquah, New York, NY, p.A6914

P715 **Factors Associated with Mortality in Patients with HIV/AIDS Admitted to the Intensive Care Unit in a Tertiary Care Public Hospital in Colombia: Case Control Study/**E.P. Vergara Vela, J. Gastelbondo, K. Bautista, J. Pedraza, J. Pulido, G. Ortiz, Bogota, Colombia, p.A6915

P716 **Contemporary Patterns of Hospital Disposition Among ICU-Managed Patients with Encephalitis Due to Herpes Simplex Virus in Texas, 2004-2013/**L. Oud, Odessa, TX, p.A6916

P717 **Secular Trends of ICU Utilization Among Patients with Herpes Simplex Virus Encephalitis: A Population-Based Study/**L. Oud, Odessa, TX, p.A6917

P718 **Bacterial Colonization of Subglottic Secretions Occurs Rapidly Following Emergent Intubation, Contributes to Prolonged Ventilation: The Role of Tracheal HSP-70 Secretion/**J. Hyde, L. Basdeo, O. Turner, J. Tumlin, Chattanooga, TN, p.A7912

THEMATIC POSTER SESSION

D41 CRITICAL CARE CASE REPORTS: CARDIOVASCULAR DISEASE AND HEMODYNAMICS I

9:00 a.m. - 3:30 p.m. **MOSCONE CENTER**
Area C, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitators: S. Vallabhajosyula, MBBS, Rochester, MN
J. Ninan, MD, Chicago, IL

P237 **Veno-Arterial Extracorporeal Membrane Oxygenation Saved a Young Patient in Refractory Cardiogenic Shock Precipitated by Thyroid Storm/**M. Al-Saadi, R. Sista, C. Lan, Houston, TX, p.A6918

P238 **Pre-Cannulation Lung Biopsy Shortens ECMO Course/**P. Lohmann, T.C. Lee, D.L. Kearney, C.J. Fernandes, Houston, TX, p.A6919

P239 **When Shortness of Breath Is the Opposite of Orthopnea/**A. Arjuna, New Jersey, NJ, p.A6920

P240 **Pre-Operative Evaluation of Type-B Aortic Dissection with 4D-Flow Cardiac Magnetic Resonance/**R. Volpe, M. Schafer, T.B. Reece, P.J. Rochon, A. Rocker, R. Arce, K.S. Hunter, O. Jazaeri, Denver, CO, p.A6921

P241 **Aorto-Right Ventricular Fistula: A Rare Complication of Abiotrophia Endocarditis/**P.T. Bhattacharya, A. Mohammed, E. Mizrahi, Philadelphia, PA, p.A6922

P242 **Dysphagia Aortica/**R. Bansal, A. Surana, Upland, PA, p.A6923

P243 **Platypnea- Orthodeoxia Syndrome in the Setting of Aortic Aneurysm and Aneurysm of Atrial Septum with Patent Foramen Ovale/**J. Yesudas, S. Helgeson, Jacksonville, FL, p.A6924

P244 **Aorto-Right Ventricular Fistula Following Percutaneous Trans-Catheter Aortic Valve Replacement/**M.-K. Konda, J. Kalavakunta, V. Gupta, Kalamazoo, MI, p.A6925

P245 **Left Main Coronary Artery Fistula to Right Pulmonary Artery Presenting as Sustained Monomorphic Ventricular Tachycardia/**A. Al Akshar, S. Daniels, A. Abu Homoud, Neptune, NJ, p.A6926

P246 **"Shot Through the Heart": Atrio-Esophageal Fistula/**C. Schuring, L. Mountjoy, Des Moines, IA, p.A6927

P247 **Nocardia Cyriacigeorgica Aortic Root Pseudoaneurysm and Prosthetic Valve Endocarditis/**S. Dooley, D.M. Kelley, M.E. Bowdish, Los Angeles, CA, p.A6928

Facilitator: S.I. Kumar, MD, Los Angeles, CA

P248 **Mild and Persistent Haemoptysis as a Rare Presentation of Aortic Pseudoaneurysm After Previous Coarctation Surgery/**A.R. Garcia, H. Karlen, S. Quadrelli, M.A. Solis, M. Heres, Buenos Aires, Argentina, p.A6929

P249 **An Unlikely Culprit: A Case of Congenital Middle Aortic Syndrome Diagnosed in the Sixth Decade of Life/**M.S. Ali, C.G. Senseng, S. Tchernodrinski, D. Mohananey, J. Sethi, C. Nolasco, Y. Golzar, J. Chua, Chicago, IL, p.A6930

P250 **Bilateral Central Retinal Artery Occlusion in Pregnant Women with Severe Preeclampsia Post Caesarian Delivery/**G. Khirfan, A. Arunachalam, S. Krishnan, Cleveland, OH, p.A6931

P251 **Undiagnosed Patent Ductus Arteriosus Complicating Closure of a Large Ventricular Septal Defect in a 25-Year Old Immigrant with Still Reversible Pulmonary Arterial Hypertension/**M. Freundt, S. Loukanov, F.-U. Sack, Denver, CO, p.A6933

P252 **Saved by the Bell: An Unusual Case of Aortic Dissection in a 40 Year Old Male/**F. Khalid, S. Rehman, K. Alluri, S. Gupta, McKeesport, PA, p.A6934

P253 **Mycotic Aortic Aneurysm Secondary to Aspergillus/** F. Christian, A. Kim, N. Sharma, Brooklyn, NY, p.A6935

P254 **Diffuse Alveolar Hemorrhage Masquerading as a Left Upper Lobe Opacity in a Patient with Mitral Regurgitation/**K. Chokshi, R.L. Arancibia, J. Mahoney, P. Krishnan, Brooklyn, NY, p.A6936

P255 **From Throat to the Heart, Until It Ripped Apart/**H. Arshad, M. Young, R. Adurty, Pittsburgh, PA, p.A6937

P256 **Huffing and Puffing with HFpEF: Revealed with Exercise Hemodynamics/**L.A. Fussner, J. Utz, Rochester, MN, p.A6938

P257 **Destructive Native Valve Endocarditis Due to Corynebacterium spp in a Severely Woman Burned - Case Report/**J.A. Victorino, S. S. Kretzer, P. L. Dutra, R. K. Dal Molin, Porto Alegre, Brazil, p.A6939

Facilitator: A. Bhardwaj, MD, Philadelphia, PA

P258 **Intracardiac Leiomyomatosis: An Unusual Case of a Fatal Benign Tumor in a Post Total Abdominal Hysterectomy with Bilateral Oosalpingo-Oophorectomy Woman/**M.N. Jao, J. Orcasitas, Davao City, Philippines, p.A6940

P259 **Tricuspid Valve Removal Without Replacement: When Less Is More/**A.H. Bonetti, A. Mercedes, A.O. Romero, Q. Feikes, Las vegas, NV, p.A6941

P260 **Aortic Dissection Presenting as Pericardial Effusion in a Young Patient/**A. Petraglia, S. Adhikari, A. King, S. Gupta, McKeesport, PA, p.A6942

P261 **A Forgotten Cause of Cardiac Tamponade/**J. Albors-Sanchez, J. Martinez-Gonzalez, W. Rodriguez-Cintron, San Juan, PR, p.A6943

P262 **Congenital Absence of Infra-Renal Inferior Vena Cava (IVC) Associated with Pelvic and Lower Extremities Thrombosis Treated with Catheter Directed Thrombolysis and Angioplasty/** I. Shahoub, F. Zeid, J. Gabi, Huntington, WV, p.A6944

P263 **Simultaneous Pulmonary and Paradoxical Emboli with Impending Paradoxical Embolus; A Rare Presentation/**M.Z. Rizwan, Z. Ahmad, S.N. Chalise, M. Al Janabi, N. Sultana, Z. Rehman, Greenville, NC, p.A6945

P264 **TKO (The Knockout) of TPA, a Rare Case of Developing a STEMI Despite Being on a Tissue Plasminogen Activator Infusion/**J.M. Chowdhury, V. Mehta, N. Pozzessere, A. Mohammed, A. Maheshwari, M. Kosa, S. Manns, Darby, PA, p.A6946

P265 **Acute Coronary Artery Thrombosis Precipitated by Eltrombopag, a Thrombopoetin Receptor Agonist/**D.W. Burke, J.S. Mulliken, A.H. Skolnick, D. Fridman, New York, NY, p.A6947

P266 **A Case of an Incidental Finding of Persistent Left SVC/**H. Hussein, H. Youness, Oklahoma City, OK, p.A6948

P267 **A Case of Non-ST Elevation Myocardial Infarction Due to Idiopathic Thrombotic Thrombocytopenic Purpura/**S. Nijjar, P. Kopparthy, A. Kahlon, U. Masood, Syracuse, NY, p.A6949

P268 **Post-Anginal Sepsis Syndrome/**C. Meenakshisundaram, H. Friedman, Evanston, IL, p.A6950

P269 **Dabigatran Absorption and Congestive Heart Failure, a Potential Mechanism for Dabigatran Failure/**A. Mack, Jacksonville, FL, p.A6951

THEMATIC POSTER SESSION

D42 CRITICAL CARE CASE REPORTS: CARDIOVASCULAR DISEASE AND HEMODYNAMICS II

9:00 a.m. - 3:30 p.m. **MOSCONE CENTER**

Area C, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitators: A.A. Hope, MD, MSCE, Bronx, NY
M. Hua, MD, MSc, New York, NY

P274 **Induced Torsades de Pointes and Takotsubo's Cardiomyopathy Secondary to Thyroid Storm/**G.W. Williams, Memphis, TN, p.A6952

P275 **Long QT Syndrome/**G.W. Williams, Memphis, TN, p.A6953

P276 **Unique Case of Reverse Takatsubo Cardiomyopathy and Shock Following a Diagnosis of Adenocarincoma/**F. Tiripicchio, B. Hayward, R. Rajmane, New York, NY, p.A6954

P277 **Takotsubo Cardiomyopathy Masquerading as STEMI After Successful Resuscitation from PEA-Arrest/**G.N. Vaidya, W. Syed, R. Shah, K. Liu, Syracuse, NY, p.A6955

P278 **Pheochromocytoma Masquerading as Infectious Myocarditis/**J. Hall, S. Uppalapu, R.A. Raschke, Phoenix, AZ, p.A6956

P279 **Tick-Borne Carditis Without Its Telltale Signs/**G. Johri, B. Alam, H. Kozman, Syracuse, NY, p.A6957

P280 **Syncope in a Well-Controlled Asthmatic with Alzheimer, as a Presentation of Albuterol Induced Takotsubo Cardiomyopathy/**G. Barmaimon, S. Thibaud, R. Kornberg, New York, NY, p.A6958

P281 **Right Ventricular Metastasis of Cervical Cancer Involving the Endomyocardium: A Case Report/**E. Vilches, A. Thekkumkattil, C. De La Cruz Luque, A. Sharim, G. Villada, R. Sancassani, Miami, FL, p.A6959

P282 **Takotsubo Cardiomyopathy Associated with High Dose Albuterol/**P. Chandar, A.P. Kamath, M.A. Shenoy, S. Kulandaisamy, C. Seneviratne, Y. Kupfer, Brooklyn, NY, p.A6960

P283 **Takotsubo Cardiomyopathy in the Setting of Myasthenia Crisis/**M. Hassanein, O. Adams, S.E. Tieku, M. Al-Jumayli, B. Nagra, P. Stillwell, D. Goldsmith, Trenton, NJ, p.A6961

P284 **Anemone or Enemy - The Cardiac Fibroelastoma/**A. Amaraneni, C. Begley, Kalamazoo, MI, p.A6962

Facilitators: M.M. Mansour, MD, Stony Brook, NY
B. Keveson, MD, Burlington, VT

P285 **Infiltrative Cardiomyopathy in Multiple Myeloma: Delayed Treatment, Devastating Consequences/**R. Beg, B. Hurwitz, I. Cendan, D. Alvarez, L. Rosario, J. Torres, S. Zeichner, Miami, FL, p.A6963

P286 **Left Ventricular Wall Rupture and Cardiac Tamponade During Transcatheter Aortic Valve Replacement/**Y. Agrawal, J. Kalavakunta, F. Saltiel, V. Gupta, Kalamazoo, MI, p.A6964

P287 **"Foreign Body in Heart", Complication from Central Venous Catheter Insertion/**W. Humayun, A. Niroula, Abington, PA, p.A6965

P288 **Large Pericardial Effusion Causing Recurrent Syncope - A Unique Presentation of Severe Untreated Hypothyroidism/**S. Mawri, R. Dirani, S. Varghese, T. Raymond, C. Calle Muller, K. Alaswad, Detroit, MI, p.A6966

P289 **Gastropericardial Fistula with Constrictive Pericarditis: A Potentially Fatal Complication After Roux-en-Y Gastric Bypass Surgery/**C. Di Felice, C. Jacob, A. Whipple, L. Hough, R. Lovy, Kalamazoo, MI, p.A6967

P290 **Delayed Cardiac Tamponade- A Rare Complication of Permanent Pacemaker Insertion/**C. Agu, M. Basunia, S. Kandel, D. Salhan, D. Enriquez, F. Schmidt, Brooklyn, NY, p.A6968

P291 **A 40-Year-Old Diabetic Male with Limb Threatening Ischemia: Where There Is Smoke There Is Fire/**K. D'Urzo, R. Thomas, A. DUrzo, Kingston, Canada, p.A6969

P292 **Revisiting Anasarca: Pleural Effusion, Ascites, and Leg Swelling in a Middle Aged Female/**K. Chatterjee, V. Wadhwa, C. Colaco, B. Colaco, R. Jagana, Little Rock, AR, p.A6970

P293 **Using Velocity Time Integral to Non-Invasively Evaluate the Response to Dobutamine in Cardiogenic Shock/**R. Pillai, B. Zakhary, V. Mukherjee, New York, NY, p.A6971

P294 **A Case of Type 1 Cardiorenal Syndrome Treated with Combination Diuretic and Dobutamine Therapy/**G.S. Thind, P. Patel, K. Kailasam, Kalamazoo, MI, p.A6972

P295 **An Uncommon Cause of Puerperal Shock/**H.B. Ouranos, D.W. Hugenberg, T.B. Kharadjian, S.M. Kloiber, G.W. Carlos, Indianapolis, IN, p.A6973

Facilitator: M.D. Langston, MD, Bronx, NY

P296 **A Unique Case of Obstructive Shock/**M.B. Lesko, V. Mukherjee, C. Maulion, D. Fridman, New York, NY, p.A6974

P297 **A Rare Cause of Cardiogenic Shock in a Young Male/**Z.S. Shakir, Kansas City, KS, p.A6975

P298 **An Unusual Cause of Obscure Gastrointestinal Bleeding Leading to PEA Cardiac Arrest/**K.J. O'Donnell, J. Scott, Grand Rapids, MI, p.A6976

P299 **General Surgery Induced Hiatal Hernia Resulting in Obstructive Shock Diagnosed on Bedside Ultrasound/**S.B. Brosnahan, M. Ward, E. Dweck, New York, NY, p.A6977

P300 **Intentional Antihypertensive Overdose: A Critical Care Monitoring Challenge/**P. Kidambi, S. Cowley, Cambridge, MA, p.A6978

P301 **Succesful Management of Bowel Ischemia and Intestinal Pneumatosis with Aggressive Fluid Resuscitation/**P. Jagtap, S. Prueksaritanond, S.S. Hoskote, R.A. Oeckler, Rochester, MN, p.A6979

P302 **Stabilizing Cardiogenic Shock Caused by Acute Papillary Muscle Rupture with Mechanical Ventricular Off-Loading/**B. Jalil, J. Frizzel, S. Clegg, S. Ahmed, Albuquerque, NM, p.A6980

P303 **Case Report: Large Left Atrial Myxoma Presenting as Pneumonia and Acute Respiratory Distress Syndrome/**R. Lai, C.P. Lee, C. Tan, D. Tai, G.S. Kang, J. Abisheganaden, Singapore, Singapore, p.A6981

P304 **Vasovagal Asystole from Bedside Pleurodesis with Doxycycline/** M. Islam, M. Harris, M. Bergman, New York, NY, p.A6982

P305 **Synthetic Cannabinoid (K2) Related Cardiac Arrest and Death in Young Drug Abuser/**E.E.-N. Wan, D. Frank, E. Bang, New York, NY, p.A6983

THEMATIC POSTER SESSION

D43 CRITICAL CARE CASE REPORTS: INFECTIONS LEADING TO CRITICAL ILLNESS

9:00 a.m. - 3:30 p.m. **MOSCONE CENTER**

Area G, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitators: G. Nair, MD, Mineola, NY/
S. Kanagalingam, MD, Burlington, VT

P721 **Laryngeal Histoplasmosis Mimicking Laryngeal Cancer with Acute Life-Threatening Upper-Airway Obstruction/**A. Rajagopal, M. Khosravi, Lexington, KY, p.A6984

P722 **An Unusual Case of Pleuroparenchymal Abscess Formation from Esophageal-Pulmonary Fistula in Chronic Aspiration/**A. Rajagopal, M. Khosravi, Lexington, KY, p.A6985

P723 **Descending Necrotizing Mediastinitis Following Tooth Extraction in a 26-Year Old Immunocompetent Patient/**M.-K. Konda, C. Barrett, L. Lutwick, Kalamazoo, MI, p.A6986

P724 **Acute Triple Valve Infective Endocarditis Involving Native Valves/**M.-K. Konda, Y. Agrawal, C. Difelice, J. Kalavakunta, V. Gupta, Kalamazoo, MI, p.A6987

P725 **Stenotrophomonas Maltophilia Necrotizing Soft Tissue Infection in an Immunocompromised Patient/**S. Shin, G. Wardi, D.G. Papamatheakis, La Jolla, CA, p.A6988

P726 **Black Esophagus After Influenza Infection/**H. Hawamdeh, S. Patel, A. Ataya, H. Alnuaimat, Gainesville, FL, p.A6989

P727 **Mucor Mayhem: A Case of Heroin Induced Invasive Fungal Rhinosinusitis/**W. Kareem, L. Kimmig, Philadelphia, PA, p.A6990

P728 **Cervical Necrotizing Fascitis: A Grave Complication of Ludwig's Angina/**N.Y. Madisi, K. Udani, A. Bassilly-Marcus, R. Kohli-Seth, J. Oropello, A. Manasia, New York, NY, p.A6991

P729 **An Unexpected Cause of Sudden Brain Death in an Immunocompetent Patient/**A. Baig, J. Scott, Grand Rapids, MI, p.A6992

P730 **HHV-6: An Unusual Cause of Psychosis in a Healthy Woman/**R. Asterita, K. Chawla, M. Ignaszewski, V. Thoguluva Chandrasekar, O. Chaudhary, M. Paul, Liverpool, NY, p.A6993

P731 **Oculomotor Dysfunction: A Clue to Invasive Aspergillosis in a Critically Ill Patient/**E.E. Bondarsky, New York, NY, p.A6994

P732 **Use of Extracorporal Membrane Oxygenation and Aminocaproic Acid in a Severe Case of Leptospirosis Pulmonary Hemorrhage Syndrome/**M.A. Pardinas Gutierrez, R. Mendirichaga, L. Rosario, R. Rico, H. Baier, S. Krick, Miami, FL, p.A6995

P733 **An Unusual Case of Acute Respiratory Failure/**T.A. Jabuonski, N. Alavian, D. Narendra, Houston, TX, p.A6996

P734 **Succesful Use of Corticosteroids for Fulminant Mulch Pneumonitis Mimicking Acute Respiratory Distress Syndrome/**E. Nolley, A. Koczo, F. Shah, Pittsburgh, PA, p.A6997

P735 **Diffuse Alveolar Hemorrhage and Acute Respiratory Distress Syndrome Secondary to Mycoplasma Pneumoniae Infection in a Young Immunocompetent Patient/**N. Choi, P. Lederer, V. Prieto-Centurion, E. Onal, Chicago, IL, p.A6998

Facilitators: N. Qadir, MD, Bronx, NY
J. Singh, MD, Charlotte, NC

P736 **A Resident of the Bronx with Legionella Pneumonia and Cardiomyopathy/**A. Gupta, M. Parekh, New York, NY, p.A6999

P737 **A Radiographically Vascular Density Occupying a Preexisting Cavitary Lesion Presenting as Massive Hemoptysis/**V.B. Nannaka, R. Duncalf, Bronx, NY, p.A7000

P738 **High-Flow Oxygen and Steroids in the Management of a 21-Year Old Co-Infected with Mycoplasma Pneumoniae and Hantavirus/**J. Giang, M. Forte, A. Patel, J. Petty, J. Gordon, Pueblo, CO, p.A7001

P739 **A Case of Severe Legionnaires' Disease with Hilar Lymph Node Necrosis in an Immunocompetent Host/**S. Baronos, O. Anozie, S. Grewal, M. Patel, A. Ghimire, Syracuse, NY, p.A7002

P740 **Legionnaire's Disease: Uncommon Presentation of a Common Disease/**R. Mishra, T. Vakde, G. Diaz-Fuentes, Bronx, NY, p.A7003

P741 **Management of Bilateral Infected Bullae in a Critically Ill Patient** /K. Medepalli, R. Hebbeler-Clark, Cincinnati, OH, p.A7004

P742 **Transbronchial Biopsy in a Severely Thrombocytopenic Patient with Cardiopulmonary Instability Required to Ultimately Diagnose Disseminated Histoplasmosis/**T. Sjulin, D. Ferraro, C. Madar, Fort Sam Houston, TX, p.A7005

P743 **Purulent Pericarditis/**Y. Hattab, S. Alhassan, M. Hewston, M. Naddour, B. Barker, Pittsburgh, PA, p.A7006

P744 **Pneumonitis, Serositis, or Endocarditis?/**R. Doobay, A.J. Shah, U. Masood, A. Kahlon, D. Savici, Syracuse, NY, p.A7007

P745 **Any Delay Can Be Too Little, Too Late: A Case of Necrotizing Myositis/**S.K. Avasarala, B. Small, C. Ray, Detroit, MI, p.A7008

P746 **An Unusual Case of Spontaneous Bacterial Peritonitis/**A. Levin, A. Taneja, Milwaukee, WI, p.A7009

P747 **Severe Generalized Tetanus: A Rare Complication of a Forgotten Disease/**V.S. Sambhara, M. Abidali, A. Abidali, J.A. O'Hea, Phoenix, AZ, p.A7010

P748 **Fungemia: An Unexpected Cause/**A. Kalakonda, K. Gupta, P. Aleksiejuk, S. Reddy, S. Zaidi, Syracuse, NY, p.A7011

P749 **Love Sepsis: A Complicated Case of Gonococcal Endocarditis/**D. Moretta, Loma Linda, CA, p.A7012

P750 **Right Sided Endocarditis Secondary to Prolonged Intravenous Canulation/**G.C. Isiguzo, C.N. Ugwu, A.U. Kalu, N.C. Obeka, G.A. Amusa, B.I. Awokola, Abakaliki, Nigeria, p.A7013

THEMATIC POSTER SESSION

D44 RESPIRATORY FAILURE: EXTRACORPOREAL LIFE SUPPORT

9:00 a.m. - 3:30 p.m. **MOSCONE CENTER**

Area C, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitators: K. Gray, MD, MSci, Denver, CO
A. Combes, MD, PhD, Paris, France

P309 **Early Prediction of ECMO-Eligibility for Severe ARDS in Adults/**J.K. Bohman, Rochester, MN, p.A7014

P310 **Exploring Expert Opinion Based Prediction of Extracorporeal Membrane Oxygenation (ECMO) Eligibility for Acute Respiratory Distress Syndrome (ARDS)/**C.M. Aiudi, J.K. Bohman, Rochester, MN, p.A7015

P311 **Factors Associated with Mortality in Adult Patients on Extracorporal Membrane Oxygenation/**S.L. Dickens, R. Mendichiraga, A. Panos, D. Kett, M. Mirsaeidi, S. Krick, Miami, FL, p.A7016

P312 **Predictors of Mortality in Adults with Acute Respiratory Failure Treated with Extracorporeal Membrane Oxygenation/**S. Sangli, S.F. Noronha, R.A. Jean, N. Kotecha, R. Jean, New York, NY, p.A7017

P313 **Outcomes of Adult Patients Managed by Veno-Venous Extracorporeal Membrane Oxygenation: Mayo Clinic Experience/**P.K. Guru, D. Sanghavi, J.K. Bohman, R. Kashyap, J.B. Riley, T. Friedrich, G.J. Shears, Rochester, MN, p.A7018

P314 **Quantitative Monitoring of Unfractionated Heparin Anticoagulation in Adult Patients Requiring Extracorporeal Membrane Oxygenation as a Predictor of Thrombotic Events/**R. Hirschfeld, A. Morse, G. Baird, J. Aliotta, C. Devers, M.M. Levy, J. Sweeney, C. Muratore, C.E. Ventetuolo, Providence, RI, p.A7019

P315 **Anticoagulation and Transfusion Management in Adult Patients Receiving Extracorporeal Membrane Oxygenation/**D. Kelly, B. Hohlfelder, M. Hoang, K. Anger, S. Lagambina, D. Silver, P. Camp, G. Weinhouse, G. Couper, R.M. Kaufman, J.M. Connors, Boston, MA, p.A7020

Facilitator: H.J. Dalton, MD, Anchorage, AK

P316 **Transfusion Requirements During Extracorporeal Membrane Oxygenation, a Retrospective Study/**M.A. Pardinas Gutierrez, R. Mendirichaga, S.L. Dickens, J. Monge, R. Rico, D. Kett, A. Panos, S. Krick, Miami, FL, p.A7021

P317 **Thrombocytopenia and Extracorporeal Membrane Oxygenation in Adults with Acute Respiratory Failure/**M.R. Baldwin, D. Abrams, M. Champion, C. Agerstrand, A. Eisenberger, M. Bacchetta, D. Brodie, New York, NY, p.A7022

P318 **Vascular Complications Arising from Hemostasis with Manual Compression Following Extracorporeal Membrane Oxygenation Decannulation/**K.S. Byun, H.J. Yeo, H.S. Kim, S.H. Yoon, S.E. Lee, D. Jeon, Y.S. Kim, W.H. Cho, Yangsan-si, Korea, Republic of, p.A7023

P319 **Outcomes of Patients on VA ECMO Who Underwent an Exploratory Laparotomy/**K.K. Sakata, R. Kashyap, P.K. Guru, T. Seelhammer, D. Barbara, G. Schears, Rochester, MN, p.A7024

P320 **Extracorporeal Carbon Dioxide Removal to Facilitate Extubation in Severe Chronic Obstructive Pulmonary Disease Exacerbation - Preliminary Experience in Chile/**J. Graf, R. Lopez, I. Caviedes, H. Cabello, F. Descalzi, A. Umana, Santiago, Chile, p.A7025

P321 **Extracorporeal Membrane Oxygenation Use in a Patient with Multiple Severe Co-Morbidities/**A.J. Shah, R. Doobay, D. Landsberg, Syracuse, NY, p.A7026

P322 **Use of Continuous Venovenous Hemofiltration to Curtail Myoglobin-Induced Pigment Nephropathy: A Case Report/**M. Yaqoob, A. Alkhatib, B.L. Jaber, Brighton, MA, p.A7027

P323 **Palliative Withdrawal of ECMO: A Clinical Case Series/**D. Gutteridge, H. Copeland, G. Makdisi, Z. Hashmi, I.-W. Wang, T. Wozniak, M. Duncan, C. Hage, D. Roe, Indianapolis, IN, p.A7028

THEMATIC POSTER SESSION

D45 CRITICAL CARE: CIRCULATORY HEMODYMANICS, SHOCK, CARDIOVASCULAR DISEASE, AND FLUID MANAGEMENT

9:00 a.m. - 3:30 p.m. **MOSCONE CENTER**

Area C, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitators: B.T. Thompson, MD, Boston, MA
K.R. Famous, MD, PhD, San Francisco, CA
D. Kadaria, MD, Memphis, TN

P327 **Adherence to Advanced Cardiac Life Support (ACLS) and Outcomes at an Inner Urban City Hospital/**J.A. Kileci, A. Patrawalla, Newark, NJ, p.A7029

P328 **Study of Ventilation During Cardio Pulmonary Resuscitation (CPR): A New Model Using Thiel Cadavers/**S. Delisle, E. Charbonney, P. Gosselin, P. Ouellet, M. Rigollot, G. Bronchti, L.J. Brochard, K. Serri, D. Savary, J.-C.M. Richard, Montreal, Canada, p.A7030

P329 **Shock Etiology, Severity, and Neurocognitive Outcome Following Out-of-Hospital Cardiac Arrest/**R.J. Anderson, L. Hsu, T.B. Ghafouri, S. Tyagi, J. Joshua, J.R. Beitler, San Diego, CA, p.A7031

P330 **Time to Achieve Goal Temperature and Neurological Outcomes for Out of Hospital Cardiac Arrest Patients Undergoing Therapeutic Hypothermia- Single Center Study/**T.R. Gogireddy, S. Katari, A. Niroula, R.A. Watson, Abington, PA, p.A7032

P331 **Elevating the Quality of Cardiopulmonary Resuscitation Using Biometric Analysis of Chest Compressions/**C. Kapp, J. Loeb, R. Cooper, J. Chae, L. Estep, A.K. Ardati, T.T. Yamanaka, D.R. Fraidenburg, Chicago, IL, p.A7033

P332 **Dynamic Arterial Waveform Changes as Predictors of Fluid Responsiveness in Intensive Care Unit Patients: A Systematic Review and Meta-Analysis/**R.V. Dy, C.T. Bach, M.J. Mador, Buffalo, NY, p.A7034

P333 **Validation of Inferior Vena Cava Distensibility Index for Evaluation of Fluid Response in Experimental Acute Respiratory Distress Syndrome/**R.D.S. Mendes, M.D.O. Vasconcellos, G.D.A. Padilha, R.S. Santos, N.D.N. Rocha, L.R. Ronir, P.R.M. Rocco, P.L. Silva, Rio de Janeiro, Brazil, p.A7035

P334 **Blood Pressure Accuracy and Treatment Decisions in the Face of Protocol- Driven Care/**M. Dupont, P. Rosier, J. Crowell, L. Drager, L. Altsman, Pittsfield, MA, p.A7036

P335 **Near-Infrared Spectroscopy (NIRS) to Monitor Cerebral Autoregulation in Sepsis: A Potential Method to Individualize Resuscitation Endpoints/**C.M. Goodson, K. Rosenblatt, L. Rivera Lara, B. Winters, P. Nyquist, C. Hogue, Baltimore, MD, p.A7037

P336 **Ultrasound Hemodynamics and Lung Ultrasound Identify Under- Resuscitated Patients in the Medical Intensive Care Unit/**V. Sharma, R. Gueret, A. Vasireddy, B. Ninan, J. Bailitz, Chicago, IL, p.A7038

P337 **Epoint to Septal Separation (EPSS) Is a Better Discriminant of Left Ventricular Function than Fractional Shortening in Critically Ill Patients/**V. Sharma, R. Gueret, B. Ninan, A. Vasireddy, J. Bailitz, Chicago, IL, p.A7039

P338 **The Effectiveness of Hemodynamics Status Among Septic Shock Patients by Airway Pressure Release Ventilation (APRV) in Comparison with Conventional Mode Ventilation (CMV): Retrospective Cohort Study/**A.M. Hussain, H. Lababidi, A.W. Mir, A. Al Ohali, N. Al Hamoud, A. Al Enezi, Riyadh, Saudi Arabia, p.A7040

Facilitators: D.A. Kaufman, MD, Bridgeport, CT
T.J. Bice, MD, Chapel Hill, NC

P339 **Blood Pressure Determination During Clinical Crisis: Is the Doppler Method More Accurate?/**R. Gamarallage, M. Dupont, J. Ringler, J. Crowell, P. Rosier, Pittsfield, MA, p.A7041

P340 **Tolerability and Feasibility of Passive Leg Raise to Assess Fluid Responsiveness and Fluid Toxicity in Septic Patients in a Mozambican Emergency Department/**S.K. Graves, L. Chambal, D. Loforte, B. Zavale, N. Palolite, N. Manguele, A. Zandamela, D.M. Smith, P.F. Fedullo, S. Patel, F. Urci, K. Akrami, La Jolla, CA, p.A7042

P341 **Specific Components of the Inflammatory Reflex: Heart Rate Variability (HRV) and IL-6 Predict Septic Shock in Critical Ill Patients/**M.J. Fernandez Sanchez, A. Riveros Rivera, O. Sanabria, Bogota, Colombia, p.A7043

P342 **Variations in Pulse Oximetry Waveforms in Critically Ill Patients to Assess Hemodynamic Changes During Mechanical and Spontaneous Ventilation: A Pilot Study to Evaluate Reliability/**K. Stern, S. Chowdhury, E. Kaptein, A. Baydur, Los Angeles, CA, p.A7044

P343 **Resuscitations Strategies in Early Septic Shock (ESS): Survey of Puerto Rico (PR) Intensive Care and Emergency Physicians/**J. Flores, J. Aleman-Ortiz, F. Del Olmo, W. Rodriguez-Cintron, San Juan, PR, p.A7045

P344 **A Novel Fluid Resuscitation Protocol in the Treatment of Septic Shock/**E. Horn, M. Boivin, W. Demaray, R. Crowell, S. Ahmed, Albuquerque, NM, p.A7046

P345 **Effects of Fluids Administration in Patients with Septic Shock with or Without Heart Failure/**L. Bigatello, W. Linde-Zwirble, J. Crowell, D. Hansell, J. Sahatjian, Brighton, MA, p.A7047

P346 **Fluid Resuscitation Dilemma in Patients with Congestive Heart Failure Presenting with Severe Sepsis/Septic Shock/**M. Duttuluri, K. Rose, J. Shapiro, J. Mathew, R. Jean, S. Kurtz, K. Mckenna, J. Salonia, H. Khouli, New York, NY, p.A7048

P347 **Pericardial Effusion in End-Stage Renal Disease/**L. Sargsyan, G.M. Aisenberg, M. Rosenthal, B. Alhafez, K.-W. Chang, Houston, TX, p.A7049

P348 **Electrocardiographic Abnormalities in HIV-Infected Adults in North-Central Nigeria/**G.A. Amusa, B.I. Awokola, M.O. Akanbi, J.A. Onuh, S.U. Uguru, P. Idoko, S.S. Danbauchi, B.N. Okeahialam, Jos, Nigeria, p.A7050

P349 **Echocardiographic Abnormalities in HIV-Infected Adults in North-Central Nigeria/**G.A. Amusa, B.I. Awokola, M.O. Akanbi, J.A. Onuh, S.U. Uguru, P. Idoko, S.S. Danbauchi, B.N. Okeahialam, Jos, Nigeria, p.A7051

P350 **Management of Atrial Fibrillation with Rapid Ventricular Response in the Intensive Care Unit: A Secondary Analysis of Electronic Health Record Data/**A. Moskowitz, K. Chen, A. Cooper, A. Chahin, M. Ghassemi, L.A. Celi, Boston, MA, p.A7052

Facilitators: P.L. Silva, PhD, Rio de Janeiro, Brazil
R.S. Stephens, MD, Baltimore, MD

P351 **Arrhythmogenic Effect of Hypokalemia Induced by Therapeutic Hypothermia/**Y.A. Al Ahwel, A. Ali, M. Taleb, D. Gachoka, A. Kubbara, S.U. Rehman, R. Assaly, J. Hammersley, D. Olson, Toledo, OH, p.A7053

P352 **Levosimendan Use Increases Cardiac Performance After Coronary Artery By-Pass Grafting in End-Stage Renal Disease Patients/**O.F. Dogan, S. Colak, H. Ozgen, A.H. Kurt, C.C. Okten, Adana, Turkey, p.A7054

P353 **A New Surgical Approach to Internal Thoracic Artery Spasm Treatment Using the Radial and Gastroepiploic Arteries during Coronary Artery Bypass Graft/**O.F. Dogan, H. Ozgen, C.C. Okten, Adana, Turkey, p.A7055

P354 **Echocardiography and Pulmonary Function Tests in Chest Deformities/**M. Aydogan, N. Ocal, M. Ozturk, D. Dogan, O. Alan, Isparta, Turkey, p.A7056

P355 **Impact of Left Ventricular Heart Failure with Preserved Ejection Fraction and Right Ventricular Systolic Heart Failure on Outcomes in the Intensive Care Unit/**J.D. Marshall, C.X. You, T. Pollard, F. Salgueiro, C. Chen, L.A. Celi, New Haven, CT, p.A7057

P356 **Accuracy of the Diagnosis of Pulmonary Hypertension in Critically Ill Patients/**B. Witt, M. Pratter, R.P. Dellinger, C. Schorr, K. Hunter, S. Akers, Camden, NJ, p.A7058

P357 **Anticoagulation May Increase the Risk of Acute Respiratory Failure in Patients with Acute Cardiogenic Pulmonary Edema/**M. Ghamloush, J. Abulkhair, M. Habib, N.S. Hill, Boston, MA, p.A7059

P358 **Serum Pregnancy-Associated Plasma Protein A (PAPP-A) Vs GRACE Scale for Risk Estimation in Patients with Acute Coronary Syndrome/**M. Ojrzanowski, A. Lipinska-Ojrzanowska, J.D. Kasprzak, Lodz, Poland, p.A7060

P359 **Association Between Serum Resistin Levels and Ischemic Stroke: A Meta-Analysis/**P. Agasthi, S. Aloor, S. Annangi, V. Yarlagadda, R. Sachdeva, Atlanta, GA, p.A7061

P360 **Predictors of Repeat Invasive Pericardial Procedures/**D. Herman, S. Lilly, Columbus, OH, p.A7062

P361 **Comparison of the Effects of a Difference in Blood Donation Experience on the Autonomic Response and Cardiovascular Dynamics During Mild Blood Loss/**M. Kamakura, M.Y. Fujiwara, E. Kanno, R. Maruyama, Sendai, Japan, p.A7063

P362 **Comparison of Resuscitation with or Without Norepinephrine in a Rat Model of Controlled Haemorrhagic Shock/**S. Dunberry Poissant, K. Gilbert, F. Baril, C. Bouchard, M. Hylands, F. Lamontagne, G. Rousseau, E. Charbonney, Montreal, Canada, p.A7064

P363 **Development of Heparin Protocols for Patients Receiving Ventricular Assist Device/**J.W.E. Fleischman, J. Shin, F. Li, Walnut Creek, CA, p.A7065

P364 **Trends in the Use of Vasopressors in Cardiac Surgery Intensive Care Unit/**N. Srivali, C. Thongprayoon, W. Cheungpasitporn, K.B. Kashani, Rochester, MN, p.A7066

P365 **Impact of Delaying Norepinephrine in Septic Shock: A Prospective Observational Study/**J.J. Patel, H. Taha, J.S. Kurman, A. Biesboer, J. Kovac, A. Szabo, M. Katz, Milwaukee, WI, p.A7913

THEMATIC POSTER SESSION

D46 CASE REPORTS IN ENVIRONMENTAL AND OCCUPATIONAL HEALTH

9:00 a.m. - 3:30 p.m. **MOSCONE CENTER**

Area B, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: R.E. de la Hoz, MD, MPH, MSc, New York, NY

P135 **Immune Response to Beryllium Unmasked by G-CSF?/**A. Mayer, L.A. Maier, D. Patel, L. Li, Denver, CO, p.A7067

P136 **Giant Cell Interstitial Pneumonia in a Patient with World Trade Center Dust Exposure/**R. Postelnicu, B. Nguyen, B.G. Wu, K. Katz, D. Mcculoch, J. Zheng, M. Bannan, E. Dweck, New York, NY, p.A7068

P137 **B-Cell Lymphocytic Bronchiolitis and Alveolar Ductitis in a Man with Exposure to Metalworking Fluids - A Novel Occupational Lung Disease/**R.J. Nett, M.L. Stanton, L. Segal, J.L. Abraham, T. Colby, F.H.Y. Green, A.D. Franko, R.J. Tallaksen, D. Wendland, V.D. Bachelder, R.J. Boylstein, J.-H. Park, K. Kreiss, K. Cummings, Morgantown, WV, p.A7069

P138 **Pleuroparynchemal Fibroelastosis Due to Long-Term Silica Exposure/**C.C. Shaffer, N. Rassaei, Hershey, PA, p.A7070

P139 **Chronic Hypersensitivity Pneumonitis Associated with Inhaled Exposure to Nylon Powder for 3-D Printing: A Variant of Nylon Flock Worker's Lung Disease?/**J. Johannes, T. Rezayat, W.D. Wallace, J.P. Lynch, Los Angeles, CA, p.A7071

P140 **An Unusual Cause of Lung Mass and Airways Discoloration/**J. MacLeod, R. Almadi, G.R. Bourjeily, R. El-Bizri, Providence, RI, p.A7072

P141 **Hidden Occupational Risk for Pulmonary Fibrosis in a Patient with Rheumatoid Arthritis/**V.K. Holden, J. Kim, S.E. Hines, Baltimore, MD, p.A7073

Facilitator: E.L. Petsonk, MD, Morgantown, WV

P142 **Analysis of Lung Particle Burden in a 28 Year Old Man with Rapidly Progressive Coal Worker's Pneumoconiosis (Accelerated Silicosis)/**J.L. Abraham, J.A. Crawford, E. Scalzetti, L.G. Kramer, Syracuse, NY, p.A7074

P143 **Airbag Pulmonary Injury in a Patient with Suspected Cryptococcal Pneumonia/**R. Prakobkit, A. Friedenberg, Stanford, CA, p.A7075

P144 **Mixed-Dust Pneumoconiosis in a Steel Foundry Core Maker Mimicking Idiopathic Pulmonary Fibrosis: Occupational History, Radiologic and Pathologic Findings, and Demonstration of Zirconium and Steel in an Explant Lung by SEM/EDS/**S. Mukhopadhyay, N. Lakis, O. Akindipe, S. Ghosh, J.L. Abraham, Cleveland, OH, p.A7076

P145 **Wet Grinder's Lung: Hypersensitivity Pneumonitis in a Titanium Metal Worker/**P.D. Jackson, B.D. Tarlow, G. Allada, Portland, OR, p.A7077

P146 **Metastatic Desmoplastic Mesothelioma Presenting with Bone Pain and Diplopia/**A. Moskowitz, P. VanderLaan, A. Anandaiah, K. Krecko, H. Koziel, Boston, MA, p.A7078

P147 **Organizing Pneumonia in a Military Deployer Returning from Iraq/**S.D. Krefft, S.P. DelVecchio, C. Rose, Aurora, CO, p.A7079

P148 **Anything to Get Out of House Work?/**Z.S. Dreyfuss, K. Proud, San Antonio, TX, p.A7080

Facilitator: K.A. Pacheco, MD, MSPH, Denver, CO

P149 **Unilateral Diaphragmatic Paralysis Following Neck Manipulation/**C.J. VanHook, B. Warner, D. Tangel, J. Gould, Longmont, CO, p.A7081

P150 **Serial Changes in Specific IgE and IgG to Methylene Diisocyanate (MDI) in a Worker with Occupational Asthma/**S.M. Tarlo, C.A. Redlich, A.V. Wisnewski, Toronto, Canada, p.A7082

P151 **Endobronchial Silicosis and Tuberculosis Presenting as the Right Middle Lobe Syndrome/**J. Anderson, S. Leong, D. Godbolt, K. Fong, H. Marshall, Brisbane, Australia, p.A7083

P152 **My Rash: The Rats on the Citrus Farm/**J. Shah, J. Gunter, S. Shome, Chattanooga, TN, p.A7084

P153 **Pneumoconiosis Presenting with Recurrent Pneumothorax/**J. Seashore, T. McGarry, Queens, NY, p.A7085

P154 **Thirty Years Evolution of a Case of Occupational Asthma/** E. Banderas, R. Diaz Campos, I. Bobolea, C. Melero, Madrid, Spain, p.A7086

Facilitator: P.S. Lai, MD, MPH, Boston, MA

P155 **Hot Tub Lung. Unique Diffuse Environmental Pulmonary Lung Disease Due to Atypical Mycobacterium/**M. Rudrappa, L. Kokatnur, Shreveport, LA, p.A7087

P156 **Silicotuberculosis/**K.E. Veron, R.B. Taylor, C. O'Neal, H. O'Neal, Baton Rouge, LA, p.A7088

P157 **9/11 Consequences; Reversible or Not?/**S. Shihadeh, Flushing, NY, p.A7089

P158 **Twenty Year Old Female with Rapidly Progressive Dyspnea/**N.R. Mohammed, Minia, Egypt, p.A7090

P159 **Pneumomediastinum: A Complication of Synthetic Cannabinoid K2 Use/**B. Bajantri, T. Singh, G. Diaz-Fuentes, S. Venkatram, Bronx, NY, p.A7091

P160 **An Unexpected Bronchoscopic Finding Associated with Marijuana Use/**M. Shafiq, G.J. Berry, Y. Sung, Stanford, CA, p.A7092

THEMATIC POSTER SESSION

D47 EPIDEMIOLOGIC ASPECTS OF TUBERCULOSIS AND BACTERIAL INFECTIONS

9:00 a.m. - 3:30 p.m. **MOSCONE CENTER**

Area B, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: M. Thomassen, PhD, Greenville, NC

P162 **Progression to Active Tuberculosis Among Immigrants and Refugees with Abnormal Overseas Chest Radiographs - California, 1999-2012/**J. Wong, P. Lowenthal, J. Flood, J. Watt, E. Murray, P.M. Barry, Richmond, CA, p.A7093

P163 **Examination of Risk Factors for Nontuberculous Mycobacterial Infections Among National Jewish Health Hospital Patients in the United States/**E.M. Lipner, D. Knox, J. French, J. Crook, J. Rudman, M. Strong, Denver, CO, p.A7094

P164 **Factors Associated with TB and HIV Co-Infection in an Urban HIV Clinic in Guatemala City/**B.S. Albury, C. Ascoli, C.R. Mejia, Guatemala City, Guatemala, p.A7095

P165 **Association Between Degree of Tuberculosis Contact and Latent Tuberculosis Infection Amongst Health Care Workers in a Peruvian University Hospital/**R. Accinelli, L.M. Lopez, Lima, Peru, p.A7096

P166 **Impact of a Tuberculosis Infection and Disease Detection Programme on Reducing Tuberculosis Disease Among Health Care Workers in a Peruvian University Hospital/**R. Accinelli, L.M. Lopez, Lima, Peru, p.A7097

P167 **Protective Effect of Isoniazid Chemoprophylaxis in Health Care Workers Under 36 Years of Age in a Peruvian University Hospital Setting/**L.M. Lopez, R. Accinelli, Lima, Peru, p.A7098

Facilitator: R.A. Accinelli Tanaka, MD, Lima, Peru

P168 **Factors Associated with Tuberculosis Infectiousness and Excess Alcohol Use in Franklin County, Ohio/**Y. Negatu, M. Exline, S. Tapyrik, T. Mathew, S.-H. Wang, Columbus, OH, p.A7099

P169 **Chernobyl Disaster and Tuberculosis Among Children and Teenagers/**L. Gorbach, Minsk, Belarus, p.A7100

P170 **Exposure to a Mycobacterial Antigen Exacerbates Inflammation and Fibrosis in a Multi-Wall Carbon Nanotube MWCNT Model of Pulmonary Granulomatous Disease/**A. Malur, B.P. Barna, M. McPeek, L. Dobbs, C.J. Wingard, M.J. Thomassen, Greenville, NC, p.A7101

P171 **Environmental Exposure of Panamanian Health Care Workers to Mycobacterium Tuberculosis at Hospital and Clinics in Colon, Panama/**D. Sambrano, C. Ordonez, V. Batista, A. De Chavez, O. Luque, A. Goodridge, City of Knowledge, Panama, p.A7102

P172 **The Effect of Simulated Microgravity on Biological Characteristics of Klebsiella Pneumoniae/**P. Wang, J. Wang, Beijing, China, p.A7103

P173 **The Central Role of Heme in the Propagation of Bacterial Infection After Acute Lung Injury/**S. Aggarwal, A. Lam, M.A. Carlisle, A. Traylor, N. Vital, A. Agarwal, S. Matalon, Birmingham, AL, p.A7104

P174 **Deaths from Acute Respiratory Infections in Indigenous Ecuadorian Population: Analysis of Sociodemographic Factors/**E.J. Cano, N.P. Suarez, Guayaquil, Ecuador, p.A7914

THEMATIC POSTER SESSION

D48 LUNG INFECTION CASE REPORTS I: FUNGAL INFECTIONS

9:00 a.m. - 3:30 p.m. **MOSCONE CENTER**

Area G, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: M. Kobayashi, MD, PhD, Sendai Miyagi, Japan

P754 **Utility of Galactomannan Testing in the Immunocompetent Host/**J.E. Hines, A. Mohamed Hosni, Ypsilanti, MI, p.A7105

P755 **Aspergillous Terrus: A New Threat for Immunocompetent Patient?/**H.J. Maldonado Quintana, San Juan, PR, p.A7106

P756 **A Case of Pulmonary Aspergillosis Unfit for Subtyping/**A.K. Tandon, S. Benzaquen, A. Aragaki-Nakahodo, Cincinnati, OH, p.A7107

P757 **Aspergillus Tracheobronchitis: A Successful Treatment of an Unusual Infection/**M.U. Khawar, M.K. Ishaq, K.R. Jones, Oklahoma City, OK, p.A7108

P758 **Invasive Aspergillosis Related to Ibrutinib Therapy for Chronic Lymphocytic Leukemia/**B. Arthurs, M. Hsu, N. Dobos, C. Grochowski, S. Kim, Portland, OR, p.A7109

P759 **Invasive Pulmonary Aspergillosis Presenting with Paraplegia/**J.S. Kurman, A. Taneja, Milwaukee, WI, p.A7110

P760 **Invasive Pulmonary Aspergillosis (IPA) in an Immunocompetent Host - A Diagnostic Conundrum/**T. Nisar, P. Puthran, Coventry, United Kingdom, p.A7111

P761 **Invasive Pulmonary Aspergillosis Revealed After Whole Lung Lavage for Pulmonary Alveolar Proteinosis/**J.M. Radbel, A. Scardella, J. Sunderram, S. Hussain, New Brunswick, NJ, p.A7112

P762 **Piperacillin-Tazobactam: An Unlikely Distractor in Invasive Aspergillosus Testing/**K.M. Dziamski, K. Gupta, V. Thoguluva Chandrasekar, S. Zaidi, Syracuse, NY, p.A7113

P763 **Chronic Necrotizing Aspergillosis/**A.J. Berglund, D. Ferraro, Ft. Sam Houston, TX, p.A7114

Facilitator: E.M. Carmona, MD, PhD, Rochester, MN

P764 **Bronchopleural Fistulas and Empyema as a Complication of Progressive Chronic Necrotizing Pulmonary Aspergillosis and Mycetoma/**R. Salehi-Rad, W. Chang, G.W. Soo Hoo, J. Betancourt, Los Angeles, CA, p.A7115

P765 **Complicated Pulmonary Hydatid Cyst with Aspergilloma/** D.A. Salazar, G.F. Velasquez, O. Gayoso, J. Diaz, W. Chavez, J. Caceres, Lima, Peru, p.A7116

P766 **Recurrent Cough and Shortness of Breath - An Interesting Case of Disseminated Histoplasmosis in an Immunocompetent Patient/**A. Prince, R. Purushothaman, C. Colaco, A. Rjoop, R. Jagana, Little Rock, AR, p.A7117

P767 **Cancer Is Not Always the Answer/**D.U. Otu, R.M. Ruggiero, Dallas, TX, p.A7118

P768 **Bat Caves and Prednisone: A Unique Case of Disseminated Histoplasmosis /**L. Cagino, J. Lascano, Gainesville, FL, p.A7119

P769 **Empyema Due to Histoplasmosis Capsulatum Without Evidence of Bronchopulmonary Fistula or Pulmonary Granulomatosis/**J.A. Stienecker, M. Junqueira, Pueblo, CO, p.A7120

P770 **Double-Edged Sword: Disseminated Histoplasmosis in Rheumatoid Arthritis Patient on Tofacitinib Therapy/**I. Waheed, D. Dhingani, L. Srinivasan, A. Fulambarker, North Chicago, IL, p.A7121

P771 **EBV Pneumonitis Complicating Disseminated Histoplasmosis and in a Non-HIV Infected Patient. A Fatal Combination/**S. Singh, J. Farrell, B. Aulakh, B. Bamberger, P. Suppatakal, M. Saavedera, Peoria, IL, p.A7122

P772 **Laryngeal Histoplasmosis as Cause of Chronic Dysphonia and Dysphagia: A Case Report and Review of Literature/**C. Villaquiran-Torres, J. Buitrago, J. Torres, Bogota, Colombia, p.A7123

P773 **Healing and Hardening: Focal Fibrosing Mediastinitis Due to Histoplasmosis/**R. Bishwakarma, R. Papani, V.G. Valentine, Galveston, TX, p.A7124

Facilitator: O. Hilberg, MD, Aarhus, Denmark

P774 **Fibrosing Mediastinitis/**A. Clerman, R. Krochmal, A. Sachdeva, E. Pickering, J. Deepak, Baltimore, MD, p.A7125

P775 **Hypercalcemia of Coccidioidomycosis, Less Prevalent and Unknown Complication of Primary Disease/**F. Jaffer, S. Patel, A. Potharaju, Tucson, AZ, p.A7126

P776 **Isolated Coccidioidomycosis Empyema Diagnosed from a Pleural Biopsy in a Serology-Negative Patient/**J. Hall, A. Thomas, Phoenix, AZ, p.A7127

P777 **An Elusive Fungus: A Case of Disseminated Angioinvasive Mucormycosis Presenting with Multi-Organ Infarcts/**J. Hall, R. GarciaOrr, Phoenix, AZ, p.A7128

P778 **A Rare Case of Coccidioides Immitis Cultured from an Immunocompetent Patient in Non-Endemic UK/**C.L. Tey, B. Prathibha, Ashford, United Kingdom, p.A7129

P779 **Successful Use of Extracorporeal Membrane Oxygenation in a Patient with Pulmonary Coccidioidomycosis-Related Acute Respiratory Distress Syndrome/**R. Baalachandran, L.R. Trutter, Y. Raz, J. Mosier, T. Kazui, J. Malo, Tucson, AZ, p.A7130

P780 **An Unusual Cause of Cavitary Lung Lesion: When Diagnosis Requires Biopsy/**P. Tsing, A. Chung, Los Angeles, CA, p.A7131

P781 **A Unique Presentation of Asymptomatic Pulmonary Mucormycosis as a Pulmonary Mass/**K. Bakhsh, G. Lenchner, Philadelphia, PA, p.A7132

P782 **Are We Missing a Fungus Among Us?/**J. Loeb, D.R. Fraidenburg, Chicago, IL, p.A7133

P783 **Break Through Pulmonary Mucormycosis in a Patient Treated with Voriconazole/**M.A. Shenoy, S. Shankar, P.K. Gorukanti, P.K. Irukulla, M. Seales, E. Chapnick, K. Chawla, W. Pascal, Brooklyn, NY, p.A7134

Facilitator: O. Epelbaum, MD, Elmhurst, NY

P784 **Pneumocystis Jirovecii Causing Necrotizing Granulomas Presenting as Multiple Pulmonary Nodules in an Immunocompetent Patient/**B.M. Walsh, Y.B. Mehta, Danville, PA, p.A7135

P785 **Pneumocystic Jirovecii Pneumonia in a Patient with Systemic Lupus Erythematosus/**S. Patel, D. Posner, A. Saxena, T. Anderson, A. Tilley, New York, NY, p.A7136

P786 **Bronchial Diverticula in a Patient with HIV and Pneumocystis Jiroveci Infection/**C. Miranda, P. Rodriguez, I. Gonzalez, S. Yousef, Miami, FL, p.A7137

P787 **AIDS and the Aging Population/**F. Siddiqui, K. Chong, M.T. Khan, R. Maroun, Staten Island, NY, p.A7138

P788 **A Case of Pulmonary Cryptococcosis in an Immunocompetent Woman /**M.K. Loya, Sayre, PA, p.A7139

P789 **A Case of Endobronchial Ultrasound Use in the Diagnosis of Thoracic Infection/**L. Frye, F. Almeida, Cleveland, OH, p.A7140

P790 **Pulmonary Cryptococcosis in Immunocompetent Patient, a Case Report/**G.F. Velasquez, D.A. Salazar, O. Gayoso, A. Aguero, W. Chavez, J. Caceres, J. Cok, Lima, Peru, p.A7141

P791 **Disseminated Blastomycosis in an Immunocompetent Patient and the Impact of Delayed Diagnosis/**G. Lockhart, E.J. Jackson, P. Nana-Sinkam, Columbus, OH, p.A7142

P792 **Blastomycosis-Associated ARDS, Case Report and Review of the Literature/**D. Smith, N. Abi Hatem, S. Ie, S. Aziz, Roanoke, VA, p.A7143

P793 **Unusual Presentation of an Unusual Fungus: Blastoschizomyces Capitatus/**H.H. Desai, M. Dalabih, A. Witten, Tucson, AZ, p.A7144

Facilitator: A. Catanzaro, MD, La Jolla, CA

P794 **Exophiala Pneumonia Presenting as an Eosinophilc Pneumonia in an Immunocompetent Patient/**J. Callaway, K. Swanson, A. Budavari, K. Yaqub, Scottsdale, AZ, p.A7145

P795 **Could There Be a Fungus Among Us?/**M.J. Sanley, R. Gross, Washington, DC, p.A7146

P796 **Paraconiothyrium Cyclothyroides Pneumonia: Report of a Unique Case/**P. Aulakh, J. Leon, J.A. Gonzales Zamora, Augusta, GA, p.A7147

P797 **Scedosporium Apiospermum Pneumonia in an Immunocompetent Patient Without Prior Lung Disease/**K.C. Ma, M. Turetz, New York, NY, p.A7148

P798 **Rare Fungal Infection in Patient with Pulmonary Tuberculosis Sequelae/**B.N. Endlich, F.M. Costa, E.P. Oliveira, C.M. Padovesi, M.C.N.T. Maiorano, A.W. Mariani, R.A. Athanazio, S.Z. Rached, R.K.B. Sales, A.N. Costa, Sao Paulo, Brazil, p.A7149

P799 **Saccharomyces Cerevisiae Empyema/**M.G. Al Janabi, M.S. Dhillon, M. Bowling, Greenville, NC, p.A7150

P800 **An Unconventional Treatment with Unconventional Results: A Tale of Three Fungi/**Z. Tushak, E. Nadler, J. Goralnik, P. Grover, Farmington, CT, p.A7151

THEMATIC POSTER SESSION

D49 LUNG INFECTION CASE REPORTS II: INFECTIONS OTHER THAN FUNGAL INFECTIONS

9:00 a.m. - 3:30 p.m. **MOSCONE CENTER**

Area G, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: G.W. Waterer, MBBS, PhD, MBA, Perth, Australia

P802 **Not an Everyday Case of Dyspnea-Pseudomembranous Tracheobronchitis Caused by Pseudomonas Aeruginosa Infection/**M.S. Khan, J.C. Claros-Sorto, A.C. Porter, Oklahoma City, OK, p.A7152

P803 **A Case of Pseudomonas Aeruginosa Bacteremic Pneumonia in a Patient with Pancreatic Cancer Who Received Pegfilgrastim Followed by Outpatient Chemotherapy/**F. Morita, Y. Hirai, K. Suzuki, Y. Uehara, K. Mitsuhashi, M. Takahashi, S. Watanabe, T. Naito, Hongo, Bunkyou-ku, Tokyo, Japan, p.A7153

P804 **Multidrug-Resistant Pseudomonas and Continuous Renal Replacement Therapy: A Case Report and Review of Literature/**J. Dhami, S. Quirk, M.A. Narayanan, H. Devineni, J. Horne, C. Destache, R. Vivekanandan, Omaha, NE, p.A7154

P805 **Community Acquired Cavitary Pneumonia from an Infrequently Encountered Community Acquired Organism/**A. Elahi, A. Sodhi, D. Kadaria, Memphis, TN, p.A7155

P806 **Necrotizing Bacterial Tracheobronchitis in a Non-Mechanically Ventilated Adult/**A. Shahmohammadi, A. Biswas, E.S. Papierniak, Gainesville, FL, p.A7156

P807 **Mediastinal Mass, Growth Hormone and Septic Arthritis/**F. Siddiqui, M.T. Khan, D. Elsayegh, Staten Island, NY, p.A7157

P808 **Development of Lung Abscess During Daptomycin Treatment for Persistent MRSA Bacteremia with Vancomycin MIC>1 lg/mL/**E. Levasseur Sanchez, J. Kingsley Tavarez, S. Subramaniam, K. Hennessey, Bronx, NY, p.A7158

Facilitator: A. Sayiner, MD, PhD, Izmir, Turkey

P809 **Papular-Purpuric Gloves and Socks Syndrome in a 46-Year-Old Man with Mycoplasma Pneumoniae Infection/**J. Jankovic, D. Pesut, Belgrade, Serbia, p.A7159

P810 **Mycoplasma Pneumoniae Infection Alone Leading to Severe, Complicated Pneumonia and Respiratory Failure in a Previously Healthy Child/**A.G.S. St-Laurent, T. Sotindjo, A. Roberts, Montreal, Canada, p.A7160

P811 **A Case of Severe Hemolytic Anemia as an Extra-Pulmonary Manifestation of Mycoplasma Pneumoniae/**V. Patel, A. Shah, A. Karki, K. Cervellione, K. Mandal, C. Thurm, Jamaica, NY, p.A7161

P812 **Bronchiectasis Secondary to Mycoplasma.pneumoniae/**S. Harsha Vardhan, J. Bishara, M. Pirzada, Mineola, NY, p.A7162

P813 **Legionella Pneumonia in a Systemic Lupus Erythematosus Patient Requiring Extracorporeal Membrane Oxygenation/**E. Espinoza Moscoso, J. Swiderek, Detroit, MI, p.A7163

P814 **Legionella Pneumonia Associated with Severe Rhabdomyolysis and Acute Kidney Injury/**C. Agu, M. Basunia, D. Salhan, S. Kandel, F. Schmidt, J. Quist, D. Enriquez, Brooklyn, NY, p.A7164

P815 **A Case of Pulmonary Nocardiosis in an Immunocompetent Host/**P. Righini, A. Oliva, V. Gallo, G. Ferrari, R. Prota, Torino, Italy, p.A7165

Facilitator: E.M. Mortensen, MD, MSc, Dallas, TX

P816 **Nocardia: An Unusual Bacteria in an Unexpected Patient/**H.H. Desai, K.K. Wickstrom, S.W. Low, N. Mahmoud, Tucson, AZ, p.A7166

P817 **Pulmonary Nocardiosis Concurrent with Lung Cancer in a Patient with Renal Transplantation Living in a Remote Island/**K. Suzuki, Y. Hirai, K. Murai, F. Morita, Y. Uehara, K. Mitsuhashi, T. Naito, Hongo, Bunkyo-ku, Tokyo, Japan, p.A7167

P818 **Pulmonary Nocardiosis Masquerading as Metastasis in a Patient with Pancreatic Neuroendocrine Cancer/**A. Selvachandran, K. McDonald, P. DeSilva, D. Datta, Farmington, CT, p.A7168

P819 **Rising Incidence of Nocardiosis: A Conundrum of Monoclonal Antibody Therapy/**A. Tirmizi, E. Galvez-Guerra, L. Beauchamps, J. Parham, Jackson, MS, p.A7169

P820 **Cavitary Pulmonary Disease Due to Achromobacter Denitrificans/**A. Tirmizi, E. Galvez-Guerra, L. Beauchamps, Jackson, MS, p.A7170

P821 **The Great Pretender/**N. Alvi, R. Almeida, Kankakee, IL, p.A7171

P822 **Actinomycosis of the Aerodigestive Tract/**U.K. Ghori, S. Ahmed, Albuquerque, NM, p.A7172

P823 **A Rare Case of Empyema Caused by Community Acquired Pulmonary Actinomycosis and Group D Streptococcus/**Y. Naidu, N. Alqsous, C. Rusu, M. Matos, Rochester, NY, p.A7173

P824 **Human Necrobacillosis: Lest We Forget/**E. Nadler, J. Goralnik, B. Considine, Z. Tushak, Farmington, CT, p.A7174

P825 **Pseudomonal Pneumonia and Empyema Complicating Lemirre's Syndrome/**M. Megally, S. Milan, R. Minkin, Brooklyn, NY, p.A7175

Facilitator: C.M. Luna, MD, PhD, Buenos Aires, Argentina

P826 **A Taste of t-PA: An Unusual Way a Bronchopleural Fistula was Diagnosed in a Patient with Lemierre's Syndrome/**S.S. Hahn, A. Palkar, E. Singas, E. Gottesman, New Hyde Park, NY, p.A7176

P827 **An Unusual Case of Cavitary Lung Lesion/**H. Arikan, B. Demirelli, E. Eryuksel, B. Bagci Ceyhan, Istanbul, Turkey, p.A7177

P828 **Salmonella sp Causing Bacteremic Pneumonia in Patient with Lung Cancer - Case Report/**J.A. Victorino, A. Vivian, M.A.B. Franzoi, H.B.R. De Oliveira, R.K. Dal Molin, Porto Alegre, Brazil, p.A7178

P829 **Aspiration Meningitis: Mediastinitis and Brain Abscess Due to Streptococcus Intermedius/**A. Alam, A. Aragaki-Nakahodo, R.R. Balestra, Cincinnati, OH, p.A7179

P830 **It's Not a Tumor: An Unusual Presentation of Chronic Klebsiella Infection/**A. Rothman, A. Love, A. Astua, New York, NY, p.A7180

P831 **A Case of Multiple Lung Abscesses from Acinetobacter Baumannii in a Nigerian Child with Suspected Job's Syndrome/**J.N. Ibeh, B. Ogunbosi, R. Oladokun, G. Ogbole, Ibadan, Nigeria, p.A7181

P832 **Bordetella Bronchiseptica Pneumonia: A Case Report/**E. Demirer, B. Bektore, T. Kula Atik, E. Ozturk, M. Ozyurt, Istanbul, Turkey, p.A7182

P833 **Curing the Contaminant/**G. Thompson, J. O'Horo, R. Vassallo, Rochester, MN, p.A7183

P834 **Rare Case of Empyema with Clostridium Septicum Lead Us to Diagnosis of GI Malignancy/**M. Alzoby, M. Shorman, M. Aldliw, M. Al-Ourni, E. Alkhankan, N. Munn, Huntington, WV, p.A7184

P835 **Vancomycin Resistant Enterococcus Pneumonia with Stongyloides Hyperinfection Syndrome/**M. Abu Omar, S. Kim, M. Abu Ghanimah, G. Howell, Kansas City, MO, p.A7185

Facilitator: J.M. Fine, MD, Norwalk, CT

P836 **Strongyloidiasis and Diffuse Alveolar Hemorrhage in a Malnourished Alcoholic Patient/**A.S. Herrera Guerra, E.J. Rendon Ramirez, C.P. Rivera Uribe, E.M. Gutierrez Delgado, R. Mercado, J. Tapia Orozco, S.S. Sanchez, Monterrey Nuevo Leon, Mexico, p.A7186

P837 **Good for Nothing: Recurrent Respiratory Failure Due to Multiple Opportunistic Infections in a 65 Year Old Man with Pure Red Cell Aplasia/**N.A. Braus, B. Patel, G. Volcheck, T. Peikert, P. Escalante, R. Vassallo, Rochester, MN, p.A7187

P838 **Severe Cytomegalovirus Pneumonia in an Immunocompetent Host/**D.B. Desai, S. Davis, J. Bukli, Worcester, MA, p.A7188

P839 **Cytomegalovirus Infection After Severe Pneumonia in Immunocompetent Subjects: A Case Report/**C. Gu, H. Chen, Y. Ding, G. Shi, China, p.A7189

P840 **Is Lung Biopsy Needed for Positive Cytomegalovirus Poly Chain Reaction (PCR) on Bronchoalveolar Lavage in Immunocompromised Host?/**F. Aldaas, D.J. Rudolph, Z. Saul, Bridgeport, CT, p.A7190

P841 **First Reported Case of Respiratory Syncytial Virus Infection Causing Guillain-Barre Syndrome/**S. Helgeson, D. Harris, Jacksonville, FL, p.A7191

P842 **Severe Pneumonia and Acute Respiratory Distress Syndrome Caused by Human Metapneumovirus in an Immunocompetent Patient/**S. Imran, S. Rasla, M. Alqadi, Pawtucket, RI, p.A7192

P843 **Rhinovirus Infection Resulting in Respiratory Failure and Acute Respiratory Distress Syndrome/**J. Krings, R.D. Shah, R.G. Wunderink, Chicago, IL, p.A7193

P844 **Motor Nerve Involvement with Herpes Zoster Infection/**S. Hadigal, S. Daouk, V. Vanam, S. Chandrashekaran, Gainesville, FL, p.A7194

P845 **Pleuropulmonary Disease as the Initial Presentation of Extra-Intestinal Amebiasis/**C.A. Goulbourne, F. Christian, T. James-Goulbourne, Brooklyn, NY, p.A7195

Facilitator: I. Martin-Loeches, MD, PhD, Barcelona, Spain

P846 **Amoebic Pneumonia: A Unique Case/**B. Lopez-Gonzalez, S. Rodriguez-Llamazares, E. Pena-Mirabal, O. Sanchez-Cabral, Mexico City, Mexico, p.A7196

P847 **A Case of Primary Pulmonary Amoebiasis/**R.C. Daya, Davao City, Philippines, p.A7197

P848 **Massive Pulmonary Echinococcal Cyst Infiltration Masquerading as a Non-Resolving Tuberculous Pleural Effusion/**A.K. Graham, Johannesburg, South Africa, p.A7198

P849 **An Unlikely Cause of Shortness of Breath in an AIDS Patient/**S. Dixit, L. Santhosh, L. Huang, San Francisco, CA, p.A7199

P850 **The Clot Thickens/**J.Y. Fung, T.J. Harkin, New York, NY, p.A7200

P851 **Microfilaria in Transbronchial Lung Biopsy (TBLB) in Patient with Multiple Lung Infections and Low Serum IgM Levels/**G.C. Khilnani, P. Tiwari, S. Arava, A.S. Bhalla, V. Hadda, K. Madan, A. Mohan, R. Guleria, New Delhi, India, p.A7201

P852 **Recurrent Pneumonia Secondary to Endobronchial Hamartoma/**J.-P. Soberano, K. Hussain, Morgantown, WV, p.A7202

THEMATIC POSTER SESSION

D50 PEDIATRIC RARE LUNG DISEASES

9:00 a.m. - 3:30 p.m. **MOSCONE CENTER**

Area E, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: L.R. Young, MD, Nashville, TN

P513 **A Panel of Novel Blood Tests Based on GM-CSF Signaling Facilitates the Differential Diagnosis of PAP-Causing Diseases/**B. Carey, C. Chalk, T. Suzuki, B.C. Trapnell, Cincinnati, OH, p.A7224

P514 **Pulmonary Abnormalities in Adults with Familial Neuroendocrine Cell Hyperplasia of Infancy (NEHI)/**L.R. Young, E.T. Garnett, R.L. Morton, L.M. Nogee, J.A. Worrell, Nashville, TN, p.A7232

P515 **Bombesein Staining May Be a Useful Marker in Idiopathic Interstitial Pneumonias Other Than NEHI/**N. Emiralioglu, D. Orhan, N. Kiper, G. Cinel, G. Tugcu, E. Yalcin, D. Dogru, U. Ozcelik, M. Griese, Ankara, Turkey, p.A7214

P516 **Respiratory Characteristics in Patients with Familial Dysautonomia/**M. Kazachkov, N. Tkachenko, J.A. Palma, L. Norcliffe-Kaufmann, N. Fefferman, C. Spalink, S. Kothare, H. Kaufman, New York, NY, p.A7206

P517 **Long Non-Coding RNA Malat1 Participates in the Pathogenesis of Pulmonary Fibrosis/**N. Xie, J. Ge, H. Cui, S. Banerjee, V.J. Thannickal, G. Liu, Birmingham, AL, p.A7238

P518 **Soluble Ephrin-B2 Is a Novel Biomarker of Pulmonary Fibrosis/**S.B. Montesi, M. Namude, A. Pardo, M. Selman, A.M. Tager, D. Lagares, Boston, MA, p.A7217

Facilitator: A.M. Casey, MD, Boston, MA

P519 **The Morphology of Tricuspid Valve at TVR in Physiologic Surgery for ccTGA Patients/**K. Hirose, K. Yamanaka, T. Nishina, A. Mizuno, Tenri City, Japan, p.A7209

P520 **The Clinical Implications of Lower Airway Anomalies in Children with Congenital Heart Disease/**C.-C.E. Wang, S.-J. Chen, E.-T. Wu, S.-C. Huang, M.-H. Wu, J.-K. Wang, Taipei, Taiwan, p.A7210

P521 **Impact of School Electrocardiography Mass Screening on the Diagnosis of Atrial Septal Defect in Children/**H. Sawada, H. Ohashi, S. Otsuki, N. Yodoya, H. Hayakawa, T. Konuma, H. Shimpo, K. Maruyama, Y. Komada, Y. Mitani, Tsu City, Mie, Japan, p.A7211

P522 **Aortic Wall Shear Stress and Left Ventricular Systolic Performance are Reduced in Pediatric Patients with Pulmonary Arterial Hypertension/**M. Schafer, K.S. Hunter, D. Ivy, S. Abman, A.J. Barker, U. Truong, Denver, CO, p.A7212

P523 **Right Ventricular Function Is a Predictor of Functional Class in Pediatric Pulmonary Hypertension/**B. Pandya, S. Moledina, V. Muthurangu, United Kingdom, p.A7228

Facilitator: D.R. Liptzin, MD, Aurora, CO

P524 **HEATR2 Regulates Ciliogenesis and Distinguishes Subclasses of Preassembly Factors Mutated in Primary Ciliary Dyskinesia/**A. Horani, T. Huang, J. Pan, S.L. Brody, St. Louis, MO, p.A7236

P525 **Cri-du-Chat Syndrome and Primary Ciliary Dyskinesia: A Genetic and Clinical Connection/**C. Donnellan, M. Leigh, M. Zariwala, M. Knowles, W. Wolf, D. Campbell, A.J. Shapiro, Chapel Hill, NC, p.A7235

P526 **Toronto Database Registry Pilot Cohort Study: Effect of Proximity to a PCD Center and Drug Insurance Coverage on Health Outcomes/**S. Deghan, S.D.M. Dell, Toronto, Canada, p.A7207

P527 **Development and Treatment of Chronic Rhinosinusitis in a Mouse Model of Primary Ciliary Dyskinesia/**L.E. Ostrowski, W. Yin, A. Ferguson, J.S. Kimbell, Chapel Hill, NC, p.A7229

P528 **Nup153 Gene Mutation Leads to Heterotaxy Through Defective SMAD1/BMP Signaling/**D.O.M. Teape, J. Endicott, F. Del Viso, M. Khokha, M. Brueckner, New Haven, CT, p.A7233

Facilitator: D. Al Alam, MS, PhD, Los Angeles, CA

P529 **Effect of Hydroxyurea on Pulmonary Function Decline in Children with Sickle Cell Disease/**A. McLaren, M. Klingel, S. Behera, M. Kirby-Allen, I. Odame, H. Grasemann, Toronto, Canada, p.A7225

P530 **Diffusing Capacity and Brain Natriuretic Peptide in Pediatric Patients with Sickle Cell Disease/**G. Chan, E.K. Fiorino, M. Santiago, Great Neck, NY, p.A7226

P531 **Lower Airway Obstruction Is Associated with Free Hemoglobin in Sickle Cell Disease/**S.C. Sadreameli, O. Uzosike, S. Ojukwu, N. Enika, J.J. Strouse, Baltimore, MD, p.A7227

P532 **A Multimodal Assessment of Adherence and Barriers to Hyperinsufflation in Children with Congenital Muscular Dystrophy/**J.E. Pascoe, C. White, J. Field, A.M. Rutkowski, O.H. Mayer, H. Sawnani, R.S. Amin, A. Modi, Cincinnati, OH, p.A7230

P533 **Natural History of Pulmonary Function Decline in Steroid Treated Patients with Duchenne Muscular Dystrophy (DMD): A Large Single Center Experience/**H. Sawnani, B. Wong, N. Simakajornboon, S. Hu, P. Horn, J. Bange, I. Rybalsky, K. Shellenbarger, A. Darmahkasih, R.S. Amin, Cincinnati, OH, p.A7231

P534 **Preliminary Results of Thromboxane-Prostanoid Receptor Antagonism in Mouse Models of Muscular Dystrophy/**E.J. Carrier, A.D. Rock, L. Pavliv, J.J. Shin, L.W. Markham, J.D. West, Nashville, TN, p.A7213

Facilitator: T.J. Vece, MD, Houston, TX

P535 **Pulmonary Function in Children with Transplant-Associated Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant: A Case Series/**L.E. Faricy, G. Church, B. Horn, San Francisco, CA, p.A7218

P536 **Prevalence and Timeline of Pulmonary Complications of Hematopoietic Stem Cell Transplantation in Children/**J.-S. Yoon, H.S. Kim, Y.H. Chun, H.H. Kim, J.T. Kim, Seoul, Korea, Republic of, p.A7221

P537 **Antibody-Mediated Rejection Is Associated with Decreased Survival Following Pediatric Lung Transplantation/**P.H. Michelson, J. Blatter, A. Faro, R.M. Grady, P. Eghtesady, S. Sweet, St. Louis, MO, p.A7222

P538 **Gastroesophageal Reflux and Gastric Motility in Pediatric Lung Transplant Recipients/**F.J. Dy, D.M. Boyer, G. Visner, D. Freiberger, R. Rosen, Boston, MA, p.A7223

Facilitator: S.D. Dell, MD, Toronto, Canada

P539 **Natural Evolution and Impact of Respiratory Tract Infections in Nasal Nitric Oxide Level During First 2 Years of Life - A Longitudinal Study/**J.K. Marthin, M.C. Philipsen, S. Rosthoj, K.G. Nielsen, Copenhagen, Denmark, p.A7203

P540 **Nasal Nitric Oxide in Primary Immunodeficiency: Helping to Distinguish Between Clinically Similar Diseases/**Z. Zysman-Colman, R. Alizadehfar, A.J. Shapiro, Montreal, Canada, p.A7204

P541 **Fractional Exhaled Nitric Oxide Levels in Children with Non-Cystic Fibrosis Bronchiectasis/**N. Bas Ikizoglu, T. Adiguzel, E. Atag, Y. Gokdemir, E. Erdem Eralp, F. Karakoc, R. Ersu, B.T. Karadag, Istanbul, Turkey, p.A7205

P542 **Ciliary Functional Biomarker Analysis in Pediatric Patients with Chronic Cough/**P.J. Shukla, A. Bangoura, L. Leatherbury, D.K. Pillai, Washington, DC, p.A7208

P543 **Mannose Binding Lectin and Its Impact on Patients with Primary Ciliary Dyskinesia/**K. Videbaek, F.F. Buchvald, F. Eriksson, P. Garred, K.G. Nielsen, Copenhagen, Denmark, p.A7234

Facilitator: A. Hilgendorff, MD, Munich, Germany

P544 **Langerhans Cell Histiocytosis and Pulmonary Involvement: Long Term Follow Up in 22 Pediatric Patients Having Pulmonary Function Tests/**C.M. Castanos, C. Samper, V.E. Aguerre, Y. Esquivel, J.L. Braier, Buenos Aires, Argentina, p.A7215

P545 **Pulmonary Complications of Stevens Johnson Syndrome: A Single Center Experience/**D.R. Liptzin, J.G. Morelli, J.P. Weinman, M.E. Kroehl, R.R. Deterding, Aurora, CO, p.A7216

P546 **Neoplasms of the Larynx, Trachea, and Bronchi in Children: A 15-Year Institutional Experience at a Single Children's Hospital/**H.-J. Cho, E. Lee, Y. Kim, S.-J. Hong, J. Yu, Seoul, Korea, Republic of, p.A7219

P547 **Treatment Practices in Pediatric Pneumothorax/**J.Z. Bronstein, N.C. Machac, Wilmington, DE, p.A7220

P548 **Predictors of Lung Function Decline Over 5 Years in Children with Early Onset Scoliosis (EOS)/**G.J. Redding, K. White, V. Bompadre, J. Emerson, J. Waldhausen, W. Krengel, A. Joshi, Seattle, WA, p.A7237

P549 **In Pulmonary Artery Smooth Muscle Cells, HIF-1α Downregulates Endothelin Expression Via microRNA-543/**C.-C.E. Wang, L. Ying, D.N. Cornfield, E. Adam, Stanford, CA, p.A7915

P550 **Diagnosing Foreign Body Aspiration in Children Using a New Clinical Algorithm and Scoring System/**I.A. Janahi, S. Khan, P. Chandra, N. Al-Marri, A. Sadoon, L. Al-Naimi, W. Greer, M. Al-Thani, Doha, Qatar, p.A7916

THEMATIC POSTER SESSION

D51 PEDIATRIC CASES II

9:00 a.m. - 3:30 p.m. **MOSCONE CENTER**

Area E, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: R. Ersu, MD, Istanbul, Turkey

P552 **A 17 Year Old Male Presenting with Recurrent Pneumonias from a Primary Pulmonary Tumor/**D.M. Mueller, R. Amirnovin, Los Angeles, CA, p.A7239

P553 **Hodgkin Lymphoma Presenting with Multiple Cavitary Pulmonary Lesions/**L.E. Ortiz, A. Meoded, M. Jassal, Baltimore, MD, p.A7240

P554 **Rare Cause of Pulmonary Involvement in a Pediatric Cancer Patient/**M. Villamil, C.E. Rodriguez-Martinez, J. Caceres-Montejo, G.R. Nino, S.M. Restrepo-Gualteros, Bogota, Colombia, p.A7241

P555 **TB and Co-Infection with Aspergillus in Pediatric Oncologic Patients/**A. Parra-Buitrago, M. Villamil, C.E. Rodriguez-Martinez, S.M. Restrepo-Gualteros, Bogota, Colombia, p.A7252

P556 **A Rare Case of Tracheobronchomegaly (Mounier-Kuhn) and Primary Ciliary Dyskinesia/**B. Ovunc, R. Wang, Boston, MA, p.A7257

P557 **Bronchiolitis Obliterans Organizing Pneumonia Complicating Acute Lymfoblastic Leukemia in a Children/**M. Villamil, C.E. Rodriguez-Martinez, S.M. Restrepo-Gualteros, Bogota, Colombia, p.A7243

P558 **Pulmonary Hemorrhage in Children with Chronic Respiratory Failure Diagnosed with Nutritional Rickets/**N. Mokhallati, G. McPhail, D. Benscoter, Cincinnati, OH, p.A7265

Facilitator: M. Arteta, MD, Ann Arbor, MI

P559 **Recurrent Pneumonia from an Unlikely Culprit/**E.E. Barsky, L. Ganapathi, D.M. Boyer, Boston, MA, p.A7244

P560 **Invasive Pulmonary Aspergillosis as the Presenting Sign in a Child with Systemic Lupus Erythematosus/**M.C. Tracy, J.D. Mark, D.N. Cornfield, Palo Alto, CA, p.A7245

P561 **A Pediatric Case of Prolonged Extracorporeal Support and Successful Lung Transplantation Following Invasive Pulmonary Aspergillosis and Influenza Infection/**A.R. Bates, J. Hanot, A. Carroll, A. Muhieldin, N. Anton, L. Lequier, Edmonton, Canada, p.A7249

P562 **Noisy Breathing in a 10 Month Old Infant/**S. Pillai, S. Worgall, V. Modi, New York, NY, p.A7250

P563 **Primary Pulmonary Langerhans Cell Hystiocytosis in a Three Year Old Patient/**B. Ovunc, M. Hawkins, R. Gill, D.M. Boyer, Boston, MA, p.A7256

P564 **Which Is the Better Treatment for Pulmonary Langerhans Cell Histiocytosis in Children?/**C. Miranda, M.D.C. Firmida, C.H.D. Costa, R. Rufino, D. Capone, E.H. Saito, C.W. Almeida, R.S. Zeitel, K. Madi, Rio de Janeiro, Brazil, p.A7258

P565 **Pulmonary Hemorrhage in Food-Induced Anaphylaxis in a Pediatric Patient/**A. Sheybani, H.S. Agarwal, Albuquerque, NM, p.A7266

Facilitator: C. Rosas-Salazar, MD, MPH, Nashville, TN

P566 **Fungus Among Us-Aspergillus Tracheobronchitis in a Previously Healthy Asthmatic Child/**H.E. Hoch, J. Spahn, J. Barker, P.C. Stillwell, Aurora, CO, p.A7251

P567 **Pseudotumor, Inusual Presentation of Allergic Bronchopulmonary Aspergillosis/**M. Villamil, C.E. Rodriguez-Martinez, S.M. Restrepo-Gualteros, Bogota, Colombia, p.A7242

P568 **Tracheal Stenosis with Two Separate Bronchogenic Cysts/**R. Brugha, J. Cook, M. Dusmet, M. Rosenthal, London, United Kingdom, p.A7261

P569 **A Rare Case of Eosinophilic Pneumonia/**F. Afolabi, T. Martinez, Dallas, TX, p.A7263

Facilitator: M. Bansal, MD, Los Angeles, CA

P570 **Infection of a Chronic Pleural Effusion Associated with Persistent Right Lung Collapse/**E. Kramer, K.M. McDowell, Cincinnati, OH, p.A7246

P571 **Novel Option for Infant Domiciliary Respiratory Support/**R. Wakeman, M. Rosenthal, H.-L. Tan, London, United Kingdom, p.A7253

P572 **Pulmonary Hemorrhage in a Child with a Single Ventricle and Glenn Physiology Found to Have Hemophagocytic Lymphohistiocytosis/**M. Mahabee, Y. Vaks, loma linda, CA, p.A7254

P573 **Right Lung Agenesis with Dextrocardia Presenting with Stridor requiring Tissue Expander Placement/**Y. Agrawal, C. Jacob, J. Kalavakunta, Kalamazoo, MI, p.A7262

P574 **Chronic Eosinophilic Pneumonia in a 15-Year-Old Girl with Persistent Cough/**E. Hamberger, K. Tsirilakis, Great Neck, NY, p.A7264

P575 **Misdiagnosis of Recurrent Pneumonia in an Obese Boy Found to Be Secondary to Protein Malnutrition/**R. Wadia, E. Fong, Oakland, CA, p.A7247

Facilitator: M. Newaskar, MD, Oakland, CA

P576 **Not Your Ordinary Pneumonia in a Teen/**B.A. Stewart, D. Macariola, M. Neal, Johnson City, TN, p.A7248

P577 **A Case of Corticosteroids to Treat Severe and Refractory Acute Respiratory Distress Syndrome Due to Mycoplasma Pneumoniae in an Obese Adolescent with Trisomy 21/**K.V. Lai, B.-T. Hoa, T. Chin, E. Nussbaum, Long Beach, CA, p.A7255

P578 **Unilateral Hyperlucent Lung in an Infant /**C. Lee, St. Louis, MO, p.A7259

P579 **Enlarged, Hyperlucent Lung in a Five Month Old Male with Multiple Congenital Anomalies/**S.J. Khalfoun, B. Allen, Columbus, OH, p.A7260

P580 **Hemorrhagic Complication of Intrapleural tPA in a One Year Old Baby/**S.Q. Ahmad, S. Agrawal, H. Lee, Brooklyn, NY, p.A7267

THEMATIC POSTER SESSION

D52 MOLECULAR INSIGHT INTO PULMONARY HYPERTENSION

9:00 a.m. - 3:30 p.m. **MOSCONE CENTER**

Area H, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: E.A. Goncharova, PhD, Pittsburgh, PA

P897 **The Genome-Wide Landscape of Oxidative DNA Damage in Human Vascular Endothelial Cells and Its Link to Transcriptional Regulation in Hypoxia/**V.M. Pastukh, J.T. Roberts, G.C. Bardwell, G.M. Borchert, M.N. Gillespie, Mobile, AL, p.A7268

P898 **Deficiency of TIMP-1 Is Protective in a Model of Hypoxia-Induced Pulmonary Hypertension/**C. Mallarino-Haeger, A. Coronata, C.A. Owen, L. Fredenburgh, Boston, MA, p.A7269

P899 **Hemolysis Reduces HUWE1 Through PPARγ Downregulation in Sickle Cell Disease-Pulmonary Hypertension/**B.-Y. Kang, J.M. Kleinhenz, T.C. Murphy, R.L. Sutliff, D. Archer, C.M. Hart, Decatur, GA, p.A7270

P900 **ASK1 Inhibition Prevents Hypoxia-Induced Pulmonary Artery Fibroblast Activation and Paracrine Effects on Vascular Smooth Muscle Cells/**K.S. Wilson, K. Suveizdyte, J. Liles, G.R. Budas, A. Peacock, D.J. Welsh, Glasgow, United Kingdom, p.A7271

P901 **Potential Role of DNA Methyltransferase 3A in Rat Models of Pulmonary Hypertension/**Y. Yan, X.-J. Wang, S.-H. Yang, S.-Q. Li, Y. Liu, S.-S. Huang, J. Ye, Z.-C. Jing, Shanghai, China, p.A7272

P902 **Genetic Deletion of TWIK-2 Leads to Greater Depolarization of Intralobar Pulmonary Vascular Smooth Muscle Cells, Contributing to Pulmonary Hypertension in the TWIK-2 Knockout Mouse/**L. Pandit, J.O. Reynolds, S.P. Marrelli, R.M. Bryan, Houston, TX, p.A7273

P903 **Macrophage Depletion Results in Worsened Secondary Pulmonary Hypertension and Improved Pulmonary Fibrosis/**A.J. Bryant, C. Fu, G. Brown, A. Biswas, V. Shenoy, M. Katovich, E. Scott, Gainesville, FL, p.A7274

P904 **Protection Conferred by Y-Chromosome Against Pulmonary Arterial Hypertension Is Not Due to Ddx3y Gene/**S. Umar, M. Barseghyan, A. Centala, N. Barakati, N. Motayagheni, A. Arnold, M. Eghbali, Los Angeles, CA, p.A7275

P905 **MicroRNA-214 Regulates Hypoxia-Mediated Pulmonary Artery Smooth Muscle Cell Proliferation and Migration by Targeting ARHGEF12/**X.-Q. Xing, J. Yang, X.-W. Wu, Y.-L. Li, L.-Q. Liu, Y. Xiao, Kunming, China, p.A7276

P906 **Oxidized Cardiolipin Causes Endothelial Specific Dysfunction and Pulmonary Hypertension in an In Vivo and Ex Vivo Model/**J.R. Buland, K.J. Wasserloos, S. Hahn, V.E. Kagan, S.P. Tofovic, A. Straub, B.R. Pitt, Pittsburgh, PA, p.A7277

P907 **Characterization of TGF-β and BMP Signaling in Rat Models of PH/**C.M. Happe, K. Kurakula, N. Rol, D. Bos, X. Sun, C. Van Der Bruggen, A. Vonk Noordegraaf, M.-J. Goumans, F.S. De Man, H.J. Bogaard, Amsterdam, Netherlands, p.A7278

P908 **MicroRNA-21 and PDCD4 Mediate Antiproliferative Effects of PPAγ in Hypoxia-Exposed Human Pulmonary Artery Smooth Muscle Cells/**D.E. Green, T.C. Murphy, C.M. Hart, Atlanta, GA, p.A7279

Facilitator: P. Dorfmuller, PhD, MD, Le Plessis Robinson, France

P909 **Isolation and Characterization of Distal Pulmonary Microvascular Endothelial Cell Clones from Wild-type and TLR4 Deficient Mice/**S. McMurtry, T. Stevens, S. Ofori-Acquah, Mobile, AL, p.A7280

P910 **The Role of Macrophage Migration Inhibitory Factor on Antioxidant Responses During Cigarette Smoke/**M. Aladdin, L. Varela, J. Fallica, P.M. Hassoun, R.L. Damico, Baltimore, MD, p.A7281

P911 **Beta Adrenergic Receptor Dysfunction in Pulmonary Arterial Hypertension/**M.K. Gupta, S. Ghosh, L.A. Mavrakis, S. Comhair, S.C. Erzurum, S.V. Naga Prasad, Cleveland, OH, p.A7282

P912 **Aerobic Glycolysis Is Sufficient, but Not Necessary, for Rapid Proliferation of Pulmonary Endothelial Cells/**J.Y. Lee, T. Stevens, Mobile, AL, p.A7283

P913 **A Comparison of the Pharmacological Profile of Beraprost-315d with Esuberaprost and Beraprost: Role of the Prostacyclin (IP) Receptor, PPARβ and Nitric Oxide in Rat Distal Pulmonary Arteries/**L. Shen, C. Picken, K.R.B. Von Kessler, P. Sista, L.H. Clapp, London, United Kingdom, p.A7284

P914 **Dysregulated Expression of Alarmins in the Pathology of Pulmonary Hypertension/**A. Petrovic, J.N. Schneider, M. Wygrecka, O. Pak, E.E. Agha, N. Weissmann, S. Bellusci, D. Kosanovic, R.T. Schermuly, Giessen, Germany, p.A7285

P915 **RP5063 Prevents Monocrotaline Induced Pulmonary Arterial Hypertension in Rats/**L. Bhat, D. Salvail, A. Bouchard, J. Hawkinson, M. Cantillon, Santa Clara, CA, p.A7286

P916 **Lactate Activates Akt Through Calpain in Pulmonary Artery Smooth Muscle Cells/**L. Kovacs, Y. Su, Augusta, GA, p.A7287

P917 **A Scratch-Induced Interaction Between Extracellular Sodium and Orai1 Is Critical for Endothelial Wound Healing/**N. Xu, T. Stevens, Mobile, AL, p.A7288

P918 **Involvement of HIV Infected and Cocaine Exposed Macrophage Derived Extracellular Vesicles in Pulmonary Smooth Muscle Hyperplasia/**P.N. Dalvi, L. Christenson, S. Upadhya, A. O'Brien-Ladner, N.K. Dhillon, Kansas City, KS, p.A7289

P919 **Alternative Splicing of the Cardiac Sodium Channel in Pulmonary Arterial Hypertension/**D. Banerjee, A. Zhou, M. Whittenhall, I. Krishnan, A. Palmisciano, J.R. Klinger, S. Dudley, C.E. Ventetuolo, Providence, RI, p.A7290

P920 **Increased Expression of NPY1R Mediated Increased Vascular Reactivity to NPY/**S. Crnkovic, P. Jain, B. Egemnazarov, L.M. Marsh, B. Ghanim, W. Klepetko, P. Holzer, H. Herzog, A. Olschewski, G. Kwapiszewska, Graz, Austria, p.A7291

Facilitator: S.A. Predescu, PhD, Chicago, IL

P921 **16α-Hydroxyestrone Increases Oxidative Stress Through NADPH Oxidase 4 and Nrf2 Dysfunction Specifically in Human Pulmonary Artery Smooth Muscle Cells/**K.Y. Hood, A.P. Harvey, M. Nilsen, A.C. Montezano, R.M. Touyz, M. MacLean, United Kingdom, p.A7292

P922 **Dynamic Mapping of Lung Vascular Development/**Y. Luo, W. Shi, Los Angeles, CA, p.A7293

P923 **Intrauterine Caloric Restriction Affects the Expression of Genes Involved in Pulmonary Endothelial Function/**I.N. Zelko, J. Roman, Louisville, KY, p.A7294

P924 **FTY720 S-Phosphonate Does Not Activate GRK2-Mediated S1PR1 Phosphorylation and Degradation/**L. Wang, R. Bittman, S.M. Dudek, Chicago, IL, p.A7295

P925 **Structure Dependent PK Profiles of Alkyl Ester Treprostinil Prodrugs (TPD) Administrated Via Metered Dose Inhaler to Rats/**A.J. Plaunt, R.W. Chapman, M.R. Corboz, Z. Li, W.R. Perkins, V.S. Malinin, Bridgewater, NJ, p.A7296

P926 **The Matrikine Acetylated Proline-Glycine-Proline (AcPGP) Couples Extracellular Matrix Fragmentation to Pulmonary Microvascular Remodeling and Pulmonary Hypertension/**G.A. Payne, L. Viera, Y. Wu, X. Xu, R.P. Patel, A. Gaggar, C.M. McNicholas-Bevensee, J.E. Blalock, J.M. Wells, Birmingham, AL, p.A7297

P927 **Hyperspectral Imaging Approaches Allow Real Time 3D Measurement of cAMP Gradients in Pulmonary Microvascular Endothelial Cells/**T. Rich, N.S. Annamdevula, R. Sweat, P. Favreau, S. Mayes, A.L. Britain, A. Arie Nakhmani, S.J. Leavesley, Mobile, AL, p.A7298

P928 **Simultaneous, Real Time, Measurement of 3D cAMP and Ca2+ Signals Using Hyperspectral Imaging and Analysis Approaches/**T. Rich, R. Sweat, N.S. Annamdevula, P. Favreau, S. Mayes, K. Webb, A.L. Britain, M. Townsley, A. Nakhmani, S.J. Leavesley, Mobile, AL, p.A7299

P929 **Differential Response to Serial Microsphere Infusions During Creation of Canine and Porcine Models of Pulmonary Hypertension/**A. Rothman, H. Restrepo, W.N. Evans, V. Sarukhanov, D. Mann, Las Vegas, NV, p.A7300

P930 **Heme Oxygenase-1 Is Cardioprotective Against Hyperoxia/**R.R. Bartz, H. Suliman, B. Kraft, A. Cherry, K. Welty-Wolf, J. Keenan, C.A. Piantadosi, Durham, NC, p.A7301

P931 **Sustained Activation of RhoGTPases Promote a Synthetic Pulmonary Artery Smooth Muscle Cell Phenotype in Neprilysin Null Mice/**V. Karoor, Z. Loomis, T. Sullivan, L. Hersh, D. Irwin, E.C. Dempsey, Aurora, CO, p.A7302

P932 **Lymphatics in Pleura in Normal, Malignant Pleural Effusion, and Septic Mouse Models/**Y. Tsukita, T. Okazaki, M. Kobayashi, M. Nihei, R. Komatsu, H. Sugiura, S. Ebihara, M. Ichinose, Sendai Miyagi, Japan, p.A7303

Facilitator: W.M. Kuebler, MD, PhD, Toronto, Canada

P933 **Bone Morphogenetic Protein 9 Enhances Toll-Like Receptor 4 Expression and Lipopolysaccharide-Induced Leukocyte Recruitment to the Vascular Endothelium Via Activin Receptor-Like Kinase-2/**S.L. Appleby, A. Crosby, C.G. Mitrofan, C.M. Yates, G.B. Nash, E.R. Chilvers, N.W. Morrell, Cambridge, United Kingdom, p.A7304

P934 **SMAD3 Contributes to Lung Vascular Remodeling in Pulmonary Arterial Hypertension Via MRTF Disinhibition: A New Pathomechanism/**D. Zabini, A. Kapus, W.M. Kuebler, Toronto, Canada, p.A7305

P935 **Bortezomib Alleviates Experimental Pulmonary Hypertension by Regulating Intracellular Calcium Homeostasis in PASMCs/**J. Zhang, E. Wang, W. Lu, J. Wang, Guangzhou, China, p.A7306

P936 **Quercetin Induce Autophagy Via FOXO1-Depentent Pathways and Autophagy Suppression Enhances Quercetin-Induced Apoptosis of PASMCs in Hypoxia/**H. Yuanzhou, X. Li, X. Min, Y. Xu, L. Xiansheng, Wuhan, China, p.A7307

P937 **Therapeutic Role of Serum Response Factor (SRF) Specific shRNA in the Treatment of Hypoxic Pulmonary Hypertension/** R. Wang, G. Sun, Anhui, China, p.A7308

P938 **Fucoidan, a Natural Polysaccharidic Ligand of P-Selectin, Obstructs Hypoxia-Induced Pulmonary Arterial Hypertension and Acute Lung Vasoconstriction/**T. Novoyatleva, B. Kojonazarov, A. Owczarek, W. Seeger, N. Weissmann, R.T. Schermuly, Germany, Germany, p.A7309

P939 **Adventitial Remodeling of Experimental Pulmonary Hypertension Induces Myofibroblast-Produced Collagen V in a Th17-Pathways-Related Manner/**A.T. Fabro, J.R. Machado, W.R. Teodoro, A.L. Dos Santos, A.A. Dos Santos, H.R. Crunivel, P.F. Milsoni, S.D.M. Fernezlian, A.B.G. Dos Santos, R.A. Oliveira, M.C.R. Medeiros, C.A. Rainho, V.L. Capelozzi, Botucatu, Brazil, p.A7310

P940 **The Regulation of Hypoxia-Inducible Factors by C-Jun N-Terminal Protein Kinases/**M. Sala, C. Chen, H.C. Do, A.V. Misharin, G.S. Budinger, J. Liu, Chicago, IL, p.A7311

P941 **The Role of Smooth Muscle Cathepsins in Pulmonary Arterial Hypertension Associated with Systemic Lupus Erythematosus/** H.-C. Hsu, H.-H. Li, Y.-J. Lai, Tao-Yuan, Taiwan, p.A7312

P942 **LIM-Only Protein FHL2 Suppresses Pulmonary Artery Endothelial Cell Proliferation Through Activation of BMP Signalling/**K. Kurakula, N. Rol, J. Smits, C.M. Happe, H.J. Bogaard, P. Ten Dijke, M.-J. Goumans, Leiden, Netherlands, p.A7313

P943 **ARDS Decreases Pulmonary Artery Compliance in a Porcine Model/**A. Santos, I. Monge-Garcia, E. Gomez Penalver, J.B. Borges, L. Lucchetta, J. Retamal, G. Tusman, G. Hedenstierna, A. Larsson, F. Suarez-Sipmann, Uppsala, Sweden, p.A7917

P944 **Galectin-3 Mediates Vascular Remodeling in Pulmonary Arterial Hypertension/**S.A. Barman, F. Chen, Y. Su, D. Stepp, J. Zhou, L. Meadows, Y. Wang, X. Li, S. Haigh, Z. Bordan, P. Traber, D. Jonigk, D. Fulton, Augusta, GA, p.A7918

P945 **Dual Targeting of CCR2 and CCR5 for Treating Pulmonary Hypertension/**A. Parpaleix, V. Amsellem, S. Abid, A. Houssaini, M. Breau, E. Marcos, D. Sawaki, E. Bizard, C. Hubeau, S.E. Evans, M. Delcroix, R. Quarck, S. Adnot, Creteil, France, p.A7919

THEMATIC POSTER SESSION

D53 THE PROMISED LAND: CLINICAL STUDIES IN PULMONARY HYPERTENSION

9:00 a.m. - 3:30 p.m. **MOSCONE CENTER**

Area H, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: Z. Jing, MD, Beijing, China

P948 **Plasma Levels of Leptin and Adiponectin Have Limited Prognostic Value in Pulmonary Arterial Hypertension/**W. Dakkak, Y. Rao, X. Zhou, R. Dweik, A.R. Tonelli, Cleveland, OH, p.A7315

P949 **Early Pulmonary Vascular Dysfunction in Exercise-induced Heart Failure with Preserved Ejection Fraction: Prognostic Implications/**W. Huang, R.K. Oliveira, D. Systrom, H. Lei, A. Waxman, Chongqing, China, p.A7316

P950 **The Long-Term Outcomes in Patients with Exercise-Induced Pulmonary Arterial Hypertension/**W. Huang, D. Systrom, A. Waxman, Chongqing, China, p.A7317

P951 **Comparative Outcome of Incident Patients with Pulmonary Hypertension Due to Lung Disease According with the Haemodynamic Classification of the 2015 ESC-ERS Pulmonary Hypertension Guidelines/**C. Bachetti, A. Rinaldi, M. Palazzini, F. Dardi, G. Mazzanti, E. Gotti, A. Albini, E. Monti, S. Fukui, D. Guarino, N. Galie, A. Manes, Bologna, Italy, p.A7318

P952 **Evaluation of Changes in Static and Pulsatile Hemodynamic Indices Across Longitudinal Vasoreactivity Tests in PAH/**A.J. Sweatt, E.F. Spiekerkoetter, A. Hsi, Y. Sung, V. De Jesus Perez, K. Kudelko, R.T. Zamanian, Stanford, CA, p.A7319

P953 **DLCO Change in PAH Reflects Vascular Function as Determined by Longitudinal Hemodynamic Response to Inhaled Nitric Oxide/**A.J. Sweatt, E.F. Spiekerkoetter, A. Hsi, Y. Sung, V. De Jesus Perez, K. Kudelko, R.T. Zamanian, Stanford, CA, p.A7320

P954 **Managing Pulmonary Arterial Hypertension Using an Implantable Hemodynamic Monitor/**R.L. Benza, P. Correa-Jaque, D.V. Thompson, M. Doyle, J. White, S. Murali, R. Agarwal, R. Davey, A. Raina, V. Franco, R. Biederman, Pittsburgh, PA, p.A7321

P955 **A Phase 2 Placebo-Controlled, Randomized, Double-Blind Clinical Study to Assess the Efficacy, Safety and Tolerability of Two Doses of Pulsed, Inhaled Nitric Oxide (iNO) in Patients with WHO Group 1 Pulmonary Arterial Hypertension (PAH): 12 Month Interim A/**R.L. Benza, R. Barst, J.T. Granton, D. Badesch, A. Frost, H. Farber, N. Hirani, W. Hill, S. Shapiro, D. Quinn, T. Fleming, C.G. Elliott, Pittsburgh, PA, p.A7322

P956 **Calcified Lesions on Computed Tomography and Their Clinical Impact in Pulmonary Arterial Hypertension/**V. F.Tanguay, G. Ruffenach, S. Chabot, D. Montani, S. Bonnet, O. Boucherat, S. Provencher, Quebec, Canada, p.A7323

P957 **Exercise Pulmonary Hypertension in Fibrotic Interstitial Lung Disease with Borderline Resting Mean Pulmonary Arterial Pressure/**R.K. Oliveira, J.A. Tracy, A.L. Karin, A. Waxman, D. Systrom, Sao Paulo, Brazil, p.A7324

P958 **Prevalence of Exercise Pulmonary Hypertension in Borderline Resting Mean Pulmonary Arterial Pressure/**R.K. Oliveira, M.F. Urbina, J.A. Tracy, A.L. Karin, A. Waxman, D. Systrom, Sao Paulo, Brazil, p.A7325

P959 **Acute Endothelin-1 Response During Exercise Is Associated with Exercise Tolerance and Ventilatory Efficiency in Idiopathic Pulmonary Arterial Hypertension/**H.-D. Zhang, L.-T. Wang, Y. Huang, X.-D. Zhang, T.-Y. Lian, S.-H. Yang, X. Jiang, Y. Wu, F.-H. Peng, X.-X. Yan, Z.-C. Jing, Shanghai, China, p.A7326

P960 **Thermodilution and Indirect Fick Are Inaccurate Methodologies to Determine Cardiac Index in Patients with Pulmonary Arterial Hypertension/**M.K. Ahmed, R. Dweik, G. Agmy, A.R. Tonelli, Assiut, Egypt, p.A7327

Facilitator: E.S. Klings, MD, Boston, MA

P961 **Transpulmonary Gradients in Pulmonary Arterial Hypertension and Their Relationship with Hemodynamic Determinations/**M.K. Ahmed, R. Dweik, A.R. Tonelli, Assiut, Egypt, p.A7328

P962 **Application of the Criteria for Satisfactory Clinical Response to Riociguat Treatment of Patients with Pulmonary Arterial Hypertension (PATENT-1 and PATENT-2)/**E. Berman-Rosenzweig, R. Allen, S. Rosenkranz, D. Busse, D. Platt, H.-A. Ghofrani, New York, NY, p.A7329

P963 **Characterization of Centers Accredited by the Pulmonary Hypertension Association (PHA) in the Pulmonary Hypertension Care Centers (PHCC) Initiative During Programmatic Year One/**M.P. Gray, O. Onyeador, K.A. Fagan, B.D. Hanna, D. Ramirez, J.S. Sager, M.A. Wilson, M.D. McGoon, E.B. Rosenzweig, S. Haneef, M.M. Chakinala, Silver Spring, MD, p.A7330

P964 **Do Patients with Pulmonary Arterial Hypertension Survive Inpatient Cardiac Arrest?/**A.G. Kassar, N.H. Kim, R. Sell, San Diego, CA, p.A7331

P965 **Cardiac Magnetic Resonance Imaging in Healthy Volunteers in Normoxic and Hypoxic Exercise/**S. Jaijee, M. Quinlan, P. Tokarczuk, B. Statton, T. Diamond, L.S. Howard, D. O'Regan, J.S. Gibbs, United Kingdom, p.A7332

P966 **Diagnostic Accuracy and Concordance of Different Criteria for Exercise Pulmonary Hypertension/**L. Godinas, E. Lau, D. Chemla, F. Lador, L. Savale, D. Montani, O. Sitbon, G. Simonneau, M.J.C. Humbert, P. Herve, Le Kremlin Bicetre, France, p.A7333

P967 **Time-Constant of the Pulmonary Arterial Windkessel in Precapillary Pulmonary Hypertension: A Reappraisal/**E. Lau, D. Chemla, K. Zhu, V. Castelain, P. Attal, M. Humbert, P. Herve, Sydney, Australia, p.A7334

P968 **Comparison of Different Types of Pulmonary Hypertension in Patients with Connective Tissue Disease/**G. Mazzanti, M. Palazzini, A. Manes, C. Bachetti, E. Gotti, F. Dardi, A. Rinaldi, A. Albini, E. Monti, S. Fukui, D. Guarino, N. Galie, Bologna, Italy, p.A7335

P969 **End Tidal CO2 as a Predictor of Outcomes in Patients with Pulmonary Arterial Hypertension/**C.E. Welch, I.M. Robbins, E.L. Brittain, J.H. Newman, A.R. Hemnes, Nashville, TN, p.A7336

P970 **Mechanisms of Gas Exchange Impairment in Chronic Obstructive Pulmonary Disease (COPD) with Severe Pulmonary Hypertension/**L. Piccari, I. Blanco, Y. Torralba, F. Burgos, C. Gistau, J. Roca, R. Rodriguez-Roisin, J.A. Barbera, Barcelona, Spain, p.A7337

P971 **The Ratio of Pulmonary Artery Over Wedge Nitrite Predicts the Pulmonary Vascular Response to Inhaled Nitric Oxide in Idiopathic Pulmonary Arterial Hypertension/**A.R. Tonelli, M.K. Ahmed, W. Dakkak, K. Aulak, R. Dweik, Cleveland, OH, p.A7338

P972 **The Prevalence of Pulmonary Hypertension in Patients with Multiple Myeloma/**U. Krishnan, T.M. Mark, R. Niesvizky, M. Karas, I. Sobol, New York, NY, p.A7339

P973 **Patient Characteristic Cluster Analysis Predicts Response to Therapy to Oral Treprostinil in Pulmonary Arterial Hypertension/**K.S. Parikh, Y. Rao, K. Shen, S. Rajagopal, Durham, NC, p.A7340

Facilitator: M.G. Risbano, MD, MA, Pittsburgh, PA

P974 **Bisoprolol in Idiopathic Pulmonary Arterial Hypertension: A Sub-Group Analysis in Patients with Low Versus High Right Ventricular Ejection Fraction/**J.S. Van Campen, K.D. Boer, M.C. Van De Veerdonk, C.E. Van Der Bruggen, C.P. Allaart, M.W. Heymans, J.T. Marcus, F.S. De Man, A. Vonk Noordegraaf, H.J. Bogaard, Den Haag, Netherlands, p.A7341

P975 **The Geometry of the Right Ventricle from CT Scans as a Predictor of Pulmonary Vascular Disease in Smokers in the COPDGene Study/**J.K. Minhas, F.N. Rahaghi, G. Vegas-Sanchez-Ferrero, R.P. Bowler, J.M. Wells, C.E. Come, I. De La Bruere, B. Fenster, G. Gonzalez, A.A. Diaz, P. Kohli, S.P. Bhatt, D.A. Lynch, M.T. Dransfield, R. San Jose Estepar, G. Washko, Boston, MA, p.A7342

P976 **Long Term Health Outcomes of Individuals with High Altitude Pulmonary Hypertension: A 55 Year Follow Up Study/** J.C. Robinson, C. Abbott, R.C. Roach, B. Honigman, T.M. Bull, Aurora, CO, p.A7343

P977 **Galectin-3 and Aldosterone as Potential Tandem Biomarkers in Pulmonary Arterial Hypertension/**G. Hansmann, L. Calvier, E. Legchenko, L. Grimm, H. Sallmon, A. Hatch, B.D. Plouffe, C. Schroeder, J. Bauersachs, S.K. Murhy, Hannover, Germany, p.A7344

P978 **Fick Principle Determinants of the 6-Minute Walk Test (6-MWT) Distance/**R. Badr Eslam, R.K. Oliveira, J.A. Tracy, A.L. Karin, M. Agarwal, A. Waxman, D. Systrom, Vienna, Austria, p.A7345

P979 **Impact of Intrathoracic Pressure in the Assessment of Pulmonary Vascular Pressure/**A. Jawad, A.R. Tonelli, R.L. Chatburn, U. Hatipoglu, Cleveland, OH, p.A7346

P980 **Pulmonary Venous Hypertension in Patients with Systemic Sclerosis: Baseline Characteristics and Survival/**K. Bourji, R.L. Damico, B. Kelemen, S.C. Mathai, T. Kolb, R. Tedford, P.M. Hassoun, Baltimore, MD, p.A7347

P981 **Pulmonary Arterial Hypertension (PAH) Specific Therapy Induce Changes in L-Arginine and Methylarginines Compared to Baseline Values in Healthy Subjects and Patients with Heart Failure/**A.M. Sandqvist, D. Henrohn, D. Kylhammar, J. Lundgren, J. Schneede, G. Radegran, G. Wikstrom, Umea, Sweden, p.A7348

P982 **The Potential Use of Left Atrial to Right Atrial Size Ratio in Discriminating Idiopathic Pulmonary Arterial Hypertension from Pulmonary Hypertension Due to Heart Failure with Preserved Ejection Fraction/**A. Huis In 't Veld, L. Handoko, O.A. Spruijt, H.J. Bogaard, A. Vonk Noordegraaf, Amsterdam, Netherlands, p.A7349

P983 **Impact of Pulmonary Arterial Hypertension on Dynamic Cerebral Autoregulation/**S. Malenfant, P. Brassard, M. Paquette, O. Le Blanc, A. Chouinard, S. Bonnet, S. Provencher, Quebec City, Canada, p.A7350

P984 **Role of Cardiac Magnetic Resonance in Stratifying the Prognosis of Patients with Pulmonary Arterial Hypertension/**F. Dardi, C. Bachetti, M. Palazzini, G. Mazzanti, E. Gotti, A. Rinaldi, A. Albini, E. Monti, S. Fukui, D. Guarino, N. Galie, A. Manes, Bologna, Italy, p.A7351

P985 **Defining The Role of Balloon Pulmonary Angioplasty (BPA): U.S. High-Volume Pulmonary Thromboendarterectomy (PTE) Single-Center Experience/**D.S. Poch, E. Mahmud, M. Patel, M.M. Madani, N.H. Kim, La Jolla, CA, p.A7352

Facilitator: N.S. Hill, MD, Boston, MA

P986 **Pulmonary Arterial Capacitance as an Indicator of Response to Therapy in Pulmonary Arterial Hypertension/**S. Medrek, C.A. Kloefkorn, Z. Safdar, Houston, TX, p.A7353

P987 **Breath Volatolome for the Detection of Pulmonary Arterial Hypertension/**M. Nakhleh, M. Humbert, E. Fadel, H. Haick, S. Cohen-Kaminsky, Le plessis Robinson, France, p.A7354

P988 **Elevated Bilirubin Levels Are Associated with Intrapulmonary Vascular Dilation in Patients wtih Cirrhosis/**S. Chuzi, L.B. VanWagner, R. Kalhan, M. Cuttica, Chicago, IL, p.A7355

P989 **Toward Theranostic Biomarkers in Pulmonary Hypertension/** A.C. Swaminathan, A. Poms, K. Kennedy, H. Zhu, E. Gaspard, T.A. Fortin, J. Senick, K. Parikh, Z.T. Kelleher, B. Fee, S. Rajagopal, K. Murray, V. Tapson, T.J. McMahon, Durham, NC, p.A7356

P990 **Riociguat Treatment for Porto-Pulmonary Hypertension: A Subgroup Analysis from the PATENT-1 Study/**R. Cartin-Ceba, M. Halank, H.-A. Ghofrani, M. Humbert, J. Mattson, A. Fritsch, M.J. Krowka, Scottsdale, AZ, p.A7357

P991 **The Prevalence of Vitamin D Deficiency in Pulmonary Hypertension Patients and Its Correlation with Parameters of Pulmonary Hypertension Severity/**B. Tashtoush, J. Mehta, J. Benavides, R. Memarpour, S. Kachur, J.B. Gleason, A. Hadeh, L. Smolley, F.F. Rahaghi, Weston, FL, p.A7358

P992 **Determining the Role of Cardiac FDG Gated PET Scan for the Assessment of Right Ventricular Size and Function in Patients with Pulmonary Hypertension/**D. Uzunaslan, M. Park, S. Chirakarnjanakorn, C. Jellis, E.C. Roach, K.B. Highland, J. Thomas, S.Y. Farha, S.C. Erzurum, W.H.W. Tang, D. Neumann, S. Patel, F. DiFilippo, Cleveland, OH, p.A7359

P993 **Is Pulmonary Hypertension a Risk Factor for Arrhythmias? A National Discharge Sample Study/**S. Aggarwal, R. Loomba, N. Gupta, V. Alla, R. Arora, R. Anderson, Omaha, NE, p.A7360

P994 **Pulmonary Arteriovenous Malformations in Non-Hereditary Hemorrhagic Telangiectasia Patients: A 15 Year Retrospective Study/**J.M. Segraves, B.S. Pannu, V.N. Iyer, Rochester, MN, p.A7361

P995 **Non-Invasive Estimation of Pulmonary Artery Wedge Pressure/** K. Zaki, X. Wang, R. Dweik, G.A. Heresi, Cleveland, OH, p.A7362

P996 **Non-Invasive Evaluation of Right Ventricular Function, Pulmonary Vascular Hemodynamic and Ventilatory Efficiency During Exercise in Pulmonary Arterial Hypertension and Heart Failure/**M. Vicenzi, G. Deboeck, V. Faoro, M. Cheli, S. Caravita, R. Naeije, J.-L. Vachiery, Brussels, Belgium, p.A7363

P997 **The Effects of Combination Therapy on Clinical Worsening: A Meta-Analysis/**A.C. Lajoie, G. Lauziere, J.C. Lega, Y. Lacasse, S. Martin, S. Simard, S. Bonnet, S. Provencher, Quebec City, Canada, p.A7920

THEMATIC POSTER SESSION

D54 CLINICAL PULMONARY HYPERTENSION

9:00 a.m. - 3:30 p.m. **MOSCONE CENTER**

Area H, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: M.R. Lammi, MD, New Orleans, LA

P999 **The UK National Cohort Study of Idiopathic and Heritable Pulmonary Arterial Hypertension/**C. Treacy, M. Blenda, C. Hadinnapola, M. Haimel, G. Coghlan, P.A. Corris, J.S. Gibbs, D.G. Kiely, A. Lawrie, A.J. Peacock, J. Pepke-Zaba, R.C. Trembath, J. Wharton, M.R. Wilkins, S.J. Wort, S. Graf, N.W. Morrell, Cambridge, United Kingdom, p.A7364

P1000 **New Approaches in Narrative Analysis Highlight Marked Issues of Adaptation and Change for Patients with Pulmonary Hypertension and Explore How Identity Is Modified in the Context of Clinical Care/**J. Goddard, I. Armstrong, B. Stone, I. Sabroe, Sheffield, United Kingdom, p.A7365

P1001 **Limitations of Pulmonary Vascular Resistance as a Primary Endpoint for Therapeutic Trials of Systemic Sclerosis Associated Pulmonary Arterial Hypertension/**R.T. Zamanian, R. Rhee, A. Pinckney, E. Goldmuntz, B. Welch, C. D'Aveta, D. Badesch, M. Nicolls, S.M. Kawut, M. Spychala, Stanford, CA, p.A7366

P1002 **Diagnostic Evaluation and Predictors of Prognosis in Pulmonary Hypertension/**M. Khalid, I. Weheba, S.M. Hassan, A.M. Al Dalaan, A. Al Sugair, A. Abdelsayed, S. Saleemi, A. Sheikh, M. Zeitouni, E. Al Mutairy, Riyadh, Saudi Arabia, p.A7367

P1003 **Developing a Pulmonary Embolism Response Team (PERT) for the treatment of Submassive Pulmoanry Embolism/**D.M. Wisa, D.I. Zapata, M. Walczyszyn, A. Conway, A. Tilley, A. Carroccio, R. Rosen, S.J. Scheinerman, M. Weinberg, B. Mina, New York, NY, p.A7368

P1004 **Evaluation of Quality of Care and Quality of Life of Pulmonary Hypertension (PH) Patients Seen in PH Care Centers: Pulmonary Hypertension Association Registry (PHAR) Study Design/**M.P. Gray, C.E. Ventetuolo, R. Oudiz, W. Hill, C. Pickles, K. Blank, K. Williams, P.J. Leary, R. Kronmal, S.M. Kawut, Silver Spring, MD, p.A7369

P1005 **In Depth Analysis of Six Minute Walk Test Parameters in Scleroderma Patients with and Without Pulmonary Hypertension/**A. Gadre, C. Ghattas, O.A. Minai, K.B. Highland, Cleveland, OH, p.A7370

P1006 **Pulmonary Function Phenotypes in Heart Failure with Preserved Ejection Fraction (HFpEF)/**N. Shea, M. Cuttica, R. Kalhan, S. Shah, Chicago, IL, p.A7371

P1007 **Genetic Counselling in a National Referral Centre for Pulmonary Hypertension/**B. Girerd, D. Montani, X. Jais, M. Eyries, L. Savale, F. Parent, O. Sitbon, F. Soubrier, G. Simonneau, M. Humbert, Le Kremlin Bicetre, France, p.A7372

P1008 **Description of the Clinical, Functional and Hemodynamic Characteristics of Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension Treated with Intravenous Epoprostenol in Colombia/**C. Villaquiran-Torres, M. Orozco-Levi, A. Londono, J. Ortega, J.E. Gomez, R. Conde, C. Borda, R. Duenas-Villamil, Bogota, Colombia, p.A7373

P1009 **Use of Treprostinil in Pregnant Women with Pulmonary Arterial Hypertension During Peripartum Period/**B. Liu, X. Huang, W. Zhang, Z. Yu, Changsha, China, p.A7374

P1010 **Comparison of Trans-Thoracic and Trans-Esophageal Echocardiography in Measurement of Tricuspid Annular Plane Systolic Excursion (TAPSE) to Diagnose Pulmonary Hypertension/**B.M. Buddhdev, K.B. Buddhdev, V. Mallavarapu, Omaha, NE, p.A7375

Facilitator: C.D. Burger, MD, Jacksonville, FL

P1011 **Right Heart Catheterism: Mandatory for Early Diagnosis of Systemic Sclerosis Related Pulmonary Arterial Hypertension/**V.S. Vilela, M. Macri, A.A. Salgado, M. Castier, R. Levy, E. Ferreira, C.H.D. Costa, R. Rufino, Rio de Janeiro, Brazil, p.A7376

P1012 **Combination Therapy for Pulmonary Arterial Hypertension. A Systematic Review and Meta-Analysis/**B.D. Fox, O. Straichman, D. Langleben, A. Shimony, M.R. Kramer, Petach Tikva, Israel, p.A7377

P1013 **Noninvasive Echocardiography Assessment of Group 3 Severe Pulmonary Hypertension/**R. Jiang, C. Wu, B. Pudasaini, L. Wang, Q.-H. Zhao, S.-G. Gong, J. He, P. Yuan, Z.-C. Jing, J.-M. Liu, Shanghai, China, p.A7378

P1014 **Establishing the Effect of Targeted Therapies on Diffusing Capacity in Patients with Pulmonary Arterial Hypertension (PAH)/**L. Thirugnanasothy, S. Sithamparanathan, J. Lordan, A.J. Fisher, G. MacGowan, G. Parry, P.A. Corris, Newcastle-upon-Tyne, United Kingdom, p.A7379

P1015 **Effects of Spironolactone in Pulmonary Arterial Hypertension: Results of SPIRO Study/**Z. Safdar, E. Tamez, A. Thakur, M. Entman, A. Basant, A. Frost, Bellaire, TX, p.A7380

P1016 **Reduced Venous Vessel Density in Pre-Capillary Pulmonary Hypertension/**M. Pienn, C. Payer, M. Urschler, C. Salvan-Schaschl, R. Neuwirth, R. Stollberger, G. Kovacs, V. Foris, A. Olschewski, H. Olschewski, Z. Balint, Graz, Austria, p.A7381

P1017 **A Proof of Concept Study of Human Volunteers and Pulmonary Hypertension Patients Breathing Nitric Oxide Produced by Electrical Pulsed Discharge/**L. Berra, J. Rodriguez-Lopez, B. Yu, E. Rezoagli, S. Strelow, D. Fisher, R.N. Channick, W.M. Zapol, Boston, MA, p.A7382

P1018 **Protocols for Identification of Portopulmonary Hypertension in Liver Transplant Candidates: The Emory Experience/**P. Rajaram, J.P. Wedd, M.R. Fisher, Atlanta, GA, p.A7383

P1019 **The Relationship Between the Modified Borg Scores and Hospitalization in Pulmonary Arterial Hypertension/**D. Banerjee, J. Kamuren, G. Baird, A. Palmisciano, I. Krishnan, M. Whittenhall, J.R. Klinger, C.E. Ventetuolo, Providence, RI, p.A7384

P1020 **Clinical Characteristics and Treatment Outcomes of Primary Pulmonary Artery Sarcoma in Korea/**Y. Lee, D.S. Lee, S.-D. Lee, J.S. Lee, Seoul, Korea, Republic of, p.A7385

P1021 **Chronic Thromboembolic Pulmonary Hypertension and Schizophrenia/**H. Suzuki, K. Sugimura, S. Tatebe, T. Aoki, H. Shimokawa, Sendai, Japan, p.A7386

P1022 **Usefulness of Echocardiography in Predicting Survival Benefit of Sildenafil in Patients with Interstitial Lung Disease/**Y. Tomita, A. Miyamoto, K. Kishi, S. Ishiwata, M. Ohno, Tokyo, Japan, p.A7387

Facilitator: J.M. Elwing, MD, Cincinnati, OH

P1023 **Riociguat as a Bridge Therapy for Balloon Pulmonary Angioplasty in Patients with Chronic Thromboembolic Pulmonary Hypertension/**J. Ueda, T. Ogo, S. Fukui, A. Tsuji, Y. Morita, T. Fukuda, S. Yasuda, H. Ogawa, N. Nakanishi, Suita, Japan, p.A7388

P1024 **Baseline Demographics of the Prospective, Multicenter, Single-Arm, Open-Label, Phase IV MOTION Study of Riociguat in Pulmonary Arterial Hypertension/**N. Sood, A. Aranda, S. Mobin, D. Platt, G. O'Brien, C. Satler, Columbus, OH, p.A7389

P1025 **Endothelial Microparticles as Biomarkers of Pulmonary Hypertension in Systemic Sclerosis/**M.R. Lammi, L.A. Saketkoo, S. Okpechi, D. Wyczechowska, N. Bauer, K. Pyakurel, M. Ghonim, S. Saito, V. Jaligam, B. DeBoisblanc, A.H. Boulares, New Orleans, LA, p.A7390

P1026 **Internal Jugular Versus Femoral Vein Access for Right Heart Catheterization in the Evaluation of Pulmonary Hypertension. Does the Site of Access Matter?/**L. Cagino, A. Ataya, L. Richards, X. Wu, H. Alnuaimat, Gainesville, FL, p.A7391

P1027 **Red Cell Distibution Width as a Biomarker of Pulmonary Hypertension/**L. Petrauskas, L.A. Saketkoo, S. Saito, V. Jaligam, B. DeBoisblanc, M.R. Lammi, New Orleans, LA, p.A7392

P1028 **Riociguat for the Treatment of Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: Real-Life Data From the EXPERT Registry/**H. Gall, H.-A. Ghofrani, M.M. Hoeper, M. Humbert, M.-A. Gomez Sanchez, D. Pittrow, M. Halank, E. Grunig, H. Wirtz, H. Klose, R. Ewert, T.J. Lange, J. Klotsche, J.-L. Vachiery, J.E. Nielsen-Kudsk, R.J. Snijder, R. Mascherbauer, S. Ulrich, J. Loffler-Ragg, V. Cottin, I. Tsangaris, A. Peacock, C. Meier, M. Brunn, G. Simonneau, Giessen, Germany, p.A7393

P1029 **Assessment of Right Ventricular Systolic Function in Patients with Precapillary Pulmonary Hypertension Using Simple Echocardiographic Parameters: A Comparison with Cardiac Magnetic Resonance Imaging/**O.A. Spruijt, M.C. Di Pasqua, H.J. Bogaard, F. Oosterveer, J.T. Marcus, A. Vonk-Noordegraaf, L. Handoko, Amsterdam, Netherlands, p.A7394

P1030 **DLCO Is a Superior Screening Tool for PAH Compared to NT-proBNP in Subjects with HIV/**R.R. Vanderpool, M.G. Risbano, N. Leo, C. Kessinger, L. Kingsley, Y. Zhang, F.C. Sciurba, T.N. Bachman, M.A. Simon, M.T. Gladwin, A.M. Morris, Pittsburgh, PA, p.A7395

P1031 **OPsumitr USers Registry (OPUS): Insights into the Safety and Tolerability of Opsumitr/**N.H. Kim, K.M. Chin, E. Muros-Le Rouzic, M. Brand, M. Selej, R.N. Channick, V.V. McLaughlin, San Diego, CA, p.A7396

P1032 **The Qutenza (8% Capsaicin) Patch for Disabling Treprostinil Infusion Site Pain/**A. Light, K. Frutiger, K. Wessman, A. Heiniger, R.J. White, Rochester, NY, p.A7397

P1033 **Development of the United States Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Registry/**K.M. Kerr, W.R. Auger, R.L. Benza, R.N. Channick, K.M. Chin, R.D. Davis, C.G. Elliott, A.Z. LaCroix, M.M. Madani, V. McLaughlin, M.H. Park, San Diego, CA, p.A7398

P1034 **Characteristics and Survival of Patients with Systemic Lupus Erythematosus Associated with Pulmonary Arterial Hypertension/**J.L. Hernandez-Oropeza, M.A. Cacho-Diaz, J.D.J. Rodriguez-Andoney, M. Moncada-Navas, E. Villegas-Antelo, E. Rivero-Sigarroa, G. Dominguez-Cherit, Mexico, Mexico, p.A7399

Facilitator: A. Vaidya, MD, Philadelphia, PA

P1035 **Relative Importance of Hemodynamics, Pulmonary Mechanics, Body Habitus, Demographics, and Time to Diagnosis and Treatment in Predicting 6 Minute Walk Test Results Before and After Treatment in Patients with Pulmonary Arterial Hypertension/** C. Pena Orbea, N. Quesada, R. Lenhardt, Chicago, IL, p.A7400

P1036 **The Effect of Lung Capacity on Response to Treatment in Patients with Pulmonary Arterial Hypertension (PAH)/**S. Shenoy, M. Avdalovic, Sacramento, CA, p.A7401

P1037 **Treatment with Parenteral Treprostinil in Patients with Advanced Pulmonary Arterial Hypertension is Associated with Improvement in Right Ventricular Coupling, Diastolic Stiffness, Mass and Relative Wall Thickness/**R. Bernardo, R.R. Vanderpool, H.H. Desai, M.A. Simon, S. Knoper, L. Hansen, F. Rischard, Tucson, AZ, p.A7402

P1038 **Predictors of Survival in Patients with Scleroderma-Related Pulmonary Arterial Hypertension (SSc-PAH)? Cleveland Clinic Experience/**M. Ghobrial, O.A. Minai, K.B. Highland, Cleveland, OH, p.A7403

P1039 **Hemodynamic Dose-Response to Parenteral Treprostinil Occurs at Low Dose and Is Poorly Related to Biomarker and Functional Improvements in Patients with Advanced Treatment Naive Pulmonary Arterial Hypertension/**L. Hansen, F. Rischard, Tucson, AZ, p.A7404

P1040 **Monocyte Subsets in Pulmonary Vascular Complications of Liver Disease/**S.M. Kawut, M.F. Doyle, M.J. Krowka, K. Forde, G.A. Heresi, R. Dweik, K.E. Roberts, K. Krok, M. Patel, G. Lin, J. Oh, M. Fallon, Philadelphia, PA, p.A7405

P1041 **Metabolomic Differences in Pulmonary Vascular Complications of Liver Disease/**S.M. Kawut, M.J. Krowka, K. Forde, G.A. Heresi, R. Dweik, K.E. Roberts, K. Krok, M. Patel, S. Batra, G. Lin, J. Oh, M. Fallon, Philadelphia, PA, p.A7406

P1042 **Effect of Steady-State Esuberaprost (BPS-314d-MR) on the Safety, Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Adult Subjects/**P. Sista, H. Coleman, G. Patel, M. Peterson, X. Chen, K.R.B.V. Kessler, J. Shin, Silver Spring, MD, p.A7407

P1043 **Methamphetamine-Induced Pulmonary Artery Hypertension—Efficacy of Oral Vasodilator Therapy in Advanced Disease/**J. Scott, I. Subramanian, Oakland, CA, p.A7408

P1044 **Clinical Utility of Measured Jugular Venous Pressure to Predict Right Atrial Pressure/**K.J. Solverson, D. Vis, M. Braganza, J. Shaw, J. Weatherald, M.V. Thakrar, R. Varughese, N. Hirani, D. Helmersen, Calgary, Canada, p.A7419

P1045 **Design and Development of the Institutional Registry of Pulmonary Hypertension in Fundacion Valle del Lili, a University Hospital of Reference in Latin America/**L. Fernandez, M. Ramos, J.E. Gomez, W. Martinez, F. Sanabria, D.C. Carrillo, Cali, Colombia, p.A7410

P1046 **The Association Between Symptoms, Health-Related Quality of Life and Exercise Capacity in Pulmonary Arterial Hypertension/**L.A. Matura, K. Boyle, J. Fargo, J. Fritz, K.A. Smith, A. Vaidya, D. Pinder, C. Archer-Chicko, H. Palevsky, A.I. Pack, M.S. Sommers, S.M. Kawut, Philadelphia, PA, p.A7921

P1047 **Pulmonary Arterial Hypertension Schistosomotic Versus Non Schistosomotic: Clinical and Hemodynamic Profile/**A.A. Mendes, C.G.P. Roncal, F.R.A. Oliveira, M.C.F.C. Silva, E.S. Albuquerque, F.A.A. Japyassu, D.C.S. Filho, M.C.A. De Britto, Recife, Brazil, p.A7922

THEMATIC POSTER SESSION

D55 LAB METHODOLOGY AND BIOENGINEERING: JUST DO IT

9:00 a.m. - 3:30 p.m. **MOSCONE CENTER**

Area D, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: G.N. Maksym, PhD, Halifax, Canada

P477 **Micro-Computed Tomography of the Lung: Imaging of Alveolar Duct and Alveolus in Human Lung/**S. Nakamura, K. Mori, T. Okasaka, K. Kawaguchi, T. Fukui, K. Fukumoto, K. Yokoi, Nagoya-City, Japan, p.A7411

P478 **Micron-Sized and Submicron-Sized Aerosol Delivery: Benefits of a New Human-Like Ex Vivo Preclinical Model to Assess Regional Deposition/**S. Perinel, L. Leclerc, N. Prevot-Bitot, A. Deville, M. Cottier, M. Durand, J.M. Vergnon, J. Pourchez, Saint Priest en Jarez, France, p.A7412

P479 **A Novel Platform to Investigate the Mechanisms of Particle Deposition in the Lung/**A. Sonnenberg, I. Puranam, M. Basile, E. Bartolak-Suki, S.D. Amin, B. Suki, Boston, MA, p.A7413

P480 **Longitudinal Comparison of Four Mathematical Prediction Models of Solitary Pulmonary Nodules Imaged on Computed Tomography/**J. Uthoff, N. Koehn, S.K.N. Dilger, E. Hammond, F. De Stefano, M. Muralidharan, E.A. Hoffman, J.D. Newell, R. Sanchez, J.C. Sieren, Iowa City, IA, p.A7414

P481 **Combinatory Simulation Study of Ventilation, Diffusion, and Perfusion by the Use of a 4D Model of the Human Pulmonary Subacinus/**H. Kitaoka, Tokyo, Japan, p.A7415

P482 **Evidence for Parallel Pathway Organization of the Pulmonary Circulation/**R.L. Conhaim, G. Segal, K.E. Watson, Madison, WI, p.A7416

P483 **Behavior of Vascular Resistance Undergoing Various Pressure Insufflation and Perfusion on Decellularized Lungs/**L. Oliveira, R.K. Da Palma, P.N. Nonaka, N. Campillo, J.J. Uriarte, J.J. Urbano, D. Navajas, R. Farre, Sao Paulo, Brazil, p.A7417

P484 **Development of a Novel Approach to Measure Traction Force by Cells Adhered to Physiological Substrate Undergoing Dynamic Stretch/**J. Imsirovic, H. Parameswaran, J.R. Mondonedo, E. Bartolak-Suki, S. Ram-Mohan, R. Krishnan, B. Suki, Boston, MA, p.A7418

P485 **Live Alveolar Imaging of Precision Cut Lung Slices During Prescribed Equibiaxial Stretch/**J.R. Mondonedo, J. Imsirovic, S. Ram-Mohan, E. Bartolak-Suki, R. Krishnan, B. Suki, Boston, MA, p.A7419

Facilitator: R. Krishnan, PhD, Boston, MA

P486 **Computational Modeling of the Evolution of Tissue Stiffness Following Surgical and Bronchoscopic Lung Volume Reduction Techniques in Emphysema/**J.R. Mondonedo, B. Suki, Boston, MA, p.A7420

P487 **Development of Scaffold-Free Trachea Tissue Engineering Using Bio 3D Printing System/**K. Matsumoto, R. Machino, D. Taniguchi, Y. Takeoka, Y. Taura, N. Yamasaki, T. Tsuchiya, T. Miyazaki, G. Hatachi, Y. Kitamura, T. Nagayasu, Nagasaki, Japan, p.A7421

P488 **Engineered Human Lung Generated from Human iPSCs was Functional in Bioreactor System In Vitro/**M. Ghaedi, L.E. Niklason, New Haven, CT, p.A7422

P489 **Fe2O3 Nanoparticles Cause Alteration of Microstructure and Rheological Properties of Simulated Mucus/**L. Deng, M. Luo, J. Wang, Y. Wang, X. Yan, Z. Sun, J. Li, Changzhou, China, p.A7423

P490 **Novel Methodology to Isolate Endothelial Cells from the Pulmonary Vasculature of Patients with Systemic Sclerosis and Pulmonary Arterial Hypertension/**S. Lenna, M. Trojanowska, H.W. Farber, Boston, MA, p.A7424

P491 **Development of a Novel ProteaseTagT Activity Immunoassay for the Specific Measurement of Neutrophil Elastase in Clinical Samples from Patients with Respiratory Disease/**K.L. Moffitt, B. Walker, P. McNally, B. Linnane, J.S. Elborn, J.D. Chalmers, D. Ribeiro, S.L. Martin, Belfast, United Kingdom, p.A7425

P492 **CallistoTM Is an Automated In Vitro Cell Culture System to Study Small Cell Populations/**A. Srivastava, Y. Sun, P. Mannam, J. Koff, New Haven, CT, p.A7426

P493 **Introduction of a New Cellular Collection Tube for Body Effusion Cytology/**Q. Li, Y. Yang, Y. Zheng, Y. Wu, Y. Zhu, L. Ren, X. Yang, Tianjin, China, p.A7427

P494 **Small Airway Hyperresponsiveness in Precision-Cut Lung Slices of Patients with Mild to Moderate COPD: Relationship Between Tissue Structure and Function/**H. Meurs, A.B. Zuidhof, C.R.S. Elzinga, M. Smit, A. Oldenburger, C.M. Bidan, R. Gosens, W. Timens, H. Maarsingh, Groningen, Netherlands, p.A7924

P495 **Characterization of Pulmonary Mechanics of the SOD1G93A ALS Mouse Model/**L. Stoica, L. Xiong, M. Kalfopoulos, K.V. Desroshers, M.K. ElMallah, Worcester, MA, p.A7923

THEMATIC POSTER SESSION

D56 CUDDLE UP A LITTLE CLOSER: SDB NONPULMONARY OVERLAPS

9:00 a.m. - 3:30 p.m. **MOSCONE CENTER**

Area J, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: B. Prasad, MD, MS, Chicago, IL

P1049 **The Relation Between Obstructive Sleep Apnea and Gastro-Esophageal Reflux Disease/**Y. Kim, H. Kang, G. Lim, Y.J. Lee, J.S. Park, Y.-J. Cho, H.I. Yoon, J.H. Lee, C.-T. Lee, S.J. Kim, Bundang-gu, Seongnam-si, Korea, Republic of, p.A7428

P1050 **Prevalence and Risk Factors of Obstructive Sleep Apnea in HIV-Infected Individuals in Yaounde, Cameroon/**A.D. Balkissou, E.W. Pefura-Yone, A.P. Kengne, Yaounde, Cameroon, p.A7429

P1051 **A Unique Sleep Phenotype of Decreased NREM Sleep, but Increased Sleep Consolidation, in the Townes Mouse Model of Sickle Cell Disease/**B. O'Donnell, L. Guo, F. Shah, B.J. McVerry, S. Ghosh, P.J. Strollo, M.T. Gladwin, G. Kato, S. Ofori-Acquah, C.P. O'Donnell, Pittsburgh, PA, p.A7430

P1052 **Clinical Correlates of Sleep Disordered Breathing in Sickle Cell Disease/**C.M. Worsham, S.T. Martin, E.S. Klings, R.T. Cohen, Boston, MA, p.A7431

P1053 **The Association Between Hypertension and Neutrophil to Lymphocyte Ratio in Patients with Obstructive Sleep Apnea Syndrome/**O. Ercen Diken, M. Arslan, H. Deniz, O. Hanedan, Corum, Turkey, p.A7432

P1054 **Genome-Wide Gene Expression Microarray Identifies Novel Genes Related to Endothelial Tight Junctions and Apoptosis in Patients with Obstructive Sleep Apnea/**Y.-C. Chen, M.-C. Lin, K.-D. Chen, M.-C. Su, C.-H. Chin, Kaohsiung, Taiwan, p.A7433

Facilitator: G.R. Bourjeily, MD, Providence, RI

P1055 **Peritoneal Dialysis and Obstructive Sleep Apnea in Patients with End Stage Renal Disease/**A. Lanis, E. Kerns, S. Hu, P. Risica, S. Martin, R. Millman, J. Parker, L. Dworkin, G.R. Bourjeily, Providence, RI, p.A7434

P1056 **Impact of Obstructive Sleep Apnea on Patients with Chronic Kidney Diseases/**E.K. Ibrahim, A.A.E.M. El Hadidy, N.E.E. Gomaa, T.H. El Shabouny, Y.M.A. Soliman, A.H. Ali, Cairo, Egypt, p.A7435

P1057 **The Impact of Renal Replacement Therapy on Sleep Disordered Breathing in Patients with End Stage Renal Disease/**A. Kaur, B. Link, D. Shemin, P. Risica, S. Martin, J. Parker, R. Millman, L. Dworkin, G.R. Bourjeily, Providence, RI, p.A7436

P1058 **Increased the Level of Uric Acid in Patients Who Have Obstructive Sleep Apnea Syndrome/**T. Yokoe, Y. Watanabe, A. Fujiwara, Y. Uchida, R. Manabe, H. Furukawa, N. Kuwahara, Y. Fukuda, T. Kimura, M. Jinno, K. Hirai, Y. Miyata, S. Ohta, T. Homma, M. Yamamoto, A. Tanaka, H. Sagara, Japan, p.A7437

P1059 **Prevalence of Obstructive Sleep Apnea Among Pregnant Women in Saudi Arabia/**A.K. Aldubayan, M.I. Alangari, A.M. Alsharidah, A.H. Olaish, Y. Saber, A. Taki, A. BaHammam, Riyadh, Saudi Arabia, p.A7438

Facilitator: S. Sinha, MD, New Delhi, India

P1060 **Incidence of Obstructive Sleep Apnea in Type 2 Diabetes Mellitus Patients in Tertiary Care Center of North India/**A.K. Kashyap, P. Dhiman, H.S. Pannu, P. Singh, U.S. Sidhu, Ludhiana, India, p.A7439

P1061 **Serum Gamma-Glutamyltransferase in Obstructive Sleep Apnea and Its Role in Predicting Concomitant Diabetes Mellitus/**C. Gu, M. Li, Q. Li, J. Zhou, J. Du, H. Yi, J. Feng, China, p.A7440

P1062 **Does Hypoxia Only Importan for Fatty Liver in OSA Patients/**B. Sertogullarindan, D. Bulut, H. Gunbatar, A. Sunnetcioglu, S. Ekin, A. Arisoy, Izmir, Turkey, p.A7441

P1063 **Up-Regulation of Selenoprotein P and HIP/PAP in Hepatocytes by Cyclic Intermittent Hypoxia/**H. Ota, M. Yamauchi, N. Koyama, Y. Fujita, A. Itaya-Hironaka, A. Yamauchi, S. Sakuramoto-Tshuchida, R. Shobatake, K. Tomoda, M. Yoshikawa, S. Takasawa, H. Kimura, Kashiara Nara, Japan, p.A7442

Facilitator: V.Y. Polotsky, MD, PhD, Baltimore, MD

P1064 **The Study of Serum Endoplasmic Reticulum Stress Protein (GRP78) in Obstructive Sleep Apnea/**J. Han, W. Wang, Z. Jiang, J. Kang, Shenyang, China, p.A7443

P1065 **The Changes of Urinary Lipocalin-Type Prostaglandin D Synthase After 3 Months CPAP Treatment in Obstructive Sleep Apnea Patients/**J. Su, S. Ouyang, L. Sun, M. Wang, X. Ma, W. Wang, C. Zhao, Zheng Zhou, China, p.A7444

P1066 **Plasma Concentration of Gelatinases and Their Inhibitors in Obstructive Sleep Apnea Syndrome/**B. Canino, E. Hopps, V. Calandrino, C. Urso, R. Lo Presti, G. Caimi, Palermo, Italy, p.A7445

P1067 **Sleep Disorders in Breast Cancer/**S. Shafazand, M. Schweitzer, M. Lippman, Miami, FL, p.A7446

P1068 **Cancer Prevalence and Intermittent Hypoxia in Obstructive Sleep Apnea/**A. Cargill, R. ElYousef, M.R. Al-Ajam, M. Cutaia, Brooklyn, NY, p.A7447

Facilitator: C. Lal, MD, Charleston, SC

P1069 **Erythrocyte Sedimentation Rate May Help Predict Severity of Obstructive Seep Apnea/**S.-N. Hong, H.J. Kim, W.H. Lee, Korea, Republic of, p.A7448

P1070 **The Analysis of Pattern Visual Evoked Potential in Obstructive Sleep Apnea Syndrome/**H. Huang, W. Wang, Shenyang City, China, p.A7449

P1071 **Baseline Data from the ROSA Trial: A Randomised Controlled Trial of the Effect of CPAP on Diabetic Macular Oedema in People with Concurrent Obstructive Sleep Apnoea/**S.D. West, J. Hughes, B. Prudon, Newcastle, United Kingdom, p.A7450

P1072 **Various Types of Sleep Disordered Breathing Associated with Multiple System Atrophy/**M. Yamauchi, Y. Fujita, H. Uyama, N. Koyama, M. Yoshikawa, H. Kimura, Kashihara, Japan, p.A7451

THEMATIC POSTER SESSION

D57 DON'T BE A DO-BADDER: NEW INTERVENTIONS FOR OSA

9:00 a.m. - 3:30 p.m. **MOSCONE CENTER**

Area J, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: R.J. Kimoff, MD, Montreal, Canada

P1074 **The Role of Volume Assured Pressure Support (AVAPS) in Patients with Amyotrophic Lateral Sclerosis: A Preliminary Report/**L.M. Fontana, P. Barkhaus, A. Anton, Milwaukee, WI, p.A7452

P1075 **Noninvasive Ventilation Efficacy for Obesity Hypoventilation Syndrome Without Severe Sleep Apnea/**J.F. Masa, J. Corral, C. Caballero, E. Barrot, J. Teran-Santos, M.L. Alonso-Alvarez, T. Gomez-Garcia, M. Gonzalez, S. Lopez-Martinez, P. De Lucas, J.M. Marin, S. Marti, T. Diaz-Cambriles, E. Chiner, C. Egea, E. Miranda, B. Mokhlesi, Caceres, Spain, p.A7453

P1076 **Low Flow Nasal Pillow Mask Meets CPAP Efficacy/**P.N. DeYoung, J.E. Orr, Y. Li, A. Malhotra, La Jolla, CA, p.A7454

P1077 **Effects of Nasal CPAP on Exhaled SIRT1 and Tumor Necrosis Factor-α in Patients with Obstructive Sleep Apnea/**C.-C. Lin, C.-H. Chiu, S.-F. Liaw, New Taipei City, Taiwan, p.A7455

Facilitator: J.M. Coleman, MD, Chicago, IL

P1078 **The Role of Nasal Resistance in CPAP Adherence in the World Trade Center First Responder Cohort/**P. Agarwala, E. Ducca, T. Gumb, A. Twumasi, K. Black, C. Lewis, S. Alimokhtari, A. Perez, S.-E. Lu, N. Chitkara, D. Harrison, I. Udasin, J. Sunderram, D. Rapoport, I.A. Ayappa, New York, NY, p.A7456

P1079 **The Effects of Adding Heated Humidification to Nasopharynx on Nasal Resistance, Breathing Pattern, and Sympathetic Nerve Activity/**Y. Fujita, M. Yamauchi, H. Oda, M. Igaki, M. Yoshikawa, H. Kimura, Kashihara, Japan, p.A7457

P1080 **Decreased CPAP Adherence in Non-Obese OSA Patients with Reversible Upper Airway Obstruction/**P.G. Belvitch, J. Doumit, I. Rubinstein, Chicago, IL, p.A7458

P1081 **Determinant Factors of Discontinuation of Continuous Positive Airway Pressure Therapy in Patients with Obstructive Sleep Apnea Syndrome/**K. Takeyama, M. Tsuji, H. Hara, A. Ichikawa, K. Orimo, R. Mizobuchi, T. Aizawa, C. Sugita, J. Nakata, J. Tamaoki, Tokyo, Japan, p.A7459

P1082 **The Use of a Validated Claustrophobia Questionnaire in Predicting Future Compliance to Continuous Positive Airway Pressure (CPAP) in Obstructive Sleep Apnea (OSA)/**M. Aljasmi, K. Agarwal, S. Uppalapati, K. Moss, L. Bazan, C. Drake, Detroit, MI, p.A7460

Facilitator: R. Arens, MD, Bronx, NY

P1083 **The Effect of Supplemental Oxygen in Obesity Hypoventilation Syndrome/**M.-A. Sanchez-Quiroga, J.F. Masa, J. Corral, A. Romero, C. Caballero, J. Teran-Santos, M.L. Alonso-Alvarez, T. Gomez-Garcia, M. Gonzalez, S. Lopez-Martinez, P. De Lucas, J.M. Marin, S. Marti, T. Diaz-Cambriles, E. Chiner, M. Merchan, C. Egea, A. Obeso, B. Mokhlesi, Plasencia, Spain, p.A7461

P1084 **Determination of the Fraction of Inspired Oxygen (Fi02) with Different Oxygen Flows and Different CPAP Levels in Domiciliary Noninvasive Ventilators (DNIV)/**J.I. Marmolejo, R.E. Gutierrez, J. Leon, T. Cortes, C. Ortiz, V.P. Vergara, F.A. Salinas, M.F. Cerda, P.A. Villagran, N.S. Gonzalez, F.P. Riquelme, C. Merino, L.A. Soto, J.E. Keymer, J.L. Molina, Santiago, Chile, p.A7462

P1085 **The Relationship Between Weight Loss and Non-Supine Apnea-Hypopnea Index/**S.A. Joosten, J.K. Khoo, J.B. Dixon, M.T. Naughton, B.A. Edwards, G.S. Hamilton, Melbourne, Australia, p.A7463

P1086 **Evaluating the Use of Quality Care Measures in the Assessment and Management of Obstructive Sleep Apnea Patients/**N. Uppal, C. Ryan, Toronto, Canada, p.A7464

Facilitator: J.E. Metz, DDS, Columbus, OH

P1087 **Effect of Positional Therapy on the Pharyngeal Structure Causing Collapse in Obstructive Sleep Apnea Patients/**M. Marques, P. Genta, S.A. Sands, A. Azarbarzin, C.M. De Melo, L. Taranto Montemurro, D.P. White, A. Wellman, Boston, MA, p.A7465

P1088 **Effects of Sleep Stage and Body Position on Snoring Severity/**M. Guzman, F. Sgambati, H. Pho, R.S. Arias, T. Otvos, E. Wolfe, I. Hawks, J.P. Kirkness, H. Schneider, P.L. Smith, A.R. Schwartz, Baltimore, MD, p.A7466

P1089 **Prediction of Outcome With Oral Appliance Therapy for Obstructive Sleep Apnea Using In-home Mandibular Titration/**J. Remmers, Z. Topor, J. Grosse, N. Vranjes, S. Charkandeh, Calgary, Canada, p.A7467

Facilitator: S. Redolfi, MD, PhD, Paris, France

P1090 **Three Year Outcomes of Upper Airway Stimulation for Obstructive Sleep Apnea/**P.J. Strollo, W. Randerath, K.P. Strohl, Pittsburgh, PA, p.A7468

P1091 **Effect of Conversion from Conventional to Nocturnal Home Hemodialysis on Fluid Volume Status and Sleep Apnea Severity in End Stage Renal Disease/**O. Lyons, T. Inami, A. Yadollahi, C.T. Chan, T.D. Bradley, Toronto, Canada, p.A7469

P1092 **Effects of Fluid Removal by Ultrafiltration on Sleep Apnea Severity and Cardiac Function in End Stage Renal Disease/**T. Inami, O. Lyons, A. Yadollahi, C.T. Chan, J.S. Floras, T.D. Bradley, Toronto, Canada, p.A7470

P1093 **Effects of Melatonin Supplementation in Obstructive Sleep Apnea Patients/**N.L. Deacon, E. Smales, R. Jen, S. Jaiswal, Y. Li, A. Malhotra, La Jolla, CA, p.A7471

P1094 **The Effect of Donepezil on Sleep Apnea in Patients with Obstructive Sleep Apnea- a Randomized, Double Blind Cross-Over Study/**Y. Li, R.L. Owens, S.A. Sands, J.E. Orr, P.N. DeYoung, E.T. Smales, R. Jen, A. Malhotra, La Jolla, CA, p.A7472

CLINICAL

WORKSHOP

CME Credits Available: 1.5

WS7 UPDATE ON EBUS: PRACTICAL QUESTIONS ANSWERED

Registration Fee: $75.00 (includes box lunch)
Attendance is limited. Pre-registration is required.

Assemblies on Clinical Problems; Thoracic Oncology

11:45 a.m. - 1:15 p.m. **MOSCONE CENTER**

Room 301 (South Building, Esplanade Level)

Target Audience
Providers of lung health;practitioners who perform or
who are interested in bronchoscopy and EBUS; physicians-in-training.

Objectives
At the conclusion of this session, the participant will be able to:

- identify the indications and diagnostic yield of EBUS;
- understand the various factors that can affect diagnostic yield, safety and efficiency of EBUS;
- apply the information learned to plan an optimal EBUS procedure with consideration of the various equipment and support available.

Endobronchial ultrasound (EBUS) was introduced in the last decade, enabling real-time guidance of transbronchial needle aspiration (TBNA) of mediastinal and hilar structures and parabronchial lung masses. Many publications about EBUS-TBNA have led to a better understanding of the performance characteristics of this procedure. The goal of this workshop is to examine the current literature on the practical aspects of EBUS-TBNA to provide evidence-based and expert guidance to clinicians.

Chairing: A.C. Argento, MD, Chicago, IL
M.M. Wahidi, MD, Durham, NC
C.T. Gillespie, MD, Chicago, IL
H. Lee, MD, Baltimore, MD

11:45 **Introduction**
A.C. Argento, MD, Chicago, IL

11:55 **EBUS Diagnostic Yield**
M.M. Wahidi, MD, Durham, NC

12:15 **Patient Factors That Affect EBUS**
A.C. Argento, MD, Chicago, IL

12:35 **Procedural Aspects of EBUS**
C.T. Gillespie, MD, Chicago, IL

12:55 **Training for EBUS**
H. Lee, MD, Baltimore, MD

BASIC • TRANSLATIONAL

WORKSHOP

CME Credits Available: 1.5

WS8 PRECISION MEDICINE IN ASTHMA: CURRENT PRACTICE, GAPS, FUTURE DIRECTIONS

Registration Fee: $75.00 (includes box lunch)
Attendance is limited. Pre-registration is required.

Assemblies on Allergy, Immunology and Inflammation; Environmental, Occupational and Population Health; Pediatrics

11:45 a.m. - 1:15 p.m. **MOSCONE CENTER**
Room 302 (South Building, Esplanade Level)

Target Audience
Clinicians will benefit by learning about the current state of the art in the treatment and prophylaxis of asthma, which they may consider applying to their practice; researchers will benefit by identifying gaps for future research; trainees will benefit by learning a cutting-edge concept in scientifically underpinned medical management.

Objectives
At the conclusion of this session, the participant will be able to:

- apply knowledge in day-to-day management of asthma patients;
- identify new areas for asthma related research;
- recognize the full scope of personal factors that affect asthma development and outcomes.

Before precision medicine became a household term and focus of research, physicians treating asthma had grappled with the different endotypes of this syndrome and had sought to understand why some patients develop hard to treat asthma, while others are protected. We are finally at the point where research insights are starting to inform treatment decisions in a tailored approach to asthma treatment. Much more needs to be done. This session will crystallize the current state of the art, that can be immediately implemented in clinical practice, as well as identify areas of interest for future research.

Chairing: S. Garantziotis, MD, Research Triangle Park, NC
D.A. Schwartz, MD, Aurora, CO

11:45 **Identifying Biologic and Genetic Risk Factors for Asthma in Minority Patients**
E.G. Burchard, MD, MPH, San Francisco, CA

12:00 **Genes, Psychosocial Stress and Asthma**
J.C. Celedon, MD, DrPH, Pittsburgh, PA

12:15 **Microbiome Factors in the Development and Severity of Asthma**
E. von Mutius, MD, MS, Munich, Germany

12:30 **Asthma Endotypes: Are the Visions Becoming Reality?**
S.E. Wenzel, MD, Pittsburgh, PA

12:45 **Role of Environmental Exposures in the Precision Medicine Approach to Asthma**
F. Gilliland, MD, MPH, PhD, Los Angeles, CA

1:00 **Plenary Session: An Integrated Approach to Precision Asthma Treatment**
S. Garantziotis, MD, Research Triangle Park, NC

CLINICAL

ADULT CLINICAL CORE CURRICULUM

CME Credits Available: 1.5

CC5 CRITICAL CARE CLINICAL CORE CURRICULUM I

Adult Core Curriculum Working Group

11:45 a.m. - 1:15 p.m. **MOSCONE CENTER**
Room 2005/2007 (West Building, Level 2)

Target Audience
Internists and subspecialists in pulmonary, critical care, and sleep medicine who work in a clinical setting and are currently engaged in maintenance of certification.

Objectives
At the conclusion of this session, the participant will be able to:

- remain current with medical knowledge relevant to their practice in pulmonary, critical care, and sleep medicine;
- evaluate their understanding of key skills and content areas in pulmonary, critical care and sleep medicine, as well as receive feedback on their comprehension of a result of a pre-test/post-test comparison;
- support clinicians who are engaged in maintenance of certification activities by providing updates on subjects included in recertification requirements.

The ATS Clinical Core Curriculum Symposia focus on a 3-year content cycle of key medical content in the areas of pulmonary, critical care, and Sleep medicine. The topics are also aligned with corresponding MOC Medical Knowledge modules. This symposium is intended to assist clinicians with staying current with the growth of information relevant to their medical practice, as well as provide an opportunity to evaluate individual knowledge and skills while earning MOC Medical Knowledge points.

Chairing: J.I. McSparron, MD, Boston, MA
A.M. Luks, MD, Seattle, WA

11:45 **Airway Emergencies**
W.G. Carlos, MD, MSCR, Indianapolis, IN

12:05 **Massive Resuscitation and Transfusion**
R. Sell, MD, San Diego, CA

12:45 **Emergent Renal Replacement and Therapy**
K. Liu, MD, PhD, San Francisco, CA

AIRWAYS CLINICAL RESEARCH CENTERS , ALA

L21 LATE BREAKING RESULTS FOR THE ALA-ACRC LASST STUDY

12:15 p.m. - 1:15 p.m. **MOSCONE CENTER**

Room 3006/3008 (West Building, Level 3)

Target Audience
Physicians, clinical scientists, nurses, paraprofessionals, educators, health care providers.

Objectives
At the conclusion of this session, the participant will be able to:

- learn new findings about new, safe, and effective approaches to asthma treatment;
- gain new strategies to manage the care of asthma;
- learn new findings about adherence, safety, and tolerability of LASST.

The ALA Airways Clinical Research Centers' (ACRC) purpose is to conduct clinical trials with practical importance to both adults and children with COPD and asthma. One of the trials was the LASST Study (Long-acting Beta Agonist Step Down Study). This trial verified these findings: to test the hypothesis that in patients with well-controlled asthma on combination ICS/LABA, discontinuing LABA while continuing with the same ICS dose will be inferior to continuing LABA and reducing the dose of ICS in preventing treatment failure during step-down therapy. This session will be the first presentation of the results of the LASST Study.

Chairing: W.C. Bailey, MD, Birmingham, AL
R.A. Wise, MD, Baltimore, MD

12:15 **LASST Background and Rationale**
K. Blake, PharmD, Jacksonville, FL

12:30 **LASST Study Design and Baseline Characteristics**
C. Bime, MD, Tucson, AZ

12:45 **LASST Main Results, Summary, and Conclusions**
L. Rogers, MD, New York, NY

1:00 **Discussion/Questions and Answers**
R.A. Wise, MD, Baltimore, MD

NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH

L22 RESPIRATORY HAZARDS OF WORKING WITH METALS: FROM MACROPHAGES TO MICROBIOMES

12:15 p.m. - 1:15 p.m. **MOSCONE CENTER**

Room 3020/3022 (West Building, Level 3)

Target Audience
Providers of lung health; clinicians caring for industrial workers; clinicians and researchers with interest in exposure-related lung disease.

Objectives
At the conclusion of this session, the participant will be able to:

- learn new findings about exposure to metals (beryllium, indium) and disease;
- recognize occupational causes of lung disease related to exposure to metals or metalworking fluid;
- improve understanding of the potential role of the lung microbiome in occupational lung disease.

This session will highlight recent research at NIOSH on unique lung diseases related to work with metals. Both well-described and novel diseases will be discussed. Findings related to clinical features and exposure-response relationships will be presented. Implications for disease prevention will be explored.

Chairing: K. Cummings, MD, MPH, Morgantown, WV

12:15 **NIOSH Research on Beryllium Disease**
E. Fechter-Leggett, DVM, Morgantown, WV

12:30 **Understanding Indium Lung Disease**
R. Harvey, DVM, Morgantown, WV

12:45 **A Novel Lung Disease Related to Metalworking Fluid**
R. Nett, MD, Morgantown, WV

1:00 **Lung and Workplace Microbiomes in a Metalworking Fluid Environment**
L. Segal, MD, New York, NY

U.S. FOOD AND DRUG ADMINISTRATION

L23 PULMONARY UPDATE FROM THE U.S. FOOD AND DRUG ADMINISTRATION

12:15 p.m. - 1:15 p.m. **MOSCONE CENTER**

Room 3016/3018 (West Building, Level 3)

Target Audience
Clinicians in practice, researchers, pharmaceutical industry representatives, international regulators.

Objectives
At the conclusion of this session, the participant will be able to:

- understand how FDA-approved biomarkers can be used to enhance clinical trial drug development;
- learn new therapeutic targets for asthma (general asthma population as well as specific phenotypic subsets);
- integrate new treatment options regarding maintenance bronchodilator choices for management of stable asthma, and understand the role of clinical and biomarker criteria for patient selection for anti-IL-5 therapy.

The most recent regulatory FDA actions including discussion of current safety and efficacy issues of products for pulmonary indications will be presented. A summary of the Agency's biomarker qualification process exemplified by the recent qualification of fibrinogen for use in COPD clinical trials will be discussed. Recent approvals for asthma highlighting targeted therapy to specific asthma phenotypes, as well as the use of a long-acting anticholinergic as a new bronchodilator in asthma will be presented.

Chairing: L.I. Gilbert-McClain, MD, Silver Spring, MD

12:15 **Update on Current Pulmonary Issues at the FDA**
L.I. Gilbert-McClain, MD, Silver Spring, MD

12:33 **Old Drug New Use: Anticholinergics and Asthma**
S.J. Chin, MD, Silver Spring, MD

12:51 **Targeted Therapy for Asthma: Lessons from the IL-5 Pathway**
K.M. Donohue, MD, Silver Spring, MD

1:09 **Questions and Answers**
L.I. Gilbert-McClain, MD, Silver Spring, MD

VARIOUS ORGANIZATIONS

L24 RESEARCH FUNDING OPPORTUNITIES

12:15 p.m. - 1:15 p.m. **MOSCONE CENTER**
Room 2001/2003 (West Building, Level 2)

Target Audience
Any ATS member who conducts research and is seeking funding.

Objectives
At the conclusion of this session, the participant will be able to:

- describe the research priorities of each funding agency represented on the panel;
- discuss practical steps that researchers take to improve quality of grant applications;
- identify a funding agency that is most closely aligned with the attendee's research interests.

This session will introduce programs and research grant opportunities offered from major funding agencies. Speakers will present current research priorities and mechanisms of research funding available from each agency.

Chairing: J. Yorke, PhD, RN, Manchester, United Kingdom
J. Choi, PhD, RN, Pittsburgh, PA

12:15 **National Institute of Nursing Research**
N. Redeker, PhD, RN, West Haven, CT

12:25 **National Heart, Lung, and Blood Institute**
L. Reineck, MD, Bethesda, MD

12:35 **Department of Veterans Affairs**
E.G. Collins, PhD, RN, Chicago, IL

12:45 **American Lung Association**
S. Rappaport, MPH, New York, NY

12:55 **ATS Program of Research**
Speaker To Be Announced

1:05 **Panel Discussion**
J. Yorke, PhD, RN, Manchester, United Kingdom

NATIONAL HEART, LUNG, AND BLOOD INSTITUTE, DIVISION OF LUNG DISEASES, NIH

L25 NEW RESULTS FROM THE COPDGENE STUDY

12:15 p.m. - 1:15 p.m. **MOSCONE CENTER**
Room 2002/2004 (West Building, Level 2)

Target Audience
Those with clinical or research responsibilities.

Objectives
At the conclusion of this session, the participant will be able to:

- learn about imaging in the COPDGene study;
- understand and learn about subtypes identified by the COPDGene study;
- learn about longitudinal follow-up in the COPDGene study.

Chronic obstructive pulmonary disease (COPD), the third leading cause of death in the United States, is a heterologous syndrome. The COPDGene study has created the largest cohort of well-characterized current and former smokers for respiratory disease research. The primary goals of COPDGene are: 1) to identify new genetic loci that influence the development of COPD and COPD-related phenotypes and 2) to reclassify COPD into subtypes that can ultimately be used to develop effective therapies. This session will describe the progress and future plans of the COPDGene study.

Chairing: E.K. Silverman, MD, PhD, Boston, MA
J.D. Crapo, MD, Denver, CO
L. Postow, PhD, Bethesda, MD

12:15 **Overview of COPDGene**
J.D. Crapo, MD, Denver, CO

12:27 **Longitudinal Follow-Up of COPDGene Subjects: Clinical Epidemiology**
M.K. Han, MD, MS, Ann Arbor, MI

12:39 **Advances in Quantitative Lung Imaging and Visual CT Assessment**
D.A. Lynch, MD, Denver, CO

12:51 **COPD Genetics: From GWAS to Sequencing**
E.K. Silverman, MD, PhD, Boston, MA

1:03 **Defining Subtypes of COPD**
M.H. Cho, MD, MPH, Boston, MA

NATIONAL HEART, LUNG, AND BLOOD INSTITUTE, DIVISION OF LUNG DISEASES, NIH

L26 ENHANCED PHENOTYPING OF PULMONARY VASCULAR DISEASES

12:15 p.m. - 1:15 p.m. **MOSCONE CENTER**
Room 2006/2008 (West Building, Level 2)

Target Audience
Health providers, trainees, and researchers.

Objectives
At the conclusion of this session, the participant will be able to:

- learn about current deep-phenotyping of PH;
- understand and learn pediatrics PH registry;
- learn about the national biorepository of PH patient samples for PH research.

Pulmonary hypertension (PH) currently has no cure, thus PH research remains a high priority for NHLBI. Recently, NHLBI launched several major multi-center clinical studies of PH including: Redefining Pulmonary Hypertension through Pulmonary Vascular Disease Phenomics (PVDOMICS); and Pulmonary Hypertension Breakthrough Initiative (PHBI), which will help us understand the molecular mechanisms of PH in adult patients, and provide phenotypic data and biomarkers for future clinical trials and measures of disease severity. Data Fusion: A Sustainable, Scalable, Open Source Registry Advancing PVD Research using a novel biomedical informatics approach will develop computable phenotypes of pediatric pulmonary vascular diseases. This session will introduce these programs and present data from these studies

Chairing: L. Xiao, MD, PhD, Bethesda, MD
C.J. Blaisdell, MD, Bethesda, MD

12:15 **NHLBI PVDOMICS Program Overview**
S.C. Erzurum, MD, Cleveland, OH

12:25 **PVDOMICS Study Design and Update**
J.H. Newman, MD, Nashville, TN

12:35 **Data Fusion: A Sustainable, Open Source Registry Advancing Pediatric Pulmonary Vascular Disease Research - Part I**
S.H. Abman, MD, Aurora, CO

12:45 **Data Fusion: A Sustainable, Open Source Registry Advancing Pediatric Pulmonary Vascular Disease Research - Part II**
K. Mandl, MD, MPH, Boston, MA

12:55 **Pulmonary Hypertension Breakthrough Initiative (PHBI) Update**
M. Geraci, MD, Indianapolis, IN

1:05 **National Biological Sample and Data Repository for Pulmonary Arterial Hypertension**
W. Nichols, PhD, Cincinnati, OH

NATIONAL HEART, LUNG, AND BLOOD INSTITUTE, DIVISION OF LUNG DISEASES, NIH

L27 OXIDANT STRESS IN HIV-RELATED CHRONIC LUNG DISEASE

12:15 p.m. - 1:15 p.m. **MOSCONE CENTER**
Room 2016/2018 (West Building, Level 2)

Target Audience
Providers of lung health; medical fellows in training; graduate post-doctoral fellows; established scientists in basic research on lung biology, HIV pathogenesis and infection disease.

Objectives
At the conclusion of this session, the participant will be able to:

- understand the role of oxidative stress in the onset of lung diseases associated with HIV infection in the HAART era;
- improve target possibilities for treating lung inflammatory diseases such as pulmonary hypertension in HAART treated HIV patients;
- learn new findings about the role of oxidative stress in the onset of lung complications in HIV (+) patients undergoing ART.

HIV-infected patients on antiretroviral therapy (ART) have now a longer life expectancy, but as a consequence chronic diseases are increasingly becoming a major cause of morbidity and death. Many pulmonary conditions, including PAH, and COPD are more prevalent in HIV infected individuals under treatment but the mechanisms by which HIV and ART induce cellular dysfunction that may trigger these pathologies are largely unknown. One such pathway is oxidative stress (OS), which results from excessive free radical production, and exceeding endogenous antioxidant defense mechanisms, which can damage a wide variety of cellular components. The session will address current research and results in this area and will give an overview of current HIV research on the oxidative stress role in HIV infection. Presenters will delineate current knowledge of lung complications in relationship to OS, and describe latest results and techniques utilized in their projects.

Chairing: H.L. Twigg, MD, Indianapolis, IN
E. Caler, PhD, Bethesda, MD

12:15 **HIV Proteins and Pulmonary Hypertension**
S. Flores, PhD, Aurora, CO

12:30 **Oxidative Stress in HIV Associated COPD**
B.D. Medoff, MD, Boston, MA

12:45 **Redox Stress and Chronic Lung Disease in HIV**
J. Roman, MD, Louisville, KY

1:00 **HIV+ Alveolar Macrophage Oxidant-Mediated Apoptosis of Pulmonary Endothelium**
M.R. Staudt, PhD, New York, NY

NATIONAL HEART, LUNG, AND BLOOD INSTITUTE, DIVISION OF LUNG DISEASES, NIH

L28 NHLBI PETAL CLINICAL TRIAL NETWORK: PREVENTION AND EARLY TREATMENT OF ACUTE LUNG INJURY

12:15 p.m. - 1:15 p.m. **MOSCONE CENTER**
Room 2020/2022 (West Building, Level 2)

Target Audience
Practicing critical care and emergency medicine clinicians and clinical researchers would benefit from this session. This includes fellows, students, nurses, and other medical professionals. Persons interested in clinical trial design and conduct would also benefit from this session.

Objectives
At the conclusion of this session, the participant will be able to:

- understand the goals and structure of the PETAL network
- understand the questions being addressed in PETAL and outreach efforts of the network
- have a better understanding of PETAL trial design and conduct including utilization of a central IRB

This session will provide information on the NHLBI Prevention and Early Treatment of Acute Lung injury (PETAL) clinical trials network. The session will describe the structure and goals of the PETAL network, provide an overview of the trials currently under way, and describe features of the PETAL network including utilization of a central IRB and outreach efforts.

Chairing: R.G. Brower, MD, Baltimore, MD
L. Reineck, MD, Bethesda, MD

12:15 **Introduction**
R.G. Brower, MD, Baltimore, MD

12:25 **ROSE Trial Update**
M. Moss, MD, Aurora, CO

12:35 **New Trial Presentation**
A. Ginde, MD, MPH, Aurora, CO

12:50 **Outreach Efforts**
B.T. Thompson, MD, Boston, MA

1:00 **General Discussion**

CLINICAL

ADULT CLINICAL CORE CURRICULUM

CME Credits Available: 2.0

CC6 CRITICAL CARE CLINICAL CORE CURRICULUM II

Adult Core Curriculum Working Group

1:30 p.m. - 3:30 p.m. **MOSCONE CENTER**

Room 2005/2007 (West Building, Level 2)

Target Audience
Internists and subspecialists in pulmonary, critical care, and sleep medicine who work in a clinical setting and are currently engaged in maintenance of certification.

Objectives
At the conclusion of this session, the participant will be able to:

- remain current with medical knowledge relevant to their practice in pulmonary, critical care, and sleep medicine;
- evaluate their understanding of key skills and content areas in pulmonary, critical care and sleep medicine, as well as receive feedback on their comprehension of a result of a pre-test/post-test comparison;
- support clinicians who are engaged in maintenance of certification activities by providing updates on subjects included in recertification requirements.

The ATS Clinical Core Curriculum Symposia focus on a 3-year content cycle of key medical content in the areas of pulmonary, critical care, and sleep medicine. The topics are also aligned with corresponding MOC Medical Knowledge modules. This symposium is intended to assist clinicians with staying current with the growth of information relevant to their medical practice, as well as provide an opportunity to evaluate individual knowledge and skills while earning MOC Medical Knowledge points.

Chairing: J.I. McSparron, MD, Boston, MA
A.M. Luks, MD, Seattle, WA

1:30 **Non-Invasive Ventilation**
B.K. Patel, MD, Chicago, IL

2:00 **Managing Exacerbations of Obstructive Lung Disease**
N.G. Shah, MD, Baltimore, MD

2:30 **Management of Severe Hypoxemic Respiratory Failure**
A. Rogers, MD, MPH, Palo Alto, CA

3:00 **Sedation, Delirium, and Mobilization in the ICU**
W.D. Schweickert, MD, Philadelphia, PA

BASIC • CLINICAL • TRANSLATIONAL

CLINICAL TOPICS IN PULMONARY MEDICINE

CME Credits Available: 2.0

D82 THE ROAD TO PRECISION MEDICINE IN IPF: BIOMARKERS AND CLINICAL PREDICTORS

Assemblies on Clinical Problems; Allergy, Immunology and Inflammation; Respiratory Cell and Molecular Biology

1:30 p.m. - 3:30 p.m. **MOSCONE CENTER**
Room 135 (North Building, Lower Level)

Target Audience
Anyone interested in idiopathic pulmonary fibrosis, other iinterstitial lung diseases, outcome prediction, biomarkers and Precision Medicine. Trainees at all levels will find the information and style of open discussion uniquely informative as will clinicians, translational researchers, health care delivery experts, and patient advocacy group members.

Objectives
At the conclusion of this session, the participant will be able to:

- gain and in depth understanding of the role of molecular markers in implementation of precision medicine approaches in IPF;
- learn new findings on the potential value of lung and BAL molecular analyses in guiding diagnosis and management of IPF;
- understand findings on the clinical management of patients with IPF.

Despite significant progress in understanding disease mechanisms, genetics, and approval of two drugs, IPF remains a significant challenge to practicing physicians, in part because of its grave prognosis and unpredictable course. In this interactive session we summarize the huge amount of information collected on the use of molecular and clinical markers and try to answer the question whether they can be used in clinical practice. Each talk will include a dynamic interaction with the audience through social media and other tools and after the talks, the chairs will provide a brief summary of the talks and open them for discussion. The session will end with a general discussion followed by a vote by the audience on the feasibility and potential for clinical application of molecular markers in IPF.

Chairing: R.P. Marshall, MBBS, MD, PhD, Stevenage, United Kingdom
J. Herazo-Maya, MD, New Haven, CT
J.S. Lee, MD, Aurora, CO

1:30 **What Does the Clinician Need from Molecular Markers?**
H.R. Collard, MD, San Francisco, CA

1:45 **The Road to Precision Medicine in IPF Goes Through the Lung**
R.G. Jenkins, MD, PhD, Nottingham, United Kingdom

2:01 **No Need for Biopsy: BAL Predicts Outcome, New Mechanisms in IPF**
A. Prasse, MD, Hannover, Germany

2:17 **It's Not Your Cells but Your Bugs: The Microbiome in IPF**
T.M. Maher, MD, MSc, PhD, London, United Kingdom

2:33 **Genetic Markers Can Lead the Way to Precision Medicine in IPF**
T. Fingerlin, PhD, Denver, CO

2:49 **All We Need Is One Drop of Blood: Peripheral Blood Markers Predict Outcome in IPF**
N. Kaminski, MD, New Haven, CT

3:05 **Will Precision Medicine Be Applicable to IPF? General Discussion**
R.P. Marshall, MBBS, MD, PhD, Stevenage, United Kingdom
J. Herazo-Maya, MD, New Haven, CT
J.S. Lee, MD, Aurora, CO

This session and the International Conference are supported by an educational grant from ***Boehringer Ingelheim Pharmaceuticals, Inc.***
All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

BASIC • BEHAVIORAL
CLINICAL • TRANSLATIONAL

CLINICAL TOPICS IN PULMONARY MEDICINE

CME Credits Available: 2.0

D83 COPD EXACERBATIONS: BIOLOGY AND TARGETS FOR NOVEL TREATMENTS

Assemblies on Clinical Problems; Allergy, Immunology and Inflammation; Respiratory Cell and Molecular Biology; Respiratory Structure and Function

1:30 p.m. - 3:30 p.m. **MOSCONE CENTER**
Room 134 (North Building, Lower Level)

Target Audience
Clinicians, clinical researchers and trainees who are involved in the research and care of patients with COPD.

Objectives
At the conclusion of this session, the participant will be able to:

- understand what cells and mechanisms are important during COPD exacerbation;
- understand the potential role of several novel treatments for COPD;
- understand the inflammation is not the only mechanism for targeted treatment in COPD exacerbations.

This session will be focused on COPD exacerbations and discussed the biology and targets for novel treatments in this disease.

Chairing: G.J. Criner, MD, Philadelphia, PA
B.R. Celli, MD, Boston, MA
S.I. Rennard, MD, Melbourn, United Kingdom

1:30 **The Biology of Acute Exacerbations of COPD**
P.J. Barnes, MD, DSc, London, United Kingdom

1:45 **The Physiology of Acute Exacerbations of COPD**
B.R. Celli, MD, Boston, MA

2:00 **Role of the Eosinophil in COPD Exacerbations**
C.E. Brightling, BSc, MBBS, PhD, Leicester, United Kingdom

2:15 **Kinases and PDE-4 Inhibitors and COPD Exacerbations**
F.J. Martinez, MD, New York, NY

2:30 **Antioxidant Therapy to Prevent COPD Exacerbations**
R.A. Wise, MD, Baltimore, MD

2:45 **Potential Role of Anti-Fibrotic Therapy in COPD**
G.J. Criner, MD, Philadelphia, PA

3:00 **Stimulating Lung Repair Following Acute Exacerbations**
S.I. Rennard, MD, Melbourn, United Kingdom

3:15 **Targeting the Neutrophil in COPD Exacerbations**
H. Magnussen, MD, PhD, Grosshansdorf, Germany

This session and the International Conference are supported by an educational grant from ***AstraZeneca LP.***
All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

CLINICAL

CRITICAL CARE TRACK

CME Credits Available: 2.0

D84 STAY AWAY FROM THE ICU: IS PREVENTING ICU ADMISSION GOOD FOR PATIENTS?

Assembly on Critical Care

1:30 p.m. - 3:30 p.m. **MOSCONE CENTER**
Room 3000/3002/3004 (West Building, Level 3)

Target Audience
Critical care and emergency medicine professionals; anesthesia clinicians, including physicians, nurses, and advanced practice providers.

Objectives
At the conclusion of this session, the participant will be able to:

- learn new data on how to identify patients at risk for clinical deterioration;
- better discuss the risks and benefits of ICU admission with patients and their families;
- better identify patients that will not benefit from ICU admission.

ICU beds and the nurses and physicians that staff them remain a scarce and costly resource. In addition, admission to an ICU is associated with both increased intensity of therapy, but also potential increased risks of treatment. One way to deal with the limitations of bed space as well as the increased risk of ICU care is to attempt to identify and treat patients at risk for critical illness earlier in their illness. This session will review available data on identification of and treatment for patients on the wards and in the prehospital phase, and whether this will prevent need for ICU admission

Chairing: J.E. Sevransky, MD, MHS, Atlanta, GA
C.R. Cooke, MD, MSc, Ann Arbor, MI
K.S. Mathews, MD, MPH, New York, NY

1:30 **Risks and Benefits of ICU Admission**
C.R. Cooke, MD, MSc, Ann Arbor, MI

1:50 **Can Patients with Severe Sepsis Be Safely Treated on the Wards?**
M.E. Mikkelsen, MD, Philadelphia, PA

2:10 **Prehosptial Identification of Severe Sepsis Patients**
C. Polito, MD, MSc, Atlanta, GA

2:30 **Early Warning Systems to Predict Clinical Deterioration: Do They Work?**
M.M. Churpek, MD, MPH, PhD, Chicago, IL

2:50 **Should Palliative Care Consultation Be Used to Prevent ICU Admissions?**
N. Khandelwal, MD, Seattle, WA

3:10 **Prevention of Lung Injury**
E. Festic, MD MS, Jacksonville, FL

BASIC • BEHAVIORAL • CLINICAL • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 2.0

D85 EARLY LIFE ORIGINS OF CHRONIC DISEASE

Assemblies on Pediatrics; Clinical Problems; Environmental, Occupational and Population Health; Pulmonary Rehabilitation; International Health Committee

1:30 p.m. - 3:30 p.m. **MOSCONE CENTER**
Room 2016/2018 (West Building, Level 2)

Target Audience
Providers of lung health; trainees; fellows; junior faculty; research scientists; clinical academics.

Objectives
At the conclusion of this session, the participant will be able to:

- learn new findings about early life origins of chronic disease;
- gain and apply new knowledge gained to thinking about disease causation;
- understand how early life exposures can increase life long disease risk.

Globally chronic disease is increasing in both developed and developing countries. Evidence is increasing that most chronic disease has it origin in early life, that is during the peri-conceptual period, during fetal development and in early postnatal life. This session will highlight current thinking in how early life exposures result in chronic disease in later life.

Chairing: M. Rosenfeld, MD, MPH, Seattle, WA
J.C. Celedon, MD, DrPH, Pittsburgh, PA

1:30 **Developmental Origins of Health and Disease: The DOHAD Studies**
M. Hanson, MA, DPhil, Southampton, United Kingdom

1:55 **Impact of Prenatal and Early Life Exposures on Development**
T. Bastain, PhD, MPH, Los Angeles, CA

2:20 **The Role of Microbiomes in Defining Health and Disease**
S.V. Lynch, PhD, San Francisco, CA

2:45 **Impact of Early Life Exposures on Respiratory Disease**
A. Bush, MD, London, United Kingdom

3:10 **Common Origins of Chronic Respiratory and Non-Respiratory Diseases**
P.D. Sly, DSc, MBBS, MD, South Brisbane, Australia

CLINICAL • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 2.0

D86 CONTROVERSIES AND ADVANCES IN THE MANAGEMENT OF VENTILATOR ASSOCIATED PNEUMONIA

Assemblies on Microbiology, Tuberculosis and Pulmonary Infections; Critical Care

1:30 p.m. - 3:30 p.m. **MOSCONE CENTER**
Room 3016/3018 (West Building, Level 3)

Target Audience
Clinicians working in the ICU,including doctors (attending and fellow), respiratory therapists, nurses and trainees.

Objectives
At the conclusion of this session, the participant will be able to:

- understand new diagnostic tools for VAP;
- learn how to apply biomarkers to manage VAP;
- discuss the value and limitation of reporting VAC rates.

Ventilator associated pneumonia (VAP) remains an important illness in the ICU, in spite of reports of “zero VAP”. In the current era, we are being asked to report rates of ventilator associated complications(VAC), although the relation to VAP remains unclear. At the same time, we may be able to improve management with the application of anti-inflammatory therapies, rapid diagnostics, and biomarker-guided therapy, and new antibiotics are being developed. This session will examine these issues.

Chairing: M.S. Niederman, MD, New York, NY
J.E. Chastre, MD, Paris, France

1:30 **Can Anti-Inflammatory Therapy Help Improve Outcomes in VAP?**
C. Feldman, MBBCh, DSc, PhD, Johannesburg, South Africa

1:50 **Are New Antibiotics Going To Help Us Manage VAP in the ICU?**
M.H. Kollef, MD, St. Louis, MO

2:10 **Can Biomarkers Help with Antibiotic Stewardship in the ICU?**
R.G. Wunderink, MD, Chicago, IL

2:30 **Does Reporting Rates of VAC Improve Patient Care?**
M.S. Niederman, MD, New York, NY

2:50 **New Diagnostic Tests for VAP: Faster and Better?**
I.S. Douglas, MD, Denver, CO

3:10 **Discussion**
J.E. Chastre, MD, Paris, France

BASIC • CLINICAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 2.0

D87 CLIMATE CHANGES AND RESPIRATORY INFECTIONS

Assemblies on Environmental, Occupational and Population Health; Clinical Problems; Microbiology, Tuberculosis and Pulmonary Infections; Pediatrics

1:30 p.m. - 3:30 p.m. **MOSCONE CENTER**
Room 3003/3005 (West Building, Level 3)

Target Audience
Scientists and clinicians seeking novel insights on the climate change and respiratory infections.

Objectives
At the conclusion of this session, the participant will be able to:

- understand the latest advances in climate changes and health impact;
- learn and understand recent epidemiological changes in respiratory infections;
- describe climate change sensitive respiratory infection and control methods.

This symposium will integrate the current state of the art knowledge on how climate change affects respiratory health and infections. Talks will be given by speakers who are experts in the field. We will also highlighting the important initiative on the impact of global climate change in respiratory diseases. The talk will be 15 minutes followed by 5 minutes of audience questions.

Chairing: M. Mirsaeidi, MD, Miami, FL
C.S. Dela Cruz, MD, PhD, New Haven, CT
K.E. Pinkerton, PhD, Davis, CA

1:30 **Climate Change, Policy and Development and Respiratory Diseases**
K. Ebi, PhD, MPH, Seattle, WA

1:50 **Epidemiology Changes of Climate Sensitive Infectious Diseases**
I. Annesi-Maesano, MD, PhD, Paris, France

2:10 **Adverse Outcome Pathways (AOP) for Infectious Disease Which Are Influenced by Climate Change**
K.E. Pinkerton, PhD, Davis, CA

2:30 **Respiratory Fungal Infections and Climate Changes**
A. Catanzaro, MD, La Jolla, CA

2:50 **Nontuberculous Mycobacteria and Climate Change**
J.O. Falkinham, PhD, Blacksburg, VA

3:10 **Poverty, Pollution and Pneumonia: A Malawian Perspective on Environment, Occupation and Infection**
S. Gordon, MD, Blantyre, Malawi

BEHAVIORAL • CLINICAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 2.0

D88 THE PATIENT-CENTERED JUGGERNAUT: THE RIGHT MOVE FOR CLINICAL CARE, POLICY, AND RESEARCH?

Assemblies on Behavioral Science and Health Services Research; Critical Care; Thoracic Oncology

1:30 p.m. - 3:30 p.m. **MOSCONE CENTER**

Room 303/305 (South Building, Esplanade Level)

Target Audience
Clinicians or researchers who incorporate patient centered outcomes in their practice or research.

Objectives
At the conclusion of this session, the participant will be able to:

- understand the benefits and limitations of patient and family satisfaction as a quality metric in critical care;
- learn about advantages and disadvantages of shared decision making as a policy requirement in lung cancer screening;
- determine if the methods to conduct high quality patient engaged research are available for implementation by researchers.

There is an emerging trend toward incorporating patients' values, opinions and feedback in both patient care and research. Patient engagement is expected to address patients' health care concerns and close the gaps in evidence needed to improve key outcomes. However, it remains unclear how this process will actually improve meaningful clinical outcomes and research products. Despite the difficulties in measuring the benefits and harms of this strategy, patient centered approaches are being adopted in clinical care, health policy and research. We will select case examples from key pillars of PCCM to highlight the current controversies for and against incorporating patient centered outcomes.

Chairing: D.R. Sullivan, MD, MA, Portland, OR
L.C. Feemster, MD, MSc, Seattle, WA
R.S. Wiener, MD, MPH, Boston, MA

1:30 **A Patient's Perspective**
J. Lefferts, San Francisco, CA

1:35 **Incorporating Patient Centered Outcomes in Clinical Practice and Research**
S.D. Halpern, MD, PhD, Philadelphia, PA

1:47 **PRO: Patient and Family Satisfaction is a Key Quality Metric in Critical Care**
E.K. Kross, MD, Seattle, WA

2:02 **CON: Patient and Family Satisfaction is a Key Quality Metric in Critical Care**
G.D. Rubenfeld, MD, MSc, Toronto, Canada

2:17 **General Discussion**

2:21 **CON: Shared Decision Making Improves Outcomes in Lung Cancer Screening**
C.G. Slatore, MD, Portland, OR

2:36 **PRO: Shared Decision Making Improves Outcomes in Lung Cancer Screening**
R.S. Wiener, MD, MPH, Boston, MA

2:51 **General Discussion**

2:55 **PRO: We Possess the Methods to Conduct High Quality Patient Engaged Research**
S. Parthasarathy, MD, Tucson, AZ

3:10 **CON: We Possess the Methods to Conduct High Quality Patient Engaged Research**
M. Helfand, MD, MS, MPH, Portland, OR

3:25 **General Discussion**

BASIC • CLINICAL • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 2.0

D89 NOVEL APPROACHES TO TREAT PULMONARY INFECTIONS

Assemblies on Allergy, Immunology and Inflammation; Microbiology, Tuberculosis and Pulmonary Infections; Pediatrics; Respiratory Cell and Molecular Biology; Respiratory Structure and Function

1:30 p.m. - 3:30 p.m. **MOSCONE CENTER**

Room 3007/3009 (West Building, Level 3)

Target Audience
Scientists, physician scientists and clinicians working on developing and utilizing novel therapeutics to treat and prevent pulmonary infections.

Objectives
At the conclusion of this session, the participant will be able to:

- identify novel strategies for treatment of respiratory infection.
- understand how these novel therapies target the pathogen or the host to promote innate immune clearance.
- recognize and understand the pitfalls and/or challenges present in the development of such therapies.

Opportunistic bacterial pathogens are a common cause of respiratory infection, especially in the immune compromised or in hospital settings. Widespread use of broad spectrum antibiotics has led to the emergence of antibiotic resistance in a group of respiratory pathogens labeled the ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa, and Enterobacter species) and damaging effects of antibiotics on the gut microbiome. These factors, coupled with a reduction in the discovery rate of new antimicrobial therapies, necessitate efforts aimed at identifying novel and potentially pathogen specific antimicrobial therapeutics. This session will highlight recent discovery of novel treatment modalities for respiratory infection and exacerbation, including strategies targeting both the microbe and the host.

Chairing: J.K. Kolls, MD, Pittsburgh, PA
T. Cohen, PhD, Gaithersburg, MD

1:30 **Antibodies: A Pathogen Specific Approach to Combating Respiratory Infection**
S. Projan, PhD, Gaithersburg, MD

1:50 **Interfering with Exacerbations in Asthma and COPD**
D.E. Davies, PhD, Southampton, United Kingdom

2:10 **Pro-Resolving Mediators: Putting the Brakes on Excessive Inflammation**
B.D. Levy, MD, Boston, MA

2:30 **Sulfrophane Therapy to Enhance Macrophage Dependent Bacterial Killing**
M. Whyte, MD, PhD, Edinburgh, United Kingdom

2:50 **Phage Targeting Gram-Positive Bacteria**
V. Fischetti, PhD, New York, NY

BEHAVIORAL • CLINICAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 2.0

D90 RESPIRATORY HEALTH IN MIGRANT POPULATIONS

1:30 p.m. - 3:30 p.m. **MOSCONE CENTER**
Room 2009/2011 (West Building, Level 2)

Target Audience
Physicians (pulmonologists, critical care providers, and sleep medicine doctors), nurses, and other health care providers as well as trainees (residents and fellows) interested in learning about the clinical problems inherent in migrant populations, in educating others about how to care for these patients, and in how to engage in research.

Objectives
At the conclusion of this session, the participant will be able to:

- summarize the challenges inherent in the delivery of care to migrants;
- discuss the social, political, and economic circumstances that prevent optimal delivery of care to migrants;
- propose innovated approaches to this issue targeting specific needs of distinct populations.

The crisis in the Middle East has raised awareness about the challenges encountered by migrant populations; in particular, health care access and delivery. Similar challenges are encountered by migrant populations all around the world including those entering the U.S. as refugees and/or survivors of torture as well as Mexicans and other Latin Americans crossing the border. Migrants suffer from medical conditions typical of other populations (e.g., asthma, tobacco-related disease, sleep disorders) and conditions relevant to the nature of their situation including infection (e.g., tuberculosis) and malnutrition. This session will discuss emerging problems related to health care access and delivery in migrant populations.

Chairing: J. Roman, MD, Louisville, KY
J.C. Celedon, MD, DrPH, Pittsburgh, PA
I.S. Douglas, MD, Denver, CO
D.J. Upson, MA, MD, Albuquerque, NM

1:30 **Introduction**
J.C. Celedon, MD, DrPH, Pittsburgh, PA

1:35 **Health Inequality in Latinos**
Speaker To Be Announced

1:55 **Rapid Deployment of International Tele-ICU During Conflict in Syria**
A.M. Moughrabieh, MD, MPH, Detroit, MI

2:20 **Asthma in Migrants: A Route to Health or More Triggers?**
F. Holguin, MD, MPH, Pittsburgh, PA

2:40 **Sleep and Migrant Health**
S.R. Patel, MD, Pittsburgh, PA

3:00 **Infectious Diseases in Migrant Populations**
J.A. Ramirez, MD, Louisville, KY

3:20 **Summary**
J.C. Celedon, MD, DrPH, Pittsburgh, PA
I.S. Douglas, MD, Denver, CO
D.J. Upson, MA, MD, Albuquerque, NM

MINI SYMPOSIUM

D91 GENETICS AND GENOMICS OF COPD

1:30 p.m. - 3:30 p.m. **MOSCONE CENTER**
Room 130-132 (North Building, Lower Level)

Chairing: E.K. Silverman, MD, PhD, Boston, MA
B.E. Himes, PhD, Philadelphia, PA

Oral Presentations

1:30 **A Multi-Omics Approach Identifies Inflammatory Patterns In The Asthma-COPD Overlap Syndrome/**M.E. Hardin, M.H. Cho, M.-L. McDonald, P.J. Castaldi, R. Tal-Singer, D.J. Maselli, B.J. Make, J.D. Crapo, R.P. Bowler, E.K. Silverman, C.P. Hersh, Boston, MA, p.A7473

1:45 **A Genomic Signature of IL-17 Related Inflammation Correlates with Neutrophilia and Predicts Lack of Response to Inhaled Corticosteroids in COPD/**S.A. Christenson, M. Van Den Berge, N.R. Bhakta, M. Lenburg, K. Steiling, A. Spira, D.S. Postma, P.G. Woodruff, San Francisco, CA, p.A7474

2:00 **Genome-Wide Association of Exercise Tolerance in Current and Former Smokers/**E.S. Wan, M.H. Cho, M.-L. McDonald, R. Tal-Singer, D.A. Lomas, P. Bakke, A. Gulsvik, R. Casaburi, S.M. Lutz, E.A. Regan, B.J. Make, J.D. Crapo, E.K. Silverman, D.L. DeMeo, Boston, MA, p.A7475

2:15 **Whole Genome Sequencing in Severe Chronic Obstructive Pulmonary Disease/**M.H. Cho, D. Qiao, C. Lange, T.H. Beaty, J.D. Crapo, E.K. Silverman, Boston, MA, p.A7476

2:30 **Whole Genome Rare Variant Association Study Identifies a Non-Genic Region and Several Genes Associated with Severe Emphysema/**J. Radder, Y. Zhang, F.C. Sciurba, S.D. Shapiro, Pittsburgh, PA, p.A7477

2:45 **Variants Tagging SERPINA1 and IL27 Show Significant Association with COPD in a Meta-Analysis with Over 16,700 Subjects/**R. Busch, B.D. Hobbs, J. Zhou, P.J. Castaldi, I. Hawrylkiewicz, P. Sliwinski, J.J. Yim, W.J. Kim, D.K. Kim, A. Agusti, B.J. Make, J.D. Crapo, P. Calverley, C.F. Donner, D.A. Lomas, E.F. Wouters, J. Vestbo, R. Tal-Singer, P. Bakke, A. Gulsvik, A.A. Litonjua, D. Sparrow, P.D. Pare, R.D. Levy, S.I. Rennard, T.H. Beaty, J. Hokanson, E.K. Silverman, M.H. Cho, Boston, MA, p.A7478

3:00 **Accelerated Ticking of the Epigenetic Clock in Smokers with and Without COPD/**D.L. DeMeo, J.D. Morrow, C.P. Hersh, V. Pinto-Plata, B. Celli, N. Marchetti, G.J. Criner, R. Bueno, G. Washko, E.K. Silverman, W. Qiu, Boston, MA, p.A7479

3:15 **Clinical and Genetic Characteristics of Emphysema Distribution Subtypes Identified by Unsupervised Learning Analysis/**A. El Boueiz, M.H. Cho, G. Washko, R. San Jose Estepar, D.A. Lynch, J.D. Crapo, E.K. Silverman, D.L. DeMeo, P.J. Castaldi, Boston, MA, p.A7480

MINI SYMPOSIUM

D92 REFINING THE EVALUATION AND TREATMENT OF CYSTIC FIBROSIS

1:30 p.m. - 3:30 p.m. **MOSCONE CENTER**

Room 2020/2022 (West Building, Level 2)

Chairing: M. Jain, MD, Chicago, IL
J.L. Taylor-Cousar, MD, Denver, CO
S.M. Rowe, MD, Birmingham, AL

Featured Speaker

1:30 **The Future of Cystic Fibrosis Care/**D.E. Tullis, MD, Toronto, Canada,

Oral Presentations

1:45 **Association of Sweat Chloride Level with Mortality Varies by Individual Cystic Fibrosis Transmembrane Receptor Genotype/**J. Espel, H. Palac, J. Ciolino, J. Cullina, M. Jain, Chicago, IL, p.A7481

2:00 **Genetic Variation in CFTR Allele Mutations and ADRB2 Polymorphisms Influence Cardiac Hemodynamic Responses to Albuterol in Individuals with Cystic Fibrosis/**E.H. Van Iterson, S.E. Baker, C.M. Wheatley, W.J. Morgan, E.M. Snyder, Rochester, MN, p.A7482

2:15 **High Sensitivity C-Reactive Protein in Adult Patients with Cystic Fibrosis Pulmonary Exacerbations/**T. Kyaw, M. Callahan, R. Klingsberg, A.H. Alraiyes, F. Kheir, New Orleans, LA, p.A7483

2:30 **Prognostic Value of Pulmonary Hypertension in Patients with Cystic Fibrosis/**D. Li, F. Wen, L. Gao, Baltimore, MD, p.A7484

2:45 **Cystic Fibrosis Related Diabetes: An Audit/**O. O'Carroll, D. Hughes, C. McCarthy, D. Smith, C. Gunaratnam, N.G. McElvaney, Dublin, Ireland, p.A7485

3:00 **Durable Improvement in Mucociliary Clearance Following a Single Dose of Hypertonic Saline in Cystic Fibrosis/**A. Trimble, B. Laube, W. Brown, K.L. Zeman, N. Lechtzin, J. Wu, D. Waltz, W.D. Bennett, S. Donaldson, Chapel Hill, NC, p.A7486

3:15 **Relationship Between Throat Culture, Sputum Culture, and Lower Respiratory Tract Culture in Adult Patients with Cystic Fibrosis/**D. Seidler, M. Griffin, A.B. Nymon, J. Schwartzman, K. Koeppen, A. Ashare, Lebanon, NH, p.A7487

MINI SYMPOSIUM

D93 RESPIRATORY FAILURE: ADVANCED MECHANISTIC INSIGHTS INFORMING TRANSLATION IN ACUTE LUNG INJURY/ARDS

1:30 p.m. - 3:30 p.m. **MOSCONE CENTER**

Room 3006/3008 (West Building, Level 3)

Chairing: C.C. Dos Santos, MD, Toronto, Canada
C. Mikacenic, MD, Seattle, WA
J.R. Jacobson, MD, Chicago, IL

Oral Presentations

1:30 **An Angiopoietin-2 Genetic Variant Associated with Plasma Angiopoietin-2 Is a Risk Factor for Sepsis-Associated ARDS/**N.J. Meyer, J.P. Reilly, T.G. Dunn, J. Abbott, F. Wang, B. Lim, C.A.G. Ittner, B.J. Anderson, M.G.S. Shashaty, J.A. Palakshappa, M.A. Matthay, C.S. Calfee, R. Feng, J.D. Christie, Philadelphia, PA, p.A7488

1:45 **A Functional Missense SNP in LRRC16A Contributes to an Improved Prognosis of ARDS Patients Mediated Through Attenuated Platelet Count Decline in ICU/**Z. Wang, Y. Wei, P. Tejera, L. Su, E.K. Bajwa, D.C. Christiani, Boston, MA, p.A7489

2:00 **ABO Genetic Variation and Acute Respiratory Distress Syndrome Risk in Sepsis/**J.P. Reilly, N.J. Meyer, M.G.S. Shashaty, B.J. Anderson, J.A. Palakshappa, C.A.G. Ittner, C.S. Calfee, M. Matthay, Z. Wang, C. Mikacenic, X. Lin, I. Barnett, K. Walley, J.A. Russell, D.C. Christiani, M.M. Wurfel, J.D. Christie, Philadelphia, PA, p.A7490

2:15 **Haptoglobin 2:2 Genotype Is Associated with Acute Respiratory Distress Syndrome in Patients with Severe Trauma/**H. Nagata, J.B. McNeil, N. Wickersham, C.M. Shaver, N.D. Putz, J.L. Kuck, J.A. Bastarache, L. Ware, Nashville, TN, p.A7491

2:30 **Critical Role of Phosphofructokinase-2/Fructose-2,6-Bisphosphatase (PFKFB) 3 in Acute Lung Injury/**C. Vohwinkel, N. Burns, J. Kraynik, K.R. Stenmark, H. Eltzschig, Aurora, CO, p.A7492

2:45 **RAGE Modulation Influences Lung Injury and AFC: In Vivo and Vitro Studies/**R. Blondonnet, J. Audard, J. Lutz, G. Clairefond, C. Belville, D. Bouvier, L. Blanchon, J.-L. Couderc, C. Damon, V. Sapin, J.-M. Constantin, M. Jabaudon, Clermont-Ferrand, France, p.A7493

3:00 **Human Mesenchymal Stem Cell Derived Microvesicles Attenuate Acute Lung Injury in Mice Partly Via Transferring Ang-1 mRNA/**X.-D. Tang, L. Shi, A. Monsel, X.-Y. Li, H.-L. Zhu, Y.-G. Zhu, J.-M. Qu, Shanghai, China, p.A7494

3:15 **Therapeutic Effects of Human Bone Marrow Derived Mesenchymal Stem Cell Microvesicles in an Ex Vivo Perfused Human Lung Injured with Severe E.coli Pneumonia/**J. Park, H. Lim, S. Hu, Q. Hao, M.A. Matthay, J.W. Lee, San Francisco, CA, p.A7495

MINI SYMPOSIUM

D94 NON-TUBERCULOUS MYCOBACTERIA: ORGANISM AND HOST

1:30 p.m. - 3:30 p.m. **MOSCONE CENTER**

Room 3020/3022 (West Building, Level 3)

Chairing: K.P. Fennelly, MD, MPH, Rockville, MD
D.E. Griffith, MD, Tyler, TX
C. Andrejak, MD, PhD, Amiens, France
R. Thomson, MBBS, PhD, Brisbane, Australia

Oral Presentations

1:30 **Establishment of the Novel Mouse Models of Human Lung Nontuberculous Mycobacterial Infections/**T. Isobe, C. Sano, R. Tanino, Y. Tatano, Y. Mori, M. Nakao, Y. Amano, T. Hotta, M. Hamaguchi, T. Okimoto, Y. Tsubata, S. Hamaguchi, H. Takeyama, Izumo, Japan, p.A7496

1:45 **Evaluation of the Airway Microbiome in Non-Tuberculous Mycobacteria/**B.D. Scaglione, B.G. Wu, Y. Li, K. Alter, J. Gilani, A. Wang, D. Kamelhar, D. Addrizzo-Harris, L. Segal, New York, NY, p.A7497

2:00 **Nitric Oxide Is a Potential Antimicrobial Against Slow- and Fast-Growing Mycobacteria/**C. Miller, B. McMullin, C. Deppisch, J. Riethmuller, Vancouver, Canada, p.A7498

2:15 **Interleukin 23 / Interleukin 17 Axis Activated by Mycobacterium Avium Complex (MAC) Is Attenuated in Patients with MAC-Lung Disease/**C.-C. Shu, J.-Y. Wang, C.-J. Yu, Taipei, Taiwan, p.A7499

2:30 **The Association of Peripheral Blood Mucosal-Associated Invariant T-Cell Cells in Patients with COPD and NTM/** R.J. Napier, E. Henkle, K.L. Winthrop, D.M. Lewinsohn, Portland, OR, p.A7500

2:45 **Clinical and Environmental Nontuberculous Mycobacteria from Hawaii Demonstrate Varying Degrees of Virulence/**J.R. Honda, N.A. Hasan, Y. Zhou, E.D. Chan, Aurora, CO, p.A7501

3:00 **Risk of Nontuberculous Mycobacterial Lung Disease Associated with Obstructive Lung Disease in Ontario, Canada/**T.K. Marras, M.A. Campitelli, J.C. Kwong, H. Lu, S.K. Brode, A. Marchand-Austin, A.S. Gershon, F.B. Jamieson, Toronto, Canada, p.A7502

3:15 **The Risk Of Pulmonary Nontuberculous Mycobacterial Disease Associated with Inhaled Corticosteroid Use/**S.K. Brode, M.A. Campitelli, J.C. Kwong, H. Lu, A. Marchand-Austin, A.S. Gershon, F.B. Jamieson, T.K. Marras, Toronto, Canada, p.A7503

MINI SYMPOSIUM

D95 DARKNESS ON THE EDGE OF TOWN: NEW MOLECULAR PATHWAYS IN PULMONARY HYPERTENSION

1:30 p.m. - 3:30 p.m. **MOSCONE CENTER**

Room 3010/3012 (West Building, Level 3)

Chairing: E.F. Spiekerkoetter, MD, Palo Alto, CA
B.B. Graham, MD, Aurora, CO

Oral Presentations

1:30 **Bone Marrow Endothelial Progenitor Cells Are the Cellular Mediators of Pulmonary Hypertension in the Murine Monocrotaline Injury Model/**J. Aliotta, M. Pereira, S. Wen, M.S. Dooner, M. Del Tatto, E. Papa, Y. Cheng, L. Goldberg, P.J. Quesenberry, J. Klinger, Providence, RI, p.A7504

1:45 **The Activation of Wnt5a-ROR2 Axis Enhances Endothelial-Pericyte Interaction During Pulmonary Angiogenesis/**K. Yuan, M. Orcholski, M. Discipulo, D. Sriram, V. De Jesus Perez, Palo Alto, CA, p.A7505

2:00 **HIPPO-Integrin Linked Kinase Crosstalk Regulates Pulmonary Vascular Smooth Muscle Cell Proliferation and Survival in Pulmonary Hypertension/**T.V. Kudryashova, D.A. Goncharov, A. Pena, N. Kelly, R.R. Vanderpool, J. Jeff Baust, A. Kobir, W. Shufesky, A.E. Morelli, J. Zhao, K. Ihida-Stansbury, H. DeLisser, R. Tuder, S.M. Kawut, H.H.W. Sillje, S.D. Shapiro, Y. Zhao, E.A. Goncharova, Pittsburgh, PA, p.A7506

2:15 **Estrogen Contributes to the Pathogenesis of Experimental Pulmonary Hypertension in Obese Male Mice/**K.M. Mair, M. Nilsen, L. Loughlin, M. MacLean, Glasgow, United Kingdom, p.A7507

2:30 **Platelet Bioenergetic Screen Reveals Increased Glycolytic Rate in Group 1 Pulmonary Hypertension and Increased Oxygen Consumption in Group 2 Pulmonary Hypertension/**Q. Nguyen, C. Corey, M. Reynolds, P. White, R.R. Vanderpool, M.T. Gladwin, M.A. Simon, S. Shiva, Pittsburgh, PA, p.A7508

2:45 **HIF2α Deletion in the Pulmonary Endothelial Prevents Hypoxia-Induced Pulmonary Hypertension/**A.S. Cowburn, A. Crosby, D. Macias-Gutierrez, M. Southwood, L. Crotty-Alexander, N.W. Morrell, E.R. Chilvers, R.S. Johnson, Cambridge, United Kingdom, p.A7509

3:00 **Thrombospondin-1 Deficient Bone Marrow and Pharmacological Inhibition of TGF-β1 Activation Protects Against Schistosomiasis Pulmonary Hypertension/**R. Kumar, C. Mickael, B. Kassa, L. Gebreab, D. Koyanangi, L. Sanders, R. Tuder, B.B. Graham, Aurora, CO, p.A7510

3:15 **Dasatinib Causes Pulmonary Endothelial Damage and Aggravates Pulmonary Hypertension/**C. Phan, A. Huertas, A. Seferian, L. Tu, R. Thuillet, C. Sattler, E.-M. Jutant, M. Le Hiress, Y. Tamura, M.-C. Chaumais, S. Bouchet, B. Maneglier, M. Molimard, P. Rousselot, O. Sitbon, G. Simonneau, D. Montani, M. Humbert, C. Guignabert, Le Plessis-Robins, p.A7511

MINI SYMPOSIUM

D96 DAMAGING EFFECTS OF INHALED PARTICULATES

1:30 p.m. - 3:30 p.m. **MOSCONE CENTER**
Room 2006/2008 (West Building, Level 2)

Chairing:

Oral Presentations

1:30 **Acute Exposure to Electronic Cigarettes in Healthy Nonsmokers Leads to Global Transcriptome Changes in Distal Airway Epithelium and Alveolar Macrophages/**M.R. Staudt, J. Salit, A.E. Tilley, R.J. Kaner, F. Agosto-Perez, C. Hollmann, R.G. Crystal, New York, NY, p.A7512

1:45 **MTOR Suppresses Cigarette Smoke-Induced Airway Inflammation and Emphysema/**J.S. Zhou, J. Liu, Y. Wang, Z.Y. Li, S.M. Ying, W. Li, H.H. Shen, Z.H. Chen, Hang Zhou, China, p.A7513

2:00 **Ergothioneine Protects Lung Epithelial Cells from Tobacco Smoke-Induced Oxidative Damage In Vitro and In Vivo/**S. Nickel, M. Selo, C. Clerkin, B. Talbot, J. Walsh, N. Nakamichi, Y. Kato, P. Reynolds, J. Lewis, C. Ehrhardt, Dublin, Ireland, p.A7514

2:15 **MKK3 Mediates Inflammatory Response and Mitochondrial Dysfunction After Cigarette Smoke Injury/**A. Srivastava, S. Erramilli, P.J. Lee, P. Mannam, New Haven, CT, p.A7515

2:30 **Macrophage Migration Inhibitory Factor (MIF) Accelerates DNA Repair Via Its Receptor CD74 in a Novel In-Vitro Model of Cigarette Smoke Mediated Endothelial Dysfunction/**T. Baker, M. Haslip, L. Leng, R. Bucala, P.J. Lee, M. Sauler, New Haven, CT, p.A7516

2:45 **RAGE Contributes to Particulate-Induced Lung Function Loss and Hyperreactivity: Mitigating the Persistent Effects of a Single Intense Particulate Exposure/**S. Kwon, S.H. Haider, E.J. Caraher, G. Crowley, A.K. Lee, M. Ebrahim, D.J. Prezant, A.M. Schmidt, A. Nolan, New York, NY, p.A7517

3:00 **Metformin Attenuates Particulate Matter Air Pollution Induced Thrombosis by Inhibiting Mitochondrial ROS Upstream of CRAC Channels in Alveolar Macrophages/**S. Soberanes, A. Jairaman, M. Chi, A.Y. Meliton, J. Cho, F.J. Gonzalez-Gonzalez, A.C. Mc Quattie-Pimentel, R. Piseaux, S. Weinberg, H.R. Perlman, N.S. Chandel, A.V. Misharin, M. Prakriya, G.M. Mutlu, G.S. Budinger, Chicago, IL, p.A7518

3:15 **Inhibition Of EGF Receptor Signaling Decreases Agricultural Dust-Mediated Lung Inflammatory Responses In Vivo and In Vitro/**D.J. Romberger, T.M. Nordgren, A.J. Heires, N.A. Schulte, M.L. Toews, Omaha, NE, p.A7519

MINI SYMPOSIUM

D97 IMAGING AND MODELING: INSIGHTS INTO LUNG STRUCTURE AND FUNCTION

1:30 p.m. - 3:30 p.m. **MOSCONE CENTER**
Room 2002/2004 (West Building, Level 2)

Chairing: K.R. Lutchen, PhD, Boston, MA
C.C. Hsia, MD, Dallas, TX
M.H. Tawhai, PhD, Auckland, New Zealand

Oral Presentations

1:30 **Postnatal Development of Pulmonary AciniA in Rats/**T.P. Cremona, D. Haberthur, E. Yao, S. Barre, M. Stampanoni, J.C. Schittny, Bern, Switzerland, p.A7520

1:45 **Deposited Particle Concentrations in Infant, Child, and Adult Image-Based Computational Fluid Dynamics (CFD) Models/**J.M. Oakes, S.C. Roth, I.E. Vignon-Clementel, S.C. Shadden, Berkeley, CA, p.A7521

2:00 **Imaging a Single Slice Provides a Representative Measure of Specific Ventilation in a Normal Lung: A Computational Modeling Study/**K.S. Burrowes, W. Kang, G.K. Prisk, M. Tawhai, Oxford, United Kingdom, p.A7522

2:15 **Comparison of Regional Ventilation and Lung Deformation for Asthmatic Vs. Healthy Human Lungs Using 4D-CT Image Data/**N. Jahani, S. Choi, J. Choi, E.A. Hoffman, A.P. Comellas, J.N. Kline, C.-L. Lin, Iowa City, IA, p.A7523

2:30 **Regional Increase in Airway Wall Thickness Could Explain Increase in Ventilation Defects (VDefs) and Heterogeneity in Ventilation in Asthma/**T. Winkler, C. Thamrin, C.S. Farah, G.G. King, Boston, MA, p.A7524

2:45 **Biomechanical Model of Inflammation-Induced Airway Smooth Muscle Mass Accumulation and Extracellular Matrix Deposition in an Ovalbumin Murine Model of Asthma/**M.R. Hill, A.L. Tatler, R.D. O'Dea, C.K. Billington, A.E. John, K. Deacon, S.R. Johnson, B.S. Brook, Nottingham, United Kingdom, p.A7525

3:00 **Novel Biomarkers of Lung Parenchyma Destruction and Emphysema Progression in COPD Using Inhaled Gas MRI Morphometry/**E. Lessard, A. Ouriadov, D.P. Capaldi, D.G. McCormack, G. Parraga, London, Canada, p.A7526

3:15 **Automated Quantitative Evaluation of Alveolar Structure on Confocal Laser Endomicroscopy/**D. Bondesson, T. Gaass, J. Behr, F. Reichenberger, J. Dinkel, E. Silbernagel, Munich, Germany, p.A7527

MINI SYMPOSIUM

D98 AFTER SERVE-HF: NOW WHAT?

1:30 p.m. - 3:30 p.m. **MOSCONE CENTER**
Room 2001/2003 (West Building, Level 2)

Chairing: S. Javaheri, MD, Cincinnati, OH
M. Arzt, MD, Regensburg, Germany
M. D'Ortho, MD, PhD, Creteil, France

Oral Presentations

1:30 **Morbidity and Mortality of Chronic Heart Failure (CHF) Patients Treated by Adaptative Servo-Ventilation (ASV): Interim Data of the FACE Multicentre National Cohort Study/**R. Tamisier, T. Damy, J.-M. Davy, P. Levy, F. Goutorbe, L. Morin, J.L. Pepin, M.-P. D'Ortho, Grenoble, France, p.A7528

1:45 **Obstructive and Central Sleep Apnea Are Associated with Increased CaMKII-Dependent Sarcoplasmic Reticulum Calcium Leak in Human Atrial Cardiomyocytes/**S. Ripfel, M.A. Drzymalski, S. Meindl, A. Biedermann, M. Durczok, T. Islam, S. Katz, M. Mendl, T. Weizenegger, B. Florchinger, D. Camboni, S. Wittmann, J. Backs, C. Schmid, L.S. Maier, S. Wagner, M. Arzt, Regensburg, Germany, p.A7529

2:00 **Adaptive Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure Does not Improve Muscle Sympathetic Nerve Activity: A SERVE-HF Substudy/**R. Tamisier, J.L. Pepin, M. Salvat, H. Woehrle, G. Barone-Rochette, C. Rocca, H. Teschler, M. Cowie, P. Levy, Grenoble, France, p.A7530

2:15 **Dissociation of Objective and Subjective Daytime Sleepiness Measures in Patients with Heart Failure and Obstructive Sleep Apnea/**S. Javaheri, R. Mehra, N. Foldvary-Schaefer, Cincinnati, OH, p.A7531

2:30 **Protective Cardiovascular Effect of Sleep Apnea Severity in Obesity Hypoventilation Syndrome/**J.F. Masa, M.-A. Sanchez-Quiroga, J. Corral, A. Romero, C. Caballero, J. Teran-Santos, M.L. Alonso-Alvarez, T. Gomez-Garcia, M. Gonzalez, S. Lopez-Martinez, P. De Lucas, J.M. Marin, S. Marti, T. Diaz-Cambriles, E. Chiner, E. Miranda, C. Egea, A. Obeso, B. Mokhlesi,Caceres, Spain p.A7532

2:45 **Associations Between Sleep Disordered Breathing and Subclinical Carotid Atherosclerosis: The Multi-Ethnic Study of Atherosclerosis/**Y.Y. Zhao, R. Wang, S. Javaheri, B. Koo, C.E. Korcarz, J.H. Stein, S. Redline, Boston, MA, p.A7533

3:00 **Long-Term Effect of CPAP on Subclinical Atherosclerosis in Obstructive Sleep Apnea/**J.M. Marin, T. Martin, V. Gil, P. Cubero, M. Forner, A.L. Simon, Zaragoza, Spain, p.A7534

Featured Speaker

3:15 **Carotid Body Targeting in Cardiovascular Disease: Taming the Roar/**J. Paton, PhD, Bristol, United Kingdom,

MINI SYMPOSIUM

D99 NOVEL TRANSLATIONAL BIOMARKERS IN LUNG CANCER

1:30 p.m. - 3:30 p.m. **MOSCONE CENTER**

Room 306/308 (South Building, Esplanade Level)

Chairing: P. Nana-Sinkam, MD, Columbus, OH
S.D. Spivack, MD, MPH, Bronx, NY

Featured Speaker

1:30 **Why Do We Need Biomarkers for Lung Cancer?/**A. Vachani, MD, MS, Philadelphia, PA,

Oral Presentations

1:45 **Nasal Epithelial Gene Expression Is Altered in Patients with Lung Cancer and Reflects the Cancer-Associated Gene Expression Changes Observed in the Bronchial Epithelium/**J. Perez-Rogers, J. Gerrein, C. Anderlind, G. Liu, S. Zhang, Y. Alekseyev, K. Porta, D. Whitney, A. Spira, M. Lenburg, Boston, MA, p.A7535

2:00 **Chemoprevention with Myo-Inositol Alters Gene-Expression in the Airway Epithelium of Smokers with Dysplasia/**Y.B. Gesthalter, M. Lenburg, P.J. Limburg, S.J. Mandrekar, S. Lam, K. Fursa, S.F. Kaufman, D. Seisler, E. Szabo, A. Spira, J. Beane, Boston, MA, p.A7536

2:15 **Discovery and Validation of a Combined Serum Protein and Auto-Antibody Test for the Identification of Lung Cancer in a High Risk Population/**P.J. Mazzone, X.-F. Wang, H. Choi, M. Seeley, V. Doseeva, R. Scherer, V. Knezevic, Cleveland, OH, p.A7537

2:30 **Plasma TIMP-1 Identifies Lung Cancer in Smokers/**V.S. Nair, H. Yu, A. Juang, A. Hattori, M. Ito, J. Rosenberg, G. Horng, W. Kuschner, S.M. Hanash, M. Beggs, L. Carbonell, S.X. Wang, Stanford, CA, p.A7538

2:45 **Telomere Shortening in COPD and Lung Cancer: A Pilot Study in Chronic Smokers/**R.P. Young, W. Whitford, R.J. Hopkins, Auckland, New Zealand, p.A7539

3:00 **Immunoproteasome Deficiency in Non-Small Cell Lung Cancer Is Associated with Mesenchymal Phenotype, Restricted Antigen Presentation, and Poor Outcome/**E.J. Ostrin, S. Tripathi, H.L. Peters, A. Taguchi, M.J. Schliekelman, H. Katayama, H. Wang, A. Momin, M. Celiktas, J. Rodriguez Canales, H. Liu, C. Behrens, I.I. Wistuba, J.J. Molldrem, S.M. Hanash, Houston, TX, p.A7540

3:15 **Next Generation Sequencing of Solid Tumor and Circulating Tumor DNA (ctDNA) for Real-Time Monitoring of Metastatic Non-Small Cell Lung Cancer/**J. Thompson, C. Langer, C. Aggarwal, J. Bauml, E. Carpenter, A. Vachani, Philadelphia, PA, p.A7541

POSTER DISCUSSION SESSION

D101 ALLERGY AND ASTHMA: NOVEL REGULATORY PATHWAYS

1:30 p.m. - 3:30 p.m. **MOSCONE CENTER**

Room 2024 (West Building, Level 2)

Poster Viewing **1:30-2:15**

Discussion **2:15-3:30**

Chairing: M. Kraft, MD, Tucson, AZ
J.L. Cho, MD, Boston, MA
C. Donovan, BSc (Hons), Parkville, Australia

601 **Identification of Transcriptional Regulators Controlling IL-17A-Mediated Enhancement of IL-13 Activity/**S.L. Hall, I. Lewkowich, Cincinnati, OH, p.A7542

602 **The Purinergic Receptor P2X4 Mediates Acute Airway Inflammation by Regulating Dendritic Cell Function/**B. Wiesler, A. Zech, M. Idzko, Freiburg, Germany, p.A7543

603 **P2Y14 Receptor Deficiency Attenuates Phenotype of Allergic Airway Inflammation in Mice/**T. Schlaich, A. Zech, B. Wiesler, M. Hobfeld, M. Idzko, Freiburg, Germany, p.A7544

604 **CARMA3 Mediates the Pulmonary Immune Response to Alternaria Alternata/**B. Causton, K. Jones, J.L. Cho, B.D. Medoff, Charlestown, MA, p.A7545

605 **Novel Nasal Sampling Techniques Identify ILC2s as Important Responders in Asthma During Nasal Allergen Challenge/**J. Dhariwal, A. Cameron, B. Trujillo-Torralbo, A. Del Rosario, M. Paulsen, D.J. Jackson, M.R. Edwards, D. Cousins, T.T. Hansel, S.L. Johnston, R.P. Walton, London, United Kingdom, p.A7546

606 **The Expression of the Interleukin-33 Receptor ST2L on Eosinophils Following Bronchial Allergen Challenge in Allergic Asthma Subjects/**P.D. Mitchell, B. Watson, J.P. Oliveria, S. Smith, D. Tworek, A. El-Gammal, G. Gauvreau, R. Sehmi, P.M. O'Byrne, Hamilton, Canada, p.A7547

607 **IL-36 Induces Inflammation in the Lung/**Y. Sun, H.A. Arnett, South San Francisco, CA, p.A7548

608 **Circadian Changes in Glucocorticoid Receptor Expression and Function in Airway Epithelial Cells/**E.D. Larson, Z. Jiang, S. Ott, K. Chmiel, A.A. Zeki, A. Haczku, Davis, CA, p.A7549

609 **Dysregulation of Type 2 Innate Lymphoid Cells and TH2 Cells Impairs Diesel-Enhanced Allergic Airway Responses/**S. Provoost, K.C. De Grove, R.W. Hendriks, L.J. Seys, S. Kumar, T. Maes, G.G. Brusselle, G.F. Joos, Ghent, Belgium, p.A7550

610 **TLR2 Contributes to Allergic Airway Inflammation Through JNK Signaling Pathway with Activation of Autophagy/**L. Fang, R. Liu, Hefei, China, p.A7551

611 **Lung-Targeted Dual PI3Kγδ Inhibition: Evidence for a Novel Therapeutic Strategy for Multiple Severe Asthma Phenotypes/**M. Thomas, P. Bold, K. Bjorhall, A. Butcher, J.F. Carlsson, P. Cygan, M. Karlsson, H. Lindmark, M. Perry, M. Mogemark, V. Morrisson, M. Norberg, S. Rodrigo Blomqvist, C. Goodyear, K. Karabelas, Gothenburg, Sweden, p.A7552

612 **Peripheral Pathological ILC2: An Inflammatory Indicator for the Assessment of Asthma Control in Clinics/**Z. Chen, Y. Jia, R. Tang, C. Bai, L. Zhu, Shanghai, China, p.A7553

613 **Role of ChemR23 Signaling in Diesel-Enhanced Allergic Airway Inflammation/**K.C. De Grove, S. Provoost, G.L. Fraser, V.J. Lannoy, G.G. Brusselle, T. Maes, G.F. Joos, Ghent, Belgium, p.A7554

614 **CLEC-2 Regulates Type 2 and Type 17 Lung Inflammation/**P. Burkett, A. Wallrapp, V.K. Kuchroo, Boston, MA, p.A7555

615 **Secreted Phospholipase A2 Group X Plays a Key Role in the Airway Response to an Inhaled Allergen and Orchestrates a Type-2 Innate Immune Response/**J.D. Nolin, H.L. Ogden, Y. Lai, D. An, A.M. Manicone, C.W. Frevert, M.W. Gelb, W.A. Altemeier, T.S. Hallstrand, Seattle, WA, p.A7556

616 **Impact of High Sugar Diet on L-Arginine Metabolism in the Lung/**A.L. Linderholm, M.R. Showalter, E.B. Nonnecke, B.L. Lonnerdal, O. Fiehn, N.J. Kenyon, Davis, CA, p.A7557

617 **Inhibition of RORα Blocks Rhinovirus-Induced Expansion of Type 2 Innate Lymphoid Cells and Expression of IL-13 in Immature Mice/**C. Rajput, J.K. Bentley, T. Cui, J. Lei, M. Han, M.B. Hershenson, Ann Arbor, MI, p.A7558

618 **Elevated Levels of Circulating CRTh2+CD4+T Cells Characterize Severe Asthma/**N. Shrestha Palikhe, C.R. Laratta, D. Nahirney, D. Vethanayagam, M. Bhutani, H. Vliagoftis, L. Cameron, Edmonton, Canada, p.A7559

619 **Peripheral Pathological Type 2 Innate Lymphoid Cells Associate with Human Asthma Control Status/**Y. Jia, X. Fang, Z. Chen, R. Tang, Shanghai, China, p.A7560

620 **Alveolar Macrophages from Subjects with Asthma Release Pro-Inflammatory LTB4 in Ratio Excess to LXA4 Upon P2X7 Stimulation, Promoting Fibrotic Remodeling/**E.C. Roti Roti, E.E. Torr, P. Fichtinger, A. Guadarrama, N. Sandbo, L.C. Denlinger, Madison, WI, p.A7561

621 **Airway Epithelium-Specific Deletion of Leptin Receptor Worsens Murine Asthma/**V. Anathy, B. Mihavics, N. Ubags, E. Dilli, A. Wallace, A.E. Dixon, B.T. Suratt, Burlington, VT, p.A7562

622 **Breastfeeding and Delivery Mode Modify the Association Between Maternal Atopy and Childhood Allergic Outcomes/**N.S. Kasmikha, A. Sitarik, H. Kim, G. Wegienka, C.C. Johnson, S. Havstad, D. Ownby, E. Zoratti, Detroit, MI, p.A7563

623 **P2Y14 Receptor Activation Mediates LPS and Allergen Induced Pulmonary Leukocyte Recruitment in Mice/**R.T. Amison, S. Arnold, B.G. O'Shaughnessey, S. Cicko, A. Meyer, M. Idzko, C.P. Page, S.C. Pitchford, London, United Kingdom, p.A7564

624 **Alternative Splicing of Exons 3 and 4 in IL-33 Is Associated with Type 2 Inflammation in Human Asthma/**E. Gordon, A. Wesolowska-Andersen, C. Urbanek, M.E. Lachowicz-Scroggins, M. Peters, M. Seibold, J.V. Fahy, San Francisco, CA, p.A7565

625 **Helicobacter Pylori Elicits a Heightened Innate Immune Response in Pediatric Airway Epithelium : Evidence of NOD1 Developmental Regulation/**M.A. Dela Pena, M.T. Jimenez, J.V. Solnick, L.A. Miller, Davis, CA, p.A7566

POSTER DISCUSSION SESSION

D102 FIGURING OUT WHAT WE DON'T KNOW: ADVANCES IN MEDICAL EDUCATION

1:30 p.m. - 3:30 p.m. **MOSCONE CENTER**

Room 304 (South Building, Esplanade Level)

Poster Viewing **1:30-2:15**

Discussion **2:15-3:30**

Chairing: M.M. Hayes, MD, Boston, MA
J.B. Richards, MD, MA, Charleston, SC
R. Adamson, MBBS, Seattle, WA

201 **Building Research Capacity in Middle and Low-Income Countries Through Research Methodology and Career Development Education/**C.M. Patino, D.H. Au, C.J. Lane, A.S. Buist, W.M. Vollmer, Los Angeles, CA, p.A7567

202 **Increased Mortality Associated with Resident Handoff in a Multi-Center Cohort/**J.L. Denson, A. Jensen, H. Saag, B. Wang, Y. Fang, L. Horwitz, L. Evans, S. Sherman, Denver, CO, p.A7568

203 **Effectiveness of ATS Core Curriculums in Pulmonary, Critical Care, Sleep, and Pediatric Pulmonary in Improving Knowledge and Providing Maintenance of Certification (MOC)/**C.S. Dela Cruz, G. Pien, M.A. Nevin, A. Kantz, E. Larsson, J. Siegel-Gasiewski, C.C. Thomson, J.T. Poston, G.C. Michaud, New Haven, CT, p.A7569

204 **Situational Awareness of Medical Residents: An OSCE Observation and Evaluation/**A. Niroula, D.G. Smith, M. Naglak, Abington, PA, p.A7570

205 **Lung Transplant Curriculum Needs Assessment - Results of a National Survey/**J.A. Town, M. Tonelli, Seattle, WA, p.A7571

206 **"Best Case/Worst Case": Training Physicians to Use a Novel Communication Tool for High-Risk, Preference-Sensitive Decision Making/**J.M. Kruser, L.J. Taylor, M.J. Nabozny, N.J. Steffens, J.L. Tucholka, A. Zelenski, S. Johnson, K.L. Kwekkeboom, T.C. Campbell, M.L. Schwarze, Chicago, IL, p.A7572

207 **The Utility of High-Fidelity Simulation for Training Critical Care Fellows in the Management of Extra-Corporeal Membrane Oxygenation Emergencies/**B. Zakhary, L. Kam, B. Kaufman, K. Felner, New York, NY, p.A7573

208 **Airway Management Outcomes from a Pulmonary and Critical Care Medicine Fellowship/**N. Nathani, I. Co, T. Valley, T. Sisson, Ann Arbor, MI, p.A7574

209 **Reinvigorating the Culture of Bedside Medicine: Results of a Needs Assessment on Residents' Cardiopulmonary Examination Attitudes and Skills/**B.T. Garibaldi, T.M. Niessen, J.V. Canzoniero, G.Y. Liu, R.S. Manesh, M.C. Corretti, E.K. Kasper, R.W. Stewart, D.J. Brotman, D. Cayea, S.V. Desai, Baltimore, MD, p.A7575

210 **Quality Improvement by Meeting Milestones: Implementation of an Evaluation System to Address Aspects of the Next Accreditation System in a Pulmonary and Critical Care Medicine Fellowship Program/**A.G. Cole, P. Lenz, Cincinnati, OH, p.A7576

211 **Barriers to House Staff Comfort in Discussing MOLST Forms/**S.E. Zaeh, M.M. Hayes, C.S. Rand, A.E. Turnbull, Baltimore, MD, p.A7577

212 **Teaching Medical Students the SMART Way: Do Better Learning Objectives Translate to Higher Exam Scores?/**L. Rice, N. Anguiano, G. Hinman, E. Theisen, L.C. Denlinger, Madison, WI, p.A7578

213 **ICU Innovations: Leveraging University Expertise into Community ICUs Via Interprofessional Education/**E. Warr, K. Sterba, A.J. Goodwin, E. Johnson, T. Hassig, B. Kilpatrick, J. Zapka, D.W. Ford, Charleston, SC, p.A7579

214 **Behavioral-Based Interviewing to Improve Candidate Selection for a Pulmonary and Critical Care Medicine Fellowship Program/**G. Tatem, M. Kokas, C.L. Smith, B. DiGiovine, Detroit, MI, p.A7580

215 **Improvement of Asthma Education and Management? Guideline Adherence Instead - See Comment Below Among Pulmonary Fellows in a County Hospital Setting/**B. Bellucci, K. Lonial, M. Valdez, J. Sablan, A.A. Balekian, Los Angeles, CA, p.A7581

216 **Effective Learning in High Cognitive Load Critical Care Simulation/**R.M. Shah, A. Verceles, K. Robinett, M.T. McCurdy, N.G. Shah, Baltimore, MD, p.A7582

217 **Creation and Validation of an EHR-Centric MICU Rounding Simulation/**J. Bordley, K.K. Sakata, J. Bierman, A. Mulanax, K.A. Artis, R. Pranaat, V. Mohan, J.A. Gold, Portland, OR, p.A7583

218 **High Fidelity Airway Trainer Teaches Novice Learners Flexible Bronchoscopy Skills/**E.M. DeBoer, R. Mohon, M. Rustici, Aurora, CO, p.A7584

219 **Central Venous Catheterization Simulation Mastery Program in Pulmonary/Critical Care Fellowship Training/**A. Sankari, S. Lee, J.A. Rowley, Detroit, MI, p.A7585

220 **Nighttime Intensivist Staffing in Academic Medical Centers: A Survey Analysis of Pulmonary Critical Care Fellowship Programs/**J. Rho, T. Patel, C. Hompesch, Dallas, TX, p.A7586

221 **ATS Postgraduate Education Needs According to Course Participants/**G.C. Michaud, J.T. Poston, J. Siegel-Gasiewski, A. Kantz, E. Larsson, C.C. Thomson, New York, NY, p.A7587

222 **Bronchoscopy Training Among Critical Care Medicine Programs in US - A Survey of Fellowship Directors/**F. Hashmi, T. Moua, Rochester, MN, p.A7588

223 **Integration of Point-of-Care Ultrasound Curriculum with Clinical Simulation in Medical Student Education: Catching Them Early/**S. Jain, L. Antes, M. Suneja, K. Ferguson, J. Rowat, B. Nassar, G.A. Schmidt, Iowa City, IA, p.A7589

224 **Case Based Lectures Vs Simulation Based Training: Which Is Better for Resident Education?/**A. Trivedi, M.H. Kollef, St. Louis, MO, p.A7590

225 **A Multi-Faceted Educational Intervention to Improve Resident Awareness and Practice in Diagnosing and Treating Intensive Care Unit Delirium/**A.J. Gangemi, D. Hynes, E.J. Yoo, Philadelphia, PA, p.A7591

POSTER DISCUSSION SESSION

D103 CRITICAL CARE: IMPROVING PALLIATIVE AND END OF LIFE CARE IN THE ICU

1:30 p.m. - 3:30 p.m. **MOSCONE CENTER**
Room 3001 (West Building, Level 3)

Poster Viewing **1:30-2:15**

Discussion **2:15-3:30**

Chairing: J.R. Curtis, MD, MPH, Seattle, WA
W.J. Ehlenbach, MD, Madison, WI
P.R. Menon, MD, Burlington, VT

701 **ICU Nurses Focus Group on Acceptability Testing of VidaTalkT/**T.T. Von Visger, J.A. Tate, B. Traughber, L. Patak, M.B. Happ, Columbus, OH, p.A7592

702 **Potential Cost-Effectiveness of Staffing the Intensive Care Unit with a Communication Facilitator/**N. Khandelwal, D. Benkeser, N.B. Coe, R.A. Engelberg, J.R. Curtis, Seattle, WA, p.A7593

703 **Towards the Best Possible End-of-Life Conversation: Describing a Data-Driven Approach to Maximizing Conversation Quality and Content During a Conversation Game/**L.J. Van Scoy, J. Reading, A.M. Scott, C. Chuang, B.H. Levi, M.J. Green, Hershey, PA, p.A7594

704 **Moral Distress in Intensive Care Personnel Related to the Provision of Perceived Non-Beneficial Care/**S. Galindo, A. Hamric, N. Henrich, P. Dodek, Vancouver, Canada, p.A7595

705 **Efficacy of Attempted Cardiopulmonary Resuscitation During Continuous Renal Replacement Therapy in Critically Ill Patients/**M.F. Odish, J.R. Beitler, R. Sell, San Diego, CA, p.A7596

706 **How Long Is Too Long: The Duration of CPR In The Hospital Setting/**R. Sekhon, P. Dave, Z. Ghazarian, M. Hanna, T. Pandya, M. Labban, R. Solis, M. Ismail, Paterson, NJ, p.A7597

707 **Dying in the Medical Intensive Care Unit/**C. Cordoba-Carrillo, J. Torres-Palacios, W. Rodriguez-Cintron, San Juan, Puerto Rico, p.A7598

708 **Stark Differences for the Goals and Realities of the Chronically Critically Ill/**D. Lamas, A. Massaro, S. Block, R.L. Owens, R.N. Nace, Boston, MA, p.A7599

709 **Advance Care Planning in Patients Admitted to the Medical Intensive Care Unit of a Urban Safety-Net Hospital for Acute Exacerbation Chronic Obstructive Pulmonary Disease/**A.R. Stephens, R.S. Wiener, M. Ieong, Boston, MA, p.A7600

710 **Citizen's Views Regarding Important Outcomes and Treatment Options During Weaning from Mechanical Ventilation/**K.E.A. Burns, S. Karottaiyamvelil Jacob, V.A. Aguirre, J. Gomes, S. Mehta, L. Rizvi, Toronto, Canada, p.A7601

711 **Performance of a Consultative Palliative Care Model for Achieving Quality Metrics in the ICU/**M.J. Hochman, N.G. Wysham, S.P. Wolf, C.E. Cox, A. Kamal, Durham, NC, p.A7602

712 **Palliative Care Referral Infrequent in Patients with Idiopathic Pulmonary Fibrosis Admitted to the Intensive Care Unit/**Z. Liang, L. Hoffman, J.M. Pilewski, M. Donahoe, M.L. Saul, N. Kaminski, K. Gibson, K.O. Lindell, Tampa, FL, p.A7603

713 **Intensive Care Unit Admissions and Palliative Care Consultations Among Patients with Advanced Cancer/**M. Kang, S. Kothadia, K. Patel, N. Duma, H. Kim, C.C. Ezeonu, M. Gonzalez Velez, B.L. Gladney, M. Gutierrez, Newark, NJ, p.A7604

714 **Understanding Inappropriate Critical Care: A Qualitative Analysis of Medical Record Documentation/**T.H. Neville, D.M. Tarn, M. Yamamoto, B. Garber, N.S. Wenger, Los Angeles, CA, p.A7605

715 **The Frailty Phenotype and Unmet Palliative Care Needs in Older ICU Survivors/**L.R. Pollack, W.C. Gonzalez, C.D. Blinderman, N.E. Goldstein, M.S. Maurer, D.J. Lederer, M.R. Baldwin, New York, NY, p.A7606

716 **Creating and Implementing an End of Life Care Order Set in Intensive Care Units: A Tertiary Care Center Experience/**A.H. Khan, E. Chen, G. Patel, K. Roadman, Chicago, IL, p.A7607

717 **Evolving Patterns of End-of-Life Hospitalizations Among Patients with Cirrhosis Admitted to ICU; a Population-Based Cohort Study/**L. Oud, Odessa, TX, p.A7608

718 **Long-Term Outcome and Health-Related Quality of Life in Patients Discharged from the ICU with a Tracheostomy and with or Without Prolonged Mechanical Ventilation/**E. Derom, S. De Raedt, S. De Smet, P. Depuydt, S. Oeyen, D. Benoit, J. Decruyenaere, Gent, Belgium, p.A7609

719 **Outcomes and Dispositions of Patient's Suffering In-Hospital Cardiac Arrest/**S. Farooqi, E. Gerio, A. Mora, Dallas, TX, p.A7610

720 **Impact of a Multi-faceted Intervention on Withdrawal of Life Support processes in a Medical Intensive Care Unit at a University Hospital/**L. Ventola, J. Mitchell, E. Yoo, L.J. Van Scoy, Hershey, PA, p.A7611

721 **Ethical Considerations in Withdrawing Extracorporeal Membranous Oxygenation Support/**E.S. DeMartino, D.P. Sulmasy, J.K. Bohman, J.M. Stulak, K.R. Fuechtmann, N. Singh, G. Schears, P.S. Mueller, Rochester, MN, p.A7612

722 **A National VA Palliative Care Quality Improvement Project for Improving Intensive Care Unit Family Meetings (ICU-FMs)/**K.M. Akgun, D. Gruenewald, D. Wertheimer, M. Gabriel, D. Rizzo, M. Zuccaro, C. Luhrs, West Haven, CT, p.A7925

723 **Disparities in Advanced Care Planning in the ICU and End of Life Decision Making/**A. Barwise, M. Wilson, R. Kashyap, O. Gajic, B.W. Pickering, Rochester, MN, p.A7926

POSTER DISCUSSION SESSION

D104 CRITICAL CARE: PRE-ICU, RAPID RESPONSE, AND INITIAL TREATMENT FOR SEPSIS

1:30 p.m. - 3:30 p.m. **MOSCONE CENTER**
Room 3024 (West Building, Level 3)

Poster Viewing **1:30-2:15**

Discussion **2:15-3:30**

Chairing: C.W. Seymour, MD, MSc, Pittsburgh, PA
R.R. Miller, MD, MPH, Murray, UT
M.P. Kerlin, MD, Philadelphia, PA

1001 **External Validation of a Prehospital Critical Illness Score: A Multi-Center Cohort Study/**D.R. Kievlan, C. Martin-Gill, J.M. Kahn, C.W. Callaway, D.M. Yealy, D.C. Angus, C.W. Seymour, Pittsburgh, PA, p.A7613

1002 **Early Detection of Impending Deterioration Outside The ICU: A Difference-in-Differences (DiD) Study/**G.J. Escobar, V. Liu, Y.S. Kim, B.J. Turk, A. Ragins, B.A. Dummett, C.L. Adams, E.A. Scruth, P. Kipnis, Oakland, CA, p.A7614

1003 **Needs and Preferences for Rapid Response Team Education for House-Staff in an Urban Academic Hospital/**C. Kapp, M. Kolosvary-Kiss, A. Thompson, A. Kobzik, G. Hughes-Strange, J. Chae, M. Joo, Chicago, IL, p.A7615

1004 **Standardizing and Improving the Hand-Off Process During Rapid Response Team Activations/**P. Jagtap, F. Hashmi, A. Kogan, A. Gallo De Moraes, J. Elmer, S. Capels, R.A. Oeckler, J. Jensen, Rochester, MN, p.A7616

1005 **Improving Prehospital Recognition of Severe Sepsis (PRESS): Knowledge and Attitudes of First Responders/**C. Polito, I. Bloom, A. Yancey, J. Lairet, A. Isakov, D. Murphy, G.S. Martin, J.E. Sevransky, Atlanta, GA, p.A7617

1006 **Biomarker Measurement During Prehospital Care: A Systematic Review/**A. Khalid, C. Martin-Gill, C.W. Callaway, D.M. Yealy, C.W. Seymour, Pittsburgh, PA, p.A7618

1007 **Utility of Pre-Hospital Glasgow Coma Scale in Predicting In-Hospital Mortality in Patients with Sepsis/**R. Dolan, C. Polito, A. Isakov, A. Yancey, I. Bloom, G.S. Martin, J.E. Sevransky, Atlanta, GA, p.A7619

1008 **The Neighborhood Effect: Is Critical Illness Contagious on Hospital Wards?/**M.M. Churpek, A. Mayampurath, G. Goksu-Gursoy, D.P. Edelson, M.D. Howell, S.L. Volchenboum, Chicago, IL, p.A7620

1009 **High Intensive Care Unit (ICU) Capacity Strain at the Time of Emergency Department Triage is Associated with Decreased ICU Admissions Among Patients with Severe Sepsis/**G.L. Anesi, S.D. Halpern, N.B. Gabler, G.J. Escobar, V. Liu, Philadelphia, PA, p.A7621

1010 **Peer Led Education to Improve Identification and Treatment of Patients with Sepsis/**L.E. Howard, K.S. Allen, J. Paulsgrove, G.T. Kinasewitz, Oklahoma City, OK, p.A7622

1011 **Sepsis Alerts in the Emergency Department to Expedite the Care of Severe Sepsis and Septic Shock/**B. Keveson, B. Smith, M. Cate, P. Steves, R. Clouser, M. Holman, G.B. Allen, Burlington, VT, p.A7623

1012 **Prediction of Acute Respiratory Failure in Severe Chronic Obstructive Respiratory Disease: What Do We Need to Learn in Emergency Department?/**A. Sadigov, K. Agayeva, S. Huseynova, G. Sadigova, Baku, Azerbaijan, p.A7624

1013 **As Assessment of Detection and Early Intervention in Patients with Sepsis at an Urban Teaching Hospital/**T.T. Yamanaka, J. Chae, L. Estep, A. Kobzik, B.A. Buchcic, S. Benken, J. Jacobson, Chicago, IL, p.A7625

1014 **Reducing the Time to Antibiotic Administration in Patients with Sepsis: One Hospital's Experience/**C.G. Hebenstreit, M.S. Narat, S.S. Patil, B. Patel, D.D. Jackson, A.A. Aman, T. Johnson, K. Gopal, K. Gomez, Houston, TX, p.A7626

1015 **Mortality Among High Risk Patients with Septic Shock admitted to U.S. Teaching-Intensive Hospitals in July: A Retrospective Observational Study /**A. Saqib, B. Pandya, M. Chahloub, Staten Island, NY, p.A7627

1016 **Identifying Variables in Unexpected ICU Admissions and Impact on Mortality in Septic Patients Following a Bundled Care Initiative: A Retrospective Case Control Analysis/**A.R. Wali, R. Sell, V. Tolia, C. Tomaszewski, G. Wardi, San Diego, CA, p.A7628

1017 **Impact of Delayed Admission to the Intensive Care Unit from the Emergency Department upon Sepsis Outcomes and Sepsis Protocol Compliance/**M. Agustin, L.L. Price, P. LaCamera, A. Andoh-Duku, Boston, MA, p.A7629

1018 **Pre-Hospitalization Use of Beta-Blockers and Clinical Outcomes in Septic Shock Patients Admitted to Intensive Care Unit/**T. Jain, S. Mawri, J. Shah, Y. Alsafadi, W. Al-Darzi, E. Abdelrahim, N. Huda, K. Ananthasubramaniam, Detroit, MI, p.A7630

1019 **Evaluation of Adjudicated Sepsis Diagnosis and a Novel, Host Response Assay in the Diagnosis of Sepsis in Critically Ill Patients/**R.R. Miller, B. Lopansri, L. McHugh, T. Seldon, J. Burke, Murray, UT, p.A7631

1020 **Trajectory of Multiscalar Variability Dynamics in Physiologic Phase Space Correlates with Mortality in Septic Patients/**M. Abas, B. Vandendriessche, T.E. Dick, K.A. Loparo, F.J. Jacono, Cleveland, OH, p.A7632

1021 **The Impact of Critical Care Outreach on Intensive Care Unit Readmissions/**S.S. Loren, F.J. Zadravecz, M.M. Churpek, N.M. Twu, M.D. Howell, D.P. Edelson, Chicago, IL, p.A7633

1022 **Hospital Readmissions for Recurrent Sepsis: New Or Recurrent Infection?/**K.M. DeMerle, H.C. Prescott, Ann Arbor, MI, p.A7634

1023 **Effect of Care Fragmentation on Outcomes of Rehospitalizations For Severe Sepsis Survivors/**M. Hua, M.N. Gong, A. Miltiades, H. Wunsch, New York, NY, p.A7635

1024 **Severe Sepsis Associated 30-Day Readmissions - Analysis of a Nationwide Medicare Sample/**B. Norman, C.R. Cooke, J. Graves, E.W. Ely, Nashville, TN, p.A7636

POSTER DISCUSSION SESSION

D105 RESPIRATORY FAILURE : ROLE OF THE DIAPHRAGM AND SKELETAL MUSCLES

1:30 p.m. - 3:30 p.m. **MOSCONE CENTER**

Room 3011 (West Building, Level 3)

Poster Viewing **1:30-2:15**

Discussion **2:15-3:30**

Poster Discussion Session

Chairing: A. Demoule, MD, PhD, Paris, France
F. Laghi, MD, Hines, IL
F.D. McCool, MD, Providence, RI

801 **Sepsis Activated Endoplasmic Reticulum Stress and Decreased Contractile Function of Diaphragm In Rats/**G. Jiao, P. Wang, L. Hao, M. Wang, B. Zhong, M. Yu, S. Zhao, R. Feng, S. Tan, L. Chen, J. Yuan, Shenyang, China, p.A7637

802 **Sepsis Induces an Early but Reversible Diaphragm Dysfunction/**M. Dres, B.-P. Dube, J. Mayaux, J. Delemazure, L. Dangers, T. Similowski, A. Demoule, Paris, France, p.A7638

803 **ICU Acquired Diaphragm and Limb Muscles Weakness: Respective Prevalence, Risk Factors and Prognostic Impact - A Prospective Study/**M. Dres, B.-P. Dube, J. Mayaux, J. Delemazure, D. Reuter, T. Similowski, A. Demoule, Paris, France, p.A7639

804 **Thiamin Mitigates Sepsis-Induced Diaphragm Muscle Dysfunction in Rats/**E. Zhu, L. Fang, V.S. Subramanian, H.M. Said, C. Sassoon, Long Beach, CA, p.A7640

805 **Ventilator-Induced Diaphragmatic Dysfunction with Exaggerated Upregulation of Proteolysis Pathways in Dystrophic (mdx) Mice/**B.J. Petrof, F. Liang, T. Li, C. Giordano, Montreal, Canada, p.A7641

806 **Diaphragm Inactivity and Eccentric Contractile Activity Are Common and Impair Diaphragm Function During Mechanical Ventilation/**E.C. Goligher, C. Urrea, S.L. Vorona, L.J. Brochard, M. Dres, C.A. Sinderby, S.-S. Bolz, G.D. Rubenfeld, B.P. Kavanagh, N.D. Ferguson, Toronto, Canada, p.A7642

807 **Electrical Activity to Determine the Start of Diaphragm Activity in Mechanically Ventilated Patients: An Observational Study/**M. Rauseo, I. Soliman, L. Chen, N. Rittayamai, G.-Q. Chen, M. Sklar, C. Campbell, E.C. Goligher, J.O. Friedrich, C.A. Sinderby, L. Heunks, L.J. Brochard, Toronto, Canada, p.A7643

808 **Measuring Tidal Volume with Electrical Impedence Tomography/**D. DiBardino, K. Tzu-Jen, D. Chong, J. Newell, B. Amm, G. Boverman, D. Shoudy, G. Saulnier, D. Isaacson, D. Davenport, J. Ashe, New York, NY, p.A7644

809 **Rapid Shallow Breathing Index Calculated by Electrical Impedance Tomography: A Case Report Before and After Extubation/**D. DiBardino, K. Tzu-Jen, D. Chong, J. Newell, B. Amm, G. Boverman, D. Shoudy, G. Saulnier, D. Isaacson, D. Davenport, J. Ashe, New York, NY, p.A7645

810 **Expiratory Diaphragm Activity Reduces Atelectasis Formation/**M. Pellegrini, G. Hedenstierna, A. Roneus, M. Segelsjo, A. Larsson, G. Perchiazzi, Uppsala, Sweden, p.A7646

811 **Predictors of Survival in a Large Cohort of Patients with Amyotrophic Lateral Sclerosis/**T.S. Panchabhai, E. Mireles-Cabodevila, E.P. Pioro, L.S. Aboussouan, Phoenix, AZ, p.A7647

812 **Course of Decline of Lung Function Based on Tolerance to Non-Invasive Ventilation in Patients with Amyotrophic Lateral Sclerosis/**T.S. Panchabhai, E.P. Pioro, L.S. Aboussouan, X.-F. Wang, Q. Zhang, E. Mireles-Cabodevila, Phoenix, AZ, p.A7648

813 **Does the Pathophysiologic Category of Respiratory Failure Predict In-Hospital Mortality for Patients on Mechanical Ventilation in the Medical Intensive Care Unit?/**M. Kakol, K. Lee Chuy, R. Lenhardt, Chicago, IL, p.A7649

814 **Patterns of Inspiratory Muscles Activation by Surface Electromyography During Weaning from Invasive Mechanical Ventilation/**G. Bellani, M. Pozzi, A. Bronco, N. Eronia, S. Arrigoni-Marocco, G. Villa, S. Stropeni, V. Sala, A.M. Pesenti, Monza, Italy, p.A7650

815 **Determinants of Patient Compliance with Non-Invasive Ventilation in Amyotrophic Lateral Sclerosis/**T.T. Nicholson, S.B. Smith, J.M. Coleman, L.F. Wolfe, Chicago, IL, p.A7651

816 **Contribution of Mechanical In-Exsufflation (MI-E) Device in Preventing Post-Extubation Respiratory Failure in Patient with Critical Illness Polyneuromyopathy (CIP). NEUROMIE/**P. Wibart, T. Reginault, M. Garcia-Fontan, A. Benard, B. Barbrel, C. Bader, M.-P. Baudier, H.-N. Bui, F. Vargas, G. Hilbert, Bordeaux, France, p.A7652

817 **Diaphragm Pacing as Successful Salvage Therapy in Failure to Wean Patients: Should This Novel Technology Be Used Earlier?/**R. Onders, M. Elmo, C. Kaplan, H. Nearman, R. Schilz, Cleveland, OH, p.A7653

818 **Completed FDA Feasibility Trial of Surgically Placed Temporary Diaphragm Pacing Electrodes: A Promising Option to Prevent and Treat Respiratory Failure/**R. Onders, A. Markowitz, J. Hardacre, A. Prabhu, Y. Novitsky, H. Nearman, M. Elmo, C. Kaplan, Cleveland, OH, p.A7654

819 **Diaphragm Activation in Ventilated Patients Using a Novel Phrenic Nerve Temporary Pacing Catheter: First-in-Humans Feasibility/**S. Reynolds, A. Ebner, T. Meffen, V. Thakkar, M. Gani, K. Taylor, L. Clark, R. Meyyappan, R. Sandoval, E. Rohrs, J.A. Hoffer, New Westminster, Canada, p.A7655

820 **Modulation of Stimulation Frequency During Neuromuscular Electrical Stimulation of Abdominal-Wall Muscles to Assist Respiration/**D. Radovanovic, A. McLachlan, T. Schnell, H. Shaikh, M.J. Tobin, F. Laghi, Hines, IL, p.A7656

821 **Manual Muscle Testing, Functional Impairment, and Recovery: Evidence for Redefining ICU-Acquired Weakness in Older ICU Survivors/**C.G. Garcia, L.R. Pollack, W.C. Gonzalez, T.H. Brannagan, L.H. Weimer, D.J. Lederer, M.R. Baldwin, New York, NY, p.A7927

822 **End-Expiratory Airway Pressure Effects on Respiratory System Mechanics and Incidence of Tidal Hyper-Inflation During Open Abdominal Surgery/**R. Huhle, D. D'Antini, J. Herrmann, M. Herzog, T. Bluth, M. Vidal-Melo, G. Cinnella, M.G.D. Abreu, Dresden, Germany, p.A7928

823 **Failed Recovery of Muscle Function in Aged Mice with Lung Injury Is Linked to Specific Metabolic Alterations by Non-Targeted Metabolomics In Vivo/**D.C. Files, A. Ilaiwy, C. Liu, T.L. Parry, J.R. Bain, M.J. Muehlbauer, M.S. Willis, Winston-Salem, NC, p.A7929

POSTER DISCUSSION SESSION

D106 BIOMASS SMOKE, VOG, AND POLLUTANTS

1:30 p.m. - 3:30 p.m. **MOSCONE CENTER**

Room 133 (North Building, Lower Level)

Poster Viewing **1:30-2:15**

Discussion **2:15-3:30**

Chairing: A. Sood, MD, MPH, Albuquerque, NM
G. Diette, MD, MHS, Baltimore, MD
J.E. Sordillo, DSc, Boston, MA

101 **Results of a Prospective Study Evaluating Non-Invasive Hemoglobin Adjustment of DLCO in a Pediatric Pulmonary Function Laboratory/**W.D. Hardie, R. Sahay, N. Zhang, K. Foster, Cincinnati, OH, p.A7657

102 **Occupational Exposure to Particulate Matter from Biomass Smoke and Its Relationship to Respiratory Symptoms and Pulmonary Function Among Rural Women Involved in Cassava Processing in Nigeria/**T.J. Okwor, O. Ozoh, A. Osibogun, Lagos, Nigeria, p.A7658

103 **Comparison of the Biological Effects of Smoke from the Combustion of Different Sources of Animal Dung/**C.E. McCarthy, P.F. Duffney, T.H. Thatcher, R.P. Phipps, P.J. Sime, Rochester, NY, p.A7659

104 **Bronchoalveolar Eosinophilia in Human Subjects After Exposure to Biomass Smoke from Wood Pellet Combustion/**J. Pourazar, G.D. Rankin, A. Muala, J. Unosson, M. Sehlstedt, A.F. Behndig, C. Boman, A. Blomberg, J. Bosson, T. Sandstrom, Umea, Sweden, p.A7660

105 **Respiratory Health Effects of Dung Biomass Smoke Exposure: Effect Modification by Tobacco Smoke and Age/**P. Khaing, S. Mazumder, B. Dube, S. Taneja, B. Yan, S.N. Chillrud, N. Bhandari, J.M. D'Armiento, A. Lee, New York, NY, p.A7661

106 **Psychometric Testing of Four-Item Magnitude of Household Air Wood Smoke Exposure (MHAWS) Demonstrates Good Reliability and Validity/**P.M. Meek, S. Schmiege, H. Petersen, H. Irshad, A. Sood, J. McDonald, Y. Tesfaigzi, Denver, CO, p.A7662

107 **Knowledge, Attitude and Beliefs About the Health Hazards of Biomass Smoke Exposure Amongst Commercial Food Vendors in Calabar and Benin Cities-Nigeria/**O.N.O. Nwankwo, N. Mokogwu, F.O. Ahmed, O. Agboghoroma, K. Mortimer, Calabar, Nigeria, p.A7663

108 **Evaluation of Pulmonary Function in Rural Women Exposed to Biomass Fuel in Western India/**S. Singh, M.D. Bargaje, R.B. Deoskar, A.T. Anokar, Pune , Maharashtra, India, p.A7664

109 **Ambient Wood Smoke and Other Particulate Pollutants and Changes in Biomarkers of Systemic Inflammation, Coagulation and Thrombosis/**D.P. Croft, S.J. Cameron, C.N. Morrell, C.J. Lowenstein, F. Ling, W. Zareba, P.K. Hopke, K. Thevenet-Morrison, K. Evans, M.J. Utell, D. Chalupa, D.Q. Rich, Rochester, NY, p.A7665

110 **Association Between Biomass Fuel, Tobacco Use and Two-Month Sputum Smear Conversion Among Pulmonary Tuberculosis Cases in India/**D. Reddy, S. Sahu, G. Roy, J. Ellner, C.R. Horsburgh, J. Pleskunas, S. Sarkar, N. Hochberg, Bronx, NY, p.A7666

111 **Epithelial-Mesenchymal Transition-Induced by Trans,Trans-2,4-Decadienal, a Component of Cooking Oil Fumes, in Human Bronchial Epithelium Cells/**J.R. Tsai, I.-W. Chong, Kaohsiung, Taiwan, p.A7667

112 **Swine Housing Dust Extract Elicits Inflammation and Oxidative Stress in Macrophages/**K. Locke, P. McIntosh, C. Murray, R. Minor, J. Waterman, Greensboro, NC, p.A7668

113 **Indoor Particulate Matter Exposure Is Associated with Increased Black Carbon Content in Airway Macrophages of Former Smokers with COPD/**L.M. Paulin, A.J. Belli, S. Bose, N.R. Aggarwal, C. DaSilva, L. Grammer, N.N. Hansel, Baltimore, MD, p.A7669

114 **Endotoxin Levels Enhance the Allergenicity of Phthalates in Adults: Findings from the NHANES 2005-2006/**J.A. Hoppin, P.D. Strassle, Raleigh, NC, p.A7670

115 **Variations in Disinfectants Used by Nurses in US Healthcare Facilities/**O. Dumas, A.S. Wiley, P.K. Henneberger, F.E. Speizer, J.-P. Zock, R. Varraso, N. Le Moual, K. Boggs, C.A. Camargo, VilleJuif, France, p.A7671

116 **Swine Production Environment Influences Expression of CaMKII in Porcine Bronchial Epithelial Tissues/**C. McClendon, R. Ranabhat, T.K. Gilbert, L. Graves, J. Waterman, Greensboro, NC, p.A7672

117 **Piloting an Unobtrusive Aerosol Sampler for Healthcare Setting Surveillance/**S.S. Blair, E. Kolderman, A.E.F. Dimmock, K.H.G. Walters, G.K. Kilper, J. Kesavan, R. Bascom, Hershey, PA, p.A7673

118 **Moisture Damage in Homes and Wheezing Phenotypes: A Birth Cohort Study/**A.M. Karvonen, A. Hyvarinen, M. Depner, P. Kirjavainen, P. Tiittanen, S. Remes, J. Genuneit, J. Pekkanen, Kuopio, Finland, p.A7674

119 **Lung Function Changes Associated with Episodes of Volcanic Sulfur Dioxide Exposure/**E.K. Tam, J. Davis, R. Miike, J. Orr, T. Divinski, T. De Marco, M. Heisman, T. Shibuya, M. Pearson, T. Elias, A.J. Sutton, Honolulu, HI, p.A7675

120 **Volcanic Sulfur Dioxide Air Pollution and Reduced FEV1/FVC Ratio in Hawai'i Island Schoolchildren/**E.K. Tam, K. Sircar, R. Miike, F. Yip, Honolulu, HI, p.A7676

121 **Electronic Cigarettes: Knowledge Beliefs and Perceptions of Risk /**V. Batra, C.B. Chasanov, R. Singh, Lewes, DE, p.A7677

122 **Effects of Particulate Matter Exposure on Glucocorticoid Responsiveness in Human Airway Epithelial Cells/**C.F. Rider, J.A. Hirota, C. Carlsten, Vancouver, Canada, p.A7930

123 **Health Impacts of Reducing PM10 Concentrations Through Different Traffic Scenarios in Paris, France/**C.N. Maesano, I. Annesi-Maesano, Paris, France, p.A7931

124 **Tidal Breathing Simulation of Ozone Uptake in the Infant Rhesus Monkey Respiratory Tract/**S.P. Motevalian, J. Ultman, R. Bascom, A. Borhan, University Park, PA, p.A7932

125 **Atopy in Relation to Endotoxin and Fungal Exposures in Early Life: Results from the National Health and Nutrition Examination Survey 2005-2006/**P.M. Salo, J. Wilkerson, R.D. Cohn, D.C. Zeldin, Research Triangle Park, NC, p.A7933

POSTER DISCUSSION SESSION

D107 TUBERCULOSIS INFECTION AND DISEASE: EPIDEMIOLOGY AND DIAGNOSIS

1:30 p.m. - 3:30 p.m. **MOSCONE CENTER**

Room 3014 (West Building, Level 3)

Poster Viewing	**1:30-2:15**
Discussion	**2:15-3:30**

Chairing: J. Bernardo, MD, Boston, MA
C. Dobler, MD, Sydney, Australia
J.J. Saukkonen, MD, West Roxbury, MA

901 **Prospects for Elimination: An Individual-Based Model to Assess TB Control Strategies in California/**A.J. Goodell, P.B. Shete, R. Vreman, J. Metcalfe, T.C. Porco, P.M. Barry, J. Flood, S. Marks, A. Cattamanchi, J.G. Kahn, San Francisco, CA, p.A7678

902 **Challenge on Tuberculosis Infection Control in Indonesia: High Close Contact History in Tuberculosis Patients with HIV and Diabetes Mellitus/**R.I. Sugiyono, N.H. Susanto, D. Arlinda, A.K. Syarif, A.D. Harso, A. Yulianto, M. Karyana, Jakarta Pusat, Indonesia, p.A7679

903 **Using Electronic Medical Records (EMR) in Urban Slum-Dwellers to Study Drivers of Tuberculosis in Rio de Janeiro/**D. Pain, V. Saraceni, S. Cohn, D. Soeiro, P. Durovni, S.C. Cavalcante, A. Zwerling, J. Golub, B. Durovni, R.E. Chaisson, Baltimore, MD, p.A7680

904 **Reactivation Risk of Latent Tuberculosis Infection by Population Subgroup: A Systematic Review and Meta-Analysis/**J. Yeats, S. Patel, P.B. Shete, A. Cattamanchi, B.J. Baker, Santa Monica, CA, p.A7681

905 **Diagnostic Accuracy of the Novel C-Tb Skin Test for Latent M.tuberculosis Infection; Results from Two Phase III Clinical Trials/**M. Ruhwald, J.A. Cayla, H. Aggerbaek, K. Dheda, P. Andersen, Copenhagen, Denmark, p.A7684

906 **Protective Efficacy of Preventive Therapy/**P. Kouw, S. Keizer, M. Mensen, W. Meijer, Amsterdam, Netherlands, p.A7685

907 **The Cost-Effectiveness of Testing and Treatment for Latent Tuberculosis Infection in Foreign-Born Persons in the United States/**B. Linas, A. Tasillo, N.A. Menzies, C.R. Horsburgh, S. Marks, J.A. Salomon, Boston, MA, p.A7686

908 **Daily Cough Frequency in Tuberculosis Is Associated with Rates of Household Infection/**R.D. Turner, R. Hooper, S.S. Birring, G.H. Bothamley, London, United Kingdom, p.A7687

909 **Cough Aerosol Cultures of Mycobacterium Tuberculosis from Index Cases Predict Incident Tuberculosis Disease in Household Contacts/**E. Jones-Lopez, M. Ssebidandi, M. Gaeddert, R. Kubiak, I. Ayakaka, L. White, M. Joloba, A. Okwera, Boston, MA, p.A7688

910 **Challenges in Laboratory Diagnosis of Tuberculosis in the Bacilloscopy Laboratory at the Maputo Central Hospital/**P.M. Zindoga, S. Peleve, S. Amade, A. Hassane, J. Pondo, A. Daniel, E. Nunes, Maputo, Mozambique, p.A7689

911 **Evaluation of Antibody Responses to Panels of M. Tuberculosis Antigens as a Screening Tool for Tuberculosis in Uganda/**P.B. Shete, A. Cattamanchi, E. Chang, R.K. Ravindran, L. Chaisson, P.A. Luciw, I.H. Khan, San Francisco, CA, p.A7690

912 **Evaluation of the Antibody in Lymphocyte Supernatant Assay in Detection of Active Tuberculosis/**M. Sariko, C. Anderson, B. Mujaga, J. Gratz, S. Mpagama, S.K. Heysell, G. Kibiki, B. Mmbaga, E. Houpt, T.A. Thomas, Moshi, Tanzania, p.A7691

913 **Sensitivity and Specificity of Cobas TaqMan MTB Real-Time Polymerase Chain Reaction for Culture-Proven Mycobacterium Tuberculosis: Meta-Analysis of 27431 Specimens from 19 Studies/**N. Horita, A. Narita, M. Ikeda, K. Nakashima, R. Ushio, H. Watanabe, K. Nagai, Y. Shibata, K. Tashiro, H. Nagakura, T. Tsukahara, M. Yamamoto, T. Sato, T. Kaneko, Yokohama, Japan, p.A7692

914 **The Use of the Xpertr MTB/RIF as a Public Health Tool to Treat MDR-TB Cases Timely - The First-Year Experience of Its Implementation in the City of Rio de Janeiro/**E.C.C. Soares, R.B. Piller, B. Durovni, J.E. Pio, M.C. Lourenco, P. Durovni, G. Abrantes, J.M. Neto, S.C. Cavalcante, Rio de Janeiro, Brazil, p.A7693

915 **Intial Experience with Xpert MTB/RIF for TB Diagnosis in a Large U.S. Urban Teaching Hospital/**S.B. Brosnahan, E. Leibert, B. Hamilton, M.E. Aguero-Rosenfeld, C. Caplan-Shaw, New York, NY, p.A7694

916 **Cartridge Based Nucleic Acid Amplification Test (CBNAAT) for the Diagnosis of Pulmonary Tuberculosis in Children/**M. Singh, G.R. Sethi, M. Mantan, A. Khanna, M. Hanif, Chandigarh, India, p.A7695

917 **A Novel Three-Gene Diagnostic for Pulmonary Tuberculosis/**T.E. Sweeney, L. Braviak, C.M. Tato, P. Khatri, Stanford, CA, p.A7696

918 **TB Airborne Transmission: First Gene Expression Signatures of Captured, Uncultured M. tuberculosis from Human Source Aerosol/**E.A. Nardell, C.M. Williams, A.J. Bell, L. Malinga, M.Y. Ramsheh, A. Bakir, N.J. Garton, A. Stoltz, E. DeKock, S. Waddell, J. Hinton, K. Fennelly, M. Barer, Boston, MA, p.A7934

919 **Effects of Traffic-Related Pollution on Tuberculosis Presentation and Outcomes in California/**R.J. Blount, L. Pascopella, P.M. Barry, D. Meltzer, M. Segal, B. Jones, J. Flood, P. English, P. Nahid, J. Balmes, D. Catanzaro, San Francisco, CA, p.A7935

920 **TB Testing in UK HIV Clinics Appears at Best only Marginally Cost-Effective/**S. Capocci, J. Sewell, C. Smith, I. Cropley, S. Bhagani, S. Morris, I. Abubakar, M. Johnson, M.C.I. Lipman, London, United Kingdom, p.A7936

POSTER DISCUSSION SESSION

D108 PEDIATRIC CASES: A ROOM FULL OF ZEBRAS

1:30 p.m. - 3:30 p.m. **MOSCONE CENTER**
Room 2014 (West Building, Level 2)

Poster Viewing **1:30-2:15**

Discussion **2:15-3:30**

Chairing: M. Santiago, MD, Great Neck, NY
B.T. Kopp, MD, Columbus, OH
A. Teper, MD, Caba, Argentina

501 **Eosinophilic Pneumonitis as Initial Presentation of Acute Lymphoblastic Leukemia/**E.B. Burgener, C.E. Milla, Palo Alto, CA, p.A7697

502 **A Teenager with Progressive Exertional Dyspnea and Intermittent Noisy Breathing/**K. Nandalike, R. Bansal, P. Belafsky, Sacramento, CA, p.A7698

503 **A Case of Concomitant Diffuse Alveor Hemorrhage and Pulmonary Embolism in Idiopathic Pulmonary Capillaritis/**J.H. Rayment, S.D.M. Dell, Toronto, Canada, p.A7699

504 **Subpleural Cysts in a Patient with Immune Dysregulation, Polyendrocrinopathy, Enteropathy, X-Linked Syndrome/**C.E. Leon Astudillo, C. Platt, T. Chatila, J. Ouahed, R. Wang, Boston, MA, p.A7700

505 **Congenital Pulmonary Artery Atresia Masquerading as a Left Sided Anomaly/**D.J. Heintz, E.D. Allen, R. Shell, Columbus, OH, p.A7701

506 **A Rare Cause of Unilateral Lung Hyperinflation in an Infant with Dyspnea/**E. Kramer, C. Towe, C. Myer, A. Hammill, W.D. Hardie, Cincinnati, OH, p.A7702

507 **An Unusual Cause of Tachypnea and Hypoxemia in an Infant/**P.J. Shukla, G. Phull, G.R. Nino, G.F. Perez, Washington, DC, p.A7703

508 **Cystic Fibrosis: Yes or No- A Case Report/**R. Siddaiah, E. Thau, G. Graff, Hershey, PA, p.A7704

509 **Respiratory Failure, Septicemia/Disseminated Intravascular Coagulation(DIC)/Hemolytic Uremic Syndrome (HUS) as Presentation of Cystic Fibrosis (CF) in Child with Homozygous S549 Mutation/**A. Jain, O. Afolabi-Brown, Philadelphia, PA, p.A7705

510 **Pulmonary Alveolar Proteinosis Associated with Secondary Hemophagocytic Lymphohistiocytosis: A Pediatric Case of Whole Lung Lavage Under Veno-Venous Extracorporeal Membrane Oxygenation/**J. Lin, M. Miksa, R. Maxwell, E. Wasserman, K. Adams, J. Weingarten, L. Figueiredo, G. Peek, A. De, Bronx, NY, p.A7706

511 **Constrictive Bronchiolitis: A Rare Complication of Toxic Epidermal Necrolysis/**S.G. Bickel, A. O'Hagan, R.L. Morton, K. Schmidt, N. Eid, Louisville, KY, p.A7707

512 **Minocycline-Induced Eosinophilic Pneumonia in a Pediatric Patient/**M. Chan, D. Chhabra, A. Krakowski, C. Leong, J. Hagood, San Diego, CA, p.A7708

513 **Extreme Tachypnea in a Neonate - A Case of Diaphragmatic Flutter with an Interesting Genetic Outcome/**M. Lambert, L. Yonker, B. Nelson, T.B. Kinane, Boston, MA, p.A7709

514 **Carotid Body Dysfunction Limits Exercise Performance/** D. Bush, T. Olin, O. Kupfer, Aurora, CO, p.A7710

515 **Respiratory Arrest Following Esophageal Manipulation: A Complex Case Between the Respiratory and Gastrointestinal Tracts/**M.D. McGraw, P.C. Stillwell, M.B. Mitchell, T.M. Wine, R.E. Kramer, R.R. Deterding, Aurora, CO, p.A7711

516 **A Case of Bronchiectasis in a 6 Year Old with STAT1 Gain of Function Mutation Associated with Chronic Mucocutaneous Candidiasis/**T.E. Duong, J. Hagood, La Jolla, CA, p.A7712

517 **Prolonged Tachypnea and Hypoxemia as Presentation of Bare Lymphocyte Syndrome, Type II/**R.J. Nevel, M.A. Wurth, C.M. Papantonakis, R.F. Brown, Y. Khan, D. Dulek, L.R. Young, Nashville, TN, p.A7713

518 **Diaphragm Pacing Can Be Used to Successfully Wean from Tracheostomy Mechanical Ventilation in SMA Type 2/**R. Onders, M. Elmo, C. Kaplan, D.I. Craven, K. Lidsky, Cleveland, OH, p.A7714

519 **Pulmonary Vascular Remodeling in a Child with High Altitude Pulmonary Edema/**K. Kalita, M.K. Dishop, J. Weinman, A. Grenolds, D.R. Liptzin, Aurora, CO, p.A7715

520 **Pulmonary Hypertension and Right Heart Failure Due to Severe Hypernatremic Dehydration/**S. Chiwane, J. Klein, M. Chauhan, Detroit, MI, p.A7716

521 **An Infant with Tachypnea and Progressive Respiratory Failure/**N. Joshi, S. Martinez, Akron, OH, p.A7717

522 **Recurrent Hemoptysis in a Teen Boy with a Ciliary Motility Disorder and a Pulmonary Vascular Malformation Occult on Contrast Enhanced CT./**R. Wadia, M. Newaskar, M. Conrad, D. Conrad, Oakland, CA, p.A7718

523 **A Rare Case of Asymptomatic Left Pulmonary Artery Sling/**S. Raj, S. Chandra, Iowa City, IA, p.A7719

524 **Presentation of Relapsing Polychondritis in an Adolescent/** M.B. Dennis, P. Sammut, H. Thomas, Omaha, NE, p.A7720

525 **An Adolescent with Asthma and Autoimmune Features: Airway Manifestations and Response to Trimethoprim-Sulfamethoxazole/**C.Y. Spencer, A.G. Vicencio, New York, NY, p.A7721

POSTER DISCUSSION SESSION

D109 WHAT'S HIDING UNDER THE COVERS: BASIC SCIENCE IN SDB

1:30 p.m. - 3:30 p.m. **MOSCONE CENTER**

Room 2010/2012 (West Building, Level 2)

Poster Viewing **1:30-2:15**

Discussion **2:15-3:30**

Chairing: C.P. O'Donnell, PhD, Pittsburgh, PA
O. Mesarwi, MD, Baltimore, MD
S. Ryan, MD, PhD, Dublin, Ireland
I. Almendros, PhD, Barcelona, Spain

401 **Leptin Induces Hypertension Acting in the Carotid Bodies/**M.-K. Shin, H. Joo, M. Shirahata, V.Y. Polotsky, Baltimore, MD, p.A7722

402 **Novel Technology Demonstrates Formation of Respiratory Stimulant S-Nitrosothiols in DeOxygenated Human Blood/**J. Seckler, S. Burton, S.J. Lewis, B. Gaston, Cleveland, OH, p.A7723

403 **Chronic Intermittent Hypoxia Increases Plasminogen Activator Inhibitor 1 Expression and Activity in Rats with Chronic Dust Mite - Induced Airway Inflammation/**O. Broytman, R.K. Braun, M. Teodorescu, Madison, WI, p.A7724

404 **Intermittent Hypoxia Augments Mesangial Matrix Expansion by Increasing Glomerular Expression of TGF-β and CTGF Proteins/**B.H. Abuyassin, M. Badran, N. Ayas, I. Laher, Vancouver, Canada, p.A7725

405 **nmMLCK: A Key Player in Intermittent Hypoxia-Induced Inflammatory Vascular Remodeling?/**C. Arnaud, S. Recoquillon, S. Bouyon, E. Lemarie, S. Cachot, M. Toral, C. Martinez, R. Andriantsitohaina, J.L. Pepin, Grenoble, France, p.A7726

406 **Circulating Plasma Exosomes and CardioMetabolic Function in Mice Exposed to Long-Term Alternating Dark-Light Cycles Mimicking Shift Work/**A. Khalyfa, Z. Qiao, V. Poroyko, A. Gileles-Hillel, A.A. Khalyfa, M. Akbarpour, D. Gozal, Chicago, IL, p.A7727

407 **Activation of Integrated Stress Response (ISR) and Intermittent Hypoxia (IH)-Induced Metabolic Dysfunction in a Mouse Model of Sleep Apnea/**A. Khalyfa, Z. Qiao, A. Gileles-Hillel, A.A. Khalyfa, M. Akbarpour, B. Popko, B, D. Gozal, Chicago, IL, p.A7728

408 **Activation of Integrated Stress Response (ISR) By Sleep Fragmentation During Late Gestation (LG-SF) in Mouse Is Critical to Emergence of Metabolic Phenotype in Adult Offspring/**A. Khalyfa, Z. Qiao, A.A. Khalyfa, A. Gileles-Hillel, M. Akbarpour, B. Poroyko, D. Gozal, Chicago, IL, p.A7729

409 **Endoplasmic Reticulum Stress as a Novel Inducer of Hypoxia Inducible Factor-1 Activity: Its Role in the Susceptibility to Myocardial Ischemia-Reperfusion Induced by Chronic Intermittent Hypoxia/**E. Belaidi, A. Thomas, G. Bourdier, S. Moulin, E. Lemarie, R. Tamisier, P. Levy, J.L. Pepin, I. Korichneva, D. Godin-Ribuot, C. Arnaud, Grenoble, France, p.A7730

410 **High-Intensity Training Reduces Intermittent Hypoxia-Induced ER Stress and Myocardial Infarct Size/**G. Bourdier, P. Flore, H. Sanchez, J.L. Pepin, E. Belaidi, C. Arnaud, Grenoble, France, p.A7731

411 **NF-kB Pathway Plays a Critical Role in Intermittent Hypoxia Induced Macrophage Foam Cell Formation/**T. Imamura, G.G. Haddad, La Jolla, CA, p.A7732

412 **Endothelial Dysfunction in Diabetic Mice Is Exacerbated by Chronic Intermittent Hypoxia (CIH)/**M. Badran, N. Ayas, I. Laher, Vancouver, Canada, p.A7733

413 **Low Frequency Intermittent Hypoxia Reduces Endothelium-Dependent Contraction in C57 Mice with Diet-Induced Obesity/**M.Y.K. Lee, J.C.W. Mak, M.S.M. Ip, Hong Kong, Hong Kong Prc, p.A7734

414 **Hepatocyte Knockout of HIF-1α Accentuates Metabolic Improvement in Sustained Hypoxia/**O. Mesarwi, M.-K. Shin, S. Bevans-Fonti, C.P. O'Donnell, V.Y. Polotsky, Baltimore, MD, p.A7735

415 **Various Degrees of Intensities of Intermittent Hypoxia on Adipogenesis in Diet-Induced Obese Mouse Model/**Y. Wang, M.Y.K. Lee, J.C.W. Mak, M.S.M. Ip, Hong Kong, Hong Kong Prc, p.A7736

416 **Late Gestational Intermittent Hypoxia Leads to Metabolic and Epigenomic Alterations in Adult Offspring/**R. Cortese, A. Khalyfa, R. Bao, J. Andrade, D. Gozal, Chicago, IL, p.A7737

417 **Role of COX-2 in Intermittent Hypoxia-Induced Tumor Growth in a Murine Model of Obstructive Sleep Apnea/**I. Almendros, N. Campillo, M. Torres, D. Gozal, J.M. Montserrat, C. Picado, R. Farre, D. Navajas, Barcelona, Spain, p.A7738

418 **Intermitent Hypoxia Increases Tumor Angiogenesis in a Mouse Model of Heterotropic Kidney Cancer/**M. Torres, A. Vilaseca, N. Campillo, M. Musquera, J.M. Montserrat, A. Alcaraz, R. Farre, I. Almendros, Barcelona, Spain, p.A7739

419 **Progression of Tumor Growth in Intermittent Hypoxia is Associated with Decreased Number of Granzyme B Expressing CD8+ T Cell Lymphocytes/**M. Akbarpour, A. Khalyfa, Q. Zhuanhong, A.A. Khalyfa, A. Gileles-Hillel, I. Almendros, R. Farre, D. Gozal, Chicago, IL, p.A7740

420 **Antioxidant Tempol Ameliorates Intermittent Hypoxia-Induced Melanoma Lung Metastasis in a Mouse Model of OSA/**L. Li, M. Liang, Y. Fang, J. Cao, B. Chen, Tianjin, China, p.A7741

421 **A Membrane Progesterone Receptor Agonist Reduces Apnea Frequency in Newborn Male and Female Rats/**N. Uppari, H. Kouchi, V. Joseph, A. Bairam, Quebec, Canada, p.A7742

422 **Severe Chronic Intermittent Hypoxia Could Mask the Severity of Lung Cancer, in Terms of Plasmatic Tumor Markers/**T. Gallego-Martin, E. Gonzalez-Obeso, E. Olea, S. Yubero, I. Docio, A. Obeso, Valladolid, Spain, p.A7743

POSTER DISCUSSION SESSION

D110 UNUSUAL TUMORS OF THE CHEST

1:30 p.m. - 3:30 p.m. **MOSCONE CENTER**

Room 309 (South Building, Esplanade Level)

Poster Viewing **1:30-2:15**

Discussion **2:15-3:30**

Chairing: D.E. Ost, MD, MPH, Houston, TX
L.T. Tanoue, MD, New Haven, CT

301 **Atypical Multifocal Pulmonary Carcinoid Tumor: A Case Report of a Very Rare Neoplasm/**C.A. Celis Preciado, P. Gil, C. Zuluaga, L. Jaramillo, Bogota, Colombia, p.A7744

302 **Bilateral Synchronous Pulmonary Carcinoid Tumors Treated with Staged Segmentectomy/**A. Attili, J. Shaw, Brooklyn, NY, p.A7745

303 **Atypical Large Hydropneumothorax in the Setting of an Uncommon Lung Neuroendocrine Tumor/**J.M. Sosa, L. Carrasco, F. Hafeez, M. Abdullahi, R. Ayinla, New York, NY, p.A7746

304 **A Rare Case of Mucoepidermoid Carcinoma of the Lung/**A. Rajagopal, A.P. Maskey, Lexington, KY, p.A7747

305 **Endobronchial Leiomyoma Presenting with Asthma-Like Symptoms: Successfully Treated by Sleeve Resection/**R. Hurezeanu, A. Kaell, L. Cardinal, Port Jefferson, NY, p.A7748

306 **Pulmonary Benign Metastasizing Leiomyoma: A Case Report/**M.M.K.S. Khan, H. Ibrahim, G.M. VanOtteren, T. Barnes, Grand Rapids, MI, p.A7749

307 **Leiomyosarcoma Arising from the Right Pulmonary Artery as a Cause for Superior Vena Cava Syndrome: A Case of Dyspnea Not Entirely Explained by Pulmonary Embolus/**V.H. Patel, H. Ballout, R. Kamath, A. Kumar, Grosse Pointe Woods, MI, p.A7750

308 **Extensive Tracheal Bifurcation Necrosis: An Usual Manifestation of Disseminated Mediastinal Osteosarcoma/** P. Tunsupon, A. Sapple, A.H. Alraiyes, Buffalo, NY, p.A7751

309 **Congenital Pulmonary Airway Malformation (CPAM) with Malignant Transformation/**V. Soriano, D. Chia, S.I. Aronin, Waterbury, CT, p.A7752

310 **Recurrent Hydropneumothorax: An Unusual Presentation for Malignant Pleural Mesothelioma/**D.A. DeLapp, P. Nystrom, Dayton, OH, p.A7753

311 **Cardiac Tamponade Due to Primary Pericardial Mesothelioma Thirty Years After Radiation-Treated Hodgkin's Lymphoma/**S.E. Richter, C.T. Sheth, Los Angeles, CA, p.A7754

312 **Tracheal Mucosa Associated Lymphoid Tissue Lymphoma as a Cause of Chronic Cough and Prandial Dyspnea/**E.J. Swanson, K.M. Kunisaki, H. Mesa, J. Silva, Minneapolis, MN, p.A7755

313 **Leukemic Infiltration in the Setting of Acute Respiratory Failure/**M.A. Fayed, T. Evans, H. Abdulhaq, Fresno, CA, p.A7756

314 **Extranodal NK/T-Cell Lymphoma Masquerading as Limited Granulomatosis with Polyangiitis/**N.A. Braus, T. Peikert, Rochester, MN, p.A7757

315 **Castleman's Disease Presenting as a Mediastinal Mass: Mimicker of Malignancy/**M.U. Khawar, H. Hussein, H. Youness, Oklahoma City, OK, p.A7758

316 **Adult Type T Cell Leukemia/Lymphoma Presenting as a Tracheal Mass/**G. Dutta, J. Qin, J. Gorga, S. Fahmy, Brooklyn, NY, p.A7759

317 **Recurrent Esophageal Adenocarcinoma with Circumferential Involvement of the Tracheal Mucosa/**A. Sapple, A.H. Alraiyes, Buffalo, NY, p.A7760

318 **Massive Thymolipoma: An Unusual Cause of Acute Respiratory Failure/**C. Di Felice, H. Chhatrala, M. Konda, S. Ansari, Kalamazoo, MI, p.A7761

319 **Spontaneous Rupture of an Anterior Mediastinal Cystic Teratoma Presenting with Hemoptysis/**R. Hiensch, M. Acho, L. DiFabrizio, New York, NY, p.A7762

320 **Pneumothorax and Lung Nodules- A Unique Presentation of Granulosa Cell Ovarian Tumor/**A. Alkhatib, M. Hundal, C. Ghattas, M. Yaqoob, S. Rafeq, Brighton, MA, p.A7763

321 **Pulmonary Metastasis from a Neurofibroma/**H. Mehta, L. Gross, K. Keshava, R. Khillan, Brooklyn, NY, p.A7764

322 **A Rare Case of Primary Pulmonary Melanoma/**G. Gilroy, C. Zhang, E. Bendaly, K. Diab, Indianapolis, IN, p.A7765

323 **An Asymptomatic Case of Tracheal Hamartoma/**A. Cilli, F. Uzer, L. Dertsiz, Antalya, Turkey, p.A7766

324 **A "Classic" Diagnosis of a Rare Disease: Classic Kaposi Sarcoma with Pulmonary Involvement in a Non-HIV Patient/**B. Graney, Z. Yunt, Denver, CO, p.A7767

325 **The Third Therapeutic Intervention in Malignant Effusion Trial (TIME3): A Randomised Controlled Trial to Assess Dyspnea Relief and Pleurodesis Success Following Intrapleural Urokinase in Patients with Non-Draining Malignant Pleural Effusion/**E.K. Mishra, A.O. Clive, G. Wills, H.E. Davies, A.E. Stanton, M. Al-Aloul, A. Hart-Thomas, J. Pepperell, M. Evison, T. Saba, R.N. Harrison, A. Guhan, M. Callister, R. Sathyamurthy, J. Corcoran, R. Hallifax, I. Psallidas, N. Russell, R. Shaw, M. Dobson, J.M. Wrightson, A. West, Y.C.G. Lee, A.J. Nunn, R.F. Miller, N.A. Maskell, N.M. Rahman, Oxford, United Kingdom, p.A7937

Where today's science meets tomorrow's care™

ATS 2016

Where today's science meets tomorrow's care™

http://conference.thoracic.org